,CID,name,smiles,7.1-Drug Indication,8.1-Pharmacodynamics,8.2-MeSH Pharmacological Classification,"8.5-Absorption, Distribution and Excretion",8.6-Metabolism/Metabolites,8.7-Biological Half-Life
0,120001,"1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carbonitrile",CCN1C2=CC3=C(C=C2C(=O)C(=N1)C#N)OCO3,,,,,,
1,120002,Butanoic acid;dibutyltin,CCCC[Sn]CCCC.CCCC(=O)O.CCCC(=O)O,,,,,,
2,120003,3-Hydroxy-4-methyl-5-propylfuran-2(5H)-one,CCCC1C(=C(C(=O)O1)O)C,,,,,,
3,120004,3-(Phenoxymethyl)-2-benzofurancarboxylic acid,C1=CC=C(C=C1)OCC2=C(OC3=CC=CC=C32)C(=O)O,,,,,,
4,120005,CID 120005,CC#CS(=O)(=O)[O-].[Na+],,,,,,
5,120006,Prop-1-yne-1-sulfonic Acid,CC#CS(=O)(=O)O,,,,,,
6,120007,Isooctyl methacrylate,CC(C)CCCCCOC(=O)C(=C)C,,,,,,
7,120008,"1,4-Didodecylnaphthalene",CCCCCCCCCCCCC1=CC=C(C2=CC=CC=C12)CCCCCCCCCCCC,,,,,,
8,120009,"1,5-Dichloro-2,3-dinitrobenzene",C1=C(C=C(C(=C1[N+](=O)[O-])[N+](=O)[O-])Cl)Cl,,,,,,
9,120010,3-Amino-1-imino-5-methoxy-1H-isoindole,COC1=CC2=C(C=C1)C(=NC2=N)N,,,,,,
10,120011,2-(4-Aminophenyl)propanenitrile,CC(C#N)C1=CC=C(C=C1)N,,,,,,
11,120012,3-(Isodecyloxy)propylammonium acetate,CC(C)CCCCCCCOCCCN.CC(=O)O,,,,,,
12,120013,"1-Propanamine, 3-(isodecyloxy)-",CC(C)CCCCCCCOCCCN,,,,,,
13,120014,ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate,CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C(=O)OCC,,,,,,
14,120015,"Tetrasodium 7,7'-(ureylenebis((2-methyl-p-phenylene)azo))dinaphthalene-1,3-disulphonate",CC1=C(C=CC(=C1)NC(=O)NC2=CC(=C(C=C2)N=NC3=CC4=C(C=C(C=C4C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-])C)N=NC5=CC6=C(C=C(C=C6C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
15,120016,"1,5-Naphthalenedisulfonic acid, 3,3'-[carbonylbis[imino(3-methoxy-4,1-phenylene)azo]]bis-, tetrasodium salt",COC1=C(C=CC(=C1)NC(=O)NC2=CC(=C(C=C2)N=NC3=CC4=C(C=CC=C4S(=O)(=O)[O-])C(=C3)S(=O)(=O)[O-])OC)N=NC5=CC6=C(C=CC=C6S(=O)(=O)[O-])C(=C5)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
16,120017,"3-[[4-[[4-[(4,8-Disulfonaphthalen-2-yl)diazenyl]-3-methoxyphenyl]carbamoylamino]-2-methoxyphenyl]diazenyl]naphthalene-1,5-disulfonic acid",COC1=C(C=CC(=C1)NC(=O)NC2=CC(=C(C=C2)N=NC3=CC4=C(C=CC=C4S(=O)(=O)O)C(=C3)S(=O)(=O)O)OC)N=NC5=CC6=C(C=CC=C6S(=O)(=O)O)C(=C5)S(=O)(=O)O,,,,,,
17,120018,(Bis(2-hydroxyethyl))methyl(2-((1-oxooctadecyl)oxy)ethyl)ammonium methyl sulphate,CCCCCCCCCCCCCCCCCC(=O)OCC[N+](C)(CCO)CCO.COS(=O)(=O)O,,,,,,
18,120019,"N,N-Bis(2-hydroxyethyl)-N-methyl-2-[(1-oxooctadecyl)oxy]ethanaminium",CCCCCCCCCCCCCCCCCC(=O)OCC[N+](C)(CCO)CCO,,,,,,
19,120020,"3-(1-Azaspiro(4,5)decyl)-2-phenylpropiophenone hydrochloride",CCC(=O)C1=C(C(=CC=C1)N2CCCC23CCCCC3)C4=CC=CC=C4.Cl,,,,,,
20,120021,1-[3-(1-Azaspiro[4.5]decan-1-yl)-2-phenylphenyl]propan-1-one,CCC(=O)C1=C(C(=CC=C1)N2CCCC23CCCCC3)C4=CC=CC=C4,,,,,,
21,120022,Butyl 2-cyano-3-(4-methoxyphenyl)-2-butenoate,CCCCOC(=O)C(=C(C)C1=CC=C(C=C1)OC)C#N,,,,,,
22,120023,"n,n'-Methylenebis[n-(hydroxymethyl)acrylamide]",C=CC(=O)N(CN(CO)C(=O)C=C)CO,,,,,,
23,120024,"Ethanesulfonic acid, 2,2'-(methylimino)bis-, disodium salt",CN(CCS(=O)(=O)[O-])CCS(=O)(=O)[O-].[Na+].[Na+],,,,,,
24,120025,2-[Methyl(2-sulfoethyl)amino]ethanesulfonic acid,CN(CCS(=O)(=O)O)CCS(=O)(=O)O,,,,,,
25,120026,"5,6,7,8,9,10-Hexahydrocycloocta[b]pyridine",C1CCCC2=C(CC1)C=CC=N2,,,,,,
26,120027,"3-Methyl-6,7-dihydro-5h-cyclopenta[b]pyridine",CC1=CC2=C(CCC2)N=C1,,,,,,
27,120028,"3-Methyl-5,6,7,8-tetrahydroquinoline",CC1=CC2=C(CCCC2)N=C1,,,,,,
28,120029,"2-Butenedioic acid (2Z)-, bis[2-(4-benzoyl-3-hydroxyphenoxy)ethyl] ester",C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)OCCOC(=O)C=CC(=O)OCCOC3=CC(=C(C=C3)C(=O)C4=CC=CC=C4)O)O,,,,,,
29,120030,"2-Ethyl-2H-1,2-benzothiazin-3(4H)-one 1,1-dioxide",CCN1C(=O)CC2=CC=CC=C2S1(=O)=O,,,,,,
30,120031,10-Methoxycarbamazepine,COC1=CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,,,,,,
31,120032,Thiodiethylene diacetoacetate,CC(=O)CC(=O)OCCSCCOC(=O)CC(=O)C,,,,,,
32,120033,Einecs 249-191-4,CC(C)CC(C)NC1=CC=C(C=C1)N(C)C2=CC=CC=C2,,,,,,
33,120034,"3-Phenyl-4,5,6,7-tetrahydro-1h-indazole",C1CCC2=C(C1)C(=NN2)C3=CC=CC=C3,,,,,,
34,120035,"1,4,5,6-Tetrahydro-3-phenylcyclopentapyrazole",C1CC2=C(C1)NN=C2C3=CC=CC=C3,,,,,,
35,120036,CID 120036,CC1=CC(=C(C=C1C2(C3=CC=CC=C3C(=O)O2)C4=CC(=C(C=C4C)OP(=O)(O)[O-])C(C)C)C(C)C)O.[Na+],,,,,,
36,120037,1-Chloroethanesulphinic acid,CC(S(=O)O)Cl,,,,,,
37,120038,"1-Propanamine, 3-(2-ethoxyethoxy)-",CCOCCOCCCN,,,,,,
38,120039,Diisopropylnaphthalenesulphonic acid,CC(C)C1=CC2=C(C=CC(=C2C=C1)S(=O)(=O)O)C(C)C,,,,,,
39,120040,"[1]Benzofuro[3,2-c][1]benzoxepin-12(6h)-one",C1C2=CC=CC=C2OC(=O)C3=C1OC4=CC=CC=C43,,,,,,
40,120041,"Quinoxalinium, 1-[(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)ethylidene]-1,2,3,4-tetrahydro-, chloride",CC1(C2=CC=CC=C2N(C1=CC=[N+]3CCNC4=CC=CC=C43)C)C.[Cl-],,,,,,
41,120042,"2-[2-[(3,4-Dihydroquinoxalin)-1(2H)-yl]vinyl]-1,3,3-trimethyl-3H-indolium",CC1(C2=CC=CC=C2N(C1=CC=[N+]3CCNC4=CC=CC=C43)C)C,,,,,,
42,120043,"3-Oxazolidineethanol, 2-(1-methylethyl)-",CC(C)C1N(CCO1)CCO,,,,,,
43,120044,"1,6-Diacetyltetrahydroimidazo[4,5-d]imidazole-2,5(1h,3h)-dione",CC(=O)N1C2C(NC1=O)NC(=O)N2C(=O)C,,,,,,
44,120045,"Dihydro-3-(octadecenyl)-2,5-furandione",C=CCCCCCCCCCCCCCCCCC1CC(=O)OC1=O,,,,,,
45,120046,Boc-ala-gly-OH,CC(C(=O)NCC(=O)O)NC(=O)OC(C)(C)C,,,,,,
46,120047,4-Propylbenzaldehyde,CCCC1=CC=C(C=C1)C=O,,,,,,
47,120048,2-Methyl-4-oxo-4H-pyran-3-yl acetate,CC1=C(C(=O)C=CO1)OC(=O)C,,,,,,
48,120049,4-Butylbenzoyl chloride,CCCCC1=CC=C(C=C1)C(=O)Cl,,,,,,
49,120050,[(2-methyl-2-methylsulfanylpropylidene)amino] N-dimethoxyphosphinothioyl-N-methylcarbamate,CC(C)(C=NOC(=O)N(C)P(=S)(OC)OC)SC,,,,,,
50,120051,"Benzenesulfonamide, 3-nitro-N-phenyl-",C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)[N+](=O)[O-],,,,,,
51,120052,1-(2-(Ethylthio)ethyl)-2-methyl-5-nitro-1H-imidazole,CCSCCN1C(=NC=C1[N+](=O)[O-])C,,,,,,
52,120053,"11-(Chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one",C1=CC=C2C(=C1)C(=O)NC3=C(N2C(=O)CCl)N=CC=C3,,,,,,
53,120054,"1,2-Dihydro-6-hydroxy-1-(2-hydroxyethyl)-4-methyl-2-oxonicotinonitrile",CC1=CC(=O)N(C(=C1C#N)O)CCO,,,,,,
54,120055,"Butanedioic acid, diisodecyl ester",CC(C)CCCCCCCOC(=O)CCC(=O)OCCCCCCCC(C)C,,,,,,
55,120056,Methyl 1-naphthoate,COC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
56,120057,"Butanedioic acid, octenyl-",C=CCCCCCCOC(=O)CCC(=O)O,,,,,,
57,120058,"10b,10c-Dipropyl-10b,10c-dihydropyrene",CCCC12C3=CC=C4C1(C(=CC=C4)C=CC2=CC=C3)CCC,,,,,,
58,120059,"(20S)-Pregnane-3alpha,20-diol",C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC[C@H](C4)O)C)C)O,,,,,,
59,120060,"2,2'-((3-Nitrophenyl)imino)bisethyl diacetate",CC(=O)OCCN(CCOC(=O)C)C1=CC(=CC=C1)[N+](=O)[O-],,,,,,
60,120061,"2H-1-Benzopyran-2-one, 7-(ethylamino)-4-methyl-",CCNC1=CC2=C(C=C1)C(=CC(=O)O2)C,,,,,,
61,120062,"3,6,9,12,15,18,21,24,27,30,33,36,39,42-Tetradecaoxatetratetracontane-1,44-diol",C(COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)O,,,,,,
62,120063,"3-Methylhexa-2,4-diene",CC=CC(=CC)C,,,,,,
63,120064,"Propanenitrile, 3-[[4-[(4,6-dibromo-2-benzothiazolyl)azo]phenyl]ethylamino]-",C1=CC(=CC=C1CCNCCC#N)N=NC2=NC3=C(S2)C=C(C=C3Br)Br,,,,,,
64,120065,5-Methyl-2-phenyl-1H-imidazole-4-carboxylic acid,CC1=C(N=C(N1)C2=CC=CC=C2)C(=O)O,,,,,,
65,120066,Ammonium 8-(phenylamino)naphthalene-1-sulfonate,C1=CC=C(C=C1)NC2=CC=CC3=C2C(=CC=C3)S(=O)(=O)[O-].[NH4+],,,,,,
66,120067,"1,2-Diphenyltryptamine",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2C4=CC=CC=C4)CCN,,,,,,
67,120068,N-(2-Hydroxyhexadecyl)diethanolamine oxide,CCCCCCCCCCCCCCC(C[N+](CCO)(CCO)[O-])O,,,,,,
68,120069,Europium phosphide (EuP),P#[Eu],,,,,,
69,120070,Dimethyl chloromalonate,COC(=O)C(C(=O)OC)Cl,,,,,,
70,120071,"N'-[3-(octadec-9-enylamino)propyl]propane-1,3-diamine",CCCCCCCCC=CCCCCCCCCNCCCNCCCN,,,,,,
71,120072,2-(Tetradecanoyloxy)ethyl 2-[(phosphonooxy)methyl]tetradecanoate,CCCCCCCCCCCCCC(=O)OCCOC(=O)C(CCCCCCCCCCCC)COP(=O)(O)O,,,,,,
72,120073,Diphenyl (7-methyloctyl)phosphonate,CC(C)CCCCCCP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
73,120074,Diisooctyl succinate,CC(C)CCCCCOC(=O)CCC(=O)OCCCCCC(C)C,,,,,,
74,120075,Diisooctyl glutarate,CC(C)CCCCCOC(=O)CCCC(=O)OCCCCCC(C)C,,,,,,
75,120076,(2-Docos-13-enoyloxy-3-hydroxypropyl) docos-13-enoate,CCCCCCCCC=CCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCC=CCCCCCCCC,,,,,,
76,120077,"Naphthalene, 1-methyl(1-methylethyl)-",CC1=CC=C(C2=CC=CC=C12)C(C)C,,,,,,
77,120078,2-Hydroxyethyl (2-(2-hydroxyethoxy)ethyl)carbamate,C(COCCO)NC(=O)OCCO,,,,,,
78,120079,2-Hydroxypropyl (2-hydroxyethyl)carbamate,CC(COC(=O)NCCO)O,,,,,,
79,120080,"Bis(2,3-dibromopropyl) chlorophosphate",C(C(CBr)Br)OP(=O)(OCC(CBr)Br)Cl,,,,,,
80,120081,"6,7-Dimethoxyquinazoline-2,4(1H,3H)-dione",COC1=C(C=C2C(=C1)C(=O)NC(=O)N2)OC,,,,,,
81,120082,"(6R-(6alpha,7beta(R*)))-3-(Acetoxymethyl)-7-(amino(4-hydroxyphenyl)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid",CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,,,,,,
82,120083,"1-Butanol, 2-amino-, hydrochloride, (2S)-",CC[C@@H](CO)N.Cl,,,,,,
83,120084,(S)-2-aminobutan-1-ol,CC[C@@H](CO)N,,,,,,
84,120085,"6,10-Dimethylundeca-1,5,9-trien-4-ol",CC(=CCCC(=CC(CC=C)O)C)C,,,,,,
85,120086,"2-Hexenoic acid, 2-methyl-, (2E)-",CCCC=C(C)C(=O)O,,,,,,
86,120087,7-Chloro-1H-indole-2-carboxylic acid,C1=CC2=C(C(=C1)Cl)NC(=C2)C(=O)O,,,,,,
87,120088,"3-(Octadecylamino)propane-1,2-diol",CCCCCCCCCCCCCCCCCCNCC(CO)O,,,,,,
88,120089,4-((3-Chloro-4-((p-hydroxyphenyl)azo)phenyl)azo)-m-cresol,CC1=C(C=CC(=C1)O)N=NC2=CC(=C(C=C2)N=NC3=CC=C(C=C3)O)Cl,,,,,,
89,120090,Einecs 249-299-1,CCCCOP(=O)(O)OP(=O)(O)OCCCC,,,,,,
90,120091,"1,2,4-Benzenetricarboxylic acid, monobutyl ester",CCCCOC(=O)C1=C(C=C(C=C1)C(=O)O)C(=O)O,,,,,,
91,120092,"Benzothiazole, 2-[(chloromethyl)thio]-",C1=CC=C2C(=C1)N=C(S2)SCCl,,,,,,
92,120093,Naphthalene-1-diazonium tetrafluoroborate,[B-](F)(F)(F)F.C1=CC=C2C(=C1)C=CC=C2[N+]#N,,,,,,
93,120094,Naphthalene-1-diazonium,C1=CC=C2C(=C1)C=CC=C2[N+]#N,,,,,,
94,120095,Hex-5-en-3-yn-1-ol,C=CC#CCCO,,,,,,
95,120096,Calcium glycerophosphate,C(C(COP(=O)([O-])[O-])O)O.[Ca+2],,,,,,
96,120097,"1-(3,5-Bis(phenylmethoxy)phenyl)-2-bromoethan-1-one",C1=CC=C(C=C1)COC2=CC(=CC(=C2)C(=O)CBr)OCC3=CC=CC=C3,,,,,,
97,120098,"Ethanone, 1-[3,5-bis(phenylmethoxy)phenyl]-",CC(=O)C1=CC(=CC(=C1)OCC2=CC=CC=C2)OCC3=CC=CC=C3,,,,,,
98,120099,1-Cyclododecylethan-1-one,CC(=O)C1CCCCCCCCCCC1,,,,,,
99,120100,"1,4,5,8-Tetrahydroxy-4a,9a-dihydroanthracene-9,10-dione",C1=CC(=C2C(=O)C3C(C(=CC=C3O)O)C(=O)C2=C1O)O,,,,,,
100,120101,"2H-1,5-Benzodioxepin-3(4H)-one, 7-methyl-",CC1=CC2=C(C=C1)OCC(=O)CO2,,,,,,
101,120102,"1-Hexadecanamine, N,N-dihexadecyl-",CCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC,,,,,,
102,120103,"N,N,N',N'-Tetramethyldodecane-1,12-diamine",CN(C)CCCCCCCCCCCCN(C)C,,,,,,
103,120104,3-Ethyl-4-[(1-methyl-5-imidazolyl)methyl]tetrahydrofuran-2-one Hydrochloride,CCC1C(COC1=O)CC2=CN=CN2C.Cl,,,,,,
104,120105,2-(Naphthalen-1-ylmethylideneamino)sulfonylacetic acid,C1=CC=C2C(=C1)C=CC=C2C=NS(=O)(=O)CC(=O)O,,,,,,
105,120106,((Isononyloxy)methyl)oxirane,CC(C)CCCCCCOCC1CO1,,,,,,
106,120107,"5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid",C1CCC(CC1)C2=CC3=C(C=C2)C(CC3)C(=O)O,,,,,,
107,120108,Clidanac,C1CCC(CC1)C2=C(C=C3C(CCC3=C2)C(=O)O)Cl,,,,,,
108,120109,(1S)-(+)-6-Chloro-5-cyclohexylindan-1-carboxylic acid,C1CCC(CC1)C2=C(C=C3[C@H](CCC3=C2)C(=O)O)Cl,,,,,,
109,120110,13-Tetradecen-1-ol,C=CCCCCCCCCCCCCO,,,,,,
110,120111,"Phenol, 2-isononyl-4-methyl-",CC1=CC(=C(C=C1)O)CCCCCCC(C)C,,,,,,
111,120112,"Nickel, bis[1,2-diphenyl-1,2-ethenedithiolato(2-)-kappaS,kappaS']-, (SP-4-1)-",C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[S-])[S-].C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[S-])[S-].[Ni],,,,,,
112,120113,"4-Dodecyl-2,6-dimethylbenzenesulfonic acid",CCCCCCCCCCCCC1=CC(=C(C(=C1)C)S(=O)(=O)O)C,,,,,,
113,120114,Bis(dodecylphenyl) disulphide,CCCCCCCCCCCCC1=CC=C(C=C1)SSC2=CC=C(C=C2)CCCCCCCCCCCC,,,,,,
114,120115,"DL-Proline, 5-oxo-, pentachlorophenyl ester",C1CC(=O)NC1C(=O)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
115,120116,N-(2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)phthalimide,CC1=NC=C(N1CCN2C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],,,,,,
116,120117,"Silane, dimethylbis(octadecyloxy)-",CCCCCCCCCCCCCCCCCCO[Si](C)(C)OCCCCCCCCCCCCCCCCCC,,,,,,
117,120118,6-Phenylnicotinic acid,C1=CC=C(C=C1)C2=NC=C(C=C2)C(=O)O,,,,,,
118,120119,4-Cyanophenyl butyrate,CCCC(=O)OC1=CC=C(C=C1)C#N,,,,,,
119,120120,"Urea, (2-hydroxy-4-methylphenyl)-",CC1=CC(=C(C=C1)NC(=O)N)O,,,,,,
120,120121,"3,3,11,11-Tetramethoxy-2,12-dioxa-7-thia-3,11-disilatridecane",CO[Si](CCCSCCC[Si](OC)(OC)OC)(OC)OC,,,,,,
121,120122,Methyl 4-butoxyphenylacetate,CCCCOC1=CC=C(C=C1)CC(=O)OC,,,,,,
122,120123,CID 120123,CC1CCN(CC1)OC(=O)C2CCC3=C2C=CC(=C3)C4CCCCC4,,,,,,
123,120124,Ammonium heptadecafluorooctanesulphonate,C(C(C(C(C(F)(F)S(=O)(=O)O)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(F)F.N,,,,,,
124,120125,"2-Propanol, 1,3-dichloro-, phosphorothioate (3:1)",C(C(CCl)OP(=S)(OC(CCl)CCl)OC(CCl)CCl)Cl,,,,,,
125,120126,"2,4-Dichloroanilinium chloride",C1=CC(=C(C=C1Cl)Cl)N.Cl,,,,,,
126,120127,"1,1,4,4-Tetramethylbutane-1,4-diyl bis(isononaneperoxoate)",CC(C)CCCCCC(=O)OOC(C)(C)CCC(C)(C)OOC(=O)CCCCCC(C)C,,,,,,
127,120128,Monoethyl tetrabromoterephthalate,CCOC(=O)C1=C(C(=C(C(=C1Br)Br)C(=O)O)Br)Br,,,,,,
128,120129,"1H-Pyrazole-3-carboxylic acid, 4-((2,5-dimethoxy-4-((2-(sulfooxy)ethyl)sulfonyl)phenyl)azo)-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-",COC1=CC(=C(C=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)O)C(=O)O)OC)S(=O)(=O)CCOS(=O)(=O)O,,,,,,
129,120130,"Antimony, compd. with thallium (1:1)",[Sb]#[Tl],,,,,,
130,120131,"3-Pyridinecarboxamide, 1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-",CCN1C(=O)C=C(C(=C1O)C(=O)N)C,,,,,,
131,120132,"Acetamide, N-[5-[bis(phenylmethyl)amino]-2-[(2-chloro-4-nitrophenyl)azo]phenyl]-",CC(=O)NC1=C(C=CC(=C1)N(CC2=CC=CC=C2)CC3=CC=CC=C3)N=NC4=C(C=C(C=C4)[N+](=O)[O-])Cl,,,,,,
132,120133,"Acetamide, N-[3-[ethyl(phenylmethyl)amino]phenyl]-",CCN(CC1=CC=CC=C1)C2=CC=CC(=C2)NC(=O)C,,,,,,
133,120134,"Acetamide, N-[3-[(phenylmethyl)amino]phenyl]-",CC(=O)NC1=CC=CC(=C1)NCC2=CC=CC=C2,,,,,,
134,120135,"Acetamide, N-[3-[bis(phenylmethyl)amino]phenyl]-",CC(=O)NC1=CC(=CC=C1)N(CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
135,120136,"Ethyl 2-amino-4,5-dihydro-3-furoate",CCOC(=O)C1=C(OCC1)N,,,,,,
136,120137,"2',5'-Difluoropropiophenone",CCC(=O)C1=C(C=CC(=C1)F)F,,,,,,
137,120138,5-Chloro-2-(methylsulfonyl)aniline,CS(=O)(=O)C1=C(C=C(C=C1)Cl)N,,,,,,
138,120139,(Methylidynetris(oxymethylene))trisbenzene,C1=CC=C(C=C1)COC(OCC2=CC=CC=C2)OCC3=CC=CC=C3,,,,,,
139,120140,Dodecylhydroxyoxostannane,CCCCCCCCCCCC[Sn](=O)O,,,,,,
140,120141,"Diethyl (2-(4,6-diamino-1,3,5-triazin-2-yl)ethyl)phosphonate",CCOP(=O)(CCC1=NC(=NC(=N1)N)N)OCC,,,,,,
141,120142,"4-Iodo-4'-nitro-1,1'-biphenyl",C1=CC(=CC=C1C2=CC=C(C=C2)I)[N+](=O)[O-],,,,,,
142,120143,p-Nitrophenylsulfonylurea,C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)NC(=O)N,,,,,,
143,120144,"Pyridine-2,4-dicarbonitrile",C1=CN=C(C=C1C#N)C#N,,,,,,
144,120145,Methacrylamide sulphate,CC(=C)C(=O)N.OS(=O)(=O)O,,,,,,
145,120146,5-Chloro-2-hydroxy-3-((3-methyl-5-oxo-1-(m-sulphophenyl)-2-pyrazolin-4-yl)azo)benzenesulphonic acid,CC1=NN(C(=O)C1N=NC2=C(C(=CC(=C2)Cl)S(=O)(=O)O)O)C3=CC(=CC=C3)S(=O)(=O)O,,,,,,
146,120147,"N,N'-Dimethyl-N-phenylhydrazine",CNN(C)C1=CC=CC=C1,,,,,,
147,120148,CID 120148,CC1=CC(=O)OC2=C1C=CC(=C2)NCS(=O)(=O)[O-].[Na+],,,,,,
148,120149,"Coumarin, 4-methyl-7-[(sulfomethyl)amino]-",CC1=CC(=O)OC2=C1C=CC(=C2)NCS(=O)(=O)O,,,,,,
149,120150,"3',6'-Bis(diethylamino)-2-(4-nitrophenyl)spiro(1H-isoindole-1,9'-(9H)xanthene)-3(2H)-one",CCN(CC)C1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)N(CC)CC)C5=CC=CC=C5C(=O)N3C6=CC=C(C=C6)[N+](=O)[O-],,,,,,
150,120151,"2-Methyl-2H-1,2-benzothiazin-3(4H)-one 1,1-dioxide",CN1C(=O)CC2=CC=CC=C2S1(=O)=O,,,,,,
151,120152,"Methyl 3,4-dihydro-2-methyl-4-oxo-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide",CN1C(C(=O)C2=CC=CC=C2S1(=O)=O)C(=O)OC,,,,,,
152,120153,"2,6-Dimethyloct-7-yne-2,6-diol",CC(C)(CCCC(C)(C#C)O)O,,,,,,
153,120154,"2,6-Dimethyloct-7-ene-2,6-diol",CC(C)(CCCC(C)(C=C)O)O,,,,,,
154,120155,CID 120155,C1=CC=C(C=C1)N2C=C(C(=CC=CC3=C(NN(C3=O)C4=CC=CC=C4)C(=O)O)C2=O)C(=O)O,,,,,,
155,120156,"1-(2,6-Xylyl)biguanide",CC1=C(C(=CC=C1)C)N=C(N)N=C(N)N,,,,,,
156,120157,N-(2-Fluorophenyl)anthranilic acid,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC=C2F,,,,,,
157,120158,N-(3-Fluorophenyl)anthranilic acid,C1=CC=C(C(=C1)C(=O)O)NC2=CC(=CC=C2)F,,,,,,
158,120159,N-(4-Fluorophenyl)anthranilic acid,C1=CC=C(C(=C1)C(=O)O)NC2=CC=C(C=C2)F,,,,,,
159,120160,Histamine hydrochloride,C1=C(NC=N1)CCN.Cl,,,['Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (See all compounds classified as Histamine Agonists.)'],,,
160,120161,"Ethanamine, N,N-diethyl-2-(4-(6-methoxy-2-phenyl-1H-inden-3-yl)phenoxy)-, hydrochloride",CCN(CC)CCOC1=CC=C(C=C1)C2=C(CC3=C2C=CC(=C3)OC)C4=CC=CC=C4.Cl,,,,,,
161,120162,2-[p-(6-Methoxy-2-phenylinden-3-yl)-phenoxy]-triethylamine,CCN(CC)CCOC1=CC=C(C=C1)C2=C(CC3=C2C=CC(=C3)OC)C4=CC=CC=C4,,,,,,
162,120163,Azapetine hydrochloride,C=CCN1CC2=CC=CC=C2C3=CC=CC=C3C1.Cl,,,,,,
163,120164,"5,5'-(o-Hydroxybenzylidene)dibarbituric acid disodium salt",C1=CC=C(C(=C1)C(C2C(=O)NC(=O)N=C2[O-])C3C(=O)NC(=O)N=C3[O-])O.[Na+].[Na+],,,,,,
164,120165,"5,5'-[(2-Hydroxyphenyl)methylene]bis[2,4,6(1H,3H,5H)-pyrimidinetrione]",C1=CC=C(C(=C1)C(C2C(=O)NC(=O)NC2=O)C3C(=O)NC(=O)NC3=O)O,,,,,,
165,120166,CID 120166,C1=CC2=C(C(=C1)O)NC3=CC=CC(=O)C3=N2,,,,,,
166,120167,"Phosphoric acid, 2,2-dichlorovinyl diisobutyl ester",CC(C)COP(=O)(OCC(C)C)OC=C(Cl)Cl,,,,,,
167,120168,"Phosphoric acid, 2,2-dichloroethenyl dipropyl ester",CCCOP(=O)(OCCC)OC=C(Cl)Cl,,,,,,
168,120169,1-(2-Phenoxyethyl)piperidine,C1CCN(CC1)CCOC2=CC=CC=C2,,,,,,
169,120170,"6-Oxo-6H-anthra(9,1-cd)isothiazole-3-carboxylic acid",C1=CC=C2C(=C1)C3=NSC4=C(C=CC(=C43)C2=O)C(=O)O,,,,,,
170,120171,Tetrophan,C1CC2=C(C3=CC=CC=C3N=C2C4=CC=CC=C41)C(=O)O,,,,,,
171,120172,Bis(hydroxyphenylmethyl)phosphinic acid,C1=CC=C(C=C1)C(O)P(=O)(C(C2=CC=CC=C2)O)O,,,,,,
172,120173,"1H-Inden-5-ol, 2,3-dihydro-, methylcarbamate",CNC(=O)OC1=CC2=C(CCC2)C=C1,,,,,,
173,120174,American cyanamid CL-38106,CNS(=O)(=O)C1=CC=C(C=C1)OP(=S)(OC)OC,,,,,,
174,120175,Plegarol,CC[N+](C)(CC)CCOCC[N+]1(CCCC1)C.[I-].[I-],,,,,,
175,120176,Diethyl-methyl-[2-[2-(1-methylpyrrolidin-1-ium-1-yl)ethoxy]ethyl]azanium,CC[N+](C)(CC)CCOCC[N+]1(CCCC1)C,,,,,,
176,120177,Calcium propanearsonate,CCC[As](=O)([O-])[O-].[Ca+2],,,,,,
177,120178,Solupront,C1=CC(=CC=C1N)S(=O)(=O)NCS(=O)(=O)O.C(CO)N(CCO)CCO,,,,,,
178,120179,"Methanesulfonic acid, [[(4-aminophenyl)sulfonyl]amino]-",C1=CC(=CC=C1N)S(=O)(=O)NCS(=O)(=O)O,,,,,,
179,120180,"Hydrazine, (2,5-dimethoxybenzyl)-",COC1=CC(=C(C=C1)OC)CNN,,,,,,
180,120181,Piperazine hexahydrate,C1CNCCN1.O.O.O.O.O.O,,,['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)'],,,
181,120182,Amylamine hydrochloride,CCCCCN.Cl,,,,,,
182,120183,Morpholine salicylate,C1COCCN1.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
183,120184,(2-Ethoxyphenyl)urea,CCOC1=CC=CC=C1NC(=O)N,,,,,,
184,120185,Butacaine sulfate,CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)O,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
185,120186,o-Chloro-beta-phenylethylhydrazine dihydrogen sulphate,C1=CC=C(C(=C1)CCNN)Cl.OS(=O)(=O)O,,,,,,
186,120187,1-[2-(2-Chlorophenyl)ethyl]hydrazine,C1=CC=C(C(=C1)CCNN)Cl,,,,,,
187,120188,"2,3,4,8,9,10-Hexathiospiro(5.5)undecane",C1C2(CSSS1)CSSSC2,,,,,,
188,120189,Perimidine,C1=CC2=C3C(=C1)NC=NC3=CC=C2,,,,,,
189,120190,"2H-Naphtho(1,8-bc)thiophene",C1C2=CC=CC3=C2C(=CC=C3)S1,,,,,,
190,120191,"4,7-Methanoindene",C1C=CC2=C3CC(=C21)C=C3,,,,,,
191,120192,"12-Azahexacyclo[14.6.1.02,14.05,13.06,11.019,23]tricosa-1(22),2(14),3,5(13),6,8,10,15,17,19(23),20-undecaene",C1=CC=C2C(=C1)C3=C(N2)C4=C(C=C3)C5=CC=CC6=C5C(=C4)C=C6,,,,,,
192,120193,1H-Benzo(a)cyclopent(h)anthracene,C1C=CC2=C1C3=CC4=C(C=C3C=C2)C5=CC=CC=C5C=C4,,,,,,
193,120194,"6H,13H-Pyrazino(1,2-a:4,5-a')bisbenzimidazole",C1C2=NC3=CC=CC=C3N2CC4=NC5=CC=CC=C5N41,,,,,,
194,120195,Cyclotriphosphazene,N1=PN=PN=P1,,,,,,
195,120196,"1,4,7,10,13-Pentaazacyclopentadecane",C1CNCCNCCNCCNCCN1,,,,,,
196,120197,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-ethyl-",CCNP(=O)(N1CC1)N2CC2,,,,,,
197,120198,CID 120198,CCCCCCCCCC[N+]1(CCCC1)CCOC(=O)C=CC2=CC=CC3=CC=CC=C32.[Br-],,,,,,
198,120199,CID 120199,CCCCCCCCCC[N+]1(CCCC1)CCOC(=O)C=CC2=CC=CC3=CC=CC=C32,,,,,,
199,120200,2-Allyloxy-3-methylbenzamide,CC1=C(C(=CC=C1)C(=O)N)OCC=C,,,,,,
200,120201,Plasmocid dihydriodide,CCN(CC)CCCNC1=C2C(=CC(=C1)OC)C=CC=N2.I.I,,,,,,
201,120202,Plasmocid,CCN(CC)CCCNC1=C2C(=CC(=C1)OC)C=CC=N2,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,,
202,120203,Perfluorodecane,C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,['Fluorine-19 NMR spectra of various bodily fluids and liver in vivo display resonances of the parent PFOA or PFDA compounds and do not reveal any evidence of metabolism. Inorganic fluoride from dietary sources is detected in urine from both exposed and control rats. Differences in the route of excretion of PFOA vs PFDA are apparent. The data suggest that PFOA is more readily excreted in the urine while PFDA is preferentially carried in bile. These apparent differences in elimination may account for their observed differences in effective toxicity. The acute transient toxicity and higher LD50 associated with PFOA may result from its rapid renal clearance.'],"['Metabolism studies were conducted using Fischer 344 and Sprague-Dawley rats following inhalation exposure to 1.0% (v/v) air atmospheres of /halon replacement candidates including/ perfluorohexane (PFH) for 2 h. There were no remarkable differences in results between the two strains of rats. For PFH studies, no metabolites were detected in the urine or tissues of exposed animals.']",
203,120204,CID 120204,C[N+]1(CCCCC1)C=CC2=CC=CC=C2.[I-],,,,,,
204,120205,CID 120205,C[N+]1(CCCCC1)C=CC2=CC=CC=C2,,,,,,
205,120206,"2,6-Methano-4H-1,4-benzoxazocine",C1C2=CNC=C1OC3=CC=CC=C23,,,,,,
206,120207,2-(3-Fluorophenyl)-1H-benzimidazole,C1=CC=C2C(=C1)NC(=N2)C3=CC(=CC=C3)F,,,,,,
207,120208,"Piperidine, 1-fluoroacetyl-",C1CCN(CC1)C(=O)CF,,,,,,
208,120209,"Heptane, 1-chloro-7-fluoro-",C(CCCF)CCCCl,,,,,,
209,120210,Perfluoroisobutyric acid,C(=O)(C(C(F)(F)F)(C(F)(F)F)F)O,,,,,,
210,120211,"3-Chloro-1,1-difluoropropane",C(CCl)C(F)F,,,,,,
211,120212,p-Fluorophenylphosphonic acid bis(2-(dimethylamino)ethyl) ester,CN(C)CCOP(=O)(C1=CC=C(C=C1)F)OCCN(C)C,,,,,,
212,120213,"Phenothiazine, 4-(trifluoromethyl)-",C1=CC=C2C(=C1)NC3=CC=CC(=C3S2)C(F)(F)F,,,,,,
213,120214,CID 120214,C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])CC=C(C(F)(F)F)C(F)(F)F,,,,,,
214,120215,CID 120215,CC(=NC1=CC=C(C=C1)F)S,,,,,,
215,120216,Dimethylsulfamoyl fluoride,CN(C)S(=O)(=O)F,,,,,,
216,120217,CID 120217,CCOP(=O)(O)F.[KH],,,,,,
217,120218,Ethoxy(fluoro)phosphinic acid,CCOP(=O)(O)F,,,,,,
218,120219,Difluoroacetonitrile,C(#N)C(F)F,,,,,,
219,120220,"2H-1,2,4-Benzothiadiazine, 3,4-dihydro-, 1,1-dioxide",C1NC2=CC=CC=C2S(=O)(=O)N1,,,,,,
220,120221,"2H-1,2,4-Benzothiadiazine, 3,4-dihydro-6,7-dichloro-, 1,1-dioxide",C1NC2=CC(=C(C=C2S(=O)(=O)N1)Cl)Cl,,,,,,
221,120222,"6,7-Dichloro-2H-1,2,4-benzothiadiazine 1,1-dioxide",C1=C2C(=CC(=C1Cl)Cl)S(=O)(=O)N=CN2,,,,,,
222,120223,Fluorothion,COP(=S)(OC)OC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,,,,,,
223,120224,"2H-1,2,4-Benzothiadiazine, 6,7-dichloro-3-methyl-, 1,1-dioxide",CC1=NS(=O)(=O)C2=CC(=C(C=C2N1)Cl)Cl,,,,,,
224,120225,"Chlorosulfuric acid, (2-fluoroethyl) ester",C(CF)OS(=O)(=O)Cl,,,,,,
225,120226,1H-Perfluorodecane,C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
226,120227,Octafluoropentanoic acid,C(C(C(C(C(=O)O)(F)F)(F)F)(F)F)(F)F,,,,,,
227,120228,"Propionic acid, 2,2,3,3-tetrafluoro-3-(trifluoromethoxy)-",C(=O)(C(C(OC(F)(F)F)(F)F)(F)F)O,,,,,,
228,120229,6-methyl-2-(trifluoromethyl)-1H-benzimidazole,CC1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
229,120230,Methyl 3-fluoropyruvate,COC(=O)C(=O)CF,,,,,,
230,120231,4-Fluorobenzenesulfonamide,C1=CC(=CC=C1F)S(=O)(=O)N,,,,,,
231,120232,5-Fluoronicotinic acid,C1=C(C=NC=C1F)C(=O)O,,,,,,
232,120233,p-Fluoro-N-methylphenethylamine hydrochloride,CNCCC1=CC=C(C=C1)F.Cl,,,,,,
233,120234,2-(4-fluorophenyl)-N-methylethanamine,CNCCC1=CC=C(C=C1)F,,,,,,
234,120235,5-Fluoropentanoic acid,C(CCF)CC(=O)O,,,,,,
235,120236,1-Bromo-5-fluoropentane,C(CCF)CCBr,,,,,,
236,120237,"Propanoyl fluoride, 2,2,3,3-tetrafluoro-3-(trifluoromethoxy)-",C(=O)(C(C(OC(F)(F)F)(F)F)(F)F)F,,,,,,
237,120238,CID 120238,CC[SnH](CC)CC.C(=O)(C(F)(F)F)O,,,,,,
238,120239,"P(sup III),P(sup III)-Diethyl P(sup V),P(sup V)-dimethyl thiodiphosphorate",CCOP(OCC)OP(=S)(OC)OC,,,,,,
239,120240,Ethyl methyl phosphorofluoridate,CCOP(=O)(OC)F,,,,,,
240,120241,"Benzanilide, N-(2-morpholinoethyl)-4-nitro-, hydrochloride",C1COCCN1CCN(C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-].Cl,,,,,,
241,120242,N-(2-Morpholinoethyl)-4-nitrobenzanilide,C1COCCN1CCN(C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
242,120243,CID 120243,C1=CC=C(C=C1)C2=NNC(=NC2=O)S,,,,,,
243,120244,N-Benzyl-N-(2-morpholinoethyl)-p-nitrobenzamide hydrochloride,C1COCCN1CCN(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-].Cl,,,,,,
244,120245,N-benzyl-N-[2-(morpholin-4-yl)ethyl]-4-nitrobenzamide,C1COCCN1CCN(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
245,120246,2-Amino-4-(trifluoromethyl)phenol,C1=CC(=C(C=C1C(F)(F)F)N)O,,,,,,
246,120247,Methyl 5-fluoronicotinate,COC(=O)C1=CC(=CN=C1)F,,,,,,
247,120248,2-Chloro-4'-fluoroacetophenone,C1=CC(=CC=C1C(=O)CCl)F,,,,,,
248,120249,Ethyl 7-fluoroheptanoate,CCOC(=O)CCCCCCF,,,,,,
249,120250,"Phosphorodifluoridic acid, ethyl ester",CCOP(=O)(F)F,,,,,,
250,120251,Ethyl difluorothionophosphate,CCOP(=S)(F)F,,,,,,
251,120252,"1-Propene, 1,1-dichloro-3,3,3-trifluoro-",C(=C(Cl)Cl)C(F)(F)F,,,,,,
252,120253,"Choline, bromide, fluoroacetate",C[N+](C)(C)CCOC(=O)CF.[Br-],,,,,,
253,120254,2-(2-Fluoroacetyl)oxyethyl-trimethylazanium,C[N+](C)(C)CCOC(=O)CF,,,,,,
254,120255,9-Fluorononanoic acid,C(CCCCF)CCCC(=O)O,,,,,,
255,120256,1-Bromo-11-fluoroundecane,C(CCCCCF)CCCCCBr,,,,,,
256,120257,11-Fluoro-1-undecanol,C(CCCCCO)CCCCCF,,,,,,
257,120258,"Phosphinic acid, bis(1-aziridinyl)-, methyl ester",COP(=O)(N1CC1)N2CC2,,,,,,
258,120259,"Phosphinic acid, bis(1-aziridinyl)-, ethyl ester",CCOP(=O)(N1CC1)N2CC2,,,,,,
259,120260,"o,o-Diethyl o,o-dimethyl thiodiphosphate",CCOP(=O)(OCC)OP(=S)(OC)OC,,,,,,
260,120261,"N,N-Bis(2-iodoethyl)methanesulfonamide",CS(=O)(=O)N(CCI)CCI,,,,,,
261,120262,"Methanesulfonamide, N,N-bis(2-(methylsulfonyloxy)ethyl)-",CS(=O)(=O)N(CCOS(=O)(=O)C)CCOS(=O)(=O)C,,,,,,
262,120263,CID 120263,C1=CC(=C(C=C1C2=COC3=CC(=O)C=C(C3=C2O)O)O)O,,,,,,
263,120264,"1,2,5,6-Tetrahydro-4H-pyrrolo(3,2,1-ij)quinoline",C1CC2=C3C(=CC=C2)CCN3C1,,,,,,
264,120265,CID 120265,COC1=CC=C(C=C1)C2=C(OC(=C(C3=CC=CC=C3)C(=O)OC)C2=O)O,,,,,,
265,120266,6-(Hydroxymethyl)-9-methoxyphenazine-1-carboxylic acid,COC1=CC=C(C2=NC3=CC=CC(=C3N=C12)C(=O)O)CO,,,,,,
266,120267,Thiamine thiazolone,CC1=C(SC(=O)N1CC2=CN=C(N=C2N)C)CCO,,,,,,
267,120268,CID 120268,C1=CC=C(C(=C1)C(=O)[O-])F.[Na+],,,,,,
268,120269,Thiazoline,C1CSC=N1,,,,,,
269,120270,Ethyl-ammonium sulfate,CCN.CCN.OS(=O)(=O)O,,,,,,
270,120271,"3',6'-Diaminofluoran",C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)N)OC5=C3C=CC(=C5)N,,,,,,
271,120272,"Ethyl 1,1,2,2-tetrafluoroethyl ether",CCOC(C(F)F)(F)F,,,,,,
272,120273,N-Iodosuccinimide,C1CC(=O)N(C1=O)I,,,,,,
273,120274,"1-Propanone, 1-(2,5-diphenyl-3-furyl)-3-morpholino-, hydrochloride",C1COCCN1CCC(=O)C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4.Cl,,,,,,
274,120275,"1-(2,5-Diphenylfuran-3-yl)-3-morpholin-4-ylpropan-1-one",C1COCCN1CCC(=O)C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
275,120276,Phenocaine,CCCCNC1=CC(=C(C=C1)O)C(=O)OCCN(CC)CC.Cl,,,,,,
276,120277,2-(Diethylamino)ethyl 5-(butylamino)-2-hydroxybenzoate,CCCCNC1=CC(=C(C=C1)O)C(=O)OCCN(CC)CC,,,,,,
277,120278,Quinolinium thiocyanate,C1=CC=C2C(=C1)C=CC=N2.C(#N)S,,,,,,
278,120279,p-Phenylenediamine hydrochloride,C1=CC(=CC=C1N)N.Cl,,,,,,
279,120280,"1,3-Thiazinane",C1CNCSC1,,,,,,
280,120281,CID 120281,C#CC#CC=C=CC=CC=CCC(=O)O,,,,,,
281,120282,Phenazine-1-carboxamide,C1=CC=C2C(=C1)N=C3C=CC=C(C3=N2)C(=O)N,,,,,,
282,120283,"p-Aminosalicylic acid, 2-(diethylamino)ethyl ester hydrochloride",CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)O.Cl,,,,,,
283,120284,"1-Propanone, 1-(2,5-diphenyl-3-furyl)-3-(4-methyl-1-piperazinyl)-, dihydrochloride",CN1CCN(CC1)CCC(=O)C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl,,,,,,
284,120285,"1-(2,5-Diphenylfuran-3-yl)-3-(4-methylpiperazin-1-yl)propan-1-one",CN1CCN(CC1)CCC(=O)C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
285,120286,Dimethocaine hydrochloride,CCN(CC)CC(C)(C)COC(=O)C1=CC=C(C=C1)N.Cl,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
286,120287,CID 120287,C(=C(C=NO)NO)N=O,,,,,,
287,120288,"Phosphonic acid, piperidino-, monomethyl ester, anhydride with diethyl phosphite",CCOP(OCC)OP(=O)(N1CCCCC1)OC,,,,,,
288,120289,"Phosphonic acid, morpholino-, methyl ester, anhydride with diethyl phosphite",CCOP(OCC)OP(=O)(N1CCOCC1)OC,,,,,,
289,120290,Aspidin,CCCC(=O)C1=C(C(=C(C(C1=O)(C)C)O)CC2=C(C(=C(C(=C2O)C)OC)C(=O)CCC)O)O,,,,,,
290,120291,"1-Pentanol, 5-fluoro-",C(CCO)CCF,,,,,,
291,120292,"Phosphonic acid, morpholino-, methyl ester, anhydride with dimethyl phosphate",COP(=O)(N1CCOCC1)OP(=O)(OC)OC,,,,,,
292,120293,"3,3-Dibromo-2-oxopropanoic acid",C(C(=O)C(=O)O)(Br)Br,,,,,,
293,120294,But-2-enedioic acid;10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.C(=CC(=O)O)C(=O)O,,,,,,
294,120295,CID 120295,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)NCC(=O)N(CCO)CCO,,,,,,
295,120296,CID 120296,CCC(=C(C)O)N=O,,,,,,
296,120297,N-(3-(Diethylamino)propyl)-2-((4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy)acetamide,CCN(CC)CCCNC(=O)COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
297,120298,CID 120298,C1CCN(CC1)CCCNC(=O)COC2=CC3=C(C=C2)C(=O)C=C(O3)C4=CC=CC=C4,,,,,,
298,120299,CID 120299,CCOC(=O)OCCC(=C(C)N(CC1=CN=C(N=C1N)C)C=O)SC(=O)OCC.Cl,,,,,,
299,120300,"1,1-Dibutylurea",CCCCN(CCCC)C(=O)N,,,,,,
300,120301,1-Benzyl-2-phenylhydrazine hydrochloride,C1=CC=C(C=C1)CNNC2=CC=CC=C2.Cl,,,,,,
301,120302,1-Benzyl-2-phenylhydrazine,C1=CC=C(C=C1)CNNC2=CC=CC=C2,,,,,,
302,120303,1-Ethoxy-3-methylbutane,CCOCCC(C)C,,,,,,
303,120304,Chromous acetate,CC(=O)[O-].CC(=O)[O-].[Cr+2],,,,,,
304,120305,"Allylphosphonic acid 2,2-dichlorovinyl propyl ester",CCCOP(=O)(CC=C)OC=C(Cl)Cl,,,,,,
305,120306,"Allylphosphonic acid 2,2-dichlorovinyl hexyl ester",CCCCCCOP(=O)(CC=C)OC=C(Cl)Cl,,,,,,
306,120307,"4-((4-Hydroxy-3-methylphenyl)(4-hydroxyphenyl)methylene)cyclohexa-2,5-dien-1-one",CC1=C(C=CC(=C1)C(=C2C=CC(=O)C=C2)C3=CC=C(C=C3)O)O,,,,,,
307,120308,3-(Methylsulfonyl)propanoic acid,CS(=O)(=O)CCC(=O)O,,,,,,
308,120309,"3,3-Dimethylbutyl methylphosphonofluoridate",CC(C)(C)CCOP(=O)(C)F,,,,,,
309,120310,Diallylphosphinic acid isopropyl ester,CC(C)OP(=O)(CC=C)CC=C,,,,,,
310,120311,Diallylphosphinic acid propyl ester,CCCOP(=O)(CC=C)CC=C,,,,,,
311,120312,Diallylphosphinic acid pentyl ester,CCCCCOP(=O)(CC=C)CC=C,,,,,,
312,120313,4-Methylsulfonylbenzenesulfonamide,CS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)N,,,,,,
313,120314,"2,4-Dichloro-3,5-dimethylphenyl methylcarbamate",CC1=CC(=C(C(=C1Cl)C)Cl)OC(=O)NC,,,,,,
314,120315,Giareg,CC(=O)C1=C(C=CC(=C1)NC(=O)C)OCCOC,,,,,,
315,120316,"4-Morpholineacetamide, N-(5-ethyl-2-methylphenyl)-",CCC1=CC(=C(C=C1)C)NC(=O)CN2CCOCC2,,,,,,
316,120317,"Ethane, 1,1-dichloro-1-nitroso-",CC(N=O)(Cl)Cl,,,,,,
317,120318,"Ethane, 1,1,2-trichloro-2,2-difluoro-1-iodo-",C(C(Cl)(Cl)Cl)(F)(F)I,,,,,,
318,120319,"3-Chloro-1,1,2,2-tetrafluoropropane",C(C(C(F)F)(F)F)Cl,,,,,,
319,120320,"Phosphonothioic acid, methyl-, O,O-dimethyl ester",COP(=S)(C)OC,,,,,,
320,120321,"S,S,S-Trimethyl phosphorotrithioate",CSP(=O)(SC)SC,,,,,,
321,120322,"Trichloromethylphosphonic acid bis(2,2,2-trichloroethyl) ester",C(C(Cl)(Cl)Cl)OP(=O)(C(Cl)(Cl)Cl)OCC(Cl)(Cl)Cl,,,,,,
322,120323,Tributyltin isocyanate,CCCC[Sn](CCCC)(CCCC)N=C=O,,,,,,
323,120324,Diethyl trichloroethyl phosphate,CCOP(=O)(OCC)OCC(Cl)(Cl)Cl,,,,,,
324,120325,Dibutyl trichloroethyl phosphate,CCCCOP(=O)(OCCCC)OCC(Cl)(Cl)Cl,,,,,,
325,120326,"O,O-Diethyl O-(2-(methylthio)ethyl) phosphorothioate",CCOP(=S)(OCC)OCCSC,,,,,,
326,120327,Diethyl trichloropentyl phosphate,CCOP(=O)(OCC)OCCCCC(Cl)(Cl)Cl,,,,,,
327,120328,CID 120328,COC(=O)CC(=N)S,,,,,,
328,120329,1-Acetyl-2-(mercaptoacetyl)hydrazine,CC(=O)NNC(=O)CS,,,,,,
329,120330,Tetramethylpyrophosphate,COP(=O)(OC)OP(=O)(OC)OC,,,,,,
330,120331,"Methylphosphonic acid bis(5,5,5-trichloropentyl) ester",CP(=O)(OCCCCC(Cl)(Cl)Cl)OCCCCC(Cl)(Cl)Cl,,,,,,
331,120332,"1-Methoxy-2,5-dihydro-1h-phosphole 1-oxide",COP1(=O)CC=CC1,,,,,,
332,120333,1-Methoxy-2-phospholene 1-oxide,COP1(=O)CCC=C1,,,,,,
333,120334,"1H-Phosphole, 1-ethoxy-2,5-dihydro-, 1-oxide",CCOP1(=O)CC=CC1,,,,,,
334,120335,"1H-Phosphole, 1-ethoxy-2,3-dihydro-, 1-oxide",CCOP1(=O)CCC=C1,,,,,,
335,120336,"3,4-Dimethyl-1-hydroxy-3-phospholene 1-oxide",CC1=C(CP(=O)(C1)O)C,,,,,,
336,120337,Chloroethylphenylarsine,CC[As](C1=CC=CC=C1)Cl,,,,,,
337,120338,4-Nitrosoresorcinol,C1=CC(=C(C=C1O)O)N=O,,,,,,
338,120339,2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine oxime,CC1=NC=C(C(=C1O)C=NO)CO,,,,,,
339,120340,"4H-3,1-Benzoxazin-4-one, 7-chloro-2-methyl-",CC1=NC2=C(C=CC(=C2)Cl)C(=O)O1,,,,,,
340,120341,1-Chloro-4-(2-nitroprop-1-enyl)benzene,CC(=CC1=CC=C(C=C1)Cl)[N+](=O)[O-],,,,,,
341,120342,"1,3-Diazaspiro(4.7)dodecane-2,4-dione, 3-methyl-",CN1C(=O)C2(CCCCCCC2)NC1=O,,,,,,
342,120343,"Xanthine, 1,3,8,8-tetramethyl-",CC1(N=C2C(=N1)N(C(=O)N(C2=O)C)C)C,,,,,,
343,120344,5-Hexylpicolinic acid,CCCCCCC1=CN=C(C=C1)C(=O)O,,,,,,
344,120345,"1,3-Bis(2-methoxypropan-2-yl)benzene",CC(C)(C1=CC(=CC=C1)C(C)(C)OC)OC,,,,,,
345,120346,"O,O-Dimethyl O-(6-nitro-m-tolyl) phosphorothioate",CC1=CC(=C(C=C1)[N+](=O)[O-])OP(=S)(OC)OC,,,,,,
346,120347,"Acetamide, 2-o-phenetidino-N-propyl-",CCCNC(=O)CNC1=CC=CC=C1OCC,,,,,,
347,120348,"Phosphoric acid, 2-chloroethyl 2,4-dichlorophenyl methyl ester",COP(=O)(OCCCl)OC1=CC(=CC(=C1)Cl)Cl,,,,,,
348,120349,"Acetamide, 2-m-phenetidino-N-propyl-",CCCNC(=O)CNC1=CC(=CC=C1)OCC,,,,,,
349,120350,"N,N'-bis(3-methylphenyl)methanediimine",CC1=CC(=CC=C1)N=C=NC2=CC=CC(=C2)C,,,,,,
350,120351,2-((4-Ethoxyphenyl)amino)-N-isopropylacetamide,CCOC1=CC=C(C=C1)NCC(=O)NC(C)C,,,,,,
351,120352,"Acetamide, 2-((4-ethoxyphenyl)amino)-N-propyl-",CCCNC(=O)CNC1=CC=C(C=C1)OCC,,,,,,
352,120353,N-(Bis(1-aziridinyl)phosphinyl)-o-fluorobenzamide,C1CN1P(=O)(NC(=O)C2=CC=CC=C2F)N3CC3,,,,,,
353,120354,N-(Bis(1-aziridinyl)phosphinyl)-m-bromobenzamide,C1CN1P(=O)(NC(=O)C2=CC(=CC=C2)Br)N3CC3,,,,,,
354,120355,N-(Bis(1-aziridinyl)phosphinyl)-m-fluorobenzamide,C1CN1P(=O)(NC(=O)C2=CC(=CC=C2)F)N3CC3,,,,,,
355,120356,Fluorobenzotepa,C1CN1P(=O)(NC(=O)C2=CC=C(C=C2)F)N3CC3,,,,,,
356,120357,"2-Chloroethyl methyl 2,4,5-trichlorophenyl phosphate",COP(=O)(OCCCl)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
357,120358,"2-Chloroethyl 2,4-dichlorophenyl ethyl phosphate",CCOP(=O)(OCCCl)OC1=C(C=C(C=C1)Cl)Cl,,,,,,
358,120359,2-Chloroethyl methyl p-nitrophenyl phosphate,COP(=O)(OCCCl)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
359,120360,CID 120360,CCN(CC)CCCN=C(NC1=CC=CC=C1)S,,,,,,
360,120361,"Benzamide, N-(bis(1-aziridinyl)phosphinyl)-3,5-dibromo-",C1CN1P(=O)(NC(=O)C2=CC(=CC(=C2)Br)Br)N3CC3,,,,,,
361,120362,2-Chloroethyl ethyl p-nitrophenyl phosphate,CCOP(=O)(OCCCl)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
362,120363,2-Chloroethyl p-nitrophenyl propyl phosphate,CCCOP(=O)(OCCCl)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
363,120364,2-Chloroethyl isopropyl p-nitrophenyl phosphate,CCOP(=O)(OCCCl)OC1=C(C=C(C=C1)[N+](=O)[O-])C,,,,,,
364,120365,Butyl 2-chloroethyl p-nitrophenyl phosphate,CCCCOP(=O)(OCCCl)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
365,120366,"4-Morpholinebutyranilide, 2'-chloro-5'-ethyl-",CCC1=CC(=C(C=C1)Cl)NC(=O)CCCN2CCOCC2,,,,,,
366,120367,"4-Morpholinebutyranilide, 5'-ethyl-2'-fluoro-",CCC1=CC(=C(C=C1)F)NC(=O)CCCN2CCOCC2,,,,,,
367,120368,"N-(3,4-Dimethoxyphenyl)-3,4,5-trimethoxybenzamide",COC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C(=C2)OC)OC)OC)OC,,,,,,
368,120369,"Methyl 6,11-dihydro-6,11-dioxo-2-ethyl-5,7,9-trihydroxy-1-naphthacenecarboxylate",CCC1=C(C2=CC3=C(C(=C2C=C1)O)C(=O)C4=C(C=CC(=C4C3=O)O)O)C(=O)OC,,,,,,
369,120370,"1,1'-(p-Phenylenedimethylene)bis(4-benzylpiperazine) dimethiodide",CI.CI.C1CN(CCN1CC2=CC=CC=C2)CC3=CC=C(C=C3)CN4CCN(CC4)CC5=CC=CC=C5,,,,,,
370,120371,1-Benzyl-4-[[4-[(4-benzylpiperazin-1-yl)methyl]phenyl]methyl]piperazine,C1CN(CCN1CC2=CC=CC=C2)CC3=CC=C(C=C3)CN4CCN(CC4)CC5=CC=CC=C5,,,,,,
371,120372,"(2,4,6-Trioxo-s-triazinetriyl)tris(tributylstannane)",CCCC[Sn](CCCC)(CCCC)N1C(=O)N(C(=O)N(C1=O)[Sn](CCCC)(CCCC)CCCC)[Sn](CCCC)(CCCC)CCCC,,,,,,
372,120373,"1,1,1,7,7,7-Hexafluoro-4-methyl-2,6-bis(trifluoromethyl)hept-3-ene-2,6-diol",CC(=CC(C(F)(F)F)(C(F)(F)F)O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
373,120374,Diallylphosphinic acid ethyl ester,CCOP(=O)(CC=C)CC=C,,,,,,
374,120375,5-Ethylpicolinic acid,CCC1=CN=C(C=C1)C(=O)O,,,,,,
375,120376,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(4-chloro-2-pyrimidinyl)-",C1CN1P(=O)(NC2=NC=CC(=N2)Cl)N3CC3,,,,,,
376,120377,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(5-bromo-2-methyl-4-pyrimidinyl)-",CC1=NC=C(C(=N1)NP(=O)(N2CC2)N3CC3)Br,,,,,,
377,120378,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(6-methoxy-4-pyrimidinyl)-",COC1=NC=NC(=C1)NP(=O)(N2CC2)N3CC3,,,,,,
378,120379,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(6-methoxy-2-methyl-4-pyrimidinyl)-",CC1=NC(=CC(=N1)OC)NP(=O)(N2CC2)N3CC3,,,,,,
379,120380,CID 120380,CC(C)CC1=CC(=CC(=C1O)CC(C)C)C=NO,,,,,,
380,120381,"5,11-Dihydro-11-(dimethylamino)-6H-dibenz(b,e)azepin-6-one",CN(C)C1C2=CC=CC=C2C(=O)NC3=CC=CC=C13,,,,,,
381,120382,"4-Morpholinebutanamide, N-(5-ethyl-2-methylphenyl)-",CCC1=CC(=C(C=C1)C)NC(=O)CCCN2CCOCC2,,,,,,
382,120383,Tris(4-methylphenyl)phosphine Oxide,CC1=CC=C(C=C1)P(=O)(C2=CC=C(C=C2)C)C3=CC=C(C=C3)C,,,,,,
383,120384,"Dimethyl (1-(difluoromethyl)-2,2-difluoro-1-hydroxyethyl)phosphonate",COP(=O)(C(C(F)F)(C(F)F)O)OC,,,,,,
384,120385,Dibutyl trichloropentyl phosphate,CCCCOP(=O)(OCCCC)OCCCCC(Cl)(Cl)Cl,,,,,,
385,120386,"2,2-Dimethyl thiazolidine hydrochloride",CC1(NCCS1)C.Cl,,,,,,
386,120387,5-(2-Chloroethyl)-4-methyloxazole,CC1=C(OC=N1)CCCl,,,,,,
387,120388,n-Allyl-4-bromobenzenesulfonamide,C=CCNS(=O)(=O)C1=CC=C(C=C1)Br,,,,,,
388,120389,"2-(Chloromethyl)-2-[(4-chlorophenoxy)methyl]propane-1,3-diol",C1=CC(=CC=C1OCC(CO)(CO)CCl)Cl,,,,,,
389,120390,"2-[(4-Chlorophenoxy)methyl]-2-(hydroxymethyl)propane-1,3-diol",C1=CC(=CC=C1OCC(CO)(CO)CO)Cl,,,,,,
390,120391,N4-(2-Bromoethyl)-N4-ethylsulfanilamide,CCN(CCBr)C1=CC=C(C=C1)S(=O)(=O)N,,,,,,
391,120392,"2-(Chloromethyl)-2-((2,4-dichlorophenoxy)methyl)-1,3-propanediol",C1=CC(=C(C=C1Cl)Cl)OCC(CO)(CO)CCl,,,,,,
392,120393,"2-(Chloromethyl)-2-((2-naphthyloxy)methyl)-1,3-propanediol",C1=CC=C2C=C(C=CC2=C1)OCC(CO)(CO)CCl,,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,,
393,120394,"Pyrrolidine, 1-(2-(2-(o-methoxyphenoxy)ethoxy)ethyl)-",COC1=CC=CC=C1OCCOCCN2CCCC2,,,,,,
394,120395,"Propionanilide, 3-(diethylamino)-5'-ethyl-2'-fluoro-",CCC1=CC(=C(C=C1)F)NC(=O)CCN(CC)CC,,,,,,
395,120396,1-(2-{2-[5-Methyl-2-(propan-2-yl)phenoxy]ethoxy}ethyl)pyrrolidine,CC1=CC(=C(C=C1)C(C)C)OCCOCCN2CCCC2,,,,,,
396,120397,"Piperazine, 1-(2-(2-(o-methoxyphenoxy)ethoxy)ethyl)-4-methyl-",CN1CCN(CC1)CCOCCOC2=CC=CC=C2OC,,,,,,
397,120398,CID 120398,C1=CC2=NC(=CC(=N)C2=CC1=N)C=CC3=CC=C(O3)N(O)O.Cl,,,,,,
398,120399,CID 120399,C1=CC2=NC(=CC(=N)C2=CC1=N)C=CC3=CC=C(O3)N(O)O,,,,,,
399,120400,"2,2-Bis[(4-chlorophenoxy)methyl]propane-1,3-diol",C1=CC(=CC=C1OCC(CO)(CO)COC2=CC=C(C=C2)Cl)Cl,,,,,,
400,120401,1-[2-(2-{2-[5-Methyl-2-(propan-2-yl)phenoxy]ethoxy}ethoxy)ethyl]pyrrolidine,CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCN2CCCC2,,,,,,
401,120402,"2,2'-Ethylenebis(1-(m-chlorophenyl)-2-thiopseudourea) dihydrobromide",C1=CC(=CC(=C1)Cl)N=C(N)SCCSC(=NC2=CC(=CC=C2)Cl)N.Br.Br,,,,,,
402,120403,2-[N'-(3-chlorophenyl)carbamimidoyl]sulfanylethyl N'-(3-chlorophenyl)carbamimidothioate,C1=CC(=CC(=C1)Cl)N=C(N)SCCSC(=NC2=CC(=CC=C2)Cl)N,,,,,,
403,120404,"Hydantoin, 3-((diethylamino)methyl)-5,5-diphenyl-",CCN(CC)CN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
404,120405,1-[2-(2-{2-[5-Methyl-2-(propan-2-yl)phenoxy]ethoxy}ethoxy)ethyl]piperidine,CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCN2CCCCC2,,,,,,
405,120406,"Morpholine, 4-(2-(2-(2-(thymyloxy)ethoxy)ethoxy)ethyl)-",CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCN2CCOCC2,,,,,,
406,120407,"Hydantoin, 5,5-diphenyl-3-(morpholinomethyl)-",C1COCCN1CN2C(=O)C(NC2=O)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
407,120408,"3,6,9-Trioxa-12-azatetradecane, 12-ethyl-1-(thymyloxy)-",CCN(CC)CCOCCOCCOCCOC1=C(C=CC(=C1)C)C(C)C,,,,,,
408,120409,"Pyrrolidine, 1-(2-(2-(2-(2-(thymyloxy)ethoxy)ethoxy)ethoxy)ethyl)-",CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCOCCN2CCCC2,,,,,,
409,120410,"Piperidine, 1-(2-(2-(2-(2-(thymyloxy)ethoxy)ethoxy)ethoxy)ethyl)-",CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCOCCN2CCCCC2,,,,,,
410,120411,4-{2-[2-(2-{2-[5-Methyl-2-(propan-2-yl)phenoxy]ethoxy}ethoxy)ethoxy]ethyl}morpholine,CC1=CC(=C(C=C1)C(C)C)OCCOCCOCCOCCN2CCOCC2,,,,,,
411,120412,CID 120412,CN(C)CCCOC1C2=CC=CC=C2CSC3=CC=CC=C13.C(=CC(=O)O)C(=O)O,,,,,,
412,120413,"3-(6,11-dihydrobenzo[c][1]benzothiepin-11-yloxy)-N,N-dimethylpropan-1-amine",CN(C)CCCOC1C2=CC=CC=C2CSC3=CC=CC=C13,,,,,,
413,120414,"1,1'-Hexane-1,6-diylbis(4-benzyl-1,4-dimethylpiperazinediium) tetraiodide",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C.[I-].[I-].[I-].[I-],,,,,,
414,120415,"1-Benzyl-4-[6-(4-benzyl-1,4-dimethylpiperazine-1,4-diium-1-yl)hexyl]-1,4-dimethylpiperazine-1,4-diium",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C,,,,,,
415,120416,"Piperazinium, 1,1'-octamethylenebis(4-benzyl-1,4-dimethyl-, tetraiodide",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C.[I-].[I-].[I-].[I-],,,,,,
416,120417,"1-Benzyl-4-[8-(4-benzyl-1,4-dimethylpiperazine-1,4-diium-1-yl)octyl]-1,4-dimethylpiperazine-1,4-diium",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C,,,,,,
417,120418,"Piperazinium, 1,1'-nonamethylenebis(4-benzyl-1,4-dimethyl-, tetraiodide",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C.[I-].[I-].[I-].[I-],,,,,,
418,120419,"1-Benzyl-4-[9-(4-benzyl-1,4-dimethylpiperazine-1,4-diium-1-yl)nonyl]-1,4-dimethylpiperazine-1,4-diium",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C,,,,,,
419,120420,Diethyl methyl phosphate,CCOP(=O)(OC)OCC,,,,,,
420,120421,AET dichloride,C(CSC(=N)N)N.Cl.Cl,,,,,,
421,120422,"Hydrazine, (3-(dimethylamino)propyl)-, dihydrochloride",CN(C)CCCNN.Cl.Cl,,,,,,
422,120423,[3-(Dimethylamino)propyl]hydrazine,CN(C)CCCNN,,,,,,
423,120424,CID 120424,C1=CC(=C(C(=C1)O)O)C(=O)[O-].[Na+],,,,,,
424,120425,O-(4-Methoxybenzyl)hydroxylamine hydrochloride,COC1=CC=C(C=C1)CON.Cl,,,,,,
425,120426,O-(4-Methoxybenzyl)hydroxylamine,COC1=CC=C(C=C1)CON,,,,,,
426,120427,3'-Chloromethylcyclohexanespiro-5'-hydantoin,C1CCC2(CC1)C(=O)N(C(=O)N2)CCl,,,,,,
427,120428,Antiphein,CNC(=O)C1=C(N(C=N1)C)C(=O)NC,,,,,,
428,120429,"4H-1,3-Thiazine, 5,6-dihydro-4,4-dimethyl-2-phenyl-",CC1(CCSC(=N1)C2=CC=CC=C2)C,,,,,,
429,120430,"1-Acetyl-1,3-diazaspiro[4.5]decane-2,4-dione",CC(=O)N1C(=O)NC(=O)C12CCCCC2,,,,,,
430,120431,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-4-pyrimidinyl-",C1CN1P(=O)(NC2=NC=NC=C2)N3CC3,,,,,,
431,120432,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-allyl-",C=CCN1C(=O)C2(CCCCC2)NC1=O,,,,,,
432,120433,"3-(2-Hydroxyethyl)-1,3-diazaspiro[4.5]decane-2,4-dione",C1CCC2(CC1)C(=O)N(C(=O)N2)CCO,,,,,,
433,120434,3'-Allyl-1'-methylcyclohexanespiro-5'-hydantoin,CN1C(=O)N(C(=O)C12CCCCC2)CC=C,,,,,,
434,120435,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(5-chloro-2-pyrimidinyl)-",C1CN1P(=O)(NC2=NC=C(C=N2)Cl)N3CC3,,,,,,
435,120436,"3-N,5-N,1-trimethylpyrazole-3,5-dicarboxamide",CNC(=O)C1=CC(=NN1C)C(=O)NC,,,,,,
436,120437,"Phosphorothioic acid, O,O-dimethyl O-(2-(fluoromethyl)-6-methyl-4-pyrimidinyl) ester",CC1=CC(=NC(=N1)CF)OP(=S)(OC)OC,,,,,,
437,120438,"1,3-Diazaspiro(4.6)undecane-2,4-dione, 1,3-bis(hydroxymethyl)-",C1CCCC2(CC1)C(=O)N(C(=O)N2CO)CO,,,,,,
438,120439,"Phosphinic amide, P,P-bis(1-aziridinyl)-N-(2,6-dimethyl-4-pyrimidinyl)-",CC1=CC(=NC(=N1)C)NP(=O)(N2CC2)N3CC3,,,,,,
439,120440,4-Amino-N-(2-methylphenyl)benzamide,CC1=CC=CC=C1NC(=O)C2=CC=C(C=C2)N,,,,,,
440,120441,2-(2-(Dimethylamino)ethyl)-6-phenyl-3(2H)-pyridazone hydrochloride,CN(C)CCN1C(C=CC(=N1)C2=CC=CC=C2)O.Cl,,,,,,
441,120442,2-[2-(dimethylamino)ethyl]-6-phenyl-3H-pyridazin-3-ol,CN(C)CCN1C(C=CC(=N1)C2=CC=CC=C2)O,,,,,,
442,120443,"1,3,5-Triazine, 2,4,6-tris(cyanomethoxy)-",C(C#N)OC1=NC(=NC(=N1)OCC#N)OCC#N,,,,,,
443,120444,"N,N-Dimethyl-delta-phenylbenzenebutanamine hydrochloride",CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2.Cl,,,,,,
444,120445,"N,N-Dimethyl-4,4-diphenyl-1-butanamine",CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
445,120446,"3-Amino-7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)N,,,,,,
446,120447,CID 120447,C1=C(OC(=C1)[N+](=O)[O-])C=CC2=NN=C(S2)N(CO)CO,,,,,,
447,120448,"6H-Dibenz(b,e)azepin-6-one, 5,11-dihydro-11-(diethylamino)-",CCN(CC)C1C2=CC=CC=C2C(=O)NC3=CC=CC=C13,,,,,,
448,120449,"3,4-Dihydro-9-(2-(dimethylamino)ethyl)-6-methoxy-9H-pyrido(3,4-b)indol-1(2H)-one",CN(C)CCN1C2=C(C=C(C=C2)OC)C3=C1C(=O)NCC3,,,,,,
449,120450,Phenylphosphonothioic acid O-ethyl O-(4-nitro-m-tolyl) ester,CCOP(=S)(C1=CC=CC=C1)OC2=CC(=C(C=C2)[N+](=O)[O-])C,,,,,,
450,120451,"6-Benzylthio-1,2,3,4-tetrahydro-1-oxo-beta-carboline",C1CNC(=O)C2=C1C3=C(N2)C=CC(=C3)SCC4=CC=CC=C4,,,,,,
451,120452,"Morpholine, 4-(2-(2-(thymyloxy)ethoxy)ethyl)-",CC1=CC(=C(C=C1)C(C)C)OCCOCCN2CCOCC2,,,,,,
452,120453,CID 120453,C1=CC(=O)C(=CC=C1N(O)O)N=NC(=O)C2=CC=C(O2)[N+](=O)[O-],,,,,,
453,120454,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-(2-hydroxyethyl)-1-(p-ethoxyphenyl)-",CCOC1=CC=C(C=C1)N2C(=O)N(C(=O)C23CCCCC3)CCO,,,,,,
454,120455,"Piperazine, 1-(2-(2-(2-(o-methoxyphenoxy)ethoxy)ethoxy)ethyl)-4-methyl-",CN1CCN(CC1)CCOCCOCCOC2=CC=CC=C2OC,,,,,,
455,120456,"2,2'-Butylenebis(1-(m-chlorophenyl)-2-thiopseudourea) dihydrobromide",C1=CC(=CC(=C1)Cl)N=C(N)SCCCCSC(=NC2=CC(=CC=C2)Cl)N.Br.Br,,,,,,
456,120457,4-[N'-(3-chlorophenyl)carbamimidoyl]sulfanylbutyl N'-(3-chlorophenyl)carbamimidothioate,C1=CC(=CC(=C1)Cl)N=C(N)SCCCCSC(=NC2=CC(=CC=C2)Cl)N,,,,,,
457,120458,CID 120458,C1=CC=C(C=C1)C(=O)O.C1=CC=C(C=C1)[SnH](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
458,120459,"2-Bromo-2,2-dinitroethanol",C(C([N+](=O)[O-])([N+](=O)[O-])Br)O,,,,,,
459,120460,CID 120460,C#CC(=O)[O-].[Na+],,,,,,
460,120461,Tridecylhexaethoxylate,CCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO,,,,,,
461,120462,"4,5-Dichloro-2-methylpyridazin-3(2h)-one",CN1C(=O)C(=C(C=N1)Cl)Cl,,,,,,
462,120463,"1,4-Diethynylbenzene",C#CC1=CC=C(C=C1)C#C,,,,,,
463,120464,"2,2,6,6-Tetramethylpiperidine hydrobromide",CC1(CCCC(N1)(C)C)C.Br,,,,,,
464,120465,"2,2,6,6-Tetramethylpiperidine hydrochloride",CC1(CCCC(N1)(C)C)C.Cl,,,,,,
465,120466,"2,2,6,6-Tetramethylpiperidine hydriodide",CC1(CCCC(N1)(C)C)C.I,,,,,,
466,120467,CID 120467,C1=CN=CC=C1C2=NC(=O)NN2,,,,,,
467,120468,"6-Phenyl-1,2,4-triazin-3-amine",C1=CC=C(C=C1)C2=CN=C(N=N2)N,,,,,,
468,120469,"3H-1,2,4-Triazol-3-one, 2,4-dihydro-2,4-dimethyl-5-phenyl-",CN1C(=NN(C1=O)C)C2=CC=CC=C2,,,,,,
469,120470,"2,4-Dihydro-4-ethyl-2-methyl-5-phenyl-3H-1,2,4-triazol-3-one",CCN1C(=NN(C1=O)C)C2=CC=CC=C2,,,,,,
470,120471,"Resorcinol, 4-amino-6-hexyl-, hydrochloride",CCCCCC1=CC(=C(C=C1O)O)N.Cl,,,,,,
471,120472,"4-Amino-6-pentylbenzene-1,3-diol",CCCCCC1=CC(=C(C=C1O)O)N,,,,,,
472,120473,"3(2H)-Pyridazinone, 4,5-dichloro-2-(2-(diethylamino)ethyl)-, monohydrochloride",CCN(CC)CCN1C(=O)C(=C(C=N1)Cl)Cl.Cl,,,,,,
473,120474,"4,5-Dichloro-2-[2-(diethylamino)ethyl]-2,3-dihydropyridazin-3-one",CCN(CC)CCN1C(=O)C(=C(C=N1)Cl)Cl,,,,,,
474,120475,"Piperidine, 1-benzyl-2,2,6,6-tetramethyl-, hydrochloride",CC1(CCCC(N1CC2=CC=CC=C2)(C)C)C.Cl,,,,,,
475,120476,"1-Benzyl-2,2,6,6-tetramethylpiperidine",CC1(CCCC(N1CC2=CC=CC=C2)(C)C)C,,,,,,
476,120477,"Benzamide, N-(bis(1-aziridinyl)phosphinyl)-o-bromo-",C1CN1P(=O)(NC(=O)C2=CC=CC=C2Br)N3CC3,,,,,,
477,120478,"Piperidine, 1-(o-bromobenzyl)-2,2,6,6-tetramethyl-, hydrochloride",CC1(CCCC(N1CC2=CC=CC=C2Br)(C)C)C.Cl,,,,,,
478,120479,"1-(2-Bromobenzyl)-2,2,6,6-tetramethylpiperidine",CC1(CCCC(N1CC2=CC=CC=C2Br)(C)C)C,,,,,,
479,120480,"Theophylline, 7-phenyl-",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)C3=CC=CC=C3,,,,,,
480,120481,3-Dimethylaminopropyldiphenylphosphine,CN(C)CCCP(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
481,120482,"Acetamide, 2-(diethylamino)-N-(2,4,6-trimethylbenzyl)-, hydrochloride",CCN(CC)CC(=O)NCC1=C(C=C(C=C1C)C)C.Cl,,,,,,
482,120483,"2-(diethylamino)-N-[(2,4,6-trimethylphenyl)methyl]acetamide",CCN(CC)CC(=O)NCC1=C(C=C(C=C1C)C)C,,,,,,
483,120484,(3-(Dimethylamino)propyl)diphenylphosphine oxide,CN(C)CCCP(=O)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
484,120485,"Phosphine sulfide, (3-(dimethylamino)propyl)diphenyl-",CN(C)CCCP(=S)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
485,120486,8-Chloro-7-phenyltheophylline,CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)Cl)C3=CC=CC=C3,,,,,,
486,120487,8-(1-Methyl-4-piperidyl)theophylline hydrochloride,CN1CCC(CC1)C2=NC3=C(N2)C(=O)N(C(=O)N3C)C.Cl,,,,,,
487,120488,"1,3-dimethyl-8-(1-methylpiperidin-4-yl)-7H-purine-2,6-dione",CN1CCC(CC1)C2=NC3=C(N2)C(=O)N(C(=O)N3C)C,,,,,,
488,120489,CID 120489,C1=CC=C(C=C1)C(=NNC2=C(C=C(C=C2)[N+](=O)[O-])Br)Br,,,,,,
489,120490,"2-(Diethylamino)-N-methyl-N-(2,4,6-trimethylbenzyl)acetamide hydrochloride",CCN(CC)CC(=O)N(C)CC1=C(C=C(C=C1C)C)C.Cl,,,,,,
490,120491,"2-(diethylamino)-N-methyl-N-[(2,4,6-trimethylphenyl)methyl]acetamide",CCN(CC)CC(=O)N(C)CC1=C(C=C(C=C1C)C)C,,,,,,
491,120492,2-(Diethylamino)-N-(5-isopropyl-2-methylbenzyl)acetamide monohydrochloride,CCN(CC)CC(=O)NCC1=C(C=CC(=C1)C(C)C)C.Cl,,,,,,
492,120493,2-(diethylamino)-N-[(2-methyl-5-propan-2-ylphenyl)methyl]acetamide,CCN(CC)CC(=O)NCC1=C(C=CC(=C1)C(C)C)C,,,,,,
493,120494,"1H-Purine-2,6-dione, 3,7-dihydro-7-(4-aminophenyl)-8-chloro-1,3-dimethyl-",CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)Cl)C3=CC=C(C=C3)N,,,,,,
494,120495,"Acetamide, 2-(diethylamino)-N-ethyl-N-(2,4,6-trimethylbenzyl)-, hydrochloride",CCN(CC)CC(=O)N(CC)CC1=C(C=C(C=C1C)C)C.Cl,,,,,,
495,120496,"2-(diethylamino)-N-ethyl-N-[(2,4,6-trimethylphenyl)methyl]acetamide",CCN(CC)CC(=O)N(CC)CC1=C(C=C(C=C1C)C)C,,,,,,
496,120497,"4-(Diethylamino)-1,1-diphenyl-2-butyn-1-ol",CCN(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
497,120498,"2-Butyn-1-ol, 4-(diethylamino)-1,1-diphenyl-, hydrochloride",CCN(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CC=C2)O.Cl,,,,,,
498,120499,"alpha,alpha-Diphenyl-1-pyrrolidinebutanol",C1CCN(C1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
499,120500,"1-Piperidin-1-yl-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCCCC2,,,,,,
500,120501,"1,1-Diphenyl-4-piperidino-2-butyn-1-ol",C1CCN(CC1)CC#CC(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
501,120502,"4-Morpholinebutanol, alpha,alpha-diphenyl-",C1COCCN1CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
502,120503,CID 120503,COC1=C2C(=O)C=C(OC2=C(C3=C1C=CO3)OC)C=NN=C(N)S,,,,,,
503,120504,3'-(2-Diethylaminoethyl)-1'-phenylcyclohexanespiro-5'-hydantoin hydrochloride,CCN(CC)CCN1C(=O)C2(CCCCC2)N(C1=O)C3=CC=CC=C3.Cl,,,,,,
504,120505,"3-[2-(Diethylamino)ethyl]-1-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione",CCN(CC)CCN1C(=O)C2(CCCCC2)N(C1=O)C3=CC=CC=C3,,,,,,
505,120506,"Tetramethyl 9-methyl-9aH-quinolizine-1,2,3,4-tetracarboxylate",CC1=CC=CN2C1C(=C(C(=C2C(=O)OC)C(=O)OC)C(=O)OC)C(=O)OC,,,,,,
506,120507,Libexin,C1CCN(CC1)CCC2=NC(=NO2)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,,,,,
507,120508,Prenoxdiazine,C1CCN(CC1)CCC2=NC(=NO2)CC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
508,120509,"disodium;(5R,6R)-6-[(3-carboxylatoquinoxaline-2-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1(C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=NC4=CC=CC=C4N=C3C(=O)[O-])C(=O)[O-])C.[Na+].[Na+],,,,,,
509,120510,"(5R,6R)-6-[(3-carboxyquinoxaline-2-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=NC4=CC=CC=C4N=C3C(=O)O)C(=O)O)C,,,,,,
510,120511,Tetramethylphosphonium iodide,C[P+](C)(C)C.[I-],,,,,,
511,120512,"Phosphonium, tetramethyl-",C[P+](C)(C)C,,,,,,
512,120513,"1-Penten-3-ol, 3-ethyl-",CCC(CC)(C=C)O,,,,,,
513,120514,CID 120514,C1CC(=O)P(=O)C1=O,,,,,,
514,120515,"Quinolizinium, bromide",C1=CC=[N+]2C=CC=CC2=C1.[Br-],,,,,,
515,120516,Quinolizinium,C1=CC=[N+]2C=CC=CC2=C1,,,,,,
516,120517,alpha-((Dimethylamino)methyl)benzenemethanethiol hydrochloride,CN(C)CC(C1=CC=CC=C1)S.Cl,,,,,,
517,120518,2-(Dimethylamino)-1-phenylethanethiol,CN(C)CC(C1=CC=CC=C1)S,,,,,,
518,120519,"Benzamide, 5-chloro-N-methyl-2-(methylamino)-",CNC1=C(C=C(C=C1)Cl)C(=O)NC,,,,,,
519,120520,3-((4-Chlorophenyl)sulfonyl)-2-propenenitrile,C1=CC(=CC=C1S(=O)(=O)C=CC#N)Cl,,,,,,
520,120521,2-Methyl-6-phenyl-4H-pyran-4-one,CC1=CC(=O)C=C(O1)C2=CC=CC=C2,,,,,,
521,120522,"1H-Indazol-3-ol, 1-butyl-6-chloro-",CCCCN1C2=C(C=CC(=C2)Cl)C(=O)N1,,,,,,
522,120523,1-Butyl-5-chloro-1H-indazol-3-ol,CCCCN1C2=C(C=C(C=C2)Cl)C(=O)N1,,,,,,
523,120524,N-((Diethylamino)methyl)pyrazinecarboxamide,CCN(CC)CNC(=O)C1=NC=CN=C1,,,,,,
524,120525,"1-Propylamine, 3,3-diphenyl-, hydrochloride",C1=CC=C(C=C1)C(CCN)C2=CC=CC=C2.Cl,,,,,,
525,120526,"Pyrazinecarboxamide, N-(piperidinomethyl)-",C1CCN(CC1)CNC(=O)C2=NC=CN=C2,,,,,,
526,120527,"5-[2-(5-Nitrofuran-2-yl)ethenyl]-1,3,4-thiadiazol-2-amine",C1=C(OC(=C1)[N+](=O)[O-])C=CC2=NN=C(S2)N,,,,,,
527,120528,Ethyl methyl p-nitrophenyl phosphate,CCOP(=O)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
528,120529,"1-Propanone, 1-(4-bromophenyl)-3-(1-piperidinyl)-, hydrochloride",C1CCN(CC1)CCC(=O)C2=CC=C(C=C2)Br.Cl,,,,,,
529,120530,"1-Propanone, 1-(4-bromophenyl)-3-(1-piperidinyl)-",C1CCN(CC1)CCC(=O)C2=CC=C(C=C2)Br,,,,,,
530,120531,4'-Methyl-3-piperidinopropiophenone hydrochloride,CC1=CC=C(C=C1)C(=O)CCN2CCCCC2.Cl,,,,,,
531,120532,"1-Propanone, 1-(4-methylphenyl)-3-(1-piperidyl)-",CC1=CC=C(C=C1)C(=O)CCN2CCCCC2,,,,,,
532,120533,"Benzenesulfonamide, 4-amino-N-(4-iodo-5-methyl-3-isoxazolyl)-",CC1=C(C(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N)I,,,,,,
533,120534,"2-[Bis(dimethylamino)phosphoryl]-5-pentyl-1,2,4-triazol-3-amine",CCCCCC1=NN(C(=N1)N)P(=O)(N(C)C)N(C)C,,,,,,
534,120535,1-(p-Chlorobenzyl)-6-chloro-1H-indazol-3-ol,C1=CC(=CC=C1CN2C3=C(C=CC(=C3)Cl)C(=O)N2)Cl,,,,,,
535,120536,"1H-Indazol-3-ol, 1-(p-methoxybenzyl)-",COC1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)N2,,,,,,
536,120537,"1-Hexyl-3-(N,N-diethylcarbamoyl)piperidine hydrobromide",CCCCCCN1CCC(CC1)C(=O)N(CC)CC.Br,,,,,,
537,120538,"N,N-diethyl-1-hexylpiperidine-4-carboxamide",CCCCCCN1CCC(CC1)C(=O)N(CC)CC,,,,,,
538,120539,"1H-Indazol-3-ol, 5-chloro-1-(p-methoxybenzyl)-",COC1=CC=C(C=C1)CN2C3=C(C=C(C=C3)Cl)C(=O)N2,,,,,,
539,120540,"Piperazine, 1-phenethyl-4-phenyl-",C1CN(CCN1CCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
540,120541,"1,5-Diphenyl-3-methylbiuret",CN(C(=O)NC1=CC=CC=C1)C(=O)NC2=CC=CC=C2,,,,,,
541,120542,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-(2-hydroxyethyl)-1-phenyl-",C1CCC2(CC1)C(=O)N(C(=O)N2C3=CC=CC=C3)CCO,,,,,,
542,120543,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-(dimethylamino)ethyl)-5-(3-methoxyphenyl)-, monohydrochloride",CN(C)CCC1(C(=O)NC(=O)NC1=O)C2=CC(=CC=C2)OC.Cl,,,,,,
543,120544,"5-[2-(Dimethylamino)ethyl]-5-(3-methoxyphenyl)-1,3-diazinane-2,4,6-trione",CN(C)CCC1(C(=O)NC(=O)NC1=O)C2=CC(=CC=C2)OC,,,,,,
544,120545,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-phenyl-5-(2-(1-pyrrolidinyl)ethyl)-, monohydrochloride",C1CCN(C1)CCC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3.Cl,,,,,,
545,120546,"5-Phenyl-5-(2-pyrrolidin-1-ylethyl)-1,3-diazinane-2,4,6-trione",C1CCN(C1)CCC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3,,,,,,
546,120547,"Piperazine, 1-(m-methoxyphenethyl)-4-phenyl-",COC1=CC=CC(=C1)CCN2CCN(CC2)C3=CC=CC=C3,,,,,,
547,120548,"Piperazine, 1-(p-methoxyphenethyl)-4-(2-pyridyl)-",COC1=CC=C(C=C1)CCN2CCN(CC2)C3=CC=CC=N3,,,,,,
548,120549,"Piperazine, 1-(1-naphthalenylmethyl)-4-phenyl-",C1CN(CCN1CC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
549,120550,CID 120550,CC(C)CC1=C(C(=O)C=C(O1)C(=O)O)O,,,,,,
550,120551,"2-(2-p-Chlorophenylethenyl)-4,4-dimethyl-2-oxazoline",CC1(COC(=N1)C=CC2=CC=C(C=C2)Cl)C,,,,,,
551,120552,"Ethanamine, 2-hydrazino-N,N-dimethyl-",CN(C)CCNN,,,,,,
552,120553,"5-(2-Chloroethyl)-4-methyloxazole 1,2-ethanedisulfonate (2:1)",CC1=C(OC=N1)CCCl.CC1=C(OC=N1)CCCl.C(CS(=O)(=O)O)S(=O)(=O)O,,,,,,
553,120554,"1-(3,4-Dimethoxyphenethyl)-4-(2,5-dimethoxyphenyl)piperazine hydrochloride",COC1=CC(=C(C=C1)OC)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC.Cl,,,,,,
554,120555,"1-(2,5-Dimethoxyphenyl)-4-[2-(3,4-dimethoxyphenyl)ethyl]piperazine",COC1=CC(=C(C=C1)OC)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
555,120556,"1,3,2-Dioxathiane, 5,5-dimethyl-, 2,2-dioxide",CC1(COS(=O)(=O)OC1)C,,,,,,
556,120557,CID 120557,CCOC1=CC=CC=C1NC(=NC2=CC=CC=C2OCC)S,,,,,,
557,120558,"Benzamide, N,N'-ethylenebis(3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NCCNC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
558,120559,CID 120559,C1=CC(=C(C=C1F)F)C(=O)[O-].[Na+],,,,,,
559,120560,"2,2-Bis(trifluoromethyl)-1,3-dioxolane",C1COC(O1)(C(F)(F)F)C(F)(F)F,,,,,,
560,120561,"Indene-3-ethylamine, 2-(p-fluorophenyl)-N,N-dimethyl-, hydrochloride",CN(C)CCC1=C(CC2=CC=CC=C21)C3=CC=C(C=C3)F.Cl,,,,,,
561,120562,"2-[2-(4-fluorophenyl)-3H-inden-1-yl]-N,N-dimethylethanamine",CN(C)CCC1=C(CC2=CC=CC=C21)C3=CC=C(C=C3)F,,,,,,
562,120563,N-(Bis(1-aziridinyl)phosphinyl)-p-trifluoromethylbenzamide,C1CN1P(=O)(NC(=O)C2=CC=C(C=C2)C(F)(F)F)N3CC3,,,,,,
563,120564,N-Hydroxypicolinimidamide,C1=CC=NC(=C1)C(=NO)N,,,,,,
564,120565,Bis(p-bromophenyl)sulfoxide,C1=CC(=CC=C1S(=O)C2=CC=C(C=C2)Br)Br,,,,,,
565,120566,"N-(1-Methylethyl)-4H-1,3,2-benzodioxaphosphorin-2-amine 2-oxide",CC(C)NP1(=O)OCC2=CC=CC=C2O1,,,,,,
566,120567,"4H-1,3,2-Benzodioxaphosphorin, 2-(dimethylamino)-, 2-oxide",CN(C)P1(=O)OCC2=CC=CC=C2O1,,,,,,
567,120568,"N-Propyl-4H-1,3,2-benzodioxaphosphorin-2-amine 2-oxide",CCCNP1(=O)OCC2=CC=CC=C2O1,,,,,,
568,120569,4-Amino-N-(2-(4-morpholinyl)ethyl)benzenesulfonamide,C1COCCN1CCNS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
569,120570,Naphthylin,C1=CC=C2C(=C1)C=CC=C2C3C(=O)C4=CC=CC=C4C3=O,,,,,,
570,120571,CID 120571,C1=C(OC(=C1)[N+](=O)[O-])C=CC2=CN=C(N=N2)N(C(=O)O)C(=O)O,,,,,,
571,120572,2-Methyl-3-(o-tolyl)-6-phenyl-4(3H)-pyrimidinone hydrochloride,CC1=CC=CC=C1N2C(=NC(=CC2=O)C3=CC=CC=C3)C.Cl,,,,,,
572,120573,2-Methyl-3-(2-methylphenyl)-6-phenyl-4(3H)-pyrimidinone,CC1=CC=CC=C1N2C(=NC(=CC2=O)C3=CC=CC=C3)C,,,,,,
573,120574,"1,3-Propanediol, 2-nitro-",C(C(CO)[N+](=O)[O-])O,,,,,,
574,120575,N-Benzylpentafluoropropionamide,C1=CC=C(C=C1)CNC(=O)C(C(F)(F)F)(F)F,,,,,,
575,120576,CID 120576,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)[O-])C.[Na+],,,,,,
576,120577,"Phosphorothioic acid, O,O-diethyl O-(4-nitro-3-(propylthio)phenyl) ester",CCCSC1=C(C=CC(=C1)OP(=S)(OCC)OCC)[N+](=O)[O-],,,,,,
577,120578,N-Benzyl-N-(2-morpholinoethyl)benzamide hydrochloride,C1COCCN1CCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3.Cl,,,,,,
578,120579,N-benzyl-N-[2-(morpholin-4-yl)ethyl]benzamide,C1COCCN1CCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
579,120580,"1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4-(p-fluorophenyl)butyl)-1-phenyl-",C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=CC=C(C=C4)F,,,,,,
580,120581,"Terephthalic acid, dipentyl ester",CCCCCOC(=O)C1=CC=C(C=C1)C(=O)OCCCCC,,,,,,
581,120582,"Piperazine, 1-(4-(p-methoxyphenoxy)butyl)-4-(2-pyridyl)-, dihydrochloride",COC1=CC=C(C=C1)OCCCCN2CCN(CC2)C3=CC=CC=N3.Cl.Cl,,,,,,
582,120583,1-[4-(4-Methoxyphenoxy)butyl]-4-pyridin-2-ylpiperazine,COC1=CC=C(C=C1)OCCCCN2CCN(CC2)C3=CC=CC=N3,,,,,,
583,120584,"Pentadecylamine, hydrochloride",CCCCCCCCCCCCCCCN.Cl,,,,,,
584,120585,"5-(m-Fluorophenylazo)-2,4,6-triaminopyrimidine",C1=CC(=CC(=C1)F)N=NC2=C(N=C(N=C2N)N)N,,,,,,
585,120586,"2H-1-Benzopyran-3-carboxamide, 2-oxo-",C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)N,,,,,,
586,120587,"2H-1-Benzopyran-3-carboxamide, 2-oxo-N-(phenylmethyl)-",C1=CC=C(C=C1)CNC(=O)C2=CC3=CC=CC=C3OC2=O,,,,,,
587,120588,"4-(Chloromethyl)-6-methoxy-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)N)CCl,,,,,,
588,120589,2-(4-Biphenylyloxy)-2-methyl-propionic acid 2-(diethylamino)ethyl ester hydrochloride,CCN(CC)CCOC(=O)C(C)(C)OC1=CC=C(C=C1)C2=CC=CC=C2.Cl,,,,,,
589,120590,2-(Diethylamino)ethyl 2-methyl-2-(4-phenylphenoxy)propanoate,CCN(CC)CCOC(=O)C(C)(C)OC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
590,120591,"Propionic acid, 2-methyl-2-(thymyloxy)-, 2-(diethylamino)ethyl ester, monohydrochloride",CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=CC(=C1)C)C(C)C.Cl,,,,,,
591,120592,2-(Diethylamino)ethyl 2-methyl-2-(5-methyl-2-propan-2-ylphenoxy)propanoate,CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=CC(=C1)C)C(C)C,,,,,,
592,120593,"Fluoren-9-one, O-(3,4,5-trimethoxybenzoyl)oxime",COC1=CC(=CC(=C1OC)OC)C(=O)ON=C2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
593,120594,"4-(Hydroxymethyl)-6,9-dimethyl-2,8-dioxopyrido[3,2-g]quinoline-1-carbaldehyde",CC1=CC(=O)N(C2=CC3=C(C=C12)C(=CC(=O)N3C=O)CO)C,,,,,,
594,120595,"Trisiloxane, 3-hexyl-1,1,1,3,5,5,5-heptamethyl-",CCCCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C,,,,,,
595,120596,"1-Piperidineacetic acid, 2,6-diisopropylphenyl ester, hydrochloride",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)CN2CCCCC2.Cl,,,,,,
596,120597,"[2,6-Di(propan-2-yl)phenyl] 2-piperidin-1-ylacetate",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)CN2CCCCC2,,,,,,
597,120598,"4-Methyl-1-piperazineacetic acid 2,6-diisopropylphenyl ester dihydrochloride",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)CN2CCN(CC2)C.Cl.Cl,,,,,,
598,120599,"[2,6-Di(propan-2-yl)phenyl] 2-(4-methylpiperazin-1-yl)acetate",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)CN2CCN(CC2)C,,,,,,
599,120600,"1-Piperidineacetic acid, 2,6-diethylphenyl ester, hydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)CN2CCCCC2.Cl,,,,,,
600,120601,"(2,6-Diethylphenyl) 2-piperidin-1-ylacetate",CCC1=C(C(=CC=C1)CC)OC(=O)CN2CCCCC2,,,,,,
601,120602,"4-Methyl-1-piperazineacetic acid 2,6-diethylphenyl ester dihydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)CN2CCN(CC2)C.Cl.Cl,,,,,,
602,120603,"(2,6-Diethylphenyl) 2-(4-methylpiperazin-1-yl)acetate",CCC1=C(C(=CC=C1)CC)OC(=O)CN2CCN(CC2)C,,,,,,
603,120604,"4-Methyl-1-piperazineacetic acid 2,6-dimethoxyphenyl ester dihydrochloride",CN1CCN(CC1)CC(=O)OC2=C(C=CC=C2OC)OC.Cl.Cl,,,,,,
604,120605,"(2,6-Dimethoxyphenyl) 2-(4-methylpiperazin-1-yl)acetate",CN1CCN(CC1)CC(=O)OC2=C(C=CC=C2OC)OC,,,,,,
605,120606,CID 120606,CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)C)CCC5C4=CC(C67C5(CCC6(C(OC7=O)(C)C8CCC(O8)(C)C)O)C)O)C)OS(=O)(=O)[O-])O)O)O)OC9C(C(C(C(O9)CO)O)OC1C(C(C(C(O1)CO)O)OC)O)O.[Na+],,,,,,
606,120607,"[5-[5-[4-[3,5-Dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-[[6-(5,5-dimethyloxolan-2-yl)-5,10-dihydroxy-2,6,13,17,17-pentamethyl-8-oxo-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-11-en-16-yl]oxy]-4-hydroxyoxan-3-yl] hydrogen sulfate",CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)C)CCC5C4=CC(C67C5(CCC6(C(OC7=O)(C)C8CCC(O8)(C)C)O)C)O)C)OS(=O)(=O)O)O)O)O)OC9C(C(C(C(O9)CO)O)OC1C(C(C(C(O1)CO)O)OC)O)O,,,,,,
607,120608,Phendimetrazine tartrate,C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
608,120609,CID 120609,C[C@H]1C(OCCN1C)C2=CC=CC=C2,,,,,,
609,120610,CID 120610,CCCCCCCCCCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
610,120611,"3-alpha-Hydroxy-16-alpha-methyl-2-beta-morpholino-5-alpha-pregnane-11,20-dione",C[C@@H]1C[C@H]2[C@@H]3CC[C@H]4C[C@@H]([C@H](C[C@@]4([C@H]3C(=O)C[C@@]2([C@H]1C(=O)C)C)C)N5CCOCC5)O,,,,,,
611,120612,"3-alpha-Hydroxy-2-beta-morpholino-5-alpha-pregnane-11,20-dione",CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C,,,,,,
612,120613,"5alpha-Pregnan-20-one, 3alpha-hydroxy-16a-methyl-2beta-morpholino-",C[C@@H]1C[C@H]2[C@@H]3CC[C@H]4C[C@@H]([C@H](C[C@@]4([C@H]3CC[C@@]2([C@H]1C(=O)C)C)C)N5CCOCC5)O,,,,,,
613,120614,N-(1-Methyl-2-(4-hydroxy-4-phenyl-1-piperidyl)ethyl)propionanilide oxalate,CCC(=O)N(C1=CC=CC=C1)C(C)CN2CCC(CC2)(C3=CC=CC=C3)O.C(=O)(C(=O)O)O,,,,,,
614,120615,N-(2-(4-Hydroxy-4-phenyl-1-piperidinyl)-1-methylethyl)-N-phenylpropanamide oxalate,CCC(=O)N(C1=CC=CC=C1)C(C)CN2CCC(CC2)(C3=CC=CC=C3)O,,,,,,
615,120616,3-alpha-Hydroxy-2-beta-morpholino-5-alpha-pregnan-20-one,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C,,,,,,
616,120617,N-Benzyl-beta-(dimethylamino)-alpha-phenylphenethylamine,CN(C)CC(C1=CC=CC=C1)N(CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
617,120618,N-Benzyl-beta-(dimethylamino)-N-phenylphenethylamine,CN(C)C(CN(CC1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
618,120619,"N',N'-Dimethyl-N-phenyl-1,2-propanediamine",CC(CNC1=CC=CC=C1)N(C)C,,,,,,
619,120620,"N',N'-Dimethyl-N-phenyl-1,2-butanediamine",CCC(CNC1=CC=CC=C1)N(C)C,,,,,,
620,120621,Diethylmethyl(1-methyl-2-phenothiazin-10-ylethyl)ammonium ethyl sulfate,CC[N+](C)(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31.CCOS(=O)(=O)[O-],,,,,,
621,120622,Diethyl-methyl-(1-phenothiazin-10-ylpropan-2-yl)azanium,CC[N+](C)(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
622,120623,Chloroquine 4-acetaminosalicylate,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.CC(=O)NC1=CC(=C(C=C1)C(=O)O)O.CC(=O)NC1=CC(=C(C=C1)C(=O)O)O,,,,,,
623,120624,CID 120624,CCCCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
624,120625,1-Phenethyl-4-phenyl-4-piperidinol propionate,CCC(=O)OC1(CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
625,120626,"3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-6-hydroxy-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-",CC1(C=CC2=C(O1)C=C(C3=C2O[C@@H]4COC5=CC(=C(C=C5C4C3=O)OC)OC)O)C,,,,,,
626,120627,"10H-Bis(1)benzopyrano(3,4-b:6',7'-e)pyran-14(6H)-one, 6a,14a-dihydro-13-hydroxy-2,3-dimethoxy-10,10-dimethyl-, (6aS-cis)-",CC1(C=CC2=C(C3=C(C=C2O1)O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC)O)C,,,,,,
627,120628,CID 120628,CC(=NNC1=NN=CC2=CC=CC=C21)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl,,,,,,
628,120629,"3-Oxatricyclo[3.2.1.02,4]octane-6-carboxylic acid",C1C2CC(C1C3C2O3)C(=O)O,,,,,,
629,120630,"(2S,5R,6R)-6-(hex-3-enoylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CCC=CCC(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O,,,,,,
630,120631,"(1R,9S,10R)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide",CN1CC[C@]23CCCC[C@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br,,,,,,
631,120632,"4bbeta,9-(3-Azabutane-1,3-diyl)-3-methoxy-4b,5,6,7,8,8a,9,10-octahydrophenanthrene",CN1CC[C@]23CCCCC2C1CC4=C3C=C(C=C4)OC,,,,,,
632,120633,"2-(Diethylamino)ethyl 2-phenylcyclopentane-1-carboxylate;ethane-1,2-disulfonic acid",CCN(CC)CCOC(=O)C1CCCC1C2=CC=CC=C2.CCN(CC)CCOC(=O)C1CCCC1C2=CC=CC=C2.C(CS(=O)(=O)O)S(=O)(=O)O,,,,,,
633,120634,2-(Diethylamino)ethyl 2-phenylcyclopentane-1-carboxylate,CCN(CC)CCOC(=O)C1CCCC1C2=CC=CC=C2,,,,,,
634,120635,"methyl (1S,15S,19S,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate",COC(=O)[C@H]1[C@H]2C[C@H]3C4=C(CCN3C[C@H]2CCC1O)C5=CC=CC=C5N4,,,,,,
635,120636,Lobeline sulfate,CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O.CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O.OS(=O)(=O)O,,,"['Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)', 'Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (See all compounds classified as Nicotinic Agonists.)', 'Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non-nicotinic effects on postganglionic neurons are not included here nor are the nonspecific cholinergic agonists. (See all compounds classified as Ganglionic Stimulants.)']",,,
636,120637,Tropine (o-tolyl)acetate hydrochloride,CC1=CC=CC=C1CC(=O)OC2C[C@H]3CC[C@@H](C2)N3C.Cl,,,,,,
637,120638,"[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-(2-methylphenyl)acetate",CC1=CC=CC=C1CC(=O)OC2C[C@H]3CC[C@@H](C2)N3C,,,,,,
638,120639,Prulaurasin,C1=CC=C(C=C1)C(C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
639,120640,Phenatine,CC(CC1=CC=CC=C1)NC(=O)C2=CN=CC=C2,,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
640,120641,Pseudoconhydrine,CCC[C@H]1CC[C@@H](CN1)O,,,,,,
641,120642,CID 120642,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@@H](C=C4)O,,,,,,
642,120643,"1-alpha-H,5-alpha-H-Tropan-3-alpha-ol, m-bromophenylacetate, hydrochloride",CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)CC3=CC(=CC=C3)Br.Cl,,,,,,
643,120644,"[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-(3-bromophenyl)acetate",CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)CC3=CC(=CC=C3)Br,,,,,,
644,120645,"1H-Indene-1,3(2H)-dione, 2-(phenylmethyl)-",C1=CC=C(C=C1)CC2C(=O)C3=CC=CC=C3C2=O,,,,,,
645,120646,"4,9-o-Benzenobenz(f)isoindolinium, 3a,4,9,9a-tetrahydro-2-methyl-2-(3-(trimethylammonio)propyl)-, diiodide",C[N+]1(CC2C(C1)C3C4=CC=CC=C4C2C5=CC=CC=C35)CCC[N+](C)(C)C.[I-].[I-],,,,,,
646,120647,"Trimethyl-[3-(17-methyl-17-azoniapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-hexaen-17-yl)propyl]azanium",C[N+]1(CC2C(C1)C3C4=CC=CC=C4C2C5=CC=CC=C35)CCC[N+](C)(C)C,,,,,,
647,120648,"N-(2,5-Dioxo-4-methyl-3-pyrrolidinyl)phthalimide",CC1C(C(=O)NC1=O)N2C(=O)C3=CC=CC=C3C2=O,,,,,,
648,120649,beta-Thalidomide,C1C(CC(=O)NC1=O)N2C(=O)C3=CC=CC=C3C2=O,,,,,,
649,120650,Biphenicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=CC=CC=C3C4=CC=CC=C4)C(=O)O)C,,,,,,
650,120651,Toliprolol hydrochloride,CC1=CC(=CC=C1)OCC(CNC(C)C)O.Cl,,,,,,
651,120652,"1-decyl-N,N-diethylpiperidine-3-carboxamide",CCCCCCCCCCN1CCCC(C1)C(=O)N(CC)CC,,,,,,
652,120653,4-Chloro-alpha-((dimethylamino)methyl)benzhydrol hydrochloride,CN(C)CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)O.Cl,,,,,,
653,120654,1-(4-Chlorophenyl)-2-(dimethylamino)-1-phenylethanol,CN(C)CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)O,,,,,,
654,120655,Carbamic acid 3-(2-biphenylyloxy)-2-hydroxypropyl ester,C1=CC=C(C=C1)C2=CC=CC=C2OCC(COC(=O)N)O,,,,,,
655,120656,"3,5-Difluorotyrosine",C1=C(C=C(C(=C1F)O)F)CC(C(=O)O)N,,,,,,
656,120657,"Barbituric acid, 5-ethyl-5-(p-fluorophenyl)-",CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)F,,,,,,
657,120658,"Biphenylene-(4,4')-bis-methyl-(3-alpha-hydroxy)-tropaniumbromide [German]",C[N+]1(C2CCC1CC(C2)O)CC3=CC=C(C=C3)C4=CC=C(C=C4)C[N+]5(C6CCC5CC(C6)O)C.[Br-].[Br-],,,,,,
658,120659,8-[[4-[4-[(3-Hydroxy-8-methyl-8-azoniabicyclo[3.2.1]octan-8-yl)methyl]phenyl]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-ol,C[N+]1(C2CCC1CC(C2)O)CC3=CC=C(C=C3)C4=CC=C(C=C4)C[N+]5(C6CCC5CC(C6)O)C,,,,,,
659,120660,"3-(2-Biphenylyloxy)-1,2-propanediol",C1=CC=C(C=C1)C2=CC=CC=C2OCC(CO)O,,,,,,
660,120661,CID 120661,CC=CC1=C(C(=CC=C1)OC)OCC(CO)O,,,,,,
661,120662,"2H-1,2,4-Benzothiadiazine-3-carboxylic acid, 3,4-dihydro-7-sulfamoyl-6-(trifluoromethyl)-, 1,1-dioxide",C1=C(C(=CC2=C1NC(NS2(=O)=O)C(=O)O)S(=O)(=O)N)C(F)(F)F,,,,,,
662,120663,CID 120663,CC=CC1=C(C=CC(=C1)OC)OCC(CO)O,,,,,,
663,120664,"3-(2-Methoxy-4-prop-1-enylphenoxy)propane-1,2-diol",CC=CC1=CC(=C(C=C1)OCC(CO)O)OC,,,,,,
664,120665,CID 120665,CC=CC1=CC(=C(C=C1)OCC(COC(=O)N)O)OC,,,,,,
665,120666,"2,3-Dimethyl-3-(m-hydroxyphenyl)-N-phenethylpiperidine hydrobromide",CC1C(CCCN1CCC2=CC=CC=C2)(C)C3=CC(=CC=C3)O.Br,,,,,,
666,120667,"3-[2,3-Dimethyl-1-(2-phenylethyl)piperidin-3-yl]phenol",CC1C(CCCN1CCC2=CC=CC=C2)(C)C3=CC(=CC=C3)O,,,,,,
667,120668,Yohimbyl alcohol cyclic sulfite ester,C1CC2C(COS(=O)O2)C3C1CN4CCC5=C(C4C3)NC6=CC=CC=C56,,,,,,
668,120669,17-beta-Chloro-16-alpha-methylyohimbane,C[C@H]1[C@@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)Cl,,,,,,
669,120670,Epiyohimbol,C1C[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C[C@@H]1O)NC5=CC=CC=C45,,,,,,
670,120671,"4-Ethenyl-3,4-dihydropyrano[3,4-c]pyridin-1-one",C=CC1COC(=O)C2=C1C=CN=C2,,,,,,
671,120672,"3,4-Dihydro-6,7-dichloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide",CC1NC2=CC(=C(C=C2S(=O)(=O)N1)Cl)Cl,,,,,,
672,120673,6-Fluoro-6-deoxy-d-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)F,,,,,,
673,120674,"(1,1,2,2-Tetrafluoroethoxy)cyclohexane",C1CCC(CC1)OC(C(F)F)(F)F,,,,,,
674,120675,1-(4-Fluorophenyl)propan-2-amine hydrochloride,CC(CC1=CC=C(C=C1)F)N.Cl,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
675,120676,Caudoside,CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3C(=O)C(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
676,120677,CID 120677,CC1C(C(CC(O1)OC2CCC3(C(C2)CC4CC5CC(C6(C5(C4C3C(=O)C6O)O)C)C7=CC(=O)OC7)C)OC)O,,,,,,
677,120678,Quinovic acid,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C(=O)O)C(=O)O,,,,,,
678,120679,"3-[3-(3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl)oxy-12,14-dihydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1C(C(C(C(O1)OC2CCC3(C(C2)CCC4C3C(=O)C(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC)O,,,,,,
679,120680,Kwangosid [German],C[C@@H]1[C@@H]([C@@H](CC(O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
680,120681,Odoroside F,CC1C(C(C(C(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CCC5C6=CC(=O)OC6)O)C)C)OC7C(C(C(C(O7)CO)O)O)O)OC)O,,,,,,
681,120682,Neoline,CCN1CC2(CCC(C34C2C(C(C31)C5(CC(C6CC4C5C6O)OC)O)OC)O)COC,,,,,,
682,120683,CID 120683,CN1CC[C@]23[C@@H]4C=C[C@@H]([C@H]2[C@@H]1CC5=C3C(=C(C=C5)O)O4)O,,,,,,
683,120684,CID 120684,CN1CC[C@]23[C@@H]4C=C[C@H]([C@H]2[C@@H]1CC5=C3C(=C(C=C5)O)O4)O,,,,,,
684,120685,CID 120685,CN1CC[C@]23[C@@H]4C=C[C@@H]([C@H]2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)Cl,,,,,,
685,120686,"(4S,4aR,5S,7aS,12bS)-9-methoxy-3-methyl-2,4,4a,5,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-5-ol",CN1CC[C@]23[C@@H]4C=C[C@@H]([C@H]2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)O,,,,,,
686,120687,"(4S,7aR,12bS)-7-methoxy-3-methyl-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol",CN1CC[C@]23[C@@H]4C(=CC=C2[C@@H]1CC5=C3C(=C(C=C5)O)O4)OC,,,,,,
687,120688,CID 120688,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@@H](C=C4)Cl,,,,,,
688,120689,"(4S,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)C=C4,,,,,,
689,120690,"(2S,3S,6R,8S,10S,11S,14R)-2,6-dimethyl-19-oxa-17-azapentacyclo[14.2.1.02,14.03,11.06,10]nonadecan-8-ol",C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H](C2)O)CC[C@H]4[C@@]3(C5CNC(C4)O5)C,,,,,,
690,120691,"5a,7a-Dimethylhexadecahydro-2,5-epoxycyclopenta[5,6]naphtho[1,2-d]azepin-9(1H)-one",C[C@]12CC[C@H]3[C@H]([C@@H]1CC(=O)C2)CC[C@H]4[C@@]3(C5CNC(C4)O5)C,,,,,,
691,120692,"3-(Hexopyranosyloxy)-14-hydroxy-19-oxocarda-5,20(22)-dienolide",CC12CCC3C(C1(CCC2C4=CC(=O)OC4)O)CC=C5C3(CCC(C5)OC6C(C(C(C(O6)CO)O)O)O)C=O,,,,,,
692,120693,Piscidic acid,C1=CC(=CC=C1CC(C(C(=O)O)O)(C(=O)O)O)O,,,,,,
693,120694,"Spiro(8-azabicyclo(3.2.1)octane-2,2'-(2H)pyran)-6'(3'H)-one, dihydro-4',8-dimethyl-",CC1CC(=O)OC2(C1)CCC3CCC2N3C,,,,,,
694,120695,4-Benzyl-4-[4-benzyl-5-(4-nitrophenyl)-5-oxopentyl]morpholin-4-ium bromide,C1COCC[N+]1(CCCC(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-])CC4=CC=CC=C4.[Br-],,,,,,
695,120696,2-Benzyl-5-(4-benzylmorpholin-4-ium-4-yl)-1-(4-nitrophenyl)pentan-1-one,C1COCC[N+]1(CCCC(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-])CC4=CC=CC=C4,,,,,,
696,120697,Eleutherol,C[C@@H]1C2=C(C=C3C=CC=C(C3=C2O)OC)C(=O)O1,,,,,,
697,120698,Capnoidine,CN1CCC2=CC3=C(C=C2[C@@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,,,,,,
698,120699,CID 120699,C[C@@H]1CCC[C@@H](C(=O)OC[C@@H](CCC[C@@H](C(=O)OC1)[C@@H]2CN=C(N2)N)C)[C@@H]3CN=C(N3)N,,,,,,
699,120700,Allitol,C([C@H]([C@H]([C@H]([C@H](CO)O)O)O)O)O,,,,,,
700,120701,Cystinol,C(C(CSSCC(CO)N)N)O,,,,,,
701,120702,Amboside,CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3C(C(=O)C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
702,120703,Strophanthidylic acid,C[C@]12CC[C@H]3[C@H]([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)C(=O)O)O,,,,,,
703,120704,Divaricoside,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
704,120705,Menabegenin,C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@H]4C5=CC(=O)OC5)O)C)O,,,,,,
705,120706,Napellonine,CCN1CC2(CCC(C34C2CC(C31)C56C4CC(=O)C(C5)C(=C)C6O)O)C,,,,,,
706,120707,CID 120707,CN1CC[C@]23[C@@H]4C=C[C@H]([C@H]2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)O,,,,,,
707,120708,Strobosid [German],CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CCC5C6=CC(=O)OC6)O)C)C=O)O)O,,,,,,
708,120709,Pauliosid [German],CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CCC5C6=CC(=O)OC6)O)C)C=O)OC)O,,,,,,
709,120710,Periplocymarin,CC1C(C(CC(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)C)OC)O,,,,,,
710,120711,CID 120711,C[C@@]1(C2=C(C=CC(=C2C(=O)O1)O)Cl)[C@H]3C[C@H]4[C@@H](C(=O)C(=C(N)O)C(=O)[C@]4(C(=O)C3)O)N(C)C,,,,,,
711,120712,Colchicide,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=CC(=O)C=C13)OC)OC)OC,,,,,,
712,120713,CID 120713,C1=C(C=C(C(=C1O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C3=C(C(=C4C(=CC(=O)C=C4O3)O)O)O,,,,,,
713,120714,CID 120714,CC=C1CC(=C)[C@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(C)O,,,,,,
714,120715,"Yohimban-17-alpha-ol, 16-alpha-chloromethyl-",C1C[C@@H]([C@@H]([C@@H]2[C@@H]1CN3CCC4=C([C@@H]3C2)NC5=CC=CC=C45)CCl)O,,,,,,
715,120716,allo-Yohimbine,COC(=O)[C@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,,,,,,
716,120717,Yohimban,C1CC[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C1)NC5=CC=CC=C45,,,,,,
717,120718,17-alpha-Fluoroyohimbane,C1C[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C[C@H]1F)NC5=CC=CC=C45,,,,,,
718,120719,"(1R,2S,5R)-2-methyl-5-[(2S)-1-oxopropan-2-yl]cyclopentane-1-carboxylic acid",C[C@H]1CC[C@@H]([C@@H]1C(=O)O)[C@H](C)C=O,,,,,,
719,120720,Penicillin X,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=C(C=C3)O)C(=O)O)C,,,,,,
720,120721,"2,3-Diphenylpropionic acid 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C(CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
721,120722,beta-Alanylaminoethanethiol,C(CN)C(=O)NCCS,,,,,,
722,120723,CID 120723,C#CC#CC=CC=CC(CCC(=O)O)O,,,,,,
723,120724,"9,13-dihydroxy-5-methyl-6-(5-oxo-2H-furan-3-yl)-15-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-19-oxapentacyclo[10.5.2.01,13.02,10.05,9]nonadecan-18-one",CC1C(C(C(C(O1)OC2CCC34C5CCC6(C(CCC6(C5CC(C3(C2)O)OC4=O)O)C7=CC(=O)OC7)C)O)O)O,,,,,,
724,120725,Sarveroside,CC1C(C(CC(O1)OC2CCC3(C(C2)CC4C5C3C(C(=O)C6(C5(C(O4)CC6C7=CC(=O)OC7)O)C)O)C)OC)O,,,,,,
725,120726,"Aconitane-1,7,8,14-tetrol, 20-ethyl-6,16-dimethoxy-4-(methoxymethyl)-, (1alpha,6beta,14alpha,16beta)-",CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4C5C6O)OC)O)O)OC)O)COC,,,,,,
726,120727,Probarbital calcium,CCC1(C(=O)NC(=O)N=C1[O-])C(C)C.CCC1(C(=O)NC(=O)N=C1[O-])C(C)C.[Ca+2],,,,,,
727,120728,Frugoside,C[C@@H]1[C@H]([C@H]([C@H](C(O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)CO)O)O)O,,,,,,
728,120729,Pempidine tartrate,CC1(CCCC(N1C)(C)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
729,120730,Tropacine hydrochloride,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,,,,,
730,120731,Tropacine,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
731,120732,"Yohimban, 16-alpha-methyl-",C[C@H]1CCC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4,,,,,,
732,120733,16-alpha-Methylyohimbol,C[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,,,,,,
733,120734,Adlumidine,CN1CCC2=CC3=C(C=C2[C@H]1[C@@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,,,,,,
734,120735,"[(3S,4R,6R,8S,13R,14R,16S,18R)-11-ethyl-5,14-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-7-oxo-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CCN1C[C@@]2([C@@H](C[C@@H](C34C2[C@H](C(C31)[C@@H]5[C@@H]6C4CC([C@@H]6OC(=O)C7=CC=CC=C7)([C@H](C5=O)OC)O)OC)OC)O)COC,,,,,,
735,120736,CID 120736,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=CC4)OC,,,,,,
736,120737,Alphaprodine hydrochloride,CCC(=O)O[C@@]1(CCN(C[C@@H]1C)C)C2=CC=CC=C2.Cl,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
737,120738,Nisintil,CCC(=O)O[C@@]1(CCN(C[C@@H]1C)C)C2=CC=CC=C2,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']","['FOLLOWING IV ADMIN TO DOGS, RAPID DISAPPEARANCE OF ALPHAPRODINE FROM PLASMA & LARGE DISTRIBUTION VOL WERE IN KEEPING WITH ITS RAPID ONSET & SHORT DURATION OF ACTION. THERE APPEARED TO BE RAPID EQUILIBRIUM BETWEEN BRAIN & PLASMA.', 'The elimination half-life of alphaprodine is 131 minutes (approximately 2 hours) compared with 247 minutes for meperidine. Plasma clearances for alphaprodine and meperidine are nearly identical: 1.04 and 1.01 l/kg/min, respectively. Although meperidine undergoes extensive biotransformation in the liver to form N-demethylated derivatives and meperidinic acid (see Meperidine) no information is available relating to alphaprodine biotransformation in man.', 'Alphaprodine is immediately absorbed from parenteral sites. Thirty-five milligrams of alphaprodine intravenously produces plasma concentrations similar to those following 100 mg meperidine. The half-life (absorption) is 4.6 minutes for alphaprodine compared with 17.2 minutes for meperidine.']",['FOLLOWING IV ADMIN TO DOGS THE ONLY EXTRACTABLE METABOLITE FROM URINE WAS NORALPHAPRODINE.'],
738,120739,Metcaraphen,CCN(CC)CCOC(=O)C1(CCCC1)C2=CC(=C(C=C2)C)C,,,,,,
739,120740,CID 120740,C[C@@H]1CC[C@]2([C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C(=O)C)C)C,,,,,,
740,120741,"1,2-Diphenyl-3,5-dioxo-4-(3-hydroxybutyl)pyrazolidine",CC(CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
741,120742,Nepitrin,COC1=C(C=C2C(=C1O)C(=O)C=C(O2)C3=CC(=C(C=C3)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
742,120743,Isoiridomyrmecin,C[C@@H]1CC[C@@H]2[C@H]1COC(=O)[C@H]2C,,,,,,
743,120744,Ngaione,CC(C)CC(=O)C[C@]1(CC[C@H](O1)C2=COC=C2)C,,,,,,
744,120745,N-Cyclohexyl-2-fluoroacetamide,C1CCC(CC1)NC(=O)CF,,,,,,
745,120746,"5-(Diethylamino)-1,2,5-trimethyl-4-piperidone dihydrochloride",CCN(CC)C1(CN(C(CC1=O)C)C)C.Cl.Cl,,,,,,
746,120747,"5-(Diethylamino)-1,2,5-trimethylpiperidin-4-one",CCN(CC)C1(CN(C(CC1=O)C)C)C,,,,,,
747,120748,"5-Ethoxy-4-oxo-1,1,2,5-tetramethylpiperidinium iodide",CCOC1(C[N+](C(CC1=O)C)(C)C)C.[I-],,,,,,
748,120749,"5-Ethoxy-1,1,2,5-tetramethylpiperidin-1-ium-4-one",CCOC1(C[N+](C(CC1=O)C)(C)C)C,,,,,,
749,120750,CID 120750,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3O)O)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O,,,,,,
750,120751,Vuzin dihydrochloride,CC[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)OCCCCCC(C)C)O.Cl.Cl,,,,,,
751,120752,Vuzin,CC[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)OCCCCCC(C)C)O,,,,,,
752,120753,"D-Glucose, 3-acetamido-3-deoxy-",CC(=O)N[C@H]([C@H](C=O)O)[C@@H]([C@@H](CO)O)O,,,,,,
753,120754,CID 120754,COC1=C(C=C2C(=C(C(=CO2)C3=CC=C(C=C3)O)O)C1=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
754,120755,"3-[(6-Deoxy-3-o-methylhexopyranosyl)oxy]-5,14,16-trihydroxy-19-oxobufa-20,22-dienolide",CC1C(C(C(C(O1)OC2CCC3(C4CCC5(C(C(CC5(C4CCC3(C2)O)O)O)C6=COC(=O)C=C6)C)C=O)O)OC)O,,,,,,
755,120756,Erychroside,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O,,,,,,
756,120757,3-(2-Guanidinoethyl)-3-azabicyclo(3.2.2)nonane sulfate (2:1),C1CC2CCC1CN(C2)CCN=C(N)N.C1CC2CCC1CN(C2)CCN=C(N)N.OS(=O)(=O)O,,,,,,
757,120758,2-[2-(3-Azabicyclo[3.2.2]nonan-3-yl)ethyl]guanidine,C1CC2CCC1CN(C2)CCN=C(N)N,,,,,,
758,120759,Spermostrychnin,CC1C2CN3CCC45C3CC2C(C4N(C6=CC=CC=C56)C(=O)C)CO1,,,,,,
759,120760,"4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione",C[C@H]1C[C@@H](C(=O)[C@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,,,,,,
760,120761,CID 120761,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C(=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O)O,,,,,,
761,120762,Allouzarigenin,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@H]4C5=CC(=O)OC5)O)C)O,,,,,,
762,120763,1-(2-(Trifluoromethyl)phenyl)-2-aminopropane,CC(CC1=CC=CC=C1C(F)(F)F)N,,,,,,
763,120764,"4-Morpholinepropanamide, N-(5-ethyl-2-methoxyphenyl)-beta-methyl-",CCC1=CC(=C(C=C1)OC)NC(=O)CC(C)N2CCOCC2,,,,,,
764,120765,Norfenfluramine hydrochloride,CC(CC1=CC(=CC=C1)C(F)(F)F)N.Cl,,,,,,
765,120766,2-Butyl-2-methylthiazolidine,CCCCC1(NCCS1)C,,,,,,
766,120767,"4-[(Dimethylamino)methyl]-1,3-dithiolane-2-thione",CN(C)CC1CSC(=S)S1,,,,,,
767,120768,"4-(1,3-Thiazolan-2-yl)pyridine",C1CSC(N1)C2=CC=NC=C2,,,,,,
768,120769,3-(2-Thiazolidinyl)pyridine,C1CSC(N1)C2=CN=CC=C2,,,,,,
769,120770,2-(2-Thiazolidinyl)pyridine,C1CSC(N1)C2=CC=CC=N2,,,,,,
770,120771,"2-Hexyl-2-methyl-1,3-thiazolidine",CCCCCCC1(NCCS1)C,,,,,,
771,120772,2-Heptylthiazolidine,CCCCCCCC1NCCS1,,,,,,
772,120773,Tecostanine,CC1CCC2C1CN(CC2CO)C,,,,,,
773,120774,"N,N-dimethyl-4-(1,3-thiazolidin-2-yl)aniline",CN(C)C1=CC=C(C=C1)C2NCCS2,,,,,,
774,120775,"N,N-Dimethyl-N'-phenyl-1,2-butanediamine",CCC(CN(C)C)NC1=CC=CC=C1,,,,,,
775,120776,4-Hydroxyimino-3-methyl-1-phenylpent-1-yn-3-ol,CC(=NO)C(C)(C#CC1=CC=CC=C1)O,,,,,,
776,120777,"1-Hydroxyimino-2,4-diphenylbut-3-yn-2-ol",C1=CC=C(C=C1)C#CC(C=NO)(C2=CC=CC=C2)O,,,,,,
777,120778,"4-Morpholinepropanamide, N-(2-chloro-5-ethylphenyl)-beta-methyl-",CCC1=CC(=C(C=C1)Cl)NC(=O)CC(C)N2CCOCC2,,,,,,
778,120779,"4-Morpholinepropanamide, N-(5-ethyl-2-fluorophenyl)-beta-methyl-",CCC1=CC(=C(C=C1)F)NC(=O)CC(C)N2CCOCC2,,,,,,
779,120780,"Barbituric acid, 1,3-diphenyl-5-methyl-",CC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
780,120781,"Barbituric acid, 1,3-diphenyl-5-ethyl-",CCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
781,120782,"1,3-Dicyclohexyl-5-isopropylbarbituric acid",CC(C)C1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
782,120783,"Barbituric acid, 1,3-diphenyl-5-isopropyl-",CC(C)C1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
783,120784,"1,3-Diphenyl-5-propylbarbituric acid",CCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
784,120785,"9,10-Diethyl-11-hydroxy-3-methyl-5,14-dioxatricyclo[10.3.0.03,7]pentadeca-1(12),7-diene-4,6,13,15-tetrone",CCC1C=C2C(=O)OC(=O)C2(CC3=C(C(C1CC)O)C(=O)OC3=O)C,,,,,,
785,120786,"4-Butyl-1-(4-nitrophenyl)-2-phenylpyrazolidine-3,5-dione",CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
786,120787,"Barbituric acid, 1,3,5-tricyclohexyl-",C1CCC(CC1)C2C(=O)N(C(=O)N(C2=O)C3CCCCC3)C4CCCCC4,,,,,,
787,120788,CID 120788,CC=CC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
788,120789,CID 120789,CN1CC[C@]23[C@@H]4C(=O)C=C[C@]2([C@@H]1CC5=C3C(=C(C=C5)OC)O4)OC(=O)CC6=CC=CC=C6,,,,,,
789,120790,CID 120790,CN1CC[C@]23[C@@H]4C(=O)C=C[C@]2([C@@H]1CC5=C3C(=C(C=C5)OC)O4)OC(=O)C=CC6=CC=CC=C6,,,,,,
790,120791,CID 120791,C[C@@]1(C2C[C@H]3[C@@H](C(=O)C(=C(NCNCC(=O)O)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O,,,,,,
791,120792,"3-[(6-Deoxy-4-O-hexopyranosyl-3-O-methylhexopyranosyl)oxy]-14,16-dihydroxycard-20(22)-enolide",CC1C(C(C(C(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CC(C5C6=CC(=O)OC6)O)O)C)C)O)OC)OC7C(C(C(C(O7)CO)O)O)O,,,,,,
792,120793,"1,2-Dimethylpropylamine hydrochloride",CC(C)C(C)N.Cl,,,,,,
793,120794,"4-Methyl-2,6,7-trioxabicyclo[2.2.2]octane",CC12COC(OC1)OC2,,,,,,
794,120795,2-Methyl-2-phenylthiazolidine,CC1(NCCS1)C2=CC=CC=C2,,,,,,
795,120796,"2-Benzyl-2-methyl-1,3-thiazolidine",CC1(NCCS1)CC2=CC=CC=C2,,,,,,
796,120797,2-(p-Tolyl)-2-methylthiazolidine,CC1=CC=C(C=C1)C2(NCCS2)C,,,,,,
797,120798,2-(p-Chlorophenyl)-2-methylthiazolidine,CC1(NCCS1)C2=CC=C(C=C2)Cl,,,,,,
798,120799,2-(4-Chloro-3-methylphenoxy)propanoic acid,CC1=C(C=CC(=C1)OC(C)C(=O)O)Cl,,,,,,
799,120800,"5-Phenyl-5-(trifluoromethyl)imidazolidine-2,4-dione",C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C(F)(F)F,,,,,,
800,120801,"s-Triazine, 2-amino-4-cyclohexylamino-6-trifluoromethyl-",C1CCC(CC1)NC2=NC(=NC(=N2)N)C(F)(F)F,,,,,,
801,120802,3-(2-Oxo-1-phenylcyclohexyl)butanoic acid,CC(CC(=O)O)C1(CCCCC1=O)C2=CC=CC=C2,,,,,,
802,120803,1-(o-Chlorobenzyl)-2-oxocyclohexanepropionic acid,C1CCC(C(=O)C1)(CCC(=O)O)CC2=CC=CC=C2Cl,,,,,,
803,120804,1-(o-Methoxybenzyl)-2-oxocyclohexanepropionic acid,COC1=CC=CC=C1CC2(CCCCC2=O)CCC(=O)O,,,,,,
804,120805,Bismuth ethyl (+)-camphorate,CCOC(=O)[C@@]1(CC[C@@H](C1(C)C)C(=O)[O-])C.CCOC(=O)[C@@]1(CC[C@@H](C1(C)C)C(=O)[O-])C.CCOC(=O)[C@@]1(CC[C@@H](C1(C)C)C(=O)[O-])C.[Bi+3],,,,,,
805,120806,CID 120806,CCOC(=O)[C@@]1(CCC(C1(C)C)C(=O)O)C,,,,,,
806,120807,alpha-((2-(4-Morpholinyl)ethoxy)methyl)benzenemethanol hydrochloride,C1COCCN1CCOCC(C2=CC=CC=C2)O.Cl,,,,,,
807,120808,2-(2-Morpholin-4-ylethoxy)-1-phenylethanol,C1COCCN1CCOCC(C2=CC=CC=C2)O,,,,,,
808,120809,5-Ethyl-5-(p-fluorophenyl)-3-(2-hydroxyethyl)hydantoin,CCC1(C(=O)N(C(=O)N1)CCO)C2=CC=C(C=C2)F,,,,,,
809,120810,"3-Amino-1,1,3-triphenyl-1-propanol",C1=CC=C(C=C1)C(CC(C2=CC=CC=C2)(C3=CC=CC=C3)O)N,,,,,,
810,120811,"1-(2,5-Dimethoxyphenyl)-3-methylamino-1-phenylbutanol hydrochloride",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)NC.Cl,,,,,,
811,120812,"1-(2,5-Dimethoxyphenyl)-3-(methylamino)-1-phenylbutan-1-ol",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)NC,,,,,,
812,120813,"Benzenemethanol, 2,5-dimethoxy-alpha-(2-(isopropylamino)propyl)-alpha-phenyl-, hydrochloride",CC(C)NC(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O.Cl,,,,,,
813,120814,"1-(2,5-Dimethoxyphenyl)-1-phenyl-3-(propan-2-ylamino)butan-1-ol",CC(C)NC(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O,,,,,,
814,120815,"alpha-(2-Diethylaminopropyl)-2,5-dimethoxybenzhydrol hydrochloride",CCN(CC)C(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O.Cl,,,,,,
815,120816,"3-(Diethylamino)-1-(2,5-dimethoxyphenyl)-1-phenylbutan-1-ol",CCN(CC)C(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O,,,,,,
816,120817,"Diethyl(4-(2,5-dimethoxyphenyl)-4-hydroxy-4-phenyl-2-butyl)methylammonium iodide",CC[N+](CC)(CC)C(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O.[I-],,,,,,
817,120818,"[4-(2,5-Dimethoxyphenyl)-4-hydroxy-4-phenylbutan-2-yl]-triethylazanium",CC[N+](CC)(CC)C(C)CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O,,,,,,
818,120819,"alpha-(2,5-Dimethoxyphenyl)-gamma-methyl-alpha-phenyl-1-piperidinepropanol hydrochloride",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)N3CCCCC3.Cl,,,,,,
819,120820,"1-(2,5-Dimethoxyphenyl)-1-phenyl-3-piperidin-1-ylbutan-1-ol",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)N3CCCCC3,,,,,,
820,120821,"3-beta,17-Dihydroxy-16-beta-morpholino-5-alpha-pregnane-11,20-dione",CC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C)N5CCOCC5)O,,,,,,
821,120822,CID 120822,[Li+].CC(C(=O)[O-])O,,,,,,
822,120823,2-Chloropropyl(diethyl)amine hydrochloride,CCN(CC)CC(C)O.Cl,,,,,,
823,120824,((Dimethylamino)methyl)ethylene thiocyanate,CN(C)CC(CSC#N)SC#N,,,,,,
824,120825,Iqciaqzimsfuir-uhfffaoysa-,C1C2CC3CC1OP(=O)(O2)O3,,,,,,
825,120826,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-(hydroxymethyl)-6-methyl-",CC1CCCCC12C(=O)N(C(=O)N2)CO,,,,,,
826,120827,"3-(Hydroxymethyl)-8-methyl-1,3-diazaspiro[4.5]decane-2,4-dione",CC1CCC2(CC1)C(=O)N(C(=O)N2)CO,,,,,,
827,120828,"1-Acetyl-6-methyl-1,3-diazaspiro[4.5]decane-2,4-dione",CC1CCCCC12C(=O)NC(=O)N2C(=O)C,,,,,,
828,120829,CID 120829,CC1C(=O)N=C(N(C1=O)C2CCCCC2)[O-].[Na+],,,,,,
829,120830,"Hydantoin, 5-methyl-5-veratryl-",CC1(C(=O)NC(=O)N1)CC2=CC(=C(C=C2)OC)OC,,,,,,
830,120831,"4-(5-Chloro-2-(methylthio)phenyl)-N,N-dimethyl-4-phenylbutylamine hydrobromide",CN(C)CCCC(C1=CC=CC=C1)C2=C(C=CC(=C2)Cl)SC.Br,,,,,,
831,120832,"4-(5-chloro-2-methylsulfanylphenyl)-N,N-dimethyl-4-phenylbutan-1-amine",CN(C)CCCC(C1=CC=CC=C1)C2=C(C=CC(=C2)Cl)SC,,,,,,
832,120833,Monocrotaline hydrochloride,C[C@H]1C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@]([C@]1(C)O)(C)O.Cl,,,,,,
833,120834,"(1R,4R,5R,6R)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.013,16]hexadec-10-ene-3,7-dione",C[C@H]1C(=O)O[C@@H]2CCN3C2C(=CC3)COC(=O)[C@]([C@]1(C)O)(C)O,,,,,,
834,120835,"Benzenemethanol, alpha-(2-(dimethylamino)propyl)-2,5-dimethoxy-alpha-phenyl-, hydrochloride",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)N(C)C.Cl,,,,,,
835,120836,"1-(2,5-Dimethoxyphenyl)-3-(dimethylamino)-1-phenylbutan-1-ol",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)N(C)C,,,,,,
836,120837,"2,3-Dihydroxybutanedioic acid--2-methyl-1,2-di(pyridin-3-yl)propan-1-one (1/1)",CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2.[C@@H](C(C(=O)O)O)(C(=O)O)O,,,,,,
837,120838,CID 120838,CCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
838,120839,CID 120839,CCCCCCCCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
839,120840,Methyl methprothion,CCOP(=S)(OCC)SC(C)C(=O)OC,,,,,,
840,120841,"5-Phenyl-4,5-dihydro-1H-pyrazole",C1C=NNC1C2=CC=CC=C2,,,,,,
841,120842,3-(2-Oxooxolan-3-yl)propanoic acid,C1COC(=O)C1CCC(=O)O,,,,,,
842,120843,(R)-alpha-((Dimethylamino)methyl)benzenemethanol hydrochloride,CN(C)C[C@@H](C1=CC=CC=C1)O.Cl,,,,,,
843,120844,Ubine,CN(C)C[C@@H](C1=CC=CC=C1)O,,,,,,
844,120845,(+-)-alpha-((Dimethylamino)methyl)benzenemethanol hydrochloride,CN(C)CC(C1=CC=CC=C1)O.Cl,,,,,,
845,120846,2-(Dimethylamino)-1-phenylethanol,CN(C)CC(C1=CC=CC=C1)O,,,,,,
846,120847,"(S-(R*,R*))-alpha-(1-(Dimethylamino)ethyl)benzenemethanethiol hydrochloride",C[C@@H]([C@H](C1=CC=CC=C1)S)N(C)C.Cl,,,,,,
847,120848,"(1S,2S)-2-(dimethylamino)-1-phenylpropane-1-thiol",C[C@@H]([C@H](C1=CC=CC=C1)S)N(C)C,,,,,,
848,120849,"[[(1R,3S,4S,6S)-3-chloro-6-cyano-2-bicyclo[2.2.1]heptanylidene]amino] N-methylcarbamate",CNC(=O)ON=C1[C@@H]2C[C@H]([C@@H]1Cl)C[C@@H]2C#N,,,,,,
849,120850,(+-)-S-(2-(Dimethylamino)-1-phenylethyl) thiosulfate,CN(C)CC(C1=CC=CC=C1)SS(=O)(=O)O,,,,,,
850,120851,CID 120851,CN(C)C[C@@H](CSS(=O)(=O)O)C1=CC=CC=C1,,,,,,
851,120852,Metalol hydrochloride,CC(C(C1=CC=C(C=C1)NS(=O)(=O)C)O)NC.Cl,,,,,,
852,120853,"3-(4-Hydroxy-3-propionylphenoxy)-1,2-propanediol",CCC(=O)C1=C(C=CC(=C1)OCC(CO)O)O,,,,,,
853,120854,"3-Piperidino-1,2-propanediol 1-carbanilate hydrochloride",C1CCN(CC1)CC(COC(=O)NC2=CC=CC=C2)O.Cl,,,,,,
854,120855,(2-hydroxy-3-piperidin-1-ylpropyl) N-phenylcarbamate,C1CCN(CC1)CC(COC(=O)NC2=CC=CC=C2)O,,,,,,
855,120856,4-(Diethylamino)-1-(furan-2-yl)-1-phenylbut-2-yn-1-ol,CCN(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CO2)O,,,,,,
856,120857,"2-Thiophenemethanol, alpha-(3-(diethylamino)-1-propynyl)-alpha-phenyl-, hydrochloride",CCN(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CS2)O.Cl,,,,,,
857,120858,4-(Diethylamino)-1-phenyl-1-(2-thienyl)-2-butyn-1-ol,CCN(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CS2)O,,,,,,
858,120859,"Carbamimidothioic acid, N-cyclohexyl-N'-((4-methylphenyl)sulfonyl)-, methyl ester",CC1=CC=C(C=C1)S(=O)(=O)NC(=NC2CCCCC2)SC,,,,,,
859,120860,Methyl N'-((4-chlorophenyl)sulfonyl)-N-cyclohexylcarbamimidothioate,CSC(=NC1CCCCC1)NS(=O)(=O)C2=CC=C(C=C2)Cl,,,,,,
860,120861,"alpha-(2,2-Diphenylethyl)-1-pyrrolidineethanol hydrochloride",C1CCN(C1)CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
861,120862,"alpha-(2,2-Diphenylethyl)-1-pyrrolidineethanol",C1CCN(C1)CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
862,120863,"alpha-(2,2-Diphenylvinyl)-1-pyrrolidineethanol hydrochloride",C1CCN(C1)CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
863,120864,"alpha-(2,2-Diphenylvinyl)-1-pyrrolidineethanol",C1CCN(C1)CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
864,120865,CID 120865,C1COCCN1CC(C=C(C2=CC=CC=C2)C3=CC=CS3)O.Cl,,,,,,
865,120866,CID 120866,C1COCCN1CC(C=C(C2=CC=CC=C2)C3=CC=CS3)O,,,,,,
866,120867,"5,6-Dihydro-11-(3-dimethylaminopropyl)-11-hydroxy-6-dibenz(b,e)azepinone",CN(C)CCCC1(C2=CC=CC=C2C(=O)NC3=CC=CC=C31)O,,,,,,
867,120868,"6,7,8,9-Tetrahydro-6-oxo-2,3,4-trimethoxy-5H-benzocycloheptene-5-propanoic acid",COC1=C(C(=C2C(C(=O)CCCC2=C1)CCC(=O)O)OC)OC,,,,,,
868,120869,CID 120869,COP(=S)(OC)SC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
869,120870,"alpha-(2,2-Diphenylethyl)-1-piperidineethanol hydrochloride",C1CCN(CC1)CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
870,120871,"alpha-(2,2-Diphenylethyl)-1-piperidineethanol",C1CCN(CC1)CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
871,120872,"alpha-(2,2-Diphenylvinyl)-1-piperidineethanol hydrochloride",C1CCN(CC1)CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
872,120873,"alpha-(2,2-Diphenylvinyl)-1-piperidineethanol",C1CCN(CC1)CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
873,120874,"1-(Morpholin-4-yl)-4,4-diphenylbutan-2-ol",C1COCCN1CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
874,120875,"alpha-(2,2-Diphenylethyl)-4-morpholineethanol hydrochloride",C1COCCN1CC(CC(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
875,120876,"alpha-(2,2-Diphenylvinyl)-4-morpholineethanol hydrochloride",C1COCCN1CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O.Cl,,,,,,
876,120877,"alpha-(2,2-Diphenylvinyl)-4-morpholineethanol",C1COCCN1CC(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
877,120878,"Methyl 6,7-didehydro-2,20-cycloaspidospermidine-3-carboxylate--hydrogen chloride (1/2)",CC1C23CC(C14C5(C2N(CC5)CC=C3)C6=CC=CC=C6N4)C(=O)OC.Cl.Cl,,,,,,
878,120879,"Methyl 6,7-didehydro-2,20-cycloaspidospermidine-3-carboxylate",CC1C23CC(C14C5(C2N(CC5)CC=C3)C6=CC=CC=C6N4)C(=O)OC,,,,,,
879,120880,CID 120880,CC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
880,120881,CID 120881,CCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
881,120882,Stauffer B-9625,CC1(OCCS1)CSP(=S)(OC)OC,,,,,,
882,120883,"O,O-Dimethyl S-((2-methyl-1,3-dithiolan-2-yl)methyl)phosphorodithioate",CC1(SCCS1)CSP(=S)(OC)OC,,,,,,
883,120884,"3,3-Dimethyl-2-phenylmorpholine",CC1(C(OCCN1)C2=CC=CC=C2)C,,,,,,
884,120885,1-Chloro-4-(phenylsulfinyl)benzene,C1=CC=C(C=C1)S(=O)C2=CC=C(C=C2)Cl,,,,,,
885,120886,alpha-Phenyl-1-piperidineethanethiol hydrochloride,C1CCN(CC1)CC(C2=CC=CC=C2)S.Cl,,,,,,
886,120887,1-Phenyl-2-piperidin-1-ylethanethiol,C1CCN(CC1)CC(C2=CC=CC=C2)S,,,,,,
887,120888,alpha-((2-Pyridylamino)methyl)cyclohexanemethanol hydrochloride,C1CCC(CC1)C(CNC2=CC=CC=N2)O.Cl,,,,,,
888,120889,1-Cyclohexyl-2-(pyridin-2-ylamino)ethanol,C1CCC(CC1)C(CNC2=CC=CC=N2)O,,,,,,
889,120890,Endosulfan hydroxyether,C1C2C(C(O1)O)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
890,120891,CID 120891,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C=CC4,,,,,,
891,120892,"Urea, N-cyclohexyl-N'-(3,4,5-trimethoxyphenyl)-",COC1=CC(=CC(=C1OC)OC)NC(=O)NC2CCCCC2,,,,,,
892,120893,CID 120893,COC1=C2C3=C(C[C@H]4[C@H]5[C@]3(CCN4CC=C)[C@@H](O2)[C@H](C=C5)O)C=C1.Br,,,,,,
893,120894,CID 120894,COC1=C2C3=C(C[C@H]4[C@H]5[C@]3(CCN4CC=C)[C@@H](O2)[C@H](C=C5)O)C=C1,,,,,,
894,120895,"3-(alpha,alpha,alpha-Trifluoro-m-tolyl)-3-pyrrolidinol hydrochloride",C1CNCC1(C2=CC=C(C=C2)C(F)(F)F)O.Cl,,,,,,
895,120896,3-[4-(Trifluoromethyl)phenyl]pyrrolidin-3-ol,C1CNCC1(C2=CC=C(C=C2)C(F)(F)F)O,,,,,,
896,120897,CID 120897,CCCCCCCCN1[C@@H]2CC[C@H]1CC(C2)OC3C4=CC=CC=C4CCC5=CC=CC=C35.C(=CC(=O)O)C(=O)O,,,,,,
897,120898,"(1R,5S)-8-octyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)-8-azabicyclo[3.2.1]octane",CCCCCCCCN1[C@@H]2CC[C@H]1CC(C2)OC3C4=CC=CC=C4CCC5=CC=CC=C35,,,,,,
898,120899,CID 120899,CC1C2C(CCC1=CC(=O)OCCNC)C3(CCC(C(C3CC2=O)(C)C)OC(=O)C=C(C)C)C,,,,,,
899,120900,CID 120900,C1CCN(CC1)CC2(COC2)COC3=CC=C(C=C3)Cl.C(=CC(=O)O)C(=O)O,,,,,,
900,120901,1-[[3-[(4-Chlorophenoxy)methyl]oxetan-3-yl]methyl]piperidine,C1CCN(CC1)CC2(COC2)COC3=CC=C(C=C3)Cl,,,,,,
901,120902,CID 120902,CN(C)CC1(COC1)COC2=CC=CC=C2.C(=CC(=O)O)C(=O)O,,,,,,
902,120903,"N,N-dimethyl-1-[3-(phenoxymethyl)oxetan-3-yl]methanamine",CN(C)CC1(COC1)COC2=CC=CC=C2,,,,,,
903,120904,"2-Thiophenemethanol, alpha-phenyl-alpha-(3-(1-pyrrolidinyl)-1-propynyl)-, hydrochloride",C1CCN(C1)CC#CC(C2=CC=CC=C2)(C3=CC=CS3)O.Cl,,,,,,
904,120905,1-(2-Thienyl)-1-phenyl-4-pyrrolizino-2-butyn-1-ol,C1CCN(C1)CC#CC(C2=CC=CC=C2)(C3=CC=CS3)O,,,,,,
905,120906,"Glutarimide, 3-butyl-3-methyl-N-phenethyl-",CCCCC1(CC(=O)N(C(=O)C1)CCC2=CC=CC=C2)C,,,,,,
906,120907,"2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-methyl-6-propyl-, (+-)-",CCCC12CCN(C(C1)CC3=C2C=C(C=C3)O)C,,,,,,
907,120908,1-(p-Chlorobenzyl)-2-oxocyclohexanepropionic acid,C1CCC(C(=O)C1)(CCC(=O)O)CC2=CC=C(C=C2)Cl,,,,,,
908,120909,Palmitoyl-L-aspartic acid,CCCCCCCCCCCCCCCC(=O)N[C@@H](CC(=O)O)C(=O)O,,,,,,
909,120910,3-(m-Acetoxyphenyl)-3-ethyl-1-methylpyrrolidine,CCC1(CCN(C1)C)C2=CC(=CC=C2)OC(=O)C,,,,,,
910,120911,CID 120911,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=C(C(=C3)OC)OC)OC.Cl,,,,,,
911,120912,CID 120912,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=C(C(=C3)OC)OC)OC,,,,,,
912,120913,"1-[3-(2-Phenylethenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)C=CC3=CC=CC=C3,,,,,,
913,120914,CID 120914,CCN(CC)CC1(COC1)COC2=C(C=C(C=C2)Cl)Cl.C(=CC(=O)O)C(=O)O,,,,,,
914,120915,"N-[[3-[(2,4-dichlorophenoxy)methyl]oxetan-3-yl]methyl]-N-ethylethanamine",CCN(CC)CC1(COC1)COC2=C(C=C(C=C2)Cl)Cl,,,,,,
915,120916,"Phenethylamine, m-trifluoromethyl-alpha,N,N-trimethyl-",CC(CC1=CC=C(C=C1)C(F)(F)F)N(C)C,,,,,,
916,120917,4-(2-((p-Fluoro-alpha-phenylbenzyl)oxy)ethyl)morpholine hydrochloride,C1COCCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F.Cl,,,,,,
917,120918,4-[2-[(4-Fluorophenyl)-phenylmethoxy]ethyl]morpholine,C1COCCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F,,,,,,
918,120919,"2-Methyl-3-(alpha,alpha,alpha-trifluoro-m-tolyl)-3-pyrrolidinol hydrochloride",CC1C(CCN1)(C2=CC(=CC=C2)C(F)(F)F)O.Cl,,,,,,
919,120920,2-Methyl-3-[3-(trifluoromethyl)phenyl]pyrrolidin-3-ol,CC1C(CCN1)(C2=CC(=CC=C2)C(F)(F)F)O,,,,,,
920,120921,CID 120921,C1CCC(CC1)OC(=O)CCC(=O)[O-].[Na+],,,,,,
921,120922,4-(Cyclohexyloxy)-4-oxobutanoic acid,C1CCC(CC1)OC(=O)CCC(=O)O,,,,,,
922,120923,"9-Hydroxy-7-(hydroxymethyl)-4-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-2H-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid",COC1=CC(=CC(=C1OC)OC)C2=C3C(=C(C4=C2C[C@H]([C@@H](C4)CO)C(=O)O)O)OCO3,,,,,,
923,120924,"17-Oxo-4-propyl-2,16,19,20-tetrahydrocuraninium chloride",CCC[N+]12CCC34[C@@H]1C[C@@H](C(=CC)C2)C(=C3NC5=CC=CC=C45)C=O.[Cl-],,,,,,
924,120925,"(11S,17S)-12-ethylidene-14-propyl-8-aza-14-azoniapentacyclo[9.5.2.01,9.02,7.014,17]octadeca-2,4,6,9-tetraene-10-carbaldehyde",CCC[N+]12CCC34[C@@H]1C[C@@H](C(=CC)C2)C(=C3NC5=CC=CC=C45)C=O,,,,,,
925,120926,"alpha,4-Dimethyl-1-piperazineacetic acid 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCN(CC2)C.Cl,,,,,,
926,120927,"(2,6-Dimethylphenyl) 2-(4-methylpiperazin-1-yl)propanoate",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCN(CC2)C,,,,,,
927,120928,"alpha-Ethyl-1-piperidineacetic acid 2,6-xylyl ester hydrochloride",CCC(C(=O)OC1=C(C=CC=C1C)C)N2CCCCC2.Cl,,,,,,
928,120929,"(2,6-Dimethylphenyl) 2-piperidin-1-ylbutanoate",CCC(C(=O)OC1=C(C=CC=C1C)C)N2CCCCC2,,,,,,
929,120930,"4-Methyl-alpha-phenyl-1-piperazineacetic acid 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)C(CC2=CC=CC=C2)N3CCN(CC3)C.Cl,,,,,,
930,120931,"(2,6-Dimethylphenyl) 2-(4-methylpiperazin-1-yl)-3-phenylpropanoate",CC1=C(C(=CC=C1)C)OC(=O)C(CC2=CC=CC=C2)N3CCN(CC3)C,,,,,,
931,120932,"alpha,4-Dimethyl-1-piperazineacetic acid 2,6-diethylphenyl ester dihydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)C(C)N2CCN(CC2)C.Cl.Cl,,,,,,
932,120933,"(2,6-Diethylphenyl) 2-(4-methylpiperazin-1-yl)propanoate",CCC1=C(C(=CC=C1)CC)OC(=O)C(C)N2CCN(CC2)C,,,,,,
933,120934,"alpha-Ethyl-4-methyl-1-piperazineacetic acid 2,6-diethylphenyl ester dihydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)C(CC)N2CCN(CC2)C.Cl.Cl,,,,,,
934,120935,"(2,6-Diethylphenyl) 2-(4-methylpiperazin-1-yl)butanoate",CCC1=C(C(=CC=C1)CC)OC(=O)C(CC)N2CCN(CC2)C,,,,,,
935,120936,"alpha,4-Dimethyl-1-piperazineacetic acid 2,6-diisopropylphenyl ester dihydrochloride",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C(C)N2CCN(CC2)C.Cl.Cl,,,,,,
936,120937,"[2,6-Di(propan-2-yl)phenyl] 2-(4-methylpiperazin-1-yl)propanoate",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C(C)N2CCN(CC2)C,,,,,,
937,120938,"4-Benzyl-alpha-methyl-1-piperazineacetic acid 2,6-diisopropylphenyl ester dihydrochloride",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C(C)N2CCN(CC2)CC3=CC=CC=C3.Cl.Cl,,,,,,
938,120939,"[2,6-Di(propan-2-yl)phenyl] 2-(4-benzylpiperazin-1-yl)propanoate",CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C(C)N2CCN(CC2)CC3=CC=CC=C3,,,,,,
939,120940,N-((6-Methyl-8-beta-ergolinyl)methyl)nicotinamide,CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CNC(=O)C5=CN=CC=C5,,,,,,
940,120941,1-Styrylpiperidine,C1CCN(CC1)C=CC2=CC=CC=C2,,,,,,
941,120942,Copper citrate,C(C(=O)O)C(CC(=O)O)(C(=O)O)O.[Cu+2].[Cu+2],,,,,,
942,120943,Butyl(triethyl)germane,CCCC[Ge](CC)(CC)CC,,,,,,
943,120944,Ketothion,CCOP(=S)(OCC)SCC(=O)C,,,,,,
944,120945,"O,O-Diethyl S-pentyl phosphorothioate",CCCCCSP(=O)(OCC)OCC,,,,,,
945,120946,"Phosphorothioic acid, O,O-diethyl S-nonyl ester",CCCCCCCCCSP(=O)(OCC)OCC,,,,,,
946,120947,"Thiocyanic acid, 2-(dimethylamino)trimethylene ester",CN(C)C(CSC#N)CSC#N,,,,,,
947,120948,CID 120948,CO[N+](=CC(=O)NC=CC(=O)N)[O-],,,,,,
948,120949,"1-(2-Chlorobenzyl)-1,2-dihydro-3H-indazol-3-one",C1=CC=C(C(=C1)CN2C3=CC=CC=C3C(=O)N2)Cl,,,,,,
949,120950,"1H-Indazol-3-ol, 1-(m-chlorobenzyl)-",C1=CC=C2C(=C1)C(=O)NN2CC3=CC(=CC=C3)Cl,,,,,,
950,120951,1-(p-Chlorobenzyl)-1H-indazol-3-ol,C1=CC=C2C(=C1)C(=O)NN2CC3=CC=C(C=C3)Cl,,,,,,
951,120952,"m-Benzenedisulfonamide, 4-amino-6-chloro-N,N'-dimethyl-",CNS(=O)(=O)C1=CC(=C(C=C1N)Cl)S(=O)(=O)NC,,,,,,
952,120953,3'-(2-Diethylaminoethyl)cyclohexanespiro-5'-hydantoin hydrochloride,CCN(CC)CCN1C(=O)C2(CCCCC2)NC1=O.Cl,,,,,,
953,120954,"3-[2-(Diethylamino)ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione",CCN(CC)CCN1C(=O)C2(CCCCC2)NC1=O,,,,,,
954,120955,"Piperazine, 1-(2-(1-naphthalenyl)ethyl)-4-phenyl-",C1CN(CCN1CCC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
955,120956,"Piperazine, 1-(2-chlorophenyl)-4-(1-naphthalenylmethyl)-",C1CN(CCN1CC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4Cl,,,,,,
956,120957,"Piperazine, 1-(4-chlorophenyl)-4-(1-naphthalenylmethyl)-",C1CN(CCN1CC2=CC=CC3=CC=CC=C32)C4=CC=C(C=C4)Cl,,,,,,
957,120958,"Piperazine, 1-(2,5-dimethoxyphenethyl)-4-(2-pyridyl)-, dihydrochloride",COC1=CC(=C(C=C1)OC)CCN2CCN(CC2)C3=CC=CC=N3.Cl.Cl,,,,,,
958,120959,"1-[2-(2,5-Dimethoxyphenyl)ethyl]-4-pyridin-2-ylpiperazine",COC1=CC(=C(C=C1)OC)CCN2CCN(CC2)C3=CC=CC=N3,,,,,,
959,120960,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-phenyl-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3)OC,,,,,,
960,120961,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(2-pyridyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=N3)OC,,,,,,
961,120962,"Piperazine, 1-((5-methoxy-2-benzofuranyl)methyl)-4-phenyl-",COC1=CC2=C(C=C1)OC(=C2)CN3CCN(CC3)C4=CC=CC=C4,,,,,,
962,120963,"Piperazine, 1-(4-chlorophenyl)-4-(2-(1-naphthalenyl)ethyl)-",C1CN(CCN1CCC2=CC=CC3=CC=CC=C32)C4=CC=C(C=C4)Cl,,,,,,
963,120964,"Piperazine, 1-(o-bromophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3Br)OC,,,,,,
964,120965,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-tolyl)-",CC1=CC=CC=C1N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
965,120966,"Piperazine, 1-(o-aminophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3N)OC,,,,,,
966,120967,"Phenol, o-(4-(3,4-dimethoxyphenethyl)-1-piperazinyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3O)OC,,,,,,
967,120968,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(p-tolyl)-",CC1=CC=C(C=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
968,120969,"Piperazine, 1-(p-chlorophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=C(C=C3)Cl)OC,,,,,,
969,120970,"Piperazine, 1-(4-chlorophenyl)-4-((5-methoxy-2-benzofuranyl)methyl)-",COC1=CC2=C(C=C1)OC(=C2)CN3CCN(CC3)C4=CC=C(C=C4)Cl,,,,,,
970,120971,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(2,6-xylyl)-",CC1=C(C(=CC=C1)C)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
971,120972,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-(methylthio)phenyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3SC)OC,,,,,,
972,120973,"Piperazine, 1-(2-(5-methoxy-2-methyl-3-benzofuranyl)ethyl)-4-phenyl-",CC1=C(C2=C(O1)C=CC(=C2)OC)CCN3CCN(CC3)C4=CC=CC=C4,,,,,,
973,120974,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(2,3-xylyl)-",CC1=C(C(=CC=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC)C,,,,,,
974,120975,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(3,4-xylyl)-",CC1=C(C=C(C=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC)C,,,,,,
975,120976,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(m-methoxyphenyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC(=CC=C3)OC)OC,,,,,,
976,120977,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(p-methoxyphenyl)-",COC1=CC=C(C=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
977,120978,"Piperazine, 1-(3-chlorophenyl)-4-(2-(5-methoxy-2-methyl-3-benzofuranyl)ethyl)-",CC1=C(C2=C(O1)C=CC(=C2)OC)CCN3CCN(CC3)C4=CC(=CC=C4)Cl,,,,,,
978,120979,"Piperazine, 1-(4-chlorophenyl)-4-(2-(5-methoxy-2-methyl-3-benzofuranyl)ethyl)-",CC1=C(C2=C(O1)C=CC(=C2)OC)CCN3CCN(CC3)C4=CC=C(C=C4)Cl,,,,,,
979,120980,"1,1'-Ethylenebis(4-benzylpiperazine) trimethiodide",CI.CI.CI.C1CN(CCN1CCN2CCN(CC2)CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
980,120981,1-Benzyl-4-[2-(4-benzyl-1-piperazinyl)ethyl]piperazine,C1CN(CCN1CCN2CCN(CC2)CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
981,120982,"1,3,8-Triazaspiro(4.5)decan-4-one, 3-acetyl-8-(3-(p-fluorobenzoyl)propyl)-1-phenyl-, hydrochloride",CC(=O)N1CN(C2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4.Cl,,,,,,
982,120983,"3-Acetyl-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one",CC(=O)N1CN(C2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4,,,,,,
983,120984,"Piperazine, 1,4-bis(3,4,5-trimethoxybenzoyl)-",COC1=CC(=CC(=C1OC)OC)C(=O)N2CCN(CC2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
984,120985,3-Aminopropyl dihydrogen phosphate,C(CN)COP(=O)(O)O,,,,,,
985,120986,(Propylsulfanyl)methanimidamide hydrobromide,CCCSC(=N)N.Br,,,,,,
986,120987,Propyl carbamimidothioate,CCCSC(=N)N,,,,,,
987,120988,CID 120988,C1CNCCC12C(=O)NC(=N2)[O-].[Na+],,,,,,
988,120989,"1,3,8-Triazaspiro[4.5]decane-2,4-dione",C1CNCCC12C(=O)NC(=O)N2,,,,,,
989,120990,"6-(4-chlorophenyl)-4,5-dihydropyridazin-3(2H)-one",C1CC(=O)NN=C1C2=CC=C(C=C2)Cl,,,,,,
990,120991,4-chloro-2-methyl-5-morpholinopyridazin-3(2H)-one,CN1C(=O)C(=C(C=N1)N2CCOCC2)Cl,,,,,,
991,120992,"Phosphinothioic acid, dimethyl-, O-(4-nitro-m-tolyl) ester",CC1=C(C=CC(=C1)OP(=S)(C)C)[N+](=O)[O-],,,,,,
992,120993,2-Methyl-1-[4-(trifluoromethyl)phenyl]propan-2-amine hydrochloride,CC(C)(CC1=CC=C(C=C1)C(F)(F)F)N.Cl,,,,,,
993,120994,2-Methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine,CC(C)(CC1=CC=C(C=C1)C(F)(F)F)N,,,,,,
994,120995,CID 120995,CC1=NC=C(C(=C1O)CO)CSS(=O)(=O)[O-].[Na+],,,,,,
995,120996,3-Hydroxy-4-(hydroxymethyl)-2-methyl-5-(sulfosulfanylmethyl)pyridine,CC1=NC=C(C(=C1O)CO)CSS(=O)(=O)O,,,,,,
996,120997,"3-Indazolinone, 4,5,6,7-tetrahydro-1-methyl-2-phenyl-",CN1C2=C(CCCC2)C(=O)N1C3=CC=CC=C3,,,,,,
997,120998,"Thioacetic acid, S-(2-phthalimidoethyl) ester",CC(=O)SCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
998,120999,"2H-1-Benzothiopyran-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide",C1CC2=CC(=C(C=C2S(=O)(=O)C1)S(=O)(=O)N)Cl,,,,,,
999,121000,Dimethyl 4-nitro-2-methylphenyl phosphate,CC1=C(C=CC(=C1)[N+](=O)[O-])OP(=O)(OC)OC,,,,,,
1000,121001,2-Methyl-4-nitrophenyl dimethyl phosphorothioate,CC1=C(C=CC(=C1)[N+](=O)[O-])OP(=S)(OC)OC,,,,,,
1001,121002,2-Amino-4-(p-(ethylthio)anilino)-s-triazine,CCSC1=CC=C(C=C1)NC2=NC=NC(=N2)N,,,,,,
1002,121003,"Acridine, 9-(2,2-dimethylhydrazino)-, monohydrochloride",CN(C)NC1=C2C=CC=CC2=NC3=CC=CC=C31.Cl,,,,,,
1003,121004,"Acridine, 9-(2,2-dimethylhydrazino)-",CN(C)NC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
1004,121005,"s-Triazine, 2-amino-4-(p-(isopropylthio)anilino)-",CC(C)SC1=CC=C(C=C1)NC2=NC=NC(=N2)N,,,,,,
1005,121006,8-(4-Pyridyl)theophylline,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=NC=C3,,,,,,
1006,121007,"1-Benzyl-2-(3-(4,5,6,7-tetrahydrobenzisoxazolyl)carbonyl)hydrazine hydrochloride",C1CCC2=C(C1)C(=NO2)C(=O)NNCC3=CC=CC=C3.Cl,,,,,,
1007,121008,"N'-benzyl-4,5,6,7-tetrahydro-1,2-benzoxazole-3-carbohydrazide",C1CCC2=C(C1)C(=NO2)C(=O)NNCC3=CC=CC=C3,,,,,,
1008,121009,CID 121009,CN(CC[N+]1=CC=C(C=C1)C=NO)CC[N+]2=CC=C(C=C2)C=NO.[Cl-].[Cl-],,,,,,
1009,121010,CID 121010,CN(CC[N+]1=CC=C(C=C1)C=NO)CC[N+]2=CC=C(C=C2)C=NO,,,,,,
1010,121011,CID 121011,C1=CC=C(C=C1)[S-].C1=CC=C(C=C1)[S-].C1=CC=C(C=C1)[Sn]C2=CC=CC=C2,,,,,,
1011,121012,"1,1'-Decamethylenebis(4-benzyl-1,4-dimethylpiperazinium) tetraiodide",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C.[I-].[I-].[I-].[I-],,,,,,
1012,121013,"1-Benzyl-4-[10-(4-benzyl-1,4-dimethylpiperazine-1,4-diium-1-yl)decyl]-1,4-dimethylpiperazine-1,4-diium",C[N+]1(CC[N+](CC1)(C)CC2=CC=CC=C2)CCCCCCCCCC[N+]3(CC[N+](CC3)(C)CC4=CC=CC=C4)C,,,,,,
1013,121014,"Propanedinitrile, [2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]-",C(#N)C(=C(C(F)(F)F)C(F)(F)F)C#N,,,,,,
1014,121015,Ethyl 3-(Dimethylamino)acrylate,CCOC(=O)C=CN(C)C,,,,,,
1015,121016,CID 121016,CC(=O)O.C[GeH](C)C,,,,,,
1016,121017,3-(Dodecylamino)propane-1-sulfonic acid,CCCCCCCCCCCCNCCCS(=O)(=O)O,,,,,,
1017,121018,5-Amino-1-isopropyl-3-methylpyrazole,CC1=NN(C(=C1)N)C(C)C,,,,,,
1018,121019,"1,3,5-Trimethyl-4-nitro-1H-pyrazole",CC1=C(C(=NN1C)C)[N+](=O)[O-],,,,,,
1019,121020,"3,4-Dihydro-1,3-benzoxazin-2-one",C1C2=CC=CC=C2OC(=O)N1,,,,,,
1020,121021,1-Phenyl-1H-pyrazol-4-amine,C1=CC=C(C=C1)N2C=C(C=N2)N,,,,,,
1021,121022,"1,3-Phenylene cyanate",C1=CC(=CC(=C1)OC#N)OC#N,,,,,,
1022,121023,Thiosulfanilic acid S-ethyl ester,CCSS(=O)(=O)C1=CC=C(C=C1)N,,,,,,
1023,121024,"6,7,8,9-Tetrahydro-dibenzofuran-2-ol",C1CCC2=C(C1)C3=C(O2)C=CC(=C3)O,,,,,,
1024,121025,3-phenyl-1H-pyrazole-5-carboxylic acid,C1=CC=C(C=C1)C2=NNC(=C2)C(=O)O,,,,,,
1025,121026,1-Phenyl-1H-pyrazole-4-carboxylic acid,C1=CC=C(C=C1)N2C=C(C=N2)C(=O)O,,,,,,
1026,121027,Iodoacetyl-1-naphthylamine,C1=CC=C2C(=C1)C=CC=C2NC(=O)CI,,,,,,
1027,121028,2-((4-Ethoxyphenyl)amino)-N-methylacetamide,CCOC1=CC=C(C=C1)NCC(=O)NC,,,,,,
1028,121029,1-Benzyl-3-methyl-1H-pyrazole-5-carboxylic acid,CC1=NN(C(=C1)C(=O)O)CC2=CC=CC=C2,,,,,,
1029,121030,"Acetamide, 2-((4-ethoxyphenyl)amino)-N-ethyl-",CCNC(=O)CNC1=CC=C(C=C1)OCC,,,,,,
1030,121031,CID 121031,C1=CC=C2C(=C1)N=C3C=CC=C(C3=N2)C(=O)[O-].[Na+],,,,,,
1031,121032,"2H-1,3,5-Thiadiazine-2-thione, tetrahydro-3-benzyl-5-(2-hydroxyethyl)-",C1N(CSC(=S)N1CC2=CC=CC=C2)CCO,,,,,,
1032,121033,2-(p-Chlorophenoxy)-N-(2-(dimethylamino)ethyl)acetamide,CN(C)CCNC(=O)COC1=CC=C(C=C1)Cl,,,,,,
1033,121034,"Theophylline, 7-isopentyl-",CC(C)CCN1C=NC2=C1C(=O)N(C(=O)N2C)C,,,,,,
1034,121035,Etifelmine hydrochloride,CCC(=C(C1=CC=CC=C1)C2=CC=CC=C2)CN.Cl,,,,,,
1035,121036,2-(4-chlorophenoxy)-N-[3-(dimethylamino)propyl]acetamide,CN(C)CCCNC(=O)COC1=CC=C(C=C1)Cl,,,,,,
1036,121037,CID 121037,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2.Cl,,,,,,
1037,121038,CID 121038,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2,,,,,,
1038,121039,2-((4-Ethoxyphenyl)amino)acetanilide,CCOC1=CC=C(C=C1)NCC(=O)NC2=CC=CC=C2,,,,,,
1039,121040,Phenylphosphonothioic acid O-ethyl O-(2-(fluoromethyl)-6-methyl-4-pyrimidinyl) ester,CCOP(=S)(C1=CC=CC=C1)OC2=NC(=NC(=C2)C)CF,,,,,,
1040,121041,"Stannane, azidotriphenyl-",C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)(C3=CC=CC=C3)N=[N+]=[N-],,,,,,
1041,121042,"1-Pyrrolidinebutanol, alpha,alpha-diphenyl-, hydrochloride",C1CCN(C1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O.Cl,,,,,,
1042,121043,"8-Quinolinol, 5-chloro-7-(2-((3-(diethylamino)propyl)amino)ethyl)-",CCN(CC)CCCNCCC1=CC(=C2C=CC=NC2=C1O)Cl,,,,,,
1043,121044,"1-(2-Chlorophenyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)piperazine",C1CN(CCN1CC2COC3=CC=CC=C3O2)C4=CC=CC=C4Cl,,,,,,
1044,121045,"1-(3-Chlorophenyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)piperazine",C1CN(CCN1CC2COC3=CC=CC=C3O2)C4=CC(=CC=C4)Cl,,,,,,
1045,121046,"1H-Indole, 5-methoxy-1-(phenylmethyl)-3-(2-(4-phenyl-1-piperazinyl)ethyl)-",COC1=CC2=C(C=C1)N(C=C2CCN3CCN(CC3)C4=CC=CC=C4)CC5=CC=CC=C5,,,,,,
1046,121047,"1H-Indole, 3-(2-(4-(4-chlorophenyl)-1-piperazinyl)ethyl)-5-methoxy-1-(phenylmethyl)-",COC1=CC2=C(C=C1)N(C=C2CCN3CCN(CC3)C4=CC=C(C=C4)Cl)CC5=CC=CC=C5,,,,,,
1047,121048,"3,3-Dimethylpiperidine-2,6-dione",CC1(CCC(=O)NC1=O)C,,,,,,
1048,121049,2-Hydroxy-3-methylbenzyldimethylamine hydrochloride,CC1=C(C(=CC=C1)CN(C)C)O.Cl,,,,,,
1049,121050,"Phenol, 2-[(dimethylamino)methyl]-6-methyl-",CC1=C(C(=CC=C1)CN(C)C)O,,,,,,
1050,121051,N-Acetyltyramine,CC(=O)NCCC1=CC=C(C=C1)O,,,,,,
1051,121052,2-Phenylbenzaldehyde,C1=CC=C(C=C1)C2=CC=CC=C2C=O,,,,,,
1052,121053,3-Phenylbenzaldehyde,C1=CC=C(C=C1)C2=CC=CC(=C2)C=O,,,,,,
1053,121054,CID 121054,CC1=CC=CC=C1NC(=NCC=C)S,,,,,,
1054,121055,"1,3,5-Benzenetricarbonitrile, 2,4,6-trimethyl-",CC1=C(C(=C(C(=C1C#N)C)C#N)C)C#N,,,,,,
1055,121056,CID 121056,COC1=CC=CC=C1NC(=NCC=C)S,,,,,,
1056,121057,"Propanedinitrile, ((2-methoxyphenyl)hydrazono)-",COC1=CC=CC=C1NN=C(C#N)C#N,,,,,,
1057,121058,"Propanedinitrile, ((2,5-dichlorophenyl)hydrazono)-",C1=CC(=C(C=C1Cl)NN=C(C#N)C#N)Cl,,,,,,
1058,121059,"Propanedinitrile, ((4-methoxyphenyl)hydrazono)-",COC1=CC=C(C=C1)NN=C(C#N)C#N,,,,,,
1059,121060,"Benzaldehyde, p-phenethyl-",C1=CC=C(C=C1)CCC2=CC=C(C=C2)C=O,,,,,,
1060,121061,"Acetamide, N-(o-chlorobenzyl)-2-(diethylamino)-, monohydrochloride",CCN(CC)CC(=O)NCC1=CC=CC=C1Cl.Cl,,,,,,
1061,121062,N-[(2-chlorophenyl)methyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NCC1=CC=CC=C1Cl,,,,,,
1062,121063,"3'-Hydroxy-2',4',6'-triiodosuccinanilic acid",C1=C(C(=C(C(=C1I)O)I)NC(=O)CCC(=O)O)I,,,,,,
1063,121064,"[2-Chloro-1-(2,5-dichlorophenyl)ethenoxy]-dimethoxy-sulfanylidene-lambda5-phosphane",COP(=S)(OC)OC(=CCl)C1=C(C=CC(=C1)Cl)Cl,,,,,,
1064,121065,5'-Chloro-2'-hydroxychalcone,C1=CC=C(C=C1)C=CC(=O)C2=C(C=CC(=C2)Cl)O,,,,,,
1065,121066,"1-Piperidineacetamide, N-(m-chlorobenzyl)-, monohydrochloride",C1CCN(CC1)CC(=O)NCC2=CC(=CC=C2)Cl.Cl,,,,,,
1066,121067,N-[(3-chlorophenyl)methyl]-2-piperidin-1-ylacetamide,C1CCN(CC1)CC(=O)NCC2=CC(=CC=C2)Cl,,,,,,
1067,121068,"4-(3-amino-2,4,6-triiodo-N-methylanilino)-4-oxobutanoic acid",CN(C1=C(C=C(C(=C1I)N)I)I)C(=O)CCC(=O)O,,,,,,
1068,121069,"Fluoren-9-amine, N-ethyl-N-(2-iodoethyl)-, hydrochloride",CCN(CCI)C1C2=CC=CC=C2C3=CC=CC=C13.Cl,,,,,,
1069,121070,N-ethyl-N-(2-iodoethyl)-9H-fluoren-9-amine,CCN(CCI)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
1070,121071,"3-Benzylidene-6-(2-methylpropylidene)piperazine-2,5-dione",CC(C)C=C1C(=O)NC(=CC2=CC=CC=C2)C(=O)N1,,,,,,
1071,121072,"4-Morpholineacetamide, N-(2,4-dimethylbenzyl)-, monohydrochloride",CC1=CC(=C(C=C1)CNC(=O)CN2CCOCC2)C.Cl,,,,,,
1072,121073,"N-[(2,4-dimethylphenyl)methyl]-2-morpholin-4-ylacetamide",CC1=CC(=C(C=C1)CNC(=O)CN2CCOCC2)C,,,,,,
1073,121074,2-(Cyclohexyloxy)-2-methyl-propionic acid 2-(diethylamino)ethyl ester hydrochloride,CCN(CC)CCOC(=O)C(C)(C)OC1CCCCC1.Cl,,,,,,
1074,121075,2-(Diethylamino)ethyl 2-cyclohexyloxy-2-methylpropanoate,CCN(CC)CCOC(=O)C(C)(C)OC1CCCCC1,,,,,,
1075,121076,"1H-Indazol-3-ol, 1-veratryl-",COC1=C(C=C(C=C1)CN2C3=CC=CC=C3C(=O)N2)OC,,,,,,
1076,121077,"3,6-Dimethoxy-4-sulfanilamidopyridazine",COC1=NN=C(C(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,,,,,,
1077,121078,"Urea, 3-(3,4-dichlorophenyl)-1-(2,2-diethoxyethyl)-1-methyl-",CCOC(CN(C)C(=O)NC1=C(C(=CC=C1)Cl)Cl)OCC,,,,,,
1078,121079,"7-[2-(Benzylamino)ethyl]-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCNCC3=CC=CC=C3.Cl,,,,,,
1079,121080,"Theophylline, 7-(2-(phenethylamino)ethyl)-, hydrochloride",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCNCCC3=CC=CC=C3.Cl,,,,,,
1080,121081,"1,3-Dimethyl-7-[2-(2-phenylethylamino)ethyl]purine-2,6-dione",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCNCCC3=CC=CC=C3,,,,,,
1081,121082,"1-(2,4-Dimethoxyphenethyl)-4-(2-pyridyl)piperazine dihydrochloride",COC1=C(C(=CC=C1)OC)CCN2CCN(CC2)C3=CC=CC=N3.Cl.Cl,,,,,,
1082,121083,"1-[2-(2,6-Dimethoxyphenyl)ethyl]-4-pyridin-2-ylpiperazine",COC1=C(C(=CC=C1)OC)CCN2CCN(CC2)C3=CC=CC=N3,,,,,,
1083,121084,2-(Carvacryloxy)-2-methyl-propionic acid 2-(diethylamino)ethyl ester hydrochloride,CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=CC(=C1)C(C)C)C.Cl,,,,,,
1084,121085,2-(Diethylamino)ethyl 2-methyl-2-(2-methyl-5-propan-2-ylphenoxy)propanoate,CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=CC(=C1)C(C)C)C,,,,,,
1085,121086,"11H-Dibenzo(b,e)(1,4)diazepin-11-one, 5,10-dihydro-7-chloro-10-(2-(morpholino)ethyl)-",C1COCCN1CCN2C3=C(C=C(C=C3)Cl)NC4=CC=CC=C4C2=O,,,,,,
1086,121087,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-fluorophenyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3F)OC,,,,,,
1087,121088,"Propionic acid, 2-(4-allyl-2-methoxyphenoxy)-2-methyl-, 2-(diethylamino)ethyl ester, monohydrochloride",CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=C(C=C1)CC=C)OC.Cl,,,,,,
1088,121089,2-(Diethylamino)ethyl 2-(2-methoxy-4-prop-2-enylphenoxy)-2-methylpropanoate,CCN(CC)CCOC(=O)C(C)(C)OC1=C(C=C(C=C1)CC=C)OC,,,,,,
1089,121090,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(m-tolyl)-",CC1=CC(=CC=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
1090,121091,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-methoxyphenyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3OC)OC,,,,,,
1091,121092,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(2,4-xylyl)-",CC1=CC(=C(C=C1)N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC)C,,,,,,
1092,121093,"Piperazine, 1-(2,4-dichlorophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=C(C=C(C=C3)Cl)Cl)OC,,,,,,
1093,121094,"Piperazine, 1-(2,5-dichlorophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=C(C=CC(=C3)Cl)Cl)OC,,,,,,
1094,121095,"4-[[4-[2-Chloroethyl(2-fluoroethyl)amino]phenyl]methylidene]-2-phenyl-1,3-oxazol-5-one",C1=CC=C(C=C1)C2=NC(=CC3=CC=C(C=C3)N(CCF)CCCl)C(=O)O2,,,,,,
1095,121096,"p-Benzoquinone, 2,5-bis((3-(diethylamino)propyl)amino)-",CCN(CC)CCCNC1=CC(=O)C(=CC1=O)NCCCN(CC)CC,,,,,,
1096,121097,Pitofenone hydrochloride,COC(=O)C1=CC=CC=C1C(=O)C2=CC=C(C=C2)OCCN3CCCCC3.Cl,,,,,,
1097,121098,Pitofenone,COC(=O)C1=CC=CC=C1C(=O)C2=CC=C(C=C2)OCCN3CCCCC3,,,,,,
1098,121099,4-Methyl-4-(2-(p-nitro-N-phenylbenzamido)ethyl)morpholinium bromide,C[N+]1(CCOCC1)CCN(C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-].[Br-],,,,,,
1099,121100,N-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]-4-nitro-N-phenylbenzamide,C[N+]1(CCOCC1)CCN(C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
1100,121101,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-nitrophenyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC=CC=C3[N+](=O)[O-])OC,,,,,,
1101,121102,"Piperazine, 1-(3,4-dimethoxyphenethyl)-4-(o-ethoxyphenyl)-",CCOC1=CC=CC=C1N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
1102,121103,CID 121103,C1=C[N+](=CC=C1C=NO)COCC(COC[N+]2=CC=C(C=C2)C=NO)(CBr)CBr.[Cl-].[Cl-],,,,,,
1103,121104,CID 121104,C1=C[N+](=CC=C1C=NO)COCC(COC[N+]2=CC=C(C=C2)C=NO)(CBr)CBr,,,,,,
1104,121105,CID 121105,O.[TlH].[TlH],,,,,,
1105,121106,"5H-Dibenzo(a,d)cycloheptene-5-carboxylic acid, 10,11-dihydro-, 2-diethylaminoethyl ester, hydrochloride",CCN(CC)CCOC(=O)C1C2=CC=CC=C2CCC3=CC=CC=C13.Cl,,,,,,
1106,121107,"2-(Diethylamino)ethyl tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxylate",CCN(CC)CCOC(=O)C1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
1107,121108,Perithiaden,CN1CCC(=C2C3=CC=CC=C3CSC4=CC=CC=C42)CC1,,,,,,
1108,121109,Tris(p-dimethylaminophenyl)phosphine sulfide,CN(C)C1=CC=C(C=C1)P(=S)(C2=CC=C(C=C2)N(C)C)C3=CC=C(C=C3)N(C)C,,,,,,
1109,121110,4-[Bis(2-chloroethyl)amino]phenyl acetate,CC(=O)OC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
1110,121111,Octaethylcyclotetrasiloxane,CC[Si]1(O[Si](O[Si](O[Si](O1)(CC)CC)(CC)CC)(CC)CC)CC,,,,,,
1111,121112,2-Methyl-2-(phenethyloxy)propionic acid 2-(diethylamino)ethyl ester hydrochloride,CCN(CC)CCOC(=O)C(C)(C)OCCC1=CC=CC=C1.Cl,,,,,,
1112,121113,2-(Diethylamino)ethyl 2-methyl-2-(2-phenylethoxy)propanoate,CCN(CC)CCOC(=O)C(C)(C)OCCC1=CC=CC=C1,,,,,,
1113,121114,Lidocaine methiodide,CC[N+](C)(C)CC(=O)NC1=C(C=CC=C1C)C.[I-],,,,,,
1114,121115,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-ethyl-dimethylazanium",CC[N+](C)(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
1115,121116,"Benzamide, N-(4-piperidino-2-butynyl)-",C1CCN(CC1)CC#CCNC(=O)C2=CC=CC=C2,,,,,,
1116,121117,"5-Chloro-2-phenyl-1,3-indandione",C1=CC=C(C=C1)C2C(=O)C3=C(C2=O)C=C(C=C3)Cl,,,,,,
1117,121118,"4-Bromo-2-phenyl-1,3-indandione",C1=CC=C(C=C1)C2C(=O)C3=C(C2=O)C(=CC=C3)Br,,,,,,
1118,121119,"1,3-Diethyl-2-(2-(dimethylamino)ethyl)-2-thiopseudourea dihydrobromide",CCNC(=NCC)SCCN(C)C.Br.Br,,,,,,
1119,121120,"2-(dimethylamino)ethyl N,N'-diethylcarbamimidothioate",CCNC(=NCC)SCCN(C)C,,,,,,
1120,121121,"2-(Bis(2-chloroethyl)amino)-N,N-diethylacetamide hydrochloride",CCN(CC)C(=O)CN(CCCl)CCCl.Cl,,,,,,
1121,121122,"2-[bis(2-chloroethyl)amino]-N,N-diethylacetamide",CCN(CC)C(=O)CN(CCCl)CCCl,,,,,,
1122,121123,"Morpholinium, 4-methyl-4-(3-(p-nitrobenzamido)propyl)-, bromide",C[N+]1(CCOCC1)CCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-].[Br-],,,,,,
1123,121124,N-[3-(4-methylmorpholin-4-ium-4-yl)propyl]-4-nitrobenzamide,C[N+]1(CCOCC1)CCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1124,121125,"Morpholinium, 4-methyl-4-(2-(p-nitrobenzamido)ethyl)-, bromide",C[N+]1(CCOCC1)CCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-].[Br-],,,,,,
1125,121126,N-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]-4-nitrobenzamide,C[N+]1(CCOCC1)CCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1126,121127,4-(3-(N-Benzylbenzamido)propyl)-4-methylmorpholinium bromide,C[N+]1(CCOCC1)CCCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Br-],,,,,,
1127,121128,N-benzyl-N-[3-(4-methylmorpholin-4-ium-4-yl)propyl]benzamide,C[N+]1(CCOCC1)CCCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
1128,121129,4-(2-(N-Benzylbenzamido)ethyl)-4-methylmorpholinium bromide,C[N+]1(CCOCC1)CCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Br-],,,,,,
1129,121130,N-benzyl-N-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]benzamide,C[N+]1(CCOCC1)CCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
1130,121131,"Benzamide, N-(2-morpholinoethyl)-p-nitro-, hydrochloride",C1COCCN1CCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-].Cl,,,,,,
1131,121132,N-[2-(morpholin-4-yl)ethyl]-4-nitrobenzamide,C1COCCN1CCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1132,121133,N-(3-morpholin-4-ylpropyl)-4-nitrobenzamide hydrochloride,C1COCCN1CCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-].Cl,,,,,,
1133,121134,N-(3-Morpholinopropyl)-4-nitrobenzamide,C1COCCN1CCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1134,121135,"Guanidine, N'-cyano-N,N-dimethyl-",CN(C)C(=NC#N)N,,,,,,
1135,121136,"4,4-Dimethyl-2-(2-phenylethenyl)-2-oxazoline",CC1(COC(=N1)C=CC2=CC=CC=C2)C,,,,,,
1136,121137,"N-Phenyl-5-(4-pyridinyl)-1,3,4-oxadiazol-2-amine",C1=CC=C(C=C1)NC2=NN=C(O2)C3=CC=NC=C3,,,,,,
1137,121138,"Succinic acid mono-3-amino-2,4,6-triiodo-N-ethylanilide",CCN(C1=C(C=C(C(=C1I)N)I)I)C(=O)CCC(=O)O,,,,,,
1138,121139,CID 121139,CC(=O)O.CC(C)(C[SnH](CC(C)(C)C1=CC=CC=C1)CC(C)(C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1139,121140,"Morpholinium, 4-(2-(N-benzyl-p-nitrobenzamido)ethyl)-4-methyl-, bromide",C[N+]1(CCOCC1)CCN(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-].[Br-],,,,,,
1140,121141,N-benzyl-N-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]-4-nitrobenzamide,C[N+]1(CCOCC1)CCN(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
1141,121142,Tripropyl phosphorotrithioate,CCCSP(=O)(SCCC)SCCC,,,,,,
1142,121143,"Phenethylamine, alpha,alpha-dimethyl-m-trifluoromethyl-",CC(C)(CC1=CC(=CC=C1)C(F)(F)F)N,,,,,,
1143,121144,"Phosphorothioic acid, O,O-diethyl S-(2-(ethyl(2-fluoroethyl)amino)ethyl) ester",CCN(CCF)CCSP(=O)(OCC)OCC,,,,,,
1144,121145,"Phosphorodithioic acid, S-(2-(bis(2-fluoroethyl)amino)ethyl) O,O-diethyl ester",CCOP(=S)(OCC)SCCN(CCF)CCF,,,,,,
1145,121146,CID 121146,CC(C)(C=NOC(=O)NC)OC,,,,,,
1146,121147,Phenylphosphoramidic acid diisopropyl ester,CC(C)OP(=O)(NC1=CC=CC=C1)OC(C)C,,,,,,
1147,121148,Ethyl methyl sulfoxide,CCS(=O)C,,,,,,
1148,121149,"Carbamic acid, acetyl-, 2-methyl-2-propyltrimethylene ester",CCCC(C)(COC(=O)NC(=O)C)COC(=O)NC(=O)C,,,,,,
1149,121150,"5-(2,3,4-Trimethoxyphenyl)-1,3,4-oxadiazol-2-amine",COC1=C(C(=C(C=C1)C2=NN=C(O2)N)OC)OC,,,,,,
1150,121151,"5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-amine",C1=CC(=CC(=C1)Cl)C2=NN=C(O2)N,,,,,,
1151,121152,"Pyrrolidinium, 1-(2-(1,3-dihydro-2-oxo-3,5,7-trimethyl-2H-azepin-1-yl)ethyl)-1-methyl-, iodide",CC1C=C(C=C(N(C1=O)CC[N+]2(CCCC2)C)C)C.[I-],,,,,,
1152,121153,"3,5,7-trimethyl-1-[2-(1-methylpyrrolidin-1-ium-1-yl)ethyl]-3H-azepin-2-one",CC1C=C(C=C(N(C1=O)CC[N+]2(CCCC2)C)C)C,,,,,,
1153,121154,"3-(p-Chlorophenyl)-N-(3,4-dimethoxyphenethyl)propylamine hydrochloride",COC1=C(C=C(C=C1)CCNCCCC2=CC=C(C=C2)Cl)OC.Cl,,,,,,
1154,121155,"3-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]propan-1-amine",COC1=C(C=C(C=C1)CCNCCCC2=CC=C(C=C2)Cl)OC,,,,,,
1155,121156,"4-Methyl-4-[2-(3,5,7-trimethyl-2-oxo-2,3-dihydro-1h-azepin-1-yl)ethyl]morpholin-4-ium iodide",CC1C=C(C=C(N(C1=O)CC[N+]2(CCOCC2)C)C)C.[I-],,,,,,
1156,121157,"3,5,7-trimethyl-1-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]-3H-azepin-2-one",CC1C=C(C=C(N(C1=O)CC[N+]2(CCOCC2)C)C)C,,,,,,
1157,121158,"1,3,5,7,2,4,6,8-Tetrazatetraphosphocine, 2,2,4,4,6,6,8,8-octakis(dimethylamino)-",CN(C)P1(=NP(=NP(=NP(=N1)(N(C)C)N(C)C)(N(C)C)N(C)C)(N(C)C)N(C)C)N(C)C,,,,,,
1158,121159,4'-Methoxy-3-morpholinopropiophenone hydrochloride,COC1=CC=C(C=C1)C(=O)CCN2CCOCC2.Cl,,,,,,
1159,121160,4'-Methoxy-3-morpholino-propiophenone,COC1=CC=C(C=C1)C(=O)CCN2CCOCC2,,,,,,
1160,121161,"Butyraldehyde, 4-chloro-4,4-difluoro-3-hydroxy-3-(chlorodifluoromethyl)-",C(C=O)C(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
1161,121162,"Morpholine, 4-((bis(2-chloroethyl)amino)acetyl)-, hydrochloride",C1COCCN1C(=O)CN(CCCl)CCCl.Cl,,,,,,
1162,121163,2-[Bis(2-chloroethyl)amino]-1-morpholin-4-ylethanone,C1COCCN1C(=O)CN(CCCl)CCCl,,,,,,
1163,121164,1-((Bis(2-chloroethyl)amino)acetyl)piperidine hydrochloride,C1CCN(CC1)C(=O)CN(CCCl)CCCl.Cl,,,,,,
1164,121165,2-[Bis(2-chloroethyl)amino]-1-piperidin-1-ylethanone,C1CCN(CC1)C(=O)CN(CCCl)CCCl,,,,,,
1165,121166,"1,4-Bis((bis(2-chloroethyl)amino)acetyl)piperazine dihydrochloride",C1CN(CCN1C(=O)CN(CCCl)CCCl)C(=O)CN(CCCl)CCCl.Cl.Cl,,,,,,
1166,121167,2-[Bis(2-chloroethyl)amino]-1-[4-[2-[bis(2-chloroethyl)amino]acetyl]piperazin-1-yl]ethanone,C1CN(CCN1C(=O)CN(CCCl)CCCl)C(=O)CN(CCCl)CCCl,,,,,,
1167,121168,"6-Methylthieno[3,4-c]pyridin-7-ol",CC1=C(C2=CSC=C2C=N1)O,,,,,,
1168,121169,"1-Pyrrolidin-1-yl-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCCC2,,,,,,
1169,121170,"1-(4-Methylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CN1CCN(CC1)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1170,121171,"Morpholine, 4-(m-(dimethylamino)benzoyl)-",CN(C)C1=CC=CC(=C1)C(=O)N2CCOCC2,,,,,,
1171,121172,"Piperidine, 1-(m-(dimethylamino)benzoyl)-",CN(C)C1=CC=CC(=C1)C(=O)N2CCCCC2,,,,,,
1172,121173,[3-(Dimethylamino)phenyl](pyrrolidin-1-yl)methanone,CN(C)C1=CC=CC(=C1)C(=O)N2CCCC2,,,,,,
1173,121174,"Theophylline, 7-(p-(dimethylamino)benzyl)-, hydrochloride",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3=CC=C(C=C3)N(C)C.Cl,,,,,,
1174,121175,"Benz(cd)indol-2(1H)-one, 1-methyl-",CN1C2=CC=CC3=C2C(=CC=C3)C1=O,,,,,,
1175,121176,"Piperidinium, 1,1'-(1,4-piperazinediylbis(1-oxopropylene))bis(1-methyl-, diiodide",C[N+]1(CCCCC1)CCC(=O)N2CCN(CC2)C(=O)CC[N+]3(CCCCC3)C.[I-].[I-],,,,,,
1176,121177,3-(1-Methylpiperidin-1-ium-1-yl)-1-[4-[3-(1-methylpiperidin-1-ium-1-yl)propanoyl]piperazin-1-yl]propan-1-one,C[N+]1(CCCCC1)CCC(=O)N2CCN(CC2)C(=O)CC[N+]3(CCCCC3)C,,,,,,
1177,121178,"(1,3-Dimethyl-2,6-dioxo-1,2,3,4,5,6-hexahydro-7H-purin-7-yl)acetic acid--7-[2-(dimethylamino)ethoxy]-2-phenyl-4H-1-benzopyran-4-one (1/1)",CN1C2C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.CN(C)CCOC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
1178,121179,"2-(1,3-Dimethyl-2,6-dioxo-4,5-dihydropurin-7-yl)acetic acid",CN1C2C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O,,,,,,
1179,121180,7-(2-Dimethylamino-ethoxy)-2-phenyl-chromen-4-one,CN(C)CCOC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
1180,121181,"1,10-Decanediaminium, N,N,N,N',N',N'-hexaethyl-, diiodide",CC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
1181,121182,Triethyl-[10-(triethylazaniumyl)decyl]azanium,CC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CC,,,,,,
1182,121183,"2,3-Xylenol, 6-isopropyl-alpha(sup 2)-morpholino-",CC1=C(C(=C(C=C1)C(C)C)O)CN2CCOCC2,,,,,,
1183,121184,"Morpholine, 4-(3-isopropyl-6-methyl-o-anisoyl)-",CC1=C(C(=C(C=C1)C(C)C)OC)C(=O)N2CCOCC2,,,,,,
1184,121185,"Morpholine, 4-(3-isopropyl-2,6-cresotoyl)-",CC1=C(C(=C(C=C1)C(C)C)O)C(=O)N2CCOCC2,,,,,,
1185,121186,2-(5-Methyl-1-benzothiophen-3-yl)acetic acid,CC1=CC2=C(C=C1)SC=C2CC(=O)O,,,,,,
1186,121187,CID 121187,CN(C)C(=NOCC1=CC=CC=C1)N.C1CCC(CC1)NS(=O)(=O)O,,,,,,
1187,121188,"1,1-Dimethyl-3-(benzyloxy)guanidine",CN(C)C(=NOCC1=CC=CC=C1)N,,,,,,
1188,121189,O-Methyl-N-phenethylhydroxylamine hydrochloride,CONCCC1=CC=CC=C1.Cl,,,,,,
1189,121190,Methoxyphenylethylamine,CONCCC1=CC=CC=C1,,,,,,
1190,121191,"2,5-Dichloroterephthalonitrile",C1=C(C(=CC(=C1Cl)C#N)Cl)C#N,,,,,,
1191,121192,"2-Chlorobenzene-1,4-dicarbonitrile",C1=CC(=C(C=C1C#N)Cl)C#N,,,,,,
1192,121193,"1,4-Benzenedicarbonitrile, 2,5-difluoro-",C1=C(C(=CC(=C1F)C#N)F)C#N,,,,,,
1193,121194,2-Fluoroterephthalonitrile,C1=CC(=C(C=C1C#N)F)C#N,,,,,,
1194,121195,Bis(prop-2-ynyl) sulfite,C#CCOS(=O)OCC#C,,,,,,
1195,121196,CID 121196,CC1=CC2=C(C(=C1)OC)C(=O)C3(C2)C(=CC(=O)C=C3OC)C(=O)OC,,,,,,
1196,121197,"2-Furoic acid, 2,2-bis(2-chloroethyl)hydrazide",C1=COC(=C1)C(=O)NN(CCCl)CCCl,,,,,,
1197,121198,"3-(4-(Diethylamino)-2-butynyl)-1-methyl-2,4(1H,3H)-quinazolinedione hydrochloride",CCN(CC)CC#CCN1C(=O)C2=CC=CC=C2N(C1=O)C.Cl,,,,,,
1198,121199,"3-[4-(Diethylamino)but-2-ynyl]-1-methylquinazoline-2,4-dione",CCN(CC)CC#CCN1C(=O)C2=CC=CC=C2N(C1=O)C,,,,,,
1199,121200,"1-(4-(Diethylamino)-2-butynyl)-3-methyl-2,4(1H,3H)-quinazolinedione hydrochloride",CCN(CC)CC#CCN1C2=CC=CC=C2C(=O)N(C1=O)C.Cl,,,,,,
1200,121201,"1-[4-(Diethylamino)but-2-ynyl]-3-methylquinazoline-2,4-dione",CCN(CC)CC#CCN1C2=CC=CC=C2C(=O)N(C1=O)C,,,,,,
1201,121202,"3-Methyl-1-(4-(1-pyrrolidinyl)-2-butynyl)-2,4(1H,3H)-quinazolinedione hydrochloride",CN1C(=O)C2=CC=CC=C2N(C1=O)CC#CCN3CCCC3.Cl,,,,,,
1202,121203,"3-Methyl-1-(4-pyrrolidin-1-ylbut-2-ynyl)quinazoline-2,4-dione",CN1C(=O)C2=CC=CC=C2N(C1=O)CC#CCN3CCCC3,,,,,,
1203,121204,CID 121204,[Li+].CC(C)(C)[O-],,,,,,
1204,121205,"1,3,5-Triazin-2-amine, 4-ethoxy-6-ethyl-",CCC1=NC(=NC(=N1)OCC)N,,,,,,
1205,121206,"Benzanilide, 5-chloro-2-(methylamino)-",CNC1=C(C=C(C=C1)Cl)C(=O)NC2=CC=CC=C2,,,,,,
1206,121207,"N-(5-benzylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)pyridine-4-carboxamide",C1=CC=C(C=C1)C=C2C(=O)N(C(=S)S2)NC(=O)C3=CC=NC=C3,,,,,,
1207,121208,"N-[5-[[4-(dimethylamino)phenyl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]pyridine-4-carboxamide",CN(C)C1=CC=C(C=C1)C=C2C(=O)N(C(=S)S2)NC(=O)C3=CC=NC=C3,,,,,,
1208,121209,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-(dimethylamino)ethyl)-5-(3-hydroxyphenyl)-, monohydrobromide",CN(C)CCC1(C(=O)NC(=O)NC1=O)C2=CC(=CC=C2)O.Br,,,,,,
1209,121210,"5-[2-(Dimethylamino)ethyl]-5-(3-hydroxyphenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione",CN(C)CCC1(C(=O)NC(=O)NC1=O)C2=CC(=CC=C2)O,,,,,,
1210,121211,"3-(2-(Diethylamino)ethyl)-2,4(1H,3H)-quinazolinedione hydrochloride",CCN(CC)CCN1C(=O)C2=CC=CC=C2NC1=O.Cl,,,,,,
1211,121212,"3-(2-Diethylamino-ethyl)-1H-quinazoline-2,4-dione",CCN(CC)CCN1C(=O)C2=CC=CC=C2NC1=O,,,,,,
1212,121213,"2,4(1H,3H)-Quinazolinedione, 3-(2-morpholinoethyl)-, hydrochloride",C1COCCN1CCN2C(=O)C3=CC=CC=C3NC2=O.Cl,,,,,,
1213,121214,"3-[2-(morpholin-4-yl)ethyl]quinazoline-2,4(1H,3H)-dione",C1COCCN1CCN2C(=O)C3=CC=CC=C3NC2=O,,,,,,
1214,121215,"Benzamide, o-amino-N-(2-(diethylamino)ethyl)-, hydrochloride",CCN(CC)CCNC(=O)C1=CC=CC=C1N.Cl,,,,,,
1215,121216,2-Amino-N-[2-(diethylamino)ethyl]benzamide,CCN(CC)CCNC(=O)C1=CC=CC=C1N,,,,,,
1216,121217,CID 121217,CCCCCP1(=O)OCC2=CC=CC=C2O1,,,,,,
1217,121218,"N,N-Diethyl-4H-1,3,2-benzodioxaphosphorin-2-amine 2-oxide",CCN(CC)P1(=O)OCC2=CC=CC=C2O1,,,,,,
1218,121219,"2-Furoic acid, 5-nitro-, 2,2-bis(2-chloroethyl)hydrazide",C1=C(OC(=C1)[N+](=O)[O-])C(=O)NN(CCCl)CCCl,,,,,,
1219,121220,"3-Chloro-2,5,6-trifluoro-1,4-benzenedicarbonitrile",C(#N)C1=C(C(=C(C(=C1F)Cl)C#N)F)F,,,,,,
1220,121221,4-Isocyano-1-methyl-2-nitrobenzene,CC1=C(C=C(C=C1)[N+]#[C-])[N+](=O)[O-],,,,,,
1221,121222,"Piperidine, 1,1'-(1,2-ethanediyl)bis-, dihydrochloride",C1CCN(CC1)CCN2CCCCC2.Cl.Cl,,,,,,
1222,121223,Sodium arsphenamine,C1=CC(=C(C=C1[As]=[As]C2=CC(=C(C=C2)[O-])N)N)[O-].[Na+].[Na+],,,,,,
1223,121224,4-Di-(beta-chloroethyl)aminomethylthiazole hydrochloride,C1=C(N=CS1)CN(CCCl)CCCl.Cl,,,,,,
1224,121225,"2-chloro-N-(2-chloroethyl)-N-(1,3-thiazol-4-ylmethyl)ethanamine",C1=C(N=CS1)CN(CCCl)CCCl,,,,,,
1225,121226,"Thiazole, 4-((bis(2-chloroethyl)amino)methyl)-2-methyl-, dihydrochloride",CC1=NC(=CS1)CN(CCCl)CCCl.Cl.Cl,,,,,,
1226,121227,"2-chloro-N-(2-chloroethyl)-N-[(2-methyl-1,3-thiazol-4-yl)methyl]ethanamine",CC1=NC(=CS1)CN(CCCl)CCCl,,,,,,
1227,121228,"Phenoxazine-10-carbothioic acid, S-(2-(dimethylamino)ethyl) ester, hydrochloride",CN(C)CCSC(=O)N1C2=CC=CC=C2OC3=CC=CC=C31.Cl,,,,,,
1228,121229,S-[2-(dimethylamino)ethyl] phenoxazine-10-carbothioate,CN(C)CCSC(=O)N1C2=CC=CC=C2OC3=CC=CC=C31,,,,,,
1229,121230,"Phenothiazine-10-carbothioic acid, S-(2-(diethylamino)ethyl) ester, hydrochloride",CCN(CC)CCSC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31.Cl,,,,,,
1230,121231,S-[2-(diethylamino)ethyl] phenothiazine-10-carbothioate,CCN(CC)CCSC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
1231,121232,Dihydronereistoxin,CN(C)C(CS)CS.C(=O)(C(=O)O)O,,,,,,
1232,121233,"2-(Dimethylamino)propane-1,3-dithiol",CN(C)C(CS)CS,,,,,,
1233,121234,"Disodium 4-amino-3-((4'-((2-amino-8-hydroxy-6-sulphonatonaphthyl)azo)(1,1'-biphenyl)-4-yl)azo)naphthalene-1-sulphonate",C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)O)S(=O)(=O)[O-])N)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
1234,121235,C.I. Direct Red 13,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)O)S(=O)(=O)O)N)S(=O)(=O)O,,,,,,
1235,121236,"Carbamic acid, diphenyldithio-, 2-(diethylamino)ethyl ester, phosphate",CCN(CC)CCSC(=S)N(C1=CC=CC=C1)C2=CC=CC=C2.OP(=O)(O)O,,,,,,
1236,121237,"2-(diethylamino)ethyl N,N-diphenylcarbamodithioate",CCN(CC)CCSC(=S)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1237,121238,"Phenoxazine-10-carbothioic acid, S-(2-(diethylamino)ethyl) ester, hydrochloride",CCN(CC)CCSC(=O)N1C2=CC=CC=C2OC3=CC=CC=C31.Cl,,,,,,
1238,121239,S-[2-(diethylamino)ethyl] phenoxazine-10-carbothioate,CCN(CC)CCSC(=O)N1C2=CC=CC=C2OC3=CC=CC=C31,,,,,,
1239,121240,CID 121240,C1=CC=C(C=C1)CCN=C(OC2=CC=C(C=C2)Cl)S,,,,,,
1240,121241,3-(2-(Methylamino)ethyl)pyrocatechol hydrochloride,CNCCC1=C(C(=CC=C1)O)O.Cl,,,,,,
1241,121242,Methylaminoathylbrenzcatechin,CNCCC1=C(C(=CC=C1)O)O,,,,,,
1242,121243,"Morpholine, 4-(3-allyl-6-(2-(dimethylamino)ethoxy)-5-methoxybenzyl)-",CN(C)CCOC1=C(C=C(C=C1OC)CC=C)CN2CCOCC2,,,,,,
1243,121244,"Stannane, isothiocyanatotriphenyl-",C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)(C3=CC=CC=C3)N=C=S,,,,,,
1244,121245,"Phosphorothioic acid, O-(2-(bis(2-fluoroethyl)amino)ethyl) O,O-diethyl ester",CCOP(=S)(OCC)OCCN(CCF)CCF,,,,,,
1245,121246,Dipropyl terephthalate,CCCOC(=O)C1=CC=C(C=C1)C(=O)OCCC,,,,,,
1246,121247,"Phosphorothioic acid, O,O-diethyl O-(3-(ethylthio)-4-nitrophenyl) ester",CCOP(=S)(OCC)OC1=CC(=C(C=C1)[N+](=O)[O-])SCC,,,,,,
1247,121248,"Morphanthridine, 8-chloro-6-(4-methyl-1-piperazinyl)-",CN1CCN(CC1)C2=NC3=CC=CC=C3CC4=C2C=C(C=C4)Cl,,,,,,
1248,121249,2-Hydroxydesipramine,CNCCCN1C2=C(CCC3=CC=CC=C31)C=C(C=C2)O,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,['2-hydroxy-desipramine is a known human metabolite of Desipramine.'],
1249,121250,"Propane, 1-(methylsulfonyl)-",CCCS(=O)(=O)C,,,,,,
1250,121251,2-Isocyano-1-methoxy-4-nitrobenzene,COC1=C(C=C(C=C1)[N+](=O)[O-])[N+]#[C-],,,,,,
1251,121252,Ethyl 4-isocyanobenzoate,CCOC(=O)C1=CC=C(C=C1)[N+]#[C-],,,,,,
1252,121253,N-Isopropyl 4-bromobenzenesulfonamide,CC(C)NS(=O)(=O)C1=CC=C(C=C1)Br,,,,,,
1253,121254,N-Butyl 4-bromobenzenesulfonamide,CCCCNS(=O)(=O)C1=CC=C(C=C1)Br,,,,,,
1254,121255,4-Bromo-N-hydroxybenzenesulfonamide,C1=CC(=CC=C1S(=O)(=O)NO)Br,,,,,,
1255,121256,"s-Triazine, 2,6-diamino-4-dipropylamino-",CCCN(CCC)C1=NC(=NC(=N1)N)N,,,,,,
1256,121257,"Morpholinium, 4,4'-(1,4-piperazinediylbis(carbonylethylene))bis(4-methyl-, diiodide",C[N+]1(CCOCC1)CCC(=O)N2CCN(CC2)C(=O)CC[N+]3(CCOCC3)C.[I-].[I-],,,,,,
1257,121258,3-(4-Methylmorpholin-4-ium-4-yl)-1-[4-[3-(4-methylmorpholin-4-ium-4-yl)propanoyl]piperazin-1-yl]propan-1-one,C[N+]1(CCOCC1)CCC(=O)N2CCN(CC2)C(=O)CC[N+]3(CCOCC3)C,,,,,,
1258,121259,"Morpholinium, 4,4'-(1,4-piperazinediylbis(carbonylethylene))bis(4-methyl-, dibromide",C[N+]1(CCOCC1)CCC(=O)N2CCN(CC2)C(=O)CC[N+]3(CCOCC3)C.[Br-].[Br-],,,,,,
1259,121260,Sinrex,C[N+](C)(C)CCOC(=O)NCCCCCCNC(=O)OCC[N+](C)(C)C.[I-].[I-],,,,,,
1260,121261,"Piperidinium, 1,1'-(1,4-piperazinediylbis(carbonylmethylene))bis(1-methyl-, diiodide",C[N+]1(CCOCC1)CC(=O)N2CCN(CC2)C(=O)C[N+]3(CCOCC3)C.[I-].[I-],,,,,,
1261,121262,2-(4-Methylmorpholin-4-ium-4-yl)-1-[4-[2-(4-methylmorpholin-4-ium-4-yl)acetyl]piperazin-1-yl]ethanone,C[N+]1(CCOCC1)CC(=O)N2CCN(CC2)C(=O)C[N+]3(CCOCC3)C,,,,,,
1262,121263,"2,4(1H,3H)-Quinazolinedione, 3-(2-piperidinoethyl)-, hydrochloride",C1CCN(CC1)CCN2C(=O)C3=CC=CC=C3NC2=O.Cl,,,,,,
1263,121264,2-hydroxy-3-[2-(piperidin-1-yl)ethyl]quinazolin-4(3H)-one,C1CCN(CC1)CCN2C(=O)C3=CC=CC=C3NC2=O,,,,,,
1264,121265,Diethylmethyl(2-(o-nitrobenzamido)ethyl)ammonium bromide,CC[N+](C)(CC)CCNC(=O)C1=CC=CC=C1[N+](=O)[O-].[Br-],,,,,,
1265,121266,Diethyl-methyl-[2-[(2-nitrobenzoyl)amino]ethyl]azanium,CC[N+](C)(CC)CCNC(=O)C1=CC=CC=C1[N+](=O)[O-],,,,,,
1266,121267,"Benzenesulfonamide, 4-amino-N-(2-(diethylamino)ethyl)-, dihydrochloride (9CI)",CCN(CC)CCNS(=O)(=O)C1=CC=C(C=C1)N.Cl.Cl,,,,,,
1267,121268,4-amino-N-(2-diethylaminoethyl)benzenesulfonamide,CCN(CC)CCNS(=O)(=O)C1=CC=C(C=C1)N,,,,,,
1268,121269,"5-(Pyridin-4-yl)-1,3,4-thiadiazol-2-amine",C1=CN=CC=C1C2=NN=C(S2)N,,,,,,
1269,121270,"Benzamide, o-amino-N-(3-(dimethylamino)propyl)-, hydrochloride",CN(C)CCCNC(=O)C1=CC=CC=C1N.Cl,,,,,,
1270,121271,2-Amino-N-[3-(dimethylamino)propyl]benzamide,CN(C)CCCNC(=O)C1=CC=CC=C1N,,,,,,
1271,121272,3-(2-Chloroethyl)-2-phenyliminooxazolidine hydrochloride,C1COC(=NC2=CC=CC=C2)N1CCCl.Cl,,,,,,
1272,121273,"3-(2-chloroethyl)-N-phenyl-1,3-oxazolidin-2-imine",C1COC(=NC2=CC=CC=C2)N1CCCl,,,,,,
1273,121274,1-Isocyano-3-nitrobenzene,[C-]#[N+]C1=CC(=CC=C1)[N+](=O)[O-],,,,,,
1274,121275,1-Isocyano-2-methoxy-4-nitrobenzene,COC1=C(C=CC(=C1)[N+](=O)[O-])[N+]#[C-],,,,,,
1275,121276,"1-Piperidineacetic acid, 2,6-xylyl ester, hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)CN2CCCCC2.Cl,,,,,,
1276,121277,"(2,6-Dimethylphenyl) 2-piperidin-1-ylacetate",CC1=C(C(=CC=C1)C)OC(=O)CN2CCCCC2,,,,,,
1277,121278,"4-Morpholineacetic acid, 2,6-xylyl ester, hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)CN2CCOCC2.Cl,,,,,,
1278,121279,"(2,6-Dimethylphenyl) 2-morpholin-4-ylacetate",CC1=C(C(=CC=C1)C)OC(=O)CN2CCOCC2,,,,,,
1279,121280,"alpha-Methyl-1-piperidineacetic acid 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCCCC2.Cl,,,,,,
1280,121281,"(2,6-Dimethylphenyl) 2-piperidin-1-ylpropanoate",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCCCC2,,,,,,
1281,121282,"alpha-Methyl-4-morpholineacetic acid 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCOCC2.Cl,,,,,,
1282,121283,"(2,6-Dimethylphenyl) 2-morpholin-4-ylpropanoate",CC1=C(C(=CC=C1)C)OC(=O)C(C)N2CCOCC2,,,,,,
1283,121284,"alpha,4-Dimethyl-1-piperazineacetic acid 6-chloro-o-tolyl ester dihydrochloride",CC1=C(C(=CC=C1)Cl)OC(=O)C(C)N2CCN(CC2)C.Cl.Cl,,,,,,
1284,121285,(2-Chloro-6-methylphenyl) 2-(4-methylpiperazin-1-yl)propanoate,CC1=C(C(=CC=C1)Cl)OC(=O)C(C)N2CCN(CC2)C,,,,,,
1285,121286,"1-Piperidineacetic acid, mesityl ester, hydrochloride",CC1=CC(=C(C(=C1)C)OC(=O)CN2CCCCC2)C.Cl,,,,,,
1286,121287,"(2,4,6-Trimethylphenyl) 2-piperidin-1-ylacetate",CC1=CC(=C(C(=C1)C)OC(=O)CN2CCCCC2)C,,,,,,
1287,121288,"Undecylamine, hydrochloride",CCCCCCCCCCCN.Cl,,,,,,
1288,121289,"Pentadecylamine, N,N-dimethyl-, hydrochloride",CCCCCCCCCCCCCCCN(C)C.Cl,,,,,,
1289,121290,Myristyldimethylamine hydrochloride,CCCCCCCCCCCCCCN(C)C.Cl,,,,,,
1290,121291,"Undecylamine, N,N-dimethyl-, hydrochloride",CCCCCCCCCCCN(C)C.Cl,,,,,,
1291,121292,"N,N-Dimethylundecylamine",CCCCCCCCCCCN(C)C,,,,,,
1292,121293,"Tridecylamine, hydrochloride",CCCCCCCCCCCCCN.Cl,,,,,,
1293,121294,Dimethyl(2-hydroxyethyl)octylammonium bromide benzilate,CCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
1294,121295,Dequalinium iodide,CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.[I-].[I-],,,,,,
1295,121296,"2,6-Xylyl pyrrolidineacetate hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)CN2CCCC2.Cl,,,,,,
1296,121297,"(2,6-Dimethylphenyl) 2-pyrrolidin-1-ylacetate",CC1=C(C(=CC=C1)C)OC(=O)CN2CCCC2,,,,,,
1297,121298,"Acetamide, 2,2'-methylenebis((3-methoxy-5-propyl-o-phenylene)oxy)bis(N,N-diethyl-",CCCC1=CC(=C(C(=C1)OC)OCC(=O)N(CC)CC)CC2=C(C(=CC(=C2)CCC)OC)OCC(=O)N(CC)CC,,,,,,
1298,121299,"Acetamide, 2-((4-allyl-6-methoxy-alpha-morpholino-o-tolyl)oxy)-N,N-diethyl-",CCN(CC)C(=O)COC1=C(C=C(C=C1OC)CC=C)CN2CCOCC2,,,,,,
1299,121300,"Acetamide, 2-((4-allyl-6-methoxy-alpha-piperidino-o-tolyl)oxy)-N,N-diethyl-",CCN(CC)C(=O)COC1=C(C=C(C=C1OC)CC=C)CN2CCCCC2,,,,,,
1300,121301,"Acetamide, 2-((4-allyl-6-methoxy-alpha-1-pyrrolidinyl-o-tolyl)oxy)-N,N-diethyl-",CCN(CC)C(=O)COC1=C(C=C(C=C1OC)CC=C)CN2CCCC2,,,,,,
1301,121302,Dicarvacrotide,CC1=C2C(=C(C=C1)C(C)C)C(=O)OC3=C(C=CC(=C3C(=O)O2)C(C)C)C,,,,,,
1302,121303,CID 121303,CCOP(=O)(OCC)OC(=C(F)Cl)C(CF)(Cl)Cl,,,,,,
1303,121304,"(2-(2,6-Xylyloxy)ethyl)amino-4,5-dihydroimidazole hydriodide",CC1=C(C(=CC=C1)C)OCCNC2=NCCN2.I,,,,,,
1304,121305,"2-[[2-(2,6-Xylyloxy)ethyl]amino]-2-imidazoline",CC1=C(C(=CC=C1)C)OCCNC2=NCCN2,,,,,,
1305,121306,CID 121306,CCN1C[C@@]2([C@@H](C[C@@H]([C@]34[C@H]1C([C@@H](C23)OC)[C@]5(C[C@@H](C6(CC4[C@@H]5[C@H]6OC(=O)C7=CC(=C(C=C7)O)O)O)OC)OC(=O)C)OC)O)COC,,,,,,
1306,121307,Streptomycin B sulfate,CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)CO)O)O)O)O)NC)(C=O)O,,,,,,
1307,121308,"Biphenyl-(4,4')-bis-methyl-(3-(p-chlor)benzoyloxy)-tropaniumbromid [German]",C[N+]1(C2CCC1CC(C2)OC(=O)C3=CC=C(C=C3)Cl)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6(C7CCC6CC(C7)OC(=O)C8=CC=C(C=C8)Cl)C.[Br-].[Br-],,,,,,
1308,121309,[8-[[4-[4-[[3-(4-Chlorobenzoyl)oxy-8-methyl-8-azoniabicyclo[3.2.1]octan-8-yl]methyl]phenyl]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 4-chlorobenzoate,C[N+]1(C2CCC1CC(C2)OC(=O)C3=CC=C(C=C3)Cl)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6(C7CCC6CC(C7)OC(=O)C8=CC=C(C=C8)Cl)C,,,,,,
1309,121310,"Biphenyl-(4,4')-bis-methyl-(3-alpha-benzoyloxy)-tropaniumbromid [German]",C[N+]1(C2CCC1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6(C7CCC6CC(C7)OC(=O)C8=CC=CC=C8)C.[Br-].[Br-],,,,,,
1310,121311,[8-[[4-[4-[(3-Benzoyloxy-8-methyl-8-azoniabicyclo[3.2.1]octan-8-yl)methyl]phenyl]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] benzoate,C[N+]1(C2CCC1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6(C7CCC6CC(C7)OC(=O)C8=CC=CC=C8)C,,,,,,
1311,121312,"[(1S,3R,4R,6S,7S,8R,10R,13R,14R,16S,18R)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CCN1C[C@@]2([C@@H](C[C@@H]([C@]34[C@H]1C([C@@H](C23)OC)[C@@]5([C@@H]6C4CC([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)O)OC)O)COC,,,,,,
1312,121313,Cycleanine,CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC=C(O3)C=C7)N(CCC6=CC(=C5OC)OC)C)OC)OC,,,,,,
1313,121314,Chlorowodorek lupaniny [Polish],C1CCN2C[C@@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3CCCC4=O.Cl,,,,,,
1314,121315,Pentoxyverine hydrochloride,CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.Cl,,,,,,
1315,121316,"1-(4-Chlorophenyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)piperazine",C1CN(CCN1CC2COC3=CC=CC=C3O2)C4=CC=C(C=C4)Cl,,,,,,
1316,121317,Difril,CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)']",,,
1317,121318,"Piperidinium, 1-(4-(2,5-dimethoxyphenyl)-4-hydroxy-4-phenyl-2-butyl)-1-methyl-, iodide",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)[N+]3(CCCCC3)C.[I-],,,,,,
1318,121319,"1-(2,5-Dimethoxyphenyl)-3-(1-methylpiperidin-1-ium-1-yl)-1-phenylbutan-1-ol",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)[N+]3(CCCCC3)C,,,,,,
1319,121320,CID 121320,CN1CCC(C1)OC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
1320,121321,"1-Methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)pyrrolidine",CN1CCC(C1)OC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
1321,121322,CID 121322,C1CNCCC1OC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
1322,121323,"4-(2-Tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)piperidine",C1CNCCC1OC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
1323,121324,CID 121324,C1CC(CNC1)OC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
1324,121325,"3-(2-Tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)piperidine",C1CC(CNC1)OC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
1325,121326,CID 121326,CCN1CCCC(C1)OC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
1326,121327,"1-Ethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)piperidine",CCN1CCCC(C1)OC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
1327,121328,"1,6-Bis(3-(N,N-diethylcarbamoyl)piperidinyl)hexane dihydrobromide",CCN(CC)C(=O)C1CCCN(C1)CCCCCCN2CCCC(C2)C(=O)N(CC)CC.Br.Br,,,,,,
1328,121329,"1,6-Bis(3-(N,N-diethylcarbamoyl)piperidino)hexane",CCN(CC)C(=O)C1CCCN(C1)CCCCCCN2CCCC(C2)C(=O)N(CC)CC,,,,,,
1329,121330,"1,10-Bis(3-(N,N-diethylcarbamoyl)piperidinyl)decane dihydrobromide",CCN(CC)C(=O)C1CCCN(C1)CCCCCCCCCCN2CCCC(C2)C(=O)N(CC)CC.Br.Br,,,,,,
1330,121331,"1,10-Bis(3-(N,N-diethylcarbamoyl)piperidino)decane",CCN(CC)C(=O)C1CCCN(C1)CCCCCCCCCCN2CCCC(C2)C(=O)N(CC)CC,,,,,,
1331,121332,"Carbamimidothioic acid, 2-(dimethylamino)-1-phenylethyl ester, dihydrochloride",C1=CC=C(C=C1)C(CN(Cl)Cl)SC(=N)N.Cl.Cl,,,,,,
1332,121333,[2-(Dichloroamino)-1-phenylethyl] carbamimidothioate,C1=CC=C(C=C1)C(CN(Cl)Cl)SC(=N)N,,,,,,
1333,121334,2-Methyl-3-piperidino-1-(p-tolyl)-1-propanol hydrochloride,CC1=CC=C(C=C1)C(C(C)CN2CCCCC2)O.Cl,,,,,,
1334,121335,2-Methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-ol,CC1=CC=C(C=C1)C(C(C)CN2CCCCC2)O,,,,,,
1335,121336,Mecambrine,CN1CCC2=CC3=C(C4=C2[C@@H]1CC45C=CC(=O)C=C5)OCO3,,,,,,
1336,121337,"2,7-Diamino-1-hydroxymitosene",CC1=C(C(=O)C2=C(C1=O)N3CC(C(C3=C2COC(=O)N)O)N)N,,,,,,
1337,121338,CID 121338,CC=C1CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(C)O.Cl,,,,,,
1338,121339,CID 121339,CC=C1CC(=C)[C@@](C(=O)OCC2=CCN3C2[C@@H](CC3)OC1=O)(C)O,,,,,,
1339,121340,CID 121340,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[Na+],,,,,,
1340,121341,"Benzeneethanamine, beta,beta'-dithiobis(N,N-dimethyl-, dihydrochloride, DL-",CN(C)CC(C1=CC=CC=C1)SSC(CN(C)C)C2=CC=CC=C2.Cl.Cl,,,,,,
1341,121342,"2-[[2-(dimethylamino)-1-phenylethyl]disulfanyl]-N,N-dimethyl-2-phenylethanamine",CN(C)CC(C1=CC=CC=C1)SSC(CN(C)C)C2=CC=CC=C2,,,,,,
1342,121343,"(2-acetamido-6-amino-3-hydroxy-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]indol-4-yl)methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC(C(C3=C2COC(=O)N)O)NC(=O)C)N,,,,,,
1343,121344,CID 121344,C1=C[N+](=CC=C1C=NO)CC(C(C[N+]2=CC=C(C=C2)C=NO)O)O.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-],,,,,,
1344,121345,CID 121345,C1=C[N+](=CC=C1C=NO)CC(C(C[N+]2=CC=C(C=C2)C=NO)O)O,,,,,,
1345,121346,"8-Azoniabicyclo(3.2.1)octane, 3-(benzoyloxy)-8-((4-cyclohexylphenyl)methyl)-8-methyl-, bromide, (endo,syn)-",C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5CCCCC5.[Br-],,,,,,
1346,121347,[8-[(4-Cyclohexylphenyl)methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] benzoate,C[N+]1(C2CCC1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5CCCCC5,,,,,,
1347,121348,Diphenylmethyl(benzoyl-alpha-tropinium) bromid [German],C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC=C5.[Br-],,,,,,
1348,121349,"[(1R,5S)-8-methyl-8-[(4-phenylphenyl)methyl]-8-azoniabicyclo[3.2.1]octan-3-yl] benzoate",C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC=C5,,,,,,
1349,121350,CID 121350,CCCCCCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
1350,121351,"Acetamide, N-(1,7-dihydroxy-5,8-dioxo-9-(hydroxymethyl)-6-methyl-2,3,5,8-tetrahydro-1H-pyrrolo(1,2-a)indol-2-yl)-, 1,7-diacetate 9-carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC(C(C3=C2COC(=O)N)OC(=O)C)NC(=O)C)OC(=O)C,,,,,,
1351,121352,Pleiatensin,CCN(CC)CCN1C2=C(C=CC(=C2)OC)C3=C1[C@H]4C[C@H]5[C@H](C[C@H]([C@@H]([C@H]5C(=O)OC)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC)CC4CC3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
1352,121353,"methyl (1S,2R,3R,4aS,12bS,13aS)-12-[2-(diethylamino)ethyl]-2,10-dimethoxy-3-(3,4,5-trimethoxybenzoyl)oxy-1,2,3,4,4a,5,5a,6,7,12b,13,13a-dodecahydronaphtho[7,6-a]carbazole-1-carboxylate",CCN(CC)CCN1C2=C(C=CC(=C2)OC)C3=C1[C@H]4C[C@H]5[C@H](C[C@H]([C@@H]([C@H]5C(=O)OC)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC)CC4CC3,,,,,,
1353,121354,"1-Pentanol, 2-(mercaptomethyl)-2-methyl-, dicarbamate",CCCC(C)(COC(=O)N)CSC(=O)N,,,,,,
1354,121355,N-Butyryl-DL-aspartic acid,CCCC(=O)N[C@@H](CC(=O)O)C(=O)O,,,,,,
1355,121356,"1-Propanaminium, 3-cyano-2-hydroxy-N,N,N-trimethyl-, chloride, (S)-",C[N+](C)(C)C[C@H](CC#N)O.[Cl-],,,,,,
1356,121357,[(2S)-3-cyano-2-hydroxypropyl]-trimethylazanium,C[N+](C)(C)C[C@H](CC#N)O,,,,,,
1357,121358,alpha-(((1-Methylethyl)amino)methyl)benzenemethanethiol hydrochloride,CC(C)NCC(C1=CC=CC=C1)S.Cl,,,,,,
1358,121359,1-Phenyl-2-(propan-2-ylamino)ethanethiol,CC(C)NCC(C1=CC=CC=C1)S,,,,,,
1359,121360,"trans-4-Methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinoline",CN1CCC[C@@H]2[C@@H]1CCC3=CC=CC=C23,,,,,,
1360,121361,CID 121361,CCCCC1(C(=O)NC(=NC1=O)S)CCN(C)C.Cl,,,,,,
1361,121362,CID 121362,CCCCC1(C(=O)NC(=NC1=O)S)CCN(C)C,,,,,,
1362,121363,"2-Cyclohexyl-2-methyl-1,3-propanediol dicarbamate",CC(COC(=O)N)(COC(=O)N)C1CCCCC1,,,,,,
1363,121364,"1,3-Indandione, 2-(p-iodophenyl)-",C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)I,,,,,,
1364,121365,CID 121365,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2CCCCC2.Cl,,,,,,
1365,121366,CID 121366,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2CCCCC2,,,,,,
1366,121367,"Acetamide, N-cyclohexyl-2-((4-ethoxyphenyl)amino)-",CCOC1=CC=C(C=C1)NCC(=O)NC2CCCCC2,,,,,,
1367,121368,CID 121368,CC(CC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2)N(C)C.Br,,,,,,
1368,121369,CID 121369,CC(CC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2)N(C)C,,,,,,
1369,121370,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(3-(dimethylamino)propyl)-5-phenyl-, monohydrochloride",CN(C)CCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.Cl,,,,,,
1370,121371,"5-[3-(Dimethylamino)propyl]-5-phenyl-1,3-diazinane-2,4,6-trione",CN(C)CCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
1371,121372,CID 121372,CN(C)CCCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2.Cl,,,,,,
1372,121373,CID 121373,CN(C)CCCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2,,,,,,
1373,121374,CID 121374,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN(CC)CC.Cl,,,,,,
1374,121375,CID 121375,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN(CC)CC,,,,,,
1375,121376,5-Ethyl-5-(4-morpholino-2-butynyl)barbituric acid,CCC1(C(=O)NC(=O)NC1=O)CC#CCN2CCOCC2,,,,,,
1376,121377,CID 121377,C1CCN(C1)CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3.Cl,,,,,,
1377,121378,CID 121378,C1CCN(C1)CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3,,,,,,
1378,121379,CID 121379,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN2CCCCC2.Cl,,,,,,
1379,121380,CID 121380,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN2CCCCC2,,,,,,
1380,121381,"N,N,beta-Trimethyl-5H-dibenz(b,f)azepine-5-propanamine monohydrochloride",CC(CN1C2=CC=CC=C2C=CC3=CC=CC=C31)CN(C)C.Cl,,,,,,
1381,121382,Dehydro trimipramine,CC(CN1C2=CC=CC=C2C=CC3=CC=CC=C31)CN(C)C,,,,,,
1382,121383,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-(4-morpholinyl)ethyl)-5-phenyl-, monohydrochloride",C1COCCN1CCC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3.Cl,,,,,,
1383,121384,"5-(2-Morpholin-4-ylethyl)-5-phenyl-1,3-diazinane-2,4,6-trione",C1COCCN1CCC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3,,,,,,
1384,121385,CID 121385,C1CCN(CC1)CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3.Cl,,,,,,
1385,121386,CID 121386,C1CCN(CC1)CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3,,,,,,
1386,121387,2-((4-Ethoxyphenyl)amino)-2-phenyl-N-propylacetamide,CCCNC(=O)C(C1=CC=CC=C1)NC2=CC=C(C=C2)OCC,,,,,,
1387,121388,1-[4-(2-Methylphenyl)piperazin-1-yl]-3-phenoxypropan-2-ol,CC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC=C3)O,,,,,,
1388,121389,Amicibone hydrochloride,C1CCCN(CC1)CCC2(CCCCC2=O)C(=O)OCC3=CC=CC=C3.Cl,,,,,,
1389,121390,CID 121390,C1CCN(CC1)CC(C=C(C2=CC=CC=C2)C3=CC=CS3)O.C(=CC(=O)O)C(=O)O,,,,,,
1390,121391,CID 121391,C1CCN(CC1)CC(C=C(C2=CC=CC=C2)C3=CC=CS3)O,,,,,,
1391,121392,CID 121392,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)OC4=CC=CC=C4)C(=O)[O-])C.[K+],,,,,,
1392,121393,"Piperazine, 1-(2-((o-chloro-alpha-phenylbenzyl)thio)ethyl)-4-(o-methylbenzyl)-, dihydrochloride",CC1=CC=CC=C1CN2CCN(CC2)CCSC(C3=CC=CC=C3)C4=CC=CC=C4Cl.Cl.Cl,,,,,,
1393,121394,Bentipimine,CC1=CC=CC=C1CN2CCN(CC2)CCSC(C3=CC=CC=C3)C4=CC=CC=C4Cl,,,,,,
1394,121395,2-Cyanobutan-2-yl acetate,CCC(C)(C#N)OC(=O)C,,,,,,
1395,121396,Carglumic acid,C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N,['For the treatment of acute and chronic hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency. This enzyme is an important component of the urea cycle to prevent build up of neurotoxic ammonium in the blood.'],['The median Tmax of Carbaglu was 3 hours (range: 2-4). The daily dose of carglumic acid ranges from 100 to 250 mg/kg and this does are normally adjusted to maintain normal plasma levels of ammonia.'],,"['30% bioavailability; Cmax, mean, 100 mg/kg dose = 2.6 g/mL (range of 1.9 - 4.8)   Carglumic acid is not subject to to intracellular degradation.', 'Following administration of a single radiolabeled oral dose of 100 mg/kg of body weight, 9% of the dose was excreted unchanged in the urine and up to 60% of the dose was excreted unchanged in the feces.', 'The apparent volume of distribution was 2657 L (range: 1616-5797).', 'The apparent total clearance was 5.7 L/min (range 3.0-9.7), the renal clearance was 290 mL/min (range 204-445), and the 24-hour urinary excretion was 4.5 % of the dose (range 3.5-7.5).']","['A proportion of carglumic acid may be metabolized by the intestinal bacterial flora. The likely end product of carglumic acid metabolism is carbon dioxide, eliminated through the lungs.']",['Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).']
1396,121397,4-Phenyl-2-pyrrolidone,C1C(CNC1=O)C2=CC=CC=C2,,,,,,
1397,121398,"Phenethylamine, beta-bromo-N,N-dimethyl-, hydrobromide",CN(C)CC(C1=CC=CC=C1)Br.Br,,,,,,
1398,121399,beta-Bromophenethyldimethylamine,CN(C)CC(C1=CC=CC=C1)Br,,,,,,
1399,121400,CID 121400,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N)C(=O)[O-])C.[Na+],,,,,,
1400,121401,"(2S,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2C(S1)[C@@H](C2=O)N)C(=O)O)C,,,,,,
1401,121402,2-(p-Dimethylamino)phenyl thiazolidine hydrochloride,CN(C)C1=CC=C(C=C1)C2NCCS2.Cl,,,,,,
1402,121403,"beta-Bromo-N,N-diethylphenethylamine hydrobromide",CCN(CC)CC(C1=CC=CC=C1)Br.Br,,,,,,
1403,121404,"2-bromo-N,N-diethyl-2-phenylethanamine",CCN(CC)CC(C1=CC=CC=C1)Br,,,,,,
1404,121405,"beta-Bromo-N,N-dipropylphenethylamine hydrobromide",CCCN(CCC)CC(C1=CC=CC=C1)Br.Br,,,,,,
1405,121406,N-(2-bromo-2-phenylethyl)-N-propylpropan-1-amine,CCCN(CCC)CC(C1=CC=CC=C1)Br,,,,,,
1406,121407,2-Diethylamino-5-phenyl-2-oxazolin-4-one,CCN(CC)C1=NC(=O)C(O1)C2=CC=CC=C2,,,,,,
1407,121408,"2H-1-Benzothiopyran-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-,1,1-dioxide",CC1CCC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl,,,,,,
1408,121409,N-(p-Chlorobenzyl)-alpha-methyl-4-morpholineacetamide hydrochloride,CC(C(=O)NCC1=CC=C(C=C1)Cl)N2CCOCC2.Cl,,,,,,
1409,121410,N-[(4-chlorophenyl)methyl]-2-morpholin-4-ylpropanamide,CC(C(=O)NCC1=CC=C(C=C1)Cl)N2CCOCC2,,,,,,
1410,121411,"2H-1-Benzothiopyran-7-sulfonamide, 2-ethyl-3,4-dihydro-6-methyl-,1,1-dioxide",CCC1CCC2=C(S1(=O)=O)C=C(C(=C2)C)S(=O)(=O)N,,,,,,
1411,121412,"1-((1,8,8-Trimethyl-3-azabicyclo(3.2.1)oct-3-yl)acetyl)piperidine",CC1(C2CCC1(CN(C2)CC(=O)N3CCCCC3)C)C,,,,,,
1412,121413,"alpha-Piperidinyl-N-(2,4-dimethylbenzyl)propionamide hydrochloride",CC1=CC(=C(C=C1)CNC(=O)C(C)N2CCCCC2)C.Cl,,,,,,
1413,121414,"N-[(2,4-dimethylphenyl)methyl]-2-piperidin-1-ylpropanamide",CC1=CC(=C(C=C1)CNC(=O)C(C)N2CCCCC2)C,,,,,,
1414,121415,1-Phenyl-3-(piperidin-1-yl)-1-(thiophen-2-yl)propan-1-ol,C1CCN(CC1)CCC(C2=CC=CC=C2)(C3=CC=CS3)O,,,,,,
1415,121416,"2-(3-Butyramido-2,4,6-triiodophenoxy)propionic acid",CCCC(=O)NC1=C(C(=C(C=C1I)I)OC(C)C(=O)O)I,,,,,,
1416,121417,Bamipine hydrochloride,CN1CCC(CC1)N(CC2=CC=CC=C2)C3=CC=CC=C3.Cl,,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
1417,121418,"4-Pyridinemethanol, 3-hydroxy-2-methyl-5-(((alpha-methylphenethyl)amino)methyl)-, dihydrochloride",CC1=NC=C(C(=C1O)CO)CNC(C)CC2=CC=CC=C2.Cl.Cl,,,,,,
1418,121419,4-(Hydroxymethyl)-2-methyl-5-[(1-phenylpropan-2-ylamino)methyl]pyridin-3-ol,CC1=NC=C(C(=C1O)CO)CNC(C)CC2=CC=CC=C2,,,,,,
1419,121420,CID 121420,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC(=CC=C2)OC.Cl,,,,,,
1420,121421,CID 121421,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC(=CC=C2)OC,,,,,,
1421,121422,CID 121422,CCN(CC)CCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2.Cl,,,,,,
1422,121423,CID 121423,CCN(CC)CCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2,,,,,,
1423,121424,2-((alpha-Ethylbenzyl)oxy)-2-methylpropionic acid 2-(diethylamino)ethyl ester hydrochloride,CCC(C1=CC=CC=C1)OC(C)(C)C(=O)OCCN(CC)CC.Cl,,,,,,
1424,121425,2-(Diethylamino)ethyl 2-methyl-2-(1-phenylpropoxy)propanoate,CCC(C1=CC=CC=C1)OC(C)(C)C(=O)OCCN(CC)CC,,,,,,
1425,121426,"Phenethylamine, beta-bromo-N,N-dibenzyl-, hydrobromide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(C3=CC=CC=C3)Br.Br,,,,,,
1426,121427,"N,N-dibenzyl-2-bromo-2-phenylethanamine",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(C3=CC=CC=C3)Br,,,,,,
1427,121428,"3,5-Pyrazolidinedione, 1,2-bis(m-hydroxyphenyl)-4-butyl-",CCCCC1C(=O)N(N(C1=O)C2=CC(=CC=C2)O)C3=CC(=CC=C3)O,,,,,,
1428,121429,3-((Diethylamino)methyl)-2-bornanol benzoate hydrochloride,CCN(CC)CC1C2CCC(C1OC(=O)C3=CC=CC=C3)(C2(C)C)C.Cl,,,,,,
1429,121430,"[3-(Diethylaminomethyl)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] benzoate",CCN(CC)CC1C2CCC(C1OC(=O)C3=CC=CC=C3)(C2(C)C)C,,,,,,
1430,121431,"N-(4-(Diethylamino)-1-methylbutyl)-3,4,5-trimethoxybenzamide",CCN(CC)CCCC(C)NC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
1431,121432,CID 121432,C1=C[N+](=CC=C1C=NO)CC(C(C[N+]2=CC=C(C=C2)C=NO)O)O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O,,,,,,
1432,121433,CID 121433,CCCCC(=O)O[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@H]2CC5=C4C(=C(C=C5)OC)O3)C,,,,,,
1433,121434,Reserpine phosphate,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC.OP(=O)(O)O,,,,,,
1434,121435,CID 121435,CC=C(C)C(=O)O[C@H]1CC[C@]2([C@H]3[C@@]1(OC24C[C@]5([C@@H]6CN7C[C@H](CC[C@H]7[C@@]([C@]6([C@H](C[C@]5([C@@H]4CC3)O)O)O)(C)O)C)O)O)C.C1=CC=C(C=C1)C(=O)O,,,,,,
1435,121436,CID 121436,C/C=C(\C)/C(=O)O[C@H]1CC[C@]2([C@H]3[C@@]1(OC24C[C@]5([C@@H]6CN7C[C@H](CC[C@H]7[C@@]([C@]6([C@H](C[C@]5([C@@H]4CC3)O)O)O)(C)O)C)O)O)C,,,,,,
1436,121437,CID 121437,C[C@@H]1CC[C@@H]2[C@@]([C@@]3([C@@H](C[C@]4([C@@H]5CC[C@@H]6[C@]7(C5(C[C@]4([C@H]3CN2C1)O)O[C@@]6([C@@H](CC7)O)O)C)O)O)O)(C)O.C1=CC=C(C=C1)C(=O)O,,,,,,
1437,121438,CID 121438,C[C@@H]1CC[C@@H]2[C@@]([C@]3([C@H](CN2C1)[C@@]4(CC56[C@H]([C@@]4(CC3O)O)CCC7[C@@]5(CCC([C@]7(O6)O)O)C)O)O)(C)O,,,,,,
1438,121439,"p,p'-Sulfonyldianiline-N,N'-digalactoside",C1=CC(=CC=C1NC2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)S(=O)(=O)C3=CC=C(C=C3)NC4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O,,,,,,
1439,121440,Cinchophylline,COC1=CC2=C(C=C1)NC3=C2CCNC3CC4CC5C6=C(CCN5CC4C=C)C7=C(N6)C=CC(=C7)OC,,,,,,
1440,121441,Delavaconitine,CCN1CC2CCC(C34C2CC(C31)C5(CC(C6(CC4C5C6OC(=O)C7=CC=CC=C7)O)OC)O)OC,,,,,,
1441,121442,CID 121442,CC(=O)O[C@@H]1CC23C4[C@H]5C[C@H]6CC2(C5(C[C@H]7C3[C@@]([C@H]1O)(CN74)C)[C@@H](C6=C)O)O,,,,,,
1442,121443,Taxine B,CC1=C2C(C(C3(CCC(C(=C)C3C(C(C2(C)C)(CC1=O)O)O)OC(=O)CC(C4=CC=CC=C4)N(C)C)C)O)OC(=O)C,,,,,,
1443,121444,CID 121444,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC2=CC=CC3=C2C4=C5C6=C(C=CC(=C6C(=O)O4)C)OC(=C5C3=O)O)O[C@@H]7[C@@H]([C@H]([C@H]([C@H](O7)C)O)OC)O)O)O.[NaH],,,,,,
1444,121445,CID 121445,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC2=CC=CC3=C2C4=C5C6=C(C=CC(=C6C(=O)O4)C)OC(=C5C3=O)O)O[C@@H]7[C@@H]([C@H]([C@H]([C@H](O7)C)O)OC)O)O)O,,,,,,
1445,121446,"11,14-Dihydroxyhetisan-2,13-diyl diacetate",CC(=O)O[C@H]1C[C@]2(CN3C4[C@H]2C5(C1)C3[C@]6(C([C@H]7[C@H](C5C6(C4)CC7=C)O)OC(=O)C)O)C,,,,,,
1446,121447,Alazopeptin,C=CCNC(CCC(=O)C=[N+]=[N-])C(=O)NC(CCC(=O)C=[N+]=[N-])C(=O)O,,,,,,
1447,121448,CID 121448,C=CCNC(CCC(=C[N+]#N)O)C(=O)NC(CCC(=C[N+]#N)O)C(=O)O,,,,,,
1448,121449,6-Diazo-2-[[6-diazo-5-oxo-2-(prop-2-enylamino)hexanoyl]amino]-5-oxohexanoic acid;hydrate,C=CCNC(CCC(=O)C=[N+]=[N-])C(=O)NC(CCC(=O)C=[N+]=[N-])C(=O)O.O,,,,,,
1449,121450,CID 121450,CC(=O)OC(C)(C)C=CC(=O)[C@@](C)([C@H]1[C@@H](C[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C=C(C(=O)C4(C)C)OC5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C)C)O)O,,,,,,
1450,121451,"2-[9-[5-(4,5-Dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2-[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxymethyl]-8,12,16-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde",CCC1C(C2C(O2)(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC3CC(C(C(O3)C)OC4CC(C(C(O4)C)O)(C)O)N(C)C)CC=O)C)C)COC5C(C(C(C(O5)C)O)OC)OC,,,,,,
1451,121452,Biformyne,C#CC#CC#C[C@H]1[C@@H](O1)CO,,,,,,
1452,121453,"33-(4-Amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid",CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,,,,,,
1453,121454,3'-Hydroxyamobarbital,CCC1(C(=O)NC(=O)NC1=O)CCC(C)(C)O,,,,,,
1454,121455,"Nicotine, tartrate (1:2), (-)-l-",CN1CCC[C@H]1C2=CN=CC=C2.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O,,,,"['Studies were conducted to localize the antinociceptive action of nicotine ditartrate within the central nervous system. Antinociceptive and biodispositional studies were carried out after the injection of (3)H-nicotine sc and intracerebroventricularly into the common carotid and vertebral arteries and into the subarachnoid space. (3)H-nicotine was more potent when given into the subarachnoid space than by any other route of administration. Further, disposition studies showed that (3)H-nicotine was almost entirely contained in the thoracic and lumbar areas. Apparently, the spinal cord is an important site for antinociception induced by nicotine.', '...The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 ug nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 ug nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. ...', 'Experiments were done to compare the time-courses of the nicotine concentration in the blood, heart, and brain of infant and adult mice after small and large single doses of radioactive nicotine tartrate. In some experiments the nicotine receptors were blocked with mecamylamine or hexamethonium, and their effects on nicotine levels were measured. The nicotine-induced tremor was allowed visually, and its effects on the heart rate were measured by ECG. In adult mice the peak levels of brain nicotine occurred at 10 min, whereas in infant mice the brain nicotine levels were still rising at 20 min. In the latter the blood and heart nicotine levels were higher than the respective brain levels, and the nicotine level in the brain stem exceeded the hemisphere level. The results were reversed in adult mice. A remarkable accumulation of nicotine in the infant heart was measured. Pretreatment with mecamylamine lowered brain nicotine levels in adult mice, and in infant mice the nicotine levels in blood and heart were lowered as well. This pretreatment abolished the nicotine tremor and its effects on the heart rate similarly in both age groups. This suggests that the difference in nicotine levels after mecamylamine in infant and adult mice may not depend solely on possible differences in circulatory changes but can represent differences in ""receptor population"" as well. Hexamethonium did not abolish the central depressant effect of nicotine on the heart rate nor did it lower the brain nicotine levels. ...']","['In man, nicotine is metabolized to cotinine, hydroxycotinine, desmethylcotinine, and other unidentified compounds ... In other studies with (14)C-labeled nicotine, nicotine isomethonium ion was isolated from urine after iv administration.']",
1455,121456,"(4aR,5aS,8aR,13aS,15aS)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one;hydrochloride",C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6C4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.Cl,,,,,,
1456,121457,CID 121457,C1CN2CC3=CCO[C@H]4CC(=O)N5C6C4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,,,,,,
1457,121458,2-Chloro-3-(phenylsulfonyl)propanenitrile,C1=CC=C(C=C1)S(=O)(=O)CC(C#N)Cl,,,,,,
1458,121459,Dihydrostreptomycin sulphate,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)O.OS(=O)(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1459,121460,CID 121460,C1COCCN1CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3.Cl,,,,,,
1460,121461,CID 121461,C1COCCN1CCC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3,,,,,,
1461,121462,CID 121462,C1=C[N+](=CC=C1C=NO)CC(C(C[N+]2=CC=C(C=C2)C=NO)O)O.[I-].[I-],,,,,,
1462,121463,"4-(m-Chlorophenyl)-N,N-dimethyl-4-phenylbutylamine hydrobromide",CN(C)CCCC(C1=CC=CC=C1)C2=CC(=CC=C2)Cl.Br,,,,,,
1463,121464,"4-(3-chlorophenyl)-N,N-dimethyl-4-phenylbutan-1-amine",CN(C)CCCC(C1=CC=CC=C1)C2=CC(=CC=C2)Cl,,,,,,
1464,121465,CID 121465,CCCC(C)(COC(=N)S)COC(=O)NC(C)C,,,,,,
1465,121466,"Carbamimidothioic acid, 2-(dimethylamino)-1-phenylpropyl ester, dihydrochloride, (S-(R*,R*))-",C[C@@H]([C@H](C1=CC=CC=C1)SC(=N)N)N(C)C.Cl.Cl,,,,,,
1466,121467,"[(1S,2S)-2-(dimethylamino)-1-phenylpropyl] carbamimidothioate",C[C@@H]([C@H](C1=CC=CC=C1)SC(=N)N)N(C)C,,,,,,
1467,121468,"5-[(1-Methylpiperidin-2-yl)methyl]-5-phenyl-1,3-diazinane-2,4,6-trione;hydrochloride",CN1CCCCC1CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3.Cl,,,,,,
1468,121469,"5-[(1-Methylpiperidin-2-yl)methyl]-5-phenyl-1,3-diazinane-2,4,6-trione",CN1CCCCC1CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3,,,,,,
1469,121470,CID 121470,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN(C)C.Cl,,,,,,
1470,121471,CID 121471,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCN(C)C,,,,,,
1471,121472,CID 121472,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC(=CC=C2)O.Cl,,,,,,
1472,121473,CID 121473,CN(C)CCC1(C(=O)NC(=NC1=O)S)C2=CC(=CC=C2)O,,,,,,
1473,121474,Disodium cantharidin,C[C@]1([C@H]2CC[C@@H]([C@]1(C)C(=O)[O-])O2)C(=O)[O-].[Na+].[Na+],,,,,,
1474,121475,"(1r,2s,3r,4s)-2,3-Dimethyl-7-Oxabicyclo[2.2.1]heptane-2,3-Dicarboxylic Acid",C[C@]1([C@H]2CC[C@@H]([C@]1(C)C(=O)O)O2)C(=O)O,,,,,,
1475,121476,5-(Dimethylamino)-2-naphthalen-1-yl-2-propan-2-ylpentanamide,CC(C)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)N,,,,,,
1476,121477,"(1S,9S,10S)-4-methoxy-17-methyl-3-phenoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-10-ol",CN1CC[C@]23CCCC[C@]2([C@@H]1CC4=C3C(=C(C=C4)OC)OC5=CC=CC=C5)O,,,,,,
1477,121478,CID 121478,CN(C)CC1(COC1)COC2=CC=C(C=C2)Cl.C(=CC(=O)O)C(=O)O,,,,,,
1478,121479,"1-[3-[(4-chlorophenoxy)methyl]oxetan-3-yl]-N,N-dimethylmethanamine",CN(C)CC1(COC1)COC2=CC=C(C=C2)Cl,,,,,,
1479,121480,CID 121480,CCN(CC)CC1(COC1)COC2=CC=C(C=C2)Cl.C(=CC(=O)O)C(=O)O,,,,,,
1480,121481,N-[[3-[(4-chlorophenoxy)methyl]oxetan-3-yl]methyl]-N-ethylethanamine,CCN(CC)CC1(COC1)COC2=CC=C(C=C2)Cl,,,,,,
1481,121482,CID 121482,CCN(CC)CC1(COC1)COC2=CC=CC=C2.C(=CC(=O)O)C(=O)O,,,,,,
1482,121483,N-ethyl-N-[[3-(phenoxymethyl)oxetan-3-yl]methyl]ethanamine,CCN(CC)CC1(COC1)COC2=CC=CC=C2,,,,,,
1483,121484,Diethylmethyl((3-(phenoxymethyl)-3-oxetanyl)methyl)ammonium bromide,CC[N+](C)(CC)CC1(COC1)COC2=CC=CC=C2.[Br-],,,,,,
1484,121485,Diethyl-methyl-[[3-(phenoxymethyl)oxetan-3-yl]methyl]azanium,CC[N+](C)(CC)CC1(COC1)COC2=CC=CC=C2,,,,,,
1485,121486,CID 121486,CC1=CC=CC=C1OCC2(COC2)CN(C)C.C(=CC(=O)O)C(=O)O,,,,,,
1486,121487,"N,N-dimethyl-1-[3-[(2-methylphenoxy)methyl]oxetan-3-yl]methanamine",CC1=CC=CC=C1OCC2(COC2)CN(C)C,,,,,,
1487,121488,CID 121488,CCN(CC)CC1(COC1)COC2=CC=CC=C2C.C(=CC(=O)O)C(=O)O,,,,,,
1488,121489,N-ethyl-N-[[3-[(2-methylphenoxy)methyl]oxetan-3-yl]methyl]ethanamine,CCN(CC)CC1(COC1)COC2=CC=CC=C2C,,,,,,
1489,121490,CID 121490,CN(C)CC1(COC1)COC2=CC=CC=C2Cl.C(=CC(=O)O)C(=O)O,,,,,,
1490,121491,"1-[3-[(2-chlorophenoxy)methyl]oxetan-3-yl]-N,N-dimethylmethanamine",CN(C)CC1(COC1)COC2=CC=CC=C2Cl,,,,,,
1491,121492,but-2-enedioic acid;N-[[3-[(2-chlorophenoxy)methyl]oxetan-3-yl]methyl]-N-ethylethanamine,CCN(CC)CC1(COC1)COC2=CC=CC=C2Cl.C(=CC(=O)O)C(=O)O,,,,,,
1492,121493,N-[[3-[(2-chlorophenoxy)methyl]oxetan-3-yl]methyl]-N-ethylethanamine,CCN(CC)CC1(COC1)COC2=CC=CC=C2Cl,,,,,,
1493,121494,CID 121494,C1CCN(CC1)CC2(COC2)COC3=CC=CC=C3Cl.C(=CC(=O)O)C(=O)O,,,,,,
1494,121495,1-[[3-[(2-Chlorophenoxy)methyl]oxetan-3-yl]methyl]piperidine,C1CCN(CC1)CC2(COC2)COC3=CC=CC=C3Cl,,,,,,
1495,121496,but-2-enedioic acid;N-ethyl-N-[[3-[(4-nitrophenoxy)methyl]oxetan-3-yl]methyl]ethanamine,CCN(CC)CC1(COC1)COC2=CC=C(C=C2)[N+](=O)[O-].C(=CC(=O)O)C(=O)O,,,,,,
1496,121497,N-ethyl-N-[[3-[(4-nitrophenoxy)methyl]oxetan-3-yl]methyl]ethanamine,CCN(CC)CC1(COC1)COC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1497,121498,CID 121498,CN(C)CC1(COC1)COC2=CC=C(C=C2)[N+](=O)[O-].C(=CC(=O)O)C(=O)O,,,,,,
1498,121499,"N,N-dimethyl-1-[3-[(4-nitrophenoxy)methyl]oxetan-3-yl]methanamine",CN(C)CC1(COC1)COC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1499,121500,"Phenol, m-(1-methyl-3-propyl-3-pyrrolidinyl)-, acetate",CCCC1(CCN(C1)C)C2=CC(=CC=C2)OC(=O)C,,,,,,
1500,121501,3-Fluoroamphetamine,CC(CC1=CC(=CC=C1)F)N,,,,,,
1501,121502,1-[4-(Trifluoromethyl)phenyl]propan-2-amine,CC(CC1=CC=C(C=C1)C(F)(F)F)N,,,,,,
1502,121503,2-(p-Iodophenyl)-N-methylsuccinimide,CN1C(=O)CC(C1=O)C2=CC=C(C=C2)I,,,,,,
1503,121504,"(R*,R*)-(+-)-1-Methyl-alpha-phenyl-2-piperidineethanol",CN1CCCC[C@@H]1C[C@H](C2=CC=CC=C2)O,,,,,,
1504,121505,CID 121505,C1C[C@H]2CC(C[C@@H]1N2CC3=CC=CC=C3)OC4C5=CC=CC=C5CCC6=CC=CC=C46.C(=CC(=O)O)C(=O)O,,,,,,
1505,121506,"(3-Endo,8-Anti)-8-Benzyl-3-(10,11-Dihydro-5h-Dibenzo[a,D][7]annulen-5-Yloxy)-8-Azoniabicyclo[3.2.1]octane",C1C[C@H]2CC(C[C@@H]1N2CC3=CC=CC=C3)OC4C5=CC=CC=C5CCC6=CC=CC=C46,,,,,,
1506,121507,2-(1-Methylpiperidine)methyl benzilate hydrochloride,CN1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.Cl,,,,,,
1507,121508,N-Methylpiperidinyl-2-methyl benzilate,CN1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
1508,121509,CID 121509,C1CCC(CC1)C2(C(=O)N(C(=O)N(C2=O)CCN3CCCCC3)CCN4CCCCC4)C5=CC=CC=C5,,,,,,
1509,121510,"4-Chloro-2-phenyl-1H-indene-1,3(2H)-dione",C1=CC=C(C=C1)C2C(=O)C3=C(C2=O)C(=CC=C3)Cl,,,,,,
1510,121511,CID 121511,CCC(=O)N1C2CCC1CN(C2)CC=CC3=C(C=CC=C3Cl)Cl.Cl,,,,,,
1511,121512,"1-[3-[3-(2,6-Dichlorophenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)CC=CC3=C(C=CC=C3Cl)Cl,,,,,,
1512,121513,"1-[3-[3-(4-Methylphenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=C(C=C3)C,,,,,,
1513,121514,CID 121514,CC1=C2C=CC=C(C2=C(C3=C1C[C@H]4[C@H](C(=O)C(=C(N)O)C(=O)[C@]4(C3=O)O)N(C)C)O)O,,,,,,
1514,121515,Dihydroquinine,CC[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)OC)O,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1515,121516,Cycloheximide palmitate,CCCCCCCCCCCCCCCC(=O)OC(CC1CC(=O)NC(=O)C1)C2CC(CC(C2=O)C)C,,,,,,
1516,121517,"Endo-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl-2-hydroxy-2,2-diphenylacetate hydrochloride",CN1C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.Cl,,,,,,
1517,121518,"1,2,2,4-Tetramethyl-1-[2-(3,5,7-trimethyl-2-oxo-2,3-dihydro-1h-azepin-1-yl)ethyl]pyrrolidinium iodide",CC1CC([N+](C1)(C)CCN2C(=CC(=CC(C2=O)C)C)C)(C)C.[I-],,,,,,
1518,121519,"3,5,7-trimethyl-1-[2-(1,2,2,4-tetramethylpyrrolidin-1-ium-1-yl)ethyl]-3H-azepin-2-one",CC1CC([N+](C1)(C)CCN2C(=CC(=CC(C2=O)C)C)C)(C)C,,,,,,
1519,121520,Chlorofluoronitroethanethioic acid S-ethyl ester,CCSC(=O)C([N+](=O)[O-])(F)Cl,,,,,,
1520,121521,Ethyl chlorofluoronitroacetate,CCOC(=O)C([N+](=O)[O-])(F)Cl,,,,,,
1521,121522,1-(3-Camphorimidopropionyl)piperidine,CC1(C2CCC1(C(=O)N(C2=O)CCC(=O)N3CCCCC3)C)C,,,,,,
1522,121523,3-((Dimethylamino)methyl)-2-bornanol benzoate hydrochloride,CC1(C2CCC1(C(C2CN(C)C)OC(=O)C3=CC=CC=C3)C)C.Cl,,,,,,
1523,121524,"Bicyclo[2.2.1]heptan-2-ol, 3-[(dimethylamino)methyl]-1,7,7-trimethyl-, 2-benzoate",CC1(C2CCC1(C(C2CN(C)C)OC(=O)C3=CC=CC=C3)C)C,,,,,,
1524,121525,2-(Bis(2-chloroethyl)amino)-N-methylpropionanilide hydrochloride,CC(C(=O)N(C)C1=CC=CC=C1)N(CCCl)CCCl.Cl,,,,,,
1525,121526,2-[bis(2-chloroethyl)amino]-N-methyl-N-phenylpropanamide,CC(C(=O)N(C)C1=CC=CC=C1)N(CCCl)CCCl,,,,,,
1526,121527,"1-(Morpholin-4-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCOCC2,,,,,,
1527,121528,"Piperidinium, 1,1'-(1,4-piperazinediylbis(carbonylethylidene))bis(1-methyl-, diiodide",CC(C(=O)N1CCN(CC1)C(=O)C(C)[N+]2(CCCCC2)C)[N+]3(CCCCC3)C.[I-].[I-],,,,,,
1528,121529,2-(1-Methylpiperidin-1-ium-1-yl)-1-[4-[2-(1-methylpiperidin-1-ium-1-yl)propanoyl]piperazin-1-yl]propan-1-one,CC(C(=O)N1CCN(CC1)C(=O)C(C)[N+]2(CCCCC2)C)[N+]3(CCCCC3)C,,,,,,
1529,121530,"3-Hydroxy-4-methoxy-1-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione",CC12C(O1)C(=O)C(=C(C2=O)O)OC,,,,,,
1530,121531,2-Fluoroamphetamine,CC(CC1=CC=CC=C1F)N,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
1531,121532,"5-Norbornene-2,3-dicarboximide, 5-(alpha-hydroxy-2-pyridylbenzyl)-N-methyl-7-(alpha-2-pyridylbenzylidene)-, endo-",CN1C(=O)C2C3C=C(C(C2C1=O)C3=C(C4=CC=CC=C4)C5=CC=CC=N5)C(C6=CC=CC=C6)(C7=CC=CC=N7)O,,,,,,
1532,121533,"Benzenamine, 4-((1,7,7-trimethylbicyclo(2.2.1)hept-2-yl)oxy)-",CC1(C2CCC1(C(C2)OC3=CC=C(C=C3)N)C)C,,,,,,
1533,121534,"1-[3-[3-(2-Methoxyphenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=CC=C3OC,,,,,,
1534,121535,N-((6-Methyl-8-beta-ergolinyl)methyl)propionamide,CCC(=O)NC[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,,,,,,
1535,121536,Himachalol,CC1=C[C@H]2[C@@H](CC1)[C@](CCCC2(C)C)(C)O,,,,,,
1536,121537,2-(Butylamino)-1-(p-nitrophenyl)ethanol hydrochloride,CCCCNCC(C1=CC=C(C=C1)[N+](=O)[O-])O.Cl,,,,,,
1537,121538,alpha-Ethyl-3'-(trifluoromethyl)-1-pyrrolidineacetanilide,CCC(C(=O)NC1=CC=CC(=C1)C(F)(F)F)N2CCCC2,,,,,,
1538,121539,CID 121539,CN1CCCCC1CC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3.Cl,,,,,,
1539,121540,CID 121540,CN1CCCCC1CC2(C(=O)NC(=NC2=O)S)C3=CC=CC=C3,,,,,,
1540,121541,"((1,6-Dimethyl-8-beta-ergolinyl)methyl)carbamic acid ethyl ester",CCOC(=O)NC[C@@H]1C[C@H]2[C@@H](CC3=CN(C4=CC=CC2=C34)C)N(C1)C,,,,,,
1541,121542,1-(1-Phenylcyclohexyl)morpholine hydrochloride,C1CCC(CC1)(C2=CC=CC=C2)N3CCOCC3.Cl,,,,,,
1542,121543,4-(1-Phenylcyclohexyl)morpholine,C1CCC(CC1)(C2=CC=CC=C2)N3CCOCC3,,,,,,
1543,121544,"Piperidine, 4-methyl-1-(1-phenylcyclohexyl)-, hydrochloride",CC1CCN(CC1)C2(CCCCC2)C3=CC=CC=C3.Cl,,,,,,
1544,121545,1-(1-Phenylcyclohexyl)-4-methylpiperidine,CC1CCN(CC1)C2(CCCCC2)C3=CC=CC=C3,,,,,,
1545,121546,"Cyclohexanecarbonitrile, 1-piperidino-, hydrochloride",C1CCC(CC1)(C#N)N2CCCCC2.Cl,,,,,,
1546,121547,Novembichin,CC(CN(CCCl)CCCl)Cl.Cl,,,,,,
1547,121548,3-Amino-1-phenylpropan-1-ol,C1=CC=C(C=C1)C(CCN)O,,,,,,
1548,121549,"Carbamic acid, (3-chlorophenyl)-, 1-methyl-2-((1-methylethyl)amino)-2-oxoethyl ester, (R)-",C[C@H](C(=O)NC(C)C)OC(=O)NC1=CC(=CC=C1)Cl,,,,,,
1549,121550,"1,1,2-Tris(4-methoxyphenyl)-3-piperidin-1-ylpropan-1-ol",COC1=CC=C(C=C1)C(CN2CCCCC2)C(C3=CC=C(C=C3)OC)(C4=CC=C(C=C4)OC)O,,,,,,
1550,121551,"Pyrrolidine, 1-(1,2-diphenylethyl)-, hydrochloride, (+)-",C1CCN(C1)C(CC2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
1551,121552,"1-(1,2-Diphenylethyl)pyrrolidine",C1CCN(C1)C(CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1552,121553,"1-[4-(2,3-Dihydroxypropoxy)-3-methylphenyl]propan-1-one",CCC(=O)C1=CC(=C(C=C1)OCC(CO)O)C,,,,,,
1553,121554,"1-[2-(2,3-Dihydroxypropoxy)-5-methylphenyl]propan-1-one",CCC(=O)C1=C(C=CC(=C1)C)OCC(CO)O,,,,,,
1554,121555,"1-[3-Chloro-2-(2,3-dihydroxypropoxy)phenyl]propan-1-one",CCC(=O)C1=C(C(=CC=C1)Cl)OCC(CO)O,,,,,,
1555,121556,"3-(p-(9-Fluorenylmethyl)phenoxy)-1,2-propanediol",C1=CC=C2C(=C1)C(C3=CC=CC=C32)CC4=CC=C(C=C4)OCC(CO)O,,,,,,
1556,121557,"3-(2-Methoxy-4-propylphenoxy)-1,2-propanediol",CCCC1=CC(=C(C=C1)OCC(CO)O)OC,,,,,,
1557,121558,"3-[4-(1-Hydroxypropyl)-2-methylphenoxy]propane-1,2-diol",CCC(C1=CC(=C(C=C1)OCC(CO)O)C)O,,,,,,
1558,121559,alpha-Ethyl-4-methyl-1-piperazineacetic acid mesityl ester dihydrochloride,CCC(C(=O)OC1=C(C=C(C=C1C)C)C)N2CCN(CC2)C.Cl.Cl,,,,,,
1559,121560,"(2,4,6-Trimethylphenyl) 2-(4-methylpiperazin-1-yl)butanoate",CCC(C(=O)OC1=C(C=C(C=C1C)C)C)N2CCN(CC2)C,,,,,,
1560,121561,3-(m-Methoxyphenyl)-1-(p-nitrophenethyl)-3-propylpyrrolidine hydrochloride,CCCC1(CCN(C1)CCC2=CC=C(C=C2)[N+](=O)[O-])C3=CC(=CC=C3)OC.Cl,,,,,,
1561,121562,3-(m-Methoxyphenyl)-1-(p-nitrophenethyl)-3-propylpyrrolidine,CCCC1(CCN(C1)CCC2=CC=C(C=C2)[N+](=O)[O-])C3=CC(=CC=C3)OC,,,,,,
1562,121563,3-Butyl-3-(m-methoxyphenyl)-1-methylpyrrolidine,CCCCC1(CCN(C1)C)C2=CC(=CC=C2)OC,,,,,,
1563,121564,Metcaraphen hydrochloride,CCN(CC)CCOC(=O)C1(CCCC1)C2=CC(=C(C=C2)C)C.Cl,,,,,,
1564,121565,2-(p-Hydroxybenzylidene)aminoethanol,C1=CC(=CC=C1C=NCCO)O,,,,,,
1565,121566,"3-(4-Allyl-2-methoxy-6-(piperidinomethyl)phenoxy)-1,2-propanediol",COC1=CC(=CC(=C1OCC(CO)O)CN2CCCCC2)CC=C,,,,,,
1566,121567,"1,3-Propanediol, 2-((p-(bis(2-chloroethyl)amino)benzylidene)amino)-1-(p-nitrophenyl)-",C1=CC(=CC=C1C=NC(CO)C(C2=CC=C(C=C2)[N+](=O)[O-])O)N(CCCl)CCCl,,,,,,
1567,121568,"1,3-Diazaspiro(4.5)decane-2,4-dione, 6-(ethoxycarbonyl)-",CCOC(=O)C1CCCCC12C(=O)NC(=O)N2,,,,,,
1568,121569,"2-Propanol, 1-(methylsulfonyl)-",CC(CS(=O)(=O)C)O,,,,,,
1569,121570,(+)-N-(alpha-Methylphenethyl)-2-thenylamine acetate,CC(CC1=CC=CC=C1)NCC2=CC=CS2.CC(=O)O,,,,,,
1570,121571,1-phenyl-N-(thiophen-2-ylmethyl)propan-2-amine,CC(CC1=CC=CC=C1)NCC2=CC=CS2,,,,,,
1571,121572,Coleon A,CC1=C2C(=C(C3=C1C(C(O3)O)(C)CC=C)O)C(=C(C(=O)C2=O)C(C)C)O,,,,,,
1572,121573,5-Butyl-3-phenylrhodanine,CCCCC1C(=O)N(C(=S)S1)C2=CC=CC=C2,,,,,,
1573,121574,3-Phenyl-5-propylrhodanine,CCCC1C(=O)N(C(=S)S1)C2=CC=CC=C2,,,,,,
1574,121575,3-(m-Acetoxyphenyl)-3-butyl-1-methylpyrrolidine,CCCCC1(CCN(C1)C)C2=CC(=CC=C2)OC(=O)C,,,,,,
1575,121576,"2-Benzimidazolinone, 1-(1-(3-(p-fluorobenzoyl)propyl)-4-piperidyl)-3-propionyl-",CCC(=O)N1C2=CC=CC=C2N(C1=O)C3CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
1576,121577,"2H-Benzimidazol-2-one, 1-acetyl-3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1,3-dihydro-",CC(=O)N1C2=CC=CC=C2N(C1=O)C3CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
1577,121578,Decoyinine,C=C1[C@H]([C@H]([C@](O1)(CO)N2C=NC3=C(N=CN=C32)N)O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1578,121579,CID 121579,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=CC4=CC=CC=C43.Cl.Cl,,,,,,
1579,121580,CID 121580,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=CC4=CC=CC=C43,,,,,,
1580,121581,"4-(2-Hydroxyethyl)-4-methyl-1,3-dioxane",CC1(CCOCO1)CCO,,,,,,
1581,121582,"4-Butyl-1-(p-(methylsulfonyl)phenyl)-2-phenyl-3,5-pyrazolidinedione",CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)S(=O)(=O)C)C3=CC=CC=C3,,,,,,
1582,121583,"N,N-Diethyl-2-hydroxy-2-phenylacetamide",CCN(CC)C(=O)C(C1=CC=CC=C1)O,,,,,,
1583,121584,"2-Benzimidazolinone, 1-(1-(3-(p-fluorobenzoyl)propyl)-4-piperidyl)-3-methyl-, hydrochloride",CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)CCC(=O)C4=CC=C(C=C4)F.Cl,,,,,,
1584,121585,1-[1-[3-(4-Fluorophenyl)-3-oxopropyl]piperidin-4-yl]-3-methylbenzimidazol-2-one,CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)CCC(=O)C4=CC=C(C=C4)F,,,,,,
1585,121586,Zoledronic acid hydrate,C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O.O,['Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.'],,['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],,,
1586,121587,Galantamine hydrobromide,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)', 'Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
1587,121588,CID 121588,C1=CC(=CC=C1N)S(=O)(=O)[O-].[K+],,,,,,
1588,121589,Tripentaerythritol octanitrate,C(C(COCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],,,,,,
1589,121590,"(3-Hydroxy-2,2-dimethoxy)propyl dihydrogen phosphate",COC(CO)(COP(=O)(O)O)OC,,,,,,
1590,121591,Taps,C(CNC(CO)(CO)CO)CS(=O)(=O)O,,,,,,
1591,121592,"(((2-Hydroxyethyl)imino)dimethylene)diphosphonic acid, tetraethyl ester",CCOP(=O)(CN(CCO)CP(=O)(OCC)OCC)OCC,,,,,,
1592,121593,Isopropyl bromoacetate,CC(C)OC(=O)CBr,,,,,,
1593,121594,2-Bromo-4-(hydroxymethyl)phenol,C1=CC(=C(C=C1CO)Br)O,,,,,,
1594,121595,5-Hydroxy-2-benzothiazolesulfonamide,C1=CC2=C(C=C1O)N=C(S2)S(=O)(=O)N,,,,,,
1595,121596,"4,6-Dimethoxy-2-methyl-5-nitropyrimidine",CC1=NC(=C(C(=N1)OC)[N+](=O)[O-])OC,,,,,,
1596,121597,"4,6-Dimethoxy-5-nitro-2-phenylpyrimidine",COC1=C(C(=NC(=N1)C2=CC=CC=C2)OC)[N+](=O)[O-],,,,,,
1597,121598,2-Ethoxycyclohex-2-en-1-one,CCOC1=CCCCC1=O,,,,,,
1598,121599,Tetrahydro-4H-pyran-4-one,C1COCCC1=O,,,,,,
1599,121600,Tris(3-chlorophenyl)phosphine,C1=CC(=CC(=C1)Cl)P(C2=CC(=CC=C2)Cl)C3=CC(=CC=C3)Cl,,,,,,
1600,121601,"Bis(1,1,3,3-tetramethylbutyl) disulphide",CC(C)(C)CC(C)(C)SSC(C)(C)CC(C)(C)C,,,,,,
1601,121602,Di-tert-tetradecyl disulphide,CC(C(C)(C)C)C(C)(C)C(C)C(C)(C)SSC(C)(C)C(C)C(C)(C)C(C)C(C)(C)C,,,,,,
1602,121603,"Benzenesulfonamide, N-4-biphenylyl-N-hydroxy-",C1=CC=C(C=C1)C2=CC=C(C=C2)N(O)S(=O)(=O)C3=CC=CC=C3,,,,,,
1603,121604,"2(1H)-Quinolinone, 1,6-dimethyl-",CC1=CC2=C(C=C1)N(C(=O)C=C2)C,,,,,,
1604,121605,O-Ethyl O-(beta-methoxyethyl) S-(prop-2-ynyl) phosphorothioate,CCOP(=O)(OCCOC)SCC#C,,,,,,
1605,121606,Methyl 4-oxopiperidine-1-carboxylate,COC(=O)N1CCC(=O)CC1,,,,,,
1606,121607,Dodecyl alpha-D-glucopyranoside,CCCCCCCCCCCCO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1607,121608,"Phenol, dioctyl-",CCCCCCCCC1=C(C(=CC=C1)O)CCCCCCCC,,,,,,
1608,121609,Methyl 2-butyramidobenzoate,CCCC(=O)NC1=CC=CC=C1C(=O)OC,,,,,,
1609,121610,CID 121610,C1=CC=C2C(=C1)C3=NC2=NC4=NC(=NC5=NC(=NC6=C7C=CC=C(C7=C(N6)N3)Cl)C8=CC=CC=C85)C9=CC=CC=C94,,,,,,
1610,121611,Buthiuron,CCCCS(=O)(=O)C1=NN=C(S1)N(C)C(=O)NC,,,,,,
1611,121612,Boc-S-tert-butylmercapto-L-cysteine,CC(C)(C)OC(=O)NC(CSSC(C)(C)C)C(=O)O,,,,,,
1612,121613,"1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-Pentacosafluoro-14-iodotetradecane",C(CI)C(C(C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
1613,121614,7-Nitro-3-phenyl-1-naphthyl 4-nitrophenylacetate,C1=CC=C(C=C1)C2=CC(=C3C=C(C=CC3=C2)[N+](=O)[O-])OC(=O)CC4=CC=C(C=C4)[N+](=O)[O-],,,,,,
1614,121615,7-Nitro-3-phenyl-1-naphthol,C1=CC=C(C=C1)C2=CC(=C3C=C(C=CC3=C2)[N+](=O)[O-])O,,,,,,
1615,121616,"3',5'-Bis(trifluoromethyl)acetophenone",CC(=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,,,"['1-[3,5-bis(trifluoromethyl)phenyl]ethanone is a known human metabolite of aprepitant.']",
1616,121617,"3,4-Dihydro-2H-1-benzothiopyran-8-ol",C1CC2=C(C(=CC=C2)O)SC1,,,,,,
1617,121618,"2-Quinolinol, acetate (ester)",CC(=O)OC1=NC2=CC=CC=C2C=C1,,,,,,
1618,121619,"alpha-(3,4-Dimethoxybenzyl)-beta-anilinoacrylonitrile",COC1=C(C=C(C=C1)CC(=CNC2=CC=CC=C2)C#N)OC,,,,,,
1619,121620,"3,4,5-Trimethoxy-alpha-(4-morpholinylmethylene)benzenepropanenitrile",COC1=CC(=CC(=C1OC)OC)CC(=CN2CCOCC2)C#N,,,,,,
1620,121621,"2-[(3,4-Dimethoxyphenyl)methyl]-3-morpholin-4-ylprop-2-enenitrile",COC1=C(C=C(C=C1)CC(=CN2CCOCC2)C#N)OC,,,,,,
1621,121622,"3,4,5-Trimethoxy-alpha-(methoxymethylene)benzenepropanenitrile",COC=C(CC1=CC(=C(C(=C1)OC)OC)OC)C#N,,,,,,
1622,121623,"3-Anilino-2-[(3,4,5-trimethoxyphenyl)methyl]prop-2-enenitrile",COC1=CC(=CC(=C1OC)OC)CC(=CNC2=CC=CC=C2)C#N,,,,,,
1623,121624,Indan-5-carbaldehyde,C1CC2=C(C1)C=C(C=C2)C=O,,,,,,
1624,121625,CID 121625,C1CCC2C(C1)NC(=N2)S,,,,,,
1625,121626,p-(p-Chlorophenoxy)phenylisocyanate,C1=CC(=CC=C1N=C=O)OC2=CC=C(C=C2)Cl,,,,,,
1626,121627,4-Isobutylaniline,CC(C)CC1=CC=C(C=C1)N,,,,,,
1627,121628,"4,6-Dibenzyl-m-cresol",CC1=CC(=C(C=C1CC2=CC=CC=C2)CC3=CC=CC=C3)O,,,,,,
1628,121629,4-Benzyl-m-cresol,CC1=C(C=CC(=C1)O)CC2=CC=CC=C2,,,,,,
1629,121630,"4,4-Dimethyl-2-oxazoline",CC1(COC=N1)C,,,,,,
1630,121631,"4H-1-Benzopyran-2-carboxylic acid, 6-nitro-4-oxo-, ethyl ester",CCOC(=O)C1=CC(=O)C2=C(O1)C=CC(=C2)[N+](=O)[O-],,,,,,
1631,121632,"Thiazole, 2-(5-nitro-2-thienyl)-4-piperidinomethyl-, hydrochloride",C1CCN(CC1)CC2=CSC(=N2)C3=CC=C(S3)[N+](=O)[O-].Cl,,,,,,
1632,121633,"2-(5-Nitrothiophen-2-yl)-4-(piperidin-1-ylmethyl)-1,3-thiazole",C1CCN(CC1)CC2=CSC(=N2)C3=CC=C(S3)[N+](=O)[O-],,,,,,
1633,121634,"2-[Methyl-[[2-(5-nitrothiophen-2-yl)-1,3-thiazol-4-yl]methyl]amino]ethanol",CN(CCO)CC1=CSC(=N1)C2=CC=C(S2)[N+](=O)[O-],,,,,,
1634,121635,CID 121635,C1COCCN1CC2=CSC(=N2)C=CC3=CC=C(S3)[N+](=O)[O-].Cl,,,,,,
1635,121636,"4-[[2-[2-(5-Nitrothiophen-2-yl)ethenyl]-1,3-thiazol-4-yl]methyl]morpholine",C1COCCN1CC2=CSC(=N2)C=CC3=CC=C(S3)[N+](=O)[O-],,,,,,
1636,121637,p-Anisyl-p-benzoquinone,COC1=CC=C(C=C1)C2=CC(=O)C=CC2=O,,,,,,
1637,121638,"N,N'-(9,10-Dihydro-4,8-dihydroxy-9,10-dioxoanthracene-1,5-diyl)bis(2,5-dichlorobenzamide)",C1=CC(=C(C=C1Cl)C(=O)NC2=C3C(=C(C=C2)O)C(=O)C4=C(C=CC(=C4C3=O)O)NC(=O)C5=C(C=CC(=C5)Cl)Cl)Cl,,,,,,
1638,121639,Disperse Red 82,CC(=O)OCCN(CCOC(=O)C)C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)[N+](=O)[O-])C#N,,,,,,
1639,121640,"7-((1,3-Dioxobutyl)amino)-3-hydroxynaphthalene-1-sulphonic acid",CC(=O)CC(=O)NC1=CC2=C(C=C(C=C2C=C1)O)S(=O)(=O)O,,,,,,
1640,121641,"1-Butyl-5-[3-(1-butyl-5-cyano-4-methyl-2,6-dioxopyridin-3-ylidene)prop-1-enyl]-6-hydroxy-4-methyl-2-oxopyridine-3-carbonitrile",CCCCN1C(=C(C(=C(C1=O)C#N)C)C=CC=C2C(=C(C(=O)N(C2=O)CCCC)C#N)C)O,,,,,,
1641,121642,"3-[2,2-Dimethyl-1-oxo-3-[(1-oxo-2-propenyl)oxy]propoxy]-2,2-dimethylpropyl acrylate",CC(C)(COC(=O)C=C)COC(=O)C(C)(C)COC(=O)C=C,,,,,,
1642,121643,"2,3,4-Tribromostyrene",C=CC1=C(C(=C(C=C1)Br)Br)Br,,,,,,
1643,121644,"beta-Alanine, N-(4-(2,2-dicyanoethenyl)-3-methylphenyl)-N-(2-phenylethyl)-, methyl ester",CC1=C(C=CC(=C1)N(CCC2=CC=CC=C2)C(C)C(=O)OC)C=C(C#N)C#N,,,,,,
1644,121645,"3-Chloro-4-morpholino-1,2,5-thiadiazole",C1COCCN1C2=NSN=C2Cl,,,,,,
1645,121646,"4-(Octahydro-5H-4,7-methanoinden-5-ylidene)butanal",C1CC2C(C1)C3CC2CC3=CCCC=O,,,,,,
1646,121647,CID 121647,CC1=CC(=CC(=C1Br)Br)OC2CO2,,,,,,
1647,121648,"Benzene, bis(phenylmethyl)-",C1=CC=C(C=C1)CC2=CC(=CC=C2)CC3=CC=CC=C3,,,,,,
1648,121649,"2-(3,4,5-Trimethoxybenzoyl)isoxazolidine",COC1=CC(=CC(=C1OC)OC)C(=O)C2NCCO2,,,,,,
1649,121650,"5-Carbethoxy-2-methyl-6,7-benzomorphan hydrochloride",CCC(=O)OC12CCN(C(C1)CC3=CC=CC=C23)C.Cl,,,,,,
1650,121651,"(10-Methyl-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-trien-1-yl) propanoate",CCC(=O)OC12CCN(C(C1)CC3=CC=CC=C23)C,,,,,,
1651,121652,"1,1,1,3,3,3-Hexafluoro-2-((2-hydroxyethyl)amino)-2-propanol",C(CO)NC(C(F)(F)F)(C(F)(F)F)O,,,,,,
1652,121653,"1-Piperazinemethanol, alpha,alpha-bis(trifluoromethyl)-, hydrate",C1CN(CCN1)C(C(F)(F)F)(C(F)(F)F)O.O,,,,,,
1653,121654,"1,1,1,3,3,3-Hexafluoro-2-piperazin-1-ylpropan-2-ol",C1CN(CCN1)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
1654,121655,"1-Piperidinemethanol, alpha,alpha-bis(trifluoromethyl)-, hydrate",C1CCN(CC1)C(C(F)(F)F)(C(F)(F)F)O.O,,,,,,
1655,121656,"1,1,1,3,3,3-Hexafluoro-2-piperidin-1-ylpropan-2-ol",C1CCN(CC1)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
1656,121657,"Benzenamine, 3,3'-[sulfonylbis(4,1-phenyleneoxy)]bis-",C1=CC(=CC(=C1)OC2=CC=C(C=C2)S(=O)(=O)C3=CC=C(C=C3)OC4=CC=CC(=C4)N)N,,,,,,
1657,121658,"1,3-Dihydroxypropan-2-yl docosanoate",CCCCCCCCCCCCCCCCCCCCCC(=O)OC(CO)CO,,,,,,
1658,121659,"2,5-Cyclohexadiene-1,4-dione, 2-(4-methylphenyl)-",CC1=CC=C(C=C1)C2=CC(=O)C=CC2=O,,,,,,
1659,121660,N-(3-Methylbutyl)cyclohexylamine,CC(C)CCNC1CCCCC1,,,,,,
1660,121661,4-Methyl-2-propylpyridine,CCCC1=NC=CC(=C1)C,,,,,,
1661,121662,"Acetic acid, 2,2'-thiobis-, diisooctyl ester",CC(C)CCCCCOC(=O)CSCC(=O)OCCCCCC(C)C,,,,,,
1662,121663,"Benzenesulfonic acid, oxybis(dodecyl-",CCCCCCCCCCCCC1=C(C=C(C=C1)S(=O)(=O)O)OC2=C(C=CC(=C2)S(=O)(=O)O)CCCCCCCCCCCC,,,,,,
1663,121664,Einecs 250-109-4,C[N+](C)(C)CCOC(=O)C1N=N1.[Br-],,,,,,
1664,121665,2-(3H-diazirine-3-carbonyloxy)ethyl-trimethylazanium,C[N+](C)(C)CCOC(=O)C1N=N1,,,,,,
1665,121666,"Benzenesulfonic acid, 4-(2-(3-(2-(dimethylphenyl)diazenyl)-2,4-dihydroxyphenyl)diazenyl)-",CC1=C(C(=CC=C1)N=NC2=C(C=C(C=C2O)N=NC3=CC=C(C=C3)S(=O)(=O)O)O)C,,,,,,
1666,121667,ethyl beta-D-glucopyranoside,CCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1667,121668,CID 121668,CC(=O)C=C(C(F)(F)F)O.CC(=O)C=C(C(F)(F)F)O.CC(=O)C=C(C(F)(F)F)O.[Ir],,,,,,
1668,121669,"Phenol, dodecyl-, 1,1'-(hydrogen phosphorodithioate)",CCCCCCCCCCCCC1=CC=C(C=C1)OP(=S)(OC2=CC=C(C=C2)CCCCCCCCCCCC)S,,,,,,
1669,121670,"1,1,1,4,5,5,5-Heptafluoro-3-(pentafluoroethyl)-2,4-bis(trifluoromethyl)pent-2-ene",C(=C(C(F)(F)F)C(F)(F)F)(C(C(F)(F)F)(C(F)(F)F)F)C(C(F)(F)F)(F)F,,,,,,
1670,121671,"3-(2-(2-Heptadecyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy)propionic acid",CCCCCCCCCCCCCCCCCC1=NCCN1CCOCCC(=O)O,,,,,,
1671,121672,3-Hydroxy-7-methylguanine,CN1C=NC2=C1C(=O)N=C(N2O)N,,,,,,
1672,121673,"Guanine, 3-hydroxy-9-methyl-",CN1C=NC2=C1N(C(=NC2=O)N)O,,,,,,
1673,121674,Tetrabutylphosphonium acetate,CCCC[P+](CCCC)(CCCC)CCCC.CC(=O)[O-],,,,,,
1674,121675,"(3,3-Dimethyl-cyclohexylidene)-acetic acid methyl ester",CC1(CCCC(=CC(=O)OC)C1)C,,,,,,
1675,121676,Benzylbiphenylol,C1=CC=C(C=C1)CC2=C(C(=CC=C2)O)C3=CC=CC=C3,,,,,,
1676,121677,"1,1,6-Trimethyl-1,2-dihydronaphthalene",CC1=CC2=C(C=C1)C(CC=C2)(C)C,,,,,,
1677,121678,CID 121678,CCCCCCCCCCCCCC(=O)N(C)CC(=O)[O-].[Na+],,,,,,
1678,121679,"2-Naphthalenecarboxamide, N-(3-acetylphenyl)-3-hydroxy-",CC(=O)C1=CC(=CC=C1)NC(=O)C2=CC3=CC=CC=C3C=C2O,,,,,,
1679,121680,"2-Naphthalenecarboxamide, 1-hydroxy-N-[3-(4-morpholinyl)propyl]-",C1COCCN1CCCNC(=O)C2=C(C3=CC=CC=C3C=C2)O,,,,,,
1680,121681,Ethyl Perfluorononanoate,CCOC(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
1681,121682,N-Ethyl-2-nitro-4-(trifluoromethyl)aniline,CCNC1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-],,,,,,
1682,121683,"1,2-Benzenediamine, N1-ethyl-4-(trifluoromethyl)-",CCNC1=C(C=C(C=C1)C(F)(F)F)N,,,,,,
1683,121684,3-[5-Chloro-3-ethyl-2-methyl-6-(trifluoromethyl)benzimidazol-1-ium-1-yl]propane-1-sulfonic acid,CCN1C(=[N+](C2=C1C=C(C(=C2)C(F)(F)F)Cl)CCCS(=O)(=O)O)C,,,,,,
1684,121685,3-[5-Chloro-2-[3-[6-chloro-1-ethyl-3-(3-sulfopropyl)-5-(trifluoromethyl)benzimidazol-3-ium-2-yl]prop-2-enylidene]-3-ethyl-6-(trifluoromethyl)benzimidazol-1-yl]propane-1-sulfonic acid,CCN1C2=C(C=C(C(=C2)Cl)C(F)(F)F)[N+](=C1C=CC=C3N(C4=C(N3CCCS(=O)(=O)O)C=C(C(=C4)Cl)C(F)(F)F)CC)CCCS(=O)(=O)O,,,,,,
1685,121686,"Ethanaminium, N,N,N-trimethyl-, hydroxide",CC[N+](C)(C)C.[OH-],,,,,,
1686,121687,"6-Octen-2-ol, 2,6-dimethyl-",CC=C(C)CCCC(C)(C)O,,,,,,
1687,121688,"2-Butoxyethyl 3-(2,4,5-trichlorophenoxy)propionate",CCCCOCCOC(=O)CCOC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
1688,121689,(2S)-1-methylsulfonylsulfanylpropan-2-ol,C[C@@H](CSS(=O)(=O)C)O,,,,,,
1689,121690,n-Methyl-4-(methylsulfonyl)-2-nitroaniline,CNC1=C(C=C(C=C1)S(=O)(=O)C)[N+](=O)[O-],,,,,,
1690,121691,1-Ethynylcyclohexylamine,C#CC1(CCCCC1)N,,,,,,
1691,121692,"1h,1h,2h-Perfluoro-1-dodecene",C=CC(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
1692,121693,2-Methylpropyl ethylmethylphosphinate,CCP(=O)(C)OCC(C)C,,,,,,
1693,121694,"4-Ethyl-2,5-dimethyloxazole",CCC1=C(OC(=N1)C)C,,,,,,
1694,121695,4-(Butylamino)-2-(4-methoxyphenyl)-1-benzopyrylium tetrafluoroborate,[B-](F)(F)(F)F.CCCC[NH+]=C1C=C(OC2=CC=CC=C21)C3=CC=C(C=C3)OC,,,,,,
1695,121696,N-butyl-2-(4-methoxyphenyl)chromen-4-imine,CCCCN=C1C=C(OC2=CC=CC=C21)C3=CC=C(C=C3)OC,,,,,,
1696,121697,4-Methylsulfanyl-2-ureido-butyric acid,CSCCC(C(=O)O)NC(=O)N,,,,,,
1697,121698,5-Hydroxymethyluridine,C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)CO,,,,,,
1698,121699,Methyl 3-oxovalerate,CCC(=O)CC(=O)OC,,,,,,
1699,121700,Methyl 3-oxohexanoate,CCCC(=O)CC(=O)OC,,,,,,
1700,121701,Methyl 5-methyl-3-oxohexanoate,CC(C)CC(=O)CC(=O)OC,,,,,,
1701,121702,"4,11-Diamino-2-(2-butoxyethyl)-2,3-dihydro-3-imino-1H-naphth[2,3-f]isoindole-1,5,10-trione",CCCCOCCN1C(=N)C2=C(C3=C(C(=C2C1=O)N)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
1702,121703,Safrole I,CN(C)CCC(=O)C1=CC2=C(C=C1)OCO2,,,,,,
1703,121704,"2-Nonen-1-ol, acetate, (2E)-",CCCCCCC=CCOC(=O)C,,,,,,
1704,121705,1-(4-Methoxyphenyl)pyrrolidin-2-one,COC1=CC=C(C=C1)N2CCCC2=O,,,,,,
1705,121706,2-Dimethylamino-p-cresol,CC1=CC(=C(C=C1)O)N(C)C,,,,,,
1706,121707,ZINC;2-(2-carbamoylphenyl)benzenethiolate,C1=CC=C(C(=C1)C2=CC=CC=C2[S-])C(=O)N.C1=CC=C(C(=C1)C2=CC=CC=C2[S-])C(=O)N.[Zn+2],,,,,,
1707,121708,2-(2-Sulfanylphenyl)benzamide,C1=CC=C(C(=C1)C2=CC=CC=C2S)C(=O)N,,,,,,
1708,121709,Isobutyl 3-methyl-2-butenoate,CC(C)COC(=O)C=C(C)C,,,,,,
1709,121710,"3,4-Dimethylcyclopent-2-en-1-one",CC1CC(=O)C=C1C,,,,,,
1710,121711,CID 121711,C1=CC=C2C(=C1)C(=C(C(=C2O)N=O)O)N=O,,,,,,
1711,121712,Di-tert-butyl phthalate,CC(C)(C)OC(=O)C1=CC=CC=C1C(=O)OC(C)(C)C,,,,,,
1712,121713,"P-[(5-Cyano-1,6-dihydro-2-hydroxy-1,4-dimethyl-6-oxo-3-pyridyl)azo]-N-(2-ethylhexyl)benzamide",CCCCC(CC)CNC(=O)C1=CC=C(C=C1)N=NC2=C(C(=C(N(C2=O)C)O)C#N)C,,,,,,
1713,121714,Cystine disulfoxide,C(C(C(=O)O)N)SS(=O)(=O)CC(C(=O)O)N,,,,,,
1714,121715,"4,4'-Dithiobisbutan-1-ol",C(CCSSCCCCO)CO,,,,,,
1715,121716,"4-[2-[3-(3-Ethyl-1,3-benzothiazol-2-ylidene)-2-methylprop-1-enyl]-1,3-benzothiazol-3-ium-3-yl]butane-1-sulfonate",CCN1C2=CC=CC=C2SC1=CC(=CC3=[N+](C4=CC=CC=C4S3)CCCCS(=O)(=O)[O-])C,,,,,,
1716,121717,"4-[2-[3-(3-Ethyl-1,3-benzothiazol-2-ylidene)-2-methylprop-1-enyl]-1,3-benzothiazol-3-ium-3-yl]butane-1-sulfonic acid",CCN1C2=CC=CC=C2SC1=CC(=CC3=[N+](C4=CC=CC=C4S3)CCCCS(=O)(=O)O)C,,,,,,
1717,121718,1-(4-Trifluoromethylphenyl)piperazine,C1CN(CCN1)C2=CC=C(C=C2)C(F)(F)F,,,,,,
1718,121719,Pinocarvone,CC1(C2CC1C(=C)C(=O)C2)C,,,,,,
1719,121720,Diethyl (ethoxyacetyl)phosphonate,CCOCC(=O)P(=O)(OCC)OCC,,,,,,
1720,121721,"Octahydrodimethyl-4,7-methano-1H-indene",CC1C(C2CC1C3C2CCC3)C,,,,,,
1721,121722,Isononyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCCCCCCC(C)C,,,,,,
1722,121723,7-Bromoheptanoic acid,C(CCCBr)CCC(=O)O,,,,,,
1723,121724,2-Chloro-6-methylnicotinic acid,CC1=NC(=C(C=C1)C(=O)O)Cl,,,,,,
1724,121725,CID 121725,CN(C)C(=C(N=O)Cl)O,,,,,,
1725,121726,1-Ethyl-2-methyl-5-(trifluoromethyl)-1H-benzimidazole,CCN1C(=NC2=C1C=CC(=C2)C(F)(F)F)C,,,,,,
1726,121727,5-(2-(Dibenzylamino)acetyl)-2-hydroxybenzamide,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(=O)C3=CC(=C(C=C3)O)C(=O)N,,,,,,
1727,121728,1-Methoxy-2-((4-methoxyphenyl)methyl)benzene,COC1=CC=C(C=C1)CC2=CC=CC=C2OC,,,,,,
1728,121729,2-Isopropenylthiophene,CC(=C)C1=CC=CS1,,,,,,
1729,121730,"Phenol, 2-[[(4-butylphenyl)imino]methyl]-5-methoxy-",CCCCC1=CC=C(C=C1)N=CC2=C(C=C(C=C2)OC)O,,,,,,
1730,121731,"1-Methyl-1,3-cyclohexadiene",CC1=CC=CCC1,,,,,,
1731,121732,1-Propyl-2-methyl-3-hydroxypyrid-4-one,CCCN1C=CC(=O)C(=C1C)O,,,,,,
1732,121733,"4(1H)-Pyridinone, 1-butyl-3-hydroxy-2-methyl-",CCCCN1C=CC(=O)C(=C1C)O,,,,,,
1733,121734,"4(1H)-Pyridinone, 3-hydroxy-2-methyl-1-pentyl-",CCCCCN1C=CC(=O)C(=C1C)O,,,,,,
1734,121735,Dibutyl phosphonite,CCCCOPOCCCC,,,,,,
1735,121736,"2,3-Dimethyl-1-(4-nitrophenyl)-3-pyrazolin-5-one",CC1=CC(=O)N(N1C)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1736,121737,4-Fluorosulphonylbenzenesulphonyl chloride,C1=CC(=CC=C1S(=O)(=O)F)S(=O)(=O)Cl,,,,,,
1737,121738,Isobutyl decanoate,CCCCCCCCCC(=O)OCC(C)C,,,,,,
1738,121739,Propyl decanoate,CCCCCCCCCC(=O)OCCC,,,,,,
1739,121740,CID 121740,CN1C(=NN=C1S)C(F)(F)F,,,,,,
1740,121741,"1alpha,2beta-Cyclopentanedicarboxylic acid diethyl ester",CCOC(=O)[C@H]1CCC[C@@H]1C(=O)OCC,,,,,,
1741,121742,Sodium 2-Amino-5-nitrobenzenesulfonate,C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)[O-])N.[Na+],,,,,,
1742,121743,Ethylene glycol acrylate phthalate,C=CC(=O)OCCOC(=O)C1=CC=CC=C1C(=O)O,,,,,,
1743,121744,"4,6-Di-O-tetradecanoylhex-2-ulofuranosyl hexopyranoside",CCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(CO)O[C@H]2[C@H]([C@@H]([C@H]([C@@H](O2)CO)O)O)O)O)OC(=O)CCCCCCCCCCCCC,,,,,,
1744,121745,CID 121745,C1C(=NN(C1=O)C2=C(C=C(C=C2Cl)Cl)Cl)NC3=C(C=CC(=C3)[N+](=O)[O-])Cl,,,,,,
1745,121746,Oxotriphenoxyvanadium,C1=CC=C(C=C1)O.C1=CC=C(C=C1)O.C1=CC=C(C=C1)O.O=[V],,,,,,
1746,121747,CID 121747,C1=CC=C2C(=C1)C=CC(=O)C2=NN=C3C=C(C4=C(C3=O)C=CC(=C4)N(O)O)S(=O)(=O)[O-].[Na+],,,,,,
1747,121748,CID 121748,C1=CC=C2C(=C1)C=CC(=O)C2=NN=C3C=C(C4=C(C3=O)C=CC(=C4)N(O)O)S(=O)(=O)O,,,,,,
1748,121749,"6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine hydrochloride",CC1(N=C(N=C(N1OCCCOC2=CC(=C(C=C2Cl)Cl)Cl)N)N)C.Cl,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
1749,121750,"6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine",CC1(N=C(N=C(N1OCCCOC2=CC(=C(C=C2Cl)Cl)Cl)N)N)C,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,,
1750,121751,3-(tert-Butyldioxy)-3-(4-chlorophenyl)phthalide,CC(C)(C)OOC1(C2=CC=CC=C2C(=O)O1)C3=CC=C(C=C3)Cl,,,,,,
1751,121752,"2-Propanol, 1-(1-methyl-2-propoxyethoxy)-",CCCOCC(C)OCC(C)O,,,,,,
1752,121753,Methyl 2-hexyl-3-oxocyclopentaneacetate,CCCCCCC1C(CCC1=O)CC(=O)OC,,,,,,
1753,121754,Pigment Yellow 120,CC(=O)C(C(=O)NC1=CC2=C(C=C1)NC(=O)N2)N=NC3=CC(=CC(=C3)C(=O)OC)C(=O)OC,,,,,,
1754,121755,"4-Ethyl-1,3-dioxolane",CCC1COCO1,,,,,,
1755,121756,"1,1'-(Isopropylidenebis(p-phenyleneoxy))bis(3-mercaptopropan-2-ol)",CC(C)(C1=CC=C(C=C1)OCC(CS)O)C2=CC=C(C=C2)OCC(CS)O,,,,,,
1756,121757,"Magnesium abietate, technical",CC(C)C1=CC2=CCC3C(C2CC1)(CCCC3(C)C(=O)[O-])C.CC(C)C1=CC2=CCC3C(C2CC1)(CCCC3(C)C(=O)[O-])C.[Mg+2],,,,,,
1757,121758,2-Amino-3-(tert-butyldisulfanyl)propanoic acid,CC(C)(C)SSCC(C(=O)O)N,,,,,,
1758,121759,"4-[4-[(2,6-Dimethoxypyrimidin-4-yl)sulfamoyl]anilino]-4-oxobut-2-enoic acid",COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NC(=O)C=CC(=O)O)OC,,,,,,
1759,121760,"Pyrrolidine, 1-(1,2,3,4-tetrahydro-8-chloro-5-methoxynaphthyl)-, hydrochloride, (R)-",COC1=C2C(CCCC2=C(C=C1)Cl)N3CCCC3.Cl,,,,,,
1760,121761,"1-(5-Chloro-8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine",COC1=C2C(CCCC2=C(C=C1)Cl)N3CCCC3,,,,,,
1761,121762,CID 121762,C(C(C(C(C(C(C(=O)[O-])O)O)O)O)O)O.[Na+],,,,,,
1762,121763,2-Ethyl-2-methyloxirane,CCC1(CO1)C,,,,,,
1763,121764,"5-Nitro-N-(4,5,5-trimethyl-2-oxazolidinylidene)-2-thiazolamine",CC1C(OC(=N1)NC2=NC=C(S2)[N+](=O)[O-])(C)C,,,,,,
1764,121765,Ethyl 3-bromo-2-oxocyclohexanecarboxylate,CCOC(=O)C1CCCC(C1=O)Br,,,,,,
1765,121766,4'-Acetamido-2-[(5-carbamoyl-2-chlorophenyl)azo]acetoacetanilide,CC(=O)C(C(=O)NC1=CC=C(C=C1)NC(=O)C)N=NC2=C(C=CC(=C2)C(=O)N)Cl,,,,,,
1766,121767,Methylcyclohexyl acetate,CC(=O)OC1(CCCCC1)C,,,,,,
1767,121768,"4H-Pyrido(1,2-a)pyrimidine-3-carboxylic acid, 1,6,7,8,9,9a-hexahydro-1-ethyl-6-methyl-4-oxo-, ethyl ester",CCN1C=C(C(=O)N2C1CCCC2C)C(=O)OCC,,,,,,
1768,121769,2-Hexadecyldimethylbenzylammonium chloride,CCCCCCCCCCCCCCC(C)[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
1769,121770,"N,N-Dimethyl-N-(1-methylpentadecyl)benzenemethanaminium",CCCCCCCCCCCCCCC(C)[N+](C)(C)CC1=CC=CC=C1,,,,,,
1770,121771,4-sec-Butylaniline,CCC(C)C1=CC=C(C=C1)N,,,,,,
1771,121772,"Benzenamine, 4-(1-methylbutyl)-",CCCC(C)C1=CC=C(C=C1)N,,,,,,
1772,121773,"2(3H)-Naphthalenone, 4,4a,5,6,7,8-hexahydro-3-methyl-",CC1CC2CCCCC2=CC1=O,,,,,,
1773,121774,"Octahydro-4,7-methano-1H-indenemethanol",C1CC2CC1C3C2C(CC3)CO,,,,,,
1774,121775,1-Ethyl citrate,CCOC(=O)CC(CC(=O)O)(C(=O)O)O,,,,,,
1775,121776,2-Bromo-4-methylpentane,CC(C)CC(C)Br,,,,,,
1776,121777,"2H-Pyran, tetrahydro-2-methyl-4-methylene-6-phenyl-",CC1CC(=C)CC(O1)C2=CC=CC=C2,,,,,,
1777,121778,"(3-Tert-butyl-1,3-oxazolidin-5-yl)methanol",CC(C)(C)N1CC(OC1)CO,,,,,,
1778,121779,5-Butylfuran-2(5H)-one,CCCCC1C=CC(=O)O1,,,,,,
1779,121780,CID 121780,CCCCCCCC=CCCC=O,,,,,,
1780,121781,"(3,5-Dihydroxy-1-methyl-2,3-dihydroindol-6-yl)iminourea",CN1CC(C2=CC(=C(C=C21)N=NC(=O)N)O)O,,,,,,
1781,121782,"2,7-Octadien-1-ol, 2,6-dimethyl-, acetate",CC(CCC=C(C)COC(=O)C)C=C,,,,,,
1782,121783,CID 121783,CC(=CC(=O)OC)NC(C1=CC=C(C=C1)O)C(=O)[O-].[Na+],,,,,,
1783,121784,Isooctyl 2-ethylhexanoate,CCCCC(CC)C(=O)OCCCCCC(C)C,,,,,,
1784,121785,Methyl 1-methyl-2-oxocyclopentanecarboxylate,CC1(CCCC1=O)C(=O)OC,,,,,,
1785,121786,3-Hydroxytridecanenitrile,CCCCCCCCCCC(CC#N)O,,,,,,
1786,121787,3-Hydroxynonadecanenitrile,CCCCCCCCCCCCCCCCC(CC#N)O,,,,,,
1787,121788,"Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[4,5-dihydro-5-oxo-3-(1-pyrrolidinyl)-1H-pyrazol-1-yl]phenyl]-",CCC(C(=O)NC1=CC=C(C=C1)N2C(=O)CC(=N2)N3CCCC3)OC4=C(C=C(C=C4)C(C)(C)CC)C(C)(C)CC,,,,,,
1788,121789,CID 121789,C=CCN1C(=NN=C1S)C2=C(C=CC=C2O)O,,,,,,
1789,121790,Ethyl 2-acetyloctanoate,CCCCCCC(C(=O)C)C(=O)OCC,,,,,,
1790,121791,CID 121791,CC(C)CNC(=NCC(C)C)S,,,,,,
1791,121792,"Ammonium, dithiodiethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCSSCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
1792,121793,Triethyl-[2-[2-(triethylazaniumyl)ethyldisulfanyl]ethyl]azanium,CC[N+](CC)(CC)CCSSCC[N+](CC)(CC)CC,,,,,,
1793,121794,Biphenyltriol,C1=CC=C(C=C1)C2=CC(=C(C(=C2)O)O)O,,,,,,
1794,121795,"4-[[[4-(diethylamino)phenyl]methylidenehydrazinylidene]methyl]-N,N-diethylaniline",CCN(CC)C1=CC=C(C=C1)C=NN=CC2=CC=C(C=C2)N(CC)CC,,,,,,
1795,121796,Dimethylcarbamic acid 2-acetylphenyl ester,CC(=O)C1=CC=CC=C1OC(=O)N(C)C,,,,,,
1796,121797,2-Methyl-5-(1-methylvinyl)cyclohex-2-en-1-yl formate,CC1=CCC(CC1OC=O)C(=C)C,,,,,,
1797,121798,"Propaneperoxoic acid, 2,2-dimethyl-, 1,1-dimethylpropyl ester",CCC(C)(C)OOC(=O)C(C)(C)C,,,,,,
1798,121799,"5-Bromo-2-(5-bromo-4-chloro-1,3-dihydro-3-oxo-2H-indol-2-ylidene)-4-chloro-1,2-dihydro-3H-indol-3-one",C1=CC(=C(C2=C1NC(=C2O)C3=NC4=C(C3=O)C(=C(C=C4)Br)Cl)Cl)Br,,,,,,
1799,121800,"2-Naphthalenecarboxamide, N-(4-dodecylphenyl)-3-hydroxy-",CCCCCCCCCCCCC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C=C2O,,,,,,
1800,121801,2-Iodoisonicotinic acid hydrazide,C1=CN=C(C=C1C(=O)NN)I,,,,,,
1801,121802,"2,3-Dibromobut-2-enedinitrile",C(#N)C(=C(C#N)Br)Br,,,,,,
1802,121803,Diethyl chloroethylmalonate,CCC(C(=O)OCC)(C(=O)OCC)Cl,,,,,,
1803,121804,"1,2-Benzisothiazole-3-acetic acid",C1=CC=C2C(=C1)C(=NS2)CC(=O)O,,,,,,
1804,121805,2-Methoxyresorcinol,COC1=C(C=CC=C1O)O,,,,,,
1805,121806,Phenyl(triaz-2-yn-2-ium-1-yl)acetate,C1=CC=C(C=C1)C(C(=O)[O-])N[N+]#N,,,,,,
1806,121807,[Carboxy-(diazonioamino)methyl]benzene,C1=CC=C(C=C1)C(C(=O)O)N[N+]#N,,,,,,
1807,121808,"3-Methyl-2-pentene-1,5-diol",CC(=CCO)CCO,,,,,,
1808,121809,"1,4-Bis((3-chloro-2-hydroxypropyl)amino)anthraquinone",C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCC(CCl)O)NCC(CCl)O,,,,,,
1809,121810,"1-Propanamine, 3-(isononyloxy)-",CC(C)CCCCCCOCCCN,,,,,,
1810,121811,"Phosphoric acid, isooctyl diphenyl ester",CC(C)CCCCCOP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
1811,121812,CID 121812,CC(O)(P(=O)(O)O)P(=O)(O)O.[NaH],,,,,,
1812,121813,"1,2-Diphenyl-1H-indole-3-carbaldehyde",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2C4=CC=CC=C4)C=O,,,,,,
1813,121814,"1-(2,5-Dichlorophenyl)-3-methyl-4-((o-nitrophenyl)azo)-2-pyrazolin-5-one",CC1=NN(C(=O)C1N=NC2=CC=CC=C2[N+](=O)[O-])C3=C(C=CC(=C3)Cl)Cl,,,,,,
1814,121815,2-[Carboxymethyl(octadec-9-enoyl)amino]acetic acid,CCCCCCCCC=CCCCCCCCC(=O)N(CC(=O)O)CC(=O)O,,,,,,
1815,121816,"3-[(5-Cyano-1,6-dihydro-2-hydroxy-1,4-dimethyl-6-oxo-3-pyridinyl)azo]phenyl dimethylsulfamate",CC1=C(C(=O)N(C(=C1C#N)O)C)N=NC2=CC(=CC=C2)OS(=O)(=O)N(C)C,,,,,,
1816,121817,3-[[[4-[(2-Furanylcarbonyl)amino]-3-hydroxyphenyl]amino]carbonyl]-5-nonadecenoic acid,CCCCCCCCCCCCCC=CCC(CC(=O)O)C(=O)NC1=CC(=C(C=C1)NC(=O)C2=CC=CO2)O,,,,,,
1817,121818,(2-Hydroxyethyl) hydrogen glutarate,C(CC(=O)O)CC(=O)OCCO,,,,,,
1818,121819,Bis(2-hydroxyethyl) glutarate,C(CC(=O)OCCO)CC(=O)OCCO,,,,,,
1819,121820,4-[[(Dichlorofluoromethyl)thio](trifluoromethyl)amino]benzoic acid,C1=CC(=CC=C1C(=O)O)N(C(F)(F)F)SC(F)(Cl)Cl,,,,,,
1820,121821,"4-Hydroxy-3-propylnaphthalene-1,2-dione",CCCC1=C(C2=CC=CC=C2C(=O)C1=O)O,,,,,,
1821,121822,Tetranitro blue tetrazolium chloride,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)[N+]3=NC(=NN3C4=CC=C(C=C4)[N+](=O)[O-])C5=CC=C(C=C5)[N+](=O)[O-])OC)[N+]6=NC(=NN6C7=CC=C(C=C7)[N+](=O)[O-])C8=CC=C(C=C8)[N+](=O)[O-].[Cl-].[Cl-],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
1822,121823,"2,2'-(3,3'-Dimethoxy-4,4'-biphenylylene)bis[3,5-bis(4-nitrophenyl)-2H-tetrazole-3-ium]",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)[N+]3=NC(=NN3C4=CC=C(C=C4)[N+](=O)[O-])C5=CC=C(C=C5)[N+](=O)[O-])OC)[N+]6=NC(=NN6C7=CC=C(C=C7)[N+](=O)[O-])C8=CC=C(C=C8)[N+](=O)[O-],,,,,,
1823,121824,Titanium tetrafluoride,F[Ti](F)(F)F,,,"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)']",,,
1824,121825,Sulphonate,C1=C(C2=NON=C2C(=C1)S(=O)(=O)O)F.N,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1825,121826,"2,1,3-Benzoxadiazole-4-sulfonic acid, 7-fluoro-",C1=C(C2=NON=C2C(=C1)S(=O)(=O)O)F,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1826,121827,Splenopentin,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N,,,,,,
1827,121828,CID 121828,CC1CC(=O)NN=C1C2=CC=C(C=C2)N3CCN=C3,,,,,,
1828,121829,"Benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-",CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
1829,121830,(3r)-3-Amino-4-(trimethylammonio)butanoate,C[N+](C)(C)C[C@@H](CC(=O)[O-])N,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)']",,,
1830,121831,[(2R)-2-amino-3-carboxypropyl]trimethylazanium,C[N+](C)(C)C[C@@H](CC(=O)O)N,,,,,,
1831,121832,CID 121832,CCC=CC=CC=CC=CCCC(CCCCCCC(=O)O)O,,,,,,
1832,121833,Merafloxacin,CCNCC1CCN(C1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CC)F,,,,,,
1833,121834,"1,5-Aedans",CC(=O)NCCNC1=CC=CC2=C1C=CC=C2S(=O)(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1834,121835,H-Gly-D-Phe-D-Ala-Asp-OH,C[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)CN,,,,,,
1835,121836,CID 121836,C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](C)O[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O.C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O,,,,,,
1836,121837,"(3R,4R,5S)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol",C(C1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O,,,,,,
1837,121838,CID 121838,C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](C)O[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O,,,,,,
1838,121839,Incromega DHA 700ESR,CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC,,,,,,
1839,121840,N-Acetyl-S-farnesyl-L-cysteine,CC(=CCCC(=CCCC(=CCSC[C@@H](C(=O)O)NC(=O)C)C)C)C,,,,,,
1840,121841,Tetraxetan,C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
1841,121842,CID 121842,CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F.CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F.C(=CC(=O)O)C(=O)O,['Insomnia'],,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
1842,121843,4-[3-[2-(Dimethylamino)ethoxyimino]-3-(2-fluorophenyl)prop-1-enyl]phenol,CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F,,,,,,
1843,121844,"11-(3-Carbamimidamidopropyl)-14-ethyl-4,7,10,16-tetrahydroxy-12-methyl-13-oxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),3,6,9,15,17,19-heptaene-5-carboxylic acid--methanesulfonic acid (1/1)",CC[C@@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)C(=O)O)CCCN=C(N)N)C.CS(=O)(=O)O,,,,,,
1844,121845,cyclo[D-Abu-N(Me)Arg-Gly-Gly(CO2H)-Unk],CC[C@@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)C(=O)O)CCCN=C(N)N)C,,,,,,
1845,121846,Chromanol 293B,CCS(=O)(=O)N(C)[C@@H]1[C@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O,,,['A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)'],,,
1846,121847,"9H-Fluoren-9-one, O-(3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)oxime, monohydrochloride",CC(C)(C)NCC(CON=C1C2=CC=CC=C2C3=CC=CC=C31)O.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
1847,121848,Fluoren-9-one O-(3-tert-butylamino-2-hydroxy-propyl)-oxime,CC(C)(C)NCC(CON=C1C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
1848,121849,CID 121849,COC1=C(C=C(C=C1)C(=CF)CN)OC,,,,,,
1849,121850,"2-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-1H-isoindole",CC1C2=CC=CC=C2CN1CC3=NCCN3,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
1850,121851,Alnespiron,CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)C3CC4=C(C=CC=C4OC)OC3.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
1851,121852,"8-[4-[Propyl(5-methoxychroman-3-yl)amino]butyl]-8-azaspiro[4.5]decane-7,9-dione",CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)C3CC4=C(C=CC=C4OC)OC3,,,,,,
1852,121853,lacto-N-neotetraose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2[C@H]([C@H](O[C@H]([C@@H]2O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)CO)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O,,,,,,
1853,121854,"(1R,3S)-5-[2-[(3aS,7aS)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](CC#CC(C)(C)O)C1=CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
1854,121855,N-acetylleucyl-leucyl-methioninal,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C=O)NC(=O)C,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
1855,121856,CID 121856,C1=CC(=NCCS(=O)(=O)O)C(=CC1=N[N+]#N)N(O)[O-],,,,,,
1856,121857,"4-[5-(5-oxo-3-phenyl-2H-1,2-oxazol-4-yl)penta-2,4-dienylidene]-3-phenyl-1,2-oxazol-5-one",C1=CC=C(C=C1)C2=C(C(=O)ON2)C=CC=CC=C3C(=NOC3=O)C4=CC=CC=C4,,,,,,
1857,121858,1-(2-Hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole,C1=C(N(C(=N1)CO)CCO)[N+](=O)[O-],,,,,,
1858,121859,"3,25-Dihydroxy-23,26-epoxy-9,10-secocholesta-5,7,10-trien-26-one",C[C@H](CC1CC(C(=O)O1)(C)O)[C@H]2CC[C@@H]3[C@@]2(CCCC3=CC=C4C[C@H](CCC4=C)O)C,,,,,,
1859,121860,12-(9-Anthroyloxy)stearic acid,CCCCCCC(CCCCCCCCCCC(=O)O)OC(=O)C1=C2C=CC=CC2=CC3=CC=CC=C31,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1860,121861,Vitapex,C(I)(I)I.[OH-].[OH-].[Ca+2],,,,,,
1861,121862,CID 121862,C1=NC2=C(N1C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(N=C2S)N,,,,,,
1862,121863,N-[2-Hydroxy-3-[(2-methyl-1-oxoallyl)oxy]propyl]-N-(4-methylphenyl)glycine,CC1=CC=C(C=C1)N(CC(COC(=O)C(=C)C)O)CC(=O)O,,,,,,
1863,121864,Mannopine,C(CC(=O)N)[C@@H](C(=O)O)NC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
1864,121865,"N-(3-((2,4-Dinitrophenyl)amino)propyl)-N-(3-aminopropyl)methylamine",CN(CCCN)CCCNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
1865,121866,CID 121866,CCCCCCCCS[C@@H]1[C@@H](C([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1866,121867,Pyridoxal 5'-diphospho-5'-adenosine,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)O,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
1867,121868,CID 121868,C1CCN(CC1)C2=CC3=C(C=C2)NC4=NC(=O)CN4C3,,,,,,
1868,121869,"1h,3h-Pyrrolo[1,2-c]thiazole-7-carboxamide, 3-(3-pyridinyl)-",C1C2=C(C=CN2C(S1)C3=CN=CC=C3)C(=O)N,,,,,,
1869,121870,CID 121870,C[C@@]1([C@H]2C[C@H]3CC(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O,,,,,,
1870,121871,Medica 16,CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O,,,['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)'],,,
1871,121872,N-(N-(1-Carboxyl-3-phenylpropyl)phenylalanyl)isoserine,C1=CC=C(C=C1)CCC(C(=O)O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(C(=O)O)O,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
1872,121873,CID 121873,C1=C(N=C2C(=N1)NC(=NC2=O)N)C(=C(C(COP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C4NC(=NC5=O)N)O)O)O)S)S,,,,,,
1873,121874,Unii-1ezj25PZ5X,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)C(=O)C)C)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
1874,121875,trapoxin A,C1CCN2[C@H](C1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=CC=C4)CCCCCC(=O)[C@@H]5CO5,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. (See all compounds classified as Histone Deacetylase Inhibitors.)']",,,
1875,121876,"Acetamide, N-hydroxy-N-(1-(4-(phenylmethoxy)phenyl)ethyl)-",CC(C1=CC=C(C=C1)OCC2=CC=CC=C2)N(C(=O)C)O,,,['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)'],,,
1876,121877,"Acetamide, 2-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)-N-(2-methoxyethyl)-, (S)-",COCCNC(=O)COC1=CC=C(C=C1)OCCNC[C@@H](COC2=CC=CC=C2)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
1877,121878,"N-[(3S,4R)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-YL]-N-hydroxyacetamide",CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1878,121879,"3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide",CC(C)(CC(=O)N[C@@H]1CCC2=CC=CC=C2N(C1=O)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N,,,,,,
1879,121880,"(1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride",CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl.Cl,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
1880,121881,SB 204070 hydrochloride,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
1881,121882,Algifen,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(C)CS(=O)(=O)[O-].C[N+]1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N.COC(=O)C1=C(C=CC(=C1)OCCN2CCCCC2)C(=O)C3=CC=CC=C3.[Na+].[Br-],,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
1882,121883,"2-(1,5-Dimethyl-3-oxo-2-phenylpyrazol-4-yl)propane-1-sulfonic acid",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(C)CS(=O)(=O)O,,,,,,
1883,121884,Methyl 2-benzoyl-5-(2-piperidin-1-ylethoxy)benzoate,COC(=O)C1=C(C=CC(=C1)OCCN2CCCCC2)C(=O)C3=CC=CC=C3,,,,,,
1884,121885,CID 121885,C1C(=NC2=C(N1)NC(=NC2=O)N)[C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
1885,121886,"1,4,7,10,13-Pentahydroxy-2-[(4-hydroxyphenyl)methyl]-1-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)imino]-8,11-bis(2-methylpropyl)-5-(propan-2-yl)-3,6,9,12-tetraazahexadeca-3,6,9,12-tetraen-16-oic acid",CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)CCC(=O)O,,,,,,
1886,121887,Xanthosine 5'-(tetrahydrogen triphosphate),C1=NC2=C(N1C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)NC(=O)NC2=O,,,,,,
1887,121888,Amibegron hydrochloride,CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=CC=C3)Cl)O)C=C1.Cl,,,['Compounds that bind to and activate ADRENERGIC BETA-3 RECEPTORS. (See all compounds classified as Adrenergic beta-3 Receptor Agonists.)'],,,
1888,121889,"ethyl 2-[[(7S)-7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate",CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NCC(C3=CC(=CC=C3)Cl)O)C=C1,,,,,,
1889,121890,"calcium;(2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;(2R)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate",C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@@H](CC3=CC=CC=C3)C(=O)[O-].C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)[O-].[Ca+2],,,,,,
1890,121891,Mitiglinide,C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O,['For the treatment of type 2 diabetes.'],['Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.'],['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)'],,,
1891,121892,Retigabine,CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N,['Adjuvant treatment of partial-onset seizures.'],"['As compared to other antiepileptic agents, ezogabine is unique in that it selectively activates potassium ion channels Kv 7.2-Kv7.5 and not cardiac Kv 7.1, thereby avoiding cardiac side effects. The antiepileptics, as a drug class, are routinely used in the treatment of a number of disease states in addition to epilepsy. Ezogabine is highly efficacious in a broad-spectrum of in vivo epilepsy and seizure models. A comparison of antiepileptic form activity of ezogabine with that of conventional anticonvulsants in in vitro models suggests that retigabine is especially likely to be useful in the treatment of pharmacoresistant epilepsy. Retigabine clearly attenuates pain-like behaviors in various animal models of neuropathic pain; it may also prove to be useful in treatment of clinical anxiety disorders. Clinical data obtained thus far indicate that retigabine is well tolerated in humans when titrated up to its therapeutic dose range. No tolerance, drug dependence, or withdrawal liability has been reported. Thus, retigabine may prove to be useful in the treatment of a diverse range of disease states in which neuronal hyperexcitability is a common underlying factor.']","['Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS. (See all compounds classified as Membrane Transport Modulators.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']","['Rapidly absorbed and distributed, with an absolute oral bioavailability of 60%. Pharmacokinetics of ezogabine suggest first-order kinetics.  Tmax, single oral dose = 30-120 minutes;  Time to steady state = 3 days', 'Urine (85%, 36% of total dose as unchanged drug, 18% of total dose as NAMR) and feces (14%, 3% of total dose as unchanged drug)', '8.7 L/kg', '0.58 - 0.76 L/hkg. Clearance may differ between ethnic groups with Black Americans having 20% lower clearance than Caucasian Americans.', 'In all tested species, retigabine was rapidly absorbed from the gastro-intestinal tract following single PO administration (< 2 hr). Dietary dosing in rodents expectedly resulted in substantially lower Cmax values obtained several hours after treatment.', 'In rat and dogs studies evaluating the excretion of retigabine and the N-acetyl metabolite of ezogabine (NAMR) showed that retigabine and metabolites were excreted in both faeces and urine, with an approximate 2:1 faeces:urine split of the eliminated dose. Studies with bile duct cannulated rats showed that a major part of the retigabine-related radioactivity in faeces originated from the bile. NAMR was excreted to a greater extent in the urine, i.e., approximately one-half to two-third of the dose. Elimination patterns were similar following both PO and IV dosing, and the elimination of drug via the faeces following IV dosing was in accordance with significant biliary excretion.', 'Data from in vitro studies indicate that ezogabine and the N-acetyl metabolite of ezogabine (NAMR) are approximately 80% and 45% bound to plasma protein, respectively. Clinically significant interactions with other drugs through displacement from proteins are not anticipated. The steady-state volume of distribution of ezogabine is 2 to 3 L/kg following intravenous dosing, suggesting that ezogabine is well distributed in the body.', 'After both single and multiple oral doses, ezogabine is rapidly absorbed with median time to maximum plasma concentration (Tmax) values generally between 0.5 and 2 hours. Absolute oral bioavailability of ezogabine relative to an intravenous dose of ezogabine is approximately 60%. High-fat food does not affect the extent to which ezogabine is absorbed based on plasma AUC values, but it increases peak concentration (Cmax) by approximately 38% and delays Tmax by 0.75 hour.', 'For more Absorption, Distribution and Excretion (Complete) data for Ezogabine (9 total), please visit the HSDB record page.']","['Ezogabine is metabolized exclusively via phase II hepatic N-glucurodination and acetylation. N-glucurodination is the major metabolic pathway of the two and form two major N-glucuronide metabolites. The enzymes involved are UGT1A1, 1A9, 1A4, and 1A3. However, the product of the N-acetyl pathway is a weak, active metabolite referred to as NAMR. The enzyme that is involved in the N-acetyl pathway is called N-acetyltransferase 2. The pharmacokinetics of NAMR and ezogabine are similar. The cytochrome P450 enzyme system is not involved with the metabolism of ezogabine.', 'The primary routes of retigabine metabolism were dominated by phase II processes involving hydrolysis/N-acetylation to form the N-acetyl metabolite of ezogabine (NAMR) and N-glucuronidation of retigabine and NAMR. There was no evidence of direct oxidative metabolism of retigabine in any species. There was no evidence of NAMR formation in the dog and little NAMR formation in the Cynomolgus monkey. All evaluated species formed N-glucuronides of retigabine. N-glucoside metabolites of RTG were also observed in dog and humans.', 'Ezogabine is extensively metabolized primarily via glucuronidation and acetylation in humans. A substantial fraction of the ezogabine dose is converted to inactive N-glucuronides, the predominant circulating metabolites in humans. Ezogabine is also metabolized to the N-acetyl metabolite of ezogabine (NAMR) that is also subsequently glucuronidated. NAMR has antiepileptic activity, but it is less potent than ezogabine in animal seizure models. Additional minor metabolites of ezogabine are an N-glucoside of ezogabine and a cyclized metabolite believed to be formed from NAMR. In vitro studies using human biomaterials showed that the N-acetylation of ezogabine was primarily carried out by NAT2, while glucuronidation was primarily carried out by UGT1A4, with contributions by UGT1A1, UGT1A3, and UGT1A9.  In vitro studies showed no evidence of oxidative metabolism of ezogabine or NAMR by cytochrome P450 enzymes. Coadministration of ezogabine with medications that are inhibitors or inducers of cytochrome P450 enzymes is therefore unlikely to affect the pharmacokinetics of ezogabine or NAMR.', 'Retigabine has known human metabolites that include retigabine N2-glucuronide.']","['Terminal half-life = 7.5 hours', 'A high variability was generally observed in the elimination half-life values of retigabine. The half-life was in the range of 1.4-9 hr in rats, 4-22 hr in rabbits, 0.9-20 hr in dogs, compared to 6-10 hr in humans. Thus, rats were generally having lower values for half-life than rabbits, dogs and humans.', 'In pregnant rats, the tissue distribution pattern was similar in dams and fetuses but the tissue exposure in fetal tissue was lower and more uniform with no high concentration organs as seen in the dams. The tissue elimination half lives in dams were between 4-18 hours and in fetuses between 6-12 hours.']"
1892,121893,protoporphyrinogen IX,CC1=C2CC3=C(C(=C(N3)CC4=C(C(=C(N4)CC5=C(C(=C(N5)CC(=C1CCC(=O)O)N2)CCC(=O)O)C)C=C)C)C=C)C,,,,,,
1893,121894,4-Bromomethyl-7-methoxycoumarin,COC1=CC2=C(C=C1)C(=CC(=O)O2)CBr,,,,,,
1894,121895,2-Amino-4-methyl-N-(4-nitrophenyl)pentanamide,CC(C)CC(C(=O)NC1=CC=C(C=C1)[N+](=O)[O-])N,,,,,,
1895,121896,2-Methyltryptoline,CN1CCC2=C(C1)NC3=CC=CC=C23,,,,,,
1896,121897,"4-[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-4-oxobutanoic acid",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OC(=O)CCC(=O)O)O)O)N,,,,,,
1897,121898,5-Oxo-prolyl-glycyl-arginine-4-nitroanilide,C1CC(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1898,121899,"4H-1-Benzopyran-2-carboxylic acid, 5-(2-hydroxypropoxy)-4-oxo-8-propyl-",CCCC1=C2C(=C(C=C1)OCC(C)O)C(=O)C=C(O2)C(=O)O,,,,,,
1899,121900,5-Fluorodopa,C1=C(C=C(C(=C1O)O)F)CC(C(=O)O)N.Br,,,,,,
1900,121901,"2-Amino-3-(3-fluoro-4,5-dihydroxyphenyl)propanoic acid",C1=C(C=C(C(=C1O)O)F)CC(C(=O)O)N,,,,,,
1901,121902,"4-[5-(5-oxo-3-propyl-2H-1,2-oxazol-4-yl)penta-2,4-dienylidene]-3-propyl-1,2-oxazol-5-one",CCCC1=C(C(=O)ON1)C=CC=CC=C2C(=NOC2=O)CCC,,,,,,
1902,121903,Piquindone,CCC1=C(NC2=C1C(=O)[C@@H]3CN(CC[C@H]3C2)C)C,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
1903,121904,6-deoxyerythronolide B,CC[C@@H]1[C@@H]([C@@H]([C@H](C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O)C)O)C)C)C)O)C,,,,,,
1904,121905,(S)-2-(2-(2-(3-(Furan-2-yl)acrylamido)-3-phenylpropanamido)acetamido)acetic acid,C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)C=CC2=CC=CO2,,,,,,
1905,121906,Trh-gly,C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)NCC(=O)O,,,,,,
1906,121907,EGTA acetoxymethyl ester,CC(=O)OCOC(=O)CN(CCOCCOCCN(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C,,,,,,
1907,121908,"(5S,6R)-6-(2-acetamido-2-carboxyethyl)sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SCC(C(=O)O)NC(=O)C,,,,,,
1908,121909,fMLPL,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCCCC[C@@H](C(=O)O)N)NC(=O)[C@H](CCSC)NC=O,,,,,,
1909,121910,CID 121910,CC1=C(C=C(C=C1)N2C=CN=C2)C(C3=C(C=C(C=C3C)C(=O)[O-])C)O.[Na+],,,,,,
1910,121911,Y-20811 free acid,CC1=C(C=C(C=C1)N2C=CN=C2)C(C3=C(C=C(C=C3C)C(=O)O)C)O,,,,,,
1911,121912,CID 121912,[C@@H]1([C@H]([C@@H]([C@H]([C@@H]([C@H]1OP(=O)(O)S)O)OP(=O)(O)S)OP(=O)(O)S)O)O,,,,,,
1912,121913,4-Chloro-2-[3-(4-pentylphenyl)prop-2-enoylamino]benzoic acid,CCCCCC1=CC=C(C=C1)C=CC(=O)NC2=C(C=CC(=C2)Cl)C(=O)O,,,,,,
1913,121914,"Cholestan-6-one, 3-hydroxy-, (3beta)-",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC(=O)C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
1914,121915,Phenylalanyl-leucyl-arginyl phenylalaninamide,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N,,,,,,
1915,121916,CID 121916,COC1=C(C=CC(=C1)C2=C3N=CN=C(N3N=C2)[O-])S(=O)C4=CC=CC=C4.[Na+],,,,,,
1916,121917,CID 121917,COC1=C(C=CC(=C1)C2=CNN3C2=NC=NC3=O)S(=O)C4=CC=CC=C4,,,,,,
1917,121918,"4-trans-2-Carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline",C1[C@H](C2=C(C=C(C=C2Cl)Cl)N[C@@H]1C(=O)O)NC(=O)NC3=CC=CC=C3,,,"['Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']",,,
1918,121919,Gidazepam,C1C(=O)N(C2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=C3)CC(=O)NN,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1919,121920,"1D-myo-Inositol 3,4,5,6-tetrakisphosphate",[C@H]1([C@@H]([C@@H]([C@H]([C@@H]([C@H]1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O)O,,,,,,
1920,121921,"5-Amino-3-(3,4-dichlorophenyl)-1,2,3$l^{5},4-oxatriazol-3-ylium",C1=CC(=C(C=C1[N+]2=NOC(=N2)N)Cl)Cl,,,,,,
1921,121922,2-Amino-3-prop-2-enylsulfinylpropanoic acid,C=CCS(=O)CC(C(=O)O)N,,,"['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
1922,121923,"2H-1-Benzopyran-2-one, 7-((2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl)oxy)-4-methyl-",CC1=CC(=O)OC2=C1C=CC(=C2)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)NC(=O)C,,,,,,
1923,121924,"N-(4,5-Dihydro-1H-imidazol-2-yl)-2-methyl-2H-indazol-4-amine monohydrochloride",CN1C=C2C(=N1)C=CC=C2NC3=NCCN3.Cl,,,['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)'],,,
1924,121925,Indanidine,CN1C=C2C(=N1)C=CC=C2NC3=NCCN3,,,['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)'],,,
1925,121926,6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester,CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
1926,121927,Arginyl-glycyl-glutamyl-serine,C(C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N,,,,,,
1927,121928,Amiprilosa,CC1(O[C@@H]2[C@H]([C@H](O[C@@H]2O1)[C@@H](CO)O)OCCCN(C)C)C,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
1928,121929,"6-aminomethyl-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide",CC1=NS(=O)(=O)C2=C(N1)C=C(C=C2)CN,,,,,,
1929,121930,Papp,C1CN(CCN1CCC2=CC=C(C=C2)N)C3=CC=CC(=C3)C(F)(F)F,,,['Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)'],,,
1930,121931,"2(1H)-Pyrimidinone, 1-(2-hydroxyethyl)-4,6-dimethyl-",CC1=CC(=NC(=O)N1CCO)C,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)']",,,
1931,121932,Nephritogenoside,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC[C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O)O)O)O)O)O)O)O,,,,,,
1932,121933,Taurodehydrocholic acid,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(C(=O)C[C@H]3[C@H]2C(=O)C[C@H]4[C@@]3(CCC(=O)C4)C)C,,,,,,
1933,121934,8-Azidoadenosine diphosphate,C1=NC(=C2C(=N1)N(C(=N2)N=[N+]=[N-])[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
1934,121935,20-Hydroxycholesterol,CC(C)CCC[C@@](C)([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O,,,,,,
1935,121936,Agropine,C1[C@@H](OC(=O)[C@@H](N1)CCC(=O)N)[C@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
1936,121937,CID 121937,C[C@@H](C(=O)N[C@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)CCl)NC(=O)CCC(=O)OC,,,,,,
1937,121938,"8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine",C1CC2=C(CNC1)C(=C(C=C2)Cl)Cl,,,,,,
1938,121939,2-(Difluoromethyl)arginine,C(CC(C(F)F)(C(=O)O)N)CN=C(N)N,,,,,,
1939,121940,6-Iodopenicillanic acid,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)I)C(=O)O)C,,,"['Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
1940,121941,Galabiose,C([C@@H]1[C@@H](C([C@H]([C@H](O1)O[C@@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O)O)O,,,,,,
1941,121942,Methyl lactoside,CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
1942,121943,"(5S,15S)-5,15-Dihydroxyicosa-6,8,11,13-tetraenoic acid",CCCCC[C@@H](C=CC=CCC=CC=C[C@H](CCCC(=O)O)O)O,,,,,,
1943,121944,CID 121944,CC1=C(N=C2C(=NC(=NC2=O)N)N1)[C@@H](C)NC3=CC=C(C=C3)C[C@@H]([C@@H]([C@@H](CO[C@@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O[C@@H](CCC(=O)O)C(=O)O)O)O)O)O)O,,,,,,
1944,121945,Dansyllysine,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCC[C@@H](C(=O)O)N,,,,,,
1945,121946,Tyr-pro-phe-pro-gly-pro-ile,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N,,,,,,
1946,121947,Shikimate-3-phosphate,C1[C@H]([C@@H]([C@@H](C=C1C(=O)O)OP(=O)(O)O)O)O,,,,,,
1947,121948,24-Hydroxycholesterol,C[C@H](CC[C@@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
1948,121949,"Imidazo(1,2-a)pyrazin-3(7H)-one, 2-methyl-7-phenyl-",CC1=NC2=CN(C=CN2C1=O)C3=CC=CC=C3,,,['Compound such as LUMINESCENT PROTEINS that cause or emit light (PHYSICAL LUMINESCENCE). (See all compounds classified as Luminescent Agents.)'],,,
1949,121950,Hypromellose acetate succinate,CC(CO)O.CC(=O)O.CO.C(CC(=O)O)C(=O)O,,,,,,
1950,121951,3alpha-Dihydroprogesterone,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C[C@@H](CC[C@]34C)O)C,,,,,,
1951,121952,"3-[4-[4-[4-(Diethylamino)phenyl]buta-1,3-dienyl]pyridin-1-ium-1-yl]propyl-triethylazanium",CCN(CC)C1=CC=C(C=C1)C=CC=CC2=CC=[N+](C=C2)CCC[N+](CC)(CC)CC,,,,,,
1952,121953,CID 121953,C1=CC(=CC=C1C2=C3C=CC(=C(C4=NC(=C(C5=CC=C([N-]5)C(=C6C=CC2=N6)C7=CC=C(C=C7)S(=O)(=O)[O-])C8=CC=C(C=C8)S(=O)(=O)[O-])C=C4)C9=CC=C(C=C9)S(=O)(=O)[O-])[N-]3)S(=O)(=O)[O-].[Mn+3],,,,,,
1953,121954,Meridol,CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCO.F.F.F[Sn]F,,,"['Solutions for rinsing the mouth, possessing cleansing, germicidal, or palliative properties. (From Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Mouthwashes.)']",,,
1954,121955,CID 121955,CC1=NC(=O)C2=C(N1)C=CC(=C2)CN(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
1955,121956,CID 121956,C(CN)CP(=O)O,,,,,,
1956,121957,"2-Azaspiro(4.5)decane-2-propanamine, N,N-dimethyl-8,8-dipropyl-",CCCC1(CCC2(CC1)CCN(C2)CCCN(C)C)CCC,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
1957,121958,CID 121958,CN1C=[N+](C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C5NC(=NC6=O)N)O)O)O)O,,,,,,
1958,121959,CID 121959,CN1C=[N+](C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C5NC(=NC6=O)N)O)O)O)O,,,,,,
1959,121960,"1-Cyclopropyl-7-(2,6-dimethyl-4-pyridinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid",CC1=CC(=CC(=N1)C)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,,,,,,
1960,121961,Perftoran,C12(C(C(C(C(C1(F)F)(F)F)(F)F)(F)F)(C(C(C(C2(F)F)(F)F)(F)F)(F)F)F)F.C1(C(C(C(C(C1(F)F)(F)F)(N2C(C(C(C(C2(F)F)(F)F)(F)F)(F)F)(F)F)F)(F)F)(F)F)(C(F)(F)F)F,,,,,,
1961,121962,"1-[1,2,2,3,3,4,5,5,6,6-Decafluoro-4-(trifluoromethyl)cyclohexyl]-2,2,3,3,4,4,5,5,6,6-decafluoropiperidine",C1(C(C(C(C(C1(F)F)(F)F)(N2C(C(C(C(C2(F)F)(F)F)(F)F)(F)F)(F)F)F)(F)F)(F)F)(C(F)(F)F)F,,,,,,
1962,121963,3-Acetoxymethyl-7-methoxy-1-aza-5-thia-8-oxo-bicyclo(4.2.0)oct-2-ene-2-carboxypyrrolidine carboxamide,CC(=O)OCC1=C(N2[C@@H]([C@H](C2=O)OC)S(=O)(=O)C1)C(=O)N3CCC[C@H]3C(=O)O,,,['Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)'],,,
1963,121964,"L-Phenylalaninamide, N-((1,1-dimethylethoxy)carbonyl)-L-tryptophyl-N6-(((2-methylphenyl)amino)carbonyl)-L-lysyl-L-alpha-aspartyl-Nalpha-methyl-",CC1=CC=CC=C1NC(=O)NCCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N(C)[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)OC(C)(C)C,,,,,,
1964,121965,2-Aminoacridone,C1=CC=C2C(=C1)C(=O)C3=C(N2)C=CC(=C3)N,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1965,121966,2'-Deoxy-thymidine-beta-L-rhamnose,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)O,,,,,,
1966,121967,"Ethanone, 2-(1-(cyclopropylmethyl)-4-piperidinyl)-1-(4-fluorophenyl)-, hydrobromide",C1CC1CN2CCC(CC2)CC(=O)C3=CC=C(C=C3)F.Br,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
1967,121968,DUP-734 free base,C1CC1CN2CCC(CC2)CC(=O)C3=CC=C(C=C3)F,,,,,,
1968,121969,"1D-myo-inositol 1,3,4,6-tetrakisphosphate",[C@H]1([C@H](C([C@H]([C@@H](C1O)OP(=O)(O)O)OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O,,,,,,
1969,121970,CID 121970,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)C)C(=C4C(=C2O)C(=CC5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)O)C.C1=CN=CC=C1C(=O)NN.C1=CN=C(C=N1)C(=O)N,,,,,,
1970,121971,CID 121971,C[C@@H]1[C@@H]([C@@H]([C@H](C(C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)C)C(=C4C(=C2O)C(=CC5=C4C(=O)[C@](O5)(OC=CC([C@H]([C@H]1OC(=O)C)C)OC)C)O)O)C)C)O)C)O,,,,,,
1971,121972,"N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-iodoacetamide",CC1(CC(CC(N1O)(C)C)NC(=O)CI)C,,,,,,
1972,121973,N-(1-anilinonaphthalyl)-4-maleimide,C1=CC=C(C=C1)NC2=CC=C(C3=CC=CC=C32)N4C(=O)C=CC4=O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
1973,121974,CID 121974,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=O)C4=C3O)OCCO)C5=CC(=C(C=C5)OCCO)OCCO)O)O)O)O)O)O.C1=CC=C2C(=C1)C=CC(=O)O2.OS(=O)(=O)O.[NaH],,,,,,
1974,121975,CID 121975,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OCC2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=O)C4=C3O)OCCO)C5=CC(=C(C=C5)OCCO)OCCO)O)O)O)O)O)O,,,,,,
1975,121976,"Thymidine-3',5'-diphosphate",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)OP(=O)(O)O,,,,,,
1976,121977,CID 121977,C[C@H](C=C[C@](C)(C(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](CCC3=C)O)C,,,,,,
1977,121978,Chitintriose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)N)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)N)O)CO)N)O)O)O,,,,,,
1978,121979,CID 121979,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5[C@@]4(CCC(C5)O)C)C)OC16CCC(CO6)C,,,,,,
1979,121980,CID 121980,CC(C)(C)C1=NC2=CC(=C(C=C2S1)N=C(S)SCCC(=O)O)OC,,,,,,
1980,121981,CID 121981,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)OCC4=C(N5[C@@H]([C@@H](C5=O)NC(=O)C(=NOC)C6=CSC(=N6)N)SC4)C(=O)O)CCF)F,,,,,,
1981,121982,rhenium-186 HEDP,CC(O)(OP(=O)(O)O)OP(=O)(O)O.[186Re],,,,,,
1982,121983,1-Hydroxyethylidenediphosphoric acid,CC(O)(OP(=O)(O)O)OP(=O)(O)O,,,,,,
1983,121984,CID 121984,CC(C)[N+](C)(C)CC(CCOC1=CC=CC2=CC=CC=C21)O,,,,,,
1984,121985,Sinitrodil,C1N(C(=O)C2=CC=CC=C2O1)CCO[N+](=O)[O-],,,,,,
1985,121986,Aluminum;3-hydroxy-2-methylpyran-4-one;2-methyl-4-oxopyran-3-olate,CC1=C(C(=O)C=CO1)O.CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].[Al+3],,,,,,
1986,121987,Broadcillin,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1987,121988,D-glucosamine-6-phosphate,C([C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)OP(=O)(O)O,,,,,,
1988,121989,CID 121989,CCCCCCC(=O)CCCCCCC=CC[C@H]([C@@H]([C@@](CO)(C(=O)O)N)O)O,,,,,,
1989,121990,2-Methylthio-adenosine-5'-diphosphate,CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
1990,121991,Nicotinic acid ribonucleotide,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)C(=O)[O-],,,,,,
1991,121992,Nicotinate mononucleotide,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)C(=O)O,,,,,,
1992,121993,"2-Amino-3-(2-aminoethylselanyl)propane-1,1-diol",C(C[Se]CC(C(O)O)N)N,,,,,,
1993,121994,Iaans,C1=CC(=CC=C1NC2=CC3=C(C=C2)C=C(C=C3)S(=O)(=O)O)NC(=O)CI,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1994,121995,"[3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] dihydrogen phosphate",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOP(=O)(O)O)C)C,,,,,,
1995,121996,CID 121996,CSCCC(C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NS(CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N,,,,,,
1996,121997,5-Fluorodihydrouracil,C1C(C(=O)NC(=O)N1)F,,,,,,
1997,121998,CID 121998,CC(C1C2CC(=C(N2C1=O)C(=O)O)CC=CN)O,,,,,,
1998,121999,Tyr-gly-gly-phe-leu-arg,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
1999,122000,"3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole",CCC1=CC=CC=C1C2=NC(=NN2)C3=CC(=CC=C3)OC,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Non-steroidal chemical compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Nonsteroidal.)']",,,
2000,122001,D-Lactyl-L-alanyl-alpha-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine,C[C@@H](C(=O)NC(CCC(=O)N[C@H](CCC[C@H](C(=O)O)N)C(=O)NCC(=O)O)C(=O)O)NC(=O)[C@@H](C)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,,
2001,122002,CID 122002,C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)OC4C[C@@H](O[C@@H]4CO)N5C=CC(=NC5=O)N)O,,,,,,
2002,122003,N-[4-(Dimethylamino)naphthalen-1-YL]cyclohexanecarboximidamide,CN(C)C1=CC=C(C2=CC=CC=C21)N=C(C3CCCCC3)N,,,,,,
2003,122004,N(4)-methylcytosine,CNC1=CC=NC(=O)N1,,,,,,
2004,122005,Sarmesin,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)OC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC,,,,,,
2005,122006,Isoleucyl-prolyl-arginine-4-nitroanilide,CC[C@@H](C)[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-])N,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
2006,122007,"5-[5-Hydroxy-6-(3-hydroxyoct-1-enyl)-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid",CCCCCC(C=CC1C(CC2C1CC(=C2)CCCCC(=O)O)O)O,,,,,,
2007,122008,9-cis-Retinyl Stearate-[d5],CCCCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(CCCC1(C)C)C,,,,,,
2008,122009,"6,6'-Methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)",CC1(C=C(C2=C(N1)C=CC(=C2)CC3=CC4=C(C=C3)NC(C=C4CS(=O)(=O)O)(C)C)CS(=O)(=O)O)C,,,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
2009,122010,4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCS(=O)(=O)C2=CC=C(C=C2)C(=O)CCC(=O)O,,,['A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)'],,,
2010,122011,D289; 4-Di-2-ASP,CCN(CC)C1=CC=C(C=C1)C=CC2=CC=[N+](C=C2)C.[I-],,,,,,
2011,122012,"Pyridinium, 4-[2-[4-(diethylamino)phenyl]ethenyl]-1-methyl-",CCN(CC)C1=CC=C(C=C1)C=CC2=CC=[N+](C=C2)C,,,,,,
2012,122013,Dimethyltetrahydrofuran methoxyphosphinyloxyethylquinolinium,CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@]1(CC[C@](O1)(C)COP(=O)([O-])OCC[N+]2=CC=CC3=CC=CC=C32)C,,,,,,
2013,122014,"[[[(2R)-5-[[(Octadecylcarbamoyl)oxy]methyl]-2alpha,5alpha-dimethyltetrahydrofuran]-2-yl]methyl][2-(quinolinium-1-yl)ethyl] phosphate",CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@]1(CC[C@](O1)(C)COP(=O)(O)OCC[N+]2=CC=CC3=CC=CC=C32)C,,,,,,
2014,122015,"Benzamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, trans-",CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)C3=CC(=C(C=C3)Cl)Cl,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
2015,122016,11-(Dansylamino)undecanoic acid,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCCCCCCC(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2016,122017,"7alpha-Methoxycarbonyl-15beta,16beta-methylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone",C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3[C@@H]5C[C@@H]5[C@@]46CCC(=O)O6)C)C(=O)OC,,,,,,
2017,122018,dysprosium DTPA,C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Dy+3],,,,,,
2018,122019,Z-FA-Fmk,CC(C(=O)CF)NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
2019,122020,"6-[(2R,4R,5S)-2-(2-Chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid",C1[C@@H]([C@@H](O[C@@H](O1)C2=CC=CC=C2Cl)C3=CC=CC=C3O)CC=CCCC(=O)O,,,,,,
2020,122021,3-Benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin,C1CCC(CC1)C(CNN2C(C(=O)N(C2=O)CC3=CC=CC=C3)CCCCCCC(=O)O)O,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
2021,122022,Helioseal,CC(=C)C(=O)OCCOCCOCCOC(=O)C(=C)C.CC(=C)C(=O)OCC(COC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OCC(COC(=O)C(=C)C)O)O,,,,,,
2022,122023,1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-YL)heptyl]oxy]phenyl]ethanone,CCC1=CC(=C(C=C1OCCCCCC(C)(C)C2=NNN=N2)O)C(=O)C,,,['A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)'],,,
2023,122024,"L-Prolinamide, N-(4-((((4-bromophenyl)sulfonyl)amino)carbonyl)benzoyl)-L-valyl-N-(3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl)-",CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Br,,,['Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)'],,,
2024,122025,CID 122025,[H+].[H+].CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C)C(=C3CCC(=O)[O-])C)CCC(=O)[O-].[Fe+2],,,,,,
2025,122026,"3-[18-(2-Carboxyethyl)-13-ethenyl-8-(1-hydroxy-5,9,13-trimethyltetradeca-4,8,12-trienyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C,,,,,,
2026,122027,Unii-7dba214Y6G,CC1([C@@H]([C@H](C2=CC3=NON=C3C=C2O1)N4CCCCC4=O)O)C,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
2027,122028,"(2-Amino-4,5-dimethylthiophen-3-yl)(3-(trifluoromethyl)phenyl)methanone",CC1=C(SC(=C1C(=O)C2=CC(=CC=C2)C(F)(F)F)N)C,,,,,,
2028,122029,"1,2-Dioxetane",C1COO1,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
2029,122030,CID 122030,C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=CC=C3)N)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O,,,,,,
2030,122031,"Guanidine, N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-, trans-",CC1([C@@H]([C@H](C2=C(O1)C=CC(=C2)C#N)N=C(NC#N)NC3=CC=C(C=C3)Cl)O)C,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
2031,122032,"(3S,6R,10R,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone",C[C@@H]1CNC(=O)[C@H](NC(=O)C=CC[C@H](OC(=O)[C@@H](OC1=O)CC(C)C)[C@H](C)[C@@H]2[C@H](O2)C3=CC=CC=C3)CC4=CC(=C(C=C4)OC)Cl,,,,,,
2032,122033,N-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine,COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CNC3CCCNC3C4=CC=CC=C4,,,,,,
2033,122034,"4,6-Dimethyl-1,4-dihydro-9h-imidazo[1,2-a]purin-9-one",CC1=CN2C(=O)C3=C(N=CN3)N(C2=N1)C,,,,,,
2034,122035,CID 122035,CN1C=[N+](C2=C1C(=O)N=C(N2)N)C3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
2035,122036,CID 122036,CN1C=[N+](C2=C1C(=O)N=C(N2)N)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
2036,122037,Adrenaline sulfate,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.OS(=O)(=O)O,,,,,,
2037,122038,Fluorescein 5-maleimide,C1=CC2=C(C=C1N3C(=O)C=CC3=O)C(=O)OC24C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2038,122039,CID 122039,CC1=C(C(=[CH-])C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].O=[V+2],,,,,,
2039,122040,CID 122040,CNC1=CC=CC=C1C(=O)O[C@@H]2[C@H](OC([C@@H]2O)N3C=NC4=C3NC(=NC4=O)N)COP(=O)(O)OP(=O)(O)O,,,,,,
2040,122041,CID 122041,C1=NC2=C(N1C3[C@@H]([C@@H]([C@H](O3)CO)O)OP(=O)(O)O)NC(=NC2=O)N,,,,,,
2041,122042,7-Diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin,CCN(CC)C1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=C(C=C3)N4C(=O)C=CC4=O)C,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2042,122043,CID 122043,C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]4[C@@]3(C[C@@H](C4=C(CCCC(C)C)C(=O)NCC(=O)O)OC(=O)C)C)O)C,,,,,,
2043,122044,4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC=N2)OCCO)OC3=CC=CC(=C3)OC,,,['Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)'],,,
2044,122045,D-arabinonic acid,C([C@H]([C@H]([C@@H](C(=O)O)O)O)O)O,,,,,,
2045,122046,"(2S,4S,5R)-hexane-1,2,4,5-tetrol",C[C@H]([C@H](C[C@@H](CO)O)O)O,,,,,,
2046,122047,beta-(5-Hydroxy-2-pyridyl)alanine,C1=CC(=NC=C1O)CC(C(=O)O)N,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2047,122048,CID 122048,C[S+](CCCN)C[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)[O-],,,,,,
2048,122049,"(3-Amino-propyl)-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-methyl-sulfonium",C[S+](CCCN)C[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
2049,122050,CID 122050,CC(C)[C@H]([C@@H](C(=O)NOP(=O)(O)OC[C@@H]1C[C@@H](C(O1)N2C=NC3=C(N=CN=C32)NP(=O)(O)OC4[C@@H]([C@H]([C@@H](O4)[C@@H](CO)O)O)O)O)O)O,,,,,,
2050,122051,Scintadren,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H](C4=C3CC[C@@H](C4)O)C[75Se]C)C,,,,,,
2051,122052,Dihydropicrotoxinin,CC(C)C1[C@@H]2C(=O)OC1[C@@H]3[C@@]4([C@]2(CC5C4(O5)C(=O)O3)O)C,,,,,,
2052,122053,Celestone-R,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C.C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,,,['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)'],,,
2053,122054,"[2-[(8S,9R,10S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C,,,,,,
2054,122055,CID 122055,C[C@H]1CC2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,,,,,,
2055,122056,3'-Monoiodothyronine,C1=CC(=CC=C1C[C@@H](C(=O)O)N)OC2=CC(=C(C=C2)O)I,,,,,,
2056,122057,(2S)-1-[(2S)-3-(4H-imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxylic acid,C1C[C@H](N(C1)C(=O)[C@H](CC2C=NC=N2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)O,,,,,,
2057,122058,S-nitroso-N-acetylcysteine,CC(=O)N[C@@H](CSN=O)C(=O)O,,,,,,
2058,122059,CID 122059,CC(CCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O)O,,,,,,
2059,122060,"[[(2R,3S,4R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)F,,,,,,
2060,122061,CID 122061,CCC=CC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O,,,,,,
2061,122062,"6-Bromocyclohex-4-ene-1,2,3-triol",C1=CC(C(C(C1O)O)O)Br,,,,,,
2062,122063,Fluorescein-digalactoside,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)OC6=C3C=CC(=C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O,,,,,,
2063,122064,"3-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)quinazoline-2,4(1H,3H)-dione hydrochloride",COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=CC=CC=C4NC3=O.Cl,,,,,,
2064,122065,"3-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)-quinazolinedione",COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=CC=CC=C4NC3=O,,,,,,
2065,122066,Formylmethionyl-leucyl-phenylalanine methyl ester,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OC)NC(=O)[C@H](CCSC)NC=O,,,,,,
2066,122067,"4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole",C1=C(C2=NON=C2C(=C1)S(=O)(=O)N)F,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2067,122068,Desethylamodiaquine,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,,,,,,
2068,122069,"2-[[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid",CC1([C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)C(=NOCC(=O)O)C2=CSC(=N2)N)C,,,,,,
2069,122070,"3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid",CC1=C(N(C2=C1C=C(C=C2)F)CC3=CC=C(C=C3)Cl)CC(C)(C)C(=O)O,,,,,,
2070,122071,"Benzoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-",CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)C(=O)O,,,,,,
2071,122072,CID 122072,C1CC2=C(C=C1C(=O)[O-])SC(=C2)CN3C=CN=C3.[Na+],,,,,,
2072,122073,Vatanidipine,CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC(=CC=C6)[N+](=O)[O-])C(=O)OC,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
2073,122074,1H-indol-2-amine,C1=CC=C2C(=C1)C=C(N2)N,,,,,,
2074,122075,CID 122075,CCNC1=C(N=CC=C1)N2CCN(CC2)CC(=O)[C@H]3[C@@H](C[C@@H]4[C@@]3(CC=C5[C@H]4CCC6=CC(=O)C=C[C@@]65C)C)C.C(=CC(=O)O)C(=O)O,,,,,,
2075,122076,"(8S,10S,13S,14S,17S)-17-[2-[4-[3-(ethylamino)pyridin-2-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one",CCNC1=C(N=CC=C1)N2CCN(CC2)CC(=O)[C@H]3C(C[C@@H]4[C@@]3(CC=C5[C@H]4CCC6=CC(=O)C=C[C@@]65C)C)C,,,,,,
2076,122077,Lintitript,C1=CC=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=CS3)C4=CC=CC=C4Cl,['For the treatment of pancreatic cancer and appetite disorders.'],"['Lintitript SR 27897 is a selective cholecystokinin type A (CCK-A) receptor antagonist. In February 2000, Sanofi announced that it was halting development of the drug for appetite disorders, and in September 2002, Sanofi announced that it had stopped investigation all together.']","['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
2077,122078,CID 122078,C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1COP(=O)(O)O)C(=O)O,,,,,,
2078,122079,8-Hydroxy-5-deazaflavin,C1=CC(=O)C=C2C1=CC3=C(N2CC(C(C(CO)O)O)O)NC(=O)NC3=O,,,,,,
2079,122080,Cyclosomatostatin,C[C@H]([C@H]1C(=O)NCCCCCCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)OCC5=CC=CC=C5,,,"['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
2080,122081,Pinokalant,COC1=C(C(=C(C=C1)CCN(CCC2=C(C(=C(C=C2)OC)OC)OC)C(=O)C(C3=CC=CC=C3)C4=NCCC5=CC(=C(C=C54)OC)OC)OC)OC,,,,,,
2081,122082,Tenax GC,CC1=CC(=C(C(=C1)C2=CC=CC=C2)OC)C3=CC=CC=C3,,,,,,
2082,122083,Deoxyhypusine,C(CCNCCCCN)C[C@@H](C(=O)O)N,,,,,,
2083,122084,5-S-cysteinyldopamine,C1=C(C=C(C(=C1O)O)SC[C@@H](C(=O)O)N)CCN,,,,,,
2084,122085,"n-[Butyl(dimethyl)silyl]-2,2,2-trifluoro-n-methylacetamide",CCCC[Si](C)(C)N(C)C(=O)C(F)(F)F,,,,,,
2085,122086,"L-Tyrosine, N-(bromoacetyl)-O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-",C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)NC(=O)CBr)I)I)O,,,,,,
2086,122087,Zoxamide,CCC(C)(C(=O)CCl)NC(=O)C1=CC(=C(C(=C1)Cl)C)Cl,,,,"['Mean plasma radioactivity concentrations peaked at 8 hr following 10 mg/kg or 1000 mg/kg zoxamide, and time of one-half peak concentration was 22 hr. Tissue levels as percentage of administered dose were generally about twice as high in the 10 mg/kg groups compared to high dose rats, consistent with the above evidences of poor absorption at 1000 mg/kg. Only the alimentary tract and liver had remarkably high concentrations at 8 hr, with marked reduction in most tissues by 22 hr after dosing. Thus zoxamide and its metabolites tend not accumulate in the body. There were no remarkable sex differences in zoxamide disposition.', 'Investigators studied all major elements of a metabolism study in male and female Crl:CD BR rats, including excretion patterns following a single gavage dose (in corn oil) of 10 mg/kg or a single dose of 1000 mg/kg labeled zoxamide, or single dose of 10 mg/kg labeled zoxamide after 2 weeks of administration of 200 ppm non-labeled zoxamide in diet. Tissue distribution of residues was determined after 8, 22, and 120 hr ... and blood kinetics were assessed. Exhaled air was evaluated for (14)C content (this was found not to be a significant route). ... Administration of 10 mg/kg zoxamide led to appreciable recovery of unaltered zoxamide in feces (12-23%). Much higher unaltered zoxamide were found in feces (72-74%) following a 1000 mg/kg dose. At least 71% of administered dose was found in feces after 10 mg/kg treatment (with or without dietary pre-treatment).', 'Zoxamide was rapidly and extensively absorbed, metabolized and excreted. Approximately 61% of the administered dose was systemically absorbed. Absorption was less complete in high dose groups. Plasma concentrations peaked approximately 8 hr post dose. Residue concentrations were highest in organs associated with absorption (liver, stomach, intestines). ... Elimination from plasma was bi-phasic with an elimination half-life of 12-14 hr. No residues were detected in expired air. Altogether, in urine and feces, 32 separate metabolites were identified; no single metabolite other than the parent accounted for more than 10% of the administered dose. Over 85% of the administered dose in single dose studies was excreted within 24-48 hr; the predominant route of excretion was hepatobiliary. No evidence of accumulation of the parent compound or its metabolites was observed. There were no apparent sex related differences.', 'The two major potato metabolites (RH-141452 and RH-141455), which were minor rat metabolites, were studied in separate metabolism studies. More than 97% of the administered dose (RH-141452) was excreted within 24 hr. Greater than 94% was eliminated unchanged in urine. Two glucuronide conjugates and a glycine conjugate (about 3% of the administered dose) were found in urine. An additional 1.6% of the administered dose was excreted unchanged in the feces. Excretion of RH-141455 was slower: 47% of the administered dose was excreted within 24 hr, with an additional 32% of the administered dose excreted between 24 and 48 hr. Greater than 92% of the administered dose was recovered (about 73% in feces, 11% in urine and 9% in cage rinse) as unchanged RH-141455 (>96%). /Metabolites/']","['Investigators studied all major elements of a metabolism study in male and female Crl:CD BR rats ... Bile ducts were cannulated to assess degree of biliary excretion and associated metabolites. Investigators isolated 36 compounds including parent zoxamide in urine and/or feces. Bile contained 17 separable components. Major metabolites by each route were identified. ... Several metabolic routes were evident from analysis of fecal metabolites, including as initial steps: reductive dehalogenation, hydrolysis to provide an alpha-keto alcohol, or glutathione conjugation at the chloro group of the side chain. Often the final metabolites were products of subsequent oxidation to provide benzoic acid substituents or oxidation of the side chain to one of several carboxylic acid moieties, depending upon the amount of degradation of the side chain. There was no single dominant urinary metabolite. Most of these had been oxidized to expose several polar groups, and included several glutathione and glucuronide conjugation products. Rats treated with 10 mg/kg [(14)C]-/zoxamide/ following 2 weeks of administration of 200 ppm non-labeled zoxamide had excretion patterns similar to those of non-pre-treated rats. Biliary metabolites in cannulated rats constituted 46-48% of dose. Various glutathione derivatives predominated in the bile, and some residues underwent hydrolysis or reductive dehalogenation followed by glucuronide formation.', 'Four male Crl:CD BR rats were dosed by gavage in water once at 1000 mg/kg with 3,5-dichloro-4-hydroxymethyl benzoic acid, (RH-141,452), a metabolic product of zoxamide. Purity of unlabeled test article was 100%. Radiopurity of (14)C-ring-labeled test article was 98%. Investigators assessed recoveries in urine, feces, and exhaled air, and identified major metabolites in urine and feces. Urinary excretion was about 98% of dose, feces 1.7%, and expired air about 0.01%. Nearly all of urinary excretion was complete within 24 hr, and most fecal excretion occurred within 48 hr. About 94% of dose was excreted in urine as the test article. Collectively, three minor metabolites accounted for another 3% of urinary label (glucuronides of the hydroxyl or carboxylic acid groups, or glycine conjugate of the carboxylic acid group). Nearly all fecal label represented test article', 'Four male Crl:CD BR rats were dosed by gavage in water once at 1000 mg/kg with ring-labeled [(14)C]- RH-141,455 (this is the dicarboxylic acid metabolite of zoxamide). Purity of unlabeled RH-141,455 was 98.77%. Radiopurity of (14)C- RH-141,455 was > 96%. Investigators assayed residues in urine, feces, and exhaled air, and identified major metabolites in urine and feces. Tissues were not analyzed at 168 hr termination of rats, since nearly all label could be found in excreta. Recoveries of radiolabel averaged 75.5% in feces, 11.0% in urine, and 9.3% in cage rinse. Due to diarrhea, much of the cage rinse may have represented fecal output. About 0.01% of dose was found in expired air. Label recovery in feces, urine, or cage rinse dropped off quickly after the first 48 hr after dosing. Parent compound was the only significant peak detected after HPLC separation of extracts of fecal and urinary samples.', '... Metabolism occurred by primary hydrolysis, glutathione mediated reactions and reductive dehalogenation; secondary oxidation of the aromatic methyl and the aliphatic side chain; and terminal glucuronic acid and amino acid conjugations. Induction of metabolism (glutathione transferase and/or glutathione cofactor) appeared to occur. ... Altogether, in urine and feces, 32 separate metabolites were identified; no single metabolite other than the parent accounted for more than 10% of the administered dose. ... There were no apparent sex related differences.', 'The in vitro mammalian metabolism of the fungicide zoxamide is related to its in vitro mammalian toxicity. After incubation of zoxamide with rat liver microsomes leading to practically 100% metabolism (mostly hydroxylated zoxamide), the cytotoxicity (methyl thiazole tetrazolium (MTT) test) and the mitosis-inhibiting potential (shown by cell count and by cell cycle analysis) for V79 were not distinguishable from those of zoxamide, demonstrating that the hydroxylation of zoxamide did not change the cytotoxicity or mitosis-inhibiting potential as determined by these assays. After incubation of zoxamide with rat liver S9 predominantly leading to conjugation with glutathione, and after incubation of zoxamide with rat liver slices predominantly leading to the glucuronide of the hydroxylated zoxamide, these activities were eliminated demonstrating that the glutathione conjugate and the glucuronide had lost the activities in these assays due either to no intrinsic potential of these conjugates or to their inability to penetrate the plasma membrane of mammalian cells. It is concluded that the metabolic hydroxylation of zoxamide did not change its activity in the assays used for investigating its influence on cell proliferation, cell cycle and cytotoxicity, while the formation of conjugates with glutathione or glucuronic acid led to the apparent loss of these activities. ...']","['Zoxamide was rapidly and extensively absorbed, metabolized and excreted. ... Elimination from plasma was bi-phasic with an elimination half-life of 12-14 hr.']"
2087,122088,"[(2R,5R)-5-(2,6-diaminopurin-9-yl)-3-fluorooxolan-2-yl]methanol",C1[C@@H](O[C@@H](C1F)CO)N2C=NC3=C(N=C(N=C32)N)N,,,,,,
2088,122089,"[[(2R,3S,5R)-5-[5-(2-bromoethenyl)-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C=CBr)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
2089,122090,N-Myristoyl glycinal diethylacetal,CCCCCCCCCCCCCC(=O)NCC(OCC)OCC,,,,,,
2090,122091,"5-O-Digalloyl-3,4-di-O-galloylquinic acid",C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)'],,,
2091,122092,5'-Deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine,CN(CCCNN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
2092,122093,CID 122093,C1[C@@H]([C@H]([C@@H]([C@H](N1CC=CC2=CC=CC=C2)CO)O)O)O,,,,,,
2093,122094,CID 122094,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)NC(=O)C,,,,,,
2094,122095,"3-Hydroxy-10-methyl-7-propan-2-yl-11-(3,5,6-trihydroxy-10-methyl-7-propan-2-yl-2-oxatricyclo[6.3.1.04,12]dodeca-1(12),3,5,7,9-pentaen-11-ylidene)-2-oxatricyclo[6.3.1.04,12]dodeca-1(12),3,7,9-tetraene-5,6-dione",CC1=CC2=C(C(=C(C3=C(OC(=C23)C1=C4C(=CC5=C(C(=O)C(=O)C6=C(OC4=C56)O)C(C)C)C)O)O)O)C(C)C,,,,,,
2095,122096,Cbz-aaphepsi((s)-CH(OH)CH2)glyvv-ome,C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)OC)O)NC(=O)[C@H](C)NC(=O)OCC2=CC=CC=C2,,,,,,
2096,122097,Soyasaponin I,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3O[C@H]4CC[C@]5([C@H]([C@@]4(C)CO)CC[C@@]6([C@@H]5CC=C7[C@]6(CC[C@@]8([C@H]7CC(C[C@H]8O)(C)C)C)C)C)C)C(=O)O)O)O)CO)O)O)O)O)O,,,,,,
2097,122098,10-Propoxydecanoic acid,CCCOCCCCCCCCCC(=O)O,,,,,,
2098,122099,11-(Ethylthio)undecanoic acid,CCSCCCCCCCCCCC(=O)O,,,,,,
2099,122100,"9-(2,3-Bis(hydroxymethyl)-1-cyclobutyl)adenine",C1C(C(C1N2C=NC3=C(N=CN=C32)N)CO)CO,,,,,,
2100,122101,"Uridine 5'-(tetrahydrogen triphosphate), 2'-deoxy-5-propyl-",CCCC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
2101,122102,CID 122102,CC=CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
2102,122103,"1,2-Dimyristoylphosphatidylazidothymidine",CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OC(=O)CCCCCCCCCCCCC,,,,,,
2103,122104,N-Carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester,COC(=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)OCC3=CC=CC=C3,,,,,,
2104,122105,Diazaquinomycin A,CCCC1=C(C(=O)NC2=C1C(=O)C3=C(C2=O)NC(=O)C(=C3CCC)C)C,,,,,,
2105,122106,Nectrisine,C1=N[C@@H]([C@H]([C@H]1O)O)CO,,,,,,
2106,122107,"3'-Amino-2',3'-dideoxyuridine",C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)N,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2107,122108,Ribavirin 5'-triphosphate,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)C(=O)N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
2108,122109,"1-[(1R,4R,5R)-4-(hydroxymethyl)-3,6-dioxabicyclo[3.1.0]hexan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)C2[C@H]3[C@H](O3)[C@H](O2)CO,,,,,,
2109,122110,"1-[(2R,3S,5S)-4-azido-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)[C@H]2[C@H](C([C@H](O2)CO)N=[N+]=[N-])O,,,,,,
2110,122111,1-(3-Deoxypentofuranosyl)cytosine,C1[C@H](O[C@H]([C@H]1O)N2C=CC(=NC2=O)N)CO,,,,,,
2111,122112,CID 122112,C1=NC2=C(N1CC(CO)OCP(=O)(O)O)NC(=NC2=O)N,,,,,,
2112,122113,"4-Thiazolidinecarboxylic acid, 2-(2-hydroxyphenyl)-3-(3-mercapto-1-oxopropyl)-",C1C(N(C(S1)C2=CC=CC=C2O)C(=O)CCS)C(=O)O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2113,122114,"isopropyl (4S)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate",CC1=C([C@@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC3=NON=C32)C(=O)OC(C)C,,,"['Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (See all compounds classified as Calcium Channel Agonists.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
2114,122115,"(+)-2-(Benzothiophen-4-yl)-N-methyl-N-((1R,2R)-2-pyrrolidin-1-ylcyclohexyl)acetamide",CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)CC3=C4C=CSC4=CC=C3,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2115,122116,3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester,COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)']",,,
2116,122117,"N-[1,3-bis[[(2R,3R,4R,5S)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxy]propan-2-yl]-4-[3-(trifluoromethyl)diazirin-3-yl]benzamide",C1=CC(=CC=C1C(=O)NC(CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)C2(N=N2)C(F)(F)F,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
2117,122118,4((2-((3-(1H-Indol-3-yl)-2-methyl-1-oxo-2-(((1.7.7-trimethylbicyclo(2.2.1)hept-2-yl)oxy)carbonyl)amino)propyl)amino)-1-phenylethyl)amino-4-oxobutanoate N-methyl-D-glucamine,C[C@]12CC[C@H](C1(C)C)CC2OC(=O)N[C@](C)(CC3CNC4=CC=CC=C34)C(=O)NC[C@@H](C5=CC=CC=C5)NC(=O)CCC(=O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
2118,122119,"4-[[(1R)-2-[[(2R)-3-(2,3-dihydro-1H-indol-3-yl)-2-methyl-2-[[(1S,4S)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl]oxycarbonylamino]propanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid",C[C@]12CC[C@H](C1(C)C)CC2OC(=O)N[C@](C)(CC3CNC4=CC=CC=C34)C(=O)NC[C@@H](C5=CC=CC=C5)NC(=O)CCC(=O)O,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
2119,122120,"Ethenol, polymer with ethene",C=C.C=CO,,,,,,
2120,122121,Phytosphingosine,CCCCCCCCCCCCCC[C@H]([C@H]([C@H](CO)N)O)O,,,,,,
2121,122122,"(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)CNC,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2122,122123,4-Fluoro-7-nitrobenzofurazan,C1=C(C2=NON=C2C(=C1)F)[N+](=O)[O-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2123,122124,Dykddddk peptide,C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NC(CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O,,,,,,
2124,122125,Lomerizine hydrochloride,COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC.Cl.Cl,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
2125,122126,"9,12-Epoxy-1H-diindolo(1,2,3-FG:3',2',1'-KL)pyrrolo(3,4-I)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-propoxy-, methyl ester, (9S,10R,12R)-",CCCOC1=CC2=C(C=C1)N3[C@H]4C[C@H]([C@](O4)(N5C6=CC=CC=C6C7=C8CNC(=O)C8=C2C3=C75)C)C(=O)OOC,,,,,,
2126,122127,Ccris 6547,CC(C)C[C@@H](C(=O)N)NCC(CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)C(C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]4CC5=C(CN4)NC6=CC=CC=C56,,,"['Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2127,122128,2-(4-((1-Acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphthyl)propanoic acid hydrocloride pentahydrate,CC(=N)N1CC[C@@H](C1)OC2=CC=C(C=C2)[C@H](CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)C(=O)O.O.O.O.O.O.Cl,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)']",,,
2128,122129,(2s)-3-(7-Carbamimidoylnaphthalen-2-Yl)-2-[4-({(3r)-1-[(1z)-Ethanimidoyl]pyrrolidin-3-Yl}oxy)phenyl]propanoic Acid,CC(=N)N1CC[C@@H](C1)OC2=CC=C(C=C2)[C@H](CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)C(=O)O,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)']",,,
2129,122130,"3-(3-methylphenyl)-1-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea",CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)CC(=O)C5=CC=CC=C5C,,,"['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
2130,122131,Eremomycin,C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC=C(O4)C=C1)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)N)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,,,,,,
2131,122132,"6,7-Dihydroxy-2-dimethylaminotetralin",CN(C)C1CCC2=CC(=C(C=C2C1)O)O,,,,,,
2132,122133,"Trimethyl-[4-(6-phenylhexa-1,3,5-trienyl)phenyl]azanium",C[N+](C)(C)C1=CC=C(C=C1)C=CC=CC=CC2=CC=CC=C2,,,,,,
2133,122134,CID 122134,C1CNC2=C(N1)C(=O)N=C(N2)N,,,,,,
2134,122135,Tetrahydroaldosterone,C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2[C@@H]4C[C@]5([C@H]3CC[C@@H]5C(=O)CO)C(O4)O)O,,,,,,
2135,122136,dopamine 3-O-sulfate,C1=CC(=C(C=C1CCN)OS(=O)(=O)O)O,,,,,['Dopamine 3-O-sulfate is a known human metabolite of Dopamine.'],
2136,122137,Octacarboxylate iron-tetrahydroporphyrin,[H+].[H+].[H+].[H+].[H+].[H+].[H+].[H+].CC1(C(C2=NC1=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=C2)[N-]5)CC(=O)[O-])CCC(=O)[O-])CCC(=O)[O-])CC(=O)[O-])C(C3CCC(=O)[O-])(C)CC(=O)[O-])CCC(=O)[O-])CC(=O)[O-].[Fe+2],,,,,,
2137,122138,"3,3',3'',3'''-[3,8,13,17-Tetrakis(carboxymethyl)-8,13-dimethyl-7,8,12,13-tetrahydroporphyrin-2,7,12,18-tetrayl]tetrapropanoic acid",CC1(C(C2=NC1=CC3=NC(=CC4=C(C(=C(N4)C=C5C(=C(C(=C2)N5)CC(=O)O)CCC(=O)O)CCC(=O)O)CC(=O)O)C(C3CCC(=O)O)(C)CC(=O)O)CCC(=O)O)CC(=O)O,,,,,,
2138,122139,Diucifon,CC1=C(C(=O)NC(=O)N1)S(=O)(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=C(NC(=O)NC4=O)C,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. (See all compounds classified as Leprostatic Agents.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)']",,,
2139,122140,substance P (6-11),CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)N,,,"['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)']",,,
2140,122141,TEC solution,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.CNC[C@@H](C1=CC(=C(C=C1)O)O)O.CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)', 'The use of two or more chemicals simultaneously or sequentially to induce anesthesia. The drugs need not be in the same dosage form. (See all compounds classified as Anesthetics, Combined.)']",,,
2141,122142,"Methyl (1R,2R,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",CN1[C@H]2CC[C@@H]1[C@H](C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,,,,"['Cocaine hydrochloride is absorbed from all sites of application, including mucous membranes and GI mucosa, and absorption may be enhanced in the presence of inflammation. In recreational cocaine users, the relative bioavailability of the drug, as determined by area under the plasma concentration-time curve (AUC), for a 2-mg/kg intranasal or oral dose of a 10% cocaine solution is the same; however, peak plasma concentrations are reportedly higher and occur sooner following oral administration than after intranasal administration. Following topical application of a 10% solution to the nasal mucosa, peak plasma cocaine concentrations occur within 15-120 minutes. Following topical application of cocaine hydrochloride solutions to mucous membranes, the onset of local anesthesia occurs within about 1 minute, is maximal within about 5 minutes, and may persist for 30 minutes or longer, depending on the dose and concentration used. /Cocaine hydrochloride/', 'Cocaine is rapidly and well absorbed from the nasal mucosa, gastrointestinal mucosa, pulmonary alveoli and by direct intravenous injection ... .', 'Cocaine is absorbed by all routes of administration, but the proportion absorbed depends on the route. After oral administration, cocaine appears in blood after about 30 minutes, reaching a maximum concentration in 50 to 90 minutes. In acid medium, cocaine is ionized, and fails to cross into cells. In alkaline medium, there is less ionization and the absorption rapidly increases. By the nasal route, clinical effects are evident 3 minutes after administration, and last for 30 to 60 minutes, the peak plasma concentration being around 15 minutes. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed. By inhalation, the absorption can vary from 20 to 60%, the variability being related to secondary vasoconstriction. Freebase does not undergo first-pass hepatic metabolism, and plasma concentrations rise immediately to 1 to 2 mg/L. The effects on the brain occur very rapidly, after about 8 to 12 seconds, are very violent (""flash""), and last only 5 to 10 minutes. By the intravenous route blood concentrations rise to a peak within a few minutes.', 'When smoked, absorption of the free base from the lung is rapid and efficient, producing concn in plasma of more than 900 ng/mL; peak values of 150 to 200 ng/mL are reached 30 to 40 minutes after the inhalation of 96 mg of crystalline cocaine hydrochloride.', 'For more Absorption, Distribution and Excretion (Complete) data for Cocaine (8 total), please visit the HSDB record page.']","['The metabolism of cocaine is complex and dependent on both genetic and acquired factors. Three major pathways of cocaine metabolism are well described. Cocaine undergoes N-demethylation in the liver to form norcocaine, a minor metabolite that rarely accounts for more than 5% of drug. However, norcocaine readily crosses the blood-brain barrier and produces clinical effects in animals that are quite similar to cocaine. Nearly half of a dose of cocaine is both nonenzymatically and enzymatically hydrolyzed to form benzoylecgonine (BE). the BE is inject into animals, some reports suggest that it is virtually inactive, while other studies demonstrate cerebral vasoconstriction and seizures. When with injected directly into the cerebral ventricles or applied to the surface of cerebral arteries, BE is a potent vasoconstrictor. Although BE tranverses the blood-brain barrier poorly, the potential effects ar of concern as some BE is probably formed form cocaine that has already entered the central nervous system (CNS). In vitro, BE has little or not effect on cardia sodium or potassium channels. Finally, plasma cholinesterase (PChE) and other esterases metabolize cocaine to ecgonine methyl ester (EME). In normal individuals, between 32% and 49% of cocaine is metabolized to EME. Like BE, EME crosses the blood-brain barrier poorly. Although many authors state that EME has little or no pharmacologic activity, diverse animal models demonstrate contradictory results, concluding that EME is a vasodilator, sedative, anticonvulsant, and protective metabolite against lethal doses of cocaine.', '1 to 9% of cocaine is eliminated unchanged in the urine, with a higher proportion in acid urine. The metabolites ecgonine methyl ester, benzoylecgonine, and ecgonine are recovered in variable proportions which depend on the route of administration. At the end of 4 hours, most of the drug is eliminated from plasma, but metabolites may be identified up to 144 hours after administration.  Unchanged cocaine is excreted in the stool and in saliva. Cocaine and benzoylecgonine can be detected in maternal milk up to 36 hours after administration, and in the urine of neonates for as much as 5 days.Freebase cocaine crosses the placenta, and norcocaine persists for 4 to 5 days in amniotic fluid, even when it is no longer detectable in maternal blood.', 'Cocaine metabolism takes place mainly in the liver, within 2 hours of administration. The rate of metabolism varies according to plasma concentration. There are 3 routes of bio-transformation: the major route is hydrolysis of cocaine by hepatic and plasma esterases, with loss of a benzoyl group to give ecgonine methyl ester. Esterase activity varies substantially from one subject to another. The secondary route is spontaneous hydrolysis, probably non-enzymatic, which leads to benzoylecgonine by demethylation. The final degradation of cocaine, which is a sequel to both the principle and secondary routes of metabolism, leads to ecgonine. N-demethylation of cocaine is a minor route leading to norcocaine. The principle metabolites are therefore benzoylecgonine, ecgonine methyl ester, and ecgonine itself, which are inactive; and norcocaine which is active, and may be relevant after acute intoxication. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself. ...', 'Cocaine is hydrolyzed  rapidly by liver and plasma esterases to ecgonine methyl ester, which accounts for 30% to 50% of of the parent product. Nonenzymatic hydrolysis result in the formation of the other major metabolite, benzoylecgonine (approximately 40% of the parent product). Minor metabolites, norcocaine, and ecgonine account for the other degradation products.']","['The observed half life depends on the route of administration, dosage, and individual subject. It is of the order of 0.7 to 1.5 hours. After oral administration, it appears to be 0.8 hours, nasal administration, 1.25 hours, parenteral administration 0.7 to  0.9 hours.', 'Benzoylecgonine and ecgonine methyl ester, the major metabolites of cocaine, have half lives of 5-8 hours and 3.5-6 hours, respectively. /Cocaine metabolites/', 'The half-life is a very important parameter for estimating the time required to eliminate the drug in the body. It takes one half-life for plasma levels to fall to half of their original level. In the case of cocaine, it takes 1.5 hr for cocaine plasma levels to fall from 102 ng/mL. This is the same time that it takes for concentrations to fall from 51 ng/mL to 25.5 ng/mL. By five half-lives (7.5 hr) the plasma concentration of cocaine decreased from 102 ng/mL to 3.1 ng/mL, which is 3% of the original drug in the body. Almost all the drug (97%) will be eliminated by five half-lives. For reaching a certain drug level, an additional half-life will be required if the dose is doubled. For example, if cocaine is given at a dose of 40 mg, it will take two half-lives to reach the level of 51 ng/mL and six half-lives to reach the level of 3.1 ng/mL.', 'The biological half-life of cocaine is 0.5 to 1.5 hours.', 'For more Biological Half-Life (Complete) data for Cocaine (6 total), please visit the HSDB record page.']"
2142,122143,Dimethyl-beta-cyclodextrin,COCC1C2C(C(C(O1)OC3C(OC(C(C3O)OC)OC4C(OC(C(C4O)OC)OC5C(OC(C(C5O)OC)OC6C(OC(C(C6O)OC)OC7C(OC(C(C7O)OC)OC8C(OC(O2)C(C8O)OC)COC)COC)COC)COC)COC)COC)OC)O,,,,,,
2143,122144,"L-proline, N2-((1S)-1-carboxy-3-phenylpropyl)-N6-((4-hydroxyphenyl)iminomethyl)-L-lysyl-",C1C[C@H](N(C1)C(=O)[C@H](CCCCN=CNC2=CC=C(C=C2)O)N[C@@H](CCC3=CC=CC=C3)C(=O)O)C(=O)O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2144,122145,Chapso,C[C@H](CCC(=O)NCCC[N+](C)(C)CC(CS(=O)(=O)[O-])O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
2145,122146,CID 122146,C[C@H](CCC(=O)NCCC[N+](C)(C)CC(CS(=O)(=O)O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
2146,122147,"5,6-Dihydro-4-(2-methylpropyl)amino-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide",CC(C)CNC1CCS(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N,,,['A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)'],,,
2147,122148,Pyroglutamyl-glutamyl-proline amide,C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CCC(=O)N2)C(=O)N,,,,,,
2148,122149,Acetyldiphenylalanyl-leucyl-aspartyl-isoleucyl-isoleucyl-tryptophan,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC3=CC=C(C=C3)C4=CC=CC=C4)NC(=O)C,,,,,,
2149,122150,Saclofen,C1=CC(=CC=C1C(CN)CS(=O)(=O)O)Cl,,,"['Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. (See all compounds classified as GABA Antagonists.)']",,,
2150,122151,CID 122151,CC(C)C[C@H]1C(=O)N[C@@H](C=CSCNC[C@@H](C(=O)N1)N)C(=O)N[C@@H](CC=O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C=O,,,,,,
2151,122152,Gadoterate sodium,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Na+].[Gd+3],,,"['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)', 'Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)']",,,
2152,122153,4-Azidobenzoyloxysuccinimide,C1CC(=O)N(C1=O)OC(=O)C2=CC=C(C=C2)N=[N+]=[N-],,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
2153,122154,CID 122154,C1CC(=O)N(C1=O)OC(=O)C2=CC=C(C=C2)N[N+]#N,,,,,,
2154,122155,delta-Hydroxylysylnorleucine,C(CCNC[C@H](CC[C@@H](C(=O)O)N)O)CC(C(=O)O)N,,,,,,
2155,122156,Calcium oxalate dihydrate,C(=O)(C(=O)[O-])[O-].O.O.[Ca+2],,,,,,
2156,122157,1-(4-Methoxyphenyl)pyridinium,COC1=CC=C(C=C1)[N+]2=CC=CC=C2,,,,,,
2157,122158,beta-D-glucosaminyl-(1->4)-aldehydo-D-glucosamine,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)N)O)N)O)O)O,,,,,,
2158,122159,Kadsurenone,C[C@@H]1[C@H](OC2=CC(=O)C(=C[C@]12OC)CC=C)C3=CC(=C(C=C3)OC)OC,,,,,,
2159,122160,"1b,6-Dihydroxy-6a-methyl-8-(prop-1-en-2-yl)hexahydrospiro[2,5-methanooxireno[3,4]cyclopenta[1,2-d]oxepine-7,2'-oxiran]-3(2h)-one",CC(=C)C1C2C(C3(C4(CO4)C5C(C3(C1C(=O)O2)O)O5)C)O,,,,,,
2160,122161,"trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran",CCCOC1=C(C=C(C=C1S(=O)(=O)C)C2CCC(O2)C3=CC(=C(C(=C3)OC)OC)OC)OC,,,,,,
2161,122162,Luzindole,CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3,,,,,,
2162,122163,CID 122163,C[C@H]1[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C(=C)N(C(=O)CC[C@@H](NC1=O)C(=O)O)C)C)CCC[N+](=N)N)C(=O)O)C)CCC[N+](=N)N)C=CC(=C[C@H](C)[C@H](CC2=CC=CC=C2)OC)C,,,,,,
2163,122164,Ono-LB457,COC1=CC=C(C=C1)C=CCCCCOC2=C(C(=CC=C2)OCCCCC(=O)O)CCC(=O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
2164,122165,"L-Proline, 1-(N-((3-((propylamino)carbonyl)oxiranyl)carbonyl)-L-isoleucyl)-, (2S-trans)-",CCCNC(=O)[C@@H]1C(O1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)O,,,"['Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)']",,,
2165,122166,"3alpha,7alpha,12alpha-Trihydroxycoprostanic acid",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@]4([C@@]3(CC[C@H](C4)O)C)C(=O)O)O)O)C,,,,,,
2166,122167,"6-(Dipropylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol",CCCN(CCC)C1CCC2=C(C1)C=CC(=C2O)O,,,,,,
2167,122168,CID 122168,CC1=C2C(C(C([N-]2)C3(C(C(C(=N3)C(=C4C(C(C(=N4)C=C5C(C(C1[N-]5)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)O.[Co+3],,,,,,
2168,122169,CID 122169,CC1=C2C(C(C(N2)C3(C(C(C(=N3)C(=C4C(C(C(=CC5=NC1C(C5(C)C)CCC(=O)N)N4)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)O,,,,,,
2169,122170,"(3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",C1=CC=C(C=C1)NC2=NC(=C3C(=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O)N,,,,,,
2170,122171,"7,8-Dimethyl-4-oxo-10-(2,3,4,5-tetrahydroxypentyl)benzo[g]pteridin-2-olate",CC1=CC2=C(C=C1C)N(C3=NC(=NC(=O)C3=N2)[O-])CC(C(C(CO)O)O)O,,,,,,
2171,122172,"7-[(1R,2R)-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid",CCCCC[C@@H](C=C[C@H]1CCC(=O)[C@@H]1CCCCCCC(=O)O)O,,,,,,
2172,122173,Thr-ser-lys-tyr-arg,C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O,,,"['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']",,,
2173,122174,"S-[2-[3-[[(2R)-4-[[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] benzenecarbothioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)C4=CC=CC=C4)O,,,,,,
2174,122175,"6-Heptyne-2,5-diamine",CC(CCC(C#C)N)N,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)']",,,
2175,122176,Adrenorphin,CC(C)[C@@H](C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
2176,122177,CID 122177,CN(CCCNC(=O)CCCCC1[C@@H]2[C@H](CS1)NC(=O)N2)CCCN=C3C=CC(=N[N+]#N)C=C3N(O)[O-],,,,,,
2177,122178,(2S)-1-[2-([(2S)-1-[(2S)-2-([2-([(2S)-2-([(2S)-2-amino-4-methylsulfanylbutanoyl]amino)-5-hydroxy-5-oxopentanoyl]amino)-3-(1H-imidazol-5-yl)propanoyl]amino)-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino)acetyl]pyrrolidine-2-carboxylic acid,CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@H]3C(=O)NCC(=O)N4CCC[C@H]4C(=O)O)N,,,,,,
2178,122179,Dimephosphon,CC(=O)CC(C)(C)P(=O)(OC)OC,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)', 'Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
2179,122180,Sulforhodamine 101,C1CC2=CC3=C(C4=C2N(C1)CCC4)OC5=C6CCC[N+]7=C6C(=CC5=C3C8=C(C=C(C=C8)S(=O)(=O)O)S(=O)(=O)[O-])CCC7,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
2180,122181,"6-[2-(Oxylatosulfonyl)-4-(hydroxysulfonyl)phenyl]-3,4,8,9-tetrahydro-1,14:11,12-dipropano-2H,10H-1-azonia-11-aza-13-oxapentacene",C1CC2=CC3=C(C4=C2N(C1)CCC4)OC5=C6CCC[N+]7=C6C(=CC5=C3C8=C(C=C(C=C8)S(=O)(=O)O)S(=O)(=O)O)CCC7,,,,,,
2181,122182,"4-Bromo-2,7-dimethoxy-3H-phenothiazin-3-one",COC1=CC2=C(C=C1)N=C3C=C(C(=O)C(=C3S2)Br)OC,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)']",,,
2182,122183,CID 122183,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
2183,122184,"beta-Alanine, N-(N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-L-phenylalanyl)-",CC1(OCC(O1)COC(=O)C(CC2=CC=CC=C2)N[C@@H](CC3=CC=CC=C3)C(=O)NCCC(=O)O)C,,,"['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)']",,,
2184,122185,Arginylphenylalaninamide,C1=CC=C(C=C1)C[C@@H](C(=O)N)NC(=O)[C@H](CCCN=C(N)N)N,,,,,,
2185,122186,Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate,CC(CC1=CC=C(C=C1)OCC(=O)OC)NCC(C2=CC(=CC=C2)Cl)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
2186,122187,5-Fhdpat,CCCN(CCC)[C@H]1CCC2=C(C=CC(=C2C1)O)F,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
2187,122188,Nifekalant hydrochloride,CN1C(=CC(=O)N(C1=O)C)NCCN(CCCC2=CC=C(C=C2)[N+](=O)[O-])CCO.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2188,122189,CID 122189,CC(C)(C)SC1C2=C(C=CC(=C2)OCC3=NC4=CC=CC=C4C=C3)[N+](=C1CC(C)(C)C(=O)O)CC5=CC=C(C=C5)Cl,,,,,,
2189,122190,3beta-(4-Iodophenyl)tropan-2beta-carboxylic acid isopropyl ester,CC(C)OC(=O)[C@@H]1[C@H]2CCC(N2C)C[C@@H]1C3=CC=C(C=C3)I,,,,,,
2190,122191,Dmrie,CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC.[Br-],,,,,,
2191,122192,"N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium",CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC,,,,,,
2192,122193,"Octadeca-8,12-dienoic acid",CCCCCC=CCCC=CCCCCCCC(=O)O,,,,,,
2193,122194,"2-[(1-Methyl-1-azoniabicyclo[2.2.2]octan-3-yl)oxy]-2-oxo-1,1-diphenylethanolate",C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)[O-],,,,,,
2194,122195,"Inositol 2,4,5-trisphosphate",[C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O,,,,,,
2195,122196,Triiodothyronine sulfate,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)OS(=O)(=O)O,,,,,,
2196,122197,Methyl 8-(3-fluoropropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylatato(2-),COC(=O)[C@@H]1[C@H]2CCC(N2CCCF)C[C@@H]1C3=CC=C(C=C3)I,,,,,,
2197,122198,Adeturon,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N.C(CSC(=N)N)N,,,"['Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)']",,,
2198,122199,"[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
2199,122200,CID 122200,CN1C(=NN=N1)SCC2=C(C3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)OC=O)SC2)C(=O)O,,,,,,
2200,122201,CID 122201,CC(C)NCC(CCOC1=CC=CC=C1C2CCCCC2)O,,,,,,
2201,122202,"(2s,4s,5r,6r)-5-Acetamido-4-hydroxy-2-(4-methyl-2-oxo-chromen-7-yl)oxy-6-[(2r)-1,2,3-trihydroxypropyl]tetrahydropyran-2-carboxylic acid",CC1=CC(=O)OC2=C1C=CC(=C2)O[C@@]3(C[C@@H]([C@H]([C@@H](O3)C([C@@H](CO)O)O)NC(=O)C)O)C(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2202,122203,"3,3'-(Propylimino-di-2,1-ethanediyl)-bisphenol",CCCN(CCC1=CC(=CC=C1)O)CCC2=CC(=CC=C2)O,,,,,,
2203,122204,"Formaldehyde, polymer with ethenol",C=CO.C=O,,,['Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)'],,,
2204,122205,Methyl 2-amino-3-(1H-indol-3-yl)propanoate,COC(=O)C(CC1=CNC2=CC=CC=C21)N,,,,,,
2205,122206,Dmmpa,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OC)OC(=O)CCCCCCCCCCCCC,,,,,,
2206,122207,CID 122207,CC1C2CCN(C1CC3=C2C=C(C=C3)O)CC4=COC=C4,,,,,,
2207,122208,"Ferrate(4-), (7,12-bis(1-((2-amino-2-carboxyethyl)thio)ethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(6-)-N21,N22,N23,N24)-, tetrahydrogen, (SP-4-2-(S-(R*,R*)))-",[H+].[H+].[H+].[H+].CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C(C)SCCC(C(=O)[O-])N)C)C(C)SCCC(C(=O)[O-])N)C)C(=C3CCC(=O)[O-])C)CCC(=O)[O-].[Fe+2],,,,,,
2208,122209,"2-Amino-4-[1-[7-[1-(3-amino-3-carboxypropyl)sulfanylethyl]-13,17-bis(2-carboxyethyl)-3,8,12,18-tetramethyl-21,22-dihydroporphyrin-2-yl]ethylsulfanyl]butanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)SCCC(C(=O)O)N)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)SCCC(C(=O)O)N,,,,,,
2209,122210,"2-Carboxyarabinitol-1,5-diphosphate",C([C@H]([C@H]([C@](COP(=O)(O)O)(C(=O)O)O)O)O)OP(=O)(O)O,,,,,,
2210,122211,"2-{2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl}-4,4-dimethyl-1,2,3,4-tetrahydronaphthalene-1,3-dione",CC1(C2=CC=CC=C2C(=O)C(C1=O)CCN3CCN(CC3)C4=CC=CC=C4OC)C,,,,,,
2211,122212,3-[7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propylchromen-2-yl]propanoic acid,CCCC1=C(C=CC(=C1O)C(=O)C)OCC(COC2=C(C3=C(C=C2)C(=O)C=C(O3)CCC(=O)O)CCC)O,,,,,,
2212,122213,Magnesium pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[Mg+2].[Mg+2],,,,,,
2213,122214,"4-(N-(iodoacetoxy)ethyl-N-methyl)amino-7-nitrobenz-2-oxa-1,3-diazole",CN(CCOC(=O)CI)C1=CC=C(C2=NON=C12)[N+](=O)[O-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2214,122215,Sandoz 58-035,CCCCCCCCCC[Si](C)(C)CCC(=O)NC(CC1=CC=C(C=C1)C)C2=CC=CC=C2,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2215,122216,"2-({[2-(4-hydroxy-2-iodophenyl)ethyl]amino}methyl)-3,4-dihydronaphthalen-1(2H)-one",C1CC2=CC=CC=C2C(=O)C1CNCCC3=C(C=C(C=C3)O)I,,,,,,
2216,122217,Muristerone a,CC(C)CC[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(C[C@H]([C@H]3C2=CC(=O)[C@]4([C@@]3(C[C@@H]([C@@H](C4)O)O)C)O)O)C)O)O)O,,,,,,
2217,122218,"(3-Hexadecanoyloxy-2-octadeca-9,12-dienoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCC=CCCCCC,,,,,,
2218,122219,"2-[(3-Hexadecanoyloxy-2-octadeca-9,12-dienoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCC=CCCCCC,,,,,,
2219,122220,N-Methyltyrosyl-glycyl-glycyl-phenylalanyl-leucyl-arginyl-N-methyl-arginyl-leucyl ethylamide,CCNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC,,,"['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)']",,,
2220,122221,CID 122221,C1=CC=C(C=C1)C[C@@H](C(=O)NCCC(=O)O)N[C@H](CC2=CC=CC=C2)C(=O)O,,,,,,
2221,122222,"Peanut oil, hydrogenated",C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
2222,122223,Alanyl-prolyl-glycyl-tryptophanamide,C[C@@H](C(=O)N1CCCC1C(=O)NCC(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)N,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
2223,122224,CID 122224,CC1=CC(=C(C=C1)N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C)OCCOC2=C(C=C3C(=C2)C=C(O3)C=C4C(=O)N=C(N4)S)N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C,,,,,,
2224,122225,DMXB-A;DMBX-anabaseine,COC1=CC(=C(C=C1)C=C2CCCN=C2C3=CN=CC=C3)OC.Cl.Cl,,,,,,
2225,122226,"2,4-Dimethoxybenzylidene anabaseine",COC1=CC(=C(C=C1)C=C2CCCN=C2C3=CN=CC=C3)OC,,,,,,
2226,122227,"kallidin, des-Arg(10)-",C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O,,,,,,
2227,122228,2-Formyl-5-(hydroxymethyl)pyrrole-1-norleucine,C1=C(N(C(=C1)C=O)CCCC[C@@H](C(=O)O)N)CO,,,,,,
2228,122229,CID 122229,CCCCCC=CCC=CCCCCCCCCO[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CCC4C3CC=C2C1)C(C)CCCC(C)C)C)C,,,,,,
2229,122230,neurokinin A(4-10),CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N,,,,,,
2230,122231,C.I. Reactive Yellow 86,CCN1C(=C(C(=C(C1=O)N=NC2=C(C=C(C(=C2)NC3=NC(=NC(=N3)Cl)Cl)S(=O)(=O)[O-])S(=O)(=O)[O-])C)C(=O)N)O.[Na+].[Na+],,,,,,
2231,122232,"4-((5-(Aminocarbonyl)-1-ethyl-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridyl)azo)-6-((4,6-dichloro-1,3,5-triazin-2-yl)amino)benzene-1,3-disulphonic acid",CCN1C(=C(C(=C(C1=O)N=NC2=C(C=C(C(=C2)NC3=NC(=NC(=N3)Cl)Cl)S(=O)(=O)O)S(=O)(=O)O)C)C(=O)N)O,,,,,,
2232,122233,Aculeacin A from aspergillus aculeatus,CCCCCCCCCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(C(CN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(C)O)C)O)O)O,,,,,,
2233,122234,2-{2-[4-(Dimethylamino)phenyl]ethenyl}-1-methylpyridin-1-ium iodide,C[N+]1=CC=CC=C1C=CC2=CC=C(C=C2)N(C)C.[I-],,,,,,
2234,122235,1-(N(sup alpha)-Dansyl-L-arginyl)-4-ethylpiperidine,CCC1CCN(CC1)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2235,122236,"1,2-Benzenediol, 4-(2-aminoethyl)-5-fluoro-, hydrobromide",C1=C(C(=CC(=C1O)O)F)CCN.Br,,,,,,
2236,122237,"4-(2-Aminoethyl)-5-fluoro-1,2-benzenediol",C1=C(C(=CC(=C1O)O)F)CCN,,,,,,
2237,122238,"5-[(3Ar,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-2-ylidene]pentanoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1C(=O)C(=CCCCC(=O)O)O2)O)O,,,,,,
2238,122239,Dansylsarcosine,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N(C)CC(=O)O,,,,,,
2239,122240,"11-(2-Hexyl-3-hydroxy-4,4-dimethyl-1,3-oxazolidin-2-yl)undecanoic acid",CCCCCCC1(N(C(CO1)(C)C)O)CCCCCCCCCCC(=O)O,,,,,,
2240,122241,3-Quinuclidinyl-4-iodobenzilate,C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=C(C=C4)I)O,,,,,,
2241,122242,1-Ethyl-3-(3-(dimethylamino)propyl)carbodiimide methiodide,CCN=C=NCCC[N+](C)(C)C.[I-],,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
2242,122243,1-[3-(Trimethylaminio)propyl]-3-ethylcarbodiimide,CCN=C=NCCC[N+](C)(C)C,,,,,,
2243,122244,Mpomeovt,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC2(CCCCC2)CC(=O)N[C@H](C(=O)N1)CC3=CC=C(C=C3)OC)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,,,,,,
2244,122245,Iodosulpride,CCS(=O)(=O)C1=C(C=C(C(=C1)C(=O)NCC2CCCN2CC3CC3)OC)I,,,,,,
2245,122246,"N(6)-(2-(3,5-Dimethoxyphenyl)-2-(2-methylphenyl)ethyl)adenosine",CC1=CC=CC=C1C(CNC2=C3C(=NC=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O)C5=CC(=CC(=C5)OC)OC,,,,,,
2246,122247,CID 122247,C1CC(=O)N([C@@H]1C(=O)O)C(=O)C(CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN,,,,,,
2247,122248,Caged insp3,CC(C1=CC=CC=C1[N+](=O)[O-])OP(=O)(O)OC2C(C(C(C(C2OP(=O)(O)O)O)O)OP(=O)(O)O)O,,,,,,
2248,122249,"Cyclopenta[b]pyrrole-2-pentanoic acid, 3,3a,4,5,6,6a-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-3-(cis-4-propylcyclohexyl)-1-propen-1-yl]-, methylester, (3aR,4R,5R,6aS)-;Cyclopenta[b]pyrrole-2-pentanoic acid, 3,3a,4,5,6,6a-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-3-(cis-4-propylcyclohexyl)-1-propen-1-yl]-, methylester, (3aR,4R,5R,6aS)-",CCCC1CCC(CC1)C(C=CC2C(CC3C2CC(=N3)CCCCC(=O)OC)O)O,,,,,,
2249,122250,beta-D-Glucose 1-phosphate,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OP(=O)(O)O)O)O)O)O,,,,,,
2250,122251,hexaamminecobalt(II),[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[Co+2],,,"['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2251,122252,N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,,,,,,
2252,122253,Benzyl-alpha-galnac,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1OCC2=CC=CC=C2)CO)O)O,,,,,,
2253,122254,"1,2-Dilauroylphosphatidylethanolamine",CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCC.CC(=O)O,,,,,,
2254,122255,"3-propyl-2-((1E,3E,5Z)-5-(3-propylbenzo[d]oxazol-2(3H)-ylidene)penta-1,3-dien-1-yl)benzo[d]oxazol-3-ium iodide",CCCN1C2=CC=CC=C2OC1=CC=CC=CC3=[N+](C4=CC=CC=C4O3)CCC.[I-],,,,,,
2255,122256,"3-Propyl-2-[5-(3-propyl-1,3-benzoxazol-3-ium-2-yl)penta-2,4-dienylidene]-1,3-benzoxazole",CCCN1C2=CC=CC=C2OC1=CC=CC=CC3=[N+](C4=CC=CC=C4O3)CCC,,,,,,
2256,122257,1-(6-Amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxyribofuranuronamide,C1CC1NC(=O)[C@@H]2[C@H]([C@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
2257,122258,CID 122258,CCCCC[C@H](C=C[C@@H]1CC2CC(C2)[C@H]1CC=CCCCC(=O)O)O,,,,,,
2258,122259,N-(1-pyrenyl)iodoacetamide,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)NC(=O)CI,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2259,122260,beta-Neoendorphin,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)N,,,,,,
2260,122261,Dansylglutamyl-glycyl-arginine chloromethyl ketone,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2261,122262,Piperaquine,C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl,"['For the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg. Used in combination with [DB11638].']","[""Piperaquine inhibits the P. Falciparum parasite's haem detoxification pathway.""]","['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']","['Piperaquine is slowly absorbed and exhibits multiple peaks in its plasma concentration curve suggestive of enterohepatic recycling occurring alongside the absorption process. Due to this complication there is no discreet value for bioavailability but piperaquine is highly absorbed into systemic circulation. When taken with food, Cmax increases by 217% and mean exposure increases by 177%. Tmax is not affected by food and remains around 5 h. Piperaquine has been observed to accumulate more in females to a degree of 30-50% more than males. It also collects in red blood cells similar to [DB11638].', 'Piperaquine is mainly excreted in the feces with a negligible amount in the urine.', 'Piperaquine is thought to distribute into a central compartment with an apparent volume of 26.7 L/kg, and two peripheral compartments with apparent volumes of 76.8 L/kg and 617 L/kg. These combine for a total volume of distribution of 720.5 L/kg.', 'The mean apparent total clearance has been observed to be 1.12 L/h/kg in adult malaria patients.']","['Piperaquine undergoes N-dealkylation, separating its aliphatic bridge from one of the nitrogen-containing rings. The resulting aldehyde is then oxidized to a carboxylic acid to form metabolite 1 (M1). The same nitrogen-containing rings can also undergo hydroxylation at one of two sites to form M3 or M4. M2 is formed via N-oxidation of one of the nitrogens in the quinoline groups at either side of the molecule. M5 results when both of these nitrogens are oxidized. M1 and M2 are the major metabolism products. Each of these metabolites were observed in the urine.']",['The terminal elimination half-life was observed to be 576h or 24 days. This is thought to be due to the extensive distribution of piperaquine.']
2262,122263,CID 122263,CC(C)C[C@H]1C(=O)N2C(N1)[C@@](C3=CC=CC=C32)(C[C@@H]4CC(=O)C5=CC=CC=C5N6C4=NC7=CC=CC=C7C6=O)O,,,,,,
2263,122264,(2S)-2-amino-3-[[(2R)-3-hexadecanoyloxy-2-octadec-9-enoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
2264,122265,2-((2-(Dimethylamino)ethyl)thio)-3-phenylquinoline,CN(C)CCSC1=NC2=CC=CC=C2C=C1C3=CC=CC=C3,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
2265,122266,CID 122266,C=CCN1CCC23[C@H]4C(=NNC(=O)C5=CC=CC=C5)CCC2([C@@H]1CC6=C3C(=C(C=C6)O)O4)O,,,,,,
2266,122267,Efegatran,CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O,,,"['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
2267,122268,CID 122268,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O)O)O)O[C@@H]2[C@@H]([C@@H]([C@H]3[C@H](O2)CO[C@](O3)(C)C(=O)O)O[C@@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O.CC(=O)O,,,,,,
2268,122269,CID 122269,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O)O)O)O[C@@H]2[C@@H]([C@@H]([C@H]3C(O2)CO[C@](O3)(C)C(=O)O)O[C@@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O,,,,,,
2269,122270,4-Aminophenylphosphate,C1=CC(=CC=C1N)OP(=O)([O-])[O-].[Ag+].[Ag+],,,,,,
2270,122271,4-Aminophenyl phosphate,C1=CC(=CC=C1N)OP(=O)(O)O,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
2271,122272,"5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide",CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2272,122273,bicyclo-PGEM,CCCCC1C2CC(=O)C(C2CCC1=O)CC=CCCCC(=O)O,,,,,,
2273,122274,"[[(2R,3S,4R)-5-(7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1=NC2=C(NN=C2C(=N1)N)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2274,122275,2-[3-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-N-(carboxymethyl)-4-(2-diazoacetyl)anilino]acetic acid,CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)N(CC(=O)O)CC(=O)O)C(=O)C=[N+]=[N-],,,,,,
2275,122276,CID 122276,CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)N(CC(=O)O)CC(=O)O)C(=C[N+]#N)O,,,,,,
2276,122277,N-butan-2-yl-1-(2-fluoro-5-nitrophenyl)-N-methylisoquinoline-3-carboxamide,CCC(C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=C(C=CC(=C3)[N+](=O)[O-])F,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
2277,122278,Chlorodimedone,CC1(CC(=O)C(C(=O)C1)Cl)C,,,,,,
2278,122279,Unk-Nle(Me)-DL-Val-Pro-ol,CCCCC[C@@H](C(=O)NC(C(C)C)C(=O)N1CCC[C@H]1CO)NC(=O)NO,,,,,,
2279,122280,Unii-Y29K672etf,C1=NC2=C(N1C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)NC(=O)NC2=O,,,,,,
2280,122281,16-Glucuronide-estriol,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)O,,,,,,
2281,122282,Mebicar,CN1C2C(N(C1=O)C)N(C(=O)N2C)C,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
2282,122283,butyryl-CoA,CCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
2283,122284,Tibirox,COCCOC1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC.C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)']",,,
2284,122285,"(3R,5S)-5-[(2R)-2-[(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-hydroxy-3-methyloxolan-2-one",C[C@H](C[C@H]1C[C@@](C(=O)O1)(C)O)[C@H]2CC[C@@H]3[C@@]2(CCCC3=CC=C4C[C@H](C[C@@H](C4=C)O)O)C,,,,,,
2285,122286,2-(2-Amino-1-hydroxyethyl)phenol,C1=CC=C(C(=C1)C(CN)O)O,,,,,,
2286,122287,"(2E,6E)-Methyl 3,7,11-trimethyldodeca-2,6,10-trienoate",CC(=CCCC(=CCCC(=CC(=O)OC)C)C)C,,,,,,
2287,122288,Glucitol-lysine,C(CCNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)C[C@@H](C(=O)O)N,,,,,,
2288,122289,"S-[2-[3-[[(2R)-4-[[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] octanethioate",CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
2289,122290,CID 122290,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC,,,,,,
2290,122291,"2-[(3-Hexadecanoyloxy-2-icosa-5,8,11,14-tetraenoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC,,,,,,
2291,122292,"3-Pyridinecarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-5-nitro-, 1-methylethyl ester, (R)-",CC1=C([C@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC3=NON=C32)C(=O)OC(C)C,,,"['Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (See all compounds classified as Calcium Channel Agonists.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
2292,122293,7-Propyl spirolactone,CC(C)[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,,,,,,
2293,122294,Argiotoxin 636,C1=CC(=C(C=C1O)O)CC(=O)N[C@@H](CC(=O)N)C(=O)NCCCCCNCCCNCCCNC(=O)[C@H](CCCN=C(N)N)N,,,,,,
2294,122295,"1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-((3-methyl-2-butenyl)oxy)-",CC(=CCOC1=C2CCN(CCC2=C(C=C1)Cl)C)C,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
2295,122296,Acetylphenylalanyl-prolyl-boroarginine,B([C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O,,,"['Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
2296,122297,5-Chloromethylfluorescein diacetate,CC(=O)OC1=CC2=C(C=C1)C3(C4=C(C=C(C=C4)CCl)C(=O)O3)C5=C(O2)C=C(C=C5)OC(=O)C,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
2297,122298,Mexidol,CCC1=C(C=CC(=N1)C)O.C(CC(=O)O)C(=O)O,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
2298,122299,7-Amino-3-(diethylamino)-2-methylphenoxazin-5-ium chloride,CC[N+](=C1C=C2C(=NC3=C(O2)C=C(C=C3)N)C=C1C)CC.[Cl-],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
2299,122300,7-Amino-3-(diethylamino)-2-methylphenoxazin-5-ium,CC[N+](=C1C=C2C(=NC3=C(O2)C=C(C=C3)N)C=C1C)CC,,,,,,
2300,122301,5-Br-Utp,C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)Br,,,,,,
2301,122302,"2-(Fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine",C1=CC(=C(C=C1C[C@@](CF)(C(=O)O)N)O)O,,,,,,
2302,122303,CID 122303,CCCCC(CC=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)OC)O)(C=C)O,,,,,,
2303,122304,Glucosylgalactosylhydroxylysine,C(CC(CN)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O[C@@H]2[C@@H](C([C@@H]([C@H](O2)CO)O)O)O)[C@@H](C(=O)O)N,,,,,,
2304,122305,3-deoxy-3-fluoro-D-glucose,C([C@H]([C@H]([C@@H]([C@H](C=O)O)F)O)O)O,,,,,,
2305,122306,"D-Glucaro-1,4-lactone",[C@H]1([C@H](C(=O)O[C@@H]1[C@@H](C(=O)O)O)O)O,,,,,,
2306,122307,"O-(2,3,4,5,6-Pentafluorobenzyl)hydroxylamine hydrochloride",C(C1=C(C(=C(C(=C1F)F)F)F)F)ON.Cl,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
2307,122308,"o-(2,3,4,5,6-Pentafluorobenzyl)hydroxylamine",C(C1=C(C(=C(C(=C1F)F)F)F)F)ON,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
2308,122309,8-(Diazonioamino)-5-ethyl-3-imino-6-phenylphenanthridine,CCN1C2=CC(=N)C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N[N+]#N,,,,,,
2309,122310,"1,2-Benzenediol, 4-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)propyl)-",CC(CC1=CC=C(C=C1)O)NC(C)C(C2=CC(=C(C=C2)O)O)O,,,,,,
2310,122311,6-Hydroxy-5-methoxy-1h-indole-2-carboxylic acid,COC1=C(C=C2C(=C1)C=C(N2)C(=O)O)O,,,,,,
2311,122312,"3Alpha,7Alpha,12Alpha-trihydroxy-5Beta-cholestan-26-oic acid",C[C@H](CCCC(C)C(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
2312,122313,Pyroglutamyl-histidyl-glycine,C1CC(=O)N[C@@H]1C(=O)N[C@@H](CC2C=NC=N2)C(=O)NCC(=O)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that are used to suppress appetite. (See all compounds classified as Appetite Depressants.)']",,,
2313,122314,O-alpha-D-Mannopyranosyl-(1-4)-O-alpha-D-mannopyranosyl-(1-4)-alpha-D-mannopyranose,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O[C@@H]2[C@H](C([C@@H]([C@H](O2)CO)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O)O,,,,,,
2314,122315,CID 122315,C1[C@@H]([C@H](OC1N2C=C(C(=O)NC2=O)C=CI)CO)O,,,,,,
2315,122316,"N-(2-Propynyl)-2,3-dihydroinden-1-amine",C#CCNC1CCC2=CC=CC=C12,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
2316,122317,Viskaldix,C[C@@H]1CCC[C@@H](N1NC(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N)C.CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2317,122318,Tyrosyl-prolyl-phenylalanyl-prolylglycine,C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)NCC(=O)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
2318,122319,CID 122319,C[N+](=C1C=CC(=C(C2=CC=C(C=C2)NCC3=CC=C(C=C3)S(=O)(=O)[O-])C4=CC(=C(C=C4S(=O)(=O)[O-])S(=O)(=O)[O-])O)C=C1)CC5=CC=CC=C5.[Na+].[Na+],,,,,,
2319,122320,"Benzyl-[4-[(5-hydroxy-2,4-disulfophenyl)-[4-[(4-sulfophenyl)methylamino]phenyl]methylidene]cyclohexa-2,5-dien-1-ylidene]-methylazanium",C[N+](=C1C=CC(=C(C2=CC=C(C=C2)NCC3=CC=C(C=C3)S(=O)(=O)O)C4=CC(=C(C=C4S(=O)(=O)O)S(=O)(=O)O)O)C=C1)CC5=CC=CC=C5,,,,,,
2320,122321,Coe Comfort,CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC.CCO.CCOC(=O)C(=C)C,,,,,,
2321,122322,Mcp-tva-argipressin,CCOC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5,,,"['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
2322,122323,S-Farnesyl cysteine,CC(=CCCC(=CCCC(=CCSC[C@@H](C(=O)O)N)C)C)C,,,,,,
2323,122324,"5,6-Dihydroxy-3-phenyl-1-aminomethylisochroman",C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
2324,122325,Vaccenic acid,CCCCCCC=CCCCCCCCCCC(=O)O,,,,,,
2325,122326,"cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one",C[C@@H]1C(=O)N([C@@H](S1)C2=CN=CC=C2)C,,,,,,
2326,122327,"2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide",CCCCCCCCCCC(C)(C)C(=O)NC1=C(C=C(C=C1OC)OC)OC,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2327,122328,"2,6-Diamino-4-oxo-5-formamidopyrimidine",C(=O)NC1C(=NC(=NC1=O)N)N,,,,,,
2328,122329,CID 122329,CS(=O)(=O)O.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@@H]2CC6=C4C(=C(C=C6)O)O5)NC(=O)C=CC7=CC=C(C=C7)Cl,,,,,,
2329,122330,CID 122330,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@@H]2CC6=C4C(=C(C=C6)O)O5)NC(=O)C=CC7=CC=C(C=C7)Cl,,,,,,
2330,122331,"1D-myo-inositol 1,2-cyclic phosphate",[C@@H]1([C@@H]([C@H]([C@H]2[C@@H]([C@@H]1O)OP(=O)(O2)O)O)O)O,,,,,,
2331,122332,3-Pentyl-2-[3-[3-pentylbenzoxazol-2(3H)-ylidene]-1-propenyl]benzoxazolium,CCCCCN1C2=CC=CC=C2OC1=CC=CC3=[N+](C4=CC=CC=C4O3)CCCCC,,,,,,
2332,122333,Val-Leu-Arg-p-nitroanilide,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)[C@@H](C(C)C)N,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
2333,122334,5-Methoxy-1-methyl-2-(n-propylamino)tetralin,CCCN[C@@H]1CCC2=C([C@@H]1C)C=CC=C2OC,,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
2334,122335,Efaproxiral,CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C,,,"['Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. (See all compounds classified as Antisickling Agents.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)']",,,
2335,122336,Trehalose-6-phosphate,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O)O)O)O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2336,122337,"L-Glutamic acid, 5-(phenylmethyl) ester",C1=CC=C(C=C1)COC(=O)CC[C@@H](C(=O)O)N,,,,,,
2337,122338,CID 122338,CN1C=C([N+](C1C=CC(C(=O)N)N)(C)C)CC(C(=O)[O-])N,,,,,,
2338,122339,CID 122339,CN1C=C([N+](C1C=CC(C(=O)N)N)(C)C)CC(C(=O)O)N,,,,,,
2339,122340,Ursocholic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
2340,122341,CID 122341,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@]4([C@@]3(CC[C@@H](C4)O)C)C[123I])C,,,,,,
2341,122342,"4,4'-Dibenzoylaminostilben-2,2'-disulfosaure",C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2342,122343,CID 122343,C1=NC2=C(N1COCC(CO)O)NC(=NC2=O)N,,,,,,
2343,122344,UD CG 212 Cl,CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)O.Cl,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
2344,122345,"4-methyl-3-[2-(4-oxocyclohexa-2,5-dien-1-ylidene)-1,3-dihydrobenzimidazol-5-yl]-4,5-dihydro-1H-pyridazin-6-one",CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)O,,,,,"['3-[2-(4-Hydroxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one is a known human metabolite of pimobendan.']",
2345,122346,1-Ethyl-3-(3-dimethylaminoethyl)carbodiimide,CCN=C=NCCN(C)C,,,,,,
2346,122347,CID 122347,C1C(NC2=C(N1)NC(=NC2=O)N)CN(C=O)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
2347,122348,"7-[(1S,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@H]1CC=CCCCC(=O)O)O)O,,,,,,
2348,122349,CID 122349,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOP(=O)(O)OC2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C)C,,,,,,
2349,122350,"(2R,3S,4R,5R)-2,4,5,6-tetrahydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal",C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@H](C=O)O)[C@@H]([C@@H](CO)O)O)O)O)O)O,,,,,,
2350,122351,CID 122351,C1[C@@H]2C[N+](=CC2C3=C(N1)NC(=NC3=O)N)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)O)C(=O)[O-],,,,,,
2351,122352,CID 122352,C1[C@@H]2C[N+](=CC2C3=C(N1)NC(=NC3=O)N)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
2352,122353,CID 122353,CC1=CC(=O)OC2=C1C=CC(=C2)S(=O)(=O)O,,,,,,
2353,122354,N-succinimidyl propionate,CCC(=O)ON1C(=O)CCC1=O,,,,,,
2354,122355,"7-[(1R,2R,3R)-3-Hydroxy-2-[(3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid",CCCC[C@H](C)C[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCC=CC(=O)O)O)O,,,,,,
2355,122356,N-acetylputrescine,CC(=O)NCCCCN,,,,,,
2356,122357,D-Erythrose 4-phosphate,C([C@H]([C@H](C=O)O)O)OP(=O)(O)O,,,,,,
2357,122358,"3-Butyl-4-hydroxynaphthalene-1,2-dione",CCCCC1=C(C2=CC=CC=C2C(=O)C1=O)O,,,,,,
2358,122359,3-(3-Methoxyphenyl)-1-methyl-3-propylpyrrolidine,CCCC1(CCN(C1)C)C2=CC(=CC=C2)OC,,,,,,
2359,122360,N-Methyltetradecylamine,CCCCCCCCCCCCCCNC,,,,,,
2360,122361,"3',4'-Dichloro-3-nitrosalicylanilide",C1=CC(=C(C(=C1)[N+](=O)[O-])O)C(=O)NC2=CC(=C(C=C2)Cl)Cl,,,,,,
2361,122362,"Benzamide, 2-hydroxy-N-(3-iodophenyl)-3-nitro-",C1=CC(=CC(=C1)I)NC(=O)C2=C(C(=CC=C2)[N+](=O)[O-])O,,,,,,
2362,122363,"s-Triazole, 3-amino-, sulfate",C1=NNC(=N1)N.OS(=O)(=O)O,,,,,,
2363,122364,"1,3,5-Triazine-2-thiol, tetrahydro-5-octyl-",CCCCCCCCN1CN[C@@H](N=C1)S,,,,,,
2364,122365,(alpha-Methylbenzyl)anisole,CC(C1=CC=CC=C1)C2=CC=CC=C2OC,,,,,,
2365,122366,"(R-(R*,R*))-2-((Dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl morpholine-4-acetate",C1COCCN1CC(=O)OC[C@@H]([C@@H](C2=CC=C(C=C2)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,,,,,,
2366,122367,CID 122367,COC1=CC(=C2C=CC(=NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])C(=C2)OC)C=CC1=NC4=C(C=C(C=C4)N(O)O)[N+](=O)[O-],,,,,,
2367,122368,Bis(2-ethylhexyl) 2-hydroxyethyl phosphate,CCCCC(CC)COP(=O)(OCCO)OCC(CC)CCCC,,,,,,
2368,122369,CID 122369,C1=CC2=C(C=C1S(=O)(=O)O)SC(=N2)S,,,,,,
2369,122370,Methylthiomethylmercaptan,CSCS,,,,,,
2370,122371,"2,2-Dimethyl-3-(3-methylenepent-4-enyl)oxirane",CC1(C(O1)CCC(=C)C=C)C,,,,,,
2371,122372,CID 122372,C(C(C(F)(F)S(=O)(=O)[O-])(F)F)(C(F)(F)F)(F)F.[K+],,,,,,
2372,122373,"3,5-Dibromo-2-methylthiophene",CC1=C(C=C(S1)Br)Br,,,,,,
2373,122374,"2,2'-((4-((2-(Methylsulphonyl)-4-nitrophenyl)azo)-m-tolyl)imino)bisethyl diacetate",CC1=C(C=CC(=C1)N(CCOC(=O)C)CCOC(=O)C)N=NC2=C(C=C(C=C2)[N+](=O)[O-])S(=O)(=O)C,,,,,,
2374,122375,m-Tolyl chloroformate,CC1=CC(=CC=C1)OC(=O)Cl,,,,,,
2375,122376,"4-Chloro-2,5-diphenyloxazole",C1=CC=C(C=C1)C2=C(N=C(O2)C3=CC=CC=C3)Cl,,,,,,
2376,122377,Allyltriethylammonium bromide,CC[N+](CC)(CC)CC=C.[Br-],,,,,,
2377,122378,CID 122378,CCCCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+],,,,,,
2378,122379,2-Decoxy-2-oxoethanesulfonic acid,CCCCCCCCCCOC(=O)CS(=O)(=O)O,,,,,,
2379,122380,"Pyrazine, 2-methyl-6-propyl-",CCCC1=NC(=CN=C1)C,,,,,,
2380,122381,2-Amino-4-benzamidobenzenesulphonic acid,C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2)S(=O)(=O)O)N,,,,,,
2381,122382,"2-(4-Aminophenyl)-2,4-dihydro-4,5-dimethyl-3H-pyrazol-3-one",CC1C(=NN(C1=O)C2=CC=C(C=C2)N)C,,,,,,
2382,122383,2-Methyl-5-propylpyrazine,CCCC1=NC=C(N=C1)C,,,,,,
2383,122384,CID 122384,CCCCCCCCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+],,,,,,
2384,122385,Myristyl sulfoacetate,CCCCCCCCCCCCCCOC(=O)CS(=O)(=O)O,,,,,,
2385,122386,CID 122386,CCCCCCCCCCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+],,,,,,
2386,122387,2-Hexadecoxy-2-oxoethanesulfonic acid,CCCCCCCCCCCCCCCCOC(=O)CS(=O)(=O)O,,,,,,
2387,122388,CID 122388,CCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+],,,,,,
2388,122389,Octylsulfoacetate,CCCCCCCCOC(=O)CS(=O)(=O)O,,,,,,
2389,122390,Tris(2-hydroxyethyl)methylammonium methyl sulphate,C[N+](CCO)(CCO)CCO.COS(=O)(=O)[O-],,,,,,
2390,122391,"2,6-Bis(1-methylpropyl)-m-cresol",CCC(C)C1=C(C(=C(C=C1)C)C(C)CC)O,,,,,,
2391,122392,Triphenylphosphonium cyclopentadienylide,C1=CC=C(C=C1)P(=C2C=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2392,122393,"4-Hydroxy-3-((2-methoxy-5-methyl-4-((2-(sulphooxy)ethyl)sulphonyl)phenyl)azo)naphthalene-2,7-disulphonic acid",CC1=CC(=C(C=C1S(=O)(=O)CCOS(=O)(=O)O)OC)N=NC2=C(C=C3C=C(C=CC3=C2O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2393,122394,2-((Methylthio)methyl)-1H-benzimidazole-5-sulphonic acid,CSCC1=NC2=C(N1)C=C(C=C2)S(=O)(=O)O,,,,,,
2394,122395,2-((2-(Ethylthio)ethyl)thio)-1H-benzimidazole-5-sulphonic acid,CCSCCSC1=NC2=C(N1)C=C(C=C2)S(=O)(=O)O,,,,,,
2395,122396,CID 122396,CC1=NN=C(S1)S,,,,,,
2396,122397,CID 122397,CCCC[Sn]CCCC.CC(CCOC(=O)CC[S-])OC.CC(CCOC(=O)CC[S-])OC,,,,,,
2397,122398,3-Methoxybutyl 3-Mercaptopropionate,CC(CCOC(=O)CCS)OC,,,,,,
2398,122399,3-(Octylamino)propionitrile,CCCCCCCCNCCC#N,,,,,,
2399,122400,"2,4,4-Trimethyl-3-oxopentanenitrile",CC(C#N)C(=O)C(C)(C)C,,,,,,
2400,122401,"6'-(diethylamino)-2'-(phenylamino)spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-3-one",CCN(CC)C1=CC2=C(C=C1)C3(C4=CC=CC=C4C(=O)O3)C5=C(O2)C=CC(=C5)NC6=CC=CC=C6,,,,,,
2401,122402,"Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-(diethylamino)-3'-methyl-2'-(phenylamino)-",CCN(CC)C1=CC2=C(C=C1)C3(C4=CC=CC=C4C(=O)O3)C5=C(O2)C=C(C(=C5)NC6=CC=CC=C6)C,,,,,,
2402,122403,1-((2-((2-((2-Aminoethyl)amino)ethyl)amino)ethyl)amino)propan-2-ol,CC(CNCCNCCNCCN)O,,,,,,
2403,122404,Cycloundecanemethanol,C1CCCCCC(CCCC1)CO,,,,,,
2404,122405,CID 122405,C(=C(C(F)(F)F)O)C(=O)C(F)(F)F.C(=C(C(F)(F)F)O)C(=O)C(F)(F)F.C(=C(C(F)(F)F)O)C(=O)C(F)(F)F.[Ir],,,,,,
2405,122406,CID 122406,CCCCN(CCCC)C1=NC(=NC(=N1)S)S,,,,,,
2406,122407,2-(Ethylthio)phenol,CCSC1=CC=CC=C1O,,,,,,
2407,122408,"2,2-Dimethyl-1,3-dichloropropane",CC(C)(CCl)CCl,,,,,,
2408,122409,Dipentaerythritol hexaacrylate,C=CC(=O)OCC(COCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C,,,,,,
2409,122410,3-(Tert-butylamino)-1-phenothiazin-10-ylpropan-1-one,CC(C)(C)NCCC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
2410,122411,"1-Propanone, 3-(4-(2-hydroxyethyl)piperazinyl)-1-(phenothiazin-10-yl)-, dihydrochloride",C1CN(CCN1CCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42)CCO.Cl.Cl,,,,,,
2411,122412,3-[4-(2-Hydroxyethyl)piperazin-1-yl]-1-phenothiazin-10-ylpropan-1-one,C1CN(CCN1CCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42)CCO,,,,,,
2412,122413,CID 122413,CCCCCCCC[Sn]CCCCCCCC.CCCCOC(=O)C=CC(=O)O.CCCCOC(=O)C=CC(=O)O,,,,,,
2413,122414,"2-Butene, 1-bromo-",CC=CCBr,,,,,,
2414,122415,11-Oxabicyclo[8.1.0]undecane,C1CCCCC2C(O2)CCC1,,,,,,
2415,122416,"Ethanamine, N,N-dimethyl(4-methyl-1-piperazinyl)-",CCN(C)CN1CCN(CC1)C,,,,,,
2416,122417,CID 122417,CCCCCCCCCCCCC1=CC=CC=C1C(=O)[O-].[Na+],,,,,,
2417,122418,2-dodecylbenzoic Acid,CCCCCCCCCCCCC1=CC=CC=C1C(=O)O,,,,,,
2418,122419,2-Hydroxypropyl butyrate,CCCC(=O)OCC(C)O,,,,,,
2419,122420,"1,3-Dihydroxypropan-2-yl 4-aminobenzoate",C1=CC(=CC=C1C(=O)OC(CO)CO)N,,,,,,
2420,122421,"Stearic acid, monoester with glycerol monopalmitate",CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC,,,,,,
2421,122422,"2,3-Dihydroxy-N-(2-hydroxyethyl)benzamide",C1=CC(=C(C(=C1)O)O)C(=O)NCCO,,,,,,
2422,122423,"2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate]",CCCCCCCCCCCCSCCC(=O)OCC(COC(=O)CCSCCCCCCCCCCCC)(COC(=O)CCSCCCCCCCCCCCC)COC(=O)CCSCCCCCCCCCCCC,,,,,,
2423,122424,"1H-Pyrrole-2,5-dione, 1-[3-(triethoxysilyl)propyl]-",CCO[Si](CCCN1C(=O)C=CC1=O)(OCC)OCC,,,,,,
2424,122425,2-(2-Aminoethylamino)-5-nitropyridine,C1=CC(=NC=C1[N+](=O)[O-])NCCN,,,,,,
2425,122426,"Nonanedioic acid, bis(2-hydroxyethyl) ester",C(CCCC(=O)OCCO)CCCC(=O)OCCO,,,,,,
2426,122427,n-[3-(Cyclohexylamino)-4-methoxyphenyl]acetamide,CC(=O)NC1=CC(=C(C=C1)OC)NC2CCCCC2,,,,,,
2427,122428,"Acetamide, N-[2-[(2-cyano-4,6-dinitrophenyl)azo]-5-(cyclohexylamino)-4-methoxyphenyl]-",CC(=O)NC1=CC(=C(C=C1N=NC2=C(C=C(C=C2[N+](=O)[O-])[N+](=O)[O-])C#N)OC)NC3CCCCC3,,,,,,
2428,122429,CID 122429,CC(C)C1C(=O)N(C(=N1)S)C2=CC=CC=C2,,,,,,
2429,122430,"Benzoic acid, 2-amino-5-[(methylamino)sulfonyl]-",CNS(=O)(=O)C1=CC(=C(C=C1)N)C(=O)O,,,,,,
2430,122431,"(4-((2-Chlorophenyl)(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-ylidene)dimethylammonium nitrate",CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3Cl.[N+](=O)([O-])[O-],,,,,,
2431,122432,3-Bromo-1-phenylpropan-1-one,C1=CC=C(C=C1)C(=O)CCBr,,,,,,
2432,122433,"1H-Imidazole-4-methanol, 5-methyl-",CC1=C(N=CN1)CO,,,,,,
2433,122434,"Benzenesulfonic acid, 4-[4-[2-(1-ethylnaphtho[1,2-d]thiazol-2(3H)-ylidene)-1-methylethylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]-",CCN1C(=CC(=C2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)O)C)C)SC4=C1C5=CC=CC=C5C=C4,,,,,,
2434,122435,"1,3-Naphthalenedisulfonic acid, 7-[(1,8-dihydroxy-3,6-disulfo-2-naphthalenyl)azo]-, tetrasodium salt",C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])O)O.[Na+].[Na+].[Na+].[Na+],,,,,,
2435,122436,"7-[(1,8-Dihydroxy-3,6-disulfonaphthalen-2-yl)diazenyl]naphthalene-1,3-disulfonic acid",C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)O)S(=O)(=O)O)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)O)O,,,,,,
2436,122437,"Benzenesulfonic acid, 4-[4-[4-(3-ethyl-2(3H)-benzoxazolylidene)-2-butenylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]-",CCN1C2=CC=CC=C2OC1=CC=CC=C3C(=NN(C3=O)C4=CC=C(C=C4)S(=O)(=O)O)C,,,,,,
2437,122438,Diethylpyrrolidinium bromide,CC[N+]1(CCCC1)CC.[Br-],,,,,,
2438,122439,"1,1-Diethylpyrrolidinium",CC[N+]1(CCCC1)CC,,,,,,
2439,122440,"Acetamide, N-(2-((2-chloro-4-nitrophenyl)azo)-5-((2-(2,5-dioxo-1-pyrrolidinyl)ethyl)ethylamino)phenyl)-",CCN(CCN1C(=O)CCC1=O)C2=CC(=C(C=C2)N=NC3=C(C=C(C=C3)[N+](=O)[O-])Cl)NC(=O)C,,,,,,
2440,122441,"N-[5-[[2-(2,5-Dioxo-1-pyrrolidinyl)ethyl]ethylamino]-2-[(4-nitrophenyl)azo]phenyl]acetamide",CCN(CCN1C(=O)CCC1=O)C2=CC(=C(C=C2)N=NC3=CC=C(C=C3)[N+](=O)[O-])NC(=O)C,,,,,,
2441,122442,"1,3,5-Triazine-2,4-diamine, 6-decyl-",CCCCCCCCCCC1=NC(=NC(=N1)N)N,,,,,,
2442,122443,Hexadecyldimethyl(ethylbenzyl)ammonium chloride,CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC(=C1)CC.[Cl-],,,,,,
2443,122444,(3-Ethylphenyl)methyl-hexadecyl-dimethylazanium,CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC(=C1)CC,,,,,,
2444,122445,"Antimony, compd. with samarium (1:1)",[Sb]#[Sm],,,,,,
2445,122446,"Benzenesulfonamidothiophosphoric acid,diethyl ester",CCOP(=S)(NS(=O)(=O)C1=CC=CC=C1)OCC,,,,,,
2446,122447,"4H-1,3-Benzodioxin-6-carboxaldehyde",C1C2=C(C=CC(=C2)C=O)OCO1,,,,,,
2447,122448,Butyl bis(chloromethyl)carbamate,CCCCOC(=O)N(CCl)CCl,,,,,,
2448,122449,"Benzoselenazolium, 2-methyl-3-(3-sulfopropyl)-, inner salt",CC1=[N+](C2=CC=CC=C2[Se]1)CCCS(=O)(=O)[O-],,,,,,
2449,122450,"3-(2-Methyl-1,3-benzoselenazol-3-ium-3-yl)propane-1-sulfonic acid",CC1=[N+](C2=CC=CC=C2[Se]1)CCCS(=O)(=O)O,,,,,,
2450,122451,"2-Methylthio-1(2H)-quinolinecarboxylic acid, ethyl ester",CCOC(=O)N1C(C=CC2=CC=CC=C21)SC,,,,,,
2451,122452,"1,4-Dichloro-2-iodobenzene",C1=CC(=C(C=C1Cl)I)Cl,,,,,,
2452,122453,"1-Bromo-2,4,5-trichlorobenzene",C1=C(C(=CC(=C1Cl)Br)Cl)Cl,,,,,,
2453,122454,"Benzenediazonium, 3,5-bis(trifluoromethyl)-",C1=C(C=C(C=C1C(F)(F)F)[N+]#N)C(F)(F)F,,,,,,
2454,122455,CID 122455,CCCCCCCCCCCCCCCCCC(=O)OCCS(=O)(=O)[O-].[Na+],,,,,,
2455,122456,Stearoyl isethionate,CCCCCCCCCCCCCCCCCC(=O)OCCS(=O)(=O)O,,,,,,
2456,122457,"Ethanol, 2,2'-[(4-fluoro-3-nitrophenyl)imino]bis-",C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])F,,,,,,
2457,122458,"2,5-Diamino-1,8-dihydroxyanthraquinone",C1=CC(=C(C2=C1C(=O)C3=C(C=CC(=C3C2=O)O)N)O)N,,,,,,
2458,122459,alpha-((4-(Benzothiazol-2-ylazo)-m-tolyl)ethylamino)-m-toluenesulphonic acid,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC(=C(C=C2)N=NC3=NC4=CC=CC=C4S3)C,,,,,,
2459,122460,"(1alpha,2beta,4beta)-2-Chloro-1-(isopropyl)-4-methylcyclohexane",C[C@H]1CC[C@H]([C@@H](C1)Cl)C(C)C,,,,,,
2460,122461,Einecs 249-792-1,CC1(C(N2C(S1=O)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)OCC4=CC=C(C=C4)[N+](=O)[O-])C,,,,,,
2461,122462,Tetradecyl heptanoate,CCCCCCCCCCCCCCOC(=O)CCCCCC,,,,,,
2462,122463,"Decanoic acid, hexadecyl ester",CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCC,,,,,,
2463,122464,2-Isopentylcyclopent-2-en-1-one,CC(C)CCC1=CCCC1=O,,,,,,
2464,122465,"4-Isothiocyanato-N,N-dimethylnaphthalen-1-amine",CN(C)C1=CC=C(C2=CC=CC=C21)N=C=S,,,,,,
2465,122466,CID 122466,CCOC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3C=N2,,,,,,
2466,122467,"Toluene-3,4-dithiol ZINC salt",CC1=CC(=C(C=C1)[S-])[S-].[Zn+2],,,,,,
2467,122468,CID 122468,C(CO)O.C(CO)O.C(CO)O.[SbH3].[SbH3],,,,,,
2468,122469,N-(4-Aminophenyl)maleimide,C1=CC(=CC=C1N)N2C(=O)C=CC2=O,,,,,,
2469,122470,"Benzamide, N-[5-[bis[2-(acetyloxy)ethyl]amino]-2-[(4-nitrophenyl)azo]phenyl]-",CC(=O)OCCN(CCOC(=O)C)C1=CC(=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)C3=CC=CC=C3,,,,,,
2470,122471,1-Chloro-4-(((3-iodo-2-propynyl)oxy)methoxy)benzene,C1=CC(=CC=C1OCOCC#CI)Cl,,,,,,
2471,122472,"4,4,8,8-Tetraethoxy-6,6-diisopropoxy-3,5,7,9-tetraoxa-4,8-disila-6-titanaundecane",CCO[Si](O)(OCC)OCC.CCO[Si](O)(OCC)OCC.CC(C)O.CC(C)O.[Ti],,,,,,
2472,122473,"Propylamine, N,1,1,2,2-pentamethyl-, hydrochloride",CC(C)(C)C(C)(C)NC.Cl,,,,,,
2473,122474,"N,2,3,3-tetramethylbutan-2-amine",CC(C)(C)C(C)(C)NC,,,,,,
2474,122475,"2-Butylamine, N,N,2,3,3-pentamethyl-, hydrobromide",CC(C)(C)C(C)(C)N(C)C.Br,,,,,,
2475,122476,"2-Dimethylamino-2,3,3-trimethylbutane",CC(C)(C)C(C)(C)N(C)C,,,,,,
2476,122477,"1,2-Ethanediol, acetate formate",CC(=O)OCCOC=O,,,,,,
2477,122478,"1,1'-Bi-1H-imidazole, 2,2'-bis(2-chlorophenyl)-4,4',5,5'-tetrakis(3-methoxyphenyl)-",COC1=CC=CC(=C1)C2=C(N(C(=N2)C3=CC=CC=C3Cl)N4C(=C(N=C4C5=CC=CC=C5Cl)C6=CC(=CC=C6)OC)C7=CC(=CC=C7)OC)C8=CC(=CC=C8)OC,,,,,,
2478,122479,O-(beta-Ethoxyethyl) O-methyl S-(prop-2-ynyl) phosphorothioate,CCOCCOP(=O)(OC)SCC#C,,,,,,
2479,122480,O-(beta-Methoxyethyl) O-methyl S-(prop-2-ynyl) phosphorothioate,COCCOP(=O)(OC)SCC#C,,,,,,
2480,122481,CID 122481,C1=CC=C2C(=C1)C=CC(=C2CS(=O)(=O)[O-])N=NC3=C(C(=CC4=CC=CC=C43)C(=O)[O-])O.[Ca+2],,,,,,
2481,122482,Methyl 4-pyridylacetate,COC(=O)CC1=CC=NC=C1,,,,,,
2482,122483,CID 122483,C1=CC=C(C(=C1)C(=O)O)C(=O)O.[KH].[KH],,,,,,
2483,122484,"2-Cyclohexen-1-ol, 1-methyl-4-(1-methylethyl)-, trans-",CC(C)[C@@H]1CC[C@@](C=C1)(C)O,,,,,,
2484,122485,cis-4-(Isopropyl)-1-methylcyclohex-2-en-1-ol,CC(C)[C@H]1CC[C@@](C=C1)(C)O,,,,,,
2485,122486,"1,2,3,6-Tetrahydro-4-(4-methylpent-3-enyl)phthalic anhydride",CC(=CCCC1=CCC2C(C1)C(=O)OC2=O)C,,,,,,
2486,122487,"5H-Cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidin-8-ol, 6,7-dihydro-",C1CC2=C(C1)N=C3N=CNN3C2=O,,,,,,
2487,122488,"Acetic acid, 2-methylhydrazide",CC(=O)NNC,,,,,,
2488,122489,"1,1,2,2-Tetrafluoro-3-(vinyloxy)propane",C=COCC(C(F)F)(F)F,,,,,,
2489,122490,Ethyl 7-bromoheptanoate,CCOC(=O)CCCCCCBr,,,,,,
2490,122491,"Undeca-1,3,5,8-tetraene",CCC=CCC=CC=CC=C,,,,,,
2491,122492,"Benzenepropanoic acid, alpha-[[(2E)-3-(4-nitrophenyl)-1-oxo-2-propenyl]oxy]-, (alphaS)-",C1=CC=C(C=C1)CC(C(=O)O)OC(=O)C=CC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2492,122493,"L-alpha-Glycerolphosphate, dicyclohexylammonium salt",C1CCC(CC1)N.C(C(COP(=O)(O)O)O)O.C(C(COP(=O)(O)O)O)O,,,,,,
2493,122494,"Benzenesulfonic acid, 3,3',3''-(1,3,5-triazine-2,4,6-triyltriimino)tris-",C1=CC(=CC(=C1)S(=O)(=O)O)NC2=NC(=NC(=N2)NC3=CC(=CC=C3)S(=O)(=O)O)NC4=CC(=CC=C4)S(=O)(=O)O,,,,,,
2494,122495,"2-(2-Ethoxyphenyl)-1-(2-(2-ethoxyphenyl)-4,5-diphenyl-2H-imidazol-2-yl)-4,5-diphenyl-1H-imidazole",CCOC1=CC=CC=C1C2=NC(=C(N2C3(N=C(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6OCC)C7=CC=CC=C7)C8=CC=CC=C8,,,,,,
2495,122496,"2-(2-Chlorophenyl)-4,5-bis(3-methoxyphenyl)-1H-imidazole",COC1=CC=CC(=C1)C2=C(N=C(N2)C3=CC=CC=C3Cl)C4=CC(=CC=C4)OC,,,,,,
2496,122497,"Magnesium, chloro[(2-chlorophenyl)methyl]-",[CH2-]C1=CC=CC=C1Cl.[Mg+2].[Cl-],,,,,,
2497,122498,"Magnesium, chloro[(2-methylphenyl)methyl]-",CC1=CC=CC=C1[CH2-].[Mg+2].[Cl-],,,,,,
2498,122499,4-Methyl-1H-benzotriazole,CC1=CC=CC2=NNN=C12,,,,,,
2499,122500,"1-(3,3-Dimethoxyprop-1-enyl)-4-hexylbenzene",CCCCCCC1=CC=C(C=C1)C=CC(OC)OC,,,,,,
2500,122501,1-Benzylpyrrolidine,C1CCN(C1)CC2=CC=CC=C2,,,,,,
2501,122502,1-Phenylhexan-3-one,CCCC(=O)CCC1=CC=CC=C1,,,,,,
2502,122503,"Cholest-5-en-3-ol (3beta)-, carbonate (2:1)",CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)OC5CCC6(C7CCC8(C(C7CC=C6C5)CCC8C(C)CCCC(C)C)C)C)C)C,,,,,,
2503,122504,"(1R-(1alpha,2beta,4beta,5alpha,6alpha))-5,7,7-Trimethyl-3-oxatricyclo(4.1.1.02,4)octane",CC1C2CC(C2(C)C)C3C1O3,,,,,,
2504,122505,3-Oxoandrost-4-en-17-yl octanoate,CCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C,,,,,,
2505,122506,"(10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) undec-10-enoate",CC12CCC3C(C1CCC2OC(=O)CCCCCCCCC=C)CCC4=CC(=O)CCC34C,,,,,,
2506,122507,"3(2H)-Furanone, 5-acetyldihydro-2-hydroxy-2,5-dimethyl-",CC(=O)C1(CC(=O)C(O1)(C)O)C,,,,,,
2507,122508,4-Fluorophenyl 4-chlorobenzoate,C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)F)Cl,,,,,,
2508,122509,"4-[2-(9-Fluoro-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethoxy]-4-oxobutanoic acid",CC12CC(C3(C(C1CC(C2(C(=O)COC(=O)CCC(=O)O)O)O)CCC4=CC(=O)C=CC43C)F)O,,,,,,
2509,122510,alpha-Cedrene epoxide,CC1CCC2C13CC(C2(C)C)C4(C(C3)O4)C,,,,,,
2510,122511,Methyl 2-methyldecanoate,CCCCCCCCC(C)C(=O)OC,,,,,,
2511,122512,4-(1-Methylvinyl)cyclohex-1-ene-1-methyl formate,CC(=C)C1CCC(=CC1)COC=O,,,,,,
2512,122513,CID 122513,CCN1C(=C[CH]C2=CC=CC=C21)C=C3N(C4=CC=CC=C4S3)CCC(C)S(=O)(=O)O,,,,,,
2513,122514,"[(2,3,4,4,5,5-Hexamethylhexan-2-yl)sulfanyl]acetic acid",CC(C(C)(C)C(C)(C)C)C(C)(C)SCC(=O)O,,,,,,
2514,122515,"13-Oxabicyclo[10.1.0]trideca-4,8-diene, 1,4,8-trimethyl-",CC1=CCCC2C(O2)(CCC(=CCC1)C)C,,,,,,
2515,122516,2-Hydroxyethyl lactate,CC(C(=O)OCCO)O,,,,,,
2516,122517,1-[2-[2-(Isopropyloxy)ethoxy]ethoxy]ethanol,CC(C)OCCOCCOC(C)O,,,,,,
2517,122518,"Glycinamide, N-acetyl-L-phenylalanyl-",CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N,,,,,,
2518,122519,Methyl 2-isopentyl-3-oxocyclopentaneacetate,CC(C)CCC1C(CCC1=O)CC(=O)OC,,,,,,
2519,122520,[(Dimethylamino)methylene]bisphosphonic acid,CN(C)C(P(=O)(O)O)P(=O)(O)O,,,,,,
2520,122521,"Dimethyl 2,2,4-trimethyladipate",CC(CC(=O)OC)CC(C)(C)C(=O)OC,,,,,,
2521,122522,"Acetamide, N-(m-anisyl)-2-(p-butoxyphenoxy)-N-(1-methyl-2-(1-pyrrolidinyl)ethyl)-, hydrochloride",CCCCOC1=CC=C(C=C1)OCC(=O)N(C2=CC(=CC=C2)OC)C(C)CN3CCCC3.Cl,,,,,,
2522,122523,2-(4-butoxyphenoxy)-N-(3-methoxyphenyl)-N-(1-pyrrolidin-1-ylpropan-2-yl)acetamide,CCCCOC1=CC=C(C=C1)OCC(=O)N(C2=CC(=CC=C2)OC)C(C)CN3CCCC3,,,,,,
2523,122524,1-((1-Hydroperoxymethylcyclohexyl)dioxy)methylcyclohexan-1-ol,C1CCC(CC1)(COOC2(CCCCC2)COO)O,,,,,,
2524,122525,"D-Glucose, 1-(dihydrogen phosphate), dipotassium salt",C(C1C(C(C(C(O1)OP(=O)([O-])[O-])O)O)O)O.[K+].[K+],,,,,,
2525,122526,"1,4-Butaendiol",C(CO)C=CO,,,,,,
2526,122527,"4H-Pyrido[1,2-a]pyrimidine-3-carboxylic acid, 1,6,7,8,9,9a-hexahydro-6-methyl-4-oxo-, ethyl ester",CCOC(=O)C1=CNC2CCCC(N2C1=O)C,,,,,,
2527,122528,2-Ethyl-3-methylvaleronitrile,CCC(C)C(CC)C#N,,,,,,
2528,122529,"2,3,4,5-Tetra-o-prop-2-en-1-ylhexitol",C=CCOC(CO)C(C(C(CO)OCC=C)OCC=C)OCC=C,,,,,,
2529,122530,2-Ethylhexyl myristate,CCCCCCCCCCCCCC(=O)OCC(CC)CCCC,,,,,,
2530,122531,1-Methyl-2-[(1-oxoallyl)oxy]ethyl acetoacetate,CC(COC(=O)C=C)OC(=O)CC(=O)C,,,,,,
2531,122532,3-Methylindan-4-ol,CC1CCC2=C1C(=CC=C2)O,,,,,,
2532,122533,"N-[7-(6,6-dimethyloxan-2-yl)oxy-4-hydroxy-2-oxo-3,4-dihydrochromen-3-yl]-4-hydroxy-3-(3-methylbut-2-enyl)benzamide",CC(=CCC1=C(C=CC(=C1)C(=O)NC2C(C3=C(C=C(C=C3)OC4CCCC(O4)(C)C)OC2=O)O)O)C,,,,,,
2533,122534,"N,1-Dimethyl-3,3-diphenylpropylamine",CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC,,,,,,
2534,122535,"N,N,1-Trimethyl-3,3-diphenylallylamine",CC(C=C(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C,,,,,,
2535,122536,"4-Chloro-1,1-dimethoxybutane",COC(CCCCl)OC,,,,,,
2536,122537,Ethyl 3-(4-acetylphenoxy)-2-methylpropanoate,CCOC(=O)C(C)COC1=CC=C(C=C1)C(=O)C,,,,,,
2537,122538,"2',3'-Di-O-acetyladenosine",CC(=O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC(=O)C)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
2538,122539,CID 122539,C[C@H]1CC2=C(C(=C3[C@H]4C[C@H]4CCC(=C)C3=C2C1=O)C)O,,,,,,
2539,122540,2-[2-[4-(1-Phenylethyl)phenoxy]ethoxy]ethanol,CC(C1=CC=CC=C1)C2=CC=C(C=C2)OCCOCCO,,,,,,
2540,122541,"methyl (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate",CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)OC)C,,,,,,
2541,122542,"1,3,4,5,6,7-Hexahydro-1,1,5,5-tetramethyl-2H-2,4a-methanonaphthalen-7-yl acetate",CC(=O)OC1CC(C23CCC(C2)C(C3=C1)(C)C)(C)C,,,,,,
2542,122543,"4,11,11-Trimethyl-8-methylidenebicyclo[7.2.0]undec-3-en-5-ol",CC1=CCC2C(CC2(C)C)C(=C)CCC1O,,,,,,
2543,122544,"17-(5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C,,,,"['... Metabolism of plant sterols and squalene administered intravenously in the form of lipid emulsion mimicking chylomicrons (CM) /was studied/. The CM-like lipid emulsion was prepared by dissolving squalene in commercially available Intralipid. The emulsion was given as an intravenous bolus injection of 30 mL containing 6.3 mg of cholesterol, 1.9 mg of campesterol, 5.7 mg of sitosterol, 1.6 mg of stigmasterol, 18.1 mg of squalene, and 6 g of triglycerides in six healthy volunteers. Blood samples were drawn from the opposite arm before and serially 2.5 -180 min after the injections. The decay of CM squalene, plant sterols, and triglycerides was monoexponential. The half-life of CM squalene was 74 +/- 8 min, that of campesterol was 37 +/- 5 min (P < 0.01 from squalene), and those of sitosterol, stigmasterol, and triglycerides were 17 +/- 2, 15 +/- 1, and 17 +/- 2 min, respectively (P < 0.01 from squalene and campesterol). The CM squalene concentration still exceeded the baseline level 180 min after injection (P = 0.02), whereas plant sterols and triglycerides returned to the baseline level between 45 and 120 min after injection. The half-lives of squalene and campesterol were positively correlated with their fasting CM concentrations. In addition, VLDL squalene, campesterol, and triglyceride concentrations, VLDL, LDL, and HDL sitosterol concentrations, as well as VLDL and LDL stigmasterol concentrations were increased significantly...', 'Rats were dosed by oral gavage with 14C-labelled samples of cholesterol, beta-sitosterol or beta-sitostanol or (3)H-labelled samples of beta-sitostanol, campesterol, campestanol or stigmasterol dissolved in sunflower seed oil. Urine and feces were collected for up to 96 hours after dosing. ... Animals were sacrificed and either prepared for whole body autoradiography or tissues and carcass remains were assayed for 14C or (3)H. The overall absorption of phytosterols was low as judged by tissue and carcass levels of radioactivity. Elimination from the body was mainly in the feces and was initially very rapid, but traces of material were still being excreted at 4 days after dosing. While total absorption of the phytosterols could not be fully quantified without biliary excretion data, it was clear that cholesterol was absorbed to the greatest extent (27% of the dose in females at 24 hours). Campesterol (13%) was absorbed more than beta-sitosterol and stigmasterol (both 4%) which were absorbed more than beta-sitostanol and campestanol (1-2%). The absorption of phytosterols was slightly greater in females than males. For each test material, the overall pattern of tissue distribution of radioactivity was similar, with the adrenal glands, ovaries and intestinal epithelia showing the highest levels and the longest retention of radioactivity.', 'Intestinal absorption of cholesterol, campesterol, campestanol, stigmasterol and sitosterol were measured in 10 healthy subjects by an intestinal perfusion technique over a 50 cm segment of the upper jejunum using sitostanol as non-absorbable marker. Cholesterol absorption was highest and averaged 33%., whereas the absorption rate of sitosterol averaged 4.2% and of stigmasterol 4.8%....', 'To study the effects of dietary stigmasterol on sterol and bile acids metabolism, Wistar rats were fed diets containing various amounts of stigmasterol. Feeding high stigmasterol doses (11, 26 or 52 mg/day) led to increased cholesterol, coprostanol and bile acid output. These effects were dose-dependent, and likely to be related to the inhibitory effect of plant sterols on cholesterol absorption. Moreover, it accounts for the beneficial effect of the stigmasterol on cholesterol lowering.', 'Tobacco sterols (cholesterol, beta-sitosterol, campesterol, and stigmasterol) are present in tobacco smoke and appear in plasma of mammals exposed to cigarette smoke. Because tobacco sterols may be important in the pathogenesis of smoking-induced lung and vascular diseases, ...  the pattern of deposition of cigarette sterols in the lungs and appearance of cigarette sterols in plasma and body organs of rats /were studied/. After exposure to twenty 5 mL ""puffs"" of smoke from tobacco labeled with [4-14C]cholesterol or beta-[4-14C]sitosterol, rats were killed just after exposure (day 0) and on days 2, 5, 8, 11, 15, and 30, and the lungs and selected body organs analyzed for activity. ... Cigarette sterols /were/ associated with particulates in cigarette smoke, deposited mostly in distal airspaces and parenchyma of the lungs, and appear in plasma and several body organs for more than 30 days after this single exposure to cigarette smoke. Bronchoalveolar lavage fluid contained relatively small amounts of radiolabel for only the first few days, suggesting that most of the sterols were rapidly incorporated in lung parenchyma...']","['Metabolism of phytosterols was investigated using rat feces and liver microsomes. Feces were collected after phytosterols (a well characterized mixture of beta-sitosterol 40%, campesterol 30% and dihydrobrasicasterol) were administered orally (0.5 g/kg) to rats. Metabolites of phytosterols were identified using GC/MS. Three peaks were eluted at 12.47, 12.65, 12.87 min and had characteristic molecular ions m/z 428, 430, 432, respectively. Three fecal metabolites were identified as androstadienedione, androstenedione, and androstanedione. No metabolites could be detected in the rat liver microsomal reaction mixture. The results suggest that the metabolites of phytosterols in rat feces are formed by oxidation at 3- position, saturation at 5- and 6- position, and 17- side chain cleavage in the rat large intestine.', 'Plant sterols are an essential component of the membranes of all eukaryotic organisms. They are either synthesized de novo or taken up from the environment. Their function appears to be to control membrane fluidity and permeability, although some plant sterols have a specific function in signal transduction. The phytosterols are products of the isoprenoid pathway. The dedicated pathway to sterol synthesis in photosynthetic plants occurs at the squalene stage through the activity of squalene synthetase. Although the activity of 3-hydroxymethyl-3-glutaryl coenzyme A (HGMR) is rate-limiting in the synthesis of cholesterol, this does not appear to be the case with the plant sterols. Up-regulation of HGMR appears to increase the biosynthesis of cycloartenol but not the delta5-sterols. A decline in sterol synthesis is associated with a suppression of squalene synthetase activity, which is probably a critical point in controlling carbon flow and end-product formation. The major post-squalene biosynthetic pathway is regulated by critical rate-limiting steps such as the methylation of cycloartenol into cycloeucalenol. Little is known about the factors controlling the biosynthesis of the end-point sterol esters or stanols.']",
2544,122545,"Ethyl 3,3,5-trimethylcyclohexaneacetate",CCOC(=O)CC1CC(CC(C1)(C)C)C,,,,,,
2545,122546,2-sulfotetradecanoic Acid,CCCCCCCCCCCCC(C(=O)O)S(=O)(=O)O,,,,,,
2546,122547,2-Pentylcyclohexanone,CCCCCC1CCCCC1=O,,,,,,
2547,122548,"3,3-Dibromo-5-methyloxolan-2-one",CC1CC(C(=O)O1)(Br)Br,,,,,,
2548,122549,"Ethanone, 1-(1,3,4,4a,5,6,7-hexahydro-2,5,5-trimethyl-2H-2,4a-ethanonaphthalen-8-yl)-",CC(=O)C1=C2CC3(CCC2(CC3)C(CC1)(C)C)C,,,,,,
2549,122550,"Ethanone, 1-(1,2,3,4,7,7a-hexahydro-1,4,4,5-tetramethyl-1,3a-ethano-3aH-inden-6-yl)-",CC1=C(CC2C3(CCC2(C1(C)C)CC3)C)C(=O)C,,,,,,
2550,122551,CID 122551,C1=NC(=O)C2=C(N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OC4C(OC(C4O)N5C=NC6=C5NC=NC6=O)CO)O)O,,,,,,
2551,122552,2-Methylbicyclo[2.2.1]heptane-2-carboxylic acid,CC1(CC2CCC1C2)C(=O)O,,,,,,
2552,122553,Eprozinol,COC(CN1CCN(CC1)CCC(C2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
2553,122554,"Tetrahydro-2,2,6-trimethyl-2H-pyran",CC1CCCC(O1)(C)C,,,,,,
2554,122555,"7-Hydroxy-3,7-dimethylnonanal",CCC(C)(CCCC(C)CC=O)O,,,,,,
2555,122556,"6-(2,3-Dibromopropionamido)-3-((5-(2,3-dibromopropionamido)-2-sulphophenyl)azo)-4-hydroxynaphthalene-2-sulphonic acid",C1=CC(=CC2=C(C(=C(C=C21)S(=O)(=O)O)N=NC3=C(C=CC(=C3)NC(=O)C(CBr)Br)S(=O)(=O)O)O)NC(=O)C(CBr)Br,,,,,,
2556,122557,"2-Methyl-4-(2,6,6-trimethylcyclohexen-1-yl)but-3-enal",CC1=C(C(CCC1)(C)C)C=CC(C)C=O,,,,,,
2557,122558,"4,9-Decadienal, 2,5,9-trimethyl-",CC(CC=C(C)CCCC(=C)C)C=O,,,,,,
2558,122559,"Uracil, 5-(dimethylamino)-1-ethyl-6-methyl-3-phenyl-",CCN1C(=C(C(=O)N(C1=O)C2=CC=CC=C2)N(C)C)C,,,,,,
2559,122560,"Uracil, 1-allyl-5-(dimethylamino)-6-methyl-3-phenyl-",CC1=C(C(=O)N(C(=O)N1CC=C)C2=CC=CC=C2)N(C)C,,,,,,
2560,122561,"(Isopropylidene)bis(4,1-phenyleneoxyethylene) dilaurate",CCCCCCCCCCCC(=O)OCCOC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OCCOC(=O)CCCCCCCCCCC,,,,,,
2561,122562,Theophylline diethanolamine,CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CO)NCCO,,,,,,
2562,122563,1-Acetyl-4-piperidone,CC(=O)N1CCC(=O)CC1,,,,,,
2563,122564,"1-Ethyl-2,2,6,6-tetramethylpiperidine",CCN1C(CCCC1(C)C)(C)C,,,,,,
2564,122565,"N-(4-Chloro-2,5-dimethoxyphenyl)-3-(phosphonooxy)naphthalene-2-carboxamide",COC1=CC(=C(C=C1NC(=O)C2=CC3=CC=CC=C3C=C2OP(=O)(O)O)OC)Cl,,,,,,
2565,122566,"2-Naphthalenecarboxamide, N-[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]-1-hydroxy-",CCC(C)(C)C1=CC(=C(C=C1)OCCCCNC(=O)C2=C(C3=CC=CC=C3C=C2)O)C(C)(C)CC,,,,,,
2566,122567,"2-Naphthalenecarboxamide, 4-[(2-acetylphenyl)azo]-N-[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]-1-hydroxy-",CCC(C)(C)C1=CC(=C(C=C1)OCCCCNC(=O)C2=C(C3=CC=CC=C3C(=C2)N=NC4=CC=CC=C4C(=O)C)O)C(C)(C)CC,,,,,,
2567,122568,"Phenol, 4-(((4-butoxyphenyl)methylene)amino)-",CCCCOC1=CC=C(C=C1)C=NC2=CC=C(C=C2)O,,,,,,
2568,122569,"2,3-dihydro-1H-inden-4-amine",C1CC2=C(C1)C(=CC=C2)N,,,,,,
2569,122570,"3-Hydroxy-2,4-dimethoxybenzaldehyde",COC1=C(C(=C(C=C1)C=O)OC)O,,,,,,
2570,122571,CID 122571,C1=CC=NC(=C1)C(C2=CC=CC=N2)C(=N)S.Cl.Cl,,,,,,
2571,122572,CID 122572,C1=CC=NC(=C1)C(C2=CC=CC=N2)C(=N)S,,,,,,
2572,122573,"3,5-Bis(trifluoromethyl)benzyl bromide",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)CBr,,,,,,
2573,122574,"Phosphonic acid, (hydroxyphenylmethylene)bis-, tetramethyl ester",COP(=O)(C(C1=CC=CC=C1)(O)P(=O)(OC)OC)OC,,,,,,
2574,122575,"Uracil, 1-cyclohexyl-3,6-dimethyl-5-morpholino-",CC1=C(C(=O)N(C(=O)N1C2CCCCC2)C)N3CCOCC3,,,,,,
2575,122576,"2,4-Diethylthiazole",CCC1=CSC(=N1)CC,,,,,,
2576,122577,"S,S-Bis(1-phenyl-1H-tetrazol-5-yl) dithiocarbonate",C1=CC=C(C=C1)N2C(=NN=N2)SC(=O)SC3=NN=NN3C4=CC=CC=C4,,,,,,
2577,122578,"Cupric 2,2-dimethyloctanoate",CCCCCCC(C)(C)C(=O)[O-].CCCCCCC(C)(C)C(=O)[O-].[Cu+2],,,,,,
2578,122579,"2,9-Bis(3-aminophenyl)anthra(2,1,9-def:6,5,10-d'e'f')diisoquinoline-1,3,8,10(2H,9H)-tetrone",C1=CC(=CC(=C1)N2C(=O)C3=C4C(=CC=C5C4=C(C=C3)C6=C7C5=CC=C8C7=C(C=C6)C(=O)N(C8=O)C9=CC=CC(=C9)N)C2=O)N,,,,,,
2579,122580,"Anthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-1,3,8,10(2H,9H)-tetrone, 2,9-bis(4-methylphenyl)-",CC1=CC=C(C=C1)N2C(=O)C3=C4C(=CC=C5C4=C(C=C3)C6=C7C5=CC=C8C7=C(C=C6)C(=O)N(C8=O)C9=CC=C(C=C9)C)C2=O,,,,,,
2580,122581,"2-Formyl-3,5-dihydroxyphenyl benzoate",C1=CC=C(C=C1)C(=O)OC2=CC(=CC(=C2C=O)O)O,,,,,,
2581,122582,"((5-((Diphenylphosphino)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)(diphenyl)phosphine",CC1(OC(C(O1)CP(C2=CC=CC=C2)C3=CC=CC=C3)CP(C4=CC=CC=C4)C5=CC=CC=C5)C,,,,,,
2582,122583,"Benzenamine, 4,4'-(methoxyphenylmethylene)bis[N,N-dimethyl-",CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)N(C)C)OC,,,,,,
2583,122584,"Hexamethylbenzene-alpha1,alpha4-diamine",CC1=C(C(=C(C(=C1CN)C)C)CN)C,,,,,,
2584,122585,Zirconium telluride,[Zr](=[Te])=[Te],,,,,,
2585,122586,N1-(5-Methoxyisoxazol-3-yl)sulphanilamide,COC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
2586,122587,"Tris(1,2-dimethylpropyl)borane",B(C(C)C(C)C)(C(C)C(C)C)C(C)C(C)C,,,,,,
2587,122588,"3-Methyl-3,4-dihydro-2h-1,3-benzoxazine",CN1CC2=CC=CC=C2OC1,,,,,,
2588,122589,"2-Naphthalenecarboxamide, 4-[(2,5-dichlorophenyl)azo]-3-hydroxy-N-(2-methylphenyl)-",CC1=CC=CC=C1NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=C(C=CC(=C4)Cl)Cl,,,,,,
2589,122590,CID 122590,C1=CC=C(C=C1)CNC2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
2590,122591,(2-Hydroxyethyl)triethylammonium bromide benzilate,CC[N+](CC)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
2591,122592,"Triethyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]azanium",CC[N+](CC)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
2592,122593,Diammonium 4-nitrophenyl phosphate,C1=CC(=CC=C1[N+](=O)[O-])OP(=O)([O-])[O-].[NH4+].[NH4+],,,,,,
2593,122594,"3,5-Dimethyl-2-propylpyrazine",CCCC1=NC=C(N=C1C)C,,,,,,
2594,122595,"Acetaldehyde, O,O'-[(2-methoxyethoxy)methylsilylene]dioxime",CC=NO[Si](C)(OCCOC)ON=CC,,,,,,
2595,122596,"Phosphorodithioic acid, S-(2-(p-chlorophenylthio)ethyl) O,O-dimethyl ester",COP(=S)(OC)SCCSC1=CC=C(C=C1)Cl,,,,,,
2596,122597,"NF-4,5-Dione",C1=CC2=C(C3=C1C=CC(=O)C3=O)OC=C2,,,,,,
2597,122598,"Phenol, 2-(1,1-dimethylethyl)-5-pentadecyl-",CCCCCCCCCCCCCCCC1=CC(=C(C=C1)C(C)(C)C)O,,,,,,
2598,122599,"Phenol, 2,4-bis(1,1-dimethylethyl)-5-pentadecyl-",CCCCCCCCCCCCCCCC1=CC(=C(C=C1C(C)(C)C)C(C)(C)C)O,,,,,,
2599,122600,Octadecyl methacrylate,CCCCCCCCCCCCCCCCCCOC(=O)C(=C)C,,,,,,
2600,122601,"2-Isopropyl-2,5,5-trimethyl-1,3-dioxane",CC(C)C1(OCC(CO1)(C)C)C,,,,,,
2601,122602,"1,3-Dioxane, 2-(1,1-dimethylethyl)-2,5,5-trimethyl-",CC1(COC(OC1)(C)C(C)(C)C)C,,,,,,
2602,122603,"6-Methoxy-2,3-dimethylquinoxalin-5-amine",CC1=C(N=C2C(=N1)C=CC(=C2N)OC)C,,,,,,
2603,122604,4-(Methylsulfanyl)butanoic acid,CSCCCC(=O)O,,,,,,
2604,122605,"Ethyl 3,4-dimethoxymandelate",CCOC(=O)C(C1=CC(=C(C=C1)OC)OC)O,,,,,,
2605,122606,"(2,5-Dihydroxy-3,6-dimethyl-1,4,2,5-dioxadiphosphorinane-3,6-diyl)bisphosphonic acid P,P'-dioxide",CC1(OP(=O)(C(OP1(=O)O)(C)P(=O)(O)O)O)P(=O)(O)O,,,,,,
2606,122607,"4-[5-(3-Carboxy-5-hydroxy-1-phenyl-1H-pyrazol-4-yl)-2,4-pentadien-1-ylidene]-4,5-dihydro-5-oxo-1-phenyl-1H-pyrazole-3-carboxylic acid",C1=CC=C(C=C1)N2C(=O)C(=C(N2)C(=O)O)C=CC=CC=C3C(=NN(C3=O)C4=CC=CC=C4)C(=O)O,,,,,,
2607,122608,"4-[5-[5-carboxy-3-oxo-2-(4-sulfophenyl)-1H-pyrazol-4-yl]penta-2,4-dienylidene]-5-oxo-1-(4-sulfophenyl)pyrazole-3-carboxylic acid",C1=CC(=CC=C1N2C(=O)C(=C(N2)C(=O)O)C=CC=CC=C3C(=NN(C3=O)C4=CC=C(C=C4)S(=O)(=O)O)C(=O)O)S(=O)(=O)O,,,,,,
2608,122609,"4-[3-[3-Carboxy-5-hydroxy-1-(4-sulfophenyl)-1H-pyrazol-4-yl]-2-propenylidene]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid",C1=CC(=CC=C1N2C(=O)C(=C(N2)C(=O)O)C=CC=C3C(=NN(C3=O)C4=CC=C(C=C4)S(=O)(=O)O)C(=O)O)S(=O)(=O)O,,,,,,
2609,122610,CID 122610,C1CCC(CC1)NC(=NCCCOCCO)S,,,,,,
2610,122611,2-[(4-chloro-2-nitrophenyl)azo]-N-(4-chloro-o-tolyl)-3-oxobutyramide,CC1=C(C=CC(=C1)Cl)NC(=O)C(C(=O)C)N=NC2=C(C=C(C=C2)Cl)[N+](=O)[O-],,,,,,
2611,122612,Bis(methacryloyloxyethyl) hydrogen phosphate,CC(=C)C(=O)OCCOP(=O)(O)OCCOC(=O)C(=C)C,,,,,,
2612,122613,N-((5-(Dimethylamino)-1-naphthyl)sulphonyl)-L-cystine,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NC(CSSCC(C(=O)O)N)C(=O)O,,,,,,
2613,122614,CID 122614,CCCCCC1=NN=C(N1NC(=O)C2=CC=CC=C2)S,,,,,,
2614,122615,"2',3'-Dideoxy-2'-fluoroadenosine triphosphate",C1[C@H](O[C@H]([C@H]1F)N2C=NC3=C(N=CN=C32)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
2615,122616,"1,4-Dideoxy-1,4-iminomannitol",C1[C@H]([C@H]([C@H](N1)[C@H](CO)O)O)O,,,,,,
2616,122617,"2-Acetamido-1,2-Dideoxynojirmycin",CC(=O)N[C@H]1CN[C@@H]([C@H]([C@@H]1O)O)CO,,,,,,
2617,122618,"(2S,3R,4S,5R)-2-methylpiperidine-3,4,5-triol",C[C@H]1[C@H]([C@H]([C@@H](CN1)O)O)O,,,,,,
2618,122619,3'-Fluoro-3'-deoxyadenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)F)O)N,,,,,,
2619,122620,CID 122620,C1[C@@H]([C@@H]([C@@H]([C@@H]1N2C=NC3=C2NC(=NC3=O)N)O)O)CO,,,,,,
2620,122621,"1-Methyl-5-(3-azido-2,3-dideoxy-2-fluoro-beta-arabinofuranosyl)uracil",CN1C=C(C(=O)NC1=O)[C@H]2[C@H](C([C@H](O2)CO)N=[N+]=[N-])F,,,,,,
2621,122622,"1-Methyl-5-(3-azido-2,3-dideoxy-beta-pentofuranosyl)uracil",CN1C=C(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],,,,,,
2622,122623,Z-Pro-prolinal,C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)OCC3=CC=CC=C3)C=O,,,,,,
2623,122624,Z-Thiopro-thiazolidine,C1CSCN1C(=O)[C@@H]2CSCN2C(=O)OCC3=CC=CC=C3,,,,,,
2624,122625,"1-(3-Azido-2,3-dideoxy-2-fluoroarabinofuranosyl)thymine",CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)N=[N+]=[N-])F,,,,,,
2625,122626,CID 122626,C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=NC(=NC(=O)C3=C(N2)C(=O)O)N)O)O)O,,,,,,
2626,122627,"[3-azido-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl 1-methyl-4H-pyridine-3-carboxylate",CN1C=CCC(=C1)C(=O)OCC2C(CC(O2)N3C=CC(=O)NC3=O)N=[N+]=[N-],,,,,,
2627,122628,"Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-",CC1=C(SC2=NC(CN12)(C)C)C(=O)NCCC3=CC=CC=C3,,,,,,
2628,122629,CID 122629,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC1C(CC(O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
2629,122630,Haha-chlorambucil,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCCC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=CC(=O)NCC[C@]35C,,,,,,
2630,122631,"6-amino-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5H-imidazo[4,5-c]pyridin-4-one",C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2C(=O)NC(=C3)N)CO)O,,,,,,
2631,122632,"N,N-Dimethyl-2-((4'-(thien-2''-yl)pyrimidin-2'-yl)thio)ethylamine",CN(C)CCSC1=NC=CC(=N1)C2=CC=CS2,,,,,,
2632,122633,2-[4-(Diaminomethylidenehydrazinylidene)hexan-3-ylideneamino]guanidine,CCC(=NN=C(N)N)C(=NN=C(N)N)CC,,,,,,
2633,122634,4alpha-Phorbol 12-myristate 13-acetate,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C,,,,,,
2634,122635,Emodin anthrone,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2)C=C(C=C3O)O,,,,,,
2635,122636,3-Deaza-2'-deoxyadenosine,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2C=CN=C3N)CO)O,,,,,,
2636,122637,4'-Azidothymidine 5'-triphosphate,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@](O2)(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-])O,,,,,,
2637,122638,CID 122638,C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)OC)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)NC(=NCC[N+]4(CCOCC4)C)NC5CCCCC5)O,,,,,,
2638,122639,S-(2-Oxopentadecyl)-coenzyme A,CCCCCCCCCCCCCC(=O)CSCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
2639,122640,Decanoyl acetaldehyde,CCCCCCCCCC(=O)CC=O,,,,,,
2640,122641,3'-Acetamido-3'-deoxythymidine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)NC(=O)C,,,,,,
2641,122642,Adenylyl-(2'-5')-adenylyl-(2'-5')adenosine,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OC4C(C(OC4N5C=NC6=C(N=CN=C65)N)COP(=O)(O)OC7C(C(OC7N8C=NC9=C(N=CN=C98)N)CO)O)O)O)O)N,,,,,,
2642,122643,(+)-Aschantin,COC1=CC(=CC(=C1OC)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC5=C(C=C4)OCO5,,,,,,
2643,122644,2-Chloro-2'-deoxyadenosine triphosphate,C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
2644,122645,"2-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)-2-oxazoline",C1CCC2=CC=CC=C2C(C1)NC3=NCCO3,,,,,,
2645,122646,"3,3'-Methylenebis(5-chloro-2-hydroxybenzenesulphonic) acid",C1=C(C=C(C(=C1CC2=C(C(=CC(=C2)Cl)S(=O)(=O)O)O)O)S(=O)(=O)O)Cl,,,,,,
2646,122647,4-Aminophenyl alpha-D-mannopyranoside,C1=CC(=CC=C1N)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
2647,122648,"1-[4-Hydroxy-5-(isocyanomethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)C2CC(C(O2)C[N+]#[C-])O,,,,,,
2648,122649,"2',5'-Dideoxy-5'-isocyanouridine",[C-]#[N+]CC1C(CC(O1)N2C=CC(=O)NC2=O)O,,,,,,
2649,122650,"1-[4-Azido-5-(isocyanomethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)C2CC(C(O2)C[N+]#[C-])N=[N+]=[N-],,,,,,
2650,122651,Didemnin B,CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](C)O)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
2651,122652,[1-(6-Aminopurin-9-yl)-3-fluoropropan-2-yl]oxymethylphosphonic acid,C1=NC(=C2C(=N1)N(C=N2)CC(CF)OCP(=O)(O)O)N,,,,,,
2652,122653,5-Ethynyl-1-ribofuranosylimidazole-4-carboxamide,C#CC1=C(N=CN1C2C(C(C(O2)CO)O)O)C(=O)N,,,,,,
2653,122654,"[3-Azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl bis(4-nitrophenyl) phosphate",CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=O)(OC3=CC=C(C=C3)[N+](=O)[O-])OC4=CC=C(C=C4)[N+](=O)[O-])N=[N+]=[N-],,,,,,
2654,122655,CID 122655,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=O)(N[C@H](C)C(=O)OC)OC3=CC=CC=C3)N=[N+]=[N-],,,,,,
2655,122656,"5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-",C1CC2=NC(=C(N2C1)C3=CC=NC=C3)C4=CC=C(C=C4)F,,,,,,
2656,122657,"2-[[1-(2-Amino-1,3-thiazol-4-yl)-2-(2,2-dihydroxyethylamino)-2-oxoethylidene]amino]oxy-2-methylpropanoic acid",CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NCC(O)O,,,,,,
2657,122658,Tris(ethylenediamine)cobalt(III),C(CN)N.C(CN)N.C(CN)N.[Co+3],,,,,,
2658,122659,Mallotojaponin,CC1=C(C(=C(C(=C1OC)CC2=C(C(=C(C(=C2O)CC=C(C)C)O)C(=O)C)O)O)C(=O)C)O,,,,,,
2659,122660,"Gossylic nitrile-1,1'-diacetate",CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C#N)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C#N)O)O)C(C)C)OC(=O)C)OC(=O)C,,,,,,
2660,122661,"3-Amino-11-(3-amino-5,6-dihydroxy-10-methyl-7-propan-2-yl-2-oxatricyclo[6.3.1.04,12]dodeca-1(12),3,5,7,9-pentaen-11-ylidene)-10-methyl-7-propan-2-yl-2-oxatricyclo[6.3.1.04,12]dodeca-1(12),3,7,9-tetraene-5,6-dione",CC1=CC2=C(C(=C(C3=C(OC(=C23)C1=C4C(=CC5=C(C(=O)C(=O)C6=C(OC4=C56)N)C(C)C)C)N)O)O)C(C)C,,,,,,
2661,122662,CID 122662,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)O,,,,,,
2662,122663,"8-[7-Hydroxy-2-[2-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-9-(5-methoxy-6-methyloxan-2-yl)oxy-4,10-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2,4,6-trimethyl-5-oxonon-6-enoic acid",CC1CC(C(OC1C2CC(C3(O2)C(C(CC(O3)C4(CCC5(O4)CC(C(C(O5)C(C)C=C(C)C(=O)C(C)CC(C)C(=O)O)C)O)C)OC6CCC(C(O6)C)OC)C)C)(CO)O)C,,,,,,
2663,122664,CID 122664,C1=NC2=C(N1C3C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)CO)NC(=NC2=O)N,,,,,,
2664,122665,Thiazolobenzimidazole,C1C2=NC3=CC=CC=C3N2C(S1)C4=C(C=CC=C4F)F,,,,,,
2665,122666,"(2S,4S,5S)-N-butyl-6-cyclohexyl-4-hydroxy-5-[[(2S)-2-[[(2S)-2-(morpholin-4-ylsulfonylamino)-3-phenylpropanoyl]amino]pent-4-enoyl]amino]-2-propan-2-ylhexanamide",CCCCNC(=O)[C@@H](C[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC=C)NC(=O)[C@H](CC2=CC=CC=C2)NS(=O)(=O)N3CCOCC3)O)C(C)C,,,,,,
2666,122667,4'-Demethylpodophyllotoxin,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,,,,,,
2667,122668,Ethylbenzoprim,CCC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)N(CC)CC3=CC=CC=C3)[N+](=O)[O-],,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
2668,122669,"1,3-Di(4-imidazolinophenoxyl)propane",C1CN=C(N1)C2=CC=C(C=C2)OCCCOC3=CC=C(C=C3)C4=NCCN4,,,,,,
2669,122670,1H-Indole-5-carboximidamide,C1=CC2=C(C=CN2)C=C1C(=N)N,,,,,,
2670,122671,CID 122671,C1=C(C2=C(N1)C(=O)N=CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
2671,122672,Didesethyl Chloroquine,CC(CCCN)NC1=C2C=CC(=CC2=NC=C1)Cl,,,,,"['N,N-didesethylchloroquinone is a known human metabolite of Monodesethylchloroquine.']",
2672,122673,"2,6-Bis(dimethylamino)-4,8-bis(cyclohexylamino)pyrimido(5,4-d)pyrimidine",CCN(CC)C1=NC2=C(C(=N1)NC3CCCCC3)N=C(N=C2NC4CCCCC4)N(CC)CC,,,,,,
2673,122674,"N,5-Bis(4-chlorophenyl)-3-(ethylimino)-3,5-dihydro-2-phenazinamine",CCN=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,,,,,,
2674,122675,CID 122675,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN=CN3CCCCC3)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2675,122676,Antibiotic BBK 311,CNC[C@@H]1C[C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)O)O,,,,,,
2676,122677,CID 122677,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN(C)C)C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2677,122678,CID 122678,CCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2678,122679,O-Carbamyl-D-serine,C([C@H](C(=O)O)N)OC(=O)N,,,,,,
2679,122680,CID 122680,C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2C(=C(N5C)C)C(=O)C)O)C,,,,,,
2680,122681,Atalaphillinine,CC(=CCC1=C2C(=C3C(=C1O)C(=O)C4=C(N3)C(=CC=C4)O)C=CC(O2)(C)C)C,,,,,,
2681,122682,"4-Amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine",C1=C(C2=C(N=CN=C2N1COCCO)N)Br,,,,,,
2682,122683,3-Methoxysampangine,COC1=CN=C2C3=CC=CC=C3C(=O)C4=NC=CC1=C24,,,,,,
2683,122684,"N,N-Dimethylpradimicin C",CC1C(C(C(C(O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)N(C)C,,,,,,
2684,122685,"1,5-Dicaffeoylquinic acid",C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)O)O,,,['Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)'],,,
2685,122686,4-Acetylphenyloxooxazolidinylmethylacetamide,CC(=O)C1=CC=C(C=C1)N2CC(OC2=O)CNC(=O)C,,,,,,
2686,122687,"(S)-7,8-Dihydro-8-oxoadenosine 5'-(methyl (2-pyrrolidinylcarbonyl)phosphoramidate)",COP(=O)(NC(=O)[C@@H]1CCCN1)OCC2C(C(C(O2)N3C4=NC=NC(=C4NC3=O)N)O)O,,,,,,
2687,122688,3-[(2-Amino-3-methylpentanoyl)amino]-5-(6-aminopurin-9-yl)-4-hydroxyoxolane-2-carboxylic acid,CCC(C)C(C(=O)NC1C(C(OC1C(=O)O)N2C=NC3=C(N=CN=C32)N)O)N,,,,,,
2688,122689,"1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-oxidopyrazin-4-ium-2-one",C1=C[N+](=CC(=O)N1C2C(C(C(O2)CO)O)O)[O-],,,,,,
2689,122690,Astragaloside A,C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O[C@H]7C([C@H](C([C@H](O7)CO)O)O)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O,,,,,,
2690,122691,Lysicamine,COC1=C(C2=C3C(=C1)C=CN=C3C(=O)C4=CC=CC=C42)OC,,,,,,
2691,122692,"2-Bromo-5-(3,7-dimethylocta-2,6-dienyl)hydroquinone",CC(=CCCC(=CCC1=CC(=C(C=C1O)Br)O)C)C,,,,,,
2692,122693,"1H-Imidazole,1-[2-(2,4-dichlorophenyl)-2-[[(2E)-3,7-dimethyl-2,6-octadien-1-yl]oxy]ethyl]-",CC(=CCCC(=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl)C)C,,,,,,
2693,122694,"3,4-Dihydroxy-5-(1,2,3,4,5-pentahydroxy-6,20,20-trimethylhenicosa-8,10,14,16-tetraenyl)oxolan-2-one",CC(CC=CC=CCCC=CC=CCCC(C)(C)C)C(C(C(C(C(C1C(C(C(=O)O1)O)O)O)O)O)O)O,,,,,,
2694,122695,"2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid",CC1C(C(C(C(O1)O[C@@H]2C(C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(CO)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)O,,,,,,
2695,122696,CID 122696,CCCCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2696,122697,CID 122697,C[C@H]1C=CC=C(C(=O)N=C2C(=CNOCCCC3=CC=CC=C3)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2697,122698,CID 122698,C[C@H]1C=CC=C(C(=O)N=C2C(=CNOC(C3=CC=CC=C3)C4=CC=CC=C4)C(=C5C(=C2O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2698,122699,CID 122699,CCCCCCCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2699,122700,CID 122700,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3C(CN(CC3C)CC4=CC=CC=C4)C)C(=C5C(=C2O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2700,122701,CID 122701,CCCCCCCCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2701,122702,CID 122702,CCCCCCCCCCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2702,122703,CID 122703,CCCCCCCCCCONC=C1C(=C2C3=C(C1=NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2703,122704,CID 122704,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3CCCCCCCCCCCCCCC3)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2704,122705,CID 122705,C[C@@H]1C[C@@H]([C@H]2C(=C1)C=C[C@]3([C@@]2(C(=O)C[C@@H](O3)O)C)C)OC(=O)C(C)C(C(=CC=CC(=CC=CC(=O)O)C)C)O,,,,,,
2705,122706,CID 122706,C[C@H]1C[C@@H]([C@H]2C(=C1)C=C[C@@]3([C@@]2(C(=O)C[C@@H](O3)O)C)C)OC(=O)C(C)C(C(=CC=CC(=CC=CC(=O)O)C)C)O,,,,,,
2706,122707,"2',3'-Dideoxycytidine diphosphoethanolamine",C1CC(OC1COP(=O)(O)OP(=O)(O)OCCN)N2C=CC(=NC2=O)N,,,,,,
2707,122708,"Pyrazinecarboxylic acid, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C1=NC=CN=C1,,,,,,
2708,122709,"Pyrazinecarboxylic acid, 2,2,2-trifluoroethyl ester",C1=CN=C(C=N1)C(=O)OCC(F)(F)F,,,,,,
2709,122710,Bis(trifluoromethyl)methyl pyrazinoate,C1=CN=C(C=N1)C(=O)OC(C(F)(F)F)C(F)(F)F,,,,,,
2710,122711,Allyl pyrazinoate,C=CCOC(=O)C1=NC=CN=C1,,,,,,
2711,122712,"Pyrazinecarboxylic acid, p-nitrophenyl ester",C1=CC(=CC=C1[N+](=O)[O-])OC(=O)C2=NC=CN=C2,,,,,,
2712,122713,"Pyrazinecarboxylic acid, 4-methylphenyl ester",CC1=CC=C(C=C1)OC(=O)C2=NC=CN=C2,,,,,,
2713,122714,"Pyrazinecarboxylic acid, 4-(1,1-dimethylethyl)phenyl ester",CC(C)(C)C1=CC=C(C=C1)OC(=O)C2=NC=CN=C2,,,,,,
2714,122715,Pentafluorophenyl pyrazinoate,C1=CN=C(C=N1)C(=O)OC2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
2715,122716,Actinomycin C,CCC(C)C1C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C3=C(C(=O)C(=C4C3=NC5=C(C=CC(=C5O4)C)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)C)N)C)C(C)C)C)C,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2716,122717,"N-(N-(N-(N-(1-Naphthoxyacetyl)-histidyl)-5-amino-3,4-dihydroxy-2-isobutyl-7-methyloctanoyl)isoleucyl)-2-pyridylmethylamine",CC[C@H](C)[C@@H](C(=O)NCC1=CC=CC=N1)NC(=O)[C@@H](CC(C)C)[C@H]([C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)COC3=CC=CC4=CC=CC=C43)O)O,,,,,,
2717,122718,"1,3(2H,9bH)-Dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-, (9bS)-",CC1=C(C(=C2C(=C1O)[C@]3(C(=CC(=O)C(C3=O)C(=O)C)O2)C)C(=O)C)O,,,,,,
2718,122719,"(3R,4aR,12bS)-4a,8,12b-trihydroxy-9-[5-(5-hydroxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl]-3-methyl-3-[(6-methyl-5-oxo-2H-pyran-2-yl)oxy]-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",CC1C(CCC(O1)OC2CCC(OC2C)C3=C(C4=C(C=C3)C(=O)C5=C(C4=O)C=C[C@]6([C@@]5(C(=O)C[C@](C6)(C)OC7C=CC(=O)C(O7)C)O)O)O)O,,,,,,
2719,122720,Diosquinone,CC1=CC2=C(C(=C1)O)C(=O)C=C(C2=O)C3=C(C4=C(C=C3C)C(=O)C5C(C4=O)O5)O,,,,,,
2720,122721,3-Chloro-N-methylbenzylamine,CNCC1=CC(=CC=C1)Cl,,,,,,
2721,122722,(3-Nitrophenyl)methanamine,C1=CC(=CC(=C1)[N+](=O)[O-])CN,,,,,,
2722,122723,"1,2,12,20-Tetrahydroxypicras-3-ene-11,16-dione",CC1C2CC(=O)OC3C2(C(C(=O)C1O)C4(C(C3)C(=CC(C4O)O)C)C)CO,,,,,,
2723,122724,Celastrol,CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O,,,,,,
2724,122725,"methyl 11-[2-(3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl)-3-methoxy-3-oxopropyl]-16-methyl-17-oxa-3-aza-13-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(13),2(10),4,6,8,11,18-heptaene-19-carboxylate",CC=C1CN2CCC3=C(C2CC1C(CC4=C[N+]5=C(CC6C(C5)C(OC=C6C(=O)OC)C)C7=C4C8=CC=CC=C8N7)C(=O)OC)NC9=CC=CC=C39,,,,,,
2725,122726,cyclo[DL-Leu-DL-OVal-DL-Val-DL-N(Me)Leu-Unk-DL-Val],CC1CC(=O)NC(C(=O)NC(C(=O)OC(C(=O)NC(C(=O)N(C(C(=O)OC1)CC(C)C)C)C(C)C)C(C)C)CC(C)C)C(C)C,,,,,,
2726,122727,Nogalarol,CC1(CC(C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C5C(=CC(=C4C3=O)O)C6(C(C(C(C(O5)O6)O)N(C)C)O)C)O)O)O,,,,,,
2727,122728,"6,6'-Dimethoxy-2,2'-dimethyloxyacanthan-7,12'-diol",CN1CCC2=CC(=C(C3=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=CC(=C(C=C7CCN6C)OC)O3)O)O)OC,,,,,,
2728,122729,CID 122729,CC1C(C2C(C(C(C(C=CC=C(C(=O)NC3=C(C(=C4C(=C(C(=C5C4=C(C(=CC(C1O)(C)O)C)OCO5)C)O)C3=O)OC(=O)C)C)C)(C)O)OC2=O)C)O)O,,,,,,
2729,122730,CID 122730,C[C@@H]1[C@@H](C=CO[C@@]2(C(=O)C3=C(O2)C(=C(C4=C3C(=CC(=NC(=O)C(=CC(=O)[C@@H]5C[C@@H]5[C@@H]([C@H]([C@H]([C@H]([C@@H]1OC(=O)C)C)O)C)O)C)C4=O)N[C@@H]6CC[C@H](O[C@H]6C)O)O)C)C)OC,,,,,,
2730,122731,Virginiamycin S1,CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=CC=C6)C,,,,,,
2731,122732,2-O-Rhamnopyranosyl-rhamnopyranosyl-3-hydroxyldecanoyl-3-hydroxydecanoate,CCCCCCCC(CC(=O)O)OC(=O)CC(CCCCCCC)OC1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O,,,,,,
2732,122733,"1,5-Dimethyl-3-methylidene-4-oxo-6-oxabicyclo[3.1.0]hexane-2-carboxylic acid",CC12C(C(=C)C(=O)C1(O2)C)C(=O)O,,,,,,
2733,122734,Phacidin,CCCCCCCCC(=O)C1=C(OC(=CC1=O)C=O)OC,,,,,,
2734,122735,CID 122735,CCCC=CC=C[C@@H]1C[C@H]([C@H](C(=O)[C@H]1CO)O)O,,,,,,
2735,122736,"3-[(2,6-Dideoxy-3-o-methylhexopyranosyl)oxy]-14-hydroxycard-20(22)-enolide",CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CCC5C6=CC(=O)OC6)O)C)C)OC)O,,,,,,
2736,122737,Quinocarmycin analog,CN1C2CC(C1C3CC4=C(C(N3C2C#N)CO)C(=CC=C4)OC)C(=O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
2737,122738,Procyanidin B2,C1[C@H]([C@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)O)O)O)C6=CC(=C(C=C6)O)O)O,,,,,,
2738,122739,"[(3R,4a'R,5'S,7'R,9a'R)-2-Formyl-5'-hydroxy-3-methyl-8'-methylene-1',9'-dioxohexahydrospiro[cyclohexane-1,4'-[2]oxa[7,9a]methanocyclohepta[c]pyran]-3-yl]methyl acetate",CC(=O)OC[C@@]1(CCCC2(C1C=O)COC(=O)[C@@]34[C@@H]2[C@H](C[C@@H](C3)C(=C)C4=O)O)C,,,,,,
2739,122740,"(1R,4aR,6aS,7R,9aS)-7,8-dimethyl-2-oxospiro[4,4a,6a,7-tetrahydropentaleno[1,6a-c]pyran-1,2'-oxirane]-5-carboxylic acid",C[C@@H]1[C@@H]2C=C([C@H]3[C@]2(C=C1C)[C@@]4(CO4)C(=O)OC3)C(=O)O,,,,,,
2740,122741,CID 122741,C[C@H]1C=CC=C(C(=O)N=C2C(=CN=NC3=C(C=C(C=C3)N(O)O)[N+](=O)O)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)[O-])O)C,,,,,,
2741,122742,CID 122742,C[C@H]1C=CC=C(C(=O)N=C2C(=CN=NC3=C(C=C(C=C3)N(O)O)[N+](=O)O)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2742,122743,Sarnovide,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC2CCC3(C(C2)CCC4C3C(CC5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC)O,,,,,,
2743,122744,"[8-Hydroxy-6-(hydroxymethyl)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)OC1CC(=CC(CC(=CC2C1C(=C)C(=O)O2)C)O)CO,,,,,,
2744,122745,Neothramycin,COC1=C(C=C2C(=C1)C(=O)N3C(CCC3O)C=N2)O,,,,,,
2745,122746,"(2S)-2-[(2R,3S,4R,5R,6R)-5-ethyl-6-[(2R,3R,4S,6R)-6-[(2R,3R,5S)-5-[(2R,3R,5S)-5-ethyl-2-hydroxy-5-[(1S)-1-hydroxybutyl]-3-methyloxolan-2-yl]-3,5-dimethyloxolan-2-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-3-methyloxan-2-yl]butanoic acid",CCC[C@@H]([C@@]1(C[C@H]([C@@](O1)([C@@]2(C[C@H]([C@@H](O2)[C@@H](CC)C(=O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]3[C@@H]([C@H]([C@@H]([C@@](O3)([C@H](CC)C(=O)O)O)C)O)CC)O)C)C)O)C)CC)O,,,,,,
2746,122747,CID 122747,CC(=O)CC1CCC(=O)C=CC(=O)OC(CCC(=O)C=CC(=O)O1)CC(=O)C,,,,,,
2747,122748,Elatine (alkaloid),CCN1CC2(CC[C@H](C34C2[C@H](C5(C31)C6(C[C@@H](C7CC4C6[C@H]7OC)OC)OCO5)OC)OC)COC(=O)C8=CC=CC=C8N9C(=O)C[C@@H](C9=O)C,,,,,,
2748,122749,"3-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]benzamide",C1=CC(=CC(=C1)C(=O)N)C2C(C(C(O2)CO)O)O,,,,,,
2749,122750,CID 122750,CCC(=O)C1(C(O1)[C@H](C)C[C@@H](C)C2[C@@H](C([C@@H](C=C[C@@H](CCCC=C(C3C(=CCC(O3)(CC(=O)O2)O)C)C)OC4C[C@@H]([C@H]([C@H](O4)C)O)OC(=O)N)C)O)C)C,,,,,,
2750,122751,"9,10-Anthracenedione, 1-amino-4-[(4-methylphenyl)amino]-",CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)N)C(=O)C4=CC=CC=C4C3=O,,,,,,
2751,122752,alpha-Methyl-1-naphthaleneacetic acid,CC(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2752,122753,4-Methylbenzamidine hydrochloride,CC1=CC=C(C=C1)C(=N)N.Cl,,,,,,
2753,122754,4-Methylbenzenecarboximidamide,CC1=CC=C(C=C1)C(=N)N,,,,,,
2754,122755,Glycine methyl ester hydrochloride,COC(=O)CN.Cl,,,,,,
2755,122756,Benzyltriethylammonium iodide,CC[N+](CC)(CC)CC1=CC=CC=C1.[I-],,,,,,
2756,122757,alpha-Hydrazinopropionic acid,CC(C(=O)O)NN,,,,,,
2757,122758,1-(p-Bromophenyl)-2-methyl-5-phenylpyrrole,CC1=CC=C(N1C2=CC=C(C=C2)Br)C3=CC=CC=C3,,,,,,
2758,122759,2-(carbamoylamino)-3-(1H-indol-3-yl)propanoic acid,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)NC(=O)N,,,,,,
2759,122760,"2,5-Diamino-1,3,4-thiadiazole",C1(=NN=C(S1)N)N,,,,,,
2760,122761,2-(p-Dimethylaminophenyl)quinoline,CN(C)C1=CC=C(C=C1)C2=NC3=CC=CC=C3C=C2,,,,,,
2761,122762,Ddcdp choline,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1CCC(O1)N2C=CC(=NC2=O)N,,,,,,
2762,122763,2-[[[5-(4-Amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxyethyl-trimethylazanium,C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OCC1CCC(O1)N2C=CC(=NC2=O)N,,,,,,
2763,122764,2-Aminoindan hydrochloride,C1C(CC2=CC=CC=C21)N.Cl,,,,,,
2764,122765,4-Aminobenzamidine hydrochloride,C1=CC(=CC=C1C(=N)N)N.Cl,,,,,,
2765,122766,1-Methyl-5-oxopyrrolidine-3-carboxylic acid,CN1CC(CC1=O)C(=O)O,,,,,,
2766,122767,(S)-(((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid,C[C@@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,,,,,,
2767,122768,2-Iodohistidine,C1=C(NC(=N1)I)CC(C(=O)O)N,,,,,,
2768,122769,CID 122769,C[C@H]1[C@H](O[C@](CC1=C)([C@@H](C(=O)NC2[C@@H]3[C@@H]([C@H](C([C@H](O3)C[C@@H](CCCC=CC=CC=CC(=O)NC(CCCN=C(N)N)C(=O)O)O)(C)C)OC)OCO2)O)OC)C,,,,,,
2769,122770,"(2S)-N-[(4aS,6R,8S,8aR)-6-(2,3-dihydroxypropyl)-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide",C[C@H]1[C@H](O[C@](CC1=C)([C@@H](C(=O)NC2[C@@H]3[C@@H]([C@H](C([C@H](O3)CC(CO)O)(C)C)OC)OCO2)O)OC)C,,,,,,
2770,122771,CID 122771,CN1C2=C(C(=O)C=CC2=C(C3=C1C(=C(C(=C3O)OC)OC)OC)O)OC,,,,,,
2771,122772,Liriodenine methiodide,C[N+]1=C2C3=C(C4=CC=CC=C4C2=O)C5=C(C=C3C=C1)OCO5.[I-],,,,,,
2772,122773,"11-Methyl-3,5-dioxa-11-azoniapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,9,11,14,16,18-octaen-13-one",C[N+]1=C2C3=C(C4=CC=CC=C4C2=O)C5=C(C=C3C=C1)OCO5,,,,,,
2773,122774,2-Hydroxypyrimidine hydrochloride,C1=CNC(=O)N=C1.Cl,,,,,,
2774,122775,"4-[2-(3,4,5-Trimethoxyphenyl)ethyl]benzene-1,2-diol",COC1=CC(=CC(=C1OC)OC)CCC2=CC(=C(C=C2)O)O,,,,,,
2775,122776,"Phenol, 2-methoxy-5-[(1E)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]-",COC1=C(C=C(C=C1)C=CC2=CC3=C(C(=C2)OC)OCO3)O,,,,,,
2776,122777,"3-Methoxy-6-[2-(3,4,5-trimethoxyphenyl)ethenyl]benzene-1,2-diol",COC1=C(C(=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O)O,,,,,,
2777,122778,CID 122778,C1CNC(=O)C2=C(C1=C3C(=O)N=C(N3)N)C=C(N2)Br,,,,,,
2778,122779,"[(2R,3S,4R,6S)-6-[(2'R,3'S,3aR,4R,4'S,6S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(2R,3aS,6S,6'R,7R,7'S,7aR)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4'-hydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-hydroxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2[C@H](OC3(C[C@@H]2O)O[C@@H]4[C@H](O[C@H](C[C@]4(O3)C)O[C@@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OC)C)O[C@@H]6[C@H](O[C@H]([C@H]([C@H]6O)OC)O[C@H]7[C@@H]([C@H]8[C@H](CO7)O[C@@]9(O8)C1C([C@@]([C@H](O9)C)(C(=O)C)O)OCO1)OC(=O)C(C)C)COC)O)C)C)O)OC(=O)C1=C(C(=C(C(=C1OC)Cl)O)Cl)C,,,,,,
2779,122780,CID 122780,C[C@@H]1C[C@@]23[C@@H](C=CCCCC[C@@H]4C=C[C@H]5[C@H]([C@@]4(C(=O)OC(=C(O2)O)C3=O)C)CCC[C@@H]5OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC(=O)C8=C(C=CC(=C8C)Cl)OC)O)C=C1C(=O)O,,,,,,
2780,122781,"[(2R,3S,4S,5R,7S,9S,10S,11R,12S,13R)-12-(5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-7-hydroxy-2-(3-hydroxybutan-2-yl)-10-(3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-oxacyclotetradec-4-yl] acetate",C[C@H]1C[C@](C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1OC2C(C(CC(O2)C)OC)O)C)OC3CC(C(C(O3)C)OC(=O)C)(C)OC)C)C(C)C(C)O)C)OC(=O)C)C)(C)O,,,,,,
2781,122782,CID 122782,CC(=CCCC(=CCCC(=CCC1=C(OC2=CC=CC=C2C1=O)O)C)C)C,,,,,,
2782,122783,8-Hydroxycoumarin,C1=CC2=C(C(=C1)O)OC(=O)C=C2,,,,,,
2783,122784,Bruceine D,CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@@]([C@@]4([C@H](C(=O)O3)O)O)(OC5)C)O)O)C)O,,,,,,
2784,122785,Brucein E,CC1=C[C@@H]([C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@@]([C@@]4([C@H](C(=O)O3)O)O)(OC5)C)O)O)C)O)O,,,,,,
2785,122786,CID 122786,C[C@@H]1CC(C(=O)[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H](C(C([C@@H]4C(C(=O)O3)OC(=O)C=C(C)C(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
2786,122787,Stigmastanyl-phosphocholine,CCC(CCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)OP(=O)([O-])OCC[N+](C)(C)C)C)C)C(C)C,,,,,,
2787,122788,"2-[[17-(5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCC(CCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)OP(=O)(O)OCC[N+](C)(C)C)C)C)C(C)C,,,,,,
2788,122789,"Anthracene-9,10-diylbis(methylene)dicarbamimidothioatedihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2CSC(=N)N)CSC(=N)N.Cl.Cl,,,,,,
2789,122790,"Carbamimidothioic acid, 9,10-anthracenediylbis(methylene) ester",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2CSC(=N)N)CSC(=N)N,,,,,,
2790,122791,Peritoxin B,CCCC(C1(C(C1C(=O)NC(CC(=O)O)C(=O)NC2C(CC(CNC2=O)N)O)C(C(=O)O)Cl)Cl)Cl,,,,,,
2791,122792,Amorphin Flavonoid,COC1=C(C=C2C(=C1)C3C(CO2)OC4=C(C3=O)C=CC5=C4CC(O5)C(=C)CO[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@H]([C@@H]([C@H](O7)CO)O)O)OC,,,,,,
2792,122793,CID 122793,COC1=CC=C(C=C1)C2=COC3=CC(=O)C(=CC3=C2O)OC,,,,,,
2793,122794,CID 122794,CC(=CCCC(=CCCC=C(C)CCC=C(C)CCC1C(O1)(C)C)C)CCCN(C)C,,,,,,
2794,122795,Pradimicin A ethyl ester,CCOC(=O)[C@@H](C)NC(=O)C1=C(C2=C(C=C1C)[C@@H]([C@H](C3=CC4=C(C(=C32)O)C(=O)C5=C(C4=O)C(=CC(=C5)OC)O)O)OC6C(C(C(C(O6)C)NC)OC7C(C(C(CO7)O)O)O)O)O,,,,,,
2795,122796,"3-Quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-",C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)F)N4CCC(C4)N)F)C(=O)O,,,,,,
2796,122797,4'-Demethylepipodophyllotoxin,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O,,,,,,
2797,122798,"10-(4-Amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-3,7,11-triethyl-azacyclotetradecan-2-one",CCC1CCCC(C(=O)NCCCC(C(CC1)OC2C(C(C(C(O2)C)O)N)O)CC)CC,,,,,,
2798,122799,Actinomycin vii,CCC(C)C1C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)CC)C)C)C(C)C)C)N)C)C)C(C)C)C)C,,,,,,
2799,122800,"Hetisan-6,11-beta,15-beta-triol",C[C@]12CCC[C@@]34[C@H]1[C@@]5(CC67[C@@H]3[C@@H](C(CC6C4N5C2)C(=C)[C@@H]7O)O)O,,,,,,
2800,122801,"[(1S,2R,4S,10R,11R,16R)-6-(Furan-3-yl)-1,7,11,15,15-pentamethyl-5,14-dioxo-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadec-12-en-18-yl] acetate",CC(=O)OC1C[C@@H]2[C@](C=CC(=O)C2(C)C)([C@@H]3[C@@]1([C@]45[C@H](O4)C(=O)C(C5(CC3)C)C6=COC=C6)C)C,,,,,,
2801,122802,Cinerubine A,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C=CC(=C4C3=O)O)O)O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O,,,,,,
2802,122803,Macrozamin,C[N+](=NCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H](CO2)O)O)O)O)O)O)[O-],,,,,,
2803,122804,Bleomycin pep-CU (formerly),CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNC(C)C7=CC=CC=C7)O.OS(=O)(=O)O,,,,,,
2804,122805,Retrochinensin,COC1=C(C=C(C=C1)C2=C3C=C4C(=CC3=CC5=C2COC5=O)OCO4)OC,,,,,,
2805,122806,Olivomycin A,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@H]2[C@@H](CC3=CC4=CC(=CC(=C4C(=C3C2=O)O)O)O[C@H]5C[C@H]([C@H]([C@H](O5)C)OC(=O)C)O[C@@H]6C[C@H]([C@H]([C@H](O6)C)OC)O)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@H]([C@@H](O8)C)OC(=O)C(C)C)(C)O)O,,,,,,
2806,122807,CID 122807,CC1=CCC[C@@]([C@@H]2C[C@H](CC[C@@]3([C@H](O3)CC1)C)C(=C)C(=O)O2)(C)O,,,,,,
2807,122808,Pacifenol,CC1(C23CC(C(CC2OC1(C=CC3(C)O)Br)(C)Cl)Br)C,,,,,,
2808,122809,"6H-Benzocyclohepten-6-one, 1,2,3,4-tetrahydro-5,7-dihydroxy-9-methyl-2-(1-methylethenyl)-, (R)-",CC1=CC(=C(C2=C1CCC(C2)C(=C)C)C(=O)O)O,,,,,,
2809,122810,"16-Butan-2-yl-10,11,14-trimethyl-13-propan-2-yl-3-prop-2-enyl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone",CCC(C)C1C(=O)N(C(C(=O)N(C(C(=O)NCCC(=O)OC(C(=O)N2CCCC2C(=O)N1)CC=C)C)C)C(C)C)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
2810,122811,NCGC00385184-01_C32H36N2O5_chaetoglobin A,C[C@H]1CC=C[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2(C(=O)C=CC(=O)[C@@H](C(=C1)C)O)C(=O)N[C@H]4CC5=CNC6=CC=CC=C65)C)C,,,,,,
2811,122812,Gynocardin,C1=CC(C(C1O)O)(C#N)OC2C(C(C(C(O2)CO)O)O)O,,,,,,
2812,122813,"methyl (1R,4aR,10aR)-1-methyl-2'-oxospiro[1,4a,5,5a,7,8,10,10a-octahydropyrano[3,4-f]indolizine-6,3'-1H-indole]-4-carboxylate",C[C@@H]1[C@H]2CN3CCC4(C3C[C@H]2C(=CO1)C(=O)OC)C5=CC=CC=C5NC4=O,,,,,,
2813,122814,CID 122814,CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=CC(C1OC)C2O)O)C)C)OC(=O)N)C)C)OC)OC,,,,,,
2814,122815,Albacarcin V,CC1C(C(C(C(O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C=C)OC)OC)O)(C)O)O,,,,,,
2815,122816,Amethyst Violet,CCN(CC)C1=CC2=C(C=C1)N=C3C=CC(=CC3=[N+]2C4=CC=CC=C4)N(CC)CC.[Cl-],,,,,,
2816,122817,"3,7-Bis(diethylamino)-5-phenylphenazin-5-ium",CCN(CC)C1=CC2=C(C=C1)N=C3C=CC(=CC3=[N+]2C4=CC=CC=C4)N(CC)CC,,,,,,
2817,122818,CID 122818,CN(C)C1=CC2=C(C=C1)NC3=C(O2)C(=O)C(=O)C=C3C(=[NH2+])O.[Cl-],,,,,,
2818,122819,"7-(dimethylamino)-3,4-dioxo-10H-phenoxazine-1-carboxamide",CN(C)C1=CC2=C(C=C1)NC3=C(O2)C(=O)C(=O)C=C3C(=O)N,,,,,,
2819,122820,Clospirazine hydrochloride,C1CN(CCC12NC(=O)CS2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl.Cl,,,,,,
2820,122821,Heminordihydroguaiaretic acid,C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)OC,,,,,,
2821,122822,CID 122822,COC(=C1C=C2C3=CC=CC=C3N=C2C(=C(O)OC)C=C4C1=NC5=CC=CC=C54)O,,,,,,
2822,122823,CID 122823,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4C[C@H](C5(C4)CCC5)N)F)C(=O)O,,,,,,
2823,122824,Ethopropazine hydrochloride,CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE. (See all compounds classified as Adrenergic Antagonists.)', 'Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
2824,122825,"2,4-Diethyl-9H-thioxanthen-9-one",CCC1=CC(=C2C(=C1)C(=O)C3=CC=CC=C3S2)CC,,,,,,
2825,122826,Aaptamine,COC1=C(C2=NC=CC3=C2C(=C1)C=CN3)OC,,,,,,
2826,122827,5-Ethyl-1-(ethoxymethyl)-6-(phenylselenenyl)uracil,CCC1=C(N(C(=O)NC1=O)COCC)[Se]C2=CC=CC=C2,,,,,,
2827,122828,CID 122828,CCOP(=O)(COCON1C=NC2=C1NC(=NC2=O)N)O,,,,,,
2828,122829,"2,3,4,5-Tetrabromo-6-[(4-hydroxyphenyl)-(4-oxocyclohexa-2,5-dien-1-ylidene)methyl]benzenesulfonic acid",C1=CC(=O)C=CC1=C(C2=CC=C(C=C2)O)C3=C(C(=C(C(=C3Br)Br)Br)Br)S(=O)(=O)O,,,,,,
2829,122830,4-Amino-2-(benzylthio)-6-chloropyrimidine,C1=CC=C(C=C1)CSC2=NC(=CC(=N2)Cl)N,,,,,,
2830,122831,5-Methylpyrazine-2-carboxylic Acid,CC1=CN=C(C=N1)C(=O)O,,,,,,
2831,122832,"3-Quinolinecarboxylic acid, 1,4-dihydro-1-(1,1-dimethylethyl)-6-fluoro-4-oxo-7-(1-piperazinyl)-",CC(C)(C)N1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,,,,,,
2832,122833,"(S)-5-methyl-3-((2R,8R,13R)-2,8,13-trihydroxy-13-((2R,5R)-5-((R)-1-hydroxytridecyl)tetrahydrofuran-2-yl)tridecyl)furan-2(5H)-one",CCCCCCCCCCCCC(C1CCC(O1)COCCCCC(CCCCCC(CC2=CC(OC2=O)C)O)O)O,,,,,,
2833,122834,"4-[(3S)-3-ethenyl-3,7-dimethylocta-1,6-dienyl]phenol",CC(=CCC[C@@](C)(C=C)C=CC1=CC=C(C=C1)O)C,,,,,,
2834,122835,7-O-Methylbavachin,CC(=CCC1=CC2=C(C=C1OC)OC(CC2=O)C3=CC=C(C=C3)O)C,,,,,,
2835,122836,Curcuphenol,CC1=CC(=C(C=C1)C(C)CCC=C(C)C)O,,,,,,
2836,122837,Pachydictyol A,CC1=CC[C@@H]2[C@@H]1[C@@H]([C@@H](CCC2=C)[C@H](C)CCC=C(C)C)O,,,,,,
2837,122838,Xestoquinone,C[C@@]12CCCC3=COC(=C31)C(=O)C4=C2C=C5C(=O)C=CC(=O)C5=C4,,,,,,
2838,122839,Sennidine A,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2C4C5=C(C(=CC=C5)O)C(=O)C6=C4C=C(C=C6O)C(=O)O)C=C(C=C3O)C(=O)O,,,,,,
2839,122840,Aloe emodin anthrone,C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=C(C=C3O)CO,,,,,,
2840,122841,Aspidinol,CCCC(=O)C1=C(C(=C(C=C1O)OC)C)O,,,,,,
2841,122842,Benzyl trisulfide,C1=CC=C(C=C1)CSSSCC2=CC=CC=C2,,,,,,
2842,122843,Calanolide F,CCCC1=CC(=O)OC2=C1C3=C(C=CC(O3)(C)C)C4=C2[C@H]([C@@H]([C@@H](O4)C)C)O,,,['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)'],,,
2843,122844,Betulonic acid,CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CCC(=O)C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)C)C(=O)O,,,,,,
2844,122845,"8-Chloro-10-[3-(dimethylamino)propyl]-3h-phenothiazine-2,3(10h)-dione",CN(C)CCCN1C2=CC(=O)C(=O)C=C2SC3=C1C=C(C=C3)Cl,,,,,,
2845,122846,Nothramicin,CC1C(C(CC(O1)OC2C(C(C(C3=CC4=C(C(=C23)O)C(=O)C5=C(C=CC(=C5C4=O)OC)O)O)(C)O)OC)(C)N(C)C)O,,,,,,
2846,122847,"2',3'-Dideoxy-2',3'-methanocytidine",C1[C@H]2[C@@H]1C(OC2CO)N3C=CC(=NC3=O)N,,,,,,
2847,122848,8-Fluorociprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)F)N4CCNCC4)F)C(=O)O,,,,,,
2848,122849,Npf-etoposide,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)NC6=CC=C(C=C6)F,,,,,,
2849,122850,Aromadendrin,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O,,,,,,
2850,122851,Licopyranocoumarin,CC1(CCC2=C(O1)C=C3C(=C2OC)C=C(C(=O)O3)C4=C(C=C(C=C4)O)O)CO,,,,,,
2851,122852,CID 122852,C[C@@H]1C23CCC4[C@](C2CCC1(OC3)O)(CC[C@@]5([C@@]4(CC[C@@]6(C5C[C@](CC6)(C)C(=O)O)C)C)C)C,,,,,,
2852,122853,ATCC 20928 factor B,CC1CCC2C(C(CCC2(C13CC4=C(O3)C=C(C(=C4O)C=O)CO)C)O)(C)C,,,,,,
2853,122854,"2-[2-(3,5-Dimethyl-2-oxoocta-4,6-dienyl)-6-oxooxan-4-yl]acetamide",CC=CC(=CC(C)C(=O)CC1CC(CC(=O)O1)CC(=O)N)C,,,,,,
2854,122855,CID 122855,CC(C)(C=C)[C@]12C=C(C(=O)N3C1(NC(=O)C3=CC4=CN=CN4)N(C5=CC=CC=C25)OC)OC,,,,,,
2855,122856,"(3S,4aR,6aR,6bR,8S,8aS,12S,12aS,12bR,14bR)-4,4,6a,6b,8a,11,12,14b-Octamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,12,12a,12b,13,14,14a,14b-eicosahydro-picene-3,8-diol",C[C@H]1[C@H]2[C@H]3CCC4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(C[C@@H]([C@]2(CC=C1C)C)O)C)C)(C)C)O)C,,,,,,
2856,122857,Germanicol,C[C@@]12CC[C@@]3([C@@H](C1=CC(CC2)(C)C)CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C,,,,,,
2857,122858,"(3S,4aR,6aR,6bS,8S,8aS,12aS,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-3,8-diol",C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3(C2CC=C4[C@]3(C[C@@H]([C@@]5([C@H]4CC(CC5)(C)C)C)O)C)C)(C)C)O,,,,,,
2858,122859,Daturaolone,C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(C[C@H]([C@@H]5[C@@]4(CCC(=O)C5(C)C)C)O)C)[C@@H]1CC(CC2)(C)C)C,,,,,,
2859,122860,"Eupha-8,24-dienol",C[C@H](CCC=C(C)C)C1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
2860,122861,"1,4b,6a,8,10a,12a-Hexamethyl-8-(4-methylpent-3-en-1-yl)hexadecahydrochrysen-2(1H)-one",C[C@H]1C(=O)CCC2[C@@]1(CCC3[C@]2(CC[C@@]4([C@@]3(CC[C@@](C4)(C)CCC=C(C)C)C)C)C)C,,,,,,
2861,122862,"9a-Methyl-3-octanoyl-6-prop-1-enylfuro[3,2-g]isochromene-2,9-dione",CCCCCCCC(=O)C1=C2C=C3C=C(OC=C3C(=O)C2(OC1=O)C)C=CC,,,,,,
2862,122863,CID 122863,CCC1C2C[C@H]3C(C2C=CCCCCCCCC(=O)O1)O3,,,,,,
2863,122864,"Scytonemin, Lyngbya sp.",C1=CC=C2C(=C1)C3=C(C(=O)C(=CC4=CC=C(C=C4)O)C3=N2)C5=C6C7=CC=CC=C7N=C6C(=CC8=CC=C(C=C8)O)C5=O,,,,,,
2864,122865,3-Hydroxydiploptene,CC(C)[C@H]1CCC2[C@@]1(CC[C@]3([C@]2(CC=C4C3CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C)C,,,,,,
2865,122866,1-Isonicotinyl-2-palmitoyl hydrazine,CCCCCCCCCCCCCCCC(=O)NNC(=O)C1=CC=NC=C1,,,,,,
2866,122867,CID 122867,C[C@H]1C=CC=C(C(=O)NC2=CC3(C4=C(C2=O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)OCC(=O)O3)C,,,,,,
2867,122868,CID 122868,CCN(CC)CC1=C2C(=C3C(=C1O)C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](C=CC=C(C(=O)N2)C)C)O)C)O)C)OC(=O)C)C)OC)C)O,,,,,,
2868,122869,"[(7S,11S,12R,13S,14R,15R,16R,17S,18S)-26-Formyl-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",C[C@H]1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=O)C,,,,,,
2869,122870,CID 122870,C[C@H]1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)O)C)OC)C)C)O)O)C=O)C,,,,,,
2870,122871,CID 122871,C[C@H]1C=CC=C(C(=O)NC2=C3C(=NC4=CC=CC=C4N3)C5=C(C2=O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)C,,,,,,
2871,122872,"(2S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol",CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3C(C(C(O3)CO)O)O)Cl)Cl,,,,,,
2872,122873,Cyclic-hpmpc,C1[C@@H](OCP(=O)(O1)O)CN2C=CC(=NC2=O)N,,,,,,
2873,122874,Imidodiphosphoric acid,N(P(=O)(O)O)P(=O)(O)O,,,,,,
2874,122875,CID 122875,CCC(=C(C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC=NN1C(=O)[C@H]([C@H](C)N)NC(=O)[C@@H](C)NC(=O)C(CO)(CO)N)C,,,,,,
2875,122876,"5,6,7,8-Tetramethoxyflavone",COC1=C(C(=C(C2=C1C(=O)C=C(O2)C3=CC=CC=C3)OC)OC)OC,,,,,,
2876,122877,Meta-tetrahydroxyphenylporphyrin,C1=CC(=CC(=C1)O)C2=C3C=CC(=C(C4=CC=C(N4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O)N3,,,,,,
2877,122878,CID 122878,C1C(C(OC1N2C=C(C(=O)NC2=O)C=CCl)CO)O,,,,,,
2878,122879,"5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione",C#CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,,,,,,
2879,122880,Dammarenediol,CC(=CCC[C@@](C)(C1CC[C@@]2(C1CC[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)O)C,,,,,,
2880,122881,7-Oxodihydrokarounidiol,C[C@]12CC[C@@](C[C@H]1[C@@]3(CCC4=C([C@]3(CC2)C)C(=O)C[C@@H]5[C@@]4(CC[C@H](C5(C)C)O)C)C)(C)CO,,,,,,
2881,122882,"Thiocyanic acid, pentyl ester",CCCCCSC#N,,,,,,
2882,122883,Butoxytitanium dichloride,CCCCO.Cl[Ti]Cl,,,,,,
2883,122884,"1-(1-ethylbenzo[e][1,3]benzothiazol-2-ylidene)-N-(4-methylphenyl)propan-2-imine",CCN1C(=CC(=NC2=CC=C(C=C2)C)C)SC3=C1C4=CC=CC=C4C=C3,,,,,,
2884,122885,"[1,2,4]Triazolo[1,5-a]pyrimidin-7-ol, 6-bromo-5-methyl-",CC1=C(C(=O)N2C(=N1)N=CN2)Br,,,,,,
2885,122886,8-Ureidoquinoline,C1=CC2=C(C(=C1)NC(=O)N)N=CC=C2,,,,,,
2886,122887,4-Ethoxyphenyl isocyanate,CCOC1=CC=C(C=C1)N=C=O,,,,,,
2887,122888,(Z)-tridec-2-enoic acid,CCCCCCCCCCC=CC(=O)O,,,,,,
2888,122889,"1,3-Diethylbarbituric acid",CCN1C(=O)CC(=O)N(C1=O)CC,,,,,,
2889,122890,"Acetamide, N,N'-(9,9',10,10'-tetrahydro-9,9',10',10'-tetraoxo[1,1'-bianthracene]-2,2'-diyl)bis-",CC(=O)NC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)C4=C(C=CC5=C4C(=O)C6=CC=CC=C6C5=O)NC(=O)C,,,,,,
2890,122891,"Ethylene bis[3,3-bis(3-tert-butyl-4-hydroxyphenyl)butyrate]",CC(C)(C)C1=C(C=CC(=C1)C(C)(CC(=O)OCCOC(=O)CC(C)(C2=CC(=C(C=C2)O)C(C)(C)C)C3=CC(=C(C=C3)O)C(C)(C)C)C4=CC(=C(C=C4)O)C(C)(C)C)O,,,,,,
2891,122892,Einecs 251-074-8,C1=CC=C2C(=C1)N=C(S2)[S-].[Cu+],,,,,,
2892,122893,Cefazolin Impurity D,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CN3C=NN=N3)SC1)C(=O)O,,,,,,
2893,122894,"5-(beta-Naphthylazo)-2,4,6-triaminopyrimidine",C1=CC=C2C=C(C=CC2=C1)N=NC3=C(N=C(N=C3N)N)N,,,,,,
2894,122895,"Octahydro-2,5,5-trimethyl-2H-2,4a-ethanonaphth-8-ol",CC1(CCC(C2C13CCC(C2)(CC3)C)O)C,,,,,,
2895,122896,(1-(Dimethylamino)ethylidene)bisphosphonic acid,CC(N(C)C)(P(=O)(O)O)P(=O)(O)O,,,,,,
2896,122897,[(Methylamino)methylene]bisphosphonic acid,CNC(P(=O)(O)O)P(=O)(O)O,,,,,,
2897,122898,1-(Methylthio)-p-menthan-3-one,CC(C)C1CCC(CC1=O)(C)SC,,,,,,
2898,122899,2-Methyl-5-(1-methylthio)-3-(methylvinyl)cyclohexan-1-one,CC1C(CC(CC1=O)C(=C)C)SC,,,,,,
2899,122900,1-O-(2-hydroxyethyl) 4-O-propan-2-yl but-2-enedioate,CC(C)OC(=O)C=CC(=O)OCCO,,,,,,
2900,122901,"N-(5-(Bis(2-hydroxyethyl)amino)-2-((5-nitro-2,1-benzisothiazol-3-yl)azo)phenyl)acetamide",CC(=O)NC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C3C=C(C=CC3=NS2)[N+](=O)[O-],,,,,,
2901,122902,"2-Anthracenecarbonitrile, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-",C1=CC=C(C=C1)NC2=C3C(=C(C(=C2)C#N)N)C(=O)C4=CC=CC=C4C3=O,,,,,,
2902,122903,Dehydroacetic acid,CC1=CC(=O)C(C(=O)O1)C(=O)C,,,,,"['METABOLITES IN RABBIT ARE: TRIACETIC ACID LACTONE, A HYDROXY DHA & POSSIBLY THE SALT OF TRIACETIC ACID LACTONE 3-CARBOXYLIC ACID.', '...NATURAL PRODUCT OF ADRENAL STEROID METABOLISM...']",
2903,122904,"Copper, [[N,N'-1,2-ethanediylbis[glycinato-kappaN,kappaO]](2-)]-",C(CNCC(=O)[O-])NCC(=O)[O-].[Cu+2],,,,,,
2904,122905,"Phosphorothioic acid, O-(3-chloro-5,7-dimethylpyrazolo(1,5-a)pyrimidin-2-yl) O,O-diethyl ester",CCOP(=S)(OCC)OC1=NN2C(=CC(=NC2=C1Cl)C)C,,,,,,
2905,122906,N-(2-Benzoyl-4-chlorophenyl)-2-bromoacetamide,C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)Cl)NC(=O)CBr,,,,,,
2906,122907,Ethyl-4-isopropylcinnamate,CCOC(=O)C=CC1=CC=C(C=C1)C(C)C,,,,,,
2907,122908,N-(2-((2-((2-Aminoethyl)amino)ethyl)amino)ethyl)stearamide,CCCCCCCCCCCCCCCCCC(=O)NCCNCCNCCN,,,,,,
2908,122909,"2-(1,1-Dimethylpropyl)anthraquinone",CCC(C)(C)C1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
2909,122910,"1H-Isoindole-1,3(2H)-dione, 2,2'-(methylenedi-4,1-phenylene)bis[4,5,6,7-tetrabromo-",C1=CC(=CC=C1CC2=CC=C(C=C2)N3C(=O)C4=C(C3=O)C(=C(C(=C4Br)Br)Br)Br)N5C(=O)C6=C(C5=O)C(=C(C(=C6Br)Br)Br)Br,,,,,,
2910,122911,"1,2-Dibromo-1-chloropropane",CC(C(Cl)Br)Br,,,,,,
2911,122912,5-Chloro-2-hydroxyisophthalaldehyde,C1=C(C=C(C(=C1C=O)O)C=O)Cl,,,,,,
2912,122913,Einecs 251-124-9,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC3CC4CCC3C4,,,,,,
2913,122914,"2,5-Cyclohexadiene-1,4-dione, 2,5-dichloro-3,6-dihydroxy-, lanthanum(3+) salt (3:2)",C1(=C(C(=O)C(=C(C1=O)Cl)[O-])Cl)[O-].C1(=C(C(=O)C(=C(C1=O)Cl)[O-])Cl)[O-].C1(=C(C(=O)C(=C(C1=O)Cl)[O-])Cl)[O-].[La+3].[La+3],,,,,,
2914,122915,CID 122915,C1=CC(=C(C=C1O)O)C(=O)[O-].C1=CC(=C(C=C1O)O)C(=O)[O-].[Cu+2],,,,,,
2915,122916,"4-(5,6-Dichloro-3-ethyl-2-methylbenzimidazol-1-ium-1-yl)butane-1-sulfonic acid",CCN1C(=[N+](C2=CC(=C(C=C21)Cl)Cl)CCCCS(=O)(=O)O)C,,,,,,
2916,122917,Butyl 3-aminosulphonyl-5-butylamino-4-phenoxybenzoate,CCCCNC1=C(C(=CC(=C1)C(=O)OCCCC)S(=O)(=O)N)OC2=CC=CC=C2,,,,,,
2917,122918,"(2S,3S,4S,5R)-1,6-bis(phenylmethoxy)hexane-2,3,4,5-tetrol",C1=CC=C(C=C1)COC[C@H]([C@@H]([C@H]([C@H](COCC2=CC=CC=C2)O)O)O)O,,,,,,
2918,122919,CID 122919,C1=CC=C(C=C1)COC[C@H]([C@H]([C@@H]([C@H](COCC2=CC=CC=C2)O)OCC3=CC=CC=C3)O)O,,,,,,
2919,122920,"Butanoic acid, diester with 1,2,3-propanetriol",CCCC(=O)OCC(COC(=O)CCC)O,,,,,,
2920,122921,"1,4-Diphenylcyclohexane-1,4-diol",C1CC(CCC1(C2=CC=CC=C2)O)(C3=CC=CC=C3)O,,,,,,
2921,122922,1-Imino-6-phenyl-1H-isoindole-3-amine,C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=NC3=N)N,,,,,,
2922,122923,"1,4-Benzenedicarbothioic acid, S,S-bis((4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl)methyl) ester",CC1=CC(=C(C(=C1CSC(=O)C2=CC=C(C=C2)C(=O)SCC3=C(C(=C(C=C3C)C(C)(C)C)O)C)C)O)C(C)(C)C,,,,,,
2923,122924,"Titanium, bis(octadecanoato-kappaO)bis(2-propanolato)-, (T-4)-",CCCCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCCCC(=O)O.CC(C)O.CC(C)O.[Ti],,,,,,
2924,122925,CID 122925,C[SnH+]C.C(C[S-])C(=O)O,,,,,,
2925,122926,(1H-Imidazol-4-yl)methanol hydrochloride,C1=C(NC=N1)CO.Cl,,,,,,
2926,122927,CID 122927,C1=CC=C(C=C1)C(=O)N[O-].[K+],,,,,,
2927,122928,"N,N'-(Methylenedicyclohexane-1,4-diyl)distearamide",CCCCCCCCCCCCCCCCCC(=O)NC1CCC(CC1)CC2CCC(CC2)NC(=O)CCCCCCCCCCCCCCCCC,,,,,,
2928,122929,2-Chloro-4-(chloromethyl)-1-(1-methylethoxy)benzene,CC(C)OC1=C(C=C(C=C1)CCl)Cl,,,,,,
2929,122930,4-tert-Butylphthalic anhydride,CC(C)(C)C1=CC2=C(C=C1)C(=O)OC2=O,,,,,,
2930,122931,4-tert-Butylphthalonitrile,CC(C)(C)C1=CC(=C(C=C1)C#N)C#N,,,,,,
2931,122932,"1,1'-(Ethane-1,2-diyl)bisimidazolidine-2,4-dione",C1C(=O)NC(=O)N1CCN2CC(=O)NC2=O,,,,,,
2932,122933,"3,5-Bis(trifluoromethyl)benzyl alcohol",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)CO,,,,,,
2933,122934,alpha-Methoxyphenoxytoluene,COCC1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
2934,122935,8-Acetyl-3H-phenothiazin-3-one,CC(=O)C1=CC2=C(C=C1)SC3=CC(=O)C=CC3=N2,,,,,,
2935,122936,4-Methoxy-3-methylbenzaldehyde,CC1=C(C=CC(=C1)C=O)OC,,,,,,
2936,122937,"9,10-Anthracenedione, 1,4-bis[(2,6-diethyl-4-methylphenyl)amino]-",CCC1=CC(=CC(=C1NC2=C3C(=C(C=C2)NC4=C(C=C(C=C4CC)C)CC)C(=O)C5=CC=CC=C5C3=O)CC)C,,,,,,
2937,122938,3-Chloro-2-methoxypropene,COC(=C)CCl,,,,,,
2938,122939,1-Chlorododec-1-ene,CCCCCCCCCCC=CCl,,,,,,
2939,122940,"Pyrazine, 2-methyl-3-(3-methylbutyl)-",CC1=NC=CN=C1CCC(C)C,,,,,,
2940,122941,2-Ethoxy-3-methylpyrazine,CCOC1=NC=CN=C1C,,,,,,
2941,122942,CID 122942,CC1=CN(C(=NC1=O)S)C2C(C(C(O2)CO)O)O,,,,,,
2942,122943,2-tert-Butylpyrazine,CC(C)(C)C1=NC=CN=C1,,,,,,
2943,122944,"Trimethyl [1,1'-biphenyl]-2,4',5-tricarboxylate",COC(=O)C1=CC=C(C=C1)C2=C(C=CC(=C2)C(=O)OC)C(=O)OC,,,,,,
2944,122945,"20-(4-Octylphenoxy)-3,6,9,12,15,18-hexaoxaicosan-1-ol",CCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCO,,,,,,
2945,122946,"1,4-Dihydro-1,4-methanoanthracene-9,10-dione",C1C2C=CC1C3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
2946,122947,"Sulfuric acid--4-imino-1-pentofuranosyl-1,4-dihydropyrimidin-2-ol (1/1)",C1=CN(C(=O)N=C1N)[C@@H]2[C@H]([C@H]([C@@H](O2)CO)O)O.OS(=O)(=O)O,,,,,,
2947,122948,"4-Amino-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one",C1=CN(C(=O)N=C1N)[C@@H]2[C@H]([C@H]([C@@H](O2)CO)O)O,,,,,,
2948,122949,CID 122949,C1=C(C=C(C(=O)C1=C2C=C(C=C(C2=O)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])N(O)O,,,,,,
2949,122950,3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl palmitate,CCCCCCCCCCCCCCCC(=O)OCC(C)(CO)CO,,,,,,
2950,122951,4-(Bromomethyl)benzophenone,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)CBr,,,,,,
2951,122952,"2-((1-Oxobutoxy)methyl)-2-(((1-oxoheptyl)oxy)methyl)propane-1,3-diyl bisheptanoate",CCCCCCC(=O)OCC(COC(=O)CCC)(COC(=O)CCCCCC)COC(=O)CCCCCC,,,,,,
2952,122953,4-Aminobutyronitrile,C(CC#N)CN,,,,,,
2953,122954,"2H-Pyran-2-one, tetrahydro-6-(3-pentenyl)-",CC=CCCC1CCCC(=O)O1,,,,,,
2954,122955,CID 122955,CC1=C(C(=CC=C1)C(=O)[O-])O.[Na+],,,,,,
2955,122956,2-(5-bromo-1H-indol-3-yl)ethanol,C1=CC2=C(C=C1Br)C(=CN2)CCO,,,,,,
2956,122957,Europium arsenide,[As]#[Eu],,,,,,
2957,122958,"Chloromethyl 2,2-dichloro-1,1,2-trifluoroethyl ether",C(OC(C(F)(Cl)Cl)(F)F)Cl,,,,,,
2958,122959,Ethyl cycloheptanecarboxylate,CCOC(=O)C1CCCCCC1,,,,,,
2959,122960,"Ethane, 1-(difluoromethoxy)-1,1,2,2-tetrafluoro-",C(C(OC(F)F)(F)F)(F)F,,,,,,
2960,122961,"2,2-Dimethyl-3-oxopropyl isobutyrate",CC(C)C(=O)OCC(C)(C)C=O,,,,,,
2961,122962,CID 122962,CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C3=NC(=O)C4=CC=CC=C4N3,,,,,,
2962,122963,4-Methylphenyl 4-cyanobenzoate,CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)C#N,,,,,,
2963,122964,"Methyl 2,5-heptadienoate",CC=CCC=CC(=O)OC,,,,,,
2964,122965,o-(p-Nitrophenoxy)anisole,COC1=CC=CC=C1OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2965,122966,Hexenyl acetate,CCCCC=COC(=O)C,,,,,,
2966,122967,2-Ethoxyethyl cyanoacetate,CCOCCOC(=O)CC#N,,,,,,
2967,122968,4-Chloro-3-ethoxy-but-2-enoic acid ethyl ester,CCOC(=CC(=O)OCC)CCl,,,,,,
2968,122969,CID 122969,CCCCCN(CCCCC)C(=S)[S-].[Na+],,,,,,
2969,122970,2-[(1-amino-1-hydroxyimino-2-methylpropan-2-yl)diazenyl]-N'-hydroxy-2-methylpropanimidamide,CC(C)(C(=NO)N)N=NC(C)(C)C(=NO)N,,,,,,
2970,122971,"2,2,4-Trimethylpentane-1,3-diyl dipropionate",CCC(=O)OCC(C)(C)C(C(C)C)OC(=O)CC,,,,,,
2971,122972,2-Nitrobutyl bromoacetate,CCC(COC(=O)CBr)[N+](=O)[O-],,,,,,
2972,122973,CID 122973,CCC(=C(C)N=O)O,,,,,,
2973,122974,"2-Pentanone, 4-methyl-, (1,1-dimethylethyl)hydrazone",CC(C)CC(=NNC(C)(C)C)C,,,,,,
2974,122975,N-[(4-methoxy-4-methylpentan-2-ylidene)amino]-2-methylpropan-2-amine,CC(=NNC(C)(C)C)CC(C)(C)OC,,,,,,
2975,122976,"3,3-Dichlorodihydro-5-methylfuran-2(3H)-one",CC1CC(C(=O)O1)(Cl)Cl,,,,,,
2976,122977,3-Pentyltetrahydro-2h-pyran-2-one,CCCCCC1CCCOC1=O,,,,,,
2977,122978,"N-(2-(Dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide",CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)S(=O)(=O)N(C)CCN(C)C,,,,,,
2978,122979,CID 122979,CC1(C2CC1C(C(C2)NCC(CC3=CC(=C(C=C3)O)I)O)CC=CCCCC(=O)O)C,,,,,,
2979,122980,Trichloromethyl radical,[C](Cl)(Cl)Cl,,,,,,
2980,122981,"1,2-Dibromo-4-chlorobutane",C(CCl)C(CBr)Br,,,,,,
2981,122982,9-Phenanthryl N-methylcarbamate,CNC(=O)OC1=CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
2982,122983,N-Nitro-N-(1-hydroxybutyl)butylamine acetate,CCCCN(C(CCC)OC(=O)C)[N+](=O)[O-],,,,,,
2983,122984,"5-Benzofuranamine, N,N-bis(2-chloroethyl)-2-nitro-",C1=CC2=C(C=C1N(CCCl)CCCl)C=C(O2)[N+](=O)[O-],,,,,,
2984,122985,"6-Benzofuranamine, N,N-bis(2-chloroethyl)-2-nitro-",C1=CC2=C(C=C1N(CCCl)CCCl)OC(=C2)[N+](=O)[O-],,,,,,
2985,122986,"7-Benzofuranamine, N,N-bis(2-chloroethyl)-4-methoxy-2-nitro-",COC1=C2C=C(OC2=C(C=C1)N(CCCl)CCCl)[N+](=O)[O-],,,,,,
2986,122987,"4-Benzofuranamine, N,N-bis(2-chloroethyl)-5-methoxy-2-nitro-",COC1=C(C2=C(C=C1)OC(=C2)[N+](=O)[O-])N(CCCl)CCCl,,,,,,
2987,122988,"4-Benzofuranamine, N,N-bis(2-chloroethyl)-7-methoxy-2-nitro-",COC1=C2C(=C(C=C1)N(CCCl)CCCl)C=C(O2)[N+](=O)[O-],,,,,,
2988,122989,9-Phenanthryl isothiocyanate,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)N=C=S,,,,,,
2989,122990,Stizophyllin,CC(=O)C1=CC[C@@H]2[C@@]1([C@@H](CC3C2=CCC4=C[C@H]([C@@H](C[C@]34C)O)O)O)C,,,,,,
2990,122991,CID 122991,COC(=O)C(=CC1=CC=CC=C1Br)C#N,,,,,,
2991,122992,"6-[(2-Amino-1,6-dimethylpyrimidin-4-ylidene)amino]-1,2-dimethylquinolin-1-ium-4-amine;hydron",[H+].CC1=CC(=NC2=CC3=C(C=C([N+](=C3C=C2)C)C)N)N=C(N1C)N,,,,,,
2992,122993,Quinapyramine,CC1=CC(=NC2=CC3=C(C=C([N+](=C3C=C2)C)C)N)N=C(N1C)N,,,['Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)'],,,
2993,122994,N-p-Nitrophenyl-D-ribosylamine triacetate,CC(=O)O[C@@H]1COC([C@@H]([C@@H]1OC(=O)C)OC(=O)C)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2994,122995,CID 122995,CC(CSC[C@@H](C(=O)OC)NOC(C)O)Br,,,,,,
2995,122996,4-(Hydroxymethyl)benzenediazonium;sulfite,C1=CC(=CC=C1CO)[N+]#N.[O-]S(=O)[O-],,,,,,
2996,122997,4-(Hydroxymethyl)benzenediazonium,C1=CC(=CC=C1CO)[N+]#N,,,,,,
2997,122998,2-(m-Nitrophenyl)adenosine,C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N,,,,,,
2998,122999,CID 122999,C1=CC(=CC=C1C2=NC(=N)C3=NC=NC3=N2)N(O)O,,,,,,
2999,123000,CID 123000,CS(=O)(=O)[N-]C1=CC=C(C=C1)N=C2C3=C(C=C(C=C3)N[N+]#N)[N-]C4=C2C=CC(=C4)N[N+]#N,,,,,,
3000,123001,CID 123001,CS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=C2C=CC(=C4)N[N+]#N)N[N+]#N,,,,,,
3001,123002,CID 123002,CC1=C2C(=CC=C1)C(=C3C=CC(=CC3=N2)N[N+]#N)[N-]C4=C(C=C(C=C4)NS(=O)(=O)C)OC,,,,,,
3002,123003,CID 123003,CC1=C2C(=CC=C1)C(=C3C=CC(=CC3=N2)N[N+]#N)NC4=C(C=C(C=C4)NS(=O)(=O)C)OC,,,,,,
3003,123004,CID 123004,CS(=O)(=O)N=C1C=CC(=NC2=C3C=C(C=CC3=NC4=C2C=CC(=C4)N[N+]#N)NN=[N-])C=C1,,,,,,
3004,123005,CID 123005,CS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=C(C=CC3=NC4=C2C=CC(=C4)N[N+]#N)N[N+]#N,,,,,,
3005,123006,CID 123006,CS(=O)(=O)[N-]C1=CC=C(C=C1)NC2=C3C=C(C=CC3=NC4=CC=CC=C42)N[N+]#N,,,,,,
3006,123007,CID 123007,CS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=C(C=CC3=NC4=CC=CC=C42)N[N+]#N,,,,,,
3007,123008,Ammonium 3-(allyloxy)-2-hydroxypropyl sulphate,C=CCOCC(COS(=O)(=O)O)O.N,,,,,,
3008,123009,"3-(2-Propenyloxy)-1,2-propanediol 1-(hydrogen sulfate)",C=CCOCC(COS(=O)(=O)O)O,,,,,,
3009,123010,N-Acetyl-S-(2-bromo-2-phenylethyl)-L-cysteine methyl ester,CCC(=O)N[C@@H](CSCC(C1=CC=CC=C1)Br)C(=C)OC,,,,,,
3010,123011,"D-Xylopyranosylamine, N-(4-nitrophenyl)-, 2,3,4-triacetate",CC(=O)O[C@@H]1COC([C@@H]([C@H]1OC(=O)C)OC(=O)C)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3011,123012,"3,5a-Dihydroxy-7,7-dimethyl-1-oxo-6,7,8,8a-tetrahydro-1H,3H,5aH-3a,8b-methanoindeno[4,5-c]furan-4-carbaldehyde",CC1(CC2C(C1)(C=C(C34C2(C3)C(=O)OC4O)C=O)O)C,,,,,,
3012,123013,"7-Nitro-1,2,8a,10a-tetrahydroanthracene-1,2-diol",C1=CC2=CC3C=CC(=CC3C=C2[C@@H]([C@H]1O)O)[N+](=O)[O-],,,,,,
3013,123014,"2-Nitroanthracene 7-keto-5,6,7,8-tetrahydro-trans-5,6-diol",C1C2=C(C=C3C=CC(=CC3=C2)[N+](=O)[O-])[C@@H]([C@H](C1=O)O)O,,,,,,
3014,123015,"3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one",CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C,,,,,,
3015,123016,3H-Cyclopenta(c)phenanthrene,C1C=CC2=C1C=CC3=C2C4=CC=CC=C4C=C3,,,,,,
3016,123017,1-Nitroso-3-methyl-4-piperidone,CC1CN(CCC1=O)N=O,,,,,,
3017,123018,N-(Acetyloxy)-N-(4-phenoxyphenyl)acetamide,CC(=O)N(C1=CC=C(C=C1)OC2=CC=CC=C2)OC(=O)C,,,,,,
3018,123019,1-(3-Hydroxypropyl)-1-nitrosourea,C(CN(C(=O)N)N=O)CO,,,,,,
3019,123020,Caffeic Acid 3-Methyl Phenethyl Ester,COC1=C(C=CC(=C1)C=CC(=O)OCCC2=CC=CC=C2)O,,,,,,
3020,123021,CID 123021,C1=CC2=CC3C=C(C=CC3C=C2[C@@H]([C@H]1O)O)[N+](=O)[O-],,,,,,
3021,123022,"Borane, compd. with pyridine",[BH3-][N+]1=CC=CC=C1,,,,,,
3022,123023,3-Phenylsydnone,C1=CC=C(C=C1)[N+]2=NOC(=C2)[O-],,,,,,
3023,123024,Phenylsydnone,C1=CC=C(C=C1)[N+]2=CC(=O)ON2,,,,,,
3024,123025,Phthalocyanine Iron(II),C1=CC=C2C(=C1)C3=NC4=NC(=NC5=C6C=CC=CC6=C([N-]5)N=C7C8=CC=CC=C8C(=N7)N=C2[N-]3)C9=CC=CC=C94.[Fe+2],,,,,,
3025,123026,"Tribenzo[de,kl,rst]pentaphene",C1=CC2=C3C(=C1)C4=C5C(=CC=C6C5=C(C=C4)C7=CC=CC8=C7C6=CC=C8)C3=CC=C2,,,,,,
3026,123027,"Naphtho(8,1,2-bcd)perylene",C1=CC2=C3C(=C1)C=C4C5=CC=CC6=C5C(=CC=C6)C7=C4C3=C(C=C2)C=C7,,,,,,
3027,123028,"Benzo(a)phenaleno(1,9-hij)naphthacene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C5C=CC6=C7C5=C4C=CC7=CC=C6)C=C32,,,,,,
3028,123029,"Dibenzo[bc,ef]coronene",C1=CC2=CC3=C4C5=C(C=CC6=C5C7=C(C=C6)C=C8C=CC=C9C8=C7C4=C2C9=C1)C=C3,,,,,,
3029,123030,"Benzo(pqr)naphtho(8,1,2-bcd)perylene",C1=CC2=C3C(=C1)C4=C5C6=C(C=CC7=C6C(=CC=C7)C8=C5C3=C(C=C2)C=C8)C=C4,,,,,,
3030,123031,"Dibenzo[a,j]coronene",C1=CC=C2C3=C4C5=C(C=C3)C=CC6=C5C7=C(C=CC8=C7C4=C(C2=C1)C=C8)C9=CC=CC=C69,,,,,,
3031,123032,"Naphtho[1,2,3,4-ghi]perylene",C1=CC=C2C3=C4C5=C(C=CC=C5C6=CC=CC7=C6C4=C(C2=C1)C=C7)C=C3,,,,,,
3032,123033,"Tetrabenzo[a,cd,j,lm]perylene",C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=C4)C6=C7C(=C25)C=CC8=C7C(=CC=C8)C9=CC=CC=C96,,,,,,
3033,123034,"Dibenzo[a,j]perylene",C1=CC=C2C(=C1)C=C3C=CC=C4C3=C2C5=CC=CC6=CC7=CC=CC=C7C4=C65,,,,,,
3034,123035,"Dibenzo(b,g)phenanthrene",C1=CC=C2C(=C1)C=CC3=C2C4=CC5=CC=CC=C5C=C4C=C3,,,,,,
3035,123036,Benzo[h]pentaphene,C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC=C4C5=CC6=CC=CC=C6C=C53,,,,,,
3036,123037,"Tribenzo(a,c,j)naphthacene",C1=CC=C2C(=C1)C=CC3=CC4=CC5=C(C=C4C=C32)C6=CC=CC=C6C7=CC=CC=C75,,,,,,
3037,123038,Benzo[b]picene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC5=CC6=CC=CC=C6C=C54,,,,,,
3038,123039,"Naphtho[2,1-a]naphthacene",C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC5=CC6=CC=CC=C6C=C5C=C43,,,,,,
3039,123040,Benzo(c)pentaphene,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC6=CC=CC=C6C=C5C4=C3,,,,,,
3040,123041,Heptaphene,C1=CC=C2C=C3C=C4C(=CC3=CC2=C1)C=CC5=CC6=CC7=CC=CC=C7C=C6C=C54,,,,,,
3041,123042,Hexaphene,C1=CC=C2C=C3C(=CC2=C1)C=CC4=CC5=CC6=CC=CC=C6C=C5C=C43,,,,,,
3042,123043,Benz[f]isoquinoline,C1=CC=C2C(=C1)C=CC3=C2C=CN=C3,,,,,,
3043,123044,Hexacene,C1=CC=C2C=C3C=C4C=C5C=C6C=CC=CC6=CC5=CC4=CC3=CC2=C1,,,,,,
3044,123045,"1H-Naphtho(2,3-d)triazole",C1=CC2=CC3=NNN=C3C=C2C=C1,,,,,,
3045,123046,Phosphorin,C1=CC=PC=C1,,,,,,
3046,123047,Triazine,C1=CN=NN=C1,,,,,,
3047,123048,"2,3,4,6-Tetrafluoroaniline",C1=C(C(=C(C(=C1F)F)F)N)F,,,,,,
3048,123049,"4,4'-Difluorobenzhydrol",C1=CC(=CC=C1C(C2=CC=C(C=C2)F)O)F,,,,,,
3049,123050,4-Bromo-2-fluoroaniline,C1=CC(=C(C=C1Br)F)N,,,,,,
3050,123051,"2,4-Difluorophenol",C1=CC(=C(C=C1F)F)O,,,,,,
3051,123052,"3',4'-Difluoroacetophenone",CC(=O)C1=CC(=C(C=C1)F)F,,,,,,
3052,123053,"3,4-Difluoronitrobenzene",C1=CC(=C(C=C1[N+](=O)[O-])F)F,,,,,,
3053,123054,4-((Trifluoromethyl)thio)aniline,C1=CC(=CC=C1N)SC(F)(F)F,,,,,,
3054,123055,"2,2'-Difluorobiphenyl",C1=CC=C(C(=C1)C2=CC=CC=C2F)F,,,,,,
3055,123056,2-Fluorostyrene,C=CC1=CC=CC=C1F,,,,,,
3056,123057,1-(Bromomethyl)-2-(trifluoromethyl)benzene,C1=CC=C(C(=C1)CBr)C(F)(F)F,,,,,,
3057,123058,"3,3'-Difluoro-1,1'-biphenyl",C1=CC(=CC(=C1)F)C2=CC(=CC=C2)F,,,,,,
3058,123059,"1,2,4-Trichloro-5-fluorobenzene",C1=C(C(=CC(=C1Cl)Cl)Cl)F,,,,,,
3059,123060,"3,5-Dinitrobenzotrifluoride",C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(F)(F)F,,,,,,
3060,123061,1-(Bromomethyl)-3-(trifluoromethyl)benzene,C1=CC(=CC(=C1)C(F)(F)F)CBr,,,,,,
3061,123062,1-(Bromomethyl)-4-(trifluoromethyl)benzene,C1=CC(=CC=C1CBr)C(F)(F)F,,,,,,
3062,123063,1-(4-Fluorophenyl)ethanamine,CC(C1=CC=C(C=C1)F)N,,,,,,
3063,123064,3-Fluorophenyl isocyanate,C1=CC(=CC(=C1)F)N=C=O,,,,,,
3064,123065,"2-Fluoro-1,3-dimethylbenzene",CC1=C(C(=CC=C1)C)F,,,,,,
3065,123066,1-(2-Fluorophenyl)ethanol,CC(C1=CC=CC=C1F)O,,,,,,
3066,123067,2-(Trifluoromethyl)benzaldehyde,C1=CC=C(C(=C1)C=O)C(F)(F)F,,,,,,
3067,123068,Benzyne,C1=CC#CC=C1,,,,,,
3068,123069,Diphenylketene,C1=CC=C(C=C1)C(=C=O)C2=CC=CC=C2,,,,,,
3069,123070,(2H4)Methane,[2H]C([2H])([2H])[2H],,,,,,
3070,123071,4-Methoxy-3-nitroaniline,COC1=C(C=C(C=C1)N)[N+](=O)[O-],,,,,,
3071,123072,"4,4'-Difluorobenzil",C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)F)F,,,,,,
3072,123073,CID 123073,C1=C(NC(=O)N=C1)S,,,,,,
3073,123074,"9,10-Dihydroxyphenanthrene",C1=CC=C2C(=C1)C3=CC=CC=C3C(=C2O)O,,,,,"['9,10-Dihydroxyphenanthrene is a known human metabolite of phenanthrene.']",
3074,123075,"2,3,5-Trinitrotoluene",CC1=CC(=CC(=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
3075,123076,"1,2,4-Trinitrobenzene",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
3076,123077,1-Anthrol,C1=CC=C2C=C3C(=CC2=C1)C=CC=C3O,,,,,,
3077,123078,"2,4'-Dimethylbiphenyl",CC1=CC=C(C=C1)C2=CC=CC=C2C,,,,,,
3078,123079,"2,4'-Dihydroxybiphenyl",C1=CC=C(C(=C1)C2=CC=C(C=C2)O)O,,,,,,
3079,123080,Benzyl 2-naphthyl ether,C1=CC=C(C=C1)COC2=CC3=CC=CC=C3C=C2,,,,,,
3080,123081,"2,5-Dinitroaniline",C1=CC(=C(C=C1[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
3081,123082,CID 123082,C1=C(C=C(C(=C1[N+](=O)[O-])N=N)[N+](=O)[O-])N(O)O,,,,,,
3082,123083,(2H4)Ethylene,[2H]C(=C([2H])[2H])[2H],,,,,,
3083,123084,3-Fluoropyridine 1-oxide,C1=CC(=C[N+](=C1)[O-])F,,,,,,
3084,123085,"1,3,5-Tris(trifluoromethyl)benzene",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C(F)(F)F,,,,,,
3085,123086,1-Chloro-3-ethynylbenzene,C#CC1=CC(=CC=C1)Cl,,,,,,
3086,123087,Malonic acid-d4,[2H]C([2H])(C(=O)O[2H])C(=O)O[2H],,,,,,
3087,123088,1-Phenyl-1-butene,CCC=CC1=CC=CC=C1,,,,,,
3088,123089,"2',4',6'-Trimethoxyacetophenone",CC(=O)C1=C(C=C(C=C1OC)OC)OC,,,,,,
3089,123090,9-Phenylphenanthrene,C1=CC=C(C=C1)C2=CC3=CC=CC=C3C4=CC=CC=C42,,,,,,
3090,123091,Bis(4-methylbenzoyl)peroxide,CC1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=C(C=C2)C,,,,,,
3091,123092,(2H)Formic (2)acid,[2H]C(=O)O[2H],,,,,,
3092,123093,Ethanol-d,[2H]OCC,,,,,,
3093,123094,"1,3-Benzodithiole-2-thione",C1=CC=C2C(=C1)SC(=S)S2,,,,,,
3094,123095,"Stannane, trimethylphenyl-",C[Sn](C)(C)C1=CC=CC=C1,,,,,,
3095,123096,4-(Trifluoromethyl)benzyl chloride,C1=CC(=CC=C1CCl)C(F)(F)F,,,,,,
3096,123097,(2H)Benzene,[2H]C1=CC=CC=C1,,,,,,
3097,123098,4-(Methylamino)pyridine,CNC1=CC=NC=C1,,,,,,
3098,123099,"8-Methoxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-2(1h)-one",CC12CCC3C(C1CCC(=O)C2)CCC4=C3C=CC(=C4)OC,,,,,,
3099,123100,CID 123100,CC(=O)[C-]1[CH-][CH-][CH-][CH-]1.CC(=O)[C-]1[CH-][CH-][CH-][CH-]1.[Fe],,,,,,
3100,123101,CID 123101,C[C-]([C-]1C[CH-][CH-]C1)[O-],,,,,,
3101,123102,CID 123102,[CH-]1[CH-][CH-][CH-][CH-]1.[CH-]1[CH-][CH-][CH-][CH-]1.[Ti](Br)Br,,,,,,
3102,123103,CID 123103,[CH-]1[CH-][CH-][CH-][CH-]1,,,,,,
3103,123104,Titanium bromide (TiBr2),[Ti](Br)Br,,,,,,
3104,123105,Niobium(V) oxide,O=[Nb](=O)O[Nb](=O)=O,,,,,,
3105,123106,Rhenium(VII) oxide,O=[Re](=O)(=O)O[Re](=O)(=O)=O,,,,,,
3106,123107,Sulfanylidenestannane,S=[SnH2],,,,,,
3107,123108,CID 123108,[SeH2].[SeH2].[SeH2].[SbH3].[SbH3],,,,,,
3108,123109,Tin selenide (SnSe),[Se]=[SnH2],,,,,,
3109,123110,Marcasite,[S-][S-].[Fe+2],,,,,,
3110,123111,Titanium(III) oxide,O=[Ti]O[Ti]=O,,,,,,
3111,123112,"1,3-Dichloro-4-fluorobenzene",C1=CC(=C(C=C1Cl)Cl)F,,,,,,
3112,123113,Methanol-d,[2H]OC,,,,,,
3113,123114,Cyclopropanecarboxaldehyde,C1CC1C=O,,,,,,
3114,123115,3-Phenyl-2-propyn-1-ol,C1=CC=C(C=C1)C#CCO,,,,,,
3115,123116,Dimethyl hexafluoroglutarate,COC(=O)C(C(C(C(=O)OC)(F)F)(F)F)(F)F,,,,,,
3116,123117,"Hexa-2,4-dienenitrile",CC=CC=CC#N,,,,,,
3117,123118,2-Azidoethanol,C(CO)N=[N+]=[N-],,,,,,
3118,123119,"S,S-Dimethyl sulfoximine",CS(=N)(=O)C,,,,,,
3119,123120,"Stannane, butyltrimethyl-",CCCC[Sn](C)(C)C,,,,,,
3120,123121,"Phenanthrene, decafluoro-",C12=C3C(=C(C(=C1C(=C(C(=C2F)F)F)F)F)F)C(=C(C(=C3F)F)F)F,,,,,,
3121,123122,N-Chlorodimethylamine,CN(C)Cl,,,,,,
3122,123123,"Hexane, 1,6-dicyclohexyl-",C1CCC(CC1)CCCCCCC2CCCCC2,,,,,,
3123,123124,(2H4)Acetaldehyde,[2H]C(=O)C([2H])([2H])[2H],,,,,,
3124,123125,"3-Pyridinamine, 1-oxide",C1=CC(=C[N+](=C1)[O-])N,,,,,,
3125,123126,1-Adamantyl methyl ketone,CC(=O)C12CC3CC(C1)CC(C3)C2,,,,,,
3126,123127,Dideuteriomethanone,[2H]C(=O)[2H],,,,,,
3127,123128,p-Terphenyl-d14,[2H]C1=C(C(=C(C(=C1[2H])[2H])C2=C(C(=C(C(=C2[2H])[2H])C3=C(C(=C(C(=C3[2H])[2H])[2H])[2H])[2H])[2H])[2H])[2H])[2H],,,,,,
3128,123129,Cyclohexane-d12,[2H]C1(C(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])[2H],,,,,,
3129,123130,"1,3-Diethynylbenzene",C#CC1=CC(=CC=C1)C#C,,,,,,
3130,123131,Methyl vinyl sulfide,CSC=C,,,,,,
3131,123132,Methanol-d3,[2H]C([2H])([2H])O,,,,,,
3132,123133,3-Chloropyridine 1-oxide,C1=CC(=C[N+](=C1)[O-])Cl,,,,,,
3133,123134,"Trisilane, 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)-",C[Si](C)(C)[SiH]([Si](C)(C)C)[Si](C)(C)C,,,,,,
3134,123135,3'-Trifluoromethyl-o-toluanilide,CC1=CC=CC=C1C(=O)NC2=CC=CC(=C2)C(F)(F)F,,,,,,
3135,123136,2-Propenyl,C=C[CH2],,,,,,
3136,123137,3-(4-Chlorophenyl)propanoic acid,C1=CC(=CC=C1CCC(=O)O)Cl,,,,,,
3137,123138,Ethyl radical,C[CH2],,,,,,
3138,123139,Methanimine,C=N,,,,,,
3139,123140,"1,3-Dithiolan-2-one",C1CSC(=O)S1,,,,,,
3140,123141,Ethyl adamantane-1-carboxylate,CCOC(=O)C12CC3CC(C1)CC(C3)C2,,,,,,
3141,123142,"2,8,9-Trioxa-5-aza-1-silabicyclo(3.3.3)undecane, 3,7-dimethyl-1-phenyl-",CC1CN2CCO[Si](O1)(OC(C2)C)C3=CC=CC=C3,,,,,,
3142,123143,Phenoxy,C1=CC=C(C=C1)[O],,,,,,
3143,123144,Methyldioxy,CO[O],,,,,,
3144,123145,Propyl radical,CC[CH2],,,,,,
3145,123146,Methoxy,C[O],,,,,,
3146,123147,Benzyl,[CH2]C1=CC=CC=C1,,,,,,
3147,123148,"Diazene, dibutyl",CCCCN=NCCCC,,,,,,
3148,123149,Methyl dithioacetate,CC(=S)SC,,,,,,
3149,123150,Methyl selenocyanate,C[Se]C#N,,,,,,
3150,123151,Acetonitrile-d3,[2H]C([2H])([2H])C#N,,,,,,
3151,123152,"3,4,5,6-Tetrahydro-2H-azepine",C1CCC=NCC1,,,,,,
3152,123153,"2,4,5-Trifluorophenol",C1=C(C(=CC(=C1F)F)F)O,,,,,,
3153,123154,Congressane,C1C2CC3C4C1C5CC(C4)CC3C5C2,,,,,,
3154,123155,1-(4-Nitrophenyl)-1H-imidazole,C1=CC(=CC=C1N2C=CN=C2)[N+](=O)[O-],,,,,,
3155,123156,4-Methyl-2-hexanol,CCC(C)CC(C)O,,,,,,
3156,123157,Hydroxyethyl,C[CH]O,,,,,,
3157,123158,Coppinger's radical,CC(C)CC1=CC(=CC(=C1[O])CC(C)C)C=C2C=C(C(=O)C(=C2)CC(C)C)CC(C)C,,,,,,
3158,123159,Phenyl,C1=CC=[C]C=C1,,,,,,
3159,123160,Trimethylphosphine sulfide,CP(=S)(C)C,,,,,,
3160,123161,Stannane,[SnH4],,,,,,
3161,123162,Cyclopropyl,C1C[CH]1,,,,,,
3162,123163,"O,O-Diethyl O-(4-nitro-m-tolyl) phosphorothioate",CCOP(=S)(OCC)OC1=CC(=C(C=C1)[N+](=O)[O-])C,,,,,,
3163,123164,Methylene,[CH2],,,,,,
3164,123165,"Phosphine, (1,1-dimethylethyl)-",CC(C)(C)P,,,,,,
3165,123166,Ethylenyl,C=[CH],,,,,,
3166,123167,n-Pentyl,CCCC[CH2],,,,,,
3167,123168,"Ethanamine, N,N-diethyl-, N-oxide",CC[N+](CC)(CC)[O-],,,,,,
3168,123169,Tetrachloromethylphosphorane,CP(Cl)(Cl)(Cl)Cl,,,,,,
3169,123170,1-Bromo-3-ethylbenzene,CCC1=CC(=CC=C1)Br,,,,,,
3170,123171,2-Chlorophenyl isothiocyanate,C1=CC=C(C(=C1)N=C=S)Cl,,,,,,
3171,123172,"2,3-Di(docos-13-enoyloxy)propyl docos-13-enoate",CCCCCCCCC=CCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCC=CCCCCCCCC)OC(=O)CCCCCCCCCCCC=CCCCCCCCC,,,,,,
3172,123173,Cyclopropene,C1C=C1,,,,,,
3173,123174,"2,3,4-Trifluorophenol",C1=CC(=C(C(=C1O)F)F)F,,,,,,
3174,123175,Pentachlorophenyl trichloroacetate,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)OC(=O)C(Cl)(Cl)Cl,,,,,,
3175,123176,"3-Cyclobutene-1,2-dione, 3,4-dichloro-",C1(=C(C(=O)C1=O)Cl)Cl,,,,,,
3176,123177,Perhydrophenalene,C1CC2CCCC3C2C(C1)CCC3,,,,,,
3177,123178,Hydrocyanic acid-D,[2H]C#N,,,,,,
3178,123179,2-Bromo-3-methylnaphthoquinone,CC1=C(C(=O)C2=CC=CC=C2C1=O)Br,,,,,,
3179,123180,"4-Methyl-1,2-benzoquinone",CC1=CC(=O)C(=O)C=C1,,,,,,
3180,123181,Propyl 4-chlorobutanoate,CCCOC(=O)CCCCl,,,,,,
3181,123182,Ethyldioxy,CCO[O],,,,,,
3182,123183,"1-Butanamine, N-nitro-",CCCCN[N+](=O)[O-],,,,,,
3183,123184,"1,3-Dimethylbenzimidazoline",CN1CN(C2=CC=CC=C21)C,,,,,,
3184,123185,Tetrakis(dimethylamino)titanium(IV),C[N-]C.C[N-]C.C[N-]C.C[N-]C.[Ti+4],,,,,,
3185,123186,"1,2,3-Trithiane",C1CSSSC1,,,,,,
3186,123187,"Benzenepentacarboxylic acid, pentamethyl ester",COC(=O)C1=CC(=C(C(=C1C(=O)OC)C(=O)OC)C(=O)OC)C(=O)OC,,,,,,
3187,123188,N-Methyl-4-biphenylamine,CNC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
3188,123189,"3,6-dihydro-2H-pyran-2-one",C1C=CCOC1=O,,,,,,
3189,123190,tert-Butyldioxy,CC(C)(C)O[O],,,,,,
3190,123191,"1,3-Dimethylbenzimidazoline-2-thione",CN1C2=CC=CC=C2N(C1=S)C,,,,,,
3191,123192,"Cyclopentene, 4-(dichloromethylene)-1,2,3,3,5,5-hexachloro-",C1(=C(C(C(=C(Cl)Cl)C1(Cl)Cl)(Cl)Cl)Cl)Cl,,,,,,
3192,123193,"Methyl, dichloro-",[CH](Cl)Cl,,,,,,
3193,123194,N-t-butyl-alpha-(4-nitrophenyl)nitrone,CC(C)(C)[N+](=CC1=CC=C(C=C1)[N+](=O)[O-])[O-],,,,,,
3194,123195,Diazene,N=N,,,,,,
3195,123196,"1-Methylimidazolidine-2,4,5-trione",CN1C(=O)C(=O)NC1=O,,,,,,
3196,123197,4-Methoxybenzyl isothiocyanate,COC1=CC=C(C=C1)CN=C=S,,,,,,
3197,123198,"N,N,N',N'-Tetramethylphosphoramide",CN(C)P(=O)(N)N(C)C,,,,,,
3198,123199,"Propylamine, N,N,1,1,2,2-hexamethyl-",CC(CN(C)C)C(C)(C)C,,,,,,
3199,123200,Benzylphosphonic acid dibutyl ester,CCCCOP(=O)(CC1=CC=CC=C1)OCCCC,,,,,,
3200,123201,Methyl 4-(methylthio)benzoate,COC(=O)C1=CC=C(C=C1)SC,,,,,,
3201,123202,"1,4-Dichlorobenzene-d4",[2H]C1=C(C(=C(C(=C1Cl)[2H])[2H])Cl)[2H],,,,,,
3202,123203,Dimethylaminosulfur trifluoride,CN(C)S(F)(F)F,,,,,,
3203,123204,(Z)-Diisopropyldiazene,CC(C)N=NC(C)C,,,,,,
3204,123205,4-Cyclopropylanisole,COC1=CC=C(C=C1)C2CC2,,,,,,
3205,123206,Mercury(2+);propane-1-thiolate,CCC[S-].CCC[S-].[Hg+2],,,,,,
3206,123207,"2-Ethyl-4,6-dinitrophenol",CCC1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
3207,123208,(1-2H1)Acetaldehyde,[2H]C(=O)C,,,,,,
3208,123209,3-Methylthymine,CC1=CNC(=O)N(C1=O)C,,,,,,
3209,123210,Nitrobenzene-d5,[2H]C1=C(C(=C(C(=C1[2H])[2H])[N+](=O)[O-])[2H])[2H],,,,,,
3210,123211,Benzen-d5-amine,[2H]C1=C(C(=C(C(=C1[2H])[2H])N)[2H])[2H],,,,,,
3211,123212,4-Isobutylphenol,CC(C)CC1=CC=C(C=C1)O,,,,,,
3212,123213,Undecylsulfate,CCCCCCCCCCCOS(=O)(=O)O,,,,,,
3213,123214,Nitrosyl cyanide,C(#N)N=O,,,,,,
3214,123215,2-(Trichloromethyl)pyridine,C1=CC=NC(=C1)C(Cl)(Cl)Cl,,,,,,
3215,123216,Tetrakis(diethylamino)titanium,CC[N-]CC.CC[N-]CC.CC[N-]CC.CC[N-]CC.[Ti+4],,,,,,
3216,123217,Nonyl isothiocyanate,CCCCCCCCCN=C=S,,,,,,
3217,123218,Dodecahedrane,C12C3C4C5C1C6C7C2C8C3C9C4C1C5C6C2C7C8C9C12,,,,,,
3218,123219,n-Butylhydroperoxide,CCCCOO,,,,,,
3219,123220,"1,4-Naphthalenedione, 5-methoxy-",COC1=CC=CC2=C1C(=O)C=CC2=O,,,,,,
3220,123221,1-Adamantaneacetic acid,C1C2CC3CC1CC(C2)(C3)CC(=O)O,,,,,,
3221,123222,5-Hexenenitrile,C=CCCCC#N,,,,,,
3222,123223,1-Ethoxy-2-methoxyethane,CCOCCOC,,,,,,
3223,123224,Bromodimethylborane,B(C)(C)Br,,,,,,
3224,123225,"3,3-Dimethyldiazirine",CC1(N=N1)C,,,,,,
3225,123226,"N,N'-Dimethylparabanic acid",CN1C(=O)C(=O)N(C1=O)C,,,,,,
3226,123227,"3,4-Dimethoxy-3-cyclobutene-1,2-dione",COC1=C(C(=O)C1=O)OC,,,,,,
3227,123228,"3,4-Diethoxy-3-cyclobutene-1,2-dione",CCOC1=C(C(=O)C1=O)OCC,,,,,,
3228,123229,Allyl ethyl sulfide,CCSCC=C,,,,,,
3229,123230,"Methyl 16-ethenyl-11-ethyl-12-(hydroxymethylidene)-22-(3-methoxy-3-oxopropyl)-17,21,26-trimethyl-4-oxo-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,5(26),6,8,10,13(25),14,16,18(24),19-decaene-3-carboxylate",CCC1=C2C=C3C(=C4C(=O)C(C(=C5C(C(C(=CC6=NC(=CC(=N2)C1=CO)C(=C6C)C=C)N5)C)CCC(=O)OC)C4=N3)C(=O)OC)C,,,,,,
3230,123231,CID 123231,C1=CC=C(C=C1)C2=NN=C(S2)S,,,,,,
3231,123232,"Octa-1,4-diene",CCCC=CCC=C,,,,,,
3232,123233,"1,2-Dimethoxy-4-propylbenzene",CCCC1=CC(=C(C=C1)OC)OC,,,,,,
3233,123234,N-Propyl hydroperoxide,CCCOO,,,,,,
3234,123235,"1-Chloro-1,3-butadiyne",C#CC#CCl,,,,,,
3235,123236,"N,N',N''-Trimethylguanidine",CNC(=NC)NC,,,,,,
3236,123237,"Ethyl, 2,2,2-trifluoro-1-oxo-",[C](=O)C(F)(F)F,,,,,,
3237,123238,3-Aminoquinuclidine,C1CN2CCC1C(C2)N,,,,,,
3238,123239,"2,6-Dichlorophenyl isothiocyanate",C1=CC(=C(C(=C1)Cl)N=C=S)Cl,,,,,,
3239,123240,Hexamethylcyclotriphosphazene,CP1(=NP(=NP(=N1)(C)C)(C)C)C,,,,,,
3240,123241,Thioacetaldehyde,CC=S,,,,,,
3241,123242,1-Azidonaphthalene,C1=CC=C2C(=C1)C=CC=C2N=[N+]=[N-],,,,,,
3242,123243,"Hex-3-en-1,5-diyne",C#CC=CC#C,,,,,,
3243,123244,Dotetracontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
3244,123245,"Benzyl alcohol, o-(o-tolyl)-",CC1=CC=CC=C1C2=CC=CC=C2CO,,,,,,
3245,123246,"3H-1,2,4-Triazole-3-thione, 2,4-dihydro-2,4-dimethyl-5-phenyl-",CN1C(=NN(C1=S)C)C2=CC=CC=C2,,,,,,
3246,123247,Methylthio radical,C[S],,,,,,
3247,123248,3-Butenal,C=CCC=O,,,,,,
3248,123249,2-Oxopentanal,CCCC(=O)C=O,,,,,,
3249,123250,3-Bromo-1-benzothiophene,C1=CC=C2C(=C1)C(=CS2)Br,,,,,,
3250,123251,2-Chloroadamantane,C1C2CC3CC1CC(C2)C3Cl,,,,,,
3251,123252,Ethyl 2-chlorobutanoate,CCC(C(=O)OCC)Cl,,,,,,
3252,123253,Ethyl 3-chlorobutanoate,CCOC(=O)CC(C)Cl,,,,,,
3253,123254,Methyl dimethylcarbamate,CN(C)C(=O)OC,,,,,,
3254,123255,Methyldichloramine,CN(Cl)Cl,,,,,,
3255,123256,(2H)Hydrogen chloride,[1H]Cl,,,,,,
3256,123257,Fluorine dioxide,O(OF)F,,,,,,
3257,123258,Lead(IV) fluoride,F[Pb](F)(F)F,,,,,,
3258,123259,"Molybdate (MoO42-), barium (1:1), (T-4)-",[O-][Mo](=O)(=O)[O-].[Ba+2],,,,,,
3259,123260,Bismuth pentafluoride,F[Bi](F)(F)(F)F,,,,,,
3260,123261,Nitrosyl fluoride,N(=O)F,,,,,,
3261,123262,Fluorine nitrate,[N+](=O)([O-])OF,,,,,,
3262,123263,Titanium tetrabromide,[Ti](Br)(Br)(Br)Br,,,,,,
3263,123264,Calcium tungsten oxide (CaWO4),[O-][W](=O)(=O)[O-].[Ca+2],,,,,,
3264,123265,Cerium triiodide,I[Ce](I)I,,,,,,
3265,123266,Chlorine fluoride,FCl,,,,,,
3266,123267,CID 123267,[Be+2].CC(=CC(=[OH+])C)[O-].CC(=CC(=[OH+])C)[O-],,,,,,
3267,123268,Lithium aluminate,[Li+].[O-][Al]=O,,,,,,
3268,123269,Boron sulfide,B(=S)SB=S,,,,,,
3269,123270,Cerium carbide (CeC2),[C-]#[C].[Ce],,,,,,
3270,123271,Ethynyl,C#[C],,,,,,
3271,123272,Chlorine heptoxide,O=Cl(=O)(=O)OCl(=O)(=O)=O,,,,,,
3272,123273,CID 123273,[GaH3].[TeH2],,,,,,
3273,123274,Sulfanylidenegermane,S=[GeH2],,,,,,
3274,123275,Magnesium titanium oxide (Mg2TiO4),[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Ti],,,,,,
3275,123276,Tellanylidenestannane,[SnH2]=[Te],,,,,,
3276,123277,CID 123277,O.[PbH4].[PbH4],,,,,,
3277,123278,Plumbane,[PbH4],,,,,,
3278,123279,Boron carbide,B12B3C14B2B43,,,,,,
3279,123280,Lanthanum carbide,[C-]#[C].[La],,,,,,
3280,123281,Thorium carbide,[C-]#[C].[Th],,,,,,
3281,123282,Yttrium carbide (YC2),[C-]#[C].[Y],,,,,,
3282,123283,CID 123283,[SiH4].[Pt],,,,,,
3283,123284,Magnesium monohydroxide,[H-].[OH-].[Mg+2],,,,,,
3284,123285,CID 123285,[CH-]=O.[CH-]=O.[CH-]1[CH-][CH-][CH-][CH-]1.[CH-]1[CH-][CH-][CH-][CH-]1.[Ni].[Ni],,,,,,
3285,123286,Tetraphosphorus,P12P3P1P23,,,,,,
3286,123287,Dichlorine dioxide,O(OCl)Cl,,,,,,
3287,123288,CID 123288,[S-][S-].[S-][S-].[SbH3].[SbH3],,,,,,
3288,123289,Iron dioxide,O=[Fe]=O,,,,,,
3289,123290,Phosphorus oxide,O1P2OP3OP1OP(O2)O3,,,,,,
3290,123291,CID 123291,[GaH3].[TeH][TeH],,,,,,
3291,123292,Ditellane,[TeH][TeH],,,,,,
3292,123293,Nitro(2H3)methane,[2H]C([2H])([2H])[N+](=O)[O-],,,,,,
3293,123294,"2-Piperidinethione, 1-methyl-",CN1CCCCC1=S,,,,,,
3294,123295,Phenol-d6,[2H]C1=C(C(=C(C(=C1[2H])[2H])O[2H])[2H])[2H],,,,,,
3295,123296,Disulphur dibromide,S(SBr)Br,,,,,,
3296,123297,2-Aminotridecane,CCCCCCCCCCCC(C)N,,,,,,
3297,123298,"2,3-Dibromonaphthalene",C1=CC=C2C=C(C(=CC2=C1)Br)Br,,,,,,
3298,123299,"3,6,9,12,15-Pentaoxaoctadecanoyl fluoride, 2,4,4,5,7,7,8,10,10,11,13,13,14,16,16,17,17,18,18,18-eicosafluoro-2,5,8,11,14-pentakis(trifluoromethyl)-",C(=O)(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F)F,,,,,,
3299,123300,N-(diethylaminodiazenyl)-N-ethylethanamine,CCN(CC)N=NN(CC)CC,,,,,,
3300,123301,N-(4-Bromophenyl)maleimide,C1=CC(=CC=C1N2C(=O)C=CC2=O)Br,,,,,,
3301,123302,Methyl 5-oxo-2-phenyloxolane-3-carboxylate,COC(=O)C1CC(=O)OC1C2=CC=CC=C2,,,,,,
3302,123303,CID 123303,CN1CCN=C1S,,,,,,
3303,123304,Nitrosyl bromide,N(=O)Br,,,,,,
3304,123305,CID 123305,[N+](=O)([O-])Cl,,,,,,
3305,123306,Strontium tungsten oxide (SrWO4),[O-][W](=O)(=O)[O-].[Sr+2],,,,,,
3306,123307,Tellurium monoxide,O=[Te],,,,,,
3307,123308,Lithium metaborate,[Li+].B(=O)[O-],,,,,,
3308,123309,Cesium perchlorate,[O-]Cl(=O)(=O)=O.[Cs+],,,,,,
3309,123310,Lead tetrachloride,Cl[Pb](Cl)(Cl)Cl,,,,,,
3310,123311,Selenium tetrafluoride,F[Se](F)(F)F,,,,,,
3311,123312,Molybdenum strontium oxide (MoSrO4),[O-][Mo](=O)(=O)[O-].[Sr+2],,,,,,
3312,123313,CID 123313,[1H]Br,,,,,,
3313,123314,Ammonia-d3,[2H]N([2H])[2H],,,,,,
3314,123315,Diiodogermane,[GeH2](I)I,,,,,,
3315,123316,Lithium (2H)hydride,[1H-].[Li+],,,,,,
3316,123317,Phosphoramide,NP(=O)(N)N,,,,,,
3317,123318,Disiloxane,O([SiH3])[SiH3],,,,,,
3318,123319,Hexabromocyclotriphosphazene,N1=P(N=P(N=P1(Br)Br)(Br)Br)(Br)Br,,,,,,
3319,123320,Bromodifluorophosphine sulfide,FP(=S)(F)Br,,,,,,
3320,123321,Dibromofluorophosphine sulfide,FP(=S)(Br)Br,,,,,,
3321,123322,Trifluorooxovanadium,O=[V].F.F.F,,,,,,
3322,123323,Difluorodisulfane,FSSF,,,,,,
3323,123324,Xenon tetrafluoride,F[Xe](F)(F)F,,,,,,
3324,123325,Potassium metaborate,B(=O)[O-].[K+],,,,,,
3325,123326,9-t-Butylanthracene,CC(C)(C)C1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
3326,123327,Osmium hexafluoride,F[Os](F)(F)(F)(F)F,,,,,,
3327,123328,Phosphoryl dichloride fluoride,O=P(F)(Cl)Cl,,,,,,
3328,123329,Amidogen,[NH2],,,,,,
3329,123330,Sulfur chloride pentafluoride,FS(F)(F)(F)(F)Cl,,,,,,
3330,123331,Silicon difluoride,F[SiH2]F,,,,,,
3331,123332,Oxonium,[OH3+],,,,,,
3332,123333,CID 123333,CC(=CC(=[OH+])C)[O-].CC(=CC(=[OH+])C)[O-].[Mg+2],,,,,,
3333,123334,Hypofluorous acid,OF,,,,,,
3334,123335,"Ethanediamide, N,N'-dipropyl-",CCCNC(=O)C(=O)NCCC,,,,,,
3335,123336,Methyl propyl sulfoxide,CCCS(=O)C,,,,,,
3336,123337,(2H)Hydrogen iodide,[1H]I,,,,,,
3337,123338,3-Acetylpyridine N-oxide,CC(=O)C1=C[N+](=CC=C1)[O-],,,,,,
3338,123339,2-Methyl-3-phenyloxirane,CC1C(O1)C2=CC=CC=C2,,,,,['2-methyl-3-phenyloxirane has known human metabolites that include (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-[(3-phenyloxiran-2-yl)methylsulfanyl]propan-2-yl]amino]-5-oxopentanoic acid.'],
3339,123340,Hypoiodous acid,OI,,,,,,
3340,123341,CID 123341,[1H]F,,,,,,
3341,123342,Phosphorus chloride difluoride,FP(F)Cl,,,,,,
3342,123343,"Copper 2,3,7,8,12,13,17,18-octaethylporphyrin-22,24-diide",CCC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C([N-]5)C=C1[N-]2)CC)CC)C(=C4CC)CC)C(=C3CC)CC)CC.[Cu+2],,,,,,
3343,123344,"Propane-1,2,3-triyl trioctadeca-9,12,15-trienoate",CCC=CCC=CCC=CCCCCCCCC(=O)OCC(COC(=O)CCCCCCCC=CCC=CCC=CCC)OC(=O)CCCCCCCC=CCC=CCC=CCC,,,,,,
3344,123345,Dibromamine,N(Br)Br,,,,,,
3345,123346,Bromamine,NBr,,,,,,
3346,123347,"2,2,4,4,6,6,8,8-Octabromo-2,2,4,4,6,6,8,8-octahydro-1,3,5,7,2,4,6,8-tetraazatetraphosphocine",N1=P(N=P(N=P(N=P1(Br)Br)(Br)Br)(Br)Br)(Br)Br,,,,,,
3347,123348,Cyclopropyl phenyl sulfide,C1CC1SC2=CC=CC=C2,,,,,,
3348,123349,Peroxynitrous acid,N(=O)OO,,,,,,
3349,123350,4-(Methylsulfonyl)phenol,CS(=O)(=O)C1=CC=C(C=C1)O,,,,,,
3350,123351,Perchlorate,[O-]Cl(=O)(=O)=O,,,,,,
3351,123352,Magnesium;hydride;chloride,[H-].[Mg+2].[Cl-],,,,,,
3352,123353,N-(1-oxidopyridin-1-ium-3-yl)acetamide,CC(=O)NC1=C[N+](=CC=C1)[O-],,,,,,
3353,123354,Pentamethylantimony,C[Sb](C)(C)(C)C,,,,,,
3354,123355,"Propanal, 2-propylidenehydrazone",CCC=NN=CCC,,,,,,
3355,123356,CID 123356,C1=CC=C(C(=C1)C(=N)S)Cl,,,,,,
3356,123357,1-Ethynylnaphthalene,C#CC1=CC=CC2=CC=CC=C21,,,,,,
3357,123358,"1H-Indene-1,2(3H)-dione",C1C2=CC=CC=C2C(=O)C1=O,,,,,,
3358,123359,"Methyl, iodo-",[CH2]I,,,,,,
3359,123360,4-Phenyl-1-butyne,C#CCCC1=CC=CC=C1,,,,,,
3360,123361,Cyclopropanol,C1CC1O,,,,,,
3361,123362,Trimethylsilyl,C[Si](C)C,,,,,,
3362,123363,1-Cyclohexyltrimethylamine,CN(C)CC1CCCCC1,,,,,,
3363,123364,Dimethylcarbamyl cyanide,CN(C)C(=O)C#N,,,,,,
3364,123365,4-Ethyl-1-hexene,CCC(CC)CC=C,,,,,,
3365,123366,3-Aminobutanenitrile,CC(CC#N)N,,,,,,
3366,123367,"N,N,N',N''-Tetramethylphosphoric triamide",CNP(=O)(NC)N(C)C,,,,,,
3367,123368,2-Chloro-3-methylnaphthoquinone,CC1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
3368,123369,Rhenium heptafluoride,F[Re](F)(F)(F)(F)(F)F,,,,,,
3369,123370,Formyl radical,[CH]=O,,,,,,
3370,123371,3-(Methacryloyloxy)propyltris(trimethylsiloxy)silane,CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C,,,,,,
3371,123372,Ethyl 4-isothiocyanatobutanoate,CCOC(=O)CCCN=C=S,,,,,,
3372,123373,(Trifluoromethyl)dioxidanyl,C(O[O])(F)(F)F,,,,,,
3373,123374,"2,3,5-Trichlorothiophene",C1=C(SC(=C1Cl)Cl)Cl,,,,,,
3374,123375,Methyl (phenylthio)acetate,COC(=O)CSC1=CC=CC=C1,,,,,,
3375,123376,1-Azoxypropane,CCCN=[N+](CCC)[O-],,,,,,
3376,123377,o-Cumylphenol,CC(C)(C1=CC=CC=C1)C2=CC=CC=C2O,,,,,,
3377,123378,"N,N-dimethylpyridin-3-amine",CN(C)C1=CN=CC=C1,,,,,,
3378,123379,"3,4'-Diisopropylbiphenyl",CC(C)C1=CC=C(C=C1)C2=CC(=CC=C2)C(C)C,,,,,,
3379,123380,Trimethyl(phenyl)plumbane,C[Pb](C)(C)C1=CC=CC=C1,,,,,,
3380,123381,CID 123381,[Be+2].[Be+2].[Be+2].[Be+2].CC(=[OH+])[O-].CC(=[OH+])[O-].CC(=[OH+])[O-].CC(=[OH+])[O-].CC(=[OH+])[O-].CC(=[OH+])[O-].[OH-],,,,,,
3381,123382,Isopropylbiphenyl,CC(C)C1=CC=CC=C1C2=CC=CC=C2,,,,"['RATS GIVEN (14)C-LABELED 4-ISOPROPYLBIPHENYL (25 MG/KG, ORALLY OR IP) EXCRETED MORE (14)C IN FECES THAN IN URINE & RETAINED 12.1%-16.1% OF DOSE IN THE CARCASS AFTER 48 HR. (14)C WAS OBSERVED IN ALL TISSUES EXAMINED AT 48 HR, BUT WAS UNUSUALLY HIGH ONLY IN FAT.']","['AN EXTENSIVE STUDY OF THE METABOLISM OF ISOPROPYLBIPHENYL IN SEVERAL SPECIES, INCLUDING MAN, WAS ACCOMPLISHED BY EXTENSIVE USE OF GAS CHROMATOGRAPHY-MASS SPECTROMETRY. THE COMPLEX METABOLITE SEQUENCES FOUND WERE DIFFERENT FOR EACH SPECIES STUDIED (RAT, DOG, MONKEY, MAN). METABOLITE PATTERNS IN EACH SPECIES WERE CONSISTENT WITH THE PHARMACOLOGICAL & TOXICOLOGICAL PROPERTIES IN THAT SPECIES. METABOLITE PATTERNS WERE A CONSEQUENCE OF SEQUENTIAL OXIDATION BEGINNING WITH HYDROXYLATION OF THE ISO-PROPYL GROUP AT THE TERTIARY CARBON IN DOG & MAN & AT BOTH THE TERTIARY & PRIMARY CARBON IN RAT & MONKEY.', 'RATS GIVEN (14)C-LABELED 4-ISOPROPYLBIPHENYL (25 MG/KG, ORALLY OR IP) EXCRETED MORE (14)C IN FECES THAN IN URINE & RETAINED 12.1%-16.1% OF DOSE IN THE CARCASS AFTER 48 HR. (14)C WAS OBSERVED IN ALL TISSUES EXAMINED AT 48 HR, BUT WAS UNUSUALLY HIGH ONLY IN FAT. THE MAIN METABOLITE IN PLASMA WAS BIPHENYLPROPIONIC ACID, WITH SMALL AMOUNTS OF BIPHENYL-2-PROPANOL & BIPHENYL-ALPHA-METHYL GLYCOLIC ACID. METABOLITES IN URINE & BILE WERE MAINLY RING-HYDROXYLATED FORMS OF THE PLASMA METABOLITES, & ALL THE PHENOLIC METABOLITES WERE CONJUGATED. ... INCUBATION OF 4-ISOPROPYLBIPHENYL WITH RAT LIVER 15,000 G SUPERNATANT YIELDED BIPHENYL-2-PROPANOL & BIPHENYL-ALPHA-METHYL GLYCOLIC ACID.']",
3382,123383,CID 123383,F[PH2](F)F.F[PH2](F)F.F[PH2](F)F.F[PH2](F)F.[Pt],,,,,,
3383,123384,CID 123384,F[PH2](F)F,,,,,,
3384,123385,"2,4-Dimethyl-1-heptene",CCCC(C)CC(=C)C,,,,,,
3385,123386,"Pyridine, 2,3,4,5-tetrahydro-6-(methylthio)-",CSC1=NCCCC1,,,,,,
3386,123387,8-Hexadecyne,CCCCCCCC#CCCCCCCC,,,,,,
3387,123388,Ethyl methyl disulfide,CCSSC,,,,,,
3388,123389,"2,2,4,4-Tetrachloro-1,3-dithietane",C1(SC(S1)(Cl)Cl)(Cl)Cl,,,,,,
3389,123390,"2,3-Dimethylbutane-2,3-diamine",CC(C)(C(C)(C)N)N,,,,,,
3390,123391,"Perimidine, 2-amino-1-methyl-",CN1C2=CC=CC3=C2C(=CC=C3)N=C1N,,,,,,
3391,123392,Germanium oxide (GeO),O=[GeH2],,,['Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)'],,,
3392,123393,1-(10-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C,,,,,,
3393,123394,Nitrilotris(ethyleneoxy)tris(trimethylsilane),C[Si](C)(C)OCCN(CCO[Si](C)(C)C)CCO[Si](C)(C)C,,,,,,
3394,123395,"Ethylenediamine-N,N'-disuccinic acid",C(CNC(CC(=O)O)C(=O)O)NC(CC(=O)O)C(=O)O,,,,,,
3395,123396,Magnesium octaethylporphyrin,CCC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C([N-]5)C=C1[N-]2)CC)CC)C(=C4CC)CC)C(=C3CC)CC)CC.[Mg+2],,,,,,
3396,123397,Mercury(2+);methanethiolate,C[S-].C[S-].[Hg+2],,,,,,
3397,123398,"Methoxy, trifluoro-",C([O])(F)(F)F,,,,,,
3398,123399,"2,4,6-Trichlorophenyl isothiocyanate",C1=C(C=C(C(=C1Cl)N=C=S)Cl)Cl,,,,,,
3399,123400,"Phosphorothioic acid, O-ethyl O-isopropyl O-(4-nitro-m-tolyl) ester",CCOP(=S)(OC1=CC(=C(C=C1)[N+](=O)[O-])C)OC(C)C,,,,,,
3400,123401,"Phosphorodifluoridic acid, methyl ester",COP(=O)(F)F,,,,,,
3401,123402,3-Diethylamino-1-phenylpropyne,CCN(CC)CC#CC1=CC=CC=C1,,,,,,
3402,123403,4-Chloro-m-tolyl-p-nitrophenyl ether,CC1=C(C=CC(=C1)OC2=CC=C(C=C2)[N+](=O)[O-])Cl,,,,,,
3403,123404,"1,2-Dibromo-(1,1,2,2-2H4)ethane",[2H]C([2H])(C([2H])([2H])Br)Br,,,,,,
3404,123405,"Benzene, 1-methyl-4-(1-methylethoxy)-",CC1=CC=C(C=C1)OC(C)C,,,,,,
3405,123406,2-Ethylbenzaldehyde,CCC1=CC=CC=C1C=O,,,,,,
3406,123407,2-Ethoxyphenyl isothiocyanate,CCOC1=CC=CC=C1N=C=S,,,,,,
3407,123408,"2,4,5-Trichlorophenyl isothiocyanate",C1=C(C(=CC(=C1Cl)Cl)Cl)N=C=S,,,,,,
3408,123409,2-Palmitoylglycerol,CCCCCCCCCCCCCCCC(=O)OC(CO)CO,,,,,,
3409,123410,"2,4-Imidazolidinedione, 1,3-dimethyl-",CN1CC(=O)N(C1=O)C,,,,,,
3410,123411,Propargyl isothiocyanate,C#CCN=C=S,,,,,,
3411,123412,"1H-Cyclopenta[a]phenanthrene, hexadecahydro-10,13-dimethyl-, [8S-(8alpha,9beta,10alpha,13alpha,14beta)]-",CC12CCCC1C3CCC4CCCCC4(C3CC2)C,,,,,,
3412,123413,2-Ethyl-3-methylbutanal,CCC(C=O)C(C)C,,,,,,
3413,123414,Diphenylphosphoryl azide,C1=CC=C(C=C1)OP(=O)(N=[N+]=[N-])OC2=CC=CC=C2,,,,,,
3414,123415,Methyl 2-chlorobutanoate,CCC(C(=O)OC)Cl,,,,,,
3415,123416,"1,4-Butanediamine, 2,3-dimethoxy-N,N,N',N'-tetramethyl-, [S-(R*,R*)]-",CN(C)CC(C(CN(C)C)OC)OC,,,,,,
3416,123417,Methoxycarbonylsulfenyl chloride,COC(=O)SCl,,,,,,
3417,123418,"p-Chlorophenyl 2-chloro-1,1,2-trifluoroethyl sulphone",C1=CC(=CC=C1S(=O)(=O)C(C(F)Cl)(F)F)Cl,,,,,,
3418,123419,3-Nitro-1H-pyrazole,C1=C(NN=C1)[N+](=O)[O-],,,,,,
3419,123420,Ditetradecyl sebacate,CCCCCCCCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCCCCCCCC,,,,,,
3420,123421,Methyldiazene,CN=N,,,,,,
3421,123422,Di(1-pyrazolyl)methane,C1=CN(N=C1)CN2C=CC=N2,,,,,,
3422,123423,Butyl 3-chloropropanoate,CCCCOC(=O)CCCl,,,,,,
3423,123424,2-Ethyl-1-pentanol,CCCC(CC)CO,,,,,,
3424,123425,2-Methylenebornane,CC1(C2CCC1(C(=C)C2)C)C,,,,,,
3425,123426,"2,6,7-Trioxabicyclo(2.2.2)octane, 1,4-dimethyl-",CC12COC(OC1)(OC2)C,,,,,,
3426,123427,"2,6-Dibromophenol acetate",CC(=O)OC1=C(C=CC=C1Br)Br,,,,,,
3427,123428,"1,1-Dimethyl-3-(3-methylphenyl)urea",CC1=CC(=CC=C1)NC(=O)N(C)C,,,,,,
3428,123429,Ethyl(methyl)mercury,CC[Hg]C,,,,,,
3429,123430,"1-alpha-H,5-alpha-H-Tropan-3-beta-ol, carbanilate",CN1C2CCC1CC(C2)OC(=O)NC3=CC=CC=C3,,,,,,
3430,123431,1-Benzyl-2-chlorobenzene,C1=CC=C(C=C1)CC2=CC=CC=C2Cl,,,,,,
3431,123432,"Mercury, chloro(1-methylethyl)-",CC(C)[Hg]Cl,,,,,,
3432,123433,CID 123433,C1=CC=C(C=C1)C(=O)C2=NC(=O)ON2,,,,,,
3433,123434,Trimethoxysilylmethanethiol,CO[Si](CS)(OC)OC,,,,,,
3434,123435,"1,4,10-Trioxa-7,13-diazacyclopentadecane",C1COCCNCCOCCOCCN1,,,,,,
3435,123436,1-Amino-1-(1H-tetrazole-5-ylazo)guanidine,C1(=NNN=N1)N=NN(C(=N)N)N,,,,,,
3436,123437,Non-3-yn-1-ol,CCCCCC#CCCO,,,,,,
3437,123438,"4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]tricosane",C1COCCN2CCOCCOCCN1CCOCCOCC2,,,,,,
3438,123439,"2-(Chloromethyl)-3-methyl-1,4-naphthalenedione",CC1=C(C(=O)C2=CC=CC=C2C1=O)CCl,,,,,,
3439,123440,2-Bromo-1-(2-methoxyphenyl)ethanone,COC1=CC=CC=C1C(=O)CBr,,,,,,
3440,123441,Ethynol,C#CO,,,,,,
3441,123442,"1,2,3,5-Tetrahydroimidazo[2,1-b]quinazoline",C1CN2CC3=CC=CC=C3NC2=N1,,,,,,
3442,123443,2-Ethylbenzonitrile,CCC1=CC=CC=C1C#N,,,,,,
3443,123444,"2,2'-Bipyrimidine",C1=CN=C(N=C1)C2=NC=CC=N2,,,,,,
3444,123445,1-Aminoindan,C1CC2=CC=CC=C2C1N,,,,,,
3445,123446,Bromoselenobenzene,C1=CC=C(C=C1)[Se]Br,,,,,,
3446,123447,"Ethyl 2,5-dichlorobenzoate",CCOC(=O)C1=C(C=CC(=C1)Cl)Cl,,,,,,
3447,123448,"4,12-Dimethylbenz[a]anthracene",CC1=C2C=CC3=CC4=CC=CC=C4C(=C3C2=CC=C1)C,,,,,,
3448,123449,(Di-tert-butyl)dimethylstannane,CC(C)(C)[Sn](C)(C)C(C)(C)C,,,,,,
3449,123450,2-Phenoxynicotinic acid,C1=CC=C(C=C1)OC2=C(C=CC=N2)C(=O)O,,,,,,
3450,123451,"Tetramethyl-1,2-dioxetane",CC1(C(OO1)(C)C)C,,,,,,
3451,123452,Pentafluorophenyl isothiocyanate,C(=NC1=C(C(=C(C(=C1F)F)F)F)F)=S,,,,,,
3452,123453,"2,8,9-Trioxa-5-aza-1-silabicyclo(3.3.3)undecane, phenylaminomethyl-",C1CO[Si]2(OCCN1CCO2)CNC3=CC=CC=C3,,,,,,
3453,123454,"1,6-Methano[10]annulen-11-one",C1=CC=C2C=CC=CC(=C1)C2=O,,,,,,
3454,123455,Acetyldioxidanyl,CC(=O)O[O],,,,,,
3455,123456,"2,4-Dibromophenyl acetate",CC(=O)OC1=C(C=C(C=C1)Br)Br,,,,,,
3456,123457,2-Isopropylimidazole,CC(C)C1=NC=CN1,,,,,,
3457,123458,1-Methoxy-2-propylamine,CC(COC)N,,,,,,
3458,123459,"2H-Tricosafluoro-5,8,11,14-tetrakis(trifluoromethyl)-3,6,9,12,15-pentaoxaoctadecane",C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F,,,,,,
3459,123460,Methyl 3-chloro-3-oxopropionate,COC(=O)CC(=O)Cl,,,,,,
3460,123461,Propyl dichloroacetate,CCCOC(=O)C(Cl)Cl,,,,,,
3461,123462,1-(4-Hexylphenyl)ethanone,CCCCCCC1=CC=C(C=C1)C(=O)C,,,,,,
3462,123463,p-Butoxybenzylidene p-propylaniline,CCCCOC1=CC=C(C=C1)C=NC2=CC=C(C=C2)CCC,,,,,,
3463,123464,2-Chloro-6-fluorophenylacetic acid,C1=CC(=C(C(=C1)Cl)CC(=O)O)F,,,,,,
3464,123465,2-Ethoxybenzylamine,CCOC1=CC=CC=C1CN,,,,,,
3465,123466,Octafluoroadipoyl difluoride,C(=O)(C(C(C(C(C(=O)F)(F)F)(F)F)(F)F)(F)F)F,,,,,,
3466,123467,"2',4'-Dichloropropiophenone",CCC(=O)C1=C(C=C(C=C1)Cl)Cl,,,,,,
3467,123468,"2,8,9-Trioxa-5-aza-1-silabicyclo(3.3.3)undecane, 1-(p-tolyl)-",CC1=CC=C(C=C1)[Si]23OCCN(CCO2)CCO3,,,,,,
3468,123469,Methyl 3-chloro-4-methoxybenzoate,COC1=C(C=C(C=C1)C(=O)OC)Cl,,,,,,
3469,123470,"Ethanone, 1-(4-butylphenyl)-",CCCCC1=CC=C(C=C1)C(=O)C,,,,,,
3470,123471,"Benzenemethanamine, 4-amino-N-methyl-",CNCC1=CC=C(C=C1)N,,,,,,
3471,123472,Diethylaminosulfur trifluoride,CCN(CC)S(F)(F)F,,,,,,
3472,123473,p-Methylbenzylidene p-butylaniline,CCCCC1=CC=C(C=C1)N=CC2=CC=C(C=C2)C,,,,,,
3473,123474,"Hydrazinecarboxaldehyde, 2-(4-methylphenyl)-",CC1=CC=C(C=C1)NNC=O,,,,,,
3474,123475,2-Methoxyethyl isothiocyanate,COCCN=C=S,,,,,,
3475,123476,"Ethanamine, 2,2-dimethoxy-N,N-dimethyl-",CN(C)CC(OC)OC,,,,,,
3476,123477,4-Chloro-3-nitrobenzoyl chloride,C1=CC(=C(C=C1C(=O)Cl)[N+](=O)[O-])Cl,,,,,,
3477,123478,3-Chloro-4-nitrotoluene,CC1=CC(=C(C=C1)[N+](=O)[O-])Cl,,,,,,
3478,123479,CID 123479,CN1C(=NN=C1S)C2=CC=CC=C2,,,,,,
3479,123480,Butylisopropylamine,CCCCNC(C)C,,,,,,
3480,123481,"(3,5-Dimethylphenyl)acetonitrile",CC1=CC(=CC(=C1)CC#N)C,,,,,,
3481,123482,"1-Amino-2,6-dimethylpiperidine",CC1CCCC(N1N)C,,,,,,
3482,123483,"1-Pentanamine, N-butyl-",CCCCCNCCCC,,,,,,
3483,123484,"4,4,6-Trimethyl-2-(prop-1-en-2-yl)-5,6-dihydro-4h-1,3-oxazine",CC1CC(N=C(O1)C(=C)C)(C)C,,,,,,
3484,123485,2-Naphthohydrazide,C1=CC=C2C=C(C=CC2=C1)C(=O)NN,,,,,,
3485,123486,3-Chloro-4-methylbenzyl alcohol,CC1=C(C=C(C=C1)CO)Cl,,,,,,
3486,123487,"N'-Cyano-N,N-dimethylmethanimidamide",CN(C)C=NC#N,,,,,,
3487,123488,"Benzenamine, N-[(4-butoxyphenyl)methylene]-4-pentyl-",CCCCCC1=CC=C(C=C1)N=CC2=CC=C(C=C2)OCCCC,,,,,,
3488,123489,5-Phenyl-o-anisidine,COC1=C(C=C(C=C1)C2=CC=CC=C2)N,,,,,,
3489,123490,"Benzenamine, 4-(octyloxy)-",CCCCCCCCOC1=CC=C(C=C1)N,,,,,,
3490,123491,"2-Quinuclidinecarboxylic acid, ethyl ester",CCOC(=O)N1CC2CCC1CC2,,,,,,
3491,123492,2-Fluoro-4-iodotoluene,CC1=C(C=C(C=C1)I)F,,,,,,
3492,123493,"Ethanedione, bis(3-methoxyphenyl)-",COC1=CC=CC(=C1)C(=O)C(=O)C2=CC(=CC=C2)OC,,,,,,
3493,123494,2-(Methyldisulfanyl)propane,CC(C)SSC,,,,,,
3494,123495,Bromine nitrate,[N+](=O)([O-])OBr,,,,,,
3495,123496,2-Acetoxyisobutyryl chloride,CC(=O)OC(C)(C)C(=O)Cl,,,,,,
3496,123497,4-Methyl-3-nitrobenzyl alcohol,CC1=C(C=C(C=C1)CO)[N+](=O)[O-],,,,,,
3497,123498,2-Chloro-5-(trifluoromethyl)phenol,C1=CC(=C(C=C1C(F)(F)F)O)Cl,,,,,,
3498,123499,"4,7-Dimethylquinoline",CC1=CC2=NC=CC(=C2C=C1)C,,,,,,
3499,123500,Methyl 4-methoxyacetoacetate,COCC(=O)CC(=O)OC,,,,,,
3500,123501,"2,6-Dichloro-N-(1,3-dimethyl-2-imidazolidinylidene)benzenamine",CN1CCN(C1=NC2=C(C=CC=C2Cl)Cl)C,,,,,,
3501,123502,"1,4,8,11-Tetramethyl-1,4,8,11-tetraazacyclotetradecane",CN1CCCN(CCN(CCCN(CC1)C)C)C,,,,,,
3502,123503,"Benzonitrile, 4-[[[4-(octyloxy)phenyl]imino]methyl]-",CCCCCCCCOC1=CC=C(C=C1)N=CC2=CC=C(C=C2)C#N,,,,,,
3503,123504,4-Chloro-4'-hydroxybenzophenone,C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)Cl)O,,,,,,
3504,123505,"Pentane-2,3-diol",CCC(C(C)O)O,,,,,,
3505,123506,1-(2-Chloroethoxy)propane,CCCOCCCl,,,,,,
3506,123507,"2,3-Dimethylcyclohexylamine",CC1CCCC(C1C)N,,,,,,
3507,123508,"1,9-Dimethylguanine",CN1C=NC2=C1N=C(N(C2=O)C)N,,,,,,
3508,123509,12-Chloro-5-dodecyne,CCCCC#CCCCCCCCl,,,,,,
3509,123510,(Nitroperoxy)methane,COO[N+](=O)[O-],,,,,,
3510,123511,4-Chloro-1-(2-thienyl)butan-1-one,C1=CSC(=C1)C(=O)CCCCl,,,,,,
3511,123512,"1,1,1-Trimethoxybutane",CCCC(OC)(OC)OC,,,,,,
3512,123513,4-tert-Butylbenzhydrazide,CC(C)(C)C1=CC=C(C=C1)C(=O)NN,,,,,,
3513,123514,3-Trimethylsilyl-2-oxazolidinone,C[Si](C)(C)N1CCOC1=O,,,,,,
3514,123515,"2,2,3,3-Tetrafluoropropyl methacrylate",CC(=C)C(=O)OCC(C(F)F)(F)F,,,,,,
3515,123516,"2,2,3,3,3-Pentafluoropropyl methacrylate",CC(=C)C(=O)OCC(C(F)(F)F)(F)F,,,,,,
3516,123517,2-(Chloromethyl)-1-methylpiperidine,CN1CCCCC1CCl,,,,,,
3517,123518,"1,3,5-Triazine, 2,4,6-tris(2,4,6-trinitrophenyl)-",C1=C(C=C(C(=C1[N+](=O)[O-])C2=NC(=NC(=N2)C3=C(C=C(C=C3[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])C4=C(C=C(C=C4[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
3518,123519,4-Formylphenyl propionate,CCC(=O)OC1=CC=C(C=C1)C=O,,,,,,
3519,123520,"Butanoic acid, 4-formylphenyl ester",CCCC(=O)OC1=CC=C(C=C1)C=O,,,,,,
3520,123521,Ethyl 2-oxovalerate,CCCC(=O)C(=O)OCC,,,,,,
3521,123522,"1,1,3,3-Tetramethylcyclopentane",CC1(CCC(C1)(C)C)C,,,,,,
3522,123523,"1,3-Butadiyne, 1,4-dichloro-",C(#CCl)C#CCl,,,,,,
3523,123524,"Propane, 2,2'-tellurobis-",CC(C)[Te]C(C)C,,,,,,
3524,123525,"4-Penten-1-ol, 3-methyl-",CC(CCO)C=C,,,,,,
3525,123526,"1-Decanol, 10-chloro-",C(CCCCCCl)CCCCO,,,,,,
3526,123527,5-Bromo-2-fluorotoluene,CC1=C(C=CC(=C1)Br)F,,,,,,
3527,123528,"2-[(2,6-dichlorophenyl)methyl]-4,5-dihydro-1H-imidazole",C1CN=C(N1)CC2=C(C=CC=C2Cl)Cl,,,,,,
3528,123529,"1,3-Diisothiocyanatopropane",C(CN=C=S)CN=C=S,,,,,,
3529,123530,1-(Chloromethyl)-4-(methylsulfonyl)benzene,CS(=O)(=O)C1=CC=C(C=C1)CCl,,,,,,
3530,123531,"Azuleno(1,2,3-cd)phenolene",C1=CC=C2C(=C3C=CC4=CC=CC5=C4C3=C2C=C5)C=C1,,,,,,
3531,123532,1-Bromo-2-(2-methoxyethoxy)ethane,COCCOCCBr,,,,,,
3532,123533,CID 123533,C1=CC(=CC(=C1)O)C(=CC(=O)O)C#N,,,,,,
3533,123534,Butyl 2-chloropropanoate,CCCCOC(=O)C(C)Cl,,,,,,
3534,123535,"3,6,9,12,15,18-Hexaoxaheneicosane, 1,1,1,2,4,4,5,7,7,8,10,10,11,13,13,14,16,16,17,19,19,20,20,21,21,21-hexacosafluoro-5,8,11,14,17-pentakis(trifluoromethyl)-",C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(OC(C(C(F)(F)F)(F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F)(F)F)F,,,,,,
3535,123536,3-Tetradecyn-1-ol,CCCCCCCCCCC#CCCO,,,,,,
3536,123537,2-Bromo-6-nitrotoluene,CC1=C(C=CC=C1Br)[N+](=O)[O-],,,,,,
3537,123538,3-Bromo-2-methylaniline,CC1=C(C=CC=C1Br)N,,,,,,
3538,123539,"Cyclooctanol, 1-ethynyl-",C#CC1(CCCCCCC1)O,,,,,,
3539,123540,2-Methyl-1-propenol,CC(=CO)C,,,,,,
3540,123541,3-Phenyl-p-anisidine,COC1=C(C=C(C=C1)N)C2=CC=CC=C2,,,,,,
3541,123542,"2-(1H-1,3-benzodiazol-2-yl)-3-phenylprop-2-enenitrile",C1=CC=C(C=C1)C=C(C#N)C2=NC3=CC=CC=C3N2,,,,,,
3542,123543,2-Propyl-1-pentanol,CCCC(CCC)CO,,,,,,
3543,123544,(1-Phenylcyclopentyl)methanol,C1CCC(C1)(CO)C2=CC=CC=C2,,,,,,
3544,123545,"N-(3,4,5,6-Tetrahydrophthalyl)glutarimide",C1CCC2=C(C1)C(=O)N(C2=O)C3CC(=O)NC(=O)C3,,,,,,
3545,123546,4-Bromo-2-nitrotoluene,CC1=C(C=C(C=C1)Br)[N+](=O)[O-],,,,,,
3546,123547,Octaethylheme,CCC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C([N-]5)C=C1[N-]2)CC)CC)C(=C4CC)CC)C(=C3CC)CC)CC.[Fe+2],,,,,,
3547,123548,Ethyl 3-(4-hydroxy-3-methoxyphenyl)propionate,CCOC(=O)CCC1=CC(=C(C=C1)O)OC,,,,,,
3548,123549,N-Methyl-1-(methylthio)-2-nitroethenamine,CNC(=C[N+](=O)[O-])SC,,,,,,
3549,123550,Propyl 3-chloropropionate,CCCOC(=O)CCCl,,,,,,
3550,123551,Isobutyl 2-chloropropionate,CC(C)COC(=O)C(C)Cl,,,,,,
3551,123552,2-Bromo-6-chlorotoluene,CC1=C(C=CC=C1Br)Cl,,,,,,
3552,123553,3-(4-Methoxyphenoxy)benzaldehyde,COC1=CC=C(C=C1)OC2=CC=CC(=C2)C=O,,,,,,
3553,123554,Methanesulfenic acid,CSO,,,,,,
3554,123555,"2-(1H-1,3-benzodiazol-2-yl)-3-(2-chlorophenyl)prop-2-enenitrile",C1=CC=C(C(=C1)C=C(C#N)C2=NC3=CC=CC=C3N2)Cl,,,,,,
3555,123556,p-Pentyloxynitrobenzene,CCCCCOC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3556,123557,"1-Bromo-2,6-difluorobenzene",C1=CC(=C(C(=C1)F)Br)F,,,,,,
3557,123558,"2,5-Difluorobenzonitrile",C1=CC(=C(C=C1F)C#N)F,,,,,,
3558,123559,Pinacol monoformate,CC(C)(C(C)(C)OC=O)O,,,,,,
3559,123560,"Benzoic acid, 2-methyl-, butyl ester",CCCCOC(=O)C1=CC=CC=C1C,,,,,,
3560,123561,"3,5-Diisopropylbiphenyl",CC(C)C1=CC(=CC(=C1)C2=CC=CC=C2)C(C)C,,,,,,
3561,123562,"3,3'-Diisopropylbiphenyl",CC(C)C1=CC=CC(=C1)C2=CC(=CC=C2)C(C)C,,,,,,
3562,123563,"2,6-Difluorobenzylamine",C1=CC(=C(C(=C1)F)CN)F,,,,,,
3563,123564,Tert-butyldimethylsilyl trifluoromethanesulfonate,CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F,,,,,,
3564,123565,Nonyl cyclohexanecarboxylate,CCCCCCCCCOC(=O)C1CCCCC1,,,,,,
3565,123566,(4-Bromophenyl)(cyclopropyl)methanol,C1CC1C(C2=CC=C(C=C2)Br)O,,,,,,
3566,123567,"Propionic acid, 2-methyl-2-(m-tolylthio)-",CC1=CC(=CC=C1)SC(C)(C)C(=O)O,,,,,,
3567,123568,3-Methyl-4-penten-1-ol acetate,CC(CCOC(=O)C)C=C,,,,,,
3568,123569,8-Methylnon-1-yne,CC(C)CCCCCC#C,,,,,,
3569,123570,3-Thiophenemethanol,C1=CSC=C1CO,,,,,,
3570,123571,"2,3,4-Trimethoxybenzyl alcohol",COC1=C(C(=C(C=C1)CO)OC)OC,,,,,,
3571,123572,"3,4-Difluorobenzylamine",C1=CC(=C(C=C1CN)F)F,,,,,,
3572,123573,"Dichloromethyl(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane",C[Si](CCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(Cl)Cl,,,,,,
3573,123574,"3,6-Dibenzylidene-2,5-dioxopiperazine",C1=CC=C(C=C1)C=C2C(=O)NC(=CC3=CC=CC=C3)C(=O)N2,,,,,,
3574,123575,2-Chloro-6-fluorophenylacetonitrile,C1=CC(=C(C(=C1)Cl)CC#N)F,,,,,,
3575,123576,"3,5-Bis(trifluoromethyl)benzyl chloride",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)CCl,,,,,,
3576,123577,"1h,1h,2h,2h-Perfluorodecyltrichlorosilane",C(C[Si](Cl)(Cl)Cl)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
3577,123578,"Trichloro(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane",C(C[Si](Cl)(Cl)Cl)C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
3578,123579,3-Bromo-4-fluorobenzonitrile,C1=CC(=C(C=C1C#N)Br)F,,,,,,
3579,123580,"1,1,1-Trifluoro-2-phenylpropan-2-ol",CC(C1=CC=CC=C1)(C(F)(F)F)O,,,,,,
3580,123581,"2,4-Difluorophenylacetic acid",C1=CC(=C(C=C1F)F)CC(=O)O,,,,,,
3581,123582,"2,2-Dibromoethanol",C(C(Br)Br)O,,,,,,
3582,123583,"7-Methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene",CN1CCCN2C1=NCCC2,,,,,,
3583,123584,Methyl 3-amino-4-methylthiophene-2-carboxylate,CC1=CSC(=C1N)C(=O)OC,,,,,,
3584,123585,"2,6-Difluorophenylacetic acid",C1=CC(=C(C(=C1)F)CC(=O)O)F,,,,,,
3585,123586,"2',4'-Difluoropropiophenone",CCC(=O)C1=C(C=C(C=C1)F)F,,,,,,
3586,123587,"3,5-Bis(trifluoromethyl)phenylacetic acid",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)CC(=O)O,,,,,,
3587,123588,"2,4-Difluorobenzamide",C1=CC(=C(C=C1F)F)C(=O)N,,,,,,
3588,123589,"2,5-Difluorobenzylamine",C1=CC(=C(C=C1F)CN)F,,,,,,
3589,123590,sec-Hexadecylnaphthalene,CCCCCCCCCCCCCCC(C)C1=CC=CC2=CC=CC=C21,,,,,,
3590,123591,Buckminsterfullerene,C12=C3C4=C5C6=C1C7=C8C9=C1C%10=C%11C(=C29)C3=C2C3=C4C4=C5C5=C9C6=C7C6=C7C8=C1C1=C8C%10=C%10C%11=C2C2=C3C3=C4C4=C5C5=C%11C%12=C(C6=C95)C7=C1C1=C%12C5=C%11C4=C3C3=C5C(=C81)C%10=C23,,,,"['This study was conducted to determine the distribution of (14)C-C60 in the pregnant rat and fetus, and in the lactating rat and off-spring. Four dams were dosed via tail vein injection on gestational day (gd) 15 with 0.28 mg/kg body weight (14)C-C60 (~ 3 uCi per rat) prepared in 5% polyvinylpyrrolidone in saline (PVP), and four dams were dosed with PVP alone. Urine (0-24 hr) and tissues (24 hr) were collected from the dams. Eight lactating rats were dosed on postnatal day (pnd) 8 with 0.36 mg/kg (14)C-C 60 prepared in PVP, and sacrificed at 24 hr or 48 hr after exposure. In the pregnant dams, radioactivity was distributed to the placenta (approximately 2% of the dose), to the fetus (1.0%), and to the female reproductive tract (3.0%). Radioactivity was distributed to the milk (< 1%) and mammary tissue (<1%) in the lactating rats, and to the GI tract (<1%) and liver of the pup (< 1%). For the pregnant dam, radioactivity was distributed to the urine (<2%), feces (2%), blood (0.9% per mL) and plasma (1.7% per mL), brain (< 1%), lung (<1%), heart (<1%), liver (~43%), spleen (4%). In comparison to the pregnant dam, lactating rats had a similar radioactivity distribution to the blood and plasma at 24 hr after exposure (with a 50% decrease by 48 hr), a higher distribution to the lung, and a decreased distribution to the liver. Metabolomics analysis of urine indicated that dams exposed to C60 had a decrease in metabolites derived from the Krebs cycle and an increase in metabolites derived from the urea cycle or glycolysis; with alterations in the levels of some sulfur-containing amino acids and purine/pyrimidine metabolites. This study indicated that C60 can cross the placenta and can be transmitted from mother to offspring via milk.', 'Dermatomed porcine skin was fixed to a flexing device and topically dosed with 33.5 mg/mL of an aqueous solution of a fullerene-substituted phenylalanine (Baa) derivative of a nuclear localization peptide sequence (Baa-Lys(FITC)-NLS). Skin was flexed for 60 or 90 min or left unflexed (control). Confocal microscopy depicted dermal penetration of the nanoparticles at 8 hr in skin flexed for 60 and 90 min, whereas Baa-Lys(FITC)-NLS did not penetrate into the dermis of unflexed skin until 24 hr. TEM analysis revealed fullerene-peptide localization within the intercellular spaces of the stratum granulosum.', '...Both microscopic imaging and biological techniques /were used/ to explore the processes of [C60(C(COOH)2)2]n nanoparticles across cellular membranes and their intracellular translocation in 3T3 L1 and RH-35 living cells. The fullerene nanoparticles are quickly internalized by the cells and then routed to the cytoplasm with punctate localization. Upon entering the cell, they are synchronized to lysosome-like vesicles. The [C60(C(COOH)2)2]n nanoparticles entering cells are mainly via endocytosis with time-, temperature- and energy-dependent manners. The cellular uptake of [C60(C(COOH)2)2]n nanoparticles was found to be clathrin-mediated but not caveolae-mediated endocytosis...', '... An overview of the nanostructure and the physical and chemical characteristics of fullerene-drug derivatives is given. The biological behavior of fullerene derivatives shows their potential to medical application fields because C(60) is rapidly absorbed by tissues and is excreted through urinary tract and enterons, which reveals low toxicity in vitro and in vivo studies. Nanomedicine has become one of the most promising areas of nanotechnology, while many have claimed its therapeutic use against cancer, human immunodeficiency virus (HIV), and neurodegenerative disorders. Water-soluble C(60) fullerene derivatives that come from chemical modification largely enhance the biological efficacy. The blood-brain barrier (BBB) is a physical barrier composed of endothelial tight junctions that restrict the paracellular permeability. A major challenge facing neuropharmacology is to find compounds that can be delivered into the brain through the bloodstream. Fullerene C(60) was demonstratively able to cross the BBB by hybridizing a biologically active moiety dyad, which provides a promising clue as a pharmacological therapy of neural disorders. /C(60) Fullerene derivatives/', 'Pristine fullerenes (C60) in different solvents will be used in many industrial and pharmaceutical manufacturing and derivatizing processes. This report explores the impact of solvents on skin penetration of C60 from different types of industrial solvents (toluene, cyclohexane, chloroform and mineral oil). Yorkshire weanling pigs (n=3) were topically dosed with 500 uL of 200 ug/mL C60 in a given solvent for 24 hr and re-dosed daily for 4 days to simulate the worst scenario in occupational exposures. The dose sites were tape-stripped and skin biopsies were taken after 26 tape-strips for quantitative analysis. When dosed in toluene, cyclohexane or chloroform, pristine fullerenes penetrated deeply into the stratum corneum, the primary barrier of skin. More C60 was detected in the stratum corneum when dosed in chloroform compared to toluene or cyclohexane. Fullerenes were not detected in the skin when dosed in mineral oil. This is the first direct evidence of solvent effects on the skin penetration of pristine fullerenes. The penetration of C60 into the stratum corneum was verified using isolated stratum corneum in vitro; the solvent effects on the stratum corneum absorption of C60 were consistent with those observed in vivo. In vitro flow-through diffusion cell experiments were conducted in pig skin and fullerenes were not detected in the receptor solutions by 24 hr. The limit of detection was 0.001 ug/mL of fullerenes in 2 mL of the receptor solutions.']",,"['Fullerenes ... are spherical molecules consisting entirely of carbon atoms (C(x)) to which side chains can be added, furnishing compounds with widely different properties. ... Absorption, distribution and excretion strongly depend on the properties of the side chains. The pristine C(60) has a very long biological half-life, whereas the most water-soluble derivatives are eliminated from the exposed animals within weeks.', '... Male rats /were exposed/ to C60 fullerene nanoparticles (2.22 mg/cu m, 55 nm diameter) and microparticles (2.35 mg/cu m, 0.93 um diameter) for 3 hr a day, for 10 consecutive days using a nose-only exposure system. Nanoparticles were created utilizing an aerosol vaporization and condensation process. Nanoparticles and microparticles were subjected to high-pressure liquid chromatography (HPLC), XRD, and scanning laser Raman spectroscopy, which cumulatively indicated no chemical modification of the C60 fullerenes occurred during the aerosol generation. ... Lung half-lives for C60 fullerene nanoparticles and microparticles were 26 and 29 days, respectively...']"
3591,123592,CID 123592,CC(=C(N=O)S(=O)C)O,,,,,,
3592,123593,"3,4-Methylenedioxyphenyl isothiocyanate",C1OC2=C(O1)C=C(C=C2)N=C=S,,,,,,
3593,123594,4-(1-Aminoethyl)phenol,CC(C1=CC=C(C=C1)O)N,,,,,,
3594,123595,Lactaroviolin,CC1=C2C=CC(=C2C=C(C=C1)C(=C)C)C=O,,,,,,
3595,123596,Imatinib Mesylate,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,['Glivec is indicated for the treatment of'],,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)']","['Imatinib is well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose. Mean absolute bioavailability for the capsule formulation is 98%. Following oral administration in healthy volunteers, the elimination half-lives of imitanib and its major active metabolite, the N-desmethyl derivative, were approximately 18 and 40 hours, respectively. Mean imatinib AUC increased proportionally with increasing dose in the range 25 mg-1000 mg. There was no signficant change in the pharmacokinetics of imatinib on repeated dosing, and accumulation is 1.5-2.5 fold at steady state when Gleevec is dosed once daily. At clinically relevant concentrations of imatinib, binding to plasma proteins in in vitro experiments is approximately 95%, mostly to albumin and (alpha)1-acid glycoprotein.', 'Fecal /elimination/ - 68% within 7 days (20% of dose unchanged); Renal /elimination/ - 13% within 7 days (5% of dose unchanged).', 'Typically, clearance of imitanib in a 50-year-old patient weighing 50 kg is expected to be 8 L/hr, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/hr. However, the inter-patient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment related toxicity.', 'In lactating female rats administered 100 mg/kg ... imatinib and/or its metabolites were extensively excreted in milk. It is estimated that approximately 1.% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight.']","['CYP3A4 is the major enzyme responsible for metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to imatinib. The plasma AUC for this metabolite is about 15% of the AUC for imatinib.']","['Elimination - Approximately 18 and 40 hours, for imatinib and its primary metabolite, respectively.']"
3596,123597,"propan-2-yl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate",CC(C)OC(=O)CCCC=CC[C@H]1[C@H](C[C@H]([C@@H]1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O,,,,,,
3597,123598,CID 123598,C1=CC2=C(N=C1)OC3=C(C2=O)C=C(C=C3Cl)C4=NN=N[N-]4.[Na+],,,,,,
3598,123599,"3,5-Ethanoquinolin-10-one, decahydro-1,7-dimethyl-, (3R,4aS,5S,7S,8aR)-",CC1CC2C3CC(CC2=O)CN(C3C1)C,,,,,,
3599,123600,Levalbuterol,CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O,"['Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.']",['It acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.'],,"['Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.', 'excreted into the urine.']",['Pure (R)-salbutamol formulation known as levosalbutamol  is metabolised up to 12 times faster than (S)-salbutamol by intestine.'],['3.3 - 4 hours']
3600,123601,Levalbuterol hydrochloride,CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O.Cl,,,,,,
3601,123602,Levomedetomidine hydrochloride,CC1=C(C(=CC=C1)[C@@H](C)C2=CN=CN2)C.Cl,,,,,,
3602,123603,Cevimeline hydrochloride,C[C@@H]1O[C@]2(CN3CCC2CC3)CS1.Cl,,,"['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)', 'Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)']",,,
3603,123604,"(2S,3S)-2-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methyl-pentanoyl]amino]-N-[(1S,2R)-2-hydroxy-1-[[(1S)-3-methyl-1-[[2-[(2R)-2-methyloxiran-2-yl]-2-oxo-ethyl]carbamoyl]butyl]carbamoyl]propyl]-3-methyl-pentanamide",CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)[C@]1(CO1)C)NC(=O)[C@H]([C@@H](C)CC)N(C)C(=O)C,,,,,,
3604,123605,"(2R,3R)-2,3-dihydroxybutanedioic acid;2-[(1S)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol",CC1=CC(=C(C=C1)O)[C@@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
3605,123606,Almotriptan,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3,['For the treatment of acute migraine headache in adults'],"['Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT<sub>1D</sub> family) having only a weak affinity for 5-HT<sub>1A</sub>, 5-HT<sub>5A</sub>, and 5-HT<sub>7</sub> receptors and no significant affinity or pharmacological activity at 5-HT<sub>2</sub>, 5-HT<sub>3</sub> or 5-HT<sub>4</sub> receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT<sub>1</sub> receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.']",['Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)'],"['Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.', '180 to 200 L', '57 L/h [healthy]']",['Almotriptan has known human metabolites that include 2-hydroxy-almotriptan and methyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine.'],['3-4 hours']
3606,123607,Almotriptan malate,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O,,,['Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)'],,,
3607,123608,5-Aminolevulinic acid hydrochloride,C(CC(=O)O)C(=O)CN.Cl,['Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5. 1) and of field cancer ization in adults.'],,['Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)'],,,
3608,123609,CID 123609,C[C@H](C=CC(C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3CC(=C)[C@H](C[C@@H]3O)O)C,,,,,,
3609,123610,Eptifibatide,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,,,,"['/MILK/ It is not known whether eptifibatide is distributed into milk in humans.', 'Eptifibatide is approximately 25% bound to plasma proteins, principally (9-16%) to albumin.The volume of distribution of eptifibatide in patients with coronary artery disease is about 185-260 mL/kg and is somewhat higher (220-270 mL/kg) in healthy individuals.', 'Eptifibatide, a synthetic peptide inhibitor of the platelet glycoprotein IIb/IIIa receptor, has been studied as an antithrombotic agent in a variety of acute ischemic coronary syndromes. The purpose of the present study was to characterize the disposition of (14)C-eptifibatide in man after a single intravenous (i.v.) bolus dose. (14)C-Eptifibatide (approximately 50 uCi) was administered to eight healthy men as a single 135-ug/kg IV bolus. Blood, breath carbon dioxide, urine, and fecal samples were collected for up to 72 hours postdose and analyzed for radioactivity by liquid scintillation spectrometry. Plasma and urine samples were also assayed by liquid chromatography with mass spectrometry for eptifibatide and deamidated eptifibatide (DE). Mean (+/- SD) peak plasma eptifibatide concentrations of 879 +/- 251 ng/mL were achieved at the first sampling time (5 minutes), and concentrations then generally declined biexponentially, with a mean distribution half-life of 5 +/- 2.5 minutes and a mean terminal elimination half-life of 1.13 +/- 0.17 hours. Plasma eptifibatide concentrations and radioactivity declined in parallel, with most of the radioactivity (82.4%) attributed to eptifibatide. A total of approximately 73% of administered radioactivity was recovered in the 72-hour period following (14)C-eptifibatide dosing. The primary route of elimination was urinary (98% of the total recovered radioactivity), whereas fecal (1.5%) and breath (0.8%) excretion was small. Eptifibatide is cleared by both renal and nonrenal mechanisms, with renal clearance accounting for approximately 40% of total body clearance. Within the first 24 hours, the drug is primarily excreted in the urine as unmodified eptifibatide (34%), DE (19%), and more polar metabolites (13%).', 'Plasma clearance of eptifibatide is proportional to body weight and estimated creatinine clearance and inversely proportional to age. Following a single IV dose of (14)C-radiolabeled eptifibatide (135 ug/kg) in healthy men, renal clearance averaged approximately 40-50% of total body clearance. Clearance is reduced by 50% in patients with moderate to severe renal impairment (estimated Clcr less than 50 mL/minute). Total body clearance in geriatric patients with coronary artery disease is lower than that in younger adults.', 'For more Absorption, Distribution and Excretion (Complete) data for Eptifibatide (9 total), please visit the HSDB record page.']","['(14)C-eptifibatide was extensively metabolized to deamidated eptifibatide and to several polar metabolites by both rats and monkeys. The drug-derived radioactivity excreted into the bile by rats, and identified as deamidated eptifibatide, was reabsorbed from the intestinal tract and further metabolized to more polar metabolites. The plasma and urine metabolite profiles in rats and monkeys indicate that the metabolic disposition of eptifibatide is similar for the two species.', 'Eptifibatide is metabolized principally through deamidation to a metabolite that has approximately 41% of the platelet-aggregation inhibitory activity of the parent compound, and through formation of other more polar metabolites. Approximately 27% of a dose of eptifibatide is broken down in plasma into naturally occurring amino acids; no major non-amino acid metabolites have been detected in plasma in humans.']","['In Cynomolgus monkeys, plasma concentrations of (14)C-eptifibatide-derived radioactivity declined with a half life of about 12 hours following a single 2 mg/kg IV dose of (14)C-eptifibatide. Unchanged eptifibatide, which accounted for approximately 93% of total plasma (14)C at 5 min post-dose, was eliminated rapidly with a half life of 17 min.', 'In rats, plasma concentrations of (14)C-eptifibatide-derived radioactivity declined rapidly with a terminal phase half life of about 5 hours following a single 2 mg/kg IV dose of the radiolabeled drug. Unchanged eptifibatide declined with an apparent half life of about 8 min. Following single 2 and 20 mg/kg IV doses, the plasma concentrations of eptifibatide were dose-proportional and the half life (11 to 12 min) was dose-independent, indicating linear kinetics within the 2 to 20 mg/kg dose range.', 'The half-life of eptifibatide in patients with coronary artery disease averages 2.5-2.8 hours. In healthy individuals, half-life of the drug reportedly averages 0.83-2.4 hours.', '... The purpose of the present study was to characterize the disposition of (14)C-eptifibatide in man after a single intravenous (IV) bolus dose. (14)C-Eptifibatide (approximately 50 uCi) was administered to eight healthy men as a single 135-ug/kg IV bolus. ... Mean (+/- SD) peak plasma eptifibatide concentrations of 879 +/- 251 ng/mL were achieved at the first sampling time (5 minutes), and concentrations then generally declined biexponentially, with a mean distribution half-life of 5 +/- 2.5 minutes and a mean terminal elimination half-life of 1.13 +/- 0.17 hours. ...']"
3610,123611,"decasodium;(2S,3S,4R,5R,6R)-6-[(2R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate",CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H](C([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
3611,123612,CID 123612,CO[C@@H]1[C@@H](C([C@H]([C@@H](O1)COS(=O)(=O)O)O[C@@H]2[C@@H]([C@@H]([C@@H]([C@H](O2)C(=O)O)O[C@@H]3[C@@H](C(C([C@@H](O3)COS(=O)(=O)O)O[C@@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C(=O)O)O[C@@H]5[C@@H](C([C@H]([C@@H](O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O,,,,,,
3612,123613,"(4R)-10-Nitro-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione",CC[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O,,,,,,
3613,123614,"7-Ethyl-10,11-methylenedioxy-20-S-camptothecin",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=CC6=C(C=C51)OCO6,,,,,,
3614,123615,CID 123615,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)NC5=CC(=O)C=CC5=C4)O,,,,,,
3615,123616,10-Bromoacetamidomethylcamptothecin,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)CNC(=O)CBr)O,,,,,,
3616,123617,9-Methoxycamptothecin,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5OC)N=C4C3=C2)O,,,,,,
3617,123618,Tecastemizole,C1CNCCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,['Investigated for use/treatment in allergic rhinitis.'],,,,['Norastemizole is a known human metabolite of astemizole.'],
3618,123619,Etoricoxib,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,"['For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.']",['Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).'],"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2. (See all compounds classified as Cyclooxygenase 2 Inhibitors.)']",['Bioavailability is 100% following oral administration.'],"['Hepatic, primarily via CYP3A4.', ""Etoricoxib has known human metabolites that include 6-Hydroxymethyletoricoxib and Etoricoxib 1'-N'-oxide.""]",['22 hours']
3619,123620,B.Mometason,C[C@@H]1C[C@H]2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C,,,,,,
3620,123621,CID 123621,CCC(C)C(CC(=O)NO)C(=O)N[C@@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@H](C)C(=O)N,,,,,,
3621,123622,Imiprothrin,CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)CN(C2=O)CC#C)C,,,,['Male and female rats receiving a single oral dose of labeled imiprothrin at 1 or 200 mg/kg  eliminated almost all of the radioactivity within 7 days. More than 83% of the radioactivity  was excreted in the urine. 14C-residues were generally low in all dosed groups with no marked  sex-related differences in excretion rates or tissue residues.'],,
3622,123623,CID 123623,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H]([C@H](NC(=O)C2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O,['- Treatment of invasive candidiasis in adult or paediatric patients.'],,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
3623,123624,CID 123624,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H]([C@H](NC(=O)C2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)C(C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O,,,,,,
3624,123625,CID 123625,C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C(=C2N5CCC(CC5)C(C6CCCCC6)C7CCCCC7)O)O)C,,,,,,
3625,123626,"2-[N-[(3,5-difluorophenyl)carbamoylamino]-C-methylcarbonimidoyl]pyridine-3-carboxylic acid",CC(=NNC(=O)NC1=CC(=CC(=C1)F)F)C2=C(C=CC=N2)C(=O)O,,,,"['Following oral administration /in rats/, Diflufenzopyr was partially absorbed and rapidly eliminated; 20-40% of the dose was eliminated in urine and 49-79% in feces. By contrast, intravenously dosed rats excreted 61-89% of the dose in urine. Elimination /half-time/ in urine and feces was 6 hr.', 'A metabolism study of diflufenzopyr was  conducted in laying hens and lactating goats. The data showed diflufenzopyr was rapidly eliminated from the animals. With a feeding level of 10 ppm in the diet, residue levels in edible tissues, milk, and eggs were less than 0.12 ppm. ...', 'Wistar rats were administered (14)C-labeled Diflufenzopyr (SAN 835 H phenyl-labeled: radiochemical purity > 98%; pyridinyllabeled: radiochemical purity > 98%; unlabeled test article purity = 99.4%) according to each of four protocols: 1) a single i.v. dose at 1 mg/kg, 2) a single oral dose at 10 mg/kg, 3) a single oral dose at 1000 mg/kg, 4) fourteen daily oral doses of unlabeled test article at10 mg/kg followed by a single oral dose of labeled compound at 10 mg/kg. For protocols 1, 2 and 3, five males and five females were monitored according to each of 3 schedules: a) until sacrifice at 72 hrs post-dosing, b) until sacrifice at 24 hrs post-dosing, c) bile-duct cannulated animals followed until sacrifice at 48 hrs post-dosing. For the repeated dosing protocol, five males and five females were sacrificed at 24 hrs and 72 hrs after dosing with the labeled test article. Intravenous administration led to rapid elimination in the urine of between approximately 58 and 68% of both labeled forms by 7 hrs, and between 70 and 90% by 72 hrs. Of the approximate 7-20% excreted in the feces, almost all was a result of bilary excretion. Oral dosing at both 10 and 1000 mg/kg resulted in elimination of both labels mainly through the feces (approximately 55-80% by 72 hrs). Excretion in the urine accounted for approximately 20-39%, with approximately 3-10% excreted in the bile. Tissue retention at 72 hrs was low after either intravenous or oral dosing, being 0.37% or less for the phenyl-labeled compound (highest in blood) and 0.04% or less for the pyridinyl compound (highest in kidney and liver). The percent absorption for both labeled compounds, calculated by dividing the amount of labeled compound excreted in the urine after oral dosing by the amount excreted in the urine after i.v. dosing, was between 30 and 50%, with no difference between the 10 and 1000 mg/kg dose levels. ... There were no significant differences in test article absorption, elimination, tissue distribution or metabolism by males versus females. Likewise, high and low dose levels gave similar results, suggesting no saturation for absorption or elimination. There was less tissue retention of the pyridinyl-labeled compound and greater retention of the phenyl-labeled compound in the blood. Lastly, single versus multiple dosing showed that the test article did not bioaccumulate or induce metabolizing enzymes.']","['Metabolite analysis of the urine, bile and feces was conducted by TLC, HPLC, mass spectrometry and NMR spectroscopy. Unaltered test article was the major labeled compound in all excreta. Major metabolic reactions included cyclization, hydrolysis and hydroxylation, yielding 7 major metabolites (M1, M2, M5, M6, M9, M10 and M19). M19, M10 and M9 were also identified in excreta from goats and hens, and in corn silage.']","['Wistar rats were administered (14)C-labeled Diflufenzopyr (SAN 835 H phenyl-labeled: radiochemical purity > 98%; pyridinyllabeled: radiochemical purity > 98%; unlabeled test article purity = 99.4%) ... Elimination rates followed a one compartmental model, yielding an average half-time of 6.3 hrs for all groups combined. Elimination rates were not different between dose levels, or between the two different labels.']"
3626,123627,Clofencet,CCC1=C(C(=O)C=NN1C2=CC=C(C=C2)Cl)C(=O)O,,,,,,
3627,123628,Glufosfamide,C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,"['Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.']",,,,,"['... /A study was conducted/ to determine the maximum tolerated dose (MTD)... and the pharmacokinetics of 6 hr infusion of glufosfamide ... a novel alkylating agent with the potential to target the glucose transporter system. Twenty-one patients (10 women, 11 men; median age 56 yr) with refractory solid tumors were treated with doses ranging from 800 to 6,000 mg/sq m. /The drug/ was admin very three weeks as a two step (fast/slow) iv infusion over a 6 hr period. All patients went under pharmacokinetic sampling at the first course. The MTD was 6,000 mg/sq m. ... Pharmacokinetics indicated linearity of the area the time-versus-concentration curve against dose over the dose range studied and a short elimination half life. ...']"
3628,123629,CID 123629,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@@H]3[C@H]4N(C3=O)[C@@H](C(S4)(C)C)C(=O)[O-].C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=CN=N3.[Na+].[Na+],,,,,,
3629,123630,Tazobactam,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,"['Tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action, treating susceptible infections. As with any other antibiotic, tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drug.  **Tazobactam-piperacillin**  When combined with piperacillin, it is used to treat a variety of infections, including those caused by aerobic and facultative gram-positive and gram-negative bacteria, in addition to gram-positive and gram-negative anaerobes. Some examples of infections treated with piperacillin-tazobactam include cellulitis, diabetic foot infections, appendicitis, and postpartum endometritis infections. Certain gram-negative bacilli infections with beta-lactamase producing organisms cannot be treated with piperacillin-tazobactam, due to a gene mutation conferring antibiotic resistance.  **Tazobactam-ceftolozane**  Tazobactam-ceftolozane combined with metronidazole is used to treat complicated urinary tract infections (UTI) and complicated intra-abdominal infections, as well as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.. This combination increases efficacy against infections with gram-negative bacilli.']","['Tazobactam inhibits the action of bacterial beta-lactamase producing organisms, which are normally resistant to beta-lactam antibiotics. This augments the effects of antibiotics which would otherwise not be effective in treating certain infections.  These antibiotics contain a beta-lactam ring in their chemical structure, which is destroyed by beta-lactam resistant organisms. When combined with other antibiotics, a variety of infections, including serious and life-threatening infections may be treated.']","['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)']","['Tazobactam is coadministered with piperacillin or ceftolozane, pharmacokinetic information will be provided for these combinations.  **Piperacillin-tazobactam**  Peak plasma concentrations occur immediately after the completion of intravenous infusion.  Following several doses of piperacillin-tazobactam infusions every 6 hours, peak concentrations were similar to those that were measured after the initial dose.  **Ceftolozane-piperacillin**  AUC: 24.4-25 mcgh/mL  Peak concentrations are reached on day 1 after the first dose and range from 18 to 18.4 mcg/mL.', 'Tazobactam and its metabolite are mainly eliminated by the kidneys with about 80% of the administered dose eliminated as unchanged drug. The remaining drug is excreted as a single metabolite.', '18.2 L when given with piperacillin  13.5-18.2 L when given with ceftolozane  Piperacillin-tazobactam is widely distributed in body tissues and fluids. These may include but are not limited to the intestine, gallbladder, lung, female reproductive organs, and the bile. Meningeal distribution of piperacillin-tazobactam increases with inflammation, but is otherwise low.', 'Because tazobactam is cleared by the kidneys and is a substrate of the transporters OAT1 and OAT3, inhibitors of these transporters should be avoided to ensure efficacy. Dosage adjustments of piperacillin-tazobactam and ceftolozane-tazobactam must be made for patients with impaired renal clearance.  The mean clearance rate of tazobactam was found to be 48.3-83.6 mL/min in patients admitted to the intensive care unit who were given renal replacement therapy and receiving intravenous piperacillin-tazobactam.    The clearance of tazobactam is dependent on renal function, as determined by renal clearance.']","['Tazobactam is mainly metabolized to M1, an inactive metabolite. Hydrolysis occurs on the beta-lactam ring to form M1 (the inactive metabolite).']","['Piperacillin-tazobactam  After a single dose in healthy volunteers, the plasma half-life of piperacillin and tazobactam was in the range of 0.7 to 1.2 hours.  Ceftolozane-tazobactam  0.91-1.03 hours']"
3630,123631,Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,['For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.'],"['Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.']","['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)']","['Absorbed slowly after oral administration with a mean bioavailability of 60%. Peak plasma levels occurs 3-7 hours post-administration. Food does not affect the bioavailability of gefitinib.', 'Elimination is by metabolism (primarily CYP3A4) and excretion in feces.  Excretion is predominantly via the feces (86%), with renal elimination of drug and metabolites accounting for less than 4% of the administered dose.', '1400 L [IV administration]', '595 mL/min [IV administration]']","['Primarily hepatic via CYP3A4. Three sites of biotransformation have been identified: metabolism of the N-propoxymorpholino-group, demethylation of the methoxy-substituent on the quinazoline, and oxidative defluorination of the halogenated phenyl group.', 'Gefitinib has known human metabolites that include 4-Defluoro-4-hydroxy Gefitinib and O-Desmethyl Gefitinib.']",['48 hours [IV administration]']
3631,123632,Endothelin Receptor A Antagonist BQ-123,CC(C)[C@H](C(=O)N[C@@H](CC(=C)C)C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C=O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](CC(=O)O)N,,,,,,
3632,123633,Lactide-caprolactone copolymer,CC1C(=O)OC(C(=O)O1)C.C1CCC(=O)OCC1,,,,,,
3633,123634,Trisekvens,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O.C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,,,"['Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)']",,,
3634,123635,CID 123635,C[C@]12CCC3C([C@@H]1CC(C2O)O)CCC4=C3C=CC(=C4)O,,,,,,
3635,123636,3-(4-(2-(6-(Dibutylamino)naphthalen-2-yl)vinyl)pyridinium-1-yl)propane-1-sulfonate,CCCCN(CCCC)C1=CC2=C(C=C1)C=C(C=C2)C=CC3=CC=[N+](C=C3)CCCS(=O)(=O)[O-],,,,,,
3636,123637,3-[4-[2-[6-(Dibutylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonic acid,CCCCN(CCCC)C1=CC2=C(C=C1)C=C(C=C2)C=CC3=CC=[N+](C=C3)CCCS(=O)(=O)O,,,,,,
3637,123638,"S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] icosa-5,8,11,14-tetraenethioate",CCCCCC=CCC=CCC=CCC=CCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3638,123639,"1,2-Benzenediol, 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butyl)amino)ethyl)-",C1=CC(=CC=C1CCCCNCC(C2=CC(=C(C=C2)O)O)O)O,,,,,,
3639,123640,13-Azaprostanoic acid,CCCCCCCN[C@H]1CCC[C@@H]1CCCCCCC(=O)O,,,,,,
3640,123641,Degammae,C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NC(CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NC([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O,,,,,,
3641,123642,Lofentanyl,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2C)CCC3=CC=CC=C3)C(=O)OC,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']","['(3)H-Lofentanil, an extremely potent opiate drug with a very long duration of action was injected intravenously into rats immediately after a ligature had been tied around the vagus nerve. Radioactivity accumulated on both sides of the ligature 24 hours and, to a larger extent, 48 hours after the injection. In contrast, there was no accumulation in animals pretreated with naloxone, neither in ligated sciatic nerves nor between two ligatures in the vagus nerve. An accumulation of stereospecific (3)H-lofentanil binding sites measured in vitro was only detected above the ligature, thus in the proximal part of the nerve. When (3)H-lofentanil was injected at different time intervals after ligation, we observed a tremendous drop of labelling in the distal and also but more slowly in the proximal part of the nerve. This could be due to a possible recycling or re-utilization of (3)H-lofentanil binding sites. The present data are compatible with an axoplasmic flow and a possible recycling of opiate receptors labelled in vivo after intravenous injection of (3)H-lofentanil.', 'The in vivo binding of (3)H-lofentanil was studied in various regions of the brain in rat. After intravenous injection of (3)H-lofentanil the disposition of the labelled drug in the brain paralleled exactly the regional distribution of opiate receptors measured in in vitro binding assays. The labelling was saturable and could be prevented by naloxone when given before (3)H-lofentanil, in all the regions except in the cerebellum. The long-lasting occurrence of the specific labelling was entirely compatible with the extremely slow dissociation rate of lofentanil and its long duration of action. This explains why (3)H-lofentanil is not displaceable by naloxone in vivo. Subcellular fractionation experiments revealed that all the labelling in the frontal cortex but not in the cerebellum was particulate-bound and entirely displaceable by naloxone. The advantages of (3)H-lofentanil in vivo are its extremely low non-specific binding and its ability to reveal very low occupancy of opiate receptors in brain.', 'The in vitro plasma protein binding and distribution in blood of fentanyl and three analogues were studied in rats, dogs and healthy volunteers. In human plasma, 84.4% of fentanyl was bound, 92.5% of sufentanil, 92.1% of alfentanil and 93.6% of lofentanil. Plasma protein binding of the four analgesics was independent of their concentration over the whole therapeutic range. Plasma protein binding of alfentanil was much less pH dependent than that of the three other analgesics. Attention was drawn to the possible contribution of the ""acute phase"" protein alpha 1-acid glycoprotein (alpha 1-AGP), of lipoproteins and of blood cells to the binding of fentanyl and its analogues in blood.', 'The influence of the pH of the incubation medium on the cellular accumulation of tritiated fentanyl, lofentanil, and alfentanil was investigated in isolated guinea pig atria. Fentanyl and lofentanil accumulated in atrial tissue up to about 30- and 50-fold, respectively. The amount of drug bound when equilibrium was attained was found to be dependent upon the pH of the medium. By plotting binding equilibria v. pH of the bath, curves were obtained which resembled titration curves. Half-maximal binding was attained at pH values close to the pKa values of fentanyl and lofentanil. Alfentanil was found to accumulate less. The uptake by the tissue was strongly proportional to the extracellular concentration. Atria equilibrated with fentanyl at pH 8.5 released the compound rapidly when exposed to a pH of 7.0, even in the continuous presence of fentanyl in the bath. The consequences of the findings for in vivo conditions are discussed with respect to a possible augmentation of the actions of fentanyl by respiratory acidosis.']",,
3642,123643,T-kinin,CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N,,,,,,
3643,123644,"5,12-Dihydroxyicosa-6,8,10,14,17-pentaenoic acid",CCC=CCC=CCC(C=CC=CC=CC(CCCC(=O)O)O)O,,,,,,
3644,123645,2-Azidoadenosine 5'-triphosphate,C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=[N+]=[N-])N,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
3645,123646,2-Nitrophenylgalactoside,C1=CC=C(C(=C1)[N+](=O)[O-])OC2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
3646,123647,CID 123647,CCN[C@@H]1CO[C@@H](C[C@H]1OC)O[C@@H]2[C@@H]([C@H]([C@@H](O[C@@H]2OC3C#CC=CC#C[C@]4(CC(=O)C(=C3C4CCSSSC)NC(=O)OC)O)C)NO[C@@H]5C[C@H]([C@H]([C@@H](O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)OC)O)I)C)O)O,,,,,,
3647,123648,5-Mercapto-2-nitro-benzoic acid,C1=CC(=C(C=C1S)C(=O)O)[N+](=O)[O-],,,,,,
3648,123649,chromozym TH,CC1=CC=C(C=C1)S(=O)(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC3=CC=C(C=C3)[N+](=O)[O-].Cl,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
3649,123650,Tos-gly-pro-arg-pna,CC1=CC=C(C=C1)S(=O)(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC3=CC=C(C=C3)[N+](=O)[O-],,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
3650,123651,pGlu-Glu-Asp-Cys-Lys,C1CC(=O)N[C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O,,,"['Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS). (See all compounds classified as Growth Inhibitors.)']",,,
3651,123652,CID 123652,CCCC[C@@H](C)C=C(C)C=C(C)C(=O)NC1=C[C@]([C@H]2[C@@H](C1=O)O2)(C=CC=CC=CC(=O)NC3=C(CCC3=O)O)O,,,,,,
3652,123653,2-[2-[2-[2-[bis(carboxymethyl)amino]-4-fluorophenoxy]ethoxy]-N-(carboxymethyl)-5-fluoroanilino]acetic acid,C1=CC(=C(C=C1F)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=C(C=C2)F)N(CC(=O)O)CC(=O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
3653,123654,Myomodulin,CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1,,,,,,
3654,123655,"(1S,2S,5R,9S,11S,12S,13R)-5,6,11-Trihydroxy-6-(hydroxymethyl)-13-methyl-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-17-en-16-one",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@@]45[C@H]3CC[C@@]4(C(OC5)(CO)O)O)O,,,,,,
3655,123656,CID 123656,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O.CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O)O)Cl)O,,,,,,
3656,123657,"(9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",C[C@]12C[C@@H]([C@]3(C([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,,,,,,
3657,123658,"D-Ribulose 1,5-bisphosphate",C([C@H]([C@H](C(=O)COP(=O)(O)O)O)O)OP(=O)(O)O,,,,,,
3658,123659,"(5s)-6,6-Dimethyl-5-[(6r)-6-methyl-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl]-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium chloride",C[C@@]1(C2=C(C3=C(C=C2)OCO3)C(=O)O1)[C@@H]4C5=CC6=C(C=C5CC[N+]4(C)C)OCO6.[Cl-],,,,,,
3659,123660,"(6R)-6-[(5S)-6,6-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6-methylfuro[3,4-g][1,3]benzodioxol-8-one",C[C@@]1(C2=C(C3=C(C=C2)OCO3)C(=O)O1)[C@@H]4C5=CC6=C(C=C5CC[N+]4(C)C)OCO6,,,,,,
3660,123661,Cholecystokinin C-terminal heptapeptide,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)N,,,,,,
3661,123662,Propyl beta-carboline-3-carboxylate,CCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,,,"['Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. (See all compounds classified as Convulsants.)']",,,
3662,123663,Ethylene glycol bis(succinimidyl succinate),C1CC(=O)N(C1=O)OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON2C(=O)CCC2=O,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
3663,123664,Loxistatin acid,CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1[C@H](O1)C(=O)O,,,,,,
3664,123665,CID 123665,C[C@H](CC1=CC=C(C=C1)C(=O)OC)NC[C@H](C2=CC=CC=C2)O.CC(=O)C=CC(=O)O,,,,,,
3665,123666,CID 123666,C[C@H](CC1=CC=C(C=C1)C(=O)OC)NC[C@H](C2=CC=CC=C2)O,,,,,,
3666,123667,"Aluminum, chloro(29H,31H-phthalocyaninato(2-)-kappaN29,kappaN30,kappaN31,kappaN32)-, (SP-5-12)-",C1=CC=C2C(=C1)C3=NC4=C5C=CC=CC5=C([N-]4)N=C6C7=CC=CC=C7C(=N6)N=C8C9=CC=CC=C9C(=N8)N=C2[N-]3.[Al+3].[Cl-],,,,,,
3667,123668,Iron nitrosyl,N#[O+].N#[O+].[Fe],,,,,,
3668,123669,"Xanthylium, 9-(4-(bis(carboxymethyl)amino)-3-(2-(2-(bis(carboxymethyl)amino)-5-methylphenoxy)ethoxy)phenyl)-3,6-bis(dimethylamino)-, chloride",CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C3=C4C=CC(=[N+](C)C)C=C4OC5=C3C=CC(=C5)N(C)C)N(CC(=O)O)CC(=O)O.[Cl-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3669,123670,"9-[4-[Bis(carboxymethyl)amino]-3-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]phenyl]-3,6-bis(dimethylamino)xanthylium",CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C3=C4C=CC(=[N+](C)C)C=C4OC5=C3C=CC(=C5)N(C)C)N(CC(=O)O)CC(=O)O,,,,,,
3670,123671,Alphazurine,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=CC=CC=C5S(=O)(=O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['The absorption, metabolism and excretion of (14)C-labelled Green S and Brilliant Blue FCF have been studied in the rat, mouse and guinea-pig. Following administration of a single oral dose of Green S at either 100 ug/kg or 10 mg/kg of Brilliant Blue FCF at either 30 ug/kg or 3 mg/kg to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hr. Pretreating male rats with unlabelled Green S or Brilliant Blue FCF in the diet (100 or 30 mg/kg day, respectively) for 21 days prior to dosing with (14)C-labelled coloring had no effect on the route of excretion or the time taken to eliminate all of the label. Similarly male mice and guinea-pigs excreted in the feces all of a single oral dose of Green S or Brilliant Blue FCF. The lack of absorption and metabolism of the labelled dye in the gastro-intestinal tract of all three species investigated was confirmed by studies using isolated loops of small intestine. It was shown that no radioactivity was taken up by the fetuses of pregnant rats given (14)C-labelled Green S or Brilliant Blue FCF.', 'Female Sprague-Dawley rats were given a single dose (0.27 mg; 1.74 uCi) of the (14)C-labelled coloring by gavage. In bile-duct ligated rats, intestinal absorption of FD & C Blue No.1 (estimated from urinary (14)C excretion, expired (14)CO2 and residual radioactivity in internal organs and tissues 96 hr after oral administration) averaged 2.05% of the dose.  Mean fecal excretion was 97.28% and the total recovery of administered radioactivity was 99.38%. Intestinal absorption (14)C-FD & C Blue No. 1 in intact rats averaged only 0.27% (91% recovery), while biliary excretion in bile-duct cannulated animals averaged 1.32% of the dose. Thin-layer chromatography of urine and bile samples revealed that about 95% of excreted radioactivity was unaltered FD & C Blue No. 1 and that about 5% was an unidentified metabolite or degradation product of FD & C Blue No. 1. The results show that FD & C Blue No.1 is poorly absorbed from the gastro-intestinal tract, and undergoes subsequent rapid and complete biliary excretion /of the absorbed compound/.', '... Less than 0.05% of a labeled dose of 3 mg/kg bw was excreted in the bile of rats over a 5-hour period. Very little radioactivity (0.004 - 0.006% of dose) was detected on day 11 in the fetuses of pregnant rats given (14)C-labelled Brilliant Blue FCF orally on day 8 of gestation. ... Brilliant Blue FCF was labeled with (14)C in the central methane ring and had a radioactive purity of greater than 95%. ...', 'Following administration of either 30 ug/kg bw or 3 mg/kg bw of (14)C-Brilliant Blue FCF by gavage to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hours (99.9% at low dose, 95.4% at high dose). No radioactivity was detected in the expired air and less than 0.5% was detected in the urine. ...', 'For more Absorption, Distribution and Excretion (Complete) data for Brilliant Blue (6 total), please visit the HSDB record page.']",,
3671,123672,(alpha-Aminoadipyl)cysteinylvaline,CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CCC[C@@H](C(=O)O)N,,,,,,
3672,123673,CID 123673,CN1[C@@H]2CC(C[C@H]1[C@@H]3[C@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
3673,123674,Siba,CC(C)CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3674,123675,"3,5-Diiodothyronine",C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I,,,,,,
3675,123676,Vibunazole,CC(C)(C)C(CN1C=NC=N1)(COC2=CC=C(C=C2)Cl)O,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
3676,123677,Fluorescein glucuronide,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,,,,,,
3677,123678,CID 123678,CCC1=C(C2=NC1=CC3=C(C(=C(O)O)C(=N3)C(=C4[C@H](CC(=CC5=NC(=C2)C(=C5C)C=C)N4)CCC(=O)O)CC(=O)N[C@@H](CC(=O)O)C(=O)O)C)C,,,,,,
3678,123679,"1',3'-Dimethylspiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one",CN1CCC2(CCN3CCC4=C(C3C2)OC5=CC=CC=C45)N(C1=O)C,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
3679,123680,"Inositol 1,3,4-triphosphate",[C@@H]1([C@@H]([C@H]([C@@H]([C@@H]([C@@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O,,,,,,
3680,123681,Glycyl-prolyl-arginyl-proline,C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)O,,,,,,
3681,123682,5-(4-acetamidophenyl)pyrazin-2(1H)-one,CC(=O)NC1=CC=C(C=C1)C2=NCC(=O)N=C2,,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
3682,123683,IB-Meca,CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O,"[""Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.""]","['CF-101 is an adenoside A3 agonist for the treatment of a variety of autoimmune-inflammatory disorders, particularly rhematoid arthritis. In clinical trials, it was found to be safe, well tolerated and showed strong evidence of an anti-inflammatory effect in rheumatoid arthritis patients. In this trial, a statistically significant correlation was found between A(3)AR expression level and response to the drug, so A(3)AR expression may serve as a biopredictor of patient response.']",,,,
3683,123684,Cholesterol hydroperoxide,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C[C@]4([C@@]3(CC[C@@H](C4)O)C)OO)C,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
3684,123685,"(2R)-2,7,8-trimethyl-2-(4,8,12,16,20,24,28,32-octamethyltritriaconta-3,7,11,15,19,23,27,31-octaenyl)-3,4-dihydrochromen-6-ol",CC1=C(C=C2CC[C@@](OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O,,,,,,
3685,123686,1-[2-[[3-(2-Cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-3-phenylurea,C1=CC=C(C=C1)NC(=O)NCCNCC(COC2=CC=CC=C2C#N)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
3686,123687,Prolyl-phenylalanyl-arginine-4-nitroanilide,C1C[C@@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC(=O)[C@H](CCCN=C(N)N)NC3=CC=C(C=C3)[N+](=O)[O-],,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
3687,123688,Speract,CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN,,,,,,
3688,123689,N8-Acetylspermidine,CC(=O)NCCCCNCCCN,,,,,,
3689,123690,CID 123690,C(C(=O)[C@@H]([C@H](O)OP(=O)(O)O)O)O,,,,,,
3690,123691,"(4S,5R,6R,7R,8R)-4,5,6,7,8,9-hexahydroxy-2-oxononanoic acid",C([C@@H]([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)C(=O)C(=O)O,,,,,,
3691,123692,1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
3692,123693,"5,6-dichloro-2-[3-(5,6-dichloro-1,3-diethyl-2H-benzimidazol-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole",CCN1C(N(C2=CC(=C(C=C21)Cl)Cl)CC)C=CC=C3N(C4=CC(=C(C=C4N3CC)Cl)Cl)CC,,,,,,
3693,123694,Diadenosine hexaphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N,,,['Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)'],,,
3694,123695,Adenophostin a,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)OP(=O)(O)O)OP(=O)(O)O)O)OP(=O)(O)O)N,,,"['Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (See all compounds classified as Calcium Channel Agonists.)']",,,
3695,123696,cis-5-Methoxy-1-methyl-2-(di-n-propylamino)tetralin,CCCN(CCC)[C@H]1CCC2=C([C@H]1C)C=CC=C2OC,,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
3696,123697,4-((2-Carboxy-3-(2-methoxyethoxy)propyl)-1-cyclopentanecarbonylamino)-1-cyclohexanecarboxylic acid,COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)O,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
3697,123698,Eperisone hydrochloride,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2.Cl,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
3698,123699,Dimyristoyl phosphatidylserine,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)OC(=O)CCCCCCCCCCCCC,,,,,,
3699,123700,Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate,CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OCC4=CC=CC=C4,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
3700,123701,Octanoylcarnitine,CCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C,,,,,,
3701,123702,(3-Carboxy-2-octanoyloxypropyl)-trimethylazanium,CCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C,,,,,,
3702,123703,"(3,4-Dihydroxyphenylamino)-2-imidazoline",C1CN=C(N1)NC2=CC(=C(C=C2)O)O,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
3703,123704,Met-enkephalinamide,CSCC[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
3704,123705,"9,10-Secocholesta-5,7,10-triene-3,25,26-triol",CC(CCCC(C)(CO)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,,,,,,
3705,123706,"Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-",CCC(C1=C(C=C(C=C1)N(C)C)C)N,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
3706,123707,Amosulalol hydrochloride,CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
3707,123708,"(2R)-2-amino-6-[[(3S,4R,5R)-3,4,5,6-tetrahydroxy-2-oxohexyl]amino]hexanoic acid",C(CCNCC(=O)[C@H]([C@@H]([C@@H](CO)O)O)O)C[C@H](C(=O)O)N,,,,,,
3708,123709,CID 123709,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O.C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3OP(=O)(O)O)N4CNC5=C(N=CN=C54)N)O,,,,,,
3709,123710,CID 123710,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O,,,,,,
3710,123711,"[(2R,3S,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-2-phosphonooxyoxolan-3-yl] [(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl hydrogen phosphate",C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3OP(=O)(O)O)N4CNC5=C(N=CN=C54)N)O,,,,,,
3711,123712,"11b,17,21-Trihydroxy-3,20-dioxo-pregn-4-en-18-al",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C=O)O,,,,,,
3712,123713,CID 123713,CCCCC1=CC=C(C=C1)NC2=NC(=O)C3=C(N2)N(C=N3)[C@H]4C[C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
3713,123714,Oxoplatinum,N.N.[OH-].[OH-].[Cl-].[Cl-].[Pt+4],,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
3714,123715,Tyr-gly-gly,C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)NCC(=O)O)N)O,,,,,,
3715,123716,"7,8-(Methylenedioxy)-14-hydroxyberbane",C1C[C@@H]2CN3CCC4=CC5=C(C=C4[C@@H]3C[C@@H]2C[C@H]1O)OCO5.Cl,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
3716,123717,CID 123717,C1C[C@@H]2CN3CCC4=CC5=C(C=C4C3C[C@@H]2C[C@H]1O)OCO5,,,,,,
3717,123718,CID 123718,CCCCCCCC(=O)N[C@@H]([C@@H](C)OP(=O)(O)O)C(=O)O,,,,,,
3718,123719,"5,5'-Dimethyl-bapta",CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C)N(CC(=O)O)CC(=O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
3719,123720,Melarsomine dihydrochloride,C1=CC(=CC=C1NC2=NC(=NC(=N2)N)N)[As](SCCN)SCCN.Cl.Cl,,,,,,
3720,123721,CID 123721,CCCCCN(CCCCC)C1=CC=C(C=C1)C=CC=CC2=CC=[N+](C=C2)CCCCS(O)(O)[O-],,,,,,
3721,123722,CID 123722,CCCCCN(CCCCC)C1=CC=C(C=C1)C=CC=CC2=CC=[N+](C=C2)CCCCS(O)(O)O,,,,,,
3722,123723,Veliflapon,C1CCC(C1)[C@H](C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O,,,"['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
3723,123724,Perhydroazepin-1-yl leucyl-tryptophyl-tryptophan,CC(C)C[C@@H](C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)N5CCCCCC5,,,,,,
3724,123725,"2,3-Bis(3-hydroxybenzyl)butane-1,4-diol",C1=CC(=CC(=C1)O)CC(CO)C(CC2=CC(=CC=C2)O)CO,,,"['Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS. (See all compounds classified as Phytoestrogens.)']",,,
3725,123726,Mergepta,C(CSCC(CS)C(=O)O)N=C(N)N,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
3726,123727,CDP-ethanolamine,C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OCCN)O)O,,,,,,
3727,123728,CID 123728,C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](CC(C3=C)O)O)C,,,,,,
3728,123729,2-Azido-ADP,C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N=[N+]=[N-])N,,,,,,
3729,123730,CID 123730,C=CCN1CC[C@]23[C@@H]4C(=NN)CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,,,,,,
3730,123731,cephamycin C,COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CCCC(C(=O)O)N,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3731,123732,D-Ribose 1-phosphate,C([C@@H]1[C@H]([C@H](C(O1)OP(=O)(O)O)O)O)O,,,,,,
3732,123733,"7-[(1R,2R,3R)-3-Hydroxy-2-[(3S)-3-hydroxyocta-1,5-dienyl]-5-oxocyclopentyl]hept-5-enoic acid",CCC=CC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O)O,,,,,,
3733,123734,CID 123734,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)NC(=NC2=O)N.[MgH2],,,,,,
3734,123735,"7-[(1R,4S,5R,6R)-6-[(3S)-3-hydroperoxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@H]2C[C@@H]([C@@H]1CC=CCCCC(=O)O)OO2)OO,,,,,,
3735,123736,CID 123736,C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)[O-])[C@H]3CCCO3)O.[Na+],,,,,,
3736,123737,CID 123737,CC(C1[C@H]2CC(=C(N2C1=O)C(=O)O)C3CCCO3)O,,,,,,
3737,123738,NO-711 hydrochloride,C1CN(CC(=C1)C(=O)O)CCON=C(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. (See all compounds classified as Neurotransmitter Uptake Inhibitors.)', 'Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. (See all compounds classified as GABA Antagonists.)']",,,
3738,123739,"8-(3,4-Dimethoxyphenyl)-7-methyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione",CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)C3=CC(=C(C=C3)OC)OC)C,,,,,,
3739,123740,Butyrolactone i,CC(=CCC1=C(C=CC(=C1)C[C@@]2(C(=C(C(=O)O2)O)C3=CC=C(C=C3)O)C(=O)OC)O)C,,,['Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)'],,,
3740,123741,"1-(beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(O-ethyl-tyr)-4-val-arginine vasopressin",CCOC1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@H]4C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5,,,"['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
3741,123742,3-[(2-Benzyl-3-sulfanylpropanoyl)amino]propanoic acid,C1=CC=C(C=C1)CC(CS)C(=O)NCCC(=O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3742,123743,7alpha-Hydroxy-4-cholesten-3-one,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](CC4=CC(=O)CC[C@]34C)O)C,,,,,,
3743,123744,Polyribophosphate,C([C@@H]1[C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O)O)O,,,,,,
3744,123745,Phosphocitrate,C(C(=O)O)C(CC(=O)O)(C(=O)O)OP(=O)(O)O,,,,,,
3745,123746,CID 123746,C1C=CC2=C(C1I)C=CC=C2N=[N+]=[N-],,,,,,
3746,123747,Norepinephrine sulfate,C1=CC(=C(C=C1[C@H](CN)O)O)OS(=O)(=O)O,,,,,,
3747,123748,3-(Hexadecanoyloxy)-2-{[10-(pyren-1-yl)decanoyl]oxy}propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3748,123749,"1-Palmitoyl-2-(pyrene-1-yl)decanoyl-sn-glycero-3-phosphocholine, >=95%",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
3749,123750,"Arginine vasopressin, (beta-mercapto)beta,beta-cyclopentamethylenepropionic acid(1)-",C1CCC2(CC1)CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSS2)C(=O)N3CCC[C@H]3C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC4=CC=CC=C4)CC5=CC=C(C=C5)O,,,,,,
3750,123751,3-Iodo-alpha-methyltyrosine,CC(CC1=CC(=C(C=C1)O)I)(C(=O)O)N,,,"['Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']",,,
3751,123752,"(5S,12S)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid",C(CCC=CC[C@@H](C=CC=CC=C[C@H](CCCC(=O)O)O)O)CCO,,,,,,
3752,123753,"[3-Hexadecanoyloxy-2-[6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoyloxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3753,123754,"2-[[3-Hexadecanoyloxy-2-[6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoyloxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-],,,,,,
3754,123755,5-Carboxyfluorescein,C1=CC2=C(C=C1C(=O)O)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,,,,,,
3755,123756,3'-O-[2-(Methylamino)benzoyl]adenosine 5'-(tetrahydrogen triphosphate),CNC1=CC=CC=C1C(=O)O[C@@H]2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C(N=CN=C43)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
3756,123757,CID 123757,C[C@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC6=CN=CN6)N,,,,,,
3757,123758,CID 123758,C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N)N,,,,,,
3758,123759,CID 123759,CC=C(C)C(=O)O[C@H]1C[C@H]([C@]2(CO[C@@H]3[C@@H]2[C@]1([C@H]4C[C@@H](O[C@H]5C[C@H](C(=C5[C@@]4([C@@H]3O)C)C)C6=COC=C6)O)C)C)OC(=O)C,,,,,,
3759,123760,(+)-Igmesine hydrochloride,CCC(CC=CC1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3.Cl,,,,,,
3760,123761,"N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine",CCC(CC=CC1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3,,,,,,
3761,123762,Aerobactin,CC(=O)N(CCCC[C@@H](C(=O)O)NC(=O)CC(CC(=O)N[C@@H](CCCCN(C(=O)C)O)C(=O)O)(C(=O)O)O)O,,,"['Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)']",,,
3762,123763,CID 123763,C[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5,,,,,,
3763,123764,Methyl ester-SP,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCN=C(N)N)N,,,,,,
3764,123765,4-(3-(1-Diphenylmethylazetidine-3-oxy)-2-hydroxypropoxy)-1H-indole-2-carbonitrile,C1C(CN1C(C2=CC=CC=C2)C3=CC=CC=C3)OCC(COC4=CC=CC5=C4C=C(N5)C#N)O,,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
3765,123766,"[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy(phosphonooxy)phosphinothioyl] hydrogen phosphate",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=S)(O)OP(=O)(O)O)O)O)N,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
3766,123767,Norketamine,C1CCC(C(=O)C1)(C2=CC=CC=C2Cl)N,,,,,,
3767,123768,"Methyl 1-(phenylmethyl)-3-piperidinyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate monohydrochloride",CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC.Cl,,,,,,
3768,123769,2-[2-(1-carboxylato-2-sulfidoethyl)azanidylethylamino]-3-sulfidopropanoate;hydron;oxo(99Tc)technetium-99(3+),[H+].[H+].C(C[N-]C(C[S-])C(=O)[O-])NC(C[S-])C(=O)[O-].O=[99Tc+3],,,,,,
3769,123770,"l,l-Ethylenedicysteine",C(CNC(CS)C(=O)O)NC(CS)C(=O)O,,,,,,
3770,123771,"1,N(6)-ethenoadenosine diphosphate",C1=CN2C=NC3=C(C2=N1)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)O)O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3771,123772,"2,5-Cyclohexadien-1-one, 4-hydroxy-2,3,5,6-tetramethyl-",CC1=C(C(=O)C(=C(C1O)C)C)C,,,,,,
3772,123773,CID 123773,CN1CN(C2=C1C(=O)N=C(N2)N(C)C)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
3773,123774,"N,N',N''-triacetylchitotriose",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)NC(=O)C)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)NC(=O)C)O)CO)CO)O)O,,,,,,
3774,123775,Changrolin,C1CCN(C1)CC2=CC(=CC(=C2O)CN3CCCC3)NC4=NC=NC5=CC=CC=C54,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
3775,123776,CID 123776,C[C@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](C)O[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C,,,,,,
3776,123777,"LHRH, Gln(8)-",CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,,,,,,
3777,123778,Argipressin (4-9),C1C[C@H](N(C1)C(=O)[C@H](CSSC[C@@H](C(=O)O)N)NC(=O)C(CC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N,,,,,,
3778,123779,CID 123779,CCNCCCNCCCCNCCCN(CC)CC,,,,,,
3779,123780,"1,3-Dibutyl-5-[3-(1,3-dibutyl-2,4,6-trioxo-1,3-diazinan-5-yl)prop-2-enylidene]-1,3-diazinane-2,4,6-trione",CCCCN1C(=O)C(C(=O)N(C1=O)CCCC)C=CC=C2C(=O)N(C(=O)N(C2=O)CCCC)CCCC,,,,,,
3780,123781,"D-Galactose, 3-O-alpha-D-galactopyranosyl-",C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]([C@H](C=O)O)[C@H]([C@@H](CO)O)O)O)O)O)O,,,,,,
3781,123782,"2-(4-Carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide",C1CC(=NN=C(N)N)C2=C1C(=CC=C2)C(=N)N,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
3782,123783,Arginyl-arginyl-prolyl-tyrosyl-isoleucyl-leucine,CC[C@H](C)[C@@H](C(=O)NC(CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N,,,,,,
3783,123784,2-Pyrrolidineacetic acid,C1CC(NC1)CC(=O)O,,,,,,
3784,123785,2-Amino-3-(4-(4-hydroxyphenoxy)-3-iodophenyl)propanoic acid,C1=CC(=CC=C1O)OC2=C(C=C(C=C2)CC(C(=O)O)N)I,,,,,,
3785,123786,Proctolin,C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)N)O,,,,,,
3786,123787,4-10-Semax,CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)O)N,,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
3787,123788,C & B-Metabond,CC(=C)C(=O)OC.CC(=C)C(=O)OCCOC(=O)C1=CC2=C(C=C1)C(=O)OC2=O,,,,,,
3788,123789,Tyr-gly-gly-phe-met-arg-phe,CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,,,,
3789,123790,"11,17-Dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one",CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C=C(C4=CC(=O)C=C[C@]34C)C)O)C)O,,,,,,
3790,123791,Tyr-gly-gly-phe-met-arg-gly-leu,CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
3791,123792,Myelopeptides,C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC3=CC=CC=C3)N)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
3792,123793,CID 123793,CCCCC[C@@H](C=C[C@@H]1C([C@H](C[C@@H](O1)O)O)CC=CCC(=O)O)O,,,,,,
3793,123794,"L-Isoleucine, N-(1-(N-(N6-(N2-((phenylmethoxy)carbonyl)-L-arginyl)-N2-(N-(3-pyridinylcarbonyl)-L-tyrosyl)-L-lysyl)-L-histidyl)-L-prolyl)-",CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)C5=CN=CC=C5,,,,,,
3794,123795,Delt II,C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
3795,123796,Pregnanediol-3-glucuronide,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C)C)O,,,,,,
3796,123797,Phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)C(CC4=CC=CC=C4)N,,,['Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)'],,,
3797,123798,Chlorophyllin A,[H+].[H+].[H+].CCC1=C(C2=CC3=NC(=CC4=NC(=C(C5=NC(=C(C5=C([O-])[O-])C)C=C1[N-]2)CC(=O)[O-])C(C4C)CCC(=O)[O-])C(=C3C=C)C)C.[Mg+2],,,['Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)'],,,
3798,123799,H-Cys(1)-Tyr-DL-Ile-Gln-Asn-Cys(1)-Pro-Ile-Gly-NH2,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,,,,,,
3799,123800,N(6)-carboxymethyllysine,C(CCNCC(=O)O)C[C@@H](C(=O)O)N,,,,,,
3800,123801,Technetium Tc 99m oxidronate,C(O)(P(=O)(O)O)P(=O)(O)O.[99Tc],"['Technetium Tc-99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis. When administered intravenously, it is able to generate a clear image of the bones which allows the physician to diagnose any bone problem. It is important to point out that this drug has to be manipulated only under the service of a nuclear specialist. The approved indications for a bone scan are 1) visualization of tumor metastasis in bone, 2) osteomyelitis, 3) fracture, 4) stress fracture, 5) avascular necrosis, 6) osteoporosis and 7) prosthetic joint evaluation. From all the major indications, the detection of a metastatic disease is the most common because it presents a 95% of sensitivity and lesion detection can be done 6 months earlier than with X-ray studies.']",['The technetium is generated in a molibdene generator. Technetium Tc-99m presents a reduction of gamma emission after 6 hours and it is considered a quasi-stable molecule. The visualization of bone lesions is possible since there is an altered uptake in areas of abnormal osteogenesis. The principal photon used for detection is the gamma-2 with an energy of 140.5 keV. Its use for bone examination should be performed 2 hours after initial injection with a recommended activity on the range of 370-740 MBq.'],"['Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']","['Technetium Tc-99m oxidronate is rapidly absorbed and cleared from blood plasma to reach the skeleton. After 27 min of intravenous administration, a range of 45-50% of the technetium Tc-99m oxidronate is accumulated in the skeleton, reaching maximum accumulation at 1-hour post injection and remaining constant until 72 hours postinjection.', 'It is recommended to empty bladder completely just prior to technetium Tc-99m oxidronate administration. It is as well recommended to drink abundant water and to empty bladder as often as possible to reduce radiation exposure in the bladder wall. The total radioactivity in blood between 5 min and 24 hours goes from 40% to 2.3% respectively. Technetium Tc-99m oxidronate whole body retention after 24 hours is a ratio of 36.6% which indicates that this drug, unlike other bone radiopharmaceuticals, presents a greater uptake. The glomerular filtration of technetium Tc-99m oxidronate can reach a 60% of the administered dose after 6 hours of the initial dose. The cumulative activity excreted in the urine after 24 hours is of approximately 59% suggesting a ratio of femur-to-muscle of 35.', 'The distribution of technetium Tc-99m oxidronate at 1-hour post injection is mainly in the bones and secondary in the liver and kidneys.', 'During the first 24 hours of technetium Tc-99m oxidronate administration, it is observed a rapid clearance from blood and non-osseous tissues. The dosage gets accumulated in skeleton and urine.']",['Technetium Tc-99m oxidronate is a diphosphonate. There have been reports showing that diphosphonates form very stable Tc(IV) complexes which provide them with a very high in vivo stability and a very low degradation.'],"['The elimination of technetium Tc-99m oxidronate is marked by the presence of three different half-times which are: 1) rapid phase of 3.5 min, 2) intermediate phase of 27 min and 3) slow phase of 144 min.']"
3801,123802,GcNeu,C1[C@@H]([C@H]([C@@H](O[C@@]1(C(=O)O)O)[C@@H]([C@@H](CO)O)O)NC(=O)CO)O,,,,,,
3802,123803,"20-Hydroxyicosa-5,8,11,14-tetraenoic acid",C(CCC=CCC=CCC=CCC=CCCCC(=O)O)CCO,,,,,,
3803,123804,Kyotorphin,C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3804,123805,Angiotensin (1-7),CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
3805,123806,Caged ATP,CC(C1=CC=CC=C1[N+](=O)[O-])OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
3806,123807,2-Chloro-N6-cyclopentyladenosine,C1CCC(C1)NC2=C3C(=NC(=N2)Cl)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
3807,123808,8-Anilino-5-(4-anilino-5-sulfonaphthalen-1-yl)naphthalene-1-sulfonic acid,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)C4=C5C=CC=C(C5=C(C=C4)NC6=CC=CC=C6)S(=O)(=O)O)C=CC=C3S(=O)(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3808,123809,Modopar,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O.C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O,,,"['Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
3809,123810,15-(4-Iodophenyl)pentadecanoic acid,C1=CC(=CC=C1CCCCCCCCCCCCCCC(=O)O)I,,,,,,
3810,123811,Gly-arg-gly-asp-ser,C(C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)CN)CN=C(N)N,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3811,123812,Heliox,[He].O=O,,,,,,
3812,123813,N-Hydroxysuccinimide iodo-p-hydroxyphenylpropionate,C1CC(=O)N(C1=O)OC(=O)CCC2=CC(=C(C=C2)O)[125I],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3813,123814,Angiotensin IV,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)N,,,,,,
3814,123815,CID 123815,COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)[O-].[Na+],,,,,,
3815,123816,"Cefpodoxime Proxetil,(S)",COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,,,,,,
3816,123817,Dodecylphosphorylcholine,CCCCCCCCCCCCOP(=O)(O)OCC[N+](C)(C)C.[Cl-],,,['Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)'],,,
3817,123818,2-[Dodecoxy(hydroxy)phosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCOP(=O)(O)OCC[N+](C)(C)C,,,,,,
3818,123819,"7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-6-oxoheptanoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC(=O)CCCCC(=O)O)O)O,,,,,,
3819,123820,CID 123820,C[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CC(=O)N)NC(=O)CN,,,,,,
3820,123821,Adipokinetic hormone (manduca sexta),C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)C4CCC(=O)N4)O,,,,,,
3821,123822,5-Iodoacetamidofluorescein,C1=CC2=C(C=C1NC(=O)CI)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,,,,,,
3822,123823,Etomoxir,CCOC(=O)C1(CO1)CCCCCCOC2=CC=C(C=C2)Cl,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)']",,,
3823,123824,"2,3,7,8,12,13,17,18,19,22-Decahydro-1H-corrin",C1CC2=NC1C3CCC(=N3)C=C4CCC(=N4)C=C5CCC(=C2)N5,,,,,,
3824,123825,3-Iodopindolol,CC(C)NC[C@@H](COC1=CC=CC2=C1C(=CN2)[125I])O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
3825,123826,N-acetylglucosaminylasparagine,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1NC(=O)C[C@@H](C(=O)O)N)CO)O)O,,,,,,
3826,123827,Technetium hedp,CC(O)(P(=O)(O)O)P(=O)(O)O.[99Tc],,,"['Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']",,,
3827,123828,2-Amino-3-(4-hydroxyphenyl)propanoyl hydrogen sulfate,C1=CC(=CC=C1C[C@@H](C(=O)OS(=O)(=O)O)N)O,,,,,,
3828,123829,Tauroselcholic acid se-75,C[C@H](C[75Se]CC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
3829,123830,Citrate phosphate dextrose,C([C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.OP(=O)(O)O,,,['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)'],,,
3830,123831,"N,N-dimethylarginine",CN(C)C(=NCCC[C@@H](C(=O)O)N)N,,"['Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion.']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3831,123832,"11a-Hydroxy-9,15-diketoprost-5-enoic acid",CCCCCC(=O)CC[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O,,,,,,
3832,123833,Maxon,C1COC(=O)OC1.C1C(=O)OCC(=O)O1,,,,,,
3833,123834,"1,3-Dioxan-2-one",C1COC(=O)OC1,,,,,,
3834,123835,Iron(3+) cyanide--hydrocyanic acid (1/3/3),C#N.C#N.C#N.[C-]#N.[C-]#N.[C-]#N.[Fe+3],,,,,,
3835,123836,Dihydrotetrabenazine,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC,,,,,,
3836,123837,Nuclear yellow,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)S(=O)(=O)N.Cl.Cl.Cl,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3837,123838,"4-(5-(4-Methylpiperazin-1-yl)-1H,1'H-[2,5'-bibenzo[d]imidazol]-2'-yl)benzenesulfonamide",CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)S(=O)(=O)N,,,,,,
3838,123839,Furaptra,C1=C2C=C(OC2=CC(=C1OCC(=O)O)N(CC(=O)O)CC(=O)O)C3=NC=C(O3)C(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3839,123840,3-Methylsulfonyl-4-piperidinobenzoyl guanidine,CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCCCC2.Cl,,,,,,
3840,123841,3-Methylsulfonyl-4-piperidin-1-ylbenzoyl guanidine,CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCCCC2,,,,,,
3841,123842,CID 123842,CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)C=C3C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)C=C4C(=C(C(=O)N4)C=C)C.[C@@H]1([C@@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,,,,,,
3842,123843,small cardioactive peptide B,C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)N,,,,,,
3843,123844,Didemnin A,CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)NC)C)CC3=CC=C(C=C3)OC)C)CC(C)C)C)C(C)C)O,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
3844,123845,CID 123845,C1NC2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)N,,,,,,
3845,123846,"2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with methyl 2-methyl-2-propenoate",CC(=C)C(=O)OC.CC(=C)C(=O)OCCO,,,"['Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. (See all compounds classified as Biocompatible Materials.)']",,,
3846,123847,cyclic ADP-ribose,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=CN(C4=N)[C@H]5[C@@H]([C@@H]([C@H](O5)COP(=O)(OP(=O)(O1)O)O)O)O)O)O,,,,,,
3847,123848,CID 123848,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)S)O)O)N,,,,,,
3848,123849,"1-(1-Hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-1h-pyrrole-2,5-dione",CC1(CC(CC(N1O)(C)C)N2C(=O)C=CC2=O)C,,,,,,
3849,123850,"2,3-Dihydroxypropyl 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethyl hydrogen phosphate",C1=C(C2=NON=C2C(=C1)[N+](=O)[O-])NCCOP(=O)(O)OCC(CO)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3850,123851,Feroxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)[O-])[O-])[O-].[Fe+3],,,"['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)', 'Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)']",,,
3851,123852,desferrioxamine B(3-),CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)[O-])[O-])[O-],,,,,,
3852,123853,D-Phenylalanyl-L-2-piperidinecarbonyl-N-(4-nitro phenyl)-L-argininamide,C1CCN([C@@H](C1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-])C(=O)[C@@H](CC3=CC=CC=C3)N,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
3853,123854,Bis(sulfosuccinimidyl)suberate,C1C(C(=O)N(C1=O)OC(=O)CCCCCCC(=O)ON2C(=O)CC(C2=O)S(=O)(=O)O)S(=O)(=O)O,,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
3854,123855,CID 123855,CC1[N+](=NCC(=O)S1)C2=CC3=C(C=C2)N(CCC3)C(=O)C4=CC(=C(C=C4)OC)OC,,,,,,
3855,123856,"2-ethyl-5,7-dimethyl-3-[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]imidazo[4,5-b]pyridine",CCC1=NC2=C(N1C3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N=C(C=C2C)C,,,"['Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. (See all compounds classified as Angiotensin Receptor Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
3856,123857,Distalgesic,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.CC(=O)NC1=CC=C(C=C1)O.Cl,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3857,123858,(Z)-1-methyl-4-((3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolinium 4-methylbenzenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)[O-].CN1C2=CC=CC=C2SC1=CC3=CC=[N+](C4=CC=CC=C34)C,,,,,,
3858,123859,"Quinolinium, 1-methyl-4-[(3-methyl-2(3H)-benzothiazolylidene)methyl]-",CN1C2=CC=CC=C2SC1=CC3=CC=[N+](C4=CC=CC=C34)C,,,,,,
3859,123860,CID 123860,CC1=CN(C(=O)N=C1N)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O,,,,,,
3860,123861,"Furo(3,4-b)pyridine-3-carboxylic acid, 1,4,5,7-tetrahydro-4-(2-(difluoromethoxy)phenyl)-2-methyl-5-oxo-, ethyl ester",CCOC(=O)C1=C(NC2=C(C1C3=CC=CC=C3OC(F)F)C(=O)OC2)C,,,"['Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (See all compounds classified as Calcium Channel Agonists.)']",,,
3861,123862,N-(4-Pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide dihydrochloride,CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N.Cl.Cl,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
3862,123863,H-Tyr-Ala-Gly-Phe-Leu-NH2,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
3863,123864,3-Tyr-octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,,,,,,
3864,123865,Geneticin,C[C@H]([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)O)O)O,,,"['Agents which are destructive to amebae, especially the parasitic species causing AMEBIASIS in man and animal. (See all compounds classified as Amebicides.)', 'Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)']",,,
3865,123866,3-(Trifluoromethyl)-3-(3-iodophenyl)diazirine,C1=CC(=CC(=C1)I)C2(N=N2)C(F)(F)F,,,"['Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Biologically active molecules which are covalently bound to the enzymes or binding proteins normally acting on them. Binding occurs due to activation of the label by ultraviolet light. These labels are used primarily to identify binding sites on proteins. (See all compounds classified as Photoaffinity Labels.)']",,,
3866,123867,"Pregnane-3,20-dione",CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CCC(=O)C4)C)C,,,,,,
3867,123868,Meldonium,C[N+](C)(C)NCCC(=O)[O-],,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']",,,
3868,123869,"2-(2-Carboxyethyl)-1,1,1-trimethyldiazanium",C[N+](C)(C)NCCC(=O)O,,,,,,
3869,123870,para-Iodoamphetamine,CC(CC1=CC=C(C=C1)I)N,,,,,,
3870,123871,Topaquinone,C1=C(C(=CC(=O)C1=O)O)C[C@@H](C(=O)O)N,,,,,,
3871,123872,Interleukin-1beta (163-171),CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
3872,123873,"1-(4-Hydroxy-3-methoxyphenyl)ethane-1,2-diol;sulfuric acid",COC1=C(C=CC(=C1)C(CO)O)O.OS(=O)(=O)O,,,,,,
3873,123874,Glycerophosphorylethanolamine,C(COP(=O)(O)OCC(CO)O)N,,,,,,
3874,123875,N-Formyl-nle-leu-phe-nle-tyr-lys,CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)NC=O,,,,,,
3875,123876,CID 123876,C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)CC=CCCCC(=O)O)C=C[C@H](COC3=CC=C(C=C3)[125I])O,,,,,,
3876,123877,Dihydrocytochalasinb,C[C@@H]1CCC[C@H](CCC(=O)O[C@]23[C@@H](C=CC1)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)O)O,,,,,,
3877,123878,Delt-I,C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
3878,123879,Ramatroban,C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
3879,123880,Benzoyl-L-arginine ethyl ester,CCOC(=O)[C@H](CCCN=C(N)N)NC(=O)C1=CC=CC=C1,,,,,,
3880,123881,Sodium benzofuran isophthalate,COC1=C(C=C2C(=C1)C=C(O2)C3=C(C=C(C=C3)C(=O)O)C(=O)O)N4CCOCCN(CCOCCOCC4)C5=C(C=C6C=C(OC6=C5)C7=C(C=C(C=C7)C(=O)O)C(=O)O)OC,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3881,123882,Cyclo(D-alpha-aspartyl-3-((4-phenylpiperazin-1-yl)carbonyl)-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl) disodium salt,CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C2=CC=CS2)CC(=O)[O-])CC(=O)N3CCN(CC3)C4=CC=CC=C4)CC(=O)[O-])CC5=CNC6=CC=CC=C65.[Na+].[Na+],,,,,,
3882,123883,"2-[(2R,5S,8S,11S,14S,17R)-8-(carboxymethyl)-17-(1H-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid",CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C2=CC=CS2)CC(=O)O)CC(=O)N3CCN(CC3)C4=CC=CC=C4)CC(=O)O)CC5=CNC6=CC=CC=C65,,,,,,
3883,123884,(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid,CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N,,,,,,
3884,123885,"(3-((1-(3,4-Dichlorophenyl)ethyl)amino)-2-hydroxypropyl)(P-benzyl)-phosphinic acid",CC(C1=CC(=C(C=C1)Cl)Cl)NCC(CP(=O)(CC2=CC=CC=C2)O)O,,,"['Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. (See all compounds classified as GABA Antagonists.)']",,,
3885,123886,"1-((3,5-Dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone",CCCCCC(=O)C1=C(C(=C(C(=C1O)Cl)OC)Cl)O,,,,,,
3886,123887,CID 123887,[H-].[H-].[H-].[B+3].[C-]#N.[Na+],,,,,,
3887,123888,H-Tyr-Ala-Gly-Phe-Met-OH,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
3888,123889,(2S)-2-amino-6-[[2-(furan-2-yl)-2-oxoethyl]amino]hexanoic acid,C1=COC(=C1)C(=O)CNCCCC[C@@H](C(=O)O)N,,,,,,
3889,123890,"15-(2-Ethyl-3-hydroxy-4,4-dimethyl-1,3-oxazolidin-2-yl)pentadecanoic acid",CCC1(N(C(CO1)(C)C)O)CCCCCCCCCCCCCCC(=O)O,,,,,,
3890,123891,CID 123891,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3891,123892,Caridex,CCC(C(=O)O)NCl,,,,,,
3892,123893,"Azacyclotridec-1-en-2-amine, N-(2-phenylcyclopentyl)-, cis-",C1CCCCCC(=NCCCCC1)N[C@@H]2CCC[C@@H]2C3=CC=CC=C3,,,,,,
3893,123894,L-Tyrosyl-D-methionylglycyl-L-phenylalanyl-L-prolinamide,CSCC[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
3894,123895,N-omega-Hydroxy-L-arginine,C(C[C@@H](C(=O)O)N)CN=C(N)NO,,,,,,
3895,123896,Octacalcium phosphate,OP(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2],,,,,,
3896,123897,"[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(CO)O)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
3897,123898,"3,7-Bis(dimethylamino)-1,9-dimethylphenothiazin-5-ium chloride",CC1=CC(=CC2=C1N=C3C(=CC(=[N+](C)C)C=C3S2)C)N(C)C.[Cl-],,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)']",,,
3898,123899,"Phenothiazin-5-ium, 3,7-bis(dimethylamino)-1,9-dimethyl-",CC1=CC(=CC2=C1N=C3C(=CC(=[N+](C)C)C=C3S2)C)N(C)C,,,,,,
3899,123900,"(2R)-2,5-diaminopentanoic acid;2-oxopentanedioic acid",C(C[C@H](C(=O)O)N)CN.C(CC(=O)O)C(=O)C(=O)O,,,,,,
3900,123901,CID 123901,CCC1=C(C(=NC1=O)C=C2C(=C(C(=CC3=C(C(=C(N3)C=C4C(=CC)[C@H](C(=O)N4)C)C)CCC(=O)O)N2)CCC(=O)O)C)C,,,,,,
3901,123902,Pglu-pro-pro-gly-gly-ser-lys-val-ile-leu-phe,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCC(=O)N4,,,,,,
3902,123903,"Inositol 1,4-diphosphate",[C@H]1([C@@H](C([C@H]([C@@H](C1OP(=O)(O)O)O)O)OP(=O)(O)O)O)O,,,,,,
3903,123904,Potassium aluminum silicate,[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Al+3].[K+],,,,,,
3904,123905,(2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-formylindol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid,CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C=O)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)N5CCCCCC5,,,,,,
3905,123906,6-Methoxy-1-phenylpyridazin-4-imine,COC1=CC(=N)C=NN1C2=CC=CC=C2,,,,,,
3906,123907,lipid X,CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO)O)OC(=O)C[C@@H](CCCCCCCCCCC)O)O,,,,,,
3907,123908,Hydroxycitric acid,C(C(=O)O)C(C(C(=O)O)O)(C(=O)O)O,,,,,,
3908,123909,methylmalonyl-CoA,CC(C(=O)O)C(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3909,123910,Kdel sequence,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
3910,123911,Phosphohistidine,C1=C(NC=N1)C[C@@H](C(=O)O)NP(=O)(O)O,,,,,,
3911,123912,alpha-D-Galactose 1-phosphate,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O)O,,,,,,
3912,123913,Glycyl-l-glutamine,C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CN,,,,,,
3913,123914,3'-Sialyllactose,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)O[C@H]2[C@H]([C@H](O[C@H]([C@@H]2O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)O,,,,,,
3914,123915,Statine,CC(C)C[C@@H]([C@H](CC(=O)O)O)N,,,,,,
3915,123916,Heptadecanoic-17-(123)I acid,C(CCCCCCCC[123I])CCCCCCCC(=O)O,,,,,,
3916,123917,"3,4-Bis[(3-hydroxyphenyl)methyl]oxolan-2-one",C1C(C(C(=O)O1)CC2=CC(=CC=C2)O)CC3=CC(=CC=C3)O,,,"['Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS. (See all compounds classified as Phytoestrogens.)']",,,
3917,123918,Indo-1 pentaacetoxymethyl ester,CC1=CC(=C(C=C1)N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C)OCCOC2=C(C=CC(=C2)C3=CC4=C(N3)C=C(C=C4)C(=O)OCOC(=O)C)N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
3918,123919,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1CNCC2=C1C=CC(=C2Cl)Cl.Cl,,,,,,
3919,123920,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",C1CNCC2=C1C=CC(=C2Cl)Cl,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
3920,123921,Octaethyleneglycol monododecyl ether,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
3921,123922,"2,3-Bis(octadec-9-enoxy)propyl-trimethylazanium;chloride",CCCCCCCCC=CCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCC=CCCCCCCCC.[Cl-],,,,,,
3922,123923,"2,3-Bis(octadec-9-enoxy)propyl-trimethylazanium",CCCCCCCCC=CCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCC=CCCCCCCCC,,,,,,
3923,123924,"4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide",CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)OC)N3C[C@H](N(C[C@@H]3C)CC=C)C,,,,,,
3924,123925,Methyl 4-mercaptobutyrimidate,COC(=N)CCCS,,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
3925,123926,3-Acetylpyridine adenine dinucleotide,CC(=O)C1=C[N+](=CC=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O,,,,,,
3926,123927,"[[(2R,3S,4R,5R)-5-(3-acetylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",CC(=O)C1=C[N+](=CC=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O,,,,,,
3927,123928,Indium tris(tropolonate),C1=CC=C(C(=O)C=C1)[O-].C1=CC=C(C(=O)C=C1)[O-].C1=CC=C(C(=O)C=C1)[O-].[In+3],,,,,,
3928,123929,Pristanic acid,CC(C)CCCC(C)CCCC(C)CCCC(C)C(=O)O,,,,,,
3929,123930,"3,5-Dibromo-2-[4-(2,4-dibromo-6-carboxyphenoxy)-4-oxobut-2-enoyl]oxybenzoic acid",C1=C(C=C(C(=C1C(=O)O)OC(=O)C=CC(=O)OC2=C(C=C(C=C2Br)Br)C(=O)O)Br)Br,,,,,,
3930,123931,[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
3931,123932,dopamine 4-O-sulfate,C1=CC(=C(C=C1CCN)O)OS(=O)(=O)O,,,,,,
3932,123933,DTSSP Crosslinker,C1C(C(=O)N(C1=O)OC(=O)CCSSCCC(=O)ON2C(=O)CC(C2=O)S(=O)(=O)O)S(=O)(=O)O,,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
3933,123934,"5-(4,6-Dichlorotriazinyl)aminofluorescein",C1=CC2=C(C=C1NC3=NC(=NC(=N3)Cl)Cl)C(=O)OC24C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O,,,,,,
3934,123935,l-Alanyl-l-glutamine,C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N,,,,,,
3935,123936,6-methoxy-N-(3-sulfopropyl)quinolinium,COC1=CC2=C(C=C1)[N+](=CC=C2)CCCS(=O)(=O)[O-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3936,123937,"Quinolinium, 6-methoxy-1-(3-sulfopropyl)-",COC1=CC2=C(C=C1)[N+](=CC=C2)CCCS(=O)(=O)O,,,,,,
3937,123938,gamma-Glutamylcysteine,C(CC(=O)N[C@@H](CS)C(=O)O)[C@@H](C(=O)O)N,,,,,,
3938,123939,CID 123939,C1=CC(=CC=C1N[N+]#N)[N-]P(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O,,,,,,
3939,123940,CID 123940,C1=CC(=CC=C1N[N+]#N)NP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O,,,,,,
3940,123941,Senazodan hydrochloride,C1CC(=O)NN=C1C2=CC=C(C=C2)NC3=CC=NC=C3.Cl,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
3941,123942,Senazodan,C1CC(=O)NN=C1C2=CC=C(C=C2)NC3=CC=NC=C3,,,,,,
3942,123943,"neurokinin A (4-10), beta-Ala(8)-",CC(C)CC(C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CCNC(=O)[C@H](C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N,,,,,,
3943,123944,"(2S,3S,4S,5R,6S)-6-[3-[2-[[3-[3-[(2S,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3-oxopropyl]-5-[(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid",CC1=C(NC(=C1CCC(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O)CC3=C(C(=C(N3)C=C4C(=C(C(=O)N4)C)C=C)C)CCC(=O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C=C6C(=C(C(=O)N6)C=C)C,,,,,,
3944,123945,CGS-12066 (maleate salt),CN1CCN(CC1)C2=NC3=C(C=CC(=C3)C(F)(F)F)N4C2=CC=C4.C(=CC(=O)O)C(=O)O,,,,,,
3945,123946,Glutamyl-glycyl-lysyl-arginyl-prolyl-tryptophyl-isoleucyl-leucyl,CC[C@H](C)C(C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]4CCC(=O)N4,,,,,,
3946,123947,19-Nordeoxycorticosterone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CO)CCC4=CC(=O)CC[C@H]34,,,,,,
3947,123948,CID 123948,C1CC1CN2CC[C@]34[C@@H]5C(=O)C(=CC6=CC=CC=C6)C[C@]3([C@@H]2CC7=C4C(=C(C=C7)O)O5)O,,,,,,
3948,123949,CID 123949,CNC1=NC(=O)C2=C(N1)N(C=N2)C.C1[C@@H]([C@@H]([C@H](O1)CO)O)O,,,,,,
3949,123950,CID 123950,CNC1=NC(=O)C2=C(N1)N(C=N2)C,,,,,,
3950,123951,CID 123951,C1[C@@H](C(C(O1)CO)O)O,,,,,,
3951,123952,Nicotinic acid adenine dinucleotide phosphate,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)O,,,,,,
3952,123953,Naadp,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)O,,,,,,
3953,123954,Amfos,N.OP(=O)(O)O,,,"['Substances or mixtures that are added to the soil to supply nutrients or to make available nutrients already present in the soil, in order to increase plant growth and productivity. (See all compounds classified as Fertilizers.)', 'Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)']",,,
3954,123955,Magnesium hydrogen phosphate,OP(=O)([O-])[O-].[Mg+2],,,,,,
3955,123956,1-[2-(Diphenylmethyl)oxyethyl]-4-(3-phenylprop-2-enyl)piperazine,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC=CC4=CC=CC=C4,,,"['Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']",,,
3956,123957,N-cyano-N'-(2-nitroxyethyl)-3-pyridinecarboximidamide methanesulfonate,CS(=O)(=O)O.C1=CC(=CN=C1)C(=NCCO[N+](=O)[O-])NC#N,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
3957,123958,N-cyano-N'-(2-nitroxyethyl)-3-pyridinecarboximidamide,C1=CC(=CN=C1)C(=NCCO[N+](=O)[O-])NC#N,,,,,,
3958,123959,"Ac-(5H-Dibenzyl(a,d)cycloheptene-10,11-dihydroglycine-leu-asp-ile-ile-trp)",CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C3C4=CC=CC=C4CCC5=CC=CC=C35)NC(=O)C,,,,,,
3959,123960,Isotocin,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N)CC(=O)N)CO,,,,,,
3960,123961,2-Amino-2-deoxymannose,C([C@H]([C@H]([C@@H]([C@@H](C=O)N)O)O)O)O,,,,,,
3961,123962,N-Acetyl-9-O-acetylneuraminic acid,CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1[C@@H]([C@@H](COC(=O)C)O)O)(C(=O)O)O)O,,,,,,
3962,123963,3-Hydroxymethylantipyrine,CN1C(=CC(=O)N1C2=CC=CC=C2)CO,,,,,['3-hydroxy-methylantipyrine is a known human metabolite of antipyrine.'],
3963,123964,Vadimezan,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C,"['Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.']",,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,"['DMXAA has known human metabolites that include (2S,3S,4S,5R)-6-[2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid and 6-hydroxy-MXAA.']",
3964,123965,"(1S,2S,13R,21S)-22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol",C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6,,,,,,
3965,123966,"alpha-1,4-Tetraglucose",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)CO)O)O)O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3966,123967,[[(2R)-2-[(1S)-1-(6-aminopurin-9-yl)-2-oxoethoxy]-3-oxopropoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H](C=O)O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C=O)N,,,,,,
3967,123968,NBD C6-Ceramide,CCCCCCCCCCCCCC=CC(C(CO)NC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-])O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3968,123969,CID 123969,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C4=C(C(=O)N=C(N4)N)N=C3SC5=CC=C(C=C5)Cl)O)OP(=O)(O1)O,,,,,,
3969,123970,N-Hydroxy-N-[3-(3-phenoxyphenyl)-2-propen-1-yl]acetamide,CC(=O)N(CC=CC1=CC(=CC=C1)OC2=CC=CC=C2)O,,,,,,
3970,123971,Pyroglutamyl-3-methylhistidyl-prolinamide,CN1C=NC=C1C[C@@H](C(=O)N2CCC[C@H]2C(=O)NC(=O)[C@@H]3CCC(=O)N3)N,,,,,,
3971,123972,CID 123972,C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1C)CC2=CC=CC=C2)C(C)C)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)N,,,,,,
3972,123973,"L-Arginine, N2-(N-(N-(N-(N-(N-(1-(1-(N2-D-arginyl-L-arginyl)-L-prolyl)-trans-4-hydroxy-L-prolyl)glycyl)-3-(2-thienyl)-L-alanyl)-L-seryl)-D-phenylalanyl)-3-(2-thienyl)-L-alanyl)-",C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)C(CCN=C(N)N)[C@@](C(=O)CNC(=O)[C@@H]2C[C@H](CN2)O)(C(=O)O)N(C(=O)[C@H](CC3=CC=CS3)N)C(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)N,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3973,123974,Azane;cyclohexanamine;platinum(4+);diacetate;dichloride,CC(=O)[O-].CC(=O)[O-].C1CCC(CC1)N.N.[Cl-].[Cl-].[Pt+4],"['Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.']",,,,,
3974,123975,Ethanediperoxoic acid,C(=O)(C(=O)OO)OO,,,,,,
3975,123976,27-Hydroxycholesterol,C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CO,,,,,,
3976,123977,Tyr-ile-gly-ser-arg,CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
3977,123978,polymyxin B nonapeptide,C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC2=CC=CC=C2)CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)N)O,,,"['Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
3978,123979,3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid,CCCC1=C(C(=C(O1)CCC(=O)O)C(=O)O)C,,,,,,
3979,123980,"5,9-Dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan",CC1[C@H]2CC3=C([C@@]1(CCN2C[C@H]4CCCO4)C)C=C(C=C3)O,,,,,,
3980,123981,Benalfocin,CN1CCC2=C(CC1)C(=CC=C2)Cl,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
3981,123982,Kelatorphan,C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)CC(=O)NO,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3982,123983,"4-(N-Ethyl-N-phenylamino)-1,2-dimethyl-6-(methylamino)pyrimidinium chloride",CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C.Cl,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']",,,
3983,123984,"N-ethyl-1,2-dimethyl-6-methylimino-N-phenylpyrimidin-4-amine",CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C,,,"['Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
3984,123985,e-64,CC(C)C[C@@H](C(=O)NCCCCN=C(N)N)NC(=O)[C@@H]1[C@H](O1)C(=O)O,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)']",,,
3985,123986,5-(beta-D-galactopyranosyloxy)-L-lysine,C(CC(CN)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)[C@@H](C(=O)O)N,,,,,,
3986,123987,"(8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-10,13-dimethyl-17-prop-1-ynyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthren-3-one",CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C=CC4=CC(=O)C=C[C@]34C)O)C)O,,,,,,
3987,123988,Dimethyl dithiobispropionimidate,COC(=N)CCSSCCC(=N)OC,,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
3988,123989,Subecholine,C[N+](C)(C)CCOC(=O)CCCCCCC(=O)OCC[N+](C)(C)C.[I-].[I-],,,"['Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. (See all compounds classified as Cholinergic Agents.)']",,,
3989,123990,Suberyldicholine,C[N+](C)(C)CCOC(=O)CCCCCCC(=O)OCC[N+](C)(C)C,,,"['Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. (See all compounds classified as Cholinergic Agents.)']",,,
3990,123991,Dehydroalanine,C=C(C(=O)O)N,,,,,,
3991,123992,Pyro(l-alpha-aminoadipyl)-L-histidyl-L-thiazolidine-4-carboxamide,C1CC(NC(=O)C1)C(=O)NC(CC2=CN=CN2)C(=O)N3CSCC3C(=O)N,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
3992,123993,"L-Tryptophan, N-(N(2)-(N-(N-(N-L-methionyl-L-alpha-glutamyl)-L-histidyl)-L-phenylalanyl)-L-arginyl)-",CSCCC(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N,,,,,,
3993,123994,(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanediamide,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CN(C)C(=O)[C@H](CC1=CC=CC=C1)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCC(=O)N3,,,,,,
3994,123995,Elmex,CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCO.CCCCCCCCCCCCCCCCN.F.F,,,"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)']",,,
3995,123996,coenzyme F420,C[C@@H](C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)OP(=O)(O)OC[C@H]([C@H]([C@H](CN1C2=CC(=O)C=CC2=CC3=C1NC(=O)NC3=O)O)O)O,,,,,,
3996,123997,CID 123997,C(=O)(C(=O)O)O.O.[CaH2],,,,,,
3997,123998,Crustacean erythrophore concentrating hormone,CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N)NC(=O)[C@@H]5CCC(=O)N5,,,,,,
3998,123999,Tilazol,CCNC1(CCCCC1=O)C2=CC=CS2.CC1=NN(C2=C1C(=NCC(=O)N2C)C3=CC=CC=C3F)C.Cl,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)']",,,
3999,124000,Epithienamycin,CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4000,124001,Hexaammine cobalt(III),N.N.N.[NH2-].[NH2-].[NH2-].[Co+3],,,,,,
4001,124002,Ruthenium(2+) azanide--ammonia (1/2/4),N.N.N.N.[NH2-].[NH2-].[Ru+2],,,,,,
4002,124003,"neurokinin A(4-10), Tyr(5)-Trp(6,8,9)-Lys(10)-",CC(C)[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
4003,124004,CID 124004,C1C(C2=C(N1)C(=O)C(=O)C=C2C3=C(C4=CC=CC=C4N3)C[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N,,,,,,
4004,124005,"(2R,3R,4R,5R)-4-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)CO)CO)O)O)O)O,,,,,,
4005,124006,3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-2-yl)propan-1-one,CC1=C(N=CN1)CCC(=O)C2=CC3=CC=CC=C3N2C,,,,,,
4006,124007,"3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one",C1CNCC=C1C2=CNC3=C2NC(=O)C=C3,,,['Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)'],,,
4007,124008,CID 124008,CC[C@H](C)C[C@H](C)C=CC(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O,,,,,,
4008,124009,"[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 4-methylpentanoate;hydrochloride",CC(C)CCC(=O)O[C@H]1[C@@H]2[C@]([C@H](CCC2(C)C)O)([C@]3(C(=O)C[C@](O[C@@]3([C@H]1OC(=O)C)C)(C)C=C)O)C.Cl,,,,,,
4009,124010,"[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 4-methylpentanoate",CC(C)CCC(=O)O[C@H]1[C@@H]2[C@]([C@H](CCC2(C)C)O)([C@]3(C(=O)C[C@](O[C@@]3([C@H]1OC(=O)C)C)(C)C=C)O)C,,,,,,
4010,124011,Dhlnl,C(C[C@@H](C(=O)O)N)[C@H](CNCC(CCC(C(=O)O)N)O)O,,,,,,
4011,124012,"(3S,4R,6R)-3-ethenyl-6-[(S)-hydroxy-(6-methoxyquinolin-4-yl)methyl]-1-azabicyclo[2.2.2]octan-3-ol",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@H]4CCN3C[C@@]4(C=C)O)O,,,,,,
4012,124013,Bouin's solution,CC(=O)O.C=O.C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-],,,['Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. (See all compounds classified as Fixatives.)'],,,
4013,124014,"(3S,3aS,5aS,9R,11aS,13aR)-3a,5a,8,8,11a,13a-hexamethyl-3-propan-2-yl-1,2,3,4,5,5b,6,7,7a,9,10,11,13,13b-tetradecahydrocyclopenta[a]chrysen-9-ol",CC(C)[C@@H]1CCC2[C@]1(CC[C@@]3([C@@]2(CC=C4C3CCC5[C@@]4(CC[C@H](C5(C)C)O)C)C)C)C,,,,,,
4014,124015,Xestobergsterol A,C[C@@H]1C[C@@]([C@@H]2[C@H]1[C@]3(CCC4C([C@H]3C2=O)[C@H]([C@@H]([C@@H]5[C@@]4(CC[C@H](C5)O)C)O)O)C)(CC(C)C)O,,,,,,
4015,124016,"3,3'-Digalloylprocyanidin B2",C1[C@H]([C@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O)O)O)C7=CC(=C(C=C7)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O,,,,,,
4016,124017,Procyanidin B5,C1[C@H]([C@H](OC2=C1C(=C(C(=C2)O)[C@@H]3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)O)O)C6=CC(=C(C=C6)O)O)O,,,,,,
4017,124018,Urs-12-en-3-one,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CCC4[C@]3(CC[C@@H]5[C@@]4(CCC(=O)C5(C)C)C)C)[C@@H]2[C@H]1C)C)C,,,,,,
4018,124019,GE20372 Factor A,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O,,,,,,
4019,124020,"1,3,4,5-tetra-O-galloylquinic acid",C1[C@H](C([C@@H](CC1(C(=O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,,,,
4020,124021,beta-Glucogallin,C1=C(C=C(C(=C1O)O)O)C(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
4021,124022,"3,5-Di-O-galloyl-4-O-digalloylquinic acid",C1[C@H](C([C@@H](CC1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C3=CC(=C(C(=C3)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,,,,
4022,124023,"3-O-Digalloyl-4,5-di-O-galloylquinic acid",C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,,,,
4023,124024,"[(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate",C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C([C@@H](O2)O)(COC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,,,,,,
4024,124025,Proanthocyanidin A2,C1[C@H]([C@H](OC2=C1C(=CC3=C2[C@@H]4[C@H]([C@](O3)(OC5=CC(=CC(=C45)O)O)C6=CC(=C(C=C6)O)O)O)O)C7=CC(=C(C=C7)O)O)O,,,,,,
4025,124026,Died66Br,CCCCCCN1C(=O)C2=CC=CC3=C2C(=CC(=C3NCCNC(=O)CCCCC(=O)NCCNC4=C(C=C5C6=C4C=CC=C6C(=O)N(C5=O)CCCCCC)Br)Br)C1=O,,,,,,
4026,124027,"Phorbol acetate, caprate",CCCCCCCCCC(=O)O[C@@]12[C@@H](C1(C)C)[C@@H]3C=C(C[C@]4([C@H]([C@]3([C@@H]([C@H]2OC(=O)C)C)O)C=C(C4=O)C)O)CO,,,,,,
4027,124028,"2-(1,2-Dihydro-2-oxo-1-(2-propenyl)-3H-indol-3-ylidene)-N,N-di-2-propenylhydrazinecarbothioamide",C=CCN1C2=CC=CC=C2C(=C1O)N=NC(=S)N(CC=C)CC=C,,,,,,
4028,124029,4-Amino-5-hydroxy-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one,C1C(C(OC1N2C=C(C(=NC2=O)N)O)CO)O,,,,,,
4029,124030,Wilforgine,CC1CCC2=C(C=CC=N2)C(=O)OC[C@]3([C@@H]4[C@H]([C@H]([C@@]5([C@H]([C@H]([C@@H](C([C@]5([C@@H]4OC(=O)C)O3)(C)O)OC1=O)OC(=O)C6=COC=C6)OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)C,,,,,,
4030,124031,"4-Amino-N-(2,6-dimethylphenyl)phthalimide",CC1=C(C(=CC=C1)C)N2C(=O)C3=C(C2=O)C=C(C=C3)N,,,,,,
4031,124032,CID 124032,C1=CC(=C(C=C1C=CCC#CC2=CC(=C(C=C2)O[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
4032,124033,"2-(4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl)prop-2-enoic acid",C[C@@H]1CCC(C2C1CCC(=C2)C)C(=C)C(=O)O,,,,,,
4033,124034,Swertisin,COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
4034,124035,Lonchocarpol A,CC(=CCC1=C(C(=C2C(=C1O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O)CC=C(C)C)O)C,,,,,,
4035,124036,CID 124036,CC[C@H](C)C=C(C)C=CC1=CC2=C(C(=O)[C@]3([C@@H](C2=CO1)[C@@H](C(=O)O3)C(=O)C)C)Cl,,,,,,
4036,124037,CID 124037,CC[C@H](C)C=C(C)C=CC1=CC2=C(C(=O)[C@]([C@@H](C2=CO1)CC(=O)C)(C)O)Cl,,,,,,
4037,124038,CID 124038,CCCCC(=O)OC1CC(OC(C1O)C)OC(C)C(C)C(C(C)C(C(C)C2C(C3C(O3)C(CCCC(CC(C[C@@H]4C[C@@H]([C@H]([C@](O4)(CC(C(CCC(CC(CC(CC=CC(=O)O2)O)O)O)C)O)O)O)O)O)OC(=O)CC(=O)O)O)C)O)O,,,,,,
4038,124039,Fraxinellone,CC1=C2C(=O)O[C@H]([C@@]2(CCC1)C)C3=COC=C3,,,,,,
4039,124040,(2-Phenyl-1-carbobenzyl-oxyvalyl-amino)-ethyl-phosphinic acid,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)P(=O)([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)OCC3=CC=CC=C3)O)NC(=O)OCC4=CC=CC=C4,,,,,,
4040,124041,Sakyomicin A,C[C@@H]1[C@@H](CC[C@H](O1)O[C@@]23C(=O)[C@H]([C@](C[C@@]2(C=CC4=C3C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C)O)O)O,,,,,,
4041,124042,Gluconamide,C([C@H]([C@H]([C@@H]([C@H](C(=O)N)O)O)O)O)O,,,,,,
4042,124043,CID 124043,C([C@H]([C@H]([C@H]1C(=O)C(=C(O1)O)O)O)O)O,,,,,,
4043,124044,2-S-Ethyl-2-thio-D-mannose diethyl dithioacetal,CCS[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)C(SCC)SCC,,,,,,
4044,124045,CID 124045,C[C@H]1[C@@H]([C@@H](C(O[C@@H]1[C@H](C)[C@H]([C@@H](C)C=CC=C(C)C(=O)NC2=CC(=O)C3=C(C2=O)C(=C(C4=C3C=C(O4)C)C)O)O)CC=O)C)OC(=O)C,,,,,,
4045,124046,"7H-Pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-3-(fluoromethyl)-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-",CN1CCN(CC1)C2=C(C=C3C4=C2SCC(N4C=C(C3=O)C(=O)O)CF)F,,,,,,
4046,124047,CID 124047,CC[C@H]1C(=CC(=C)C[C@@H](C=C(CC(C(=O)[C@H](C(=O)O1)C)(CO)O)OC)C)C,,,,,,
4047,124048,"3-Quinolinecarboxylic acid, 1,4-dihydro-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-",COC1=C2C(=CC(=C1N3CCC(C3)N)F)C(=O)C(=CN2C4CC4)C(=O)O,,,,,,
4048,124049,Glabranin,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=CC=C3)C,,,,,,
4049,124050,Isoglycyrol,CC1(CCC2=C(O1)C=C3C(=C2OC)C4=C(C5=C(O4)C=C(C=C5)O)C(=O)O3)C,,,,,,
4050,124051,CID 124051,C1=CC(=C(C=C1O)O)C2=CC(=C3C(=CC(=O)C=C3O2)O)O,,,,,,
4051,124052,Glabridin,CC1(C=CC2=C(O1)C=CC3=C2OC[C@H](C3)C4=C(C=C(C=C4)O)O)C,,,,,,
4052,124053,CID 124053,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=O)C3=C2O)O)CC=C(C)C)C4=CC=C(C=C4)O)O)O)O,,,,,,
4053,124054,CID 124054,C[C@H]1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)N5CCCC5C(C)O)C,,,,,,
4054,124055,CID 124055,CCC(=O)N(C)C(C)C(=O)O[C@H]1CC(=O)N(C2=C(C(=CC(=C2)CC(=CC=C[C@H]([C@]3(C[C@@H]([C@H]([C@H]4[C@]1(O4)C)C)OC(=O)N3)O)OC)C)OC)Cl)C,,,,,,
4055,124056,CID 124056,C[C@@H]1[C@@H]2C[C@]([C@@H](C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)C(C)N(C)C(=O)C(C)C)C)C)OC)(NC(=O)O2)O,,,,,,
4056,124057,CID 124057,C[C@@H]1[C@@H]2C[C@]([C@@H](C=CC=C(C(C3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)C(C)N(C)C(=O)C(C)C)C)O)C)OC)(NC(=O)O2)O,,,,,,
4057,124058,CID 124058,CC[C@@H]1[C@H](C=C(C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)C)CO,,,,,,
4058,124059,3-Deoxycaryoptinol,C[C@@H]1C[C@@H]([C@@]2([C@@H]([C@@]1(C)[C@@H]3CC4C=COC4O3)CCC[C@]25CO5)COC(=O)C)OC(=O)C,,,,,,
4059,124060,CID 124060,COC1=CC=C(C=C1)C2=C(C(=C3C(=CC(=O)C(=C3O)OC)O2)O)OC,,,,,,
4060,124061,"(3S,6aR,6bS,8aR,9R,14bR)-4,4,6a,6b,8a,11,11,14b-Octamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-eicosahydro-picene-3,9-diol",C[C@@]12CC[C@@]3(C(=CCC4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C1CC(C[C@H]2O)(C)C)C,,,,,,
4061,124062,Rubiadin,CC1=C(C=C2C(=C1O)C(=O)C3=CC=CC=C3C2=O)O,,,,,,
4062,124063,Soranjidiol,CC1=C(C2=C(C=C1)C(=O)C3=C(C2=O)C=CC(=C3)O)O,,,,,,
4063,124064,CID 124064,C1=CC=C(C(=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O)O,,,,,,
4064,124065,"Diethyl 4,7-dihydroxy-1,10-phenanthroline-3,8-dicarboxylate",CCOC(=O)C1=CNC2=C(C1=O)C=CC3=C2NC=C(C3=O)C(=O)OCC,,,,,,
4065,124066,"(15S)-15-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.01,13.02,10.04,8]nonadeca-2,4(8),9,16-tetraene-11,18-diol",CO[C@H]1CC2C3(C=C1)C(CN2C(C4=CC5=C(C=C34)OCO5)O)O,,,,,,
4066,124067,CID 124067,C1C(C(SC1N2C=C(C(=O)NC2=O)C=CBr)CO)O,,,,,,
4067,124068,"Benzenecarboximidamide, N,3,4-trihydroxy-",C1=CC(=C(C=C1C(=NO)N)O)O,,,,,,
4068,124069,Dihydrosanguinarine,CN1CC2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6,,,,,,
4069,124070,4-Oxo-enoxacin,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNC(=O)C3)F)C(=O)O,,,,,,
4070,124071,CID 124071,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)CC=C)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
4071,124072,Tetrahydrocurcumin,COC1=C(C=CC(=C1)CCC(=O)CC(=O)CCC2=CC(=C(C=C2)O)OC)O,,,,,,
4072,124073,2-Bromo-5-(2-bromo-2-nitroethenyl)furan,C1=C(OC(=C1)Br)C=C([N+](=O)[O-])Br,,,,,,
4073,124074,5-Bromosalicylanilide,C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)Br)O,,,,,,
4074,124075,Casimiroin,CN1C(=O)C=C(C2=C1C3=C(C=C2)OCO3)OC,,,,,,
4075,124076,"Acridine, 9-(ethylthio)-",CCSC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
4076,124077,9-Diethylaminoethylthioacridine,CCN(CC)CCSC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
4077,124078,CID 124078,CCCN(C(=O)COC1=C2C3=C(C(=C1)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)N(C)C,,,,,,
4078,124079,CID 124079,CCCCN(C(=O)COC1=C2C3=C(C(=C1)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)N(C)C,,,,,,
4079,124080,CID 124080,CCN(CC)N(C)C(=O)COC1=C2C3=C(C(=C1)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O,,,,,,
4080,124081,CID 124081,C[C@H]1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)OCC(=O)N(C)N(C)C)C,,,,,,
4081,124082,CID 124082,CCCCN(C(=O)COC1=C2C3=C(C(=C1)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)N(CCC)CCC,,,,,,
4082,124083,CID 124083,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN)C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
4083,124084,CID 124084,C[C@H]1C(=O)N(C2([C@@]1([C@H](C[C@@H](C)C(C=CC=CCNC(=O)C(C)(C)C(C(=CC=CC=CCC3=CN=CO3)C)O)O)OC)O)COC2=O)C,,,,,,
4084,124085,[[(2S)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;but-2-enedioic acid,C[C@@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=CC(=O)O)C(=O)O,,,,,,
4085,124086,CID 124086,C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C(=C2N5CCN(CC5)CC(C)C)O)O)C,,,,,,
4086,124087,Desloratadine,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,"['For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.']","['Desloratadine is a long-acting second-generation H<sub>1</sub>-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be ""activated,"" releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.']","['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)', 'Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)']","['Desloratadine administered orally for ten days to healthy volunteers as a 5 mg tablet once daily resulted in a mean T<sub>max</sub> of approximately 3 hours, a mean steady-state C<sub>max</sub> of 4 ng/ml, and a mean steady-state AUC of 56.9 ng\\*hr/ml. A similar profile was observed using 10 ml of an oral solution containing 5 mg of desloratadine. Food was found not to affect desloratadine absorption.', 'Approximately 87% of a <sup>14</sup>C-desloratadine dose was equally recovered in urine and feces as metabolic products.']","['Desloratadine is metabolized to the active metabolite 3-hydroxydesloratadine, which is subsequently glucuronidated.', 'Desloratadine is a known human metabolite of Rupatadine and loratadine.']",['Desloratadine has a mean plasma elimination half-life of approximately 27 hours.']
4087,124088,Amdoxovir,C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N,['Investigated for use/treatment in HIV infection and acquired immune deficiency syndrome (AIDS) and aids-related infections.'],,,,,
4088,124089,"3-Thiophenamine, N-(2-methoxy-1-methylethyl)-2,4-dimethyl-",CC1=CSC(=C1NC(C)COC)C,,,,,,
4089,124090,5-Dodecylsalicylaldoxime,CCCCCCCCCCCCC1=CC(=C(C=C1)O)C=NO,,,,,,
4090,124091,CID 124091,CC(=O)ON1C2C1C3(C(C4=C(C=C(C=C4O)C=O)N(C2)O3)COC(=O)N)O,,,,,,
4091,124092,"(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(3R)-3-[(1S,2R)-1-methoxy-2-methyl-3-oxo-3-(2-phenylethylamino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide",CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CC[C@H](C1)[C@@H]([C@@H](C)C(=O)NCCC2=CC=CC=C2)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C,,,,,,
4092,124093,Garenoxacin,C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F,['Investigated for use/treatment in bacterial infection.'],,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']",,,
4093,124094,"3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl)-1,4-dihydro-4-oxo-, monomethanesulfonate",C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F.CS(=O)(=O)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']",,,
4094,124095,N-[(4-methoxyphenyl)methylideneamino]phthalazin-1-amine,COC1=CC=C(C=C1)C=NNC2=NN=CC3=CC=CC=C32,,,,,,
4095,124096,"Propanoic acid, 2-(2-(1-phthalazinyl)hydrazinylidene)-",CC(=NNC1=NN=CC2=CC=CC=C21)C(=O)O,,,,,,
4096,124097,Metformin orotate,CN(C)C(=N)N=C(N)N.C1=C(NC(=O)NC1=O)C(=O)O,,,,,,
4097,124098,Metoclopramide sulfide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OCCSC)N)Cl,,,,,,
4098,124099,Metoclopramide sulfone,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OCCS(=O)(=O)C)N)Cl,,,,,,
4099,124100,Metronidazole myristate,CCCCCCCCCCCCCC(=O)OCCN1C(=NC=C1[N+](=O)[O-])C,,,,,,
4100,124101,"2-[[2-[4-(1,2-Diphenylbut-1-enyl)phenoxy]acetyl]amino]acetic acid",CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCC(=O)NCC(=O)O)C3=CC=CC=C3,,,,,,
4101,124102,"1a,2,7,7a-Tetrahydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecen-1-yl)naphth[2,3-b]oxirene-2,7-diol",CC(C)CCCC(C)CCCC(C)CCCC(=CCC12C(C3=CC=CC=C3C(C1(O2)C)O)O)C,,,,,,
4102,124103,N-(4-Hydroxy-3-methyl-1-naphthyl)acetamide,CC1=C(C2=CC=CC=C2C(=C1)NC(=O)C)O,,,,,,
4103,124104,"3,7-Dimethyl-9-(2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)nona-2,4,6,8-tetraen-1-ol",CC(=CCO)C=CC=C(C)C=CC12C(CCCC1(O2)C)(C)C,,,,,,
4104,124105,CID 124105,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N.[Na+].[Na+],,,,,,
4105,124106,CID 124106,CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OP(=O)(O)OC3=C(O[C@@H](C3=O)[C@H](CO)O)O)C.[K+],,,,,,
4106,124107,CID 124107,CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OP(=O)(O)OC3=C(O[C@@H](C3=O)[C@H](CO)O)O)C,,,,,,
4107,124108,Amantadine Sulfate,C1C2CC3CC1CC(C2)(C3)N.C1C2CC3CC1CC(C2)(C3)N.OS(=O)(=O)O,,,"['Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)']",,,
4108,124109,Amantadine-N-mustard,C1C2CC3CC1CC(C2)(C3)N(CCCl)CCCl,,,,,,
4109,124110,"1-Phenyl-2,4,5,6(1H,3H)-pyrimidinetetrone 5-oxime",C1=CC=C(C=C1)N2C(=C(C(=O)NC2=O)N=O)O,,,,,,
4110,124111,Erythromycin 2'-dodecyl glutaramide,CCCCCCCCCCCCNC(=O)CCCC(=O)OC1C(CC(OC1OC2C(C(C(C(=O)OC(C(C(C(C(=O)C(CC2(C)O)C)C)O)(C)O)CC)C)OC3CC(C(C(O3)C)O)(C)OC)C)C)N(C)C,,,,,,
4111,124112,Biotin-nonapeptide,CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=C(C=C3)N=[N+]=[N-])C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)CCCCCNC(=O)CCCCC5C6C(CS5)NC(=O)N6,,,,,,
4112,124113,CID 124113,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)CC=CC)OC(=O)C)C)C(C)C)C)CC(C)C)(C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,,,,,,
4113,124114,CID 124114,CC[C@H]1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)CC=CCO)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,,,,,,
4114,124115,Copper bleomycin,CC1=C(N=C(N=C1N)C(CC(=N)[O-])NCC(C(=N)[O-])N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=N)[O-])O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.[Cu+2],,,,,,
4115,124116,Bleomycin A2-iron(2+)complex,CC1=C(N=C(N=C1N)C(CC(=N)[O-])NCC(C(=N)[O-])N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=N)[O-])O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.[Fe+2],,,,,,
4116,124117,Iron bleomycin,CC1=C(N=C(N=C1N)C(CC(=N)[O-])NCC(C(=N)[O-])N)C(=NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=N)[O-])O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O)[O-].[Fe+3],,,,,,
4117,124118,CID 124118,CC1=C2C(C(C([N-]2)C3(C(C(C(=N3)C(=C4C(C(C(=N4)C=C5C(C(C1=N5)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)OP(=O)([O-])OC6C(OC(C6O)N7C=NC8=NC(=NC(=C87)N)S(=O)C)CO.[C-]#N.[Co+3],,,,,,
4118,124119,CID 124119,CC1=C2C(C(C(=N2)C=C3C(C(C(=C(C4=NC(C5C(C(C1=N5)(C)CCC(=O)NCC(C)OP(=O)(O)OC6C(OC(C6O)N7C=NC8=NC(=NC(=C87)N)S(=O)C)CO)CC(=O)N)(C(C4CCC(=O)N)(C)CC(=O)N)C)C)N3)(C)CC(=O)N)CCC(=O)N)(C)C)CCC(=O)N,,,,,,
4119,124120,CID 124120,CC1=C2C(C(C([N-]2)C3(C(C(C(=N3)C(=C4C(C(C(=N4)C=C5C(C(C1=N5)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)OP(=O)([O-])OC6C(OC(C6O)N7C=NC8=NC(=NC(=C87)N)S(=O)(=O)C)CO.[C-]#N.[Co+3],,,,,,
4120,124121,CID 124121,CC1=C2C(C(C(=N2)C=C3C(C(C(=C(C4=NC(C5C(C(C1=N5)(C)CCC(=O)NCC(C)OP(=O)(O)OC6C(OC(C6O)N7C=NC8=NC(=NC(=C87)N)S(=O)(=O)C)CO)CC(=O)N)(C(C4CCC(=O)N)(C)CC(=O)N)C)C)N3)(C)CC(=O)N)CCC(=O)N)(C)C)CCC(=O)N,,,,,,
4121,124122,CID 124122,CC1=C[C@@H]2[C@@]3(CC1)COC(=O)C=C4CCO[C@](C4O)(C=CC=CC(=O)O[C@H]5[C@]3([C@]6(CO6)[C@@H](C5)O2)C)[C@H](C)O,,,,,,
4122,124123,Lead fluoride (PbF2),[F-].[F-].[Pb+2],,,,,,
4123,124124,CID 124124,CC(=CN=NC(=NC)[S-])NNC(=NC)[S-].[Cu+2],,,,,,
4124,124125,"1-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl)-, (1E)-",CCCCCCCC(=O)C=CC1=CC(=C(C=C1)O)OC,,,,,,
4125,124126,3-Deazaadenosylhomocysteine,C1=CN=C(C2=C1N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O)N,,,,,,
4126,124127,"Phorbol-13-acetate, 12-O-palmitoyl-16-hydroxy",CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4C1([C@]4(C)CO)OC(=O)C)O)C,,,,,,
4127,124128,"Quinolinium, 6-amino-4-((3-amino-4-(((4-((1-methylpyridinium-4-yl)amino)phenyl)amino)carbonyl)phenyl)amino)-1-methyl-, diiodide",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)C3=C(C=C(C=C3)NC4=C5C=C(C=CC5=[N+](C=C4)C)N)N.[I-].[I-],,,,,,
4128,124129,"4-[4-[2-Amino-4-[4,6-(N-methylquinolinium)amino]benzamido]anilino]-N-methylpyridinium mesylate",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)C3=C(C=C(C=C3)NC4=C5C=C(C=CC5=[N+](C=C4)C)N)N,,,,,,
4129,124130,S-N(6)-Methyladenosylhomocysteine,CNC1=C2C(=NC=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O,,,,,,
4130,124131,"(2s,3s,4s)-3,4-Dimethyl-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran",C[C@H]1[C@@H](C(O[C@@H]1C2=CC(=C(C(=C2)OC)OC)OC)C3=CC(=C(C(=C3)OC)OC)OC)C,,,,,,
4131,124132,"4-Pyrimidinecarboxylic acid, 5-fluorohexahydro-2,6-dioxo-",C1(C(NC(=O)NC1=O)C(=O)O)F,,,,,,
4132,124133,2-Chloroethyl-S-carbamoylcysteine,C(CCl)NC(=O)OC(=O)[C@H](CS)N,,,,,,
4133,124134,"(3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone",CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCC(=O)[C@@H]3CO3)CC4=CC=CC=C4)C,,,,,,
4134,124135,CID 124135,CC(=CCC(=CCCC(=CCCC=C(C)CCC=C(C)CCC1C(N1)(C)C)C)C)C,,,,,,
4135,124136,"3,9-Epoxy-3H-azirino(2,3-c)(1)benzazocine-5,8-dimethanol, 1,1a,2,8,9,9a-hexahydro-7,9-dihydroxy-, alpha(8)-carbamate",C1C2C(N2)C3(C(C4=C(N1O3)C=C(C=C4O)CO)COC(=O)N)O,,,,,,
4136,124137,"4,4'-Methylenebis(2-chloroaniline)-N-glucuronide",C1=CC(=C(C=C1CC2=CC(=C(C=C2)N[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)Cl)Cl)N,,,,,,
4137,124138,"2-[[(2S,4aS,6aR,6aS,6bR,8aR,10S,12aS)-10-(2-carboxybenzoyl)oxy-2,4a,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12-dodecahydropicen-2-yl]methoxycarbonyl]benzoic acid",C[C@]12CC[C@](CC1=C3C=C[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C6=CC=CC=C6C(=O)O)C)(C)COC(=O)C7=CC=CC=C7C(=O)O,,,,,,
4138,124139,5-(Hexyloxy)psoralen,CCCCCCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3,,,,,,
4139,124140,CID 124140,CN1C(=O)C2=C3C4=CC=CC=C4NC3=C5C(=C2C1=O)C6=CC=CC=C6N5C7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8C[C@@H]([C@H](CO8)N)O)OC)O)O,,,,,,
4140,124141,CID 124141,CN[C@H]1CO[C@H](C[C@@H]1O)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8NC7=C53)C(=O)N(C6=O)C)O)O)OC,,,,,,
4141,124142,"1,2-Dihydroxy-5,6-dioxohexane-3-sulfonic acid",C(C(C(CO)O)S(=O)(=O)O)C(=O)C=O,,,,,,
4142,124143,Carboxyifosfamide,C(COP(=O)(NCCCl)NCCCl)C(=O)O,,,,,,
4143,124144,CID 124144,CC(=O)C=C(C1=CC=CC=C1)[O-].CC(=O)C=C(C1=CC=CC=C1)[O-].[Cl-].[Cl-].[Ti+4],,,,,,
4144,124145,"3-(2-(2,4,6-Trimethylphenyl)thioethyl)-4-methylsydnone",CC1=CC(=C(C(=C1)C)SCC[N+]2=NOC(=C2C)[O-])C,,,,,,
4145,124146,"4-methyl-3-[2-(2,4,6-trimethylphenyl)sulfanylethyl]-2H-oxadiazol-3-ium-5-one",CC1=CC(=C(C(=C1)C)SCC[N+]2=C(C(=O)ON2)C)C,,,,,,
4146,124147,Bdert,CCOC1C(C(=O)NC(=O)N1C2CC(C(O2)CO)O)(C)Br,,,,,,
4147,124148,(s)-n-Methylsalsolinol,C[C@H]1C2=CC(=C(C=C2CCN1C)O)O,,,,,,
4148,124149,CID 124149,CCCCCCCCC=CCCCCCCCC(=O)OC[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O[C@H]2CC[C@]3([C@@H]4CC[C@]5([C@@H]([C@@H]4CC=C3C2)CC[C@H]5[C@H](C)CC[C@@H](CC)C(C)C)C)C)O)O)O,,,,,,
4149,124150,Tripiperaquine,C1C[N+]2(C1CN(CC2)N3CCN(CC3)N4CC[N+]5(CCC5C4)C6=C7C=CC(=CC7=NC=C6)Cl)C8=C9C=CC(=CC9=NC=C8)Cl,,,,,,
4150,124151,"Methyl 8-acetyl-3-(3,4-dimethylpent-2-enoyloxy)-11,12-dihydroxy-9-(2-methoxy-2-oxoethyl)-9-methyl-4-oxo-5,14-dioxatetracyclo[8.5.0.01,6.02,13]pentadecane-13-carboxylate",CC(C)C(=CC(=O)OC1C2C34COC2(C(C(C3C(C(CC4OC1=O)C(=O)C)(C)CC(=O)OC)O)O)C(=O)OC)C,,,,,,
4151,124152,"Benz(7,8)anthra(1,2-b)oxirene-2,3-diol, 1a,2,3,11b-tetrahydro-",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C5C(O5)C(C4O)O,,,,,,
4152,124153,CID 124153,CC1=C(C=C(C=C1C(=O)[O-])C(C)C)C(C)C.CC1=C(C=C(C=C1C(=O)[O-])C(C)C)C(C)C.[Zn+2],,,,,,
4153,124154,CID 124154,CC1=C(C=C(C=C1C(=O)O)C(C)C)C(C)C,,,,,,
4154,124155,alpha-D-tagatofuranose 6-phosphate,C([C@@H]1[C@@H]([C@@H]([C@@](O1)(CO)O)O)O)OP(=O)(O)O,,,,,,
4155,124156,6-Azido-9-beta-D-ribofuranosyl-9H-purine,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=[N+]=[N-],,,,,,
4156,124157,"Ethyl 4-[[3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate",CCOC(=O)C1=CC=C(C=C1)NC(=O)C=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C,,,,,,
4157,124158,11-Oxo-thc,CCCCCC1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C=O)O,,,,,,
4158,124159,"1,4-Diamino-2-butyne",C(C#CCN)N,,,,,,
4159,124160,Dihexanoyl-lecithin,CCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCC,,,,,,
4160,124161,"N,N,N-Trimethyl-2-[[2,3-bis(hexanoyloxy)propoxy]phosphonyloxy]ethanaminium",CCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCC,,,,,,
4161,124162,beta-Ghmu,C1[C@@H]([C@H](OC1N2C=C(C(=O)NC2=O)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO)O,,,,,,
4162,124163,"1:2,5:6-Di-O-isopropylidene-3-O-(3-(dimethylamino)propyl)-alpha-D-glucofuranose",CC1(OC[C@@H](O1)[C@@H]2[C@@H]([C@@H]3[C@H](O2)OC(O3)(C)C)OCCCN(C)C)C,,,,,,
4163,124164,"3-O-(3-(N',N'-Dimethylamino)-n-propyl)glucose",CN(C)CCCO[C@H]([C@H](C=O)O)[C@@H]([C@@H](CO)O)O,,,,,,
4164,124165,"2,2'-((4,8-Bis(diethylamino)pyrimido(5,4-d)pyrimidine-2,6-diyl)bis((2-methoxyethyl)imino))bisethanol",CCN(CC)C1=NC(=NC2=C1N=C(N=C2N(CC)CC)N(CCO)CCOC)N(CCO)CCOC,,,,,,
4165,124166,"N(1),N(8)-Bis(2,3-dihydroxybenzoyl)spermidine",C1=CC(=C(C(=C1)O)O)C(=O)NCCCCNCCCNC(=O)C2=C(C(=CC=C2)O)O,,,,,,
4166,124167,"Piperidine, 4-(1a,10b-dihydro-6H-dibenzo(3,4:6,7)cyclohept(1,2-b)oxiren-6-ylidene)-",C1CNCCC1=C2C3=CC=CC=C3C4C(O4)C5=CC=CC=C52,,,,,,
4167,124168,Oxovinca,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O.C(CC(=O)O)C(=O)C(=O)O,,,,,,
4168,124169,CID 124169,C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)O)O.C1=CN(C(=O)N=C1N)C2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
4169,124170,"[(2R,3S,4R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=CN(C(=O)N=C1N)C2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
4170,124171,CID 124171,C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)O)O,,,,,,
4171,124172,5-Chloro-N-(6-phenylhexyl)-1-naphthalenesulfonamide,C1=CC=C(C=C1)CCCCCCNS(=O)(=O)C2=CC=CC3=C2C=CC=C3Cl,,,,,,
4172,124173,1-(4-Isothiocyanatobenzyl)diethylenetriaminepentaacetic acid,C1=CC(=CC=C1C[C@@H](CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)N=C=S,,,,,,
4173,124174,Denpt,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2([C@H]4CO4)O)CCC5=C3C=CC(=C5)O,,,,,,
4174,124175,CID 124175,C1=C(C2=C(N1)C(=O)N=CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CI)O)O,,,,,,
4175,124176,1-(N-(2-Hydroxyethyl)acetamido)-2-hydroxylaminoimidazole,C1=CN(C(=N1)NO)CC(=O)NCCO,,,,,,
4176,124177,CID 124177,C1=CC(=CC=C1CNC2=C(C3=C(C=C2)NC(=NC3=O)N)Cl)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4177,124178,2-Heptyl-10-oxononadec-11-enoic acid,CCCCCCCC=CC(=O)CCCCCCCC(CCCCCCC)C(=O)O,,,,,,
4178,124179,2-Heptyl-12-oxohenicos-13-enoic acid,CCCCCCCC=CC(=O)CCCCCCCCCC(CCCCCCC)C(=O)O,,,,,,
4179,124180,"1-Nitro-5H-phenanthro(4,5-bcd)pyran-5-one",C1=CC2=C3C(=C1)C(=O)OC4=C3C(=C(C=C4)[N+](=O)[O-])C=C2,,,,,,
4180,124181,4-Benzoyl-5-sulfamoyl-3-(3-thenyloxy)benzoic acid,C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2S(=O)(=O)N)C(=O)O)OCC3=CSC=C3,,,,,,
4181,124182,"3,6-Bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-one dihydrochloride",CN(C)CCOC1=CC2=C(C=C1)C(=O)C3=C(O2)C=C(C=C3)OCCN(C)C.Cl.Cl,,,,,,
4182,124183,"3,6-Bis(2-dimethylaminoethyloxy)xanthen-9-one",CN(C)CCOC1=CC2=C(C=C1)C(=O)C3=C(O2)C=C(C=C3)OCCN(C)C,,,,,,
4183,124184,"(3S,8S,9S,10R,13S,17R)-17-[(2S,3R)-3-hydroxy-6-methylhept-5-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@@H]([C@H]1CCC2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)[C@@H](CC=C(C)C)O,,,,,,
4184,124185,"(1-Hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)methanamine",CC1(CC(C(N1O)(C)C)CN)C,,,,,,
4185,124186,"Phosphonic acid, ((2-hydroxytrimethylene)bis(nitrilodimethylene))tetra-",C(C(CN(CP(=O)(O)O)CP(=O)(O)O)O)N(CP(=O)(O)O)CP(=O)(O)O,,,,,,
4186,124187,CID 124187,C(C1=NC2=C(NC(=NC2=NC1=O)N)N)O,,,,,,
4187,124188,"1,3,3-Trimethyl-2-[3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene;2,4,4-trimethyl-3-[3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-2-en-1-one",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C.CC1=C(C(CCC1=O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)CCC2(C)C)C)C)C,,,,,,
4188,124189,Mannostatin A,CS[C@@H]1[C@H]([C@H]([C@H]([C@H]1O)O)O)N,,,,,,
4189,124190,CID 124190,C1=CC(=CC=C1N[N+]#N)[N-]P(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
4190,124191,CID 124191,C1=CC(=CC=C1N[N+]#N)NP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
4191,124192,CID 124192,CC1CCC(=C(C1(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCC(C2(C)C)C)C)C)C)C,,,,,,
4192,124193,"2,3,8,9-Tetramethoxy-5-methylbenzo[c]phenanthridin-5-ium chloride",C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC(=C(C=C4C=C3)OC)OC)OC)OC.[Cl-],,,,,,
4193,124194,1-Methylamsacrine,CC1=CC=CC2=NC3=CC=CC=C3C(=C12)NC4=C(C=C(C=C4)NS(=O)(=O)C)OC,,,,,,
4194,124195,N-Ethylcarbaminomethyl-L-isoleucine,CC[C@H](C)[C@@H](C(=O)O)NCNC(=O)OCC,,,,,,
4195,124196,5-[Bis(4-chlorophenyl)(1H-imidazol-1-yl)methyl]pyrimidine,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C3=CN=CN=C3)N4C=CN=C4)Cl,,,,,,
4196,124197,Nitrosoheme,[H+].[H+].CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)[O-])CCC(=O)[O-].N#[O+].[Fe],,,,,,
4197,124198,Cupresol,CC(C)C1=C(C=C2C(=C1)C(=O)O[C@]3([C@@]2(CCCC3(C)C)C)O)OC,,,,,,
4198,124199,Mthdaz,C1CC2=C(C(=NC(=N2)N)N)N3C1CC(C3)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4199,124200,Ahdmp,N.N.O.[OH-].[Pt+2],,,,,,
4200,124201,5'-Chloro-2'-deoxyformycin A,C1[C@@H]([C@H](O[C@H]1C2=C3C(=NN2)C(=NC(=N3)Cl)N)CO)O,,,,,,
4201,124202,Dthpsad,C[C@H]1CC(=O)C2=C(C3=C(C=CC(=C3O)C4=C(C5=C(C=C4)O[C@]6([C@@H]([C@H](CC(=O)C6=C5O)C)OC7CCCCO7)C(=O)OC)O)O[C@]2([C@@H]1OC8CCCCO8)C(=O)OC)O,,,,,,
4202,124203,CID 124203,C1=C([C@H]([C@H]([C@@H]1N2C=NC3=C2N=CN=C3Cl)O)O)C=O,,,,,,
4203,124204,CID 124204,CCCCO.C=CC1=CC=CC=C1.C(=CC(=O)O)C(=O)O,,,,,,
4204,124205,"1H-Imidazole, 1-(1,2,3,4-tetrahydro-1-naphthalenyl)-",C1CC(C2=CC=CC=C2C1)N3C=CN=C3,,,,,,
4205,124206,7-Deaza-ehna,CCCCCC[C@@H](C(C)O)N1C=CC2=C(N=CN=C21)N,,,['Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)'],,,
4206,124207,"Bicyclo[3.2.1]octane-2-carboxylic acid, 2-amino-",C1CC2CC1CCC2(C(=O)O)N,,,,,,
4207,124208,"3-ethylidene-6-(1H-indol-3-ylmethyl)-1-methylpiperazine-2,5-dione",CC=C1C(=O)N(C(C(=O)N1)CC2=CNC3=CC=CC=C32)C,,,,,,
4208,124209,CID 124209,CCCCCC[C@@H]([C@@H](C)O)[N+]1=CNC2=C(C=CC=C21)N,,,,,,
4209,124210,12-beta-(Benzoyloxy)daphnetoxin,C[C@@H]1[C@H]([C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5([C@@H]([C@@]6([C@H]4O6)CO)O)O)C)O[C@@](O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C8=CC=CC=C8,,,,,,
4210,124211,Skullcapflavone II,COC1=CC=CC(=C1C2=CC(=O)C3=C(C(=C(C(=C3O2)OC)OC)OC)O)O,,,,,,
4211,124212,Glutathionedopa,C1=C(C=C(C(=C1O)O)SC[C@@H](C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)N)C[C@@H](C(=O)O)N,,,,,,
4212,124213,Penicillide,CC1=CC2=C(C(=C1)O)OC3=C(C(=C(C=C3)[C@H](CC(C)C)O)OC)C(=O)OC2,,,,,,
4213,124214,Sericic acid,C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4[C@@H](C(CC5)(C)C)O)C(=O)O)C)(C[C@H]([C@@H]([C@]3(C)CO)O)O)C,,,,,,
4214,124215,"1,4-Bis(methoxypropylamino)benzophthalazine",COCCCNC1=NN=C(C2=CC3=CC=CC=C3C=C21)NCCCOC,,,,,,
4215,124216,"2-Naphthalenol, 8-(dimethylamino)-",CN(C)C1=CC=CC2=C1C=C(C=C2)O,,,,,,
4216,124217,"N-(3,5-Dichloro-4-hydroxyphenyl)-2-hydroxybenzamide",C1=CC(=CC(=C1)O)C(=O)NC2=CC(=C(C(=C2)Cl)O)Cl,,,,,,
4217,124218,"Pyrimido[1,2-a]purin-10(1H)-one",C1=CN2C(=O)C3=C(N=CN3)N=C2N=C1,,,,,,
4218,124219,Mollugin,CC1(C=CC2=C(O1)C3=CC=CC=C3C(=C2C(=O)OC)O)C,,,,,,
4219,124220,4-(Pyren-1-yl)butanehydrazide,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)CCCC(=O)NN,,,,,,
4220,124221,"2,3-Dihydro-N,N-dimethyl-1H-phenalen-2-amine",CN(C)C1CC2=CC=CC3=C2C(=CC=C3)C1,,,,,,
4221,124222,Iron(2+) acrylate,C=CC(=O)[O-].C=CC(=O)[O-].[Fe+2],,,,,,
4222,124223,deoxyilludin M,CC1=C2CC(C=C2C(=O)[C@](C13CC3)(C)O)(C)C,,,,,,
4223,124224,6-Deoxyilludin S,CC1=C2C[C@](C=C2C(=O)[C@](C13CC3)(C)O)(C)CO,,,,,,
4224,124225,Ulifloxacin,CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCNCC4,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']",,,
4225,124226,Hexahydrodifenidol,C1CCC(CC1)C(CCCN2CCCCC2)(C3=CC=CC=C3)O,,,,,,
4226,124227,CID 124227,CC(=CC[C@]12CCN([C@H]1NC3=CC=CC=C23)C)CO,,,,,,
4227,124228,"1-Methyl-3-phenyl-1,2,4-triazin-5-one",C[N+]1=NC(=NC(=C1)[O-])C2=CC=CC=C2,,,,,,
4228,124229,CID 124229,C[N+]1=CC(=O)N=C(N1)C2=CC=CC=C2,,,,,,
4229,124230,CID 124230,C1COC(=O)N1N=CC(=O)C(CC#N)SCCO,,,,,,
4230,124231,"10-(2-Aminoethylamino)-14-[2-(ethylamino)ethyl]-8-thia-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,3,6,9,11,13(16)-hexaen-5-one",CCNCCN1C2=C3C(=C4C=CC(=O)C=C4SC3=C(C=C2)NCCN)N1,,,,,,
4231,124232,CID 124232,CCNCCN1C2=C3C(=C(C=C2)NCCN)SC4=C(C3=N1)C=C(C=C4)O,,,,,,
4232,124233,"5-Fluoro-1-(5-fluoro-3,4-dihydroxy-5-methyloxolan-2-yl)pyrimidine-2,4-dione",CC1(C(C(C(O1)N2C=C(C(=O)NC2=O)F)O)O)F,,,,,,
4233,124234,CID 124234,CC1=C(C(=O)NC(=O)N1)C=CC(=O)N[C@@H](C)CS(CSC)O,,,,,,
4234,124235,CID 124235,C1CCC(C1)NC2=CC(=NC3=C2NCN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)Cl,,,,,,
4235,124236,Trombodipine,CCOC(=O)C1=C(NC(=C(C1C)C(=O)OCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C)C,,,,,,
4236,124237,"2,2-Difluorobutane-1,4-diamine",C(CN)C(CN)(F)F,,,,,,
4237,124238,4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C3=CSC(=N3)NC,,,,,,
4238,124239,Benzo(l)cyclopenta(cd)pyrene,C1=CC=C2C(=C1)C3=C4C5=C(C=CC5=CC6=C4C2=CC=C6)C=C3,,,,,,
4239,124240,Pirotiodecane,CCCCCCCCCCSCCN1CCCC1=O,,,,,,
4240,124241,"3-(2-Chloroethyl)-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid",C1=NC(=C2N1C(=O)N(N=N2)CCCl)C(=O)O,,,,,,
4241,124242,"8-methyl-2,3,4,4a,5,6,6a,7,8,9,10,11,11a,11b-tetradecahydro-1H-cyclohepta[a]naphthalene",CC1CCCC2C(C1)CCC3C2CCCC3,,,,,,
4242,124243,5'-Deoxyxanthosine,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C2NC(=O)NC3=O)O)O,,,,,,
4243,124244,CID 124244,CN(C=O)C1=C(NC(=NC1=O)N)N[C@H]2C[C@@H]([C@H](O2)CO)COP(=O)(O)O,,,,,,
4244,124245,"2,3-Dihydroxy-4-(hydroxymethyl)cyclopent-2-en-1-one",C1C(C(=C(C1=O)O)O)CO,,,,,,
4245,124246,Iguratimod,CS(=O)(=O)NC1=C(C=C2C(=C1)OC=C(C2=O)NC=O)OC3=CC=CC=C3,,,,,,
4246,124247,"2,6-Dimethyl-L-tyrosine",CC1=CC(=CC(=C1C[C@@H](C(=O)O)N)C)O,,,,,,
4247,124248,Mannosylhydrazine,C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)NN)O)O)O)O,,,,,,
4248,124249,"1,2-Dimethyl-2,3,9,13b-tetrahydro-1Hdibenzo(c,f)imidazo(1,5-a)azepine",C[C@H]1[C@H]2C3=CC=CC=C3CC4=CC=CC=C4N2CN1C,,,,,,
4249,124250,8-Hydroxy-7-methoxy-3-[(4-methoxyphenyl)methylidene]chromen-4-one,COC1=CC=C(C=C1)C=C2COC3=C(C2=O)C=CC(=C3O)OC,,,,,,
4250,124251,CID 124251,C1=CC(=C(C=C1C2=COC3=C(C(=CC(=O)C3=C2O)O)Cl)O)O,,,,,,
4251,124252,Pyrenemethyl laurate,CCCCCCCCCCCC(=O)OCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
4252,124253,CID 124253,COC1=CC(=O)C2=C(OC(=CC2=C1)CO)O,,,,,,
4253,124254,20-Fluoromibolerone,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C[18F])O,,,,,,
4254,124255,"2,3-Dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol",C1C(OC2=CC(=C(C=C21)O)CCCOC3=CC=CC=C3)CCC4=CC=CC=C4,,,['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)'],,,
4255,124256,N-Ohanabas,CCCCCCCC(CCC(=O)N1CCCCC1C2=CN=CC=C2)O,,,,,,
4256,124257,4-Amino-3-hydroxyphenylacetic acid,C1=CC(=C(C=C1CC(=O)O)O)N,,,,,,
4257,124258,Eriodictyol 7-glucuronide,C1[C@@H](OC2=CC(=CC(=C2C1=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)C4=CC(=C(C=C4)O)O,,,,,,
4258,124259,"(2S,3R)-3-[(1R)-1-hydroxyhexyl]oxirane-2-carbaldehyde",CCCCC[C@H]([C@@H]1[C@H](O1)C=O)O,,,,,,
4259,124260,CID 124260,C1=CC(=C2C=CC(=N)C=C2[N+](=O)[O-])C(=N)C=C1N(O)O,,,,,,
4260,124261,3-Hydroxylanost-7-en-32-oic acid,C[C@H](CCCC(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C(=O)O,,,,,,
4261,124262,"(3S,5R,6R,7S)-12-methyl-4-oxapentacyclo[9.8.0.02,8.03,5.013,18]nonadeca-1(19),2(8),9,11,13,15,17-heptaene-6,7-diol",CC1=C2C=CC3=C(C2=CC4=CC=CC=C14)[C@H]5[C@H](O5)[C@@H]([C@H]3O)O,,,,,,
4262,124263,CID 124263,CC1(C=CC2=C(O1)C=C(C3=C2N(C4C(C3=O)C=CC=C4[N+](=O)[O-])C)O)C,,,,,,
4263,124264,CID 124264,CC1(C=CC2=C(O1)C=C(C3=C2N(C4C=C(C=CC4C3=O)[N+](=O)[O-])C)O)C,,,,,,
4264,124265,CID 124265,CC(=CCC1=C2C(=C(C(=CO2)C3=CC(=C(C=C3)O)OC)O)C(=O)C4=C1OC(C=C4)(C)C)C,,,,,,
4265,124266,2-amino-4-hydroxy-3-methyl-4H-imidazol-5-one,CN1C(C(=O)N=C1N)O,,,,,,
4266,124267,"4-Hydroxy-2,2-dimethyl-1-oxa-4-azaspiro[4.5]decane",CC1(CN(C2(O1)CCCCC2)O)C,,,,,,
4267,124268,Tanshinaldehyde,CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C=O,,,,,,
4268,124269,CID 124269,CCNC(=O)C(CCN(C)C)N=O,,,,,,
4269,124270,"6-Bromo-8-methylaminoimidazo(1,2-a)pyrazine-2-carbonitrile",CNC1=NC(=CN2C1=NC(=C2)C#N)Br,,,,,,
4270,124271,CID 124271,C[C@H]1CC[C@@H](O[C@@H]1C(=CC=C[C@@H](C)C[C@@]2([C@H](O2)[C@H](C)[C@H]([C@@H](C)O)OC)C)C)CC(=O)O,,,,,,
4271,124272,CID 124272,CC1=NC2=C(N1O)C(=O)N=C(N2)N,,,,,,
4272,124273,5-nitro-N-(oxiran-2-ylmethyl)furan-2-carboxamide,C1C(O1)CNC(=O)C2=CC=C(O2)[N+](=O)[O-],,,,,,
4273,124274,"2-(1-Hydroxy-2-(1,2,3,4,4a,7,8,8a-octahydro-3-hydroxy-5-(hydroxymethyl)-1,2,4a-trimethyl-4-oxo-1-naphthalenyl)ethyl)-alpha-oxooxiraneacetaldehyde",CC1C(C(=O)C2(C(C1(C)CC(C3(CO3)C(=O)C=O)O)CCC=C2CO)C)O,,,,,,
4274,124275,"11-Hydroxyoctadeca-9,12-dienoic acid",CCCCCC=CC(C=CCCCCCCCC(=O)O)O,,,,,,
4275,124276,"4,5-Dihydro-4,5-dihydroxybenzo(j)fluoranthene",C1=CC=C2C(=C1)C=CC3=C2C4=C5C3=CC(C(C5=CC=C4)O)O,,,,,,
4276,124277,Et-OH-Deoxyamino-C,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)N)C2=NC5=C1C=C(C=C5)O,,,,,,
4277,124278,"3,4-Dimethoxy-1-nitro-1,3,5(10)-estratrien-17-one",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C(=CC(=C4OC)OC)[N+](=O)[O-],,,,,,
4278,124279,Brmeneo,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C(C(=C(C=C34)[N+](=O)[O-])OC)Br,,,,,,
4279,124280,CID 124280,C1=C(C(=C(C(=C1F)F)OC(=O)CCC=CI)F)F,,,,,,
4280,124281,"(2,3,5,6-Tetrafluorophenyl) 5-iodo-3,3-dimethylpent-4-enoate",CC(C)(CC(=O)OC1=C(C(=CC(=C1F)F)F)F)C=CI,,,,,,
4281,124282,CID 124282,C1=CN(C(=C(C1=O)[N+](=O)[O-])O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
4282,124283,"N-Octyl-3-nitro-2,4,6-trihydroxybenzamide",CCCCCCCCNC(=O)C1=C(C(=C(C=C1O)O)[N+](=O)[O-])O,,,,,,
4283,124284,2-[4-[2-[4-[1-(2-Methylprop-2-enoyloxy)propan-2-yloxy]phenyl]propan-2-yl]phenoxy]propyl 2-methylprop-2-enoate,CC(COC(=O)C(=C)C)OC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OC(C)COC(=O)C(=C)C,,,,,,
4284,124285,3-Bdamhnf,CN(C)C[C@H]1CO[C@@]2([C@H]1C3=CC=CC=C3CC2)CC4=CC=CC=C4,,,,,,
4285,124286,"3-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-5-iodo-2H-indol-2-one",C1=CC=C2C(=C1)C(=O)C(=N2)C3=C(NC4=C3C=C(C=C4)I)O,,,,,,
4286,124287,CID 124287,CC(C)(C=NO)C(CN1C=NC=N1)(C2CCC(CC2)Cl)O,,,,,,
4287,124288,3-[[[N'-[(3-carbamimidoylphenyl)methylideneamino]carbamimidoyl]hydrazinylidene]methyl]benzenecarboximidamide;trihydrochloride,C1=CC(=CC(=C1)C(=N)N)C=NNC(=NN=CC2=CC(=CC=C2)C(=N)N)N.Cl.Cl.Cl,,,,,,
4288,124289,3-[[[N'-[(3-carbamimidoylphenyl)methylideneamino]carbamimidoyl]hydrazinylidene]methyl]benzenecarboximidamide,C1=CC(=CC(=C1)C(=N)N)C=NNC(=NN=CC2=CC(=CC=C2)C(=N)N)N,,,,,,
4289,124290,2-(Methylseleninyl)benzanilide,C[Se](=O)C1=CC=CC=C1C(=O)NC2=CC=CC=C2,,,,,,
4290,124291,CID 124291,CCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C6CCC(=O)N6,,,,,,
4291,124292,Crezacin,CC1=CC=CC=C1OCC(=O)O.C(CO)N(CCO)CCO,,,,,,
4292,124293,N-(1-Phenylethyl)-1H-purin-6-amine,CC(C1=CC=CC=C1)NC2=NC=NC3=C2NC=N3,,,,,,
4293,124294,5-Cfdru,C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)CO)O)F)Cl,,,,,,
4294,124295,5-Bromo-1-(2-fluoro-2-deoxyribofuranosyl)uracil,C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)CO)O)F)Br,,,,,,
4295,124296,5-Br-2'-Cl-2'-dU,C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)CO)O)Cl)Br,,,,,,
4296,124297,5-Iodo-1-(2-fluoro-2-deoxyribofuranosyl)uracil,C1=C(C(=O)NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)CO)O)F)I,,,,,,
4297,124298,N-Acetylglucosaminyl(1-3)-N-acetylglucosaminyl(1-6)-galactopyranose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@H]([C@@H](C([C@H](C=O)O)OC2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)O)O)CO)O)O,,,,,,
4298,124299,"Carbamic acid, (2-chloroethyl)-, 4-nitrophenyl ester",C1=CC(=CC=C1[N+](=O)[O-])OC(=O)NCCCl,,,,,,
4299,124300,CID 124300,C1=CN2C(=CC=NC2=O)N1,,,,,,
4300,124301,N-(o-Aminobenzoyloxy)succinimide,C1CC(=O)N(C1=O)OC(=O)C2=CC=CC=C2N,,,,,,
4301,124302,CID 124302,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H](C(O2)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O,,,,,,
4302,124303,Amigluracil,CC1=CC(=O)NC(=O)N1.CN[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
4303,124304,"2,2-Dimethyl-5-tert-butyl-1,3-benzodioxole",CC1(OC2=C(O1)C=C(C=C2)C(C)(C)C)C,,,,,,
4304,124305,N(4)-(4-Carboxybutyryl)-1-beta-arabinofuranosylcytosine,C1=CN(C(=O)N=C1NC(=O)CCCC(=O)O)C2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
4305,124306,CID 124306,CCCCCCCCC=CCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
4306,124307,CID 124307,CN1C=[N+](C2=C1C(=NC(=N2)N)[S-])C3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
4307,124308,CID 124308,CN1C=[N+](C2=C1C(=NC(=N2)N)S)C3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
4308,124309,"[3-(Hydroxymethyl)-2,2,5,5-tetramethyl-2,5-dihydro-1h-pyrrol-1-yl]oxidanyl",CC1(C=C(C(N1[O])(C)C)CO)C,,,,,,
4309,124310,"2,3-Diamino-2,3-dideoxy-D-glucose",C([C@H]([C@H]([C@@H]([C@H](C=O)N)N)O)O)O,,,,,,
4310,124311,"4-Azido-7-phenylpyrazolo[1,5-a][1,3,5]triazine",C1=CC=C(C=C1)C2=NN3C(=C2)N=CN=C3N=[N+]=[N-],,,,,,
4311,124312,"5-(7-Methoxy-2H-1,3-benzodioxol-5-yl)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one",COC1=CC(=CC2=C1OCO2)C3[C@H]4[C@@H](CC5=CC6=C(C=C35)OCO6)COC4=O,,,,,,
4312,124313,"1,3,6-Hexanetriamine",C(CC(CCN)N)CN,,,,,,
4313,124314,1-[2-Hydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one,CC(=CCC1=C(C=CC(=C1O)C(=O)C=CC2=CC=C(C=C2)O)OC)C,,,,,,
4314,124315,2-Nitroso-1-phenylpropane,CC(CC1=CC=CC=C1)N=O,,,,,,
4315,124316,3-Deazaguanosine,C1=C(NC(=O)C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,,,,,,
4316,124317,"Uridine, 5'-amino-2',5'-dideoxy-5-iodo-",C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CN)O,,,,,,
4317,124318,Cyclocholine,C[N+]1(CC1)CCO,,,,,,
4318,124319,Aurantiamide acetate,CC(=O)OC[C@H](CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
4319,124320,"5,12-Naphthacenedione, 8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-",COC1=CC=CC2=C1C(=O)C3=C(C4=C(C[C@](C[C@@H]4O)([C@H](CO)O)O)C(=C3C2=O)O)O,,,,,,
4320,124321,Rhenocene,[CH-]1C=CC=C1.[CH-]1C=CC=C1.[Re],,,,,,
4321,124322,"1,4-Dihydro-9h-imidazo[1,2-a]purin-9-one",C1=CN2C(=O)C3=C(NC2=N1)N=CN3,,,,,,
4322,124323,Phenyl-D-galactopyranoside,C1=CC=C(C=C1)OC2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
4323,124324,CID 124324,C1=CC=C(C=C1)C2C=C(C3=CC=CC=C23)C=C(C#N)C(=O)O,,,,,,
4324,124325,"[(2R,3S,4R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-imidazol-1-ylphosphinic acid",C1=CN(C(=O)NC1=O)C2[C@@H]([C@@H]([C@H](O2)COP(=O)(N3C=CN=C3)O)O)O,,,,,,
4325,124326,"2-[4,7-Bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid",C1CN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O,,,,,,
4326,124327,"(Z)-2-(heptadec-10-enyl)-6-methoxycyclohexa-2,5-diene-1,4-dione",CCCCCCC=CCCCCCCCCCC1=CC(=O)C=C(C1=O)OC,,,,,,
4327,124328,CID 124328,CC1=CC2=C(C(=C(C(=CC3=C(NC(=O)NC3=O)O)C2=C(C1=C4C(=CC5=C(C(=O)C(=O)C(=CC6=C(NC(=O)NC6=O)O)C5=C4O)C(C)C)C)O)O)O)C(C)C,,,,,,
4328,124329,CID 124329,CC1=CC=CC=CC=CCC(NC(=O)C=CC=CC=CC=CC2(C(C(C(=O)C2=C(O1)O)OC)O)C)C3=CC=CC=C3,,,,,,
4329,124330,"1,1,1,2,2,3,3,4,4,5,5,6,6,9,9,10,10,11,11,12,12,13,13,14,14,14-Hexacosafluorotetradec-7-ene",C(=CC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4330,124331,Dabequin,CCN(CC)CCNC1=CC=NC2=CC3=CC=CC=C3C=C12.OP(=O)(O)O.OP(=O)(O)O,,,,,,
4331,124332,Dabequine,CCN(CC)CCNC1=CC=NC2=CC3=CC=CC=C3C=C12,,,,,,
4332,124333,"2,2'-Pyridylisatogen tosylate",CC1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C2C(=C1)C(=O)C(=[N+]2[O-])C3=CC=CC=N3,,,['Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS. (See all compounds classified as Purinergic P2 Receptor Antagonists.)'],,,
4333,124334,1-Oxido-2-(2-pyridinyl)-3-indol-1-iumone,C1=CC=C2C(=C1)C(=O)C(=[N+]2[O-])C3=CC=CC=N3,,,,,,
4334,124335,Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium,CN(C)[P+](N(C)C)(N(C)C)ON1C2=CC=CC=C2N=N1,,,,,,
4335,124336,"1-Butyl-3,3-dimethyl-1-nitrosourea",CCCCN(C(=O)N(C)C)N=O,,,,,,
4336,124337,Demethoxyviridin,C[C@]12[C@@H](CC(=O)C3=COC(=C31)C(=O)C4=C2C=CC5=C4CCC5=O)O,,,,,,
4337,124338,"5,7-Dimethoxyphenanthren-4-ol",COC1=CC(=C2C(=C1)C=CC3=C2C(=CC=C3)O)OC,,,,,,
4338,124339,"L-Arginine, N2-(1-(N2-L-leucyl-L-lysyl)-L-prolyl)-",CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N,,,,,,
4339,124340,CID 124340,C[C@H](CC[C@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](CCC3=C)O)C,,,,,,
4340,124341,Manganese adenosine triphosphate,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N.[Mn+2],,,,,,
4341,124342,"4,8,13,17,21-Pentamethyldocosa-4,8,12,16,20-pentaenoic acid",CC(=CCCC(=CCCC(=CCCC=C(C)CCC=C(C)CCC(=O)O)C)C)C,,,,,,
4342,124343,5-hydroxy-1H-imidazole-4-carboxamide,C1=NC(=C(N1)C(=O)N)O,,,,,,
4343,124344,Flemichin D,CC(=CCC1=C2C(=C(C3=C1O[C@@H](CC3=O)C4=C(C=C(C=C4)O)O)O)C=CC(O2)(C)C)C,,,,,,
4344,124345,Pseudoisocytidine,C1=C(C(=O)NC(=N1)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
4345,124346,CID 124346,CC1=C(C[C@@H](C[C@H]1O)O)C=CC2=CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C,,,,,,
4346,124347,CID 124347,CO[C@@H]1[C@@H]([C@H](OC1N2C=CC(=O)C=C2O)CO)O,,,,,,
4347,124348,4-Hydroxy-6-methoxy-2-phenylquinoline,COC1=CC2=C(C=C1)NC(=CC2=O)C3=CC=CC=C3,,,,,,
4348,124349,S-tubercidinylhomocysteine,C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O,,,,,,
4349,124350,"(1S,3R,12S)-1,5,9-Trimethyl-12-propan-2-ylcyclotetradeca-4,8,13-triene-1,3-diol",CC1=CCCC(=C[C@@H](C[C@](C=C[C@@H](CC1)C(C)C)(C)O)O)C,,,,,,
4350,124351,CID 124351,C1[C@@H](O[C@@H]([C@H]1O)CO)CC=O,,,,,,
4351,124352,1-Ethoxymethyl-5-fluorouracil,CCOCN1C=C(C(=O)NC1=O)F,,,,,,
4352,124353,[Methyl(nitroso)amino]methyl benzoate,CN(COC(=O)C1=CC=CC=C1)N=O,,,,,,
4353,124354,"1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)dihydro-5-methyl-",CN1CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
4354,124355,"(1R,3R)-3-Aminocyclopentanecarboxylic acid",C1C[C@H](C[C@@H]1C(=O)O)N,,,,,,
4355,124356,CID 124356,C[C@@]12C[C@H]3[C@]4(C56[C@H]1C(=O)C(O5)([C@@H]7C[C@@H]8[C@]9(O8)CC=CC(=O)[C@@]9([C@H]7CC[C@@]6(C(=O)O4)O)C)OC[C@H]2C(=O)O3)C,,,,,,
4356,124357,omega-Aminoarginine,C(C[C@@H](C(=O)O)N)CN=C(N)NN,,,,,,
4357,124358,"2-Furancarboxaldehyde, 4-nitro-",C1=C(OC=C1[N+](=O)[O-])C=O,,,,,,
4358,124359,4-Bis(2-chloroethyl)aminophenylalanine isopropyl ester,CC(C)OC(=O)C(CC1=CC=C(C=C1)N(CCCl)CCCl)N.Cl,,,,,,
4359,124360,Propan-2-yl 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate,CC(C)OC(=O)C(CC1=CC=C(C=C1)N(CCCl)CCCl)N,,,,,,
4360,124361,Avocettin,CC(C)C1CC[C@@]2(CO2)[C@@H]3[C@@H]1C=C(COC3=O)C(=O)O,,,,,,
4361,124362,HdUrd,CCCCCCC1=CN(C(=O)NC1=O)C2C[C@@H]([C@H](O2)CO)O,,,,,,
4362,124363,"(4R,9R,10S,12R,13S,14R)-10,12,13,14-tetrahydroxy-5,5,9-trimethyl-11-oxotetracyclo[11.2.1.01,10.04,9]hexadecane-14-carbaldehyde",C[C@@]12CCCC([C@H]1CCC34[C@]2(C(=O)[C@@H]([C@@](C3)([C@](C4)(C=O)O)O)O)O)(C)C,,,,,,
4363,124364,Thymine bromohydrin,C[C@@]1([C@@H](NC(=O)NC1=O)O)Br,,,,,,
4364,124365,"Methyl 11-acetyloxy-12-ethyl-4-[1-(16-ethyl-16-hydroxy-3,13-diazatetracyclo[11.2.2.02,10.04,9]heptadeca-2(10),4,6,8-tetraen-15-yl)-3-methoxy-3-oxoprop-1-en-2-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5,13-tetraene-10-carboxylate",CCC1(CN2CCC3=C(C1C(C2)C=C(C4=CC5=C(C=C4OC)N(C6C57CCN8C7C(C=CC8)(C(C6(C(=O)OC)O)OC(=O)C)CC)C)C(=O)OC)NC9=CC=CC=C39)O,,,,,,
4365,124366,CID 124366,C1NC2=C(N1[C@H](C=O)O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C=O)NC(=NC2=O)N,,,,,,
4366,124367,"1,1,1,3,3-Pentafluoro-2-(fluoromethoxy)-3-methoxypropane",COC(C(C(F)(F)F)OCF)(F)F,,,,,,
4367,124368,"5,5-Dimethyl-2-phenyl-1-pyrroline-N-oxide",CC1(CCC(=[N+]1[O-])C2=CC=CC=C2)C,,,,,,
4368,124369,3-O-Arabinopyranosyloleanolic acid,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O[C@H]6[C@H]([C@@H]([C@@H](CO6)O)O)O,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)'],,,
4369,124370,2-Piperazinotetralin,CC(CN1CCN(CC1)[C@H]2CC3=CC=CC=C3C[C@@H]2O)C(=O)C4=CC=CC=C4,,,,,,
4370,124371,4-[4-(2-Chlorophenyl)phenyl]-2-methyl-4-oxobut-2-enoic acid,CC(=CC(=O)C1=CC=C(C=C1)C2=CC=CC=C2Cl)C(=O)O,,,,,,
4371,124372,Mecigestone,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2C[C@@H]4[C@]3(CCCC4)C(=O)C)C)[C@@]5(C1=CC(=O)CC5)C,,,,,,
4372,124373,"1,2,8-Trihydroxy-3-methyl-4a,9a-dihydroanthracene-9,10-dione",CC1=CC2C(C(=C1O)O)C(=O)C3=C(C2=O)C=CC=C3O,,,,,,
4373,124374,CID 124374,C1=CC(=C(C(=C1)C(F)(F)F)N=NC2=C(C=CC(=C2)C(F)(F)F)C#N)C#N,,,,,,
4374,124375,Glucogallin,CO[C@@H]1[C@H]([C@@H]([C@H](C(O1)OC(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O,,,,,,
4375,124376,"Methyl 4-(acetyloxy)-15-[3-formyl-7-(methoxycarbonyl)-5-(2-oxobutyl)-1,2,3,4,5,6,7,8-octahydroazonino[5,4-b]indol-7-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate",CCC(=O)CC1CC(C2=C(CCN(C1)C=O)C3=CC=CC=C3N2)(C4=C(C=C5C(=C4)C67CCN8C6C(C=CC8)(C(C(C7N5C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,,,,,,
4376,124377,CID 124377,CCC=C[C@@H]([C@@H](C1=C(C(=O)C2(O1)[C@H]([C@@](NC2=O)(C(=O)C3=CC=CC=C3)OC)O)C)O)O,,,,,,
4377,124378,"[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4S,5R,9S,10R)-12-[(2R,3R,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate",C[C@@]12CCC[C@@]([C@H]1CCC34[C@H]2CC(C(C3)C(=C)C4)O[C@H]5[C@@H](C([C@@H]([C@H](O5)CO)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)(C)C(=O)OC8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O,,,,,,
4378,124379,3'-Deoxy-3'-azidoadenosine,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)N=[N+]=[N-])O)N,,,,,,
4379,124380,CID 124380,CCC1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,,,,,,
4380,124381,"1,2-Dihydroanthracene",C1CC2=CC3=CC=CC=C3C=C2C=C1,,,,,,
4381,124382,"(2S)-2-[(2R,3R,4S,5R,6S)-2-hydroxy-6-[(1S)-1-[(2S,7S,8R,9S)-2-[(2R,5S)-5-[(2R,3S,4R,5R)-5-[(2S,3S,4S,5R,6S)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]ethyl]-4-methoxy-3,5-dimethyloxan-2-yl]propanoic acid",C[C@@H]1[C@H](CC2(CC[C@@](O2)(C)[C@H]3CC[C@@](O3)(C)[C@H]4[C@H]([C@H]([C@@H](O4)[C@@H]5[C@H]([C@@H]([C@H]([C@@](O5)(C)O)C)OC)C)OC)C)O[C@@H]1[C@@H](C)[C@@H]6[C@@H]([C@@H]([C@H]([C@@](O6)([C@H](C)C(=O)O)O)C)OC)C)OC,,,,,,
4382,124383,CID 124383,CC1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)CC(C)C)C(=C4C(=C2O)C(=C(C5=C4C(=O)C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
4383,124384,"1-Phenyl-3,5,8-trimethyl-1,4,5,6,7,8-hexahydropyrazolo(3,4-e)(1,4)diazepin-4,7-dione",CC1=NN(C2=C1C(=O)N(CC(=O)N2C)C)C3=CC=CC=C3,,,,,,
4384,124385,"1-Phenyl-5,8-dimethyl-1,4,5,6,7,8-hexahydropyrazolo(3,4-e)(1,4)diazepin-4,7-dione",CN1CC(=O)N(C2=C(C1=O)C=NN2C3=CC=CC=C3)C,,,,,,
4385,124386,3-Chloro-2-phosphonooxyprop-2-enoic acid,C(=C(C(=O)O)OP(=O)(O)O)Cl,,,,,,
4386,124387,"2-(7,13-Dihydroxyoctadec-2-enoylamino)ethanesulfonic acid",CCCCCC(CCCCCC(CCCC=CC(=O)NCCS(=O)(=O)O)O)O,,,,,,
4387,124388,CID 124388,CC(=O)ON1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,,,,,,
4388,124389,"4-[3-[(3S,5S)-3,5-dimethyl-6-oxopiperidin-2-ylidene]-2-oxopropyl]piperidine-2,6-dione",C[C@H]1C[C@@H](C(=O)NC1=CC(=O)CC2CC(=O)NC(=O)C2)C,,,,,,
4389,124390,3-Dodec-11-ynylidene-5-(hydroxymethyl)oxolan-2-one,C#CCCCCCCCCCC=C1CC(OC1=O)CO,,,,,,
4390,124391,"2H-Pyran-2-one, 3-(11-dodecenylidene)tetrahydro-5-hydroxy-, (E)-(-)-",C=CCCCCCCCCCC=C1CC(OC1=O)CO,,,,,,
4391,124392,8-Guanidinooctanoyl-asp-2-(4-methoxyphenyl)ethylamide,COC1=CC=C(C=C1)CCNC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCN=C(N)N,,,,,,
4392,124393,Isoleucyl-phenylalanyl-lysine chloromethyl ketone,CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCCN)C(=O)CCl)N,,,,,,
4393,124394,CID 124394,C[C@@H]1C[C@H]2C(=CCC3=C2C=CC(=C3)S(=O)(=O)[O-])[C@H]4C1[C@H](CC4)O,,,,,,
4394,124395,CID 124395,C[C@@H]1C[C@H]2C(=CCC3=C2C=CC(=C3)S(=O)(=O)O)[C@H]4C1C(CC4)O,,,,,,
4395,124396,1-Ethoxyethyl-2-dimethylaminoethylthiobenzimidazole,CCOCCN1C2=CC=CC=C2N=C1SCCN(C)C,,,,,,
4396,124397,2-Chlorohistidine,C1=C(NC(=N1)Cl)C[C@@H](C(=O)O)N,,,,,,
4397,124398,N-Hydroxythalidomide,C1CC(=O)N(C(=O)C1N2C(=O)C3=CC=CC=C3C2=O)O,,,,,,
4398,124399,CID 124399,CC1=NC=C(C(=C1O)C2C(CC(N2)C(=O)O)C(=O)O)CP(=O)(O)O,,,,,,
4399,124400,"4,4-Dicarboxy-5-pyridoxylproline",CC1=NC=C(C(=C1O)C2C(CC(N2)C(=O)O)(C(=O)O)C(=O)O)CO,,,,,,
4400,124401,CID 124401,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(CCl)O)O)N)O,,,,,,
4401,124402,Pulcherosine,C1=CC(=CC=C1CC(C(=O)O)N)OC2=CC(=CC(=C2O)C3=C(C=CC(=C3)CC(C(=O)O)N)O)CC(C(=O)O)N,,,,,,
4402,124403,CID 124403,C1=CC=C(C=C1)CN(C[C@@H]([C@H]([C@@H]([C@@H](CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OO)O)O)O)O)O)C(S)S,,,,,,
4403,124404,3-(2-Furoyl)quinoline-2-carboxaldehyde,C1=CC=C2C(=C1)C=C(C(=N2)C=O)C(=O)C3=CC=CO3,,,,,,
4404,124405,3-Benzoyl-N-(1-phenylethyl)-4-thiazolidinecarboxamide,CC(C1=CC=CC=C1)NC(=O)C2CSCN2C(=O)C3=CC=CC=C3,,,,,,
4405,124406,N-(2-Aminoethyl)-N-methyl-3-nitro-4-(1-methyl-1-nitroethyl)benzenesulfonamide,CC(C)(C1=C(C=C(C=C1)S(=O)(=O)N(C)CCN)[N+](=O)[O-])[N+](=O)[O-].Cl,,,,,,
4406,124407,N-(2-Aminoethyl)-N-methyl-4-(1-methyl-1-nitroethyl)-3-nitrobenzenesulfonamide,CC(C)(C1=C(C=C(C=C1)S(=O)(=O)N(C)CCN)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4407,124408,CID 124408,CCCCCCCCC=CCCCCCCC1=NC=C[N+]1(CCO)CCO.[Cl-],,,,,,
4408,124409,CID 124409,CCCCCCCCC=CCCCCCCC1=NC=C[N+]1(CCO)CCO,,,,,,
4409,124410,"N(2),3-Ethanoguanine",C1CN2C3=C(C(=O)N=C2N1)NC=N3,,,,,,
4410,124411,3'-Thiothymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)S,,,,,,
4411,124412,"3-(2,3-Dihydroxypropyl)deoxyuridine",C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)N(C2=O)CC(CO)O)CO)O,,,,,,
4412,124413,"4-(5-(5-(4-Methyl-1-piperazinyl)-1H-imidazo(4,5-b)pyridin-2-yl)-2-benzoxazolyl)phenol",CN1CCN(CC1)C2=NC3=C(C=C2)NC(=N3)C4=CC5=C(C=C4)N=C(O5)C6=CC=C(C=C6)O,,,,,,
4413,124414,CID 124414,C1=CC=C(C(=C1)CN(CC(CC2=CC=C(C=C2)NC(=O)CBr)CN(CC3=CC=CC=C3O)CC(=O)O)CC(=O)O)O,,,,,,
4414,124415,CID 124415,CN(C)C1=CC2=C(C=C1)N=C(C(=O)O2)C=CC3=CC=C(C=C3)C=CC(=O)O,,,,,,
4415,124416,Trijuganone B,CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCC=C4C,,,,,,
4416,124417,"3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-5-((4-methoxyphenyl)methyl)imidazo(1,5-a)quinoxalin-4(5H)-one",COC1=CC=C(C=C1)CN2C3=CC=CC=C3N4C=NC(=C4C2=O)C5=NOC(=N5)C6CC6,,,,,,
4417,124418,1-(Dimethylamino)-3-[2-[2-(4-methoxyphenyl)ethyl]phenoxy]propan-2-ol,CN(C)CC(COC1=CC=CC=C1CCC2=CC=C(C=C2)OC)O,,,,,,
4418,124419,ethyl (2S)-3-ethyl-1-(4-nitrophenyl)sulfonyl-4-oxoazetidine-2-carboxylate,CCC1[C@H](N(C1=O)S(=O)(=O)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)OCC,,,,,,
4419,124420,CID 124420,CP(O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C3=C(C(=O)N=C(N3)N)NC2=O)O,,,,,,
4420,124421,19-Acetylenic-deoxycorticosterone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CO)CCC4=CC(=O)CC[C@]34CC#C,,,,,,
4421,124422,Tetrazole-aminopterin,C1=CC(=CC=C1C(=O)N[C@@H](CCC2=NNN=N2)C(=O)O)NCC3=CN=C4C(=N3)C(=NC(=N4)N)N,,,,,,
4422,124423,CID 124423,C(CBr)C(CCBr)NC(=O)N(CCCl)N=O,,,,,,
4423,124424,CID 124424,CN(CCCl)CNC(=O)N(CCCl)N=O,,,,,,
4424,124425,"1,1-Di-(2-chloroethyl)-4-nitroso-4-(2-chloroethyl)semicarbazide",C(CCl)N(CCCl)NC(=O)N(CCCl)N=O,,,,,,
4425,124426,"3',4-O-Dimethylcedrusin",COC1=C(C=C(C=C1)[C@@H]2[C@H](C3=C(O2)C(=CC(=C3)CCCO)OC)CO)OC,,,,,,
4426,124427,CID 124427,COC1=CC=CC2=C1C(=NC3=NC(=O)C4=C(N3)N(C=N4)C5C[C@@H]([C@H](O5)CO)O)C6=C7C2=C8C(=CC7=C(N6)O)OCO8,,,,,,
4427,124428,dA-Aai,COC1=CC=CC2=C1C(=NC3=C4C(=NC=N3)N(C=N4)C5CC(C(O5)CO)O)C6=C7C2=C8C(=CC7=C(N6)O)OCO8,,,,,,
4428,124429,Ethyl 9H-fluoren-9-ylmethyl carbonate,CCOC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
4429,124430,7-Azaprostanoic acid,CCCCCCCC[C@H]1CCC[C@@H]1NCCCCCC(=O)O,,,,,,
4430,124431,"Piperidine, 1-(2-(1,3-benzodioxol-5-yl)ethyl)-3-(diphenylmethoxy)-",C1CC(CN(C1)CCC2=CC3=C(C=C2)OCO3)OC(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4431,124432,"Azetidine-2,4-dicarboxylic acid",C1[C@@H](N[C@H]1C(=O)O)C(=O)O,,,,,,
4432,124433,1-(Cyclohexylamino)-3-(1H-indol-4-yloxy)-2-propanol,C1CCC(CC1)NCC(COC2=CC=CC3=C2C=CN3)O,,,,,,
4433,124434,Calystegine B2,C1C[C@]2([C@H]([C@@H]([C@H]([C@@H]1N2)O)O)O)O,,,,,,
4434,124435,Hexbutinol,C1CCC(CC1)C(C#CCN2CCCCC2)(C3=CC=CC=C3)O,,,,,,
4435,124436,CID 124436,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)OCC)C(CC)O,,,,,,
4436,124437,((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid,C1=CC=C(C=C1)CCCC(C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)SCC(=O)O,,,,,,
4437,124438,CID 124438,COC(=O)CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)O)O)O)O,,,,,,
4438,124439,"1,3-Dichloro-4,4,5,5-tetramethyl-2-imidazolidinone",CC1(C(N(C(=O)N1Cl)Cl)(C)C)C,,,,,,
4439,124440,"Methyl 2,4,9,10,12,14,16-heptahydroxy-3,7,9,11,15,17,21,25-octamethyl-6,22,26,28-tetraoxo-23-azatricyclo[22.3.1.05,27]octacosa-1,3,5(27),7,18,20,24-heptaene-13-carboxylate",CC1C=CC=C(C(=O)NC2=C(C(=O)C3=C(C(=C(C(=C3C2=O)O)C)O)C(=O)C(=CC(C(C(C(C(C(C(C1O)C)O)C(=O)OC)O)C)O)(C)O)C)C)C,,,,,,
4440,124441,Phosphonium choline,C[P+](C)(C)CCO.[Cl-],,,,,,
4441,124442,Phosphacholine,C[P+](C)(C)CCO,,,,,,
4442,124443,"4,4'-(1-Ethyl-1,2-ethanediyl)bis-2,6-piperazinedione",CCC(CC1C(=O)NC(=O)CN1)N2CC(=O)NC(=O)C2,,,,,,
4443,124444,"(1-Hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)azanide;platinum(4+);dichloride",CC1(CC(CC(N1O)(C)C)[NH-])C.CC1(CC(CC(N1O)(C)C)[NH-])C.[Cl-].[Cl-].[Pt+4],,,,,,
4444,124445,2-tert-Butyl-4-methoxy-6-nitrophenol,CC(C)(C)C1=C(C(=CC(=C1)OC)[N+](=O)[O-])O,,,,,,
4445,124446,1-Cyano-4-dimethylaminopyridinium,CN(C)C1=CC=[N+](C=C1)C#N,,,,,,
4446,124447,CID 124447,CC1=CN=C(C2=C1C(=CC=C2)N)C=NN=C(N)S,,,,,,
4447,124448,"D-Glucose, 3-deoxy-3-iodo-",C([C@H]([C@H]([C@@H]([C@H](C=O)O)I)O)O)O,,,,,,
4448,124449,4-Hydroxymidazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2O)C4=CC=CC=C4F,,,,,['4-Hydroxymidazolam is a known human metabolite of midazolam.'],
4449,124450,"6-(6-Methyl-5-oxopyrido[4,3-c][1]benzazepin-11-ylidene)hexanoic acid",CN1C2=CC=CC=C2C(=CCCCCC(=O)O)C3=C(C1=O)C=CN=C3,,,,,,
4450,124451,"1,2-Benzocyclononen-3-ol",C1CC[C@H](CC2=CC=CC=C2CC1)O,,,,,,
4451,124452,"(6S)-6,7,8,9,10,11-hexahydro-5H-benzo[9]annulen-6-ol",C1CC[C@@H](CC2=CC=CC=C2CC1)O,,,,,,
4452,124453,"[(2R,4R)-4-(6-aminopurin-9-yl)oxolan-2-yl]methanol",C1[C@H](CO[C@H]1CO)N2C=NC3=C(N=CN=C32)N,,,,,,
4453,124454,Methyl 4-benzyloxy-2-hydroxy-3-iodo-6-methylbenzoate,CC1=CC(=C(C(=C1C(=O)OC)O)I)OCC2=CC=CC=C2,,,,,,
4454,124455,"Methyl 4-hydroxy-5-iodo-2,3-dimethoxy-6-methylbenzoate",CC1=C(C(=C(C(=C1I)O)OC)OC)C(=O)OC,,,,,,
4455,124456,"4-((5-Chloronaphthalen-2-yl)methyl)-3H-1,2,3,5-oxathiadiazole 2-oxide",C1=CC2=C(C=CC(=C2)CC3=NS(=O)ON3)C(=C1)Cl,,,,,,
4456,124457,CID 124457,CC(=O)NC(CCSC)C(=O)NCCC1=CC(=CC=C1)O,,,,,,
4457,124458,Senecioylchrysarobin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2C(=O)C=C(C)C)C=CC=C3O,,,,,,
4458,124459,"ethyl 4-(4,5-dihydroxy-2-methyl-10-oxo-9H-anthracen-9-yl)-4-oxobutanoate",CCOC(=O)CCC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=C(C=C3O)C,,,,,,
4459,124460,"10-hexa-2,4-dienoyl-1,8-dihydroxy-3-methyl-10H-anthracen-9-one",CC=CC=CC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=C(C=C3O)C,,,,,,
4460,124461,"9-acetyl-7-(4-amino-5-hydroxy-3,6-dimethyloxan-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1C(C(C(OC1OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)C)O)N,,,,,,
4461,124462,CID 124462,C1CC(=NOCC(=O)O)C2=C(OC3=C4C(=CC(=O)C3=C21)O[C@@H]5[C@]4(C=CO5)O)O,,,,,,
4462,124463,CID 124463,CCC=CCC(C=CCO)O,,,,,,
4463,124464,CID 124464,CC.C1=CC=C(C=C1)CCCCCCCCC2=CC(=CC=C2)[C@H](CCCC(=O)O)CC(=O)O,,,,,,
4464,124465,CID 124465,C1=CC=C(C=C1)CCCCCCCCC2=CC(=CC=C2)[C@H](CCCC(=O)O)CC(=O)O,,,,,,
4465,124466,5-Formyloxymethyluridine,C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)COC=O,,,,,,
4466,124467,Dchpep II,C1=CC(=CC=C1C(C(C2=CC=C(C=C2)O)N)N)O.[Cl-].[Cl-].[Pt+2],,,,,,
4467,124468,"1,2-Bis(4-hydroxyphenyl)ethylenediamine",C1=CC(=CC=C1C(C(C2=CC=C(C=C2)O)N)N)O,,,,,,
4468,124469,"6-((3-Fluorophenyl)amino)-5,8-quinoxalinedione",C1=CC(=CC(=C1)F)NC2=CC(=O)C3=NC=CN=C3C2=O,,,,,,
4469,124470,N-Acetyl-4-S-cysteaminylphenol,CC(=O)NCCSC1=CC=C(C=C1)O,,,,,,
4470,124471,N-(4-Chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea,C1=CC(=CC(=C1)Cl)NC(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
4471,124472,"2-Pyrrolidinepropanoic acid, 1-(4-methoxybenzoyl)-5-oxo-",COC1=CC=C(C=C1)C(=O)N2C(CCC2=O)CCC(=O)O,,,,,,
4472,124473,"8-Chloro-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine",C1=CC=C(C=C1)C2=NN=C3N2C4=C(C=CC(=C4)Cl)N=C3N,,,,,,
4473,124474,N'-Propylnornicotine,CCCN1CCCC1C2=CN=CC=C2,,,,,,
4474,124475,N4-Methoxy-2'-deoxy-cytidine-5'-monophosphate,CONC1=NC(=O)N(C=C1)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)O,,,,,,
4475,124476,1-Methoxyindole-3-carboxylic acid,CON1C=C(C2=CC=CC=C21)C(=O)O,,,,,,
4476,124477,3-Ethoxy-beta-carboline,CCOC1=NC=C2C(=C1)C3=CC=CC=C3N2,,,,,,
4477,124478,"1-(2-Furyl)-1,2,3,4-tetrahydro-9H-pyrido(3,4-b)indole-3-carboxylic acid",C1[C@H](N[C@H](C2=C1C3=CC=CC=C3N2)C4=CC=CO4)C(=O)O,,,,,,
4478,124479,N-Nitrosoallylethanolamine,C=CCN(CCO)N=O,,,,,,
4479,124480,N-Nitrosoallyl-2-hydroxypropylamine,CC(CN(CC=C)N=O)O,,,,,,
4480,124481,N-Nitrosoallyl-2-oxopropylamine,CC(=O)CN(CC=C)N=O,,,,,,
4481,124482,Cyclo FC,C1=C(C(=N)N=C2N1[C@H]3C(O2)[C@@H]([C@H](O3)CO)O)F.Cl,,,,,,
4482,124483,CID 124483,C(CC(C(=O)O)(NC(=O)CC(CC(=O)O)(C(=O)O)O)O)CNC(=O)CC(CC(=O)O)(C(=O)O)O,,,,,,
4483,124484,CID 124484,C[C@H]1C[C@@H](CC=C1CCO)C(C)(C)O,,,,,,
4484,124485,"8-Benzoyl-2-(3-but-1-enyloxiran-2-yl)-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione",CCC=CC1C(O1)C2=C(C(=O)C3(O2)C(C(NC3=O)(C(=O)C4=CC=CC=C4)OC)O)C,,,,,,
4485,124486,"7,7,16-Trifluorohexadecanoic acid",C(CCCCC(CCCCCC(=O)O)(F)F)CCCCF,,,,,,
4486,124487,CID 124487,CC1CN(CC1N)C2=C(C=C3C(=C2C)C(C=C(C3=O)C(=O)O)C4CC4)F,,,,,,
4487,124488,"Acetamide, 2-((2-hydroxyethyl)thio)-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-",C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CSCCO,,,,,,
4488,124489,CID 124489,C1=CC=C2C(=C1)C=CC3=C2N=C(C=C3)C=CC4=CC=C[C-]=C4,,,,,,
4489,124490,Styrylbenzoquinoline,C1=CC=C(C=C1)C=CC2=NC3=C(C=CC4=CC=CC=C43)C=C2,,,,,,
4490,124491,1-Amino-5-bromouracil,C1=C(C(=O)NC(=O)N1N)Br,,,,,,
4491,124492,"7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-9-ethyl-6,9,10,11-tetrahydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",CCC1(CC(C2=C(C1O)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)C)O)N)O,,,,,,
4492,124493,"[2-[2-(Dimethylamino)ethyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] acetate;hydrochloride",CC1=C(C(=C(C2=C1OC(CC2)(C)CCN(C)C)C)OC(=O)C)C.Cl,,,,,,
4493,124494,"6-Acetyloxy-3,4-dihydro-N,N,2,5,7,8-hexamethyl-2H-1-benzopyran-2-ethanamine",CC1=C(C(=C(C2=C1OC(CC2)(C)CCN(C)C)C)OC(=O)C)C,,,,,,
4494,124495,CID 124495,CCNCCNC1=C2C3=C(C=C1)N=NN3C4=C(C2=O)C=C(C=C4)C,,,,,,
4495,124496,"5-(2-(Diethylamino)ethylamino)-8-hydroxy-6H-(1,2,3)triazolo(4,5-1-de)acridin-6-one",CN(C)CCNC1=C2C3=C(C=C1)N=NN3C4=C(C2=O)C=C(C=C4)O,,,,,,
4496,124497,CID 124497,CN([C@H]1CNC(=CC1=O)NC(=O)N)C(=O)C[C@H](CCCN=C(N)N)N,,,,,,
4497,124498,"(3S)-3-amino-N-[(5R)-2-(carbamoylamino)-6-oxo-4,5-dihydro-1H-pyrimidin-5-yl]-6-(diaminomethylideneamino)-N-methylhexanamide",CN([C@@H]1CN=C(NC1=O)NC(=O)N)C(=O)C[C@H](CCCN=C(N)N)N,,,,,,
4498,124499,5-Iodobenzovesamicol,C1CN(CCC1C2=CC=CC=C2)[C@@H]3CC4=C(C[C@H]3O)C=CC=C4I,,,,,,
4499,124500,"3-(2,3-Dihydro-1H-indol-1-yl)benzylmethylamine",C1CN(C2=C1CC=CC2)C3=CC=CC(=C3)CCN,,,,,,
4500,124501,2-Isopropyl-6-methoxynaphthalene,CC(C)C1=CC2=C(C=C1)C=C(C=C2)OC,,,,,,
4501,124502,3-Carbamimidoylsulfanylprop-2-enoic acid,C(=CSC(=N)N)C(=O)O,,,,,,
4502,124503,2-Hydroxy-3-propyl-4-(6-(tetrazol-5-yl)hexyloxy)acetophenone,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCCC2=NNN=N2,,,,,,
4503,124504,2-Methylene-3(2H)-furanone,C=C1C(=O)C=CO1,,,,,,
4504,124505,"2-Amino-2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene",CC1(CCC2=CC(=C(C=C2C1)O)O)N,,,,,,
4505,124506,"5,6-Heptadiene-1,4-diamine",C=C=CC(CCCN)N,,,['Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)'],,,
4506,124507,"4-Pyridineethanaminium, N,N-diethyl-N-methyl-, iodide",CC[N+](C)(CC)CCC1=CC=NC=C1.[I-],,,,,,
4507,124508,(2-(4-Pyridyl)ethyl)diethylmethylammonium,CC[N+](C)(CC)CCC1=CC=NC=C1,,,,,,
4508,124509,CID 124509,CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)C(C#C)O)O)O,,,,,,
4509,124510,1-Amino-3-methoxypropan-2-ol,COCC(CN)O,,,,,,
4510,124511,4-Chloro-6-methoxyindole,COC1=CC2=C(C=CN2)C(=C1)Cl,,,,,,
4511,124512,CID 124512,C1=CC(=O)C2=NC3=C(C(=C(C=C3)Cl)O)NC2=C1,,,,,,
4512,124513,(3-Nitrophenyl) piperidine-3-carboxylate,C1CC(CNC1)C(=O)OC2=CC=CC(=C2)[N+](=O)[O-],,,,,,
4513,124514,"tert-butyl 9H-pyrido[3,4-b]indole-3-carboxylate",CC(C)(C)OC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,,,,,,
4514,124515,(R)-4-Fluorophenylglycine,C1=CC(=CC=C1[C@H](C(=O)O)N)F,,,,,,
4515,124516,CID 124516,C1=CNC2=C(C(=CC(=O)C2=C1)N=O)O,,,,,,
4516,124517,"3-(3,4-Dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide",CCCN1CCC(C1)C2=CC(=C(C=C2)O)O.Br,,,,,,
4517,124518,"1,2-Benzenediol, 4-(1-propyl-3-pyrrolidinyl)-",CCCN1CCC(C1)C2=CC(=C(C=C2)O)O,,,,,,
4518,124519,"1,6-Dioxapyrene",C1=CC2=C3C(=CC=C4C3=C1C=CO4)C=CO2,,,,,,
4519,124520,"3,4-Diphenyl-1H-pyrazole-1-propanamine",C1=CC=C(C=C1)C2=CN(N=C2C3=CC=CC=C3)CCCN,,,,,,
4520,124521,"(1,4-Dinitro-3-phenylbut-2-en-2-yl)benzene",C1=CC=C(C=C1)C(=C(C[N+](=O)[O-])C2=CC=CC=C2)C[N+](=O)[O-],,,,,,
4521,124522,2-((4-Hydroxyphenyl)amino)-5-methoxybenzenemethanol,COC1=CC(=C(C=C1)NC2=CC=C(C=C2)O)CO,,,,,,
4522,124523,"4,4'-Bis(ethylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl",CCS(=O)(=O)C1=C(C=C(C(=C1)Cl)C2=CC(=C(C=C2Cl)S(=O)(=O)CC)Cl)Cl,,,,,,
4523,124524,"N-(4,6-Dimethyl-2-pyridinyl)benzamide",CC1=CC(=NC(=C1)NC(=O)C2=CC=CC=C2)C,,,,,,
4524,124525,Methoxycarbonyl phosphate,COC(=O)OP(=O)([O-])[O-],,,,,,
4525,124526,Methyl phosphono carbonate,COC(=O)OP(=O)(O)O,,,,,,
4526,124527,"1-(4-Chlorobenzoyl)piperazine-2,3-dicarboxylic acid",C1CN(C(C(N1)C(=O)O)C(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
4527,124528,"1-(4-Bromobenzoyl)piperazine-2,3-dicarboxylic acid",C1CN(C(C(N1)C(=O)O)C(=O)O)C(=O)C2=CC=C(C=C2)Br,,,,,,
4528,124529,5-(2-Carboxyethylsulfanyl)-4-hydroxynonadec-6-enoic acid,CCCCCCCCCCCCC=CC(C(CCC(=O)O)O)SCCC(=O)O,,,,,,
4529,124530,7-((Methylethoxyphosphinyl)oxy)-1-methylquinolinium,CCOP(C)OC1=CC2=C(C=CC=[N+]2C)C=C1.[I-],,,,,,
4530,124531,Ethoxy-methyl-(1-methylquinolin-1-ium-7-yl)oxyphosphane,CCOP(C)OC1=CC2=C(C=CC=[N+]2C)C=C1,,,,,,
4531,124532,7-(2-(4-Hydroxyphenethylamino)cyclopentyl)heptanoic acid,C1CC(C(C1)NCCC2=CC=C(C=C2)O)CCCCCCC(=O)O,,,,,,
4532,124533,5-((5-Methyl-3-thienyl)oxy)-2(1H)-pyrimidinone,CC1=CC(=CS1)OC2=CNC(=O)N=C2,,,,,,
4533,124534,2-Benzyl-3-formylpropanoic acid,C1=CC=C(C=C1)CC(CC=O)C(=O)O,,,,,,
4534,124535,1-Nitroso-1-ethyl-3-(2-hydroxyethyl)urea,CCN(C(=O)NCCO)N=O,,,,,,
4535,124536,1-Nitroso-1-(2-hydroxyethyl)-3-ethylurea,CCNC(=O)N(CCO)N=O,,,,,,
4536,124537,1-Nitroso-1-(2-hydroxyethyl)-3-(2-chloroethyl)urea,C(CCl)NC(=O)N(CCO)N=O,,,,,,
4537,124538,1-Nitroso-1-(2-hydroxypropyl)-3-(2-chloroethyl)urea,CC(CN(C(=O)NCCCl)N=O)O,,,,,,
4538,124539,"2,3-Bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane",CC(C)(C1=C(C=C(C=C1)O)F)C(C)(C)C2=C(C=C(C=C2)O)F,,,,,,
4539,124540,Methyl 4-pyridyl disulfide,CSSC1=CC=NC=C1,,,,,,
4540,124541,"2,2-Dimethyl-n-benzylmalonamide",CC(C)(C(=O)N)C(=O)NCC1=CC=CC=C1,,,,,,
4541,124542,3-tert-Butylphenyl sec-butylcarbamate,CCC(C)NC(=O)OC1=CC=CC(=C1)C(C)(C)C,,,,,,
4542,124543,"3-Hydroxy-1,2,2,3-tetramethylcyclopentane-1-carboxylic acid",CC1(C(CCC1(C)O)(C)C(=O)O)C,,,,,,
4543,124544,"1-(6,10-Dimethylundeca-4,9-dienoxy)-2,3,5-trimethylbenzene",CC1=CC(=C(C(=C1)OCCCC=CC(C)CCC=C(C)C)C)C,,,,,,
4544,124545,"1-(4-Azidophenyl)-4-t-butyl-2,6,7-trioxabicyclo(2.2.2)octane",CC(C)(C)C12COC(OC1)(OC2)C3=CC=C(C=C3)N=[N+]=[N-],,,,,,
4545,124546,"1-Methyl-3-(N-(4-iodophenylethyl)carbamoyl)-1,4-dihydropyridine",CC(C1=CC=C(C=C1)I)NC(=O)C2=CN(C=CC2)C,,,,,,
4546,124547,1-Methyl-3-(N-(4-iodophenyl)carbamoyl)pyridinium iodide,C[N+]1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)I.[I-],,,,,,
4547,124548,N-(4-iodophenyl)-1-methylpyridin-1-ium-3-carboxamide,C[N+]1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)I,,,,,,
4548,124549,"1-Methyl-3-(N-(4-iodophenyl)carbamoyl)-1,4-dihydropyridine",CN1C=CCC(=C1)C(=O)NC2=CC=C(C=C2)I,,,,,,
4549,124550,N-Nitrosoethanolamine,C(CO)NN=O,,,,,,
4550,124551,6-Bromobenzamil,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Br)N)N,,,,,,
4551,124552,1-(2-(2-Iodophenoxy)ethyl)-2-nitroimidazole,C1=CC=C(C(=C1)OCCN2C=CN=C2[N+](=O)[O-])I,,,,,,
4552,124553,"1-(3,4-Dimethoxyphenyl)-2-phenylethanediol",COC1=C(C=C(C=C1)C(CC2=CC=CC=C2)(O)O)OC,,,,,,
4553,124554,2-Amino-6-nitrobenzyl alcohol,C1=CC(=C(C(=C1)[N+](=O)[O-])CO)N,,,,,,
4554,124555,N-Cyclohexyl-N'-(1-pyrenyl)carbodiimide,C1CCC(CC1)N=C=NC2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C=C2,,,,,,
4555,124556,2-Nitro-5-(6-bromohexanoylamino)benzoic acid,C1=CC(=C(C=C1NC(=O)CCCCCBr)C(=O)O)[N+](=O)[O-],,,,,,
4556,124557,"2-Methoxy-4-(1,3-thiazolidin-2-yl)phenol",COC1=C(C=CC(=C1)C2NCCS2)O,,,,,,
4557,124558,4-Aminopyrrolidine-2-carboxylic acid,C1C(CNC1C(=O)O)N,,,,,,
4558,124559,"5-Ethyl-1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-2,4(1H,3H)-pyrimidinedione",CCC1=CN(C(=O)NC1=O)C2CC(C(C2)O)CO,,,,,,
4559,124560,"5-Ethynyl-1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-2,4(1H,3H)-pyrimidinedione",C#CC1=CN(C(=O)NC1=O)C2CC(C(C2)O)CO,,,,,,
4560,124561,"1,3,3-Trimethyl-4-phenyl-1,2,3,6-tetrahydropyridine",CC1(CN(CC=C1C2=CC=CC=C2)C)C,,,,,,
4561,124562,CID 124562,C1=CC=C(C=C1)NC(=NCCCCCN)S,,,,,,
4562,124563,CID 124563,C=C(CCOP(=O)([O-])[O-])CF,,,,,,
4563,124564,CID 124564,C=C(CCOP(=O)(O)O)CF,,,,,,
4564,124565,CID 124565,CC(C)(C)C(=O)NC1N(C(C(S1)N=O)OC)CC(=O)N,,,,,,
4565,124566,CID 124566,C=CC1CN=C(N1C2=CC=CC=C2)S,,,,,,
4566,124567,CID 124567,COP(=O)([O-])OC1=CC=C(C=C1)C=O.[Na+],,,,,,
4567,124568,(4-Formylphenyl) methyl hydrogen phosphate,COP(=O)(O)OC1=CC=C(C=C1)C=O,,,,,,
4568,124569,CID 124569,CCCCCCCCCCCCCCCCOP(=O)([O-])OC1=CC=C(C=C1)C=O.[Na+],,,,,,
4569,124570,(4-Formylphenyl) hexadecyl hydrogen phosphate,CCCCCCCCCCCCCCCCOP(=O)(O)OC1=CC=C(C=C1)C=O,,,,,,
4570,124571,CID 124571,CC1=NN=C(CC1=CC2=CC(=CC=C2)C(F)(F)F)N(C)C,,,,,,
4571,124572,"4,5-Diaminopentanoic acid",C(CC(=O)O)C(CN)N,,,,,,
4572,124573,4-Fluoro-1-(1-(2-thienyl)cyclohexyl)piperidine,C1CCC(CC1)(C2=CC=CS2)N3CCC(CC3)F,,,,,,
4573,124574,"6-(3,4-Dichlorophenoxy)-3-(ethylthio)-2-pyridinecarbonitrile",CCSC1=C(N=C(C=C1)OC2=CC(=C(C=C2)Cl)Cl)C#N,,,,,,
4574,124575,2-Amino-2-(4-chlorophenyl)ethanesulfonic acid,C1=CC(=CC=C1C(CS(=O)(=O)O)N)Cl,,,,,,
4575,124576,(1-Amino-2-propenyl)phosphonic acid,C=CC(N)P(=O)(O)O,,,,,,
4576,124577,"3-Bromo-6,7-dimethoxy-1,5-dimethylquinoxalin-2-one",CC1=C2C(=CC(=C1OC)OC)N(C(=O)C(=N2)Br)C,,,,,,
4577,124578,"[4-[(3,5-Dibromopyridin-2-yl)diazenyl]-2-propylphenyl]-ethylsulfamic acid",CCCC1=C(C=CC(=C1)N=NC2=C(C=C(C=N2)Br)Br)N(CC)S(=O)(=O)O,,,,,,
4578,124579,Tetrachlorosalicylanilide,C1=CC=C(C=C1)NC(=O)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)O,,,,,,
4579,124580,7-(Diphenylmethylene)bicyclo(2.2.1)heptan-2-ol,C1CC2C(CC1C2=C(C3=CC=CC=C3)C4=CC=CC=C4)O,,,,,,
4580,124581,"18-[2-Amino-3-(2,3-dihydroxyphenyl)propanoyl]-17,18,19-trihydroxypentatriacontane-16,20-dione",CCCCCCCCCCCCCCCC(=O)C(C(C(C(=O)CCCCCCCCCCCCCCC)O)(C(=O)C(CC1=C(C(=CC=C1)O)O)N)O)O,,,,,,
4581,124582,3-((Benzyloxy)methyl)morpholine,C1COCC(N1)COCC2=CC=CC=C2,,,,,,
4582,124583,Dehmd,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)COCCO,,,,,,
4583,124584,16-Iodo-3-methylhexadecanoic acid,CC(CCCCCCCCCCCCCI)CC(=O)O,,,,,,
4584,124585,1-Methyl-5-(methyldithio)-1H-tetrazole,CN1C(=NN=N1)SSC,,,,,,
4585,124586,"4-tert-Butyl-2,6-bis(1-hydroxy-1-(trifluoromethyl)-2,2,2-trifluoroethyl)iodobenzene",CC(C)(C)C1=CC(=C(C(=C1)C(C(F)(F)F)(C(F)(F)F)O)I)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
4586,124587,"6-(5-Azido-5,6,7,8-tetrahydro-8,8-dimethyl-2-naphthalenyl)-2-naphthalenecarboxylic acid",CC1(CCC(C2=C1C=C(C=C2)C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)N=[N+]=[N-])C,,,,,,
4587,124588,"6-(5-Azido-5,6,7,8-tetrahydro-5,8,8-trimethyl-2-naphthalenyl)-2-naphthalenecarboxylic acid",CC1(CCC(C2=C1C=C(C=C2)C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)(C)N=[N+]=[N-])C,,,,,,
4588,124589,3-Ethyl-3-(4-phenylpiperazin-1-yl)pentan-2-amine,CCC(CC)(C(C)N)N1CCN(CC1)C2=CC=CC=C2,,,,,,
4589,124590,"12-Hydroperoxyicosa-5,8,11,14,17-pentaenoic acid",CCC=CCC=CCC(=CCC=CCC=CCCCC(=O)O)OO,,,,,,
4590,124591,4-(Bromomethyl)benzoylformate,C1=CC(=CC=C1CBr)C(=O)C(=O)[O-],,,,,,
4591,124592,2-[4-(Bromomethyl)phenyl]-2-oxoacetic acid,C1=CC(=CC=C1CBr)C(=O)C(=O)O,,,,,,
4592,124593,"3-[3-(5,5-Dimethyl-4-oxofuran-2-yl)but-2-enoxy]xanthen-9-one",CC(=CCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)C4=CC(=O)C(O4)(C)C,,,,,,
4593,124594,"Ethyl 2,5-dimethylphenoxyisobutyrate",CCOC(=O)C(C)(C)OC1=C(C=CC(=C1)C)C,,,,,,
4594,124595,N-(4-Chlorobenzyl)-2-(1H-imidazol-1-ylmethyl)benzenamine,C1=CC=C(C(=C1)CN2C=CN=C2)NCC3=CC=C(C=C3)Cl,,,,,,
4595,124596,1-azabicyclo[2.2.2]octan-3-yl 1H-xanthene-9-carboxylate,C1CN2CCC1C(C2)OC(=O)C3=C4CC=CC=C4OC5=CC=CC=C53,,,,,,
4596,124597,"5,12,20-Trihydroxyicosa-6,8,14-trienoic acid",C(CCC=CCC(CCC=CC=CC(CCCC(=O)O)O)O)CCO,,,,,,
4597,124598,"5,12,20-Trihydroxyicosa-8,10,14-trienoic acid",C(CCC=CCC(C=CC=CCCC(CCCC(=O)O)O)O)CCO,,,,,,
4598,124599,"1,2-Bis(4-hydroxyphenyl)-3,4-dihydro-6-hydroxynaphthalene",C1CC(=C(C2=C1C=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,,,,,,
4599,124600,"3-Butyl-3-(4-pyridyl)piperidine-2,6-dione",CCCCC1(CCC(=O)NC1=O)C2=CC=NC=C2,,,,,,
4600,124601,"N,N-dimethyl-1-(2-methyl-1,3-oxathiolan-5-yl)methanamine;iodomethane",CC1OC(CS1)CN(C)C.CI,,,,,,
4601,124602,"N,N-dimethyl-1-(2-methyl-1,3-oxathiolan-5-yl)methanamine",CC1OC(CS1)CN(C)C,,,,,,
4602,124603,N-(Acetoxymethyl)-4-chlorobenzamide,CC(=O)OCNC(=O)C1=CC=C(C=C1)Cl,,,,,,
4603,124604,"Heptane-1,2,3-triol",CCCCC(C(CO)O)O,,,,,,
4604,124605,Prop-2-ynyl 4-methoxybenzoate,COC1=CC=C(C=C1)C(=O)OCC#C,,,,,,
4605,124606,"2,3-Dibenzylbutane-1,4-diol",C1=CC=C(C=C1)CC(CO)C(CC2=CC=CC=C2)CO,,,,,,
4606,124607,"2,2-Dicyclohexyl-5-((dimethylamino)methyl)-1,3-oxathiolane methiodide",CN(C)CC1CSC(O1)(C2CCCCC2)C3CCCCC3.CI,,,,,,
4607,124608,"1-(2,2-dicyclohexyl-1,3-oxathiolan-5-yl)-N,N-dimethylmethanamine",CN(C)CC1CSC(O1)(C2CCCCC2)C3CCCCC3,,,,,,
4608,124609,"1-Ethyl-4-(3-methoxyphenyl)-1,2,3,6-tetrahydropyridine",CCN1CCC(=CC1)C2=CC(=CC=C2)OC,,,,,,
4609,124610,"Benzenemethanaminium, N,N,N-tributyl-, salt with 4-hydroxy-1-naphthalenesulfonic acid (1:1)",CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1.C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])O,,,,,,
4610,124611,"N,N,N-Tributylbenzenemethanaminium",CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1,,,,,,
4611,124612,CID 124612,C1CC(=O)N(C1=O)C2=C(C=CC(=C2)C=C[N+](=O)[O-])C(=O)[O-],,,,,,
4612,124613,CID 124613,C1CC(=O)N(C1=O)C2=C(C=CC(=C2)C=C[N+](=O)[O-])C(=O)O,,,,,,
4613,124614,"5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentyl isothiocyanate",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(CN=C=S)C2=CC(=C(C=C2)OC)OC,,,,,,
4614,124615,2-Formylcyclopropane-1-carboxylic acid,C1C(C1C(=O)O)C=O,,,,,,
4615,124616,3-(1-Aminocyclopropyl)prop-2-enoic acid,C1CC1(C=CC(=O)O)N,,,,,,
4616,124617,CID 124617,C1=CC2=C(C=C1Cl)C(=O)C(=C(O2)O)O,,,,,,
4617,124618,"2,5,6-Trihydroxy-9H-fluorene-9-methanamine",C1=CC2=C(C=C1O)C(C3=C2C(=C(C=C3)O)O)CN,,,,,,
4618,124619,"3-Methoxy-N,N'-diaminophthalamide",COC1=CC=CC(=C1C(=O)NN)C(=O)NN,,,,,,
4619,124620,CID 124620,C1CC1CN2CC[C@]34[C@@H]5[C@@H]2CC6=C3C(=C(C=C6)O)O[C@H]4C(=O)C=C5,,,,,,
4620,124621,Isononanoyl oxybenzene sulfonate,CC(C)CCCCCC(=O)OS(=O)(=O)OC1=CC=CC=C1,,,,,,
4621,124622,Valyl-leucyl-prolyl-phenylalanyl-phenylalanyl-valyl-leucine,CC(C)C[C@H](C(=O)N1CCCC1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N,,,,,,
4622,124623,((3-(3-(4-Acetyl-3-hydroxy-2-phenylpropylphenoxy)-2-hydroxypropoxy)-2-cyanophenyl)amino)oxoacetic acid ethyl ester,CCCC1=C(C=CC(=C1O)C(=O)C)OCC(COC2=CC=CC(=C2C#N)NC(=O)C(=O)OCC)O,,,,,,
4623,124624,5-Amino-5-deoxymannopyranoside,C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)N)O,,,,,,
4624,124625,CID 124625,CC1[C@H](CC[C@@]2([C@@H]1C[C@H](C34[C@H]2C[C@@H](C([C@H]3O)C(=C)C4=O)O)O)C)CO,,,,,,
4625,124626,"1,5-Dihydro-3-(3-sulfopropyl)lumiflavin",CC1=CC2=C(C=C1C)N(C3=C(N2)C(=O)N(C(=O)N3)CCCS(=O)(=O)O)C,,,,,,
4626,124627,CID 124627,C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)S)O)O)OP(=O)(O)O,,,,,,
4627,124628,2-[2-[[1-Carboxy-4-(diaminomethylideneamino)-3-hydroxybutyl]amino]ethylamino]butanedioic acid,C(CNC(CC(=O)O)C(=O)O)NC(CC(CN=C(N)N)O)C(=O)O,,,,,,
4628,124629,CID 124629,C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(OP(=O)(O)O)S)O)O)OP(=O)(O)O,,,,,,
4629,124630,CID 124630,C1C[C@]2([C@@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1NC(=O)CBr)OC5=C(C=C4)O)O,,,,,,
4630,124631,Benfluron N-oxide,C[N+](C)(CCOC1=CC2=C(C3=CC=CC=C31)C4=CC=CC=C4C2=O)[O-],,,,,,
4631,124632,CID 124632,CC[N+](C)(CC)CCCN1C2=CC(=N)C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N[N+]#N.[Cl-].[Cl-],,,,,,
4632,124633,3-[8-(Diazonioamino)-3-imino-6-phenylphenanthridin-5-yl]propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCN1C2=CC(=N)C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N[N+]#N,,,,,,
4633,124634,Berlopentin,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C,,,,,,
4634,124635,3'-Isothiocyanatobenzamidecholic acid,C[C@H](CCC(=O)O)[C@H]1CCC2[C@@]1([C@H](C[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)NC(=O)C5=CC(=CC=C5)N=C=S)O)C,,,,,,
4635,124636,Stenophylline B,C[C@@H]1CC[C@H](NC1)[C@@](C)([C@H]2CC[C@@H]3[C@@]2(CC[C@@H]4[C@@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)O,,,,,,
4636,124637,"(6R,14R,19R)-5-(cyclopropylmethyl)-17,17,18,18-tetramethyl-13,16-dioxa-5-azaheptacyclo[13.5.2.12,8.01,6.02,14.015,19.012,23]tricosa-8(23),9,11-trien-11-ol",CC1([C@H]2CC34CCC2([C@H]5C36CCN([C@@H]4CC7=C6C(=C(C=C7)O)O5)CC8CC8)OC1(C)C)C,,,,,,
4637,124638,"[(2R,7R,9R,10R)-1,2,5-Trimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-10-yl] acetate",CC1=C[C@@H]2[C@](CC1)(C3(C[C@H]([C@H](C34CO4)O2)OC(=O)C)C)C,,,,,,
4638,124639,CID 124639,CCC(C)[C@@H](C=CCC(=O)O)N,,,,,,
4639,124640,Dioxolamycin,C[C@@]1(O[C@@H]2C=C(CC([C@H]2O1)O)C(=O)OC)C(=O)N,,,,,,
4640,124641,"2-[4,5-Dihydroxy-3-(1-hydroxy-3-oxopent-1-enyl)-9,10-dioxoanthracen-2-yl]acetic acid",CCC(=O)C=C(C1=C(C2=C(C=C1CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O)O)O,,,,,,
4641,124642,"[(2R,3S,4R,5R)-5-(6-amino-2-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl N-(2-aminopropanoyl)sulfamate",CC(C(=O)NS(=O)(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)N)O)O)N,,,,,,
4642,124643,Anhydromaggiemycin,CCC1=CC(=C2C(=C1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O,,,,,,
4643,124644,Teloxantrone,CNCCN=C1C=CC2=C3C1=C(C4=C(C=CC(=O)C4=C3NN2CCNCCO)O)O,,,,,,
4644,124645,7-(Chlorocarbonylmethoxy)-4-methylcoumarin,CC1=CC(=O)OC2=C1C=CC(=C2)OCC(=O)Cl,,,,,,
4645,124646,"2,5-Pyrrolidinedione, 1-((3-iodobenzoyl)oxy)-",C1CC(=O)N(C1=O)OC(=O)C2=CC(=CC=C2)I,,,,,,
4646,124647,CID 124647,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=[N+](C)[O-])C)C,,,,,,
4647,124648,"Tuftsin, (3,4-dehydro-pro)(3)-",C[C@H]([C@@H](C(=O)NC(CCCCN)C(=O)N1CC=C[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O,,,,,,
4648,124649,5-(2-(1-Imidazolyl)ethoxy)thiophene-2-carboxylic acid,C1=CN(C=N1)CCOC2=CC=C(S2)C(=O)O.Cl,,,,,,
4649,124650,5-[2-(1H-Imidazole-1-yl)ethoxy]-2-thiophenecarboxylic acid,C1=CN(C=N1)CCOC2=CC=C(S2)C(=O)O,,,,,,
4650,124651,5-(2-(1-Imidazolyl)ethoxy)-4-chlorothiophene-2-carboxylic acid,C1=CN(C=N1)CCOC2=C(C=C(S2)C(=O)O)Cl.Cl,,,,,,
4651,124652,5-[2-(1H-Imidazole-1-yl)ethoxy]-4-chloro-2-thiophenecarboxylic acid,C1=CN(C=N1)CCOC2=C(C=C(S2)C(=O)O)Cl,,,,,,
4652,124653,6alpha-Methylprednisone,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(CC(=O)[C@@H]2[C@@]4(C1=CC(=O)C=C4)C)C)(C(=O)CO)O,,,,,,
4653,124654,CID 124654,CCCC(=O)OC1C(=CC(=O)OC)CC2CC(OC(=O)CC(CC3CC(C(C(O3)(CC4CC(=CC(=O)OC)CC(O4)C=CC(C1(O2)O)(C)C)O)(C)C)OC(=O)C(C)CC)O)C(C)O,,,,,,
4654,124655,"4-[(3,4-Dihydronaphthalen-2-yl)methyl]-2,5-dihydro-1H-imidazole",C1CC(=CC2=CC=CC=C21)CC3=NCNC3,,,,,,
4655,124656,Isoquinoline-3-carboxylic Acid,C1=CC=C2C=NC(=CC2=C1)C(=O)O,,,,,,
4656,124657,"1,4-Anhydro-2-deoxy-D-ribitol",C1CO[C@@H]([C@H]1O)CO,,,,,,
4657,124658,CID 124658,CCC(C)C(C(=O)O)NC(=O)C(=CC1=CC=CC=C1)NC(=O)CNC(=O)C(C)NC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
4658,124659,CID 124659,CCCCCCCCCCCCCC=CCCCCC1=CC(=CC(=C1)O)O,,,,,,
4659,124660,9-Amino-(N-(2-dimethylamino)butyl)acridine-4-carboxamide,CN(C)CCCCNC(=O)C1=CC=CC2=C(C3=CC=CC=C3N=C21)N,,,,,,
4660,124661,"2-(2,6-Dimethylphenoxy)-N,N-dimethylethanamine",CC1=C(C(=CC=C1)C)OCCN(C)C,,,,,,
4661,124662,"3-(4-Aminophenyl)-3-ethylpyrrolidine-2,5-dione",CCC1(CC(=O)NC1=O)C2=CC=C(C=C2)N,,,,,,
4662,124663,[(2R)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)NC,,,,,,
4663,124664,2-[[(2R)-3-hexadecoxy-2-(methylcarbamoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)NC,,,,,,
4664,124665,"[(2R,3S,5R)-3-Acetyloxy-5-[5-(2-bromoethenyl)-2,4-dioxopyrimidin-1-yl]oxolan-2-yl]methyl acetate",CC(=O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C=CBr)OC(=O)C,,,,,,
4665,124666,CID 124666,C1CC2=C(C3=C(C=C2)NC4=NC(=O)CN4C3)NC1,,,,,,
4666,124667,4'-Aminostearanilide,CCCCCCCCCCCCCCCCCC(=O)NC1=CC=C(C=C1)N,,,,,,
4667,124668,"Pyridinium, 2-(((2-carboxy-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)thio)methyl)-1-methyl-, hydroxide, inner salt, (5R-(5alpha,6alpha(R*)))-",C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)[O-])SCC3=CC=CC=[N+]3C)O,,,,,,
4668,124669,"(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[(1-methylpyridin-1-ium-2-yl)methylsulfanyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCC3=CC=CC=[N+]3C)O,,,,,,
4669,124670,1-(2-Chloroethyl)-3-(2-pyrazinylmethyl)urea,C1=CN=C(C=N1)CNC(=O)NCCCl,,,,,,
4670,124671,CID 124671,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC(=CC(=C3C[C@H](CCC3=C)O)F)CC2)C,,,,,,
4671,124672,CID 124672,C1=CC(=CC=C1C2C3=NC(=C(C4=CC=C([N-]4)C(=C5C=CC(=C(C6=CC=C2[N-]6)C7=CC=C(C=C7)S(=O)(=O)[O-])[N-]5)C8=CC=C(C=C8)S(=O)(=O)[O-])C9=CC=C(C=C9)S(=O)(=O)[O-])C=C3)S(=O)(=O)[O-].[Co],,,,,,
4672,124673,CID 124673,C1=CC(=CC=C1C2C3=CC=C(N3)C(=C4C=CC(=C(C5=NC(=C(C6=CC=C2N6)C7=CC=C(C=C7)S(=O)(=O)O)C=C5)C8=CC=C(C=C8)S(=O)(=O)O)N4)C9=CC=C(C=C9)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4673,124674,"[3-[Hydroxy-[2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]ethoxy]phosphoryl]oxy-2-octadec-9-enoyloxypropyl] octadec-9-enoate",CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-])OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
4674,124675,N-Benzyloxycarbonylvalylprolinal,CC(C)[C@@H](C(=O)N1CCCC1C=O)NC(=O)OCC2=CC=CC=C2,,,,,,
4675,124676,Spirost-5-en-2-yl 6-deoxyhexopyranosyl-(1->2)-[hexopyranosyl-(1->3)hexopyranosyl-(1->4)]hexopyranoside,CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CC(CC6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)O)OC9C(C(C(C(O9)CO)O)O)O)O)O)OC2C(C(C(C(O2)C)O)O)O)C)C)C)OC1,,,,,,
4676,124677,"azane;[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl] hydrogen sulfate",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)OS(=O)(=O)O)O)O)O)O.N,,,,,,
4677,124678,CID 124678,C([C@@H]1C([C@@H]([C@H](C(O1)OC2[C@@H]([C@H](C([C@H](O2)CO)O)O)OS(=O)(=O)O)O)O)O)O,,,,,,
4678,124679,"5,7-Dihydroxy-4-imino-2-oxochroman",C1C(=N)C2=C(C=C(C=C2OC1=O)O)O,,,,,,
4679,124680,3-Dodecanoyltetradecanoic acid,CCCCCCCCCCC[C@H](CC(=O)O)OC(=O)CCCCCCCCCCC,,,,,,
4680,124681,CID 124681,C[C@H]1C[C@H]([C@H]([C@@H](C=C([C@H]([C@@H](C=CC=C(C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)C)OC)OC(=O)N)C)C)O)OC,,,,,,
4681,124682,2'-(4-Nitrophenoxy)oxirane,C1C(O1)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4682,124683,O2-Et-dT,CCOC1=NC(=O)C(=CN1C2C[C@@H]([C@H](O2)CO)O)C,,,,,,
4683,124684,2-Methylarginine,C[C@](CCCN=C(N)N)(C(=O)O)N,,,,,,
4684,124685,Di-n-butyltin glycylglycinate,CCC[CH2-].CCC[CH2-].C(C(=NCC(=O)[O-])[O-])N.[Sn+4],,,,,,
4685,124686,Neothramycin B,COC1=C(C=C2C(=C1)C(=O)N3[C@@H](CC[C@H]3O)C=N2)O,,,,,,
4686,124687,"2-{3-[(4-Amino-2-methylpyrimidin-5-YL)methyl]-4-methyl-2-oxo-2,3-dihydro-1,3-thiazol-5-YL}ethyl trihydrogen diphosphate",CC1=C(SC(=O)N1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O,,,,,,
4687,124688,8-Hydroxycarteolol,CC(C)(C)NCC(COC1=C2CCC(=O)NC2=C(C=C1)O)O,,,,,,
4688,124689,"4,6-Dimethyl-1-amino-3,4,5-trimethoxyphenylpyrimidine",CC1=CC(=NC(=N1)NC2=CC(=C(C(=C2)OC)OC)OC)C,,,,,,
4689,124690,4-Nitrophenyl 2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-alpha-D-galactopyranoside,CC(=O)N[C@H]1[C@H](O[C@@H]([C@@H](C1O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)CO)OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
4690,124691,CID 124691,CCC12CCCN3C1C4(CC3)C(C(C2O)(C(=O)O)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)OC)C,,,,,,
4691,124692,Medermycin,CC1C(C(CC(O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C(OC5C4OC(=O)C5)C)O)N(C)C)O,,,,,,
4692,124693,"2,5-Diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone",C1CN1C2=C(C(=O)C(=C(C2=O)NCCO)N3CC3)NCCO,,,,,,
4693,124694,Disaccharide tetrapeptide,CC(C(=O)NC(CCC(=O)NC(CCCC(C(=O)O)N)C(=O)NC(C)C(=O)O)C(=O)O)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C,,,,,,
4694,124695,Sygethin free acid,CC[C@H](C1=CC=C(C=C1)S(=O)(=O)O)[C@@H](CC)C2=CC=C(C=C2)S(=O)(=O)O,,,,,,
4695,124696,2-Amino-N(6)-methoxyadenine,CONC1=NC(=NC2=C1NC=N2)N,,,,,,
4696,124697,CID 124697,C1=CN(C(=O)NC1=O)[C@H](C=O)O[C@H](COP(=O)(O)OP(=O)(O)O)C=O,,,,,,
4697,124698,(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfinylbutanoic acid,CS(=O)CC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
4698,124699,"2,4-Pyrimidinediamine, 6-chloro-N2-ethyl-5-(methylthio)-",CCNC1=NC(=C(C(=N1)Cl)SC)N,,,,,,
4699,124700,N-Acetyl-demethylmuramyl-alanyl-isoglutamine,CC(C(=O)NCC(=O)N[C@H](CCC(=O)N)C(=O)O)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C,,,,,,
4700,124701,N(6)-(2-Hydroxyethylcarbamoyl)-L-lysine,C(CCNC(=O)NCCO)C[C@@H](C(=O)O)N,,,,,,
4701,124702,"2,5-Dideoxy-2,5-imino-D-mannitol",C([C@@H]1[C@H]([C@@H]([C@H](N1)CO)O)O)O,,,,,,
4702,124703,6-O-Stearoyl-N-acetylmuramyl-alanylisoglutamine,CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)NC(=O)C)OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N)C(=O)O)O,,,,,,
4703,124704,2-Pyrazinoylguanidine,C1=CN=C(C=N1)C(=O)N=C(N)N,,,,,,
4704,124705,Dichlorobis(glycylglycine ethyl ester)platinum II,CCOC(=O)CNC(=O)CN.CCOC(=O)CNC(=O)CN.[Cl-].[Cl-].[Pt+2],,,,,,
4705,124706,"Glycine, N-glycyl-, ethyl ester",CCOC(=O)CNC(=O)CN,,,,,,
4706,124707,CID 124707,COC1=C2C3=C(C(=NOCC(=O)O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,,,,,,
4707,124708,CID 124708,[H+].[H+].[H+].[H+].CC1=C(C2=CC3=NC(=CC4=NC(=C(C4(C)CC(=O)[O-])[O-])C=C5C(C(=O)C(=N5)C=C1[N-]2)(C)CC(=O)[O-])C(=C3C=CC(=O)[O-])C)CCC(=O)[O-].[Fe+2],,,,,,
4708,124709,CID 124709,CC1=C(C2=CC3=C(C(=C(N3)C=C4C(C(=O)C(=N4)C=C5C(C(=O)C(=N5)C=C1N2)(C)CC(=O)O)(C)CC(=O)O)C)C=CC(=O)O)CCC(=O)O,,,,,,
4709,124710,H-D-Phe-pro-arginal,C1CC(N(C1)C(=O)C(CC2=CC=CC=C2)N)C(=O)NC(CCCN=C(N)N)C=O,,,,,,
4710,124711,(S)-4-Hydroxycyclopent-2-enone,C1[C@@H](C=CC1=O)O,,,,,,
4711,124712,9-Aminoacridylpropranolol,CC(CNC1=C2C=CC=CC2=NC3=CC=CC=C31)NCC(COC4=CC=CC5=CC=CC=C54)O,,,,,,
4712,124713,"L-Cysteine, S-(2-nitrophenyl)-",C1=CC=C(C(=C1)[N+](=O)[O-])SC[C@@H](C(=O)O)N,,,,,,
4713,124714,CID 124714,CCCC1C(=O)NCC(CC(C(CCC(=CC=CC(CCCC(=O)CCCCC(CC(C(=O)O1)C)C)CC)COC)O)O)O,,,,,,
4714,124715,"(2R,3S)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)oxolan-3-ol",C1[C@@H]([C@H](OC1N2C=CC3=C(N=CN=C32)N)CO)O,,,,,,
4715,124716,4-Methoxymethylfentanyl,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)COC,,,,,,
4716,124717,"4,4'-(Pimeloylbis(imino-p-phenyleneimino))bis(1-methylpyridinium) dibromide",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)CCCCCC(=O)NC3=CC=C(C=C3)NC4=CC=[N+](C=C4)C.[Br-].[Br-],,,,,,
4717,124718,"N,N'-bis[4-[(1-methylpyridin-1-ium-4-yl)amino]phenyl]heptanediamide",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)CCCCCC(=O)NC3=CC=C(C=C3)NC4=CC=[N+](C=C4)C,,,,,,
4718,124719,"Spiro(azuleno(6,5-b)furan-3(2H),5'-(5H-4a,7)ethanoazuleno(6,5-b)furan)-2,2'5,11'(3'H,3aH)-tetrone, 3'a,4,4',4a,6',7',7a,7'a,8,8',9,9'a-tetradecahydro-4-hydroxy-4a,8,8'-trimethyl-3'-methylene-, (3'aR-(3'aalpha,4'abeta,5'alpha(3aS*,4S*,4aR*,7aR*,8R*,9aR*),7'beta,7'aalpha,8'alpha,9'aalpha))-",CC1CC2C(C(C3(C1C=CC3=O)C)O)C4(CC5C6C4(CC7C(CC6C)OC(=O)C7=C)CC5=O)C(=O)O2,,,,,,
4719,124720,"(7S,9S)-9-acetyl-6,7,9,11-tetrahydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione",CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O)O,,,,,,
4720,124721,"1-N,4-N-bis[4-[(1-methylpyridin-1-ium-3-yl)carbamoyl]phenyl]bicyclo[2.2.2]octane-1,4-dicarboxamide",C[N+]1=CC=CC(=C1)NC(=O)C2=CC=C(C=C2)NC(=O)C34CCC(CC3)(CC4)C(=O)NC5=CC=C(C=C5)C(=O)NC6=C[N+](=CC=C6)C,,,,,,
4721,124722,"Benzo(c)phenanthrene 5,6-oxide",C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC=C4C5C3O5,,,,,,
4722,124723,"4-Methylpiperazine-2,6-dione",CN1CC(=O)NC(=O)C1,,,,,,
4723,124724,"5-Androstene-3beta,17beta-diol sulfate",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC=C4[C@@]3(CC[C@@H](C4)O)C.OS(=O)(=O)O,,,,,,
4724,124725,CID 124725,C[C@]12CCC3[C@H]([C@@H]1CC[C@@H]2O)CC=C4[C@@]3(CC[C@@H](C4)O)C,,,,,,
4725,124726,"5'-Adenylic acid, 8-azido-",C1=NC(=C2C(=N1)N(C(=N2)N=[N+]=[N-])C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N,,,,,,
4726,124727,"N,N-Dimethyl-1-methyldodecylamine oxide",CCCCCCCCCCCC(C)[N+](C)(C)[O-],,,,,,
4727,124728,"Ethanaminium, 2-((6-(((5-(dimethylamino)-1-naphthalenyl)sulfonyl)amino)-1-oxohexyl)oxy)-N,N,N-trimethyl-",CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCC(=O)OCC[N+](C)(C)C.[Br-],,,,,,
4728,124729,6-[[5-(Dimethylamino)-1-naphthyl]sulfonylamino]hexanoic acid 2-(trimethylaminio)ethyl ester,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCC(=O)OCC[N+](C)(C)C,,,,,,
4729,124730,Tmd D-form [MI],C[C@]12CCCC[C@@H]1C([C@@H](CC2)O)(C)C,,,,,,
4730,124731,"10,11-Dihydrobenz(a)anthracene-10,11-diol",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C(C(C=C4)O)O,,,,,,
4731,124732,1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one,CC1=NN(C(=O)C1)C2=CC=C(C=C2)OC,,,,,,
4732,124733,"Benz(a)anthracene-1,2-diol",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3C(C(C=C4)O)O,,,,,,
4733,124734,"2,2':6',2''-Terpyridine Platinum(Ii) Chloride",C1=CC=NC(=C1)C2=NC(=CC=C2)C3=CC=CC=N3.[Cl-].[Pt+2],,,,,,
4734,124735,D-erythro-MAPP,CCCCCCCCCCCCCC(=O)N[C@H](C)[C@H](C1=CC=CC=C1)O,,,,,,
4735,124736,"2(1H)-Pyridinone, 5-(2-methyl-1-oxo-2-(3-pyridinyl)propyl)-",CC(C)(C1=CN=CC=C1)C(=O)C2=CNC(=O)C=C2,,,,,,
4736,124737,Salifluor,CCCCCCCC(=O)C1=CC(=C(C=C1)O)C(=O)NC2=CC=CC(=C2)C(F)(F)F,,,,,,
4737,124738,6-(4-Arsono-2-nitrophenyl)lysine,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])NCCCC[C@@H](C(=O)O)N,,,,,,
4738,124739,alpha-(4-Arsono-2-nitrophenyl)-L-lysine,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])N[C@@H](CCCCN)C(=O)O,,,,,,
4739,124740,"1H-Inden-1-one, 4-(beta-D-glucopyranosyloxy)-2,3-dihydro-6-(2-hydroxyethyl)-2,2,5,7-tetramethyl-",CC1=C(C(=C(C2=C1C(=O)C(C2)(C)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C)CCO,,,,,,
4740,124741,N-Demethylvancomycin,CCC(C)[C@H](C(=O)N[C@@H]1[C@@H](C2=CC(=C(C=C2)OC3=CC4=CC(=C3O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6C[C@]([C@@H]([C@@H](O6)C)O)(C)N)OC7=C(C=C(C=C7)[C@H]([C@H]8C(=O)N[C@@H](C9=C(C(=CC(=C9)O)O)C2=C(C=CC(=C2)[C@H](C(=O)N8)NC(=O)[C@@H]4NC(=O)[C@@H](NC1=O)CC(=O)N)O)C(=O)O)O)Cl)Cl)O)N,,,,,,
4741,124742,"4-(4-Methoxy-3-sulfophenyl)-2,6-bis-(4-sulfophenyl)pyrylium",COC1=C(C=C(C=C1)C2=CC(=[O+]C=C2C3=CC=C(C=C3)S(=O)(=O)O)C4=CC(=CC=C4)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4742,124743,CID 124743,C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O,,,,,,
4743,124744,1-(N-(N-Acetylisoleucyl)-tyrosyl)amino-2-(4-hydroxyphenyl)ethylphosphonic acid,CCC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC2=CC=C(C=C2)O)P(=O)(OCC)OCC)NC(=O)C,,,,,,
4744,124745,CID 124745,CC=C1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
4745,124746,Mono-O-demethylated bdd,COC1=C2C(=C(C(=C1)C(=O)OC)C3=C4C(=C(C=C3C(=O)OC)O)OCO4)OCO2,,,,,['Mono-O-demethylated bdd is a known human metabolite of bifendate.'],
4746,124747,1-(N-6-Amino-n-hexyl)carbamoylimidazole,C1=CN(C=N1)C(=O)NCCCCCCN.Cl,,,,,,
4747,124748,N-(6-aminohexyl)imidazole-1-carboxamide,C1=CN(C=N1)C(=O)NCCCCCCN,,,,,,
4748,124749,[3-[Hydroxy-(2-hydroxy-3-sulfanylpropoxy)phosphoryl]oxy-2-octadec-9-enoyloxypropyl] octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC(CS)O)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
4749,124750,Cyclo(prolylphenylalanyl-epsilon-aminocaproyl),C1CCC(=O)N2CCCC2C(=O)NC(C(=O)NCC1)CC3=CC=CC=C3,,,,,,
4750,124751,Vhmdp,CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C(=C(C(=N5)C=C1N2)CO)C)C=C)C)C(=C3CCC(=O)OC)C)CCC(=O)OC,,,,,,
4751,124752,"2-(3,4-Dihydroxyphenyl)naphtho(1,2-d)thiazole",C1=CC=C2C(=C1)C=CC3=C2N=C(S3)C4=CC(=C(C=C4)O)O,,,,,,
4752,124753,"Carbamimidothioic acid, 4-(1H-pyrazol-4-yl)butyl ester",C1=C(C=NN1)CCCCSC(=N)N,,,,,,
4753,124754,P-P-P-mo4Cyt-dRibf,CONC1=NC(=O)N(C=C1)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
4754,124755,Cyclo(phenylalanylprolyl-epsilon-aminocaproyl),C1CCC(=O)NC(C(=O)N2CCCC2C(=O)NCC1)CC3=CC=CC=C3,,,,,,
4755,124756,N-Methylthiobenzamide S-oxide,CNC(=S=O)C1=CC=CC=C1,,,,,,
4756,124757,6-Methoxypurine arabinoside,COC1=NC=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
4757,124758,CID 124758,C[N+](=CC1=CC=C[C-]=C1)C.[Cl-].[Cl-].[Au+3],,,,,,
4758,124759,Benzylidenedimethyliminium,C[N+](=CC1=CC=CC=C1)C,,,,,,
4759,124760,3-(Methoxycarbonyl)amino-beta-carboline,COC(=O)NC1=NC=C2C(=C1)C3=CC=CC=C3N2,,,,,,
4760,124761,Dotmp,C1CN(CCN(CCN(CCN1CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O,,,,,,
4761,124762,3-(2-Iodobenzoyl)estrone,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5I,,,,,,
4762,124763,"(3R,5S,7R,8R,9S,10S,12S,13R)-10,13-dimethyl-17-[(2R)-5,6,7-trihydroxyheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol",C[C@H](CCC(C(CO)O)O)C1CCC2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
4763,124764,CID 124764,C1CC2=C(C(=O)N=C(N2)N)N(C1CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O)CC4=CN(C(=O)NC4=O)C5CC(C(O5)COP(=O)(O)O)O,,,,,,
4764,124765,Poly(glycyl-valyl-hydroxyproline),CC(C)[C@H](C(=O)N1C[C@@H](C[C@H]1C(=O)O)O)NC(=O)CN,,,,,,
4765,124766,"[(2S,4R)-5-(6-aminopurin-9-yl)-3-azido-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H](C([C@H](O3)COP(=O)(O)O)N=[N+]=[N-])O)N,,,,,,
4766,124767,CID 124767,C1=NC2=C(N1C3[C@@H](C([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-])O)NC(=NC2=O)N,,,,,,
4767,124768,"[[(2S,4R)-5-(6-aminopurin-9-yl)-3-azido-4-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H](C([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-])O)N,,,,,,
4768,124769,Nitro-argininosuccinate,C(C[C@@H](C(=O)O)N)CN=C(N)N[C@@H](C[N+](=O)[O-])C(=O)O,,,,,,
4769,124770,CID 124770,COC1=CC=C(C=C1)C2=COC3=C(C(=O)C=CC3=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
4770,124771,CID 124771,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O[C@H]3C[C@@H](O[C@@H]3CO)N4C=NC5=C(N=CN=C54)N)S)O,,,,,,
4771,124772,"(2R,4S,6R)-5-acetamido-2-[(2R)-2,3-di(tetradecoxy)propoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid",CCCCCCCCCCCCCCOC[C@H](CO[C@@]1(C[C@@H](C([C@@H](O1)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O)OCCCCCCCCCCCCCC,,,,,,
4772,124773,"3-(Hydroxymethyl)phenytoin N,N-dimethylaminoethyl carbonate",CN(C)CCOC(=O)OCN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3.CS(=O)(=O)O,,,,,,
4773,124774,"2-(Dimethylamino)ethyl (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl carbonate",CN(C)CCOC(=O)OCN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4774,124775,2-(5-Methylhexoxycarbonyl)benzoic acid,CC(C)CCCCOC(=O)C1=CC=CC=C1C(=O)O,,,,,,
4775,124776,Dimethylaziridine platinum(II),CC1(NN1)C.CC1(NN1)C.[Cl-].[Cl-].[Pt+2],,,,,,
4776,124777,"3,3-Dimethyldiaziridine",CC1(NN1)C,,,,,,
4777,124778,Diethyldiaziridine platinum(II),CCC1(NN1)CC.CCC1(NN1)CC.[Cl-].[Cl-].[Pt+2],,,,,,
4778,124779,"3,3-Diethyldiaziridine",CCC1(NN1)CC,,,,,,
4779,124780,Azetidine platinum(II),C1CNC1.C1CNC1.[Cl-].[Cl-].[Pt+2],,,,,,
4780,124781,2-Tetradecylglycidyl-coa,CCCCCCCCCCCCCCC1C(O1)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O)O)O,,,,,,
4781,124782,N(epsilon)-Dichloroacetyllysine,C(CCNC(=O)C(Cl)Cl)C[C@@H](C(=O)O)N,,,,,,
4782,124783,N-Benzyloxycarbonylglycyl-leucyl-aminohexylamino-sepharose,CCC(C)C(C(=O)NCCCCCCNC(=O)N)NC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
4783,124784,"(S)-2,6-Bis(dimethylamino)hexanoic acid",CN(C)CCCC[C@@H](C(=O)O)N(C)C,,,,,,
4784,124785,CID 124785,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)OS(=O)(=O)O)N,,,,,,
4785,124786,Hcbp-gly,C1=CC=C(C=C1)CC(CC(=O)NO)C(=O)NCC(=O)O,,,,,,
4786,124787,(S)-3-(Boc-amino)-2-piperidone,CC(C)(C)OC(=O)N[C@H]1CCCNC1=O,,,,,,
4787,124788,Diammineascorbatoplatinum(II),C(C(C1C(=C(C(=O)O1)[O-])[O-])O)O.N.N.[Pt+2],,,,,,
4788,124789,Poly(8-Br-2-DA),C1[C@@H]([C@H](OC1N2C3=NC=NC(=C3N=C2Br)N)COP(=O)(O)O)O,,,,,,
4789,124790,"2-[(8R,9S,10R,13S,14S,16R,17S)-16-ethyl-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoacetaldehyde",CC[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]2([C@H]1C(=O)C=O)C,,,,,,
4790,124791,4-Hydroxybenzoylglycylphenylalanine,C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)CNC(=O)C2=CC=C(C=C2)O,,,,,,
4791,124792,N-(3-(2-Pyridyldithio)propionyl)stearylamine,CCCCCCCCCCCCCCCCCCNC(=O)CCSSC1=CC=CC=N1,,,,,,
4792,124793,"4,5-Dimethoxy-2-nitrobenzyl cyclic amp",COC1=C(C=C(C(=C1)COP2(=O)OC[C@@H]3[C@@H](O2)[C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)[N+](=O)[O-])OC,,,,,,
4793,124794,CID 124794,COC1=C(C=C(C(=C1)COP2(=O)OC[C@@H]3[C@@H](O2)[C@H]([C@@H](O3)N4C=NC5=C4NC(=NC5=O)N)O)[N+](=O)[O-])OC,,,,,,
4794,124795,N-Acetyl-lysyl-arginyl-tyrosyl-asparaginyl-leucyl-threonyl-seryl-valinamide,C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)C)O,,,,,,
4795,124796,N-Acetyllysyl-arginyl-tyrosyl-asparaginyl-leucinamide,CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)C,,,,,,
4796,124797,Phs(terpy)Pt,C1=CC=C(C=C1)[S-].C1=CC=NC(=C1)C2=NC(=CC=C2)C3=CC=CC=N3.[Pt+2],,,,,,
4797,124798,"N-[5-amino-4-[6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[3,5-dihydroxy-6-(hydroxymethyl)-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-3-hydroxycyclohexyl]pentadecanamide",CCCCCCCCCCCCCCC(=O)NC1CC(C(C(C1OC2C(C(C(C(O2)CO)O)NC(=O)C(F)(F)F)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,,,,,,
4798,124799,"(4S,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3'-methylidenespiro[2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,5'-oxolane]-2'-one",C=C1CC2(CC[C@]3([C@@H]4CC5=C6[C@]3([C@H]2OC6=C(C=C5)O)CCN4CC7CC7)O)OC1=O,,,,,,
4799,124800,"(4S,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-3'-methylidenespiro[2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,5'-oxolane]-2'-one",CN1CC[C@]23[C@@H]4C5(CC[C@]2([C@@H]1CC6=C3C(=C(C=C6)O)O4)O)CC(=C)C(=O)O5,,,,,,
4800,124801,CID 124801,CC1=CC(=C2C(=NN(C2=N1)C)C3CCCC3)C4=CC(=CC(=C4)[N+](=O)[O-])C(=O)OC,,,,,,
4801,124802,dPLOT,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSC(CC(=O)N1)(C)C)C(=O)N2CCCC2C(=O)NC(C(C)CC)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)C(C)CC,,,,,,
4802,124803,"Tert-butyl 2-[(1-hydroxy-2,2,5,5-tetramethylpyrrolidine-3-carbonyl)amino]-3-phenylpropanoate",CC1(CC(C(N1O)(C)C)C(=O)NC(CC2=CC=CC=C2)C(=O)OC(C)(C)C)C,,,,,,
4803,124804,"Phosphonofluoridic acid, methyl-, 5-(7-nitro-4-benzofurazanyl)pentyl ester",CP(=O)(OCCCCCC1=CC=C(C2=NON=C12)[N+](=O)[O-])F,,,,,,
4804,124805,"Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-dihydroxy-5-isothiocyanato-4',5'-dimethyl-",CC1=C(C=CC2=C1OC3=C(C24C5=C(C=C(C=C5)N=C=S)C(=O)O4)C=CC(=C3C)O)O,,,,,,
4805,124806,"2H-Furo(2,3-b)pyrrole, 2-(2,5-dimethylphenyl)hexahydro-",CC1=CC(=C(C=C1)C)C2CC3CCNC3O2,,,,,,
4806,124807,CID 124807,CC1C(NC2=C(N1)NC(=NC2=O)N)C(C)NC3=CC=C(C=C3)CC(C(C(COC4C(C(C(O4)COP(=O)(O)OC(CCC(=O)O)C(=O)O)O)O)O)O)O,,,,,,
4807,124808,CID 124808,C[C@@H](CC1=CC(=C(C=C1)O)I)NC2=C3C(=NC=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
4808,124809,"Bis(1,10-phenanthroline)(dipyrido(3,2-a:2',3'-c)phenazine)ruthenium (II)",C1=CC=C2C(=C1)N=C3C4=C(C5=C(C3=N2)C=CN=C5)N=CC=C4.C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1.C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1.[Ru+2],,,,,,
4809,124810,"Quinoxalino[2,3-f][1,9]phenanthroline",C1=CC=C2C(=C1)N=C3C4=C(C5=C(C3=N2)C=CN=C5)N=CC=C4,,,,,,
4810,124811,2'-Chloro-2'-deoxyuridine 5'-phosphate,[3H]C(C1C(C(C(O1)N2C=CC(=O)NC2=O)Cl)O)OP(=O)(O)O,,,,,,
4811,124812,6-Desmethylsulfadimethoxine,COC1=NC=C(C(=O)N1)NS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
4812,124813,Di-(5-hexenyl)phthalate,C=CCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCC=C,,,,,,
4813,124814,Di-(9-decenyl)phthalate,C=CCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCC=C,,,,,,
4814,124815,"(4aR,6R,7R,8R,8aR)-7,8-dihydroxy-6-methoxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-2-carboxylic acid",CC1(OC[C@@H]2[C@H](O1)[C@@H]([C@H]([C@@H](O2)OC)O)O)C(=O)O,,,,,,
4815,124816,"2-(4,5-Dimethyl-2-thiazolylazo)-5-diethylaminophenol",CCN(CC)C1=CC(=C(C=C1)N=NC2=NC(=C(S2)C)C)O,,,,,,
4816,124817,N-tert-Butoxycarbonyl-2-piperidinecarboxylic acid; N-Boc-DL-pipecolinic acid;1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid,C1C(OC(C1=O)COP(=O)(O)OP(=O)(O)O)N2C=CC(=O)NC2=O,,,,,,
4817,124818,CID 124818,C1C(=NC2=C(N1)NC(=NC2=O)N)[C@@H]([C@@H](COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O,,,,,,
4818,124819,"(2R,5S,6S)-2,6-dihydroxy-3-(hydroxymethyl)-5-(4-nitroanilino)cyclohex-3-en-1-one",C1=CC(=CC=C1N[C@H]2C=C([C@H](C(=O)[C@H]2O)O)CO)[N+](=O)[O-],,,,,,
4819,124820,"(5r)-5-Hydroxy-4-{2-[(2r,4ar,8ar)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}furan-2(5h)-one",C[C@@H]1CC[C@@]2([C@@H](C1(C)CCC3=CC(=O)O[C@H]3O)CCC=C2C)C,,,,,,
4820,124821,N-(2-Hydroxyethyl)-N-(formylmethyl)nitrosamine,C(CO)N(CC=O)N=O,,,,,,
4821,124822,Copper(2+) bis[2-amino-3-(1H-imidazol-5-yl)propanoate],C1=C(NC=N1)CC(C(=O)[O-])N.C1=C(NC=N1)CC(C(=O)[O-])N.[Cu+2],,,,,,
4822,124823,Heptulose-2-Phosphate,C[C@]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)OP(=O)(O)O,,,,,,
4823,124824,CID 124824,CCCCC[C@@H](C=C[C@H]1C=CC(=O)C1=CCCCCCC(=O)OC)O,,,,,,
4824,124825,"9-(3-Diethylaminopropyloxy)-3H-naphtho(2,1-b)pyran-3-one",CCN(CC)CCCOC1=CC2=C(C=C1)C=CC3=C2C=CC(=O)O3.Cl,,,,,,
4825,124826,9-[3-(Diethylamino)propoxy]benzo[f]chromen-3-one,CCN(CC)CCCOC1=CC2=C(C=C1)C=CC3=C2C=CC(=O)O3,,,,,,
4826,124827,"6-[3-Hydroxy-5-(2-methylbutanoyloxy)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,6-dimethylocta-2,7-dienoic acid",CCC(C)C(=O)OC1COC(C(C1OC2C(C(C(C(O2)CO)O)O)O)O)OC(C)(CCC=C(C)C(=O)O)C=C,,,,,,
4827,124828,CID 124828,CC(=CCC[C@@](C)(C=C)O[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)C(=O)O,,,,,,
4828,124829,"2-amino-9-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpurin-6-one",CN1C2=C(C(=O)N=C1N)N=CN2C3C[C@@H]([C@H](O3)CO)O,,,,,,
4829,124830,"1,2-Chrysenediol, 12-fluoro-1,2-dihydro-5-methyl-, trans-",CC1=CC2=CC=CC=C2C3=CC(=C4[C@H]([C@@H](C=CC4=C13)O)O)F,,,,,,
4830,124831,"1,2-Chrysenediol, 6-fluoro-1,2-dihydro-11-methyl-, trans-",CC1=CC2=C(C=C[C@H]([C@@H]2O)O)C3=C1C4=CC=CC=C4C(=C3)F,,,,,,
4831,124832,1-(2-{2-[Bis(2-chloroethyl)amino]ethoxy}-5-nitrophenyl)butan-1-one,CCCC(=O)C1=C(C=CC(=C1)[N+](=O)[O-])OCCN(CCCl)CCCl,,,,,,
4832,124833,"N,N-Bis(2-(2-butanoyl)-4-nitrophenoxyethyl)-N-(2-chloroethyl)amine",CCCC(=O)C1=C(C=CC(=C1)[N+](=O)[O-])OCCN(CCOC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)CCC)CCCl,,,,,,
4833,124834,1-Aminobenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)N)C=C3,,,,,,
4834,124835,1-O-Myristoyl-2-acetyl-glycerol,CCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)C,,,,,,
4835,124836,beta-Chloroalanyl-beta-chloroalanyl-beta-chloroalanine,C([C@H](C(=O)N[C@@H](CCl)C(=O)N[C@@H](CCl)C(=O)O)N)Cl,,,,,,
4836,124837,1-[2-[6-(Carbamoylamino)hexylamino]-2-oxoethyl]pyridin-1-ium-3-carboxamide,C1=CC(=C[N+](=C1)CC(=O)NCCCCCCNC(=O)N)C(=O)N,,,,,,
4837,124838,CID 124838,C[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N,,,,,,
4838,124839,6-(1-Hydroxyethyl)-2-(1-acetimidoylpyrrolidin-3-ylthio)-1-methyl-1-carbapen-2-em-3-carboxylic acid,C[C@H]1[C@@H]2[C@@H](C(=O)N2C(=C1SC3CCN(C3)C(=N)C)C(=O)O)[C@@H](C)O,,,,,,
4839,124840,17-Hmhedo,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1C4CC=C[C@@H]([C@]4(CC3)C)O,,,,,,
4840,124841,CID 124841,CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C5=C(C=C4)OC=N5)C)C,,,,,,
4841,124842,Mpb-PE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)CCCC1=CC=C(C=C1)N2C(=O)C=CC2=O)OC(=O)CCCCCCCCCCCCC,,,,,,
4842,124843,"7-(1,3-Thiazolidin-2-ylmethyl)theophylline",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3NCCS3,,,,,,
4843,124844,"N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine",CCC(CC1=CC2=C(C=C1)OCO2)NC,,,,,,
4844,124845,6-[2-(1H-imidazol-5-yl)ethylamino]-N-(4-methylphenyl)heptanamide,CC1=CC=C(C=C1)NC(=O)CCCCC(C)NCCC2=CN=CN2,,,,,,
4845,124846,Htfmt,CC(CCCCC(=O)NC1=CC=C(C=C1)C(F)(F)F)NCCC2=CN=CN2,,,,,,
4846,124847,Thioridazine N-oxide,C[N+]1(CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC)[O-],,,,,,
4847,124848,Tagppl,CCC(C)C(C(=O)O)SCC(CC1=CC=CC=C1)NC(=O)CNC(=O)C(C)NC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
4848,124849,"13,18-Dehydro-6alpha-senecioyloxychaparrin",CC1=C[C@@H]([C@H]([C@]2([C@H]1[C@H]([C@@H]3[C@]45[C@@H]2[C@]([C@@H](C(=C)[C@@H]4CC(=O)O3)O)(OC5)O)OC(=O)C=C(C)C)C)O)O,,,,,,
4849,124850,CID 124850,CC1=NN(C(=O)C1=CC2=CC=C(C=C2)O)C(=O)C3=CC=NC=C3,,,,,,
4850,124851,"1-[3-(2,5-Dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid",C1C(C(=O)N(C1=O)OC(=O)C2=CC(=CC=C2)N3C(=O)C=CC3=O)S(=O)(=O)O,,,,,,
4851,124852,12-Dehydro-6alpha-senecioyloxychaparrin,C[C@@H]1[C@@H]2CC(=O)O[C@H]3[C@@]24CO[C@]([C@@H]4[C@@]5([C@@H]([C@H]3OC(=O)C=C(C)C)C(=C[C@@H]([C@H]5O)O)C)C)(C1=O)O,,,,,,
4852,124853,"6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[4-hydroxy-3-(2-hydroxyethylamino)-5-methyloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1COC(C(C1O)NCCO)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O,,,,,,
4853,124854,Imidazolium-bis(imidazole)tetrachlororuthenate(III),C1=CN=CN1.C1=CN=CN1.C1=CN=CN1.[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3],,,,,,
4854,124855,4-(2-Oxo-3-(1H-tetrazol-5-yl)-2H-chromen-8-yloxy)butyric acid,C1=CC2=C(C(=C1)OCCCC(=O)O)OC(=O)C(=C2)C3=NNN=N3,,,,,,
4855,124856,Dopamine-4-phosphate ester,C1=CC(=C(C=C1CCN)O)OP(=O)(O)O,,,,,,
4856,124857,Dopamine-3-phosphate ester,C1=CC(=C(C=C1CCN)OP(=O)(O)O)O,,,,,,
4857,124858,Tclgpl,CCC(C)[C@H]1C(=O)NCCCCC(C(=O)NCC(=O)N[C@H](CS1)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,,,,
4858,124859,CID 124859,C1=NC2=C(N1C3[C@H]([C@@H]([C@H](O3)CO)O)F)NC(=NC2=O)N,,,,,,
4859,124860,"2-Benzamido-4-cyano-1-oxo-1H,5H-pyrido(1,2-a)benzimidazole",C1=CC=C(C=C1)C(=O)NC2=CC(=C3N(C2=O)C4=CC=CC=C4S3)C#N,,,,,,
4860,124861,5-Isothiocyanatoalrestatin,C1=CC2=CC(=CC3=C2C(=C1)C(=O)N(C3=O)CC(=O)O)N=C=S,,,,,,
4861,124862,N-Formyl-1-aminopyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)NC=O,,,,,,
4862,124863,"7-O-(2,6-Dideoxy-2-fluorotalopyranose)adriamycinone",C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)F)O)O,,,,,,
4863,124864,3-(Methylthio)catechol,CSC1=CC=CC(=C1O)O,,,,,,
4864,124865,3-Bromopropyl trifluoromethanesulfonate,C(COS(=O)(=O)C(F)(F)F)CBr,,,,,,
4865,124866,"(7S,9S)-9-acetyl-7-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)F)O)O,,,,,,
4866,124867,"N-[(3R,4R,5S,6R)-4,5-dihydroxy-2-hydroxyimino-6-(hydroxymethyl)oxan-3-yl]acetamide",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1=NO)CO)O)O,,,,,,
4867,124868,CID 124868,C[C@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2O)CO)OC3=CC=CC=C3)NC(=O)C)CO,,,,,,
4868,124869,"1,8-Dihydroxy-4-hydroxymethylanthraquinone",C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC(=C3C2=O)CO)O,,,,,,
4869,124870,"6-Methyl-6,11-dihydro-11-((N,N-dimethylamino)acetyl)dibenzo(c,f)-(1,2,5)-thiadiazepine 5,5-dioxide",CN1C2=CC=CC=C2N(C3=CC=CC=C3S1(=O)=O)C(=O)CN(C)C,,,,,,
4870,124871,CID 124871,CC1=CC(=C2C(=CC(=O)C=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)OO)O)O)O)O1)O,,,,,,
4871,124872,Ethyl N-benzyl-N-methyloxamate,CCOC(=O)C(=O)N(C)CC1=CC=CC=C1,,,,,,
4872,124873,CID 124873,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@H]([C@H]([C@@H]5O)O)O)NC6=NC(=O)C7=C(N6)N(C=N7)[C@H]8[C@@H]([C@@H]([C@H](O8)CO)O)O)C=C2,,,,,,
4873,124874,CID 124874,C1=NC2=C(N1[C@H](C=O)O[C@H](CO)C=O)NC(=NC2=O)N,,,,,,
4874,124875,CID 124875,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)OP(=O)(OCC5C([C@H]([C@@H](O5)N6C=NC7=C6NC(=NC7=O)N)O)OP(=O)(O1)O)O,,,,,,
4875,124876,Almurtide,C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)CO[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O,,,,,,
4876,124877,2'-Deoxy-3-methylguanosine,CN1C2=C(C(=O)N=C1N)NCN2[C@@H]3C[C@@H]([C@H](O3)CO)O,,,,,,
4877,124878,CID 124878,CCO[C@H]1[C@]([C@H]([C@@H]([C@H](O1)COC(=O)C=CC2=CC(=C(C=C2)O)O)O)O[C@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)O)O)(C4=CC(=C(C=C4)O)O)O,,,,,,
4878,124879,Schottenol glucoside,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C)C(C)C,,,,,,
4879,124880,3-Butenyl-(3-hydroxypropyl)nitrosamine,C=CCCN(CCCO)N=O,,,,,,
4880,124881,4-Phenylbutyl isothiocyanate,C1=CC=C(C=C1)CCCCN=C=S,,,,,,
4881,124882,2-(3-(Diallylamino)propionyl)benzothiophene,C=CCN(CCC(=O)C1=CC2=CC=CC=C2S1)CC=C,,,,,,
4882,124883,CID 124883,CO[C@@H]1[C@H](OC([C@@H]1O)N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
4883,124884,CID 124884,C1=CC(=CC=C1NN=C(N)N)NN=C(N)S,,,,,,
4884,124885,"(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;7-[(1R,2S)-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopent-3-en-1-yl]heptanoic acid",CCCCC[C@@H](C=C[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O)O.C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,,,,,,
4885,124886,Glutathione,C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,"['For nutritional supplementation, also for treating dietary shortage or imbalance']",,,"['Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.']",,
4886,124887,N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride,C1=CC2=C(C=CC=C2Cl)C(=C1)S(=O)(=O)NCCCCCCN.Cl,,,,,,
4887,124888,"N-(1-(Hydroxymethyl)-2-(((methylsulfinyl)methyl)sulfinyl)ethyl)-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-2-propenamide",CC1=C(C(=O)NC(=O)N1)C=CC(=O)NC(CO)CS(=O)CS(=O)C,,,,,,
4888,124889,CID 124889,CN1CC[C@]23[C@@H]4[C@@H](CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O)F,,,,,,
4889,124890,Bromide mucin fragment,CC(=O)N[C@H]1[C@@H](O[C@@H]([C@H](C1O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)COC(=O)C)O[C@@H]3[C@@H]([C@@H](O[C@H]([C@H]3OC(=O)C)Br)COC(=O)C)OC(=O)C,,,,,,
4890,124891,6-O-Stearoyl-N-acetylmuramyl-alpha-aminobutyryl-isoglutamine,CCCCCCCCCCCCCCCCCC(=O)OCC(C(C(C(C=O)NC(=O)C)OC(C)C(=O)NC(CC)C(=O)NC(CCC(=O)O)C(=O)N)O)O,,,,,,
4891,124892,"3,4-Diisovaleryl adrenalone",CCC(C)C(=O)OC1=C(C=C(C=C1)C(=O)CNC)OC(=O)C(C)CC,,,,,,
4892,124893,Tapadmg,CC(=O)N[C@@H]1[C@H](C([C@H](O[C@H]1OC2=CC=C(C=C2)NC(=O)C(F)(F)F)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
4893,124894,CID 124894,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)OC)O2)O)O,,,,,,
4894,124895,"1,2-Dipalmitoyl-3-acetyl-sn-glycerol",CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)C)OC(=O)CCCCCCCCCCCCCCC,,,,,,
4895,124896,Phosphocyclocreatine,C1CN(C(=N)N1CC(=O)O)P(=O)(O)O,,,,,,
4896,124897,Hydrazinosuccinate,C(C(C(=O)O)NN)C(=O)O,,,,,,
4897,124898,2-Hydroxyethyl 12-hydroxyoctadecanoate,CCCCCCC(CCCCCCCCCCC(=O)OCCO)O,,,,,,
4898,124899,Tyrosylarginine methyl ester,COC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
4899,124900,Ethyltyrosylarginine methyl ester,CCOC1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)OC)N,,,,,,
4900,124901,Linear benzo-ATP,C1=C2C(=CC3=C1N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=CN=C2N,,,,,,
4901,124902,Linear-benzoadenosine diphosphate,C1=C2C(=CC3=C1N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)O)O)O)N=CN=C2N,,,,,,
4902,124903,N-Acetylgalactosaminyl-(1-4)-glucose,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)O,,,,,,
4903,124904,"{4-[(1e)-3,3-Dimethyltriaz-1-en-1-yl]phenyl}acetic acid",CN(C)N=NC1=CC=C(C=C1)CC(=O)O,,,,,,
4904,124905,Depogen,CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OCC)OCC)OCC.CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O,,,,,,
4905,124906,CID 124906,CCCCC(C)(C)[C@@H](C=C[C@H]1C=CC(=O)[C@@H]1CC=CCCCC(=O)OC)O,,,,,,
4906,124907,"(2S,5R,6R)-6-[[(2R)-2-[[(2-chloro-3,4-dihydroxybenzoyl)-(3-hydroxypropyl)carbamoyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N(CCCO)C(=O)C4=C(C(=C(C=C4)O)O)Cl)C(=O)O)C,,,,,,
4907,124908,Bredinin 5'-monophosphate,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O)C(=O)N,,,,,,
4908,124909,"(2s,5r,6r)-6-{[(2r)-2-{[(2,5-Dichloro-3,4-dihydroxybenzoyl)(3-hydroxypropyl)carbamoyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N(CCCO)C(=O)C4=CC(=C(C(=C4Cl)O)O)Cl)C(=O)O)C,,,,,,
4909,124910,"Card-20(22)-enolide, 3-((3-O-(9-anthracenylcarbonyl)-6-deoxy-alpha-L-mannopyranosyl)oxy)-1,5,11,14,19-pentahydroxy-, (1beta,3beta,5beta,11alpha)-",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)C5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)OC(=O)C7=C8C=CC=CC8=CC9=CC=CC=C97)O,,,,,,
4910,124911,Cbz-cck (27-32)-NH2,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)OS(=O)(=O)O)NC(=O)OCC4=CC=CC=C4,,,,,,
4911,124912,Disuccinimidyl tartarate,C1CC(=O)N(C1=O)OC(=O)[C@@H]([C@H](C(=O)ON2C(=O)CCC2=O)O)O,,,,,,
4912,124913,3-Amino-2-hydroxy-4-phenylbutanoic acid,C1=CC=C(C=C1)CC(C(C(=O)O)O)N,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)']",,,
4913,124914,(2-Propylpyridin-4-yl)-sulfinylmethanamine,CCCC1=NC=CC(=C1)C(=S=O)N,,,,,,
4914,124915,Fucosyl-N-acetylglucosaminylasparagine,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)NC(=O)CC(C(=O)O)N)NC(=O)C)O)O)O)O)O,,,,,,
4915,124916,"4-Chloro-11-hydroxy-17-methylandrosta-1,4-dien-3-one",C[C@@H]1CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=C(C(=O)C=C[C@]34C)Cl)O)C,,,,,,
4916,124917,"4-Methyl-N-ethyl pyrrolo(3,2-g)coumarin",CCN1C=CC2=CC3=C(C=C21)OC(=O)C=C3C,,,,,,
4917,124918,"1-(4,4-Dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)ethanone",CC(=O)C1=CC2=C(C=C1)S(=O)(=O)CCC2(C)C,,,,,,
4918,124919,Lacto-N-difucohexose II,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)NC(=O)C)O[C@H]4[C@H]([C@H](O[C@H]([C@@H]4O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O[C@H]5[C@H]([C@@H]([C@@H]([C@@H](O5)C)O)O)O)CO)O)CO)O)O)O,,,,,,
4919,124920,"N,N'-Bis(5-bromo-2-hydroxybenzyl)ethylenediamine diacetic acid",C1=CC(=C(C=C1Br)CN(CCN(CC2=C(C=CC(=C2)Br)O)CC(=O)O)CC(=O)O)O,,,,,,
4920,124921,(4-Isothiocyanatophenyl)arsonic acid,C1=CC(=CC=C1N=C=S)[As](=O)(O)O,,,,,,
4921,124922,"2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-hydroxyacetic acid",C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(C(=O)O)O)O)CCC4=CC(=O)C=C[C@]34C)O,,,,,,
4922,124923,"3-(d-Ribofuranosyl)-3,4-dihydro-9h-imidazo[1,2-a]purin-9-one",C1=CN2C(=O)C3=C(NC2=N1)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
4923,124924,Hexa(methacryloylethylenedioxy)cyclotriphosphazene,CC(=C)C(=O)OCCOP1(=NP(=NP(=N1)(OCCOC(=O)C(=C)C)OCCOC(=O)C(=C)C)(OCCOC(=O)C(=C)C)OCCOC(=O)C(=C)C)OCCOC(=O)C(=C)C,,,,,,
4924,124925,"2'-Deoxy-7,8-dihydro-8-oxoadenosine",C1[C@@H]([C@H](OC1N2C3=NC=NC(=C3NC2=O)N)CO)O,,,,,,
4925,124926,"4-Amino-7,8,9,10-tetrahydro-6h-7,10-epoxyazepino[1,2-e]purine-6,8,9-triol",C1=NC(=C2C(=N1)N3C4C(C(C(O4)C(C3=N2)O)O)O)N,,,,,,
4926,124927,CID 124927,CC(CCl)(C1CC2=C3C(=C(C4=CC=CC=C4N3C)O)C(=O)C=C2O1)O,,,,,,
4927,124928,Thr-dah-pro,C[C@H]([C@@H](C(=O)N[C@H](CC#CCN)C(=O)N1CCC[C@H]1C(=O)O)N)O,,,,,,
4928,124929,"Crotonyloxymethyl-4,5,6-trihydroxycyclohex-2-enone",CC=CC(=O)OCC1=C[C@H]([C@H]([C@H](C1=O)O)O)O,,,,,,
4929,124930,"(betaR)-beta,3-dihydroxy-N-methyl-L-tyrosine",CN[C@@H]([C@@H](C1=CC(=C(C=C1)O)O)O)C(=O)O,,,,,,
4930,124931,"1-O-[(2S,3S)-4-Methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(3-hydroxy-3-methylbutyl)butanedioate",CC(C)(CCC(CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,,,,,,
4931,124932,6-(4-(N-2-Cyanoethyl-N-methylamino)phenylazo)benzothiazole,CN(CCC#N)C1=CC=C(C=C1)N=NC2=CC3=C(C=C2)N=CS3,,,,,,
4932,124933,Progesterone 11-hemisuccinate,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)OC(=O)CCC(=O)O)C,,,,,,
4933,124934,Val-Gly-Val-Ala-Pro-Gly,C[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](C(C)C)N,,,,,,
4934,124935,CID 124935,C1[C@@H]([C@H](OC1N2CNC3=C2NC(=NC3=O)NC4C(C(C(C5=C4C6=C7C(=C5)C=CC8=C7C(=CC=C8)C=C6)O)O)O)CO)O,,,,,,
4935,124936,6-((p-(Methylamino)phenyl)azo)benzothiazole,CNC1=CC=C(C=C1)N=NC2=CC3=C(C=C2)N=CS3,,,,,,
4936,124937,"1-Nitroso-5,6-dihydrothymine",CC1CN(C(=O)NC1=O)N=O,,,,,,
4937,124938,"3-[(1E,3E,5E,7E)-9-hydroxy-3,7-dimethyl-nona-1,3,5,7-tetraenyl]-2,4,4-trimethyl-cyclohex-2-en-1-one",CC1=C(C(CCC1=O)(C)C)C=CC(=CC=CC(=CCO)C)C,,,,,,
4938,124939,"1-({3-[2-(Trifluoromethyl)-10h-phenothiazin-10-yl]propanoyl}oxy)pyrrolidine-2,5-dione",C1CC(=O)N(C1=O)OC(=O)CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,,,,,,
4939,124940,"Methyl 2-ethyl-4-(hexopyranosyloxy)-2,5,7,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate",CCC1(CC(C2=C(C1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)OC5C(C(C(C(O5)CO)O)O)O)O,,,,,,
4940,124941,"2-[2-[7a-methyl-1-(6-methylheptan-2-yl)-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-hydroxycyclohexan-1-one",CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=O)O)C,,,,,,
4941,124942,N-Mesitylenesulfonyltryptophan,CC1=CC(=C(C(=C1)C)S(=O)(=O)N2C=C(C3=CC=CC=C32)C[C@@H](C(=O)O)N)C,,,,,,
4942,124943,CID 124943,CC1(C=CC2=C(O1)C(=C3C(=CC(=C(O3)O)C(C)(C)C=C)C2=O)C(C)(C)C=C)C,,,,,,
4943,124944,"3-[(2S)-18-(2-carboxyethyl)-3,3,7,12,17-pentamethyl-22,23-dihydro-2H-porphyrin-2-yl]propanoic acid",CC1=CC2=CC3=C(C=C(N3)C=C4C(=C(C(=N4)C=C5[C@H](C(C(=N5)C=C1N2)(C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
4944,124945,"(4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,17R)-3-azido-7,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-N-[2-(2-iodo-1H-imidazol-5-yl)ethyl]pentanamide",C[C@H](CCC(=O)NCCC1=CN=C(N1)I)[C@H]2CCC3[C@@]2([C@H](C[C@H]4[C@H]3[C@@H](C[C@H]5[C@@]4(CC[C@@H](C5)N=[N+]=[N-])C)O)O)C,,,,,,
4945,124946,Estromustine,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,,,,,,
4946,124947,"2,7-Dinitro-5,10-dioxo-4,9-dioxapyrene",C1=C(C=C2C3=C1C(=O)OC4=CC(=CC(=C43)C(=O)O2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4947,124948,CID 124948,CC=C(C)C(=O)O[C@H]1[C@@H](C(C[C@@H]2[C@]1([C@@H]([C@@H]([C@@]3(C2=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C)O)O)CO)(C)C)OC(=O)C(=CC)C,,,,,,
4948,124949,"1-[3-(3,7-Dimethylocta-2,6-dienyl)-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one",CC(=CCCC(=CCC1=C(C=CC(=C1O)C(=O)C=CC2=CC=C(C=C2)O)O)C)C,,,,,,
4949,124950,7-Acetyl Paclitaxel,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OC(=O)C)C)OC(=O)C,,,,,,
4950,124951,2'-Acetyltaxol,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)OC(=O)C)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,,,,,,
4951,124952,"Benzenebutanamide, N-(4-(aminoiminomethyl)phenyl)-alpha-(((4-methylphenyl)sulfonyl)amino)-",CC1=CC=C(C=C1)S(=O)(=O)NC(CCC2=CC=CC=C2)C(=O)NC3=CC=C(C=C3)C(=N)N,,,,,,
4952,124953,CID 124953,CC1=C(C(CCC1)(C)C)C=CC(=C2CCC(C=C2)CC=O)C,,,,,,
4953,124954,CID 124954,C([C@@H]([C@@H]1C(=O)C(=C(O1)O)O)O)Cl,,,,,,
4954,124955,CID 124955,C=C1NC(=O)C(CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)N=[N+]=[N-])O)CCC(=O)O,,,,,,
4955,124956,"1,3-Bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione",C1CC(OC1)N2C=C(C(=O)N(C2=O)C3CCCO3)F,,,,,,
4956,124957,"Benzo(5,6)phenanthro(1,2-b)oxirene, 1a,11a-dihydro-",C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C3)C5C(O5)C=C4,,,,,,
4957,124958,"1,1,2-Triphenylbut-1-ene",CCC(=C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4958,124959,CID 124959,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=C(C5=C(C=C24)OCO5)O)O,,,,,,
4959,124960,Naphterpin,CC1=C[C@@H]2[C@H](CC1)C(OC3=C2C(=O)C4=CC(=C(C(=C4C3=O)O)C)O)(C)C,,,,,,
4960,124961,Tevcv,CCOC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@H]4C(=O)NC(CCCNC(=O)N)C(=O)NCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5,,,,,,
4961,124962,Dnp-Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4962,124963,2-Methyl-2-(4-methylpent-3-enyl)-2H-chromen-6-ol,CC(=CCCC1(C=CC2=C(O1)C=CC(=C2)O)C)C,,,,,,
4963,124964,Methyl 3-[(diethoxyphosphorothioyl)oxy]but-2-enoate,CCOP(=S)(OCC)OC(=CC(=O)OC)C,,,,,,
4964,124965,"7,14-Dimethyldibenz(a,j)anthracene",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1C=CC5=CC=CC=C54)C,,,,,,
4965,124966,Dioscoretine,C[C@H](CC(=O)O)CC1(C[C@H]2CC[C@@H]1CN2C)O,,,,,,
4966,124967,"5H-(2)Benzopyrano(3,4-g)(1,4)benzodioxin-5-one",C1=CC=C2C(=C1)C3=CC4=C(C=C3OC2=O)OC=CO4,,,,,,
4967,124968,"2-(2,3-Naphthalimino)ethyl trifluoromethanesulfonate",C1=CC=C2C=C3C(=CC2=C1)C(=O)N(C3=O)CCOS(=O)(=O)C(F)(F)F,,,,,,
4968,124969,"1,1,1-Trifluoro-3-acetamido-4-phenyl butan-2-one(n-acetyl-l-phenylalanyl trifluoromethyl ketone)",CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)C(F)(F)F,,,,,,
4969,124970,Ribavirin 5'-diphosphate,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O)C(=O)N,,,,,,
4970,124971,Dithyreanitrile,COC1=CC=CC2=C1NC=C2C(C#N)(SC)SC,,,,,,
4971,124972,"Tuftsin, lys(4)-",C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N)O,,,,,,
4972,124973,CID 124973,C1CC1N2CC(C(=O)C3=CC(=C(C=C32)SCCN)F)C(=O)O,,,,,,
4973,124974,4-[2-(Acetyloxy)ethyl]-4-methylmorpholin-4-ium iodide,CC(=O)OCC[N+]1(CCOCC1)C.[I-],,,,,,
4974,124975,Acetic acid 2-(4-methylmorpholinium-4-yl)ethyl ester,CC(=O)OCC[N+]1(CCOCC1)C,,,,,,
4975,124976,"2-Propenoic acid, 2-methyl-, 4-(1,1-dimethylethyl)-2-hydroxycyclohexyl ester",CC(=C)C(=O)OC1CCC(CC1O)C(C)(C)C,,,,,,
4976,124977,"3-Ethenyl-11-(1-methylpyrrolidin-2-yl)-2-[(2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl)methyl]-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-10-ol",CN1CCCC1C2=C(C=CC3=C2NC4=C3CCN5C4CC(C(C5)C=C)CC6C7=C(CCN6C)C8=CC=CC=C8N7)O,,,,,,
4977,124978,Diprofos,CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC.C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
4978,124979,"2-[2-Nitro-4-[3-nitro-4-[(2,2,5,5-tetramethyl-1-oxidopyrrolidin-3-yl)amino]phenyl]sulfonylanilino]pentanedioic acid",CC1(CC(C(N1[O-])(C)C)NC2=C(C=C(C=C2)S(=O)(=O)C3=CC(=C(C=C3)NC(CCC(=O)O)C(=O)O)[N+](=O)[O-])[N+](=O)[O-])C,,,,,,
4979,124980,1-Benzyl-4-ethenylpyridinium bromide,C=CC1=CC=[N+](C=C1)CC2=CC=CC=C2.[Br-],,,,,,
4980,124981,1-Benzyl-4-vinylpyridinium,C=CC1=CC=[N+](C=C1)CC2=CC=CC=C2,,,,,,
4981,124982,"[[5-[2,4-Dioxo-5-[3-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]prop-1-enyl]pyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1C(C(OC1N2C=C(C(=O)NC2=O)C=CCNC(=O)CCCCC3C4C(CS3)NC(=O)N4)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
4982,124983,CID 124983,C[C@H](C(=O)NC(C)C(=O)N[C@@H](CCCCN)C(=O)NC1=CC2=CC=CC=C2C(=C1)OC)NC(=O)OCC3=CC=CC=C3,,,,,,
4983,124984,Hypothiocyanite ion,C(#N)S[O-],,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
4984,124985,Hypothiocyanite,C(#N)SO,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
4985,124986,Versicolorin A hemiacetal,C1C2C(OC1O)OC3=C2C(=C4C(=C3)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)O,,,,,,
4986,124987,1-Propargyl-5-chloropyrimidin-2-one,C#CCN1C=C(C=NC1=O)Cl,,,,,,
4987,124988,1-Propargyl-5-bromopyrimidin-2-one,C#CCN1C=C(C=NC1=O)Br,,,,,,
4988,124989,Ara-cdp-dipalmitin,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O)OC(=O)CCCCCCCCCCCCCCC,,,,,,
4989,124990,"3,5-Dichlorobenzidine",C1=CC(=CC=C1C2=CC(=C(C(=C2)Cl)N)Cl)N,,,,,,
4990,124991,"3,3',5-Trichlorobenzidine",C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)N)Cl)Cl)N,,,,,,
4991,124992,N-(Phosphonoacetyl)-L-ornithine,C(C[C@@H](C(=O)O)N)CNC(=O)CP(=O)(O)O,,,,,,
4992,124993,"2,4-Dihydroxybenzylamine",C1=CC(=C(C=C1O)O)CN,,,,,,
4993,124994,(211At)Audr,C1[C@@H]([C@H](OC1N2C=C(C(=O)NC2=O)[At])CO)O,,,,,,
4994,124995,Acetoxymethylbenzylnitrosamine,CC(=O)OCN(CC1=CC=CC=C1)N=O,,,,,,
4995,124996,"(7,9-Dihydroxy-10-methyl-3,6-dimethylidene-2-oxo-4,5,7,8,9,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl) 2-methylbut-2-enoate",CC=C(C)C(=O)OC1CC(=C)C(CC(C(=CC2C1C(=C)C(=O)O2)C)O)O,,,,,,
4996,124997,H-D-Val-Leu-Lys-pNA,CCC(C)C(C(=O)N[C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)[C@@H](C(C)C)N,,,,,,
4997,124998,4-(4'-Chlorobenzyloxy)benzyl nicotinate,C1=CC(=CN=C1)C(=O)OCC2=CC=C(C=C2)OCC3=CC=C(C=C3)Cl,,,,,,
4998,124999,6-O-Methyl guanosine-5'-monophosphate,COC1=NC(=NC2=C1N=CN2[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)O)O)N,,,,,,
4999,125000,"2,16-Dipiperidinoandrostane-3,17-diol dipivalate",C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2OC(=O)C(C)(C)C)N4CCCCC4)CC[C@@H]5[C@@]3(C[C@@H]([C@H](C5)OC(=O)C(C)(C)C)N6CCCCC6)C,,,,,,
5000,125001,10-Desacetylbaccatin III,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)O,,,,,,
5001,125002,"3,7-Dihydroxy-22,23-methylene-cholan-24-oic acid (2-sulfoethyl)amide",CC([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C)C5CC5C(=O)NCCS(=O)(=O)O,,,,,,
5002,125003,"(2S,5R)-6-(Methoxymethylidene)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)C(=COC)C2=O)C(=O)O)C,,,,,,
5003,125004,"1D-myo-inositol 4,5-bisphosphate",[C@H]1([C@@H]([C@@H]([C@H]([C@@H]([C@H]1O)OP(=O)(O)O)OP(=O)(O)O)O)O)O,,,,,,
5004,125005,Dimethyl 3-hydroxydecanedioate,COC(=O)CCCCCCC(CC(=O)OC)O,,,,,,
5005,125006,Cpm-dea,CCN(CC)C1=CC2=C(C=C1)C(=C(C(=O)O2)N3C(=O)C=CC3=O)C,,,,,,
5006,125007,Glcnac branched hexasaccharide,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2[C@H]([C@@H](OC([C@@H]2O)CO[C@H]3[C@@H]([C@H](C([C@H](O3)CO)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)NC(=O)C)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)NC(=O)C)O)O)CO)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)O,,,,,,
5007,125008,4-Bromophenacyl triflate,C1=CC(=CC=C1C(=O)COS(=O)(=O)C(F)(F)F)Br,,,,,,
5008,125009,"6-((Bis(2-chloroethyl)amino)methyl)-2,4-pteridinediamine",C1=C(N=C2C(=NC(=NC2=N1)N)N)CN(CCCl)CCCl,,,,,,
5009,125010,"Arabinose 1,5-diphosphate",C([C@@H]1[C@H]([C@@H]([C@@H](O1)OP(=O)(O)O)O)O)OP(=O)(O)O,,,,,,
5010,125011,Mmucpp,COC1O[C@@H]2[C@H](OC([C@@H]2O1)N3C=CC(=O)NC3=O)COP(=O)(O)OC4=CC=C(C=C4)Cl,,,,,,
5011,125012,"N-[(1S,3aS,3bR,10aR,10bS,12aS)-10a,12a-dimethyl-7-oxo-2,3,3a,3b,4,5,8,9,10,10b,11,12-dodecahydro-1H-indeno[4,5-i][3]benzazepin-1-yl]acetamide",CC(=O)N[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)NCC[C@]34C)C,,,,,,
5012,125013,"11,18:18,21-Diepoxypregn-4-ene-3,20-dione",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@@H]4CC56[C@H]3CC[C@@H]5C(=O)COC6O4,,,,,,
5013,125014,5-Mercapto-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)S)C(=O)N,,,,,,
5014,125015,Gvapspat amide,CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N)NC(=O)[C@@H]5CCC(=O)N5,,,,,,
5015,125016,"17-(3'-Hydroxypropyl)-1,3,5,6,8(9)-estrapentaene-3,17-diol",C[C@]12CCC3=C([C@@H]1CC[C@]2(CCCO)O)C=CC4=C3C=CC(=C4)O,,,,,,
5016,125017,Desvenlafaxine,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,['Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.'],"['Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H<sub>1</sub>-histaminergic, or &alpha;<sub>1</sub>-adrenergic receptors <i>in vitro</i>. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, <i>in vitro</i>. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose.']","['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)']","['Oral bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.', 'Desvenlafaxine is mainly excreted in the urine. 45% of the dose is unchanged in the urine, 19% is excreted as a glucuronide metabolite, and <5% is excreted as N,O-didesmethylvenlafaxine. No dosage adjustment is necessary for gender, ethnicity, food, or combination with other psychotropics.', '3.4L/kg.', 'The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.', 'The absolute oral bioavailability of Pristiq after oral administration is about 80%. Mean time to peak plasma concentrations (Tmax) is about 7.5 hours after oral administration.', 'Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and < 5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine', 'Desvenlafaxine is excreted into human milk.', 'For more Absorption, Distribution and Excretion (Complete) data for Desvenlafaxine (6 total), please visit the HSDB record page.']","['Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.', 'Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 is the cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine. The CYP2D6 metabolic pathway is not involved, and after administration of 100 mg, the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype. ...  Approximately 19% of the administered dose is excreted as the glucuronide metabolite and < 5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine']","['The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.', 'The mean half life changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively.', 'The mean terminal half-life, is approximately 11 hours.']"
5017,125018,Badgfg,CC1C(C(C(C(O1)OC2C(C(OC(C2O)COC3C(C(C(C(O3)CO)O)O)NC(=O)C)CC4=CC=CC=C4)NC(=O)C)O)O)O,,,,,,
5018,125019,4-Iabsc,CC1C(C(CC(O1)OC2CCCC3(C2(C4CCC5(C(CCC5(C4CC3)O)C6=CC(=O)OC6)C)C=O)O)OC)OS(=O)(=O)C7=CC(=C(C=C7)N=[N+]=[N-])I,,,,,,
5019,125020,Med-fgal-gal,CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)F)O)O)O)O,,,,,,
5020,125021,Gltptpat amide,CCC(C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCCC2C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N)NC(=O)C5CCC(=O)N5,,,,,,
5021,125022,CID 125022,CC1=CC=[N+](C2=CC=CC=C12)CC(=NO)C3=CC=CC=C3.[Cl-],,,,,,
5022,125023,N-[2-(4-methylquinolin-1-ium-1-yl)-1-phenylethylidene]hydroxylamine,CC1=CC=[N+](C2=CC=CC=C12)CC(=NO)C3=CC=CC=C3,,,,,,
5023,125024,CID 125024,CC1=CC2=C(C=C1)[N+](=CC=C2)CC(=NO)C3=CC=CC=C3.[Cl-],,,,,,
5024,125025,N-[2-(6-methylquinolin-1-ium-1-yl)-1-phenylethylidene]hydroxylamine,CC1=CC2=C(C=C1)[N+](=CC=C2)CC(=NO)C3=CC=CC=C3,,,,,,
5025,125026,Dansyl-12-O-tetradecanoyl phorbol 13-acetate,CCCCCCCCCCCC(CC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)C)O)C)NS(=O)(=O)C5=CC=CC6=C5C=CC=C6N(C)C,,,,,,
5026,125027,CID 125027,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)C)C,,,,,,
5027,125028,N-Acetylphenylalanyl-adenosine monophosphate-anhydride,CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OP(=O)(O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
5028,125029,"3-(2-(2-Thienyl)ethyl)-2,4-oxazolidenedione",C1C(=O)N(C(=O)O1)CCC2=CC=CS2,,,,,,
5029,125030,Galactopyranosyl(1-4)acetylglucosaminyl(1-3)acetylgalactosamine,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]([C@H]([C@@H](CO)O)O)C(C=O)NC(=O)C)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O,,,,,,
5030,125031,Btfap,CC(CCCNC(=O)C(F)(F)F)NC1=CC(=C(C2=C1N=CC=C2)C(=O)C(F)(F)F)OC,,,,,,
5031,125032,CID 125032,C[C@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](C(C)C)N,,,,,,
5032,125033,2-Bromo-1-decanal,CCCCCCCCC(C=O)Br,,,,,,
5033,125034,PDCoA,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCC4=C5C=CC6=CC=CC7=C6C5=C(C=C7)C=C4)O,,,,,,
5034,125035,3-(12-Pyren-1-yldodecanoyloxy)-4-(trimethylazaniumyl)butanoate,C[N+](C)(C)CC(CC(=O)[O-])OC(=O)CCCCCCCCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
5035,125036,[3-Carboxy-2-(12-pyren-1-yldodecanoyloxy)propyl]-trimethylazanium,C[N+](C)(C)CC(CC(=O)O)OC(=O)CCCCCCCCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
5036,125037,"5,5-Difluorocamphor",CC1(C2CC(=O)C1(CC2(F)F)C)C,,,,,,
5037,125038,1-[(E)-2-methoxyethenyl]pyrene,COC=CC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
5038,125039,"1-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one",C1[C@@H]([C@H](OC1N2C=C(C=NC2=O)I)CO)O,,,,,,
5039,125040,"Carbamic acid, (2-((dibutylamino)sulfonyl)ethyl)-, 2-methylpropyl ester",CCCCN(CCCC)S(=O)(=O)CCNC(=O)OC(C)CC,,,,,,
5040,125041,"Propanoic acid, 2-((methylsulfonyl)oxy)-, 1-methylethyl ester",CC(C)OC(=O)C(C)OS(=O)(=O)C,,,,,,
5041,125042,"Propanoic acid, 2-oxo-, hydrazide",CC(=O)C(=O)NN,,,,,,
5042,125043,"N-Biotinyl-N'-(iodoacetyl)-1,6-hexanediamine",C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCCCCCNC(=O)CI)NC(=O)N2,,,,,,
5043,125044,Hexa(beta-glucopyranosyl)glucitol,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H](O[C@H]([C@@H]2O)OC[C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)O)O)O)O)O)O,,,,,,
5044,125045,Methyl 5-phenyl-2-propionyl-3-pyrrolecarboxylate,CCC(=O)C1=C(C=C(N1)C2=CC=CC=C2)C(=O)OC,,,,,,
5045,125046,CID 125046,CCC=CCC=CCC=CCCCCCCCC(=O)OCC(COC(=O)CCCN)OC(=O)CCCCCCCC=CCC=CCC=CCC,,,,,,
5046,125047,"2-(Phenylalanylglycyl)amino-3-(4-nitrophenyl)-1,3-propanediol",C1=CC=C(C=C1)C[C@@H](C(=O)NC(=O)CN[C@H](CO)[C@@H](C2=CC=C(C=C2)[N+](=O)[O-])O)N,,,,,,
5047,125048,"(4r,7r,7Ar,9ar)-4-hydroxy-4-(hydroxymethyl)-6,7-dimethyl-3-oxo-1,3,4,7,7a,9a-hexahydropentaleno[1,6a-c]pyran-9-carboxylic acid",C[C@@H]1[C@H]2C=C([C@H]3C2(C=C1C)[C@](C(=O)OC3)(CO)O)C(=O)O,,,,,,
5048,125049,[N'-(4-methoxyphenyl)carbamimidoyl] N-methylmorpholine-4-carboximidothioate;dihydrochloride,CN=C(N1CCOCC1)SC(=NC2=CC=C(C=C2)OC)N.Cl.Cl,,,,,,
5049,125050,[N'-(4-methoxyphenyl)carbamimidoyl] N-methylmorpholine-4-carboximidothioate,CN=C(N1CCOCC1)SC(=NC2=CC=C(C=C2)OC)N,,,,,,
5050,125051,CID 125051,C1C(C(=O)N(C1=O)OC(=O)CCN=C(C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)N[N+]#N)I)[O-])S(=O)(=O)O.[Na+],,,,,,
5051,125052,CID 125052,C1C(C(=O)N(C1=O)OC(=O)CCNC(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)N[N+]#N)I)S(=O)(=O)O,,,,,,
5052,125053,"6,6'-Dicorynomycolyl trehalose",CCCCCCCCCCCCCCCC(C(CCCCCCCCCCCCCC)C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C(CCCCCCCCCCCCCC)C(CCCCCCCCCCCCCCC)O)O)O)O)O)O)O)O,,,,,,
5053,125054,CID 125054,CCC=CCC=CCC=CCCCCCCCC(=O)OCC(COC(=O)CCCN)OC(=O)CCCN,,,,,,
5054,125055,"4,4,4-Trifluoro-2-oxobutyl dihydrogen phosphate",C(C(=O)COP(=O)(O)O)C(F)(F)F,,,,,,
5055,125056,H-Arg-Gly-Asp-Ala-OH,C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N,,,,,,
5056,125057,Poly(rgdt),CC([C@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N)O,,,,,,
5057,125058,Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylate,CN1C2CCC1C(=C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,,,,,,
5058,125059,"4-[(3,5-Dibromo-2-hydroxyphenyl)methoxy]-4-oxobut-2-enoic acid",C1=C(C=C(C(=C1COC(=O)C=CC(=O)O)O)Br)Br,,,,,,
5059,125060,Leuconolam sesquihydrate,CCC12CCCN3C1(C(=CC3=O)C4=CC=CC=C4NC(=O)CC2)O,,,,,,
5060,125061,"[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-[(3-hydroxy-2-tetradecyloctadecanoyl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate",CCCCCCCCCCCCCCCC(C(CCCCCCCCCCCCCC)C(=O)OC[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC2[C@H]([C@H]([C@@H]([C@H](O2)COC(=O)C(CCCCCCCCCCCCCC)C(CCCCCCCCCCCCCCC)O)O)O)O)O)O)O)O,,,,,,
5061,125062,CID 125062,CC1=C2C(=C(C(=C(O2)O)NC(=O)OCC3=CC=CC=C3)O)C=CC1=O,,,,,,
5062,125063,CID 125063,CN1C(=C(NC2=NC=C(C=C2)O)O)C(=O)C3=C(S1(=O)=O)C=CS3,,,,,,
5063,125064,Mu-Glcnacs,CC1=CC(=O)OC2=C1C=CC(=C2)OC3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)O)O)O)NC(=O)C,,,,,,
5064,125065,"n-[(1s,5s,6s)-5-Hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]acetamide",CC(=O)NC1=C[C@@H]([C@H]2[C@@H](C1=O)O2)O,,,,,,
5065,125066,CID 125066,CC1=CC(=O)C2=C(O1)C=C3C(=C(OC(=C3O)C(=O)OC)O)C2=O,,,,,,
5066,125067,Z-Ala-arg-arg-afc,C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC1=CC2=C(C=C1)C(=CC(=O)O2)C(F)(F)F)NC(=O)OCC3=CC=CC=C3,,,,,,
5067,125068,N-2-Methylpropyl-N-1-methylacetonylnitrosamine,CC(C)CN(C(C)C(=O)C)N=O,,,,,,
5068,125069,"(11R,24S)-4,19,30-Trimethoxy-10,25-dimethyl-2-oxa-10,25-diazaheptacyclo[22.7.1.13,7.113,17.118,22.06,11.028,32]pentatriaconta-1(32),3,5,7(35),13(34),14,16,18,20,22(33),28,30-dodecaene-16,31-diol",CN1CCC2=CC3=C(C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC,,,,,,
5069,125070,[2-(4-hydroxyphenyl)-1-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]propanoyl]amino]ethyl]phosphonic acid,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NC(CC2=CC=C(C=C2)O)P(=O)(O)O)NC,,,,,,
5070,125071,CID 125071,CC(=CCCC1(CC(C2=C(C3=C(C(=C2O1)CC=C(C)C)OC45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)O)C)C,,,,,,
5071,125072,Tyrosyl-isoleucyl-phenylalanyl-valine,CC[C@H](C)[C@@H](C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
5072,125073,2-Deoxy-2-formamidogalacturonic acid,C(=O)[C@@H]([C@H]([C@H]([C@@H](C(=O)O)O)O)O)NC=O,,,,,,
5073,125074,"1H-Indole, 3-(2-butyl-5-oxazolyl)-",CCCCC1=NC=C(O1)C2=CNC3=CC=CC=C32,,,,,,
5074,125075,"1H-Indole, 3-(2-propyl-5-oxazolyl)-",CCCC1=NC=C(O1)C2=CNC3=CC=CC=C32,,,,,,
5075,125076,Bcnbdi,C[N+](C)(C)CCOC(=O)CCN(CCC(=O)OCC[N+](C)(C)C)C1=CC=C(C2=NON=C12)[N+](=O)[O-].[Br-].[Br-],,,,,,
5076,125077,"Trimethyl-[2-[3-[(4-nitro-2,1,3-benzoxadiazol-7-yl)-[3-oxo-3-[2-(trimethylazaniumyl)ethoxy]propyl]amino]propanoyloxy]ethyl]azanium",C[N+](C)(C)CCOC(=O)CCN(CCC(=O)OCC[N+](C)(C)C)C1=CC=C(C2=NON=C12)[N+](=O)[O-],,,,,,
5077,125078,Bis(2-hydroxyethyl)ammonium bis(2-hydroxyhexadecyl) phosphate,CCCCCCCCCCCCCCC(COP(=O)(O)OCC(CCCCCCCCCCCCCC)O)O.C(CO)NCCO,,,,,,
5078,125079,Bis(2-hydroxyhexadecyl) hydrogen phosphate,CCCCCCCCCCCCCCC(COP(=O)(O)OCC(CCCCCCCCCCCCCC)O)O,,,,,,
5079,125080,CID 125080,CC1(CCCC23[C@@H]1[C@@H](C4([C@]56[C@H]2[C@H](C[C@H]([C@@H]5O[C@H]3O4)C(=C)C6=O)O)O)O)C,,,,,,
5080,125081,2-Acetamido-2-deoxygalacturonamide,CC(=O)N[C@@H](C=O)[C@H]([C@H]([C@@H](C(=O)N)O)O)O,,,,,,
5081,125082,"N-Methyl-N-(3,7,12-trihydroxy-24-oxocholan-24-yl)glycine",C[C@H](CCC(=O)N(C)CC(=O)O)[C@H]1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
5082,125083,3-(1-(2-Benzoxazolyl)hydrazino)propanenitrile,C1=CC=C2C(=C1)N=C(O2)N(CCC#N)N,,,,,,
5083,125084,"7-[(1R,2R,3R)-2-[(3R)-3,7-dihydroxy-4,4-dimethyloct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid",CC(CCC(C)(C)[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
5084,125085,"3-[2-(4-Aminophenyl)ethyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one",C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCC4=CC=C(C=C4)N)CCCC(=O)C5=CC=C(C=C5)F,,,,,,
5085,125086,CID 125086,CC1=CC=C(C=C1)CNCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC(=CCCC(=CCCC=C(C)CCC=C(C)C)C)C,,,,,,
5086,125087,CID 125087,C1=CC2=C(C=CC=C2N[N+]#N)C(=C1)C(=O)[O-],,,,,,
5087,125088,CID 125088,C1=CC2=C(C=CC=C2N[N+]#N)C(=C1)C(=O)O,,,,,,
5088,125089,2-(4-Hydroxyphenyl)oxirane,C1C(O1)C2=CC=C(C=C2)O,,,,,,
5089,125090,Mgombg,COC1C(C(C(C(O1)CO)OCCCC(OC)OC2C(C(C(C(O2)OC)O)O)O)O)O,,,,,,
5090,125091,Dbhep,C1=CC(=CC(=C1)O)C(C(C2=CC(=CC=C2)O)N)N.[Cl-].[Cl-].[Pt+2],,,,,,
5091,125092,"[1,2-Bis(3-hydroxyphenyl) ethylenediamine]",C1=CC(=CC(=C1)O)C(C(C2=CC(=CC=C2)O)N)N,,,,,,
5092,125093,CID 125093,CCCCC[C@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(O2)C(CCCC(=O)O)[N+](=O)[O-])O)O,,,,,,
5093,125094,2-Methylerythritol,C[C@@](CO)([C@H](CO)O)O,,,,,,
5094,125095,"3,8-Dihydroxy-2-ethoxymethyl-1-methoxyanthraquinone",CCOCC1=C(C=C2C(=C1OC)C(=O)C3=C(C2=O)C=CC=C3O)O,,,,,,
5095,125096,"1,1,1,2,2-Pentafluorohexane",CCCCC(C(F)(F)F)(F)F,,,,,,
5096,125097,"[(8S,9S,10S)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1C2=CC(=C(C(=C2C3=C(C4=C(C=C3C[C@@H]([C@]1(C)O)C)OCO4)OC)OC)OC)OC,,,,,,
5097,125098,Icaridin,CCC(C)OC(=O)N1CCCCC1CCO,"['Icaridin is indicated for use to repel insects, such as mosquitoes, biting flies, ticks, chiggers, and fleas, via topical use or over clothing.']",['Icaridin is a cyclic amine and piperidine compound that is expected to stimulate the sensory hairs on the antennae of insects.'],,"['In a dermal metabolism rat study, dermal application of 20 mg/kg of radio-labeled icaridin resulted in 61-66% of the dose absorbed through the skin. Following topical application of 20 mg/kg on rats, the peak plasma concentrations were measured to be 0.5 g/mL in male rats and 0.8-1.6 g/mL in female rats. In a study of human volunteers, less than 6% of the applied doses were absorbed after topical application of 14.7 or 15.0 mg of technical grade icaridin and covering the application site with a protective wrap for eight hours.', 'Following topical administration on rats at doses of 20 mg/kg, urinary excretion was reported to be the primary route of elimination where 73-88% of the parent compound was recovered in the urine. At doses of 200 mg/kg, 33-40% of the administered dose was excreted in the urine or feces. No data were available on the composition of parent compound and metabolites in the urine of either animals or humans.', 'In a rat study, dermal application of icaridin at doses of either 20 mg/kg or 200 mg/kg resulted in plasma concentrations ranging from 0.5 g/ml for males and 0.8-1.6 g/ml for females in the 20 mg/kg test group, and 4.48 g/ml in male rats and 1.70 g/ml and female rats in the 200 mg/kg test group. Icaridin applied to the arms of human volunteers was not found in blood plasma.', 'There is no available information on the clearance of icaridin.', 'Picaridin and oxybenzone are two active ingredients found in repellent and sunscreen preparations, respectively. We performed a series of in vitro diffusion studies to evaluate the transmembrane permeation of picaridin and oxybenzone across human epidermis and poly(dimethylsiloxane) (PDMS) membrane. Permeation of picaridin (PCR) and oxybenzone (OBZ) across human epidermis was suppressed when both active ingredients were used concurrently; increasing concentration of the test compounds further reduced the permeation percentage of picaridin and oxybenzone. While permeation characteristics were correlative between human epidermis and PDMS membrane, permeability of PDMS membrane was significantly larger than that of human epidermis. The findings were different from concurrent use of repellent DEET and sunscreen oxybenzone in which a synergistic permeation enhancement was observed. Further comparative studies are therefore needed to understand permeation mechanisms and interactions between picaridin and oxybenzone.', 'Increased awareness of skin cancer and mosquito-transmitted diseases has increased use of insect repellents and sunscreens. The challenge in setting recommendations for use and reapplication, especially when used concomitantly, lies in finding the balance between applying a durable product effective in withstanding natural and physical factors such as water, sweat, temperature and abrasion, while limiting percutaneous absorption and decreasing risk of potential dermal and systemic toxicity. Inorganic sunscreens show no or little percutaneous absorption or toxic effects in comparison to organic sunscreens, which show varying levels of dermal penetration and cutaneous adverse effects. An alternative to N,N-diethyl-m-toluamide (DEET), the traditional gold standard compound in insect repellents, picaridin appears as efficacious, has lower risk of toxicity, and when used simultaneously with sunscreen may decrease percutaneous absorption of both compounds. Conversely, combined use of DEET and sunscreen results in significantly higher absorption of both compounds. It is important to increase consumer awareness of ""washing in"" of various compounds leading to increased risk of toxicity, as well as differences in reapplication need due to ""washing off"" caused by water, sweat and abrasion. Although much remains to be studied, to maximize efficacy and decrease toxicity, contemporary research tools, including dermatopharmokinetics, should aid these prospective advances.', 'The skin of 6 male human volunteers/group was exposed to 15.0 or 14.7 mg/person (37 uCi/person) of 14C-KBR 3023 (undiluted) or as a preparation in ethanol (15% (w/w). The subjects were exposed to the test material for 8 hours under a non-occlusive protective wrap. At the end of the treatment period, the treated area was swabbed with isopropyl alcohol and rinsed with the alcohol. The swabs and alcohol were saved for further analysis. Tape stripping in the proximity of the dosing site was performed at 1, 23 and 45 hours post-exposure. Blood samples were drawn at 0, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 120 hours post-application from both the ipsilateral and contralateral arms. Urine was collected prior to dosing and in the following intervals: 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 60, 60 to 72, 72 to 84, 84 to 96, 96 to 108, 108 to 120, and 120 to 128 hours post-application. Feces were collected throughout the 128 hour collection period. Most of the applied dose was recovered in the rinsate and on the swabs, protective covering and duoderm at the end of the exposure period, 94.16% and 95.23% of the test material in ethanol and the undiluted test material, respectively. Radiolabel was recovered in the urine of the test subjects (mean values: 3.76% (range: 2.20 to 7.00%) and 1.66% (range: 0.70 to 2.29%) of the applied dose for the solution and undiluted material, respectively). Ninety three to 94% of the label was recovered in the 1st 24 hours. Recovery of radiolabelled compound from the plasma was negligible. Absorption of the radiolabelled compound through the skin was quite limited under the conditions of the study. The use of a vehicle (ethanol) seemed to enhance its absorption.', '... The skin of a total of 5 rats/sex was treated daily for 2 weeks with 20 mg/kg of unlabeled KBR 3023 technical (purity: 99.1%), followed by exposure to a single dose of 20 mg/kg of the radiolabeled test material for 7 days. /In a second test/ the skin of a total of 5 rats/sex was exposed to a single dose of 200 mg/kg of the radiolabeled test material for 7 days. ... The primary route of excretion was the urine (73 to 88% of the absorbed dose). Pretreatment did not appear to affect the excretion profile. For the 200 mg/kg dermal treatment, the mean percentages of the administered dose which were recovered in the urine and feces ranged between 33 and 40% for the males and females, respectively. The radioactivity recovered in the urine represented 78 and 91% of the total for males and females, respectively.']","['There is limited data on the metabolism and resulting metabolites of the drug; however, it is estimated that icaridin undergoes phase I metabolic reactions involving  2-methylpropyl side chain or the piperidine ring being hydroxylated. It is also noted that the hydroxyethyl sidechain was oxidized to produce a carbonyl group. There was very little Phase 2 metabolism of the icaridin.', 'Analysis of the metabolites revealed that the predominant modifications of the parent compound were phase 1 reactions in which the piperidine ring or the 2-methylpropyl sidechain was hydroxylated or the hydroxyethyl sidechain was oxidized to the carbonyl moiety. Phase 2 conjugation reactions with glucuronide, linoleic or oleic acid constituted a very minor fraction of the recovered metabolites.']","['The first elimination half-lives of icaridin were determined in a study of five male and female rats treated with a single dose of 20 mg/kg icaridin dermally. The half-lives were 35.7 hours for male and 23.9 hours in female rats. In another study of rats treated daily for 2 weeks with 20 mg/kg of unlabeled icaridin, followed by exposure to a single dose of 20 mg/kg of the radiolabeled icaridin for 7 days, the 1st elimination half-lives were 10.9 and 9.1 hours for the males and females, respectively. The 2nd half-lives were 144 and 105 hours, respectively.', 'Five rats/sex were dosed iv in the femoral vein with a single dose of 20 mg/kg of the test material. The test material was prepared in physiological saline. ... The 1st , 2nd and 3rd elimination half-lives were 0.9, 5.2 and 45.5 hours for the males and 0.7, 2.8 and 73.0 hours for the females.', '... The skin of a total of 5 rats/sex was exposed to a single dose of 20 mg/kg of the radiolabeled test material for 7 days. ... Only 1st elimination half-lives were determined for the low dose dermal studies. These half-lives were 35.7 ... hours for the males and 23.9 ... hours for the females.', '... The skin of a total of 5 rats/sex was treated daily for 2 weeks with 20 mg/kg of unlabeled KBR 3023 technical (purity: 99.1%), followed by exposure to a single dose of 20 mg/kg of the radiolabeled test material for 7 days.  ... For the high dose dermal treatments, the 1st elimination half-lives were 10.9 and 9.1 hours for the males and females, respectively. The 2nd half-lives were 144 and 105 hours, respectively.']"
5098,125099,Fletooh,CCN1C2=C(C=C(C=C2)C)N(C3=NC(=O)N(C(=O)C31OO)C)C,,,,,,
5099,125100,6-Hydroxydihydrodaidzein,C1C(C(=O)C2=CC(=C(C=C2O1)O)O)C3=CC=C(C=C3)O,,,,,,
5100,125101,"6,7,4'-Trihydroxyisoflavan",C1C(COC2=CC(=C(C=C21)O)O)C3=CC=C(C=C3)O,,,,,,
5101,125102,S-(Acetonyl)glutathione,CC(=O)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
5102,125103,"1,4-Bis(4-aminophenoxy)-2-phenylbenzene",C1=CC=C(C=C1)C2=C(C=CC(=C2)OC3=CC=C(C=C3)N)OC4=CC=C(C=C4)N,,,,,,
5103,125104,"L-Alaninamide, L-lysyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-",CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)N,,,,,,
5104,125105,"Phosphatidylinositol 4,5-diphosphate",C(C(COP(=O)(O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H]([C@H]1O)OP(=O)(O)O)OP(=O)(O)O)O)O)O)O,,,,,,
5105,125106,"9-hydroxy-3,8a-dimethyl-5-methylidene-4a,6,7,8,9,9a-hexahydro-4H-benzo[f][1]benzofuran-2-one",CC1=C2CC3C(=C)CCCC3(C(C2OC1=O)O)C,,,,,,
5106,125107,8-Hydroxyaporphine,CN1CCC2=C3C1CC4=C(C3=CC=C2)C=CC=C4O,,,,,,
5107,125108,N-(1-Ethoxycyclopropyl)benzamide,CCOC1(CC1)NC(=O)C2=CC=CC=C2,,,,,,
5108,125109,"(3S,8S)-heptadeca-1,9,16-trien-4,6-diyne-3,8-diol",C=CCCCCCC=C[C@@H](C#CC#C[C@H](C=C)O)O,,,,,,
5109,125110,3-(2-Tetrahydrofuryl)-5-fluorouracil,C1CC(OC1)N2C(=O)C(=CNC2=O)F,,,,,,
5110,125111,CID 125111,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)OC2[C@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)NC(=O)C)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
5111,125112,"Bis[3-(diethylamino)propyl] fluoranthene-3,8-dicarboxylate",CCN(CC)CCCOC(=O)C1=CC2=C(C=C1)C3=C4C2=CC=CC4=C(C=C3)C(=O)OCCCN(CC)CC,,,,,,
5112,125113,Dctpalphas,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=S)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
5113,125114,1-Methyl-4-(2-oxazolin-2-ylamino)indazole,CN1C2=CC=CC(=C2C=N1)NC3=NCCO3,,,,,,
5114,125115,"[(1S,6R,7R)-4-ethylidene-6,7-dimethyl-3,8,15-trioxo-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadeca-11(17),12-dien-7-yl] acetate",CC=C1C[C@H]([C@@](C(=O)OCC2=C3[C@H](CC(=O)N3C=C2)OC1=O)(C)OC(=O)C)C,,,,,,
5115,125116,CID 125116,CC=CCCCCC[C@@]12C[C@H]([C@H](C1)N=N2)CC=CCCCC(=O)O,,,,,,
5116,125117,1'-Sulfooxysafrole,C=CC(C1=CC2=C(C=C1)OCO2)OS(=O)(=O)O,,,,,,
5117,125118,CID 125118,CCCCC[C@@H](C=CC=CC=CC=C[C@H]1[C@@H](O1)CCCC(=O)O)O,,,,,,
5118,125119,Hhcti,C1C2=C(CC3=C(CC4=C1NC5=CC=CC=C45)NC6=CC=CC=C36)NC7=CC=CC=C27,,,,,,
5119,125120,CID 125120,C1CC(=O)N(C1=O)OC(=O)CCCCCN=C2C=CC(=N[N+]#N)C=C2N(O)[O-],,,,,,
5120,125121,Boc-wld-NH2,CC(C)(C)[C@@H](C(=O)N[C@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)OC(C)(C)C,,,,,,
5121,125122,Baumycins,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)OC(CC(C)O)OC(C)CO,,,,,,
5122,125123,(2S)-3-(6-bromo-1H-indol-3-yl)-2-(trimethylazaniumyl)propanoate,C[N+](C)(C)[C@@H](CC1=CNC2=C1C=CC(=C2)Br)C(=O)[O-],,,,,,
5123,125124,[2-(6-bromo-1H-indol-3-yl)-1-carboxyethyl]-trimethylazanium,C[N+](C)(C)C(CC1=CNC2=C1C=CC(=C2)Br)C(=O)O,,,,,,
5124,125125,N-Nonylsuccinimide,CCCCCCCCCN1C(=O)CCC1=O,,,,,,
5125,125126,5-Hydroperoxypent-1-enylbenzene,C1=CC=C(C=C1)C=CCCCOO,,,,,,
5126,125127,CID 125127,B([C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](C)NC(=O)C(C)NC(=O)CCC(=O)OC)(O)O,,,,,,
5127,125128,6-Sialyllactosamine,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)NC(=O)C)O)CO)O)O)O)O,,,,,,
5128,125129,CID 125129,CC1=CC=CC=C1N=C(NNC(=O)C)S,,,,,,
5129,125130,4-(Ethoxymethylene)-2-(2-phenylethenyl)-5(4H)-oxazolone,CCOC=C1C(=O)OC(=N1)C=CC2=CC=CC=C2,,,,,,
5130,125131,"L-Tyrosine, N-(bromoacetyl)-O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-",C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)NC(=O)CBr,,,,,,
5131,125132,"2-[3-(2-Hydroxy-1,1-dihydroxymethyl-ethylamino)-propylamino]-2-hydroxymethyl-propane-1,3-diol",C(CNC(CO)(CO)CO)CNC(CO)(CO)CO,,,,,,
5132,125133,"(3S,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol",C1=CN(C2=NC=NC(=C21)N)C3[C@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
5133,125134,Di-N-desethylamiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN)I,,,,,,
5134,125135,"4-(2,3-Bis(bis(carboxymethylamino))propyl)phenyl isothiocyanate",C1=CC(=CC=C1C[C@@H](CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)N=C=S,,,,,,
5135,125136,"Dibutyryl cyclic 3',5'-cytidine monophosphate",CCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@@H]([C@H]3[C@H](O2)COP(=O)(O3)O)OC(=O)CCC,,,,,,
5136,125137,7-Cysteinyldehydroretronecine,C1CN2C=CC(=C2[C@@H]1SC[C@@H](C(=O)O)N)CO,,,,,,
5137,125138,Oetedg,CCSCCOC1=NC(=NC2=C1N=CN2C3C[C@@H]([C@H](O3)CO)O)N,,,,,,
5138,125139,Glutathione-dehydro-retronecine Conjugate,C1CN2C=CC(=C2[C@@H]1SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)CO,,,,,,
5139,125140,"N-Acetyl-7H-dibenzo(c,g)carbazole",CC(=O)N1C2=C(C3=CC=CC=C3C=C2)C4=C1C=CC5=CC=CC=C54,,,,,,
5140,125141,4-[[(2S)-1-[[3-(4-hydroxyphenyl)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid,CCC(C)[C@@H](C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC2=CC3=C(C=C2)C(=CC(=O)O3)C)NC(=O)CCC(=O)O,,,,,,
5141,125142,Isomucronulatol 7-O-glucoside,COC1=C(C(=C(C=C1)C2CC3=C(C=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC2)O)OC,,,,,,
5142,125143,"Ergost-5-ene-3,7-diol",C[C@H](CC[C@@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C,,,,,,
5143,125144,Benzo(a)pyrenyl-1-sulfate,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)OS(=O)(=O)O)C=C3,,,,,,
5144,125145,Dns-papl,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NC3=CC=C(C=C3)O[C@H]4[C@@H]([C@H](C([C@H](O4)CO)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
5145,125146,CID 125146,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O.C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)O)N4C=NC5=C(N=CN=C54)N)O,,,,,,
5146,125147,CID 125147,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)O,,,,,,
5147,125148,"[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S)-5-(6-aminopurin-9-yl)-2-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate",C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)O)N4C=NC5=C(N=CN=C54)N)O,,,,,,
5148,125149,16-(9-Anthroyloxy)palmitic acid,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)OCCCCCCCCCCCCCCCC(=O)O,,,,,,
5149,125150,"[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dimethyl phosphate",COP(=O)(OC)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
5150,125151,"5,8-Dimethoxy-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene",COC1=C2C[C@@H]([C@H](CC2=C(C=C1)OC)O)NCCO,,,,,,
5151,125152,"6,8,11-Trihydroxy-1-methoxytetracene-5,12-dione",COC1=CC=CC2=C1C(=O)C3=C(C4=C(C=C(C=C4)O)C(=C3C2=O)O)O,,,,,,
5152,125153,"[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4S,5R,9S,10R,13S)-5,9-dimethyl-14-methylidene-13-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate",C[C@@]12CCC[C@@]([C@H]1CCC34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)(C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
5153,125154,CID 125154,CC(=O)N[C@H](CSCCCCC=C(C(=O)O)NC(=O)[C@H]1CC1(C)C)C(=O)O,,,,,,
5154,125155,"20,22-Dihydroxycholest-4-en-3-one",CC(C)CC[C@H]([C@@](C)([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O)O,,,,,,
5155,125156,5-Hydroxy-2-aminotetralin,C1CC2=C(CC1N)C=CC=C2O,,,,,,
5156,125157,CID 125157,COC1=CC=C(C=C1)C=CC(=O)C2=C(C=C(C=C2O)OC)O,,,,,,
5157,125158,"2-methyl-N-[4-methyl-2-oxo-7-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-6-yl]pentadecanamide",CCCCCCCCCCCCCC(C)C(=O)NC1=C(C=C2C(=C1)C(=CC(=O)O2)C)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O,,,,,,
5158,125159,CID 125159,C1=CC2=C(C=C1O)C(=CN2)CCN=C3C=CC(=N[N+]#N)C=C3N(O)[O-],,,,,,
5159,125160,3-(Adenin-9-yl)-2-hydroxypropanoic acid 2-methylpropyl ester,CCC(C)OC(=O)C(CN1C=NC2=C(N=CN=C21)N)O,,,,,,
5160,125161,CID 125161,CCSC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
5161,125162,CID 125162,CCCCSC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
5162,125163,12-Hydroxymethylbenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C=C(C5=CC=C4)CO,,,,,,
5163,125164,11-Hydroxymethylbenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=CC5=CC=C4)CO,,,,,,
5164,125165,Synovex-H,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,,,,,,
5165,125166,17-(Propionyloxy)androsta-4-ene-3-one,CCC(=O)OC1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,,,,,,
5166,125167,2'-Deoxyshowdomycin,C1[C@@H]([C@H](OC1C2=CC(=O)NC2=O)CO)O,,,,,,
5167,125168,"9,21-Dehydroryanodine",CC(C)[C@]1([C@H]([C@]2([C@]3(C[C@]4([C@@]1([C@@]2([C@@]5([C@@]3(CCC(=C)[C@H]5O)O)O4)O)C)O)C)O)OC(=O)C6=CC=CN6)O,,,,,,
5168,125169,CID 125169,C1=NC2=C(N(C=NC2=N1)CCC(=O)O)N,,,,,,
5169,125170,11alpha-Methoxyquinestrol,C[C@]12C[C@H]([C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5)OC,,,,,,
5170,125171,"2-[[2-[[(2S)-1-[(3R,4S,7S,10S,11S)-14-chloro-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-prop-1-en-2-yl-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]-2,5-dihydropyrrole-2-carbonyl]amino]-3-methylpent-2-enoyl]amino]but-2-enedioic acid",CCC(=C(C(=O)NC(=CC(=O)O)C(=O)O)NC(=O)[C@@H]1C=CCN1C(=O)[C@@H]2[C@@](OC3=C(C(=CC(=C3)[C@@H]([C@@H](C(=O)N[C@H](C(=O)N2)C(=C)C)NC)O)Cl)O)(C)CC)C,,,,,,
5171,125172,Methyl 1-(5-fluoro-1H-2-oxopyrimidin-4-yl)-beta-D-glucopyranuronate,COC(=O)[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=C(C=NC(=O)N2)F)O)O)O,,,,,,
5172,125173,Epdad,C1=CC=[N+](C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C4N=CN6C5=NC=C6)O)O)O)O,,,,,,
5173,125174,"[[(2R,3S,4R)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4-dihydroxy-5-pyridin-1-ium-1-yloxolan-2-yl]methyl hydrogen phosphate",C1=CC=[N+](C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C4N=CN6C5=NC=C6)O)O)O)O,,,,,,
5174,125175,Smcc,C1CC(CCC1CN2C(=O)C=CC2=O)C(=O)ON3C(=O)CCC3=O,,,,,,
5175,125176,1-(9H-Fluoren-2-yl)-1-propanone,CCC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
5176,125177,Nitro dimethylamino methylethylamino acridine,CC(CN(C)C)NC1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-].Cl.Cl,,,,,,
5177,125178,"n1,n1-Dimethyl-n2-(1-nitroacridin-9-yl)propane-1,2-diamine",CC(CN(C)C)NC1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-],,,,,,
5178,125179,4-Hcpdad,C1=C[N+](=CC=C1C(=O)NN)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C4N=CN6C5=NC=C6)O)O)O)O,,,,,,
5179,125180,"[[(2R,3S,4R)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-[4-(hydrazinecarbonyl)pyridin-1-ium-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=C[N+](=CC=C1C(=O)NN)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C4N=CN6C5=NC=C6)O)O)O)O,,,,,,
5180,125181,"3,5-Dioxooctanedioic acid",C(CC(=O)O)C(=O)CC(=O)CC(=O)O,,,,,,
5181,125182,"1a,9b-Dihydrooxireno[2,3-f][1,10]phenanthroline",C1=CC2=C(C3=C(C=CC=N3)C4C2O4)N=C1,,,,,,
5182,125183,CID 125183,C1=CC(=CC=C1C=CC(=O)OC2C(OC(C(C2O)OC(=O)C=CC3=CC=C(C=C3)O)OC4=C(OC5=CC(=O)C=C(C5=C4O)O)C6=CC=C(C=C6)O)CO)O,,,,,,
5183,125184,1-((2-(5-Dimethylamino)naphthalene-1-sulfonylaminoethyl)amino)-3-(1-naphthaleneoxy)-2-propanol,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCNCC(COC3=CC=CC4=CC=CC=C43)O,,,,,,
5184,125185,tertiary-Butyloxycarbonyl-valyl-prolyl-arginyl-7-amino-4-methylcoumarin,CC1=CC(=O)OC2=C1C=CC(=C2)N[C@@H](CCCN=C(N)N)C(=O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C,,,,,,
5185,125186,Tmpte,CC1(C2C(C1(C)C)C(=O)OC3=C2C=C4C5C(C6C5(C(=O)NC(=O)N6C7C[C@@H]([C@H](O7)CO)O)C)OC4=C3OC)C,,,,,,
5186,125187,Benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide,CC1=CC(=O)OC2=C1C=CC(=C2)N[C@@H](CCCN=C(N)N)C(=O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
5187,125188,"1-(2-chloroethyl)-3-[(2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]-1-nitrosourea",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)NC(=O)N(CCCl)N=O,,,,,,
5188,125189,"6-[4,5-Bis(hydroxymethyl)-2-sulfooxyoxolan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid",C(C1C(OC(C1OC2C(C(C(C(O2)C(=O)O)O)O)O)OS(=O)(=O)O)CO)O,,,,,,
5189,125190,Benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone,C1=CC=C(C=C1)C[C@@H](C(=O)C=[N+]=[N-])NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
5190,125191,CID 125191,C1=CC=C(C=C1)C[C@@H](C(=C[N+]#N)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
5191,125192,CID 125192,CC(CC(=O)O)(N)P(=O)O,,,,,,
5192,125193,"6,11-Dimethyl-5H-pyrido(3',4':4,5)pyrrolo(2,3-g)isoquinoline",CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=NC=C4)C,,,,,,
5193,125194,CID 125194,C1CCN(CC1)CC2=CC=C(C=C2)OCCCNC3=NS(=O)(=O)C4=CSC=C43,,,,,,
5194,125195,N-epsilon-Lithocholyllysine,C[C@H](CCC(=O)NCCCC[C@@H](C(=O)O)N)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,,,,,,
5195,125196,"Platinate(1-), (1,2,4-benzenetricarboxylato(3-)-O1,O2)(1,2-cyclohexanediamine-N,N')-, hydrogen, (SP-4-3-(trans))-",[H+].C1CCC(C(C1)N)N.C1=CC(=C(C=C1C(=O)[O-])C(=O)[O-])C(=O)[O-].[Pt+2],,,,,,
5196,125197,CID 125197,CC(=O)OC1=C2C3=C(C[C@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)[C@@H](CC5)F)O)C=C1,,,,,,
5197,125198,S-Propyl-L-cysteine,CCCSCC(C(=O)O)N,,,,,,
5198,125199,"9-(4-Hydroxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)O,,,,,,
5199,125200,p-Azidophenylglyoxal,C1=CC(=CC=C1C(=O)C=O)N=[N+]=[N-],,,,,,
5200,125201,CID 125201,C1=CC(=CC=C1C(=O)C=O)N[N+]#N,,,,,,
5201,125202,"4-(((((3,5-Diamino-6-chloropyrazinyl)carbonyl)amino)iminomethyl)amino)-2,2,6,6-tetramethyl-1-piperidinyloxy",CC1(CC(CC(N1[O-])(C)C)N=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N)C,,,,,,
5202,125203,(2R)-2-amino-5-[[hydroxy(sulfamoyloxy)phosphoryl]amino]pentanoic acid,C(C[C@H](C(=O)O)N)CNP(=O)(O)OS(=O)(=O)N,,,,,,
5203,125204,"Propanamide, 2-hydroxy-2-methyl-N-(3,4,5-trichlorophenyl)-",CC(C)(C(=O)NC1=CC(=C(C(=C1)Cl)Cl)Cl)O,,,,,,
5204,125205,"2,7-Diiodo-9-diazofluorene",C1=CC2=C(C=C1I)C(=[N+]=[N-])C3=C2C=CC(=C3)I,,,,,,
5205,125206,CID 125206,COC1=C2C3CCC(=O)C3C(=O)OC2=C4[C@H]5[C@H](C[C@H]([C@@H]5O)N(C=O)C6=C(NC(=NC6=O)N)N)OC4=C1,,,,,,
5206,125207,11-Dodecenoic acid,C=CCCCCCCCCCC(=O)O,,,,,,
5207,125208,Nitrosonipecotic acid,C1CC(CN(C1)N=O)C(=O)O,,,,,,
5208,125209,2'-Bromo-2'-deoxyadenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)Br)N,,,,,,
5209,125210,Phytolaccoside E,CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)OC6COC(C(C6O)O)OC7C(C(C(C(O7)CO)O)O)O)O)C)C)C2C1)C)C(=O)O)C(=O)OC,,,,,,
5210,125211,Desacetylnantradol,CC1C2CCC(CC2C3=C(N1)C=C(C=C3O)OC(C)CCCC4=CC=CC=C4)O,,,,,,
5211,125212,CID 125212,CCCCCCCCCCCCCCCCCCN=C(NC1=CC2=C(C=C1)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O)S,,,,,,
5212,125213,N-feruloyltyramine; Moupinamide,COC1=C(C=CC(=C1)C=CC(=O)NCCC2=CC=C(C=C2)O)O,,,,,,
5213,125214,CID 125214,C[C@H]1[C@@H]2CC[C@]3(C(O3)CCC(=CCC[C@]([C@@H](C2)OC1=O)(C)O)C)C,,,,,,
5214,125215,N-(9H-Fluoren-9-ylidene)-4-[bis(2-hydroxyethyl)amino]phenylamineN-oxide,C1=CC=C2C(=C1)C3=CC=CC=C3C2=[N+](C4=CC=C(C=C4)N(CCO)CCO)[O-],,,,,,
5215,125216,2-(2-Aminothiazole-4-yl)-2-methoxyiminoacetic acid,CON=C(C1=CSC(=N1)N)C(=O)O,,,,,,
5216,125217,CID 125217,C[C@H]1[C@H](C[C@@H](CC1=CC=C2CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C)O)O,,,,,,
5217,125218,Sialyllactitol,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OC2[C@H]([C@H](O[C@H]([C@@H]2O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)CO)O)O,,,,,,
5218,125219,Octadecylphosphocholine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,,,,,,
5219,125220,2-[Hydroxy(octadecoxy)phosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCCCOP(=O)(O)OCC[N+](C)(C)C,,,,,,
5220,125221,N-Amino-N'-1-octylguanidine,CCCCCCCCN=C(N)NN,,,,,,
5221,125222,CID 125222,CCCCN=C(N)NNC(=CN=NC(=NCCCC)N)C,,,,,,
5222,125223,"[(2S)-1-hydroxy-3-octadecanoyloxypropan-2-yl] icosa-5,8,11,14-tetraenoate",CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC,,,,,,
5223,125224,"1-Deoxy-1-(5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-beta-D-glucopyranuronic acid",C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O)F,,,,,,
5224,125225,N-Amino-3-bromophenylsuccinimide,C1C(C(=O)N(C1=O)N)C2=CC(=CC=C2)Br,,,,,,
5225,125226,Poly(ethyleneglycol-lactide),C[C@H]1C(=O)O[C@H](C(=O)O1)C.C(CO)O,,,,,,
5226,125227,Saframycin C,CC1=C(C(=O)C2=C(C1=O)C[C@H]3[C@H]4C5=C([C@@H]([C@H](N4C)CN3[C@H]2CNC(=O)C(=O)C)OC)C(=O)C(=C(C5=O)OC)C)OC,,,,,,
5227,125228,Saframycin E,CC1=C(C2=C([C@@H]3[C@@H]4CC5=C([C@@H](N4C[C@H]([C@H]2O)N3C)CNC(=O)C(=O)C)C(=O)C(=C(C5=O)C)OC)C(=C1OC)O)O,,,,,,
5228,125229,Adenosine triphosphate adenosine monophosphate adenosine monophosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OC4[C@@H]([C@H](O[C@H]4N5C=NC6=C(N=CN=C65)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)OP(=O)(O)OC[C@@H]7[C@H]([C@H](C(O7)N8C=NC9=C(N=CN=C98)N)O)O)N,,,,,,
5229,125230,(3-Bromo-4-hydroxyphenyl)(2-ethylbenzofuran-3-yl)methanone,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C=C3)O)Br,,,,,,
5230,125231,"(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]naphthalen-1-yl]oxyoxane-2-carboxylic acid",CC(C)NCC(COC1=CC=C(C2=CC=CC=C21)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)O,,,,,,
5231,125232,Perforatic acid,CC1(C=CC2=C3C(=C(C=C2O1)OC)C(=O)C=C(O3)C(=O)O)C,,,,,,
5232,125233,CID 125233,CCCCCCCCC=CCCCCCCCCO[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C,,,,,,
5233,125234,"4-(2,3-Dichlorophenyl)-6-methyl-2-[(carbamoyloxy)methyl]pyridine-3,5-dicarboxylic acid 3-isopropyl 5-methyl ester",CC1=C(C(=C(C(=N1)COC(=O)N)C(=O)OC(C)C)C2=C(C(=CC=C2)Cl)Cl)C(=O)OC,,,,,,
5234,125235,"Dimethyl 2-(carbamoyloxymethyl)-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",CC1=C(C(C(=C(N1)COC(=O)N)C(=O)OC)C2=C(C(=CC=C2)Cl)Cl)C(=O)OC,,,,,,
5235,125236,"3,5-Pyridinedicarboxylic acid, 2-(((aminocarbonyl)oxy)methyl)-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester",CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)COC(=O)N,,,,,,
5236,125237,CID 125237,CCC(C)C(=O)OC(C)C1(C(OC(CC1OC)OC2C(C(OC(C2O)C3C(C(=O)C(=C(C3=O)C(=O)O)N)O)COC(=O)C)O)C)O,,,,,,
5237,125238,Poly(hydroxyethylmethacrylate bisglycolacrylate),CC(=C)C(=O)OCCO.C=CC(=O)OCCOC(=O)C=C,,,,,,
5238,125239,1-Amino-2-hydroxyethane P-methyl phosphonic acid,CP(=O)(C(CO)N)O,,,,,,
5239,125240,"Propanamide, 3-(2-benzoyl-4-chlorophenoxy)-N-methyl-",CNC(=O)CCOC1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
5240,125241,7(alpha-Fluoro-2-thienylacetamido)cephalosporanic acid,CC(=O)OCC1=C(N2C([C@@H](C2=O)NC(=O)C(C3=CC=CS3)F)SC1)C(=O)O,,,,,,
5241,125242,"33-(4-Amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,7,9,13,37-heptahydroxy-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid",CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(CC(CC(CC(=O)CC(CC(=O)OC1C(C)CCC(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)O)O)O)C(=O)O)OC4C(C(C(C(O4)C)O)N)O,,,,,,
5242,125243,"5-[5-(Furan-3-yl)-2-methylpent-2-enyl]-2,3-dimethoxycyclohexa-2,5-diene-1,4-dione",CC(=CCCC1=COC=C1)CC2=CC(=O)C(=C(C2=O)OC)OC,,,,,,
5243,125244,"1,3-Benzodioxole-5-carboxylic acid, 5-(aminocarbonyl)-1H-imidazol-4-yl ester",C1OC2=C(O1)C=C(C=C2)C(=O)OC3=C(NC=N3)C(=O)N,,,,,,
5244,125245,Spermic acid 1,C(CCNCCC(=O)O)CNCCCN,,,,,,
5245,125246,"6-(Dipropylamino)-5,6,7,8-tetrahydronaphthalene-2,3-diol",CCCN(CCC)C1CCC2=CC(=C(C=C2C1)O)O,,,,,,
5246,125247,"3-Methoxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=CC(=C3)OC,,,,,,
5247,125248,"2-Methoxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C(C=C3)OC,,,,,,
5248,125249,Hippeastidine,COC1CCC23CCN(C2C1)CC4=CC(=C(C(=C34)O)OC)OC,,,,,,
5249,125250,3'-Epidaunorubicin,C[C@H]1[C@H]([C@@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,,,,,,
5250,125251,Impletol depot bayer,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C=CN1CCCC1=O,,,,,,
5251,125252,N-(Bromoacetylamino)cyanopindolol,CC(C)(CNC(=O)CBr)NCC(COC1=CC2=C(C=C1)NC(=C2)C#N)O,,,,,,
5252,125253,Val-glu-pro-ile-pro-tyr,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N,,,,,,
5253,125254,"9-(2,6-Dichloro-4-methoxy-3-methylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",CC1=C(C(=C(C=C1OC)Cl)C=CC(=CC=CC(=CC(=O)O)C)C)Cl,,,,,,
5254,125255,"1,2-Dideoxy-1-phenyl-beta ribofuranose",C1[C@@H]([C@H](O[C@H]1C2=CC=CC=C2)CO)O,,,,,,
5255,125256,Alldimycin C,CC[C@]1(C[C@@H](C2=CC3=C(C(=C2[C@H]1O[C@H]4C[C@@H]([C@@H]([C@@H](O4)C)O)N(C)C)O)C(=O)C5=C(C=CC(=C5C3=O)O)O)O)O,,,,,,
5256,125257,Spenolimycin,C[C@@H]1C=C([C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O)OC,,,,,,
5257,125258,Chitinovorin-A,CC(C(=O)NC(CCCN=C(N)N)C(CC(=O)OCC1=C(N2C(C(C2=O)(NC=O)NC(=O)CCCC(C(=O)O)N)SC1)C(=O)O)O)N,,,,,,
5258,125259,"5-Hydroxymethyl-1,2,3,4-cyclohexanetetrol",C1[C@@H]([C@H]([C@@H]([C@H]([C@H]1O)O)O)O)CO,,,,,,
5259,125260,CID 125260,CC(=CCCC(=CCOC(=O)C=NN)C)CC[C@@H]1C(O1)(C)C,,,,,,
5260,125261,N-Benzoyltyrosine butylamide,CCCCNC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)C2=CC=CC=C2,,,,,,
5261,125262,CID 125262,C1=CC2=C(C(=C1)O)NC3=CC(=O)C=C(C3=N2)C(=O)O,,,,,,
5262,125263,CID 125263,COC1=CC(=C(C=C1C(=NC2CCN(CC2)CC3=CC=CC=C3)[O-])I)N[N+]#N,,,,,,
5263,125264,CID 125264,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)I)N[N+]#N,,,,,,
5264,125265,Boc-meglu-glu-val,CC(C)[C@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=C)C(=O)O)NC(=O)OC(C)(C)C,,,,,,
5265,125266,"3-(2-Furoyl)-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)C3=CC=CO3,,,,,,
5266,125267,SL-Procion,CC1(CC(CC(N1[O-])(C)C)NC2=NC(=NC(=N2)NC3=C(C=C(C=C3)NC4=CC(=C(C5=C4C(=O)C6=CC=CC=C6C5=O)N)S(=O)(=O)O)S(=O)(=O)O)Cl)C,,,,,,
5267,125268,N-Succinimidyl ((bromoacetyl)amino)benzoate,C1CC(=O)N(C1=O)OC(=O)C2=CC=C(C=C2)NC(=O)CBr,,,,,,
5268,125269,Des-O-methylolivoretin C,CC(C)C1C(=O)NC(CC2=CNC3=C4C(=CC(=C23)N1C)C(CCC4(C)C(C)C)(C)C=C)CO,,,,,,
5269,125270,"2-[2-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3-dihydroindol-3-yl]acetic acid",C1=CC2=C(C=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(C(=O)N2)CC(=O)O,,,,,,
5270,125271,Chitinovorin C,C1C(=C(N2[C@H](S1)[C@](C2=O)(NC=O)NC(=O)CCC[C@H](C(=O)O)N)C(=O)O)CO,,,,,,
5271,125272,3-O-Methyldobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)OC,,,,,,
5272,125273,Resorufin galactopyranoside,C1=CC2=C(C=C1O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)OC4=CC(=O)C=CC4=N2,,,,,,
5273,125274,"2-[6-(2-hydroxyethyl)-3a,6-dimethyl-3-(6-methylheptan-2-yl)-2,3,4,5,5a,7,8,9,9a,9b-decahydro-1H-cyclopenta[a]naphthalen-7-yl]propan-1-ol",CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC(C3(C)CCO)C(C)CO)C,,,,,,
5274,125275,3'-C-Methyldaunorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)(C)N)O,,,,,,
5275,125276,"[3-[(2R)-2-[[(2S)-2-[2-[(2S,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-5-amino-5-oxopentanoyl]oxy-2-hexadecanoyloxypropyl] hexadecanoate",CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C)OC(=O)CCCCCCCCCCCCCCC,,,,,,
5276,125277,"Nicotinic acid, 2-tert-butyl-4-cyclohexylphenyl ester, 1-oxide",CC(C)(C)C1=C(C=CC(=C1)C2CCCCC2)OC(=O)C3=C[N+](=CC=C3)[O-],,,,,,
5277,125278,4-Phosphonyl-3-carboxy-3-hydroxybutanoic acid,C(C(=O)O)C(CP(=O)O)(C(=O)O)O,,,,,,
5278,125279,CID 125279,CCC1(C(=O)C(=C(S1)O)C)C=C(C)C=C,,,,,,
5279,125280,6-Deoxyallitol,C[C@H]([C@H]([C@H]([C@H](CO)O)O)O)O,,,,,,
5280,125281,"[7,19-Dimethyl-2-(3-methylhexa-3,5-dienyl)-20-methylidene-22-oxo-1-oxacyclodocosa-4,6,12,14,16-pentaen-8-yl] dihydrogen phosphate",CC1CC=CC=CC=CCCCC(C(=CC=CCC(OC(=O)CC1=C)CCC(=CC=C)C)C)OP(=O)(O)O,,,,,,
5281,125282,CID 125282,CCC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](C)N(C)C(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CNC,,,,,,
5282,125283,CID 125283,CCC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN(C)C(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CNC,,,,,,
5283,125284,2-Cyanoprogesterone,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)[C@@H](C[C@]34C)C#N)C,,,,,,
5284,125285,Ketomethine,CC(CO)O.CSCC[C@@H](C(=O)O)N.Cl[Co]Cl,,,,,,
5285,125286,"9-chloro-5-(4-hydroxyphenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol",COC1=C(C=C2C(CNCCC2=C1Cl)C3=CC=C(C=C3)O)O,,,,,,
5286,125287,8-Methoxyfenoldopam,COC1=C(C(=C2CCNCC(C2=C1)C3=CC=C(C=C3)O)Cl)O,,,,,,
5287,125288,Prolyl-tyrosyl-prolyl-phenylalanyl-valyl-glutamyl-prolyl-isoleucinamide,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N,,,,,,
5288,125289,"N-(4-(2-Chlorophenyl)-6,7-dimethyl-3-quinolyl)-N'-(2,4-difluorophenyl)urea",CC1=CC2=C(C(=CN=C2C=C1C)NC(=O)NC3=C(C=C(C=C3)F)F)C4=CC=CC=C4Cl,,,,,,
5289,125290,5-Iodo-2-hydroxyglyburide,C1CCC(CC1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)CCNC(=O)C3=C(C=CC(=C3)I)O,,,,,,
5290,125291,4-[N-[4alpha-(Aminomethyl)cyclohexane-1beta-ylcarbonyl]-L-phenylalanylamino]benzeneacetic acid,C1CC(CCC1CN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC3=CC=C(C=C3)CC(=O)O,,,,,,
5291,125292,"(8S,13S,14S,17S)-17-[(2R)-2-fluoropropanoyl]-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",C[C@H](C(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C)F,,,,,,
5292,125293,CID 125293,C[C@H](C(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O)OC(=O)C,,,,,,
5293,125294,10-Acetylsalicyldithranol,CC(=O)OC1=CC=CC=C1C(=O)C2C3=C(C(=CC=C3)O)C(=O)C4=C2C=CC=C4O,,,,,,
5294,125295,"8-O-Methyl-7,9-di-O-acetyl-N-glycolylneuraminic acid",CC(=O)OC[C@H]([C@H]([C@@H]([C@@H]([C@H](CC(=O)C(=O)O)O)NC(=O)CO)O)OC(=O)C)OC,,,,,,
5295,125296,"5,8-Dihydroxy-2-(2-(4-methoxyphenyl)ethyl)chromone",COC1=CC=C(C=C1)CCC2=CC(=O)C3=C(C=CC(=C3O2)O)O,,,,,,
5296,125297,3-Hydroxyoct-6-enoic acid,CC=CCCC(CC(=O)O)O,,,,,,
5297,125298,"6,7-Cyclopentano-5-methylchrysene",CC1=C2CCC3=C2C(=CC=C3)C4=C1C5=CC=CC=C5C=C4,,,,,,
5298,125299,Methyl 2-O-alpha-rhamnopyranosyl-beta-galactopyranoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2OC)CO)O)O)O)O)O,,,,,,
5299,125300,"1-Methyl-2-nitro-6-phenylimidazo[4,5-b]pyridine",CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1[N+](=O)[O-],,,,,,
5300,125301,"1,3-Propanediol, 2-(((10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-",CC(CO)(CO)NCC1=C2C=CC=CC2=C(C3=CC=CC=C31)OCCO,,,,,,
5301,125302,"L-Leucine, L-asparaginyl-L-arginyl-L-valyl-L-tyrosyl-L-valyl-L-histidyl-L-prolyl-L-phenylalanylglycyl-",CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N,,,,,,
5302,125303,"N,N'-Bis(2,2,6,6-tetramethyl-1-oxyl-4-piperidinyl)-1,2-diaminocyclopropane",CC1(CC(CC(N1[O-])(C)C)N[C@@H]2CC2NC3CC(N(C(C3)(C)C)[O-])(C)C)C,,,,,,
5303,125304,CID 125304,CC1(CC(CC(N1[O-])(C)C)NCCN(C)C)C.C(=CC(=O)O)C(=O)O,,,,,,
5304,125305,"N',N'-dimethyl-N-(2,2,6,6-tetramethyl-1-oxidopiperidin-4-yl)ethane-1,2-diamine",CC1(CC(CC(N1[O-])(C)C)NCCN(C)C)C,,,,,,
5305,125306,"N-(2-aminoethyl)-8-chloro-6-(2-chlorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide",C1C2=NC(=NN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4Cl)C(=O)NCCN,,,,,,
5306,125307,4-(13-Bromotridec-12-enyltellanyl)butanoic acid,C(CCCCCC=CBr)CCCCC[Te]CCCC(=O)O,,,,,,
5307,125308,CID 125308,C[C@H](C=C[C@@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CCC(=CC=C3C[C@H](C[C@@H](C3=C)O)O)C2)C,,,,,,
5308,125309,Cyrtominetin,CC1=C(C(=C2C(=C1O)C(=O)CC(O2)C3=CC(=C(C=C3)O)O)C)O,,,,,,
5309,125310,"1,4-Butanediamine, N,N'-bis(1-methyl-2-phenylethyl)-",CC(CC1=CC=CC=C1)NCCCCNC(C)CC2=CC=CC=C2,,,,,,
5310,125311,CID 125311,CN=C(NNC(=CN=NC(=NC)S)C1=CC=C(C=C1)CCC(=O)O)S,,,,,,
5311,125312,"10-(Hydroxymethyl)-2,6,14-trimethylhexadeca-2,6,10,14-tetraenedioic acid",CC(=CCCC(=CCCC(=CC(=O)O)C)CO)CCC=C(C)C(=O)O,,,,,,
5312,125313,"7-(Hydroxymethyl)-3,11,15-trimethylhexadeca-6,10,14-trienoic acid",CC(CCC=C(CCC=C(C)CCC=C(C)C)CO)CC(=O)O,,,,,,
5313,125314,CID 125314,C1[C@H]([C@@H](CC1N2C=C(C(=NC2=O)N)C=CBr)O)CO,,,,,,
5314,125315,N-Nitroso-prolylalanine,C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1N=O,,,,,,
5315,125316,Dhs-amp,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)O.C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N,,,,,,
5316,125317,Nitramarine,C1=CC=C2C=NC(=CC2=C1)C3=NC=CC4=C3NC5=CC=CC=C45,,,,,,
5317,125318,CID 125318,CC1C=CC(=C(C(=O)NC2=C3C(=C4C(=C2)C=CC5=C4C(=O)C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)N=C6N3C=CC=C6Br)C)C,,,,,,
5318,125319,Radermachol,CC(=CC1=C2C3=C(O1)C4=CC=CC=C4C(=O)C3=C(C5=CC=CC=C5C2=O)O)C,,,,,,
5319,125320,CID 125320,CN1CC[C@]23[C@@H]4[C@]5(C=C[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)C[C@H]5NC(=O)CC7=CC=C(C=C7)NC(=O)C=CC(=O)OC)OC,,,,,,
5320,125321,"DH-1,6-OH-rotenone",CC(CO)C1CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4(C3=O)O)OC)OC,,,,,,
5321,125322,3'-Deamino-3'-hydroxydaunorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)O)O,,,,,,
5322,125323,"4-Methoxy-2,2,6,6-tetramethyl-1-oxidopiperidine",CC1(CC(CC(N1[O-])(C)C)OC)C,,,,,,
5323,125324,10-Dihydrocurvularin,C[C@H]1CCCCCC(C2=C(CC(=O)O1)C=C(C=C2O)O)O,,,,,,
5324,125325,(3-Anilino-2-octadec-9-enoyloxypropyl) octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OCC(CNC1=CC=CC=C1)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
5325,125326,CID 125326,C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)N,,,,,,
5326,125327,Glycyl-glycyl-cysteine,C([C@@H](C(=O)O)NC(=O)CNC(=O)CN)S,,,,,,
5327,125328,"1'-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,4'-piperidine]",C1CC2=CC=CC=C2C3(C1)CCN(CC3)CC4=CC=CC=C4,,,,,,
5328,125329,"3,5-Pyridinedicarboxylic acid, 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester",CC1=C(C(C(=C(N1)CF)C(=O)OC)C2=C(C=CC(=C2C(F)(F)F)Cl)F)C(=O)OC(C)C,,,,,,
5329,125330,"2,4-Pyrimidinediamine, 5-(3-azido-4-chlorophenyl)-6-ethyl-",CCC1=C(C(=NC(=N1)N)N)C2=C(C(=CC=C2)Cl)N=[N+]=[N-],,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
5330,125331,"Mercury, bromo(3-(4-(3-((5alpha,7alpha)-4,5-epoxy-3,6-dimethoxy-17-methyl-6,14-ethenomorphinan-7-yl)-(3R)-3-hydroxybutyl)phenoxy)-2-methoxypropyl)-",CC(COC1=CC=C(C=C1)CCC(C)(C2CC34C=CC2(C5C36CCN(C4CC7=C6C(=C(C=C7)OC)O5)C)OC)O)OC.[Br-].[Hg+2],,,,,,
5331,125332,"2-(11,15-Dimethoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,18-tetraen-16-yl)-4-[4-(2-methoxypropoxy)phenyl]butan-2-ol",CC(COC1=CC=C(C=C1)CCC(C)(C2CC34C=CC2(C5C36CCN(C4CC7=C6C(=C(C=C7)OC)O5)C)OC)O)OC,,,,,,
5332,125333,DH-6-OH-rotenone,CC(C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@]4(C3=O)O)OC)OC,,,,,,
5333,125334,"6-(2-(2,4-Dichloro-6-hydroxyphenyl)ethyl)-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one",C1[C@@H](CC(=O)O[C@H]1CCC2=C(C=C(C=C2Cl)Cl)O)O,,,['Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)'],,,
5334,125335,AnTPP,C1=CC=C(C=C1)N.OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
5335,125336,"2,4-Diaminopteridine glyoxal",C1=CC(=CC=C1C(=O)C=O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,,,,,,
5336,125337,4-Carboxamidopiperidine-N-dithiocarboxylate,C1CN(CCC1C(=O)N)C(=S)S,,,,,,
5337,125338,CID 125338,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC(=CC=C3C[C@H](CCC3=O)O)CC2)C,,,,,,
5338,125339,Estasol,COC(=O)CCCCC(=O)OC.COC(=O)CCCC(=O)OC.COC(=O)CCC(=O)OC,,,,,,
5339,125340,Abdkt,C(CCN)CC1C(=O)NC(=O)S1,,,,,,
5340,125341,gamma-tert-Butyl aminopterin,CC(C)(C)OC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,,,,,,
5341,125342,CID 125342,C[C@]12CCC3[C@H](C1CC[C@@H]2C4(CC4C(=O)O)C)[C@H](C[C@H]5[C@@]3(CC[C@H](C5)O)C)O,,,,,,
5342,125343,"(2S,3S)-3-[[(2S)-1-(4-acetamidobutylamino)-3-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid",CCC(C)[C@@H](C(=O)NCCCCNC(=O)C)NC(=O)[C@@H]1[C@H](O1)C(=O)O,,,,,,
5343,125344,Suc-DL-Lys(Cbz)-DL-Val-DL-Pro-DL-Val-al,CC(C)C(C=O)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)C(CCCCNC(=O)OCC2=CC=CC=C2)NC(=O)CCC(=O)O,,,,,,
5344,125345,Gliderinin,C[C@@]1(CC[C@H]2CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C2=C1)C)C(=O)O,,,,,,
5345,125346,Hyodeoxyoxazoline,C[C@H](CCC1=NC(CO1)(C)C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3C[C@@H]([C@H]5[C@@]4(CC[C@H](C5)O)C)O)C,,,,,,
5346,125347,N-[(4-Aminophenyl)methyl]adenosine,C1=CC(=CC=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N,,,,,,
5347,125348,3-Iodo-N(6)-4-aminobenzyladenosine,C1=CC(=C(C=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)I)N,,,,,,
5348,125349,Corynebactin,C[C@@H]1[C@@H](C(=O)O[C@@H]([C@@H](C(=O)O[C@@H]([C@@H](C(=O)O1)NC(=O)CNC(=O)C2=C(C(=CC=C2)O)O)C)NC(=O)CNC(=O)C3=C(C(=CC=C3)O)O)C)NC(=O)CNC(=O)C4=C(C(=CC=C4)O)O,,,,,,
5349,125350,CID 125350,C[C@@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=C(C=C1)N=[N+]=[N-])C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N.C(=O)(C(F)(F)F)O,,,,,,
5350,125351,CID 125351,C[C@@H](C(=O)NCC(=O)N(C)C(CC1=CC=C(C=C1)N=[N+]=[N-])C(=O)NCCO)NC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
5351,125352,AZ-Dtlet,CCC(C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)N=[N+]=[N-])NC(=O)CNC(=O)[C@@H]([C@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N.C(=O)(C(F)(F)F)O,,,,,,
5352,125353,CID 125353,CCC(C)C(C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)N=[N+]=[N-])NC(=O)CNC(=O)[C@@H]([C@H](C)O)NC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
5353,125354,N-(3-Acetylaminophenyl)piperazine,CC(=O)NC1=CC(=CC=C1)N2CCNCC2.Cl,,,,,,
5354,125355,N-(3-piperazin-1-ylphenyl)acetamide,CC(=O)NC1=CC(=CC=C1)N2CCNCC2,,,,,,
5355,125356,Methacyne,CC1(CC(CC(N1[O-])(C)C)CC[N+](C)(C)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.[I-],,,,,,
5356,125357,"2-(2-Hydroxy-2,2-diphenylacetyl)oxyethyl-dimethyl-[2-(2,2,6,6-tetramethyl-1-oxidopiperidin-4-yl)ethyl]azanium",CC1(CC(CC(N1[O-])(C)C)CC[N+](C)(C)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,,,,,,
5357,125358,"10-(3-Aminopropyl)-8-chlorophenothiazine-2,3-diol",C1=CC2=C(C=C1Cl)N(C3=CC(=C(C=C3S2)O)O)CCCN,,,['Compounds that bind to and inhibit the action of ADENYLYL CYCLASES. (See all compounds classified as Adenylyl Cyclase Inhibitors.)'],,,
5358,125359,CID 125359,C1=CC(=C(C=C1[C@H]2[C@@H](C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)OO)O)O)O)O)O,,,,,,
5359,125360,"7-[(2R,3S,4S)-4-Hydroxy-2-(3-hydroxyocta-1,5-dienyl)-6-oxooxan-3-yl]hept-5-enoic acid",CCC=CCC(C=C[C@@H]1[C@H]([C@H](CC(=O)O1)O)CC=CCCCC(=O)O)O,,,,,,
5360,125361,6-Fluoroaminopurine,C1=NC2=C(N1)C(=NC=N2)NF,,,,,,
5361,125362,3-(Aminomethyl)-5-(4-chlorophenyl)oxolan-2-one,C1C(C(=O)OC1C2=CC=C(C=C2)Cl)CN,,,,,,
5362,125363,2-Aminomethyl-4-(4-chlorophenyl)-4-hydroxybutyric acid,C1=CC(=CC=C1C(CC(CN)C(=O)O)O)Cl,,,,,,
5363,125364,Armillaric acid,CC1=CC(=CC(=C1C(=O)O[C@@H]2C[C@]3([C@@]2(C(=C[C@H]4[C@@H]3CC(C4)(C)C)C(=O)O)O)C)O)O,,,,,,
5364,125365,4-Fluorobenzo(j)fluoranthene,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C(C=CC3=C54)F,,,,,,
5365,125366,10-Fluorobenzo(j)fluoranthene,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C5=C(C=C4)C=C(C=C5)F,,,,,,
5366,125367,"[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] carbamate",CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)N)OC)C,,,,,,
5367,125368,"8,9-Dihydro-10-methyl-7-((5-methyl-1H-imidazol-4-yl)methyl)pyrido(1,2-a)indol-6(7H)-one",CC1=C2CCC(C(=O)N2C3=CC=CC=C13)CC4=C(NC=N4)C,,,,,,
5368,125369,Iacpa,C([C@H](C(=O)O)N)NC(=O)CI,,,,,,
5369,125370,CID 125370,CCC(C=NOCCCC1=CC=CC=C1)C(=O)O,,,,,,
5370,125371,N-Acryloyl-N'-phenylpiperazine,C=CC(=O)N1CCN(CC1)C2=CC=CC=C2,,,,,,
5371,125372,"1,2,6,7-Tetrahydroxypyrrolizidine",C1[C@H]([C@H](C2N1C[C@@H]([C@@H]2O)O)O)O,,,,,,
5372,125373,CID 125373,CC1=C(C(=CC=C1)C)CCC(C)N.CO,,,,,,
5373,125374,"4-(2,6-Dimethylphenyl)butan-2-amine",CC1=C(C(=CC=C1)C)CCC(C)N,,,,,,
5374,125375,CID 125375,C1CC(OC1C(=O)OCC2CO2)[N+](=O)[O-],,,,,,
5375,125376,CID 125376,C1CC(OC1C=CC(=O)NCC2CO2)[N+](=O)[O-],,,,,,
5376,125377,alpha-(((2-Bromoethyl)amino)methyl)-2-nitro-1H-imidazole-1-ethanol monohydrobromide,C1=CN(C(=N1)[N+](=O)[O-])CC(CNCCBr)O.Br,,,['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)'],,,
5377,125378,alpha-[[(2-Bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol,C1=CN(C(=N1)[N+](=O)[O-])CC(CNCCBr)O,,,['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)'],,,
5378,125379,4-Ethoxyamphetamine,CCOC1=CC=C(C=C1)CC(C)N,,,,,,
5379,125380,CID 125380,CC1C(NCN1)CC2NC(CS2)C3=CC=CC=C3OC,,,,,,
5380,125381,2-Hydroxynonafluoroazobenzene,C1(=C(C(=C(C(=C1F)F)F)F)O)N=NC2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
5381,125382,2'-Deoxy-2'-methylidene-5-fluorocytidine,C=C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)F)CO)O,,,,,,
5382,125383,Azatoxin,COC1=CC(=CC(=C1O)OC)[C@@H]2C3=C(C[C@@H]4N2C(=O)OC4)C5=CC=CC=C5N3,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
5383,125384,2'-Deoxy-5-(methoxymethyl)cytidine,COCC1=CN(C(=O)N=C1N)[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
5384,125385,CID 125385,CCNCC1=C(C=CC(=C1)C2=COC3=C(C2=O)C=C(C=C3)OC)O,,,,,,
5385,125386,CID 125386,C1=CC=C(C=C1)C(=O)C2(C=CC(=CC2=O)C(=O)O)O,,,,,,
5386,125387,CID 125387,CC1=CC2=C(CCN[C@@H]3[C@@H]2C4=CC=CC=C4CC3)C=C1Cl,,,,,,
5387,125388,CID 125388,C1C2C3C(C1SC3=O)C(=O)S2,,,,,,
5388,125389,"N-Methyl-2,7-diazapyrenium",C[N+]1=CC2=C3C(=C1)C=CC4=CN=CC(=C43)C=C2,,,,,,
5389,125390,Lipoyl-4-aminobenzoic acid,C1CSS[C@@H]1CCCCC(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
5390,125391,7-Deoxycastanospermine,C1CN2C[C@H](C[C@@H]([C@H]2[C@H]1O)O)O,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],,,
5391,125392,O(6)-Benzyl-2'-deoxyguanosine,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(N=C3OCC4=CC=CC=C4)N)CO)O,,,,,,
5392,125393,CID 125393,C1=CC=C2C=C3C=C4C(=CC3=CC2=C1)[SiH]=[Si]5N=NN=N[Si]5=[SiH]4,,,,,,
5393,125394,Tetraazatetracene,C1=CC=C2C=C3C=C4C(=CC3=CC2=C1)N=NN=N4,,,,,,
5394,125395,1-Pyrenecarboxylic acid,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)C(=O)O,,,,,,
5395,125396,CID 125396,CC(C)(C(=O)NC1CCC(CC1)ON=O)N,,,,,,
5396,125397,CID 125397,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)N[N+]#N)[O-],,,,,,
5397,125398,CID 125398,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)N[N+]#N)O,,,,,,
5398,125399,CID 125399,C1CCC([C@H](C1)CO)CN2C=NC3=C2NC(=NC3=O)N,,,,,,
5399,125400,"2-Butenedioic acid(2Z)-, mono[1-[[(2-methyl-1-oxo-2-propenyl)oxy]methyl]propyl] ester (9CI)",CCC(COC(=O)C(=C)C)OC(=O)C=CC(=O)O,,,,,,
5400,125401,CID 125401,CC=CC1C(O1)(C)C2=CC(=O)C3=C(C=C4C=C5C(CCC(=O)C5=C(C4=C3O2)O)OC(=O)C)CCOO,,,,,,
5401,125402,4-(2-Nitroxyethyl)piperidine,C1CNCCC1CCO[N+](=O)[O-],,,,,,
5402,125403,5-Ethoxy-3-methyl-5-oxopent-2-enoic acid,CCOC(=O)CC(=CC(=O)O)C,,,,,,
5403,125404,Ccris 6332,C1=CC=C2C(=C1)C=C3C(C(C4=CC=CC5=C4C3=C2C6=CC=CC=C56)O)O,,,,,,
5404,125405,CID 125405,CN1C(CC2=C1C=CC(=C2)O)CN(C)CC#C,,,,,,
5405,125406,alpha-Amino-3-carboxymethoxy-5-methyl-4-isoxazolepropionic acid,CC1=C(C(=NO1)OCC(=O)O)CC(C(=O)O)N,,,,,,
5406,125407,alpha-Amino-2-(3-hydroxy-5-methyl-4-isoxazolyl)methyl-5-methyl-3-oxo-4-isoxazoline-4-propionic acid,CC1=C(C(=O)N(O1)CC2=C(ONC2=O)C)CC(C(=O)O)N,,,,,,
5407,125408,"N-Succinimidyl-2,4-dimethoxy-3-iodobenzoate",COC1=C(C(=C(C=C1)C(=O)ON2C(=O)CCC2=O)OC)I,,,,,,
5408,125409,beta-D-Xylopyranose,C1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O)O,,,,,,
5409,125410,1-(N-Diphenylacetamido)-2-butanol,CCC(CNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)O,,,,,,
5410,125411,S-(Bromophenyl)cysteine,[2H]SCC(C(=O)O)N.[2H]Br.C1=CC=CC=C1,,,,,,
5411,125412,2-Amino-3-deuteriosulfanylpropanoic acid,[2H]SCC(C(=O)O)N,,,,,,
5412,125413,2-(4'-Isothiocyanatobenzyl)imidazoline,C1CN=C(N1)CC2=CC=C(C=C2)N=C=S,,,,,,
5413,125414,L-glycero-alpha-D-manno-Heptopyranose,C([C@@H]([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O)O)O)O,,,,,,
5414,125415,Glutamate thiol,C(CC(=O)O)[C@H](CS)N,,,,,,
5415,125416,3-(4-Methylphenyl)tropane-2-carboxylic acid methyl ester,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,,,,,,
5416,125417,CID 125417,CC(=O)SCC(CS(=O)(=O)N)C(=O)S,,,,,,
5417,125418,CID 125418,CCCCC[C@H](C=C[C@@H]1[C@H]([C@H](CC1=NOC)O)CC=CCCCC(=O)O)O,,,,,,
5418,125419,Cyclopentenyl-3-deazacytidine,C1=CN(C(=O)C=C1N)C2C=C([C@H]([C@H]2O)O)CO,,,,,,
5419,125420,CID 125420,C1=CN(C(=CC1=O)O)[C@@H]2C=C([C@H]([C@H]2O)O)CO,,,,,,
5420,125421,"1,2,3,6-Tetrahydro-1-methyl-4-styrylpyridine",CN1CCC(=CC1)C=CC2=CC=CC=C2,,,,,,
5421,125422,N-(2-Nitro-4-isothiocyanophenyl)imidazole,C1=CC(=C(C=C1N=C=S)[N+](=O)[O-])N2C=CN=C2,,,,,,
5422,125423,CID 125423,CCOC(=O)N(C)NC=C1C(=O)C2=CC=CC=C2C1=O,,,,,,
5423,125424,"3,3-Difluoro-DL-glutamic acid",C(C(=O)O)C(C(C(=O)O)N)(F)F,,,,,,
5424,125425,"9,13,15-Octadecatrienoicacid, 14,18-dihydroxy-12-oxo-, (9Z,13Z,15E)-",C(CCCC=CCC(=O)C=C(C=CCCO)O)CCCC(=O)O,,,,,,
5425,125426,"4-Amino-2,6-anhydro-3,4,5-trideoxy-5-[(1-hydroxyethylidene)amino]non-2-enonic acid",CC(=O)NC1[C@H](C=C(O[C@H]1[C@H]([C@H](CO)O)O)C(=O)O)N,,,,,,
5426,125427,CID 125427,CO[C@H]1[C@@H]([C@@H]1C(=O)O)[C@@H](C(=O)O)N,,,,,,
5427,125428,"[(1R,5S,6R)-8-azabicyclo[3.2.1]octan-6-yl] acetate",CC(=O)O[C@@H]1C[C@H]2CCC[C@@H]1N2,,,,,,
5428,125429,Hydantocidin,C([C@@H]1[C@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)O,,,,,,
5429,125430,"4'-Hydroxy-3,4,5,3',5'-pentachlorobiphenyl",C1=C(C=C(C(=C1Cl)O)Cl)C2=CC(=C(C(=C2)Cl)Cl)Cl,,,,,,
5430,125431,CID 125431,C[C@H](C[C@H](C)C=CC=C(C1=CC=CC=C1)C2=CC=CC=C2)CC(=O)OC,,,,,,
5431,125432,CID 125432,C1C(C(C(C2=CC(=C(C=C21)O)O)C3=CC(=C(C=C3)O)O)C(=O)O)C(=O)O,,,,,,
5432,125433,CID 125433,C(CCCCCCC(C=O)I)CCCCCCI,,,,,,
5433,125434,CID 125434,CCC(C)CN(C)[N+](=O)[O-],,,,,,
5434,125435,"4,4-Difluoroglutamic acid",C([C@@H](C(=O)O)N)C(C(=O)O)(F)F,,,,,,
5435,125436,N-(2-Hydroxyethyl)phenazinium,C1=CC=C2C(=C1)N=C3C=CC=CC3=[N+]2CCO,,,,,,
5436,125437,[(2R)-2-hydroxy-3-oxobutyl] dihydrogen phosphate,CC(=O)[C@@H](COP(=O)(O)O)O,,,,,,
5437,125438,N(epsilon)-(Carboxymethyl)hydroxylysine,C(C[C@@H](C(=O)O)N)[C@H](CNCC(=O)O)O,,,,,,
5438,125439,"Methyl 14-hydroxy-1,7,17-trioxoandrost-8-ene-19-oate",C[C@@]12CCC3=C([C@@]1(CCC2=O)O)C(=O)C[C@H]4[C@@]3(C(=O)CCC4)C(=O)OC,,,,,,
5439,125440,Carbazole-1-acetic acid,C1=CC=C2C(=C1)C3=CC=CC(=C3N2)CC(=O)O,,,,,,
5440,125441,4-Aminophenylalanine anilide,C1=CC=C(C=C1)NC(=O)C(CC2=CC=C(C=C2)N)N,,,,,,
5441,125442,N-[(1-ethylpyrrolidin-2-yl)methyl]-2-hydroxy-6-methoxybenzamide,CCN1CCCC1CNC(=O)C2=C(C=CC=C2OC)O,,,,,,
5442,125443,CID 125443,C1CN(CCC1CCCCl)C2=NC3=CC=CC=C3C=C2,,,,,,
5443,125444,"(3S,8R,9S,10S,13S,14S,16R)-16-hydroxy-13-methyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,10-dicarbaldehyde",C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H](C2=O)O)CC=C4[C@@]3(CC[C@@H](C4)C=O)C=O,,,,,,
5444,125445,"2-[2-Amino-3,4-dihydroxy-5-(hydroxymethyl)cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C1C(C(C(C(C1OC2C(C(C(C(O2)CO)O)O)O)N)O)O)CO,,,,,,
5445,125446,CID 125446,C[C@@H](C1[C@H]([C@@H]([C@@H](C1O)OC)OC)O)O,,,,,,
5446,125447,N-(3-Mercapto-3-methylbutyryl)-beta-alanine,CC(C)(CC(=O)NCCC(=O)O)S,,,,,,
5447,125448,3-(4-Carboxybenzoyl)-2-quinolinecarboxaldehyde,C1=CC=C2C(=C1)C=C(C(=N2)C=O)C(=O)C3=CC=C(C=C3)C(=O)O,,,,,,
5448,125449,"1H-Imidazole, 5-((4-iodophenyl)sulfonyl)-1-methyl-4-nitro-",CN1C=NC(=C1S(=O)(=O)C2=CC=C(C=C2)I)[N+](=O)[O-],,,,,,
5449,125450,CID 125450,C.C[C@]1(CC[C@]2([C@@H](C1)C3=CC[C@@H]4[C@]5(CC[C@@H]([C@](C5CC[C@]4([C@@]3(CC2=O)C)C)(C)CO)O)C)C)C(=O)O,,,,,,
5450,125451,CID 125451,C[C@]1(CC[C@]2([C@@H](C1)C3=CC[C@@H]4[C@]5(CC[C@@H]([C@](C5CC[C@]4([C@@]3(CC2=O)C)C)(C)CO)O)C)C)C(=O)O,,,,,,
5451,125452,CID 125452,CC1=CC2=C(O1)CC[C@H]3C2=CCC4[C@H]3CCC4=O,,,,,,
5452,125453,"3-(1,1-Difluoroethyl)-3-methyloxolan-2-one",CC1(CCOC1=O)C(C)(F)F,,,,,,
5453,125454,CID 125454,CC1=CSC(N1)NC2NC3=CC=CC=C3N2,,,,,,
5454,125455,CID 125455,CC1=NN2C=CC=CC2=C1C3=[N+](N=C(C=C3)N)CCCC(=O)O,,,,,,
5455,125456,"2,6-Dimethyl-9-methoxy-4H-pyrrolo(3,2,1-ij)quinolin-4-one",CC1=CC(=O)N2C(=CC3=C(C=CC1=C32)OC)C,,,,,,
5456,125457,CID 125457,CC1=C(C=C(C2=CC3=C(C=C12)C(CCC3(C)C)(C)C)N[N+]#N)C4=CC=C(C=C4)C(=O)[O-],,,,,,
5457,125458,CID 125458,CC1=C(C=C(C2=CC3=C(C=C12)C(CCC3(C)C)(C)C)N[N+]#N)C4=CC=C(C=C4)C(=O)O,,,,,,
5458,125459,"N-(2-Chloromethylphenyl)-3,3-difluoroazetidin-2-one",C1C(C(=O)N1C2=CC=CC=C2CCl)(F)F,,,,,,
5459,125460,1-(2-Azido-2-deoxyarabinofuranosyl)thymine,CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)N=[N+]=[N-],,,,,,
5460,125461,CID 125461,C1=CC=C(C=C1)CC[C@H]2[C@@H]([C@H]([C@@H]([C@H]([C@H]2O)O)O)OCC3=CC=CC=C3)CCC4=CC=CC=C4,,,,,,
5461,125462,5-Methyl-2-iminothiolane,CC1CCC(=N)S1.Cl,,,,,,
5462,125463,5-Methyl-2-thiolanimine,CC1CCC(=N)S1,,,,,,
5463,125464,"2-[(3,4-Dioxonaphthalen-1-yl)amino]benzamide",C1=CC=C2C(=C1)C(=CC(=O)C2=O)NC3=CC=CC=C3C(=O)N,,,,,,
5464,125465,2-(Acetoxymethyl)-3-(hydroxymethyl)bicyclo-(2.2.1)-hept-5-ene,CC(=O)OCC1C2CC(C1CO)C=C2,,,,,,
5465,125466,CID 125466,CCC1=CC=CC2=C1C(=C(C=C2)OC)O.CC=C(C)C(=O)O,,,,,,
5466,125467,8-Ethyl-2-methoxynaphthalen-1-ol,CCC1=CC=CC2=C1C(=C(C=C2)OC)O,,,,,,
5467,125468,Tiglic acid,C/C=C(\C)/C(=O)O,,,,,,
5468,125469,3-(4-Acetyloxy-5-ethyl-3-methoxynaphthalen-1-yl)-2-methylprop-2-enoic acid,CCC1=C2C(=CC=C1)C(=CC(=C2OC(=O)C)OC)C=C(C)C(=O)O,,,,,,
5469,125470,CID 125470,CN1C2=CC(=C(C=C2N=C(C1=O)CCC(=O)N[N+](=O)[O-])OC)OC,,,,,,
5470,125471,CID 125471,C(CO)N(CO)C1=C(NC(=NC1=O)N)N,,,,,,
5471,125472,4-(Dimethylaminodiazenyl)benzenesulfinate,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)O,,,,,,
5472,125473,Daggp,C1[C@@H]2[C@H](O1)[C@@H]([C@H]([C@H](O2)O[C@@H]3[C@@H]([C@H]([C@@H]4[C@H](O3)CO4)O)O)O)O,,,,,,
5473,125474,CID 125474,CCCCC[C@H](C=CC=CCC=CCCCCCCC(=O)O)O,,,,,,
5474,125475,CID 125475,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H](C2=O)O)CCC4=CC(=O)CC[C@]34O,,,,,,
5475,125476,"(2R,3R)-7-ethyl-3-(3-hydroxybenzoyl)oxy-7-azabicyclo[2.2.1]heptane-2-carboxylic acid",CCN1C2CCC1[C@@H]([C@@H]2C(=O)O)OC(=O)C3=CC(=CC=C3)O,,,,,,
5476,125477,"N-Acetyl-2-deoxy-2,3-difluoroneuraminic acid",CC(=O)NC(C(C(C(CO)O)O)O)C(C(C(C(=O)O)[18F])[18F])O,,,,,,
5477,125478,CID 125478,CC(CCC1CC1(C)C)CC2CCC3C2(CCC4C3CC=C5C4(CCC(C5)O)C)C,,,,,,
5478,125479,"1,1-Dichloro-2,3-diphenyl-2-(4-methoxyphenyl)cyclopropane",COC1=CC=C(C=C1)[C@]2([C@H](C2(Cl)Cl)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5479,125480,3-(Tridecafluoroundecyl)catechol,C1=CC(=C(C(=C1)O)O)CCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
5480,125481,3-(Nonafluoropentadecyl)catechol,C1=CC(=C(C(=C1)O)O)CCCCCCCCCCCC(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
5481,125482,CID 125482,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C=CI)O,,,,,,
5482,125483,4-Nitrososulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N=O,,,,,"['4-Nitrososulfamethoxazole has known human metabolites that include [(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-[4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-oxoazanium.']",
5483,125484,"2-Hydroxy-4-methylpyrimido(4,5-b)(1,5)benzodiazepin-5-one",CC1=C2C(=NC(=O)N1)NC3=CC=CC=C3NC2=O,,,,,,
5484,125485,CID 125485,CN1CC[C@]23[C@@H]4[C@@H]1[C@H](C5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O)O,,,,,,
5485,125486,Tisch,CN1CCC2=CC(=C(C=C2C(C1)C3=CC(=CC=C3)I)O)Cl,,,,,,
5486,125487,Padspo,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)[Se]C2=CC=CC=C2)O,,,,,,
5487,125488,"2,4-Difluoro-5-nitrobenzenesulfonic acid",C1=C(C(=CC(=C1S(=O)(=O)O)F)F)[N+](=O)[O-],,,,,,
5488,125489,CID 125489,C[C@]12C(=O)CC[C@@]3([C@]14CCN([C@H]3CC5=C4C(=C(C=C5)O)O2)C)OC,,,,,,
5489,125490,1-(2-Amino-4-(5-nitro-2-furyl)-2-thiazolyl)-1-deoxy-beta-D-glucopyranuronic acid,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)N[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,,,,,,
5490,125491,CID 125491,CN1C(=C(C2=C1C(=O)C=C(C2=O)NCCO)CO)C=CCO,,,,,,
5491,125492,1-Fluoro-1-deoxyribulose-5-phosphate,C([C@@H]([C@@H](C(=O)CF)O)O)OP(=O)(O)O,,,,,,
5492,125493,"4'-Benzyloxy-3'-methoxy-7,8-benzoflavone",COC1=C(C=CC(=C1)C2=CCC3=C(O2)C4=CC=CC=C4C=C3)OCC5=CC=CC=C5,,,,,,
5493,125494,Bergaptol-O-glucopyranoside,C1=CC(=O)OC2=CC3=C(C=CO3)C(=C21)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
5494,125495,CID 125495,C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)N=C(N3)N)N=C2N)O)O)I,,,,,,
5495,125496,Mycenon,CC(=CCl)C#CC1=C(C(=O)C(=O)C(=C1O)Cl)Cl,,,,,,
5496,125497,"4-Quinolinamine, 8-methoxy-N-(2-methylphenyl)-",CC1=CC=CC=C1NC2=C3C=CC=C(C3=NC=C2)OC,,,['Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)'],,,
5497,125498,"(+)-(S)-1,3-Dimethyl-6-oxiranyl-2,4-pyrimidinedione",CN1C(=CC(=O)N(C1=O)C)[C@H]2CO2,,,,,,
5498,125499,"L-Cysteine, N-acetyl-S-(2,3-dihydro-7-(hydroxymethyl)-1H-pyrrolizin-1-yl)-",CC(=O)NC(CSC1CCN2C1=C(C=C2)CO)C(=O)O,,,,,,
5499,125500,"1-Fluoro-2-hydroxybutane-1,2,4-tricarboxylic acid",C(CC(C(C(=O)O)F)(C(=O)O)O)C(=O)O,,,,,,
5500,125501,7-Phenoxyquinoline,C1=CC=C(C=C1)OC2=CC3=C(C=CC=N3)C=C2,,,,,,
5501,125502,"7-Benzylandrosta-1,4,6-triene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)C(=CC4=CC(=O)C=C[C@]34C)CC5=CC=CC=C5,,,,,,
5502,125503,"7-Phenethyl-1,4,6-androstatriene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)C(=CC4=CC(=O)C=C[C@]34C)CCC5=CC=CC=C5,,,,,,
5503,125504,CID 125504,CCCC(=O)OCCNC(=O)C1=C(C(=CC(=C1)N[N+]#N)[125I])[O-].CC(=O)OC1C(=O)CCC1=O,,,,,,
5504,125505,CID 125505,CCCC(=O)OCCNC(=O)C1=C(C(=CC(=C1)N[N+]#N)[125I])O,,,,,,
5505,125506,"Acetic acid 2,5-dioxo-cyclopentyl ester",CC(=O)OC1C(=O)CCC1=O,,,,,,
5506,125507,Fuc(a1-2)Fuc3S(a)-O-Me,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2[C@@H]([C@@H]([C@@H](O[C@H]2OC)C)O)OS(=O)(=O)O)O)O)O,,,,,,
5507,125508,"1-[(1S,3R)-2,2-dichloro-1,3-bis(4-methoxyphenyl)cyclopropyl]-4-phenylmethoxybenzene",COC1=CC=C(C=C1)[C@@H]2[C@](C2(Cl)Cl)(C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OCC5=CC=CC=C5,,,,,,
5508,125509,N-Succinimidyl-5-iodo-3-pyridinecarboxylic acid,C1CC(=O)N(C1=O)OC(=O)C2=CC(=CN=C2)I,,,,,,
5509,125510,2-Benzylmorpholine,C1COC(CN1)CC2=CC=CC=C2,,,,,,
5510,125511,16-Hydroxyequilenin,C[C@]12CCC3=C([C@@H]1C[C@H](C2=O)O)C=CC4=C3C=CC(=C4)O,,,,,,
5511,125512,Neopyrrolomycin,C1=CN(C(=C1Cl)Cl)C2=C(C(=C(C=C2O)Cl)Cl)Cl,,,,,,
5512,125513,N-Methylaminobenzovesamicol,[11CH3]NC1=CC=CC2=C1C[C@H]([C@@H](C2)O)N3CCC(CC3)C4=CC=CC=C4,,,,,,
5513,125514,2-(4-Hydroxyethoxyphenyl)acetic acid,C1=CC(=CC=C1CC(=O)O)OCCO,,,,,,
5514,125515,6-(1-Hydroxyethyl)-2-phenyl-1-oxa-2-penem-3-carboxylic acid,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(O2)C3=CC=CC=C3)C(=O)O)O,,,,,,
5515,125516,Miridesap,C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O,['Treatment of transthyretin amyloidosis (ATTR)'],,,,,
5516,125517,2-Methyl-5-((dimethylamino)methyl)-3-oxoisoxazolidine methiodide,CN1C(=O)CC(O1)C[N+](C)(C)C.[I-],,,,,,
5517,125518,Trimethyl[(2-methyl-3-oxoisoxazolidin-5-yl)methyl]aminium,CN1C(=O)CC(O1)C[N+](C)(C)C,,,,,,
5518,125519,Aminogenistein,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)O)N,,,,,,
5519,125520,5-(4-Piperidyl)isoxazol-3-ol,C1CNCCC1C2=CC(=O)NO2,,,,,,
5520,125521,CID 125521,CC1=C(C2=C(C=C1O)OC(C(C2=O)OC)C3=CC=C(C=C3)O)C,,,,,,
5521,125522,2-Ethyl-8-methyl-1-oxa-8-azaspiro[4.5]decan-3-one,CCC1C(=O)CC2(O1)CCN(CC2)C,,,,,,
5522,125523,CID 125523,CCCCCCC(C=CC#CC#CC(C=C)O)O,,,,,,
5523,125524,CID 125524,[C-]#[N+]C[C@@H]1[C@H](CC(O1)N2C=CC(=O)NC2=O)C(N)(N)N,,,,,,
5524,125525,CID 125525,C1=CSC=C1C2=CNC3=C2NC(=NC3=O)N,,,,,,
5525,125526,"(2S,3S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methyl-2,3-dihydrochromen-4-one",C[C@H]1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,,,,,,
5526,125527,N-3-Fluoropropylputrescine,C(CCNCCCF)CN,,,,,,
5527,125528,CID 125528,CNCCC(COC1=C(C(=C(C=C1)O)O)F)O,,,,,,
5528,125529,2-(4-Fluorophenoxy)-1-(2-hydroxyphenyl)ethane,C1=CC=C(C(=C1)CCOC2=CC=C(C=C2)F)O,,,,,,
5529,125530,"6-Methyl-8-iodo-1,3-dichlordibenzofuran",CC1=CC(=CC2=C1OC3=C2C(=CC(=C3)Cl)Cl)I,,,,,,
5530,125531,CID 125531,CC1CCSC1C(CCC2=CC(=CC=C2)N)C(=N)C,,,,,,
5531,125532,3-Ethynylperylene,C#CC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC5=C4C3=CC=C5,,,,,,
5532,125533,"4-(1,2-Diamino-ethyl)-pyrocatechol",C1=CC(=C(C=C1C(CN)N)O)O,,,,,,
5533,125534,Dcptcl,CC1COC2(CC1O)C(C3CCC(CC3O2)C(=O)O)(CO)O,,,,,,
5534,125535,"Chrysene-5,6-imine",C1=CC=C2C(=C1)C=CC3=C2C4C(N4)C5=CC=CC=C35,,,,,,
5535,125536,"Benzo(g)chrysene-9,10-imine",C1=CC=C2C(=C1)C3C(N3)C4=C2C5=CC=CC=C5C6=CC=CC=C64,,,,,,
5536,125537,4-Methyl-5-(4-pyridinyl)-2(3H)-oxazolone,CC1=C(OC(=O)N1)C2=CC=NC=C2,,,,,,
5537,125538,Glucosylthiazolidine-4-carboxylic acid,C1C(NC(S1)[C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)C(=O)O,,,,,,
5538,125539,CID 125539,CC(C(C=CC(=O)OC1CCC2(CO2)C(C1OC)C3(C(O3)CCC=C(C)C)C)O)O,,,,,,
5539,125540,"(2S-cis)-8-Chloro-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methyl-4H-1-benzopyran-4-one",C[C@H]1[C@H](OC2=C(C1=O)C(=CC(=C2Cl)O)O)C3=CC=C(C=C3)O,,,,,,
5540,125541,N-(3-Aminobenzoyloxy)succinimide,C1CC(=O)N(C1=O)OC(=O)C2=CC(=CC=C2)N,,,,,,
5541,125542,N-(4-Aminobenzoyloxy)succinimide,C1CC(=O)N(C1=O)OC(=O)C2=CC=C(C=C2)N,,,,,,
5542,125543,"3,4-Dimethyl-2-nitro-3H-imidazo[4,5-f]quinoline",CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)[N+](=O)[O-])C,,,,,,
5543,125544,"1,N(6)-Propanodeoxyadenosine",C1CN2C=NC3=C(C2=NC1O)N=CN3[C@H]4C[C@@H]([C@H](O4)CO)O,,,,,,
5544,125545,"(2,2-Difluoro-3,6-dihydroxy-4,5-diphosphonooxycyclohexyl) dihydrogen phosphate",C1(C(C(C(C(C1OP(=O)(O)O)(F)F)O)OP(=O)(O)O)OP(=O)(O)O)O,,,,,,
5545,125546,O-(2-Acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenyl carbamate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1=NOC(=O)NC2=CC=CC=C2)CO)O)O,,,,,,
5546,125547,"(2-Fluoro-3,6-dihydroxy-4,5-diphosphonooxycyclohexyl) dihydrogen phosphate",C1(C(C(C(C(C1OP(=O)(O)O)F)O)OP(=O)(O)O)OP(=O)(O)O)O,,,,,,
5547,125548,"2,3,4-Trimethoxy-4'-acetyl-1,1'-biphenyl",CC(=O)C1=CC=C(C=C1)C2=C(C(=C(C=C2)OC)OC)OC,,,,,,
5548,125549,CID 125549,C1C([C@@H]([C@H](O1)CO)CO)N2C=NC3=C2NC(=NC3=O)N,,,,,,
5549,125550,CID 125550,C1C(C(C(O1)CO)CO)N2C=C(C(=O)NC2=O)C=CBr,,,,,,
5550,125551,2-Methylthio-N(6)-(N-threonylcarbonyl)adenine,C[C@@H]([C@H](C(=O)O)NC(=O)NC1=NC(=NC2=C1NC=N2)SC)O,,,,,,
5551,125552,CID 125552,CC=CC1[C@@](O1)(C)C2=CC(=O)C3=C(C2)C4=C(C=C3CC(=O)O)C(=O)C5=C(C=CC(=C5C4=O)O)O,,,,,,
5552,125553,CID 125553,CC(=O)C1CC2C34COC(C3C(C(=O)O2)OC(=O)C5=CC=CC=C5)(C(C(C4C1(C)CC(=O)O)O)O)C(=O)OC,,,,,,
5553,125554,Isophosphamide bromide mustard,C(CCl)NP(=O)(NCCBr)O,,,,,,
5554,125555,5-Isopropenyl-2-methyl-1-(N-(2-phenylcyclohexyloxycarbonyl)amino)-2-cyclohexene,CC1=CC[C@@H](C[C@H]1NC(=O)O[C@@H]2CCCC[C@H]2C3=CC=CC=C3)C(=C)C,,,,,,
5555,125556,"(3S,4S)-3-amino-1-hydroxy-4-methylpyrrolidin-2-one",C[C@H]1CN(C(=O)[C@H]1N)O,,,,,,
5556,125557,4-(2-Fluorophenyl)-4-(4-fluorophenyl)butanoic acid,C1=CC=C(C(=C1)C(CCC(=O)O)C2=CC=C(C=C2)F)F,,,,,,
5557,125558,"5,6-Methylenedioxy-2-aminoindane",C1C(CC2=CC3=C(C=C21)OCO3)N,,,,,,
5558,125559,"5,6-Methylenedioxy-2-methylaminoindan",CNC1CC2=CC3=C(C=C2C1)OCO3,,,,,,
5559,125560,CID 125560,CC(=O)C(CC1=CC(=C(C(=C1)O)O)N)C(=O)C,,,,,,
5560,125561,"2-Dimethylamino-1-oxa-2,3-dihydro-1H-phenalene",CN(C)C1CC2=CC=CC3=C2C(=CC=C3)O1,,,,,,
5561,125562,CID 125562,C1[C@@H]([C@@H]([C@H](N1)C(=O)O)C(=O)O)C2=CC=CC=C2O,,,,,,
5562,125563,CID 125563,COC1=CC=CC=C1[C@H]2CN[C@@H]([C@H]2C(=O)O)C(=O)O,,,,,,
5563,125564,Blonanserin,CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F,['Used for the treatment of schizophrenia.'],['Blonanserin antagonizes dopamine and serotonin receptors to reduce symptoms of schizophrenia.'],,"['Blonanserin has a Tmax of 1.5 h and a bioavailablity of 55%. Tmax has been observed to be prolonged and relative bioavailability increased when administered with food.', '57% of blonanserin is excreted in the urine and 30% in the feces. Only 5% of the drug in the feces is the parent drug with no parent drug excreted through the urine.', 'Blonanserin has a Vc of 9500 L and a Vt of 8560 L for a total Vd of 18060 L.', 'Blonanserin has a clearance of 1230 L/h.']",['Blonanserin is mainly metabolized by CYP3A4. It undergoes hydoxylation of the cyclooctane ring as well as N-oxidation and N-deethylation of the piperazine ring. The N-deethylated and hydroxylated metabolites are active but to a lesser degree than the parent drug.'],['Blonanserin has a half life of elimination of 10.7-16.2 h.']
5564,125565,CID 125565,C1=CC=C(C=C1)N2C(=O)[C@@H](N=C2S)CC3=CC(=C(C=C3)O)O,,,,,,
5565,125566,"7-(3-Amino-2-methyl-1-azetidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid",C[C@H]1[C@@H](CN1C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F)N,,,,,,
5566,125567,Anis-AM,CC(=O)OCOC(=O)CN(CC(=O)OCOC(=O)C)C1=CC(=CC=C1)OC,,,,,,
5567,125568,[N-acetyl-4-(4-fluorophenyl)anilino] hydrogen sulfate,CC(=O)N(C1=CC=C(C=C1)C2=CC=C(C=C2)F)OS(=O)(=O)O,,,,,,
5568,125569,"5-Chloro-2-methyl-1,2,3,4,8,9,10,10a-octahydronaphth-(1,8-cd)-azepine",CN1CCC2=C(C=CC3=C2C(C1)CCC3)Cl.Cl,,,,,,
5569,125570,"2-Chloro-11-methyl-11-azatricyclo[7.4.1.0^{5,14}]tetradeca-1,3,5(14)-triene",CN1CCC2=C(C=CC3=C2C(C1)CCC3)Cl,,,,,,
5570,125571,6-O-Demethyl-5-deoxyanhydrofusarubin,CC1=CC2=C(CO1)C(=O)C3=C(C2=O)C=C(C=C3O)O,,,,,,
5571,125572,5-Deoxyfusarubin,CC1(CC2=C(CO1)C(=O)C3=C(C2=O)C=C(C=C3O)OC)O,,,,,,
5572,125573,5-Deoxyanhydrofusarubin,CC1=CC2=C(CO1)C(=O)C3=C(C2=O)C=C(C=C3O)OC,,,,,,
5573,125574,CID 125574,CC1=CC(C2=C(C3=C(C=C(C=C3C=C2O1)OC)O[C@H]4[C@@H]([C@H](O[C@H]([C@@H]4O)O)CO)O)O)O,,,,,,
5574,125575,CID 125575,CC1=CC(C2=C(O1)C=C3C(=C(C=C(C3=C2O)O[C@H]4[C@@H]([C@H](O[C@H]([C@@H]4O)O)CO)O)OC)C)O,,,,,,
5575,125576,"1-(3,4-Dimethoxyphenylethyl)-6-methyl-3,4-dihydroisoquinoline",CC1=CC2=C(C=C1)C(=NCC2)CCC3=CC(=C(C=C3)OC)OC.Cl,,,,,,
5576,125577,"1-(3,4-Dimethoxyphenethyl)-6-methyl-3,4-dihydroisoquinoline",CC1=CC2=C(C=C1)C(=NCC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
5577,125578,4-Chlorothreonine,C(C(C(C(=O)O)N)O)Cl,,,,,,
5578,125579,Tetrahydropyridostigmine,CN1CCC=C(C1)OC(=O)N(C)C.Br,,,,,,
5579,125580,"(1-methyl-3,6-dihydro-2H-pyridin-5-yl) N,N-dimethylcarbamate",CN1CCC=C(C1)OC(=O)N(C)C,,,,,,
5580,125581,"2,5-Dioxopyrrolidin-1-yl 6-hydrazinylnicotinate hydrochloride",C1CC(=O)N(C1=O)OC(=O)C2=CN=C(C=C2)NN.Cl,,,,,,
5581,125582,"(2,5-Dioxopyrrolidin-1-yl) 6-hydrazinylpyridine-3-carboxylate",C1CC(=O)N(C1=O)OC(=O)C2=CN=C(C=C2)NN,,,,,,
5582,125583,CID 125583,CCOC(=O)C(=CC1=CC(=C(C=C1)O)O)NC(=O)C,,,,,,
5583,125584,alpha-(beta-Alanyl)hypusine,C(CCNC[C@@H](CCN)O)C[C@H](C(=O)O)NC(=O)CCN,,,,,,
5584,125585,Rhynchotechol,CC1=C(C2=C(C=C1)C(=O)C3=CC(=C(C(=C3C2=O)OC)OC)O)O,,,,,,
5585,125586,CID 125586,C=C(CCl)C=C[C@H]([C@@H](C=CBr)Cl)Cl,,,,,,
5586,125587,Funebradiol,C[C@@H]1C(=C(C(=O)O1)N2C(=CC=C2CO)CO)C,,,,,,
5587,125588,CID 125588,C1[C@@H](N1C(=O)CCC(=O)CC2=CC=CC=C2)C(=O)OCC3=CC=CC=C3,,,,,,
5588,125589,CID 125589,CC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)OC1=C(C=C(C=C1O)O)C=CC2=CC=C(C=C2)O,,,,,,
5589,125590,CID 125590,C1=CC(=CC=C1C[C@@H](CO)NC(=O)CCl)[N+](=O)[O-],,,,,,
5590,125591,3-Amino-1-(3-trifluoromethylphenyl)-6-methyl-1H-pyridazin-4-one,CC1=CC(=O)C(=NN1C2=CC=C(C=C2)C(F)(F)F)N,,,,,,
5591,125592,CID 125592,C([C@@H]1[C@H]([C@H](C(O1)C2=C3C(=NN2)C(=O)N=C(O3)N)O)O)O,,,,,,
5592,125593,CID 125593,CC(C)CCCCCCCCC=CCCC=CCCC(O)O,,,,,,
5593,125594,CID 125594,C(CN(CCN(CCCS)CCS)CCS)CS,,,,,,
5594,125595,"10-(3-Aminopropyl)-8-chlorophenothiazine-2,3-dione",C1=CC2=C(C=C1Cl)N(C3=CC(=O)C(=O)C=C3S2)CCCN,,,['Compounds that bind to and inhibit the action of ADENYLYL CYCLASES. (See all compounds classified as Adenylyl Cyclase Inhibitors.)'],,,
5595,125596,Glycyl-prolyl-methionyl-2-naphthylamide,CSCC[C@@H](C(=O)NC1=CC2=CC=CC=C2C=C1)NC(=O)[C@@H]3CCCN3C(=O)CN,,,,,,
5596,125597,Gly-pro-leu-NH-nap,CCC(C)[C@@H](C(=O)NC1=CC2=CC=CC=C2C=C1)NC(=O)[C@@H]3CCCN3C(=O)CN,,,,,,
5597,125598,"5-(Acetylamino)-2,7-anhydro-3,5-dideoxy-D-glycero-alpha-D-galacto-2-Nonulopyranosonic acid",CC(=O)N[C@@H]1[C@H](CC2(O[C@@H](C1O2)[C@@H](CO)O)C(=O)O)O,,,,,,
5598,125599,"N,N-Diallylpentobarbital",CCC1(C(=O)N(C(=O)N(C1=O)CC=C)CC=C)CCC(C)C,,,,,,
5599,125600,Procainamide 4-hydroxylamine,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NO,,,,,,
5600,125601,4-Nitrosoprocainamide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N=O,,,,,,
5601,125602,"7-Decyl-4-(3,5-dichloro-4-hydroxyphenyl)imino-2-methylnaphthalen-1-one",CCCCCCCCCCC1=CC2=C(C=C1)C(=NC3=CC(=C(C(=C3)Cl)O)Cl)C=C(C2=O)C,,,,,,
5602,125603,"3-Methoxy-4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridine",COC1=NOC2=C1CNCC2,,,,,,
5603,125604,"1,2,3,6-Tetrahydropyridine-4-sulfonic acid",C1CNCC=C1S(=O)(=O)O,,,,,,
5604,125605,Pyrrolidin-3-ylmethanesulfonamide,C1CNCC1CS(=O)(=O)N,,,,,,
5605,125606,N-2-Cyanoethyltranylcypromine,C1[C@H]([C@@H]1NCCC#N)C2=CC=CC=C2,,,,,,
5606,125607,Antibiotic A447 C,CCC1(CC(C2=C(C1OC3CC(C(C(O3)C)OC4CCC(C(O4)C)OC5CCC(C(O5)C)O)N(C)C)C(=C6C(=C2O)C(=O)C7=C(C6=O)C=CC=C7O)O)OC8CC(C(C(O8)C)OC9CCC(C(O9)C)OC1CCC(C(O1)C)O)N(C)C)O,,,,,,
5607,125608,Hernandulcin,CC1=CC(=O)[C@@H](CC1)[C@](C)(CCC=C(C)C)O,,,,,,
5608,125609,CID 125609,CCC(C)[C@@H](C(=O)N[C@H](C)C(=O)NCC(=O)N)N(C(=O)CCl)O,,,,,,
5609,125610,Probimane,CC(CN1CC(=O)N(C(=O)C1)CN2CCOCC2)N3CC(=O)N(C(=O)C3)CN4CCOCC4,,,,,,
5610,125611,Daibs,C1=CC(=C(C=C1C(=O)OC[C@@]2([C@H]([C@@H]([C@H](O2)CO)O)O)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)I)[N+]#N,,,,,,
5611,125612,3-(Bromoacetyl)chloramphenicol,C1=CC(=CC=C1[C@H]([C@@H](COC(=O)CBr)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],,,,,,
5612,125613,Maz sugar,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H]([C@H](O1)OC(=O)C)N(C)NC(=O)N(C)N=O)OC(=O)C)OC(=O)C,,,,,,
5613,125614,"5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-(2-hydroxyethyl)pentanamide",C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCO)NC(=O)N2,,,,,,
5614,125615,"2-[[4-[2-[[5-[7-[[5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-2,4-dioxopyrimido[4,5-b]quinolin-10-yl]-2,3,4-trihydroxypentoxy]-hydroxyphosphoryl]oxypropanoylamino]-4-carboxybutanoyl]amino]pentanedioic acid",CC(C(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)OP(=O)(O)OCC(C(C(CN1C2=C(C=C(C=C2)OP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C(N=CN=C54)N)O)O)C=C6C1=NC(=O)NC6=O)O)O)O,,,,,,
5615,125616,Phenylmethaneselenic acid,C1=CC=C(C=C1)C[Se](=O)O,,,,,,
5616,125617,2-Nitro-4-azidophenylsulfenyl chloride,C1=CC(=C(C=C1N=[N+]=[N-])[N+](=O)[O-])SCl,,,,,,
5617,125618,5-Trifluoromethyl-2'-deoxycytidine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)C(F)(F)F)CO)O,,,,,,
5618,125619,"11-Azapentacyclo(6.2.1).0(2,7).0(4,10).0(5,9)decane",C1C2C3CC4C1C5C2C3C4N5,,,,,,
5619,125620,CID 125620,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C(C(C(C5O)O)O)N6C=NC7=C6C(=O)N=C(N7)N)C=C2,,,,,,
5620,125621,6-Chloro-6-deoxyfructose,C([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)Cl,,,,,,
5621,125622,CID 125622,CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C=CCC1(C)C)C,,,,,,
5622,125623,5'-Sulfamoyl-2-chloroadenosine,C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COS(=O)(=O)N)O)O)Cl)N,,,,,,
5623,125624,Monoacetoacetin,CC(=O)CC(=O)O.C(C(CO)O)O,,,,,,
5624,125625,"(2R,3R,4S,5S,6R)-2-hex-3-enoxy-6-(hydroxymethyl)oxane-3,4,5-triol",CCC=CCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
5625,125626,"2-Ethyl-3-hydroxy-2,4,4-trimethyloxazolidine",CCC1(N(C(CO1)(C)C)O)C,,,,,,
5626,125627,(2S)-2-[[(2R)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-methylsulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid,CCC(C)[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC(=O)OC(C)(C)C,,,,,,
5627,125628,Butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine,CC(C)C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C,,,,,,
5628,125629,4-Hydroxy-13-cis-retinoic acid,CC1=C(C(CCC1O)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,,,,,,
5629,125630,gamma-Ketotriazole,CC(C)(C)C(=O)C=C(C1=CC=CC=C1OC)N2C=NC=N2,,,,,,
5630,125631,4-((Bromoacetyl)amino)phenyl arsenoxide,C1=CC(=CC=C1NC(=O)CBr)[As]=O,,,,,,
5631,125632,5-Aza-cytidine-5'monophosphate,C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)COP(=O)(O)O)O,,,,,,
5632,125633,"N,N,N'-Tri(beta-chloroethyl)-N'-(4-formylphenyl)-1,3-propylenediamine",C1=CC(=CC=C1C=O)N(CCCN(CCCl)CCCl)CCCl,,,,,,
5633,125634,Rugulin,CC1=CC2=C(C(=C1)O)C(=O)C34C(=O)C5C(C6C3(C2=O)C7C(C6C58C4(C7=O)C(=O)C9=C(C8=O)C=C(C=C9O)C)OC)OC,,,,,,
5634,125635,Cyclamiretin C,CC1(C2CCC3(C(C2(CCC1O)C)CC=C4C3(CC(C56C4CC(CC5)(C(OC6)O)C)O)C)C)C,,,,,,
5635,125636,"(5,14-Diacetyloxy-17-hydroxy-4,8,12-trimethyl-16-methylidene-3,18-dioxatricyclo[13.3.0.02,4]octadeca-7,11-dien-9-yl) acetate",CC1=CCC(C(=CCC(C2(C(O2)C3C(C(C1)OC(=O)C)C(=C)C(O3)O)C)OC(=O)C)C)OC(=O)C,,,,,,
5636,125637,7alpha-Apta,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)[C@@H](CC4=CC(=O)CC[C@]34C)SC5=CC=C(C=C5)N,,,,,,
5637,125638,CID 125638,C[C@@]1(CC[C@]2(CC[C@@]3(C(=CC[C@H]4[C@@]3(CC[C@@H]5C4C[C@H]([C@H]([C@]5(C)CO)O[C@@H]6[C@@H]([C@@H]([C@@H](CO6)O[C@@H]7C[C@H]([C@H]([C@H]([C@@H]7O)O)O)CO)O)O)O)C)[C@@H]2C1)C)C(=O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)O)C(=O)OC,,,,,,
5638,125639,"3,12-Dihydroxyhexadecanoic acid",CCCCC(CCCCCCCCC(CC(=O)O)O)O,,,,,,
5639,125640,"L-Prolinamide, glycyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-",CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@@H]3CCCN3C(=O)CN,,,,,,
5640,125641,7-Hydroxycoumarin glucuronide,C1=CC(=CC2=C1C=CC(=O)O2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,,,,,,
5641,125642,CID 125642,CC(=O)C=C(C1=CC=CC=C1)[O-].CC(=O)C=C(C1=CC=CC=C1)[O-].[Ti+4].[Br-].[Br-],,,,,,
5642,125643,"[[(2R,3S,4R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R,4S,5S,6R)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate",C1=CN(C(=O)NC1=O)C2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)F)O)O,,,,,,
5643,125644,"2,5-Diamino-6-[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-ylidene]hexanoic acid",C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(=CC(CCC(C(=O)O)N)N)O3)O)O)N,,,,,,
5644,125645,CID 125645,C1=C(C=C(C=C1N[N+]#N)O)C(=O)[O-],,,,,,
5645,125646,CID 125646,C1=C(C=C(C=C1N[N+]#N)O)C(=O)O,,,,,,
5646,125647,CID 125647,CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)C(=O)OC[C@H]([C@H]([C@@H]([C@H](C=O)NC(=O)C)O[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)N)O)O,,,,,,
5647,125648,CID 125648,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)F)O)O)NC(=NC2=O)N,,,,,,
5648,125649,"9H-Xanthene-2-carboxylic acid, 5-hexyl-7-(S-methylsulfonimidoyl)-9-oxo-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)",CCCCCCC1=C2C(=CC(=C1)S(=N)(=O)C)C(=O)C3=C(O2)C=CC(=C3)C(=O)O.C(C(CO)(CO)N)O,,,,,,
5649,125650,"1H-Imidazo(4,5-c)pyridin-4-amine, 1-(5-S-(2-methylpropyl)-5-thio-beta-D-ribofuranosyl)-",CC(C)CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C2C=CN=C3N)O)O,,,,,,
5650,125651,Methylazoxyprocarbazine,CC(C)NC(=O)C1=CC=C(C=C1)CN=[N+](C)[O-],,,,,,
5651,125652,Gal-xyl-ser,C1C([C@@H]([C@H]([C@@H](O1)OC[C@@H](C(=O)O)N)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
5652,125653,Methylphosphonofluoridic acid 4-(1-pyrenyl)butyl ester,CP(=O)(OCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1)F,,,,,,
5653,125654,Cytarazid,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)N=[N+]=[N-],,,,,,
5654,125655,"Propanamide, N-(3,4-dichlorophenyl)-N-(2-(dimethylamino)cyclopentyl)-, cis-",CCC(=O)N([C@@H]1CCC[C@@H]1N(C)C)C2=CC(=C(C=C2)Cl)Cl,,,,,,
5655,125656,"(4S,4aS,7R,7aR,12bS)-7-amino-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol",C1C[C@]2([C@@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1N)OC5=C(C=C4)O)O,,,,,,
5656,125657,"8,9,10,11-Tetrahydrobenz(a)anthracene",C1CCC2=C(C1)C=C3C=CC4=CC=CC=C4C3=C2,,,,,,
5657,125658,1beta-D-Arabinofuranosylcytosine diphosphate choline,C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
5658,125659,ara-CDP-choline,C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
5659,125660,"13-Hydroxyoctadeca-9,12-dienoic acid",CCCCCC(=CCC=CCCCCCCCC(=O)O)O,,,,,,
5660,125661,"1a,9b-Dihydro-1H-phenanthro(9,10-b)azirine",C1=CC=C2C(=C1)C3C(N3)C4=CC=CC=C42,,,,,,
5661,125662,"trans-9,10-Dihydro-9,10-dihydroxy-3-methylcholanthrene",CC1=C2CCC3=C2C(=CC4=C3C=CC5=C4C=CC(C5O)O)C=C1,,,,,,
5662,125663,7-Hydroxyellipticine,CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=CC=C4O)C,,,,,,
5663,125664,CID 125664,CC1C(C(CC(O1)OC2CC(CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)C)O)N(C)C)O,,,,,,
5664,125665,"2-[6-[4-amino-5-(hydroxymethyl)-2-oxopyrimidin-1-yl]-3-[(2-amino-3-hydroxypropanoyl)amino]-3,6-dihydro-2H-pyran-2-yl]-5-(diaminomethylideneamino)-2,4-dihydroxypentanoic acid",C1=CC(OC(C1NC(=O)C(CO)N)C(CC(CN=C(N)N)O)(C(=O)O)O)N2C=C(C(=NC2=O)N)CO,,,,,,
5665,125666,"(3S,4aR,10aS)-3,6,9-trihydroxy-7-methoxy-3-methyl-1,4,4a,10a-tetrahydrobenzo[g]isochromene-5,10-dione",C[C@]1(C[C@@H]2[C@@H](CO1)C(=O)C3=C(C2=O)C(=C(C=C3O)OC)O)O,,,,,,
5666,125667,S-Nitrosocysteamine,C(CSN=O)N,,,,,,
5667,125668,"[2-(2,2-Dimethylpropanoyloxy)-4-[1-hydroxy-2-[[2-methyl-1-[(2-phenoxyacetyl)amino]propan-2-yl]amino]ethyl]phenyl] 2,2-dimethylpropanoate",CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC(C)(C)CNC(=O)COC2=CC=CC=C2)O)OC(=O)C(C)(C)C,,,,,,
5668,125669,Esterastin,CCCCCCC1C(OC1=O)CC(CC=CCC=CCCCCC)OC(=O)C(CC(=O)N)NC(=O)C,,,,,,
5669,125670,CID 125670,CCC1(CC2CN(C1)C3C2C(C4=C(C3)C5=CC=CC=C5N4)(C6=C(C=C7C(=C6)C89CCN1C8C(C=CC1)(C(C1(C9N7C)C(=O)N(C(=O)O1)CCCl)OC(=O)C)CC)OC)C(=O)OC)O,,,,,,
5670,125671,"2-Naphthalenamine, 1,2,3,4-tetrahydro-5,8-dimethoxy-N,N-dimethyl-",CN(C)C1CCC2=C(C=CC(=C2C1)OC)OC,,,,,,
5671,125672,"L-Valine, N-(1-L-lysyl-L-prolyl)-",CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N,,,,,,
5672,125673,"3-Methyl-2-nitro-1-(2,3-epoxypropoxy)benzene",CC1=C(C(=CC=C1)OCC2CO2)[N+](=O)[O-],,,,,,
5673,125674,Fluorene-9-spiro-5'-oxazolidinedione,C1=CC=C2C(=C1)C3=CC=CC=C3C24C(=O)NC(=O)O4,,,,,,
5674,125675,"14-Methyl-5-oxo-7,8,8a,13a-tetrahydro-5h-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-14-ium-13-ide",C[N+]1=C2C3C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5[N-]3,,,,,,
5675,125676,"21-Methyl-3,13-diaza-21-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),4,6,8,15,17,19-heptaen-14-one",C[N+]1=C2C3C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3,,,,,,
5676,125677,"7-Hydroxy-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinoline",C1C[C@H]2[C@@H](CCC3=C2C=CC=C3O)NC1.Br,,,,,,
5677,125678,"(4aR,10bR)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-7-ol",C1C[C@H]2[C@@H](CCC3=C2C=CC=C3O)NC1,,,,,,
5678,125679,"10-Azabenzo(a)pyrene 4,5-oxide",C1=CC2=C3C(=C1)C4C(O4)C5=C3C(=C6C(=C5)C=CC=N6)C=C2,,,,,,
5679,125680,"(8S,11S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-11-thiophen-2-yl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O)C5=CC=CS5,,,,,,
5680,125681,"N-(2,4-diaminoquinazolin-6-yl)-N-[[4-[[(2,4-diaminoquinazolin-6-yl)-formylamino]methyl]phenyl]methyl]formamide",C1=CC(=CC=C1CN(C=O)C2=CC3=C(C=C2)N=C(N=C3N)N)CN(C=O)C4=CC5=C(C=C4)N=C(N=C5N)N,,,,,,
5681,125682,"Cholestan-3-ol, 24,25-epoxy-, (3alpha,5beta)-",C[C@H](CCC1C(O1)(C)C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4(CC[C@H](C5)O)C)C,,,,,,
5682,125683,o-Methyl o-naphthalen-1-yl o-(4-nitrophenyl) phosphorothioate,COP(=S)(OC1=CC=C(C=C1)[N+](=O)[O-])OC2=CC=CC3=CC=CC=C32,,,,,,
5683,125684,CID 125684,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C=C(C=C4)N[N+]#N)N=C3[O-],,,,,,
5684,125685,CID 125685,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C=C(C=C4)N[N+]#N)NC3=O,,,,,,
5685,125686,"4-(2-(2-Chlorophenyl)ethyl)amino-8-methoxy-3,10-dimethyl-2,9-dioxatricyclo(4,3,1,0(3,7))decane",C[C@H]1[C@@H]2C[C@@H]([C@@]3([C@@H]2[C@H](O[C@H]1O3)OC)C)NCCC4=CC=CC=C4Cl,,,,,,
5686,125687,"Tributan-2-yl 3-(2,2,3,3,4,4,4-heptafluorobutanoylamino)propane-1,1,3-tricarboxylate",CCC(C)OC(=O)C(CC(C(=O)OC(C)CC)NC(=O)C(C(C(F)(F)F)(F)F)(F)F)C(=O)OC(C)CC,,,,,,
5687,125688,"Methyl 4-(acetyloxy)-15-[3-ethyl-6-(methoxycarbonyl)-3,4,5,5a,6,7,12,12a-octahydro-2H-1,5-methanoazepino[3,2-b]carbazol-6-yl]-1-formyl-3-hydroxy-16-methoxyaspidospermidine-3-carboxylate",CCC1CC2CN(C1)C3C2C(C4=C(C3)C5=CC=CC=C5N4)(C6=C(C=C7C(=C6)C89CCN1C8C(CCC1)(C(C(C9N7C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,,,,,,
5688,125689,"3-(3,5-Dioxo-1,2,4-triazolidin-1-yl)alanine",C(C(C(=O)O)N)N1C(=O)NC(=O)N1,,,,,,
5689,125690,CID 125690,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(C)C(C=O)F)C,,,,,,
5690,125691,2'-Deoxy-2'-fluoroadenosine 5'-(dihydrogen phosphate),C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)F)N,,,,,,
5691,125692,"3-(4,6-dihydroxy-3-methyl-11-oxo-5,6,6a,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-N-methylprop-2-enamide",CC1=C(C2=C(C=C1)C(=O)N3CC(=CC3C(N2)O)C=CC(=O)NC)O,,,,,,
5692,125693,Diphenylphosphoric toluene-4-sulfonic anhydride,CC1=CC=C(C=C1)S(=O)(=O)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
5693,125694,"4-[(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]-3-methylphenol;hydrochloride",CC1=C(C=CC(=C1)O)C=NNC2=NCCN2.Cl,,,,,,
5694,125695,"4-[(4,5-Dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]-3-methylphenol",CC1=C(C=CC(=C1)O)C=NNC2=NCCN2,,,,,,
5695,125696,Pyridoxal diphosphate,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)OP(=O)(O)O,,,,,,
5696,125697,"N-[2-[[(2R,11bS)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]-methylsulfonylamino]ethyl]methanesulfonamide",CS(=O)(=O)NCCN([C@@H]1CCN2CCC3=CC=CC=C3[C@@H]2C1)S(=O)(=O)C,,,,,,
5697,125698,CID 125698,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5[C@H]([C@H](O[C@@H]5OC4=C1)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,,,,
5698,125699,Hsal-chlorambucil,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC(=O)N4)C)OC(=O)CCCC5=CC=C(C=C5)N(CCCl)CCCl,,,,,,
5699,125700,Amcccdb,CC(=O)OCC1=C(N2[C@@H]([C@H](C2=O)Cl)S(=O)(=O)C1)C(=O)OC(C)(C)C,,,,,,
5700,125701,N-Fluoroacetylgalactosamine,C([C@H]([C@@H]([C@@H]([C@H](C=O)NC(=O)CF)O)O)O)O,,,,,,
5701,125702,N-Carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)OCC4=CC=CC=C4,,,,,,
5702,125703,"2-[5-Methyl-6-(3,5,7,13-tetrahydroxy-4,6,12,14,16-pentamethylnonadeca-10,14-dien-2-yl)oxan-2-yl]propanoic acid",CCCC(C)C=C(C)C(C(C)C=CCCC(C(C)C(C(C)C(C(C)C1C(CCC(O1)C(C)C(=O)O)C)O)O)O)O,,,,,,
5703,125704,"5,10-Dideazaaminopterin",C1=CC(=CC=C1CCC2=CC3=C(N=C(N=C3N=C2)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
5704,125705,"(2S)-2-[[4-[2-(2,4-diamino-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioic acid",C1C(CNC2=NC(=NC(=C21)N)N)CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
5705,125706,CID 125706,CCCCCC(NC1=CC=CC=C1C2=C3C=CC(=N3)C(=C4C=CC(=N4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC=CC=C7NC(=O)CCCCC)C8=CC=CC=C8NC(=O)CCCCC)C9=CC=CC=C9NC(CCCCC)O)O,,,,,,
5706,125707,"1H-Indole-4-ethanamine, 5-ethyl-",CCC1=C(C2=C(C=C1)NC=C2)CCN,,,,,,
5707,125708,Dibromobimane,CC1=C(N2C(=C(C(=O)N2C1=O)C)CBr)CBr,,,,,,
5708,125709,Basacv,CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)OCC(C(=O)N1)NC3=C4C=CC=CC4=NC5=CC=CC=C53)C(C)C)NC(=O)C(NC(=O)C(COC(=O)C(NC2=O)C(C)C)NC6=C7C=CC=CC7=NC8=CC=CC=C86)C,,,,,,
5709,125710,"(6R)-7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxo-N-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhepta-2,4-dienamide",C[C@H](C=C(C)C=CC(=O)NO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C(=O)C2=CC=C(C=C2)N(C)C,,,,,,
5710,125711,"2,4(1H,3H)-Pyrimidinedione, 1-(2,3-dihydro-2-furanyl)-5-fluoro-",C1C=COC1N2C=C(C(=O)NC2=O)F,,,,,,
5711,125712,"1,1'-(p-Phenylenebis(vinylene-p-phenylene))bis(pyridinium) di-p-toluenesulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].CC1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=[N+](C=C1)C2=CC=C(C=C2)C=CC3=CC=C(C=C3)C=CC4=CC=C(C=C4)[N+]5=CC=CC=C5,,,,,,
5712,125713,1-[4-[2-[4-[2-(4-Pyridin-1-ium-1-ylphenyl)ethenyl]phenyl]ethenyl]phenyl]pyridin-1-ium,C1=CC=[N+](C=C1)C2=CC=C(C=C2)C=CC3=CC=C(C=C3)C=CC4=CC=C(C=C4)[N+]5=CC=CC=C5,,,,,,
5713,125714,"Naphthalene-1-carboxylic acid 1-hydroxy-2,2,6,6-tetramethylpiperidine-4-yl ester",CC1(CC(CC(N1O)(C)C)OC(=O)C2=CC=CC3=CC=CC=C32)C,,,,,,
5714,125715,"4-[[4-(Dimethylamino)-5-[4-hydroxy-5-(5-hydroxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]methyl]-1-[4-(dimethylamino)-5-[4-hydroxy-5-(5-hydroxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-3-ethyl-3,5,10,12-tetrahydroxy-1,4-dihydronaphtho[2,3-g]isochromene-6,11-dione",CCC1(C(C2=C(C(O1)OC3CC(C(C(O3)C)OC4CC(C(C(O4)C)OC5CCC(C(O5)C)O)O)N(C)C)C(=C6C(=C2O)C(=O)C7=C(C6=O)C(=CC=C7)O)O)CC8CC(C(C(O8)C)OC9CC(C(C(O9)C)OC1CCC(C(O1)C)O)O)N(C)C)O,,,,,,
5715,125716,"1,3-Bis(dimethylamino)propan-2-yl 2-(4-chlorophenoxy)acetate;dihydrochloride",CN(C)CC(CN(C)C)OC(=O)COC1=CC=C(C=C1)Cl.Cl.Cl,,,,,,
5716,125717,"1,3-Bis(dimethylamino)propan-2-yl 2-(4-chlorophenoxy)acetate",CN(C)CC(CN(C)C)OC(=O)COC1=CC=C(C=C1)Cl,,,,,,
5717,125718,Dmupdab,CCCCCCCCCCC[N+](C)(C)CCN(C)CC[N+](C)(C)CCCCCCCCCCC.[Br-].[Br-],,,,,,
5718,125719,2-[2-[Dimethyl(undecyl)azaniumyl]ethyl-methylamino]ethyl-dimethyl-undecylazanium,CCCCCCCCCCC[N+](C)(C)CCN(C)CC[N+](C)(C)CCCCCCCCCCC,,,,,,
5719,125720,1-(6-Methylergoline-8-yl)hydantoin,CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC5=O,,,,,,
5720,125721,"(R)-2-((5-Fluoro-2,4-dinitrophenyl)amino)propanamide",C[C@H](C(=O)N)NC1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])F,,,,,,
5721,125722,"N,N-Diethylcyclohexaneacetamide",CCN(CC)C(=O)CC1CCCCC1,,,,,,
5722,125723,CID 125723,CCCCCC=CC[C@H]1[C@@H](O1)C=CC=CC=CCCCC(=O)O,,,,,,
5723,125724,"3,4-Dihydro-2,4,5,7-tetrahydroxy-3-methoxy-2-methyl-1,6,11(2H)-naphthacenetrione",CC1(C(C(C2=C(C3=C(C=C2C1=O)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O)OC)O,,,,,,
5724,125725,Chitinovorin B,CC(C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(CC(=O)OCC1=C(N2C(C(C2=O)(NC=O)NC(=O)CCCC(C(=O)O)N)SC1)C(=O)O)O)N,,,,,,
5725,125726,"1,2,3,4-Tetrahydro-1,3-bis(hydroxymethyl)-8-hydroxy-6-methyl-7-methoxyisoquinoline",CC1=CC2=C([C@H](N[C@H](C2)CO)CO)C(=C1OC)O,,,,,,
5726,125727,"3-Azido-2-methyl-5-methoxy-6-(3,7-dimethyloctyl)-1,4-benzoquinone",CC1=C(C(=O)C(=C(C1=O)CCC(C)CCCC(C)C)OC)N=[N+]=[N-],,,,,,
5727,125728,CID 125728,CC1=C(C(=O)C(=C(C1=O)CCC(C)CCCC(C)C)OC)N[N+]#N,,,,,,
5728,125729,15-Deacetylsergeolide,CC1C2CC3C45COC(C4C(C(=O)O3)O)(C(C(C5C2(C=C6C1=CC(=O)O6)C)O)O)C(=O)OC,,,,,,
5729,125730,"[(2R)-2,3-di(hexadecanoyloxy)propyl] 2-[dimethyl-[(1,2,6-trimethyl-3,5-dioxopyrazolo[1,2-a]pyrazol-7-yl)methyl]azaniumyl]ethyl phosphate",CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)CC1=C(C(=O)N2N1C(=C(C2=O)C)C)C)OC(=O)CCCCCCCCCCCCCCC,,,,,,
5730,125731,"2-[[(2R)-2,3-di(hexadecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-dimethyl-[(1,2,6-trimethyl-3,5-dioxopyrazolo[1,2-a]pyrazol-7-yl)methyl]azanium",CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)CC1=C(C(=O)N2N1C(=C(C2=O)C)C)C)OC(=O)CCCCCCCCCCCCCCC,,,,,,
5731,125732,I-N3-Naps,C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCC4=CC(=C(C=C4)N=[N+]=[N-])[125I])CCCC(=O)C5=CC=C(C=C5)F,,,,,,
5732,125733,2alpha-Hydroxyalantolactone,C[C@H]1C[C@@H](C[C@]2(C1=C[C@H]3[C@@H](C2)OC(=O)C3=C)C)O,,,,,,
5733,125734,"8-Amino-3-D-ribofuranosyl-1,2,4-triazolo(4,3-a)pyrazine",C1=CN2C(=NN=C2C(=N1)N)C3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
5734,125735,beta-Fluoroaspartic acid,[C@H]([C@H](C(=O)O)F)(C(=O)O)N,,,,,,
5735,125736,"8,11,12-Trihydroxyicosa-5,9,14-trienoic acid",CCCCCC=CCC(C(C=CC(CC=CCCCC(=O)O)O)O)O,,,,,,
5736,125737,1-(7-Carboxyheptyl)imidazole,C1=CN(C=N1)CCCCCCCC(=O)O,,,,,,
5737,125738,"trans-1,2-Dihydro-1,2-dihydroxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)[C@H]([C@@H](C=C3)O)O,,,,,,
5738,125739,5-Trimethylsilyl-2'-deoxyuridine,C[Si](C)(C)C1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
5739,125740,Ergotamine tartrate and caffeine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCCC3C2O1)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.CN1C=NC2=C1C(=O)N(C(=O)N2C)C.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O,,,,,,
5740,125741,"(6aR,9R)-N-[(4R,7S)-7-benzyl-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide",C[C@@]1(C(=O)N2[C@H](C(=O)N3CCCC3C2O1)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,,,,,,
5741,125742,Dvllap,CC(C)C[C@@H](C(=O)NC(=O)[C@H](CCCCN)NC1=CC(=CC(=C1)C(=O)OC)C(=O)OC)NC(=O)[C@@H](C(C)C)N.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O,,,,,,
5742,125743,"dimethyl 5-[[(2S)-6-amino-1-[[(2S)-2-[[(2R)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-1-oxohexan-2-yl]amino]benzene-1,3-dicarboxylate",CC(C)C[C@@H](C(=O)NC(=O)[C@H](CCCCN)NC1=CC(=CC(=C1)C(=O)OC)C(=O)OC)NC(=O)[C@@H](C(C)C)N,,,,,,
5743,125744,"1-[(3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione",C1=CN(C(=O)NC1=O)C2[C@H]([C@@H]([C@H](O2)CO)O)F,,,,,,
5744,125745,"5-fluoro-1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-4-hydroxy-pyrimidin-2-one",C1=C(C(=O)NC(=O)N1[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F)F,,,,,,
5745,125746,Dhbdu,B(C1=CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)CO)O)(O)O,,,,,,
5746,125747,beta-Ethylstyrene oxide,CC[C@@H]1[C@@H](O1)C2=CC=CC=C2,,,,,,
5747,125748,Anthglutin,C1=CC=C(C(=C1)C(=O)O)NNC(=O)CC[C@@H](C(=O)O)N,,,,,,
5748,125749,"(1)Benzopyrano(5,4,3-cde)(1,3)dioxolo(4,5-h)(1)benzopyran-5,11-dione, 1,2,3-trimethoxy-",COC1=C(C(=C2C3=C1C(=O)OC4=C3C(=CC5=C4OCO5)C(=O)O2)OC)OC,,,,,,
5749,125750,"(2S)-2-amino-3-[[(2R)-2,3-di(octadec-9-enoyloxy)propoxy]-hydroxyphosphoryl]oxypropanoic acid",CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
5750,125751,N-Butyl-N-(3-formylpropyl)nitrosamine,CCCCN(CCCC=O)N=O,,,,,,
5751,125752,"Phosphonic acid, (1-(1-hydroxy-2,2,2-trichloroethoxy)-2,2,2-trichloroethyl)-, dimethyl ester",COP(=O)(C(C(Cl)(Cl)Cl)OC(C(Cl)(Cl)Cl)O)OC,,,,,,
5752,125753,CID 125753,C1=[N+](C2=C(N1CCF)C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)[O-],,,,,,
5753,125754,CID 125754,C1=[N+](C2=C(N1CCF)C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H](C(O3)CO)O)O,,,,,,
5754,125755,"methyl 2-(3-ethylidene-5-methyl-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-5-ium-2-yl)-3-hydroxypropanoate",CC=C1C[N+]2(CCC3=C(C2CC1C(CO)C(=O)OC)NC4=CC=CC=C34)C,,,,,,
5755,125756,N-Methyldimaprit,CN=C(N)SCCCN(C)C,,,,,,
5756,125757,"5-Hexyne-1,4-diamine",C#CC(CCCN)N,,,['Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)'],,,
5757,125758,p-Hydroxylevamisole,C1CSC2=N[C@H](CN21)C3=CC=C(C=C3)O,,,,,,
5758,125759,Ige decapeptide,C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CCCCN)N)O,,,,,,
5759,125760,Cycloa-cyclocptltc,CC(C1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)NC(=O)CCCCCCNC2=O)O,,,,,,
5760,125761,4-methoxy-5-[(2Z)-2-[(2-methoxy-4-nitro-5-sulfo-phenyl)diazenyl-(phenylcarbamoyl)methylidene]hydrazinyl]-2-nitro-benzenesulfonic acid,COC1=CC(=C(C=C1NN=C(C(=O)NC2=CC=CC=C2)N=NC3=CC(=C(C=C3OC)[N+](=O)[O-])S(=O)(=O)O)S(=O)(=O)O)[N+](=O)[O-],,,,,,
5761,125762,CID 125762,CC=C(C)C(=O)O[C@@H]1[C@H]2C(=CC(=O)[C@H]([C@@]2(C3C(=O)[C@@H]([C@@H]([C@H]4[C@@]3(C1OC(=O)C4)COC(=O)C)C)OC(=O)C)C)OC(=O)C)C,,,,,,
5762,125763,"1alpha,2alpha-Epoxyhexahydrocannabinol",CCCCCC1=CC(=C2C3C(CCC4(C3O4)C)C(OC2=C1)(C)C)O,,,,,,
5763,125764,2-(5-Fluorouracil-1-yl)tetrahydrothiophene 1-oxide,C1CC(S(=O)C1)N2C=C(C(=O)NC2=O)F,,,,,,
5764,125765,"4-Ethoxy-1,4-dihydro-2,3-benzodioxin-1-ol",CCOC1C2=CC=CC=C2C(OO1)O,,,,,,
5765,125766,2-Deoxy-2-fluoro-L-fucose,C[C@@H]([C@H]([C@H]([C@@H](C=O)F)O)O)O,,,,,,
5766,125767,Dachp,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)OC(=O)C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)OC(=O)C,,,,,,
5767,125768,His-PG,CC(=O)[C@H]1CCC2[C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)OC(=O)CCC(=O)NCCC5=CN=CN5)C,,,,,,
5768,125769,6-O-Methylbouvardin,C[C@@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N(C2CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H](C(=O)N1)N(C2=O)C)OC)C)C)CC5=CC=C(C=C5)OC)C)CO,,,,,,
5769,125770,"9-Hydroxy-2,5,6,11-tetramethylpyrido(4,3-b)carbazolium chloride",CC1=C2C=C[N+](=CC2=C(C3=C1N(C4=C3C=C(C=C4)O)C)C)C,,,,,,
5770,125771,2-Methylellipticinium,CC1=C2C=C[N+](=CC2=C(C3=C1NC4=CC=CC=C43)C)C,,,,,,
5771,125772,"7-[4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(1-hydroxyethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(C)O)O)N(C)C)O,,,,,,
5772,125773,2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid,C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
5773,125774,Vinthionine,C=CSCC[C@@H](C(=O)O)N,,,,,,
5774,125775,"2,4-Dinitroimidazole-1-ethanol",C1=C(N=C(N1CCO)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5775,125776,Canavalmine,C(CCNCCCNCCCCN)CN,,,,,,
5776,125777,3-(2-Hydroxyethyl)histidine,C1=C(N(C=N1)CCO)C[C@@H](C(=O)O)N,,,,,,
5777,125778,CID 125778,C[C@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NC(=O)[C@H](CC2=CC=CC=C2)NC3=CC=C(C=C3)[N+](=O)[O-])NC(=O)CCC(=O)O,,,,,,
5778,125779,Dttp gamma-4-(N-2-chloroethyl-N-methylamino)benzylamidate,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(NCC3=CC=C(C=C3)N(C)CCCl)O)O,,,,,,
5779,125780,3-Nitrosomethylaminopyridine,CN(C1=CN=CC=C1)N=O,,,,,,
5780,125781,CID 125781,CC1=C(OC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C)S(=O)(=O)[O-].[Na+],,,,,,
5781,125782,Tanshinone iia sulfonic acid,CC1=C(OC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C)S(=O)(=O)O,,,,,,
5782,125783,CID 125783,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3CC(O[C@@H]3COP(=O)(O)OC4C[C@@H](O[C@@H]4CO)N5C=CC(=NC5=O)N)N6C=NC7=C6NC(=NC7=O)N)O,,,,,,
5783,125784,(S)-1-Fluoro-3-(1H-imidazol-4-yl)propan-2-amine,C1=C(NC=N1)C[C@@H](CF)N,,,,,,
5784,125785,4-Diazophenylphosphocholine,C[N+](C)(C)CCOP(=O)(O)OC1=CC=C(C=C1)N=[N-],,,,,,
5785,125786,2-[(4-Diazenylphenoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium,C[N+](C)(C)CCOP(=O)(O)OC1=CC=C(C=C1)N=N,,,,,,
5786,125787,CID 125787,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OP(=O)(C)S,,,,,,
5787,125788,CID 125788,CCCCC[C@H](C=CC1C[C@H]2C[C@@H]([C@@H]1CC=CCCCC(=O)O)C2(C)C)O,,,,,,
5788,125789,3-Hydroxy-5-cholenoylglycine,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
5789,125790,3-(Naphthalen-1-ylamino)-1-phenylprop-2-en-1-one,C1=CC=C(C=C1)C(=O)C=CNC2=CC=CC3=CC=CC=C32,,,,,,
5790,125791,Prochlorperazine mesilate,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
5791,125792,CID 125792,CC1CC(=O)C(C(C1=O)C)C(C)(C)CC(=O)O,,,,,,
5792,125793,CID 125793,C1=CC=C(C(=C1)C(=CC=CC(=O)C(=O)O)O)O,,,,,,
5793,125794,Actiketal,CC1=CC(=C2C(=C1)C(=O)C(O2)(C3CC(=O)NC(=O)C3)O)C,,,,,,
5794,125795,3-[4-(4-Hydroxyphenyl)hex-3-en-3-yl]phenol,CCC(=C(CC)C1=CC(=CC=C1)O)C2=CC=C(C=C2)O,,,,,,
5795,125796,[(4R)-4-hydroxy-6-oxocyclohexen-1-yl] benzoate,C1C=C(C(=O)C[C@@H]1O)OC(=O)C2=CC=CC=C2,,,,,,
5796,125797,CID 125797,CC1=C(C(CCC1OCCO)(C)C)C=CC=CC=CC(=CC(=O)O)C,,,,,,
5797,125798,CID 125798,B(C1CCCN1C(C2CCCN2)O)(O)O,,,,,,
5798,125799,"2-Amino-2,3-methano-4-phosphonobutanoic acid",C1[C@H]([C@]1(C(=O)O)N)CP(=O)(O)O,,,,,,
5799,125800,"2,3,4a,5,6,10b-Hexahydro-7-hydroxy-2-methylbenzo(f)quinoline-4(1H)-ethanol",C[C@H]1C[C@@H]2[C@H](CCC3=C2C=CC=C3O)N(C1)CCO,,,,,,
5800,125801,5-Amino-N-(2-(diethylamino)ethyl)-5-fluoro-2-methoxybenzamide,CCN(CC)CCNC(=O)C1=C(C(=CC(=C1)F)N)OC,,,,,,
5801,125802,5-Amino-N-(2-(diethylamino)ethyl)-4-fluoro-2-methoxybenzamide,CCN(CC)CCNC(=O)C1=C(C(=CC(=C1)N)F)OC,,,,,,
5802,125803,2-Methoxy-4-fluoro-3-amino-N-((2-methylcyclopropylamino)ethyl)benzamide,CC1CC1NCCNC(=O)C2=C(C(=C(C=C2)F)N)OC,,,,,,
5803,125804,S-(2-Hydroxy-3-buten-1-yl)glutathione,C=CC(CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,,,,
5804,125805,S-(1-Hydroxy-3-buten-2-yl)glutathione,C=CC(CO)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
5805,125806,"2,6-Dimethyl-4-furyl-1,4-dihydropyridine-5-dicarboxylate",CC1=C(C(C(=C(N1)C)C(=O)O)C2=CC=CO2)C(=O)O,,,,,,
5806,125807,4-Azidophenylpropionamide,C1=CC(=CC=C1CCC(=O)N)N=[N+]=[N-],,,,,,
5807,125808,"1-Thyminylglucosamine-4,6-disulfate",CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O)OS(=O)(=O)O)O)N,,,,,,
5808,125809,CID 125809,C1=CC=C2C(=C1)C=CC=C2CCCC3=C(N=C(C(=N3)Cl)N)N,,,,,,
5809,125810,4-Borono-2-fluoro-L-phenylalanine,B(C1=CC(=C(C=C1)CC(C(=O)O)N)[18F])(O)O,,,,,,
5810,125811,Trimethoxyphosphorane,COP([O-])([O-])(OC)OC,,,,,,
5811,125812,Trimethoxyphosphoranediol,COP(O)(O)(OC)OC,,,,,,
5812,125813,"2,4(1H,3H)-Quinolinedione, 3-heptyl-3-hydroxy-",CCCCCCCC1(C(=O)C2=CC=CC=C2NC1=O)O,,,,,,
5813,125814,"4-Methoxy-1,2-benzoquinone",COC1=CC(=O)C(=O)C=C1,,,,,,
5814,125815,"L-Alanine, N-acetyl-, 1-naphthalenyl ester",C[C@@H](C(=O)OC1=CC=CC2=CC=CC=C21)NC(=O)C,,,,,,
5815,125816,N-Acetylmethionine alpha-naphthyl ester,CC(=O)N[C@@H](CCSC)C(=O)OC1=CC=CC2=CC=CC=C21,,,,,,
5816,125817,CID 125817,CCCCCCCCCCCCCC=C[C@H]([C@H](CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)OS(=O)(=O)O)[O-])N)O.[Na+],,,,,,
5817,125818,CID 125818,CCCCCCCCCCCCCC=C[C@H]([C@H](CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)OS(=O)(=O)O)O)N)O,,,,,,
5818,125819,N-(2-Chloroethyl)-N-nitroso-N'-(3-pyridinylmethyl)urea N-oxide,C1=CC(=C[N+](=C1)[O-])CNC(=O)N(CCCl)N=O,,,,,,
5819,125820,3-Hydroxyphenazepam,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Br)O)Cl,,,,,,
5820,125821,Picrosteganol,COC1=C(C(=C2C(=C1)C(C3C(CC4=CC5=C(C=C42)OCO5)COC3=O)O)OC)OC,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
5821,125822,9-Hydroxyolivacine,CC1=C2C=CNC(=C2C=C3C1=NC4=C3C=C(C=C4)O)C,,,,,,
5822,125823,"9-Methoxy-2,5,11-trimethyl-6H-pyrido(4,3-b)carbazolium iodide",CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)OC)C)C,,,,,,
5823,125824,"1-butan-2-yl-3-(2-chloroethyl)-1-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]-3-nitrosourea",CCC(C)N([C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)C(=O)N(CCCl)N=O,,,,,,
5824,125825,Gly-gly-tyr-arg,C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)CNC(=O)CN)O,,,,,,
5825,125826,"N,N-Dimethyladriamycin",C[C@H]1[C@H]([C@H](C[C@@H](O1)OC2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N(C)C)O,,,,,,
5826,125827,Neominophagen C,C[C@]12CC[C@@](C[C@@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C(C5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O.C([C@@H](C(=O)O)N)S.C(C(=O)O)N,,,,,,
5827,125828,"(2R,4aS,6aR,6aS,6bR,10S,12aS,14bS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid",C[C@]12CC[C@@](C[C@@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C(C5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,,,,,,
5828,125829,1-Bromo-2-pentadecanone,CCCCCCCCCCCCCC(=O)CBr,,,,,,
5829,125830,1-(4-Carbethoxyphenyl)-3-hydroxymethyl-3-methyltriazene,CCOC(=O)C1=CC=C(C=C1)N=NN(C)CO,,,,,,
5830,125831,[3-Chloro-4-(oxiran-2-ylmethoxy)phenyl]acetic acid,C1C(O1)COC2=C(C=C(C=C2)CC(=O)O)Cl,,,,,,
5831,125832,"Anthra(1,2-b)oxirene, 1a,9b-dihydro-",C1=CC=C2C=C3C4C(O4)C=CC3=CC2=C1,,,,,,
5832,125833,3-(Methylnitrosoamino)-1-propanol,CN(CCCO)N=O,,,,,,
5833,125834,"2-[3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenylidene]-5,5-dimethylcyclohexane-1,3-dione",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=C2C(=O)CC(CC2=O)(C)C)C)C,,,,,,
5834,125835,"2-[(1r,3s)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol",CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2CCC[C@@H](C2)O)O,,,,,,
5835,125836,5'-o-Aminothymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CON)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
5836,125837,Aecep-NAD,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)OCCC(=O)NCCN)O)O)[O-])C(=O)N,,,,,,
5837,125838,"[[(2R,3R,4R,5R)-4-[[3-(2-aminoethylamino)-3-oxopropoxy]-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)OCCC(=O)NCCN)O)O)O)C(=O)N,,,,,,
5838,125839,Aecenadp,C1=CC=[N+](C=C1)[C@H]2[C@@H]([C@]([C@H](O2)COP(=O)(OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)NCCC(=O)NCCN)OP(=O)(O)O)O)OP(=O)(O)O)(C(=O)N)O)[O-],,,,,,
5839,125840,"[(2R,3R,4R,5R)-5-[6-[[3-(2-aminoethylamino)-3-oxopropyl]amino]purin-9-yl]-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-3-carbamoyl-3,4-dihydroxy-5-pyridin-1-ium-1-yloxolan-2-yl]methyl phosphono phosphate",C1=CC=[N+](C=C1)[C@H]2[C@@H]([C@]([C@H](O2)COP(=O)(OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)NCCC(=O)NCCN)OP(=O)(O)O)O)OP(=O)(O)O)(C(=O)N)O)O,,,,,,
5840,125841,Acpacnad,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)NCCC(=O)NCCN)OP(=O)(O)OCCC(=O)NCCN)O)O)[O-])C(=O)N,,,,,,
5841,125842,"[[(2R,3R,4R,5R)-4-[[3-(2-aminoethylamino)-3-oxopropoxy]-hydroxyphosphoryl]oxy-5-[6-[[3-(2-aminoethylamino)-3-oxopropyl]amino]purin-9-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)NCCC(=O)NCCN)OP(=O)(O)OCCC(=O)NCCN)O)O)O)C(=O)N,,,,,,
5842,125843,"2-[[4-[(2,4-Diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-4-fluoropentanedioic acid",CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CC(C(=O)O)F)C(=O)O,,,,,,
5843,125844,CID 125844,CC(C)C=C(C(=O)OC)NC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C,,,,,,
5844,125845,3-(4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)phenyl)alanine,C1=CC(=CC=C1C[C@H](C(=O)O)N)C2(N=N2)C(F)(F)F,,,,,,
5845,125846,Cefotiam hexetil,CC(OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)CC3=CSC(=N3)N)CSC4=NN=NN4CCN(C)C)OC(=O)OC5CCCCC5,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
5846,125847,2-bromo-N-[2-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-2-methylpropyl]acetamide,CC(C)(CNC(=O)CBr)NCC(COC1=CC=CC2=C1C=CN2)O,,,,,,
5847,125848,Alteichin,C1[C@@H]([C@@H]2C3=C(C=CC(=C3C1=O)O)C4=C5[C@]2(C=CC(=O)C5=C(C=C4)O)O)O,,,,,,
5848,125849,(3R)-3-(2-propylpentanoyloxy)-4-(trimethylazaniumyl)butanoate,CCCC(CCC)C(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,,,,,,
5849,125850,[(2R)-3-carboxy-2-(2-propylpentanoyloxy)propyl]-trimethylazanium,CCCC(CCC)C(=O)O[C@H](CC(=O)O)C[N+](C)(C)C,,,,,,
5850,125851,"3,3',5-Triiodothyroacetic acid sulfate",C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)OS(=O)(=O)O,,,,,,
5851,125852,CID 125852,CC(CC(CC(C)(C)O)(F)F)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,,,,,,
5852,125853,20beta-Cortolone-3-glucuronide,CC12CC(CCC1CCC3C2C(=O)CC4(C3CCC4(C(CO)O)O)C)OC5C(C(C(C(O5)C(=O)O)O)O)O.[Ba+2],,,,,,
5853,125854,"6-[[17-(1,2-dihydroxyethyl)-17-hydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-2-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid",CC12CC(CCC1CCC3C2C(=O)CC4(C3CCC4(C(CO)O)O)C)OC5C(C(C(C(O5)C(=O)O)O)O)O,,,,,,
5854,125855,"7',10-Dihydroxy-5,5'-dimethyl-3,3',3a,3'a,5,5',11b,11'b-octahydro-2H,2'H-[8,9'-bifuro[3,2-b]naphtho[2,3-d]pyran]-2,2',6,6',11,11'-hexone",CC1C2=C(C3C(O1)CC(=O)O3)C(=O)C4=C(C2=O)C=C(C=C4O)C5=CC6=C(C(=C5)O)C(=O)C7=C(C6=O)C8C(CC(=O)O8)OC7C,,,,,,
5855,125856,"11,14-Dihydroxypregn-4-ene-3,20-dione",CC(=O)[C@H]1CC[C@@]2([C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O,,,,,,
5856,125857,"Guanidine, [4-[3-[[(methylamino)methylene]amino]phenyl]-2-thiazolyl]-",CN=CNC1=CC=CC(=C1)C2=CSC(=N2)N=C(N)N.Cl.Cl,,,,,,
5857,125858,N-Methyl-N'-[3-(2-guanidino-4-thiazolyl)-phenyl]-formamidine,CN=CNC1=CC=CC(=C1)C2=CSC(=N2)N=C(N)N,,,,,,
5858,125859,"7-Dehydrocholesterol 5,6-oxide",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=C[C@@H]4[C@]5([C@@]3(CC[C@@H](C5)O)C)O4)C,,,,,,
5859,125860,"8,13-Dtndo",C1CC(=O)N2[C@@H]1N3CCC4=C([C@H]3CC2)C=CS4,,,,,,
5860,125861,19-Iodononadec-18-enoic acid,C(CCCCCCCCC(=O)O)CCCCCCCC=CI,,,,,,
5861,125862,"3-Amino-5-(3-(4-(1-piperidinoindanyloxy))propylamino)-1-methyl-1H-1,2,4-triazole",CN1C(=NC(=N1)N)NCCCOC2=CC=CC3=C2CCC3N4CCCCC4,,,,,,
5862,125863,S-4-Nitrobenzoxycarbonylglutathione,C1=CC(=CC=C1COC(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](C(=O)O)N)[N+](=O)[O-],,,,,,
5863,125864,S-(2-Nitrocarbobenzoxy)glutathione,C1=CC=C(C(=C1)COC(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](C(=O)O)N)[N+](=O)[O-],,,,,,
5864,125865,S-(3-Nitrocarbobenzoxy)glutathione,C1=CC(=CC(=C1)[N+](=O)[O-])COC(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](C(=O)O)N,,,,,,
5865,125866,20-Hmaop,C[C@H](CO)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(COC(=O)N4C)C)C,,,,,,
5866,125867,O(4)-Ethylthymidine 5'-triphosphate,CCOC1=NC(=O)N(C=C1C)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
5867,125868,1-(2-Hydroxyethoxymethyl)-6-azauracil,C1=NN(C(=O)NC1=O)COCCO,,,,,,
5868,125869,"2,3-Diphosphonooxypropyl 6-aminohexanoate",C(CCC(=O)OCC(COP(=O)(O)O)OP(=O)(O)O)CCN,,,,,,
5869,125870,"2-(4-(2,2-Dichlorovinyl)phenyl)propionic acid",CC(C1=CC=C(C=C1)C=C(Cl)Cl)C(=O)O,,,,,,
5870,125871,(5-Dimethylaminocarbonylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)penem-3-carboxylic acid,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)O,,,,,,
5871,125872,3-Hydroxy-2-[[2-[[15-methyl-3-(13-methyltetradec-4-enoyloxy)hexadecanoyl]amino]acetyl]amino]propanoic acid,CC(C)CCCCCCCCCCCC(CC(=O)NCC(=O)NC(CO)C(=O)O)OC(=O)CCC=CCCCCCCCC(C)C,,,,,,
5872,125873,3-Hydroxy-2-[[2-[[14-methyl-3-(13-methyltetradec-4-enoyloxy)pentadecanoyl]amino]acetyl]amino]propanoic acid,CC(C)CCCCCCCCCCC(CC(=O)NCC(=O)NC(CO)C(=O)O)OC(=O)CCC=CCCCCCCCC(C)C,,,,,,
5873,125874,"2-Benzyl-5,5,5-trifluoro-4-oxopentanoic acid",C1=CC=C(C=C1)CC(CC(=O)C(F)(F)F)C(=O)O,,,,,,
5874,125875,"Methyl 1,2,3,4-tetrahydro-3-hydroxymethyl-beta-carboline-2-carbodithioate",CSC(=S)N1CC2=C(C[C@H]1CO)C3=CC=CC=C3N2,,,,,,
5875,125876,3-Spirooxiranylpregnan-20-ol,C[C@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@]5(C4)CO5)C)C)O,,,,,,
5876,125877,CID 125877,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC2C(O2)CCCC(=O)O)O)O)O,,,,,,
5877,125878,2-(N-Piperidine)ethylamine-1-naphthyl-5-sulfonylchloride,C1CCN(CC1)CCNC2=CC=CC3=C2C=CC=C3S(=O)(=O)Cl,,,,,,
5878,125879,(2S)-3-hydroxy-2-[[2-[[(3R)-15-methyl-3-(13-methyltetradecanoyloxy)hexadecanoyl]amino]acetyl]amino]propanoic acid,CC(C)CCCCCCCCCCC[C@H](CC(=O)NCC(=O)N[C@@H](CO)C(=O)O)OC(=O)CCCCCCCCCCCC(C)C,,,,,,
5879,125880,"L-Serine, N-(N-(14-methyl-3-((13-methyl-1-oxotetradecyl)oxy)-1-oxopentadecyl)glycyl)-, (R)-",CC(C)CCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC(C)C)CC(=O)NCC(=O)N[C@@H](CO)C(=O)O,,,,,,
5880,125881,"A-Norpregn-20-yne-2,17-diol, 2-ethynyl-, 2-(hydrogen butanedioate), (2-beta,5-alpha,17-alpha)-",C[C@]12CC[C@H]3[C@H](C1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(C[C@](C4)(C#C)OC(=O)CCC(=O)O)C,,,,,,
5881,125882,CID 125882,CON=C(C1=CSC(=N)N1O)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4=NN5C(=NN=N5)C=C4)C(=O)O,,,,,,
5882,125883,3'-O-Benzyl-2'-deoxy-5-trifluoromethyluridine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)OCC3=CC=CC=C3,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
5883,125884,5-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin,CCCN(CCC)[C@H]1CCC2=C([C@H]1C)C=CC=C2O,,,,,,
5884,125885,"2-[(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]ethyl-phosphonooxyphosphinic acid",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CCP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
5885,125886,Pnaic,CCCN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)OC,,,,,,
5886,125887,CID 125887,C1=CC(=NCCOP(=O)(O)OP(=O)(O)O)C(=CC1=N[N+]#N)N(O)[O-],,,,,,
5887,125888,Ethyl 2-(benzyloxycarbonylamino)-3-sulfamoylpropionate,CCOC(=O)[C@@H](CS(=O)(=O)N)NC(=O)OCC1=CC=CC=C1,,,,,,
5888,125889,(3R)-3-(aminomethyl)-5-methylhexanoic acid,CC(C)C[C@H](CC(=O)O)CN,,,,,,
5889,125890,"(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-5-(2,4,4-trimethyl-3-oxido-1,3-oxazolidin-2-yl)pentan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@H](CCCC1(N(C(CO1)(C)C)[O-])C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(CC[C@@H](C5)O)C)C,,,,,,
5890,125891,CID 125891,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],,,,,,
5891,125892,3-Chloropropionyl-coa,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CCCl)O,,,,,,
5892,125893,"Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-",CCCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=O)NC2=C(C=C(C=C2)F)F,,,,,,
5893,125894,CID 125894,CCC=CC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)C2)O)O,,,,,,
5894,125895,BrPdR,C1[C@@H]([C@H](OC1N2C=C(C=NC2=O)Br)CO)O,,,,,,
5895,125896,Nirurin,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(C(=C(C4=C3C(=O)CC(O4)C5=CC=C(C=C5)O)CC=C(C)C)O)O)O)O)O)O)O)O,,,,,,
5896,125897,CID 125897,CC1=CC(=O)C2=C(C3=C(C(=CC(=O)OC3C(=O)OC)Cl)OC2=C1)O,,,,,,
5897,125898,CID 125898,CCCCCCCCC(C)OP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2.C1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
5898,125899,CID 125899,CCCCCCCCC(C)OP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
5899,125900,"3-N-Acetylhydroxyamino-4,6-dimethyldipyrido(1,2-a-3',2'-d)imidazole",CC1=CC=CN2C1=NC3=C(C(=CN=C32)N(C(=O)C)O)C,,,,,,
5900,125901,CID 125901,CC1=CC=CN2C1=NC3=C(C(=CN=C32)N(C4=NC5=C(N4C6[C@@H]([C@@H]([C@H](O6)CO)O)O)NC(=NC5=O)N)C(=O)C)C,,,,,,
5901,125902,"Phosphonofluoridic acid, methyl-, 2-((7-nitro-4-benzofurazanyl)amino)ethyl ester",CP(=O)(OCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-])F,,,,,,
5902,125903,"Phosphonofluoridic acid, methyl-, 5-((7-nitro-4-benzofurazanyl)amino)pentyl ester",CP(=O)(OCCCCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-])F,,,,,,
5903,125904,Thyrsiferyl 23-acetate,CC(=O)OC(C)(C)[C@H]1CC[C@](O1)(C)[C@H](CC[C@@](C)([C@H]2CC[C@@H]3[C@@](O2)(CC[C@@H](O3)[C@@]4(CC[C@H](C(O4)(C)C)Br)C)C)O)O,,,,,,
5904,125905,3-Drmop,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CC(=O)C(=O)O)O)[C@@H]([C@@H](CO)O)O)O)O)O,,,,,,
5905,125906,Pentacos-7-ene,CCCCCCCCCCCCCCCCCC=CCCCCCC,,,,,,
5906,125907,CID 125907,C1[C@H](C1C=CC2=CC3=CC=CC=C3C=C2)CCCC(=O)O,,,,,,
5907,125908,Dach-mida,CN(CC(=O)[O-])CC(=O)[O-].C1CCC(C(C1)N)N.[Pt+2],,,,,,
5908,125909,"(R,R-Dach)(O,C-shikimato)",C1CCC(C(C1)N)N.C1C(C(C(C=C1C(=O)[O-])O)O)O.C1C(C(C(C=C1C(=O)[O-])O)O)O.[Pt+2],,,,,,
5909,125910,"Bis(cyclopentenecarboxylato)-1,2-diaminocyclohexane-platinum(II)",C1CCC(C(C1)N)N.C1CC=C(C1)C(=O)[O-].C1CC=C(C1)C(=O)[O-].[Pt+2],,,,,,
5910,125911,Diammine platinum(II) lactate,CC(C(=O)[O-])[O-].N.N.[Pt+2],,,,,,
5911,125912,"Adenosine, N-(2,3-dihydro-1H-inden-2-yl)-",C1C(CC2=CC=CC=C21)NC3=C4C(=NC=N3)N(C=N4)C5[C@@H]([C@@H]([C@H](O5)CO)O)O,,,,,,
5912,125913,Adechlorin,C1[C@H](C2=C(NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)Cl)O,,,['Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)'],,,
5913,125914,1-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)-5-benzyluracil,C1=CC=C(C=C1)CC2=CN(C(=O)NC2=O)COC(CO)CO,,,,,,
5914,125915,CID 125915,C1=CN(C(=N1)[N+](=O)[O-])CC(CC=CI)O,,,,,,
5915,125916,4-Amino-3-(5-methyl-2-thienyl)butyric acid,CC1=CC=C(S1)C(CC(=O)O)CN,,,,,,
5916,125917,4-Amino-3-(5-chlorothiophen-2-yl)butanoic acid,C1=C(SC(=C1)Cl)C(CC(=O)O)CN,,,,,,
5917,125918,CID 125918,CCC(CCC=CCC=CCC=CCC=CCCC(=O)OC)OC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
5918,125919,CID 125919,CC(CCCC=CCC=CCC=CCC=CCCC(=O)OC)OC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
5919,125920,4-Amino-5-phosphonoheptanoic acid,CCC(C(CCC(=O)O)N)P(=O)(O)O,,,,,,
5920,125921,"3-(Cyclohexylmethyl)-1-(4-aminophenyl)-3-azabicyclo(3.1.0)hexane-2,4-dione",C1CCC(CC1)CN2C(=O)C3CC3(C2=O)C4=CC=C(C=C4)N,,,,,,
5921,125922,"1,2,3-Trimethoxy-5-[2-(4-methoxyphenyl)ethenyl]benzene",COC1=CC=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
5922,125923,Lamiophlomiol A,CC12C3C(C(C1O2)O)C(=COC3O)C(=O)OC,,,,,,
5923,125924,"1-[(4S,5R)-4-Hydroxy-5-(hydroxymethyl)thiolan-2-yl]cytosine",C1[C@@H]([C@H](SC1N2C=CC(=NC2=O)N)CO)O,,,,,,
5924,125925,1-(2-Deoxy-4-thiopentofuranosyl)-4-hydroxypyrimidin-2(1H)-one,C1[C@@H]([C@H](SC1N2C=CC(=O)NC2=O)CO)O,,,,,,
5925,125926,"Methyl 2-[(3-acetyloxy-4,5-dimethoxyoxan-2-yl)methoxy]acetate",CC(=O)OC1C(OCC(C1OC)OC)COCC(=O)OC,,,,,,
5926,125927,Methyl 2-[5-acetyloxy-6-(methoxymethyl)-4-(2-methoxy-2-oxoethoxy)oxan-3-yl]oxyacetate,CC(=O)OC1C(OCC(C1OCC(=O)OC)OCC(=O)OC)COC,,,,,,
5927,125928,4-Aammg,CC(=O)OC1C(OCC(C1OCC(=O)OC)OCC(=O)OC)COCC(=O)OC,,,,,,
5928,125929,Carbamoylpyridoxal 5'-phosphate,CC1=NC=C(C2=C1OC(=O)NC2O)COP(=O)(O)O,,,,,,
5929,125930,CID 125930,CC1(C=C(C2=C(O1)C=CC(=C2)[N+]#[C-])C(=NC)S)C,,,,,,
5930,125931,CID 125931,C[C@H]1CO[C@@]2(C(=C(C=C(O2)O)OC)C1=O)C,,,,,,
5931,125932,"N,N-Diacetylhomotaurine",C(CN(CC(=O)O)CC(=O)O)CS(=O)(=O)O,,,,,,
5932,125933,"(1S,9S,10S)-17-(cyclopropylmethyl)-3,10-dimethoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene",COC1=CC=CC2=C1[C@@]34CCCC[C@]3([C@H](C2)N(CC4)CC5CC5)OC,,,,,,
5933,125934,"(1S,9S,10S)-17-(cyclopropylmethyl)-10-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-3-ol",CO[C@@]12CCCC[C@@]13CCN([C@H]2CC4=C3C(=CC=C4)O)CC5CC5,,,,,,
5934,125935,N-Methyl-N-propargyl-2-aminotetralin,CN(CC#C)C1CCC2=CC=CC=C2C1,,,,,,
5935,125936,"14-Hydroxy-7,10,12-nonadecatrienoic acid",CCCCCC(C=CC=CCC=CCCCCCC(=O)O)O,,,,,,
5936,125937,Dianoside G,CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)C2C1)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)O)O)O)O)OC8C(C(C(C(O8)CO)O)O)O)O)C,,,,,,
5937,125938,9-Amino-3-azido-7-methoxyacridine,COC1=CC2=C(C3=C(C=C(C=C3)N=[N+]=[N-])N=C2C=C1)N,,,,,,
5938,125939,Tnpal cholesterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCCCCCCCCCCNC5=C(C=C(C=C5[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])C)C,,,,,,
5939,125940,CID 125940,CC1=NNC(=O)CC1=CC2=C(C=CC=C2Cl)Cl,,,,,,
5940,125941,"1,3,5,7,2,4,6,8-Tetrazatetraphosphocine, 2,2,4,4,6,6,8,8-octahydro-2,6-bis(1-aziridinyl)-2,4,4,6,8,8-hexakis(methylamino)-, cis-",CN[P@]1(=NP(=N[P@@](=NP(=N1)(NC)NC)(NC)N2CC2)(NC)NC)N3CC3,,,,,,
5941,125942,Cyclo-topa,C1C[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)NC1)C(=O)N)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,,,,
5942,125943,Phenylalanyl-cyclo(cysteinyl-tyrosyltryptophyl-lysyl-threonyl-penicillamine)threoninamide,CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CC3=CC=CC=C3N2)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O,,,,,,
5943,125944,Phenylalanyl-cysteinyl-phenylalanyl-tryptophyl-lysyl-threonyl-penicillamine-threoninamide,CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CC3=CC=CC=C3N2)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O,,,,,,
5944,125945,CID 125945,CC(=NNC(=NC1=CC=CC=C1)S)[C@@H]2[C@H]3CC[C@H](C3)[C@H]2CC=CCCCC(=O)O,,,,,,
5945,125946,Boc-phe-phe-lys-H,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)O,,,,,,
5946,125947,"Ergosta-7,22-dien-3-ol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CCC4[C@@]3(CCC(C4)O)C)C,,,,,,
5947,125948,"O-Glucopyranosyl(1-6)(3) 1,6''-anhydride nonaacetate",CC(=O)O[C@@H]1[C@H]2CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC4[C@@H]([C@H]([C@@H](C(O4)CO[C@H](O2)[C@@H]([C@H]1OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
5948,125949,"1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-",CC(CO)(CO)NCC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43,,,,,,
5949,125950,Goniotriol,C1=CC=C(C=C1)[C@H]([C@H]([C@H]2[C@H](C=CC(=O)O2)O)O)O,,,,,,
5950,125951,"Acetamide, 2-bromo-N-(10-(beta-D-glucopyranosyloxy)decyl)-, (R)-",C(CCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)CCCCNC(=O)CBr,,,,,,
5951,125952,N'-(2-Chloroethyl)-N-(2-(methylsulfinyl)ethyl)-N'-nitrosourea,CS(=O)CCNC(=O)N(CCCl)N=O,,,,,,
5952,125953,CID 125953,C[C@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
5953,125954,"Dermorphin, arg(2)-",C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CO)C(=O)N,,,,,,
5954,125955,8-Methoxy-2'-chloro-pat,CC(C)N(CC(C)Cl)C1CCC2=C(C1)C(=CC=C2)OC.Cl,,,,,,
5955,125956,"N-(2-chloropropyl)-8-methoxy-N-propan-2-yl-1,2,3,4-tetrahydronaphthalen-2-amine",CC(C)N(CC(C)Cl)C1CCC2=C(C1)C(=CC=C2)OC,,,,,,
5956,125957,"9-(Trifluoromethyl)-2,3,4,4a,5,6-hexahydro-1h-pyrazino[1,2-a]quinoline",C1CC2=C(C=C(C=C2)C(F)(F)F)N3C1CNCC3,,,,,,
5957,125958,Famiraprinium chloride,CC1=CC(=NN(C1=N)CCCC(=O)O)C2=CC=CC=C2.Cl,,,,,,
5958,125959,Famiraprinium,CC1=CC(=NN(C1=N)CCCC(=O)O)C2=CC=CC=C2,,,,,,
5959,125960,"(2,5-Dioxopyrrolidin-1-yl) 3-(2-nitroethenyl)benzoate",C1CC(=O)N(C1=O)OC(=O)C2=CC=CC(=C2)C=C[N+](=O)[O-],,,,,,
5960,125961,CID 125961,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@@H]2C(=O)C6=C4C(=C(C=C6)O)O5)O,,,,,,
5961,125962,CID 125962,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@@H]1C(=O)C5=C3C(=C(C=C5)O)O4)O,,,,,,
5962,125963,"1-(2-Hydroxyethoxymethyl)-1,2,4-tiazole-5-carboxamide",C1=NN(C(=N1)C(=O)N)COCCO,,,,,,
5963,125964,"S-[2-[3-[[4-[[[5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] oct-2-ynethioate",CCCCCC#CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
5964,125965,"ethyl (2'S,4S,4aS,7aR,12bS)-4a,9-dihydroxy-3-methylspiro[2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,3'-oxirane]-2'-carboxylate",CCOC(=O)[C@@H]1C2(O1)CC[C@]3([C@@H]4CC5=C6[C@]3([C@H]2OC6=C(C=C5)O)CCN4C)O,,,,,,
5965,125966,"ethyl (2'R,4S,4aS,7aR,12bS)-4a,9-dihydroxy-3-methylspiro[2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,3'-oxirane]-2'-carboxylate",CCOC(=O)[C@H]1C2(O1)CC[C@]3([C@@H]4CC5=C6[C@]3([C@H]2OC6=C(C=C5)O)CCN4C)O,,,,,,
5966,125967,3-Butoxy-2-acetylaminopropionic acid,CCCCOCC(C(=O)O)NC(=O)C,,,,,,
5967,125968,CID 125968,CCC(=C(C1=CC=C(C=C1)OCCN(C)C)C2=C(C=C(C=C2)O)C)C3=CC=CC=C3,,,,,,
5968,125969,"33-[3,5-Dihydroxy-6-methyl-4-[6-[methyl-(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoylamino]oxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid",CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)NC(=O)CCCCCN(C)C4=CC=C(C5=NON=C45)[N+](=O)[O-])O,,,,,,
5969,125970,1-N-Amidino-1-N-demethyl-2-hydroxydestomycin A,C(C1C(C2C(C(O1)OC3C(C(C(C(C3O)N=C(N)N)O)N)O)OC4(O2)C(C(C(C(O4)C(CO)N)O)O)O)O)O.Cl,,,,,,
5970,125971,"2-[3-amino-5-[6'-(1-amino-2-hydroxyethyl)-3',4',5',7-tetrahydroxy-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-4-yl]oxy-2,4,6-trihydroxycyclohexyl]guanidine",C(C1C(C2C(C(O1)OC3C(C(C(C(C3O)N=C(N)N)O)N)O)OC4(O2)C(C(C(C(O4)C(CO)N)O)O)O)O)O,,,,,,
5971,125972,CID 125972,CC(=NOC[C@@H](CNC(C)(C)C)O)C1CC1,,,,,,
5972,125973,Hddsm,C(C1C(C(C(C(O1)OC2C(OC(C2(CO)O)CO)OC3C(C(C(C(C3O)O)N=C(N)N)O)N=C(N)N)N)O)O)O.Cl.Cl.Cl,,,,,,
5973,125974,"2-[2-[3-[3-Amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-4,5-bis(hydroxymethyl)oxolan-2-yl]oxy-5-(diaminomethylideneamino)-3,4,6-trihydroxycyclohexyl]guanidine",C(C1C(C(C(C(O1)OC2C(OC(C2(CO)O)CO)OC3C(C(C(C(C3O)O)N=C(N)N)O)N=C(N)N)N)O)O)O,,,,,,
5974,125975,Cotapp,C1=CC=C(C(=C1)C2=C3C=CC(=C(C4=CC=C([N-]4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC=CC=C7N)C8=CC=CC=C8N)C9=CC=CC=C9N)[N-]3)N.[Co+2],,,,,,
5975,125976,"2-[10,15,20-Tris(2-aminophenyl)-21,24-dihydroporphyrin-5-yl]aniline",C1=CC=C(C(=C1)C2=C3C=CC(=C(C4=CC=C(N4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC=CC=C7N)C8=CC=CC=C8N)C9=CC=CC=C9N)N3)N,,,,,,
5976,125977,"6,7-Dibromostearic acid",CCCCCCCCCCCC(C(CCCCC(=O)O)Br)Br,,,,,,
5977,125978,"Butanoic acid, 2-methyl-3-oxo-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester",CC1CC(C2C(C(C=CC2=C1)C)CCC3CC(CC(=O)O3)O)OC(=O)C(C)C(=O)C,,,,,,
5978,125979,N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-toluidine,CCN(CC(CS(=O)(=O)O)O)C1=CC=CC(=C1)C,,,,,,
5979,125980,N-Nitrosooxprenolol,CC(C)N(CC(COC1=CC=CC=C1OCC=C)O)N=O,,,,,,
5980,125981,Maoto,CC1C2=C(CCC3N2CCC4=CC=CC=C34)C(=O)O1,,,,,,
5981,125982,"1,4-Bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthraquinone",C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCN,,,,,,
5982,125983,CID 125983,CCC(C)C1CN2CCC3=CC(=C(C=C3C2CC1NC(=O)CCCN=C4C=CC(=N[N+]#N)C=C4N(O)[O-])OC)OC,,,,,,
5983,125984,"1-(Dimethylamino)-3-[4-(2,4,7-triaminopteridin-6-yl)phenoxy]propan-2-ol",CN(C)CC(COC1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N)O,,,,,,
5984,125985,N-Acetylglutamic acid-N-(N(2)-(5-n-butyl-2-pyridyl)hydrazide),CCCCC1=CN=C(C=C1)NNC(=O)CC[C@@H](C(=O)O)NC(=O)C.N,,,,,,
5985,125986,(2S)-2-acetamido-5-[2-(5-butylpyridin-2-yl)hydrazinyl]-5-oxopentanoic acid,CCCCC1=CN=C(C=C1)NNC(=O)CC[C@@H](C(=O)O)NC(=O)C,,,,,,
5986,125987,Szechenyine,CCN1C[C@@]2([C@@H](C[C@@H](C34C2[C@H](C(C31)[C@]5([C@H]([C@@H]([C@]6(C[C@@H]4C5[C@H]6OC(=O)C7=CC=CC=C7)O)OC)O)OCC)OC)OC)OC(=O)C)COC,,,,,,
5987,125988,CID 125988,CCC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]5CCC(=O)N5,,,,,,
5988,125989,2-Amino-3-(hydroxycarbamoyl)-5-oxopentanoic acid,C(C=O)C(C(C(=O)O)N)C(=O)NO,,,,,,
5989,125990,"(2R)-3-(3,4-dihydroxyphenyl)-2-[3-[2-[2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyloxy]propanoic acid",C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)C=CC2=C(C(=C(C=C2)O)O)C=CC3=CC(=C(C=C3)O)O)O)O,,,,,,
5990,125991,"2,3-Dehydrobrevicomin",CC[C@@H]1[C@H]2C=CC[C@](O2)(O1)C,,,,,,
5991,125992,Ethoxyidazoxan,CCOC1(COC2=CC=CC=C2O1)C3=NCCN3,,,,,,
5992,125993,"3,5,10-Trihydroxy-3-(hydroxyacetyl)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside",C[C@H]1[C@H]([C@H](C[C@@H](O1)OC2C[C@@](CC3=C(C4=C(C=C23)C(=O)C5=C(C4=O)C=CC=C5O)O)(C(=O)CO)O)N)O,,,,,,
5993,125994,CID 125994,C1CC(=O)N(C1=O)OC(=O)C2=C(C=C(C=C2)N[N+]#N)[O-],,,,,,
5994,125995,CID 125995,C1CC(=O)N(C1=O)OC(=O)C2=C(C=C(C=C2)N[N+]#N)O,,,,,,
5995,125996,Fdnb-bmpa,C1=C(C(=CC(=C1F)[N+](=O)[O-])[N+](=O)[O-])C(CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)COC([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O,,,,,,
5996,125997,CID 125997,C1=CC(=NC(CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)COC([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)C(=CC1=N[N+]#N)N(O)[O-],,,,,,
5997,125998,CID 125998,CN(N=NC1=CC=CC=C1[N+](=O)[O-])O,,,,,,
5998,125999,"Pregna-1,4-diene-3,20-dione, 21-((8-((2-(diethylamino)ethyl)ethylamino)-1,8-dioxooctyl)oxy)-11,17-dihydroxy-6-methyl-, (6alpha,11beta)-",CCN(CC)CCN(CC)C(=O)CCCCCCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)C)O)C)O,,,,,,
5999,126000,1-(4'-tert-Butylphenyl)-3-(4'carboxymethylaminocarbonylphenoxy)-2-propanol,CC(C)(C)C1=CC=C(C=C1)CC(COC2=CC=C(C=C2)C(=O)NCC(=O)O)O,,,,,,
6000,126001,2-Hydrazino-5-n-butylpyridine,CCCCC1=CN=C(C=C1)NN,,,,,,
6001,126002,CID 126002,CC(CCCC(C)(C)O)C1CCC2C1(CCC(=CC3C(CCC4=C3CCCC4)O)C2)C,,,,,,
6002,126003,CID 126003,C[C@@H]1CCC=C([C@@]1(C)CCC(=CCCC(=CCS(=O)(=O)CCN=C(N)N)C)C)C,,,,,,
6003,126004,4a-Hydroxy-fad,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3(N2)O)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H](C(O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
6004,126005,CID 126005,C1=CC(=C(C=C1N[N+]#N)[O-])C(=O)NC(CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)CO[C@@H]([C@@H](C(C=O)O)O)C(CO)O,,,,,,
6005,126006,CID 126006,C1=CC(=C(C=C1N[N+]#N)O)C(=O)NC(CO[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)CO[C@@H]([C@@H](C(C=O)O)O)C(CO)O,,,,,,
6006,126007,Halenaquinol sulfate,C[C@@]12CCC(=O)C3=COC(=C31)C(=O)C4=CC5=C(C=CC(=C5C=C24)OS(=O)(=O)O)O.[Na+],,,,,,
6007,126008,CID 126008,C[C@@]12CCC(=O)C3=COC(=C31)C(=O)C4=CC5=C(C=CC(=C5C=C24)OS(=O)(=O)O)O,,,,,,
6008,126009,Yuehchukene,CC1=C[C@@H]2[C@@H]([C@H](C3=C2C4=CC=CC=C4N3)C5=CNC6=CC=CC=C65)C(C1)(C)C,,,,,,
6009,126010,N-((6-Methyl-5-oxo-3-thiomorpholinyl)carbonyl)-L-histidyl-L-proline,CC1C(=O)NC(CS1)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)O,,,,,,
6010,126011,Nudaphantin,CCOC1C2=CC(O1)CC3(C(O3)C4C(C(C2)OC(=O)C(=C)C)C(=C)C(=O)O4)C,,,,,,
6011,126012,Iscag,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O[C@H]4C([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
6012,126013,CID 126013,CC1CC(N(C1)CCNS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C.C(=CC(=O)O)C(=O)O,,,,,,
6013,126014,"N-[2-(2,4-dimethylpyrrolidin-1-yl)ethyl]naphthalene-2-sulfonamide",CC1CC(N(C1)CCNS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C,,,,,,
6014,126015,3-(Fluoromethyl)-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}pentanoic acid,C(COP(=O)(O)OP(=O)(O)O)C(CC(=O)O)(CF)O,,,,,,
6015,126016,3-Hydroxy-7-methylcholanoic acid,CC1C[C@@H]2C[C@@H](CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)[C@H](C)CCC(=O)O)C)O,,,,,,
6016,126017,Monofucosyllacto-n-hexaose,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](C[C@@H]([C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)CO)OO[C@@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O[C@H]5[C@@H](C([C@@H]([C@H](O5)CO)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O)O)NC(=O)C)O)NC(=O)C)O)O)O,,,,,,
6017,126018,Nabpa,C[C@@H]1[C@H](C2(C(C2(C)C)C3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C)OC(=O)C5=C(C=CC(=C5)N=[N+]=[N-])[N+](=O)[O-],,,,,,
6018,126019,CID 126019,C[C@@H]1[C@H](C2(C(C2(C)C)C3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C)OC(=O)C5=C(C=CC(=C5)N[N+]#N)[N+](=O)[O-],,,,,,
6019,126020,"(3As,7as)-hexahydro[1,2]oxazolo[5,4-c]pyridin-3(2h)-one",C1CNC[C@@H]2[C@H]1C(=O)NO2,,,,,,
6020,126021,Bianfugecine,COC1=CC2=C(C=C1)C3=NC=CC4=CC(=CC(=C43)C2=O)OC,,,,,,
6021,126022,"5,6-Methylenedioxy-9-methoxy-7H-dibenzo(de,h)quinoline-7-one",COC1=CC2=C(C=C1)C3=NC=CC4=CC5=C(C(=C43)C2=O)OCO5,,,,,,
6022,126023,14beta-Hydroxygelsedine,CCC1C2C3COC(C2O)C4(CC3N1)C5=CC=CC=C5N(C4=O)OC,,,,,,
6023,126024,"3-Pentenoic acid, 2,5-diamino-2-(fluoromethyl)-, methyl ester, (E)-",COC(=O)C(CF)(C=CCN)N,,,,,,
6024,126025,CID 126025,C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)NC4=CN(C5=CC=CC=C5C4=N)O)CO)O,,,,,,
6025,126026,gamma-Glutamyl-seryl-glycine,C(CC(=O)N[C@H](CO)C(=O)NCC(=O)O)[C@H](C(=O)O)N.Br,,,,,,
6026,126027,(2R)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid,C(CC(=O)N[C@H](CO)C(=O)NCC(=O)O)[C@H](C(=O)O)N,,,,,,
6027,126028,1-(4-Iodophenyl)-2-methylpropan-2-amine,CC(C)(CC1=CC=C(C=C1)I)N,,,,,,
6028,126029,Streptonigrone,CC1=C(C(=C(NC1=O)C2=NC3=C(C=C2)C(=O)C(=C(C3=O)N)OC)N)C4=C(C(=C(C=C4)OC)OC)O,,,,,,
6029,126030,Chitinovorin D,CC(C(=O)NC(CCCN=C(N)N)C(CC(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(CC(=O)OCC1=C(N2C(C(C2=O)(NC=O)NC(=O)CCCC(C(=O)O)N)SC1)C(=O)O)O)O)N,,,,,,
6030,126031,"[(2S,2aR,4aR,7aR,7bS)-3-formyl-2a-hydroxy-6,6,7b-trimethyl-1,2,4a,5,7,7a-hexahydrocyclobuta[e]inden-2-yl] 3-chloro-6-hydroxy-4-methoxy-2-methylbenzoate",CC1=C(C(=CC(=C1Cl)OC)O)C(=O)O[C@H]2C[C@@]3([C@]2(C(=C[C@@H]4[C@H]3CC(C4)(C)C)C=O)O)C,,,,,,
6031,126032,"(2S,5R,10R,18R,20R)-2,20-dihydroxy-5-methyl-13-methylidene-7,9-dioxahexacyclo[8.7.2.111,14.01,8.05,18.011,17]icosan-12-one",C[C@@]12CC[C@@H](C34[C@@H]1C[C@H](C56C3CCC([C@H]5O)C(=C)C6=O)OC4OC2)O,,,,,,
6032,126033,7-Dimethylaminocoumarin-4-acetic acid succinimidyl ester,CN(C)C1=CC2=C(C=C1)C(=CC(=O)O2)CC(=O)ON3C(=O)CCC3=O,,,,,,
6033,126034,5-Hydroxy-1h-indol-6-yl hydrogen sulfate,C1=CNC2=CC(=C(C=C21)O)OS(=O)(=O)O,,,,,,
6034,126035,[(2R)-3-[hydroxy-[2-(methylamino)ethoxy]phosphoryl]oxy-2-octadec-9-enoyloxypropyl] octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
6035,126036,2-[[2-Amino-5-(diaminomethylideneamino)pentanoyl]amino]-2-(1-hydroxy-2-oxocyclopent-3-en-1-yl)acetic acid,C1C=CC(=O)C1(C(C(=O)O)NC(=O)C(CCCN=C(N)N)N)O,,,,,,
6036,126037,Fujianmycin A,C[C@H]1CC(=O)C2=C([C@@H]1O)C=CC3=C2C(=O)C4=C(C3=O)C(=CC=C4)O,,,,,,
6037,126038,Fujianmycin B,C[C@H]1CC(=O)C2=C([C@@H]1O)C=CC3=C2C(=O)C4=C(C3=O)C(=CC=C4)OC,,,,,,
6038,126039,Etfak,CCCCCCCCCCCCCCCCCCCC(=O)NC1CC(C(C(C1OC2C(C(C(C(O2)CO)O)NC(=O)C(F)(F)F)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,,,,,,
6039,126040,Infusamine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)NC(=O)N(CCCl)N=O,,,,,,
6040,126041,Ectoine,CC1=NCC[C@H](N1)C(=O)O,,,,,,
6041,126042,Rhodilunancin A,CC[C@]1(CCC2=C([C@H]1O[C@H]3C[C@@H]([C@@H]([C@@H](O3)C)O[C@H]4CC[C@@H]([C@@H](O4)C)O[C@H]5CC[C@@H]([C@@H](O5)C)O)N(C)C)C(=C6C(=C2O)C(=O)C7=C(C6=O)C=CC=C7O)O)O,,,,,,
6042,126043,4-Dibenzofurancarboxaldehyde,C1=CC=C2C(=C1)C3=CC=CC(=C3O2)C=O,,,,,,
6043,126044,"7-Methyl-10,17-diacetoxy-4-estren-3-one",C[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)OC(=O)C)OC(=O)C,,,,,,
6044,126045,5'-O-Palmitoyl-5-fluoro-2'-deoxyuridine,CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)F)O,,,,,,
6045,126046,"(7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid",C1C[C@H](N2[C@H](C1)SCCC(C2=O)NC(=O)[C@H](CC3=CC=CC=C3)S)C(=O)O,,,,,,
6046,126047,CID 126047,CC1=C2C=CC(=O)C=C2OC(=C1CC(=O)ON3C(=O)CCC3=O)O,,,,,,
6047,126048,"6beta-acetoxy-24-methylcholestan-3beta,5alpha,22R,24-tetrol",C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H]([C@@]4([C@@]3(CC[C@@H](C4)O)C)O)OC(=O)C)C)[C@@H](CC(C)(C(C)C)O)O,,,,,,
6048,126049,18-Hydroxycortisone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)CO,,,,,,
6049,126050,"(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[4-(thiophene-2-carbonyl)phenyl]propanoyloxy]oxane-2-carboxylic acid",CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,,,,,,
6050,126051,Ethyl 2-(5-hydroxy-2-methyl-4-nitro-1-imidazolyl)ethylsulfone,CCS(=O)(=O)CCN1C(=NC(=C1O)[N+](=O)[O-])C,,,,,,
6051,126052,"2-Formamido-4,4-diphenyl-5-heptanone",CCC(=O)C(CC(C)NC=O)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
6052,126053,CID 126053,CCCCCCC(C#CC1C(CC2C1CC(=CC3=CC(=CC=C3)C(=O)O)O2)O)O,,,,,,
6053,126054,Adenosine amine congener,C1=CC(=CC=C1CC(=O)NC2=CC=C(C=C2)CC(=O)NCCN)NC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O,,,,,,
6054,126055,"1,4-Anhydro-2-deoxy-D-erythro-pent-1-enitol",C1=CO[C@@H]([C@H]1O)CO,,,,,,
6055,126056,9-Oopaa,C1CNP(=O)(OC1)OC[C@@H]2[C@H]([C@@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
6056,126057,Cetylmannoside,CCCCCCCCCCCCCCCCOC1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
6057,126058,"5-[4-(3,4-Dichloro-2-propylphenoxy)butyl]-2h-tetrazole",CCCC1=C(C=CC(=C1Cl)Cl)OCCCCC2=NNN=N2,,,,,,
6058,126059,"6-(2-Chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo(2,1-a)isoquinoline hbr",C1C[C@@H]2C3=CC=CC=C3[C@@H](CN2C1)C4=CC=CC=C4Cl.Br,,,,,,
6059,126060,"1,2,3,5,6,10balpha-Hexahydro-6beta-(2-chlorophenyl)pyrrolo[2,1-a]isoquinoline",C1C[C@@H]2C3=CC=CC=C3[C@@H](CN2C1)C4=CC=CC=C4Cl,,,,,,
6060,126061,6-Hydroxybenzo(b)thiophene-2-sulfonamide acetate ester,CC(=O)OC1=CC2=C(C=C1)C=C(S2)S(=O)(=O)N,,,,,,
6061,126062,N-Didemethylbromadoline,C1CC[C@H]([C@@H](C1)N)NC(=O)C2=CC=C(C=C2)Br,,,,,,
6062,126063,"Benzamide, 4-bromo-N-(2-(methylamino)cyclohexyl)-, trans-",CN[C@@H]1CCCC[C@H]1NC(=O)C2=CC=C(C=C2)Br,,,,,,
6063,126064,5-Iipph,C1=CC=C(C=C1)P(=O)(O)OC2=CNC3=C2C=C(C=C3)I.N,,,,,,
6064,126065,(5-iodo-1H-indol-3-yl)oxy-phenylphosphinic acid,C1=CC=C(C=C1)P(=O)(O)OC2=CNC3=C2C=C(C=C3)I,,,,,,
6065,126066,1-Hydroxy-2-(quinolin-2-ylmethylideneamino)guanidine,C1=CC=C2C(=C1)C=CC(=N2)C=NN=C(N)NO,,,,,,
6066,126067,1-Hydroxy-2-(isoquinolin-1-ylmethylideneamino)guanidine,C1=CC=C2C(=C1)C=CN=C2C=NN=C(N)NO,,,,,,
6067,126068,CID 126068,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H](C3(O2)[C@@H](CC[C@@H](O3)[C@@]4(CCC5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)C=C(C)C(=O)C(=C[C@H](C)C(=O)O)C)C)O)C)CO[C@H]6CC[C@@H]([C@H](O6)C)OC)C)(C)O)C,,,,,,
6068,126069,CID 126069,CCCCCCC1C(OC1=O)C[C@H](CC=CCC=CCCCCC)OC(=O)[C@H](C(C)CC)NC=O,,,,,,
6069,126070,S-Acrylyl-N-acetylcysteamine,CC(=O)NCCSC(=O)C=C,,,,,,
6070,126071,Tanshinol B,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)O,,,,,,
6071,126072,Tanshindiol C,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CC[C@H]([C@]4(C)O)O,,,,,,
6072,126073,"Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-7-hydroxy-6-(hydroxymethyl)-1-methyl-",CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCC(C4CO)O,,,,,,
6073,126074,3-(4-Hydroxy-1-naphthoxy)lactic acid,C1=CC=C2C(=C1)C(=CC=C2OCC(C(=O)O)O)O,,,,,,
6074,126075,"Phosphonium, (2-carboxy-2-((methoxycarbonyl)amino)ethyl)triphenyl-, (S)-",COC(=O)N[C@H](C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)O.[Cl-],,,,,,
6075,126076,[(2S)-2-carboxy-2-(methoxycarbonylamino)ethyl]-triphenylphosphanium,COC(=O)N[C@H](C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)O,,,,,,
6076,126077,CID 126077,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)SC3CCS(=O)C3)C(=O)[O-])O.[Na+],,,,,,
6077,126078,(5R)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(1-oxothiolan-3-yl)sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,C[C@H](C1[C@@H]2N(C1=O)C(=C(S2)SC3CCS(=O)C3)C(=O)O)O,,,,,,
6078,126079,"[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy]acetic acid",CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)O,,,,,,
6079,126080,1-Amino-1-methyl-2-tetralone,CC1(C(=O)CCC2=CC=CC=C21)N,,,,,,
6080,126081,2-Amino-2-methyl-1-tetralone,CC1(CCC2=CC=CC=C2C1=O)N,,,,,,
6081,126082,7-Methylwye,CC1=C(N2C(=O)C3=C(N=CN3)N(C2=N1)C)C,,,,,,
6082,126083,"Methanesulfonamide, N-(5-(2-(dipropylamino)ethyl)-2-hydroxyphenyl)-",CCCN(CCC)CCC1=CC(=C(C=C1)O)NS(=O)(=O)C,,,,,,
6083,126084,CID 126084,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(N4C=CN=C4)O)OP(=O)(N5C=CN=C5)O,,,,,,
6084,126085,Cholesteryl-6-pyrenylhexanoate,C[C@H](CCCC(C)C)C1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCCCCC5=C6C=CC7=CC=CC8=C7C6=C(C=C8)C=C5)C)C,,,,,,
6085,126086,"4,4'-(1-Methyl-1,2-ethanediyl)bis(1-methyl-2,6-piperazinedione)",C[C@H](CN1CC(=O)N(C(=O)C1)C)N2CC(=O)N(C(=O)C2)C,,,,,,
6086,126087,Anhydro-aklavinone,CCC1=C(C2=CC3=C(C(=C2C(C1)O)O)C(=O)C4=C(C3=O)C=CC=C4O)C(=O)OC,,,,,,
6087,126088,Corticosterone 21-stearate,CCCCCCCCCCCCCCCCCC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C,,,,,,
6088,126089,"2-methyl-5-[(7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]cyclohexa-2,5-diene-1,4-dione",CC1=CC(=O)C(=CC1=O)CC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C,,,,,,
6089,126090,CID 126090,C=C[C@H](C=CC1=CC=C(C=C1)O)C2=CC=C(C=C2)O,,,,,,
6090,126091,CID 126091,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(=NOCC3=CN=CN3)C4=CSC(=N4)N)C(=O)O)C[N+]5=CC=CC=C5.[Cl-],,,,,,
6091,126092,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1H-imidazol-5-ylmethoxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(=NOCC3=CN=CN3)C4=CSC(=N4)N)C(=O)O)C[N+]5=CC=CC=C5,,,,,,
6092,126093,Dnpppapapa,CCCCCCCCCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)OP(=O)(O)OC[C@@H]7[C@H]([C@H]([C@@H](O7)N8C=NC9=C(N=CN=C98)N)O)O)O)O,,,,,,
6093,126094,Lactose-carrying polystyrene,C[C@H](CO)[C@H]([C@@H]([C@H](C(=O)NCC1=CC=C(C=C1)C=C)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
6094,126095,CID 126095,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCN=C1C=CC(=CC1=N[N+]#N)N(O)[O-],,,,,,
6095,126096,CID 126096,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCN=C1C=CC(=CC1=N[N+]#N)N(O)[O-],,,,,,
6096,126097,CID 126097,CCCCCCCCC=CCCCCCCCC(=O)OCC(=O)C1CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C,,,,,,
6097,126098,Lysyl-5-fluorotryptophyl-lysine,C1=CC2=C(C=C1F)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
6098,126099,Oxa-glycol,C[C@H]1C(=O)N2CCS(=O)(=O)N3CCC[C@H]3[C@]2(O1)O,,,,,,
6099,126100,CID 126100,C1[C@@H]([C@H](OC1N2C3=C(C(=O)N=C(N3)N)N=C2NC4=CC5=C6C(=C4)C=CC7=C6C(=CC=C7)C=C5)CO)O,,,,,,
6100,126101,N-(Deoxyadenosin-8-yl)-2-aminopyrene,C1[C@@H]([C@H](OC1N2C3=NC=NC(=C3N=C2NC4=CC5=C6C(=C4)C=CC7=C6C(=CC=C7)C=C5)N)CO)O,,,,,,
6101,126102,CID 126102,C1C(C2C3=C(C1O2)C=C(C=C3)C(F)(F)F)NCO,,,,,,
6102,126103,4-((2-Aminoethyl)amino)-4-(2-thienyl)-1-butanone,C1=CSC(=C1)C(=O)CCCNCCN,,,,,,
6103,126104,S-Benzyl-N-malonylcysteine,C1=CC=C(C=C1)CSC[C@@H](C(=O)O)NC(=O)CC(=O)O,,,,,,
6104,126105,5-(5-Bromothien-2-yl)-2'-deoxyuridine,C1[C@@H]([C@H](OC1N2C=C(C(=O)NC2=O)C3=CC=C(S3)Br)CO)O,,,,,,
6105,126106,"5-(5-chlorothiophen-2-yl)-1-[(4S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione",C1[C@@H](C(OC1N2C=C(C(=O)NC2=O)C3=CC=C(S3)Cl)CO)O,,,,,,
6106,126107,N-(5-Nitro-2-thiazolyl)-N'-carboxymethylurea,C1=C(SC(=N1)NC(=O)NCC(=O)O)[N+](=O)[O-],,,,,,
6107,126108,"Oxazolo(4,5-b)pyridin-2(3H)-one, 3-(3-(4-phenyl-1-piperazinyl)propyl)-",C1CN(CCN1CCCN2C3=C(C=CC=N3)OC2=O)C4=CC=CC=C4,,,,,,
6108,126109,CID 126109,CC(C(C)O)C(C(=O)NC(CO)C(=O)O)O,,,,,,
6109,126110,S-(2-Carboxy-1-(1H-imidazol-4-yl) ethyl)cysteine,C1=C(NC=N1)C(CC(=O)O)SCC(C(=O)O)N,,,,,,
6110,126111,"1-Ethylphenoxathiin 10,10-dioxide",CCC1=C2C(=CC=C1)OC3=CC=CC=C3S2(=O)=O,,,,,,
6111,126112,4'-Fluorococaine,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=C(C=C3)F)C(=O)OC,,,,,,
6112,126113,p-Azidophenyl alpha-D-glucopyranoside,C1=CC(=CC=C1N=[N+]=[N-])O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
6113,126114,S-(2-Thiopyridyl)cysteine hydrazide,C1=CC=NC(=C1)SSC[C@@H](C(=O)NN)N,,,,,,
6114,126115,CID 126115,C1=CC(=CC=C1C#N)NC(=O)NCS(=O)(=O)O.[NaH],,,,,,
6115,126116,[(4-Cyanophenyl)carbamoylamino]methanesulfonic acid,C1=CC(=CC=C1C#N)NC(=O)NCS(=O)(=O)O,,,,,,
6116,126117,3-O-Methyltolcapone,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)OC)O)[N+](=O)[O-],,,,,,
6117,126118,"2-(1,5-Dihydroxyhexyl)-1,3,6,8-tetrahydroxyanthracene-9,10-dione",CC(CCCC(C1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C=C(C=C3O)O)O)O)O,,,,,,
6118,126119,"(S)-4,4-diethoxy-2-(hydroxymethyl)butyl acetate",CCOC(C[C@@H](CO)COC(=O)C)OCC,,,,,,
6119,126120,"7-(Hydroxymethyl)-3,11,15-trimethylhexadeca-2,4,6,10,14-pentaenoic acid",CC(=CCCC(=CCCC(=CC=CC(=CC(=O)O)C)CO)C)C,,,,,,
6120,126121,CID 126121,CCCCCCCCCCCCC[C@H]([C@H]1CCC(=O)O1)O,,,,,,
6121,126122,"2-(5-Thiophen-3-yl-2,5-dihydrotetrazol-1-yl)acetic acid",C1=CSC=C1C2N=NNN2CC(=O)O,,,,,,
6122,126123,2-Phenyl-1-benzazocin-8-ol,C1=CC=C(C=C1)C2=NC3=C(C=CC=C2)C=C(C=C3)O,,,,,,
6123,126124,(Bromoacetyl)phosphonic acid,C(C(=O)P(=O)(O)O)Br,,,,,,
6124,126125,"(3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(3-fluoropropylsulfanylmethyl)oxolane-3,4-diol",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CSCCCF)O)O)N,,,,,,
6125,126126,"(16alpha)-21-(Fluoro-18F)-16-methyl-19-norpregn-4-ene-3,20-dione",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]2([C@H]1C(=O)C[18F])C,,,,,,
6126,126127,Methyl [5-[(4-Fluorophenyl) (Hydroxyimino)Methyl]-1H-Benzimidazol-2-yl]Carbamate,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=NO)C3=CC=C(C=C3)F,,,,,,
6127,126128,CID 126128,C1=CC=C(C=C1)CN=C(NC(=O)C2=CC=CC=C2O)S,,,,,,
6128,126129,CID 126129,CO[C@H]1[C@@H]([C@H]([C@@H](O1)OOC(=O)C=CC2=CC(=C(C=C2)O)OC)O)O,,,,,,
6129,126130,"(4R,4aS)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4aH-pyrido[1,2-c]pyrimidin-3-one",CC1=NC(=O)[C@]([C@H]2N1CCCC2)(CCN(C(C)C)C(C)C)C3=CC=CC=C3,,,,,,
6130,126131,CID 126131,COC(=O)C=CC(=O)NC[C@@H](C(=O)O)N,,,,,,
6131,126132,CID 126132,C1CN=C2C(=C(N(C2=O)C3=CC=CC=C3)S)C(=N1)C4=CC5=CC=CC=C5C=C4,,,,,,
6132,126133,"[[(2R,3S,4R)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate",C1=CN2C=NC3=C(C2=N1)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]5[C@H]([C@H](C(O5)N6C=NC7=C6N=CN8C7=NC=C8)O)O)O)O,,,,,,
6133,126134,(4-Fluorophenyl)(8-methyl-8-azabicyclo[3.2.1]oct-2-yl)methanone,CN1C2CCC(C1CC2)C(=O)C3=CC=C(C=C3)F,,,,,,
6134,126135,3-Amino-2-methyl-N-(2-(phosphonooxy)ethyl)propanamide,CC(CN)C(=O)NCCOP(=O)(O)O,,,,,,
6135,126136,CID 126136,C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@@H]3CCCN3,,,,,,
6136,126137,"[5,6,11,14-Tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-prop-1-en-2-yl-3-oxatetracyclo[9.4.0.02,4.06,10]pentadec-8-en-15-yl] deca-2,4-dienoate",CCCCCC=CC=CC(=O)OC1C2C3C(O3)(C(C4(C(C2(C(CC1(C(=C)C)O)C)O)C=C(C4=O)C)O)O)CO,,,,,,
6137,126138,"[5,6,11,15-Tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-prop-1-en-2-yl-3-oxatetracyclo[9.4.0.02,4.06,10]pentadec-8-en-14-yl] deca-2,4-dienoate",CCCCCC=CC=CC(=O)OC1(CC(C2(C3C=C(C(=O)C3(C(C4(C(C2C1O)O4)CO)O)O)C)O)C)C(=C)C,,,,,,
6138,126139,"4,16,17-Trimethoxy-1,12-dimethyl-6,8-dioxa-12-azapentacyclo[11.8.0.02,10.05,9.014,19]henicosa-2,4,9,14,16,18-hexaen-21-ol",CC12C(CC3=CC(=C(C=C3C1N(CC4=C5C(=C(C=C24)OC)OCO5)C)OC)OC)O,,,,,,
6139,126140,CID 126140,CC1CC(OC1OCC2C(C(C(C(O2)OC3=CC4=C(C=C3)OC5=CC=CC(=O)C5=C4O)O)O)O)(CO)O,,,,,,
6140,126141,CID 126141,C1=CC(=O)C2=C(C3=C(C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC2=C1)O,,,,,,
6141,126142,CID 126142,C1CN=C2C(=C(N(C2=O)C3=CC=C(C=C3)Cl)S)C(=N1)C4=CC5=CC=CC=C5C=C4,,,,,,
6142,126143,"2-bromo-N-[4-[[(7R,8R,9S,10R,13S)-10,13-dimethyl-3,17-dioxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-7-yl]sulfanyl]phenyl]acetamide",C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@@H]2CC[C@]4(C3CCC4=O)C)SC5=CC=C(C=C5)NC(=O)CBr,,,,,,
6143,126144,"5-(2-Dodecylphenyl)-4,6-dithianonanedioic acid",CCCCCCCCCCCCC1=CC=CC=C1C(SCCC(=O)O)SCCC(=O)O,,,,,,
6144,126145,"5-(2-(8-Phenyloctyl)phenyl)-4,6-dithianonanedioic acid",C1=CC=C(C=C1)CCCCCCCCC2=CC=CC=C2C(SCCC(=O)O)SCCC(=O)O,,,,,,
6145,126146,"[5-[5-(2-Deca-2,4-dienoyloxy-1-hydroxyethyl)-3,4-dihydroxyoxolan-2-yl]oxy-2-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-3-hydroxy-6-(hydroxymethyl)oxan-4-yl] 7-hydroxy-12-methyltrideca-2,4,8,10-tetraenoate",CCCCCC=CC=CC(=O)OCC(C1C(C(C(O1)OC2C(OC(C(C2OC(=O)C=CC=CCC(C=CC=CC(C)C)O)O)C3=C(C=C(C=C3O)O)CO)CO)O)O)O,,,,,,
6146,126147,3-(2-(4-Methylphenyl)thioethyl)-5-sydnone,CC1=CC=C(C=C1)SCC[N+]2=NOC(=C2)[O-],,,,,,
6147,126148,3-[2-(4-Methylphenylthio)ethyl]-4-H-sydnone,CC1=CC=C(C=C1)SCC[N+]2=CC(=O)ON2,,,,,,
6148,126149,Puqiedinone,C[C@H]1CC[C@H]2[C@@H]([C@@H]3CCC4[C@H]([C@@H]3CN2C1)C[C@H]5[C@H]4CC(=O)[C@@H]6[C@@]5(CC[C@@H](C6)O)C)C,,,,,,
6149,126150,CID 126150,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC3C4=C(CCC(C4)O)C(O3)O)C,,,,,,
6150,126151,CID 126151,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC3=C4CC(CCC4=CO3)O)C,,,,,,
6151,126152,3-(3-Hydroxyphenyl)-5-((methylmercapto)methyl)-N-n-propylpiperidine,CCCN1C[C@@H](C[C@@H](C1)C2=CC(=CC=C2)O)CSC,,,,,,
6152,126153,Proline cetyl ester,CCCCCCCCCCCCCCCCOC(=O)[C@@H]1CCCN1,,,,,,
6153,126154,"(S)-Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione",C1C[C@H]2C(=O)NCC(=O)N2C1,,,,,,
6154,126155,"3-((3-(Acetyloxy)-4-(hexadecyloxy)butyl)sulfonyl)-N,N,N-trimethyl-1-propanaminium",CCCCCCCCCCCCCCCCOCC(CCS(=O)(=O)CCC[N+](C)(C)C)OC(=O)C.[Cl-],,,,,,
6155,126156,3-(3-Acetyloxy-4-hexadecoxybutyl)sulfonylpropyl-trimethylazanium,CCCCCCCCCCCCCCCCOCC(CCS(=O)(=O)CCC[N+](C)(C)C)OC(=O)C,,,,,,
6156,126157,4-Amino-N-(1-phenylethyl)benzamide,CC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)N,,,,,,
6157,126158,Icaria chemotactic peptide,CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N,,,,,,
6158,126159,"14-Hydroxypregna-1,4-diene-3,20-dione",CC(=O)[C@H]1CC[C@@]2([C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)C)O,,,,,,
6159,126160,4-Methylumbelliferyl Phosphocholine,CC1=CC(=O)OC2=C1C=CC(=C2)OP(=O)([O-])OCC[N+](C)(C)C,,,,,,
6160,126161,2-[Hydroxy-(4-methyl-2-oxochromen-7-yl)oxyphosphoryl]oxyethyl-trimethylazanium,CC1=CC(=O)OC2=C1C=CC(=C2)OP(=O)(O)OCC[N+](C)(C)C,,,,,,
6161,126162,"S-(2-Chloro-1,1,2-trifluoroethyl)glutathione",C(CC(=O)NC(CSC(C(F)Cl)(F)F)C(=O)NCC(=O)O)C(C(=O)O)N,,,,,,
6162,126163,15-(4-Iodophenyl)-10-methylpentadecanoic acid,CC(CCCCCCCCC(=O)O)CCCCCC1=CC=C(C=C1)I,,,,,,
6163,126164,Fluorescein n-acetylimidazole,C1=CC2=C(C=C1CC(=O)N3C=CN=C3)C(=O)OC24C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O,,,,,,
6164,126165,CID 126165,C[C@@H]1[C@@H]([C@]([C@H](C(O1)OC2=CC=CC3=C2C4=C5C6=C(C=CC(=C6C(=O)O4)C)OC(=C5C3=O)O)O)(C)O)O,,,,,,
6165,126166,Factor xiiib,CC1=C2C(=CC(=C1O)O)NC=C2CCN.CN1CC(=O)N=C1N.OS(=O)(=O)O,,,,,,
6166,126167,"3-(2-aminoethyl)-4-methyl-1H-indole-5,6-diol",CC1=C2C(=CC(=C1O)O)NC=C2CCN,,,,,,
6167,126168,"3-(2-aminoethyl)-4,7-dimethyl-1H-indole-5,6-diol;2-amino-3-methyl-4H-imidazol-5-one;sulfuric acid",CC1=C2C(=CNC2=C(C(=C1O)O)C)CCN.CN1CC(=O)N=C1N.OS(=O)(=O)O,,,,,,
6168,126169,"4,7-Dimethyl-5,6-dihydroxytryptamine",CC1=C2C(=CNC2=C(C(=C1O)O)C)CCN,,,,,,
6169,126170,Guanidinooxypropylamine,C(CN)CON=C(N)N,,,,,,
6170,126171,CID 126171,C1=C(C=C(C2(C1[N+](=O)[O-])O[C@@H]3[C@H](OC([C@@H]3O2)N4C=NC5=C4NC(=NC5=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6171,126172,CID 126172,C1=C(C=C(C2(C1[N+](=O)[O-])O[C@@H]3[C@H](OC([C@@H]3O2)N4C=NC5=C4NC(=NC5=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6172,126173,CID 126173,C1=CC(=CC(=C1)O)C(=CF)[C@@H](C(=O)O)N,,,,,,
6173,126174,Madhp,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CCC24[C@@H](OC(O4)(C)C)C(=O)OC)CCC5=CC(=O)C=C[C@]35C)O,,,,,,
6174,126175,Pdhpa,CCCNC(=O)[C@H]([C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O)O,,,,,,
6175,126176,"Benzamide, N-(2-((dibutylamino)sulfonyl)ethyl)-2,3,4,5,6-pentafluoro-",CCCCN(CCCC)S(=O)(=O)CCNC(=O)C1=C(C(=C(C(=C1F)F)F)F)F,,,,,,
6176,126177,CID 126177,C[C@@H]1CCCCCCC(=O)C=CC(=O)O1,,,,,,
6177,126178,pBMBA,C1=CC(=CC=C1CBr)C(=O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
6178,126179,Kallikrein Inhibitor,CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2C(=O)C,,,,,,
6179,126180,7-Deacetoxyolepupuane,CC(=O)O[C@H]1[C@H]2C(=CO1)CC[C@@H]3[C@@]2(CCCC3(C)C)C,,,,,,
6180,126181,CID 126181,C[C@H](C([C@@H]([C@H](CO)NC(=O)C)O)NC(=O)CC(C)O)O,,,,,,
6181,126182,2-[[(2-Amino-5-chlorophenyl)-phenylmethylidene]amino]guanidine,C1=CC=C(C=C1)C(=NN=C(N)N)C2=C(C=CC(=C2)Cl)N,,,,,,
6182,126183,3-Carboxy-5-methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide,CC1=C(C(=NO1)C(=O)O)C(=O)NC2=CC=C(C=C2)C(F)(F)F,,,,,,
6183,126184,CID 126184,C1[C@H](O[C@H]([C@@H]1F)N2C=NC3=C2NC=NC3=O)CO,,,,,,
6184,126185,"6-Methoxy-N-ethyl-1,2-dihydroquinoline",CCN1CC=CC2=C1C=CC(=C2)OC,,,,,,
6185,126186,6-Methoxy-N-ethylquinolinium,CC[N+]1=CC=CC2=C1C=CC(=C2)OC.[Cl-],,,,,,
6186,126187,1-Ethyl-6-methoxyquinolinium,CC[N+]1=CC=CC2=C1C=CC(=C2)OC,,,,,,
6187,126188,CID 126188,C(CS(C(=O)N)NC(=O)N)C(=O)N,,,,,,
6188,126189,"3-Nitroso-7,8,9,10-tetrahydrobenzo(a)pyrene",C1CCC2=C(C1)C=C3C=CC4=C(C=CC5=C4C3=C2C=C5)N=O,,,,,,
6189,126190,CID 126190,CC=C(C)C(=O)C[C@@]1([C@@H](C[C@@H]2[C@@H]([C@@H]3[C@@]14C=C[C@@]3(OO4)C)OC(=O)C2=C)O)C,,,,,,
6190,126191,Selenonium choline,C[Se+](C)CCO,,,,,,
6191,126192,CID 126192,C1=CC=C2C(=C1)C(=CC(=N2)C(=O)O)S,,,,,,
6192,126193,CID 126193,C1=CC2=C(C=C1Cl)N=C(C=C2S)C(=O)O,,,,,,
6193,126194,"3-(beta-Phenylethyl)-9beta-methoxy-9-alpha-(m-(1-cyclopentyl-propionoxyphenyl))-3-azabicyclo(3,3,1)nonane",COC1([C@@H]2CCC[C@H]1CN(C2)CCC3=CC=CC=C3)C4=CC(=CC=C4)OC(=O)CCC5CCCC5,,,,,,
6194,126195,CID 126195,C1=CC=C(C=C1)C=NN2C(=O)C3=NC4=CC=CC=C4C3=NN2,,,,,,
6195,126196,CID 126196,CC(C=C)C12COC(OC1)(OC2)C3=CC=C(C=C3)C=N,,,,,,
6196,126197,19-Ethynyl-19-hydroxyandrost-4-en-17-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CCCC[C@]34[C@H](C#C)O,,,,,,
6197,126198,Isocrasifoline,CN1CCC2=C([C@@H]1CC3=CC(=C(C=C3)O)OC)C(=C(C=C2)OC)O,,,,,,
6198,126199,2-chloro-2-fluoro-N-[2-(4-nitrophenyl)ethyl]acetamide,C1=CC(=CC=C1CCNC(=O)C(F)Cl)[N+](=O)[O-],,,,,,
6199,126200,"2-(5-Amino-1-methyl-4,7-dioxoindol-3-yl)-1,3-thiazole-4-carboxamide",CN1C=C(C2=C1C(=O)C=C(C2=O)N)C3=NC(=CS3)C(=O)N,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
6200,126201,"3-Hydroxyicosa-5,8,11,14-tetraenoic acid",CCCCCC=CCC=CCC=CCC=CCC(CC(=O)O)O,,,,,,
6201,126202,1-Nitro-2-methyl-4-aminopyrrole,CC1=CC(=CN1[N+](=O)[O-])N,,,,,,
6202,126203,"4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one",CC1C2=CC=CC=C2CCN1C3=C(C(=O)SS3)Cl,,,,,,
6203,126204,9-Keto-cannabinoid methyl ether,CCCCCC1=CC2=C([C@@H]3CC(=O)CC[C@H]3C(O2)(C)C)C(=C1)OC,,,,,,
6204,126205,"N,N-Methylethylphenylcarbamate",CCN(C)C(=O)OC1=CC=CC=C1,,,,,,
6205,126206,CID 126206,CC1=CC(=NN1C2=NNC(=C3C2=NC4=CC=CC=C43)NN)C,,,,,,
6206,126207,CID 126207,C1=CC=C(C=C1)C(=O)OC[C@H](C=C2C=CC(=O)O2)O,,,,,,
6207,126208,"[(2S)-2-hydroxy-7-methoxy-4,7-dioxohept-5-enyl] benzoate",COC(=O)C=CC(=O)C[C@@H](COC(=O)C1=CC=CC=C1)O,,,,,,
6208,126209,"(7-Ethoxy-4,7-dioxohepta-2,5-dienyl) benzoate",CCOC(=O)C=CC(=O)C=CCOC(=O)C1=CC=CC=C1,,,,,,
6209,126210,"1,3,7-Trihydroxy-8-methoxy-3-methyl-1,2,4,7-tetrahydrobenzo[a]anthracen-12-one",CC1(CC(C2=C(C1)C=CC3=C2C(=O)C4=C(C3O)C(=CC=C4)OC)O)O,,,,,,
6210,126211,6-Obhepo,CC12CCC3=C(C1=CCCC2=O)COC4=C3C=CC5=CC=CC=C54,,,,,,
6211,126212,"3,4,5,13-Tetrahydro-3H-2-benzothieno(5,4-d)naphtho(1,2-b)pyran",C1CC2=C(COC3=C2C=CC4=CC=CC=C43)C5=CSCC51,,,,,,
6212,126213,"2,5-Diisothiocyanatobenzenesulfonate",C1=CC(=C(C=C1N=C=S)S(=O)(=O)O)N=C=S,,,,,,
6213,126214,N-(3-Iodophenyl)maleimide,C1=CC(=CC(=C1)I)N2C(=O)C=CC2=O,,,,,,
6214,126215,"4,5-Dioxohexadec-2-enoic acid",CCCCCCCCCCCC(=O)C(=O)C=CC(=O)O,,,,,,
6215,126216,"3-(7-Methoxy-1,3-benzodioxol-5-yl)phenol",COC1=CC(=CC2=C1OCO2)C3=CC(=CC=C3)O,,,,,,
6216,126217,"3-Methoxy-4-(7-methoxy-1,3-benzodioxol-5-yl)phenol",COC1=CC(=CC2=C1OCO2)C3=C(C=C(C=C3)O)OC,,,,,,
6217,126218,5-Methoxymethylene-hydantoin,COC=C1C(=O)NC(=O)N1,,,,,,
6218,126219,"5,9-Dimethyl-12-oxabicyclo[9.2.1]tetradeca-1(14),4,8-trien-13-one",CC1=CCCC2=CC(CC(=CCC1)C)OC2=O,,,,,,
6219,126220,"6-Hydroxyl-1,6-dihydropurine ribonucleoside",C1=N[C@@H](C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
6220,126221,"2,19-(Methyleneoxy)androst-4-ene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)[C@@H]5C[C@]34COC5,,,,,,
6221,126222,3-Hydroxy-24-dimethylaminochol-8(14)-en-15-one,C[C@H](CCCN(C)C)[C@H]1CC(=O)C2=C3CC[C@H]4C[C@H](CC[C@@]4([C@H]3CC[C@]12C)C)O,,,['Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)'],,,
6222,126223,2-Ateco,CC1(N=N1)CCS[C@H]2C=C[C@@H]3[C@H]([C@@H]2O)O3,,,,,,
6223,126224,2-[2-(2-Acetyloxyacetyl)pyrrol-1-yl]ethyl acetate,CC(=O)OCCN1C=CC=C1C(=O)COC(=O)C,,,,,,
6224,126225,"7-Chloro-2-ethenyl-3,4,5,6-tetrahydro-4-methylthieno(4,3,2-ef)(3)benzazepine",CN1CCC2=C(C=CC3=C2C(=C(S3)C=C)C1)Cl,,,,,,
6225,126226,CID 126226,CC(=CCCC(=CCC(=CCCC1=CC(=O)OC1O)O)C)C,,,,,,
6226,126227,CID 126227,C[C@@H]([C@@H]([C@@H]1CNC2=C(N1)NC(=NC2=O)N)O)O,,,,,,
6227,126228,5-Hydroxy-3-methoxypent-2-enoic acid,COC(=CC(=O)O)CCO,,,,,,
6228,126229,4-Phenyl-1-(5-phenylpentyl)piperidine,C1CN(CCC1C2=CC=CC=C2)CCCCCC3=CC=CC=C3,,,,,,
6229,126230,(2S)-2-[(2R)-2-aminopropanoyl]oxypropanoic acid,C[C@H](C(=O)O[C@@H](C)C(=O)O)N,,,,,,
6230,126231,"1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one",C1=CN(C(=O)N=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F,,,,,,
6231,126232,CID 126232,C1=CC=C(C=C1)CC(C(=O)OCCCO)N,,,,,,
6232,126233,9-Deoxygoniopypyrone,C1[C@@H]2CC(=O)O[C@H]1[C@@H]([C@@H](O2)C3=CC=CC=C3)O,,,,,,
6233,126234,"2,4,5-Trihydroxyamphetamine",CC(CC1=CC(=C(C=C1O)O)O)N,,,,,,
6234,126235,"6-Hydroxy-N-methyl-3,4-methylenedioxyamphetamine",C[C@@H](CC1=CC2=C(C=C1O)OCO2)NC,,,,,,
6235,126236,7-Goniofufurone,C1[C@@H]2[C@@H]([C@H]([C@H](O2)C(C3=CC=CC=C3)O)O)OC1=O,,,,,,
6236,126237,"4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)butan-1-amine",C1CNC(C2=C1C3=CC=CC=C3N2)CCCCN,,,,,,
6237,126238,N-(4-Iodophenethyl)maleimide,C1=CC=C(C(=C1)CCN2C(=O)C=CC2=O)I,,,,,,
6238,126239,Decahydro-6-(2H-tetrazol-5-ylmethyl)-3-isoquinolinecarboxylic acid,C1C[C@@H]2CN[C@H](C[C@@H]2C[C@@H]1CC3=NNN=N3)C(=O)O,,,,,,
6239,126240,CID 126240,COC1=CC2=C(C=C1)O[C@H]([C@H]2CO)C3=C(C=C(C(=C3)O)C=CO)OC,,,,,,
6240,126241,N-[2-(2-cyclohexylethylsulfanyl)ethyl]dec-2-enamide,CCCCCCCC=CC(=O)NCCSCCC1CCCCC1,,,,,,
6241,126242,Icos-11-en-14-ynoic acid,CCCCCC#CCC=CCCCCCCCCCC(=O)O,,,,,,
6242,126243,2-Nitro-5-carbamylthiobenzoic acid,C1=CC(=C(C=C1SC(=O)N)C(=O)O)[N+](=O)[O-],,,,,,
6243,126244,"5-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-(hydroxymethyl)pent-2-enoic acid",C[C@@H]1CC[C@@]2([C@@H]([C@@]1(C)CCC(=CC(=O)O)CO)CCC=C2C)C,,,,,,
6244,126245,"4,5-Difluorobenzo[a]pyrene",C1=CC=C2C3=C4C(=CC2=C1)C(=C(C5=CC=CC(=C54)C=C3)F)F,,,,,,
6245,126246,Norcocaethylene,CCOC(=O)[C@@H]1[C@H]2CC[C@H](N2)C[C@@H]1OC(=O)C3=CC=CC=C3,,,,,,
6246,126247,4-[(3-Amino-2-oxoazetidin-1-yl)methyl]cyclohexane-1-carboxylic acid,C1CC(CCC1CN2CC(C2=O)N)C(=O)O,,,['Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)'],,,
6247,126248,3-Amino-2-(4-chloro-3-hydroxyphenyl)propane-1-sulfonic acid,C1=CC(=C(C=C1C(CN)CS(=O)(=O)O)O)Cl,,,"['Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. (See all compounds classified as GABA Antagonists.)']",,,
6248,126249,"3-hydroxy-2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylcyclohexa-2,5-diene-1,4-dione",CCCCCC1=CC(=O)C(=C(C1=O)O)C2C=C(CC[C@H]2C(=C)C)C,,,,,,
6249,126250,CID 126250,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CO)C[C@@H]1OC(=O)C3=CC=CC=C3,,,,,,
6250,126251,1-Methylsulfinyl-2-(2-methylsulfinylethylsulfonyl)ethane,CS(=O)CCS(=O)(=O)CCS(=O)C,,,,,,
6251,126252,1-Methylsulfinyl-2-(2-(methylthio)ethylsulfonyl)ethane,CSCCS(=O)(=O)CCS(=O)C,,,,,,
6252,126253,"3-(4-Aminophenyl)-3-cyclohexylpiperidine-2,6-dione",C1CCC(CC1)C2(CCC(=O)NC2=O)C3=CC=C(C=C3)N,,,,,,
6253,126254,alpha-Amino-gamma-oxo-3-pyridinebutanoic acid,C1=CC(=CN=C1)C(=O)CC(C(=O)O)N,,,,,,
6254,126255,Glutathione maleimide,C1=CC(=O)N(C1=O)[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,,,,,,
6255,126256,"(4R)-2-amino-4-hydroxy-9-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purine-6,8-dione",C1[C@@H]([C@H](OC1N2C(=O)N=C3[C@]2(N=C(NC3=O)N)O)CO)O,,,,,,
6256,126257,1-Benzyl-1-(2-chloroethyldiazenyl)-3-methylurea,CNC(=O)N(CC1=CC=CC=C1)N=NCCCl,,,,,,
6257,126258,CID 126258,CCOC1C(OC(CC1(C)N(C)C)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C5=C(C(=C4)C)C(=O)C=C(O5)C6(C(O6)C=CC)C)O)C,,,,,,
6258,126259,CID 126259,CCOC1C(OC(CC1(C)N(C)C)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C5=C(C(=C4)C)C(=O)C=C(O5)C6(C(O6)C)C)O)C,,,,,,
6259,126260,Mebut-indpip,CC(=CCN1CCC2(CCC3=CC=CC=C32)CC1)C,,,,,,
6260,126261,Glycyl-alanyl-isoleucine,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)CN,,,,,,
6261,126262,"Pregnane-3,7,17,20-tetrol",C[C@H]([C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)O)C)O)C)O)O,,,,,,
6262,126263,Neocarazostatin A,CC1=C(C2=C(C3=C(N2)C=CC(=C3)CC=C(C)C)C(=C1OC)O)C(C(C)O)O,,,,,,
6263,126264,1-(2-hydroxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-enyl)-9H-carbazol-4-ol,CC1=C(C2=C(C3=C(N2)C=CC(=C3)CC=C(C)C)C(=C1OC)O)CC(C)O,,,,,,
6264,126265,"1,1-Bis(4-hydroxyphenyl)-2-iodo-2-phenylethylene",C1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)[125I],,,,,,
6265,126266,2-(Ethylsulfanyl)-6-methoxy-1h-benzimidazole,CCSC1=NC2=C(N1)C=C(C=C2)OC,,,,,,
6266,126267,CID 126267,C1=NC2=C(N1CSC(CO)CO)NC(=NC2=O)N,,,,,,
6267,126268,"3'-(4-Guanidinobenzoyloxy)spiro(isobenzofuran-1-(3H),9'-(9H)xanthen)-3-one",C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)OC(=O)C5=CC=C(C=C5)N=C(N)N)OC6=CC=CC=C36,,,,,,
6268,126269,N(1)-Methyl-2-iodo-lysergic acid diethylamide,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(N(C4=CC=CC(=C34)C2=C1)C)I)C,,,,,,
6269,126270,CID 126270,C[C@@H]1CCC(=O)C2C(O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O,,,,,,
6270,126271,tert-Butyloxycarbonyl-phenylalanyl-phenylalanyl-glycine hydroxylamine,CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)NO,,,,,,
6271,126272,Ippgnhoh,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)NO)NC(=O)CCC3=CC(=C(C=C3)O)I,,,,,,
6272,126273,Ibh-substance P hexapeptide,CCC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)CCC3=CC(=C(C=C3)O)I,,,,,,
6273,126274,Meisoindigo,CN1C2=CC=CC=C2C(=C1O)C3=C4C=CC=CC4=NC3=O,,,,,,
6274,126275,"2-Naphthacenecarboxylic acid, 3-((6-deoxy-2,3,4-tri-O-methyl-alpha-L-mannopyranosyl)oxy)-6,6a,7,10,10a,11-hexahydro-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-, methyl ester, (6aR-(6aalpha,7alpha,10aalpha))-",C[C@H]1[C@H]([C@@H]([C@H](O[C@@H]1OC2=CC3=CC4=C(C(=C3C(=C2C(=O)OC)C)O)C(=O)[C@@]5(C(=O)C=C([C@H]([C@@]5(C4=O)O)O)OC)OC)OC)OC)OC,,,,,,
6275,126276,8alpha-N-Imidazolylriboflavin,CC1=CC2=C(C=C1CN3C=CN=C3)N(C4=NC(=O)NC(=O)C4=N2)CC(C(C(CO)O)O)O,,,,,,
6276,126277,Mtnppp,CCC(=O)N(C1CCN(CC1C)C2CCC3=CC=CC=C3C2)C4=CC=CC=C4,,,,,,
6277,126278,"Benzamide, 4-chloro-N-(2-(3-oxo-4-morpholinyl)ethyl)-",C1COCC(=O)N1CCNC(=O)C2=CC=C(C=C2)Cl,,,,,,
6278,126279,"2-[4-[2-[3-[[4-[[[5-(6-Aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-4-oxobutanoyl]benzoic acid",CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CCC(=O)C4=CC=CC=C4C(=O)O)O,,,,,,
6279,126280,Indatraline,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,,,,,,
6280,126281,8-Amino-6-fluoro-9-ribofuranosyl-9H-purine,C1=NC2=C(C(=N1)F)N=C(N2C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,,,,,,
6281,126282,Tipentosin,CC1=CC2=C(S1)CCC(C2=O)CN[C@H]3CC[C@@H]([C@H]3O)OC4=CC=CC=C4,,,,,,
6282,126283,"4-amino-1-[(2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]pyrimidin-2-one",C1[C@@H]([C@H]([C@H](C1N2C=CC(=NC2=O)N)O)O)CO,,,,,,
6283,126284,CID 126284,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@H](CNC(=O)C=O)C(C(CO)O)O[C@@H]2C[C@@H]([C@@H]([C@@H]([C@H]2O)O)O)CO)O)O)O,,,,,,
6284,126285,CID 126285,CC(=O)NCC(=O)O.CC(=O)NCC(=O)O.C1=CC(=C(N)N)C=CC1=CN=NC2=CC=C(C=C2)C(=N)N,,,,,,
6285,126286,CID 126286,C1=CC(=C(N)N)C=CC1=CN=NC2=CC=C(C=C2)C(=N)N,,,,,,
6286,126287,4-Methylumbelliferyl beta-D-cellobioside,CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
6287,126288,"(1R,2R)-6,10,14-trimethyl-3-propan-2-ylcyclotetradeca-3,5,9,13-tetraene-1,2-diol",CC1=CCCC(=CC=C([C@H]([C@@H](C(=CCC1)C)O)O)C(C)C)C,,,,,,
6288,126289,CID 126289,CCC(=C(CC)C1=CC(=C(C(=C1)F)O)F)C2=CC(=C(C(=C2)F)O)F,,,,,,
6289,126290,Cymegesolate,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=C[C@H](CC4)OC(=O)CCC5CCCC5)C,,,,,,
6290,126291,Epispongiatriol,C[C@]12CC(=O)[C@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CCC4=COC=C43)CO)(C)CO)O,,,,,,
6291,126292,Stegane,COC1=C(C(=C2C(=C1)CC3C(CC4=CC5=C(C=C42)OCO5)COC3=O)OC)OC,,,,,,
6292,126293,4-[2-(4-Carbamimidoyl-2-methylphenyl)iminohydrazinyl]-3-methylbenzenecarboximidamide,CC1=C(C=CC(=C1)C(=N)N)NN=NC2=C(C=C(C=C2)C(=N)N)C,,,,,,
6293,126294,"(3R)-4,6-dimethoxy-3-(4-oxo-6-prop-1-enylpyran-3-yl)-3H-2-benzofuran-1-one",CC=CC1=CC(=O)C(=CO1)[C@H]2C3=C(C=C(C=C3OC)OC)C(=O)O2,,,,,,
6294,126295,"((4-Hydroxy-3,5-dimethylphenyl)methylene)propanedinitrile",CC1=CC(=CC(=C1O)C)C=C(C#N)C#N,,,['Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that ATP synthesis does not occur. Included here are those IONOPHORES that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Uncoupling Agents.)'],,,
6295,126296,(2S)-5-amino-2-[(4-methyl-2-oxochromen-7-yl)amino]-5-oxopentanoic acid,CC1=CC(=O)OC2=C1C=CC(=C2)N[C@@H](CCC(=O)N)C(=O)O,,,,,,
6296,126297,"Butanedioic acid, bis(2,4-dibromo-6-carboxyphenyl) ester",C1=C(C=C(C(=C1C(=O)O)OC(=O)CCC(=O)OC2=C(C=C(C=C2Br)Br)C(=O)O)Br)Br,,,,,,
6297,126298,CID 126298,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N3C(=O)CN=C3S,,,,,,
6298,126299,"(1S,3R)-5-[2-[(1R,3aS,7aR)-1-[(2R)-5,5-difluoro-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](CCC(C(C)(C)O)(F)F)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C,,,,,,
6299,126300,CID 126300,C1=CC=NC(=C1)C=NN=C(N)[S-].[Cu+2],,,,,,
6300,126301,"9-((4-Aminobutyl)ethylamino)-2,3-dihydrobenzo(f)phthalazine-1,4-dione",CCN(CCCCN)C1=CC2=C(C=C1)C=CC3=C2C(=O)NNC3=O,,,,,,
6301,126302,Suc-Gly-Pro-Leu-Gly-Pro-amc,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)CCC(=O)O,,,,,,
6302,126303,"5,5a-Dihydro-4bh-benzo[3,4]phenanthro[1,2-b]azirene",C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC=C4C5C3N5,,,,,,
6303,126304,Methyl 3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-enoate,CC(=CCC1=C(C=CC(=C1)C=CC(=O)OC)O)C,,,,,,
6304,126305,"2,4-Bis(2-methoxyethoxy)-1,3,5-triazine",COCCOC1=NC(=NC=N1)OCCOC,,,,,,
6305,126306,3-(2-Cyanoethyl)thymidine,CC1=CN(C(=O)N(C1=O)CCC#N)[C@H]2C[C@@H]([C@H](O2)CO)O,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']",,,
6306,126307,"4,4'-Dihydroxyantipyrine",CC1=C(C(=O)N(N1C)C2=CC=C(C=C2)O)O,,,,,,
6307,126308,1-Deoxy-1-(fluoren-2-ylamino)-beta-D-glucopyranuronic acid,C1C2=CC=CC=C2C3=C1C=C(C=C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,,,,,,
6308,126309,CID 126309,C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C4(C[C@H]5[C@@]3(CC[C@H](C5)O)C)N=N4)O)C.[Na+],,,,,,
6309,126310,"7-Deoxy-7,7-azotaurocholic acid",C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C4(C[C@H]5[C@@]3(CC[C@H](C5)O)C)N=N4)O)C,,,,,,
6310,126311,Arginine(ADP-ribose),C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)NC(CCCN=C(N)N)C(=O)O)O)O)O)O)N,,,,,,
6311,126312,"(3r)-8-[(2r,3s)-3-Heptyloxiran-2-yl]oct-1-ene-4,6-diyn-3-ol",CCCCCCC[C@H]1[C@H](O1)CC#CC#C[C@@H](C=C)O,,,,,,
6312,126313,CID 126313,COC1=CC(=CC(=C1O)C(=CC2=CC(=C(C=C2)O)OC)CO)[C@H]3[C@@H](OC4=C(O3)C=C(C=C4)C5=CC(=C6C(=CC(=O)C=C6O5)O)O)CO,,,,,,
6313,126314,CID 126314,C1=CC=C(C=C1)C2=C(C(=O)N=C(N2)N)I,,,,,,
6314,126315,"4-Hydroxy-3,5-diprenylcinnamic acid",CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)C=CC(=O)O)C,,,,,,
6315,126316,CID 126316,COC1=C(C=CC(=C1)[C@@H]2[C@@H](C3=C(C4=CC(=C(C=C24)O)O)OC5=CC(=O)C=C(C5=C3O)O)CO)O,,,,,,
6316,126317,"4,9-Dihydro-4,9-dihydroxy-2,7-dinitro-pyrido(2,3,4,5-lmn)phenanthridine-5,10-dione",C1=C(C=C2C3=C1C(=O)N(C4=CC(=CC(=C43)C(=O)N2O)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
6317,126318,"3-Ethyl-2-[3-(1-ethylquinolin-1-ium-2-yl)prop-2-enylidene]-1,3-benzoxazole;iodide",CCN1C2=CC=CC=C2OC1=CC=CC3=[N+](C4=CC=CC=C4C=C3)CC.[I-],,,,,,
6318,126319,1-Ethyl-2-[3-(3-ethylbenzoxazol-2(3H)-ylidene)-1-propenyl]quinolinium,CCN1C2=CC=CC=C2OC1=CC=CC3=[N+](C4=CC=CC=C4C=C3)CC,,,,,,
6319,126320,CID 126320,C1CN=C(N1)NN=CC2C3=CC=CC=C3C(C4=CC=CC=C24)C=NNC5=NCCN5,,,,,,
6320,126321,"4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl]-benzyl alcohol",CC(=CC1=CC=C(C=C1)CO)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
6321,126322,5-Hexadecanoylaminofluorescein,CCCCCCCCCCCCCCCC(=O)NC1=CC2=C(C=C1)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O,,,,,,
6322,126323,N(1)-Methylisoguanosine,CN1C(=C2C(NC1=O)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,,,,,,
6323,126324,Heterotropan,CC1C(C(C1C2=CC(=C(C=C2OC)OC)OC)C3=CC(=C(C=C3OC)OC)OC)C,,,,,,
6324,126325,"N,N'-Hexamethylenebis(3-pyridinecarboxamide)",C1=CC(=CN=C1)C(=O)NCCCCCCNC(=O)C2=CN=CC=C2,,,,,,
6325,126326,Ephedradine A,C1CCN2CCCNC(=O)C[C@@H](C3=CC4=C(C=C3)O[C@H]([C@@H]4C2=O)C5=CC=C(C=C5)O)NCCCNC1,,,,,,
6326,126327,CID 126327,C1=CC=C(C(=C1)C2=CC(=C3C(=CC(=O)C=C3O2)O)O)O,,,,,,
6327,126328,"Benzo(c)phenanthrene-5,6-diol, 5,6-dihydro-, trans-",C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC=C4[C@@H]([C@H]3O)O,,,,,,
6328,126329,"(1s,2s)-1,2-Dihydrobenzo[c]phenanthrene-1,2-diol",C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C[C@@H]([C@H]4O)O)C=C3,,,,,,
6329,126330,26-Aminocholesterol,C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CN,,,,,,
6330,126331,"4',6-Dichloroflavan",C1CC2=C(C=CC(=C2)Cl)OC1C3=CC=C(C=C3)Cl,,,,,,
6331,126332,beta-Apopolygamatin,COC1=C(C2=C(CC3=C([C@@H]2C4=CC5=C(C=C4)OCO5)C(=O)OC3)C=C1)OC,,,,,,
6332,126333,CID 126333,C[C@H](C=O)O[C@H](C=O)N1C=NC2=C1NC=NC2=O,,,,,,
6333,126334,Disialosyl galactosyl globoside,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OC[C@H]([C@@H]([C@@H]([C@H](C=O)NC(=O)C)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O)O)O)O)O,,,,,,
6334,126335,Clazamycin B,C1[C@@H](CN2[C@]1(C=CC2=N)O)Cl,,,,,,
6335,126336,"LHRH, leu(6)-N-Et-glynh2(10)-",CCC(C)[C@H](C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CN5C=CN=C5)NC(=O)[C@@H]6CCC(=O)N6,,,,,,
6336,126337,"1,5-((3,3'-Dimethylphosphate)diphenoxy)-3-oxapentane",CP(=O)(O)OC1=CC=CC=C1OCCOCCOC2=CC=CC=C2OP(=O)(C)O,,,,,,
6337,126338,Clazamycin A,C1[C@@H](CN2[C@@]1(C=CC2=N)O)Cl,,,,,,
6338,126339,"5-tert-Butyl-2,4-dinitro-m-xylene",CC1=CC(=C(C(=C1[N+](=O)[O-])C)[N+](=O)[O-])C(C)(C)C,,,,,,
6339,126340,3-[5-[[3-(2-carboxyethyl)-5-[[3-(2-carboxyethyl)-5-[[3-(2-carboxyethyl)-5-(carboxymethyl)-4-(hydroxymethyl)-1H-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1H-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1H-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid,C1=C(C(=C(N1)CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4=C(C(=C(N4)CC(=O)O)CO)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O,,,,,,
6340,126341,4-Nitrophenoxycarbonyl methyl disulfide,CSSC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6341,126342,"1-Acetyl-3,2-toluyl-5-fluorouracil",CC1=CC=CC=C1C(=O)N2C(=O)C(=CN(C2=O)C(=O)C)F,,,,,,
6342,126343,"D-Glucose, 3-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-",C(CCl)N(C(=O)N[C@H]([C@H](C=O)O)[C@@H]([C@@H](CO)O)O)N=O,,,,,,
6343,126344,4-S-Cysteinylphenol,C1=CC(=CC=C1O)SC[C@@H](C(=O)O)N,,,,,,
6344,126345,CID 126345,C(C=C(CO)C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
6345,126346,6-Iodoacetamidofluorescein,C1=CC2=C(C=C1NC(=O)CI)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O,,,,,,
6346,126347,6-Ethynyluracil,C#CC1=CC(=O)NC(=O)N1,,,,,,
6347,126348,(2S)-2-amino-5-[[(2R)-2-amino-3-[2-(4-azidophenyl)-2-oxoethyl]sulfanylpropanoyl]-(carboxymethyl)amino]-5-oxopentanoic acid,C1=CC(=CC=C1C(=O)CSC[C@@H](C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)N)N=[N+]=[N-],,,,,,
6348,126349,CID 126349,C1=CC(=CC=C1C(=O)CSC[C@@H](C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)N)N[N+]#N,,,,,,
6349,126350,CID 126350,CCC=CCC(C=CC1C(C(CC(O1)O)O)CC=CCCCC(=O)O)O,,,,,,
6350,126351,alpha-Amino-(4-hydroxybenzylidene)diphosphonate,C1=CC(=CC=C1C(N)(P(=O)(O)O)P(=O)(O)O)O,,,,,,
6351,126352,Tdmcpo,CC1=CC2=C(CCC2=O)C3=C1C4=C(C=C3)[C@@H]([C@H](C=C4)O)O,,,,,,
6352,126353,"methyl (3S,4S)-4-methoxy-2-(methoxymethylidene)-3-methyl-6-phenylhex-5-enoate",C[C@H]([C@H](C=CC1=CC=CC=C1)OC)C(=COC)C(=O)OC,,,,,,
6353,126354,beta-Fluoroasparagine,[C@H]([C@H](C(=O)N)F)(C(=O)O)N,,,,,,
6354,126355,"15,16-Dihydro-1,11-methanocyclopenta(a)phenanthren-17-one",C1CC(=O)C2=C1C3=C4C(=C2)CC5=CC=CC(=C54)C=C3,,,,,,
6355,126356,4-Amino-5-(imidazol-2-yl)imidazole,C1=CN=C(N1)C2=C(N=CN2)N,,,,,,
6356,126357,5-Aza-2'-deoxycytidine-5'-triphosphate,C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
6357,126358,CID 126358,C1C[N+]2(CC[N+]1(C2)CCCl)CCCl.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
6358,126359,"1,4-Bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane",C1C[N+]2(CC[N+]1(C2)CCCl)CCCl,,,,,,
6359,126360,"Chryseno[4,5-bcd]thiophene",C1=CC=C2C3=C4C(=CC2=C1)SC5=CC=CC(=C54)C=C3,,,,,,
6360,126361,Octadecyl L-tyrosinate,CCCCCCCCCCCCCCCCCCOC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
6361,126362,1-Pyrenenonanol,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)CCCCCCCCCO,,,,,,
6362,126363,"Piperidine, 1-(3-(3-(aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)-",CC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC(=CC=C2)C(=N)N)C(=O)N3CCCCC3,,,,,,
6363,126364,Pyroglutamyl-prolyl-arginine-4-nitroanilide,C1C[C@H](N(C1)C(=O)[C@@H]2CCC(=O)N2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
6364,126365,2'-Deoxy-2'-fluoroadenosine triphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)F)N,,,,,,
6365,126366,S-Nitrosopenicillamine,CC(C)([C@H](C(=O)O)N)SN=O,,,,,,
6366,126367,N-Succinimidyl-4-((iodoacetyl)amino)benzoate,C1CC(=O)N(C1=O)OC(=O)C2=CC=C(C=C2)NC(=O)CI,,,,,,
6367,126368,Lysyl-lysyl-glycyl-glutamic acid,C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)N,,,,,,
6368,126369,CID 126369,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1OC[C@H]([C@@H]([C@@H](C(C=O)NC(=O)C)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O)CO)O)O,,,,,,
6369,126370,"10-Methoxy-2-(2-(1-piperidinyl)ethyl)-7H-pyrido(4,3-c)carbazolium",CC(=O)[O-].CC(=O)[O-].CN1C2=C(C=C(C=C2)OC)C3=C1C=CC4=C3C=[N+](C=C4)CCN5CCCCC5.CN1C2=C(C=C(C=C2)OC)C3=C1C=CC4=C3C=[N+](C=C4)CCN5CCCCC5,,,,,,
6370,126371,"10-Methoxy-7-methyl-2-(2-piperidin-1-ylethyl)pyrido[4,3-c]carbazol-2-ium",CN1C2=C(C=C(C=C2)OC)C3=C1C=CC4=C3C=[N+](C=C4)CCN5CCCCC5,,,,,,
6371,126372,"[(1R,2R,4R,6R,8S,11R)-8-hydroxy-4,9-dimethyl-14-methylidene-13-oxo-5,12-dioxatricyclo[9.3.0.04,6]tetradec-9-en-2-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1C[C@@]2([C@H](O2)C[C@@H](C(=C[C@@H]3[C@@H]1C(=C)C(=O)O3)C)O)C,,,,,,
6372,126373,"1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-3-((4-methyl-1-piperazinyl)methyl)-2-phenyl-, dihydrochloride, cis-(-)-",CN1CCN(CC1)C[C@@H]2[C@@H](SC3=CC=CC=C3NC2=O)C4=CC=CC=C4.Cl.Cl,,,,,,
6373,126374,"cis-2,3-dihydro-3-[(4-methylpiperazinyl)methyl]-2-phenyl-1,5-benzothiazepin-4(5H)-one",CN1CCN(CC1)C[C@@H]2[C@@H](SC3=CC=CC=C3NC2=O)C4=CC=CC=C4,,,,,,
6374,126375,Boc-Val-Leu-Lys-MCA,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C,,,,,,
6375,126376,"4-(4,5-Dihydroxy-3-methoxy-6-methyloxan-2-yl)oxy-2,5,7-trihydroxy-3-methoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione",CC1C(C(C(C(O1)OC2C(C(C(=O)C3=CC4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5O)(C)O)OC)OC)O)O,,,,,,
6376,126377,Boc-phe-ser-arg-mca,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C,,,,,,
6377,126378,"2-[4-[1-(4-fluorophenyl)-2-phenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine",CCC(=C(C1=CC=C(C=C1)OCCN(C)C)C2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
6378,126379,CID 126379,CN(C=O)C1=C(NC(=NC1=O)N)N[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
6379,126380,"(6R)-7,9-Dibromo-N-[3-[2,6-dibromo-4-[2-[[(6R)-7,9-dibromo-6-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carbonyl]amino]-1-hydroxyethyl]phenoxy]-2-hydroxypropyl]-6-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carboxamide",COC1=C([C@@H](C2(CC(=NO2)C(=O)NCC(COC3=C(C=C(C=C3Br)C(CNC(=O)C4=NOC5(C4)C=C(C(=C([C@@H]5O)Br)OC)Br)O)Br)O)C=C1Br)O)Br,,,,,,
6380,126381,Pyrene-1-carbonyl fluoride,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)C(=O)F,,,,,,
6381,126382,Iodoazomycin arabinoside,C1=CN(C(=N1)[N+](=O)[O-])[C@H]2[C@H]([C@@H]([C@H](O2)C[125I])O)O,,,,,,
6382,126383,2-amino-2-(2H-tetrazol-5-yl)acetic acid,C1(=NNN=N1)C(C(=O)O)N,,,,,,
6383,126384,CID 126384,C1CC(=O)N(C1)S(=O)(=O)O.[KH],,,,,,
6384,126385,Sulfopyrrolidone,C1CC(=O)N(C1)S(=O)(=O)O,,,,,,
6385,126386,3-Amino-6-methoxy-9-(2-hydroxyethylamino)acridine,COC1=C2C=CC(=CC2=NC3=C1C=CC(=C3)N)NCCO,,,,,,
6386,126387,"Hydroperoxide, 1-ethoxyethyl",CCOC(C)OO,,,,,,
6387,126388,"N-(2-(3,4-Dichlorophenyl)ethyl)-N-methyl-2-(1-pyrrolidinyl)ethylamine",CN(CCC1=CC(=C(C=C1)Cl)Cl)CCN2CCCC2,,,,,,
6388,126389,Dynemicin O,CC1C(=O)C(C2C3=C(C=CC=C3O)C4C1(C2(C5=CC(=C6C(=C5N4)C(=O)C7=C(C=CC(=C7C6=O)O)O)O)O)O)OC,,,,,,
6389,126390,Dynemicin P,CC1C(=O)C(C2C3=CC=CC=C3C4C1(C2(C5=CC(=C6C(=C5N4)C(=O)C7=C(C=CC(=C7C6=O)O)O)O)O)O)O,,,,,,
6390,126391,Dynemicin Q,CC1=C(C(=O)C2C3=CC=CC=C3C4C1(C2(C5=CC(=C6C(=C5N4)C(=O)C7=C(C=CC(=C7C6=O)O)O)O)O)O)O,,,,,,
6391,126392,Flavone-8-acetic acid dimethylaminoethyl ester,CN(C)CCOC(=O)CC1=C2C(=CC=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
6392,126393,"6,7-Benzoidazoxan",C1CN=C(N1)C2COC3=CC4=CC=CC=C4C=C3O2,,,,,,
6393,126394,4-Sulfoxyphenylacetyl dehydroalanine,C=C(C(=O)O)NC(=O)CC1=CC=C(C=C1)OS(=O)(=O)O,,,,,,
6394,126395,CID 126395,CSC1=C(C(=CC(=C1)O)S(C)O)N=NC(=O)N,,,,,,
6395,126396,CID 126396,CN=C(C1=CN=CC=C1)NCCO,,,,,,
6396,126397,"3-Pyridinecarboximidamide, N-(2-(acetyloxy)ethyl)-N'-cyano-",CC(=O)OCCN=C(C1=CN=CC=C1)NC#N,,,,,,
6397,126398,"Phosphonofluoridic acid, P-methyl-, (2E)-2-buten-1-yl ester",CC=CCOP(=O)(C)F,,,,,,
6398,126399,1-Nitro-6-azabenzo(a)pyrene N-oxide,C1=CC=C2C(=C1)C3=C4C(=[N+]2[O-])C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,,,,,,
6399,126400,3-Nitro-6-azabenzo(a)pyrene N-oxide,C1=CC=C2C(=C1)C3=C4C(=[N+]2[O-])C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],,,,,,
6400,126401,1-Nitro-6-azabenzo(a)pyrene,C1=CC=C2C(=C1)C3=C4C(=N2)C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,,,,,,
6401,126402,2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate,C1CCC(CC1)(C2=CC=CC=C2)C(=O)OCCN3CCOCC3,,,,,,
6402,126403,(2R)-2-amino-3-(3-chloroprop-2-enylsulfanyl)propanoic acid,C(C=CCl)SC[C@@H](C(=O)O)N,,,,,,
6403,126404,CID 126404,CCCCC[C@@H](C=C[C@H]1CCC(=O)[C@@H]1CC=CCCCCO)O,,,,,,
6404,126405,CID 126405,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)C2CC=C3C=COC3=O)(C)CO)OC(=O)CCC(=O)O,,,,,,
6405,126406,CID 126406,CC(CCC(=O)OC[C@]1([C@H]2CCC(=C)C([C@@]2(CC[C@H]1O)C)CC=C3C=COC3=O)C)O,,,,,,
6406,126407,19-Octacosynoic acid,CCCCCCCCC#CCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
6407,126408,Benastatin A,CCCCCC1=C(C(=C2C(=C1)C=CC3=C(C4=C(C=C32)C(C5=C(C4=O)C(=CC(=C5)O)O)(C)C)O)O)C(=O)O,,,,,,
6408,126409,Benastatin B,CCCCCC1=C(C(=C2C(=C1)CCC3=C(C4=C(C=C32)C(C5=C(C4=O)C(=CC(=C5)O)O)(C)C)O)O)C(=O)O,,,,,,
6409,126410,N-phenyl-2-selanylbenzamide,C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2[SeH],,,,,,
6410,126411,6-methyl-2-(2-methylcyclohex-2-en-1-yl)-2H-pyran-5-one,CC1C(=O)C=CC(O1)C2CCCC=C2C,,,,,,
6411,126412,CID 126412,CC(=O)N[C@H]1[C@H](C[C@@H]([C@@H]([C@@H]1O)O)COP(=O)(CCN)O)O,,,,,,
6412,126413,6-(3-Acetamidoanilino)naphthalene-2-sulfonic acid,CC(=O)NC1=CC=CC(=C1)NC2=CC3=C(C=C2)C=C(C=C3)S(=O)(=O)O,,,,,,
6413,126414,Goniodiol 7-acetate,CC(=O)O[C@@H]([C@H]1CC=CC(=O)O1)[C@@H](C2=CC=CC=C2)O,,,,,,
6414,126415,CID 126415,CCOP(=O)(OCC)ONC(C1CC1)C2CC2,,,,,,
6415,126416,"5-[(1-Hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-methylamino]pentanoic acid",CC1(CC(CC(N1O)(C)C)N(C)CCCCC(=O)O)C,,,,,,
6416,126417,Antibiotic AB3217A,COC1=CC=C(C=C1)[C@@H]2[C@@H]3[C@@H]([C@H](CN3)O)O[C@H]4[C@@H]([C@H]([C@H](O4)CO2)O)O,,,,,,
6417,126418,CID 126418,CC(C)(CCCC(=O)O[C@@H]1[C@H]([C@H]2CO[C@@H]([C@@H]3[C@@H]([C@H](CN3)O)O[C@@H]1O2)C4=CC=C(C=C4)OC)O)O,,,,,,
6418,126419,"Pentanoic acid, 4-methyl-, decahydro-3,7-dihydroxy-11-(4-methoxyphenyl)-5,8-epoxy-5H-(1,5)dioxecino(3,2-b)pyrrol-6-yl ester",CC(C)CCC(=O)O[C@@H]1[C@H]([C@H]2CO[C@@H]([C@@H]3[C@@H]([C@H](CN3)O)O[C@@H]1O2)C4=CC=C(C=C4)OC)O,,,,,,
6419,126420,"3,5-dibromo-6,7-dihydro-5H-1,2-benzoxazol-4-one",C1CC2=C(C(=O)C1Br)C(=NO2)Br,,,,,,
6420,126421,CID 126421,CC(=CCC1=C(C(=CC(=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O)O)O)C,,,,,,
6421,126422,CID 126422,CC(=CCOC1=C(C=CC(=C1)C2=C(C(=C3C=C(C(=O)C=C3O2)O)O)O)O)C,,,,,,
6422,126423,"Potassium 2,2',2'',2'''-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanetriyl))tetraacetate",C1=CC=C(C(=C1)N(CC(=O)[O-])CC(=O)[O-])OCCOC2=CC=CC=C2N(CC(=O)[O-])CC(=O)[O-].[K+].[K+].[K+].[K+],,,,,,
6423,126424,CID 126424,C1=NC2=C(N1CCN3C=NC4=C3C(=O)N=C(N4)N)C(=O)N=C(N2)N,,,,,,
6424,126425,"2,4-Dicarbamimidamido-3,5,6-trihydroxycyclohexyl dihydrogen phosphate",C1(C(C(C(C(C1O)O)OP(=O)(O)O)N=C(N)N)O)N=C(N)N,,,,,,
6425,126426,Megosin,CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=NCCOS(=O)(=O)O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=NCCOS(=O)(=O)O)O)O)C(C)C)O)O.[Na+].[Na+],,,,,,
6426,126427,"2-[[2,3,8-Trihydroxy-6-methyl-4-propan-2-yl-7-[1,6,7-trihydroxy-3-methyl-5-propan-2-yl-8-(2-sulfooxyethyliminomethyl)naphthalen-2-yl]naphthalen-1-yl]methylideneamino]ethyl hydrogen sulfate",CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=NCCOS(=O)(=O)O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=NCCOS(=O)(=O)O)O)O)C(C)C)O)O,,,,,,
6427,126428,Epc-nph,C[N+](C)(C)CCOP(=O)([O-])OCCCCCC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6428,126429,2-[Hydroxy-[6-(4-nitrophenoxy)-6-oxohexoxy]phosphoryl]oxyethyl-trimethylazanium,C[N+](C)(C)CCOP(=O)(O)OCCCCCC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6429,126430,"(1xi)-1-(7-Amino-2h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-5-chloro-5-deoxy-d-ribitol",C1=NC2=C(NN=C2C(=N1)N)C3[C@@H]([C@@H]([C@H](O3)CCl)O)O,,,,,,
6430,126431,2-Fluoromethylornithine,C(CC(CF)(C(=O)O)N)CN,,,,,,
6431,126432,"trans-10,11-Dihydro-7,12-dimethylbenz(a)anthracene-10,11-diol",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1C=CC(C4O)O)C,,,,,,
6432,126433,alpha-(Fluoromethyl)-5-hydroxytryptophan,C1=CC2=C(C=C1O)C(=CN2)CC(CF)(C(=O)O)N,,,,,,
6433,126434,1-Nitroso-1-ethyl-3-methylurea,CCN(C(=O)NC)N=O,,,,,,
6434,126435,alpha-(Fluoromethyl)tryptophan,C1=CC=C2C(=C1)C(=CN2)CC(CF)(C(=O)O)N,,,,,,
6435,126436,CID 126436,C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)NC(=NC2=O)N,,,,,,
6436,126437,Furamidine,C1=CC(=CC=C1C2=CC=C(O2)C3=CC=C(C=C3)C(=N)N)C(=N)N,,,,,,
6437,126438,4-(N-Methyl-N-nitroso)aminoantipyrine,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)N=O,,,,,,
6438,126439,CID 126439,CC(C)CCOC1=C2C(=O)C=C(OC2=C(C=C1)CC=C)C(=O)[O-].[Na+],,,,,,
6439,126440,8-allyl-5-(3-methyl n-butoxy)-4-oxo-4H-1-benzopyran-2-carboxylic acid,CC(C)CCOC1=C2C(=O)C=C(OC2=C(C=C1)CC=C)C(=O)O,,,,,,
6440,126441,5-(p-Chlorobenzyl)-6-aminouracil,C1=CC(=CC=C1CC2=C(NC(=O)NC2=O)N)Cl,,,,,,
6441,126442,"N-[2-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]pentadec-2-enamide",CCCCCCCCCCCCC=CC(=O)NC1C(C(C(OC1OC2C(C(C(C(O2)CO)O)O)NC(=O)C)CC(C3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O)O,,,,,,
6442,126443,"3-(4-(3,6-Dihydro-4-phenyl-1(2H)-pyridyl)butyl)-1H-indole monohydrochloride",C1CN(C=CC1C2=CC=CC=C2)CCCCC3=CNC4=CC=CC=C43.Cl,,,,,,
6443,126444,"3-[4-(4-phenyl-3,4-dihydro-2H-pyridin-1-yl)butyl]-1H-indole",C1CN(C=CC1C2=CC=CC=C2)CCCCC3=CNC4=CC=CC=C43,,,,,,
6444,126445,CID 126445,CC1(CC[C@@H]([C@@]2([C@@H]1C[C@H](C34[C@H]2CCC([C@H]3O)C(=O)C4=O)O)CO)O)C,,,,,,
6445,126446,"4-Butyl-1,3-dioxolane",CCCCC1COCO1,,,,,,
6446,126447,CID 126447,C1CN(C(=N1)C2=CC=NC=C2)CCCC(=O)NC3=CC=C(C=C3)C(=O)O,,,,,,
6447,126448,4-((4-(Dimethylamino)phenyl)azo)benzenesulfonic acid hydrazide,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)NN,,,,,,
6448,126449,"N,N'-Bis(2-chloroethyl)-N,N'-dimethyl-1,16-hexadecanediamine",CN(CCCCCCCCCCCCCCCCN(C)CCCl)CCCl,,,,,,
6449,126450,"3-Piperidinol, 1-(3-(5-methyl-3-phenyl-1H-1,2,4-triazol-1-yl)propyl)-",CC1=NC(=NN1CCCN2CCCC(C2)O)C3=CC=CC=C3,,,,,,
6450,126451,Psorospermin,C[C@@]1(CO1)[C@H]2CC3=C4C(=C(C=C3O2)OC)C(=O)C5=C(O4)C(=CC=C5)O,,,,,,
6451,126452,Imndp,CC1=CC(=C2C=C(C=CC2=C1OP(=O)(O)O)[125I])OP(=O)(O)O.N.N.N.N,,,,,,
6452,126453,(6-(125I)iodanyl-2-methyl-4-phosphonooxynaphthalen-1-yl) dihydrogen phosphate,CC1=CC(=C2C=C(C=CC2=C1OP(=O)(O)O)[125I])OP(=O)(O)O,,,,,,
6453,126454,"2-(2-Chloro-1-hydroxy-1-methylethyl)-1,2-dihydro-10-hydroxy-5-methoxy-6H-furo(2,3-c)xanthen-6-one",C[C@](CCl)([C@@H]1CC2=C3C(=C(C=C2O1)OC)C(=O)C4=C(O3)C(=CC=C4)O)O,,,,,,
6454,126455,Bgg-spermidine,C(CCNC(=O)CC[C@@H](C(=O)O)N)CNCCCNC(=O)CC[C@@H](C(=O)O)N,,,,,,
6455,126456,"4-Piperidinemethanamine, 1-(2,3-bis(decyloxy)propyl)-4-phenyl-, dihydrochloride",CCCCCCCCCCOCC(CN1CCC(CC1)(CN)C2=CC=CC=C2)OCCCCCCCCCC.Cl.Cl,,,,,,
6456,126457,"1-(2,3-Bis(decyloxy)propyl)-4-phenyl-4-piperidinemethanamine",CCCCCCCCCCOCC(CN1CCC(CC1)(CN)C2=CC=CC=C2)OCCCCCCCCCC,,,,,,
6457,126458,"Benzoic acid, 5-((2-amino-4-methyl-1-oxopentyl)amino)-2-hydroxy-, (S)-",CC(C)C[C@@H](C(=O)NC1=CC(=C(C=C1)O)C(=O)O)N,,,,,,
6458,126459,(5-Nitroisoquinolin-1-yl)methylene-N-hydroxy-N'-aminoguanidine,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)CCN3CCOCC3,,,,,,
6459,126460,"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-6-amino-8a-methoxy-1,5-dimethyl-8-methylene-, (1aS-(1a-alpha,8a-alpha,8b-alpha))-",CC1=C(C(=O)C2=C(C1=O)N3[C@@H]4[C@@H](N4C)C[C@@]3(C2=C)OC)N,,,,,,
6460,126461,Parabactin,C[C@@H]1[C@H](N=C(O1)C2=CC=CC=C2O)C(=O)N(CCCCNC(=O)C3=C(C(=CC=C3)O)O)CCCNC(=O)C4=C(C(=CC=C4)O)O,,,,,,
6461,126462,"N-[1-[[12-(3-amino-3-oxopropyl)-3-[3-(diaminomethylideneamino)propyl]-6,21-bis(1-hydroxyethyl)-7,25-dimethyl-18-(2-methylpropyl)-2,5,8,11,14,17,20,23-octaoxo-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-1-oxobut-2-en-2-yl]-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecanamide",CCCCCCCCCCCC(CC(=O)NC(=CC)C(=O)NC1C(OC(=O)C(NC(=O)C(N(C(=O)CNC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC1=O)C(C)O)CC(C)C)CCC(=O)N)C)C(C)O)CCCN=C(N)N)C)OC2C(C(C(C(O2)CO)O)O)O,,,,,,
6462,126463,Arabinose 5-triphosphate,C([C@H]([C@H]([C@@H](C=O)O)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
6463,126464,1-O-(6-Carboxylhexyl)glycero-3-phosphoserine,C(CCCOC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O)CCC(=O)O,,,,,,
6464,126465,1-Ethyl-2-(1-hydroxyethyl)-3-hydroxypyridin-4-one,CCN1C=CC(=O)C(=C1C(C)O)O,,,,,,
6465,126466,"Uridine, 3-(1,3-benzodioxol-5-ylcarbonyl)-2'-deoxy-5-fluoro-",C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)N(C2=O)C(=O)C3=CC4=C(C=C3)OCO4)F)CO)O,,,,,,
6466,126467,"7,16-Diethyl-4,6-dihydroxy-5,9,13,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione",CCC1CC(C(=O)C=CC(=CC(C(OC(=O)CC(C(C1O)C)O)CC)C)C)C,,,,,,
6467,126468,CID 126468,C1=CC2=C(C(=O)C(=O)C(=C2C=C1Cl)O)O,,,,,,
6468,126469,Serine-7-amino-4-methylcoumarin carbamate,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)OC[C@@H](C(=O)O)N,,,,,,
6469,126470,CID 126470,C1=CC=C(C=C1)C2=CC=C(C=C2)NC3=NC4=C(N3[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)NC(=NC4=O)N,,,,,,
6470,126471,CID 126471,CC1=C2C3=CC=CC=C3N=C2C=C(N1)NO,,,,,,
6471,126472,"(13S)-13-hydroxyoctadeca-6,9,11-trienoic acid",CCCCC[C@@H](C=CC=CCC=CCCCCC(=O)O)O,,,,,,
6472,126473,"Hexanoic acid, 2-amino-5-oxo-6-phosphono-, (S)-",C(CC(=O)CP(=O)(O)O)[C@@H](C(=O)O)N,,,,,,
6473,126474,"Acridinium, 3,6-diamino-10-(6-((4-nitrobenzoyl)oxy)hexyl)-, chloride",C1=CC=C(C(=C1)C(=O)OCCCCCC[N+]2=C3C=C(C=CC3=CC4=C2C=C(C=C4)N)N)[N+](=O)[O-].[Cl-],,,,,,
6474,126475,"6-(3,6-Diaminoacridin-10-ium-10-yl)hexyl 2-nitrobenzoate",C1=CC=C(C(=C1)C(=O)OCCCCCC[N+]2=C3C=C(C=CC3=CC4=C2C=C(C=C4)N)N)[N+](=O)[O-],,,,,,
6475,126476,"3,6-Diamino-10-(6-(4-nitrobenzamido)hexyl)acridinium",C1=CC=C(C(=C1)C(=O)NCCCCCC[N+]2=C3C=C(C=CC3=CC4=C2C=C(C=C4)N)N)[N+](=O)[O-].[Cl-],,,,,,
6476,126477,"N-[6-(3,6-diaminoacridin-10-ium-10-yl)hexyl]-2-nitrobenzamide",C1=CC=C(C(=C1)C(=O)NCCCCCC[N+]2=C3C=C(C=CC3=CC4=C2C=C(C=C4)N)N)[N+](=O)[O-],,,,,,
6477,126478,"1,1,2,2-Tetramethyl-1,2-bis(4'-hydroxyphenyl)ethane",CC(C)(C1=CC=C(C=C1)O)C(C)(C)C2=CC=C(C=C2)O,,,,,,
6478,126479,Estrosteron,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C)CCC4=C3C=CC(=C4)OC(=O)CCCCCCCCC=C,,,,,,
6479,126480,Dimethylthionocarbamylcholine,CN(C)C(OCC[N+](C)(C)C)S.[Br-],,,,,,
6480,126481,2-[Dimethylamino(sulfanyl)methoxy]ethyl-trimethylazanium,CN(C)C(OCC[N+](C)(C)C)S,,,,,,
6481,126482,CID 126482,C1=CC(=C(C(=C1)O)O)C2=CC(=C3C(=CC(=O)C=C3O2)O)O,,,,,,
6482,126483,"Acetamide, N-(3,5-dimethyl-4-oxo-2,5-cyclohexadien-1-ylidene)-",CC1=CC(=NC(=O)C)C=C(C1=O)C,,,,,,
6483,126484,Phenylalanyl-phenylalanyl-arginine chloromethyl ketone,C1=CC=C(C=C1)C[C@H](C(=O)NC(=O)[C@H](CC2=CC=CC=C2)N[C@@H](CCCN=C(N)N)C(=O)CCl)N,,,,,,
6484,126485,(2R)-2-amino-6-[[amino(hydrazinyl)methylidene]amino]hexanoic acid,C(CCN=C(N)NN)C[C@H](C(=O)O)N,,,,,,
6485,126486,CID 126486,CCCCCC(CCC=CCC=CCC=CCCC(=O)O)O,,,,,,
6486,126487,"5-Phenyl-1H-imidazo(4,5-c)(1,8)naphthyridin-4(5H)-one",C1=CC=C(C=C1)N2C3=C(C=CC=N3)C4=C(C2=O)NC=N4,,,,,,
6487,126488,Adipoylbisphosphonic acid,C(CCC(=O)P(=O)(O)O)CC(=O)P(=O)(O)O,,,,,,
6488,126489,"1,7-Dioxoheptane-1,7-diylbisphosphonic acid",C(CCC(=O)P(=O)(O)O)CCC(=O)P(=O)(O)O,,,,,,
6489,126490,Genkdaphine,C1[C@@H]2[C@H]([C@@H](O1)C3=CC4=C(C=C3)OCO4)C(=O)O[C@H]2C5=C6C(=CC=C5)OCO6,,,,,,
6490,126491,CID 126491,C(CSNO)[C@@H](C(=O)O)N,,,,,,
6491,126492,CID 126492,C1=CC(=O)N(C1=O)CCC(=O)NCC2=C(C(=C(C(=C2F)F)N[N+]#N)F)F,,,,,,
6492,126493,8-Amino-3-benzylhypoxanthine,C1=CC=C(C=C1)CN2C=NC(=O)C3=C2N=C(N3)N,,,,,,
6493,126494,CID 126494,C=CCN=C(N)NCCC[C@@H](C(=O)O)N,,,,,,
6494,126495,CID 126495,C[C@H]([C@H]1C(O1)C=C[C@H]2[C@@H](O2)[C@@H](C=C)O)O,,,,,,
6495,126496,(+)(-)-3-(Aminooxy)-2-fluoropropanamine dihydrochloride,C(C(CON)F)N.Cl.Cl,,,['Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)'],,,
6496,126497,3-(Aminooxy)-2-fluoropropanamine,C(C(CON)F)N,,,['Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)'],,,
6497,126498,"[[(2R,3S,4S)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate",C1=NC2=C(N=C(N=C2N1C3[C@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)F)N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
6498,126499,CID 126499,CCC(C)C1C2=NC(=CS2)C(=O)NC(C3=NC(=CS3)C(=O)NC(C(=O)N4CCCC4C5=NC(C(O5)C)C(=O)N1)CC6=CC=CC=C6)C,,,,,,
6499,126500,"7,11,12-Trimethylbenz(a)anthracene",CC1=C2C(=C3C(=C(C2=CC=C1)C)C=CC4=CC=CC=C43)C,,,,,,
6500,126501,5-Vinyl-1-arabinofuranosyluracil,C=CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
6501,126502,6-Iodocholesterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC(=C4[C@@]3(CC[C@@H](C4)O)C)I)C,,,,,,
6502,126503,4-Amino-3-hydroxyphenylalanine,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)N,,,,,,
6503,126504,"N-(3,5-Dinitrobenzoyl)phenylglycine",C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)C2=CC(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6504,126505,1-Arabinofuranosyl-5-ethynylcytosine,C#CC1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
6505,126506,3-Triethoxycholesterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OCCOCCOCCO)C)C,,,,,,
6506,126507,CID 126507,C[C@@H]1CCC[C@@H]([C@H]1[C@H](C)C(=O)C2=C(OCC2=O)O)C=C(CO)[C@H]3[C@@H](CCC(O3)C=C[C@H](C)[C@H]4[C@H](C[C@@H](O4)[C@H](C)OC)C)C.[Na+],,,,,,
6507,126508,CID 126508,C[C@@H]1CCCC([C@H]1[C@H](C)C(=O)C2=C(OCC2=O)O)C=C(CO)C3[C@@H](CCC(O3)C=C[C@H](C)[C@H]4[C@H](C[C@@H](O4)[C@@H](C)OC)C)C,,,,,,
6508,126509,CID 126509,C1=CC(=CC=C1C2=COC3=C(C(=O)C=CC3=C2O)O)O,,,,,,
6509,126510,CID 126510,CCC=CCC=CCC=CC=CC=CC([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)N,,,,,,
6510,126511,Lithocholate 3-O-glucuronide,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C)C,,,,,,
6511,126512,3-Methoxybenzyl isothiocyanate,COC1=CC=CC(=C1)CN=C=S,,,,,,
6512,126513,"4-Amino-1,6-dihydropyrimidine-2,5-dione",C1C(=O)C(=NC(=O)N1)N,,,,,,
6513,126514,Dendrodoine,CN(C)C1=NSC(=N1)C(=O)C2=CNC3=CC=CC=C32,,,,,,
6514,126515,Bromotrimethylammoniobimane,CC1=C(N2C(=C(C(=O)N2C1=O)C)CBr)C[N+](C)(C)C,,,,,,
6515,126516,"2,4(1H,3H)-Pyrimidinedione, 3-acetyl-5-fluoro-",CC(=O)N1C(=O)C(=CNC1=O)F,,,,,,
6516,126517,"1,5-Anhydro-D-fructose",C1C(=O)[C@H]([C@@H]([C@H](O1)CO)O)O,,,,,,
6517,126518,CID 126518,C1CN2C(=N[C@H]([C@H]3C2([C@@H]1O)N=C(N3)N)COC(=O)N)N,,,,,,
6518,126519,CID 126519,CC1=C(C(=O)C2=C(C1=O)CC3C4C5=C(CC(N4C)C(N3C2CNC(=O)C(=O)C)O)C(=O)C(=C(C5=O)OC)C)OC,,,,,,
6519,126520,Boc-pyrimidoblamic acid,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NCC(C(=O)N)NC(=O)OC(C)(C)C)C(=O)O,,,,,,
6520,126521,2-[(2-Amino-2-oxoethyl)-[2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]propyl]amino]acetic acid,CC(CN(CC(=O)N)CC(=O)O)N(CC(=O)N)CC(=O)O,,,,,,
6521,126522,10-Propionyl dithranol,CCC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O,,,,,,
6522,126523,10-Valeryl dithranol,CCCCC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O,,,,,,
6523,126524,"Dodecanediamide, N,N'-bis(2-((5-(((5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-propyl-1H-pyrrol-3-yl)amino)carbonyl)-1-propyl-1H-pyrrol-3-yl)amino)-2-oxoethyl)-, dihydrochloride",CCCN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCC(=N)N)CCC)NC(=O)CNC(=O)CCCCCCCCCCC(=O)NCC(=O)NC3=CN(C(=C3)C(=O)NC4=CN(C(=C4)C(=O)NCCC(=N)N)CCC)CCC.Cl.Cl,,,,,,
6524,126525,"N,N'-Bis[2-[[5-[[5-[(2-amidinoethyl)carbamoyl]-1-propyl-1H-pyrrole-3-yl]carbamoyl]-1-propyl-1H-pyrrole-3-yl]amino]-2-oxoethyl]dodecanediamide",CCCN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCC(=N)N)CCC)NC(=O)CNC(=O)CCCCCCCCCCC(=O)NCC(=O)NC3=CN(C(=C3)C(=O)NC4=CN(C(=C4)C(=O)NCCC(=N)N)CCC)CCC,,,,,,
6525,126526,"1,3-Dimethyl-2-cyano-1-nitrosoguanidine",CN=C(NC#N)N(C)N=O,,,,,,
6526,126527,1-(4-Carbamoyl-1H-imidazol-5-yl)-3-hydroxymethyl-3-methyltriazene,CN(CO)N=NC1=C(NC=N1)C(=O)N,,,,,,
6527,126528,Iremycin,CC[C@]1(CCC2=C([C@H]1O[C@H]3C[C@@H]([C@@H]([C@@H](O3)C)O)N(C)C)C(=C4C(=C2O)C(=O)C5=C(C4=O)C=CC=C5O)O)O,,,,,,
6528,126529,"Methyl 9-(1,2-dihydroxy-2,6,6-trimethylcyclohexyl)-3,7-dimethylnona-2,4,6,8-tetraenoate",CC(=CC=CC(=CC(=O)OC)C)C=CC1(C(CCCC1(C)O)(C)C)O,,,,,,
6529,126530,NP-O-SU,C1CC(=O)N(C1=O)OC(=O)CC2=CC(=C(C=C2)O)[N+](=O)[O-],,,,,,
6530,126531,Dehydropirlindole,CC1=CC2=C(C=C1)N3CCN=C4C3=C2CCC4,,,,,,
6531,126532,Leu-val-val-tyr-pro-trp-thr-gln-arg-phe,C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O,,,,,,
6532,126533,Val-val-tyr-pro-trp-thr-gln-arg-phe,C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O,,,,,,
6533,126534,CID 126534,CCCCCC=CCC=CC=CC=CC1[C@H](O1)CCCC(=O)OC,,,,,,
6534,126535,Pepsinogen (1-12),CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N,,,,,,
6535,126536,"N,N-Diacetylcysteine",CC(=O)N([C@@H](CS)C(=O)O)C(=O)C,,,,,,
6536,126537,Anethofuran,C[C@@H]1CO[C@@H]2[C@H]1CCC(=C2)C,,,,,,
6537,126538,1a-Demethylmitomycin G,CC1=C(C(=O)C2=C(C1=O)N3C[C@@H]4[C@H]([C@@]3(C2=C)OC)N4)N,,,,,,
6538,126539,"Phenanthridinium, 3-amino-5-ethyl-6-phenyl-",CC[N+]1=C(C2=CC=CC=C2C3=C1C=C(C=C3)N)C4=CC=CC=C4,,,,,,
6539,126540,Cristacarpin,CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@]2(COC4=C3C=CC(=C4)O)O)OC)C,,,,,,
6540,126541,Cortisol-p-ara-C,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)COP(=O)(O)OCC5C(C(C(O5)N6C=CC(=NC6=O)N)O)O)O)C)O,,,,,,
6541,126542,Caffeidine acid,CNC(=O)N(C)C1=C(N(C=N1)C)C(=O)O,,,,,,
6542,126543,Ganodine,C1=CC=C(C=C1)CCN2C(=CC=C2C=O)CO,,,,,,
6543,126544,"2(1H)-Pyridinone, 3-(2-(2-benzoxazolyl)ethyl)-5-ethyl-6-(hydroxymethyl)-",CCC1=C(NC(=O)C(=C1)CCC2=NC3=CC=CC=C3O2)CO,,,,,,
6544,126545,Glutaryl-2-(hydroxymethyl)anthraquinone,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)COC(=O)CCCC(=O)O,,,,,,
6545,126546,CID 126546,C1CCCC(CC1)CC=CC2=CC(=C(C=C2)C3CCCCC3)Cl.Cl,,,,,,
6546,126547,[3-(3-Chloro-4-cyclohexylphenyl)prop-2-en-1-yl]cycloheptane,C1CCCC(CC1)CC=CC2=CC(=C(C=C2)C3CCCCC3)Cl,,,,,,
6547,126548,"3-(2-chloroethoxymethyl)-5-fluoro-1H-pyrimidine-2,4-dione",C1=C(C(=O)N(C(=O)N1)COCCCl)F,,,,,,
6548,126549,"3-(6-chlorohexoxymethyl)-5-fluoro-1H-pyrimidine-2,4-dione",C1=C(C(=O)N(C(=O)N1)COCCCCCCCl)F,,,,,,
6549,126550,"3-[2-(2-chloroethoxy)ethoxymethyl]-5-fluoro-1H-pyrimidine-2,4-dione",C1=C(C(=O)N(C(=O)N1)COCCOCCCl)F,,,,,,
6550,126551,(125I)-5-Iodo-6-nitro-2-piperazinylquinoline,C1CN(CCN1)C2=NC3=C(C=C2)C(=C(C=C3)[N+](=O)[O-])[125I],,,,,,
6551,126552,"4-[2-[4-(11-Ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl)-3-hydroxypentan-2-yl]-2-hydroxy-5,6-dimethyloxan-4-yl]oxy-4-oxobut-2-enoic acid",CCC1C(C(CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C)C)OC(=O)C=CC(=O)O)O)O)OC)C)C)O,,,,,,
6552,126553,"[6-[2-[4-(11-Ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl)-3-hydroxypentan-2-yl]-2-hydroxy-5,6-dimethyloxan-4-yl]oxy-4-hydroxy-2-methyloxan-3-yl] carbamate",CCC1C(C(CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C)C)OC3CC(C(C(O3)C)OC(=O)N)O)O)O)OC)C)C)O,,,,,,
6553,126554,CID 126554,CC(=CC(=O)OC)CC[C@H]1C(=C)CC[C@@H]2[C@@]1(CCC[C@@]2(C)C(=O)O)C,,,,,,
6554,126555,"methyl 7-(hydroxymethyl)-2,4a,5,7a-tetrahydro-1H-cyclopenta[c]pyridine-4-carboxylate",COC(=O)C1=CNCC2C1CC=C2CO,,,,,,
6555,126556,16-Hydroxytriptolide,C[C@@H](CO)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C,,,,,,
6556,126557,CID 126557,CC1=C(C(=CC2[C@@H]1CC(C2)(C)C)CO)C(=O)C(=O)O,,,,,,
6557,126558,9-(3-Iodoprop-2-enoxymethyl)purin-6-amine,C1=NC(=C2C(=N1)N(C=N2)COCC=CI)N,,,,,,
6558,126559,Methyl 3-[3-methyl-5-(3-methylbut-2-enyl)imidazol-4-yl]prop-2-enoate,CC(=CCC1=C(N(C=N1)C)C=CC(=O)OC)C,,,,,,
6559,126560,"1,4-Bis(2-methylaminoethoxy)benzene",CNCCOC1=CC=C(C=C1)OCCNC,,,,,,
6560,126561,Methyl 4-O-(6-deoxy-manno-heptopyranosyl)galactopyranoside,CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CCO)O)O)O)O)O,,,,,,
6561,126562,CID 126562,CC=CN1C(=C2C(=NC1=O)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,,,,,,
6562,126563,CID 126563,CC(C)C(=NN=C(COC(=O)C)C=NN=C(N(C)C)S)S,,,,,,
6563,126564,CID 126564,CCCN1C[C@H](C[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)CC)O)F,,,,,,
6564,126565,Lestaurtinib,C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O,"['Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).']",,,,,
6565,126566,Mahmoodin,CC(=O)O[C@@H]1C[C@@H]2[C@](C=CC(=O)C2(C)C)([C@@H]3[C@@]1(C4=CC(=O)O[C@]([C@@]4(CC3)C)(C5=COC=C5)OCCO)C)C,,,,,,
6566,126567,"N-(3-(2,4-Dichloro-6-iodophenoxy)propyl)-N-methyl-2-propynylamine",CN(CCCOC1=C(C=C(C=C1[125I])Cl)Cl)CC#C,,,,,,
6567,126568,"4-Methyl-4,5-secocholestane",CCCCCC1(CCCC2C1CCC3(C2CCC3C(C)CCCC(C)C)C)C,,,,,,
6568,126569,"2-Amino-3-(5-fluoro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-YL)-propionic acid",C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)F,,,,,,
6569,126570,"Benzo(f)quinolin-7-ol, 1,2,3,4,4a,5,6,10b-octahydro-4-methyl-, hydrobromide, trans-(+-)-",CN1CCC[C@@H]2[C@@H]1CCC3=C2C=CC=C3O.Br,,,,,,
6570,126571,"4-Methyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-7-ol",CN1CCCC2C1CCC3=C2C=CC=C3O,,,,,,
6571,126572,"1,4-Dihydrotrigonelline",CN1C=CCC(=C1)C(=O)O,,,,,,
6572,126573,"3-Carboxy-5-phosphono-1,2,3,4-tetrahydroisoquinoline",C1C(NCC2=C1C(=CC=C2)P(=O)(O)O)C(=O)O,,,,,,
6573,126574,2-[[9-[5-(Phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid,C1CC(OC1COP(=O)(O)O)N2C=NC3=C(N=CN=C32)NC(CC(=O)O)C(=O)O,,,,,,
6574,126575,CID 126575,C[C@H](COCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
6575,126576,CID 126576,C1[C@@H]([C@H](CC1N2C=NC3=C2NC(=NC3=O)N)O)O,,,,,,
6576,126577,CID 126577,C1[C@@H](C[C@H]([C@@H]2[C@@H]1[C@H]([C@@H](O2)N3CC(NC3=O)CO)O)O)C(=O)O,,,,,,
6577,126578,methyl (2S)-2-[[2-(2-nitroimidazol-1-yl)acetyl]amino]-3-phenylpropanoate,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN2C=CN=C2[N+](=O)[O-],,,,,,
6578,126579,"7,8-Dihydroxy-2',4',5'-trimethoxyisoflavan",COC1=CC(=C(C=C1[C@@H]2CC3=C(C(=C(C=C3)O)O)OC2)OC)OC,,,,,,
6579,126580,CID 126580,CC1CC2C(O2)C=CC(CC(=O)O1)O,,,,,,
6580,126581,"8-hydroxy-2-methyl-3,4,8,9-tetrahydro-2H-oxecine-5,10-dione",CC1CCC(=O)C=CC(CC(=O)O1)O,,,,,,
6581,126582,1-Amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid,C1C(=CP(=O)(O)O)CC1(C(=O)O)N,,,,,,
6582,126583,"3-Cyclohexyl-1,2,3,4,4a,5,6,10b-octahydrobenz(f)isoquinoline",C1CCC(CC1)N2CC[C@@H]3[C@@H](C2)CCC4=CC=CC=C34,,,,,,
6583,126584,CID 126584,CCCCCC(CC(=O)NO)C(=O)N1CC(CCN1)C(=O)NC(C2=CC=[N+]3N2C(CCC3)C([O-])[O-])C(C)CC,,,,,,
6584,126585,CID 126585,CCCCCC(CC(=O)NO)C(=O)N1CC(CCN1)C(=O)NC(C2=CC=[N+]3N2C(CCC3)C(O)O)C(C)CC,,,,,,
6585,126586,Isoxochitlolone,CC1=CC2=C(C=C3C=CCC([C@@H]3CC2=O)(C)C)C=C1O,,,,,,
6586,126587,Diethylpyruvamide,CCN(CC)C(=O)C(=O)C,,,,,,
6587,126588,"1-(p-Tosyl)-3,4,4-trimethylimidazolidine",CC1=CC=C(C=C1)S(=O)(=O)N2CC(N(C2)C)(C)C,,,,,,
6588,126589,"N,N-Dimethyl-2-(5-methoxybenzofuran-3-yl)ethanamine",CN(C)CCC1=COC2=C1C=C(C=C2)OC,,,,,,
6589,126590,CID 126590,C(=CC(=O)O)C(=O)C=C(C(=O)O)O,,,,,,
6590,126591,CID 126591,CC1CN(C(=O)CC1=O)C2C[C@@H]([C@H](O2)CO)NC,,,,,,
6591,126592,"4-amino-1-[(2R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one",C1C(O[C@@H](O1)CO)N2C=CC(=NC2=O)N,,,"['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
6592,126593,CID 126593,C1=CC(=C(C=C1Cl)Cl)CC[C@H](C[C@H](CS(=O)(=O)O)O)O.[KH],,,,,,
6593,126594,"(2R,4R)-6-(2,4-dichlorophenyl)-2,4-dihydroxyhexane-1-sulfonic acid",C1=CC(=C(C=C1Cl)Cl)CC[C@H](C[C@H](CS(=O)(=O)O)O)O,,,,,,
6594,126595,CID 126595,C[C@]12CCCC(=CC=C3C[C@H](C[C@@H](C3=C)O)O)[C@@]1(CC[C@@H]2CCCC(C)(C)O)C,,,,,,
6595,126596,CID 126596,C=C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)N)CO)O,,,,,,
6596,126597,CID 126597,CC=CC=CC=C(C)C1C(C(C(CO1)C)OC)OC(=O)CN,,,,,,
6597,126598,3-Azi-1-((2-acetamido-2-deoxy-1-galactopyranosyl)thio)butane,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1SCCC2(N=N2)C)CO)O)O,,,,,,
6598,126599,3-Azi-1-((2-acetamido-2-deoxy-1-glucopyranosyl)thio)butane,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1SCCC2(N=N2)C)CO)O)O,,,,,,
6599,126600,"4-(2-(3,4-Dichlorophenoxy)ethyl)-1-pentylpiperidine hydrochloride",CCCCCN1CCC(CC1)CCOC2=CC(=C(C=C2)Cl)Cl.Cl,,,,,,
6600,126601,"4-[2-(3,4-Dichlorophenoxy)ethyl]-1-pentylpiperidine",CCCCCN1CCC(CC1)CCOC2=CC(=C(C=C2)Cl)Cl,,,,,,
6601,126602,N-[2-(Phenylamino)pyridin-3-yl]-4-methoxybenzenesulfonamide,COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=CC=C3,,,,,,
6602,126603,6-(2'-Hydroxypropyl)chromone-2-carboxylate,C[C@@H](CC1=CC2=C(C=C1)OC(=CC2=O)C(=O)O)O,,,,,,
6603,126604,"3-(8-Chloro-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-6-yl)phenol",CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC(=CC=C4)O,,,,,,
6604,126605,CID 126605,CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)C)CCC5(C4CC=C6C5CCC7(C6CC(CC7)(C)C)C(=O)O)C)C)O)O)O)OC8C(C(C(CO8)O)OC9C(C(C(C(O9)C)OC1C(C(C(CO1)O)OC1C(C(C(CO1)O)O)O)O)O)O)O)O,,,,,,
6605,126606,CID 126606,CC1COC(C(C1OC2C(C(C(CO2)O)OC3C(C(C(CO3)OC4C(C(C(CO4)O)O)O)O)O)O)O)OC5C(COC(C5O)OC6C(C(OC(C6O)OC7C(C(COC7OC8CCC9(C(C8(C)C)CCC1(C9CC=C2C1(CCC1(C2CC(CC1)(C)C)C(=O)O)C)C)C)O)O)C)O)O,,,,,,
6606,126607,CID 126607,C[C@H]1[C@@H](C([C@H]([C@H](O1)OC)O[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)CC3C[C@@]45CC[C@@]6([C@]7(CC[C@@H]8[C@@]([C@@]7(C=C[C@]6(C4CC3(C)C)OC5)C)(CC[C@H]([C@]8(C)CO)CO)C)C)C)O)O)O)O[C@@H]9[C@@H]([C@@H](C([C@@H](O9)CO)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)O)O)O)O,,,,,,
6607,126608,4-Bromoacetamidoprocaine,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)CBr,,,,,,
6608,126609,"N,N-Bis(2-chloroethyl)-4-(methylsulfinyl)benzenamine",CS(=O)C1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
6609,126610,CID 126610,COP(=O)(O)OC[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C2NC=NC3=O)O)O,,,,,,
6610,126611,CID 126611,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)O)C.[NaH],,,,,,
6611,126612,CID 126612,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)O)C,,,,,,
6612,126613,CID 126613,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4)O)C)OS(=O)(=O)O)C.[NaH],,,,,,
6613,126614,CID 126614,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4)O)C)OS(=O)(=O)O)C,,,,,,
6614,126615,N(6)-Endonorbornan-2-yl-9-methyladenine,CN1C=NC2=C(N=CN=C21)N[C@@H]3C[C@@H]4CC[C@H]3C4,,,,,,
6615,126616,"2-Acetyl-N-(3,4-dimethyl-5-isoxazolyl)-1,4-naphthoquinone imine",CC1=C(ON=C1C)N=C2C=C(C(=O)C3=CC=CC=C32)OC(=O)C,,,,,,
6616,126617,CID 126617,C1CC(=O)N(C1=O)OC(=O)C2C=CC(C=C2)[18F],,,,,,
6617,126618,2-(3-Ethylureido)-6-methylpyridine,CCNC(=O)NC1=CC=CC(=N1)C,,,,,,
6618,126619,"6-Hydroxy-2,4-hexadienol",C(C=CC=CCO)O,,,,,,
6619,126620,"1-(2,5-Dimethyl-4-iodophenyl)-2-aminopropane",CC1=CC(=C(C=C1I)C)CC(C)N,,,,,,
6620,126621,CID 126621,CC(C)CCCC(C)CCCC(C)CCCC1(CCC2CC(=O)CCC2(O1)OO)C,,,,,,
6621,126622,"3-[1-Carboxy-2,6-dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)octa-1,3,5,7-tetraen-3-yl]benzoic acid",CC1=C(C(CCC1)(C)C)C=CC(=CC=C(C2=CC(=CC=C2)C(=O)O)C(=CC(=O)O)C)C,,,,,,
6622,126623,"2-Phenyl-3-(N,N-dimethylaminopropyl)-1,3-thiazolidin-4-one",CN(C)CCCN1C(SCC1=O)C2=CC=CC=C2.Cl,,,,,,
6623,126624,2-(Phenyl)-3-[3-(dimethylamino)propyl]thiazolidin-4-one,CN(C)CCCN1C(SCC1=O)C2=CC=CC=C2,,,,,,
6624,126625,"N-Hydroxy-2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline",CC1=CC2=C(C=CC3=C2N=C(N3C)NO)N=C1,,,,,,
6625,126626,4-(3'-Di(2-chloroethyl)aminopropionyl)biphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(CCCl)CCCl,,,,,,
6626,126627,4-(3'-Di(2-bromoethyl)aminopropionyl)biphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(CCBr)CCBr,,,,,,
6627,126628,CID 126628,CN(C)N=[N+](C1=CC=C(C=C1)C(=O)N)[O-],,,,,,
6628,126629,Fluoromoxestrol,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@H]([C@]2(C#C)O)F)CCC4=C3C=CC(=C4)O)OC,,,,,,
6629,126630,CID 126630,CN(C)C(=O)CNN(CCCN)C(=O)OC,,,,,,
6630,126631,"N-(alpha)-(N,N-Dimethylcarbamoyl)-alpha-azaornithine 4-nitrophenyl ester",CN(C)C(=O)NN(CCCN)C(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6631,126632,"N(alpha)-(N,N-Dimethylcarbamoyl)alpha-azalysine phenyl ester",CN(C)C(=O)NN(CCCCN)C(=O)OC1=CC=CC=C1,,,,,,
6632,126633,"N(alpha)-(N,N-Dimethylcarbamoyl)-alpha-azalysine 4-nitrophenyl ester",CN(C)C(=O)NN(CCCCN)C(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6633,126634,Dehydroagastol,C[C@H]1CC[C@]2([C@H](C1=C)CC(=O)C3=C2C(=C(C(=C3O)C(=C)C)OC)O)C,,,,,,
6634,126635,CID 126635,CC1(C[C@@H](N[C@@H]1C(=O)O)C(=O)O)C,,,,,,
6635,126636,CID 126636,C1NC2=C(N=CN=C2N1[C@H]3C=C[C@H]([C@@H]3CO)O)N,,,,,,
6636,126637,"Ethyl 4,6,6-trichloro-3,3-dimethylhexanoate",CCOC(=O)CC(C)(C)C(CC(Cl)Cl)Cl,,,,,,
6637,126638,CID 126638,C1C(C(=O)NC(=O)N1C2(C(NC(=O)NC2=O)O)F)F,,,,,,
6638,126639,2-((4-(5-(3-Phenylpropyl)-2-thienyl)butyl)oxy)acetic acid,C1=CC=C(C=C1)CCCC2=CC=C(S2)CCCCOCC(=O)O,,,,,,
6639,126640,CID 126640,CN1C2C(C(=O)N(C1=O)C)N=CN2C3C=C(C(=O)[C@H](O3)CO)F,,,,,,
6640,126641,Cortisone-p-ara-C,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)(O)O)OC[C@@H]5[C@H]([C@@H]([C@@H](O5)N6C=CC(=NC6=O)N)O)O)C,,,,,,
6641,126642,Mannopinic acid,C(CC(=O)O)[C@@H](C(=O)O)NC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
6642,126643,"2'-Deoxy-3',5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine",CC1=CC(=CC=C1)C(=O)N2C(=O)C(=CN(C2=O)[C@H]3C[C@@H]([C@H](O3)COC(=O)C)OC(=O)C)F,,,,,,
6643,126644,CID 126644,C1=CC=C(C(=C1)C2=C(C(=O)N=C(N2)N)Br)F,,,,,,
6644,126645,CID 126645,C1=CC(=CC(=C1)F)C2=C(C(=O)N=C(N2)N)Br,,,,,,
6645,126646,CID 126646,C1=CC(=CC(=C1)F)C2=C(C(=O)N=C(N2)N)I,,,,,,
6646,126647,Ravidomycin,C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C=C)OC)OC)O)N(C)C)OC(=O)C,,,,,,
6647,126648,"2',6'-Dimethoxyflavone",COC1=C(C(=CC=C1)OC)C2=CC(=O)C3=CC=CC=C3O2,,,,,,
6648,126649,"Nalorphine-7,8-epoxide",C=CCN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C6C4O6)O,,,,,,
6649,126650,CID 126650,C1=CN=CC=C1CN(C(=N[N+](=O)[O-])N)N=O,,,,,,
6650,126651,Dipalmitoyl-diglu,CCCCCCCCCCCCCCCC(=O)OCC(CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)OC(=O)CCCCCCCCCCCCCCC,,,,,,
6651,126652,Unk-Ala-Pro-OH.DCHA,C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3.C1CCC(CC1)NC2CCCCC2,,,,,,
6652,126653,CID 126653,CC(C(=O)N1CCC[C@H]1C(=O)O)NP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
6653,126654,tert-butyl (2S)-1-[(2S)-2-[bis(4-nitrophenoxy)phosphorylamino]propanoyl]pyrrolidine-2-carboxylate,C[C@@H](C(=O)N1CCC[C@H]1C(=O)OC(C)(C)C)NP(=O)(OC2=CC=C(C=C2)[N+](=O)[O-])OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
6654,126655,(2S)-1-((2S)-2-{[phenylethyl(phenoxy)phosphoryl]amino}propanoyl)pyrrolidine-2-carboxylic acid,C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NP(=O)(CCC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
6655,126656,"BP-3,6-Quinol-dgl",C1=CC=C2C(=C1)C3=C4C(=C2OC5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C=CC6=C(C=CC(=C64)C=C3)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O,,,,,,
6656,126657,"3-O-ethyl 5-O-methyl 2-[2-(2-amino-5-oxo-4H-imidazol-3-yl)ethoxymethyl]-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)COCCN3CC(=O)N=C3N,,,,,,
6657,126658,Human growth hormone (32-38),CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N,,,,,,
6658,126659,N-Glycylglycyl-S-acetylcysteamine trifluoroacetate,CC(=O)SCCNC(=O)CNC(=O)CN.C(=O)(C(F)(F)F)O,,,,,,
6659,126660,S-[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]ethyl] ethanethioate,CC(=O)SCCNC(=O)CNC(=O)CN,,,,,,
6660,126661,Dopa 3-phosphate,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)OP(=O)(O)O)O,,,,,,
6661,126662,"1,3-Di-(2-pyrenyl)propane",C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)CCCC5=CC6=C7C(=C5)C=CC8=C7C(=CC=C8)C=C6)C=C2,,,,,,
6662,126663,Hypoestestatin 2,COC1=CC2=C(C=C1)C3=C([C@H]([C@@H]4CCCN4C3)O)C5=CC(=C(C=C52)OC)OC,,,,,,
6663,126664,"4-[2-(1H-benzimidazol-2-yl)hydrazinyl]cyclohexa-3,5-diene-1,2-dione",C1=CC=C2C(=C1)NC(=N2)N=NC3=CC(=C(C=C3)O)O,,,,,,
6664,126665,"2-(2',4'-Dihydroxyphenyl-1-azo)benzimidazole",C1=CC=C2C(=C1)NC(=N2)N=NC3=C(C=C(C=C3)O)O,,,,,,
6665,126666,Tpcet,CC12C3C4C1(C(=O)NC(=O)N4C5CC(C(O5)CO)OP(=O)(OCC6C(CC(N3C(=O)NC2=O)O6)O)OCCC#N)C,,,,,,
6666,126667,"[6-[[5-(6-Ethyl-5-hydroxy-4-methyl-7-oxononan-2-yl)-1,7-dihydroxy-6,8,16,18-tetramethyl-3-oxo-4,21-dioxabicyclo[15.3.1]henicosa-9,15,18-trien-11-yl]oxy]-3-hydroxy-2-methyloxan-4-yl] carbamate",CCC(C(C(C)CC(C)C1C(C(C(C=CC(CCCC=C(C2C(=CCC(O2)(CC(=O)O1)O)C)C)OC3CC(C(C(O3)C)O)OC(=O)N)C)O)C)O)C(=O)CC,,,,,,
6667,126668,"4-oxo-8-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-quinoline-2-carboxylic acid",C1=CC2=C(C(=C1)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)NC(=CC2=O)C(=O)O,,,,,,
6668,126669,3-Aminopropylarsonic acid,C(CN)C[As](=O)(O)O,,,,,,
6669,126670,"5-(1,1-Dimethylheptyl)-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-1,3-benzenediol",CCCCCCC(C)(C)C1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O,,,,,,
6670,126671,Tyrosyl-prolyl-glycyl-prolyl-phenylalanyl-prolyl-isoleucine,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N,,,,,,
6671,126672,"2,6-Bis(3,4-dihydroxybenzylidene) cyclohexanone",C1CC(=CC2=CC(=C(C=C2)O)O)C(=O)C(=CC3=CC(=C(C=C3)O)O)C1,,,,,,
6672,126673,Pentachlorophenyl palmitate,CCCCCCCCCCCCCCCC(=O)OC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
6673,126674,"6-(3-Oxoindolin-2-ylidene) indolo(2,1-b)quinazolin-12-one",C1=CC=C2C(=C1)C(=O)C(=C3C4=CC=CC=C4N5C3=NC6=CC=CC=C6C5=O)N2,,,,,,
6674,126675,[2-Butoxy-3-(dimethylamino)prop-2-enylidene]-dimethylazanium,CCCCOC(=CN(C)C)C=[N+](C)C,,,,,,
6675,126676,pBABC,CC(C)(CC1=CC=C(C=C1)NC(=O)CBr)NCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,,,,,,
6676,126677,Ipbabc,CC(C)(CC1=CC=C(C=C1)NC(=O)CBr)NCC(COC2=C3C4=CC=CC=C4NC3=C(C=C2)I)O,,,,,,
6677,126678,Desproglumideproglumetacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCCN4CCN(CC4)CCCO,,,,,,
6678,126679,Gly-arg-gly-asp,C(C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)CN=C(N)N,,,,,,
6679,126680,Me-Dfgal-gal-fgal,CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)COC2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)F)O)O)O)O)O)F)O,,,,,,
6680,126681,"3-(2-Benzothiazolyl)-4,5-dimethoxy-N-(3-(4-phenylpiperidinyl)propyl)benzenesulfonamide",COC1=CC(=CC(=C1OC)C2=NC3=CC=CC=C3S2)S(=O)(=O)NCCCN4CCC(CC4)C5=CC=CC=C5,,,,,,
6681,126682,CID 126682,CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)CC2(CC(C(C(O2)C)C)OC(=O)C=CC(=O)O)O)O)OC)C,,,,,,
6682,126683,CID 126683,CCC(CC)(CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CCC(=CC=C3C[C@H](C[C@@H](C3=C)O)O)C2)C)O,,,,,,
6683,126684,CID 126684,CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C(=O)C(C(C)C(C)O)OC(=O)C=CC(=O)O)O)OC)C,,,,,,
6684,126685,CID 126685,CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(C2)COC(=O)C=CC(=O)O)C)C)OC)O)OC)C,,,,,,
6685,126686,"N-(2,3-Dihydroxypropyl)asparagine",C([C@@H](C(=O)O)N)C(=O)NCC(CO)O,,,,,,
6686,126687,4-Phosphonomethyl-L-phenylalanine,C1=CC(=CC=C1C[C@@H](C(=O)O)N)CP(=O)(O)O,,,,,,
6687,126688,Amthamine,CC1=C(SC(=N1)N)CCN,,,,,,
6688,126689,CID 126689,C1C(C(=O)C(C1=O)OC(=O)C2=CC=C(C=C2)S(=O)(=O)F)S(=O)(=O)O,,,,,,
6689,126690,"5-[Bis-2(chloro-ethyl)-amino]-2,4-dintro-benzamide",C1=C(C(=CC(=C1N(CCCl)CCCl)[N+](=O)[O-])[N+](=O)[O-])C(=O)N,,,,,,
6690,126691,pp(Chbr)pA,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(C(P(=O)(O)OP(=O)(O)O)Br)O)O)O)N,,,,,,
6691,126692,CID 126692,C([C@@H]([C@@H]1C(=O)C(=C(O1)O)O)O)[18F],,,,,,
6692,126693,"Ethyl 2,5-diamino-2-(fluoromethyl)pent-3-enoate",CCOC(=O)C(CF)(C=CCN)N,,,,,,
6693,126694,CID 126694,C[N+](C)(CCC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl)[O-],,,,,,
6694,126695,CID 126695,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)CO)O)C,,,,,,
6695,126696,CID 126696,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)CO)O)C,,,,,,
6696,126697,2-Piperidinoethyl dibenzylglycolate,C1CCN(CC1)CCOC(=O)C(CC2=CC=CC=C2)(CC3=CC=CC=C3)O,,,,,,
6697,126698,"Cholest-8(14)-ene-3,15,26-triol",C[C@H](CCC[C@@H](C)[C@H]1C[C@H](C2=C3CC[C@H]4C[C@H](CC[C@@]4([C@H]3CC[C@]12C)C)O)O)CO,,,,,,
6698,126699,"1,2-Dihydroxy-9-nitro-1,2-dihydroanthracene",C1=CC=C2C(=C1)C=C3C=C[C@H]([C@@H](C3=C2[N+](=O)[O-])O)O,,,,,,
6699,126700,Adiaft,CC1=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)I)OC2=NC1=O,,,,,,
6700,126701,"S-(2-Bromo-2-chloro-1,1-difluoroethyl)cysteine",C([C@@H](C(=O)O)N)SC(C(Cl)Br)(F)F,,,,,,
6701,126702,S-(Phenylsulfonyl)glutathione,C1=CC=C(C=C1)S(=O)(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
6702,126703,"2-Methylicosa-8,12,14-trienoic acid",CCCCCC=CC=CCCC=CCCCCCC(C)C(=O)O,,,,,,
6703,126704,"(1S,2R,3S,4R)-4-(6-aminopurin-9-yl)cyclopentane-1,2,3-triol",C1[C@H]([C@@H]([C@@H]([C@H]1O)O)O)N2C=NC3=C(N=CN=C32)N,,,,,,
6704,126705,Triethylstannylmaleimide,CC[Sn](CC)(CC)N1C(=O)CC1=O,,,,,,
6705,126706,"Azetidine-2,4-dione",C1C(=O)NC1=O,,,,,,
6706,126707,N-Formylmethionyl-leucyl-tyrosine,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCSC)NC=O,,,,,,
6707,126708,CID 126708,CC1=CC=CC=C1N=C(NNC(=O)C2=CC=CC=C2)S,,,,,,
6708,126709,CID 126709,CC(=CCCC(=CCCC(=CCCCN(C)CCC=C(C)CCC1C(O1)(C)C)C)C)C,,,,,,
6709,126710,CID 126710,C[C@H]([C@H](C(=O)N)NC(=O)[C@H](CCCCN=C(C1=CC=C(C=C1)N[N+]#N)[O-])NC(=O)[C@@H](CC(=O)N)NC(=O)C)O,,,,,,
6710,126711,CID 126711,C[C@H]([C@H](C(=O)N)NC(=O)[C@H](CCCCNC(=O)C1=CC=C(C=C1)N[N+]#N)NC(=O)[C@@H](CC(=O)N)NC(=O)C)O,,,,,,
6711,126712,CID 126712,CC(=O)NC1C(CC(CN1)C(=O)O)O,,,,,,
6712,126713,"3-(Phosphonooxy)propane-1,2-diyl dihexanoate",CCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCC,,,,,,
6713,126714,"[1-Methyl-2-(6-methylhept-5-en-2-yl)-6-oxo-5-oxatricyclo[6.3.1.04,12]dodecan-9-yl] acetate",CC(CCC=C(C)C)C1CC2C3C1(CCC(C3CC(=O)O2)OC(=O)C)C,,,,,,
6714,126715,CID 126715,C1=CC=C(C=C1)CNCCCCCCCCCCCCN2C=NC3=C2NC(=NC3=O)N.Cl,,,,,,
6715,126716,CID 126716,C1=CC=C(C=C1)CNCCCCCCCCCCCCN2C=NC3=C2NC(=NC3=O)N,,,,,,
6716,126717,"1-Cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine",C1CC1N2CCC(=CC2)C3=CC=CC=C3,,,,,,
6717,126718,N-(dipyridin-2-ylmethylideneamino)furan-2-carboxamide,C1=CC=NC(=C1)C(=NNC(=O)C2=CC=CO2)C3=CC=CC=N3,,,,,,
6718,126719,CID 126719,CC(=CCNC1CC1)C2=CC=CC=C2,,,,,,
6719,126720,"4-Cyclopropyl-1-methyl-1,2,3,6-tetrahydropyridine",CN1CCC(=CC1)C2CC2,,,,,,
6720,126721,CID 126721,CCCCC(C=CC=CCC=CC=CC(=O)CCCC(=O)O)O,,,,,,
6721,126722,"L-Glutamic acid, N-(4-(((2,4-diamino-5-chloro-6-quinazolinyl)amino)methyl)benzoyl)-",C1=CC(=CC=C1CNC2=C(C3=C(C=C2)N=C(N=C3N)N)Cl)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
6722,126723,CID 126723,CC(=CCC1=C2C3=CC=CC=C3NC2=C(C=C1CO)O)C,,,,,,
6723,126724,"(S)-1,2,3,4-Tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinemethanol",CN1CCC2=CC(=C(C=C2[C@H]1CO)OC)OC,,,,,,
6724,126725,"Benzenepropanoic acid, 3-fluoro-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, ethyl ester",CCOC(=O)CCC1=CC(=C(C=C1)OCC(CNC(C)C)O)F,,,,,,
6725,126726,"1,6-Dihydroxy-2,4-dimethoxyanthraquinone",COC1=CC(=C(C2=C1C(=O)C3=C(C2=O)C=CC(=C3)O)O)OC,,,,,,
6726,126727,Homoanatoxin,CCC(=O)C1=CCC[C@@H]2CC[C@H]1N2,,,,,,
6727,126728,"4-Isothiocyanato-N,N,N-trimethylbenzeneethanaminium chloride",C[N+](C)(C)CCC1=CC=C(C=C1)N=C=S.[Cl-],,,,,,
6728,126729,2-(4-Isothiocyanatophenyl)ethyl-trimethylazanium,C[N+](C)(C)CCC1=CC=C(C=C1)N=C=S,,,,,,
6729,126730,CID 126730,C1[C@H]([C@H]([C@@H]([C@@](O1)(O)ONCC(=O)O)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
6730,126731,N-(2-(2-Bromo-5-methoxy-1H-indol-3-yl)ethyl)acetamide,CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)Br,,,,,,
6731,126732,4-Iodotomoxetine,CC1=C(C=CC(=C1)[125I])O[C@H](CCNC)C2=CC=CC=C2,,,,,,
6732,126733,4-Propionyloxy-6-(4-fluorophenyl)-1-azabicyclo(3.3.1)non-6-ene hydrochloride,CCC(=O)O[C@@H]1CCN2CC=C([C@H]1C2)C3=CC=C(C=C3)F.Cl,,,,,,
6733,126734,[6-(4-Fluorophenyl)-1-azabicyclo[3.3.1]non-6-en-4-yl] propanoate,CCC(=O)OC1CCN2CC=C(C1C2)C3=CC=C(C=C3)F,,,,,,
6734,126735,Leflutrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)(N3C=NC=N3)F,,,,,,
6735,126736,CID 126736,C[C@H]1[C@H]2[C@](N=C(N2)N)(N(C(=N1)N)CCO)O,,,,,,
6736,126737,"2,3-Methanomethionine",CSC[C@H]1C[C@]1(C(=O)O)N,,,,,,
6737,126738,CID 126738,CC(=C)C(=O)OC1=CC=C(C=C1)CC(C(N)O)N,,,,,,
6738,126739,1-(N-Methylanilinoethyl)indole,CN(CCN1C=CC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
6739,126740,(3-Hydroxy-2-phosphonooxypropyl) 2-aminobenzoate,C1=CC=C(C(=C1)C(=O)OCC(CO)OP(=O)(O)O)N,,,,,,
6740,126741,"Pyrido(3,4-d)pyridazine-1,4-dione, 8-amino-5-chloro-2,3-dihydro-7-phenyl-",C1=CC=C(C=C1)C2=C(C3=C(C(=O)NNC3=O)C(=N2)Cl)N,,,,,,
6741,126742,CID 126742,CCCCCC=CCC=C[C@H](CCCCCC(=O)O)OO,,,,,,
6742,126743,"1H-Pyrido(3,4-b)indole-3-carboxylic acid, 2,3,4,9-tetrahydro-1-(hydroxymethyl)-, cis-",C1C(N[C@H](C2=C1C3=CC=CC=C3N2)CO)C(=O)O,,,,,,
6743,126744,4-(4-N-Maleimidophenyl)butyric acid hydrazide,C1=CC(=CC=C1CCCC(=O)NN)N2C(=O)C=CC2=O,,,,,,
6744,126745,1-[3-(1H-imidazol-5-yl)propylsulfanyl]-N'-[2-(4-(125I)iodanylphenyl)ethyl]methanediamine,C1=CC(=CC=C1CCNC(N)SCCCC2=CN=CN2)[125I],,,,,,
6745,126746,CID 126746,CCCCCC1CCCC(C1)C=CCCCC(C(C(=O)NCCS(=O)(=O)O)O)O,,,,,,
6746,126747,"2C-Methyl-D-erythritol 2,4-cyclodiphosphate",C[C@@]1([C@@H](COP(=O)(OP(=O)(O1)O)O)O)CO,,,,,,
6747,126748,Acetylselenonium choline,CC(=O)OCC[Se+](C)C,,,,,,
6748,126749,CID 126749,CC1=CC(=NC=C1O)C=NN=C(N)S,,,,,,
6749,126750,Isocantleyine,C[C@H]1[C@@H](CC2=C(C=NC=C12)C(=O)OC)O,,,,,,
6750,126751,"(3R,4aR,6aS,10aS,10bR)-3-ethyl-5,10b-dimethyl-4,4a,6a,7,8,9,10,10a-octahydro-3H-benzo[h]isochromen-1-one",CC[C@@H]1C[C@@H]2C(=C[C@@H]3CCCC[C@@H]3[C@]2(C(=O)O1)C)C,,,,,,
6751,126752,CID 126752,C1=CC(=C(N=C1)C=NN=C(N)S)N,,,,,,
6752,126753,CID 126753,CC1=C(C(=NC=C1)C=NN=C(N)S)N,,,,,,
6753,126754,Drfbpi,C1[C@@H]([C@H](O[C@H]1N2C=C(N=C2)C3=CC(=CC=C3)NC(=O)C4=CC=CC=C4)CO)O,,,,,,
6754,126755,CID 126755,C1=CC=C(C=C1)C=C2C(=O)OC3=CC=CC(=C(O)O)C3=N2,,,,,,
6755,126756,"1-(4-Aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine",CC1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3,,,,,,
6756,126757,GYKI53655 hydrochloride,CC1CC2=CC3=C(C=C2C(=NN1C(=O)NC)C4=CC=C(C=C4)N)OCO3.Cl,,,"['Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']",,,
6757,126758,"1-(4-Aminophenyl)-3-methylcarbamoyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine",CC1CC2=CC3=C(C=C2C(=NN1C(=O)NC)C4=CC=C(C=C4)N)OCO3,,,"['Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']",,,
6758,126759,CID 126759,CCCCCCC(=O)C1=CC=C(C=C1)N=[N+]=[N-],,,,,,
6759,126760,CID 126760,CCCCCCC(=O)C1=CC=C(C=C1)N[N+]#N,,,,,,
6760,126761,5-(2'-(18F)Fluoroethyl)flumazenil,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)CC[18F],,,,,,
6761,126762,Offado,CCCCCCCCCCCC(=O)N1CC[C@H]2[C@@H]([C@H](CC[C@@]2(C1)C)O)C,,,,,,
6762,126763,Cochinmicin I,CC1C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O1)C2=CC(=CC(=C2)O)O)C3=CC(=CC(=C3)O)O)C)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C6=CC=CN6,,,,,,
6763,126764,3-(N-(Phthalimidomethyl)amino)-5-ethyl-6-methylpyridin-2-(1H)-one,CCC1=C(C=C(C(=O)N1)NCN2C(=O)C3=CC=CC=C3C2=O)C,,,,,,
6764,126765,"7-Methyl-3-(2-propynyloxy)-4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridine",C[C@@H]1CNCC2=C1SN=C2OCC#C,,,,,,
6765,126766,"2,5-Dihydrothiophene sulfoxide-2-mercapturic acid",CC(=O)NC(CSC1C=CCS1=O)C(=O)O,,,,,,
6766,126767,"2,4-Dihydroxy-3,3,4-trimethylpyroglutamic acid",CC1(C(C(=O)NC1(C(=O)O)O)(C)O)C,,,,,,
6767,126768,"5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidine-2,4-dione",C1[C@H](O[C@H](S1)CO)N2C=C(C(=O)NC2=O)F,,,,,,
6768,126769,N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea,CN1C=CC2=C1C=CC(=C2)NC(=O)NC3=CN=CC=C3,,,,,,
6769,126770,3-Amino-5-C-phenylaltrofuranose,CC(C1C(C(C(O1)O)O)N)(C2=CC=CC=C2)O,,,,,,
6770,126771,"1a,7b-Dihydrooxireno[2,3-c]chromen-2-one",C1=CC=C2C(=C1)C3C(O3)C(=O)O2,,,,,"['Coumarin 3,4-epoxide is a known human metabolite of coumarin.']",
6771,126772,Pseudo-laminarabiose,C1C(C(C(C(C1O)O)OC2C(C(C(C(O2)CO)O)O)O)O)CO,,,,,,
6772,126773,Neurokinin B (4-10),CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)N,,,,,,
6773,126774,"1-[3,4-Dihydroxy-6-(hydroxymethyl)-5-(4,5,6-trihydroxy-3-methyloxan-2-yl)oxyoxan-2-yl]oxy-4-hydroxycyclopent-2-ene-1-carbonitrile",CC1C(C(C(OC1OC2C(OC(C(C2O)O)OC3(CC(C=C3)O)C#N)CO)O)O)O,,,,,,
6774,126775,"1-[3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-(4,5,6-trihydroxy-3-methyloxan-2-yl)oxycyclopent-2-ene-1-carbonitrile",CC1C(C(C(OC1OC2CC(C=C2)(C#N)OC3C(C(C(C(O3)CO)O)O)O)O)O)O,,,,,,
6775,126776,2-O-Acetyl-3-O-allyl-4-O-benzyl-6-O-tert-butyldiphenylsilylglucopyranosyl chloride,CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1Cl)CO[Si](C2=CC=CC=C2)(C3=CC=CC=C3)C(C)(C)C)OCC4=CC=CC=C4)OCC=C,,,,,,
6776,126777,"(2-formyl-7-methoxy-6-methyl-5,8-dioxo-1H-isoquinolin-1-yl)methyl 2-methylbut-2-enoate",CC=C(C)C(=O)OCC1C2=C(C=CN1C=O)C(=O)C(=C(C2=O)OC)C,,,,,,
6777,126778,1-(2-Hydroxy-3-propyl-4-((4-(1H-tetrazol-5-ylmethyl)phenoxy)methyl)phenyl)ethanone,CCCC1=C(C=CC(=C1O)C(=O)C)COC2=CC=C(C=C2)CC3=NNN=N3,,,,,,
6778,126779,10-Carboxy-13-deoxycarminomycin,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)O)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)O,,,,,,
6779,126780,Alldimycin B,CCC1(CC(C2=CC3=C(C(=C2C1OC4CC(C(C(O4)C)O)N(C)C)O)C(=O)C5=C(C=CC(=C5C3=O)O)O)OC6CC(C(C(O6)C)O)N(C)C)O,,,,,,
6780,126781,"5-(9-Ethoxy-5,9-dimethyldec-3-enoxy)-1,3-benzodioxole",CCOC(C)(C)CCCC(C)C=CCCOC1=CC2=C(C=C1)OCO2,,,,,,
6781,126782,Acridine trimer 2,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCNCCCCCNCCC(CCNCCCCCNCCCNC4=C5C=C(C=CC5=NC6=C4C=CC(=C6)Cl)OC)NC7=C8C=C(C=CC8=NC9=C7C=CC(=C9)Cl)OC.Cl.Cl.Cl.Cl.Cl.Cl.Cl,,,,,,
6782,126783,"3-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,5-N-bis[5-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propylamino]pentyl]pentane-1,3,5-triamine",COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCNCCCCCNCCC(CCNCCCCCNCCCNC4=C5C=C(C=CC5=NC6=C4C=CC(=C6)Cl)OC)NC7=C8C=C(C=CC8=NC9=C7C=CC(=C9)Cl)OC,,,,,,
6783,126784,Acridine trimer 1,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCC(=O)NCCCCCNC(=O)CC(CC(=O)NCCCCCNC(=O)CCNC4=C5C=CC=CC5=NC6=CC=CC=C64)NC7=C8C=CC=CC8=NC9=CC=CC=C97.Cl.Cl.Cl,,,,,,
6784,126785,"3-(acridin-9-ylamino)-N,N'-bis[5-[3-(acridin-9-ylamino)propanoylamino]pentyl]pentanediamide",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCC(=O)NCCCCCNC(=O)CC(CC(=O)NCCCCCNC(=O)CCNC4=C5C=CC=CC5=NC6=CC=CC=C64)NC7=C8C=CC=CC8=NC9=CC=CC=C97,,,,,,
6785,126786,CID 126786,CCC(C)OCC(CN(CC1=CC=CC=C1)C2=CC3=C(C=C2)OCO3)N4CCCC4.C(=CC(=O)O)C(=O)O,,,,,,
6786,126787,"N-benzyl-N-(3-butan-2-yloxy-2-pyrrolidin-1-ylpropyl)-1,3-benzodioxol-5-amine",CCC(C)OCC(CN(CC1=CC=CC=C1)C2=CC3=C(C=C2)OCO3)N4CCCC4,,,,,,
6787,126788,"2-Anthracenamine, N-(1,1-dimethylethyl)-N-hydroxy-9,10-dimethoxy-",CC(C)(C)N(C1=CC2=C(C3=CC=CC=C3C(=C2C=C1)OC)OC)O,,,,,,
6788,126789,Uridine diphosphopyridoxal,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=CC(=O)NC3=O)O)O,,,,,,
6789,126790,CID 126790,C1=CC=NC(=C1)SSCCN=C(C2=CC=C(C=C2)N[N+]#N)[O-],,,,,,
6790,126791,CID 126791,C1=CC=NC(=C1)SSCCNC(=O)C2=CC=C(C=C2)N[N+]#N,,,,,,
6791,126792,CID 126792,CC1C(OCC(C1(C(C)OC(=O)C(C)C)O)OC)OC2C(C(OC(C2O)C3(CC(=O)C(=C(C3=O)C(=O)O)N)O)COC(=O)C)O,,,,,,
6792,126793,"Inositol 1,2-cyclic 4-bisphosphate",C1(C(C(C(C2C1OP(=O)(O2)O)O)OP(=O)(O)O)O)O,,,,,,
6793,126794,"12-[16-(3,5-Dihydroxy-6-methyl-4-oxooxan-2-yl)oxy-4-hydroxy-3,7,15,19-tetramethyl-8,10-dioxo-9-oxatetracyclo[9.9.0.02,6.012,17]icosa-1,6,18-trien-20-yl]-3-hydroxy-2,5,7-trimethyldodeca-7,9,11-trienoic acid",CC1CCC2C(C1OC3C(C(=O)C(C(O3)C)O)O)C=C(C(C4=C5C(C(CC5=C(C(=O)OC(=O)C24)C)O)C)C=CC=CC=C(C)CC(C)CC(C(C)C(=O)O)O)C,,,,,,
6794,126795,CID 126795,COC1=CC=C(C=C1)[C@@]23CC4=C([C@@]2([C@@H]([C@@H]([C@H]3C5=CC=CC=C5)C(=O)OC)O)O)C(=CC(=C4)OC)OC,,,,,,
6795,126796,"1'-[3-(2-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl][1,4'-bipiperidine]-4'-carboximidic acid",C1CCN(CC1)C2(CCN(CC2)CCCN3C4=C(CCC5=CC=CC=C53)C=C(C=C4)O)C(=O)N,,,,,,
6796,126797,"5-Chloro-1-(2-chloro-2-deoxypentofuranosyl)-4-imino-1,4-dihydropyrimidin-2-ol",C1=C(C(=NC(=O)N1C2[C@@H]([C@@H]([C@H](O2)CO)O)Cl)N)Cl,,,,,,
6797,126798,Ethazolastone,CCN1C(=O)N2C=NC(=C2N=N1)C(=O)N,,,,,,
6798,126799,CID 126799,C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C2NC(=NC3=O)N)O)O)COP(=O)(O)O,,,,,,
6799,126800,CID 126800,C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C2NC=NC3=O)O)O)COP(=O)(O)O,,,,,,
6800,126801,N-Methylnornicotinium,C[N+]1=CC=CC(=C1)[C@@H]2CCCN2,,,,,,
6801,126802,"L-Cysteine, N-acetyl-S-(3-chloro-2-hydroxypropyl)-",CC(=O)N[C@@H](CSCC(CCl)O)C(=O)O,,,,,,
6802,126803,Mitoxantrone carboxylic acid,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCC(=O)O,,,,,,
6803,126804,Tuftsinyl-n-heptylamide,CCCCCCCNC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C(C(C)O)N,,,,,,
6804,126805,Mitoxantrone dicarboxylic acid,C1=CC(=C2C(=C1NCCNCC(=O)O)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCC(=O)O,,,,,,
6805,126806,"(2s,5r,6s)-6-Chloro-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4-oxide",CC1([C@@H](N2[C@H](S1=O)[C@H](C2=O)Cl)C(=O)O)C,,,,,,
6806,126807,"Acetic acid, bromophosphono-",C(C(=O)O)(P(=O)(O)O)Br,,,,,,
6807,126808,1-[6-amino-2-[(2-amino-3-hydroxybutanoyl)amino]hexanoyl]-N-[5-(diaminomethylideneamino)-1-(hexylamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide,CCCCCCNC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C(C(C)O)N,,,,,,
6808,126809,Cytochrophin-4,C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)N)O,,,,,,
6809,126810,"2,5-Dihydro-2,5-dioxo-3-hydroxy-8-methyl-1H-benzazepine",CC1=CC2=C(C=C1)C(=CC(=O)C(=O)N2)O,,,,,,
6810,126811,CID 126811,C1CS(=O)(=O)CC1N=C(S)S.[KH],,,,,,
6811,126812,CID 126812,C1CS(=O)(=O)CC1N=C(S)S,,,,,,
6812,126813,"6-(2,5-dihydroxy-3-methylphenyl)-1-[(1R,6S,7R)-2,4-dihydroxy-6,7,9,9-tetramethyl-7-bicyclo[4.2.1]nona-2,4-dienyl]-4-methylhex-4-en-2-one",CC1=CC(=CC(=C1O)CC=C(C)CC(=O)C[C@]2(C[C@H]3C(=CC(=C[C@@]2(C3(C)C)C)O)O)C)O,,,,,,
6813,126814,Cianopramine hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)C#N.Cl,,,,,,
6814,126815,Cyan-desipramine,CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)C#N.Cl,,,,,,
6815,126816,"11-[3-(Methylamino)propyl]-5,6-dihydrobenzo[b][1]benzazepine-2-carbonitrile",CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)C#N,,,,,,
6816,126817,2-(4-Hydroxyethoxyphenyl)propionic acid,CC(C1=CC=C(C=C1)OCCO)C(=O)O,,,,,,
6817,126818,"4-Bromomethyl-6,7-methylenedioxycoumarin",C1OC2=C(O1)C=C3C(=C2)C(=CC(=O)O3)CBr,,,,,,
6818,126819,CID 126819,CC(C=CCC(C)(CO)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,,,,,,
6819,126820,"2-Methylimidazo[1,2-b]pyridazine-3-carboxylic acid",CC1=C(N2C(=N1)C=CC=N2)C(=O)O,,,,,,
6820,126821,"2-Piperidinone, 1-(6,7-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-5H-thieno(3,2-b)pyran-7-yl)-, cis-(+-)-",CC1([C@H]([C@H](C2=C(O1)C=C(S2)[N+](=O)[O-])N3CCCCC3=O)O)C,,,,,,
6821,126822,CID 126822,[C@H]1([C@@H](C([C@H]([C@@H](C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)F)OP(=O)(O)O)OP(=O)(O)O,,,,,,
6822,126823,CID 126823,CC(C)C=CCCC(C)(CCCC(C)(CCCC(C)(CCCC(C)(CCCC(=CCCC(=CCCC(=CCCC(=CCO)C)C)C)C)O)O)O)O,,,,,,
6823,126824,CID 126824,CC(=CCCC(=CCCC(=CCO)C)C)CCCCC=C(C)CCCC(C)(CCCC(C)(CCCC(C)(CCCC(C)(CCCC1(CCC(O1)C(C)(C)O)C)O)O)O)O,,,,,,
6824,126825,"4-Diphenylacetoxy-1,1-dimethylcyclohexane",CC1(CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C,,,,,,
6825,126826,4-[[2-(3-Hydroxybut-1-enyl)-5-oxooxolan-3-yl]amino]benzoic acid,CC(C=CC1C(CC(=O)O1)NC2=CC=C(C=C2)C(=O)O)O,,,,,,
6826,126827,4-[[2-(3-Hydroxybut-1-enyl)-5-oxooxolan-3-yl]amino]benzaldehyde,CC(C=CC1C(CC(=O)O1)NC2=CC=C(C=C2)C=O)O,,,,,,
6827,126828,5-(3-Hydroxybut-1-enyl)-4-[4-(hydroxymethyl)anilino]oxolan-2-one,CC(C=CC1C(CC(=O)O1)NC2=CC=C(C=C2)CO)O,,,,,,
6828,126829,5-(3-Hydroxybut-1-enyl)-4-[4-(methoxymethyl)anilino]oxolan-2-one,CC(C=CC1C(CC(=O)O1)NC2=CC=C(C=C2)COC)O,,,,,,
6829,126830,3-(1-Hydroxyoctyl)-5-methyl-2(5H)-furanone,CCCCCCC[C@H](C1=C[C@H](OC1=O)C)O,,,,,,
6830,126831,N(3)-Phenacyluridine,C1=CC=C(C=C1)C(=O)CN2C(=O)C=CN(C2=O)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
6831,126832,4-Benzyl-3-((1-methoxy-5-methylcyclohexen-4-yl)carbonyl)-2-oxazolidinone,C[C@H]1CC(=CC[C@@H]1C(=O)N2[C@H](COC2=O)CC3=CC=CC=C3)OC,,,,,,
6832,126833,CID 126833,CC=CC1C(C(CC(O1)(C(C)C(C(C)C2C(C=CC=C(CC(C(CC(C(C=C(C=C(C(=O)O2)OC)C)C)O)O)C)C)OC)O)O)OC3CC(C(C(O3)C)O)O)C,,,,,,
6833,126834,"[6-[2-[4-(10,12-Dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl)-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-prop-1-enyloxan-4-yl]oxy-4-hydroxy-2-methyloxan-3-yl] carbamate",CC=CC1C(C(CC(O1)(C(C)C(C(C)C2C(C=CC=C(CC(C(CC(C(C=C(C=C(C(=O)O2)OC)C)C)O)O)C)C)OC)O)O)OC3CC(C(C(O3)C)OC(=O)N)O)C,,,,,,
6834,126835,"2-Acetoylhydrazono-1,3-dithiolane",CC(=O)NN=C1SCCS1,,,,,,
6835,126836,"2-Pyruvoylhydrazono-1,3-dithiolane",CC(=O)C(=O)NN=C1SCCS1,,,,,,
6836,126837,4-Cyanotiazofurin,C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C#N,,,,,,
6837,126838,CID 126838,COC(C1=CSC(=N1)C2C(C(C(O2)CO)O)O)N,,,,,,
6838,126839,Lavendustin C6,CCCCCCN(CC1=C(C=CC(=C1)O)O)C2=CC(=C(C=C2)O)C(=O)O,,,,,,
6839,126840,CID 126840,C(C(=O)C(=O)O)P(=O)(C(=O)O)O.[NaH].[NaH].[NaH],,,,,,
6840,126841,Carboxyphosphonopyruvate,C(C(=O)C(=O)O)P(=O)(C(=O)O)O,,,,,,
6841,126842,CID 126842,CCCCCCC(C)(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,,,,,,
6842,126843,"3,7-Diamino-2-hydroxyheptanoyl-alanyl-proline",CC(C(=O)N1CCCC1C(=O)O)NC(=O)C(C(CCCCN)N)O,,,,,,
6843,126844,27-Oxooctacosanoic acid,CC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
6844,126845,S-(N-Hydroxy-N-methylcarbamoyl)glutathione,CN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,,,,
6845,126846,"4-Nonyl-3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethylpyridine",CCCCCCCCCC1C(=C(NC(=C1C(=O)OCC)C)C)C(=O)OCC,,,,,,
6846,126847,"4-Dodecyl-3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethylpyridine",CCCCCCCCCCCCC1C(=C(NC(=C1C(=O)OCC)C)C)C(=O)OCC,,,,,,
6847,126848,1-Nitro-3-nitrosopyrene,C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)N=O)[N+](=O)[O-],,,,,,
6848,126849,"[(2R,6R)-2-(cyclohexen-1-ylmethyl)-5-oxo-2H-pyran-6-yl]methyl acetate",CC(=O)OC[C@@H]1C(=O)C=C[C@H](O1)CC2=CCCCC2,,,,,,
6849,126850,2-Hydroxydesmethyltrimipramine,C[C@@H](CNC)CN1C2=C(CCC3=CC=CC=C31)C=C(C=C2)O,,,,,,
6850,126851,"2,6-Piperidinedione, 4-(2-(2-hydroxy-3-(hydroxymethyl)-5-methylphenyl)-2-oxoethyl)-",CC1=CC(=C(C(=C1)C(=O)CC2CC(=O)NC(=O)C2)O)CO,,,,,,
6851,126852,1-Hydroxyoxaunomycin,CCC1(CC(C2=C(C1O)C(=C3C(=C2O)C(=O)C4=C(C=CC(=C4C3=O)O)O)O)OC5CC(C(C(O5)C)O)N)O,,,,,,
6852,126853,6-Deoxyoxaunomycin,CCC1(CC(C2=CC3=C(C(=C2C1O)O)C(=O)C4=C(C3=O)C(=CC=C4)O)OC5CC(C(C(O5)C)O)N)O,,,,,,
6853,126854,CID 126854,CCCCC=CC(C=CCC=CCCCCC(=O)O)O,,,,,,
6854,126855,"3-(4-(2-Dimethylamino-1-methylethoxy)phenyl)-1H-pyrazolo(3,4-b)pyridine-1-acetic acid",CC(CN(C)C)OC1=CC=C(C=C1)C2=NN(C3=C2C=CC=N3)CC(=O)O,,,,,,
6855,126856,2-Dimethylaminoethyl(dimethylamido)phosphonofluoridate,CN(C)CCP(=O)(N(C)C)F,,,,,,
6856,126857,Acetylprolyl-alanyl-alanine-N-methylamide,CC(C(=O)NC(C)C(=O)NC)NC(=O)C1CCCN1C(=O)C,,,,,,
6857,126858,Mannonolactam amidrazone,C([C@@H]1[C@H]([C@@H]([C@@H](C(=N1)N)O)O)O)O,,,,,,
6858,126859,"6-(2-Aminopropyl)-1,3-benzodioxol-5-ol",CC(CC1=CC2=C(C=C1O)OCO2)N,,,,,,
6859,126860,5-((6-((Aminomethyl)amino)-1-oxohexyl)amino)pentanoic acid,C(CCC(=O)NCCCCC(=O)O)CCN=C(N)N,,,,,,
6860,126861,"1,4-Benzenediol, 2,3,5,6-tetrakis(methylthio)-",CSC1=C(C(=C(C(=C1SC)O)SC)SC)O,,,,,,
6861,126862,4-Hydroxyhernandulcin,CC1=CC(=O)[C@@H](C[C@H]1O)[C@](C)(CCC=C(C)C)O,,,,,,
6862,126863,1-(Hydroxymethyl)-4-(2-hydroxypropan-2-yl)cyclohexan-1-ol,CC(C)(C1CCC(CC1)(CO)O)O,,,,,,
6863,126864,"2-Hydroxy-5-methoxy-3-[3-methyl-5-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-2-enyl]cyclohexa-2,5-diene-1,4-dione",CC1=CCCC(C1CCC(=CCC2=C(C(=O)C=C(C2=O)OC)O)C)(C)C,,,,,,
6864,126865,Mononitrosocaffeidine,CNC(=O)C1=C(N=CN1C)N(C)N=O,,,,,,
6865,126866,Dinitrosocaffeidine,CN1C=NC(=C1C(=O)N(C)N=O)N(C)N=O,,,,,,
6866,126867,Mmhda,C[C@@]1(CC[C@@H]2C1(CCC3=C4CC[C@@H](CC(=C)[C@H]4C[C@@H]23)O)C)O,,,,,,
6867,126868,"4a,17-Dimethyl-A-homo-B,19-dinor-3,4-secoandrost-9-ene-3,17-diol",CC(=C)[C@H]1C[C@H]2[C@@H]3CC[C@]([C@]3(CCC2=C1CCCO)C)(C)O,,,,,,
6868,126869,CID 126869,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC(=CC=C3C[C@H](C[C@@H](C3=C)O)O)C2)C,,,,,,
6869,126870,"4-(2-Amino-6-chloro-9H-purin-9-yl)-1,3-dioxolane-2-methanol",C1[C@H](O[C@@H](O1)CO)N2C=NC3=C2N=C(N=C3Cl)N,,,,,,
6870,126871,Norcdc-sul,C[C@H](CCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
6871,126872,Homocdc-sul,C[C@H](CCCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
6872,126873,1-(7-(2-Hydroxyethyl)dodecahydro-3a-methyl-1H-benz(e)inden-3-yl)ethanone,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H](C3)CCO)C,,,,,,
6873,126874,CID 126874,C[C@]12CCC[C@@]([C@@H]1[C@H]3CC(=O)C(=C3CC2)CO)(C)O,,,,,,
6874,126875,"(2R,3R,4S,5R,6S)-5-[(2S,3S,4R,5S,6R)-3-azido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-methyloxane-2,3,4-triol",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O)O)O)O[C@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N=[N+]=[N-],,,,,,
6875,126876,CID 126876,C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C=CI)O)C,,,,,,
6876,126877,"2-Hydroxy-4,4-dimethyl-2-(p-tolyl)morpholinium bromide",CC1=CC(=CC=C1)C2(C[N+](CCO2)(C)C)O.[Br-],,,,,,
6877,126878,"4,4-Dimethyl-2-(3-methylphenyl)morpholin-4-ium-2-ol",CC1=CC(=CC=C1)C2(C[N+](CCO2)(C)C)O,,,,,,
6878,126879,beta-Lysinamide,C(C[C@H](CC(=O)N)N)CN,,,,,,
6879,126880,N-(3-Mercapto-2-((2-methylphenyl)methyl)-1-oxopropyl)methionine,CC1=CC=CC=C1CC(CS)C(=O)N[C@@H](CCSC)C(=O)O,,,,,,
6880,126881,"4-Acetoxymethyl-N,N,N-trimethylbenzenemethanaminium",CC(=O)OCC1=CC=C(C=C1)C[N+](C)(C)C.[I-],,,,,,
6881,126882,"4-[(Acetyloxy)methyl]-N,N,N-trimethylbenzenemethanaminium",CC(=O)OCC1=CC=C(C=C1)C[N+](C)(C)C,,,,,,
6882,126883,"3-Acetoxymethyl-N,N,N-trimethylbenzenemethanaminium iodide",CC(=O)OCC1=CC=CC(=C1)C[N+](C)(C)C.[I-],,,,,,
6883,126884,"3-[(Acetyloxy)methyl]-N,N,N-trimethylbenzenemethanaminium",CC(=O)OCC1=CC=CC(=C1)C[N+](C)(C)C,,,,,,
6884,126885,"2-Acetoxymethyl-N,N,N-trimethylbenzenemethanaminium",CC(=O)OCC1=CC=CC=C1C[N+](C)(C)C.[I-],,,,,,
6885,126886,"2-[(Acetyloxy)methyl]-N,N,N-trimethylbenzenemethanaminium",CC(=O)OCC1=CC=CC=C1C[N+](C)(C)C,,,,,,
6886,126887,"(3S,5S)-1-(4-hydroxy-3,5-dimethoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol",COC1=CC(=CC(=C1O)OC)CC[C@@H](C[C@H](CCC2=CC(=C(C=C2)O)OC)O)O,,,,,,
6887,126888,"[3-(3,4-Dihydroxyphenyl)-2-oxopropyl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C1=CC(=C(C=C1CC(=O)COC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,,,,,,
6888,126889,"2,2-Dimethyl-3-(3,7,12-trimethyl-16-prop-2-enylhenicosa-3,7,11,15,19-pentaenyl)oxirane",CC=CCCC(=CCCC(=CCCC=C(C)CCC=C(C)CCC1C(O1)(C)C)C)CC=C,,,,,,
6889,126890,6-Gingesulfonic acid,CCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)S(=O)(=O)O,,,,,,
6890,126891,Artemisinin B,C[C@@H]1CC[C@H]([C@@]2([C@H]1CC=C([C@H]2O)C)O)C(=C)C(=O)O,,,,,,
6891,126892,N-Hydroxy-4-phosphonobutanamide,C(CC(=O)NO)CP(=O)(O)O,,,,,,
6892,126893,trans-2-Amino-2-methyl-N-(4-nitroxycyclohexylmethyl)propionamide,CC(C)(C(=O)NCC1CCC(CC1)O[N+](=O)[O-])N,,,,,,
6893,126894,Pivaloylcarnitine,CC(C)(C)C(=O)OC(CC(=O)[O-])C[N+](C)(C)C,,,,,,
6894,126895,"3-Carboxylato-2-(tert-butylcarbonyloxy)-N,N,N-trimethyl-1-propaneaminium",CC(C)(C)C(=O)OC(CC(=O)O)C[N+](C)(C)C,,,,,,
6895,126896,"3,5-Diamino-N-(aminoiminomethyl)-6-bromopyrazine-N-methylcarboxamide",CN(C(=O)C1=C(N=C(C(=N1)Br)N)N)C(=N)N,,,,,,
6896,126897,Cytidine monophosphate-N-glycoloylneuraminic acid,C1[C@@H]([C@H]([C@@H](O[C@@]1(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=CC(=NC3=O)N)O)O)[C@@H]([C@@H](CO)O)O)NC(=O)CO)O,,,,,,
6897,126898,5-BROMO-3-INDOLYL-beta-D-GALACTOPYRANOSIDE,C1=CC2=C(C=C1Br)C(=CN2)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O,,,,,,
6898,126899,"21-(4'-Methoxyphenylazo)-1,4,7,14,23-pentaoxa(7.2.2)orthometaorthobenzenophane",COC1=CC=C(C=C1)N=NC2=C3COC4=CC=CC=C4OCCOCCOC5=CC=CC=C5OCC2=CC=C3,,,,,,
6899,126900,3-(2-Nitro-1h-imidazol-1-yl)propanoic acid,C1=CN(C(=N1)[N+](=O)[O-])CCC(=O)O,,,,,,
6900,126901,CID 126901,C1[C@H]([C@H]([C@@H](O1)C2=CN=C(N2)S)O)O,,,,,,
6901,126902,"5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(hydroxyacetyl)-7,8,9,10-tetrahydro-11-methoxy-1,6,8-trihydroxy-",CC1C(C(CC(O1)OC2C3=C(CCC2(C(=O)CO)O)C(=C4C(=C3OC)C(=O)C5=C(C4=O)C=CC=C5O)O)N)O,,,,,,
6902,126903,4-Amino-5-(4-hydroxyphenyl)-3-oxopentanoic acid--2-amino-5-(methanesulfinyl)-4-nitrophenylalanyl-N-(aminoacetyl)-N-butanoylprolinamide (1/1),CCCC(=O)N(C(=O)CN)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC(=C(C=C2N)[N+](=O)[O-])S(=O)C)N.C1=CC(=CC=C1C[C@@H](C(=O)CC(=O)O)N)O,,,,,,
6903,126904,CID 126904,CCCC(=O)N(C(=O)CN)C(=O)[C@@H]1CCCN1C(=O)C(CC2=CC(=C(C=C2N)[N+](=O)[O-])S(=O)C)N,,,,,,
6904,126905,(4S)-4-amino-5-(4-hydroxyphenyl)-3-oxopentanoic acid,C1=CC(=CC=C1C[C@@H](C(=O)CC(=O)O)N)O,,,,,,
6905,126906,"2,2-Dimethylpenam sulfone",CC1(CN2C(S1(=O)=O)CC2=O)C,,,['Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)'],,,
6906,126907,Hycanthone N-methylcarbamate,CCN(CC)CCNC1=C2C(=C(C=C1)COC(=O)NC)SC3=CC=CC=C3C2=O,,,,,,
6907,126908,"5-Methyl-6-(4-pyridinyl)-2H-1,4-thiazine-3(4H)one hcl",CC1C(SCC(=O)N1)C2=CN=CC=C2.Cl,,,,,,
6908,126909,5-Methyl-6-pyridin-3-ylthiomorpholin-3-one,CC1C(SCC(=O)N1)C2=CN=CC=C2,,,,,,
6909,126910,5-Cchph,C1CCC(CC1)[C@@H](CCN2C(CNC2=O)CCCCCCC(=O)O)O,,,,,,
6910,126911,CID 126911,CC[C@]1(C(=O)C(=C(S1)O)CC(=O)N)C=C(C)C=C,,,,,,
6911,126912,CID 126912,CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCCN1C(=O)CCC1=O)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
6912,126913,CID 126913,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)S)C,,,,,,
6913,126914,"5-[(2,6-dichlorophenyl)methylidene]-N,N,6-trimethyl-4H-pyridazin-3-amine",CC1=NN=C(CC1=CC2=C(C=CC=C2Cl)Cl)N(C)C,,,,,,
6914,126915,2-Aminoformycin,C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=C3C(=NN2)C(=NC(=N3)N)N)O)O)O,,,,,,
6915,126916,2-Fluoroformycin,C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=C3C(=NN2)C(=NC(=N3)F)N)O)O)O,,,,,,
6916,126917,"4-(N,N-Dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole",CN(C)S(=O)(=O)C1=CC=C(C2=NON=C12)F,,,,,,
6917,126918,7-(N-Benzyloxycarbonylglycyl-glycyl-leucyl)amino-4-methylcoumarin,CCC(C)C(C(=O)NC1=CC2=C(C=C1)C(=CC(=O)O2)C)NC(=O)CNC(=O)CNC(=O)OCC3=CC=CC=C3,,,,,,
6918,126919,2-[(2-Amino-3-methylbutanoyl)amino]-3-hydroxy-4-(7-oxo-4-oxa-1-azabicyclo[3.2.0]heptan-3-yl)butanoic acid,CC(C)C(C(=O)NC(C(CC1CN2C(O1)CC2=O)O)C(=O)O)N,,,,,,
6919,126920,"11H-Dibenzo(b,e)(1,4)diazepin-11-one, 5-((bis(2-hydroxyethyl)amino)acetyl)-8-chloro-5,10-dihydro-, monohydrochloride",C1=CC=C2C(=C1)C(=O)NC3=C(N2C(=O)CN(CCO)CCO)C=CC(=C3)Cl.Cl,,,,,,
6920,126921,Siltenzepine,C1=CC=C2C(=C1)C(=O)NC3=C(N2C(=O)CN(CCO)CCO)C=CC(=C3)Cl,,,,,,
6921,126922,7-(N-Benzyloxycarbonyl-beta-benzylaspartyl-prolyl-leucyl)amino-4-methylcoumarin,CCC(C)[C@H](C(=O)NC1=CC2=C(C=C1)C(=CC(=O)O2)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)OCC4=CC=CC=C4)NC(=O)OCC5=CC=CC=C5,,,,,,
6922,126923,n-Ribosylhistidine,C1=C(N=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C[C@@H](C(=O)O)N,,,,,,
6923,126924,N-Nitroso-N-acetylglycine,CC(=O)N(CC(=O)O)N=O,,,,,,
6924,126925,"N-(2,2-Diphenylethyl)-9-pentofuranosyl-9H-purin-6-amine",C1=CC=C(C=C1)C(CNC2=C3C(=NC=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O)C5=CC=CC=C5,,,,,,
6925,126926,Selenodjenkolate,C([C@@H](C(=O)O)N)[Se]C[Se]C[C@@H](C(=O)O)N,,,,,,
6926,126927,gamma-Kainylglutamic acid,CC(=C)[C@H]1CNC([C@H]1CC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O,,,,,,
6927,126928,"2-((tert-Butylamino)methyl)-7-methyl-2,7-benzofurandimethanol",C[C@H](C1=CC=CC2=C1OC(=C2)[C@H](CNC(C)(C)C)O)O,,,,,,
6928,126929,1-Mipcp iodide,C[N+]1=CC=CC(=C1)C(=O)NCCC2=CC=C(C=C2)I.[I-],,,,,,
6929,126930,N-[2-(4-iodophenyl)ethyl]-1-methylpyridin-1-ium-3-carboxamide,C[N+]1=CC=CC(=C1)C(=O)NCCC2=CC=C(C=C2)I,,,,,,
6930,126931,Serotonin azidobenzamidine,C1=CC(=CC=C1C(=NCCC2=CNC3=C2C=C(C=C3)O)N)N=[N+]=[N-],,,,,,
6931,126932,"(S)-2-[[4-[[(2,4-Diaminopteridin-6-yl)methyl]methylamino]benzoyl]amino]-4-[N-[2-[[[2,3-bis(tetradecanoyloxy)propoxy]hydroxyphosphinyl]oxy]ethyl]carbamoyl]butanoic acid",CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N)OC(=O)CCCCCCCCCCCCC,,,,,,
6932,126933,Tetra-Ac-bracgal,C([C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1CC(=O)O)COC(=O)CBr)CC(=O)O)CC(=O)O)C(=O)O,,,,,,
6933,126934,Miraxid,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C,,,,,,
6934,126935,"6alpha-[[(alpha-Aminobenzyl)carbonyl]amino]penicillanic acid [(2,2-dimethyl-1-oxopropyl)oxy]methyl ester",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C,,,,,,
6935,126936,"4a,6a-Dimethyl-9-(methylsulfanyl)-4b,6,6a,7a,8,8a,8b,8c,9,10-decahydro-4aH-spiro[cyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-7,2'-oxolane]-2,5'(5H)-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1C4CC4C25CCC(=O)O5)[C@@H](CC6=CC(=O)C=C[C@]36C)SC,,,,,,
6936,126937,Butixocort 21-propionate,CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CSC(=O)CC,,,,,,
6937,126938,Cordatolide A,C[C@@H]1[C@H](OC2=C([C@H]1O)C3=C(C(=CC(=O)O3)C)C4=C2C=CC(O4)(C)C)C,,,,,,
6938,126939,Isochuanliansu,CC(=O)O[C@@H]1C[C@@H]([C@@]23COC(C1([C@@H]2C[C@H]([C@@]4([C@@H]3C(=O)[C@@H]([C@@]5([C@H]4C(=O)C[C@H]5C6=COC=C6)C)OC(=O)C)C)O)C)O)O,,,,,,
6939,126940,CID 126940,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O.C1CC(=O)N(C1=O)O,,,,,,
6940,126941,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,"[""Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.  Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.""]",['Methotrexate inhibits enzymes responsible for nucleotide synthesis which prevents cell division and leads to anti-inflammatory actions. It has a long duration of action and is generally given to patients once weekly. Methotrexate has a narrow therapeutic index.  Do not take methotrexate daily.'],"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Non-steroidal chemical compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Nonsteroidal.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']","['Methotrexate has a bioavailability of 64-90%, though this decreases at oral doses above 25mg due to saturation of the carrier mediated transport of methotrexate.. Methotrexate has a T<sub>max</sub> of 1 to 2 hours. oral doses of 10-15g reach serum levels of 0.01-0.1M.', 'Methotrexate is >80% excreted as the unchanged drug and approximately 3% as the 7-hydroxylated metabolite. Methotrexate is primarily excreted in the urine with 8.7-26% of an intravenous dose appearing in the bile.', 'The volume of distribution of methotrexate at steady state is approximately 1L/kg.', 'Methotrexate clearance varies widely between patients and decreases with increasing doses. Currently, predicting clearance of methotrexate is difficult and exceedingly high serum levels of methotrexate can still occur when all precautions are taken.', 'In adults, oral absorption of methotrexate appears to be dose dependent. Peak serum levels are reached within one to two hours. At doses of 30 mg/sq m or less, methotrexate is generally well absorbed with a mean bioavailability of about 60%. The absorption of doses greater than 80 mg/sq m is significantly less, possibly due to a saturation effect.', 'After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight).', 'Protein binding: Moderate (approximately 50%), primarily to albumin.', 'At serum methotrexate concentrations exceeding 0.1 umol/mL passive diffusion becomes a major means of intracellular transport of the drug. The drug is widely distributed into body tissues with highest concn in the kidneys, gallbladder, spleen, liver, and skin.', 'For more Absorption, Distribution and Excretion (Complete) data for METHOTREXATE (10 total), please visit the HSDB record page.']","['Methotrexate is metabolized by folylpolyglutamate synthase to methotrexate polyglutamate in the liver as well as in tissues. Gamma-glutamyl hydrolase hydrolyzes the glutamyl chains of methotrexate polyglutamates converting them back to methotrexate. A small amount of methotrexate is also converted to 7-hydroxymethotrexate.', 'After absorption, methotrexate undergoes hepatic and intracellular metabolism to form methotrexate polyglutamate, metabolites which by hydrolysis may be converted back to methotrexate. Methotrexate polyglutamates inhibit dihydrofolate reductase and thymidylate synthetase. Small amounts of these polyglutamate metabolites may remain in tissues for extended periods; the retention and prolonged action of these active metabolites vary among different cells, tissues, and tumors. In addition, small amounts of methotrexate polyglutamate may be converted to 7-hydroxymethotrexate; accumulation of this metabolite may become substantial following administration of high doses of methotrexate, since the aqueous solubility of 7-hydroxymethotrexate is threefold to fivefold lower than that of the parent compound. Following oral administration of methotrexate, the drug also is partially metabolized by the intestinal flora.']","['The half life of low dose methotrexate is 3 to 10 hours in adults. The half life for high dose methotrexate is 8 to 15 hours. Pediatric patients taking methotrexate for acute lymphoblastic anemia experience a terminal half life of 0.7 to 5.8 hours. Pediatric patients taking methotrexate for juvenile idiopathic arthritis experience a half life of 0.9 to 2.3 hours.', 'Terminal: Low doses: 3 to 10 hours. High doses: 8 to 15 hours. Note: There is wide interindividual variation in clearance rates. Small amounts of methotrexate and its metabolites are protein-bound and may remain in tissues (kidneys, liver) for weeks to months; the presence of fluid loads, such as ascites or pleural effusion, and renal function impairment will also delay clearance.']"
6941,126942,"2-[3-(5a,5b,8,8,11a,13b-Hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-2-yl)butyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol",CC(CCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC5CCC6(C(C5(C4)C)CCC7C6(CCC8C7(CCCC8(C)C)C)C)C,,,,,,
6942,126943,Kerriamycin A,C[C@H]1[C@H](CC[C@@H](O1)O[C@]23C(=O)CC(C[C@]2(C=CC4=C3C(=O)C5=C(C4=O)C(=C(C=C5)[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7CC[C@@H]([C@@H](O7)C)O[C@H]8CC(=O)[C@@H]([C@H](O8)C)O)O)O)(C)O)O,,,,,,
6943,126944,"2-[[3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]-3-phenylpropanoic acid",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC(CC2=CC=CC=C2)C(=O)O)C)C,,,,,,
6944,126945,"(2R,3R,4S,5R)-2-[4-[(1R)-1-hydroxyethyl]-5-methylimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol",CC1=C(N=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)[C@@H](C)O,,,['Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)'],,,
6945,126946,Hyrtial,CC(=O)O[C@@H]1C[C@@H]2[C@]3(CCCC([C@@H]3CC[C@]2([C@H]4[C@]1(CC(=CC4)C=O)C)C)(C)C)C,,,,,,
6946,126947,CID 126947,C[C@H](CCO)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
6947,126948,Agp-dermorphin,C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CO)C(=O)N,,,,,,
6948,126949,CID 126949,CCC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)C[C@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(=O)O)NC(=O)[C@@H]4CCC(=O)N4,,,,,,
6949,126950,"N-(S-(2-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine",C1=CC(=O)N(C1=O)CCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](C(=O)O)N,,,,,,
6950,126951,Kerriamycin C,C[C@H]1[C@H](CC[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)C3=C(C4=C(C=C3)C(=O)C5=C(C4=O)C=C[C@]6([C@@]5(C(=O)C[C@](C6)(C)O)O)O)O)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O,,,,,,
6951,126952,S-Acetyl-3-mercaptopropanoyl-coa,CC(=O)SCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
6952,126953,"2-Propanol, 1-((2-methyl-2-((7-nitro-4-benzofurazanyl)amino)propyl)amino)-3-(2-(2-propenyl)phenoxy)-",CC(C)(CNCC(COC1=CC=CC=C1CC=C)O)NC2=CC=C(C3=NON=C23)[N+](=O)[O-],,,,,,
6953,126954,CID 126954,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C=CC(=C4)N[N+]#N)N=C3[O-],,,,,,
6954,126955,CID 126955,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C=CC(=C4)N[N+]#N)NC3=O,,,,,,
6955,126956,"4,4'-(3,7,12,16-Tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaen-1,18-diyl) bis(1-ethylpyridinium) dibromide",CC[N+]1=CC=C(C=C1)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=CC=[N+](C=C2)CC)C)C.[Br-].[Br-],,,,,,
6956,126957,"1-Ethyl-4-[18-(1-ethylpyridin-1-ium-4-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]pyridin-1-ium",CC[N+]1=CC=C(C=C1)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=CC=[N+](C=C2)CC)C)C,,,,,,
6957,126958,Dilactitol tyramine,C1=CC(=C(C=C1CCN(C[C@@H]([C@H]([C@@H]([C@@H](CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O)C[C@@H]([C@H]([C@@H]([C@@H](CO)O)OC3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O)I)O,,,,,,
6958,126959,(4S)-4-amino-5-[(4-methyl-2-oxochromen-7-yl)amino]-5-oxopentanoic acid,CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCC(=O)O)N,,,,,,
6959,126960,Glucuronate 2-sulfate,C(=O)[C@@H]([C@H]([C@@H]([C@@H](C(=O)O)O)O)O)OS(=O)(=O)O,,,,,,
6960,126961,Phoac proglumide,CCCN(CCC)C(=O)[C@H](CCC(=O)O)NC(=O)COC1=CC=CC=C1,,,,,,
6961,126962,"6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine N-oxide",C[N+]1(CCC2=C(CC1)C(=CC=C2)Cl)[O-],,,,,,
6962,126963,"[6-(4a,8,12b-trihydroxy-3-methyl-1,7,12-trioxo-4H-benzo[a]anthracen-9-yl)-4-hydroxy-2-methyloxan-3-yl] deca-2,4-dienoate",CCCCCC=CC=CC(=O)OC1C(OC(CC1O)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C=CC5(C4(C(=O)C=C(C5)C)O)O)O)C,,,,,,
6963,126964,CID 126964,CCCN1CCC[C@H]1CN=C(C2=CC(=C(C=C2OC)N[N+]#N)S(=O)(=O)NC)[O-],,,,,,
6964,126965,CID 126965,CCCN1CCC[C@H]1CNC(=O)C2=CC(=C(C=C2OC)N[N+]#N)S(=O)(=O)NC,,,,,,
6965,126966,CID 126966,C1C(C(OC1N2C=C(C(=O)NC2=O)C=CCNC(=O)CCCCC3C4C(CS3)NC(=O)N4)COP(=O)(O)O)O,,,,,,
6966,126967,CID 126967,C1=CC(=CC=C1C(=O)[N-][C@@H](CSSC[C@@H](C(=O)O)N=C(C2=CC=C(C=C2)N[N+]#N)[O-])C(=O)O)N[N+]#N,,,,,,
6967,126968,CID 126968,C1=CC(=CC=C1C(=O)N[C@@H](CSSC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)N[N+]#N)C(=O)O)N[N+]#N,,,,,,
6968,126969,Mallotochromene,CC1=C(C(=C(C(=C1OC)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)C)O)O)C(=O)C)O,,,,,,
6969,126970,"8-Chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-3(2H)-one",CN1[C@H]2CCC3=C([C@@H]2CCC1=O)C=CC(=C3)Cl,,,['Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)'],,,
6970,126971,"(2,9)(6,9)-Purinophane",C1CCN2C=NC3=C(N=C(CCCN=C4C5C(=NC=N4)N(C1)C=N5)N=C32)N,,,,,,
6971,126972,CID 126972,C1=CC=C(C(=C1)C=NN2C(=NN=C2S)C3=CC=CO3)O,,,,,,
6972,126973,Cholyldiglycylhistamine,C[C@H](CCC(=O)NCC(=O)NCC(=O)NCCC1=CN=CN1)[C@H]2CC[C@@H]3[C@@]2([C@H](C[C@H]4[C@H]3[C@@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)O)C,,,,,,
6973,126974,"2-(4-Methoxy-2-pyridylmethylsulfinyl)-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole",COC1=CC(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(C(F)F)(F)F,,,,,,
6974,126975,"4-((3,4-Dimethylbenzoyl)amino)-5-oxopentanoic acid",CCCCN(CCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)C)C,,,,,,
6975,126976,Cholyltetraglycylhistamine,C[C@H](CCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCC1=CN=CN1)[C@H]2CC[C@@H]3[C@@]2([C@H](C[C@H]4[C@H]3[C@@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)O)C,,,,,,
6976,126977,N-[1-(2-aminoethylsulfanyl)propan-2-yl]-6-methoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-amine,CC1=C2C(=C(C=C(C2=NC=C1)NC(C)CSCCN)OC)OC3=CC=CC(=C3)C(F)(F)F,,,,,,
6977,126978,CID 126978,C1=COC(=C1)C2=NN=C(C2CCC3=CC=C(O3)[N+](=O)[O-])S,,,,,,
6978,126979,7-((3-(2-Furoyl)ureido)phenylacetamido)cephalosporanic acid,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)NC(=O)C4=CC=CO4)SC1)C(=O)O,,,,,,
6979,126980,"8-Quinolinamine, N-(2-((2-aminoethyl)thio)propyl)-6-methoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-",CC1=C2C(=C(C=C(C2=NC=C1)NCC(C)SCCN)OC)OC3=CC=CC(=C3)C(F)(F)F,,,,,,
6980,126981,"2,2-Difluoro-6-((4-methoxy-3-methyl-2-pyridyl)methylsulfinyl)-5H-(1,3)-dioxolo(4,5-f)benzimidazole",CC1=C(C=CN=C1CS(=O)C2=NC3=CC4=C(C=C3N2)OC(O4)(F)F)OC,,,,,,
6981,126982,"2,5-Dimethoxy-3-nitroamphetamine",CC(CC1=C(C(=CC(=C1)OC)[N+](=O)[O-])OC)N,,,,,,
6982,126983,1-(N-Carbobenzoxy-gamma-glutamyl)indoline-2-carboxylic acid,C1[C@H](N(C2=CC=CC=C21)C(=O)CC[C@H](C(=O)O)NC(=O)OCC3=CC=CC=C3)C(=O)O,,,,,,
6983,126984,1-(N-Carbobenzoxy-gamma-glutamyl)perhydroindoline-2-carboxylic acid,C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)CC[C@H](C(=O)O)NC(=O)OCC3=CC=CC=C3)C(=O)O,,,,,,
6984,126985,"2,3-Bis-(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinylserine",CCCCCCCCCCCCCCCC(=O)N[C@@H](CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)N[C@@H](CO)C(=O)O,,,,,,
6985,126986,(((1-Ethynylcyclohexyl)oxy)methyl)-1-piperazine-ethanol,C#CC1(CCCCC1)OCC(CN2CCNCC2)O,,,,,,
6986,126987,"beta-D-Glucopyranose, 6-O-beta-D-fructofuranosyl-",C([C@@H]1[C@H]([C@@H]([C@](O1)(CO)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)O)O)O)O,,,,,,
6987,126988,"6-(2-Chlorophenyl)-4-hydroxy-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxamide",C1=CC=C2C(=C1)C(=NC(C3=C(N=CN23)C(=O)N)O)C4=CC=CC=C4Cl,,,,,,
6988,126989,CID 126989,C[C@@H](C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
6989,126990,CID 126990,CC(C(=O)SCC(C(=O)NCC(=O)OC)NC(CCC(C(=O)O)N)O)O,,,,,,
6990,126991,"Acetyl-N,N-diethylhomocholine",CC[N+](C)(CC)CCCOC(=O)C,,,,,,
6991,126992,"1-Phosphoryloxy-2,3-dihydroxycyclohexane",C1CC(C(C(C1)OP(=O)(O)O)O)O,,,,,,
6992,126993,Mg MV-Protoporphyrin,[H+].[H+].CCC1=C(C2=NC1=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)[O-])CCC(=O)[O-])C)C(=C3C)C=C)C.[Mg+2],,,,,,
6993,126994,"3-[18-(2-Carboxyethyl)-13-ethenyl-8-ethyl-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",CCC1=C2C=C3C(=C(C(=CC4=NC(=CC5=NC(=CC(=C1C)N2)C(=C5CCC(=O)O)C)C(=C4C)CCC(=O)O)N3)C=C)C,,,,,,
6994,126995,CID 126995,C1=NC2=C(N1CCNCCO)C(=O)N=C(N2)N,,,,,,
6995,126996,"1-Amino-19-guanidino-11-methoxy-4,9,12-triazanonadecane-10,13-dione",COC(C(=O)NCCCCNCCCN)NC(=O)CCCCCCN=C(N)N,,,,,,
6996,126997,Chlorobromofosfamide,C1CN(P(=O)(OC1)NCCCl)CCBr,,,,,,
6997,126998,CID 126998,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC1=CC2=CC3=CC=CC=C3C=C2C=C1,,,,,,
6998,126999,DH-Thymine,CC1=CNC(=O)N(C1=O)C2C=CC(=O)[C@H](O2)CO,,,,,,
6999,127000,"2,5-Anhydro-1-o-sulfo-3-o-(2-o-sulfohexopyranuronosyl)hexitol",C(C1C(C(C(O1)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)O)O)OS(=O)(=O)O)O)O,,,,,,
7000,127001,CID 127001,CCCCCC1CCCC(O1)C=CCCCC(C(C(=O)O)O)O,,,,,,
7001,127002,"[(4S,6S,7R,8S)-11-amino-12-(hydroxymethyl)-7-methoxy-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CO[C@@]12[C@@H](C3=C(N1C[C@H]4[C@@H]2N4)C(=O)C(=C(C3=O)N)CO)COC(=O)N,,,,,,
7002,127003,CID 127003,CCOC(C(C=C(C)CP(=O)(O)O)N)O,,,,,,
7003,127004,Tripalmitoyl-s-glyceryl-cysteinyl-seryl-serine,CCCCCCCCCCCCCCCC(=O)N[C@@H](CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O,,,,,,
7004,127005,Trpyrth,C1CN2C(=C3C(=NC2=O)N=NN3)SC1,,,,,,
7005,127006,"2-(3,4-Diacetoxyphenyl)-2-chloro-N-isopropyl-1-ethanamine",CC(C)NCC(C1=CC(=C(C=C1)OC(=O)C)OC(=O)C)Cl,,,,,,
7006,127007,Pyrizinostatin,CC(=O)CC12C(=NN(C(=O)N1)C)N(C(=O)N(C2=O)C)C,,,,,,
7007,127008,"1H-Indole, 3-(2-ethyl-5-oxazolyl)-",CCC1=NC=C(O1)C2=CNC3=CC=CC=C32,,,,,,
7008,127009,"4-Hydroxy-3-[4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl]naphthalene-1,2-dione",CC(C)(CO)C1CCC(CC1)C2=C(C3=CC=CC=C3C(=O)C2=O)O,,,,,['298C84 is a known human metabolite of 58c80.'],
7009,127010,CID 127010,CCNCCNC1=C2C(=C(C=C1)CNS(=O)(=O)C)SC3=CC=CC=C3C2=O,,,,,,
7010,127011,4-O-Methylyellamycin A,CCC1(CC(C2=CC3=C(C(=C2C1O)O)C(=O)C4=C(C3=O)C(=CC=C4)OC)OC5CC(C(C(O5)C)O)N(C)C)O,,,,,,
7011,127012,4-O-Methyl-6-deoxyoxaunomycin,CCC1(CC(C2=CC3=C(C(=C2C1O)O)C(=O)C4=C(C3=O)C(=CC=C4)OC)OC5CC(C(C(O5)C)O)N)O,,,,,,
7012,127013,2-Deoxy-l-threopentitol,C(CO)[C@@H]([C@H](CO)O)O,,,,,,
7013,127014,3-Hydroxy Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=C(C=CC3=C2C4=CC=CC=C4N3)O)O,,,,,,
7014,127015,CID 127015,CC(CC(C)C(CCl)(Cl)Cl)C(=O)C1=C(NC(=C(C1=O)OC)OC)O,,,,,,
7015,127016,3-(2-Hydroxyphenyl)prop-2-enamide,C1=CC=C(C(=C1)C=CC(=O)N)O,,,,,,
7016,127017,CID 127017,C1=CC=C(C(=C1)C(CC(=O)N)O)O,,,,,,
7017,127018,CID 127018,CC(C)C(C1=CC=C(C=C1)C(=O)O)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
7018,127019,"4-[2-(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid",CC1(CCC(C2=C1C=CC(=C2)C3(OCCO3)C4=CC=C(C=C4)C(=O)O)(C)C)C,,,,,,
7019,127020,CID 127020,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCCN4)C)OC(=O)CC5=CC=C(C=C5)N(CCl)CCl,,,,,,
7020,127021,CID 127021,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC(=O)N4C)C)OC(=O)CC5=CC=C(C=C5)N(CCl)CCl,,,,,,
7021,127022,Pongapinone B,CC(=CCC1=C2C(=C(C=C1OC)OC)C(=O)C[C@H](O2)C3=CC4=C(C=C3)OCO4)C,,,,,,
7022,127023,"3-(1,3-Benzodioxol-5-yl)-1-(5,7-dimethoxy-2,2-dimethylchromen-6-yl)-3-hydroxyprop-2-en-1-one",CC1(C=CC2=C(C(=C(C=C2O1)OC)C(=O)C=C(C3=CC4=C(C=C3)OCO4)O)OC)C,,,,,,
7023,127024,Dichloropane,COC(=O)[C@@H]1[C@H]2CC[C@H](N2)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl,,,,,,
7024,127025,CID 127025,CC(CC(C)C(=O)C1=C(NC(=C(C1=O)OC)OC)O)C(CCl)Cl,,,,,,
7025,127026,28-O-Glucopyranosylepiederagenin,C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)CO)O,,,,,,
7026,127027,3-beta-D-Glucopyranosyloxy-2-butanol,CC(C(C)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
7027,127028,"2-(8-Hydroxy-3,7-dimethylocta-1,6-dien-3-yl)oxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxane-3,4,5-triol",CC(=CCCC(C)(C=C)OC1C(C(C(C(O1)COC2C(C(C(CO2)O)O)O)O)O)O)CO,,,,,,
7028,127029,3-(4-Hydroxy-2-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one,COC1=CC=C(C=C1)C(=O)C=CC2=C(C=C(C=C2)O)OC,,,,,,
7029,127030,2-Methylene-3-oxocyclopentaneacetic acid,C=C1C(CCC1=O)CC(=O)O,,,,,,
7030,127031,"2-Naphthacenecarboxylic acid, 6,6a,7,10,10a,11-hexahydro-6a,7,10a,12-tetrahydroxy-3,8-dimethoxy-1-methyl-6,10,11-trioxo-, methyl ester",CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4(C(=O)C=C(C(C4(C3=O)O)O)OC)O)OC)C(=O)OC,,,,,,
7031,127032,"6-(3-Aminopropyl)-1,3-diazacyclohexan-4-one",C1[C@H](NC[15NH][13C]1=O)CCCN,,,,,,
7032,127033,N-[(1H-Pyrrol-2-yl)methylene]pyrimidin-2-amine,C1=CNC(=C1)C=NC2=NC=CC=N2,,,,,,
7033,127034,CID 127034,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC(C4[C@@]3(CC[C@@H](C4)O)C)[75Se]C)C,,,,,,
7034,127035,"3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole",C1CC2=C(CC1N)C3=C(N2)C=CC(=C3)C(=O)N.Cl,,,,,,
7035,127036,"6-amino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide",C1CC2=C(CC1N)C3=C(N2)C=CC(=C3)C(=O)N,,,,,,
7036,127037,"Pyrrolidine-2,3-dicarboxylic acid",C1CNC(C1C(=O)O)C(=O)O,,,,,,
7037,127038,CID 127038,CCCCCCCCC(=O)NCC1=CC(=C(C=C1)C(CO)O)OC,,,,,,
7038,127039,CID 127039,CCNCCCCNCCCCNCCCCNCCCN,,,,,,
7039,127040,Propinqualin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC=C(C=C3)O)OC4C(C(C(C(O4)CO)O)O)O,,,,,,
7040,127041,Hancogenin B,CC12CC(C(CC1=CCC3C2CCC4=COC5(C4(C(CO5)OC3=O)O)C)O)O,,,,,,
7041,127042,CID 127042,CC=CCC=CCC[C@]1(CC(=O)[C@H]2[C@@H]1O2)O,,,,,,
7042,127043,"7-N,N-Dimethylaminosulfonyl-4-(2,1,3-benzoxadiazolyl)isothiocyanate",CN(C)S(=O)(=O)C1=CC=C(C2=NON=C12)N=C=S,,,,,,
7043,127044,1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-5-iodo-2-phenylpent-4-enoate,C1CN2CCC1C(C2)OC(=O)C(CC=CI)(C3=CC=CC=C3)O,,,,,,
7044,127045,CID 127045,CC(C1CCCCC1)C(=O)NCCCN2CCCCCC2,,,,,,
7045,127046,"2'-(4-Fluorophenyl)2'H-pregna-2,4-dien-20-yno(3,2c)pyrazol-11,17-diol",C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NN5C6=CC=C(C=C6)F)O,,,,,,
7046,127047,CID 127047,C(C(=O)C(=O)O)OS(=O)(=O)O,,,,,,
7047,127048,CID 127048,CCCCC1C(=O)[C@H](C(=O)C(C1=O)C2CCCCC2)C3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)C(=O)[O-].[Na+],,,,,,
7048,127049,CID 127049,CCCCC1C(=O)[C@H](C(=O)C(C1=O)C2CCCCC2)C3CC([C@H]([C@@H]([C@H]3O)O)O)C(=O)O,,,,,,
7049,127050,2'-O-Anthraniloyl adenosine monophosphate,C1=CC=C(C(=C1)C(=O)O[C@@H]2[C@@H]([C@H](OC2N3C=NC4=C(N=CN=C43)N)COP(=O)(O)O)O)N,,,,,,
7050,127051,"4-Piperidinamine, 1-(6-bromo-2-pyridinyl)-",C1CN(CCC1N)C2=NC(=CC=C2)Br,,,,,,
7051,127052,"6-Ethyl-5H-dibenz(c,e)azepine",CC[N+]1=CC2=CC=CC=C2C3=CC=CC=C3C1,,,,,,
7052,127053,"1-sec-Butyl-piperidine-2-carboxylic acid (2,4,6-trimethyl-phenyl)-amide",CCC(C)N1CCCCC1C(=O)NC2=C(C=C(C=C2C)C)C.Cl,,,,,,
7053,127054,"1-butan-2-yl-N-(2,4,6-trimethylphenyl)piperidine-2-carboxamide",CCC(C)N1CCCCC1C(=O)NC2=C(C=C(C=C2C)C)C,,,,,,
7054,127055,"1,6-Bis(acetyloxy)-5,7-dimethoxy-9H-fluoren-9-one",CC(=O)OC1=CC=CC2=C1C(=O)C3=CC(=C(C(=C23)OC)OC(=O)C)OC,,,,,,
7055,127056,"5-[2-[1-(4,4-difluoro-6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",CC(CC(CC(C)(C)O)(F)F)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,,,,,,
7056,127057,Isolamtidin,CN1C(=NC(=N1)NCCCOC2=CC=CC(=C2)CN3CCCCC3)N,,,,,,
7057,127058,Erysulfone,CS(=O)(=O)CC[C@H]1CCC(=O)O1,,,,,,
7058,127059,Erysulfoxide,CS(=O)CC[C@H]1CCC(=O)O1,,,,,,
7059,127060,"4,5-Didehydroisocarbacyclin",C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=CC=CC=C64.Cl.Cl,,,,,,
7060,127061,"1'-[3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one",C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=CC=CC=C64,,,,,,
7061,127062,CID 127062,CC1(C[C@@H]([C@H](C1=O)SCCCCCC(=O)O)C=C[C@H](COC2=CC(=CC=C2)Cl)O)C,,,,,,
7062,127063,CID 127063,CCCCC[C@@H](C=C[C@H]1CC(C(=O)[C@@H]1CC(=O)CCCCC(=O)O)(C)C)O,,,,,,
7063,127064,CID 127064,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N(CC(=O)O)N2CCCC2,,,,,,
7064,127065,4-Hydroxypentadec-2-enal,CCCCCCCCCCCC(C=CC=O)O,,,,,,
7065,127066,1-Diethylcarbamyl-4-ethylpiperazine,CCN1CCN(CC1)C(=O)N(CC)CC,,,,,,
7066,127067,CID 127067,C1=NC2=C(N1C3C(N(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)NC(=O)CCl)O)NC(=NC2=O)N,,,,,,
7067,127068,4-Methoxy-n-(3-methylphenoxy)benzamide,CC1=CC(=CC=C1)ONC(=O)C2=CC=C(C=C2)OC,,,,,,
7068,127069,IV-Tcdbd,C1=C(C=C2C(=C1NC(=O)CCCCI)OC3=CC(=C(C=C3O2)Cl)Cl)Cl,,,,,,
7069,127070,"2,3-Didehydro-2-deoxydothistromin",C1=CC(=C2C(=C1O)C(=O)C3=CC4=C(C(=C3C2=O)O)[C@@]5(C=CO[C@@H]5O4)O)O,,,,,,
7070,127071,"(5S,6R,7S,9R,11R,12R,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol",C([C@@]1([C@@H]2[C@@H]3[C@@H](N=C(NC34[C@H]([C@H]1O[C@@]([C@H]4O)(O2)O)O)N)O)O)O,,,,,,
7071,127072,Bromoacetyltrichodermin,CC1=C[C@@H]2[C@](CC1)(C3([C@@H](C[C@H](C34CO4)O2)OC(=O)CBr)C)C,,,,,,
7072,127073,N-Sulfooxy-2-aminofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)NOS(=O)(=O)O,,,,,,
7073,127074,CID 127074,COC1=C2C(=C(C=CN2)O)C=CC1=O,,,,,,
7074,127075,CID 127075,CC(=CCOC1=CC2=C(C=C1)C=CC(=O)O2)C3CC(=O)C(O3)(C)C,,,,,,
7075,127076,Taumustine,C(CS(=O)(=O)O)N(CCCl)CCCl,,,,,,
7076,127077,"(2,5-Dioxopyrrolidin-1-yl) 3-(3-hydroxy-5-iodophenyl)propanoate",C1CC(=O)N(C1=O)OC(=O)CCC2=CC(=CC(=C2)I)O,,,,,,
7077,127078,"[(3R,4R,5R)-2-[5-(4-Bromo-2,3-dioxobutyl)sulfanyl-1H-imidazo[2,1-f]purin-3-ium-3-yl]-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate",C1=CN2C(=N1)C3=C(N=C2SCC(=O)C(=O)CBr)[N+](=CN3)C4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)OP(=O)(O)O,,,,,,
7078,127079,CID 127079,C1NC2=C(N1C3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)OP(=O)(O)O)NC(=[N+]4C2=NC=C4)SCC(=O)C(=O)CBr,,,,,,
7079,127080,CID 127080,CC1=CC2=C(C=C1)NC=C2CCN=C(C3=CC=C(C=C3)N=[N+]=[N-])N,,,,,,
7080,127081,CID 127081,C1=NC2=C(N1C3C(N(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)NC(=O)CCl)O)NC(=NC2=O)N,,,,,,
7081,127082,Boc-achpa,CC(C)(C)OC(=O)N[C@@H](CC1CCCCC1)[C@H](CC(=O)O)O,,,,,,
7082,127083,"Ethyl 2-(2-phenylthiazolo(3,2-b)(1,2,4)triazol-6-yl)-4-thiazolecarboxylate",CCOC(=O)C1=CSC(=N1)C2=CSC3=NC(=NN23)C4=CC=CC=C4,,,,,,
7083,127084,CID 127084,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC(=O)C(CCCC(=O)O)O)O)O)O,,,,,,
7084,127085,Hydrochlorothiazide mixture with pindolol,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,,,,,,
7085,127086,"Urea, N-(1,3-dimethyl-2,5-dioxo-4-imidazolidinyl)-N'-methyl-",CNC(=O)NC1C(=O)N(C(=O)N1C)C,,,,,,
7086,127087,5-(7-(5-Hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole,C[C@H]1COC(=N1)C2=CC=C(C=C2)OCCCCCCCC3=CC(=NO3)C,,,,,,
7087,127088,"1H-Indol-5-ol, 6-methoxy-, (+-)-",COC1=C(C=C2C(=C1)C=CN2)O.COC1=C(C=C2C=CNC2=C1)OS(=O)(=O)O,,,,,,
7088,127089,6-Hydroxy-5-methoxyindole,COC1=C(C=C2C(=C1)C=CN2)O,,,,,,
7089,127090,6-Methoxy-1H-indol-5-yl hydrogen sulfate,COC1=C(C=C2C=CNC2=C1)OS(=O)(=O)O,,,,,,
7090,127091,CID 127091,CNC1=NC(=O)C2=C(N1)NC(=O)N2,,,,,,
7091,127092,Pyroglutamyl diazomethyl ketone,C1CC(=O)NC1C(=O)C=[N+]=[N-],,,,,,
7092,127093,2-Hydroxy-2-(5-oxopyrrolidin-2-yl)ethenediazonium,C1CC(=O)NC1C(=C[N+]#N)O,,,,,,
7093,127094,3-Aminobenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)N,,,,,,
7094,127095,"[6-[(3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl)oxy]-3,4-bis[(4-nitrobenzoyl)oxy]oxan-2-yl]methyl 4-nitrobenzoate",CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)COC(=O)C6=CC=C(C=C6)[N+](=O)[O-])OC(=O)C7=CC=C(C=C7)[N+](=O)[O-])OC(=O)C8=CC=C(C=C8)[N+](=O)[O-])O,,,,,,
7095,127096,"2-[3-[4-(4-Chlorophenyl)piperazin-1-yl]propyl]-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-1,2,4-triazol-3-one",CC(C1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC=C(C=C4)Cl)O,,,,,,
7096,127097,"2-{3-[4-(4-Chlorophenyl)piperazin-1-yl]propyl}-4-ethyl-5-(1-hydroxyethyl)-2,4-dihydro-3h-1,2,4-triazol-3-one",CCN1C(=NN(C1=O)CCCN2CCN(CC2)C3=CC=C(C=C3)Cl)C(C)O,,,,,,
7097,127098,CID 127098,C1=CC(=C(C=C1Cl)Cl)C(=CN2C=CN=C2)Cl.Cl,,,,,,
7098,127099,"1-[2-Chloro-2-(2,4-dichlorophenyl)ethenyl]imidazole",C1=CC(=C(C=C1Cl)Cl)C(=CN2C=CN=C2)Cl,,,,,,
7099,127100,n-[3-(Pyridin-2-yldisulfanyl)propanoyl]glutamic acid,C1=CC=NC(=C1)SSCCC(=O)NC(CCC(=O)O)C(=O)O,,,,,,
7100,127101,"(9-Methyl-6-propan-2-yl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl) 3-hydroxy-2-phenylpropanoate",CC(C)C1C(CC2C3C(C1N2C)O3)OC(=O)C(CO)C4=CC=CC=C4,,,,,,
7101,127102,CID 127102,C1[C@H](N=C(S1)S)C(=O)O,,,,,,
7102,127103,N-((((5-chloro-2-benzothiazolyl)thio)phenyl)acetyl)cysteine,C1=CC=C(C=C1)C(C(=O)NC(CS)C(=O)O)SC2=NC3=C(S2)C=CC(=C3)Cl,,,,,,
7103,127104,3-[7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-methyl-4-oxo-8-propyl-3H-chromen-2-yl]propanoic acid,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCOC2=C(C3=C(C=C2)C(=O)CC(O3)(C)CCC(=O)O)CCC,,,,,,
7104,127105,CID 127105,C[C@@]12[C@H](CC[C@@]1([C@@H]3CCC45C[C@@H]6CC([C@@]4([C@H]3[C@@H](C2=O)O)C=O)OC(O6)(O5)C)O)C7=COC(=O)C=C7,,,,,,
7105,127106,Saframycin-Yd2,CC1=C(C(=O)C2=C(C1=O)C[C@H]3[C@@H]4C5=C(C[C@@H](N4C)C(N3[C@H]2CNC(=O)CN)C#N)C(=O)C(=C(C5=O)OC)C)OC,,,,,,
7106,127107,Saframycin Y3,CC1=C(C(=O)C2=C(C1=O)C[C@H]3[C@@H]4C5=C(C[C@@H](N4C)C(N3[C@H]2CNC(=O)[C@H](C)N)C#N)C(=O)C(=C(C5=O)OC)C)OC,,,,,,
7107,127108,Saframycin-Yd1,CCC(C(=O)NCC1C2=C(C[C@@H]3N1C(C4CC5=C(C3N4C)C(=O)C(=C(C5=O)C)OC)C#N)C(=O)C(=C(C2=O)OC)C)N,,,,,,
7108,127109,CID 127109,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)S,,,,,,
7109,127110,(4S)-4-amino-5-fluoropent-2-enoic acid,C([C@H](C=CC(=O)O)N)F,,,,,,
7110,127111,"3,6-Diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine",CS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=C2C=CC(=C4)N)N,,,,,,
7111,127112,Fsbn-ethenoadenosine,C1=CC(=CC=C1C(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=CN5C4=NC=C5)O)O)S(=O)(=O)F,,,,,,
7112,127113,19-Noraldosterone,C1C[C@@H]([C@@]2([C@@H]1[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@H](C2)O)C=O)C(=O)CO,,,,,,
7113,127114,"7-(4-amino-5-hydroxy-6-methyloxan-3-yl)oxy-9-ethyl-4,6,9,11-tetrahydroxy-8,10-dihydro-7H-tetracene-5,12-dione",CCC1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)OC5COC(C(C5N)O)C)O,,,,,,
7114,127115,3-Amino-5-hydroxybenzoic acid,C1=C(C=C(C=C1N)O)C(=O)O,,,,,,
7115,127116,CID 127116,CCC(=C(C1=CC=CC=C1)C2=CC(=C(C=C2)OCCN(C)C)I)C3=CC=CC=C3,,,,,,
7116,127117,CID 127117,C[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)C=CC1=CC=CO1,,,,,,
7117,127118,Epirubicinol,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)([C@H](CO)O)O)N)O,,,,,,
7118,127119,"1-(2-Chloroethyl)-3-[4-[2-chloroethylcarbamoyl(nitroso)amino]-2,3-dihydroxybutyl]-1-nitrosourea",C(CCl)NC(=O)N(CC(C(CNC(=O)N(CCCl)N=O)O)O)N=O,,,,,,
7119,127120,CID 127120,CC(=O)NC1=CC=C(C=C1)C2=N[C@@H]3CCN(C[C@@H]3C4=CC(=C(C=C42)OC)OC)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
7120,127121,CID 127121,CC(=O)NC1=CC=C(C=C1)C2=N[C@@H]3CCN(CC3C4=CC(=C(C=C42)OC)OC)C,,,,,,
7121,127122,Juliprosopin,CC1C(CCC(N1)CCCCCCCCCCC2C3CCCN3CC=C2CCCCCCCCCCC4CCC(C(N4)C)O)O,,,,,,
7122,127123,"(13-Hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl) carbamate",CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C=C(C1)C2=O)C)OC)OC(=O)N)C)C)O)OC,,,,,,
7123,127124,Betaclamycin A,CC[C@]1(CC(C2=C([C@H]1O)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O[C@H]5C[C@@H](C([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,,,,,,
7124,127125,5-(Dimethylaminodiazenyl)-1-methylimidazole-4-carboxamide,CN1C=NC(=C1N=NN(C)C)C(=O)N,,,,,,
7125,127126,Bromoacetylalprenololmenthane,CC1(CCC(CC1)C(C)(C)NC(=O)CBr)NCC(COC2=CC=CC=C2CC=C)O,,,,,,
7126,127127,"Enkephalin-met, arg(6)-",CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7127,127128,CID 127128,C1CCN(C1)CCOC2=CC=C(C=C2)C(=C(C3=CC=CC=C3)[N+](=O)[O-])C4=CC=C(C=C4)O,,,,,,
7128,127129,CID 127129,C[C@H](CCC(=O)C(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C,,,,,,
7129,127130,Pyr-dppe,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNS(=O)(=O)C1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1)OC(=O)CCCCCCCCCCCCCCC,,,,,,
7130,127131,Diethyl-4'-hydroperoxycyclophosphamide,CCN(CC)P1(=O)NC(CCO1)OO,,,,,,
7131,127132,"2-Acetamido-1,3,4,6-tetra-O-acetyl-2-deoxymannopyranose",CC(=O)N[C@H]1[C@H]([C@@H]([C@H](OC1OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C,,,,,,
7132,127133,CID 127133,CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C.C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,,,,,,
7133,127134,N-(1-Carboxy-3-phenylpropyl)leucyltryptophan,CCC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(CCC3=CC=CC=C3)C(=O)O,,,,,,
7134,127135,"4-[4-(3-ethyl-1,3-benzothiazol-3-ium-2-yl)buta-1,3-dienyl]-N,N-dimethylaniline;perchlorate",CC[N+]1=C(SC2=CC=CC=C21)C=CC=CC3=CC=C(C=C3)N(C)C.[O-]Cl(=O)(=O)=O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
7135,127136,"2-[4-[4-(Dimethylamino)phenyl]-1,3-butadienyl]-3-ethylbenzothiazolium",CC[N+]1=C(SC2=CC=CC=C21)C=CC=CC3=CC=C(C=C3)N(C)C,,,,,,
7136,127137,"1-(Bromomethyl)-2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzene",C(C1=C(C(=C(C(=C1F)F)C(F)(F)F)F)F)Br,,,,,,
7137,127138,cBIMP,C1C2C([C@H]([C@@H](O2)N3C=NC4=CC=CC=C43)O)OP(=O)(O1)O,,,,,,
7138,127139,4-Sulfamoylphenyl 4-guanidinobenzoate methanesulfonate,C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)S(=O)(=O)N)N=C(N)N,,,,,,
7139,127140,N-Benzyloxycarbonylarginyl-L-arginine-2-naphthylamide,C1=CC=C(C=C1)COC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC3=CC=CC=C3C=C2,,,,,,
7140,127141,CID 127141,CCCCC(C)(C)[C@H](C=C[C@H]1CC(C(=O)[C@@H]1SCCCCCC(=O)O)(C)C)O,,,,,,
7141,127142,CID 127142,C(C(CO)OCN1C2=C(C(=O)N=C(N2)N)N=C1N)O,,,,,,
7142,127143,"4-(4-Hydroxybenzyl)-2,6-bis(hydroxymethyl)phenol",C1=CC(=CC=C1CC2=CC(=C(C(=C2)CO)O)CO)O,,,,,,
7143,127144,CID 127144,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3CC(C[C@@H](C3=C)O)OC(=O)CN=C4C=CC(=N[N+]#N)C=C4N(O)[O-])C,,,,,,
7144,127145,CID 127145,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)N=[N+]=[N-])C(=O)NC(CCSC)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7145,127146,3-O-Arabinofuranosylchlormadinol acetate,CC(=O)C1(CCC2C1(CCC3C2C=C(C4C3(CC(C=C4)OC5C(C(C(O5)CO)O)O)C)Cl)C)OC(=O)C,,,,,,
7146,127147,3-O-Rhamnosylchlormadinol acetate,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2CC[C@@]3([C@H]4CC[C@]5([C@H]([C@@H]4C=C(C3=C2)Cl)CC[C@@]5(C(=O)C)OC(=O)C)C)C)O)O)O,,,,,,
7147,127148,"Androstane-3,14-diol",C[C@H]1CC[C@]2(C1CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@@H](C4)O)C)O,,,,,,
7148,127149,Desacetyluvaricin,CCCCCCCCCC[C@@H]([C@H]1CC[C@@H](O1)[C@H]2CC[C@@H](O2)[C@@H](CCCCCCCCCCCCC3=C[C@@H](OC3=O)C)O)O,,,,,,
7149,127150,Reboxetine mesylate,CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']",,,
7150,127151,Reboxetine,CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,['For the treatment of clinical depression.'],"['Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders.']","['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']","['Reboxetine is rapidly and extensively absorbed following oral administration.', 'Multiple samples of blood and milk were obtained over a dose interval at steady-state from four women who were taking reboxetine for postnatal depression. Drug concentrations in plasma and milk were measured by high performance liquid chromatography and milk/plasma ratio (M/P), absolute infant dose and relative infant dose were estimated by standard methods. Their four, breastfed, infants were also examined clinically, and a blood sample was taken for drug analysis. The median (range) dose taken by the women was 6 (4-10) mg/day. There was no significant difference in reboxetine concentration between paired fore-and hind-milk samples. The mean (95% CI) M/P was 0.06 (0.03, 0.09). Absolute infant dose was 1.7 (0.7, 2.4) ug/kg/day for reboxetine while the relative infant dose was 2.0% (1.3, 2.7%). ... The concentrations of reboxetine in plasma from the four infants were <4 ug/L, 2.6 ug/L, 2.3 ug/L and 5 ug/L, respectively.', 'Reboxetine is known to be excreted in breast milk.', 'The drug appears to be distributed into total body water. Reboxetine is 97% bound to human plasma proteins in young and 92% in elderly (with affinity markedly higher for alpha1 acid glycoprotein than albumin), with no significant dependence of the concentration of drug.', 'After oral administration of a single 4 mg reboxetine dose to healthy volunteers, peak levels of about 130 ng/mL are achieved within 2 hr post-dosing. Data indicate that absolute bioavailability is at least 60%. Reboxetine plasma levels decreased monoexponentially with a half-life of about 13 hr. Steady-state conditions are observed within 5 days. Linearity of the pharmacokinetics was shown in the range of single oral doses in the clinically recommended dose-ranges.', 'For more Absorption, Distribution and Excretion (Complete) data for REBOXETINE (6 total), please visit the HSDB record page.']","['Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4.', 'The purpose of this study was to compare the disposition and the metabolic pattern of Reboxetine in several species, including man. (14)C-Reboxetine was given orally to the rat, the dog, the monkey (5 mg/kg) and man (2 and 4 mg/kg). Radioactivity was eliminated both by the renal and faecal route in the rat and the dog, mainly in urine in the monkey and man. Reboxetine was extensively metabolized. A number of urinary metabolites were quantified by radio-HPLC and tentatively identified by comparison with the retention times of reference compounds. Suggested routes of metabolic transformation are: 2-O-dealkylation; hydroxylation of the ethoxyphenoxy ring; oxidation of the morpholine ring; morpholine ring-opening; and combinations of these. Metabolites were partially or completely conjugated with glucuronic acid and/or sulphuric acid.', 'Reboxetine is predominantly metabolized in vitro via cytochrome P4503A (CYP3A4). In vitro studies have shown that reboxetine does not inhibit the activity of the following isozymes of cytochrome P450: CYP1A2, CYP2C9, CYP2C19, and CYP2E1. Reboxetine inhibits both CYP2D6 and CYP3A4 with low binding affinities, but has shown no effect on the in vivo clearance of drugs metabolized by these enzymes. Reboxetine should be co-prescribed with caution with potent inhibitors of CYP3A4.']","['12.5 hours', 'After oral administration of a single 4 mg reboxetine dose to healthy volunteers ... reboxetine plasma levels decreased monoexponentially with a half-life of about 13 hr.']"
7151,127152,"Benz(cd)indol-4-amine, 1,3,4,5-tetrahydro-6-methoxy-N,N-dipropyl-, monohydrochloride",CCCN(CCC)C1CC2=CNC3=C2C(=C(C=C3)OC)C1.Cl,,,,,,
7152,127153,"6-methoxy-N,N-dipropyl-1,3,4,5-tetrahydrobenzo[cd]indol-4-amine",CCCN(CCC)C1CC2=CNC3=C2C(=C(C=C3)OC)C1,,,,,,
7153,127154,"5-Pyrimidinecarboxylic acid, 1,4-dihydro-2-((2-(2-methylpropoxy)phenyl)amino)-4-oxo-",CCC(C)OC1=CC=CC=C1NC2=NC=C(C(=O)N2)C(=O)O,,,,,,
7154,127155,1-Hydroxy-11-deoxycarminomycin II,CC1C(C(CC(O1)OC2CC(CC3=CC4=C(C(=C23)O)C(=O)C5=C(C=CC(=C5C4=O)O)O)(C(=O)C)O)N)OC(CC(C)O)OC(C)CO,,,,,,
7155,127156,2-Deoxy-2-fluorotalose,C([C@H]([C@@H]([C@@H]([C@@H](C=O)F)O)O)O)O,,,,,,
7156,127157,"(7R,8S,9S,15S,16R)-16-[(2S,3R,4S,8S,9R)-3,9-dihydroxy-4,8,10-trimethyl-5-oxoundec-6-en-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one",C[C@H]1CC(=CC=C[C@@H]([C@H](OC(=O)C(=CC(=C[C@H]([C@H]1O)C)C)OC)[C@@H](C)[C@H]([C@H](C)C(=O)C=C[C@H](C)[C@@H](C(C)C)O)O)OC)C,,,,,,
7157,127158,"4,6,9-trihydroxy-7-(4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl)oxy-2,8-dimethoxy-9-methyl-8,10-dihydro-7H-tetracene-5,12-dione",CC1C(C(C(C(O1)OC2C(C(CC3=CC4=C(C(=C23)O)C(=O)C5=C(C4=O)C=C(C=C5O)OC)(C)O)OC)OC)O)OC,,,,,,
7158,127159,N-Hydroxymethyl-3-methylpyrazole,CC1=NN(C=C1)CO,,,,,,
7159,127160,"(5S,5aS,8aR)-5-(1,3-benzodioxol-4-yl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-6-one",C1[C@H]2COC(=O)[C@H]2[C@@H](C3=CC4=C(C=C31)OCO4)C5=C6C(=CC=C5)OCO6,,,,,,
7160,127161,"2,4-Dihydro-1h-[1,2,4]triazolo[3,4-c][1,4]benzothiazin-1-one",C1C2=NNC(=O)N2C3=CC=CC=C3S1,,,,,,
7161,127162,CID 127162,C[C@H]1CC[C@@H](CC1=CC=C2CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)C=C[C@H](C)C(C)(C)O)C)O,,,,,,
7162,127163,Tyrosyl-prolyl-arginyl chloromethyl ketone,C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl,,,,,,
7163,127164,Tyr-met(O)-gly-etphe-nhnhcoch3,CCN([C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)C)C(=O)CNC(=O)[C@@H](CCS(=O)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N.CC(=O)O,,,,,,
7164,127165,H-Tyr-(D)-Met(O)-Gly-EtPhe-NHNHCOCH3,CCN([C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)C)C(=O)CNC(=O)[C@@H](CCS(=O)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7165,127166,N(6)-(3-Iodo-4-azidobenzyl)adenosine,C1=CC(=C(C=C1CNC2=C3C(=NC=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O)I)N=[N+]=[N-],,,,,,
7166,127167,"(3,4,5-Tribenzoyloxy-6-prop-2-enyloxan-2-yl)methyl benzoate",C=CCC1C(C(C(C(O1)COC(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3)OC(=O)C4=CC=CC=C4)OC(=O)C5=CC=CC=C5,,,,,,
7167,127168,"1,3,3-Trimethyl-4-phenyl-4-(propionyloxy)piperidine",CCC(=O)O[C@@]1(CCN(CC1(C)C)C)C2=CC=CC=C2,,,,,,
7168,127169,3-Acetamido-4-trimethylaminobutyric acid,CC(=O)NC(CC(=O)[O-])C[N+](C)(C)C,,,,,,
7169,127170,3-(Acetylamino)-4-(trimethylaminio)butanoate,CC(=O)NC(CC(=O)O)C[N+](C)(C)C,,,,,,
7170,127171,Rupestric acid,C[C@H]1CC[C@@H](C=C2[C@H]1CC[C@H]2C)C(=C)C(=O)O,,,,,,
7171,127172,Danshenxinkun D,CC1COC2=C(C1(C)CO)C(=O)C3=C(C2=O)C4=CC=CC(=C4C=C3)C,,,,,,
7172,127173,"1,3,5-Trihydroxy-2-methyl-6-methoxyanthraquinone",CC1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C(=C(C=C3)OC)O)O,,,,,,
7173,127174,"2-(6-aminopurin-9-yl)-5-(carboxymethyl)-3-hydroxy-3,3a-dihydro-2H-furo[3,2-b]furan-5-carboxylic acid",C1=C2C(C(C(O2)N3C=NC4=C(N=CN=C43)N)O)OC1(CC(=O)O)C(=O)O,,,,,,
7174,127175,"(15,22-Dihydroxy-5-methoxy-14,16-dimethyl-3-oxo-2-azabicyclo[18.3.1]tetracosa-1(23),6,8,10,16,20(24),21-heptaen-13-yl) 2-(cyclohexanecarbonylamino)propanoate",CC1C(CC=CC=CC=CC(CC(=O)NC2=CC(=CC(=C2)CCC=C(C1O)C)O)OC)OC(=O)C(C)NC(=O)C3CCCCC3,,,,,,
7175,127176,"(15,24-Dihydroxy-5,22-dimethoxy-14,16-dimethyl-3-oxo-2-azabicyclo[18.3.1]tetracosa-1(23),6,8,10,16,20(24),21-heptaen-13-yl) 2-(cyclohexanecarbonylamino)propanoate",CC1C(CC=CC=CC=CC(CC(=O)NC2=CC(=CC(=C2O)CCC=C(C1O)C)OC)OC)OC(=O)C(C)NC(=O)C3CCCCC3,,,,,,
7176,127177,CID 127177,CCC(C(=NNC1=C(C=C(C=C1Cl)Cl)Cl)C2=CC=CC=C2)N3C=CN=C3.Cl,,,,,,
7177,127178,CID 127178,CCC(C(=NNC1=C(C=C(C=C1Cl)Cl)Cl)C2=CC=CC=C2)N3C=CN=C3,,,,,,
7178,127179,CID 127179,CCCCC[C@H]1C(S1)CC=CCC=CCC=CCCCC(=O)O,,,,,,
7179,127180,Octacyclomycin,CC1CC(C(OC1C2CC(C(O2)C3(CCC(O3)C4(CCC5(O4)CC(C(C(O5)C(C)C6C(C(C(C(O6)(CC(=O)O)O)C)OC7CCC(C(O7)C)OC)OC)C)O)C)C)OC8CCC(C(O8)C)OC)(CO)O)C,,,,,,
7180,127181,CID 127181,C1C(C(=O)N(C1=O)OC(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)[O-])S(=O)(=O)O,,,,,,
7181,127182,CID 127182,C1C(C(=O)N(C1=O)OC(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)O)S(=O)(=O)O,,,,,,
7182,127183,CID 127183,C1=CC(=C(C(=C1C(=O)NC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)O)[O-])[125I])N[N+]#N,,,,,,
7183,127184,CID 127184,C1=CC(=C(C(=C1C(=O)NC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)O)O)[125I])N[N+]#N,,,,,,
7184,127185,CID 127185,C[C@@H](CC1=CC=C(C=C1)O)N=C2C3=C([N-]C(=N2)N[N+]#N)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
7185,127186,CID 127186,C[C@@H](CC1=CC=C(C=C1)O)NC2=C3C(=NC(=N2)N[N+]#N)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
7186,127187,N(6)-Hydroxymethyladenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NCO,,,,,,
7187,127188,"(1Bs,4s,7ar,7br,8r,9r)-9a-(acetyloxy)-3-[(acetyloxy)methyl]-4,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl 12-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)dodecanoate",C[C@@H]1[C@H](C2(C(C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)C4[C@@H](C(=C3)COC(=O)C)O)C)O)OC(=O)C)OC(=O)CCCCCCCCCCCNS(=O)(=O)C5=CC=CC6=C5C=CC=C6N(C)C,,,,,,
7188,127189,Atrial natriuretic factor (1-11),CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CO)N,,,,,,
7189,127190,CID 127190,C[C@@H]1[C@H](C2(C(C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)C4[C@@H](C(=C3)CO)O)C)O)O)OC(=O)CCCCCCCCCCCNS(=O)(=O)C5=CC=CC6=C5C=CC=C6N(C)C,,,,,,
7190,127191,"Enkephalinamide, gly(2)-psi-(methyleneoxy)-gly(3)-leu(5)-",CCC(C)C(C(=O)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)COCCNC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
7191,127192,"Substance P (6-11), pglu(6)-phe(8)-psi-(methyleneoxy)-gly(9)-",CCC(C)C(C(=O)NC(CCSC)C(=O)N)NC(=O)COCC(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C3CCC(=O)N3,,,,,,
7192,127193,"2-(4-Diphenylmethyl-1-piperazinyl)ethyl 5-(4,6-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate",CC1CC(OP(=O)(O1)C2=C(NC(=C(C2C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN4CCN(CC4)C(C5=CC=CC=C5)C6=CC=CC=C6)C)C)C,,,,,,
7193,127194,Nndav,CCCCC(=O)OCC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)O)C)N(C)C)O,,,,,,
7194,127195,"(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoic acid",C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)CCN3C(=O)C=CC3=O)NC(=O)N2,,,,,,
7195,127196,CID 127196,CC1=C(C(=O)NC(=O)N1)C=CC(=O)NC(CO)CS(=O)C2=CC=C(C=C2)O,,,,,,
7196,127197,Sitoindoside IV,CCCCCCCCCCCCCCCC(=O)OC1C(C(C(C(C1OCC2C(C(C(C(O2)OC3CCC4(C5CCC6(C(C5CC=C4C3)CCC6C(C)CCC(CC)C(C)C)C)C)O)O)O)O)O)O)O,,,,,,
7197,127198,Thiosultap,CN(C)C(CSS(=O)(=O)O)CSS(=O)(=O)O,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
7198,127199,"1,4,5,6,7,8-Hexahydro-3h-[1,2]oxazolo[4,3-c]azepin-3-one",C1CC2=C(CNC1)C(=O)ON2,,,,,,
7199,127200,Pyrilamine N-oxide,C[N+](C)(CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2)[O-],,,,,,
7200,127201,N-Benzyladriamycin-14-valerate,CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NCC6=CC=CC=C6)O,,,,,,
7201,127202,6-Hydroxycevan-2-yl hexopyranoside,CC1CCC2C(C3CCC4C(C3CN2C1)CC5C4CC(C6C5(CC(CC6)OC7C(C(C(C(O7)CO)O)O)O)C)O)C,,,,,,
7202,127203,6-Oxocevan-2-yl hexopyranoside,CC1CCC2C(C3CCC4C(C3CN2C1)CC5C4CC(=O)C6C5(CC(CC6)OC7C(C(C(C(O7)CO)O)O)O)C)C,,,,,,
7203,127204,"2-Pyridinecarboxylic acid, 5-(3,4-dihydroxybutyl)-",C1=CC(=NC=C1CCC(CO)O)C(=O)O,,,,,,
7204,127205,CID 127205,COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)NC(=O)CCCCCN=C4C=CC(=N[N+]#N)C=C4N(O)[O-],,,,,,
7205,127206,"[3-[3-[2,3-Di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxypropoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCCOP(=O)(O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC,,,,,,
7206,127207,"2-Bupranolol-succinyl-1,3-dipalmitoylglycerol",CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC(=O)OC(CNC(C)(C)C)COC1=C(C=CC(=C1)C)Cl.Cl,,,,,,
7207,127208,"1-O-[1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-yl] 4-O-[1,3-di(hexadecanoyloxy)propan-2-yl] butanedioate",CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC(=O)OC(CNC(C)(C)C)COC1=C(C=CC(=C1)C)Cl,,,,,,
7208,127209,2-[[4-(Hydroxyamino)-4-oxo-2-[phenyl(tritio)methyl]-2-tritiobutanoyl]amino]acetic acid,[3H]C(C1=CC=CC=C1)C([3H])(CC(=O)NO)C(=O)NCC(=O)O,,,,,,
7209,127210,7-((N-Tosylphenylalanyl)amino)-4-chloro-3-methoxyisocoumarin,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC3=CC4=C(C=C3)C(=C(OC4=O)OC)Cl,,,,,,
7210,127211,Celad,CC(C)CC(C(=O)NCCSSCCNC(=O)C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)C(C)NC(=O)C(CC2=CC=C(C=C2)O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)CNC(=O)C(C)NC(=O)C(CC4=CC=C(C=C4)O)N,,,,,,
7211,127212,CID 127212,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCCS)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7212,127213,4-[[5-Methoxy-3-(2-methoxyethyl)-2-methylinden-1-ylidene]methyl]benzenesulfonamide,CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)(=O)N)C=CC(=C2)OC)CCOC,,,,,,
7213,127214,"4-(2-((1-(4-Amino-4-methylcyclohexyl)-1-methylethyl)amino)-1-hydroxyethyl)-1,2-benzenediol",CC1(CCC(CC1)C(C)(C)NCC(C2=CC(=C(C=C2)O)O)O)N,,,,,,
7214,127215,Baamnp,CC1(CCC(CC1)C(C)(C)NCC(C2=CC(=C(C=C2)O)O)O)NC(=O)CBr.Br,,,,,,
7215,127216,"2-bromo-N-[4-[2-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]propan-2-yl]-1-methylcyclohexyl]acetamide",CC1(CCC(CC1)C(C)(C)NCC(C2=CC(=C(C=C2)O)O)O)NC(=O)CBr,,,,,,
7216,127217,"10(9H)-Acridineacetic acid, 2,7-dibromo-9-oxo-",C1=CC2=C(C=C1Br)C(=O)C3=C(N2CC(=O)O)C=CC(=C3)Br,,,,,,
7217,127218,"6-(5-bromonaphthalen-2-yl)-N-(3-methylbutan-2-yl)hexa-2,4-dienamide",CC(C)C(C)NC(=O)C=CC=CCC1=CC2=C(C=C1)C(=CC=C2)Br,,,,,,
7218,127219,Mttch,C[C@@H]1[C@@H]([C@@H]2C=CC(=O)C[C@@H]2[C@H](O1)OC)O,,,,,,
7219,127220,"[(2R,3S,4R,5R)-5-[6-amino-2-(4-bromo-2,3-dioxobutyl)sulfanylpurin-7-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=NC2=NC(=NC(=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N)SCC(=O)C(=O)CBr,,,,,,
7220,127221,MG-Pyridoxine,CC1=NC=C(C(=C1O)CO)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)CC(=O)O)O)O)O,,,,,,
7221,127222,"2,3,4,5,6-Pentahydroxycyclohexyl 6'-bromo-2,2',4,6-tetrahydroxy-6-methyl-8,8a,9,10-tetrahydro-6H-spiro[cyclopenta[e]pyrimido[4,5-b][1,4]diazepine-7,3'-indole]-8-carboxylate",CC1(C2=NC3=C(NCC2C(C14C5=C(C=C(C=C5)Br)NC4=O)C(=O)OC6C(C(C(C(C6O)O)O)O)O)NC(=O)NC3=O)O,,,,,,
7222,127223,Inositol cyclic trisphosphate,C1(C2C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)O)OP(=O)(O2)O)O,,,,,,
7223,127224,(2r)-2-(Acetyloxy)-3-(octadecyloxy)propyl 6-(trimethylammonio)hexyl phosphate,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCCCCCC[N+](C)(C)C)OC(=O)C,,,,,,
7224,127225,6-[[(2R)-2-acetyloxy-3-octadecoxypropoxy]-hydroxyphosphoryl]oxyhexyl-trimethylazanium,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCCCCCC[N+](C)(C)C)OC(=O)C,,,,,,
7225,127226,2-(Acetyloxy)-3-(octadecyloxy)propyl 10-(trimethylazaniumyl)decyl phosphate,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCCCCCCCCCC[N+](C)(C)C)OC(=O)C,,,,,,
7226,127227,10-[[(2R)-2-acetyloxy-3-octadecoxypropoxy]-hydroxyphosphoryl]oxydecyl-trimethylazanium,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCCCCCCCCCC[N+](C)(C)C)OC(=O)C,,,,,,
7227,127228,"3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-6,10,14,18,22,26,30,34,38-nonaenyl dihydrogen phosphate",CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCOP(=O)(O)O,,,,,,
7228,127229,"1H-Imidazole, 1-(2-chloroethyl)-2-(chloromethyl)-4,5-dihydro-, monohydrochloride",C1CN(C(=N1)CCl)CCCl.Cl,,,,,,
7229,127230,"1-(2-Chloroethyl)-2-(chloromethyl)-4,5-dihydro-1H-imidazole",C1CN(C(=N1)CCl)CCCl,,,,,,
7230,127231,"5-Aminomethylene-1,3-dibutylbarbituric acid",CCCCN1C(=C(C(=O)N(C1=O)CCCC)C=N)O,,,,,,
7231,127232,2-Methyl-6-(4-methylcyclohex-3-en-1-ylidene)hept-2-en-1-ol,CC1=CCC(=C(C)CCC=C(C)CO)CC1,,,,,,
7232,127233,Norethisterone acetate 3-cyclopentylpropionate,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4C3[C@H](C=CC4)OC(=O)CCC5CCCC5)C)C#C,,,,,,
7233,127234,Kushenol E,CC(=CCC1=C(C(=C2C(=C1O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)CC=C(C)C)O)C,,,,,,
7234,127235,"2,3-Diethyl-4-methoxynaphthalen-1-yl acetate",CCC1=C(C2=CC=CC=C2C(=C1CC)OC(=O)C)OC,,,,,,
7235,127236,"1,4-Benzenediamine, 2-(bis(4-chlorophenyl)methyl)-N4-(3-(bis(4-chlorophenyl)methyl)-4-(dimethylamino)phenyl)-N1,N1-dimethyl-",CN(C)C1=C(C=C(C=C1)NC2=CC(=C(C=C2)N(C)C)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)C(C5=CC=C(C=C5)Cl)C6=CC=C(C=C6)Cl,,,,,,
7236,127237,(2S)-2-Amino-6-[(3-oxoprop-1-en-1-yl)amino]hexanoic acid,C(CCNC=CC=O)C[C@@H](C(=O)O)N,,,,,,
7237,127238,Pameton,CC(=O)NC1=CC=C(C=C1)O.CSCC[C@@H](C(=O)O)N,,,,,,
7238,127239,N-Ethylmaleimide-cysteinyl-glycine,CCN1C(=O)C=C(C1=O)SC[C@@H](C(=O)NCC(=O)O)N,,,,,,
7239,127240,CID 127240,CCC1C2=CC3=C(C(=C(N3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C6=CC(=C(O)OCC)C1(C6=N2)CC)CC)CC)CC)CC)CC)CC,,,,,,
7240,127241,CID 127241,C(=C(C#N)OP(=O)(O)O)C(=O)O,,,,,,
7241,127242,3'-Desamino-3'-dimethylformamidine rubomycin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N=CN(C)C)O,,,,,,
7242,127243,CID 127243,CCCCCCCCCCCCCCCCCCNC(=O)C1=C(C(=CC=C1)N[N+]#N)[O-],,,,,,
7243,127244,CID 127244,CCCCCCCCCCCCCCCCCCNC(=O)C1=C(C(=CC=C1)N[N+]#N)O,,,,,,
7244,127245,"(1S,9S)-10-(3-Fluoropropyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol",CC1[C@@H]2CC3=C([C@]1(CCN2CCCF)C)C=C(C=C3)O,,,,,,
7245,127246,"6-[1-[2-(Hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5-benzofuranol",C1COC2=CC(=C(C=C21)O)CC=CC3=CC=CC=C3CO,,,,,,
7246,127247,2-[4-(Butan-2-yl)phenyl]propanenitrile,CCC(C)C1=CC=C(C=C1)C(C)C#N,,,,,,
7247,127248,Formadicin,C1C(C(=O)N1C(C2=CC=C(C=C2)OC3C(C(C(C(O3)C(=O)O)O)O)O)C(=O)O)(NC=O)NC(=O)C(C4=CC=C(C=C4)OCCC(C(=O)O)N)O,,,,,,
7248,127249,N-(N-Acetylvalyl)-N-nitrosoglycine,CC(C)[C@H](C(=O)N(CC(=O)O)N=O)NC(=O)C,,,,,,
7249,127250,CID 127250,C1NC2=C(N=CN=C2N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)OC(=O)C(CS)N)O)O)O)O)N,,,,,,
7250,127251,(n-Octanoylthio)phosphatidylcholine,CCCCCCCC(=O)SCCOP(=O)([O-])OCC[N+](C)(C)C,,,,,,
7251,127252,2-[Hydroxy(2-octanoylsulfanylethoxy)phosphoryl]oxyethyl-trimethylazanium,CCCCCCCC(=O)SCCOP(=O)(O)OCC[N+](C)(C)C,,,,,,
7252,127253,11-Pstmac,CC(=O)[C@H]1CC[C@@H]2[C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)OC(=O)CCC(=O)NCCC5=CC=C(C=C5)OC(=O)C6=C7C=CC=CC7=NC8=CC=CC=C86)C,,,,,,
7253,127254,"5-Pregnen-3,20-diol glucopyranoside",CC(C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)OC5C(C(C(C(O5)CO)O)O)O,,,,,,
7254,127255,CID 127255,CC(C)NC1CNCC(N1)C(=N)S,,,,,,
7255,127256,15-Hexadecynoic acid,C#CCCCCCCCCCCCCCC(=O)O,,,,,,
7256,127257,N(1)-Nitroso-3-nitromethylindole,C1=CC=C2C(=C1)C(=CN2N=O)C[N+](=O)[O-],,,,,,
7257,127258,"4-(((1,3-Benzodioxol)-5-yl)methyl)aminobenzoic acid",C1C(=O)C2=C(C1=O)C=C(C=C2)CNC3=CC=C(C=C3)C(=O)O,,,,,,
7258,127259,Mannose 6-sulfate,C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)OS(=O)(=O)O,,,,,,
7259,127260,Caesalpin J,COC1C2(CC3=CC(=C(C=C3C14C=CC(=O)C=C4OC2)O)O)O,,,,,,
7260,127261,"1-[2,4-Dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one",CC(=CCC1=CC(=C(C=C1O)O)C(=O)C=CC2=CC(=C(C=C2)O)O)C,,,,,,
7261,127262,"2,3,4,5-Tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol",CN1CCC2=C(C=C(C=C2)O)C(C1)C3=CC=CC=C3,,,,,,
7262,127263,Glycyl-prolyl-arginyl-valyl-valyl-glutamic acid,CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)CN,,,,,,
7263,127264,N-Methylstreptothricin F,CN1CC(C2C(C1=O)N=C(N2)NC3C(C(C(C(O3)CO)OC(=O)N)O)NC(=O)CC(CCCN)N)O,,,,,,
7264,127265,Epoxykidamycin,CC1C(C(CC(O1)C2=C3C(=C(C=C2C4CC(C(C(O4)C)O)(C)N(C)C)O)C(=O)C5=C(C3=O)C=C(C6=C5OC(=CC6=O)C7(C(O7)C)C)C)N(C)C)O,,,,,,
7265,127266,"Methyl 2,6-bis(benzyloxycarbonylamino)-2,3,4,6,7-pentadeoxy-beta-lyxo-heptopyranoside",C[C@@H]([C@@H]1CC[C@H]([C@H](O1)OC)NC(=O)OCC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
7266,127267,Stlpn,CCC(C)[C@H](C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)CCC(=O)O,,,,,,
7267,127268,3-c-(Hydroxymethyl)pentose,C(C(C(CO)(C(C=O)O)O)O)O,,,,,,
7268,127269,"N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[5-methoxy-2-(2-phenylethynyl)phenyl]-N-methylbutan-2-amine",CC(CCC1=C(C=CC(=C1)OC)C#CC2=CC=CC=C2)N(C)CCC3=CC(=C(C=C3)OC)OC,,,,,,
7269,127270,2-Fluoro-2-deoxy-6-phosphogluconate,C([C@H]([C@H]([C@@H]([C@H](C(=O)O)F)O)O)O)OP(=O)(O)O,,,,,,
7270,127271,Saquayamycin,CC1C(CCC(O1)OC2(CC(=O)C3(C4=C(C=CC3(C2)O)C(=O)C5=C(C4=O)C=CC(=C5O)C6CC(C(C(O6)C)OC7C=CC(=O)C(O7)C)O)O)C)OC8C=CC(=O)C(O8)C,,,,,,
7271,127272,Saquayamycin B,CC1C(CCC(O1)OC2(CC(=O)C3(C4=C(C=CC3(C2)O)C(=O)C5=C(C4=O)C=CC(=C5O)C6CC7C(C(O6)C)OC8C(O7)CC(=O)C(O8)C)O)C)OC9C=CC(=O)C(O9)C,,,,,,
7272,127273,Saquayamycin C,CC1C(CCC(O1)OC2(CC(=O)C3(C4=C(C=CC3(C2)O)C(=O)C5=C(C4=O)C=CC(=C5O)C6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)O)C)OC8CCC(=O)C(O8)C,,,,,,
7273,127274,Saquayamycin D,CC1C(CCC(O1)OC2(CC(=O)C3(C4=C(C=CC3(C2)O)C(=O)C5=C(C4=O)C=CC(=C5O)C6CC7C(C(O6)C)OC8C(O7)CC(=O)C(O8)C)O)C)OC9CCC(=O)C(O9)C,,,,,,
7274,127275,"6,11-Dihydroxy-8-(1-hydroxyethyl)-1-methoxytetracene-5,12-dione",CC(C1=CC2=C(C=C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C(=CC=C4)OC)O)O,,,,,,
7275,127276,"N-[3-(4-aminobutylamino)propyl]-3-[4-[5-[[3-(carbamoylamino)-4,5-dihydroxyoxan-2-yl]carbamoylamino]-3-(diaminomethylideneamino)-4-hydroxy-6-methyloxan-2-yl]oxyphenyl]prop-2-enamide",CC1C(C(C(C(O1)OC2=CC=C(C=C2)C=CC(=O)NCCCNCCCCN)N=C(N)N)O)NC(=O)NC3C(C(C(CO3)O)O)NC(=O)N,,,,,,
7276,127277,"15-Hydroxy-2-(6-hydroxy-3,7-dimethyldeca-1,7,9-trienyl)-5,10,14,16,18-pentamethyl-1-oxa-9-azacyclononadec-17-ene-6,8,13,19-tetrone",CC1CCC(OC(=O)C(=CC(C(C(C(=O)CCC(NC(=O)CC1=O)C)C)O)C)C)C=CC(C)CCC(C(=CC=C)C)O,,,,,,
7277,127278,CID 127278,C1=CC=C(C(=C1)C(=NN=C(C2=CC=CO2)S)[O-])[O-].[Cu+2],,,,,,
7278,127279,CID 127279,C1=CC=C(C(=C1)C(=O)NN=C(C2=CC=CO2)S)O,,,,,,
7279,127280,Gsk peptide,C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1)O,,,,,,
7280,127281,"1,2-Cyclohexanedicarboxamide, N,N-dicyclohexyl-N',N'-bis(2-methylpropyl)-, cis-",CCC(C)N(C(C)CC)C(=O)[C@H]1CCCC[C@H]1C(=O)N(C2CCCCC2)C3CCCCC3,,,,,,
7281,127282,CID 127282,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCCCC(=O)O)O2)O)O,,,,,,
7282,127283,(N-Piperidinomethyl)-2-chroman,C1CCN(CC1)CC2CCC3=CC=CC=C3O2,,,,,,
7283,127284,CID 127284,CC(C)OC(=O)C(=C(S)S[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)C(=O)O)O)O)O)C(=O)OC(C)C,,,,,,
7284,127285,"Benzeneethanamine, 4-amino-3,5-dichloro-N-(1,1-dimethylethyl)-beta-(((1,2-dimethylpropyl)dimethylsilyl)oxy)-",CC(C)C(C)[Si](C)(C)OC(CNC(C)(C)C)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
7285,127286,"N-[3-hydroxy-2-methyl-6-[[3,5,12-trihydroxy-3-(1-hydroxyethyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]acetamide",CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(C)O)O)NC(=O)C)O,,,,,,
7286,127287,CID 127287,CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC=CCC=CCC=CCC=CCC=CCC=CCC,,,,,,
7287,127288,CID 127288,CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCC=CCC=CCC=CCC=CCC=CCC=CCC,,,,,,
7288,127289,"6,7-Dimethoxy-2-(4-thiomorpholinyl)-4-quinazolinamine",COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCSCC3)N)OC,,,,,,
7289,127290,CID 127290,C1CN2C(CN(CS2(=O)=O)C(C3=CC=CC=C3)O)C4=CC=CC=C41,,,,,,
7290,127291,CID 127291,CC1CCC2C(CC(=O)CC2C13CC(OC3=O)C4=CC(=O)OC4O)C,,,,,,
7291,127292,CID 127292,CC1CCC2C(C13CC(OC3=O)C4=CC(OC4O)O)CC(=O)C=C2C,,,,,,
7292,127293,3-Oxo-octanoic acid (2-oxo-tetrahydro-furan-3-YL)-amide,CCCCCC(=O)CC(=O)N[C@H]1CCOC1=O,,,,,,
7293,127294,CID 127294,C1=CC=C(C=C1)COC2=CC=C(C=C2)C3NN(C(=O)O3)CCC#N,,,,,,
7294,127295,Repandiol,C(C1C(O1)C#CC#CC2C(O2)CO)O,,,,,,
7295,127296,1-Diphosinositol pentakisphosphate,[C@H]1([C@H](C([C@@H]([C@@H](C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,,,,,,
7296,127297,"Bis(1,4)-diphosphoinositol tetrakisphosphate",[C@H]1([C@H](C([C@H]([C@H](C1OP(=O)(O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,,,,,,
7297,127298,4-Deoxysiastatin B,CC(=O)N[C@@H]1[C@H](C[C@H](CN1)C(=O)O)O,,,,,,
7298,127299,N(alpha)-(2-Methyl-4-oxocyclopentanecarbonyl)-L-histidyl-L-prolinamide,C[C@@H]1CC(=O)C[C@@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,,,,,,
7299,127300,5a-Cdiman-mannopyranose,C1C(C(C(C(C1O)O)OC2C(C(C(C(O2)CO)O)O)O)O)COC3C(C(C(C(O3)CO)O)O)O,,,,,,
7300,127301,CID 127301,C1CC(=O)N(C1)CC(=O)CN2CCN(CC2)C3=CC=CC=C3,,,,,,
7301,127302,CID 127302,CC=CC=CC=CC=CCCCCCCCCO,,,,,,
7302,127303,5-N-Acetylardeemin,C[C@@H]1C(=O)N2[C@@H](C[C@@]3([C@H]2N(C4=CC=CC=C43)C(=O)C)C(C)(C)C=C)C5=NC6=CC=CC=C6C(=O)N15,,,,,,
7303,127304,CID 127304,C1CCC(CC1)C2CCN(CC2)[C@H]3CN(CC[C@@H]3O)CC4=CC(=CC=C4)I,,,,,,
7304,127305,4-Perfluoro-tert-butyl-phenyliodoacetamide,C1=CC(=CC=C1C(C(F)(F)F)(C(F)(F)F)C(F)(F)F)NC(=O)CI,,,,,,
7305,127306,2-fluoro-5-hydroxy-L-phenylalanine,C1=CC(=C(C=C1O)C[C@@H](C(=O)O)N)F,,,,,,
7306,127307,6-Amino-2-((4-butylphenyl)amino)-9H-purine,CCCCC1=CC=C(C=C1)NC2=NC(=C3C(=N2)N=CN3)N,,,,,,
7307,127308,Buadatp,CCCCC1=CC=C(C=C1)NC2=NC(=C3C(=N2)N(C=N3)[C@H]4C[C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)N,,,['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)'],,,
7308,127309,"(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-[(2R,3S,4R,5R,6R)-6-[(2R,3S,4R,5R,6R)-6-[(2R,3S,4R,5R,6S)-6-(2-chloro-4-nitrophenoxy)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C1=CC(=C(C=C1[N+](=O)[O-])Cl)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)O)O)O)O)O,,,,,,
7309,127310,CID 127310,C1=CC(=O)NC1=CC2=CC(=C(N2)CC3=C(C=C(N3)C=C4C=CC(=O)N4)CCNC(=O)CCS(=O)(=O)O)CCC(=O)NCCS(=O)(=O)O.[Na+].[Na+],,,,,,
7310,127311,CID 127311,C1=CC(=O)NC1=CC2=CC(=C(N2)CC3=C(C=C(N3)C=C4C=CC(=O)N4)CCNC(=O)CCS(=O)(=O)O)CCC(=O)NCCS(=O)(=O)O,,,,,,
7311,127312,M-bromoacetyldistamycin,CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CC=C(N3C)C(=O)NCCCN)C)NC(=O)CBr,,,,,,
7312,127313,CID 127313,CC1=C(C=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)OC(=O)CCN=C3C=CC(=N[N+]#N)C=C3N(O)[O-],,,,,,
7313,127314,Gal(1-4)galnac(1-6)gal,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)CO)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O,,,,,,
7314,127315,3-Chlorofluocinolone acetonide 21-acetate,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CC(=C5[C@@]4(C=CC(=C5)Cl)C)F)F)O)C)OC(O2)(C)C,,,,,,
7315,127316,"3-Hydroxy-7,8-dihydro-7,8-dihydroxybenzo(a)pyrene",C1=CC2=C(C=C3C=CC4=C(C=CC5=C4C3=C2C=C5)O)[C@H]([C@@H]1O)O,,,,,,
7316,127317,"N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxybenzamide",C[C@@H]1CCC[C@H]2N1CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3O)N)Cl,,,,,,
7317,127318,CID 127318,CCOC1=C(C=C(C=C1)C=C2CC3=CC(=C(C=C3CN2)OCC)OCC)OCC.C1=CC(=CN=C1)C(=O)O.Cl,,,,,,
7318,127319,CID 127319,CCOC1=C(C=C(C=C1)C=C2CC3=CC(=C(C=C3CN2)OCC)OCC)OCC,,,,,,
7319,127320,"[7-Methoxy-12-methyl-10,13-dioxo-11-[4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanilino]-2,4-diazatetracyclo[7.4.0.02,7.03,5]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3C4C(N4)CC3(C2COC(=O)N)OC)NC5=CC=C(C=C5)OC6C(C(C(C(O6)CO)O)O)O,,,,,,
7320,127321,Spirocardin A,CC1C(C(=O)C2(C(C1(C)CC3C4(CO4)C(C(O3)O)O)CCC=C2C)C)O,,,,,,
7321,127322,Spirocardin B,CC1C(C(=O)C2(C(C1(C)CC(C3(CO3)C(CO)O)O)CCC=C2C)C)O,,,,,,
7322,127323,"8'-Chloro-2',3'-dihydrospiro(pyrrolidine-3,6'(5'H)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione",C1COC2=CC(=CC3=C2N1C(=O)C34CC(=O)NC4=O)Cl,,,,,,
7323,127324,"3,5-Dicarbomethoxy-3'-carboxymethyl-4'-hydroxyazobenzene",COC(=O)C1=CC(=CC(=C1)N=NC2=CC(=C(C=C2)O)CC(=O)O)C(=O)OC,,,,,,
7324,127325,Ethyl 2-(3-chloropyrazin-2-yl)-2-cyanoacetate,CCOC(=O)C(C#N)C1=NC=CN=C1Cl,,,,,,
7325,127326,CID 127326,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCC(=CC=C3C[C@H](CCC3=C)OS(=O)(=O)O)C2)C,,,,,,
7326,127327,"3-(Dimethylamino)-2,2-dimethyl-7-hydroxy-1-tetralone",CC1(C(CC2=C(C1=O)C=C(C=C2)O)N(C)C)C,,,,,,
7327,127328,Dppaaoe,CC1=C(SC=[N+]1CC2=CN=C(NC2=O)C)CCOC(=O)CC3(C4=CC=CC=C4C(O3)(C)C)C5=CC=CC=C5,,,,,,
7328,127329,"3-(beta-Phenylethyl)-9beta-methoxy-9alpha-(m-propionoxyphenyl)-3-azabicyclo(3,3,1)nonane",CCC(=O)OC1=CC=CC(=C1)C2(C3CCCC2CN(C3)CCC4=CC=CC=C4)OC,,,,,,
7329,127330,1-Benzamido-1-methoxycarbonyl-2-chlorocyclopropane,COC(=O)[C@]1(C[C@H]1Cl)NC(=O)C2=CC=CC=C2,,,,,,
7330,127331,CID 127331,CC1C(N(C2=C(N1)NC(=NC2=O)N)C=O)C(C)NC3=CC=C(C=C3)CC(C(C(COC4C(C(C(O4)COP(=O)(O)OC(CCC(=O)O)C(=O)O)O)O)O)O)O,,,,,,
7331,127332,N(alpha)-Tosylglycyl-4-amidinophenylalanine piperidide,CC1=CC=C(C=C1)S(=O)(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)C(=N)N)C(=O)N3CCCCC3,,,,,,
7332,127333,"5,12-Naphthacenedione, 9-acetyl-7,9-bis((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, dihydrochloride, (7S-cis)-",CC1C(C(CC(O1)OC2CC3=C(CC2(C(=O)C)OC4CC(C(C(O4)C)O)N)C(=C5C(=C3O)C(=O)C6=CC=CC=C6C5=O)O)N)O.Cl.Cl,,,,,,
7333,127334,"9-acetyl-8,9-bis[(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy]-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1C(C(CC(O1)OC2CC3=C(CC2(C(=O)C)OC4CC(C(C(O4)C)O)N)C(=C5C(=C3O)C(=O)C6=CC=CC=C6C5=O)O)N)O,,,,,,
7334,127335,7-Amino-3-benzyloxycarbonylamino-1-chloroheptan-2-one,C1=CC=C(C=C1)COC(=O)NC(CCCCN)C(=O)CCl,,,,,,
7335,127336,1-[(2-Hydroxyethyl)amino]-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol,C1=CN(C(=N1)[N+](=O)[O-])CC(CNCCO)O,,,,,,
7336,127337,CID 127337,CCC(C)N(CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)O)C(C)CC.C(=CC(=O)O)C(=O)O,,,,,,
7337,127338,"4-[Di(butan-2-yl)amino]-1,1-diphenylbutan-1-ol",CCC(C)N(CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)O)C(C)CC,,,,,,
7338,127339,CID 127339,CCC(C)NCCCC(C1=CC=CC=C1)(C2=CC=CC=C2)O.C(=CC(=O)O)C(=O)O,,,,,,
7339,127340,"4-(Butan-2-ylamino)-1,1-diphenylbutan-1-ol",CCC(C)NCCCC(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7340,127341,5'-Tma-thc,CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)CCCCC[N+](C)(C)C)O,,,,,,
7341,127342,7-(Pyridin-3-yl)quinolin-2-ol,C1=CC(=CN=C1)C2=CC3=C(C=C2)C=CC(=O)N3,,,,,,
7342,127343,CID 127343,CC1(C2CC1C(C(C2)NCC(CC3=CC=C(C=C3)OC)O)CC=CCCCC(=O)O)C,,,,,,
7343,127344,CID 127344,C[C@H](C(=O)O)OC(=O)C=CC1=CC=C(C=C1)Cl,,,,,,
7344,127345,"L-Methionine, N-(1-carboxyethyl)-",CC(C(=O)O)N[C@H](CCSC)C(=O)O,,,,,,
7345,127346,CID 127346,CCCCCCCCCCCCCCCC=CC(C(COC1C(C(C(C(O1)CO)OC2C3C(C(C(O2)CO)O)OC4(CC(C(C(O4)C(C(CO)O)O)NC(=O)C)O)C(=O)O3)O)O)NC(=O)CCCCCCCC=CCCCCCCCC)O,,,,,,
7346,127347,"2-[5-[3-(2,4-Dichlorophenyl)prop-2-enoyl]-2-hydroxyphenyl]acetic acid",C1=CC(=C(C=C1C(=O)C=CC2=C(C=C(C=C2)Cl)Cl)CC(=O)O)O,,,,,,
7347,127348,"[5-(3,5-Dichlorobenzoyl)-2-hydroxyphenyl]acetic acid",C1=CC(=C(C=C1C(=O)C2=CC(=CC(=C2)Cl)Cl)CC(=O)O)O,,,,,,
7348,127349,"11-(4,5-Dihydroxy-6-methyloxan-2-yl)oxy-1,7-dihydroxy-6,8,16,18-tetramethyl-5-[4-(3-methyl-3-propanoyloxiran-2-yl)pentan-2-yl]-4,21-dioxabicyclo[15.3.1]henicosa-9,15,18-trien-3-one",CCC(=O)C1(C(O1)C(C)CC(C)C2C(C(C(C=CC(CCCC=C(C3C(=CCC(O3)(CC(=O)O2)O)C)C)OC4CC(C(C(O4)C)O)O)C)O)C)C,,,,,,
7349,127350,CID 127350,COC1=CC=C(C=C1)C2=C(C(=C3C(=CC(=C(C3=O)O)OC)O2)O)O,,,,,,
7350,127351,CID 127351,COC1=C(C=C(C=C1)C2=C(C(=C3C(=CC(=C(C3=O)O)OC)O2)O)O)OC,,,,,,
7351,127352,"4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-((chlorocarbonyl)oxy)-3a,4,7,7a-tetrahydro-",C1C2C=CC1C3C2C(=O)N(C3=O)OC(=O)Cl,,,,,,
7352,127353,CID 127353,C1[C@@H]([C@H](O[C@H]1N2C3=C(C(=O)N=C(N3)N)N=C2NC4=CC5=C(C=C4)C6=CC=CC=C6C=C5)CO)O,,,,,,
7353,127354,CID 127354,C[C@H](CCCC(C)C)[C@@H]1CC[C@H]2[C@@]1(CC[C@@H]3[C@H]2CC=C4[C@]3(CC[C@@H](C4)OC(=O)[C@H](C)NC(=O)CC[C@@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](C)O[C@H]([C@@H](C=O)NC(=O)C)[C@H]([C@H](O)OC)O)C)C,,,,,,
7354,127355,Edadg,C1=CC2=C(C(=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)CO)C=C(C=C4O)CO,,,,,,
7355,127356,"3,7,11,15,18,22,26,30-Octamethyldotriacontane-1,32-diol",C[C@@H](CCC[C@@H](C)CCC[C@@H](C)CCO)CCC[C@H](C)CC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCO,,,,,,
7356,127357,CID 127357,C[C@@]12C(C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
7357,127358,"1,1,1-Trifluoro-3-((4-mercaptobutyl)thio)-2-propanone",C(CCSCC(=O)C(F)(F)F)CS,,,,,,
7358,127359,"2-Propanone, 3-((4-butylphenyl)thio)-1,1,1-trifluoro-",CCCCC1=CC=C(C=C1)SCC(=O)C(F)(F)F,,,,,,
7359,127360,2-(2-Hydroxy-3-{[1-(5-hydroxy-1h-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile,CC(C)(CC1=CNC2=C1C=C(C=C2)O)NCC(COC3=CC=CC=C3C#N)O,,,,,,
7360,127361,"35-Aminobacteriohopane-30,31,32,33,34-pentol",C[C@@H]([C@H]1CC[C@]2([C@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCCC5(C)C)C)C)C)C)[C@H]([C@H]([C@H]([C@H]([C@H](CN)O)O)O)O)O,,,,,,
7361,127362,Ambhp,C[C@H]1CC[C@@]2([C@H]3CC[C@@H]4[C@]5(CC[C@@H]([C@@H]5CC[C@]4([C@@]3(CC[C@H]2C1(C)C)C)C)[C@H](C)[C@H]([C@H]([C@H]([C@H]([C@H](CN)O)O)O)O)O)C)C,,,,,,
7362,127363,Bipinnatin B,CC1=C2C(C(CC(C34C(O3)C(CC5(C(O5)C(=C1)O2)C)OC4=O)OC(=O)C)C(=C)C=O)OC(=O)C,,,,,,
7363,127364,6-Dfcmh,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](OC([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CF)CO)O)O)O,,,,,,
7364,127365,Mpoe cholesterol,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OCCOC)C)C,,,['Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)'],,,
7365,127366,CID 127366,CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-],,,,,,
7366,127367,CID 127367,C[C@@H](C=C[C@@H]1[C@H]([C@H](CC1=O)O)CC=CCCCC(=O)O)O,,,,,,
7367,127368,H-Pro-Val-Lys-Val-Tyr-Pro-OH,CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@@H]3CCCN3,,,,,,
7368,127369,"Acetic acid, 2-[[(1r,2r,3as,9as)-1-[(3r)-3-cyclohexyl-3-hydroxypropyl]-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1h-benz[f]inden-5-yl]oxy]-",C1CCC(CC1)[C@@H](CC[C@H]2[C@@H](C[C@H]3[C@@H]2CC4=C(C3)C(=CC=C4)OCC(=O)O)O)O,,,,,,
7369,127370,N2-Succinyl-L-ornithine,C(C[C@@H](C(=O)O)NC(=O)CCC(=O)O)CN,,,,,,
7370,127371,"Diethyl 3,12-bis(2-ethoxy-2-oxoethyl)-6,9-dioxa-3,12-diazatetradecanedioate",CCOC(=O)CN(CCOCCOCCN(CC(=O)OCC)CC(=O)OCC)CC(=O)OCC,,,,,,
7371,127372,"Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione, 2,3-dihydro-6-chloro-2,2-dimethyl-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-",CC1(CC2(C3=C(O1)C=CC(=C3)Cl)C(=O)N(C(=O)N2)CCCN4CCC(CC4)O)C,,,,,,
7372,127373,"[(2R,7R,9R,10R)-10-acetyloxy-3-hydroxy-1,5-dimethyl-4-oxospiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl]methyl acetate",CC1=C[C@@H]2[C@](C(C1=O)O)(C3(C[C@H]([C@H](C34CO4)O2)OC(=O)C)C)COC(=O)C,,,,,,
7373,127374,2-(2-Thienyl)allylamine,C=C(CN)C1=CC=CS1,,,,,,
7374,127375,CID 127375,C[C@]12CCC3[C@H]([C@@H]1CC[C@]2(C=C[125I])O)CCC4=CC(=O)CC[C@H]34,,,,,,
7375,127376,Clarkeanidine,COC1=C(C2=C(CCN3[C@H]2CC4=C(C3)C(=C(C=C4)OC)O)C=C1)O,,,,,,
7376,127377,Eatuo,CC(C)[C@H]1[C@H]2[C@@H]3CC[C@]4([C@@]3([C@@H]([C@@H]1OC2=O)N(C4=O)C)C)O,,,,,,
7377,127378,CID 127378,C1CN=C([N-]1)NC2=C(C=C(C=C2Cl)N[N+]#N)Cl,,,,,,
7378,127379,CID 127379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N[N+]#N)Cl,,,,,,
7379,127380,"(2S,3R,7R,9R,11R)-1,2,5-Trimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-3,11-diol",CC1=C[C@@H]2[C@]([C@@H](C1)O)(C3([C@@H](C[C@H](C34CO4)O2)O)C)C,,,,,,
7380,127381,Paeonimetabolin I,CC1C2CC3(C(CC2=O)(OC1O3)C)O,,,,,,
7381,127382,"Tert-butyl 5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate",CC(C)(C)OC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CS3)C,,,,,,
7382,127383,(2S)-2-amino-5-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxopentanoic acid,C1=CC(=CC=C1C(CNC(=O)CC[C@@H](C(=O)O)N)O)O,,,,,,
7383,127384,"(3,3'-Bimorpholine)-2,2'-dione, 5,5'-bis(hydroxymethyl)-3,3',5,5'-tetramethyl-",CC1(COC(=O)C(N1)(C)C2(C(=O)OCC(N2)(C)CO)C)CO,,,,,,
7384,127385,CID 127385,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)CO)OP(=O)(O)OCC4[C@H](C[C@@H](O4)N5C=C(C(=NC5=O)N)Br)O,,,,,,
7385,127386,"3-{7-[2-Ethoxy-3-(hexadecyloxy)propoxy]heptyl}-1,3-thiazol-3-ium methanesulfonate",CCCCCCCCCCCCCCCCOCC(COCCCCCCC[N+]1=CSC=C1)OCC.CS(=O)(=O)[O-],,,,,,
7386,127387,"3-[7-(2-Ethoxy-3-hexadecoxypropoxy)heptyl]-1,3-thiazol-3-ium",CCCCCCCCCCCCCCCCOCC(COCCCCCCC[N+]1=CSC=C1)OCC,,,,,,
7387,127388,"10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide",CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(C(C)O)C(=O)N,,,,,,
7388,127389,CID 127389,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC(COC(=O)CCCC=CCC=CCC=CCC=CCC=CCC)OC(=O)CCCC=CCC=CCC=CCC=CCC=CCC,,,,,,
7389,127390,"1-[Bis(4-fluorophenyl)methyl]-4-[3-(3,4-dimethoxyphenyl)prop-2-enyl]piperazine;dihydrochloride",COC1=C(C=C(C=C1)C=CCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC.Cl.Cl,,,,,,
7390,127391,"1-[Bis(4-fluorophenyl)methyl]-4-[3-(3,4-dimethoxyphenyl)-2-propenyl]piperazine Dihydrochloride",COC1=C(C=C(C=C1)C=CCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC,,,,,,
7391,127392,"6-Ethoxycarbonyl-5,7-dimethyl-1-(3-(4-phenethyl-1-piperazinyl)propyl)-3-(alpha,alpha,alpha-trifluoro-2-tolyl)-2,4(1H,3H)-quinazolinedione dihydrochloride",CCOC(=O)C1=C(C2=C(C=C1C)N(C(=O)N(C2=O)C3=CC=CC=C3C(F)(F)F)CCCN4CCN(CC4)CCC5=CC=CC=C5)C.Cl.Cl,,,,,,
7392,127393,"Ethyl 5,7-dimethyl-2,4-dioxo-1-[3-[4-(2-phenylethyl)piperazin-1-yl]propyl]-3-[2-(trifluoromethyl)phenyl]quinazoline-6-carboxylate",CCOC(=O)C1=C(C2=C(C=C1C)N(C(=O)N(C2=O)C3=CC=CC=C3C(F)(F)F)CCCN4CCN(CC4)CCC5=CC=CC=C5)C,,,,,,
7393,127394,Isofenphos-methyl,CC(C)NP(=S)(OC)OC1=CC=CC=C1C(=O)OC(C)C,,,,,,
7394,127395,(4-methyl-2-oxochromen-7-yl) (2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoate,CC1=CC(=O)OC2=C1C=CC(=C2)OC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4,,,,,,
7395,127396,"1H-Tetrazole-5-carboxamide, N-(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenyl)-",CC(C)C1=C(C=CC(=C1O)C(=O)C)OCCCOC2=CC=C(C=C2)NC(=O)C3=NNN=N3,,,,,,
7396,127397,"Barbituric acid, 1-allyl-5-ethyl-5-(1-methylbutyl)-",CCCC(C)C1(C(=O)NC(=O)N(C1=O)CC=C)CC,,,,,,
7397,127398,"2-(Hexadecanoyloxy)-3-[(hydroxy{2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethoxy}phosphoryl)oxy]propyl hexadecanoate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC1=CC=C(C2=NON=C12)[N+](=O)[O-])OC(=O)CCCCCCCCCCCCCCC,,,,,,
7398,127399,4-Chloro-6-methoxy-2-hydroxy-1-nitroso-indolin-3-one oxime,COC1=CC2=C(C(=C1)Cl)C(=NO)C(N2N=O)O,,,,,,
7399,127400,Somatostatin RC 102,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(C(C)O)C(=O)N)O,,,,,,
7400,127401,CID 127401,CC1(CC(=C(C(=NN=C(N)S)C1)N=O)NO)C,,,,,,
7401,127402,"Sulfamoyl chloride, dicyclohexyl-",C1CCC(CC1)N(C2CCCCC2)S(=O)(=O)Cl,,,,,,
7402,127403,Isamoltane,CC(C)NCC(COC1=CC=CC=C1N2C=CC=C2)O.Cl,,,"['Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Antagonists.)']",,,
7403,127404,Isamoltan,CC(C)NCC(COC1=CC=CC=C1N2C=CC=C2)O,,,"['Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Antagonists.)']",,,
7404,127405,LL-D49194beta2,CC1C(C(CC(O1)OC2CC(C(=O)C3=C(C4=C(C=C(C5=C4OC6(C7C5OC(C68CO8)(O7)C(OC)OC9CC(C(C(O9)C)OC1CC(C(C(O1)C)O)(C)O)(C)O)OC)C)C(=C23)OC)O)O)(C)O)O,,,,,,
7405,127406,"3,4,5-Tri-O-galloylquinic acid",C1[C@H](C([C@@H](CC1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,,,,,,
7406,127407,"1-[[9-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]-7,12-dimethyl-1,2,3,4-tetrahydrobenzo[a]anthracene-2,3,4-triol",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C(C(C(C3O)O)O)NC5=C6C(=NC=N5)N(C=N6)C7C[C@@H]([C@H](O7)CO)O,,,,,,
7407,127408,CID 127408,C1C2[C@H]([C@H]([C@@H](O2)N3C4=C(C(=NC(=N4)N)[O-])N=C3N[N+]#N)O)OP(=O)(O1)O,,,,,,
7408,127409,CID 127409,C1C2[C@H]([C@H]([C@@H](O2)N3C4=C(C(=O)N=C(N4)N)N=C3N[N+]#N)O)OP(=O)(O1)O,,,,,,
7409,127410,LL-D49194alpha1,CC1C(C(CC(O1)OC2C(OC(CC2(C)O)OC(C34C5(CO5)C6(C(O3)C(O4)C7=C(O6)C8=C(C=C7C)C(=C9C(CC(C(=O)C9=C8O)O)OC1CC(C(C(O1)C)OC(=O)C)(C)O)OC)OC)OC)C)(C)O)O,,,,,,
7410,127411,Wubangziside C,CO[C@@H]1[C@H]([C@@H]([C@H](C(O1)C2=C(C(=C3C(=C2O)C(=O)C4=C(O3)C=CC(=C4)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O)O,,,,,,
7411,127412,"6H-Pyrido(4,3-b)carbazolium, 2,5,6,11-tetramethyl-",CC1=C2C=C[N+](=CC2=C(C3=C1N(C4=CC=CC=C43)C)C)C,,,,,,
7412,127413,CID 127413,CCN1C[C@@]2(CC[C@@H](C34[C@@H]2[C@@H](C(C31)[C@]5(CC[C@@H]6CC4C5C(=O)O6)O)OC(=O)C7=CC=CC=C7)OC)C,,,,,,
7413,127414,2-Benzyl-3-[ethoxy(hydroxy)phosphoryl]propanoic acid,CCOP(=O)(CC(CC1=CC=CC=C1)C(=O)O)O,,,,,,
7414,127415,2-Benzyl-3-phosphonopropionic acid,C1=CC=C(C=C1)CC(CP(=O)(O)O)C(=O)O,,,,,,
7415,127416,N-[4-(hydroxymethyl)-1-(2-thiophen-3-ylethyl)piperidin-4-yl]-N-phenylpropanamide,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CSC=C3)CO,,,,,,
7416,127417,"2(3H)-Furanone, 3-((diethylamino)methyl)dihydro-5,5-diphenyl-",CCN(CC)CC1CC(OC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7417,127418,"n-Ethyl-2-methyl-5-(1,6,6,9-tetramethyl-6a,7,10,10a-tetrahydro-6h-benzo[c]chromen-3-yl)pentanamide",CCNC(=O)C(C)CCCC1=CC2=C(C3CC(=CCC3C(O2)(C)C)C)C(=C1)C,,,,,,
7418,127419,4-Benzylphenoxy-N-ethylmorpholine,C1COCCN1CCOC2=CC=C(C=C2)CC3=CC=CC=C3,,,,,,
7419,127420,"1,2-Dihydroxy-3,4-epoxy-1,2,3,4-tetrahydro-6-methylchrysene",CC1=CC2=C(C=CC3=C2C4C(O4)C(C3O)O)C5=CC=CC=C15,,,,,,
7420,127421,Cyclo(lysyl-tyrosyl-glycyl-glycyl-phenylalanyl-leucyl),CCC(C)[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)CCCCN,,,,,,
7421,127422,"3-Amino-2,3,6-trideoxy-2-fluorogalactose",C[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)OC)F)N)O,,,,,,
7422,127423,"Methyl 3-amino-2,3,6-trideoxy-2-fluoro-alpha-D-Altropyranoside",C[C@@H]1[C@H]([C@H]([C@@H]([C@H](O1)OC)F)N)O,,,,,,
7423,127424,CID 127424,C1=NC2=C(N1CC=C(CO)CO)NC(=NC2=O)N,,,,,,
7424,127425,"2,3,4-Trihydroxy-6-oxoheptanedioic acid",C(C(C(C(C(=O)O)O)O)O)C(=O)C(=O)O,,,,,,
7425,127426,"(2S)-2-amino-3-[3,5-diiodo-4-[3-iodo-4-(phenylcarbamoyloxy)phenoxy]phenyl]propanoic acid",C1=CC=C(C=C1)NC(=O)OC2=C(C=C(C=C2)OC3=C(C=C(C=C3I)C[C@@H](C(=O)O)N)I)I,,,,,,
7426,127427,3-Mercaptopyridine-2-sulfonamide,C1=CC(=C(N=C1)S(=O)(=O)N)S,,,,,,
7427,127428,Chlorophenol red galactopyranoside,C1=CC=C2C(=C1)C(OS2(=O)=O)(C3=CC(=C(C=C3)O)Cl)C4=CC(=C(C=C4)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)Cl,,,,,,
7428,127429,"N-ethoxy-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-imine",CCON=CC=C(C)C=CC=C(C)C=CC1=C(CCCC1(C)C)C,,,,,,
7429,127430,N(alpha)-Benzyloxycarbonyl-4-guanidinophenylalanine beta-naphthylamide,C1=CC=C(C=C1)COC(=O)N[C@@H](CC2=CC=C(C=C2)N=C(N)N)C(=O)NC3=CC4=CC=CC=C4C=C3.Cl,,,,,,
7430,127431,Cbz-Phe(4-guanidino)-NA,C1=CC=C(C=C1)COC(=O)N[C@@H](CC2=CC=C(C=C2)N=C(N)N)C(=O)NC3=CC4=CC=CC=C4C=C3,,,,,,
7431,127432,"6-Azido-9-chloro-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine",CN1CCC2=C(C=CC(=C2CC1)Cl)N=[N+]=[N-],,,,,,
7432,127433,CID 127433,CC(CCOP(=O)(O)OP(=O)(O)S)(CC(=O)O)O,,,,,,
7433,127434,4-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-methylamino]-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]butanamide,CN(CCCC(=O)N[C@@H](CC1=CC=CC=C1)CO)C(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7434,127435,Nitrosofenitrothion,CC1=C(C=CC(=C1)OP(=S)(OC)OC)N=O,,,,,,
7435,127436,Sippr 113,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)CCC(=O)O)CC[C@@H]4[C@@]3(C[C@](C4)(C#C)OC(=O)CCC(=O)O)C,,,,,,
7436,127437,"1,11-Dihydroxy-8-methoxy-2,25-dimethyl-1,3,4,4a,6a,7,8,11,12,19,20,23,23a,25b-tetradecahydro-10aH,18H-3,25a-epoxyfuro[3,4-j]naphtho[1',2':6,7]oxecino[3,2-c][1,7]dioxacyclotetradecine-9,16,18,21(2H)-tetrone",C[C@H]1[C@H]2C[C@@H]3C=C[C@@H]4CC(C(=O)O[C@H]5C(COC(=O)CCC6=C(C=COCC5O)C(=O)OC6=O)C=C([C@]4([C@@H]3[C@@H]1O)O2)C)OC,,,,,,
7437,127438,Katoxyn,C1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=CC=C2.[Ag],,,,,,
7438,127439,"1,4,5,6-Tetrahydropyridine-2-carboxylic acid",C1CC=C(NC1)C(=O)O,,,,,,
7439,127440,"2,2'-[2-Hydroxybenzylidenebis(nitrilomethylidyne)]bisphenol",C1=CC=C(C(=C1)C=NC(C2=CC=CC=C2O)N=CC3=CC=CC=C3O)O,,,,,,
7440,127441,Prolame,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2NCCCO)CCC4=C3C=CC(=C4)O,,,,,,
7441,127442,N-Formylmethionyl-leucyl-phenylalanyl tert-butyl ester,CCC(C)C(C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OC(C)(C)C)NC(=O)[C@H](CCSC)NC=O,,,,,,
7442,127443,"[4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](bicyclo[2.2.2]oct-5-en-2-yl)methanone hydrochloride(1:1)",COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CC5CCC4C=C5)N)OC.Cl,,,,,,
7443,127444,"4-Amino-2-[4-[(bicyclo[2.2.2]oct-2-en-5-yl)carbonyl]-1-piperazinyl]-6,7-dimethoxyquinazoline",COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CC5CCC4C=C5)N)OC,,,,,,
7444,127445,"15-Hydroperoxyicosa-5,8,11,14,17-pentaenoic acid",CCC=CCC(=CCC=CCC=CCC=CCCCC(=O)O)OO,,,,,,
7445,127446,"(2r,3s,3As,11ar)-7-amino-2-(hydroxymethyl)-2,3,3a,4,5,11a-hexahydrofuro[3',2':5,6]pyrido[1,2-e]purin-3-ol",C1CC2=NC3=C(N=CN=C3N2[C@H]4[C@@H]1[C@@H]([C@H](O4)CO)O)N,,,,,,
7446,127447,"2'-Deoxy-8,2'-methylene-cycloadenosine",C1[C@H]2[C@@H]([C@H](O[C@H]2N3C1=NC4=C(N=CN=C43)N)CO)O,,,,,,
7447,127448,Octanoylglucuronide,CCCCCCCC(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)C(=O)O)O)O)O,,,,,,
7448,127449,"[(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-(2-hydroxyphenyl)prop-2-enoate",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)C=CC5=CC=CC=C5O)C)C,,,,,,
7449,127450,CID 127450,C1C2C(C(OC2N3C1=NC4=C3NC(=NC4=O)N)CO)O,,,,,,
7450,127451,CID 127451,CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)OC)N=C(C(CCSC)NC=O)S,,,,,,
7451,127452,N-Acetyl-2'-O-methyllactosamine,CC(=O)NC(C=O)[C@H]([C@@H]([C@@H](CO)O)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)OC)O,,,,,,
7452,127453,CID 127453,C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=N)S,,,,,,
7453,127454,"6-Hydroxy-4,7-dimethyl-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4,4a,5,6,7a-hexahydrocyclopenta[c]pyran-3-one",CC1C2CC(C(C2COC1=O)(C)OC3C(C(C(C(O3)CO)O)O)O)O,,,,,,
7454,127455,3-(1H-imidazol-5-yl)prop-2-en-1-amine,C1=C(NC=N1)C=CCN,,,,,,
7455,127456,Imidazolyl-4-propargylamine,C1=C(NC=N1)C#CCN,,,,,,
7456,127457,"Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-ol",C1CC[N+]2(C1)C3CCC2CC(C3)O,,,,,,
7457,127458,"3-(4-Aminophenyl)-3-ethyl-1-methylpyrrolidine-2,5-dione",CCC1(CC(=O)N(C1=O)C)C2=CC=C(C=C2)N,,,,,,
7458,127459,Ursodeoxycholyl N-carboxymethylglycine,C[C@H](CCC(=O)N(CC(=O)O)CC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CCC3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
7459,127460,"19-(Ethyldithio)androst-4-ene-3,17-dione",CCSSC[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,,,,,,
7460,127461,N-Formylnorleucyl-leucyl-phenylalanyl-tyrosine,CCC(C)[C@@H](C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC=O,,,,,,
7461,127462,"3',4'-Dihydroxyetoposide",C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)O)O)O,,,,,,
7462,127463,"6-[4-[5-[(2,8-dihydroxy-7-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid",CC1C(C2C(COC(O2)O)OC1OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OC8C(C(C(C(O8)C(=O)O)O)O)O)OC)O,,,,,,
7463,127464,Glycinamide-beta-carboline-3-carboxylate methyl ester,COC(=O)CNC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,,,,,,
7464,127465,Caustinerf,CC1(C2CCC1(C(=O)C2)C)C.C=O.C1=CC(=CC=C1O)Cl,,,,,,
7465,127466,"2,3-Bis(5-phenylpentanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate",C[N+](C)(C)CCOP(=O)([O-])OCC(COC(=O)CCCCC1=CC=CC=C1)OC(=O)CCCCC2=CC=CC=C2,,,,,,
7466,127467,"2-[2,3-Bis(5-phenylpentanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium",C[N+](C)(C)CCOP(=O)(O)OCC(COC(=O)CCCCC1=CC=CC=C1)OC(=O)CCCCC2=CC=CC=C2,,,,,,
7467,127468,Daq-nampc,CC(=O)O.CC(=O)O.C1=CC2=C(C=C1N(CC3=C(C(=C(C(=C3Cl)Cl)CN(C4=CC5=C(C=C4)N=C(N=C5N)N)N=O)Cl)Cl)N=O)N=C(N=C2N)N,,,,,,
7468,127469,"N-(2,4-diaminoquinazolin-6-yl)-N-[[2,3,5,6-tetrachloro-4-[[(2,4-diaminoquinazolin-7-yl)-nitrosoamino]methyl]phenyl]methyl]nitrous amide",C1=CC2=C(C=C1N(CC3=C(C(=C(C(=C3Cl)Cl)CN(C4=CC5=C(C=C4)N=C(N=C5N)N)N=O)Cl)Cl)N=O)N=C(N=C2N)N,,,,,,
7469,127470,"3-(4,5-dibromofuran-2-yl)-N-(2-hydroxypropyl)prop-2-enamide",CC(CNC(=O)C=CC1=CC(=C(O1)Br)Br)O,,,,,,
7470,127471,Ethyl 2-[3-(4-bromo-5-nitrofuran-2-yl)prop-2-enoylamino]acetate,CCOC(=O)CNC(=O)C=CC1=CC(=C(O1)[N+](=O)[O-])Br,,,,,,
7471,127472,CID 127472,C1CCN(CC1)CCNC(=O)C=CC2=CC(=C(O2)[N+](=O)[O-])Br,,,,,,
7472,127473,CID 127473,C1=CC2=C3C=C(NC(=C3N=C2C=C1)C4=CC=C(O4)CO)C(=O)O,,,,,,
7473,127474,"2-Amino-5-[[3-[6-(2-carboxyethenyl)-2,3-dihydroxyphenyl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid",C1=CC(=C(C(=C1C=CC(=O)O)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)O)O,,,,,,
7474,127475,CID 127475,C[C@H]1CC(=O)CCC[C@H](CC(=O)O[C@@H]([C@H]([C@@H](CC=CC2=NC(=CO2)C3=NC(=CO3)C4=NC1=CO4)OC)C)C[C@H]([C@@H](C)CCC(=O)[C@H](C)[C@@H]([C@H](C)C=CN(C)C=O)OC(=O)C)OC)O,,,,,,
7475,127476,"3-Methyl-7-phenyl-1,2,4-triazolo(4,3-b)pyridazine",CC1=NN=C2N1N=CC(=C2)C3=CC=CC=C3,,,,,,
7476,127477,2-((Methoxycarbonylamino)-(2-nitro-5-(n-propylthio)phenylimino)methylamino)ethansulfonic acid,CCCSC1=CC(=C(C=C1)[N+](=O)[O-])N=CNOS(=O)(=O)CCNC(=O)OC.C(C(CO)(CO)N)O,,,,,,
7477,127478,[(2-Nitro-5-propylsulfanylphenyl)iminomethylamino] 2-(methoxycarbonylamino)ethanesulfonate,CCCSC1=CC(=C(C=C1)[N+](=O)[O-])N=CNOS(=O)(=O)CCNC(=O)OC,,,,,,
7478,127479,"2-[2-(3-Chlorophenyl)ethenyl]-4,4,6-trimethyl-5,6-dihydro-1,3-oxazine",CC1CC(N=C(O1)C=CC2=CC(=CC=C2)Cl)(C)C,,,,,,
7479,127480,CID 127480,COC1=C([C@H](C2(CC(=NO2)C(=O)NCCCOC3=C(C=C(C=C3Br)CC(=C(NCCC4=CN=C(N4)N)O)N=O)Br)C=C1Br)O)Br,,,,,,
7480,127481,Murrayaquinone A,CC1=CC(=O)C2=C(C1=O)C3=CC=CC=C3N2,,,,,,
7481,127482,tert-Butyloxycarbonyl-(S-(3-nitro-2-pyridinesulfenyl))cysteine-N-hydroxysuccinimide,CC(C)(C)OC(=O)N[C@@H](CSSC1=C(C=CC=N1)[N+](=O)[O-])C(=O)ON2C(=O)CCC2=O,,,,,,
7482,127483,Oxyplicacetin,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)N2C=CC(=NC2=O)NC(=O)C3=CC=C(C=C3)N)O)O[C@H]4C[C@@H]([C@H]([C@@H]([C@H]4O)O)N(C)C)O,,,,,,
7483,127484,"4',5'-Dimethyl-5-carboxyfluorescein",CC1=C(C=CC2=C1OC3=C(C24C5=C(C=C(C=C5)C(=O)O)C(=O)O4)C=CC(=C3C)O)O,,,,,,
7484,127485,Cdmfda,CC1=C(C=CC2=C1OC3=C(C24C5=C(C=CC(=C5)C(=O)O)C(=O)O4)C=CC(=C3C)O)O,,,,,,
7485,127486,"(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-[(2S,4R,5R,6S)-6-[(2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-2,4,5-trihydroxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-[2-(pyridin-2-ylamino)ethyl]oxane-3,4,5-triol",C1=CC=NC(=C1)NCC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)OC4[C@@H]([C@H]([C@H](O[C@@H]4O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)OC7=CC=C(C=C7)[N+](=O)[O-])CO)CO)O)O)CO)O)O)O,,,,,,
7486,127487,"Octadecanoic acid, 3-hydroxy-2-methoxypropyl ester",CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC,,,,,,
7487,127488,CID 127488,CC1=CC2=C3C4=C(C5=C(CC4OCO3)C(=C6C(=C(C7=C(O6)C(CCC7O)O)O)C5=O)OC)C(=O)C2=C(N1C)O,,,,,,
7488,127489,CID 127489,CC[C@H]1C(=CC(=C)C[C@@H](C=C(C[C@@](C(=O)[C@H](C(=O)O1)C)(CO)O)C)C)C,,,,,,
7489,127490,"(1S,3R,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,3-diol",C1[C@@H]([C@H](C[C@H]([C@H]1N)O)O)CO,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],,,
7490,127491,"6-([1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6H-furo[3,4-g][1,3]benzodioxol-8-one",C1OC2=C(O1)C3=C(C=C2)C(OC3=O)C4=NC=CC5=CC6=C(C=C54)OCO6,,,,,,
7491,127492,"1-[(3R,4S,6R)-6-[(S)-hydroxy-(6-methoxy-1-oxidoquinolin-1-ium-4-yl)methyl]-1-azabicyclo[2.2.2]octan-3-yl]ethane-1,2-diol",COC1=CC2=C(C=C[N+](=C2C=C1)[O-])[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C(CO)O)O,,,,,,
7492,127493,"2,4,6-Trimethyl-7-oxa-2,4-diazabicyclo[4.1.0]heptane-3,5-dione",CC12C(O1)N(C(=O)N(C2=O)C)C,,,,,,
7493,127494,Cortisol-17 acid,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@]4(C(=O)O)O)C)O,,,,,,
7494,127495,"2-Methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-1-amine",B1(OC(C(O1)(C)C)(C)C)C(C(C)CC)N,,,,,,
7495,127496,CID 127496,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C.COC1=C(C=CC(=C1)C=C2CCCC(=CC3=CC(=C(C=C3)O)OC)C2=O)O.C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)O,,,,,,
7496,127497,CID 127497,CC(=O)NC1=CC=C(C=C1)O.CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O.C(CC(=O)O)C(=O)O.OP(=O)(O)O,,,,,,
7497,127498,"8,5'-Cyclo-damp",C1C(C2C(C3=NC4=C(N=CN=C4N3C1O2)N)OP(=O)(O)O)O,,,,,,
7498,127499,6-(2-chloroethoxy)-7H-purin-2-amine,C1=NC2=C(N1)C(=NC(=N2)N)OCCCl,,,,,,
7499,127500,Biphenomycin B,C1[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC2=C(C=CC(=C2)C3=CC1=C(C=C3)O)O)C(=O)O)C[C@H](CN)O)N,,,,,,
7500,127501,Pyroglutamyl-seryl-phenylalanine amide,C1CC(=O)N[C@@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N,,,,,,
7501,127502,CID 127502,C1=NC2=C(N1CCC#N)C(=O)N=C(N2)N,,,,,,
7502,127503,Resorcinomycin B,CCC1=C(C=C(C=C1O)[C@@H](C(=O)NCC(=O)O)N=C(N)N)O,,,,,,
7503,127504,3-Methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine,CC1=CC(=CC=C1)N2CCN(CC2)C3=NN=C(C=C3)OC,,,,,,
7504,127505,CID 127505,C1=CC=C(C=C1)C2=C3C=CC(=O)C=C3OC(=C2C4=CC=C(C=C4)O)O,,,,,,
7505,127506,"2-(6-aminopurin-9-yl)-5-(carboxymethyl)-3-hydroxy-3,3a,6,6a-tetrahydro-2H-furo[3,2-b]furan-5-carboxylic acid",C1C2C(C(C(O2)N3C=NC4=C(N=CN=C43)N)O)OC1(CC(=O)O)C(=O)O,,,,,,
7506,127507,CID 127507,C1CNCCC1CCCC[C@@H](C(=O)O)NC2CSC3=CC=CC=C3C(C2=O)CC(=O)O,,,,,,
7507,127508,LL AF283alpha,C1[C@@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C2=C(C=CC(=C2)C3=CC1=C(C=C3)O)O)O)C(=O)O)C[C@H](CN)O)N,,,,,,
7508,127509,Apiopaeonoside,CC(=O)C1=C(C=C(C=C1)OC)OC2C(C(C(C(O2)COC3C(C(CO3)(CO)O)O)O)O)O,,,,,,
7509,127510,Tyrosyl-arginyl-phenylalanyl-glycinamide,C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
7510,127511,CID 127511,CCCCCC=CC[C@]1(C=C(C(=O)C1=CC=CCCCC(=O)OC)Cl)O,,,,,,
7511,127512,"3-O-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl] 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-2,5-dihydropyridine-3,5-dicarboxylate",CC1C(=C(C(C(=N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCCN3CCN(CC3)C4=CC=CC=C4OC,,,,,,
7512,127513,CID 127513,CCCCC[C@@H](C=CC1[C@H]2CCC(=CCCC(=O)O)O[C@H]2C[C@H]1O)O,,,,,,
7513,127514,"5-[(3aR,4R,5R,6aS)-5-hydroxy-4-(3-oxooct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid",CCCCCC(=O)C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O,,,,,,
7514,127515,Corti-fluoral,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@@]43C)F)O.C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],,,,,,
7515,127516,Isoflupredone,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@@]43C)F)O,,,,,,
7516,127517,"2,2-dichloro-N-[(1R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide",C1=CC(=CC=C1[C@H](C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],,,,,,
7517,127518,CID 127518,CCC(C)N1CCC2(CC1)N=C3C4=C5C(=C(C6=C4C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@@H](C([C@@H]([C@H]([C@H](C=CC=C(C(=O)NC(=C5O)C3=N2)C)C)O)C)O)C)O)C)OC)C)C)O,,,,,,
7518,127519,"4'-Ethoxy-2'-hydroxy-4,6'-dimethoxy chalcone",CCOC1=CC(=C(C(=C1)OC)C(=O)C=CC2=CC=C(C=C2)OC)O,,,,,,
7519,127520,CID 127520,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N)C(=O)N[C@@H](CN(N=O)O)C(=O)O,,,,,,
7520,127521,"(2S,3S,5S)-5-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-2-methyloxolane-3-carbaldehyde",C[C@H]1[C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)C=O,,,,,,
7521,127522,"7H-Furo(2,3-f)(1)benzopyran-7-one, 3,4,9-trimethyl-",CC1=CC2=C(C(=CC(=O)O2)C)C3=C1C(=CO3)C,,,,,,
7522,127523,(2r)-2-[4-(3-Methylthiophen-2-yl)phenyl]propanoic acid,CC1=C(SC=C1)C2=CC=C(C=C2)[C@@H](C)C(=O)O,,,,,['(2r)-2-[4-(3-methylthiophen-2-yl)phenyl]propanoic acid has known human metabolites that include (2R)-2-[4-(4-methyl-2-oxo-3H-thiophen-5-yl)phenyl]propanoic acid.'],
7523,127524,2-Amino-alpha-(methoxymethyl)-1H-imidazole-1-ethanol,COCC(CN1C=CN=C1N)O,,,,,,
7524,127525,"N-[3-hydroxy-2-methyl-6-[[3,5,10,12-tetrahydroxy-3-(1-hydroxyethyl)-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]formamide",CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(C)O)O)NC=O)O,,,,,,
7525,127526,CID 127526,CCN1CCN(C(=O)C1=O)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]2([C@@H]3N(C2=O)C(=C(CS3)CSC4=NN=NN4C)C(=O)[O-])OC.[Na+],,,,,,
7526,127527,Cefbuperazone,CCN1CCN(C(=O)C1=O)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]2([C@@H]3N(C2=O)C(=C(CS3)CSC4=NN=NN4C)C(=O)O)OC,,,,,,
7527,127528,2-[[3-(Diaminomethylidenehydrazinylidene)cyclopenta[b]naphthalen-1-ylidene]amino]guanidine,C1C(=NN=C(N)N)C2=CC3=CC=CC=C3C=C2C1=NN=C(N)N,,,,,,
7528,127529,CID 127529,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=NNC(=NC4=CC5=C(C=C4)C6(C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)OC5=O)S)CCC9=C3C=CC(=C9)O,,,,,,
7529,127530,N-(4-(7-Diethylamino 4-methylcoumarin-3-yl)phenyl)iodoacetamide,CCN(CC)C1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=C(C=C3)NC(=O)CI)C,,,,,,
7530,127531,"N-(undeca-2,4,6-trienylideneamino)nitrous amide",CCCCC=CC=CC=CC=NNN=O,,,,,,
7531,127532,"2,5-Dioxopyrrolidin-1-yl 2-(acetylthio)acetate",CC(=O)SCC(=O)ON1C(=O)CCC1=O,,,,,,
7532,127533,"Hexahydro-3a,7a-dimethyl-4,7-epoxy-1H-isoindole-1,3(2H)-dione",CC12C3CCC(C1(C(=O)NC2=O)C)O3,,,,,,
7533,127534,Cantharidin methylimide,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)N(C2=O)C)C)O3,,,,,,
7534,127535,Iodipamide ethyl ester,CCOC(=O)C1=C(C(=C(C=C1I)I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)OCC)I)I)I,,,,,,
7535,127536,"2,5-Bis(2-hydroxyethylamino)-3,6-bis(carboethoxyamino)-1,4-benzoquinone",CCOC(=O)NC1=C(C(=O)C(=C(C1=O)NCCO)NC(=O)OCC)NCCO,,,,,,
7536,127537,"Acetamide, N-(4-((4-(dimethylamino)phenyl)azo)phenyl)-2-iodo-",CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)NC(=O)CI,,,,,,
7537,127538,"Dibenzo(b,f)thiepin-3-methanol, 5,5-dioxide",C1=CC=C2C(=C1)C=CC3=C(S2(=O)=O)C=C(C=C3)CO,,,,,,
7538,127539,Agrocinopine,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)OP(=O)(O)O[C@@H](C=O)[C@H]([C@H](CO)O)O)O)CO)O)O)O)O,,,,,,
7539,127540,"3,4-Epoxy-1,2,3,4-tetrahydrobenzene-1,2-diol",C1=CC2C(O2)C(C1O)O,,,,,,
7540,127541,CID 127541,CCCCCCCCC=CC=CC=CC([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
7541,127542,4-((6-Methoxyquinolin-8-yl)amino)pentanoic acid,CC(CCC(=O)O)NC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
7542,127543,"Piperazine, 1,2,6-trimethyl-4-nitroso-, cis-",C[C@@H]1CN(C[C@@H](N1C)C)N=O,,,,,,
7543,127544,1-(4-Nitroimidazol-1-yl)-3-(1-oxidopiperidin-1-ium-1-yl)propan-2-ol,C1CC[N+](CC1)(CC(CN2C=C(N=C2)[N+](=O)[O-])O)[O-],,,,,,
7544,127545,CID 127545,CCOC(=O)NC1=C(C(=NCCO)C(=NC(=O)OCC)C(=C1N2CC2)N)N,,,,,,
7545,127546,CID 127546,CN(C=O)C1=C(NC(=NC1=O)N)N,,,,,,
7546,127547,Ditiomustine,C(CSSCCNC(=O)N(CCCl)N=O)NC(=O)N(CCCl)N=O,,,,,,
7547,127548,Guanidinopropylsuccinic acid,C(CC(CC(=O)O)C(=O)O)CN=C(N)N,,,,,,
7548,127549,"L-Cysteine, S-(3,4-dihydroxyphenyl)-",C1=CC(=C(C=C1SC[C@@H](C(=O)O)N)O)O,,,,,,
7549,127550,CID 127550,CC=CC=CC=CC=CCCCCCCCCC(=O)OC(CO)COP(=O)([O-])OCC[N+](C)(C)C,,,,,,
7550,127551,CID 127551,CC=CC=CC=CC=CCCCCCCCCC(=O)OC(CO)COP(=O)(O)OCC[N+](C)(C)C,,,,,,
7551,127552,"2-(4'-Chlorophenyl)benzothiopyrano(4,3-c)pyrazol-3-one",C1C=CC(C(=C1)C2=CC=C(C=C2)Cl)CSN3C(=O)C4=COC=CC4=N3,,,,,,
7552,127553,Prinomide trolamine,CN1C=CC=C1C(=O)C(C#N)C(=O)NC2=CC=CC=C2.C(CO)N(CCO)CCO,,,,,,
7553,127554,"1,11,12-Trihydroxy-2,16-dioxo-11,20-epoxypicrasan-15-yl acetate",C[C@H]1CC(=O)[C@H]([C@]2(C1C[C@@H]3[C@]45[C@@H]2[C@]([C@@H]([C@@H]([C@H]4[C@H](C(=O)O3)OC(=O)C)C)O)(OC5)O)C)O,,,,,,
7554,127555,Rigin,C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
7555,127556,CID 127556,C[C@H](CC(CC(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](CCC3=C)O)C,,,,,,
7556,127557,"3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-ethyl-4-oxo-7-(4-pyridinyl)-",CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)C3=CC=NC=C3)F)C(=O)O,,,,,,
7557,127558,"1,2-Dimethyl-5-phenyl-4-(quinazolin-4-ylamino)pyrazol-3-one",CN1C(=C(C(=O)N1C)NC2=NC=NC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
7558,127559,"(3S,4R)-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]piperidine",COC1=CC=C(C=C1)OC[C@@H]2CNCC[C@H]2C3=CC=C(C=C3)F,,,,,,
7559,127560,"(2S,3S)-N-[2-(4-hydroxyphenyl)ethyl]-1-methyl-5-oxo-2-pyridin-3-ylpyrrolidine-3-carboxamide",CN1[C@@H]([C@H](CC1=O)C(=O)NCCC2=CC=C(C=C2)O)C3=CN=CC=C3,,,,,,
7560,127561,"5-Acetamido-3,5,7,9-tetradeoxy-7-(3-hydroxybutyramido)nonulosonic acid",C[C@H](CC(=O)N[C@@H]([C@H](C)O)[C@@H]([C@H]([C@H](CC(=O)C(=O)O)O)NC(=O)C)O)O,,,,,,
7561,127562,3'-Deoxy-3'-fluorokanamycin A,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)F)O)O)OC3C(C(C(C(O3)CO)O)N)O)N,,,,,,
7562,127563,3'-Deoxy-3'-fluorokanamycin B,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)F)N)N,,,,,,
7563,127564,7-(Diethylamino)coumarin-3-carbohydrazide,CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C(=O)NN,,,,,,
7564,127565,"7-O-(2,3,5-Trideoxy-3-C-formylpentafuranosyl)adriamycinone",C[C@H]1[C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)C=O,,,,,,
7565,127566,CID 127566,COC1=C(C=C(C(=C1)C2=C(C(=C3C(=C(C(=O)C(=C3O2)OC)OC)O)O)OC)O)OC,,,,,,
7566,127567,Dan shen spiroketal lactone,C[C@@H]1CC2(C3=C(C4=CC=CC(=C4C=C3)C)C(=O)O2)OC1,,,,,,
7567,127568,Terpentecin,C[C@@H]1[C@H](C(=O)[C@]2([C@H]([C@]1(C)C[C@H]([C@@]3(CO3)C(=O)C=O)O)CCC=C2C)C)O,,,,,,
7568,127569,4-Heptylumbelliferyl-beta-glucoside,CCCCCCCC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
7569,127570,4-Nonylumbelliferyl glucoside,CCCCCCCCCC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
7570,127571,"1,3,4,5,6,11a-Hexahydro-2-methyl-2H-3,6a-methanobenzofuro(2,3-c)azocin-10-ol",CN1CC2C3(CCCC1C3)C4=C(O2)C(=CC=C4)O,,,,,,
7571,127572,"5,6-Dihydroxy-1-(2-imidazolinyl)tetralin",C1CC(C2=C(C1)C(=C(C=C2)O)O)C3=NCCN3,,,,,,
7572,127573,Indapamide mixture with tertatolol,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N.CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O,,,,,,
7573,127574,Pyroglutamylalanine amide,C[C@H](C(=O)N)NC(=O)[C@@H]1CCC(=O)N1,,,,,,
7574,127575,Methyl-2-butylmercapto-4-catechol,CCC(C)CSC1=CC(=C(C=C1)O)O,,,,,,
7575,127576,"4,6,7-Trimethyl-2-propyl-1,3-benzoxathiol-5-ol",CCCC1OC2=C(S1)C(=C(C(=C2C)C)O)C,,,,,,
7576,127577,"2-(3-Hydroxypropyl)-4,6,7-trimethyl-1,3-benzoxathiol-5-ol",CC1=C(C2=C(C(=C1O)C)SC(O2)CCCO)C,,,['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)'],,,
7577,127578,"(1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R,5R)-5,6-dihydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](C=C[C@](C)(C(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
7578,127579,3-(1-Nitrosopyrrolidin-2-yl)-1-oxidopyridin-1-ium,C1CC(N(C1)N=O)C2=C[N+](=CC=C2)[O-],,,,,"[""NNN N-Oxide is a known thirdhand smoke metabolite of N'-Nitrosonornicotine (NNN).""]",
7579,127580,5-Hydroxybenzo[c]fluoren-7-one,C1=CC=C2C(=C1)C(=CC3=C2C4=CC=CC=C4C3=O)O,,,,,,
7580,127581,6-(Decyldithio)-1H-purine,CCCCCCCCCCSSC1=NC=NC2=C1NC=N2,,,,,,
7581,127582,6-(Decyldithio)-1H-purin-2-amine,CCCCCCCCCCSSC1=NC(=NC2=C1NC=N2)N,,,,,,
7582,127583,"(2,5-Dioxopyrrolidin-1-yl) 5-(2-hydroxyethoxy)-4-oxopentanoate",C1CC(=O)N(C1=O)OC(=O)CCC(=O)COCCO,,,,,,
7583,127584,7-Ethylcamptothecin,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=CC=CC=C51,,,,,,
7584,127585,"2-Bromo-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C(C=C3)Br,,,,,,
7585,127586,"3-Bromo-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=CC(=C3)Br,,,,,,
7586,127587,"4-Bromo-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=CC=C3Br,,,,,,
7587,127588,"2(3H)-Naphthalenone, 4,4a,5,6,7,8-hexahydro-4a-methyl-6-(3-oxobutyl)-",CC(=O)CCC1CCC2=CC(=O)CCC2(C1)C,,,,,,
7588,127589,N-(4-methylphenyl)-N-[3-(4-methylphenyl)iminoprop-1-enyl]benzamide,CC1=CC=C(C=C1)N=CC=CN(C2=CC=C(C=C2)C)C(=O)C3=CC=CC=C3,,,,,,
7589,127590,1-[2-(Hydroxyamino)imidazol-1-yl]-3-methoxypropan-2-ol,COCC(CN1C=CN=C1NO)O,,,,,,
7590,127591,"9-(2,6-Dichloro-4-methoxy-5-methyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid ethyl ester",CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C=C(C(=C1Cl)C)OC)Cl,,,,,,
7591,127592,"5-(dimethylamino)-N-[(2R,3R,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]naphthalene-1-sulfonamide",CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N[C@@H](C=O)[C@H]([C@H]([C@@H](CO)O)O)O,,,,,,
7592,127593,"1H-Pyrrolo(1,2-a)indole-5,8-dione, 2,7-diamino-9-(((aminocarbonyl)oxy)methyl)-2,3-dihydro-1-hydroxy-6-methyl-, trans-",CC1=C(C(=O)C2=C(C1=O)N3C[C@@H]([C@H](C3=C2COC(=O)N)O)N)N,,,,,,
7593,127594,"1,2-Dimethyl-1,2-bis(3'-hydroxyphenyl)ethane",C[C@H](C1=CC(=CC=C1)O)[C@@H](C)C2=CC(=CC=C2)O,,,,,,
7594,127595,S-Carbamidomethylglutathione,C(CC(=O)N[C@@H](CSCC(=O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,,,,,,
7595,127596,"5,6-Dihydroxy-alpha-naphthoflavone",C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4[C@H]([C@@H]3O)O,,,,,,
7596,127597,"4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 5,6-dihydro-5-methyl-6-oxo-, ethyl ester",CCOC(=O)C1=C2CN(C(=O)C3=CC=CC=C3N2C=N1)C,,,,,,
7597,127598,Ptilocaulin,CCCCC1=C2[C@@H]3[C@@H](CC[C@@H]3N=C(N2)N)C[C@@H]1C,,,,,,
7598,127599,(2r)-3-(Hexadecyloxy)-2-methoxypropyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC,,,,,,
7599,127600,2-O-Methyl PAF,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC,,,,,,
7600,127601,Isoursodeoxycholic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@@H](C4)O)C)O)C,,,,,"['Isoursodeoxycholic acid has known human metabolites that include 3,6,7-Trihydroxycholan-24-oic acid and 4-(7-Hydroxy-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl)pentanoic acid.']",
7601,127602,Acetyl hypofluorite,CC(=O)OF,,,,,,
7602,127603,4-(2-Aminoethyl)thio-2-methylimidazole-1-ethanol,CC1=NC(=CN1CCO)SCCN,,,,,,
7603,127604,"Pregn-5-en-3-ol, 20-methyl-21-((7-nitro-4-benzofurazanyl)amino)-, (3beta,20S)-",C[C@H](CNC1=CC=C(C2=NON=C12)[N+](=O)[O-])[C@H]3CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O)C)C,,,,,,
7604,127605,21-Amino-20-methyl-pregn-5-en-3-ol,C[C@H](CN)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
7605,127606,"Oxirane, 2,3-bis(4-ethoxyphenyl)-2,3-diethyl-",CCC1(C(O1)(CC)C2=CC=C(C=C2)OCC)C3=CC=C(C=C3)OCC,,,,,,
7606,127607,Griseolic acid,C1=C2C(C(C(O2)N3C=NC4=C(N=CN=C43)N)O)OC1(C(C(=O)O)O)C(=O)O,,,,,,
7607,127608,"Ethanamine, 2-(2-(4-chlorophenoxy)ethoxy)-N,N-dimethyl-, hydrochloride",CN(C)CCOCCOC1=CC=C(C=C1)Cl.Cl,,,,,,
7608,127609,"p-chlorophenoxyethyl N,N-dimethylaminoethyl ether",CN(C)CCOCCOC1=CC=C(C=C1)Cl,,,,,,
7609,127610,gamma-Glutamyl ppdm,C1=CC(=CC=C1N[C@@H](CCC(=O)N)C(=O)O)N(CCCl)CCCl.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O,,,,,,
7610,127611,5-Amino-2-[4-[bis(2-chloroethyl)amino]anilino]-5-oxopentanoic acid,C1=CC(=CC=C1NC(CCC(=O)N)C(=O)O)N(CCCl)CCCl,,,,,,
7611,127612,"9H-Fluorene-9-carboxamide, 9-(3-aminopropyl)-",C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCN)C(=O)N,,,,,,
7612,127613,"2-(4-Hydroxytoluene-3-yl)-4,5-dihydro-4-carboxythiazole",CC1=CC(=C(C=C1)O)C2=NC(CS2)C(=O)O,,,,,,
7613,127614,Cysteine isopropyl ester,CC(C)OC(=O)[C@H](CS)N,,,,,,
7614,127615,N-(9H-Fluoren-9-ylacetyl)tryptophan,C1=CC=C2C(=C1)C(C3=CC=CC=C32)CC(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)O,,,,,,
7615,127616,Hainanensine,CC1(C2=C3C(=CC4=C2OCO4)CCN5CCCC5=C3C1=O)O,,,,,,
7616,127617,"Benz(a)anthracene 10,11-epoxide",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C5C(O5)C=C4,,,,,,
7617,127618,CID 127618,C(NC1=NN=C(S1)S)NC2=NN=C(S2)S,,,,,,
7618,127619,"15-Acetoxy-3-hydroxy-3,4-O,O-ethylidene-12,13-epoxytrichothec-9-ene",C[C@H]1O[C@@H]2[C@](O1)([C@@H]3C4(C2([C@]5(CCC(=C[C@H]5O3)C)COC(=O)C)C)CO4)O,,,,,,
7619,127620,1-Phenyl-3-trimethylaminopropyl carbodiimide,C[N+](C)(C)CCCN=C=NC1=CC=CC=C1.[I-],,,,,,
7620,127621,CID 127621,C[N+](C)(C)CCCN=C=NC1=CC=CC=C1,,,,,,
7621,127622,"(2S,3S,4S,5R,6R)-6-[4-[butyl(nitroso)amino]butoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid",CCCCN(CCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)C(=O)O)O)O)O)N=O,,,,,,
7622,127623,"Destruxin B, 1-L-2-piperidinecarboxylic acid-",CC[C@H](C)[C@H]1C(=O)N([C@H](C(=O)N([C@H](C(=O)NCCC(=O)O[C@@H](C(=O)N2CCCC[C@H]2C(=O)N1)C(C)CC)C)C)C(C)C)C,,,,,,
7623,127624,Negram-citrat,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+],,,,,,
7624,127625,"methyl 8-ethoxy-6a,7,10a,12-tetrahydroxy-3-methoxy-1-methyl-6,10,11-trioxo-7H-tetracene-2-carboxylate",CCOC1=CC(=O)C2(C(=O)C3=C(C=C4C=C(C(=C(C4=C3O)C)C(=O)OC)OC)C(=O)C2(C1O)O)O,,,,,,
7625,127626,"7,14-Dihydroxykaur-16-ene-3,15-dione",C[C@@]12CCC(=O)C([C@H]1C[C@H](C34[C@H]2CCC(C3O)C(=C)C4=O)O)(C)C,,,,,,
7626,127627,"5,5'-((1,1'-Biphenyl)-2,5-diylbis(oxy))bis(2,2-dimethylpentanoic acid)",CC(C)(CCCOC1=CC(=C(C=C1)OCCCC(C)(C)C(=O)O)C2=CC=CC=C2)C(=O)O,,,,,,
7627,127628,(4-benzoyl-2-nitrophenyl) 2-(9H-fluoren-9-yl)acetate,C1=CC=C(C=C1)C(=O)C2=CC(=C(C=C2)OC(=O)CC3C4=CC=CC=C4C5=CC=CC=C35)[N+](=O)[O-],,,,,,
7628,127629,CID 127629,CC1=CCCC(=CC[C@]2(CC=C([C@@H]2CC1)C(C)(C)O)C)C,,,,,,
7629,127630,"1-[9-(2-Chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]ethanol",CC1=NN=C2N1C3=C(C=C(S3)C(C)O)C=NC2C4=CC=CC=C4Cl,,,,,,
7630,127631,"5-(Difluoromethyl)-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid",C1OC2=C(O1)C=C3C(=C2)C(=O)C(=CN3C(F)F)C(=O)O,,,,,,
7631,127632,CID 127632,C[C@@]1(CC(=O)[C@]2([C@@]3([C@@H](CCC([C@H]3[C@H]([C@H]([C@@]2(O1)C)O)O)(C)C)O)C)O)C=C,,,,,,
7632,127633,Ibuprofen diethylaminoethyl ester,CCN(CC)CCOC(=O)C(C)C1=CC=C(C=C1)CC(C)C,,,,,,
7633,127634,"L-Cysteine, N-acetyl-S-(2,4,5-trichlorophenyl)-",CC(=O)N[C@@H](CSC1=CC(=C(C=C1Cl)Cl)Cl)C(=O)O,,,,,,
7634,127635,CID 127635,C1=CC(=NCCCC(=O)O[C@@H]2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C(N=CN=C43)N)COP(=O)(O)OP(=O)(O)O)C(=CC1=N[N+]#N)N(O)[O-],,,,,,
7635,127636,"2-(2,4-Dichlorophenoxymethyl)-3-fluoroallylamine",C1=CC(=C(C=C1Cl)Cl)OCC(=CF)CN,,,,,,
7636,127637,"Piperazine, 1-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-4-(2-(2-methoxyphenoxy)ethyl)-",COC1=CC=CC=C1OCCN2CCN(CC2)CC3COC4=CC=CC=C4O3,,,,,,
7637,127638,"10-(N-(4-(4-Guanidinophenyl)butanoyl)-L-seryl)-1,5,10-triazadecane",C1=CC(=CC=C1CCCC(=O)N[C@@H](CO)C(=O)NCCCCNCCCN)N=C(N)N,,,,,,
7638,127639,"5-Hydroxytryptamine-4,7-dione",C1=C(C2=C(C(=CN2)CCN)C(=O)C1=O)O,,,,,,
7639,127640,CID 127640,C[C@]12CCC(=O)C(C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)SC5=CC=CC=C5,,,,,,
7640,127641,O(4)-Isopropylthymidine 5'-phosphate,CC1=CN(C(=O)N=C1OC(C)C)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
7641,127642,"3',4'-Hexestrol quinone",CC[C@H](C1=CC=C(C=C1)O)[C@@H](CC)C2=CC(=O)C(=O)C=C2,,,,,,
7642,127643,4-[3-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]prop-1-enyl]phenol,C1CN(CCN1CC=CC2=CC=C(C=C2)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
7643,127644,"2-((5-(Diethylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)(hexyl)amino)ethanol",CCCCCCN(CCO)C1=CC(=NC2=NC=NN12)N(CC)CC,,,,,,
7644,127645,"2-[Hexyl-(5-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]ethanol",CCCCCCN(CCO)C1=CC(=NC2=NC=NN12)N3CCCCC3,,,,,,
7645,127646,N(gamma)-(Octyl)glutaminyl-uracil polyoxin C,CCCCCCCCNC(=O)CC[C@@H](C(=O)N[C@@H]([C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)O)C(=O)O)N,,,,,,
7646,127647,Oct-lys-upoc,CCCCCCCNC(=O)CCCC[C@@H](C(=O)N[C@@H]([C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)O)C(=O)O)N,,,,,,
7647,127648,"5-Benzothiazolamine, 4,5,6,7-tetrahydro-N-methyl-(hydrochloride)",CNC1CCC2=C(C1)N=CS2.Cl,,,,,,
7648,127649,"5-Benzothiazolamine, 4,5,6,7-tetrahydro-N-methyl-",CNC1CCC2=C(C1)N=CS2,,,,,,
7649,127650,Porphycene,C1=CC2=CC=C(N2)C3=CC=C(N3)C=CC4=NC(=C5C=CC1=N5)C=C4,,,,,,
7650,127651,Crisamicin C,CC1C2=C(C3C(O1)CC(=O)O3)C(=O)C4=C(C2=O)C=C(C=C4O)C5=CC6=C(C(=C5)O)C(=O)C78C9C(CC(=O)O9)OC(C7(C6=O)O8)C,,,,,,
7651,127652,"16-(3,9-Dihydroxy-4,8-dimethyl-5-oxodec-6-en-2-yl)-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one",CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C(=O)C=CC(C)C(C)O)O)OC)C,,,,,,
7652,127653,CID 127653,C[C@H](C[C@@H](C[C@](C)(CO)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
7653,127654,8-Azidoadenosine diphosphate glucose,C1=NC(=C2C(=N1)N(C(=N2)N=[N+]=[N-])[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)N,,,,,,
7654,127655,"1,3,3-trimethyl-6-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)indol-2-one",CC1CC(=O)NN=C1C2=CC3=C(C=C2)C(C(=O)N3C)(C)C,,,,,,
7655,127656,4-nitrophenyl beta-D-galactofuranoside,C1=CC(=CC=C1[N+](=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H](O2)[C@@H](CO)O)O)O,,,,,,
7656,127657,Triclabendazole sulfoxide,CS(=O)C1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl,,,['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)'],,,
7657,127658,Dhtthn,C[C@H]1[C@H]([C@H](C[C@H](O1)O[C@H]2C[C@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(CO)O)O)O,,,,,,
7658,127659,"1,2-Epoxyestrenolone",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)[C@@H]5[C@H]([C@H]34)O5,,,,,,
7659,127660,"(15,22-Dihydroxy-5-methoxy-14,16-dimethyl-3-oxo-2-azabicyclo[18.3.1]tetracosa-1(23),6,8,10,16,20(24),21-heptaen-13-yl) 2-(2-methylbutanoylamino)propanoate",CCC(C)C(=O)NC(C)C(=O)OC1CC=CC=CC=CC(CC(=O)NC2=CC(=CC(=C2)CCC=C(C(C1C)O)C)O)OC,,,,,,
7660,127661,Dpc-nhss,C1C(C(=O)N(C1=O)OC(=O)C(CSSC[C@@H](C(=O)O)NC2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C=C2)NC6=C7C=CC8=CC=CC9=C8C7=C(C=C9)C=C6)S(=O)(=O)O,,,,,,
7661,127662,Ahed-man,C1CO[C@@H]2[C@H](O[C@@H]([C@H]2O1)CO)CO,,,,,,
7662,127663,"2,3-Dihydro-6-(2,5-dimethoxyphenyl)imidazo(2,1-b)thiazole",COC1=CC(=C(C=C1)OC)C2=CN3CCSC3=N2,,,,,,
7663,127664,Ethyl iopanoate,CCC(CC1=C(C(=C(C=C1I)I)N)I)C(=O)OCC,,,,,,
7664,127665,"(+-)-4,5,6,7-Tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo-(4,5,1-jk)(1,4)-benzodiazepin-2(1H)-one",CC1CN2C3=C(CN1CC=C(C)C)C=CC=C3NC2=O,,,,,,
7665,127666,"3-Methylbut-2-enyl 3-(3,4-dihydroxyphenyl)prop-2-enoate",CC(=CCOC(=O)C=CC1=CC(=C(C=C1)O)O)C,,,,,,
7666,127667,"(2S)-2-amino-5-[(4-methyl-5-oxo-1,4-dihydroimidazol-2-yl)amino]pentanoic acid",CC1C(=O)NC(=N1)NCCC[C@@H](C(=O)O)N,,,,,,
7667,127668,CID 127668,C1=CC=C(C=C1)CN2C3=C(C(=O)N=C(N3)N)N=C2N,,,,,,
7668,127669,"6-Methyl-2-oxo-6,7-dihydro-[1,3]benzodioxolo[5,6-a]quinolizine-3-carboxylic acid",CC1CC2=CC3=C(C=C2C4=CC(=O)C(=CN14)C(=O)O)OCO3,,,,,,
7669,127670,"(8r)-8-Hydroperoxy-5,9,11,14-eicosatetraenoic acid",CCCCCC=CCC=CC=C[C@@H](CC=CCCCC(=O)O)OO,,,,,,
7670,127671,Galphimine B,CC1=CC[C@@]2(CC[C@@]3([C@H]4[C@@H](C[C@]5(COC(=O)C=C[C@H]5[C@@]4(CC[C@]3([C@@]2(C1)O)C(=O)OC)C)[C@@H](C)O)O)C)C,,,,,,
7671,127672,"(1,1,1-Trifluoro-4-oxo-4-phenylbut-2-en-2-yl) 4-methylsulfanylbenzoate",CSC1=CC=C(C=C1)C(=O)OC(=CC(=O)C2=CC=CC=C2)C(F)(F)F,,,,,,
7672,127673,"2-Buten-1-one,3-(acetyloxy)-4,4,4-trifluoro-1-phenyl-",CC(=O)OC(=CC(=O)C1=CC=CC=C1)C(F)(F)F,,,,,,
7673,127674,CID 127674,C1=CC=C(C=C1)CCCCNC(=O)C(=CC2=CC(=C(C=C2)O)O)CN,,,,,,
7674,127675,Chlorolissoclimide,C[C@]12C[C@H](CC([C@@H]1C[C@@H](C(=C)[C@@H]2C[C@@H]([C@H]3CC(=O)NC3=O)O)O)(C)C)Cl,,,,,,
7675,127676,Emate,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)N,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
7676,127677,Benzamidomethylboronic acid,B(CNC(=O)C1=CC=CC=C1)(O)O,,,,,,
7677,127678,2-(2-n-Propoxyphenyl)-5-(5-1H-tetrazolyl)pyrimidin-4(3H)-one,CCCOC1=CC=CC=C1C2=NC=C(C(=O)N2)C3=NNN=N3,,,,,,
7678,127679,Coumarin-3-carboxylic acid succinimidyl ester,C1CC(=O)N(C1=O)OC(=O)C2=CC3=CC=CC=C3OC2=O,,,,,,
7679,127680,CID 127680,CC(C)NC(=O)OC1=CC2=C(C=C1)N(CC2(C)C)C,,,,,,
7680,127681,Acetylcarnitine arginyl amide,CC(=O)O[C@H](CC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C[N+](C)(C)C,,,,,,
7681,127682,CID 127682,CC1(C2CCCC2C=C3C1(C(=O)C4=C(C3=O)C=C(C=C4)O)OC)CO,,,,,,
7682,127683,"2,10a-Dihydro-8,10a-dihydroxy-3,11-dimethyl-1H-cyclopent(b)anthracene-5,10-dione",CC1=C2C=C3C(=O)C4=C(C=C(C=C4)O)C(=O)C3(C(=C2CC1)C)O,,,,,,
7683,127684,7-Hydroxyhexahydrocannabinol,CCCCCC1=CC(=C2[C@@H]3C[C@@H](CC[C@H]3C(OC2=C1)(C)C)CO)O,,,,,,
7684,127685,Bungeiside A,CC(=O)C1=C(C=CC(=C1)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
7685,127686,Bungeiside C,CC(=O)C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H](CO3)O)O)O)O)O)O,,,,,,
7686,127687,Bungeiside D,CC(=O)C1=C(C=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H](CO3)O)O)O)O)O)O)O,,,,,,
7687,127688,"trans-7,8-Dihydroxy-anti-9,10-epoxy-7,8,9,10-tetrahydro-3-nitrobenzo(a)pyrene",C1=CC2=C3C(=CC4=C2[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O)C=CC6=C(C=CC1=C63)[N+](=O)[O-],,,,,,
7688,127689,Bungeiside B,CC(=O)C1=C(C=C(C=C1)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
7689,127690,"6',7'-bis(hydroxymethyl)-1,1,4a,6-tetramethylspiro[3,4,6,7,8,8a-hexahydro-2H-naphthalene-5,2'-3H-1-benzofuran]-2,4'-diol",CC1CCC2C(C(CCC2(C13CC4=C(C=C(C(=C4O3)CO)CO)O)C)O)(C)C,,,,,,
7690,127691,CID 127691,C1CCC(CC1)C#C[C@H]2[C@@H](C[C@H]3[C@@H]2CC(=CCCCC(=O)O)C3)O,,,,,,
7691,127692,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-[4-(methylamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate",CNC1=NC(=O)N(C=C1)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
7692,127693,Tetracenomycin F1,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3)C=C(C=C4O)O)O)C(=O)O,,,,,,
7693,127694,CID 127694,CS(CC[C@@](CO)(C1=CC=CC=C1)C(=O)O[C@H]2CN3CCC2CC3)O,,,,,,
7694,127695,"1,2,3,4-Tetraacetoxy-5-(acetoxymethyl)cyclohexane",CC(=O)OC[C@H]1C[C@H]([C@@H]([C@H]([C@@H]1OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
7695,127696,Ethyl 3-((4-(aminocarbonyl)phenyl)dithio)propanimidothioate monohydrochloride,CCSC(=N)CCSSC1=CC=C(C=C1)C(=O)N.Cl,,,,,,
7696,127697,3-[(4-Carbamoylphenyl)dithio]propanimidothioic acid ethyl ester,CCSC(=N)CCSSC1=CC=C(C=C1)C(=O)N,,,,,,
7697,127698,"1,2,3,6-Tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine",C1C[C@H](CC(=C1)C2=CC=CC=C2)CN3CCC(=CC3)C4=CC=CC=C4,,,,,,
7698,127699,Nmns-bop,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])SCC(=O)CBr)O)O)C(=O)N,,,,,,
7699,127700,"(3-bromo-2-oxopropyl)sulfanyl-[[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]phosphinic acid",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)SCC(=O)CBr)O)O)C(=O)N,,,,,,
7700,127701,Dichlotran K,CC1=C(C(=CC=C1)C2=C(C(=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O)C)C)C,,,,,,
7701,127702,"4-(4-Chloro-phenyl)-1-{3-[2-(4-fluoro-phenyl)-[1,3]dithiolan-2-YL]-propyl}-piperidin-4-OL",C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC3(SCCS3)C4=CC=C(C=C4)F,,,,,,
7702,127703,CID 127703,C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
7703,127704,"N-(2,3-Dichlorophenyl)-2-hydroxy-4-oxo-1,5-dioxaspiro(5.5)undec-2-ene-3-carboxamide",C1CCC2(CC1)OC(=C(C(=O)O2)C(=O)NC3=C(C(=CC=C3)Cl)Cl)O,,,,,,
7704,127705,CID 127705,CN1CC[C@]23[C@@H]4C(=O)C5(CC6=CC=CC=C6C5)C[C@]2([C@@H]1CC7C3C(O4)C(CC7)O)O,,,,,,
7705,127706,Methyl pyroglutamyl-histidyl-pipecolate,COC(=O)C1CCCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3,,,,,,
7706,127707,"3,22-Dihydroxyolean-12-en-29-oic acid",C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(C[C@@H]5O)(C)C(=O)O)C)C)C)(C)C)O,,,,,,
7707,127708,11-Hydroxy-N-n-propylnoraporphine,CCCN1CCC2=C3C1CC4=C(C3=CC=C2)C(=CC=C4)O,,,,,,
7708,127709,CID 127709,C1C2[C@H]([C@H]([C@@H](O2)N3C4=C(C(N=C(N4)N)O)N=C3Br)O)OP(=O)(O1)S,,,,,,
7709,127710,CID 127710,C1=CC=NC(=C1)C2(C(=O)NC(=N2)S)C3=CC=CC=N3,,,,,,
7710,127711,Cholecystokinin (10-20),CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N,,,,,,
7711,127712,Panamycin 607,CCC[C@H]1C[C@@H]2CC[C@@H](O2)[C@@H](C(=O)O[C@H]([C@@H]([C@@H]3CC[C@@H](O3)[C@H](C(=O)O1)C)C)[C@H](C)[C@H]4CC[C@H](O4)CC(CCC)N(C)C)C,,,,,,
7712,127713,8-Azido-cyclic adenosine diphosphate ribose,C1C2C(C(C(O2)N3C=NC4=C(C3=N)N=C(N4C5C(C(C(O5)COP(=O)(OP(=O)(O1)O)O)O)O)N=[N+]=[N-])O)O,,,,,,
7713,127714,"3',6-Dinitroflavone",C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-],,,,,,
7714,127715,2-Naphthoxyacetic acid ethylene monoamide,C1=CC=C2C=C(C=CC2=C1)OCC(=O)NCCN,,,,,,
7715,127716,"1,4-Dideoxy-1,4-imino-L-arabinitol",C1[C@@H]([C@H]([C@@H](N1)CO)O)O,,,,,,
7716,127717,"Methyl 7-[2-[2-(8-methoxycarbonyl-4b,8-dimethyl-5,6,7,8a,9,10-hexahydrophenanthren-2-yl)propan-2-ylperoxy]propan-2-yl]-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate",CC12CCCC(C1CCC3=C2C=CC(=C3)C(C)(C)OOC(C)(C)C4=CC5=C(C=C4)C6(CCCC(C6CC5)(C)C(=O)OC)C)(C)C(=O)OC,,,,,,
7717,127718,"N-[1'-(6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide",CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)C4CCC5=C(C4)C=CC(=C5)C#N)CC2O,,,,,,
7718,127719,CID 127719,CC(C)C1C(=O)OCC(C(=O)N2CCCCC2C(=O)NCC(=O)N(CC(=O)N(C(C(=O)OCC(C(=O)N3CCCCC3C(=O)NCC(=O)N(CC(=O)N1C)C)NC(=O)C4=NC5=CC=CC=C5C=C4O)C(C)C)C)C)NC(=O)C6=NC7=CC=CC=C7C=C6O,,,,,,
7719,127720,"5-[(3Ar,4R,5R,6aS)-4-[(3S)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-2-ylidene]pentanoic acid;(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol",C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C1CCC(C1)[C@@H](C=C[C@H]2[C@@H](C[C@H]3[C@@H]2C(=O)C(=CCCCC(=O)O)O3)O)O,,,,,,
7720,127721,CID 127721,C1CCC(C1)[C@@H](C=C[C@H]2[C@@H](C[C@H]3C2C(=O)C(=CCCCC(=O)O)O3)O)O,,,,,,
7721,127722,2-Amino-1-(4-chlorobenzyl)-5-trifluoromethylbenzimidazole,C1=CC(=CC=C1CN2C3=C(C=C(C=C3)C(F)(F)F)N=C2N)Cl,,,,,,
7722,127723,"5-[(3aR,4R,5R,6aS)-4-[(3S)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-2-ylidene]pentanoic acid",C1CCC(C1)[C@@H](C=C[C@H]2[C@@H](C[C@H]3[C@@H]2C(=O)C(=CCCCC(=O)O)O3)O)O,,,,,,
7723,127724,"2-((5-Chloro-2-methylphenyl)sulfonyl)-1H-isoindole-1,3(2H)-dione",CC1=C(C=C(C=C1)Cl)S(=O)(=O)N2C(=O)C3=CC=CC=C3C2=O,,,,,,
7724,127725,"1H-Isoindole-1,3(2H)-dione, 2-((2-(bromomethyl)-5-chlorophenyl)sulfonyl)-",C1=CC=C2C(=C1)C(=O)N(C2=O)S(=O)(=O)C3=C(C=CC(=C3)Cl)CBr,,,,,,
7725,127726,Phenylketophosphamide,C1=CC=C(C=C1)C(=O)CCOP(=O)(N)N(CCCl)CCCl,,,,,,
7726,127727,Phenylketoisophosphamide,C1=CC=C(C=C1)C(=O)CCOP(=O)(NCCCl)NCCCl,,,,,,
7727,127728,"Methyl 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]pyridine-3-carboxylate",COC(=O)C1=C(N=CC=C1)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,,,"['Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)']",,,
7728,127729,"2-(4-(4,4-Bis-(4-fluorophenyl)butyl)-1-piperazinyl)-3-pyridinecarboxamide",COC(=O)C1=C(N=CC=C1)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC(=CC=C4)F.Cl,,,,,,
7729,127730,Methyl 2-[4-[4-(3-fluorophenyl)-4-(4-fluorophenyl)butyl]piperazin-1-yl]pyridine-3-carboxylate,COC(=O)C1=C(N=CC=C1)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC(=CC=C4)F,,,,,,
7730,127731,"N,N-Dichlorophenytoin",C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2Cl)Cl)C3=CC=CC=C3,,,,,,
7731,127732,tert-butyl N-[1-[[3-hydroxy-5-[[1-(3-methylbutylamino)-1-oxopropan-2-yl]amino]-1-naphthalen-2-yl-5-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate,CC(C)CCNC(=O)C(C)NC(=O)CC(C(CC1=CC2=CC=CC=C2C=C1)NC(=O)C(C(C)C)NC(=O)OC(C)(C)C)O,,,,,,
7732,127733,CID 127733,CC(=C1C(=CC(=O)CC(=O)O)C=C2C=C3C=C(C=C(C3=C(C2=C1O)O)O)O)O,,,,,,
7733,127734,N'-Methyl-N(4)-aminocytidine,CNNC1=NC(=O)N(C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
7734,127735,"(+)-1,3,8,11-Tetrahydroxy-10-(4-hydroxy-2-oxopentyl)-2-methyl-5,12-naphthacenedione",CC1=C(C=C2C(=C1O)C(=O)C3=C(C4=C(C=C(C=C4C=C3C2=O)O)CC(=O)CC(C)O)O)O,,,,,,
7735,127736,Desethyl kbt-3022,COC1=CC=C(C=C1)C2=C(SC(=N2)C3=CC=CN3CC(=O)O)C4=CC=C(C=C4)OC,,,,,,
7736,127737,"N-(5-(2,3-Dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea",C1COC2=C1C=C(C=C2)S(=O)(=O)NC(=O)NC3=CC(=C(C=C3)Cl)Cl,,,,,,
7737,127738,N-Iodoacetyl-3-iodotyrosine,C1=CC(=C(C=C1C[C@@H](C(=O)O)NC(=O)CI)[125I])O,,,,,,
7738,127739,2-Hydroxy-1-methylthioindane,CSC1C(CC2=CC=CC=C12)O,,,,,,
7739,127740,CID 127740,C[C@H]1CCC=CC=C(CC(=CC[C@@H]([C@H](C=CC=CC(=O)NC1)C)O[C@H]2C[C@@H]([C@@H]([C@H](O2)C)NC)O)C)C,,,,,,
7740,127741,Rhizopine,CO[C@H]1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1O)O)O)N)O,,,,,,
7741,127742,"(1R,4S,5R,12S,13R)-1,5-Dimethyl-9-methylidene-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one",C[C@@H]1CCC2C(=C)C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C,,,,,,
7742,127743,"3-(3,4-dihydro-2H-pyrrol-5-ylamino)-2-methylphenol;hydrochloride",CC1=C(C=CC=C1O)NC2=NCCC2.Cl,,,,,,
7743,127744,"3-((3,4-Dihydro-2H-pyrrol-5-yl)amino)-2-methylphenol",CC1=C(C=CC=C1O)NC2=NCCC2,,,,,,
7744,127745,CID 127745,C1CCCC(CCC1)NC2=C(C=NC=C2)S(=O)(=O)NC(=NC3CCCCC3)S,,,,,,
7745,127746,CID 127746,CC1=CC(=O)C2=C(C3=C(C(=CC(=O)OC3C(=O)OC)Br)OC2=C1)O,,,,,,
7746,127747,"6-(3-methylbut-2-enyl)-1H-indole-2,3-dione",CC(=CCC1=CC2=C(C=C1)C(=O)C(=O)N2)C,,,,,,
7747,127748,"Methyl 2-[2-(2-hydroxyphenyl)-1,3-benzoxazol-4-yl]-1,3-benzoxazole-4-carboxylate",COC(=O)C1=C2C(=CC=C1)OC(=N2)C3=C4C(=CC=C3)OC(=N4)C5=CC=CC=C5O,,,,,,
7748,127749,CID 127749,CN1CCC[C@@H]1CC2=CN=C3C2=CC(=NC4=C(C=CC=N4)N(O)O)C=C3,,,,,,
7749,127750,Rhodamine 800,C1CC2=CC3=C(C4=C2N(C1)CCC4)OC5=C6CCC[N+]7=C6C(=CC5=C3C#N)CCC7.[O-]Cl(=O)(=O)=O,,,,,,
7750,127751,"13-Cyano-4,5:7,8-dipropano-2,3,8,9,10,11-hexahydro-1H-6-oxa-4-azonia-8-azapentacene",C1CC2=CC3=C(C4=C2N(C1)CCC4)OC5=C6CCC[N+]7=C6C(=CC5=C3C#N)CCC7,,,,,,
7751,127752,3-Arsonoalanine,C(C(C(=O)O)N)[As](=O)(O)O,,,,,,
7752,127753,"N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide hydrochloride",COC1=C(C=C2C(=C1)C=C(S2)C(=NO)N)OC.Cl,,,,,,
7753,127754,"N-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide",COC1=C(C=C2C(=C1)C=C(S2)C(=NO)N)OC,,,,,,
7754,127755,Hmpiq,CN1CC[C@H]2[C@@H]1C3=C(CC2)C=CN=C3.Br.Br,,,,,,
7755,127756,"(3aS,9bR)-1-Methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-h]isoquinoline",CN1CC[C@H]2[C@@H]1C3=C(CC2)C=CN=C3,,,,,,
7756,127757,"(S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride",CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C5C[C@H](CCN5C6=CC=CC=C64)CN(C)C,,,,,,
7757,127758,"8-[(4-Hydroxyphenyl)methyl]-18-(6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl)-1,5,12,19-tetramethyl-2-methylidene-15-(2-methylsulfanylethyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid",CC1C(NC(=O)C(NC(=O)C(C(NC(=O)C(NC(=O)C(NC(=O)C(=C)N(C(=O)CCC(NC1=O)C(=O)O)C)C)CC2=CC=C(C=C2)O)C(=O)O)C)CCSC)C=CC(=CC(C)C(CC3=CC=CC=C3)OC)C,,,,,,
7758,127759,N-(4-(2-(6-Dimethylamino)benzofuranyl)phenyl)maleimide,CN(C)C1=CC2=C(C=C1)C=C(O2)C3=CC=C(C=C3)N4C(=O)C=CC4=O,,,,,,
7759,127760,"5-Oxoicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=CCC(=O)CCCC(=O)O,,,,,,
7760,127761,"(+-)-alpha-Amino-2,3-dihydro-2-oxo-1H-imidazole-4-propanoic acid",C1=C(NC(=O)N1)CC(C(=O)O)N,,,,,,
7761,127762,N-Nitrosoarginine,C(C[C@@H](C(=O)O)N)CN=C(N)N=O,,,,,,
7762,127763,"(2R,3R)-3-ethyl-2-[(2R,3S,4R,5S)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-enyl]-2,3-dihydropyran-6-one",CC[C@@H]1C=CC(=O)O[C@@H]1C[C@H]([C@H](C)[C@@H]([C@@H](C)CC=CC)OC)O,,,,,,
7763,127764,"(2S)-4-[[(3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoic acid",CC(=O)N[C@@H]1[C@H]([C@H]([C@H](OC1NC(=O)C[C@@H](C(=O)O)N)CO)O)O,,,,,,
7764,127765,"ethyl 4-(methoxymethyl)-5-propan-2-yloxy-9H-pyrido[3,4-b]indole-3-carboxylate",CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OC(C)C,,,,,,
7765,127766,Levodopa-4'-monophosphate,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O,,,,,,
7766,127767,6-Hydroxy-methyl 1'-epiacarviosin,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)N[C@@H]2C=C([C@H]([C@@H]([C@H]2O)O)O)CO)O)O,,,,,,
7767,127768,CID 127768,CC1C(C(CC(O1)C2=C3C(=C(C=C2C4CC(C(C(O4)C)O)(C)N(C)C)O)C(C5=C(C3=O)C=CC6=C5OC(=CC6=O)C7(C(O7)C8C(O8)C)C)C9=CC=C(N9C)C(=O)NCCC(=O)O)N(C)C)O,,,,,,
7768,127769,"4-Ethyl-5-(4-imidazol-1-ylbenzoyl)-1,3-dihydroimidazol-2-one",CCC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)N3C=CN=C3,,,,,,
7769,127770,"4-Ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one",CCC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)N3C=CN=C3C,,,,,,
7770,127771,Nbg-gma,CC(=C)C(=O)OCC(CN(CC1=CC=CC=C1)CC(=O)O)O,,,,,,
7771,127772,"Guanidine, N-(4-(2-methyl-1H-imidazol-4-yl)-2-thiazolyl)-N'-pentyl-",CCCCCN=C(N)NC1=NC(=CS1)C2=CN=C(N2)C,,,,,,
7772,127773,"4,10,14,20-Tetrahydroxy-3,7,9,11,17,21-hexamethyl-31-methylsulfanyl-29-azatricyclo[28.3.1.05,33]tetratriaconta-1(33),2,4,7,12,16,22,24,26,30-decaene-6,18,28,32,34-pentone",CC1C=CC=CC=CC(=O)NC2=C(C(=O)C3=C(C2=O)C=C(C(=C3C(=O)C(=CC(C(C(C=CC(CC=C(C(=O)CC1O)C)O)C)O)C)C)O)C)SC,,,,,,
7773,127774,N-Hydroxypyridine-4-thione,C1=CN(C=CC1=S)O,,,,,,
7774,127775,"4,10,14,20-Tetrahydroxy-31-methoxy-3,7,9,11,17,21-hexamethyl-29-azatricyclo[28.3.1.05,33]tetratriaconta-1(33),2,4,7,12,16,22,24,26,30-decaene-6,18,28,32,34-pentone",CC1C=CC=CC=CC(=O)NC2=C(C(=O)C3=C(C2=O)C=C(C(=C3C(=O)C(=CC(C(C(C=CC(CC=C(C(=O)CC1O)C)O)C)O)C)C)O)C)OC,,,,,,
7775,127776,Laidlomycin phenylcarbamate,CCC(=O)OC(C(C)C1C(C(CC2(O1)CCC(O2)(C)C3CCC(O3)(C)C4C(CC(O4)C5C(CC(C(O5)(COC(=O)NC6=CC=CC=C6)O)C)C)C)O)C)C(C)C(=O)O,,,,,,
7776,127777,CID 127777,C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)N=C(N3)N)N=C2N)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
7777,127778,Dhaptp,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NO)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
7778,127779,9-(2-fluorobenzyl)-6-(methylamino)-9H-purine,CNC1=C2C(=NC=N1)N(C=N2)CC3=CC=CC=C3F,,,,,,
7779,127780,Buprenorphine B-D-glucuronide,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=CC(=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)O4)CC8CC8)OC)(C(C)(C)C)O,,,,,,
7780,127781,CID 127781,C[N+]1=C2CCCC2=C(C=C1)SCC3=C(N4[C@@H]([C@@H](C4=O)NC(=O)C(=NOCC(=O)O)C5=CSC(=N5)N)SC3)C(=O)[O-],,,,,,
7781,127782,CID 127782,C[N+]1=C2CCCC2=C(C=C1)SCC3=C(N4[C@@H]([C@@H](C4=O)NC(=O)C(=NOCC(=O)O)C5=CSC(=N5)N)SC3)C(=O)O,,,,,,
7782,127783,"2-Methyl-3-(piperidinomethyl)pyrido(2,3-d)pyrimidin-4(3H)-one",CC1=NC2=C(C=CC=N2)C(=O)N1CN3CCCCC3,,,,,,
7783,127784,"[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadec-9-enoate",CCCCCCCCC=CCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
7784,127785,CID 127785,C1CCC(C(C1)N)N.C(=O)C(=C(C(=O)[O-])Br)Br.C(=O)C(=C(C(=O)[O-])Br)Br.[Pt+2],,,,,,
7785,127786,6-Hydroxyeburamonine,CC[C@@]12CCCN3[C@@H]1C4=C(C(C3)O)C5=CC=CC=C5N4C(=O)C2,,,,,,
7786,127787,CID 127787,C#CCN(CC1=CC2=C(C=C1)NC(=NC2=O)N)C3=CC=C(C=C3)C(=O)O,,,,,,
7787,127788,(5'-((N-Triphosphoamino)methyl)adenosyl)homocysteine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)[C@@H](CP(=O)(O)OP(=O)(O)OP(=O)(O)O)SCC[C@@H](C(=O)O)N)O)O)N,,,,,,
7788,127789,Platinum(II) pentamidine,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.[Cl-].[Cl-].[Pt+2],,,,,,
7789,127790,Duartin,COC1=C(C(=C(C=C1)[C@H]2CC3=C(C(=C(C=C3)O)OC)OC2)OC)O,,,,,,
7790,127791,"[(2R,3S,4S,6R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[[(2R)-2-amino-3-methylbutanoyl]amino]-2-methylpropan-2-yl]sulfanylacetate",C[C@@H]1CCC23CCC(=O)[C@H]2C1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC(C)(C)CNC(=O)[C@@H](C(C)C)N)C,,,,,,
7791,127792,5'-Iodoacetamido-5'-deoxythymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CNC(=O)CI)O,,,,,,
7792,127793,"[2-[[10-Formyl-5,11,14-trihydroxy-13-methyl-12-oxo-17-(6-oxopyran-3-yl)-1,2,3,4,6,7,8,9,11,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-3-hydroxy-6-methyloxan-4-yl] acetate",CC1CC(C(C(O1)OC2CCC3(C4C(CCC3(C2)O)C5(CCC(C5(C(=O)C4O)C)C6=COC(=O)C=C6)O)C=O)O)OC(=O)C,,,,,,
7793,127794,Amiloride caproate,C(CCC(=O)O)CCN=C(N)NC(=O)C1=C(N=C(C(=N1)Cl)N)N,,,,,,
7794,127795,CID 127795,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC)OC3=C(OC4=CC(=CC(=O)C4=C3O)OC)C5=CC(=C(C=C5)O)O)O)O)O)O)O,,,,,,
7795,127796,N-Desmethylrufloxacin,C1CN(CCN1)C2=C(C=C3C4=C2SCCN4C=C(C3=O)C(=O)O)F,,,,,,
7796,127797,Irisoquin,CCCCCCCCCCCCCCCCCCC1=C(C(=O)C=C(C1=O)OC)O,,,,,,
7797,127798,CID 127798,CN1CC[C@]23[C@@H]4C(=NNC5=CC=CC=C5)CC[C@]2([C@@H]1CC6=C3C(=C(C=C6)O)O4)O,,,,,,
7798,127799,CID 127799,CN1CC[C@]23[C@@H]4C(=NNC5=CC=C(C=C5)[N+](=O)[O-])CC[C@]2([C@@H]1CC6=C3C(=C(C=C6)O)O4)O,,,,,,
7799,127800,Methyl 2-[ethoxy-(propan-2-ylamino)phosphinothioyl]oxybenzoate,CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC,,,,,,
7800,127801,CID 127801,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N(CC2=CC3=C(C=C2)NC(=NC3=O)N)C(=O)CBr,,,,,,
7801,127802,At-Ncl,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H](C4=C3CC[C@@H](C4)O)C[211At])C,,,,,,
7802,127803,"5,7-Dihydro-2-(((4-methoxy-3-methyl-2-pyridyl)methyl)sulfinyl)-5,5,7,7-tetramethylindeno(5,6-d)imidazol-6(1H)-one",CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C4C(=C3)C(C(=O)C4(C)C)(C)C)OC,,,,,,
7803,127804,Bruceanol B,CCCCCC(=O)O[C@@H]1[C@H]2[C@@]3([C@H]([C@@H]([C@H]4C2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H](C(=O)C=C5C)O)C)OC1=O)O)O)C(=O)OC,,,,,,
7804,127805,Bruceanol A,CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3C45[C@@H]2[C@H]([C@@H]([C@@]([C@@H]4[C@H](C(=O)O3)OC(=O)C6=CC=CC=C6)(OC5)C(=O)OC)O)O)C)O,,,,,,
7805,127806,"Thiophene, tetrahydro-2,5-bis(3,4,5-trimethoxyphenyl)-, trans-",COC1=CC(=CC(=C1OC)OC)[C@@H]2CCC(S2)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7806,127807,"N-(5-Aminopentyl)-N'-(4-methoxybenzyl)-N-methyl-N'-2-pyridinyl-1,2-ethanediamine",CN(CCCCCN)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,,,,,,
7807,127808,Iodobolpyramine,CN(CCCCCNC(=O)CCC1=CC(=C(C=C1)O)[125I])CCN(CC2=CC=C(C=C2)OC)C3=CC=CC=N3,,,,,,
7808,127809,"2-(4-Hydrazinocarbonylphenyl)-4,5-diphenylimidazole",C1=CC=C(C=C1)C2=C(N=C(N2)C3=CC=C(C=C3)C(=O)NN)C4=CC=CC=C4,,,,,,
7809,127810,[2-(Dimethylamino)-3-hydroxyoctadec-4-enyl] dihydrogen phosphate,CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N(C)C)O,,,,,,
7810,127811,"1,3-Diaziridino-2,4,6-triaza-1,3,5,5-tetraaminomethyl-1,3,5-triphosphorin",CNP1(=NP(=NP(=N1)(NC)N2CC2)(NC)N3CC3)NC,,,,,,
7811,127812,"1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1-methyl-1-((6-(1H-1,2,4-triazol-1-yl)-3-pyridazinyl)thio)ethyl)-, (+)-",CC(C)(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)SC3=NN=C(C=C3)N4C=NC=N4,,,,,,
7812,127813,CID 127813,C1=CC(=CC=C1NN=NCO[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[N+](=O)[O-],,,,,,
7813,127814,"1,5,6,7-Tetrahydro-7-hydroxy-9H-imidazo(1,2-a)purin-9-one",C1C(N2C(=O)C3=C(N=CN3)N=C2N1)O,,,,,,
7814,127815,Dhnpyo,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@]4([C@@H]3CCC(=O)C4)O,,,,,,
7815,127816,"N(1)-Ethyl-N-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine",CCNCCCNCCCNCCCNCC1CC1.Br.Br.Br.Br,,,,,,
7816,127817,CPEN-spm,CCNCCCNCCCNCCCNCC1CC1,,,,,,
7817,127818,"5-Acetamido-3,5,7,9-tetradeoxy-7-formamido-L-glycero-L-manno-nonulosonic acid",C[C@@H]([C@@H]([C@@H]([C@H]([C@H](CC(=O)C(=O)O)O)NC(=O)C)O)NC=O)O,,,,,,
7818,127819,"2-Methyl-4,6-bis(N,N-dimethylaminophenyl)pyrylium iodide",CC1=CC=C(C=C1)C2=C(C=CC(=[O+]2)C)C3=CC=C(C=C3)N(C)C.[I-],,,,,,
7819,127820,"N,N-dimethyl-4-[6-methyl-2-(4-methylphenyl)pyrylium-3-yl]aniline",CC1=CC=C(C=C1)C2=C(C=CC(=[O+]2)C)C3=CC=C(C=C3)N(C)C,,,,,,
7820,127821,CID 127821,COC1=C(C=CC(=C1)C=CC(=O)O[C@@H]2[C@H]([C@@H](O[C@H]2OC[C@@H]([C@@H]([C@H](CO)O)O)O)CO)O)O,,,,,,
7821,127822,(+)-4-(3-(Phosphonooxy)propyl)-2-piperazinecarboxylic acid,C1CN(CC(N1)C(=O)O)CCCOP(=O)(O)O,,,,,,
7822,127823,CID 127823,CC(=CN=NC(=NC1=CC=CC=C1)S)NNC(=NC2=CC=CC=C2)S,,,,,,
7823,127824,Salicylazobenzoic acid,C1=CC(=CC=C1C(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,,,,,,
7824,127825,N-(4-Methylbenzylthiocarbonyl)phenylalanine,CC1=CC=C(C=C1)CSC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O,,,,,,
7825,127826,"1H-Imidazole, 2,5-dihydro-1,2,2,4,5,5-hexamethyl-, 3-oxide",CC1=[N+](C(N(C1(C)C)C)(C)C)[O-],,,,,,
7826,127827,"N,N-Dimethyl-(6-benzyl-4,4-dimethyl-2-cyclohexenyl)methylamine",CC1(C[C@@H]([C@H](C=C1)CN(C)C)CC2=CC=CC=C2)C.Cl,,,,,,
7827,127828,"1-[(1R,6R)-6-benzyl-4,4-dimethylcyclohex-2-en-1-yl]-N,N-dimethylmethanamine",CC1(C[C@@H]([C@H](C=C1)CN(C)C)CC2=CC=CC=C2)C,,,,,,
7828,127829,"(2R,3R,10S,12S,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-2,3,12-triol",C[C@H](CC[C@H](C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1([C@H](CC3=C2CCC4[C@@]3(C[C@H]([C@@H](C4(C)C)O)O)C)O)C)C,,,,,,
7829,127830,4-Benzyl-6-chloro-o-cresol,CC1=CC(=CC(=C1O)Cl)CC2=CC=CC=C2,,,,,,
7830,127831,"1,2,3-Trichlorobut-2-ene",CC(=C(CCl)Cl)Cl,,,,,,
7831,127832,1-Methoxy-5-methylphenazinium methyl sulfate,C[N+]1=C2C=CC=C(C2=NC3=CC=CC=C31)OC.COS(=O)(=O)[O-],,,,,,
7832,127833,1-Methoxy-5-methylphenazin-5-ium,C[N+]1=C2C=CC=C(C2=NC3=CC=CC=C31)OC,,,,,,
7833,127834,"2-Thiazolidinecarboxamide, 3-(N-L-prolyl-L-leucyl)-",CC(C)C[C@@H](C(=O)N1CCSC1C(=O)N)NC(=O)[C@@H]2CCCN2,,,,,,
7834,127835,Ara-ada,CC(=O)O[C@@H]1[C@H](O[C@H]([C@H]1OC(=O)C)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
7835,127836,"Benzoic acid, 2-((3,5-dibromo-4-hydroxyphenyl)(3,5-dibromo-4-oxo-2,5-cyclohexadien-1-ylidene)methyl)-, methyl ester",COC(=O)C1=CC=CC=C1C(=C2C=C(C(=O)C(=C2)Br)Br)C3=CC(=C(C(=C3)Br)O)Br,,,,,,
7836,127837,"5,6,7,8-Tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol",C1CC2=C(CNC1)C(=O)NO2,,,,,,
7837,127838,beta-Ethynylserine,C#C[C@H]([C@@H](C(=O)O)N)O,,,,,,
7838,127839,Pyroglutamylhistidyl-N-ethylamide,CCN[C@@H](CC1=CN=CN1)C(=O)NC(=O)[C@@H]2CCC(=O)N2,,,,,,
7839,127840,"2,6-Bis(iodomethyl)piperidine hydrochloride",C1CC(NC(C1)CI)CI.Cl,,,,,,
7840,127841,CID 127841,C1CC(NC(C1)CI)CI,,,,,,
7841,127842,"(3-Hexadecanoyloxy-2-hexa-2,4-dienoyloxypropyl) hexadecanoate",CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)C=CC=CC,,,,,,
7842,127843,"[4-Hydroxy-7-(1-hydroxyethyl)-3-[6-(4-methoxy-3-methyl-6-oxopyran-2-yl)hexa-1,3,5-trienyl]-1,5-dimethyl-2,6-dioxabicyclo[3.2.1]octan-8-yl] acetate",CC1=C(OC(=O)C=C1OC)C=CC=CC=CC2C(C3(C(C(O2)(C(O3)C(C)O)C)OC(=O)C)C)O,,,,,,
7843,127844,"3-(2-Hydroxypentyl)-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol",CCCC(CC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O)O,,,,,,
7844,127845,Ethyl 3-hydroxy-2-oxo-3-phenylpiperidine-1-carboxylate,CCOC(=O)N1CCCC(C1=O)(C2=CC=CC=C2)O,,,,,,
7845,127846,"7-Ethoxy-6-methoxy-2,2-dimethylchromene",CCOC1=C(C=C2C=CC(OC2=C1)(C)C)OC,,,,,,
7846,127847,Liriodendronine,C1=CC=C2C(=C1)C3=C(C(=O)C=C4C3=C(C2=O)NC=C4)O,,,,,,
7847,127848,15-Carboxymethyltestosterone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3[C@H](C[C@@H]4O)CC(=O)O)C,,,,,,
7848,127849,"10-[(3-Chlorophenyl)methyl]-7,8-dimethylbenzo[g]pteridine-2,4-dione",CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC4=CC(=CC=C4)Cl,,,,,,
7849,127850,"(3,4-Dihydroxyphenyl)methyl 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate",C1CNC(C2=CC(=C(C=C21)O)O)C(=O)OCC3=CC(=C(C=C3)O)O,,,,,,
7850,127851,"7,11-Dimethyloctadecane",CCCCCCCC(C)CCCC(C)CCCCCC,,,,,,
7851,127852,Acetyl-asparaginyl-methylglycinamide,CC(=O)N[C@@H](CC(=O)N)C(=O)NC(=O)CNC,,,,,,
7852,127853,N-(alpha-Methylbenzylidene)-p-toluenesulfinamide,CC1=CC=C(C=C1)S(=O)N=C(C)C2=CC=CC=C2,,,,,,
7853,127854,4-Chloronitrosopiperidine,C1CN(CCC1Cl)N=O,,,,,,
7854,127855,"3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-",COC1=CC=CC(=C1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,,,,,,
7855,127856,N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide,C1CC(C1)C(=O)NCCC2=CC=CC3=CC=CC=C32,,,,,,
7856,127857,"1-Acetoxy-2,5-dioxopyrrolidine-3-sulfonic acid",CC(=O)ON1C(=O)CC(C1=O)S(=O)(=O)O,,,,,,
7857,127858,CID 127858,CN1CCCC1C2=C[N+](=CC=C2)[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C([O-])[O-])O)O)O,,,,,,
7858,127859,CID 127859,CN1CCCC1C2=C[N+](=CC=C2)[C@@H]3[C@@H](C([C@@H]([C@H](O3)C(O)O)O)O)O,,,,,,
7859,127860,CID 127860,CC1=NC(=O)C2=C(N1)C=CC(=C2)CN(CC#C)C3=CC=C(C=C3)S(=O)(=O)N4C=CC5=CC=CC=C54,,,,,,
7860,127861,Bmy 45778,C1=CC=C(C=C1)C2=C(OC(=N2)C3=C(OC=N3)C4=CC(=CC=C4)OCC(=O)O)C5=CC=CC=C5,,,,,,
7861,127862,2-Propanoyl-3-(4-tolyl)tropane,CCC(=O)[C@@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC=C(C=C3)C,,,,,,
7862,127863,"3-Benzylidene-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrrolidine-2,5-dione",COC1=CC(=CC(=C1OC)OC)C=C2C(=CC3=CC=CC=C3)C(=O)NC2=O,,,,,,
7863,127864,N-(3-Oxododecanoyl)homoserine lactone,CCCCCCCCCC(=O)CC(=O)NC1CCOC1=O,,,,,,
7864,127865,"7-(7-Heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)-3-methylocta-2,4,6-trienoic acid",CCCCCCCOC1=CC2=C(C=C1C(=CC=CC(=CC(=O)O)C)C)C(CCS2(=O)=O)(C)C,,,,,,
7865,127866,"2-Cyclopropyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)oxy)-4-quinolinecarboxylic acid",C1CC1C2=NC3=CC=CC=C3C(=C2OC4=CC=C(C=C4)C5=CC=CC=C5C6=NNN=N6)C(=O)O,,,['Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)'],,,
7866,127867,3-Amino-5-[1-cyano-2-(1H-indol-3-yl)ethenyl]-1H-pyrazole-4-carbonitrile,C1=CC=C2C(=C1)C(=CN2)C=C(C#N)C3=C(C(=NN3)N)C#N,,,,,,
7867,127868,(m-Nitrobenzoyl)alanine,C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)CC(C(=O)O)N,,,,,,
7868,127869,"2-N,N-Dimethylamino-4,6-bis(1-H-imidazol-1-yl)-1,3,5-triazine",CN(C)C1=NC(=NC(=N1)N2C=CN=C2)N3C=CN=C3,,,,,,
7869,127870,Veranisatin A,CC1CCC2(C13CC(C(C24COC4=O)(COC)O)OC(=O)C3O)O,,,,,,
7870,127871,Veranisatin B,CC1CCC2(C13CC(C(C24COC4=O)(C(=O)OC)O)OC(=O)C3O)O,,,,,,
7871,127872,"5-Chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione",C1=C(C=C(C2=C1NC(=O)C(=O)N2)Cl)C(F)(F)F,,,,,,
7872,127873,2-(N-Methyl-3-pyridinyl)-1-hydroxyethylidene bisphosphonic acid,C[N+]1=CC=CC(=C1)CCC(O)(P(=O)(O)O)P(=O)(O)O.[OH-],,,,,,
7873,127874,[1-Hydroxy-3-(1-methylpyridin-1-ium-3-yl)-1-phosphonopropyl]phosphonic acid,C[N+]1=CC=CC(=C1)CCC(O)(P(=O)(O)O)P(=O)(O)O,,,,,,
7874,127875,"6-(Trifluoroacetamido)-4,5-dihydroxypiperidine-3-carboxylic acid",C1[C@@H]([C@@H]([C@@H]([C@H](N1)NC(=O)C(F)(F)F)O)O)C(=O)O,,,,,,
7875,127876,3-Bromobenzylguanidine,C1=CC(=CC(=C1)[76Br])CN=C(N)N,,,,,,
7876,127877,CID 127877,CC=C(C(=O)OC1C(OC(C(C1OC2CC(C(C(O2)C)(C(C)OC(=O)C)O)OC)O)C3(CC(=O)C(=C(C3=O)C(=O)O)N)O)COC(=O)C)N=C=S,,,,,,
7877,127878,CID 127878,CCC(C)C(=O)OC(C)C1(C(OC(CC1OC)OC2C(C(OC(C2OC(=O)C(=CC)N=C=S)COC(=O)C)C3(CC(=O)C(=C(C3=O)C(=O)O)N)O)O)C)O,,,,,,
7878,127879,CID 127879,CC=C(C(=O)OC1C(OC(C(C1OC2CC(C(C(O2)C)(C(=O)C)O)OC)O)C3(CC(=O)C(=C(C3=O)C(=O)O)N)O)COC(=O)C)N=C=S,,,,,,
7879,127880,"5-((N,N-Dimethylamino)ethylthio)-8-chloro-6-phenyl-6H-(1,2,4)triazolo(4,3-a)(1,5)benzodiazepine",CC1=NN=C2N1C3=C(C=C(C=C3)Cl)N(C(=C2)SCCN(C)C)C4=CC=CC=C4,,,,,,
7880,127881,"8-Chloro-1-methyl-5-(4-methylpiperazin-1-yl)-6-phenyl-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine",CC1=NN=C2N1C3=C(C=C(C=C3)Cl)N(C(=C2)N4CCN(CC4)C)C5=CC=CC=C5,,,,,,
7881,127882,"2-Amino-4-hydroxymethyl-3,8-dimethylimidazo(4,5-f)quinoxaline",CC1=CN=C2C=C(C3=C(C2=N1)N=C(N3C)N)CO,,,,,,
7882,127883,2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid,C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NCP(=O)(OC4=CC=CC=C4)OC5=CC=CC=C5,,,,,,
7883,127884,2-Amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid,C1=CC=C(C=C1)C2=C(C(=O)NO2)C[C@H](C(=O)O)N,,,,,,
7884,127885,4-(s)-[(1-Oxo-7-phenylheptyl)amino]-5-[4-(phenylmethyl)phenylthio]pentanoic acid,C1=CC=C(C=C1)CCCCCCC(=O)N[C@@H](CCC(=O)O)CSC2=CC=C(C=C2)CC3=CC=CC=C3,,,,,,
7885,127886,2-(1-Carboxy-2-phenylethyl)-4-phenylazophenol,C1=CC=C(C=C1)CC(C2=C(C=CC(=C2)N=NC3=CC=CC=C3)O)C(=O)O,,,,,,
7886,127887,Fluoroclebopride,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=C(C=C3)F)Cl)N,,,,,,
7887,127888,"4-Phenyl-1,3,3-trimethyl-2,3-dihydropyridinium",CC1(C[N+](=CC=C1C2=CC=CC=C2)C)C,,,,,,
7888,127889,3-Nitro-1-propylamine,C(CN)C[N+](=O)[O-],,,,,,
7889,127890,1-(18F)Fluoranyl-3-iodopropane,C(C[18F])CI,,,,,,
7890,127891,"2-(3-{3,3-Dimethyl-1-[3-(3-methyl-3H-diaziren-3-yl)propyl]-1,3-dihydro-2H-indol-2-ylidene}prop-1-en-1-yl)-1,3,3-trimethyl-3H-indol-1-ium chloride",CC1(C2=CC=CC=C2[N+](=C1C=CC=C3C(C4=CC=CC=C4N3CCCC5(N=N5)C)(C)C)C)C.[Cl-],,,,,,
7891,127892,"3,3-Dimethyl-1-[3-(3-methyldiazirin-3-yl)propyl]-2-[3-(1,3,3-trimethylindol-1-ium-2-yl)prop-2-enylidene]indole",CC1(C2=CC=CC=C2[N+](=C1C=CC=C3C(C4=CC=CC=C4N3CCCC5(N=N5)C)(C)C)C)C,,,,,,
7892,127893,5-Benzamido-2-benzyl-4-oxopentanoic acid,C1=CC=C(C=C1)CC(CC(=O)CNC(=O)C2=CC=CC=C2)C(=O)O,,,,,,
7893,127894,Tezampanel,C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O,['Investigated for use/treatment in pain (acute or chronic) and migraine and cluster headaches.'],,,,,
7894,127895,4-Fluorobenzyltrozamicol,C1CN(C[C@@H]([C@H]1O)N2CCC(CC2)C3=CC=CC=C3)CC4=CC=C(C=C4)[18F],,,,,,
7895,127896,"2-Methyl-5-(dimethylamino)methyl-1,3-oxathiolane-3-oxide",C[C@H]1O[C@H](CS1=O)C[N+](C)(C)C.[I-],,,,,,
7896,127897,"trimethyl-[[(2S,5S)-2-methyl-3-oxo-1,3-oxathiolan-5-yl]methyl]azanium",C[C@H]1O[C@H](CS1=O)C[N+](C)(C)C,,,,,,
7897,127898,N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide,C1CCN(CC1)CCNC(=O)C2=CC=C(C=C2)I,,,,,,
7898,127899,"4-Methoxy-2,3,5-trimethylpyridine",CC1=CN=C(C(=C1OC)C)C,,,,,,
7899,127900,CID 127900,CNCC(C1=C(C(=CC=C1)O)F)O.C(=O)(C(=O)O)O,,,,,,
7900,127901,2-Fluoro-3-[1-hydroxy-2-(methylamino)ethyl]phenol,CNCC(C1=C(C(=CC=C1)O)F)O,,,,,,
7901,127902,2-[1-(4-Piperonyl)piperazinyl]benzothiazole,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC5=CC=CC=C5S4,,,,,,
7902,127903,2-Fluoro-5-[1-hydroxy-2-(methylamino)ethyl]phenol;oxalic acid,CNCC(C1=CC(=C(C=C1)F)O)O.C(=O)(C(=O)O)O,,,,,,
7903,127904,"Benzeneethanamine, 4-fluoro-beta,3-dihydroxy-N-methyl-",CNCC(C1=CC(=C(C=C1)F)O)O,,,,,,
7904,127905,Adenosine triphosphopyridoxal,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
7905,127906,"5-Cyclopropyl-7-(2,6-dimethyl-4-pyridinyl)-8-fluoro-2-hydroxypyrimido(1,6-a)benzimidazole-1,3(2H,5H)-dione",CC1=CC(=CC(=N1)C)C2=CC3=C(C=C2F)N4C(=CC(=O)N(C4=O)O)N3C5CC5,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
7906,127907,4-[2-[Ethyl(4-hydroxybutyl)amino]propyl]phenol,CCN(CCCCO)C(C)CC1=CC=C(C=C1)O,,,,,,
7907,127908,Adenosine tetraphosphopyridoxal,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
7908,127909,"(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide",CCNC(=O)CCCC=CC[C@H]1[C@H](C[C@H]([C@@H]1C=C[C@H](CCC2=CC=CC=C2)O)O)O,,,,,,
7909,127910,"(4R)-4-[(11R)-11-methoxy-8-methyltetradeca-1,5,7,13-tetraenyl]-2-[(2S)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole",C[C@H]1CC1C2=N[C@@H](CS2)C=CCCC=CC=C(C)CC[C@H](CC=C)OC,,,,,,
7910,127911,"(R*,S*)-(+-)-2-(2-(1-((4-Chlorophenyl)methyl)-4,5-dihydro-4-methyl-6-((5-phenyl-2-pyridinyl)methoxy)-1H-thiopyrano(2,3,4-cd)indol-2-yl)ethoxy)butanoic acid",CC[C@H](C(=O)O)OCCC1=C2C3=C(N1CC4=CC=C(C=C4)Cl)C=CC(=C3C[C@@H](S2)C)OCC5=NC=C(C=C5)C6=CC=CC=C6,,,,,,
7911,127912,"2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide",C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2N)C3=NSC4=CC=CC=C43,,,,,,
7912,127913,"methyl (1R,2S,3S,5S)-3-(4-chlorophenyl)-8-(3-iodoprop-2-enyl)-8-azabicyclo[3.2.1]octane-2-carboxylate",COC(=O)[C@@H]1[C@H]2CC[C@H](N2CC=CI)C[C@@H]1C3=CC=C(C=C3)Cl,,,,,,
7913,127914,"2-(3,4-Dichlorophenyl)-N-methyl-N-(1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl)acetamide",CN([C@H](CN1CCCC1)C2=CC(=CC=C2)N=C=S)C(=O)CC3=CC(=C(C=C3)Cl)Cl,,,,,,
7914,127915,"3-Bromo-N-((1-ethyl-2-pyrrolidinyl)-methyl)-5-hydroxy-2,6-dimethoxybenzamide hydrochloride",CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Br)O)OC,,,,,,
7915,127916,"4,8-diamino-N-[1-amino-3-(carbamoylamino)-1-oxopropan-2-yl]-2,3,5,7,9-pentahydroxynonanamide",C(C(C(CO)N)O)C(C(C(C(C(=O)NC(CNC(=O)N)C(=O)N)O)O)N)O,,,,,,
7916,127917,N-Desethylatevirdine,COC1=CC2=C(C=C1)NC(=C2)C(=O)N3CCN(CC3)C4=C(C=CC=N4)N,,,,,,
7917,127918,2-[(1-Hydroxy-1-{[1-hydroxy-3-(4-methoxyphenyl)-1-(methylimino)propan-2-yl]imino}-3-methylpentan-2-yl)amino]-4-[(1-hydroxy-2-phenylethylidene)amino]butanoic acid,CCC(C)C(C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC)NC(CCNC(=O)CC2=CC=CC=C2)C(=O)O,,,,,,
7918,127919,3-Fluoro-alpha-fluoromethyltyrosine,C1=CC(=C(C=C1C[C@@](CF)(C(=O)O)N)[18F])O,,,,,,
7919,127920,"2-(2',3',5'-Triiodobenzoyl)ethyl methacrylate",CC(=C)C(=O)OCCOC(=O)C1=C(C(=CC(=C1)I)I)I,,,,,,
7920,127921,3-Methylfentanyl isothiocyanate,CCC(=O)N([C@@H]1CCN(C[C@@H]1C)CCC2=CC=C(C=C2)N=C=S)C3=CC=CC=C3,,,,,,
7921,127922,(R)-2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine,CC1=C(C=CC=N1)OC[C@H]2CCCN2,,,,,,
7922,127923,"3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone",CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC(=C(C=C3)F)F,,,,,,
7923,127924,Glycyl-leucyl-leucyl-aspartyl-leucyl-lysine,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN,,,,,,
7924,127925,Methyl 4-hydroxy-3-(3'-methyl-2'-butenyl)benzoate,CC(=CCC1=C(C=CC(=C1)C(=O)OC)O)C,,,,,,
7925,127926,Propyldapsone,CCCNC1=CC(=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)N)C,,,,,,
7926,127927,CID 127927,C1[C@@H]([C@H](O[C@H]1N2C=CC3=C2NC(=NC3=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
7927,127928,4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine,COC1=C(C=C(C=C1)[C@H](CC2=CC=NC=C2)C3=CC=CC=C3)OC4CCCC4,,,,,,
7928,127929,Ipabc,CC(C)NC1=C(C2=C(C=C1)N(C3=CC=CC=C32)CC4=CC(=C(C=C4)N=[N+]=[N-])I)OCC(C)O,,,,,,
7929,127930,CID 127930,CCC(C1=CC=CC=C1)C2=C(OC3=C(C2=O)CCCCCC3)O,,,,,,
7930,127931,alpha-Fluorothymidine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)CF)CO)O,,,,,,
7931,127932,CID 127932,CNC(=O)[C@H]1C[C@H]([C@@H]([C@@H]1O)O)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I,,,,,,
7932,127933,5-(1-Hydroxy-2-aminoethyl)-1H-indole-7-carboxamide,C1=CNC2=C(C=C(C=C21)C(CN)O)C(=O)N,,,,,,
7933,127934,beta-Casomorphin 11,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC6=CC=C(C=C6)O)N,,,,,,
7934,127935,CID 127935,C1=CC(=C(C=C1S(=O)(=O)O)[N+](=O)[O-])OC(=O)CCCCCN2C(=O)C=CC2=O.[Na+],,,,,,
7935,127936,"6-(2,5-Dioxo-1-pyrrolyl)hexanoic acid 2-nitro-4-sulfophenyl ester",C1=CC(=C(C=C1S(=O)(=O)O)[N+](=O)[O-])OC(=O)CCCCCN2C(=O)C=CC2=O,,,,,,
7936,127937,"4-(2,6-Dichlorophenyl)-1,2,5-thiadiazol-3-yl ethylmethylcarbamate",CCN(C)C(=O)OC1=NSN=C1C2=C(C=CC=C2Cl)Cl,,,,,,
7937,127938,"(1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R,6S)-6,7-dihydroxy-6-methylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](C=CC[C@@](C)(CO)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
7938,127939,S-4-Bromobenzylglutathione cyclopentyl diester,C1CCC(C1)OC(=O)CNC(=O)[C@H](CSCC2=CC=C(C=C2)Br)NC(=O)CC[C@@H](C(=O)OC3CCCC3)N,,,,,,
7939,127940,5-(1-Hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-1H-indole-7-carboxamide,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C3C(=C2)C=CN3)C(=O)N)O,,,,,,
7940,127941,3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one,C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)C(F)(F)F,,,,,,
7941,127942,"5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indole-3-acetic acid",CC1=C(C2=C(N1C(=O)C3=C(C=C(C=C3Cl)Cl)Cl)C=CC(=C2)OC)CC(=O)O,,,,,,
7942,127943,(2-Methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine,COC1=C(C=C(C=C1)N2C=NN=N2)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4.Cl.Cl,,,['Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS. (See all compounds classified as Neurokinin-1 Receptor Antagonists.)'],,,
7943,127944,"(2S,3S)-N-[[2-methoxy-5-(tetrazol-1-yl)phenyl]methyl]-2-phenylpiperidin-3-amine",COC1=C(C=C(C=C1)N2C=NN=N2)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4,,,['Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS. (See all compounds classified as Neurokinin-1 Receptor Antagonists.)'],,,
7944,127945,2-(2-Hydroxy-3-methyl-4-oxo-1(4H)-naphthalenylidene)hydrazinecarboxamide,CC1=C(C2=CC=CC=C2C(=C1O)N=NC(=O)N)O,,,,,,
7945,127946,CID 127946,C1=CC=C(C(=C1)NCCSSC2=NC=C(C=C2)NC(=NC3=CC4=C(C=C3)C5(C6=C(C=C(C=C6)O)OC7=C5C=CC(=C7)O)OC4=O)S)[N+](=O)[O-],,,,,,
7946,127947,CID 127947,COC1=CC2=C(C=C1)[C@](C(=O)N2C3=CC=CC=C3F)(CCC(=O)O)NC(=O)C4CCC5=CC=CC=C5C4.[NaH],,,,,,
7947,127948,"3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid",COC1=CC2=C(C=C1)[C@](C(=O)N2C3=CC=CC=C3F)(CCC(=O)O)NC(=O)C4CCC5=CC=CC=C5C4,,,,,,
7948,127949,Hydroxyethylthiomethacrylate,CC(=C)C(=O)SCCO,,,,,,
7949,127950,"1-[2-[5-(3-Methoxy-4-hydroxyphenyl)-2,4-pentadienoyl]aminoethyl]4-benzhydroxypiperidine",COC1=C(C=CC(=C1)C=CC=CC(=O)NCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)O,,,,,,
7950,127951,4-Chloro-2-(imidazolin-2-yl)isoindoline,C1CN=C(N1)N2CC3=C(C2)C(=CC=C3)Cl,,,,,,
7951,127952,"2-[(2R,3S,4S,5R,6S)-2-hydroxy-6-[(1R)-1-[(2S,7S,8R,9S)-7-hydroxy-2-[(2R,5S)-5-[(2R,3S)-5-[(2S,3S,5R,6S)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-[(2S,5S,6R)-5-methoxy-6-methyloxan-2-yl]oxyoxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]ethyl]-5-methoxy-4-[(2S,5S,6R)-5-methoxy-6-methyloxan-2-yl]oxy-3-methyloxan-2-yl]acetic acid",C[C@H]1C[C@H]([C@@](O[C@@H]1C2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CCC5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)O[C@H]7CC[C@@H]([C@H](O7)C)OC)OC)C)O)C)C)O[C@H]8CC[C@@H]([C@H](O8)C)OC)(C)O)C,,,,,,
7952,127953,CID 127953,CC1=CC(=NO1)NC(=C2C(=O)C(C(=O)C(C2=O)(CC=C)CC=C)(CC=C)CC=C)O.[Na+],,,,,,
7953,127954,CID 127954,CC1=CC(=NO1)NC(=C2C(=O)C(C(=O)C(C2=O)(CC=C)CC=C)(CC=C)CC=C)O,,,,,,
7954,127955,"2-(Hydroxymethyl)-6-[[3,4,5-trihydroxy-6-(oxiran-2-ylmethoxy)oxan-2-yl]methoxy]oxane-3,4,5-triol",C1C(O1)COC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)O)O,,,,,,
7955,127956,2-bromo-N-[4-[2-[[3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenyl]acetamide,CC(C)(CC1=CC=C(C=C1)NC(=O)CBr)NCC(COC2=CC=C(C=C2)CCOCC3CC3)O,,,,,,
7956,127957,CID 127957,CC1=CC2=C(C3=C1NC(=O)C3(C)C)O[C@@]([C@H]2Cl)(C)CN,,,,,,
7957,127958,CID 127958,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1C(=CO2)[C@@H](CCCC(=O)[O-])F)O)O.[Na+],,,,,,
7958,127959,CID 127959,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1C(=CO2)[C@@H](CCCC(=O)O)F)O)O,,,,,,
7959,127960,3-Aza-lipid X,CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)OP(=O)(O)O)NC(=O)C[C@@H](CCCCCCCCCCC)O)O,,,,,,
7960,127961,CID 127961,CCCCCCC(CCC(CCCCC)CNC(=O)O)(COS(=O)(=O)[O-])NC(=O)O.[Na+],,,,,,
7961,127962,[10-[(Carboxyamino)methyl]-7-(sulfooxymethyl)pentadecan-7-yl]carbamic acid,CCCCCCC(CCC(CCCCC)CNC(=O)O)(COS(=O)(=O)O)NC(=O)O,,,,,,
7962,127963,"[(2R,3S,4R,5R,6R)-2-(hydroxymethyl)-4,5-bis[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-3-yl] dihydrogen phosphate",CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1OP(=O)(O)O)CO)OP(=O)(O)O)NC(=O)C[C@@H](CCCCCCCCCCC)O)O,,,,,,
7963,127964,4-(2-(4-Hydroxybenzyl)-phenoxy)-N-methylbutylamine,CNCCCCOC1=CC=CC=C1CC2=CC=C(C=C2)O,,,,,,
7964,127965,3-Benzyl-4-[4-(methylamino)butoxy]phenol,CNCCCCOC1=C(C=C(C=C1)O)CC2=CC=CC=C2,,,,,,
7965,127966,Pentamidoxime,C1=CC(=CC=C1C(=NO)N)OCCCCCOC2=CC=C(C=C2)C(=NO)N,,,,,,
7966,127967,"[(1R,2S,3aR,9aR)-2-hydroxy-1-[3-hydroxy-3-(oxan-4-yl)propyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl] ethaneperoxoate",CC(=O)OOC1=CC=CC2=C1C[C@@H]3C[C@@H]([C@@H]([C@@H]3C2)CCC(C4CCOCC4)O)O,,,,,,
7967,127968,CID 127968,C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)O[C@@H]2[C@@H]3[C@H]([C@H](OC2OC4=CC=CC5=C4C6=C7C8=C(C=CC(=C8C(=O)O6)C)OC(=C7C5=O)O)C)O[C@H](O3)C9=CC=CC=C9)O)OC)O,,,,,,
7968,127969,Carprofilin,CCOC(=O)CC(=O)CN1C(=O)C2=C(N=CN2C)N(C1=O)C,,,,,,
7969,127970,"(3S)-1-methyl-3-[(1S)-1-[(2S,5R)-5-(methylsulfanylmethyl)-6-oxo-3-(2-oxocyclopent-3-en-1-ylidene)piperazin-2-yl]ethyl]-3H-indol-2-one",C[C@@H]([C@H]1C2=CC=CC=C2N(C1=O)C)[C@H]3C(=C4CC=CC4=O)N[C@H](C(=O)N3)CSC,,,,,,
7970,127971,"6-Formyl-4,7,9-trihydroxy-8-methyl-1-phenazinecarboxylic acid, methyl ester",CC1=C(C(=CO)C2=C(C1=O)NC3=C(C=CC(=O)C3=N2)C(=O)OC)O,,,,,,
7971,127972,CID 127972,C#CCN(CC1=CN=C2C(=N1)C(=O)N=C(N2)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
7972,127973,CID 127973,CC1=CC2=C(C(=C1C)N[N+]#N)N=C3C(=NC(=NC3=O)[O-])N2CC(C(C(CO)O)O)O,,,,,,
7973,127974,CID 127974,CC1=CC2=C(C(=C1C)N[N+]#N)N=C3C(=O)NC(=O)N=C3N2CC(C(C(CO)O)O)O,,,,,,
7974,127975,CID 127975,CC1=CC2=C(C(=C1C)N[N+]#N)N=C3C(=NC(=NC3=O)[O-])N2CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
7975,127976,CID 127976,CC1=CC2=C(C(=C1C)N[N+]#N)N=C3C(=O)NC(=O)N=C3N2CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
7976,127977,6-Thiocyanato-fad,CC1=CC2=C(C(=C1C)SC#N)N=C3C(=O)NC(=O)N=C3N2CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
7977,127978,CID 127978,CC1=CC2=C(C(=C1C)S)N=C3C(=O)NC(=O)N=C3N2CC(C(C(CO)O)O)O,,,,,,
7978,127979,CID 127979,CC1=CC2=C(C(=C1C)S)N=C3C(=O)NC(=O)N=C3N2CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
7979,127980,CID 127980,CC12CCC(=O)C=C1C3(CC3)CC4C2CCC5(C4C6CC6C57CCC(=O)O7)C,,,,,,
7980,127981,"4-[6-(1,2-Dihydroxyethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,5-trihydroxy-7,8-dioxooctanoic acid",C(C(C(C(C(C(=O)O)O)O)OC1C(C(C(C(O1)C(CO)O)O)O)O)O)C(=O)C=O,,,,,,
7981,127982,Phenylacetylcysteinylvaline,CC(C)[C@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CC1=CC=CC=C1,,,,,,
7982,127983,N-(N-(1 (Ethoxycarbonyl)-3-phenylpropyl)alanyl)-N-(phenylmethyl)glycine,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC2=CC=CC=C2)CC(=O)O,,,,,,
7983,127984,Astrasieversianin XV,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](CO[C@H]2OC3CC[C@]45CC46CC[C@@]7([C@H]([C@@H](C[C@]7(C6C[C@H](C5C3(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)C)O)[C@]9(CC[C@H](O9)C(C)(C)O)C)C)O)O)O)O)O,,,,,,
7984,127985,Astrasieversianin XI,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](CO[C@H]2OC3CC[C@]45CC46CC[C@@]7([C@H]([C@@H](C[C@]7(C6C[C@H](C5C3(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)C)O)[C@]9(CC[C@H](O9)C(C)(C)O)C)C)OC(=O)C)O)O)O)O,,,,,,
7985,127986,Tributylribavirin,CCCCOC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC(=N2)C(=O)N)OCCCC)OCCCC,,,,,,
7986,127987,Sex pheromone inhibitor iad1,C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)N)O,,,,,,
7987,127988,"4,6-dichloro-1H-indole-2-carboxylic acid",C1=C(C=C(C2=C1NC(=C2)C(=O)O)Cl)Cl,,,,,,
7988,127989,"(5S,6S)-6-(4-hydroxyphenyl)-6-methyl-5-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7,8-dihydro-5H-naphthalen-2-ol",C[C@@]1(CCC2=C([C@H]1CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F)C=CC(=C2)O)C3=CC=C(C=C3)O,,,,,,
7989,127990,CID 127990,C[C@@H]1C=C(C(=O)[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
7990,127991,Epinine 3-O-sulfate,CNCCC1=CC(=C(C=C1)O)OS(=O)(=O)O,,,,,,
7991,127992,Epinine 4-O-sulfate,CNCCC1=CC(=C(C=C1)OS(=O)(=O)O)O,,,,,,
7992,127993,"5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol",C1=CN=CC2=C1C3=C(C(=C(C=C3N2)Br)O)Br,,,,,,
7993,127994,5-Carbafructofuranose 6-phosphate,C1[C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)COP(=O)(O)O,,,,,,
7994,127995,Valanimycin,CC(C)C[N+](=NC(=C)C(=O)O)[O-],,,,,,
7995,127996,Oligophosphoglycerol-ATP,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)OP(=O)(O)OCC(C(=O)O)O)O)N,,,,,,
7996,127997,2-Chloronorepinephrine,C1=CC(=C(C(=C1[C@H](CN)O)Cl)O)O,,,,,,
7997,127998,Esonarimod,CC1=CC=C(C=C1)C(=O)CC(CSC(=O)C)C(=O)O,,,,,,
7998,127999,CID 127999,CC1=C2C=C(C(=O)C(=C2OC(=C1)O)C)C#N,,,,,,
7999,128000,"4-[(1R)-2-amino-1-hydroxyethyl]-5-chlorobenzene-1,2-diol",C1=C(C(=CC(=C1O)O)Cl)[C@H](CN)O,,,,,,
8000,128001,Protosappanin A,C1C(=O)COC2=C(C=CC(=C2)O)C3=CC(=C(C=C31)O)O,,,,,,
8001,128002,6-(Bis(2-chloroethyl)amino)-6-deoxyglucose,C(CCl)N(CCCl)C[C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O,,,,,,
8002,128003,3-Deoxysucrose,C1[C@@H]([C@H](O[C@@H]([C@@H]1O)O[C@@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)CO)O,,,,,,
8003,128004,3-Deoxy-3-fluorosucrose,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)F)O)O,,,,,,
8004,128005,CID 128005,CC=C(C)[C@@H]1[C@H]([C@H](CC2(O1)CC3C[C@H](O2)CC=C(C[C@H](C=CC=C4CO[C@H]5[C@@]4(C(C=C([C@H]5O)C)C(=O)O3)O)C)C)O)C,,,,,,
8005,128006,CID 128006,CC[C@H]1C=CC=CC[C@H]([C@]([C@@](C(=O)[C@H]([C@@H]([C@H](C(=O)[C@H]([C@@H]([C@H](C=CC(=O)OC2CC(CC1O)OC3([C@H]2C)CC[C@@H]([C@@H](O3)C[C@@H](C)O)C)C)O)C)C)O)C)(C)O)(C)O)C,,,,,,
8006,128007,CID 128007,C[C@@H]1CC(=CC[C@@H]2C[C@@H](CC3(O2)C[C@@H]([C@@H]([C@H](O3)C(=CC(C)C)C)C)O)OC(=O)C4C=C([C@H]([C@@H]5[C@]4(C(=CC=C1)CO5)O)OC)C)C,,,,,,
8007,128008,CID 128008,CC=C(C)[C@@H]1[C@H]([C@H](CC2(O1)C[C@@H]3C[C@H](O2)CC=C(C[C@H](C=CC=C4CO[C@H]5[C@@]4(C(C=C([C@H]5OC)C)C(=O)O3)O)C)C)O)C,,,,,,
8008,128009,Homoursodeoxycholic acid,C[C@H](CCCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
8009,128010,PNU 101387;Sonepiprazole,C1COC(C2=CC=CC=C21)CCN3CCN(CC3)C4=CC=C(C=C4)S(=O)(=O)N,,,,,,
8010,128011,"19-Azidoandrost-4-ene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)CC[C@]34CN=[N+]=[N-],,,,,,
8011,128012,5-Hydroxy-4-methoxypropafenone,CCCNCC(COC1=CC(=C(C=C1C(=O)CCC2=CC=CC=C2)O)OC)O,,,,,,
8012,128013,CID 128013,C1CN(C(=N1)[N+](=O)[O-])[C@H]2[C@@H]([C@@H]([C@H](O2)CI)O)O,,,,,,
8013,128014,Isoannonacin,CCCCCCCCCCCCC(C1CCC(O1)C(CCCCC(CCCCCC2CC(C(=O)O2)CC(=O)C)O)O)O,,,,,,
8014,128015,alpha-Methyl-3-carboxyphenylalanine,C[C@](CC1=CC(=CC=C1)C(=O)O)(C(=O)O)N,,,,,,
8015,128016,"4-(5,7,7,10,10-Pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid",CC1(CCC(C2=C1C=C3C(=C2)N(C4=CC=CC=C4N=C3C5=CC=C(C=C5)C(=O)O)C)(C)C)C,,,,,,
8016,128017,3-(3-(Dimethylamino)propyl)-4-hydroxy-N-(4-(4-pyridinyl)phenyl)benzamide,CN(C)CCCC1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C3=CC=NC=C3)O.Cl,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
8017,128018,3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide,CN(C)CCCC1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C3=CC=NC=C3)O,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
8018,128019,"alpha-Amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid",C1=CC=C(C(=C1)C2=CC(=CC(=C2)CP(=O)(O)O)C[C@@H](C(=O)O)N)Cl,,,,,,
8019,128020,CID 128020,C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)COC(=O)CC5=CC(=C(C=C5)O)OC)O)C)O)C(=O)C)OC(=O)CC6=CC=CC=C6,,,,,,
8020,128021,"2-[[6-Methyl-5-[2-[[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid",CC1=C(C2=C(CC1)C(=CC=C2)OCC(=O)O)CCON=C(C3=CC=CC=C3)C4=CN=CC=C4,,,,,,
8021,128022,CID 128022,C=C(CCN1C=NC2=C1NC(=NC2=O)N)COCP(=O)(O)O,,,,,,
8022,128023,2-(1-Fluoropropan-2-ylamino)-1-phenylpropan-1-ol,CC(CF)NC(C)C(C1=CC=CC=C1)O,,,,,,
8023,128024,"N-[4-(7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)phenyl]acetamide",CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC=C(C=C3)NC(=O)C,,,,,,
8024,128025,4-Nitrophenyl 2-fluoropropionate,CC(C(=O)OC1=CC=C(C=C1)[N+](=O)[O-])F,,,,,,
8025,128026,4-Azidophenacyl fluoride,C1=CC(=CC=C1C(=O)C[18F])N=[N+]=[N-],,,,,,
8026,128027,CID 128027,C1=CC(=CC=C1C(=O)C[18F])N[N+]#N,,,,,,
8027,128028,CID 128028,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1OC2=C(C=CC(=C2)C=CC(=O)O[C@H](CC3=CC(=C(C=C3)O)O)C(=O)O)O)O)O)O)CO,,,,,,
8028,128029,CID 128029,C1CC(=NN=C(N)N)C2=C1C(=CC=C2)C(=O)N,,,,,,
8029,128030,"1-(1-Oxo-3,3-diphenylpropyl)-alpha-3-pyridinyl-4-piperidineacetonitrile",C1CN(CCC1C(C#N)C2=CN=CC=C2)C(=O)CC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
8030,128031,"3,5-Dichloro-4-(4-chlorobenzoyl)benzoic acid",C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)C(=O)O)Cl)Cl,,,,,,
8031,128032,1-(3-Fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine,C1CN(CCC1COC2=CC=C(C=C2)C#N)CCCF,,,,,,
8032,128033,Glucose 6-arsenate,C([C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O)O[As](=O)(O)O,,,,,,
8033,128034,"Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate",CC1=C(C(=C(C(=N1)C)C(=O)OC)C2=CC=CC=C2N=O)C(=O)OC,,,,,,
8034,128035,"3,4-Dibromo-6-(bromomethyl)chroman-2-one",C1=CC2=C(C=C1CBr)C(C(C(=O)O2)Br)Br,,,,,,
8035,128036,4-Amidinophenylbenzoate,C1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)C(=N)N,,,,,,
8036,128037,Epilactose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O)O)O)O)O,,,,,,
8037,128038,"2-Hydroxypenta-2,4-dienoic acid",C=CC=C(C(=O)O)O,,,,,,
8038,128039,"Ethyl 1-ethyl-4-ethylthio-1H-pyrazolo(3,4-b)pyridine-5-carboxylate",CCN1C2=NC=C(C(=C2C=N1)SCC)C(=O)OCC,,,,,,
8039,128040,"N,N'-Dimethylthiourea dioxide",CNC(=S(=O)=O)NC,,,,,,
8040,128041,"10,11-Epoxy-3,11-dimethyl-7-ethyl-2,6-tridecadienoic acid",CCC(=CCCC(=CC(=O)O)C)CCC1C(O1)(C)CC,,,,,,
8041,128042,"1,3-Propanediamine, N-(3,3-diphenylpropyl)-N'-(1-methyl-2-phenylethyl)-, dihydrochloride",CC(CC1=CC=CC=C1)NCCCNCCC(C2=CC=CC=C2)C3=CC=CC=C3.Cl.Cl,,,,,,
8042,128043,"N-(3,3-Diphenylpropyl)-N'-(1-phenylpropan-2-yl)-1,3-propanediamine",CC(CC1=CC=CC=C1)NCCCNCCC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8043,128044,Tomizine,COC1=C2C(=NC=N1)SCC(=N2)N.Cl,,,,,,
8044,128045,"4-methoxy-7H-pyrimido[4,5-b][1,4]thiazin-6-amine",COC1=C2C(=NC=N1)SCC(=N2)N,,,,,,
8045,128046,CID 128046,C1=COC(=CC1=O)O,,,,,,
8046,128047,"1-(2-Pyrimidyl)-4-(3,4-dihydroxybenzyl)piperazine",C1CN(CCN1CC2=CC(=C(C=C2)O)O)C3=NC=CC=N3,,,,,,
8047,128048,CID 128048,CC1=C2CN3CC(=O)N=C3NC2=CC=C1.Cl,,,,,,
8048,128049,CID 128049,CC1=C2CN3CC(=O)N=C3NC2=CC=C1,,,,,,
8049,128050,8-tert-Butyladenine,CC(C)(C)C1=NC2=NC=NC(=C2N1)N,,,,,,
8050,128051,Crabescein,C1=CC(=C(C=C1C(=O)NCCS)C(=O)NCCS)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O,,,,,,
8051,128052,CID 128052,CC1=C(C(C(=C(N1)C)P2(OCCCO2)[O-])C3=CC=CC=C3[N+](=O)[O-])C(=O)OC,,,,,,
8052,128053,CID 128053,CC1=C(C(C(=C(N1)C)P2(OCCCO2)O)C3=CC=CC=C3[N+](=O)[O-])C(=O)OC,,,,,,
8053,128054,2-(N-n-Propyl-N-3-thienylethylamino)-5-hydroxytetralin,CCCN(CCC1=CSC=C1)C2CCC3=C(C2)C=CC=C3O,,,,,,
8054,128055,Alanyl-alanyl-phenylalanine chloromethyl ketone,C[C@@H](C(=O)NC(=O)[C@H](C)N[C@@H](CC1=CC=CC=C1)C(=O)CCl)N,,,,,,
8055,128056,CID 128056,CC(CCC1=CC=CC=C1)(C=C[C@H]2[C@@H](C[C@@H]([C@@H]2CC=CCCCC(=O)OC)O)O)O,,,,,,
8056,128057,4-Fluorothreonine,C([C@H]([C@@H](C(=O)O)N)O)F,,,,,,
8057,128058,"2,4-Dimethoxy-N,N-dimethylphenylisopropylamine",CC(CC1=C(C=C(C=C1)OC)OC)N(C)C,,,,,,
8058,128059,"2,4-Dimethoxy-N,N-dimethyl-5-iodo(122I)-phenylisopropylamine",CC(CC1=CC(=C(C=C1OC)OC)[122I])N(C)C,,,,,,
8059,128060,"(2S)-5-amino-2-[[(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoic acid",C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCN)C(=O)O,,,,,,
8060,128061,4-Aminophenylphosphorylcholine,C[N+](C)(C)CCOP(=O)([O-])OC1=CC=C(C=C1)N,,,,,,
8061,128062,2-[(4-Aminophenoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium,C[N+](C)(C)CCOP(=O)(O)OC1=CC=C(C=C1)N,,,,,,
8062,128063,"2-(4-Chlorophenyl)-2,3,6,7,8,9-hexahydropyrazolo(4,3-c)quinolin-3(5H)-one hcl",C1CCC2=NC=C3C(=C2C1)NN(C3=O)C4=CC=C(C=C4)Cl.Cl,,,,,,
8063,128064,"2-(4-Chloro-phenyl)-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]quinolin-3-one",C1CCC2=NC=C3C(=C2C1)NN(C3=O)C4=CC=C(C=C4)Cl,,,,,,
8064,128065,alpha-(4-Aminobutyryl)hypusine,C(CCNC[C@@H](CCN)O)C[C@@H](C(=O)O)NC(=O)CCCN,,,,,,
8065,128066,"Carbamimidothioic acid, (2-((phenylmethyl)thio)ethyl)-, 3-(1H-imidazol-4-yl)propyl ester",C1=CC=C(C=C1)CSCCN=C(N)SCCCC2=CN=CN2,,,,,,
8066,128067,CID 128067,C[C@H]1CC(=O)C(=CC[C@@H](C=C[C@@H]([C@@H]([C@H](C=C(C(=O)C2=C(C(=CC3=C2C(=O)C(C(C3=O)NC(=O)C=CC=CC=C[C@H]1C)SC[C@@H](C(=O)O)NC(=O)C)C)O)C)O)O)C)O)C,,,,,,
8067,128068,Spirohydantoin aziridine,C1CCC2(CC1)C(=O)N(C(=O)N2)CCN3CC3,,,,,,
8068,128069,"Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-(3-(ethylsulfonyl)-1-oxopropyl)hydrazide",CCS(=O)(=O)CCC(=O)NNC(=O)N1CC2=CC=CC=C2OC3=C1C=C(C=C3)Cl,,,,,,
8069,128070,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[4-(1,3-oxazol-5-yl)pyridin-1-ium-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(C=C4)C5=CN=CO5)C(=O)[O-],,,,,,
8070,128071,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[4-(1,3-oxazol-5-yl)pyridin-1-ium-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(C=C4)C5=CN=CO5)C(=O)O,,,,,,
8071,128072,CID 128072,C1C(C(C(C(O1)OC(CO)C(C(C=O)O)O)O)OC2C(C(C(O2)COC(=O)C=CC3=CC=C(C=C3)O)O)O)O,,,,,,
8072,128073,CID 128073,CC(C)C[C@@H]1CO[C@@H]([C@@H]([C@H]1OC(=O)C)OC(=O)C)SOC(=O)C,,,,,,
8073,128074,Bssdp,CC1(COC(N1[O])(CCC(=O)ON2C(=O)CC(C2=O)S(=O)(=O)O)CCC(=O)ON3C(=O)CC(C3=O)S(=O)(=O)O)C,,,,,,
8074,128075,"N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide",C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H](O[C@@H]([C@H]3O)CO)OC)NC(=O)C)CO)O)O)O)O)O,,,,,,
8075,128076,CID 128076,C[C@@H]1C=CC=CC=CC(=O)NC2=C(C3=C(C(=C(C(=C3)C)O)C(=O)C(=C[C@@H]([C@H]([C@H](C=C[C@H](CC=C(C(=O)C[C@@H]1O)C)O)C)O)C)C)C(=O)C2=O)O,,,,,,
8076,128077,Fluorescein mono-beta-d-galactopyranoside,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O)O,,,,,,
8077,128078,"2,5-Anhydro-1-deoxy-1-phosphonohexitol-6-phosphate",C([C@@H]1[C@H]([C@@H]([C@H](O1)CP(=O)(O)O)O)O)OP(=O)(O)O,,,,,,
8078,128079,"2,5-Anhydro-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-D-altritol 1-(hydrogen sulfate)",C(C1C(C(C(O1)COS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)OS(=O)(=O)O)O,,,,,,
8079,128080,"(2S,5S,11S,14S,24S)-24-amino-2,5-dibenzyl-11-butan-2-yl-14-(2-methylsulfanylethyl)-1,4,7,10,13,16,20-heptazacyclopentacosane-3,6,9,12,15,21,25-heptone",CCC(C)[C@H]1C(=O)N[C@H](C(=O)NCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC2=CC=CC=C2)CC3=CC=CC=C3)N)CCSC,,,,,,
8080,128081,CID 128081,COC1=C(C=CC(=C1)C=CC(=O)OC[C@H]2[C@@H]([C@H](C(O2)O[C@H]3[C@@H](CO[C@H]([C@@H]3O)O[C@H](CO)[C@@H]([C@H](C=O)O)O)O)O)O)O,,,,,,
8081,128082,"2,2'-Dicarbomethoxyamino-5-5'-dibenzimidazolyl ketone",COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC4=C(C=C3)N=C(N4)NC(=O)OC,,,,,,
8082,128083,CID 128083,CC=C1COC=C2[C@H]1C[C@H]3C4=C(CCN3C2=O)C5=CC=CC=C5N4,,,,,,
8083,128084,Spirasine XI,CC12CCCC34C1C5CC67C3CC(C(C6C4N5C2)O)C(=C)C7,,,,,,
8084,128085,CID 128085,CC=C1CN2[C@H]3CC1C([C@@H]2CC4=C3NC5=C4C=C(C=C5)O)COC(=O)C,,,,,,
8085,128086,"3,7,12-Trihydroxy-7-methylcholanoic acid",C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](CC3[C@H]2[C@](C[C@H]4[C@@]3(CC[C@H](C4)O)C)(C)O)O)C,,,,,,
8086,128087,CID 128087,C1[C@H]2[C@H](N2)[C@]3([C@H](C4=C(N1O3)C=C(C=C4O)C=O)COC(=O)N)O,,,,,,
8087,128088,Spirasine IX,C[C@@]12CCCC34[C@@H]1[C@@H]5CC67[C@H]3C(=O)[C@H](C[C@@H]6C4N5C2)C(=C)C7,,,,,,
8088,128089,Spirasine IV,C[C@@]12CCCC34[C@@H]1[C@@H]5CC67[C@H]3C[C@@H](C(=C)C6)C(=O)[C@@H]7C4N5C2,,,,,,
8089,128090,(3-Anilino-2-hydroxypropyl) octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OCC(CNC1=CC=CC=C1)O,,,,,,
8090,128091,"2,6-Dichloro-4-(2-(4-((2,3,4-trimethoxyphenyl)methyl)-1-piperazinyl)-1-((trimethylsilyl)oxy)ethyl)benzenamine dihydrochloride",COC1=C(C(=C(C=C1)CN2CCN(CC2)CC(C3=CC(=C(C(=C3)Cl)N)Cl)O[Si](C)(C)C)OC)OC.Cl.Cl,,,,,,
8091,128092,"2,6-Dichloro-4-(2-(4-((2,3,4-trimethoxyphenyl)methyl)-1-piperazinyl)-1-((trimethylsilyl)oxy)ethyl)benzeneamine",COC1=C(C(=C(C=C1)CN2CCN(CC2)CC(C3=CC(=C(C(=C3)Cl)N)Cl)O[Si](C)(C)C)OC)OC,,,,,,
8092,128093,3-Carboxylic acid-picumast,CC1=C(C(=O)OC2=C1C=CC(=C2)OCCCN3CCN(CC3)CC4=CC=C(C=C4)Cl)C(=O)O,,,,,,
8093,128094,2-Piperazino-4-isopropylamino-5-methyl-6-chloropyrimidine,CC1=C(N=C(N=C1Cl)N2CCNCC2)NC(C)C,,,,,,
8094,128095,3-Hydroxymethyl-picumast,CC1=C(C(=O)OC2=C1C=CC(=C2)OCCCN3CCN(CC3)CC4=CC=C(C=C4)Cl)CO,,,,,,
8095,128096,"5-[2-[[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]ethylamino]naphthalene-1-sulfonic acid",C1=CC2=C(C=CC=C2S(=O)(=O)O)C(=C1)NCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O,,,,,,
8096,128097,"2-[[(2S,4aS,6aR,6aS,6bR,8aR,12aR,14bR)-10-(2-carboxybenzoyl)oxy-2,4a,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicen-2-yl]methoxycarbonyl]benzoic acid",C[C@]12CC[C@](C[C@H]1C3=CC[C@@H]4[C@]5(CCC(C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C6=CC=CC=C6C(=O)O)C)(C)COC(=O)C7=CC=CC=C7C(=O)O,,,,,,
8097,128098,Odddh,C[C@]12CC[C@](C[C@H]1C3=CC=C4[C@]5(CCC(C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C6=CC=CC=C6C(=O)O)C)(C)COC(=O)C7=CC=CC=C7C(=O)O,,,,,,
8098,128099,propyl N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]carbamate,CCCOC(=O)NC1=CC=C(C=C1)OCC(CNC(C)C)O,,,,,,
8099,128100,4-(N-1-Dimethylaminonaphthalene-5-sulfonylamino)phenyl isothiocyanate,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NC3=CC=C(C=C3)N=C=S,,,,,,
8100,128101,"6-Amino-1,5-anhydro-6-deoxyglucitol",C1C(C(C(C(O1)CN)O)O)O,,,,,,
8101,128102,"1,5-Bis(6-methyl-4-pyrimidyl)carbazone",CC1=CC(=NC=N1)NNC(=O)N=NC2=NC=NC(=C2)C,,,,,,
8102,128103,"10,10',17,17'-Tetrahydroxy-4,4'-dimethyl-9,9'-bisarpaganium",CC=C1C[N+]2(C3CC1C(C2CC4=C3NC5=C4C(=C(C=C5)O)C6=C(C=CC7=C6C8=C(N7)C9CC1C(C(C8)[N+]9(CC1=CC)C)CO)O)CO)C,,,,,,
8103,128104,CID 128104,CN(C)C1=NC2=C(NC3=C(C2=N1)C4=CC=CC=C4N3)C(=O)C5=CC=C(C=C5)O,,,,,,
8104,128105,"(2R)-2-hydroxy-N-[(2S)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]octadecanamide",CCCCCCCCCCCCCCCC[C@H](C(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C(CCCCCCCCCCCCCCC)O)O,,,,,,
8105,128106,CID 128106,CC=C1CN2[C@H]3CC1C([C@@H]2CC4=C3NC5=C4C=C(C=C5)O)CO,,,,,,
8106,128107,"3-[(3S,5R,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C5=CC(=O)OC5)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
8107,128108,Oxofangchirine,CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C4)OC)OC5=CC=C(C=C5)C(=O)C6=NC=CC7=CC(=C(O3)C=C76)OC)OC)OC,,,,,,
8108,128109,"10-Benzyl-9-methyl-1,4-dioxa-9-azaspiro[4.5]decane",CN1CCCC2(C1CC3=CC=CC=C3)OCCO2,,,,,,
8109,128110,6-4-Imdasd,CN1CCCC2(C1CC3=C4C=CNC4=CC=C3)OCCO2,,,,,,
8110,128111,"Benzo[b]thiophene-2-carboxamide, 3-hydroxy-N-[2-phenyl-2-(2-thienyl)ethenyl]-5-(trifluoromethyl)-",C1=CC=C(C=C1)C(=CNC(=O)C2=C(C3=C(S2)C=CC(=C3)C(F)(F)F)O)C4=CC=CS4,,,,,,
8111,128112,CID 128112,C1C(C(=O)N(C1=O)OC(=O)CCCCCN=C2C=CC(=N[N+]#N)C=C2N(O)[O-])S(=O)(=O)O,,,,,,
8112,128113,"3,5,5-Trimethylhexanoyloxybenzene sulfonate",CC(CC(=O)OC1=CC=C(C=C1)S(=O)(=O)O)CC(C)(C)C,,,,,,
8113,128114,"Ethyl 4-azidophenyl-1,4-dithiobutyrimidate",CCSC(=N)CCCSC1=CC=C(C=C1)N=[N+]=[N-].Cl,,,,,,
8114,128115,Ethyl 4-(4-azidophenyl)sulfanylbutanimidothioate,CCSC(=N)CCCSC1=CC=C(C=C1)N=[N+]=[N-],,,,,,
8115,128116,Sulfosuccinimidyl (4-azidophenyldithio)propionate,C1C(C(=O)N(C1=O)OC(=O)CCSSC2=CC=C(C=C2)N=[N+]=[N-])S(=O)(=O)O,,,,,,
8116,128117,"2,3-Bis(4-methylphenyl)-1,3-dihydrotetrazol-3-ium-5-carbonitrile;chloride",CC1=CC=C(C=C1)[NH+]2N=C(NN2C3=CC=C(C=C3)C)C#N.[Cl-],,,,,,
8117,128118,"2,3-bis(4-methylphenyl)-1H-tetrazole-5-carbonitrile",CC1=CC=C(C=C1)N2NC(=NN2C3=CC=C(C=C3)C)C#N,,,,,,
8118,128119,Glycyl-phenylalanyl-glycine-semicarbazone,C1=CC=C(C=C1)C[C@@H](C(=O)NC(=O)CN)NC/C=N/NC(=O)N,,,,,,
8119,128120,"[12-Butanoyloxy-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-25-yl] butanoate",CCCC(=O)OC1CC2CC(CC(=O)OC(CC3CC(=CC(=O)OC)C(C(O3)(C(C=CC4CC(=CC(=O)OC)CC(O4)CC(C1(C)C)(O2)O)(C)C)O)OC(=O)CCC)C(C)O)O,,,,,,
8120,128121,"[1,11,21-Trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-25-yl] 2-methylbutanoate",CCC(C)C(=O)OC1CC2CC(CC(=O)OC(CC3CC(=CC(=O)OC)CC(O3)(C(C=CC4CC(=CC(=O)OC)CC(O4)CC(C1(C)C)(O2)O)(C)C)O)C(C)O)O,,,,,,
8121,128122,CID 128122,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](C(=O)O)SC2=CC=CC=C2)N,,,,,,
8122,128123,1-Dimethylaminopropyl-3-methyl-6-chloroquinoxaline-2(1H)-one,CC1=NC2=C(C=CC(=C2)Cl)N(C1=O)CCCN(C)C,,,,,,
8123,128124,Tris-(2-hydroxyethyl)ammonium 4-fluorophenylsulfonylacetate,C1=CC(=CC=C1F)S(=O)(=O)CC(=O)O.C(CO)N(CCO)CCO,,,,,,
8124,128125,(4-Fluoro-benzenesulfonyl)-acetic acid,C1=CC(=CC=C1F)S(=O)(=O)CC(=O)O,,,,,,
8125,128126,CID 128126,CC1=C(C(=CC=C1)C)C=CC2=CN=CN2.Cl,,,,,,
8126,128127,"5-[2-(2,6-dimethylphenyl)ethenyl]-1H-imidazole",CC1=C(C(=CC=C1)C)C=CC2=CN=CN2,,,,,,
8127,128128,CID 128128,C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CCCCN=C(C1=CC=C(C=C1)N[N+]#N)[O-])NC(=O)[C@H](CC(=O)N)NC(=O)CCC2=CC=C(C=C2)O)O,,,,,,
8128,128129,CID 128129,C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CCCCNC(=O)C1=CC=C(C=C1)N[N+]#N)NC(=O)[C@H](CC(=O)N)NC(=O)CCC2=CC=C(C=C2)O)O,,,,,,
8129,128130,I-Rau-papc,C1C[C@@H]([C@H]([C@@H]2[C@H]1CN3CCC4=C(C3C2)NC5=CC=CC=C45)C(=O)NCCC6=CC(=C(C=C6)N)[125I])O,,,,,,
8130,128131,"Ergosta-5,24(28),25-trien-3-ol",C[C@H](CCC(=C)C(=C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
8131,128132,7-Chloro-2-((4-methoxyphenyl)methyl)-3-methyl-5-propyl-4-benzofuranol,CCCC1=CC(=C2C(=C1O)C(=C(O2)CC3=CC=C(C=C3)OC)C)Cl,,,,,,
8132,128133,2-amino-3-[[2-amino-3-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-3-oxopropyl]disulfanyl]-N-[4-[(6-methoxyquinolin-8-yl)amino]pentyl]propanamide,CC(CCCNC(=O)C(CSSCC(C(=O)NCCCC(C)NC1=C2C(=CC(=C1)OC)C=CC=N2)N)N)NC3=C4C(=CC(=C3)OC)C=CC=N4,,,,,,
8133,128134,"8-Hydroxyoctadeca-9,12-dienoic acid",CCCCCC=CCC=CC(CCCCCCC(=O)O)O,,,,,,
8134,128135,Mefenamic acid glucuronide,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)C,,,,,,
8135,128136,Methyl helicterilate,CC(=O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)COC(=O)C6=CC=CC=C6)C)C,,,,,,
8136,128137,"methyl (1R,3aS,5aS,5bR,7aR,9S,11aR,11bR,13aR,13bS)-9-acetyloxy-5a-(benzoyloxymethyl)-5b,8,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate",CC(=C)[C@@H]1CC[C@]2([C@@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)COC(=O)C6=CC=CC=C6)C)(C)C)OC(=O)C)C)C(=O)OC,,,,,,
8137,128138,Helicterilic acid,CC(=O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)COC(=O)C6=CC=CC=C6)C)C,,,,,,
8138,128139,Rabdophyllin H,CC(=O)OC[C@]1([C@@H]2CC[C@H]3[C@]45CCCC([C@H]4[C@@H]([C@]([C@@]3([C@@H]1O)C2O)(OC5)O)OC(=O)C)(C)C)O,,,,,,
8139,128140,CID 128140,CN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)N(C3=C5C(=C2C1=O)C6=CC=CC=C6N5)[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8C[C@@H]([C@H](CO8)N)O)OC)O)O,,,,,,
8140,128141,CID 128141,CN[C@H]1CO[C@H](C[C@@H]1O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)N3C4=C(C=CC=C4Cl)C5=C6C(=C7C8=CC=CC=C8NC7=C53)C(=O)N(C6=O)C)O)O)OC,,,,,,
8141,128142,3-(4-heptan-2-yloxy-1H-indol-7-yl)cyclohexan-1-ol,CCCCCC(C)OC1=C2C=CNC2=C(C=C1)C3CCCC(C3)O,,,,,,
8142,128143,"6-(3-Indolylmethyl)-7-methyl-1,4-dioxa-7-azaspiro(4,5)-decane",CN1CCCC2(C1CC3=CNC4=CC=CC=C43)OCCO2,,,,,,
8143,128144,"N-(4-Pyridylcarbamoyl)amino 1,2,3,6-tetrahydropyridine",C1CN(CC=C1)NC(=O)NC2=CC=NC=C2,,,,,,
8144,128145,3-Methylglutarylcarnitine,CC(CC(=O)[O-])CC(=O)OC(CC(=O)O)C[N+](C)(C)C,,,,,,
8145,128146,"3-carboxy-2-[(4-carboxy-3-methylbutanoyl)oxy]-N,N,N-trimethylpropan-1-aminium",CC(CC(=O)O)CC(=O)OC(CC(=O)O)C[N+](C)(C)C,,,,,,
8146,128147,"(7R,14S)-7,14-Dihydroxyoctadeca-4,8,10,12-tetraenedioic acid",C(C[C@@H](C=CC=CC=C[C@@H](CC=CCCC(=O)O)O)O)CC(=O)O,,,,,,
8147,128148,26-Deoxylaidlomycin,CCC(=O)OC(C(C)C1C(C(CC2(O1)CCC(O2)(C)C3CCC(O3)(C)C4C(CC(O4)C5C(CC(C(O5)(C)O)C)C)C)O)C)C(C)C(=O)O,,,,,,
8148,128149,"2,3,8-Trihydroxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",CC1(CC2=C(C(=O)C1O)C3=C(C=C2)C(=O)C4=C(C3=O)C=CC=C4O)O,,,,,,
8149,128150,(+/-)-Gomisin M1,C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@H]1C)OC)OC)O)OC)OCO3,,,,,,
8150,128151,"3,4-Dimethylpyridine adenine dinucleotide",CC1=C(C=[N+](C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C,,,,,,
8151,128152,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3,4-dimethylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",CC1=C(C=[N+](C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C,,,,,,
8152,128153,3-((Bis(diisopropylamino)phosphino)oxy)propanenitrile,CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N,,,,,,
8153,128154,CID 128154,CO[N+](=CC(=O)NCCCC(=O)N)[O-],,,,,,
8154,128155,Stemphyltoxin III,C1=CC(=C2C3=C1C4=C5C(=C(C=C4)O)C(=O)C=C[C@]5([C@@H]3C6C(C2=O)O6)O)O,,,,,,
8155,128156,1-Methyl-4-piperidyl 4'-fluorobenzoate,CN1CCC(CC1)OC(=O)C2=CC=C(C=C2)F,,,,,,
8156,128157,3-Diethylamino-1-propanol 2-phenylbenzoate,CCN(CC)CCCOC(=O)C1=CC=CC=C1C2=CC=CC=C2.Cl,,,,,,
8157,128158,Biphenyl-2-carboxylic acid 3-diethylamino-propyl ester,CCN(CC)CCCOC(=O)C1=CC=CC=C1C2=CC=CC=C2,,,,,,
8158,128159,Methylitaconic acid,CC=C(CC(=O)O)C(=O)O,,,,,,
8159,128160,"1-[4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-3-(4-azidophenyl)prop-2-en-1-one",COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C=CC4=CC=C(C=C4)N=[N+]=[N-])N)OC,,,,,,
8160,128161,CID 128161,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C=CC4=CC=C(C=C4)N[N+]#N)N)OC,,,,,,
8161,128162,t-Butyloxycarbonyl-methionyl-aminobutyryl-phenylalanine methyl ester,CC(C)(C)OC(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OC,,,,,,
8162,128163,"N-[4-[3,5-dihydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]-2,2,2-trifluoroacetamide",C1=CC(=CC=C1NC(=O)C(F)(F)F)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)OC4C(C(C(C(O4)CO)O)O)O)O,,,,,,
8163,128164,"(2S,3R,4S,5R,6R)-2-[(2S,3S,5R,6S)-6-[(2R,3R,4R,5S,6S)-5-hydroxy-4-methoxy-6-methyl-2-propoxyoxan-3-yl]oxy-4,5-dimethoxy-2-methyloxan-3-yl]oxy-4-methoxy-6-(methoxymethyl)oxane-3,5-diol",CCCO[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)OC)O[C@H]2[C@@H](C([C@H]([C@@H](O2)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC)O)OC)O)OC)OC,,,,,,
8164,128165,3-Oxo-11-methoxytabersonine,CC[C@]12CC(=C3C4([C@H]1N(CC4)C(=O)C=C2)C5=C(N3)C=C(C=C5)OC)C(=O)OC,,,,,,
8165,128166,CID 128166,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC(=O)C=CC2=CC=C(C=C2)O)O)O)O,,,,,,
8166,128167,"1,2-Dioctanoyl-sn-glycero-3-phosphate",CCCCCCCC(=O)OC[C@H](COP(=O)(O)O)OC(=O)CCCCCCC,,,,,,
8167,128168,2-(2-Fluoro-5-pyridyl)-7-azabicyclo(2.2.1)heptane,C1C[C@@H]2[C@H](C[C@H]1N2)C3=CN=C(C=C3)[18F],,,,,,
8168,128169,Punctaporonin D,C[C@]12CC[C@@]3([C@@H]([C@]1(C=C[C@@H]2O)CO)CC3(C)C)O,,,,,,
8169,128170,10-Isobutyryl dithranol,CC(C)C(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O,,,,,,
8170,128171,"3-Nitro-5H-phenanthro(4,5-bcd)pyran-5-one",C1=CC2=C3C(=C1)C(=O)OC4=C(C=CC(=C34)C=C2)[N+](=O)[O-],,,,,,
8171,128172,Pgaan,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CC#N,,,,,,
8172,128173,"5-(aminomethyl)-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide",CN(C)C(=O)C1=NN(C(=N1)CN)C2=C(C=C(C=C2)Cl)C(=O)C3=CC=CC=C3Cl,,,,,,
8173,128174,Mannostatin B,CS(=O)[C@@H]1[C@H]([C@H]([C@H]([C@H]1O)O)O)N,,,,,,
8174,128175,3-(4-((3-Octadecylaminocarbonyloxy-2-methoxy)propoxy)butyl)thiazolium bromide,CCCCCCCCCCCCCCCCCCNC(=O)OCC(COCCCC[N+]1=CSC=C1)OC.[Br-],,,,,,
8175,128176,"[2-methoxy-3-[4-(1,3-thiazol-3-ium-3-yl)butoxy]propyl] N-octadecylcarbamate",CCCCCCCCCCCCCCCCCCNC(=O)OCC(COCCCC[N+]1=CSC=C1)OC,,,,,,
8176,128177,"2-(4-Hydroxy-1,3-thiazol-3-ium-3-yl)ethyl [2-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl phosphate",CCCCCCCCCCCCCCCCCCNC(=O)OCC1(CCCO1)COP(=O)([O-])OCC[N+]2=CSC=C2O,,,,,,
8177,128178,"[2-[[hydroxy-[2-(4-hydroxy-1,3-thiazol-3-ium-3-yl)ethoxy]phosphoryl]oxymethyl]oxolan-2-yl]methyl N-octadecylcarbamate",CCCCCCCCCCCCCCCCCCNC(=O)OCC1(CCCO1)COP(=O)(O)OCC[N+]2=CSC=C2O,,,,,,
8178,128179,"(5R,9R,10R,13R)-4,4,8,10,14-pentamethyl-1,2,5,6,7,9,11,12,13,15-decahydrocyclopenta[a]phenanthren-3-one",C[C@]12CCC(=O)C([C@@H]1CCC3([C@@H]2CC[C@H]4C3(CC=C4)C)C)(C)C,,,,,,
8179,128180,CID 128180,CCCC(C)C1(C(=O)NC(=NC1=O)NO)CC,,,,,,
8180,128181,Selenobetaine methyl ester,COC(=O)C[Se+](C)C,,,,,,
8181,128182,CID 128182,CCCC1(C(=O)NC(=NC1=O)NO)CC,,,,,,
8182,128183,"[4-[2-[2-[(4-Chlorobenzoyl)amino]ethylamino]-1-hydroxyethyl]-2-(2,2-dimethylpropanoyloxy)phenyl] 2,2-dimethylpropanoate",CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNCCNC(=O)C2=CC=C(C=C2)Cl)O)OC(=O)C(C)(C)C,,,,,,
8183,128184,1-(4-Nitrophenyl)-2-dichloroacetamidoethane,C1=CC(=CC=C1CCNC(=O)C(Cl)Cl)[N+](=O)[O-],,,,,,
8184,128185,"5-S-Cysteinyl-3,4-dihydroxyphenylacetic acid",C1=C(C=C(C(=C1O)O)SC[C@@H](C(=O)O)N)CC(=O)O,,,,,,
8185,128186,"2,4,6,8-Nonatetraenoicacid, 3,7-dimethyl-9-[2-(nonyloxy)phenyl]-, (2E,4E,6E,8E)-",CCCCCCCCCOC1=CC=CC=C1C=CC(=CC=CC(=CC(=O)O)C)C,,,,,,
8186,128187,"3,7-Dimethyl-9-[2-nonoxy-6-(trifluoromethyl)phenyl]nona-2,4,6,8-tetraenoic acid",CCCCCCCCCOC1=CC=CC(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C(F)(F)F,,,,,,
8187,128188,"Pyrano(3,4-b)indole-1-acetic acid, 1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)-",CCOC(=O)CC1C2=C(C(CO1)CC3=CC=CC=C3)C4=CC=CC=C4N2,,,,,,
8188,128189,"5,6,9,10-Tetrahydro-N,N-dimethyl-5,9-methanobenzocycloocten-11-amine",CN(C)C1C2CC=CC1CC3=CC=CC=C23,,,,,,
8189,128190,Crebanine N-oxide,C[N@+]1(CCC2=CC3=C(C4=C2C1CC5=C4C=CC(=C5OC)OC)OCO3)[O-],,,,,,
8190,128191,2-[2-(Tert-butylamino)-1-hydroxyethyl]phenol,CC(C)(C)NCC(C1=CC=CC=C1O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
8191,128192,N-(Pivaloyloxy)phenacetin,CCOC1=CC=C(C=C1)N(C(=O)C)OC(=O)C(C)(C)C,,,,,,
8192,128193,Hyacinthoside,CC1CCC2C(C3C(N2C1)CC4C3(CCC5C4CC=C6C5(CC(CC6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)O)OC9C(C(C(C(O9)CO)O)O)O)O)O)OC1C(C(C(C(O1)C)O)O)O)C)C)C,,,,,,
8193,128194,"[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl] (6R)-2-methyl-1,4,5,6-tetrahydropyrimidine-6-carboperoxoate",CC1=NCC[C@@H](N1)C(=O)OO[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8194,128195,3-O-Demethylsporaricin A,CC(C1CCC(C(O1)OC2C(CC(C(C2O)N(C)C(=O)CN)O)N)N)N.Cl.Cl.Cl.Cl,,,,,,
8195,128196,"2-amino-N-[4-amino-3-[3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2,6-dihydroxycyclohexyl]-N-methylacetamide",CC(C1CCC(C(O1)OC2C(CC(C(C2O)N(C)C(=O)CN)O)N)N)N,,,,,,
8196,128197,Biocytin hydrazide,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCCC[C@@H](C(=O)NN)N)NC(=O)N2,,,,,,
8197,128198,7-Aminoketanserin,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C=C(C=C4)N)NC3=O,,,,,,
8198,128199,CID 128199,CCCCC[C@@H](C=C[C@]12C[C@@H]1CC(=O)[C@@H]2CC=CCCCC(=O)O)O,,,,,,
8199,128200,CID 128200,CO[C@H]1[C@H]([C@@H](O[C@@H]1[C@@H](C(=O)N)O[C@@H]2[C@H]([C@H](C=C(O2)C(=O)N[C@H]3CCCCNC3=O)O)O)N4C=CC(=O)NC4=O)O,,,,,,
8200,128201,Sucrose octaisobutyrate,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)COC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,,,,,,
8201,128202,"2-[(3aS,5aR,5bR,7S,7aS,11aR,11bR,13aR,13bS)-7-hydroxy-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-3-yl]prop-2-enoic acid",C[C@]12CCC([C@@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@]3(C[C@@H]([C@@H]5[C@@]4(CCCC5(C)C)C)O)C)C)C(=C)C(=O)O,,,,,,
8202,128203,"3-[(Z)-2-ethylbut-2-enyl]-1,6,8-trihydroxy-9,10-dioxoanthracene-2-carboxylic acid",CCC(=CC)CC1=CC2=C(C(=C1C(=O)O)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,,,,,,
8203,128204,"N-benzyl-3-phenyl-N-(3-piperidin-1-ylpropyl)-1,2-oxazol-5-amine hydrochloride",C1CCN(CC1)CCCN(CC2=CC=CC=C2)C3=CC(=NO3)C4=CC=CC=C4.Cl,,,,,,
8204,128205,N-Benzyl-N-(3-piperidinopropyl)-3-phenylisoxazole-5-amine,C1CCN(CC1)CCCN(CC2=CC=CC=C2)C3=CC(=NO3)C4=CC=CC=C4,,,,,,
8205,128206,3-(2-Amino-2-phenylacetamido)-2-methyl-4-oxo-1-azetidinesulfonic acid,C[C@H]1[C@H](C(=O)N1S(=O)(=O)O)NC(=O)C(C2=CC=CC=C2)N,,,,,,
8206,128207,"6-bromo-2-(3,4-dichlorophenyl)-3,4-dihydro-2H-pyrano[2,3-b]pyridine",C1CC2=C(N=CC(=C2)Br)OC1C3=CC(=C(C=C3)Cl)Cl,,,,,,
8207,128208,"6-chloro-2-(3,4-dichlorophenyl)-3,4-dihydro-2H-pyrano[2,3-b]pyridine",C1CC2=C(N=CC(=C2)Cl)OC1C3=CC(=C(C=C3)Cl)Cl,,,,,,
8208,128209,"2-(3,4-dichlorophenyl)-6-methylsulfonyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine",CS(=O)(=O)C1=CC2=C(N=C1)OC(CC2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
8209,128210,4-Hydroxyandrostenedione glucuronide,C[C@]12CCC(=O)C(=C1CCC3C2CC[C@]4(C3CCC4=O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,['4-Hydroxyandrostenedione glucuronide is a known human metabolite of 4-Hydroxyandrostenedione.'],
8210,128211,"methyl 3-[(3aR,5aR,6S,7S,9aR,9bR)-9a,9b-dimethyl-7-prop-1-en-2-yl-3a,4,5,5a,6,7,8,9-octahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoate",CC(=C)[C@H]1CC[C@@]2([C@@H]([C@H]1CCC(=O)OC)CC[C@H]3[C@]2(CC=C3)C)C,,,,,,
8211,128212,2-Chlorodopamine,C1=CC(=C(C(=C1CCN)Cl)O)O,,,,,,
8212,128213,"25,26-Dihydroxy-10,16-dimethylspiro[2,5,13,18,27,31-hexaoxaheptacyclo[22.4.3.114,17.01,3.07,12.07,16.024,28]dotriaconta-10,20,22-triene-15,2'-oxirane]-4,19-dione",CC1=CC2C3(CC1)COC(=O)C4C5(O4)CCOC6(C5OC(C6O)O)C=CC=CC(=O)OC7C3(C8(CO8)C(C7)O2)C,,,,,,
8213,128214,1-Cyanoethyl(diethylamino)dimethylsilane,CCN(CC)[Si](C)(C)C(C)C#N,,,,,,
8214,128215,4-[(4-Phenyldiazenylphenyl)diazenyl]benzoic acid,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=CC=C(C=C3)C(=O)O,,,,,,
8215,128216,7'-Hydroxydoxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=C(O4)C=CC(=C5)O)N)OC,,,,,,
8216,128217,6'-Hydroxy Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=C(O4)C=C(C=C5)O)N)OC,,,,,,
8217,128218,Propioxatin A,CCC[C@H](CC(=O)NO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O,,,,,,
8218,128219,Propioxatin B,CC(C)C[C@H](CC(=O)NO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O,,,,,,
8219,128220,CID 128220,CC(C)(C(C)(C)[O-])[O-].CC(C)(C(C)(C)[O-])[O-].C1=C[C+]=CC(=C1)N.[As+3],,,,,,
8220,128221,3-Aminobenzene-1-ylium,C1=C[C+]=CC(=C1)N,,,,,,
8221,128222,"N,N'-Bis-(6-((2-methoxybenzyl)amino)hexyl)-1,6-hexanediamine tetrahydrochloride",COC1=CC=CC=C1CNCCCCCCNCCCCCCNCCCCCCNCC2=CC=CC=C2OC,,,,,,
8222,128223,CID 128223,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)NCCNC(=O)C1=C(C(=C(C=C1)N[N+]#N)[125I])[O-])O)O)CC)OC)C(=O)OC)O,,,,,,
8223,128224,CID 128224,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)NCCNC(=O)C1=C(C(=C(C=C1)N[N+]#N)[125I])O)O)O)CC)OC)C(=O)OC)O,,,,,,
8224,128225,beta-Methylene-thiazole-4-carboxyamide-adenine dinucleotide,C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)O)C(=O)N,,,,,,
8225,128226,"2,3-Dihydro-5-fluorotryptophan",C1[C@@H](C2=C(N1)C=CC(=C2)F)C[C@@H](C(=O)O)N,,,,,,
8226,128227,"Substance P (6-11), orn(6)-",CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN)N,,,,,,
8227,128228,CID 128228,CC1=NN(C2=C1C(=NC(=N2)C(F)(F)F)S)C3=CC=CC=C3,,,,,,
8228,128229,Uralsaponin A,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,,,,"['GLYCYRRHIZIN WAS ABSORBED IN RAT SMALL INTESTINE; THERE WAS NO DETECTABLE AMT OF GLYCYRRHETINIC ACID IN BLOOD AFTER BOLUS INJECTION OF GLYCYRRHIZIN INTO PORTAL VEIN; GLYCYRRHETINIC ACID WAS PRESENT IN DETECTABLE AMT IN BLOOD AFTER ORAL ADMIN.', 'Glycyrrhizic acid (GZA) and glycyrrhetinic acid (GRA) can be determined rapidly and precisely by high-performance liquid chromatography (HPLC) in biological fluids and tissues from experimental animals and humans. From plasma and tissues, glycyrrhizic acid and glycyrrhetinic acid are extracted by organic solvents and the extracts can directly be used for HPLC. From bile or urine, extraction and determination of glycyrrhizic acid and glycyrrhetinic acid are more difficult due to interfering endogenous compounds and conjugation of glycyrrhetinic acid with glucuronides or sulfates. Extraction of glycyrrhizic acid and glycyrrhetinic acid from urine or bile can be performed by ion-pairing followed by extraction with organic solvents or by solid phase extraction. Glycyrrhetinic acid conjugates can be determined by chromatographic separation or by pretreatment with beta-glucuronidase. The pharmacokinetics of glycyrrhetinic acid and glycyrrhizic acid can be described by a biphasic elimination from the central compartment with a dose-dependent second elimination phase. Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours for glycyrrhizic acid and between 10-30 hours for glycyrrhetinic acid. The major part of both glycyrrhetinic acid or glycyrrhizic acid is eliminated by the bile. While glycyrrhizic acid can be eliminated unmetabolized and undergoes enterohepatic cycling, Glycyrrhetinic acid is conjugated to glycyrrhetinic acid glucuronide or sulfate prior to biliary excretion. Orally administered glycyrrhizic acid is almost completely hydrolyzed by intestinal bacteria and reaches the systemic circulation as glycyrrhetinic acid.', 'Glycyrrhizic acid is currently of clinical interest for treatment of chronic hepatitis. It is also applied as a sweetener in food products and chewing tobacco. In some highly exposed subgroups of the population, serious side effects such as hypertension and electrolyte disturbances have been reported. In order to analyze the health risks of exposure to this compound, the kinetics of glycyrrhizic acid and its active metabolites were evaluated quantitatively. Glycyrrhizic acid and its metabolites are subject to complex kinetic processes, including enterohepatic cycling and presystemic metabolism. In humans, detailed information on these processes is often difficult to obtain. Therefore, a model was developed that describes the systemic and gastrointestinal tract kinetics of glycyrrhizic acid and its active metabolite glycyrrhetic acid in rats. Due to the physiologically based structure of the model, data from earlier in vitro and in vivo studies on absorption, enterohepatic cycling, and presystemic metabolism could be incorporated directly. The model demonstrates that glycyrrhizic acid and metabolites are transported efficiently from plasma to the bile, possibly by the hepatic transfer protein 3-alpha-hydroxysteroid dehydrogenase. Bacterial hydrolysis of the biliary excreted metabolites following reuptake of glycyrrhetic acid causes the observed delay in the terminal plasma clearance of glycyrrhetic acid. These mechanistic findings, derived from analysis of experimental data through physiologically based pharmacokinetic modeling, can eventually be used for a quantitative health risk assessment of human exposure to glycyrrhizic acid containing products. Copyright 2000 Academic Press.', 'To assess the multiplicity for the biliary excretion of xenobiotic conjugates, glycyrrhizic acid (glycyrrhizin) was studied in rats after intravenous (IV) injection of 10 mg/kg glycyrrhizic acid and IV infusion of inhibitors, dibromosulfophthalein and indocyanine green. Indocyanine green did not affect the biliary excretion of glycyrrhizic acid, whereas dibromosulfophthalein reduced it significantly. The plasma level of glycyrrhizic acid was increased by dibromosulfophthalein, but not by indocyanine green. In Eisai hyperbilirubinemic rats, the biliary excretion of glycyrrhizic acid was severely impaired, resulting in an increased plasma level. The findings suggested that the biliary excretion of glycyrrhizic acid is mediated by the system shared by liquiritigenin glucuronides and dibromosulfophthalein, but not by indocyanine green, and that the system is hereditarily defective in Eisai hyperbilirubinemic rats.']","['BOLUS INJECTION OF GLYCYRRHIZIN GIVEN RATS IN PORTAL VEIN, GAVE RISE IN BLOOD LEVEL OF SUBSTANCE WHICH APPEARS TO BE GLUCURONIC ACID CONJUGATE FORMED AS METABOLITE OF GLYCYRRHETINIC ACID.']",
8229,128230,CID 128230,CCCCCCOC[C@H]1[C@@H]2CC[C@H]([C@H]1CC=CCCCC(=O)O)O2,,,,,,
8230,128231,Cholesteryl ether ester,C[C@H](CCCC(C)C)[C@H]1CCC2[C@@]1(CCC3C2CC=C4[C@@]3(CC[C@@H](C4)OCCCCCC(=O)ON5C(=O)CCC5=O)C)C,,,,,,
8231,128232,"1,5-Pyrimidino-6,9-purinophane",CN1C(=O)C2=CN(C1=O)CCCN3C=NC4=C3N=CN=C4SCCC2,,,,,,
8232,128233,"5,6,9,10-Tetrahydro-N-methyl-5,9-methanobenzocycloocten-11-amine",CN[C@@H]1[C@@H]2CC=C[C@@H]1CC3=CC=CC=C23,,,,,,
8233,128234,"Acetamide, 2-(diethylamino)-N-(4-(2-fluorobenzoyl)-1,3-dimethyl-1H-pyrazol-5-yl)-, monohydrochloride",CCN(CC)CC(=O)NC1=C(C(=NN1C)C)C(=O)C2=CC=CC=C2F.Cl,,,,,,
8234,128235,"N-(6-(2-Carboxy-4,6-dinitrophenylamino)hexanoyl)glucopyranosylamine",C1=C(C=C(C(=C1C(=O)O)NCCCCCC(=O)NC2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
8235,128236,N-tert-Butyloxycarbonyl-prolyl-alanyl-alanyl-methylamide,C[C@@H](C(=O)NC(=O)[C@@H](C)NC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C)NC,,,,,,
8236,128237,"4-(4-phenylbutoxy)-N-[3-(2H-tetrazol-5-yl)-2,3-dihydro-1,4-benzodioxin-5-yl]benzamide",C1C(OC2=C(C=CC=C2O1)NC(=O)C3=CC=C(C=C3)OCCCCC4=CC=CC=C4)C5=NNN=N5,,,,,,
8237,128238,CID 128238,CCC=CCC=CCC1C(O1)C=CC(CC=CCCCC(=O)O)O,,,,,,
8238,128239,Fmoc-Cys(Trt)-OH,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SC[C@@H](C(=O)O)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
8239,128240,N-(1-Carboxy-5-(4-(2-hydroxy-3-isopropylaminopropoxy)-1H-indole-2-carboxamido)pentyl)alanylproline,CC(C)NCC(COC1=CC=CC2=C1C=C(N2)C(=O)NCCCCC(C(=O)O)NC(C)C(=O)N3CCC[C@H]3C(=O)O)O,,,,,,
8240,128241,"(4S,7R,7aS,12bS)-3-(cyclopropylmethyl)-7-fluoro-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol",C1CC2([C@@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@@H]([C@@H]1F)OC5=C(C=C4)O)O,,,,,,
8241,128242,Oxociprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNC(=O)C4)F)C(=O)O,,,,,,
8242,128243,19-Hydroxyaldosterone,C1C[C@@H]([C@@]2([C@@H]1[C@@H]3CCC4=CC(=O)CC[C@@]4([C@H]3[C@H](C2)O)CO)C=O)C(=O)CO,,,,,,
8243,128244,"2-Propoxyethyl-1,4-dihydro-5-((isopropylsulfamoyl)acetyl)-2,6-dimethyl-4-(3-nitrophenyl)nicotinate",CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)CS(=O)(=O)NC(C)C)C)C,,,,,,
8244,128245,"8,11,12-Trihydroxyicosa-5,9,14,17-tetraenoic acid",CCC=CCC=CCC(C(C=CC(CC=CCCCC(=O)O)O)O)O,,,,,,
8245,128246,"6,7-Dihydro-8-phenyl-9-(4-(2-(dimethylamino)ethoxy)phenyl)-5-H-benzocycloheptene",CN(C)CCOC1=CC=C(C=C1)C2=C(CCCC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
8246,128247,tert-Butyloxycarbonylvalyl-valyl-valyl-valyl-valyl-valyl-valyl-valine methyl ester,CC(C)[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)OC)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C,,,,,,
8247,128248,gamma-Glutamyl tyramine,C1=CC(=CC=C1CCN[C@@H](CCC(=O)N)C(=O)O)O,,,,,,
8248,128249,Adiol 3-G,C[C@]12CCC3C(C1CC[C@H]2O)CCC4[C@@]3(CCC(C4)O[C@H]5[C@@H]([C@@H]([C@@H]([C@@H](O5)C(=O)O)O)O)O)C,,,,,,
8249,128250,"[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6S)-3,5-diacetyloxy-6-[(2S,3R,4S,5R,6R)-2,3,5-triacetyloxy-6-(acetyloxymethyl)oxan-4-yl]oxy-4-[(2S,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxan-2-yl]methyl acetate",CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@@H]([C@H](O[C@H]([C@@H]3OC(=O)C)OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
8250,128251,3-Hydroxyestran-17-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4[C@@H]3CCC(C4)O,,,,,,
8251,128252,5'-Deoxytoyocamycin,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)N)C#N)O)O,,,,,,
8252,128253,o-Nitrophenylsulfenyl-lysyl-tryptophan,C1=CC=C2C(=C1)C(=C(N2)SC3=CC=CC=C3[N+](=O)[O-])C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
8253,128254,"10-(4-Chlorophenyl)-3-methylbenzo[g]pteridine-2,4(3h,10h)-dione",CN1C(=O)C2=NC3=CC=CC=C3N(C2=NC1=O)C4=CC=C(C=C4)Cl,,,,,,
8254,128255,"7,16,18-Trichloro-11,22-dihydroxy-4,19,19-trimethyl-8-methylidene-20-oxatetracyclo[11.7.1.110,14.01,16]docosa-3,10,12,14(22)-tetraene-15,21-dione",CC1=CCC23C(=O)C4=CC(=C(CC(=C)C(CC1)Cl)C(=C4C(=O)C2(CC(C(O3)(C)C)Cl)Cl)O)O,,,,,,
8255,128256,"16,18-Dichloro-11,22-dihydroxy-4,8,19,19-tetramethyl-20-oxatetracyclo[11.7.1.110,14.01,16]docosa-3,7,10,12,14(22)-pentaene-15,21-dione",CC1=CCC23C(=O)C4=CC(=C(CC(=CCC1)C)C(=C4C(=O)C2(CC(C(O3)(C)C)Cl)Cl)O)O,,,,,,
8256,128257,Dysidenine,CC(CC(C(=O)NC(C)C1=NC=CS1)N(C)C(=O)CC(C)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
8257,128258,"(2R,4aR,6aR,6aS,6bR,9R,10R,11S,12aR,14bR)-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-10-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-2,4a-dicarboxylic acid",C[C@]1(CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(C[C@@H]([C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)O)C)C)[C@H]2C1)C)C(=O)O)C(=O)O,,,,,,
8258,128259,CID 128259,CC(=CCCC(=CC[C@]12C(=O)C3=C(C(=CC(=C3)O)O)C(=O)[C@]1(C[C@H](C(O2)(C)C)Cl)Cl)C)C,,,,,,
8259,128260,4-Hydroxytriazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2O)C4=CC=CC=C4Cl,,,,,['4-Hydroxytriazolam is a known human metabolite of triazolam.'],
8260,128261,Prolyl-histidyl-prolyl-phenylalanyl-histidyl-statine-isoleucyl-phenylalaninamide,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)CC([C@H](CC(C)C)N)O)NC(=O)[C@H](CC2C=NC=N2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5C=NC=N5)NC(=O)[C@@H]6CCCN6,,,,,,
8261,128262,2-(Aminomethyl)-4-tert-butyl-6-iodophenyl hydrogen sulfate,CC(C)(C)C1=CC(=C(C(=C1)I)OS(=O)(=O)O)CN,,,,,,
8262,128263,3-Deazaguanosine triphosphate,C1=C(NC(=O)C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
8263,128264,"Lanost-8-ene-2,3,12,21,24,25-hexol",C[C@@]12CC[C@@H]([C@]1([C@H](CC3=C2CCC4[C@@]3(C[C@H]([C@@H](C4(C)C)O)O)C)O)C)[C@@H](CC[C@H](C(C)(C)O)O)CO,,,,,,
8264,128265,"[(2R,3R,10S,12S,13R,14S,17R)-2,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(2R,5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate",C[C@@]12CC[C@@H]([C@]1([C@H](CC3=C2CCC4[C@@]3(C[C@H]([C@@H](C4(C)C)OC(=O)CC(C)(CC(=O)NCC(=O)OC)O)O)C)O)C)[C@@H](CC[C@H](C(C)(C)O)O)CO,,,,,,
8265,128266,delta-Sleep-inducing peptide (1-6),C[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)N,,,,,,
8266,128267,N-tert-Butyloxycarbonyl-prolyl-glycyl-alanyl-methylamide,C[C@@H](C(=O)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C)NC,,,,,,
8267,128268,N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine,COC1=CC=C(C=C1)NC2=NN(C=C2)C3=CC=CC=C3,,,,,,
8268,128269,CID 128269,CCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H](C([C@H]([C@H](O2)COP(=O)(CCN)O)O)O[C@@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)OC)O)NC(=O)C)O[C@@H]5[C@@H]([C@H]([C@H]([C@H](O5)COP(=O)(CCN)O)O)O)O)O)O)[C@H](C=CCCCCCCCCCCCC)O,,,,,,
8269,128270,"[(2R,3R,10S,12S,13R,14S,17R)-3,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(2R,5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-2-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate",C[C@@]12CC[C@@H]([C@]1([C@H](CC3=C2CCC4[C@@]3(C[C@H]([C@@H](C4(C)C)O)OC(=O)CC(C)(CC(=O)NCC(=O)OC)O)C)O)C)[C@@H](CC[C@H](C(C)(C)O)O)CO,,,,,,
8270,128271,Carbaton,CC1=C(CC(=C(N1)C)C(=O)OCC(=O)[O-])C(=O)OCC(=O)[O-].[Na+].[Na+],,,,,,
8271,128272,"2-[5-(Carboxymethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carbonyl]oxyacetic acid",CC1=C(CC(=C(N1)C)C(=O)OCC(=O)O)C(=O)OCC(=O)O,,,,,,
8272,128273,6-Methoxydihydro-2h-pyran-3(4h)-one,COC1CCC(=O)CO1,,,,,,
8273,128274,"(2R)-2-(4-chlorophenyl)-3-cyclopropyl-3-methyl-1-(1,2,4-triazol-1-yl)butan-2-ol",CC(C)(C1CC1)[C@](CN2C=NC=N2)(C3=CC=C(C=C3)Cl)O,,,,,,
8274,128275,"(4aR)-5,8,10-trihydroxy-6-methoxy-1,1,4a-trimethyl-7-propan-2-yl-3,4-dihydro-2H-phenanthren-9-one",CC(C)C1=C(C2=C(C(=C1OC)O)[C@]3(CCCC(C3=C(C2=O)O)(C)C)C)O,,,,,,
8275,128276,"Ethyl 1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-naphthyridine-3-carboxylate",CCOC(=O)C1=C(NC2=C(C1C3=CC=CC=C3C(F)(F)F)C(=NC=C2)OC(C)C)C,,,,,,
8276,128277,"N(4)-(2-(2,3-Dihydroxyphenyl)-5-methyl-2-oxazolin-4-yl)carboxy-N(1),N(7)-bis(2,3-dihydroxybenzoyl)norspermidine",CC1C(N=C(O1)C2=C(C(=CC=C2)O)O)C(=O)N(CCCNC(=O)C3=C(C(=CC=C3)O)O)CCCNC(=O)C4=C(C(=CC=C4)O)O,,,,,,
8277,128278,N-Acetyldopamine quinone,CC(=O)NCCC1=CC(=O)C(=O)C=C1,,,,,,
8278,128279,"1,2,3,4,5,10b-Hexahydropyrido(2,3-g)indolizine",C1CC2C3=C(CCN2C1)N=CC=C3,,,,,,
8279,128280,4-(Carboethoxynitrosamino)butanal,CCOC(=O)N(CCCC=O)N=O,,,,,,
8280,128281,CID 128281,CCCC(C=C=CC)[C@]1(CO1)[C@@H](C=CCC=CCCCC(=O)O)O,,,,,,
8281,128282,CID 128282,CN1CCN(C1=NN=CC2C3=CC=CC=C3C(C4=CC=CC=C24)C=NN=C5N(CCN5C)C)C,,,,,,
8282,128283,CID 128283,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCN(CCNCC1=CC(=C(C=C1)OC)OC)CC2=CC(=C(C=C2)OC)OC)C)C)C)C)C)C)C)C)C,,,,,,
8283,128284,CID 128284,C1=NC2=C(N1C(C=O)OC(COP(=O)(O)O)C=O)NC(=NC2=O)N.[Na+],,,,,,
8284,128285,CID 128285,C1=NC2=C(N1C(C=O)OC(COP(=O)(O)O)C=O)NC(=NC2=O)N,,,,,,
8285,128286,"Hexanamide, N-hydroxy-N-methyl-",CCCCCC(=O)N(C)O,,,,,,
8286,128287,Glycyl-leucyl-phenylalanine,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)CN,,,,,,
8287,128288,Bis(benzotriazol-1-yloxy)-methylphosphane,CP(ON1C2=CC=CC=C2N=N1)ON3C4=CC=CC=C4N=N3,,,,,,
8288,128289,CID 128289,C[C@]12C[C@H](C3C(C1CC[C@@]2(C(=O)COC(=O)CCC(=O)[O-])O)CCC4=CC(=O)C=C[C@]34C)OC(=O)CC(C)(C)C.[Na+],,,,,,
8289,128290,"4-[2-[(10R,11R,13S,17R)-11-(3,3-dimethylbutanoyloxy)-17-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid",C[C@]12C[C@H](C3C(C1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)OC(=O)CC(C)(C)C,,,,,,
8290,128291,"(3S,8S,9S,10R,11S,13R,14S,17S)-3,11-dihydroxy-17-(2-hydroxyacetyl)-10-methyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-13-carbaldehyde",C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O)O,,,,,,
8291,128292,"6-[(3-Butanoyl-2,6-dihydroxy-4-methoxy-5-methylphenyl)methyl]-3,5-dihydroxy-4,6-dimethyl-2-(2-methylbutanoyl)cyclohexa-2,4-dien-1-one",CCCC(=O)C1=C(C(=C(C(=C1O)CC2(C(=C(C(=C(C2=O)C(=O)C(C)CC)O)C)O)C)O)C)OC,,,,,,
8292,128293,"7-(Hydroxymethyl)-3,11,15-trimethylhexadeca-2,6,10,14-tetraenoic acid",CC(=CCCC(=CCCC(=CCCC(=CC(=O)O)C)CO)C)C,,,,,,
8293,128294,"19-[(2-acetamido-3-phenylpropanoyl)amino]-10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide",CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C)C(=O)NC(C(C)O)C(=O)N,,,,,,
8294,128295,"5-[[2-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-2-oxoacetyl]amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-N,3-N-dimethylbenzene-1,3-dicarboxamide",CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)NC(=O)C(=O)NC2=C(C(=C(C(=C2I)C(=O)N(C)CC(CO)O)I)C(=O)N(C)CC(CO)O)I)I)C(=O)N(C)CC(CO)O)I,,,,,,
8295,128296,Pereniporin A,C[C@]12CCCC([C@@H]1[C@@H](C=C3[C@@]2([C@@H](OC3)O)O)O)(C)C,,,,,,
8296,128297,Criasbetaine,COC1=C(C=C2C(=C1)C=[N+]3CCC4=C3C2=CC(=C4)[O-])OC,,,,,,
8297,128298,"4,5-Dimethoxy-9-azoniatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,4,6,8,12(16),13-heptaen-14-ol",COC1=C(C=C2C(=C1)C=[N+]3CCC4=C3C2=CC(=C4)O)OC,,,,,,
8298,128299,"Acetamide, 2-amino-N-(1,1-dimethylhexyl)-",CCCCCC(C)(C)NC(=O)CN,,,,,,
8299,128300,"3-Octyl-3-pyridin-4-ylpiperidine-2,6-dione",CCCCCCCCC1(CCC(=O)NC1=O)C2=CC=NC=C2,,,,,,
8300,128301,"3-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)-4-hydroxybenzoic acid",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=C(C=CC(=C1)C(=O)O)O)C)C)C)C)C)C,,,,,,
8301,128302,Ta 0910 Acid-type,CN1C[C@@](NC1=O)(C[C@@H](C(=O)N2CCC[C@H]2C(=O)O)N)C(=O)C3=NC=CC(=O)N3,,,,,,
8302,128303,CID 128303,C[C@H](C=C[C@](CO)(C(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
8303,128304,CID 128304,C[C@H](C=C[C@](C)(C(C)(CO)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
8304,128305,CID 128305,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CN5C=CC=CC5=C4)C(=O)[O-],,,,,,
8305,128306,CID 128306,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CN5C=CC=CC5=C4)C(=O)O,,,,,,
8306,128307,"2,3-Naphthalenediol, 7-amino-1-chloro-5,6,7,8-tetrahydro-",C1CC2=CC(=C(C(=C2CC1N)Cl)O)O,,,,,,
8307,128308,5-Methyl-1-phenyl-2-(3-piperidin-1-ylpropylamino)hexan-1-ol,CC(C)CCC(C(C1=CC=CC=C1)O)NCCCN2CCCCC2,,,,,,
8308,128309,N-bromo-N-phenylacetamide,CC(=O)N(C1=CC=CC=C1)Br,,,,,,
8309,128310,"12-Keto-5,8,10-heptadecatrienoic acid",CCCCCC(=O)C=CC=CCC=CCCCC(=O)O,,,,,,
8310,128311,1-Ethylisatin-S-n-butylisothiosemicarbazone,CCCCSC(=N)N=NC1=C(N(C2=CC=CC=C21)CC)O,,,,,,
8311,128312,CID 128312,CCSC(=NN=CC1=NC2=CC=CC=C2O1)N,,,,,,
8312,128313,4-Nitrosobibenzyl,C1=CC=C(C=C1)CCC2=CC=C(C=C2)N=O,,,,,,
8313,128314,4-(S-Ethanol)-sulfido-cyclophosphamide,C1COP(=O)(NC1SCCO)N(CCCl)CCCl,,,,,,
8314,128315,"((6,7-Dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid",CC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3=CC=C(C=C3)F,,,,,,
8315,128316,N(alpha)-Formyltetragastrin,CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CN(C3=CC=CC=C32)C=O)N,,,,,,
8316,128317,"Acetamide, N-(4-aminobutyl)-N-(3-aminopropyl)-",CC(=O)N(CCCCN)CCCN,,,,,,
8317,128318,"4,4'-(1,2-Cyclopropanediyl)bis(2,6-piperazinedione)",C1[C@H]([C@H]1N2CC(=O)NC(=O)C2)N3CC(=O)NC(=O)C3,,,,,,
8318,128319,"2-[4-(3,4-Dihydroxyphenyl)-3-fluorophenyl]propanoic acid",CC(C1=CC(=C(C=C1)C2=CC(=C(C=C2)O)O)F)C(=O)O,,,,,,
8319,128320,3'-Hydroxy-4'-methoxyflurbiprofen,CC(C1=CC(=C(C=C1)C2=CC(=C(C=C2)OC)O)F)C(=O)O,,,,,,
8320,128321,CID 128321,COC1=CC=C2C(=CC1=O)C(CCC3=CC(=C(C(=C32)OC)OC)OC)N=C(NC4=CC5=C(C=C4)C6(C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)OC5=O)S,,,,,,
8321,128322,Acetylmuramyl-valylisoglutamine,CC(C)[C@@H](C(=O)N[C@H](CCC(=O)N)C(=O)O)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C,,,,,,
8322,128323,"2,2-Diethyl-2,3,5,10-tetrahydro-1H-pyrazolo(1,2-b)phthalazine-1,3-dione",CCC1(C(=O)N2CC3=CC=CC=C3CN2C1=O)CC,,,,,,
8323,128324,Benzoylarginine leucinamide,CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C1=CC=CC=C1,,,,,,
8324,128325,"Benzamide, N-(2-((2,5-dioxo-1-pyrrolidinyl)oxy)-2-oxoethyl)-",C1CC(=O)N(C1=O)OC(=O)CNC(=O)C2=CC=CC=C2,,,,,,
8325,128326,"ethyl (2S,3S,4S)-3-(2-ethoxy-2-oxoethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylate",CCOC(=O)C[C@H]1[C@H](CN[C@@H]1C(=O)OCC)C(=C)C,,,,,,
8326,128327,CID 128327,C[C@@H]1CC2(C3C(O3)(C(O2)O)C)O[C@@H]4[C@H]1[C@]5([C@H](CC67C[C@@]68CCC(C(C8CC=C7[C@@]5(C4)C)(C)C)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)OC(=O)C)C,,,,,,
8327,128328,"Oxazolidine, 3,3'-methylenebis[5-methyl-",CC1CN(CO1)CN2CC(OC2)C,,,,,,
8328,128329,N-(4-Methylphenyl)diphenimide,CC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C4=CC=CC=C4C2=O,,,,,,
8329,128330,22-epi-Hippurin-1,C[C@H]1C[C@@]2([C@]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C[C@@H]([C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@H](C6)O)OC(=O)C)C)O)C)(C)O)OC1(C)C,,,,,,
8330,128331,"2-(N-(Cyclopropylmethyl)-N-(2,6-dibromophenyl)amino)-2-imidazoline",C1CC1CN(C2=C(C=CC=C2Br)Br)C3=NCCN3,,,,,,
8331,128332,N-tert-Butoxycarbonylphenylalanine benzyl ester,CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OCC2=CC=CC=C2,,,,,,
8332,128333,"4-Methylsulfonyl-2,4',5-trichlorobiphenyl",CS(=O)(=O)C1=C(C=C(C(=C1)Cl)C2=CC=C(C=C2)Cl)Cl,,,,,,
8333,128334,benzyl N-[2-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(4-nitroanilino)pentanoyl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate,C1C[C@H](N(C1)C(=O)CNC(=O)OCC2=CC=CC=C2)C(=O)NC(=O)[C@H](CCCN=C(N)N)NC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
8334,128335,"2-Hydroxy-2-(hydroxymethyl)cyclopent-4-ene-1,3-dione",C1=CC(=O)C(C1=O)(CO)O,,,,,,
8335,128336,Dhtba,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4OC(=O)CBr)C,,,,,,
8336,128337,CID 128337,C1=NC(=O)C2=C(N1)N(C=N2)[C@H](C=O)O[C@H](COP(=O)(O)O)C=O,,,,,,
8337,128338,N(4)-Methoxy-5-methylcytosine,CC1=C(NC(=O)N=C1)NOC,,,,,,
8338,128339,CID 128339,CCC(CCS(=N)(=O)C)(C(=O)O)N,,,,,,
8339,128340,2-(3-Phenoxyphenyl)-3-(4-chlorophenyl)-4-methylpentanenitrile,CC(C)C(C1=CC=C(C=C1)Cl)C(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,,,,,,
8340,128341,CID 128341,CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C(=C(C=C1C)O)C)C,,,,,,
8341,128342,CID 128342,CCCCCCCCCCCCCCCCOC(COCCCCCCCCC=CCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C,,,,,,
8342,128343,CID 128343,CCCCCCCCCCCCCCCCOC(COCCCCCCCCC=CCCCCCCCC)COP(=O)(O)OCC[N+](C)(C)C,,,,,,
8343,128344,Julifloricine,CC1C(CCC(N1)CCCCCCCCCCC2C=C(CN3C2CCC3)CCCCCCCCCCC4CCC(C(N4)C)O)O,,,,,,
8344,128345,"2-n-Propyl-3-dimethylamino-5,6-methylenedioxyindene",CCCC1=C(C2=CC3=C(C=C2C1)OCO3)N(C)C,,,,,,
8345,128346,"2-n-Butyl-3-(dimethylamino)-5,6-methylenedioxyindene",CCCCC1=C(C2=CC3=C(C=C2C1)OCO3)N(C)C,,,,,,
8346,128347,"Morpholine, 4-(3-(4-(2-chlorophenyl)-9-cyclopropyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-1-oxopropyl)-",C1CC1C2=NN=C3N2C4=C(C=C(S4)CCC(=O)N5CCOCC5)C(=NC3)C6=CC=CC=C6Cl,,,,,,
8347,128348,"6-(4-Chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo(2,1-a)isoquinoline",C1CC2C3=CC=CC=C3C(CN2C1)C4=CC=C(C=C4)Cl,,,,,,
8348,128349,"Morpholine, 4-(3-(4-(2-chlorophenyl)-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-1-oxopropyl)-",C1COCCN1C(=O)CCC2=CC3=C(S2)N4C=NN=C4CN=C3C5=CC=CC=C5Cl,,,,,,
8349,128350,"N,N-Diethyl-alpha-methyl-2-phenyl-4-quinolinepropanamide",CCN(CC)C(=O)C(C)CC1=CC(=NC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
8350,128351,Dihydrotetramethylrosamine,CN(C)C1=CC2=C(C=C1)C(C3=C(O2)C=C(C=C3)N(C)C)C4=CC=CC=C4,,,,,,
8351,128352,CID 128352,C1CCC(CC1)[C@@H](C#C[C@@H]2[C@H](CC[C@@H]3[C@@H]2CC3=CCCC(=O)O)O)O,,,,,,
8352,128353,beta-(2-(p-Chlorophenoxy)-2-methylpropionyl)phenylalanine methyl ester,CC(C)(C(=O)NC(CC1=CC=CC=C1)C(=O)OC)OC2=CC=C(C=C2)Cl,,,,,,
8353,128354,"Ethyl 2,5-dihydro-4-methoxy-5-oxo-3-phenyl-2-furanpropanoate",CCOC(=O)CCC1C(=C(C(=O)O1)OC)C2=CC=CC=C2,,,,,,
8354,128355,"Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-",C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)NC4=CC=CC=C4C(=O)O,,,,,,
8355,128356,3-(4-hydroxy-5-oxo-3-phenyl-2H-furan-2-yl)propanoic acid,C1=CC=C(C=C1)C2=C(C(=O)OC2CCC(=O)O)O,,,,,,
8356,128357,Phocaecholic acid,C[C@H](C[C@H](C(=O)O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
8357,128358,"6,7-Diphenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetaldehyde",C1CC2=C(C(=C(N2C1)CC=O)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
8358,128359,5-Amino-4-(diazoacetyl)-1-ribofuranosylimidazole,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)C=[N+]=[N-],,,,,,
8359,128360,CID 128360,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=C[N+]#N)O,,,,,,
8360,128361,Methyl 3-oxo-4-methyl-4-aza-5alpha-androst-1-ene-17beta-carboxylate,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)OC)CC[C@@H]4[C@@]3(C=CC(=O)N4C)C,,,,,,
8361,128362,CID 128362,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N(CC#N)CC2=CC3=C(C=C2)NC(=NC3=O)N,,,,,,
8362,128363,Tilivalline,C1C[C@H]2[C@@H](NC3=C(C=CC=C3O)C(=O)N2C1)C4=CNC5=CC=CC=C54,,,,,,
8363,128364,Phenylalanyl-diiodotyrosine,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC(=C(C(=C2)I)O)I)C(=O)O)N,,,,,,
8364,128365,CID 128365,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=O)C(=O)N2.[Na+],,,,,,
8365,128366,N-Isopropyliodoacetamide,CC(C)NC(=O)CI,,,,,,
8366,128367,"4-Octadecene-1,3-diol,2-azido-, (2S,3R,4E)-",CCCCCCCCCCCCCC=C[C@H]([C@H](CO)N=[N+]=[N-])O,,,,,,
8367,128368,"[(1R,2R,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxycyclopentyl]methyl 3-ethoxypropanoate",CCOCCC(=O)OC[C@H]1CC([C@H]([C@@H]1O)O)N2C=NC3=C(N=CN=C32)N,,,,,,
8368,128369,"1,7,9,11-Tetrahydroxy-8,13-dioxo-3-(2-oxopropyl)-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid",CC(=O)CC1=C(C(=C2C(=C1)CCC3=C(C4=C(C=C32)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)O)O)C(=O)O,,,,,,
8369,128370,CID 128370,CCCCCCCCCCCCCCCCCCOCC(COP(O)([O-])OP(O)([O-])OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O)OC(=O)CCCCCCCCCCCCCCC,,,,,,
8370,128371,CID 128371,CCCCCCCCCCCCCCCCCCOCC(COP(O)(O)OP(O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O)OC(=O)CCCCCCCCCCCCCCC,,,,,,
8371,128372,Arginyl-hydroxyprolyl-prolyl-glycyl-(2-thienyl)alanyl-seryl-phenylalanyl-2-(thienyl)alanyl-arginine,C1C[C@H](N(C1)C(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CS5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
8372,128373,"L-Arginine, N2-(N-(N-(N-(N-(N-(1-(trans-4-hydroxy-1-(N2-(N2-L-lysyl-L-lysyl)-L-arginyl)-L-prolyl)-L-prolyl)glycyl)-3-(2-thienyl)-L-alanyl)-L-seryl)-D-phenylalanyl)-3-(2-thienyl)-L-alanyl)-",C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N(C(=O)[C@H](CC3=CC(=CS3)O)N)[C@](CCCN=C(N)N)(C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)OC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)N,,,,,,
8373,128374,"L-Arginine, N2-(N-(N-(N-(N-(N-(trans-4-hydroxy-1-(1-(N2-(N2-L-lysyl-L-lysyl)-L-arginyl)-L-prolyl)-L-prolyl)glycyl)-3-(2-thienyl)-L-alanyl)-L-seryl)-D-phenylalanyl)-3-(2-thienyl)-L-alanyl)-",C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)C(CCN=C(N)N)[C@@](C(=O)CNC(=O)[C@@H]2C[C@H](CN2)O)(C(=O)O)N(C(=O)[C@H](CC3=CC=CS3)N)C(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)N,,,,,,
8374,128375,"3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2-(1H-imidazol-1-ylmethyl)-6-methyl-4-(3-nitrophenyl)-, 3-ethyl 5-methyl ester",CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)CN3C=CN=C3,,,,,,
8375,128376,"4-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylcyclopropyl]-2-methoxyphenol",COC1=C(C=CC(=C1)C2(CC2C3=NCCN3)C4=CC=CC=C4)O,,,,,,
8376,128377,Rhcbz,C1CC(N2C1=NCC2)(C3=CC=CC=C3)C4=CC=C(C=C4)O,,,,,,
8377,128378,17-Tetracosenal,CCCCCCC=CCCCCCCCCCCCCCCCC=O,,,,,,
8378,128379,"Pyrrolidinium, 1-methyl-1-(1-((2-methylpropoxy)methyl)-2-(phenyl(phenylmethyl)amino)ethyl)-, bromide",CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)[N+]3(CCCC3)C.[Br-],,,,,,
8379,128380,N-benzyl-N-[3-(2-methylpropoxy)-2-(1-methylpyrrolidin-1-ium-1-yl)propyl]aniline,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)[N+]3(CCCC3)C,,,,,,
8380,128381,CID 128381,CC1=C[C@@H]2[C@@]([C@H]([C@@H](C(=CCC1)C)OC(=O)C(C)C)O)(C(=C)C(=O)O2)O,,,,,,
8381,128382,N(4)-Hexadecyl-1-arabinofuranosylcytosine,CCCCCCCCCCCCCCCCNC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8382,128383,Quantacure qtx,CC1=C(C=C2C(=C1C)SC3=CC=CC=C3C2=O)OCC(C[N+](C)(C)C)O.[Cl-],,,,,,
8383,128384,"[3-(3,4-Dimethyl-9-oxo-9H-thioxanthene-2-yloxy)-2-hydroxypropyl]trimethylammonium",CC1=C(C=C2C(=C1C)SC3=CC=CC=C3C2=O)OCC(C[N+](C)(C)C)O,,,,,,
8384,128385,"[2-[[(2S,4R)-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl] (2R)-2-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-2-[[(2S)-2-amino-3,3-dithiophen-2-ylpropanoyl]-[(2R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoate",C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N(C(=O)[C@H](C(C2=CC=CS2)C3=CC=CS3)N)[C@](CCCN=C(N)N)(C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N)C(=O)OC(=O)CNC(=O)[C@@H]5C[C@H](CN5)O)N,,,,,,
8385,128386,"2-[2-Chloro-4-(6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl)phenoxy]-N-[2-(4-morpholinyl)ethyl]acetamide",C1CC(=O)NN=C1C2=CC(=C(C=C2)OCC(=O)NCCN3CCOCC3)Cl,,,,,,
8386,128387,"3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2-(4-((2-hydroxy-3-phenoxypropyl)amino)butoxy)-5-nitrophenyl)-2,6-dimethyl-, dimethyl ester",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=C(C=CC(=C2)[N+](=O)[O-])OCCCCNCC(COC3=CC=CC=C3)O)C(=O)OC,,,,,,
8387,128388,8-Amino-3-deazaguanine,C1=C(NC(=O)C2=C1NC(=N2)N)N,,,,,,
8388,128389,2'-Iodospiperone,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=C(C=C(C=C4)F)I,,,,,,
8389,128390,"2H-Pyrazolo(3,4-d)pyrimidine-2-carboxylic acid, 7-butyl-4,5,6,7-tetrahydro-3-(methylamino)-4,6-dioxo-5-propyl-, methyl ester",CCCCN1C2=NN(C(=C2C(=O)N(C1=O)CCC)NC)C(=O)OC,,,,,,
8390,128391,Methyl 2-[2-(2-phenylethenyl)phenyl]-3-methoxyacrylate,COC=C(C1=CC=CC=C1C=CC2=CC=CC=C2)C(=O)OC,,,,,,
8391,128392,Cosmomycin B',CCC1(CCC2=C(C1OC3CC(C(C(O3)C)OC4CC(C(C(O4)C)O)O)N(C)C)C(=C5C(=C2O)C(=O)C6=C(C5=O)C=CC=C6O)O)O,,,,,,
8392,128393,Cosmomycin A',CCC1(CCC2=C(C1OC3CC(C(C(O3)C)OC4CCC(C(O4)C)O)N(C)C)C(=C5C(=C2O)C(=O)C6=C(C5=O)C=CC=C6O)O)O,,,,,,
8393,128394,"4-(2-Methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)octane-5,6-diol",CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@H](CC[C@]23CO3)O)O)C,,,,,,
8394,128395,3'-(4-Methoxy-1-piperidinyl)-3'-deaminodaunorubicin,CC1C(C(CC(O1)OC2C3=C(CCC2(C(=O)C)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C=CC=C5OC)O)N6CCC(CC6)OC)O,,,,,,
8395,128396,H-Glu-his-phe-argoh,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N,,,,,,
8396,128397,"2-[2-[2-[2-[bis(carboxymethyl)amino]-5-[methoxy-(6-nitro-1,3-benzodioxol-5-yl)methyl]phenoxy]ethoxy]-N-(carboxymethyl)-4-methylanilino]acetic acid",CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C(C3=CC4=C(C=C3[N+](=O)[O-])OCO4)OC)N(CC(=O)O)CC(=O)O,,,,,,
8397,128398,(2R)-1-[[(2R)-1-hydroxypropan-2-yl]amino]-3-naphthalen-1-yloxypropan-2-ol,C[C@H](CO)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,,,,,,
8398,128399,N-Acetyl-aspartyl-O-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartyl-phenylalaninamide,CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C)N,,,,,,
8399,128400,CID 128400,C1=CC=C(C=C1)C=CC(=O)OC2=CC=C(C=C2)C(=N)N,,,,,,
8400,128401,"3,5,12-Trihydroxy-3-{1-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)hydrazinylidene]ethyl}-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside--hydrogen chloride (1/1)",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NN=C6CC(N(C(C6)(C)C)O)(C)C)C)O)N)O.Cl,,,,,,
8401,128402,"(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[N-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-C-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NN=C6CC(N(C(C6)(C)C)O)(C)C)C)O)N)O,,,,,,
8402,128403,(4-Carbamimidoylphenyl) 2-methyl-3-phenylprop-2-enoate,CC(=CC1=CC=CC=C1)C(=O)OC2=CC=C(C=C2)C(=N)N,,,,,,
8403,128404,Gfsamide,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N)NC(=O)CN.Cl,,,,,,
8404,128405,CID 128405,C1=CC=C(C=C1)CC(C(=O)N[C@@H](CO)C(=O)N)NC(=O)CN,,,,,,
8405,128406,CID 128406,CC(C)C(C(C(C)C(=O)O)O)NC(=O)C=[N+]([O-])OC,,,,,,
8406,128407,CID 128407,CCC(C(C(C(C)C)NC(=O)C=[N+]([O-])OC)O)C(=O)O,,,,,,
8407,128408,Deoxycholyltyrosine,C[C@H](CCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)[C@H]2CCC3[C@@]2([C@H](CC4C3CC[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C,,,,,,
8408,128409,Chenodeoxycholyltyrosine,C[C@H](CCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)[C@H]2CCC3[C@@]2(CCC4C3[C@@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C,,,,,,
8409,128410,"6-Fluoro-7-(1-piperazinyl)-1-(2'-phenyl-1'-cyclopropyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid",C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)[C@@H]4C[C@H]4C5=CC=CC=C5)F,,,,,,
8410,128411,"[3,4-Dihydroxy-2-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)phenyl] acetate",CC(=CCCC(=CCCC(=CCCC(=CCC1=C(C=CC(=C1O)O)OC(=O)C)C)C)C)C,,,,,,
8411,128412,Clausenamide,CN1[C@@H]([C@@H]([C@H](C1=O)O)C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)O,,,,,,
8412,128413,"7-Chloro-2-methyl-5-phenyl-(1,2,4)triazolo(5,1-c)(1,2,4)benzothiadiazine-5-oxide",CC1=NN2C3=C(C=C(C=C3)Cl)S(=NC2=N1)(=O)C4=CC=CC=C4,,,,,,
8413,128414,6-Amino-alpha-(((1-methyl-3-phenylpropyl)amino)methyl)-3-pyridinemethanol,CC(CCC1=CC=CC=C1)NCC(C2=CN=C(C=C2)N)O,,,,,,
8414,128415,"4-amino-1-pent-3-ynyl-N-prop-2-enylpyrazolo[3,4-b]pyridine-5-carboxamide",CC#CCCN1C2=NC=C(C(=C2C=N1)N)C(=O)NCC=C,,,,,,
8415,128416,CID 128416,COC=C(C#N)S(=O)(=O)C(=COC)C#N,,,,,,
8416,128417,"methyl 2-[(1R,3aS,4S,7aS)-4-[2-(5-hydroxy-2-methylphenyl)ethyl]-7a-methyl-5-oxo-2,3,3a,4,6,7-hexahydro-1H-inden-1-yl]propanoate",CC1=C(C=C(C=C1)O)CC[C@H]2[C@@H]3CC[C@@H]([C@]3(CCC2=O)C)C(C)C(=O)OC,,,,,,
8417,128418,4-Fluorodeprenyl,CC(CC1=CC=C(C=C1)F)N(C)CC#C,,,,,,
8418,128419,"Inositol 1,3-bisphosphate",[C@H]1([C@H](C([C@H]([C@@H](C1O)O)OP(=O)(O)O)O)OP(=O)(O)O)O,,,,,,
8419,128420,Aminobutylethylisoluminol-biotin,CCN(CCCCNC(=O)CCCC[C@H]1[C@@H]2[C@H](CS1)NC(=O)N2)C3=CC4=C(C=C3)C(=O)NNC4=O,,,,,,
8420,128421,2-Chloro-4-nitrophenyl-N-acetyl-beta-D-glucosaminide,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C(C=C(C=C2)[N+](=O)[O-])Cl)CO)O)O,,,,,,
8421,128422,Pipecolyl-leucyl-glycinamide,CC(C)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@H]1CCCCN1,,,,,,
8422,128423,alpha-Emtbl,CCC1(CCSC1=O)C,,,,,,
8423,128424,4-Ethyl-4-methylthiolan-2-one,CCC1(CC(=O)SC1)C,,,,,,
8424,128425,"2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-(2-isothiocyanatoethyl)-, monohydrochloride",C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=C(C=C3)Cl)CCN=C=S.Cl,,,,,,
8425,128426,"7-Chloro-5-(4-chlorophenyl)-1-(2-isothiocyanatoethyl)-1H-1,4-benzodiazepin-2(3H)-one",C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=C(C=C3)Cl)CCN=C=S,,,,,,
8426,128427,Pphpc,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
8427,128428,[O-(1-O-Palmitoyl-2-O-[6-(1-pyrenyl)hexanoyl]-L-glycero-3-phospho)choline]anion,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,,,,,,
8428,128429,"4-(2-(3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)benzoic acid",CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)C(=O)O)C,,,,,,
8429,128430,CID 128430,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H]([C@H](CC3=C)F)O)C,,,,,,
8430,128431,"Bis(4-nitro-2-(3,6,9-trioxadecyloxycarbonyl)phenyl)oxalate",COCCOCCOCCOC(=O)C1=C(C=CC(=C1)[N+](=O)[O-])OC(=O)C(=O)OC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)OCCOCCOCCOC,,,,,,
8431,128432,CID 128432,CC(CCCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
8432,128433,"7-Amino-4,5,6-triethoxy-3-hydroxyphthalide",CCOC1=C(C(=C(C2=C1C(OC2=O)O)N)OCC)OCC,,,,,,
8433,128434,"9-(aminomethyl)-9H-fluorene-3,4-diol",C1=CC=C2C(=C1)C(C3=C2C(=C(C=C3)O)O)CN,,,,,,
8434,128435,"4-[(3,5-Dihydroxy-3-methylpentanoyl)amino]butanoic acid",CC(CCO)(CC(=O)NCCCC(=O)O)O,,,,,,
8435,128436,CID 128436,CCC(C)(CC=C[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C)O,,,,,,
8436,128437,Carbazomycin E,CC1=C(C2=C(C3=CC=CC=C3N2)C(=C1OC)O)C=O,,,,,,
8437,128438,Carbazomycin F,CC1=C(C2=C(C3=C(N2)C=CC(=C3)OC)C(=C1OC)O)C=O,,,,,,
8438,128439,Postin,C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
8439,128440,"5-[[4-[2-Hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione",CC1=C(N=C(O1)C2=CC=CC=C2)C(COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)O,,,,,,
8440,128441,"(4-Acetamidophenyl) 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)OC2=CC=C(C=C2)NC(=O)C)C)C,,,,,,
8441,128442,5-Azidoalrestatin,C1=CC2=CC(=CC3=C2C(=C1)C(=O)N(C3=O)CC(=O)O)N=[N+]=[N-],,,,,,
8442,128443,"3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-(3-((methyl(phenylmethyl)amino)methyl)-1,2,4-oxadiazol-5-yl)-4-(3-nitrophenyl)-, methyl ester",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C3=NC(=NO3)CN(C)CC4=CC=CC=C4,,,,,,
8443,128444,Tyrosyl-prolyl-tryptophyl-threonine,C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)O,,,,,,
8444,128445,N2-(N-(N-(1-L-Tyrosyl-L-prolyl)-L-tryptophyl)-L-threonyl)-L-glutamine,C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)O,,,,,,
8445,128446,"1H-Azepinium, 3-ethylhexahydro-3-(3-hydroxyphenyl)-1,1-dimethyl-",CCC1(CCCC[N+](C1)(C)C)C2=CC(=CC=C2)O,,,,,,
8446,128447,Shikonin leucoacetate,CC(=CCC(C1=C(C2=C(C=CC(=C2C(=C1)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C,,,,,,
8447,128448,"4H-Anthra(1,2-b)pyran-4,7,12-trione, 2-(2,2'-bioxiran)-2-yl-11-hydroxy-5-methyl-",CC1=CC2=C(C3=C1C(=O)C=C(O3)C4(CO4)C5CO5)C(=O)C6=C(C2=O)C=CC=C6O,,,,,,
8448,128449,2-(((3-Chloro-4-morpholino-2-pyridyl)methyl)sulfinyl)-5-methoxy-(1H)-benzimidazole,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC3=NC=CC(=C3Cl)N4CCOCC4,,,,,,
8449,128450,N(3)-Allyluridine,C=CCN1C(=O)C=CN(C1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8450,128451,N(3)-Allylthymidine,CC1=CN(C(=O)N(C1=O)CC=C)[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
8451,128452,"2-(Ethoxymethyl)-3,5-dihydroxy-1-methoxyanthracene-9,10-dione",CCOCC1=C(C=C2C(=C1OC)C(=O)C3=C(C2=O)C(=CC=C3)O)O,,,,,,
8452,128453,Argininal dibutylacetal,CCCCOC([C@H](CCCN=C(N)N)N)OCCCC,,,,,,
8453,128454,N(6)-Ribosyladenine,C1[C@H]([C@H]([C@H]([C@@H](O1)NC2=NC=NC3=C2NC=N3)O)O)O,,,,,,
8454,128455,Versicolactone C,CC(=C)[C@H]1CC[C@@]2([C@H](CC[C@]23C([C@H]1OC3=O)O)O)C,,,,,,
8455,128456,CID 128456,C1C(C(=O)N(C1=O)C(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)[O-])S(=O)(=O)O,,,,,,
8456,128457,CID 128457,C1C(C(=O)N(C1=O)C(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)O)S(=O)(=O)O,,,,,,
8457,128458,2-Hydroxydecanedioic acid,C(CCCC(C(=O)O)O)CCCC(=O)O,,,,,,
8458,128459,CID 128459,C1CC(=O)N=C2C1=CC(=C3CSC(=O)NN3)C=C2,,,,,,
8459,128460,"3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(4-hydroxyphenyl)-4-oxo-",CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)C3=CC=C(C=C3)O)F)C(=O)O,,,,,,
8460,128461,CID 128461,CC(C)C(CCCNCCCOC1=CC=CC=C1OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC.C(=CC(=O)O)C(=O)O,,,,,,
8461,128462,"3,4,5-Trimethoxy-alpha-[3-[[3-(2-methoxyphenoxy)propyl]amino]propyl]-alpha-(1-methylethyl)benzeneacetonitrile",CC(C)C(CCCNCCCOC1=CC=CC=C1OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8462,128463,"(1R,2S,4R,5R,8R,9S,11S)-9-formyl-2-(hydroxymethyl)-5-methyl-13-propan-2-yltetracyclo[7.4.0.02,11.04,8]tridec-12-ene-1-carboxylic acid",C[C@@H]1CC[C@@H]2[C@@H]1C[C@@]3([C@H]4C[C@]2([C@]3(C(=C4)C(C)C)C(=O)O)C=O)CO,,,,,,
8463,128464,((2-Dimethylphenylsilyl)ethylthio)ethylamine,C[Si](C)(CCSCCN)C1=CC=CC=C1,,,,,,
8464,128465,rac (Bromoacetamidophenylmethyl)ethylenediaminetetraacetic acid,C1=CC(=CC=C1CC(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)NC(=O)CBr,,,,,,
8465,128466,"[(4S,12S,13R,16R,17R)-17-hydroxy-12-methyl-8-oxapentacyclo[14.2.1.01,13.04,12.05,9]nonadeca-5(9),6-dien-17-yl]methyl hexadecanoate",CCCCCCCCCCCCCCCC(=O)OC[C@]1(CC23CC[C@@H]4C5=C(CC[C@]4([C@@H]2CC[C@@H]1C3)C)OC=C5)O,,,,,,
8466,128467,1-Phthalidyl-5-fluorouracil,C1=CC=C2C(=C1)C(OC2=O)N3C=C(C(=O)NC3=O)F,,,,,,
8467,128468,"3-[5-(Hexa-2,4-dienoyloxymethyl)-3-(hydroxymethyl)-4-methoxy-6-oxopyran-2-yl]prop-2-enoic acid",CC=CC=CC(=O)OCC1=C(C(=C(OC1=O)C=CC(=O)O)CO)OC,,,,,,
8468,128469,"5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-6a-methyl-1,3,3a,4,5,6-hexahydropentalen-2-ylidene]pentanoic acid",CCCCC[C@@H](C=C[C@@H]1[C@H]2CC(=CCCCC(=O)O)C[C@]2(C[C@H]1O)C)O,,,,,,
8469,128470,CID 128470,C1=CC=C(C=C1)[Sn]C2=CC=CC=C2.C1=NC2=C(N=CN=C2[N-]1)N.C1=NC2=C(N=CN=C2[N-]1)N,,,,,,
8470,128471,N-Chloroethylnitrosourea asparaginamide,C(CCl)N(C(=O)N[C@@H](CC(=O)N)C(=O)N)N=O,,,,,,
8471,128472,"(1R,2R,6R,7S,10R,12S,13S)-13-hydroxy-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecan-5-one",C[C@@]12CCC(=O)[C@@]([C@H]1CC[C@H]3[C@]24CC[C@]([C@@H](C3)C4)(CO)O)(C)CO,,,,,,
8472,128473,Antibiotic OA 6129A,CC[C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)CO)O,,,,,,
8473,128474,N-Nitrosotaurocholic acid,C[C@H](CCC(=O)N(CCS(=O)(=O)O)N=O)[C@H]1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
8474,128475,9-(2-Anthryl)nonanoic acid,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)CCCCCCCCC(=O)O,,,,,,
8475,128476,5-Aminoimidazole-4-carboxamide-1-ribofuranosyl triphosphate,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N)C(=O)N,,,,,,
8476,128477,"9,9-Dimethyl-3-methylidene-2-oxooctahydro-3a,7-ethanoindene-4-carboxylic acid",CC1(C[C@H]2CC[C@H]([C@@]13[C@@H]2CC(=O)C3=C)C(=O)O)C,,,,,,
8477,128478,"(8S,11R,13S,14S)-11-(4-aminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",CC#CC1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N)C)O,,,,,,
8478,128479,"(8S,11R,13S,14S)-17-hydroxy-13-methyl-11-[4-(methylamino)phenyl]-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",CC#CC1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)NC)C)O,,,,,,
8479,128480,"2-(4-Hydroxy-3,5-dimethylphenyl)-5-methoxy-3-methylindole",CC1=CC(=CC(=C1O)C)C2=C(C3=C(N2)C=CC(=C3)OC)C,,,,,,
8480,128481,CID 128481,CCC(=CC(=O)O[C@@H]1C[C@H]([C@H]2[C@H](C1=C)CC(=O)[C@H]2C(C)OC(=O)C)C(C)C)C,,,,,,
8481,128482,"Glucono-1,5-lactone oxime",C([C@@H]1[C@H]([C@@H]([C@H](C(=NO)O1)O)O)O)O,,,,,,
8482,128483,4-Nitrophenyl(phenylselenyl)acetate,C1=CC=C(C=C1)[Se]CC(=O)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
8483,128484,"Pyridinium, 4-((2-carboxy-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)amino)-1-(phenylmethyl)-, hydroxide, inner salt, monosodium salt, (6R-trans)-",CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@H](C3=O)N=C4C=CN(C=C4)CC5=CC=CC=C5)SC2)C(=O)[O-].[Na+],,,,,,
8484,128485,"(6R,7S)-7-[(1-benzylpyridin-4-ylidene)amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@H](C3=O)N=C4C=CN(C=C4)CC5=CC=CC=C5)SC2)C(=O)O,,,,,,
8485,128486,Isocimetidine,CN=C(NCCSCC1=NC=CN1C)NC#N,,,,,,
8486,128487,"2-(4-(2,3-Dihydroxypropoxy)phenyl)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid",CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)OCC(CO)O)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,,,,,,
8487,128488,4-Azidophenacetylthiocarnitine,C[N+](C)(C)CC(CC(=O)[O-])SCC(=O)C1=CC=C(C=C1)N=[N+]=[N-],,,,,,
8488,128489,CID 128489,C[N+](C)(C)CC(CC(=O)O)SCC(=O)C1=CC=C(C=C1)N[N+]#N,,,,,,
8489,128490,2-tert-Butyl-6-isothiocyanato-5-(piperidin-1-yl)benzthiazole,CC(C)(C)C1=NC2=CC(=C(C=C2S1)N=C=S)N3CCCCC3,,,,,,
8490,128491,"Acetic acid, ((5-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)thio)-1,3,4-thiadiazol-2-yl)thio)-",CCCC1=C(C=CC(=C1O)C(=O)C)OCCCSC2=NN=C(S2)SCC(=O)O,,,,,,
8491,128492,"2,4-Dinitrophenylaminocaproyltyrosine",C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)CCCCCNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
8492,128493,4-Amino-3-hydroxyphenylethylamine,C1=CC(=C(C=C1CCN)O)N,,,,,,
8493,128494,"2',3'-Dideoxycytidine diphosphate",C1C[C@H](O[C@@H]1COP(=O)(O)OP(=O)(O)O)N2C=CC(=NC2=O)N,,,,,,
8494,128495,"(1S,2S,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol",C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H]([C@@H]([C@H](C3=C)O)OCCCO)O)C,,,,,,
8495,128496,N(6)-(Amido-3-propyl)adenosine,C1=NC(=C2C(=N1)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NCCCC(=O)N.Cl,,,,,,
8496,128497,"4-[[9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]butanamide",C1=NC(=C2C(=N1)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NCCCC(=O)N,,,,,,
8497,128498,1-Amidino-2-pyrrolidone-5-carboxylic acid,C1CC(=O)N([C@@H]1C(=O)O)C(=N)N,,,,,,
8498,128499,"N-(5,5-Dimethylhex-3-yn-1-yl)-N-methyl-1-naphthalenemethanamine",CC(C)(C)C#CCCN(C)CC1=CC=CC2=CC=CC=C21,,,,,,
8499,128500,Bromofosfamide,C1CN(P(=O)(OC1)NCCBr)CCCl,,,,,,
8500,128501,CID 128501,CCCCCCOC[C@H]1[C@@H]2CC[C@H]([C@H]1CC=CCCC(C)(C)C(=O)O)O2,,,,,,
8501,128502,(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoic acid,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]3CCCN3,,,,,,
8502,128503,Sdz-nvi-085,CN1CCO[C@H]2[C@H]1CC3=C(C=CC(=C3C2)SC)OC,,,,,,
8503,128504,"N,N-Dimethyldeoxynojirimycin",C[N+]1(C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)C,,,,,,
8504,128505,"3,3'-Neotrehalosadiamine",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)N)O)O,,,,,,
8505,128506,CID 128506,C1CCN2CC[C@@H]3C=C([C@@](CCC=CC1)([C@H]4C3(C2)C[C@H]5N4CCCCC=C5)O)C6=NC=CC7=C6NC8=CC=CC=C78,,,,,,
8506,128507,"N,N-Diethyl-1-methyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide",CCN(CC)C(=O)C1CCC2C1CCC3C2CCC4C3CCC(=O)N4C,,,,,,
8507,128508,"Estriol 3,17-dipropionate",CCC(=O)O[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)OC(=O)CC)C)O,,,,,,
8508,128509,"Estriol 3,17-dihexanoate",CCCCCC(=O)O[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)OC(=O)CCCCC)C)O,,,,,,
8509,128510,CID 128510,C[C@H](C=CC(C)(C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C,,,,,,
8510,128511,CID 128511,C[C@H](C=CC(C)(C)C(C)(C)O)[C@@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C,,,,,,
8511,128512,"(2,5-dioxopyrrolidin-1-yl) (4R)-4-[(3R,5R,10S,13R,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate",C[C@H](CCC(=O)ON1C(=O)CCC1=O)[C@@H]2CCC3[C@@]2(CCC4C3CC[C@H]5[C@@]4(CC[C@H](C5)O)C)C,,,,,,
8512,128513,Cbz-E-lcl,C[C@H](CCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)OCC1=CC=CC=C1)[C@@H]2CCC3[C@@]2(CCC4C3CC[C@H]5[C@@]4(CC[C@H](C5)O)C)C,,,,,,
8513,128514,"5-Methoxy-2-phenyl-1,3-dioxane",COC1COC(OC1)C2=CC=CC=C2,,,,,,
8514,128515,"N-benzyl-1,1-dioxo-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]thieno[3,4-d][1,2]thiazol-3-amine",C1CCN(CC1)CC2=CC(=CC=C2)OCCCN(CC3=CC=CC=C3)C4=NS(=O)(=O)C5=CSC=C54,,,,,,
8515,128516,"4,11-Dihydroxy-13-(4-methoxyphenyl)-1-pyrrolidin-1-yltrideca-5,7,9-trien-1-one",COC1=CC=C(C=C1)CCC(C=CC=CC=CC(CCC(=O)N2CCCC2)O)O,,,,,,
8516,128517,6-Deoxypenciclovir,C1=C2C(=NC(=N1)N)N(C=N2)CCC(CO)CO,,,,,,
8517,128518,7-(3-(4-(2-Pyrimidinyl)-1-piperazinyl)propoxy)-2H-1-benzopyran-2-one sulfate,C1CN(CCN1CCCOC2=CC3=C(C=C2)C=CC(=O)O3)C4=NC=CC=N4,,,,,,
8518,128519,"4-(4-(Bis(2-chloroethyl)amino)phenyl)-1-hydroxybutane-1,1-bisphosphonic acid",C1=CC(=CC=C1CCCC(O)(P(=O)(O)O)P(=O)(O)O)N(CCCl)CCCl,,,,,,
8519,128520,CID 128520,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCNC(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)[O-])C(=O)O)NC(=O)[C@H](CCSC)NC=O,,,,,,
8520,128521,CID 128521,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCNC(=O)CCSSCCNC(=O)C2=C(C=C(C=C2)N[N+]#N)O)C(=O)O)NC(=O)C(CCSC)NC=O,,,,,,
8521,128522,Anguibactin,C1C(N=C(S1)C2=C(C(=CC=C2)O)O)C(=O)N(CCC3=CN=CN3)O,,,"['Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)']",,,
8522,128523,"[1-Hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid)",C1=CC(=CN=C1)CCC(O)(P(=O)(O)O)P(=O)(O)O,,,,,,
8523,128524,Carbocyclic puromycin,CN(C)C1=NC=NC2=C1N=CN2[C@H]3C[C@H]([C@@H]([C@@H]3O)NC(=O)C(CC4=CC=C(C=C4)OC)N)CO,,,,,,
8524,128525,1-Propylxanthine,CCCN1C(=O)C2=C(NC1=O)N=CN2,,,,,,
8525,128526,Prednisolone 17-Ethyl Carbonate,CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)CO,,,,,,
8526,128527,"1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-",C1=CN(C(=N1)[N+](=O)[O-])CC(COC(C(F)(F)F)C(F)(F)F)O,,,,,,
8527,128528,CID 128528,CCCCCCCCCC=C(CCCCCC)CN=C(N)NN,,,,,,
8528,128529,"2-(4-(Diphenylmethyl)-1-piperazinyl)ethylmethyl-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate",CC1=C(C(=C(C(=N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,,,,,,
8529,128530,"2-[5-Methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl]oxyacetic acid",CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)O)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC,,,,,,
8530,128531,"N-(3,3-Dimethylamino)propyl-8-methoxynaphtho(2,1-b)thiophene-4-carboxamide",CN(C)CCCNC(=O)C1=C2C(=C3C=C(C=CC3=C1)OC)C=CS2,,,,,,
8531,128532,CID 128532,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC(=C(C=C4)O)O)O)OC(=O)NCCCCCCN=C5C=CC(=N[N+]#N)C=C5N(O)[O-])O,,,,,,
8532,128533,CID 128533,C1=NC(=O)C2=C(N1)N(C=N2)CCCCCOC(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
8533,128534,7-Dihydrobenfluron,CN(C)CCOC1=CC2=C(C3=CC=CC=C3C2O)C4=CC=CC=C41,,,,,,
8534,128535,Hydroxypropentofylline,CC(CN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C)O,,,,,,
8535,128536,Admdnl,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCC[C@@H](C(=O)O)NC(=O)C3=CC=C(C=C3)N(C)CC4=CN=C5C(=N4)C(=NC(=N5)N)N,,,,,,
8536,128537,"Sulfamide, N,N-dimethyl-N'-((8alpha)-6-propylergolin-8-yl)-",CCCN1C[C@H](CC2[C@H]1CC3=CNC4=CC=CC2=C34)NS(=O)(=O)N(CC)CC,,,,,,
8537,128538,"7H-Benzo(c)fluorene-6-carboxylic acid, 5-(2-(diethylamino)ethoxy)-7-oxo-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC1=C(C2=C(C3=CC=CC=C31)C4=CC=CC=C4C2=O)C(=O)OCCN(CC)CC,,,,,,
8538,128539,2-Aza-2-cyclopentenespirocyclopentane 2-oxide,C1CCC2(C1)CCC=[N+]2[O-],,,,,,
8539,128540,"7H-Benzo(c)fluorene-6-carboxylic acid, 5-(2-(diethylamino)ethoxy)-3,9-diethyl-7-oxo-, 2-(diethylamino)ethyl ester, dihydrochloride",CCC1=CC2=C(C=C1)C3=C(C(=C2OCCN(CC)CC)C(=O)OCCN(CC)CC)C(=O)C4=C3C=CC(=C4)CC.Cl.Cl,,,,,,
8540,128541,"2-(Diethylamino)ethyl 5-[2-(diethylamino)ethoxy]-3,9-diethyl-7-oxobenzo[c]fluorene-6-carboxylate",CCC1=CC2=C(C=C1)C3=C(C(=C2OCCN(CC)CC)C(=O)OCCN(CC)CC)C(=O)C4=C3C=CC(=C4)CC,,,,,,
8541,128542,CID 128542,C1=NC2=C(N1CCC(CO)O)NC(=NC2=O)N,,,,,,
8542,128543,3-(2-Quinolinylmethoxy)benzeneacetic acid,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)CC(=O)O,,,,,,
8543,128544,pAIBC,CC(C)(CC1=CC(=C(C=C1)N=[N+]=[N-])I)NCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,,,,,,
8544,128545,N-(4-Diazophenyl)maleimide,C1=CC(=CC=C1[N+]#N)N2C(=O)C=CC2=O,,,,,,
8545,128546,2-(Pyridin-2-yldisulfanyl)ethanamine,C1=CC=NC(=C1)SSCCN,,,,,,
8546,128547,7-Cysteaminomitosane,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCCS,,,,,,
8547,128548,"Methyl 1-C-[3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-yl]hexopyranoside",CO[C@]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C2[C@@H]([C@H]([C@@H]([C@H](N2)CO)O)O)O,,,,,,
8548,128549,1-(2-((1-Carboxy-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indole-2-carboxylic acid,CC(C(=O)N1C2CCCCC2CC1C(=O)O)NC(CCC3=CC=CC=C3)C(=O)O,,,,,,
8549,128550,"4-[5-(3,4-Dihydroxyphenyl)pent-1-en-4-ynyl]benzene-1,2-diol",C1=CC(=C(C=C1C=CCC#CC2=CC(=C(C=C2)O)O)O)O,,,,,,
8550,128551,"4-N,N-Dimethylamino-1-hydroxybutylidene-1,1-diphosphonic acid",CN(C)CCCC(O)(P(=O)(O)O)P(=O)(O)O,,,,,,
8551,128552,3-[1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol,CCC(=C(C1=CC=C(C=C1)OCCNC)C2=CC(=CC=C2)O)C3=CC=CC=C3,,,,,,
8552,128553,"2,3,5-Trichlorophenyl methyl sulfone",CS(=O)(=O)C1=C(C(=CC(=C1)Cl)Cl)Cl,,,,,,
8553,128554,6-Anilino-1-naphthalenesulfonic acid,C1=CC=C(C=C1)NC2=CC3=C(C=C2)C(=CC=C3)S(=O)(=O)O,,,,,,
8554,128555,Pgs-IN-1,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C2CCOC2=O,,,,,,
8555,128556,"N-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-2-benzothiazolamine",C1CN(CCC1CNC2=NC3=CC=CC=C3S2)CC4COC5=CC=CC=C5O4,,,,,,
8556,128557,1-Deazatubercidin,C1=CN=C2C(=C1N)C=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
8557,128558,Yuanhunine,C[C@@H]1[C@@H]2C3=CC(=C(C=C3CCN2CC4=C1C=CC(=C4OC)O)OC)OC,,,,,,
8558,128559,2-(2-Benzothiazolylazo)-5-dimethylaminobenzoic acid,CN(C)C1=CC(=C(C=C1)N=NC2=NC3=CC=CC=C3S2)C(=O)O,,,,,,
8559,128560,CID 128560,CC1=C2C=CN(C=C2C(=C3C1[NH2+]C4=C3C5=C(C=C4)OC(=N5)C(C)C)C)C,,,,,,
8560,128561,CID 128561,CC1=C2C=CN(C=C2C(=C3C1NC4=C3C5=C(C=C4)OC(=N5)C(C)C)C)C,,,,,,
8561,128562,"N',N'-dimethyl-N-(4-thiophen-2-ylpyrimidin-2-yl)ethane-1,2-diamine",CN(C)CCNC1=NC=CC(=N1)C2=CC=CS2,,,,,,
8562,128563,Salvinorin A,CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC,,,"['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)']","['Salvinorin A (SA) is a highly selective kappa opioid receptor agonist and the putative psychoactive compound in Salvia divinorum (SD), an increasingly abused hallucinogenic plant. The objectives of this study were to characterize the physiological and subjective effects of SA versus placebo and measure drug and metabolite levels. Sublingual SA doses up to 4 mg were administered in dimethyl sulfoxide/polyethylene glycol 400 solution to eight SD-experienced subjects using a placebo-controlled ascending-dose design. No dose of SA produced significantly greater physiological or subjective effects than placebo. Furthermore, effects did not resemble reported ""typical"" effects of smoked SD. SA was detectable in plasma and urine, but was, in most cases, below the reliable limit of quantification (0.5 ng/mL). Our results suggest that the sublingual bioavailability of SA is low. Higher doses, alternate formulations, or alternate routes of administration will be necessary to study the effects of SA in humans.', 'Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the Salvia divinorum plant, which has been used for hallucinogenic effects. Previous research on salvinorin A pharmacokinetics likely underestimated plasma levels typically resulting from the doses administered due to inefficient vaporization and not collecting samples during peak drug effects. Six healthy adults inhaled a single high dose of vaporized salvinorin A (n = 4, 21 ug/kg; n = 2, 18 ug/kg). Participant- and monitor-rated effects were assessed every 2 min for 60 min post-inhalation. Blood samples were collected at 13 time points up to 90 min post-inhalation. Drug levels peaked at 2 min and then rapidly decreased. Drug levels were significantly, positively correlated with participant and monitor drug effect ratings. Significant elevations in prolactin were observed beginning 5 min post-inhalation and peaking at 15 min post-inhalation. Cortisol showed inconsistent increases across participants. Hormonal responses were not well correlated with drug levels. This is the first study to demonstrate a direct relationship between changes in plasma levels of salvinorin A and drug effects in humans. The results confirm the efficacy of an inhalation technique for salvinorin A.', 'The diterpene salvinorin A from Salvia divinorum (Epling and Jativa-M), in doses of 200-500 ug produces effects which are subjectively identical to those experienced when the whole herb is ingested. Salvinorin A is effectively deactivated by the gastrointestinal system, so alternative routes of absorption must be used to maintain its activity. Traditionally the herb is consumed either by chewing the fresh leaves or by drinking the juices of freshly crushed leaves. The effects of the herb when consumed this way depend on absorption of salvinorin A through the oral mucosa before the herb is swallowed.']",,['... Salvinorin A /has a/ half-life approximately 8 min in non-human primates ... .']
8563,128564,n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide,CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=C(C=C1)OC)C(=O)NC,,,['Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES. (See all compounds classified as Matrix Metalloproteinase Inhibitors.)'],,,
8564,128565,"Benzo(a)pyrene-7,8-diol, 6-fluoro-7,8-dihydro-",C1=CC2=C3C(=C1)C=CC4=C3C(=C5C=CC(C(C5=C4F)O)O)C=C2,,,,,,
8565,128566,CID 128566,C(CC(=O)O)C=CCC=CCC=CCC=CCC=CCC=CCCOO,,,,,,
8566,128567,"Cezomycin-, 3-hydroxy-",C[C@@H]1CCC2([C@@H](C[C@H]([C@H](O2)[C@H](C)C(=O)C3=CC=CN3)C)C)O[C@@H]1CC4=NC5=C(O4)C=CC(=C5C(=O)O)O,,,,,,
8567,128568,"Ethylene-2,2'-bis(dithio)bis(ethanol)",C(CSSCCSSCCO)O,,,,,,
8568,128569,Ohnpdte,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2SSC4=CC=C(C=C4)[N+](=O)[O-])CCC5=C3C=CC(=C5)O,,,,,,
8569,128570,"3,7,11,15-Tetramethyl-2,6,10,14-hexadecatetraenic acid",CC(=CCCC(=CCCC(=CCCC(=CC(=O)O)C)C)C)C,,,,,,
8570,128571,Indomethacin-nhs,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)ON4C(=O)CCC4=O,,,"['Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)']",,,
8571,128572,CID 128572,C(CCC=CC[C@@H](C=CC=CC=C[C@@H](CCCC(=O)O)O)O)CCC(=O)O,,,,,,
8572,128573,"15-(4-Iodophenyl)-3,3-dimethylpentadecanoic acid",CC(C)(CCCCCCCCCCCCC1=CC=C(C=C1)[123I])CC(=O)O,,,,,,
8573,128574,"Diethyl (((3-(2,6-dimethyl-4-pyridinyl)-4-fluorophenyl)amino)methylene)propanedioate",CCOC(=O)C(=CNC1=CC(=C(C=C1)F)C2=CC(=NC(=C2)C)C)C(=O)OCC,,,,,,
8574,128575,CID 128575,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCCCN=C(NC4=CC5=C(C=C4)C6(C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)OC5=O)S)C(=O)O,,,,,,
8575,128576,Aristoloside,COC1=CC(=CC2=C3C(=C(C=C12)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
8576,128577,1-[4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]-3-(propoxymethyl)phenyl]ethanone,CCCOCC1=C(C=CC(=C1)C(=O)C)OCC(CNC(C)C)O,,,,,,
8577,128578,1-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)-3-(pentyloxymethyl)phenyl)ethanone,CCCCCOCC1=C(C=CC(=C1)C(=O)C)OCC(CNC(C)C)O,,,,,,
8578,128579,"9,10-Dihydro-9-glutathionyl-10-hydroxyphenanthrene",C1=CC=C2C(=C1)[C@H]([C@@H](C3=CC=CC=C32)SC[C@@H](C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)N)O,,,,,,
8579,128580,5-Butyl-5-methyl-1-pyrroline 1-oxide,CCCCC1(CCC=[N+]1[O-])C,,,,,,
8580,128581,DilC12(3) (iodide),CCCCCCCCCCCCN1C2=CC=CC=C2C(C1=CC=CC3=[N+](C4=CC=CC=C4C3(C)C)CCCCCCCCCCCC)(C)C.[O-]Cl(=O)(=O)=O,,,,,,
8581,128582,"1,1'-Didodecyl-3,3,3',3'-tetramethylindocarbocyanine",CCCCCCCCCCCCN1C2=CC=CC=C2C(C1=CC=CC3=[N+](C4=CC=CC=C4C3(C)C)CCCCCCCCCCCC)(C)C,,,,,,
8582,128583,"5,5-Dipropyl-1-pyrroline 1-oxide",CCCC1(CCC=[N+]1[O-])CCC,,,,,,
8583,128584,"2-[3-[(1,3-Dihydro-3,3-dimethyl-1-tetradecyl-2H-indol)-2-ylidene]-1-propenyl]-3,3-dimethyl-1-tetradecyl-3H-indolium",CCCCCCCCCCCCCCN1C2=CC=CC=C2C(C1=CC=CC3=[N+](C4=CC=CC=C4C3(C)C)CCCCCCCCCCCCCC)(C)C,,,,,,
8584,128585,"7-Methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine",CC1=C(N2C=CN=CC2=C1SC)SC,,,,,,
8585,128586,2-(2-Oxo-3-sulfanylpyrrolidin-1-yl)acetic acid,C1CN(C(=O)C1S)CC(=O)O,,,,,,
8586,128587,2-Oxo-3-((2-thienylcarbonyl)thio)-1-pyrrolidineacetic acid,C1CN(C(=O)C1SC(=O)C2=CC=CS2)CC(=O)O,,,,,,
8587,128588,Methyl 2-(4-chlorophenyl)-3-methylbutanoate,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC,,,,,,
8588,128589,Adecypenol,C1C(C2=C(NC=N1)N(C=N2)C3C=C(C(C3O)O)CO)O,,,['Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)'],,,
8589,128590,"Substance P (5-11), asp(5,6)-mephe(8)-",CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)N(C(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
8590,128591,CID 128591,C1[C@@H]([C@H]2[C@@H](C3=NC4=C(N3C1O2)NC(=NC4=O)N)O)O,,,,,,
8591,128592,"N-[2-(6,7-dichloro-5-methoxy-2-methyl-1H-indol-3-yl)ethyl]acetamide",CC1=C(C2=CC(=C(C(=C2N1)Cl)Cl)OC)CCNC(=O)C,,,,,,
8592,128593,"N-(Aminoacetyl)-1-aza-4,7,10-13-tetraoxacyclopentadecane",C1COCCOCCOCCOCCN1C(=O)CN,,,,,,
8593,128594,(4-Bromo-5-nitrofuran-2-yl)methanimine,C1=C(OC(=C1Br)[N+](=O)[O-])C=N,,,,,,
8594,128595,"4-ethenyl-N-phenyl-4,5-dihydro-1,3-thiazol-2-amine",C=CC1CSC(=N1)NC2=CC=CC=C2,,,,,,
8595,128596,(4S-cis)-4-(2-Methylpropyl)-5-phenyl-3-(3-(1-piperidinyl)propyl)-2-oxazolidinone,CC(C)C[C@H]1[C@H](OC(=O)N1CCCN2CCCCC2)C3=CC=CC=C3,,,,,,
8596,128597,N(5)-(L-1-carboxyethyl)-L-ornithine,C[C@@H](C(=O)O)NCCC[C@@H](C(=O)O)N,,,,,,
8597,128598,CID 128598,CCOC(=O)C=CC=C(C)C=CC1C(C(=O)CCC1(C)C(=O)OCC)C,,,,,,
8598,128599,N-Succinyldesferrioxamine B,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)O)O)O)O,,,,,,
8599,128600,"6,4'-Dihydroxy-3-methyl-3',5'-dibromoflavone",CC1=C(OC2=C(C1=O)C=C(C=C2)O)C3=CC(=C(C(=C3)Br)O)Br,,,,,,
8600,128601,CID 128601,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]2[C@@H]1C(C(=CCCCC(=O)O)O2)F)O)O,,,,,,
8601,128602,Biolf-70,C1=CC=C(C=C1)COCC(COCC2=CC=CC=C2)OCN3C=NC4=C3N=C(N=C4Cl)N,,,,,,
8602,128603,"2-(Hydroxymethyl)-1-((7-oxo-8-phenyl-7H-thieno(2,3-a)quinolizin-10-yl)carbonyl)pyrrolidine",C1C[C@@H](N(C1)C(=O)C2=C3C4=C(C=CN3C(=O)C(=C2)C5=CC=CC=C5)C=CS4)CO,,,,,,
8603,128604,"2-(Methoxymethyl)-1-((7-oxo-8-phenyl-7H-thieno(2,3-a)quinolizin-10-yl)carbonyl)pyrrolidine",COC[C@H]1CCCN1C(=O)C2=C3C4=C(C=CN3C(=O)C(=C2)C5=CC=CC=C5)C=CS4,,,,,,
8604,128605,"Dicyclohexyl 2,3-epoxysuccinate",C1CCC(CC1)OC(=O)[C@@H]2[C@H](O2)C(=O)OC3CCCCC3,,,,,,
8605,128606,10-Ethyldithranol,CCC1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O,,,,,,
8606,128607,CID 128607,CC1=CC[C@@H]([C@H]2C[C@@H](CC[C@@H]1O)C(=O)O2)C(=C)C,,,,,,
8607,128608,"4-Methyl-3-phenylcarbamoyl-1,2,5-selenadiazole",CC1=N[Se]N=C1C(=O)NC2=CC=CC=C2,,,,,,
8608,128609,Hexyl vanillate,CCCCCCOC(=O)C1=CC(=C(C=C1)O)OC,,,,,,
8609,128610,"6,8-Difluoro-1-(2-fluoroethyl)-7-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-4-oxoquinoline-3-carboxylic acid",C[N+]1(CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F)[O-],,,,,,
8610,128611,"[(2R,3S,4S,5R,6R)-6-[(2R,3R,4S,5S,6R)-6-(decanoyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl decanoate",CCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)CCCCCCCCC)O)O)O)O)O)O,,,,,,
8611,128612,N-Hydroxypropranolol,CC(C)N(CC(COC1=CC=CC2=CC=CC=C21)O)O,,,,,,
8612,128613,CID 128613,CC(C)[N+](=CC(COC1=CC=CC2=CC=CC=C21)O)[O-],,,,,,
8613,128614,N-Nitrosopropranolol,CC(C)N(CC(COC1=CC=CC2=CC=CC=C21)O)N=O,,,,,,
8614,128615,Fourphit,C1CCC(CC1)(C2=CC=CC=C2)N3CCC(CC3)N=C=S,,,,,,
8615,128616,"2-[2-chloro-4-formyl-5-hydroxy-3-methyl-6-[3-methyl-5-[(1R,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]penta-2,4-dienyl]phenoxy]acetic acid",C[C@@H]1CCC(=O)[C@@H]([C@@]1(C)C=CC(=CCC2=C(C(=C(C(=C2OCC(=O)O)Cl)C)C=O)O)C)C,,,,,,
8616,128617,5-Methoxymethyl-1-(2'-deoxylyxofuranosyl)uracil,COCC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@H](O2)CO)O,,,,,,
8617,128618,Nbbcc,CCCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,,,,,,
8618,128619,S-(1-Carboxyethyl)cysteine,CC(C(=O)O)SC[C@@H](C(=O)O)N,,,,,,
8619,128620,"1,1,1,2,2,3,3,4,4,7,7,8,8,9,9,10,10,10-Octadecafluorodec-5-ene",C(=CC(C(C(C(F)(F)F)(F)F)(F)F)(F)F)C(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
8620,128621,CID 128621,CCCCC(C)C1(N(C(=CC(=O)CI)C(N1[O])(C)C)C)C,,,,,,
8621,128622,"1-Piperazineethanol, alpha-(4-amino-3,5-dichlorophenyl)-4-((2,3,4-trimethoxyphenyl)methyl)-",COC1=C(C(=C(C=C1)CN2CCN(CC2)CC(C3=CC(=C(C(=C3)Cl)N)Cl)O)OC)OC,,,,,,
8622,128623,"5-(Hydroxymethyl)-4-methoxy-13-methyl-5,7,8,9,10,11,11a,12-octahydro-8,11-epiminoazepino[1,2-b]isoquinoline-10-carboxylic acid",CN1C2CC(C1C3CC4=C(C(N3C2)CO)C(=CC=C4)OC)C(=O)O,,,,,,
8623,128624,CID 128624,CCCCCCCCCCCCCCCCOC[C@H](COP(O)([O-])OCCNC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
8624,128625,CID 128625,CCCCCCCCCCCCCCCCOC[C@H](COP(O)(O)OCCNC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
8625,128626,"1H-Indole-3-methanamine, N-methyl-N-nitroso-",CN(CC1=CNC2=CC=CC=C21)N=O,,,,,,
8626,128627,"3-(4-(4-(3-Methylphenyl)-1-piperazinyl)butyl)-2,4-imidazolidinedione",CC1=CC(=CC=C1)N2CCN(CC2)CCCCN3C(=O)CNC3=O,,,,,,
8627,128628,CID 128628,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCOC(=O)NCCCl)C3=CC=CC=C3,,,,,,
8628,128629,"7-[(4S,5R)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]hept-5-enoic acid",CC1(OC[C@H]([C@H](O1)C2=CC=CC=C2)CC=CCCCC(=O)O)C,,,,,,
8629,128630,"1,2,11,12,14,15-Hexahydroxy-11,20-epoxypicrasa-3,13(21)-dien-16-one",CC1=C[C@@H]([C@H]([C@]2([C@H]1C[C@@H]3C45[C@@H]2C([C@@H](C(=C)[C@@]4([C@H](C(=O)O3)O)O)O)(OC5)O)C)O)O,,,,,,
8630,128631,"2,3-Dihydroxypropyl 14-methylpentadecanoate",CC(C)CCCCCCCCCCCCC(=O)OCC(CO)O,,,,,,
8631,128632,"2,3-Dihydroxypropyl 15-methylhexadecanoate",CC(C)CCCCCCCCCCCCCC(=O)OCC(CO)O,,,,,,
8632,128633,CID 128633,C[C@@H]1C[C@@H]([C@@]2([C@@H]([C@@]1(C)CCC(=CCO)C)CCC=C2C(=O)O)C)O,,,,,,
8633,128634,CID 128634,C[C@H](CCC=C(C)CO)[C@@H]1CC[C@@]2([C@@]1(CC=C3C2=CCC4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
8634,128635,6-((p-Piperidinophenyl)azo)benzothiazole,C1CCN(CC1)C2=CC=C(C=C2)N=NC3=CC4=C(C=C3)N=CS4,,,,,,
8635,128636,"1H-Imidazole-1-propanoic acid, 2-amino-4,5-dihydro-",C1CN(C(=N1)N)CCC(=O)O,,,,,,
8636,128637,N-tert-Butyloxycarbonyl-S-9-fluorenylmethylcysteine 4-nitrophenyl ester,CC(C)(C)OC(=O)N[C@@H](CSCC1C2=CC=CC=C2C3=CC=CC=C13)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-],,,,,,
8637,128638,CID 128638,C[C@H]1[C@H](CC=CC=CC=C[C@@H](CC(=O)NC2=CC(=CC(=C2O)CCC=C([C@@H]1O)C)O)OC)O,,,,,,
8638,128639,N-(4-Hydroxyphenyl)-1-isopropyladenosine,CC(C)C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC4=CC=C(C=C4)O,,,,,,
8639,128640,Spergualin-15-phosphate,C(CCN=C(N)N)CC(CC(=O)NC(C(=O)NCCCCNCCCN)O)OP(=O)(O)O.[Na+].Cl.Cl.Cl,,,,,,
8640,128641,[1-[[2-[4-(3-Aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]amino]-7-(diaminomethylideneamino)-1-oxoheptan-3-yl] dihydrogen phosphate,C(CCN=C(N)N)CC(CC(=O)NC(C(=O)NCCCCNCCCN)O)OP(=O)(O)O,,,,,,
8641,128642,"3-[p-(6-Phenyl-1,3,5-hexatrienyl)phenyl] propionic acid",C1=CC=C(C=C1)C=CC=CC=CC2=CC=C(C=C2)CCC(=O)O,,,,,,
8642,128643,Sirofluor,C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)NC3=CC=C(C=C3)S(=O)(=O)O)NC4=CC=C(C=C4)S(=O)(=O)O,,,,,,
8643,128644,Lysyl-asparaginyl-prolyl-tyrosyl-isoleucyl-leucinol,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N,,,,,,
8644,128645,"Propanoic acid, 2-((2',4'-difluoro(1,1'-biphenyl)-4-yl)oxy)-",CC(C(=O)O)OC1=CC=C(C=C1)C2=C(C=C(C=C2)F)F,,,,,,
8645,128646,"3,7-Dihydroxytropolone",C1=CC(=O)C(=C(C(=C1)O)O)O,,,,,,
8646,128647,CID 128647,CNC1=CC=CC=C1C(=O)O[C@@H]2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C3NC(=NC4=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
8647,128648,CID 128648,C1=CC(=CC=C1CNC2=CC3=C(C=C2)NC(=NC3=O)N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
8648,128649,4-(5-Amino-2-furyl)thiazole,C1=C(OC(=C1)N)C2=CSC=N2,,,,,,
8649,128650,"Cyclic 1,N(2)-propanodeoxyguanosine",C[C@@H]1C[C@H](N2C(=O)C3=C(N=C2N1)N(C=N3)[C@H]4C[C@@H]([C@H](O4)CO)O)O,,,,,,
8650,128651,Methyl 2-(((2-aminoethyl)amino)methyl)-6-carboxylpyridinehistidinate,COC(=O)[C@H](CC1=CN=CN1)NC(=O)C2=CC=CC(=N2)CNCCN,,,,,,
8651,128652,N-(9H-Fluoren-9-ylacetyl)-S-methylcysteine,CSC[C@@H](C(=O)O)NC(=O)CC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
8652,128653,CID 128653,C1=C2C(=NC(=NC2=O)N)N(N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
8653,128654,CID 128654,C[C@H](CCC=C(C)CO)[C@@H]1CC[C@@]2([C@@]1(CC=C3C2=CCC4[C@@]3(CCC(=O)C4(C)C)C)C)C,,,,,,
8654,128655,2-(Acetamido)ethyl-2'-pyridyl disulfide,CC(=O)NCCSSC1=CC=CC=N1,,,,,,
8655,128656,"2-Buten-1-ol,4-(6-amino-9H-purin-9-yl)-, (2E)-",C1=NC(=C2C(=N1)N(C=N2)CC=CCO)N,,,,,,
8656,128657,"5-Fluoro-1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-6,7-isoquinolinediol",COC1=CC(=CC(=C1OC)OC)CC2C3=CC(=C(C(=C3CCN2)F)O)O,,,,,,
8657,128658,"8-Fluoro-1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-6,7-isoquinolinediol",COC1=CC(=CC(=C1OC)OC)CC2C3=C(C(=C(C=C3CCN2)O)O)F,,,,,,
8658,128659,Testiphenon,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C,,,,,,
8659,128660,MC(5) tianeptine,CN1C2=CC=CC=C2C(C3=C(S1([O-])[O-])C=C(C=C3)Cl)NCCCCC(=O)O,,,,,,
8660,128661,"5-[(3-chloro-5,5-dihydroxy-6-methyl-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]pentanoic acid",CN1C2=CC=CC=C2C(C3=C(S1(O)O)C=C(C=C3)Cl)NCCCCC(=O)O,,,,,,
8661,128662,N-(4-(3-Chlorodiazirin-3-yl)benzoyl)glycine,C1=CC(=CC=C1C(=O)NCC(=O)O)C2(N=N2)Cl,,,,,,
8662,128663,"3-(Dimethylamino)-1,2,3,4-tetrahydro-2,2-dimethyl-1,7-naphthalenediol",CC1(C(CC2=C(C1O)C=C(C=C2)O)N(C)C)C,,,,,,
8663,128664,"1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene",COC1=C(C=C(C=C1)C2=C(C(=C(C3=CC(=C(C(=C32)OC)OC)OC)O)C(=O)OC)C(=O)OC)OC,,,,,,
8664,128665,"Benz(a)anthracene, 5-fluoro-1,2,3,4-tetrahydro-7,12-dimethyl-",CC1=C2C=C(C3=C(C2=C(C4=CC=CC=C14)C)CCCC3)F,,,,,,
8665,128666,"Benz(a)anthracene, 1,2,3,4-tetrahydro-7,12-dimethyl-6-fluoro-",CC1=C2C3=C(CCCC3)C=C(C2=C(C4=CC=CC=C14)C)F,,,,,,
8666,128667,"6-fluoro-7-methyl-12-methylidene-2,3,4,7-tetrahydro-1H-benzo[a]anthracene",CC1C2=CC=CC=C2C(=C)C3=C4CCCCC4=CC(=C13)F,,,,,,
8667,128668,CID 128668,C1[C@@H]([C@H](O[C@H]1[N+]2=CN(C3=C2NC(=NC3=O)N)CC(CO)O)CO)O,,,,,,
8668,128669,"[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OC(=O)C=CC3=CC(=C(C=C3)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O,,,,,,
8669,128670,4-Hydroxytranylcypromine,C1[C@H]([C@@H]1N)C2=CC=C(C=C2)O,,,,,,
8670,128671,"2,4,6-Trichlorobenzenesulfonic acid",C1=C(C=C(C(=C1Cl)S(=O)(=O)O)Cl)Cl,,,,,,
8671,128672,CID 128672,C1[C@@H]([C@H](O[C@H]1[N+]2=CN(C3=C2NC(=NC3=O)N)CC(C(Cl)(Cl)Cl)O)CO)O,,,,,,
8672,128673,CID 128673,C1[C@@H]([C@H](O[C@H]1[N+]2=CN(C3=C2NC(=NC3=O)N)CC(CCl)O)CO)O,,,,,,
8673,128674,"Cholest-5-ene-3,7,22-triol",C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C)[C@@H](CCC(C)C)O,,,,,,
8674,128675,N-Formamidosalicylic acid,C1=CC(=C(C=C1NC=O)C(=O)O)O,,,,,,
8675,128676,Cloturin,C1=NC2=C(N1)C(=NC=N2)SC(=O)NCCCl,,,,,,
8676,128677,3-Isopropoxy-5-methoxybenzo(b)thiophene-2-carboxamide,CC(C)OC1=C(SC2=C1C=C(C=C2)OC)C(=O)N,,,,,,
8677,128678,Dethiosecoemestrin,CN1C(=O)C2=CC3=COC=C[C@@H]([C@H]3N2C(=O)C1=O)OC(=O)C4=CC(=C(C=C4)OC)OC5=C(C=CC(=C5)C=O)O,,,,,,
8678,128679,"N,N'-Di-(6-((2-methoxybenzyl)amino)hexyl)-1,9-nonanediamine tetrahydrochloride",COC1=CC=CC=C1CNCCCCCCNCCCCCCCCCNCCCCCCNCC2=CC=CC=C2OC,,,,,,
8679,128680,4-Azido-N-methylspiperone,CN1CN(C2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)N=[N+]=[N-],,,,,,
8680,128681,8''-Hydroxypactamycin,CC1=C(C(=CC=C1)O)C(=O)OC[C@]2([C@H]([C@@H]([C@]([C@@]2(C)O)(C(C)O)NC(=O)N(C)C)N)NC3=CC=CC(=C3)C(=O)CO)O,,,,,,
8681,128682,Dihydroethidium,CCN1C(C2=C(C=CC(=C2)N)C3=C1C=C(C=C3)N)C4=CC=CC=C4,,,,,,
8682,128683,Cloflumide,CS(=O)(=O)O.C1CN(CCN1CCC(=O)N)C2CC3=C(C=CC(=C3)Cl)SC4=C2C=CC(=C4)F,,,,,,
8683,128684,"3-[4-(3-Chloro-9-fluoro-5,6-dihydrobenzo[b][1]benzothiepin-6-yl)piperazin-1-yl]propanamide",C1CN(CCN1CCC(=O)N)C2CC3=C(C=CC(=C3)Cl)SC4=C2C=CC(=C4)F,,,,,,
8684,128685,"N-Acetyl-2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole",CC1=CC=CN2C1=NC3=C2N=C(C=C3)NC(=O)C,,,,,"[""N-Acetyl-2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole is a known human metabolite of Glu-P-1.""]",
8685,128686,Bagougeramine A,CNCC(=O)N[C@H](CN=C(N)N)C(=O)N[C@H]1[C@@H]([C@H]([C@@H](O[C@@H]1C(=O)N)N2C=CC(=NC2=O)N)O)O,,,,,,
8686,128687,17-(1-Oxo-3-ethoxy-2-propynyl)androst-4-en-3-one,CCOC#CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,,,,,,
8687,128688,"(4bS,7S,8aS)-7-[(1R)-1-hydroxyprop-2-ynyl]-7-methyl-5,6,8,8a,9,10-hexahydro-4bH-phenanthren-2-ol",C[C@@]1(CC[C@H]2[C@H](C1)CCC3=C2C=CC(=C3)O)[C@H](C#C)O,,,,,,
8688,128689,9-Iodooctadecanoic acid,CCCCCCCCCC(CCCCCCCC(=O)O)I,,,,,,
8689,128690,10-Iodooctadecanoic acid,CCCCCCCCC(CCCCCCCCC(=O)O)I,,,,,,
8690,128691,9-Iodostearyl carnitine,CCCCCCCCCC(CCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)I,,,,,,
8691,128692,[3-Carboxy-2-(9-iodooctadecanoyloxy)propyl]-trimethylazanium,CCCCCCCCCC(CCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C)I,,,,,,
8692,128693,"Piperidinium, 1-((2beta,3alpha,5alpha,16beta)-3-hydroxy-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide",C[C@]12CCC3C(C1C[C@@H](C2)[N+]4(CCCCC4)CC=C)CC[C@@H]5[C@@]3(C[C@@H]([C@H](C5)O)N6CCCCC6)C.[Br-],,,,,,
8693,128694,"(2S,3S,5S,10S,13R,16S)-10,13-dimethyl-2-piperidin-1-yl-16-(1-prop-2-enylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@]12CCC3C(C1C[C@@H](C2)[N+]4(CCCCC4)CC=C)CC[C@@H]5[C@@]3(C[C@@H]([C@H](C5)O)N6CCCCC6)C,,,,,,
8694,128695,"4-amino-N-((3S,4R)-1-(4,4-bis(4-fluorophenyl)butyl)-3-methoxypiperidin-4-yl)-5-chloro-2-methoxybenzamide hydrochloride",CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl,,,,,,
8695,128696,"4-amino-N-[(3S,4R)-1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxypiperidin-4-yl]-5-chloro-2-methoxybenzamide",CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
8696,128697,Bishop,CCCCCCCCCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCCCCCCCCC.[Cl-],,,,,,
8697,128698,"1-Propanaminium, 2,3-bis(hexadecyloxy)-N,N,N-trimethyl-",CCCCCCCCCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCCCCCCCCC,,,,,,
8698,128699,CID 128699,C1=NC2=C(N1COC(CCP(=O)(O)O)CO)NC(=NC2=O)N,,,,,,
8699,128700,2-Iododesmethylimipramine,CNCCCN1C2=C(CCC3=CC=CC=C31)C=C(C=C2)[131I],,,,,,
8700,128701,3-(10-Iodooctadecanoyloxy)-4-(trimethylazaniumyl)butanoate,CCCCCCCCC(CCCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)I,,,,,,
8701,128702,[3-Carboxy-2-(10-iodooctadecanoyloxy)propyl]-trimethylazanium,CCCCCCCCC(CCCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C)I,,,,,,
8702,128703,N-n-Undecylgluconamide,CCCCCCCCCCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
8703,128704,"Piperidinium, 1-((2beta,3alpha,5alpha,16beta)-3-(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide",CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5(C3C[C@@H](C5)[N+]6(CCCCC6)CC=C)C.[Br-],,,,,,
8704,128705,"[(2S,3S,5S,10S,13R,16S)-10,13-dimethyl-2-piperidin-1-yl-16-(1-prop-2-enylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5(C3C[C@@H](C5)[N+]6(CCCCC6)CC=C)C,,,,,,
8705,128706,Hemiacetylcarnitinium,C[C@]1(C[N+](C[C@@H](O1)CC(=O)O)(C)C)O.[Cl-],,,,,,
8706,128707,"2-[(2S,6S)-6-hydroxy-4,4,6-trimethylmorpholin-4-ium-2-yl]acetic acid",C[C@]1(C[N+](C[C@@H](O1)CC(=O)O)(C)C)O,,,,,,
8707,128708,4-Phenyl-6-O-malonylglucoside,C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)CC(=O)O)O)O)O,,,,,,
8708,128709,"1H-Imidazole-4,5-diol, 2-amino-4,5-dihydro-1-(2-hydroxy-3-methoxypropyl)-",COCC(CN1C(C(N=C1N)O)O)O,,,,,,
8709,128710,3'-O-(4-Benzoyl)benzoylcytidine 5'-triphosphate,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C(=O)O[C@@H]3[C@H](O[C@@H]([C@@H]3O)N4C=CC(=NC4=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
8710,128711,"2,2-dimethyl-N'-[4-phenoxy-2,6-di(propan-2-yl)phenyl]propanimidamide",CC(C)C1=CC(=CC(=C1N=C(C(C)(C)C)N)C(C)C)OC2=CC=CC=C2,,,,,,
8711,128712,alpha-((2-(1-Methylethyl)-1-aziridinyl)methyl)-2-nitro-1H-imidazole-ethanol,CC(C)C1CN1CC(CN2C=CN=C2[N+](=O)[O-])O,,,,,,
8712,128713,"1-(2,4-Dichlorophenoxy)-3-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-propanol",COC1=C(C=C(C=C1)CCNCC(COC2=C(C=C(C=C2)Cl)Cl)O)OC,,,,,,
8713,128714,Methyl (4R)-4-[(2R)-2-acetamido-3-phenylpropanoyl]oxy-4-[(2R)-2-methyloxiran-2-yl]but-2-enoate,CC(=O)N[C@H](CC1=CC=CC=C1)C(=O)O[C@H](C=CC(=O)OC)[C@]2(CO2)C,,,,,,
8714,128715,N-Nitrosopyridinol carbamate,CNC(=O)OCC1=NC(=CC=C1)COC(=O)N(C)N=O,,,,,,
8715,128716,"[13-Acetyloxy-9-hydroperoxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,7-dienyl] undeca-2,4-dienoate",CCCCCCC=CC=CC(=O)OC1C(C2(C3C=C(C(=O)C3(C=C(C(C2C4C1(C4(C)C)OC(=O)C)OO)CO)O)C)O)C,,,,,,
8716,128717,"(1R,3aS,5aS,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-3a-[3-(4-hydroxyphenyl)prop-2-enoyloxymethyl]-5b,8,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-5a-carboxylic acid",CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C(=O)O)C)(C)C)O)C)COC(=O)C=CC6=CC=C(C=C6)O,,,,,,
8717,128718,4-[3-(Trifluoromethyl)-3H-diazirin-3-YL]benzoic acid,C1=CC(=CC=C1C(=O)O)C2(N=N2)C(F)(F)F,,,,,,
8718,128719,Benzidine N-glucuronide,C1=CC(=CC=C1C2=CC=C(C=C2)N[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)N,,,,,,
8719,128720,CID 128720,C1=CC(=CC=C1CCC2=CC3=C(NC(=NC3=O)N)N=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
8720,128721,"8-(Dimethylaminodiazenyl)-7-ethyl-1,3-dimethylpurine-2,6-dione",CCN1C2=C(N=C1N=NN(C)C)N(C(=O)N(C2=O)C)C,,,,,,
8721,128722,CID 128722,C[C@H](C(=O)N[C@H](C)C(=O)NC(=O)[C@H](CC1=CC=CC=C1)NC2=CC3=CC=CC=C3C(=C2)OC)NC(=O)CCC(=O)O,,,,,,
8722,128723,8-(N-Methyl)mitozolomide,CNC(=O)C1=C2N=NN(C(=O)N2C=N1)CCCl,,,,,,
8723,128724,"8-(N,N-Dimethyl)mitozolomide",CN(C)C(=O)C1=C2N=NN(C(=O)N2C=N1)CCCl,,,,,,
8724,128725,Deoxypentalenylglucuron,CC1CC[C@@H]2C13CC(C[C@H]3C=C2C(=O)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)(C)C,,,,,,
8725,128726,N(omega)-Nitro-L-arginine p-nitroanilide,C1=CC(=CC=C1NC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
8726,128727,CID 128727,CCCCCC=CCC1(C=CC(=O)C1=CC=C[C@@H](CCC(=O)OC)OC(=O)C)OC(=O)C,,,,,,
8727,128728,25-Aminolanosterol,C[C@H](CCCC(C)(C)N)[C@@H]1CC[C@@]2([C@@]1(CCC3=C2CCC4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
8728,128729,CID 128729,CC1=C[C@H](CC(=C[C@H]2[C@H]([C@H](CC(=CCC1)C)O)C(=C)C(=O)O2)C)O,,,,,,
8729,128730,CID 128730,CC1=C[C@H](CC(=C[C@H]2[C@H]([C@H](CC(=CCC1)C)O)C(=C)C(=O)O2)C)OC(=O)C,,,,,,
8730,128731,CID 128731,CC1=C[C@@H](CC(=C[C@@H]2[C@@H]([C@@H](CC(=CCC1)C)OC(=O)C)C(=C)C(=O)O2)C)OC(=O)C,,,,,,
8731,128732,CID 128732,CC1=CC[C@H](C(=CCCC(=C[C@H]2[C@H](CC1)C(=C)C(=O)O2)C)C)OC(=O)C,,,,,,
8732,128733,CID 128733,CC1=CCCC(=C[C@H](CC(=C[C@H]2[C@H](CC1)C(=C)C(=O)O2)C)OC(=O)C)C,,,,,,
8733,128734,"(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxy-1-propynyl)estra-4,9-dien-3-one",C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(C#CCO)O)C5=CC=C(C=C5)N(C)C,,,,,,
8734,128735,Isobaimuxinol,C[C@@]12CCC[C@H]([C@@]13C[C@@H](CC2)C(O3)(C)C)CO,,,,,,
8735,128736,Dehydrobaimuxinol,C[C@@]12CCC=C([C@@]13C[C@@H](CC2)C(O3)(C)C)CO,,,,,,
8736,128737,1-(2-(4-Azidophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine,C1CN(CCN1CCC2=CC=C(C=C2)N=[N+]=[N-])C3=CC=CC(=C3)C(F)(F)F,,,,,,
8737,128738,N-[2-(Amino)-1-hydroxy-2-methylpropylidene]phenylalanine,CC(C)(C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N(C(=O)[C@H](CC2=CC=C(C=C2)O)N(CC=C)CC=C)C(=O)C(C)(C)N,,,,,,
8738,128739,"1-(2-Nitroimidazol-1-yl)-3-(2,2,3,3-tetramethylaziridin-1-yl)propan-2-ol",CC1(C(N1CC(CN2C=CN=C2[N+](=O)[O-])O)(C)C)C,,,,,,
8739,128740,"(4aS,10aS)-7-(2-hydroxypropan-2-yl)-1,1,4a-trimethyl-3,4,10,10a-tetrahydro-2H-phenanthren-9-one",C[C@]12CCCC([C@@H]1CC(=O)C3=C2C=CC(=C3)C(C)(C)O)(C)C,,,,,,
8740,128741,CID 128741,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,,,,
8741,128742,Ibscmab,CC(C)CS(=O)C1=CC2=C(C=C1)N=C(N2)NC(=O)OC,,,,,,
8742,128743,"21-Hydroxy-2,2-dimethyl-19-norpregn-4-ene-3,20-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CO)CCC4=CC(=O)C(C[C@H]34)(C)C,,,,,,
8743,128744,"(3r)-5-(2-Fluorophenyl)-1,3-dimethyl-7-nitro-1,3-dihydro-2h-1,4-benzodiazepin-2-one",C[C@@H]1C(=O)N(C2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3F)C,,,,,,
8744,128745,N-Allylnorcocaine,COC(=O)C1[C@H]2CCC(N2CC=C)CC1OC(=O)C3=CC=CC=C3,,,,,,
8745,128746,4-Methyl-2-oxo-2H-1-benzopyran-7-yl alpha-L-ido-pyranosiduronic acid,CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](O3)C(=O)O)O)O)O,,,,,,
8746,128747,"3,4-Epoxy-1,2,3,4-tetrahydrophenanthrene",C1CC2=C(C3C1O3)C4=CC=CC=C4C=C2,,,,,,
8747,128748,"1-(2-Hydroxyethyl)-3,5-diphenyl-1H-pyrazole",C1=CC=C(C=C1)C2=CC(=NN2CCO)C3=CC=CC=C3,,,,,,
8748,128749,N-Acetyl-5-hydroxy-L-tryptophan,CC(=O)N[C@@H](CC1=CNC2=C1C=C(C=C2)O)C(=O)O,,,,,,
8749,128750,N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]-3-iodobenzamide,CC(C)NCC(COC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)I)C(=O)C)O,,,,,,
8750,128751,Ohcos,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)C,,,,,,
8751,128752,3alpha-Sulfooxy-12alpha-hydroxy-5beta-cholan-24-oic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)O)C)O)C,,,,,,
8752,128753,"Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate",CC1=C(C(=C(C(=N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,,,,,['Oxidized nifedipine is a known human metabolite of nifedipine.'],
8753,128754,Cephedrine,CC(C(C1=CC=CC=C1)O)N(C)CCC#N,,,,,,
8754,128755,"1H-Imidazole-2-methanamine, N-(2,3-dimethylphenyl)-4,5-dihydro-",CC1=C(C(=CC=C1)NCC2=NCCN2)C,,,,,,
8755,128756,"Thiazolidine, 2-(3-bromophenyl)-",C1CSC(N1)C2=CC(=CC=C2)Br,,,,,,
8756,128757,Isocoformycin,C1C(N=CNC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
8757,128758,CID 128758,C[C@@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)OC(C)(C)C,,,,,,
8758,128759,"4,5-dichloro-2,3-dihydro-1H-inden-1-amine",C1CC2=C(C1N)C=CC(=C2Cl)Cl,,,,,,
8759,128760,3-Ketopropylpentanoic acid ethyl ester,CCCC(C(=O)CC)C(=O)OCC,,,,,,
8760,128761,"3H-Pyrrolo(1,2-a)imidazole, 6-(2-chloro-6-fluorophenyl)-2,5,6,7-tetrahydro-",C1CN2CC(CC2=N1)C3=C(C=CC=C3Cl)F,,,,,,
8761,128762,Hydroxyethylflurazepam,CCN(CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F)CCO,,,,,,
8762,128763,"1,4-Bis(methylthio)-2,3,5,6-tetrachlorobenzene",CSC1=C(C(=C(C(=C1Cl)Cl)SC)Cl)Cl,,,,,,
8763,128764,"1,2,4-Tris(methylthio)-3,5,6-trichlorobenzene",CSC1=C(C(=C(C(=C1Cl)SC)Cl)Cl)SC,,,,,,
8764,128765,"2H-1-Benzopyran-6(8aH)-one, 3,4-dihydro-8a-hydroperoxy-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-",CC1=C(C2(C(=C(C1=O)C)CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)OO)C,,,,,,
8765,128766,"7-[(1R,2R,3R)-2-[(3S)-3,6-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]heptanoic acid",CCC(CC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O)O,,,,,,
8766,128767,CID 128767,CCC(CC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
8767,128768,"3,5-Dibromo-n-[4-chloro-3-(4-chlorobenzoyl)phenyl]-2-hydroxybenzamide",C1=CC(=CC=C1C(=O)C2=C(C=CC(=C2)NC(=O)C3=C(C(=CC(=C3)Br)Br)O)Cl)Cl,,,,,,
8768,128769,2-Oxo-3-(4-(1-oxo-2-isoindolinyl)phenyl)butanamide,CC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)C(=O)N,,,,,,
8769,128770,CID 128770,C[C@H](CC(=O)C(=CCC[C@]1(C(CCC(=CCO)CO1)O)C)C)C(C)C,,,,,,
8770,128771,Clc-9-ado,C1=CN=C(C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CCl)O)O)N,,,,,,
8771,128772,N-((1-Ethyl-5-oxo-2-pyrrolidinyl)methyl)-5-sulfamoyl-2-anisamide,CCN1C(CCC1=O)CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,,,,,,
8772,128773,"7-[2-[(3S)-3,7-Dihydroxyoct-1-enyl]-5-oxocyclopenten-1-yl]hept-5-enoic acid",CC(CCC[C@@H](C=CC1=C(C(=O)CC1)CC=CCCCC(=O)O)O)O,,,,,,
8773,128774,"(2S,5S)-5-amino-2-benzyl-8-(diaminomethylideneamino)-4-oxooctanoic acid;hydrochloride",C1=CC=C(C=C1)C[C@@H](CC(=O)[C@H](CCCN=C(N)N)N)C(=O)O.Cl,,,,,,
8774,128775,"(2S,5S)-5-amino-2-benzyl-8-(diaminomethylideneamino)-4-oxooctanoic acid",C1=CC=C(C=C1)C[C@@H](CC(=O)[C@H](CCCN=C(N)N)N)C(=O)O,,,,,,
8775,128776,Bismethidium spermine,CC[N+]1=C(C2=CC=CC=C2C3=CC=CC=C31)C4=C5C(=C(C=C4)CCCCC6=C7C(=C(C=C6)C8=[N+](C9=CC=CC=C9C1=CC=CC=C18)CC)NCCCN7)NCCCN5,,,,,,
8776,128777,Meophc-val-thmp-pro,CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)C1CCCN1C(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2,,,,,,
8777,128778,2'-Fluoroaminopterin,C1=CC(=C(C=C1NCC2=CN=C3C(=N2)C(=NC(=N3)N)N)F)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
8778,128779,"18-Hydroxy-4-methyl-16-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraene-2,8-dione",CC1CCCC(=O)CCCC=CC2=C(C(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)C(=O)O1,,,,,,
8779,128780,3'-Fluoroaminopterin,C1=CC(=C(C=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)F)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
8780,128781,Sulfociprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCN(CC4)S(=O)(=O)O)F)C(=O)O,,,,,,
8781,128782,Hemicholinium 3 A-5,CC1CC[N+](CC1)(C)CC(C2=CC=C(C=C2)C3=CC=C(C=C3)C(C[N+]4(CCC(CC4)C)C)O)O.[I-].[I-],,,,,,
8782,128783,"1,1'-[Biphenyl-4,4'-diylbis(2-hydroxyethane-2,1-diyl)]bis(1,4-dimethylpiperidinium)",CC1CC[N+](CC1)(C)CC(C2=CC=C(C=C2)C3=CC=C(C=C3)C(C[N+]4(CCC(CC4)C)C)O)O,,,,,,
8783,128784,"1,3-Dipropyl-8-phenylxanthine",CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=CC=C3,,,,,,
8784,128785,Moellendorffiline,COC1=C(C2=C(C=CO2)C3=C1C4C5C(C4C(=O)O3)C(=O)OC6=C5C(=C(C7=C6C=CO7)OC)OC)OC,,,,,,
8785,128786,o-Carboxybenzalpyruvic acid,C1=CC=C(C(=C1)C=CC(=O)C(=O)O)C(=O)O,,,,,,
8786,128787,10-Thiastearic acid,CCCCCCCCSCCCCCCCCC(=O)O,,,,,,
8787,128788,CID 128788,C1CCC(CC1)[C@@H](C=C[C@@H]2[C@H]3CC[C@@H]([C@H]2CC=CCCCC(=O)O)O3)O,,,,,,
8788,128789,"3,6-Dimethylcholanthrene",CC1=C2CCC3=C2C(=C(C4=C3C=CC5=CC=CC=C54)C)C=C1,,,,,,
8789,128790,CID 128790,C[C@H](CCCC(C)(C)O)[C@@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](CCC3=O)O)C,,,,,,
8790,128791,"4-Diazo-3-methoxy-2,5-cyclohexadien-1-one",COC1=C(C=CC(=C1)[O-])[N+]#N,,,,,,
8791,128792,4-Hydroxy-2-methoxybenzenediazonium,COC1=C(C=CC(=C1)O)[N+]#N,,,,,,
8792,128793,"1-[4-(1,2-Diphenylbut-1-enyl)phenoxy]butane-2,3-diol",CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCC(C(C)O)O)C3=CC=CC=C3,,,,,,
8793,128794,N-Cyanoethyltryptamine,C1=CC=C2C(=C1)C=C(N2)CCNCCC#N,,,,,,
8794,128795,2-(4-Ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole,CCN(CC)CCN1C2=C(C=C(C=C2)N=C=S)N=C1CC3=CC=C(C=C3)OCC,,,,,,
8795,128796,9-Anthroylcyanide,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)C#N,,,,,,
8796,128797,"3,4'-Dimethyl-8-methoxypsoralen",CC1=CC2=CC3=C(C(=C2OC1=O)OC)OC=C3C,,,,,,
8797,128798,Nuclomedone,C1CSC2=NC(=O)C(C(=O)N21)CC3=CC=C(C=C3)Cl,,,,,,
8798,128799,Fmoc-Cys(Acm)-OH,CC(=O)NCSC[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
8799,128800,1-Ethyl-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol,CCN1C2=C(C=C(C=C2)O)C(=C1C3=CC=C(C=C3)O)C,,,,,,
8800,128801,2-[[6-amino-2-[[[4-cyclohexyl-2-hydroxy-3-[[3-(4H-imidazol-4-yl)-2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]propanoyl]amino]butyl]-propan-2-ylcarbamoyl]amino]hexanoyl]amino]-3-phenylpropanoic acid,CC(C)N(CC(C(CC1CCCCC1)NC(=O)C(CC2C=NC=N2)NC(=O)C(CC3=CC=CC=C3)NC(=O)OC(C)(C)C)O)C(=O)NC(CCCCN)C(=O)NC(CC4=CC=CC=C4)C(=O)O,,,,,,
8801,128802,2-[2-[2-[8-[bis(carboxymethyl)amino]-6-methoxyquinolin-2-yl]ethenyl]-N-(carboxymethyl)anilino]acetic acid,COC1=CC(=C2C(=C1)C=CC(=N2)C=CC3=CC=CC=C3N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
8802,128803,N-(4-(5-Bromo-2-pyrimidinyloxy)-3-chlorophenyl)-N'-(2-nitrobenzoyl)urea,C1=CC=C(C(=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)OC3=NC=C(C=N3)Br)Cl)[N+](=O)[O-],,,,,,
8803,128804,4-Diazophenylgalactoside,C1=CC(=CC=C1[N+]#N)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
8804,128805,"1,2,3,4-Tetrahydro-8-methoxy-5-(methylthio)-2-naphthalenamine",COC1=C2CC(CCC2=C(C=C1)SC)N,,,,,,
8805,128806,TF-Des quinone,CCC(=C1C=C(C(=O)C(=C1)F)F)C(=C2C=C(C(=O)C(=C2)F)F)CC,,,,,,
8806,128807,alpha-Lactorphin,CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
8807,128808,beta-Lactorphin,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
8808,128809,"[6-(2-Hydroxyethoxy)-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl hydrogen carbonimidate",CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4C(C3(C2COC(=O)N)OC)N4)OCCO,,,,,,
8809,128810,2-Azachlormadinone acetate,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)NC[C@]34C)Cl)C)OC(=O)C,,,,,,
8810,128811,Tmtd-BF,CC1=C(C2=C(CC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C,,,,,,
8811,128812,"1,2-Dioctanoyl-sn-glycero-3-phosphoinositol",CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)O)O)O)O)OC(=O)CCCCCCC,,,,,,
8812,128813,CID 128813,CCCCCC=CC(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
8813,128814,Ragaglitazar,CCO[C@H](CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O,['Investigated for use/treatment in diabetes mellitus type 2.'],,,,,
8814,128815,"(7S-cis)-7,8,9,10-Tetrahydro-6,7,9,11-tetrahydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione",C1[C@@H](C2=C(C[C@]1(C(=O)CO)O)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O,,,,,,
8815,128816,CID 128816,C1C(COP(=O)(O1)O)OCN2C=NC3=C2NC(=NC3=O)N.[Na+],,,,,,
8816,128817,CID 128817,C1C(COP(=O)(O1)O)OCN2C=NC3=C2NC(=NC3=O)N,,,,,,
8817,128818,"(1R,2R,5R,6R,10R,13S,15R)-5-[(2R,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.01,9.02,6.010,15]nonadeca-8,18-dien-13-ol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC=C3[C@@]24C=C[C@]5([C@@]3(CC[C@@H](C5)O)C)OO4)C,,,,,,
8818,128819,(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)OS(=O)(=O)O)N,,,,,,
8819,128820,N-Depropylpropafenone,C1=CC=C(C=C1)CCC(=O)C2=CC=CC=C2OCC(CN)O,,,,,['N-Despropylpropafenone is a known human metabolite of Propafenone.'],
8820,128821,CID 128821,C1[C@@H]([C@H](O[C@H]1N2C=CC3=C2NC(=NC3=O)N)CO)O,,,,,,
8821,128822,Daabp,C1[C@@H]([C@H](O[C@@H]1N2C(=NC3=C(N=CN=C32)N)C4=CC=C(C=C4)C5=CC=C(C=C5)N)CO)O,,,,,,
8822,128823,"N-Nitrosomethyl-2,3-dihydroxypropylamine",CN(CC(CO)O)N=O,,,,,,
8823,128824,CID 128824,C[C@@H]([C@H]1[C@H]([C@H]([C@H](O1)N2C=NC3=C2C(=O)N=CN3)O)O)O,,,,,,
8824,128825,CID 128825,C[C@@H]([C@H]1[C@H]([C@H]([C@H](O1)N2C=NC3=C2NC=NC3=O)O)O)O,,,,,,
8825,128826,Misonidazole glucuronide,COCC(CN1C=CN=C1[N+](=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O,,,,,,
8826,128827,N-Nitrosothioproline,C1[C@H](N(CS1)N=O)C(=O)O,,,,,,
8827,128828,2-((4-Methoxy-3-methyl-2-pyridylmethyl)sulfo)-5-trifluoromethyl-1H-benzimidazole,CC1=C(C=CN=C1CSC2=NC3=C(N2)C=C(C=C3)C(F)(F)F)OC,,,,,,
8828,128829,1-((3-Acetylthio)-3-benzoyl-2-methylpropionyl)-L-proline,C[C@@H]([C@@H](C(=O)C1=CC=CC=C1)SC(=O)C)C(=O)N2CCC[C@H]2C(=O)O,,,,,,
8829,128830,Perfluoro-N-methyldecahydroisoquinoline,C12(C(C(C(C(C1(F)F)(F)F)(F)F)(F)F)(C(N(C(C2(F)F)(F)F)C(F)(F)F)(F)F)F)F,,,,,,
8830,128831,"5-Bromotetrahydro-5-methyl-3-phenyl-2-(phenylimino)-4H-1,3-thiazin-4-one",CC1(CSC(=NC2=CC=CC=C2)N(C1=O)C3=CC=CC=C3)Br,,,,,,
8831,128832,"2-Amino-11H-pyrido(2,1-b)quinazolin-11-one",C1=CC2=NC3=C(C=C(C=C3)N)C(=O)N2C=C1,,,,,,
8832,128833,5-Phenyl-4-pentenol,C1=CC=C(C=C1)C=CCCCO,,,,,,
8833,128834,Chalepensin,CC(C)(C=C)C1=CC2=C(C=C3C(=C2)C=CO3)OC1=O,,,,,,
8834,128835,1-[(5-Hydroxy-4-methoxycyclohex-2-en-1-yl)methyl]-6-methoxyisoquinolin-7-ol,COC1C=CC(CC1O)CC2=NC=CC3=CC(=C(C=C32)O)OC,,,,,,
8835,128836,"4-Methyl-9h-pyrido[2,3-b]indole",CC1=C2C3=CC=CC=C3NC2=NC=C1,,,,,,
8836,128837,Lysyllysine,C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
8837,128838,Thiochrome diphosphate,CC1=C(SC2=NC3=NC(=NC=C3CN12)C)CCOP(=O)(O)OP(=O)(O)O,,,,,,
8838,128839,6-O-Galloylglucose,C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O,,,,,,
8839,128840,"2,4-Pyrimidinediamine, 5-((4-chlorophenyl)methyl)-6-ethyl-, 3-oxide",CCC1=NC(=N)N(C(=C1CC2=CC=C(C=C2)Cl)N)O,,,,,,
8840,128841,Alanine glutamate,C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)N,,,,,,
8841,128842,"Tauro-3alpha,12alpha-dihydroxy-7-keto-5-beta-cholanoic acid",C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CCC2[C@@]1([C@H](CC3C2C(=O)C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
8842,128843,"4-Methoxy-2,4-dioxobutanoic acid",COC(=O)CC(=O)C(=O)O,,,,,,
8843,128844,6-Hydroxybenzofuran,C1=CC(=CC2=C1C=CO2)O,,,,,,
8844,128845,"4,6-Estradiene-3,17-dione",C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C=C[C@H]3[C@@H]1CCC2=O,,,,,,
8845,128846,Octadec 9-en-12-ynoic acid,CCCCCC#CCC=CCCCCCCCC(=O)O,,,,,,
8846,128847,2-(4-Methoxybenzamido)acetic acid,COC1=CC=C(C=C1)C(=O)NCC(=O)O,,,,,,
8847,128848,Benoxaprofen glucuronide,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,,,,,,
8848,128849,"5,9,12-Octadecatrienic acid",CCCCCC=CCC=CCCC=CCCCC(=O)O,,,,,,
8849,128850,"(5-Oxo-2,5-dihydrofuran-2-yl)acetyl hydrogen carbonate",C1=CC(=O)OC1CC(=O)OC(=O)O,,,,,,
8850,128851,Acetyl isothiocyanate,CC(=O)N=C=S,,,,,,
8851,128852,2-Ethyl-6-methylpyridin-3-ol hydrochloride,CCC1=C(C=CC(=N1)C)O.Cl,,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
8852,128853,"3,3',4',5,5',7-Hexahydroxyflavylium",C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O,,,,,,
8853,128854,"4-Methyl-1,2,4-triazoline-3,5-dione",CN1C(=O)N=NC1=O,,,,,,
8854,128855,"Cholestane-3,7,15,16-tetrol",C[C@H](CCCC(C)C)[C@H]1C(C([C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C)O)O,,,,,,
8855,128856,4-(beta(N-Pyrrolidinyl)ethoxy)-4'-methoxybenzophenone,COC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)OCCN3CCCC3,,,,,,
8856,128857,"2-Butynoic acid, 4-chloro-",C(C#CC(=O)O)Cl,,,,,,
8857,128858,2-Chloro-3-(4-hydroxyphenyl)-1-propene,C=C(CC1=CC=C(C=C1)O)Cl,,,,,,
8858,128859,3-Oxooctanoic acid,CCCCCC(=O)CC(=O)O,,,,,,
8859,128860,1-[N-[N-(2-Aminobenzoyl)glycyl]-4-nitro-L-phenylalanyl]-L-proline,C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CNC(=O)C3=CC=CC=C3N)C(=O)O,,,,,,
8860,128861,Cyanidin,C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O)O,,,,,"['Cyanidin has known human metabolites that include 2,4,6-Trihydroxybenzaldehyde and 3,4-dihydroxyphenylacetic acid.']",
8861,128862,Phenolphthalein monophosphate,C1=CC=C2C(=C1)C(OC2=O)C3=CC=C(C=C3)OP(=O)(O)OC4=CC=C(C=C4)O,,,,,,
8862,128863,"16alpha-Ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-laurate",CCCCCCCCCCCC(=O)OCC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)CC,,,,,,
8863,128864,"Octadeca-9,15-dienoic acid",CCC=CCCCCC=CCCCCCCCC(=O)O,,,,,,
8864,128865,2-Amino-3-(methylamino)butanoic acid,CC(C(C(=O)O)N)NC,,,,,,
8865,128866,Misonidazole-guanosine product,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C4NC(C(N4C2=O)O)O,,,,,,
8866,128867,CID 128867,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCCN(C)C)O)O)O,,,,,,
8867,128868,Methyl 4-(3-ethyl-3-hydroxymethyltriazen-1-yl)benzoate,CCN(CO)N=NC1=CC=C(C=C1)C(=O)OC,,,,,,
8868,128869,D-Galactonic acid,C([C@H]([C@@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,,,,,,
8869,128870,"4-Bromomethyl-6,7-dimethoxycoumarin",COC1=C(C=C2C(=C1)C(=CC(=O)O2)CBr)OC,,,,,,
8870,128871,2-Acetamido-4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid,CC(=O)NC(CC(=O)C1=C(C(=CC=C1)O)N)C(=O)O,,,,,,
8871,128872,N-(3-chlorophenyl)quinazolin-4-amine,C1=CC=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl,,,,,,
8872,128873,CID 128873,C1CC2CCC3CC(C(C(C3)OC4CCC(CCC5=C(C(=CC=C5)O)OC(C1)C2)C=C4)O)O,,,,,,
8873,128874,CID 128874,C1=C(N=C2C(=N1)NC(=NC2=O)N)C(C(C(CO)O)O)O,,,,,,
8874,128875,"L-Cysteine, N-acetyl-S-(2-hydroxycyclohexyl)-",CC(=O)N[C@@H](CSC1CCCCC1O)C(=O)O,,,,,,
8875,128876,Cysteine-2-mercaptopyridine,C1=CC=NC(=C1)SSC[C@@H](C(=O)O)N,,,,,,
8876,128877,CID 128877,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)N(CCCl)CCCl)C(=O)OC)NC(=O)[C@H](CC3=CC=C(C=C3)O)N,,,,,,
8877,128878,2-Iminobiotin,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)N=C(N2)N,['Treatment of perinatal asphyxia'],,,,,
8878,128879,3-Aminonocardicinic acid,C1[C@@H](C(=O)N1[C@H](C2=CC=C(C=C2)O)C(=O)O)N,,,,,,
8879,128880,"(2S,5S)-5-amino-8-(diaminomethylideneamino)-2-[(4-hydroxyphenyl)methyl]-4-oxooctanoic acid;hydrochloride",C1=CC(=CC=C1C[C@@H](CC(=O)[C@H](CCCN=C(N)N)N)C(=O)O)O.Cl,,,,,,
8880,128881,"(2S,5S)-5-amino-8-(diaminomethylideneamino)-2-[(4-hydroxyphenyl)methyl]-4-oxooctanoic acid",C1=CC(=CC=C1C[C@@H](CC(=O)[C@H](CCCN=C(N)N)N)C(=O)O)O,,,,,,
8881,128882,3'-Phosphate-adenosine-5'-diphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)OP(=O)(O)O)O)N,,,,,,
8882,128883,CID 128883,CC1[C@H]2CC3=C([C@@]1(CCN2CCC4=CC=C(C=C4)NC(=O)CBr)C)C=C(C=C3)O,,,,,,
8883,128884,CID 128884,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CCC(=C)C(=CC=C2CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C)C1,,,,,,
8884,128885,N-Nitroso-prolylglycine,C1C[C@H](N(C1)N=O)C(=O)NCC(=O)O,,,,,,
8885,128886,"1H-Pyrazole-1-carboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-3-methyl-",CC1=NN(C=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,,,,,,
8886,128887,N-Nitroso-prolyl-4-hydroxyproline,C1C[C@H](N(C1)N=O)C(=O)N2C[C@@H](C[C@H]2C(=O)O)O,,,,,,
8887,128888,N(6)-acetyl-N(6)-hydroxy-L-lysine,CC(=O)N(CCCC[C@@H](C(=O)O)N)O,,,,,,
8888,128889,methyl beta-D-fructofuranoside,CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO,,,,,,
8889,128890,9-(3-Azido-2-hydroxypropyl)adenine,C1=NC(=C2C(=N1)N(C=N2)CC(CN=[N+]=[N-])O)N,,,,,,
8890,128891,4-Amino-3-(3-aminopropyl)phenol,C1=CC(=C(C=C1O)CCCN)N,,,,,,
8891,128892,"trans-7,8-Dihydroxy-anti-9,10-epoxy-7,8,9,10-tetrahydro-1-nitrobenzo(a)pyrene",C1=CC2=CC3=C(C4C(O4)[C@H]([C@@H]3O)O)C5=C2C6=C1C=CC(=C6C=C5)[N+](=O)[O-],,,,,,
8892,128893,"1H-1,2,4-Triazole, 1-((2-(4-chlorophenyl)-3-phenyloxiranyl)methyl)-",C1=CC=C(C=C1)C2C(O2)(CN3C=NC=N3)C4=CC=C(C=C4)Cl,,,,,,
8893,128894,2-Thiophenecarboxylic acid (4-acetamidophenyl) ester,CC(=O)NC1=CC=C(C=C1)OC(=O)C2=CC=CS2,,,,,,
8894,128895,"4-Imidazolepropionamide, N-(alpha-methylphenethyl)-alpha-((2-oxo-5-pyrrolidinyl)formamido)-",CC(CC1=CC=CC=C1)N[C@@H](CC2=CN=CN2)C(=O)NC(=O)[C@@H]3CCC(=O)N3,,,,,,
8895,128896,L-Histidyl-N-(1-methyl-2-phenylethyl)-5-oxo-L-prolyl-L-prolinamide,CC(CC1=CC=CC=C1)N2CCC[C@H]2C(=O)NC(=O)[C@H](CC3C=NC=N3)NC(=O)[C@@H]4CCC(=O)N4,,,,,,
8896,128897,Glutamyl-glycyl-arginine-4-nitroanilide,C1=CC(=CC=C1N[C@@H](CCCN=C(N)N)C(=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N)[N+](=O)[O-],,,,,,
8897,128898,"Benzamide, 4-amino-2-(2-(diethylamino)ethyl)-N-(1-oxopropyl)-",CCC(=O)NC(=O)C1=C(C=C(C=C1)N)CCN(CC)CC,,,,,,
8898,128899,(5-Fluoro-12-methylbenzo[a]anthracen-7-yl)methyl acetate,CC1=C2C3=CC=CC=C3C(=CC2=C(C4=CC=CC=C14)COC(=O)C)F,,,,,,
8899,128900,Eudistomin E,C1CN2[C@@H]([C@@H](CSCO2)N)C3=C1C4=C(N3)C=CC(=C4Br)O,,,,,,
8900,128901,"2,3,4,5,6-Pentafluorobenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate",CC1(C(C1C(=O)OCC2=C(C(=C(C(=C2F)F)F)F)F)C=C(Cl)Cl)C,,,,,,
8901,128902,"3-(4-Amino-1H-pyrrolo(2,3-d)pyrimidin-1-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol",C1[C@H]([C@@H]([C@@H]([C@H]1N2C=CC3=C(N=CN=C32)N)O)O)CO,,,,,,
8902,128903,H-Norleucyl-hexahydrotyrosyl-lysine-4-nitroanilide,CCCC[C@H](C(=O)N(C(=O)[C@H](CCCCN)NC1=CC=C(C=C1)[N+](=O)[O-])C(=O)[C@H](CC2CCC(CC2)O)N)N,,,,,,
8903,128904,1-Methyl-4-{[4-({4-[(1-methylpyridinium-4-yl)amino]phenyl}carbamoyl)phenyl]amino}quinolinium,C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)NC4=CC=[N+](C5=CC=CC=C45)C,,,,,,
8904,128905,"7-[(1R,2R,3S,5S)-3-Fluoro-5-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)F)O,,,,,,
8905,128906,CID 128906,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)F)O,,,,,,
8906,128907,p-Hydroxyfentiazac,C1=CC(=CC=C1C2=NC(=C(S2)CC(=O)O)C3=CC=C(C=C3)Cl)O,,,,,,
8907,128908,3-Hydroxyflunitrazepam,CN1C2=C(C=C(C=C2)[N+](=O)[O-])C(=NC(C1=O)O)C3=CC=CC=C3F,,,,,['3-hydroxyflunitrazepam is a known human metabolite of flunitrazepam.'],
8908,128909,"5-amino-3-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-d][1,3]oxazin-7-one",C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C2N=C(OC3=O)N)CO)O,,,,,,
8909,128910,CID 128910,C[C@H](CCCOC(=O)N(CCCl)CCCl)[C@H]1CC[C@H]2[C@@]1(CCC3([C@@H]2CC=C4[C@@]3(CC[C@H](C4)O)C)CCCCCCCCCCCCCCC=CCC(=O)O)C,,,,,,
8910,128911,"4,5-Dihydro-4-methyl-6-oxo-5-phenyl-6H-pyrazolo(4,5-c)isoselenazole",CN1C2=C[Se]N=C2C(=O)N1C3=CC=CC=C3,,,,,,
8911,128912,6-Methylangelicin,CC1=CC2=C(C3=C1OC=C3)OC(=O)C=C2,,,,,,
8912,128913,"5H-Furo[3,2-g][1]benzopyran-5-one",C1=COC2=CC3=C(C=C21)C(=O)C=CO3,,,,,,
8913,128914,"6-Methyl-2-nitrosoimidazo[1,2-a:5,4-b']dipyridine",CC1=CC=CN2C1=NC3=C2N=C(C=C3)N=O,,,,,,
8914,128915,3-Methylandrost-5-en-17-one,C[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=O)C)C,,,,,,
8915,128916,"6H-Dibenzo(b,d)pyran-1-ol, 6a,7,10,10a-tetrahydro-3,6,6,9-tetramethyl-",CC1=CCC2C(C1)C3=C(C=C(C=C3OC2(C)C)C)O,,,,,,
8916,128917,"3,7,11,15,19,23,27-Heptamethyl-6,10,14,18,22,26-octacosahexaenol",CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCO,,,,,,
8917,128918,Xaliproden hydrochloride,C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3.Cl,,,['Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)'],,,
8918,128919,Xaliproden,C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3,"[""Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.""]",,['Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)'],,,
8919,128920,"(2R,3R,4S,5R,6R)-2-[[(10S,13R,14R,17S)-14-amino-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC2CC[C@]3(C(C2)CCC4C3CC[C@]5([C@]4(CC[C@@H]5C(C)O)N)C)C)O)O)O,,,,,,
8920,128921,Benzyloxycarbonylarginyl-arginine 4-methylcoumarin-7-ylamide,CC1=CC(=O)OC2=C1C=CC(=C2)N[C@@H](CCCN=C(N)N)C(=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3,,,,,,
8921,128922,"3-(2-Chloroethyl)-3,4-dihydro-4-oxopyrazolo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide",C1=NN2C(=C1C(=O)N)N=NN(C2=O)CCCl,,,,,,
8922,128923,CID 128923,C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=C3C(=NN2)C(=O)NC(=O)O3)O)O)O,,,,,,
8923,128924,5'-Thioadenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CS)O)O)N,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
8924,128925,3-Dimethylamino-2-dimethylaminomethyl-1-(4-methoxyphenyl)-1-propanone,CN(C)CC(CN(C)C)C(=O)C1=CC=C(C=C1)OC.Cl.Cl,,,,,,
8925,128926,3-(Dimethylamino)-2-[(dimethylamino)methyl]-1-(4-methoxyphenyl)propan-1-one,CN(C)CC(CN(C)C)C(=O)C1=CC=C(C=C1)OC,,,,,,
8926,128927,"[(2R,3S,4R,5R,6R)-3,4-diacetyloxy-5-azido-6-chlorooxan-2-yl]methyl acetate",CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)Cl)N=[N+]=[N-])OC(=O)C)OC(=O)C,,,,,,
8927,128928,Glycyl-histidyl-arginyl-proline,C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O,,,,,,
8928,128929,[2-(methylamino)acetyl] (2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoate,CNCC(=O)OC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
8929,128930,4-Hydroxy-4-phenylhexanamide,CCC(CCC(=O)N)(C1=CC=CC=C1)O,,,,,,
8930,128931,"16-Hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraen-4-one",CC(=CC(=O)CC(=CCCC(=CCCC(=CCO)C)C)C)C,,,,,,
8931,128932,Disodium 2-nitro-5-(sulfonatosulfanyl)benzoate,C1=CC(=C(C=C1SS(=O)(=O)[O-])C(=O)[O-])[N+](=O)[O-].[Na+].[Na+],,,,,,
8932,128933,2-nitro-5-sulfosulfanyl-benzoic Acid,C1=CC(=C(C=C1SS(=O)(=O)O)C(=O)O)[N+](=O)[O-],,,,,,
8933,128934,2-Methacryloyloxyethyl phosphorylcholine,CC(=C)C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C,,,,,,
8934,128935,Methacryloyloxyphosphorylcholine,CC(=C)C(=O)OCCOP(=O)(O)OCC[N+](C)(C)C,,,,,,
8935,128936,(1s)-Cyclopent-2-ene-1-carboxylic acid,C1C[C@@H](C=C1)C(=O)O,,,,,,
8936,128937,Cyclopentenyluracil,C1=CN(C(=O)NC1=O)[C@@H]2C=C([C@H]([C@H]2O)O)CO,,,,,,
8937,128938,"4'-Trifluoromethyl-2,3,4,5-tetrachlorobiphenyl",C1=CC(=CC=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)C(F)(F)F,,,,,,
8938,128939,"L-Alanine, N-(((2-chloroethyl)nitrosoamino)carbonyl)-, (5alpha,17beta)-3-oxoandrostan-17-yl ester",C[C@@H](C(=O)O[C@H]1CCC2[C@@]1(CCC3C2CC[C@@H]4[C@@]3(CCC(=O)C4)C)C)NC(=O)N(CCCl)N=O,,,,,,
8939,128940,"2-Propanol, 1-((phenylmethyl)amino)-3-(3-(trifluoromethyl)phenoxy)-, hydrochloride",C1=CC=C(C=C1)CNCC(COC2=CC=CC(=C2)C(F)(F)F)O.Cl,,,,,,
8940,128941,1-(Benzylamino)-3-[3-(trifluoromethyl)phenoxy]propan-2-ol,C1=CC=C(C=C1)CNCC(COC2=CC=CC(=C2)C(F)(F)F)O,,,,,,
8941,128942,CID 128942,CC(=C[C@@H](CC(=C1CC[C@]([C@H](C1)Br)(C)Cl)C)O)C,,,,,,
8942,128943,CID 128943,CC(=C[C@@H](CC(=C1CC[C@]([C@H](C1)Cl)(C)Br)C)O)C,,,,,,
8943,128944,"Isoquinoline, 1,2,3,4-tetrahydro-4-phenyl-, (R)-",C1[C@@H](C2=CC=CC=C2CN1)C3=CC=CC=C3,,,,,,
8944,128945,"1,3-Dichloropyrene",C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)Cl)Cl,,,,,,
8945,128946,"1,8-Dichloropyrene",C1=CC2=C3C(=C(C=C2)Cl)C=CC4=C(C=CC1=C43)Cl,,,,,,
8946,128947,"[3-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadeca-9,12-dienoyloxypropyl] octadeca-9,12-dienoate",CCCCCC=CCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC(CO)O)OC(=O)CCCCCCCC=CCC=CCCCCC,,,,,,
8947,128948,"N,N-Bis(2-chloroethyl)-3-chloropropionamidine",C(CCl)C(=N)N(CCCl)CCCl,,,,,,
8948,128949,CID 128949,CCCCN(CCCC)C1=CC=C(C=C1)C=CC=CC2=CC=[N+](C=C2)CCCN(CC)CC,,,,,,
8949,128950,Azepinomycin,C1C(NC(=O)C2=C(N1)N=CN2)O,,,,,,
8950,128951,N-Nitrosomethyl(2-oxobutyl)amine,CCC(=O)CNCN=O,,,,,,
8951,128952,N-Nitrosomethyl(3-oxobutyl)amine,CC(=O)CCNCN=O,,,,,,
8952,128953,"2,4-Dideoxyhexopyranose",C(C=O)[C@H](C[C@@H](CO)O)O,,,,,,
8953,128954,"3-[[(6R,7S)-7-methoxy-5,5,8-trioxo-2-(pyrrolidine-1-carbonyl)-5lambda6-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methylsulfanyl]-2-methyl-1H-1,2,4-triazine-5,6-dione",CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@H](C3=O)OC)S(=O)(=O)C2)C(=O)N4CCCC4,,,,,,
8954,128955,"[3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indol-5-yl] methanesulfonate",CS(=O)(=O)OC1=CC2=C(C=C1)NC=C2CCCCN3CCC(=CC3)C4=CC=CC=C4,,,,,,
8955,128956,CID 128956,CCC(=CC(=O)CC(C)CC(C)CCC(C(C)C(=O)CC(C(C)C(C)OC(=O)CC(C1=C(C(=O)OC1=O)C)O)O)O)C=C,,,,,,
8956,128957,Eryloside A,CC1C2CCC3=C([C@]2(CCC1O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)C)CC[C@]6(C3=CC[C@@H]6[C@H](C)CC(CC(C)C)O)C,,,,,,
8957,128958,Maesol,CC1=C(C=C(C=C1OC)CCCCCCCCCCCCC2=CC(=C(C(=C2)OC)C)O)O,,,,,,
8958,128959,Phyllanthostatin A,CC(=O)OCC1=C(C(=C2C=C(C(=CC2=C1)OC)OC)C3=CC4=C(C=C3)OCO4)C(=O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
8959,128960,CID 128960,C1=CC(=CC=C1CCCC2=CN=C3C(=N2)C(=O)N=C(N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
8960,128961,"Ethanone,1-(2-thienyl)-, 2-(2-thiazolyl)hydrazone",CC(=NNC1=NC=CS1)C2=CC=CS2,,,,,,
8961,128962,9-Amino-n-[2-(dimethylamino)ethyl]-4-acridinecarboxamide,CN(C)CCNC(=O)C1=CC=CC2=C(C3=CC=CC=C3N=C21)N,,,,,,
8962,128963,CID 128963,CC(CC1=CC=C(C=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
8963,128964,Indaniline,CN(C)C1=CC=C(C=C1)N=C2C=CC(=O)C(=C2)C(=O)N,,,,,,
8964,128965,2-Fluoroapomorphine,CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)F)C(=C(C=C4)O)O,,,,,,
8965,128966,"7,8-Ddmbp",C[C@@]1(C=CC2=C([C@@H]1O)C=C3C=CC4=C5C3=C2C=CC5=CC=C4)O,,,,,,
8966,128967,"3,5-diamino-N-[2-[[3-[2-[(3-bromo-5-tert-butyl-2-hydroxyphenyl)methylamino]ethylamino]-3-oxopropyl]-methylamino]ethyl]-6-chloropyrazine-2-carboxamide",CC(C)(C)C1=CC(=C(C(=C1)Br)O)CNCCNC(=O)CCN(C)CCNC(=O)C2=C(N=C(C(=N2)Cl)N)N,,,,,,
8967,128968,Chicamycin A,CO[C@@H]1[C@@H]2C[C@@H](CN2C(=O)C3=CC(=C(C=C3N1)O)OC)O,,,,,,
8968,128969,CID 128969,CCCCCCSCC1C2CCC(C1CC=CCCCC(=O)O)O2,,,,,,
8969,128970,CID 128970,CCN(CC)C1=CC2=C(C=C1)C=C(O2)C(=O)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5CC6C[C@@]67C5=CC(=O)C8=C7C(=CN8)C,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']",,,
8970,128971,CID 128971,CC1=C2C=CN(C=C2C(=C3C1=NC4=C3C(=C(C=C4)O)[NH+]=C(C(C)C)C(=O)O)C)C,,,,,,
8971,128972,CID 128972,CC1=C2C=CN(C=C2C(=C3C1=NC4=C3C(=C(C=C4)O)N=C(C(C)C)C(=O)O)C)C,,,,,,
8972,128973,CID 128973,CC(=O)C(=O)C1CNC2=C(N1)C(=O)N=C(N2)N,,,,,,
8973,128974,3-(3-Fluorophenyl)-N-n-propylpiperidine,CCCN1CCCC(C1)C2=CC(=CC=C2)F,,,,,,
8974,128975,"5,12-Naphthacenedione, 10-((4-aminotetrahydro-6-methyl-2H-pyran-2-yl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-",CC1CC(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(CO)O)O)N,,,,,,
8975,128976,"2-Desamino-2,3-dimethyl-N(10)-propargyl-5,8-dideazafolic acid",CC1=NC2=C(C=C(C=C2)CN(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1C,,,,,,
8976,128977,"N-Nitroso-2,3-dihydroxypropylethanolamine",C(CO)N(CC(CO)O)N=O,,,,,,
8977,128978,N-[1-[[1-cyclohexyl-3-hydroxy-4-(1-methyltetrazol-5-yl)sulfanylbutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-4-morpholin-4-yl-2-(naphthalen-1-ylmethyl)-4-oxobutanamide,CN1C(=NN=N1)SCC(C(CC2CCCCC2)NC(=O)C(CC3=CN=CN3)NC(=O)C(CC4=CC=CC5=CC=CC=C54)CC(=O)N6CCOCC6)O,,,,,,
8978,128979,CID 128979,C[C@H](CCCC(C(OC)(F)F)C(F)(F)F)C1CCC2[C@@]1(CCCC2=CC=C3C[C@H](CC(C3=C)O)O)C,,,,,,
8979,128980,N-Hydroxy-N-glucuronosyl-2-aminofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)N([C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O,,,,,,
8980,128981,Aflatoxin Q2a,COC1=C2C3=C(C(=O)CC3O)C(=O)OC2=C4C5CC(OC5OC4=C1)O,,,,,,
8981,128982,3-(Adenin-9-yl) prop-2-enal,C1=NC(=C2C(=N1)N(C=N2)C=CC=O)N,,,,,,
8982,128983,CID 128983,CC1=CN(C(=O)N(C1=O)C=CC=O)[C@@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
8983,128984,"(1s,2r,4r)-2-Azido-4-hydroxy-6-oxocyclohexyl benzoate",C1[C@H](CC(=O)[C@H]([C@@H]1N=[N+]=[N-])OC(=O)C2=CC=CC=C2)O,,,,,,
8984,128985,"Urea, N-(2-chloroethyl)-N'-(2-mercaptoethyl)-N-nitroso-",C(CS)NC(=O)N(CCCl)N=O,,,,,,
8985,128986,"5-(2-Chloroethyl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione",C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)CCCl)CO)O,,,,,,
8986,128987,BEUdR,C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)CCBr)CO)O,,,"['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
8987,128988,Methylmalonyl-methylalanyl-arginyl-p-nitroaniline,CC(C)(C(=O)NC(=O)[C@H](CCCN=C(N)N)NC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)CC(=O)OC,,,,,,
8988,128989,"(1-Octadecanoyloxy-3-phosphonooxypropan-2-yl) icosa-5,8,11,14-tetraenoate",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC,,,,,,
8989,128990,CID 128990,C[C@H](C(=O)NC(=O)CCC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NCS,,,,,,
8990,128991,7-(2-Amino-6-hexylcyclohexyl)heptanoic acid,CCCCCCC1CCCC(C1CCCCCCC(=O)O)N,,,,,,
8991,128992,CID 128992,C[C@@]12CCCC([C@H]1CCC3([C@H]2CC=C(CC=O)C=O)CO3)(C)C,,,,,,
8992,128993,Bis(pentafluorobenzyl)disulfide,C(C1=C(C(=C(C(=C1F)F)F)F)F)SSCC2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
8993,128994,Dehydrotanshinone II A,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3C=CCC4(C)C,,,,,,
8994,128995,4-(3-(4-Fluorobenzoyl)propyl)-N-cyclohexyl-1-piperazinecarboxamide hydrochloride,C1CCC(CC1)NC(=O)N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F.Cl,,,,,,
8995,128996,N-cyclohexyl-4-[4-(4-fluorophenyl)-4-oxobutyl]piperazine-1-carboxamide,C1CCC(CC1)NC(=O)N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
8996,128997,Thionapthene-2-carboxylic acid-lysine,C1=CC=C2C(=C1)C=C(S2)C(=O)O.C(CCN)C[C@@H](C(=O)O)N,,,,,,
8997,128998,Naktiivql nanopeptide,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N,,,,,,
8998,128999,"Methyl 5-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-2-oxo-4-furancarboxylate",COC1=C(C=C(C=C1)[C@@H]2[C@H](CC(=O)O2)C(=O)OC)OC,,,,,,
8999,129000,CID 129000,CCC(C)C=C(C)C=CC1=CC2=C(C(=O)[C@@]([C@H](C2=CO1)O)(C)O)Cl,,,,,,
9000,129001,Sodium 4-methoxy-6-[(6-methoxy-1H-benzimidazole-2-sulfinyl)methyl]-5-methylpyridine-3-carboxylate (1/1),CC1=C(C(=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)OC)C(=O)[O-])OC.CC1=C(C(=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)OC)C(=O)[O-])OC.[Na+].[Na+],,,,,,
9001,129002,4-Methoxy-6-(((6-methoxy-1H-benzimidazol-2-yl)sulfinyl)methyl)-5-methyl-3-pyridinecarboxylic acid,CC1=C(C(=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)OC)C(=O)O)OC,,,,,,
9002,129003,"Methyl 6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate",CC1=C(C(C2=C(N1)SC=C2CC(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,,,,,,
9003,129004,CID 129004,C[C@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCCCCCCN)C(=O)O,,,,,,
9004,129005,(2R)-N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methyl-2-(sulfanylmethyl)pentanamide,C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(C)C)CS,,,,,,
9005,129006,CID 129006,CC1=C(C(=CC(=C1OC)OC)C=C2C(=O)NCC(=O)N2C)OC,,,,,,
9006,129007,"1-Methyl-3-(2,4,5-trimethoxy-3-methylphenylmethyl)-2,5-piperazinedione",CC1=C(C(=CC(=C1OC)OC)CC2C(=O)N(CC(=O)N2)C)OC,,,,,,
9007,129008,"Propan-2-yl 11-hydroxy-13-iodo-3,7,11-trimethyltrideca-2,4,12-trienoate",CC(C)OC(=O)C=C(C)C=CCC(C)CCCC(C)(C=CI)O,,,,,,
9008,129009,"14-Hydroxyandrost-4-ene-3,6,17-trione",C[C@]12CCC(=O)C=C1C(=O)C[C@@H]3[C@@H]2CC[C@]4(C3(CCC4=O)O)C,,,,,,
9009,129010,2-[1-(3-Hydroxyfuran-2-yl)ethylidene]furan-3-one,CC(=C1C(=O)C=CO1)C2=C(C=CO2)O,,,,,,
9010,129011,CID 129011,CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NCCN=C(NC4=CC(=CC=C4)N=C=S)S,,,,,,
9011,129012,CID 129012,C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)N)N[C@@H](CC1=CN=CN1)C(=O)O,,,,,,
9012,129013,"6,7-Bis(1-aziridinyl)-4-((3-(N,N-dimethylamino)propyl)amino)-5,8-quinazolinedione",CN(C)CCCNC1=NC=NC2=C1C(=O)C(=C(C2=O)N3CC3)N4CC4,,,,,,
9013,129014,7-O-Ribofuranosyldaunomycinone,CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
9014,129015,CID 129015,C(C1=NC2=C(N1)C(=O)N=C(N2)N)C(C(CO)O)O,,,,,,
9015,129016,"1,3-Dimethyl-1,2,3,4-tetrahydroisoquinoline",CC1CC2=CC=CC=C2C(N1)C,,,,,,
9016,129017,7-O-Ribofuranosyladriamycinone,COC1=CC=CC2=C1C(=O)C3=C(C4=C(C[C@](C[C@H]4O[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)(C(=O)CO)O)C(=C3C2=O)O)O,,,,,,
9017,129018,Cpdmea,C[C@H](CCCC(C)C)C1CCC2[C@@]1(CCC3C2CC=C4[C@@]3(CCC(C4)C(CN(C)C)(O)P(=O)(O)O)C)C,,,,,,
9018,129019,CID 129019,C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)N=C2[O-])N[N+]#N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
9019,129020,CID 129020,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)N[N+]#N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
9020,129021,Northalibroline,CN1[C@H](CC2=C([C@@H]1CC3=CC(=C(C=C3)O)OC4=CC=C(C=C4)CC5C6=CC(=C(C=C6CCN5)OC)O)C=CC(=C2)OC)O,,,,,,
9021,129022,Benzoylcarnitine,C[N+](C)(C)C[C@@H](CC(=O)[O-])OC(=O)C1=CC=CC=C1,,,,,,
9022,129023,(2-Benzoyloxy-3-carboxypropyl)-trimethylazanium,C[N+](C)(C)CC(CC(=O)O)OC(=O)C1=CC=CC=C1,,,,,,
9023,129024,CID 129024,CCC=CCC(C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCC(=O)O)O)O,,,,,,
9024,129025,4-Amidino-2-nitrophenyl 4'-anisate,COC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(=N)N)[N+](=O)[O-],,,,,,
9025,129026,"2,3-Di-O-phytanyl-1-(phosphoryl-2-acetamido-2-deoxyglucopyranosyl)glycerol",CC(C)CCCC(C)CCCC(C)CCCC(C)CCOCC(COP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
9026,129027,"Cholecystokinin (26-33), N-alpha-hydroxysulfonyl-nle(28,31)-",CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)[O-])C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)[O-])NC(=O)[C@H](CC(=O)O)NS(=O)(=O)O)N.[Na+].[Na+],,,,,,
9027,129028,(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-aminohexanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-2-[[(2S)-3-carboxy-2-(sulfoamino)propanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid,CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NS(=O)(=O)O)N,,,,,,
9028,129029,Ovothiol C,CN1C=NC(=C1C[C@@H](C(=O)O)N(C)C)S,,,,,,
9029,129030,(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-[2-[[(2S)-2-amino-3-methyl-3-sulfanylbutanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoic acid,CC(C)[C@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N(C(=O)CNC(=O)[C@@H](C(C)(C)S)N)C(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
9030,129031,CID 129031,CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)[O-])C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C)N.[Na+],,,,,,
9031,129032,CID 129032,CCCC[C@@H](C(=O)NCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C)N,,,,,,
9032,129033,"6,7-Diphenyl-1-pyrrolizinone",C1=CC=C(C=C1)C2=CN3C=CC(=O)C3=C2C4=CC=CC=C4,,,,,,
9033,129034,"6,7-Diphenyl-3-pyrrolizinone",C1=CC=C(C=C1)C2=CN3C(=C2C4=CC=CC=C4)C=CC3=O,,,,,,
9034,129035,1-(N-Methyl-N-nitrosoamino)ethyl phosphate,CC(N(C)N=O)OP(=O)(O)O,,,,,,
9035,129036,3-(3-Methylaminopropylamino)propylmercaptan,CNCCCNCCCS.Cl.Cl,,,,,,
9036,129037,3-[3-(Methylamino)propylamino]propane-1-thiol,CNCCCNCCCS,,,,,,
9037,129038,"[(3R)-4-[[3-[2-(2-bromoacetyl)sulfanylethylamino]-3-oxopropyl]amino]-3-hydroxy-2,2-dimethyl-4-oxobutyl] 2,2-dimethylpropanoate",CC(C)(C)C(=O)OCC(C)(C)[C@H](C(=O)NCCC(=O)NCCSC(=O)CBr)O,,,,,,
9038,129039,Chrysobactin,C1=CC(=C(C(=C1)O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O,,,,,,
9039,129040,CID 129040,C1=C(C(=O)N=C(N1[C@@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)[O-])N[N+]#N,,,,,,
9040,129041,CID 129041,C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N[N+]#N,,,,,,
9041,129042,Thrazarine,C[C@H](C(=[N+]=[N-])C(=O)OC[C@@H](C(=O)O)N)O,,,,,,
9042,129043,CID 129043,C[C@H](C(=C(O)OC[C@@H](C(=O)O)N)[N+]#N)O,,,,,,
9043,129044,2-((4-((2-(1H-Tetrazol-5-ylmethyl)phenyl)methoxy)phenoxy)methyl)quinoline,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)OCC4=CC=CC=C4CC5=NNN=N5,,,['A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)'],,,
9044,129045,6-(5-Methylimidazol-1-yl)methyl-2-naphthoic acid hydrochloride,CC1=CN=CN1CC2=CC3=C(C=C2)C=C(C=C3)C(=O)O.Cl,,,,,,
9045,129046,6-[(5-Methyl-1H-imidazol-1-yl)methyl]-2-naphthalenecarboxylic acid,CC1=CN=CN1CC2=CC3=C(C=C2)C=C(C=C3)C(=O)O,,,,,,
9046,129047,1-[Ethyl(nitroso)amino]ethyl dihydrogen phosphate,CCN(C(C)OP(=O)(O)O)N=O,,,,,,
9047,129048,9-O-Demethylmaritidine,COC1=C(C=C2C(=C1)CN3CCC24[C@@H]3C[C@@H](C=C4)O)O,,,,,,
9048,129049,"1(6H)-Pyridazinebutanoic acid, 3-(4-chlorophenyl)-6-imino-, monohydrochloride",C1=CC(=CC=C1C2=NN(C(=N)C=C2)CCCC(=O)O)Cl.Cl,,,,,,
9049,129050,4-[6-(4-Chlorophenyl)-3-iminopyridazin-2(3H)-yl]butanoic acid,C1=CC(=CC=C1C2=NN(C(=N)C=C2)CCCC(=O)O)Cl,,,,,,
9050,129051,"3,4,5,5'-O-Tetramethyl-3',4'-O,O-methylidenecoruleoellagic acid d",COC1=C2C(=C3C4=C1C(=O)OC5=C(C(=C(C(=C45)C(=O)O3)OC)OC)OC)OCO2,,,,,,
9051,129052,"(3S,8S,9S,10R,13R,14S,17S)-10,13-dimethyl-17-[(2R)-6-[methyl-(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@H](CCCC(C)N(C)C1=CC=C(C2=NON=C12)[N+](=O)[O-])[C@@H]3CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O)C)C,,,,,,
9052,129053,CID 129053,CCC=C1C=CC(=O)[C@@H](C12[C@H](C(=C)N(C2=O)OC)O)O,,,,,,
9053,129054,"3-amino-5H-benzo[b][1,4]benzothiazepin-6-one",C1=CC=C2C(=C1)C(=O)NC3=C(S2)C=CC(=C3)N,,,,,,
9054,129055,"(8S,11R,13R,14S)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-11-[4-(methylamino)phenyl]-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CCC2(CCCO)O)C5=CC=C(C=C5)NC,,,,,,
9055,129056,Meproadifen mustard,CCC(C1=CC=CC=C1)C2=CC=CC=C2CC(=O)OCCN(C)CCCl.Cl,,,,,,
9056,129057,2-[2-Chloroethyl(methyl)amino]ethyl 2-[2-(1-phenylpropyl)phenyl]acetate,CCC(C1=CC=CC=C1)C2=CC=CC=C2CC(=O)OCCN(C)CCCl,,,,,,
9057,129058,CID 129058,CC(=CCC=C(C)[C@H]1CC[C@]2([C@@H]1[C@H](CC3[C@]2(CCC4[C@@]3(CCC(C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C)O)C)C,,,,,,
9058,129059,Adtepp,CC1=NC=C(C(=C1O)C=NCCSCCNC2=C3C(=NC=N2)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)CO)O)O)COP(=O)(O)O,,,,,,
9059,129060,"9,11-Epoxycholest-7-ene-3,5,6-triol",C[C@H](CCCC(C)C)C1CC[C@@H]2[C@@]1(C[C@@H]3C4(C2=C[C@H]([C@@]5([C@@]4(CC[C@@H](C5)O)C)O)O)O3)C,,,,,,
9060,129061,4-Hydroxybevantolol,CC1=C(C=CC(=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O)O,,,,,,
9061,129062,CID 129062,CC(CN(C)C)OC1=CC=C(C=C1)C(=O)C2=C(N=CC=C2)OC(C)CN(C)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
9062,129063,[4-[1-(Dimethylamino)propan-2-yloxy]phenyl]-[2-[1-(dimethylamino)propan-2-yloxy]pyridin-3-yl]methanone,CC(CN(C)C)OC1=CC=C(C=C1)C(=O)C2=C(N=CC=C2)OC(C)CN(C)C,,,,,,
9063,129064,"Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride",CC1=C(C(=C(C2=C1N=C(S2)NCC3=CC=C(C=C3)S(=O)(=O)N)C)O)C.Cl,,,,,,
9064,129065,"4-[[(6-Hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide",CC1=C(C(=C(C2=C1N=C(S2)NCC3=CC=C(C=C3)S(=O)(=O)N)C)O)C,,,,,,
9065,129066,"1,4-Bis(3-(4-chlorophenyl)propyl)piperazine",C1CN(CCN1CCCC2=CC=C(C=C2)Cl)CCCC3=CC=C(C=C3)Cl,,,,,,
9066,129067,"7-[(1R,2R,3R,5R)-5-chloro-2-[(3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-3-hydroxycyclopentyl]hept-5-enoic acid",C1CCC(CC1)[C@@H](C=C[C@H]2[C@@H](C[C@H]([C@@H]2CC=CCCCC(=O)O)Cl)O)O,,,,,,
9067,129068,Amyl-O-(6-amino-3-imino-3H-xanthene-9-yl)benzoate,CCCCCOC(=O)C1=CC=CC=C1C2=C3C=CC(=N)C=C3OC4=C2C=CC(=C4)N,,,,,,
9068,129069,N-(3-Dimethylaminopropyl)benzylpenicillinamide,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)NCCCN(C)C)C,,,,,,
9069,129070,"2-Hexa-1,3-dienyl-2,6-dimethyl-5,6-dihydrofuro[2,3-b]pyran-3,4-dione",CCC=CC=CC1(C(=O)C2=C(O1)OC(CC2=O)C)C,,,,,,
9070,129071,"(3S,5S,9R,10S,13R)-3-hydroxy-17-[(2R)-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,6,7,9,11,12,16,17-dodecahydrocyclopenta[a]phenanthren-15-one",C[C@H](CCC(C(C)C)O)C1CC(=O)C2=C3CC[C@H]4C[C@H](CC[C@@]4([C@H]3CC[C@]12C)C)O,,,,,,
9071,129072,CID 129072,CCN(C(=O)NC(=O)C(=NOC)C#N)N=O,,,,,,
9072,129073,CID 129073,C(CCCN)CCCNCCOP(=O)(O)S,,,,,,
9073,129074,2-(N-Hydroxy-C-undecylcarbonimidoyl)-4-methylphenol,CCCCCCCCCCCC(=NO)C1=C(C=CC(=C1)C)O,,,,,,
9074,129075,"3,25-Dihydroxycholest-8(14)-en-15-one",C[C@H](CCCC(C)(C)O)C1CC(=O)C2=C3CCC4CC(CC[C@@]4([C@H]3CC[C@]12C)C)O,,,['Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)'],,,
9075,129076,"N,N-di(propan-2-yl)decan-1-amine",CCCCCCCCCCN(C(C)C)C(C)C.I,,,,,,
9076,129077,"N,N-Diisopropyldecane-1-amine",CCCCCCCCCCN(C(C)C)C(C)C,,,,,,
9077,129078,"2,2,6,6-Tetramethyldecylpiperidine",CCCCCCCCCCN1C(CCCC1(C)C)(C)C.Cl,,,,,,
9078,129079,"1-Decyl-2,2,6,6-tetramethylpiperidine",CCCCCCCCCCN1C(CCCC1(C)C)(C)C,,,,,,
9079,129080,gamma-Glutamyl-gamma-glutamylcysteinylglycine,C(CC(=O)N[C@@H](CS)C(=O)N(CC(=O)O)C(=O)CC[C@@H](C(=O)O)N)[C@@H](C(=O)O)N,,,,,,
9080,129081,"Pyrrolidinium, 1-ethyl-1-(5-(triethylammonio)pentyl)-, diiodide",CC[N+]1(CCCC1)CCCCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9081,129082,Triethyl-[5-(1-ethylpyrrolidin-1-ium-1-yl)pentyl]azanium,CC[N+]1(CCCC1)CCCCC[N+](CC)(CC)CC,,,,,,
9082,129083,Cyclopentylmethyl decanoate,CCCCCCCCCC(=O)OCC1CCCC1,,,,,,
9083,129084,CID 129084,CCCCCC=CC(=O)NCCSSCCNC(=O)C=CCCCCC,,,,,,
9084,129085,Xylopyranosyl-seryl-glycyl-isoleucyl-glycine,CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)CNC(=O)[C@H](CO[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)N,,,,,,
9085,129086,"N,N'-Bis(2,3-dihydroxybenzoyl)lysinol",C1=CC(=C(C(=C1)O)O)C(=O)NCCCCC(CO)NC(=O)C2=C(C(=CC=C2)O)O,,,,,,
9086,129087,CID 129087,CCC(C)(CCC[C@@H](C)[C@@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C)O,,,,,,
9087,129088,"2,3-Tpaamp",C[C@@H]1[C@H]([C@H](C(O1)N2C3=NC=NC(=C3N=C2N=[N+]=[N-])N)OOP(=O)(O)O)OC4=C(C=C(C=C4[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
9088,129089,Xenocoumacin 2,CC(C)CC(C1CC2=C(C(=CC=C2)O)C(=O)O1)NC(=O)C(C(C3CCCN3)O)O,,,,,,
9089,129090,CID 129090,C1=CSC(=C1)C=C2C(=O)NC(=NC2=O)S,,,,,,
9090,129091,"3-Hydroxy-4,5,6,7-tetrahydro-isoxazolo(4,5-c)pyridine-4-carboxylic acid",C1CNC(C2=C1ONC2=O)C(=O)O,,,,,,
9091,129092,"1-Oleoyl-2-(9,10-dibromostearoyl)-sn-glycero-3-phosphocholine",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC(C(CCCCCCCC)Br)Br,,,,,,
9092,129093,"2-[[2-(9,10-Dibromooctadecanoyloxy)-3-octadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC(C(CCCCCCCC)Br)Br,,,,,,
9093,129094,"3-Hydroxy-4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridine-6-carboxylic acid",C1C(NCC2=C1ONC2=O)C(=O)O,,,,,,
9094,129095,2-(3-Pyridylmethyl)indazolinone,C1=CC=C2C(=C1)C(=O)N(N2)CC3=CN=CC=C3,,,,,,
9095,129096,1-Phenyl-2-carbamoylethylgermanium sesquioxide,C1=CC=C(C=C1)C(CC(=O)N)[Ge](=O)O[Ge](=O)C(CC(=O)N)C2=CC=CC=C2,,,,,,
9096,129097,"[5,5,5-Trichloro-1,3-dihydroxy-3-(2,2,2-trichloroethyl)pentan-2-yl]phosphonic acid",C(C(C(CC(Cl)(Cl)Cl)(CC(Cl)(Cl)Cl)O)P(=O)(O)O)O,,,,,,
9097,129098,CID 129098,C1=CC=C(C=C1)C(CC(=O)N)[GeH]=S.C1=CC=C(C=C1)C(CC(=O)N)[GeH]=S.[SH-],,,,,,
9098,129099,CID 129099,C1=CC=C(C=C1)C(CC(=O)N)[GeH]=S,,,,,,
9099,129100,"2,3-Bis(3,7,11,15-tetramethylhexadecoxy)propyl 3-phosphonooxypropyl hydrogen phosphate",CC(C)CCCC(C)CCCC(C)CCCC(C)CCOCC(COP(=O)(O)OCCCOP(=O)(O)O)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
9100,129101,"3-(4-Cyano-4-(3,4-dimethoxyphenyl)-5-methylhex-1-yl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline",CC(C)C(CCCC1CC2=CC(=C(C=C2CN1C)OC)OC)(C#N)C3=CC(=C(C=C3)OC)OC.Cl,,,,,,
9101,129102,"3-[4-(3,4-dimethoxyphenyl)-4-isopropyl-4-cyanobutyl]-6,7-dimethoxy-N-methyl-1,2,3,4-tetrahydroisoquinoline",CC(C)C(CCCC1CC2=CC(=C(C=C2CN1C)OC)OC)(C#N)C3=CC(=C(C=C3)OC)OC,,,,,,
9102,129103,Dpg-propanediol,CC(C)CCCC(C)CCCC(C)CCCC(C)CCOCC(COP(=O)(O)OCCCO)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
9103,129104,3-[(2R)-1-hydroxy-1-methylpyrrolidin-1-ium-2-yl]-1-methylpyridin-1-ium,C[N+]1=CC=CC(=C1)[C@H]2CCC[N+]2(C)O,,,,,,
9104,129105,N-(4-Ethylbenzoyl)phenylalanine,CCC1=CC=C(C=C1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,,,,,,
9105,129106,CID 129106,C[C@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](C(C)C)N,,,,,,
9106,129107,"Methyl 5-[3-[2-(3,3-dimethyloxiran-2-yl)ethyl]-3-methyloxiran-2-yl]-3-methylpent-2-enoate",CC(=CC(=O)OC)CCC1C(O1)(C)CCC2C(O2)(C)C,,,,,,
9107,129108,"1,2-Diacetyl-3-decanoylglycerol",CCCCCCCCCC(=O)OCC(COC(=O)C)OC(=O)C,,,,,,
9108,129109,3-(2-(N-(1-Carboxy-3-phenylpropyl)amino)propionyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,CC(C(=O)N1C(CN(C1=O)C)C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O,,,['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)'],,,
9109,129110,"Butanoic acid, 4-(hydroxy(3-(2-quinolinylmethoxy)phenyl)amino)-4-oxo-, methyl ester",COC(=O)CCC(=O)N(C1=CC(=CC=C1)OCC2=NC3=CC=CC=C3C=C2)O,,,['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)'],,,
9110,129111,Clitocine,C1=NC(=C(C(=N1)N[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)[N+](=O)[O-])N,,,,,,
9111,129112,CID 129112,C1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4O2)SC(=C3)C(=O)[O-].[Na+],,,,,,
9112,129113,ZY-15850A free acid,C1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4O2)SC(=C3)C(=O)O,,,,,,
9113,129114,"[(8S,11S,13S,14S)-3,9-dihydroxy-13-methyl-17-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-11-yl] nitrate",C[C@]12C[C@@H](C3([C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O)O)O[N+](=O)[O-],,,,,,
9114,129115,"2-Methylestra-4,9-dien-3-one-17-ol",C[C@H]1CC2=C3CC[C@]4([C@H]([C@@H]3CCC2=CC1=O)CC[C@@H]4O)C,,,,,,
9115,129116,CID 129116,CCCCCCC(C)CCCC(C)C1CCC(O1)C2CCC(O2)C(CCCCCCCCCCCCC3=CC(OC3=O)C)O,,,,,,
9116,129117,2'-Dehydropipecuronium,CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5(C3CC([C@@H]5OC(=O)C)N6CC[N+](C=C6)(C)C)C.[Br-].[Br-],,,,,,
9117,129118,"[(2S,3S,5S,10S,13S,17R)-17-acetyloxy-16-(4,4-dimethyl-2,3-dihydropyrazin-4-ium-1-yl)-2-(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5(C3CC([C@@H]5OC(=O)C)N6CC[N+](C=C6)(C)C)C,,,,,,
9118,129119,6-Nitrotryptophol,C1=CC2=C(C=C1[N+](=O)[O-])NC=C2CCO,,,,,,
9119,129120,1-Nitrosotryptophol,C1=CC=C2C(=C1)C(=CN2N=O)CCO,,,,,,
9120,129121,CID 129121,C[C@H](CCCC1CC1)C2CC[C@@H]3[C@@]2(CCCC3=CC=C4C[C@@H](C[C@H](C4=C)O)O)C,,,,,,
9121,129122,CID 129122,C[C@H]1CC[C@@H]([C@@H](C1)OC(=O)C=CS(=O)C2=CC=CC=N2)C(C)C,,,,,,
9122,129123,Splenotritin,C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N,,,,,,
9123,129124,2-(Oxolan-2-yloxy)oxane,C1CCOC(C1)OC2CCCO2,,,,,,
9124,129125,Barbourgenin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(CC[C@@H](C5)O)C)C)O[C@]16CC[C@H](CO6)CO,,,,,,
9125,129126,"methyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidate",COC(=N)C1=NN(C=N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
9126,129127,"Ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate",CCOC(=N)C1=NN(C=N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
9127,129128,"1',2'-Dimethylheptyl-1-deoxy-delta(8)-tetrahydrocannabinol",CCCCCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)C,,,,,,
9128,129129,Oxphalin,CC1=CC(=C(C(=C1)C)N=CC2=CC(=C(C=C2)O)O)C,,,,,,
9129,129130,3-(N-Hydroxycarboxamido-2-benzylpropanoyl)phenylalanine,C1=CC=C(C=C1)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O,,,,,,
9130,129131,"6-Amino-4,4,5,7,8-pentamethyldihydrocoumarin",CC1=C(C2=C(C(=C1N)C)C(CC(=O)O2)(C)C)C,,,,,,
9131,129132,N(6)-2-(4-Amino-3-iodophenyl)ethyladenosine,C1=CC(=C(C=C1CCNC2=C3C(=NC=N2)N(C=N3)[C@@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)I)N,,,,,,
9132,129133,5-(Benzyloxybenzyloxybenzyl)acyclouridine,C1=CC=C(C=C1)COC2=CC=C(C=C2)COC3=CC=CC(=C3)CC4=CN(C(=O)NC4=O)COCCO,,,,,,
9133,129134,"Acetyl-(6-oxocyclohexa-2,4-dien-1-ylidene)azanium;arsenic(3+);2,3-dimethylbutane-2,3-diolate",CC(=O)[NH+]=C1C=CC=CC1=O.CC(C)(C(C)(C)[O-])[O-].CC(C)(C(C)(C)[O-])[O-].[As+3],,,,,,
9134,129135,"N-(6-oxocyclohexa-2,4-dien-1-ylidene)acetamide",CC(=O)N=C1C=CC=CC1=O,,,,,,
9135,129136,CID 129136,C1=NC2=C(N1CC(CCO)CO)NC(=NC2=O)N,,,,,,
9136,129137,"4-[(3,7-Dihydroxy-24-oxocholan-24-yl)amino]benzoic acid",C[C@H](CCC(=O)NC1=CC=C(C=C1)C(=O)O)[C@@H]2CCC3[C@@]2(CCC4C3[C@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C,,,,,,
9137,129138,Pyrroxamycin,C1O[C@@H](C2=C(O1)C(=CC(=C2)Cl)Cl)C3=C(C(=C(N3)Cl)Cl)[N+](=O)[O-],,,,,,
9138,129139,"6-Chloro-5,10-dihydro-5-((1-methyl-4-piperidyl)acetyl)-11H-dibenzo(b,e)(1,4)-diazepine-11-one",CN1CCC(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2C(=CC=C4)Cl.Cl,,,,,,
9139,129140,"1-chloro-11-[2-(1-methylpiperidin-4-yl)acetyl]-5H-benzo[b][1,4]benzodiazepin-6-one",CN1CCC(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2C(=CC=C4)Cl,,,,,,
9140,129141,CID 129141,COC1=CC(=C(O)O)C2=NC(=O)C(=C)OC2=C1,,,,,,
9141,129142,CID 129142,C1=C(C2=C(N=CN=C2N1COCCO)N)C(=N)S,,,,,,
9142,129143,"3,7-dimethyl-N-(2-oxothiolan-3-yl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2CCSC2=O)C)C,,,,,,
9143,129144,Killer III,C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])C(=O)CBr,,,,,,
9144,129145,2-(Hexahydro-1H-azepin-1-yl)-1-(methoxymethyl)ethyl (2-(pentyloxy)phenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC(CN2CCCCCC2)COC,,,,,,
9145,129146,"2-((2-Nitro-1H-imidazol-1-yl)methoxy)-1,3-propanediol",C1=CN(C(=N1)[N+](=O)[O-])COC(CO)CO,,,,,,
9146,129147,N-Cyano-3-((2-guanidino-5-thiazolyl)methylthio)propionamidine,C1=C(SC(=N1)N=C(N)N)CSCCC(=NC#N)N,,,,,,
9147,129148,1-O-Octyl-2-heptylphosphonyl-SN-glycero-3-phosphoethanolamine,CCCCCCCCOC[C@H](COP(=O)(O)OCCN)OP(=O)(CCCCCCC)O,,,,,,
9148,129149,CID 129149,C[C@H](C(=O)NN=C(CC1=CC=CC=C1)CNC(=O)C2=CC=CC=C2)NC(=O)C,,,,,,
9149,129150,3-(4-Chlorophenyl)pyrrolidine,C1CNCC1C2=CC=C(C=C2)Cl,,,,,,
9150,129151,Valproyl-2-pyrrolidinone,CCCC(CCC)C(=O)N1CCCC1=O,,,,,,
9151,129152,"2,5-Bis(4-methoxyphenylhydroxymethyl)thiophene",COC1=CC=C(C=C1)[C@H](C2=CC=C(S2)[C@H](C3=CC=C(C=C3)OC)O)O,,,,,,
9152,129153,Calphostin A,CC(CC1=C2C3=C(C(=C(C4=C3C(=C5C2=C(C(=O)C=C5OC)C(=C1OC)O)C(=CC4=O)OC)O)OC)CC(C)OC(=O)C6=CC=CC=C6)OC(=O)C7=CC=CC=C7,,,,,,
9153,129154,O-Desmethylbrofaromine,C1CNCCC1C2=CC3=CC(=CC(=C3O2)Br)O,,,,,['O-desmethyl-brofaromine is a known human metabolite of brofaromine.'],
9154,129155,"4,4',5'-Trimethylazapsoralen",CC1=CC(=O)OC2=NC3=C(C=C12)C(=C(O3)C)C,,,,,,
9155,129156,10'-O-Demethylstreptonigrin,CC1=C(C(=C(N=C1C(=O)O)C2=NC3=C(C=C2)C(=O)C(=C(C3=O)N)OC)N)C4=C(C(=C(C=C4)O)OC)O,,,,,,
9156,129157,"9,12-Octadecadienamide,N-[2-(3,4-dihydroxyphenyl)ethyl]-, (9Z,12Z)-",CCCCCC=CCC=CCCCCCCCC(=O)NCCC1=CC(=C(C=C1)O)O,,,,,,
9157,129158,CID 129158,C1=CC=C(C=C1)N2C(=O)C(N=C2S)CC3=CC(=C(C=C3)O)[N+](=O)[O-],,,,,,
9158,129159,Diaba,C1CN=C(N1)NC2=CC=C(C=C2)C(=O)O,,,,,,
9159,129160,5-[(6-Aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one,CC1(CC(=C)C(=O)O1)CN2C=NC3=C(N=CN=C32)N,,,,,,
9160,129161,1-((2-Methyl-5-methylene-5-oxotetrahydrofuran-2-yl)methyl)guanine,CC1(CC(=C)C(=O)O1)CN2C(=O)C3=C(N=CN3)N=C2N,,,,,,
9161,129162,CID 129162,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C4SCCS4)C(=O)O,,,,,,
9162,129163,"10-(2,6-Dideoxy-beta-L-arabino-hexopyranosyl)-1,4,6-trihydroxy-8-methyl-5,12-naphthacenedione",C[C@@H]1[C@H]([C@@H](C[C@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C=C5C(=CC(=CC5=C4O)C)O)O)O)O,,,,,,
9163,129164,9-Amtbtq,CN1CCC2=C3C1CC4=C(C3=CC=C2)N=C(S4)N,,,,,,
9164,129165,"10-Acetoxy-8,9-epoxythymol isobutyrate",CC1=CC(=C(C=C1)C2C(O2)COC(=O)C)OC(=O)C(C)C,,,,,,
9165,129166,CID 129166,C[C@H]1C(=C(N2[C@H](O1)[C@@H](C2=O)NC(=O)C(=NOC(C)(C)C(=O)O)C3=CSC(=N3)N)C(=O)[O-])CSC4=CC=[N+](C=C4)C,,,,,,
9166,129167,CID 129167,C[C@H]1C(=C(N2[C@H](O1)[C@@H](C2=O)NC(=O)C(=NOC(C)(C)C(=O)O)C3=CSC(=N3)N)C(=O)O)CSC4=CC=[N+](C=C4)C,,,,,,
9167,129168,CID 129168,C1=CC(=C(C(=C1C(=O)O)OC(=O)C=CC(=O)OC2=C(C=CC(=C2Br)Br)C(=O)O)Br)Br,,,,,,
9168,129169,Hoechst 33342 analog 2,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC(=C(C=C6)O)I,,,,,,
9169,129170,"1-{3-Azido-2,3-dideoxy-5-O-[hydroxy(phosphonooxy)phosphoryl]pentofuranosyl}-4-hydroxy-5-methylpyrimidin-2(1H)-one",CC1=CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)N=[N+]=[N-],,,,,,
9170,129171,CID 129171,CCON=C(C1=CSC(=N1)N)C(=O)N[C@@H]2[C@H]3N(C2=O)C(=C(CS3)CSC4=CC=[N+](C=C4)CC(=O)[O-])C(=O)O,,,,,,
9171,129172,CID 129172,CCON=C(C1=CSC(=N1)N)C(=O)N[C@@H]2[C@H]3N(C2=O)C(=C(CS3)CSC4=CC=[N+](C=C4)CC(=O)O)C(=O)O,,,,,,
9172,129173,3alpha-Hydroxy-6-fluoroindoline,C1COC2C1(C3=C(N2)C=C(C=C3)F)O,,,,,,
9173,129174,"3-Cyano-3,4-dihydroquinoline-2(1H)-one",C1C(C(=O)NC2=CC=CC=C21)C#N,,,,,,
9174,129175,CID 129175,CCCN(CCCN=C1C=CC(=N[N+]#N)C=C1N(O)[O-])C2CCC3=C(C2)C(=CC=C3)OC,,,,,,
9175,129176,2-Aphpd,CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)C(CSSC2=CC=CC=N2)O,,,,,,
9176,129177,"2-(4-Chlorophenyl)-1,1-dimethylethyl 2-amino-3-methylbutanoate",CC(C)[C@@H](C(=O)OC(C)(C)CC1=CC=C(C=C1)Cl)N,,,,,,
9177,129178,"4',11-Dihydroxy-2,4',9-trimethyl-1'-oxospiro[19-thia-3,20-diazabicyclo[15.2.1]icosa-1(20),9,13,15,17-pentaene-6,5'-dithiolane]-3',4,12-trione",CC1C2=NC(=CS2)C=CC=CC(=O)C(C=C(CCC3(CC(=O)N1)C(C(=O)SS3=O)(C)O)C)O,,,,,,
9178,129179,CID 129179,C1C(=O)NC2=C(C=C(C=C2)[125I])C(=N1)C3=CC=CC=C3Cl,,,,,,
9179,129180,"1-(1,2-Hydroquinone)-N-acetyltryptophan",CC(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C3=CC(=C(C=C3)O)O)C(=O)O.Cl,,,,,,
9180,129181,"(2S)-2-acetamido-3-[1-(3,4-dihydroxyphenyl)indol-3-yl]propanoic acid",CC(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C3=CC(=C(C=C3)O)O)C(=O)O,,,,,,
9181,129182,Duokvin,CC1=CC(NC2=C1C=C(C=C2)C(C)(C)C3=CC4=C(C=C3)NC(C=C4C)(C)C)(C)C,,,,,,
9182,129183,Hopantenic acid glucoside,CC(C)(CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@H](C(=O)NCCCC(=O)O)O,,,,,,
9183,129184,"[hydroxy-[[(2R,3S,5S)-3-hydroxy-5-[(5S)-5-methyl-2,4-dioxo-1,3-diazinan-1-yl]oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate",C[C@H]1CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
9184,129185,Anthrasteroid 1,CC1=C2CC[C@]3([C@H]([C@@H]2C[C@H]4C1=CC(=O)CC4)CC[C@@H]3O)C,,,,,,
9185,129186,Anthrasteroid 2,CC1=C2CC[C@]3([C@H]([C@@H]2C[C@H]4C1=CC(=O)CC4)CCC3=O)C,,,,,,
9186,129187,(5-Azido-2-nitrobenzoyl)spermine,C1=CC(=C(C=C1N=[N+]=[N-])C(=O)NCCCNCCCCNCCCN)[N+](=O)[O-],,,,,,
9187,129188,CID 129188,C1=CC(=C(C=C1N[N+]#N)C(=O)NCCCNCCCCNCCCN)[N+](=O)[O-],,,,,,
9188,129189,CID 129189,C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCCCCCCNC(=O)CCCCCN=C2C=CC(=N[N+]#N)C=C2N(O)[O-],,,,,,
9189,129190,"3-(1H-Indol-3-yl)-1,1,3-trimethyl-1,2,3,4-tetrahydro-cyclopent(b)indole",CC1(CC(C2=C1C3=CC=CC=C3N2)(C)C4=CNC5=CC=CC=C54)C,,,,,,
9190,129191,"5-(4-Methoxyphenyl)-N-[(2R)-5-pyridin-3-ylpentan-2-yl]deca-2,4-dienamide",CCCCCC(=CC=CC(=O)N[C@H](C)CCCC1=CN=CC=C1)C2=CC=C(C=C2)OC,,,,,,
9191,129192,"5,6-Dihydro-5,6-dihydroxythymidine 5'-(tetrahydrogen triphosphate)",CC1(C(N(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)O,,,,,,
9192,129193,"3-Chloro-5-hydroxy-2-methyl-6-decyl-1,4-benzoquinone",CCCCCCCCCCC1=C(C(=C(C(=O)C1=O)Cl)C)O,,,,,,
9193,129194,CID 129194,C1=C(N=C(S1)N)C(=C(O)O)N=O,,,,,,
9194,129195,"2-Amino-7-(bis(2-chloroethyl)amino)-1,2,3,4-tetrahydro-2-naphthoic acid",C1CC2=C(CC1C(=O)ON)C=C(C=C2)N(CCCl)CCCl,,,,,,
9195,129196,"Amino 5-[bis(2-chloroethyl)amino]-1,2,3,4-tetrahydronaphthalene-2-carboxylate",C1CC2=C(CC1C(=O)ON)C=CC=C2N(CCCl)CCCl,,,,,,
9196,129197,3-Iodopropyl-1-trifluoromethanesulfonate,C(COS(=O)(=O)C(F)(F)F)CI,,,,,,
9197,129198,3-N-(2-Fluoroethyl)spiperone,C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCF)CCCC(=O)C4=CC=C(C=C4)F,,,"['Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']",,,
9198,129199,N-(3-Fluoropropyl)spiroperidol,C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCCF)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
9199,129200,1-Dodecanoyl-sn-glycero-3-phosphoethanolamine,CCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)O,,,,,,
9200,129201,CID 129201,CCC(=NN=C(N)N)C(=NN=C(N)N)C.OS(=O)(=O)O,,,,,,
9201,129202,Ethylmethyl-glyoxal bis(amidinohydrazone),CCC(=NN=C(N)N)C(=NN=C(N)N)C,,,,,,
9202,129203,Sdmdd,CC1(CCC2C(=C1)C(CC3C2(CCCC3(C)CO)C)O)C=C,,,,,,
9203,129204,4-Hydroxybenzoylglycylarginine,C1=CC(=CC=C1C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)O,,,,,,
9204,129205,4-Hydroxybenzoylglycyllysine,C1=CC(=CC=C1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)O,,,,,,
9205,129206,Imphilline,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)NNC(C(Cl)(Cl)Cl)O,,,,,,
9206,129207,N-Desisopropyl Pentisomide,CC(C)CC(CCNC(C)C)(C1=CC=CC=N1)C(=O)N,,,,,,
9207,129208,CID 129208,C1=CN(C(=CC1=O)O)O,,,,,,
9208,129209,"2-Amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl)propionamide",CC1=C(C(=CC=C1)C)N(CCCC2=CN=CC=C2)C(=O)C(C)N.Cl.Cl,,,,,,
9209,129210,"2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide",CC1=C(C(=CC=C1)C)N(CCCC2=CN=CC=C2)C(=O)C(C)N,,,,,,
9210,129211,Tamsulosin,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,"['Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.  Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.']","['Tamsulosin is an alpha adrenoceptor blocker with specificity for the alpha-1A and alpha-1D subtypes, which are more common in the prostate and submaxillary tissue. The final subtype, alpha-1B, are most common in the aorta and spleen. Tamsulosin binds to alpha-1A receptors 3.9-38 times more selectively than alpha-1B and 3-20 times more selectively than alpha-1D. This selectivity allows for a significant effect on urinary flow with a reduced incidence of adverse reactions like orthostatic hypotension.']","['Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)', 'Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)']","['Oral tamsulosin is 90% absorbed in fasted patients. The area under the curve is 151-199ng/mL\\*hr for a 0.4mg oral dose and 440-557ng/mL*hr for a 0.8mg oral dose. The maximum plasma concentration is 3.1-5.3ng/mL for a 0.4mg oral dose and 2.5-3.6ng/mL for a 0.8mg oral dose. Taking tamsulosin with food increases the time to maximum concentration from 4-5 hours to 6-7 hours but increases bioavailability by 30% and maximum plasma concentration by 40-70%.', '97% of an orally administered does is recovered in studies, which 76% in the urine and 21% in the feces after 168 hours. 8.7% of the dose is excreted as unmetabolized tamsulosin.', '16L after intravenous administration.', '2.88L/h.', 'In patients with moderate hepatic impairment, protein binding is altered, resulting in changes in overall plasma concentrations; however, no substantial alterations in intrinsic clearance and concentrations of unbound drug.', 'In patients with renal impairment, protein binding is altered, resulting in changes in overall plasma concentrations, however, no substantial alterations in intrinsic clearance and concentrations of unbound drug.', 'Absorption of tamsulosin hydrochloride ... is essentially complete (>90%) following oral administration under fasting conditions. Tamsulosin hydrochloride exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-a-day dosing.', 'Essentially completely absorbed following oral administration under fasting conditions; peak plasma concentrations attained within 4-5 hours.', 'For more Absorption, Distribution and Excretion (Complete) data for Tamsulosin (14 total), please visit the HSDB record page.']","['Tamsulosin is mostly metabolized in the liver by cytochrome P450 (CYP) 3A4 and 2D6, with some metabolism by other CYPs. CYP3A4 can deacetylate tamsulosin to the M-1 metabolite or perform oxidative deamination to the AM-1 metabolite. CYP2D6 can hydroxylate tamsulosin to the M-3 metabolite or demethylate tamsulosin to the M-4 metabolite. Finally, an unknown enzyme can hydroxylate tamsulosin at a different position to form the M-2 metabolite. The M-1, M-2, M-3, and M-4 metabolites can be glucuronidated or the M-1 and M-3 metabolites can undergo sulfate conjugation to form other metabolites before excretion.', 'Extensively metabolized by CYP enzymes (specific isoenzyme[s] not identified) in the liver. Metabolites undergo further conjugation prior to excretion.', 'There is no enantiomeric bioconversion from tamsulosin hydrochloride [R(-) isomer] to the S(+) isomer in humans. Tamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been established. In vitro results indicate that CYP3A4 and CYP2D6 are involved in metabolism of tamsulosin as well as some minor participation of other CYP isoenzymes. Inhibition of hepatic drug metabolizing enzymes may lead to increased exposure to tamsulosin. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.', '... After a single oral administration of 14C-tamsulosin at a dose of 0.2 mg /to/ four healthy male subjects... unchanged tamsulosin (TMS) and 11 metabolites in 0-24-hr urine samples were quantified. TMS accounted for 8.7% of the dose. Extensive excretion of the sulphate of the O-deethylated metabolite (M-1-Sul) and o-ethoxyphenoxy acetic acid (AM-1) was seen, accounting for 15.7 and 7.5% of the dose respectively.', 'The metabolism of tamsulosin hydrochloride (TMS), a potent alpha 1-adrenoceptor blocking agent, was studied after a single oral administration to rat and dog. Eleven metabolites (1, 2, 3, 4 and their glucuronides, sulphates of 1 and 3, and A-1) were identified from the urine and bile of rat and dog administered TMS. Unchanged drug and metabolites in urine and bile were quantified in rat and dog dosed with 14C-TMS(1 mg/kg). In rat the main metabolic routes were de-ethylation of the o-ethoxyphenoxy moiety, demethylation of the methoxybenzenesulphonamide moiety, and conjugation of the resultant metabolites by glucuronic acid and sulphuric acid. In dog the main pathways were de-ethylation of the ethoxyphenoxy moiety, conjugation of the de-ethylated product by sulphuric acid, and oxidative deamination of the side chain. The organ responsible for the metabolism of TMS in rat was estimated using 9000g supernatants of liver, kidney, small and large intestine homogenate and plasma. The drug was rapidly metabolized in liver but hardly metabolized in the other organs or plasma.', 'For more Metabolism/Metabolites (Complete) data for Tamsulosin (6 total), please visit the HSDB record page.', 'Tamsulosin has known human metabolites that include 5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-hydroxybenzenesulfonamide, 5-[2-[2-(2-ethoxy-5-hydroxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide, and 5-[2-[2-(2-hydroxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide.']","['The half life in fasted patients is 14.93.9 hours. The elimination half life is 5-7 hours and the apparent half life is 9 to 13 hours in healthy subjects. In patients who require tamsulosin, the apparent half life is 14-15 hours.', 'Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma range from five to seven hours.', 'Because of absorption rate-controlled pharmacokinetics of tamsulosin capsules, apparent half-life is about 9-13 hours in healthy individuals and 14-15 hours in patients with benign prostatic hyperplasia.', 'The pharmacokinetics of tamsulosin hydrochloride was investigated after single iv and oral dosing to rats and dogs, and oral dosing to healthy male volunteers. After iv dosing, plasma tamsulosin concentrations declined in an apparent biexponential manner with terminal half-lives of 0.32 hr in rats and 1.13 hr in dogs. ...']"
9211,129212,"3,9-dimethyl-6-methylimino-7H-purin-8-one",CN=C1C2=C(N(C=N1)C)N(C(=O)N2)C,,,,,,
9212,129213,Benzyl edta,C1=CC=C(C=C1)CC(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
9213,129214,CID 129214,C([C@H]([C@H]([C@@H]([C@H](CN)O)O)O)O)[C@@H](C(=O)O)O,,,,,,
9214,129215,"1-(1,3-Benzodioxol-5-yl)-4,4-dimethylpentan-3-ol",CC(C)(C)C(CCC1=CC2=C(C=C1)OCO2)O,,,,,,
9215,129216,1-(Ethoxycarbonyloxymethyl)-5-fluorouracil,CCOC(=O)OCN1C=C(C(=O)NC1=O)F,,,,,,
9216,129217,"2,2',3,4,4',6,6'-Heptachlorodiphenyl ether",C1=C(C=C(C(=C1Cl)OC2=C(C(=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
9217,129218,6-Fluoro-1-(2-fluoroethyl)-4-oxo-7-pyrrol-1-ylquinoline-3-carboxylic acid,C1=CN(C=C1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)CCF)F,,,,,,
9218,129219,CID 129219,CN(C)CCNC(=O)C1=C2C(=NC3=C(N2)C=C(C(=C3)OC)C(=O)OC)C4=CC=CC=C4C1=O,,,,,,
9219,129220,1-Docosanoyl-2-dodecanoyl-sn-glycero-3-phosphocholine,CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC,,,,,,
9220,129221,2-[[(2R)-3-docosanoyloxy-2-dodecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC,,,,,,
9221,129222,"2-Butenoic acid,(6-oxo-1-cyclohexen-1-yl)methyl ester",CC=CC(=O)OCC1=CCCCC1=O,,,,,,
9222,129223,4'-Methyl-7-(2-hydroxy-3-isopropylaminopropoxy)flavone hydrochloride,CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)OCC(CNC(C)C)O.Cl,,,,,,
9223,129224,4'-Methyl-7-[2-hydroxy-3-(isopropylamino)propoxy]flavone,CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)OCC(CNC(C)C)O,,,,,,
9224,129225,4-Hydroxymephentermine,CC(C)(CC1=CC=C(C=C1)O)NC,,,,,,
9225,129226,"Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxobutoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide",CCCC(=O)O[C@H]1[C@H](CC2[C@@]1(CCC3C2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C.[Br-],,,,,,
9226,129227,CID 129227,CCCC(=O)O[C@H]1[C@H](CC2[C@@]1(CCC3C2CCC4[C@@]3(C[C@@H]([C@H](C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C,,,,,,
9227,129228,Rufinamide,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,['Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.'],['At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate.'],"['A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']","['The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses);  Tmax, fed and fasted states= 4-6 hours;  Cmax, 10 mg/kg/day= 4.01 L/mL;  Cmax, 30mg/kg/day= 8.68 L/mL; AUC (0h-12h), 10mg/kg/day= 37.847 gh/mL;  AUC (0h-12h), 30mg/kg/day= 89.359 gh/mL.', 'Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated.', 'Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear.']","['Rufinamide is extensively metabolized but has no active metabolites. Metabolism by carboxyesterases into inactive metabolite CGP 47292, a carboxylic acid derivative, via hydrolysis is the primary biotransformation pathway. A few minor additional metabolites were detected in urine, which appeared to be acyl-glucuronides of CGP 47292. The cytochrome P450 enzyme system or glutathiones are not involved with the metabolism of rufinamide. Rufinamide is a weak inhibitor of CYP 2E1. Rufinamide is a weak inducer of CYP 3A4 enzymes.']","['Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.']"
9228,129229,CID 129229,CC1=C2C(=CC=C1)C(=O)N(C2=O)CCC(=NNC(=O)N)C,,,,,,
9229,129230,CID 129230,CCCCC[C@@H](C#C[C@@H]1[C@H](C[C@@H]2[C@H]1CC(=CCCCC(=O)O)C2)O)F,,,,,,
9230,129231,"(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[2-(oxiran-2-yl)ethoxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C1C(O1)CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
9231,129232,N-Hydroxy-N-methyl-4-benzyloxyphenylacetamide,CN(C(=O)CC1=CC=C(C=C1)OCC2=CC=CC=C2)O,,,,,,
9232,129233,CID 129233,CN(C)CCNC(=O)C1=C2C(=NC3=C(N2)C=C(C(=C3)OC)C(=O)[O-])C4=CC=CC=C4C1=O.[Na+],,,,,,
9233,129234,CID 129234,CN(C)CCNC(=O)C1=C2C(=NC3=C(N2)C=C(C(=C3)OC)C(=O)O)C4=CC=CC=C4C1=O,,,,,,
9234,129235,Ribavirin 5'-sulfamate,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COS(=O)(=O)N)O)O)C(=O)N,,,,,,
9235,129236,N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide,C1=CC(=C2C=CN=CC2=C1S(=O)(=O)NCCN)Cl,,,,,,
9236,129237,"2-Aziridinyl-5-hydroxy-1,4-naphthoquinone",C1CN1C2=CC(=O)C3=C(C2=O)C=CC=C3O,,,,,,
9237,129238,N-Desmethylidaverine,CCN(CCCC(=O)N1CCC(CC1)C(=O)NC)C(C)CC2=CC=C(C=C2)OC,,,,,,
9238,129239,"2,3,4-Trimethoxy-4'-carbomethoxy-1,1'-biphenyl",COC1=C(C(=C(C=C1)C2=CC=C(C=C2)C(=O)OC)OC)OC,,,,,,
9239,129240,"(3-heptyl-5-hydroxyphenyl) 2-[(2S,3R,4R)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-heptyl-4-hydroxybenzoate",CCCCCCCC1=CC(=CC(=C1)OC(=O)C2=C(C=C(C=C2O[C@H]3[C@@H]([C@H](C(O3)[C@@H](CO)O)O)O)O)CCCCCCC)O,,,,,,
9240,129241,"7-Phenyl-8-oxa-1-azabicyclo[5.2.1]decane-9,10-dione",C1CCC2(C(=O)N(CC1)C(=O)O2)C3=CC=CC=C3,,,,,,
9241,129242,"4-[2-[(2S,3R,4R)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-heptyl-4-hydroxybenzoyl]oxy-2-heptyl-6-hydroxybenzoic acid",CCCCCCCC1=C(C(=CC(=C1)O)O[C@H]2[C@@H]([C@H](C(O2)[C@@H](CO)O)O)O)C(=O)OC3=CC(=C(C(=C3)O)C(=O)O)CCCCCCC,,,,,,
9242,129243,3-Hydroxy-7-octenoic acid,C=CCCCC(CC(=O)O)O,,,,,,
9243,129244,"8-Chloro-5-(4-iodophenyl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol",CN1CCC2=CC(=C(C=C2C(C1)C3=CC=C(C=C3)I)O)Cl,,,,,,
9244,129245,CID 129245,C1CN(CCCN(CCCN(C1)C(P(=O)([O-])[O-])P(=O)([O-])[O-])C(P(=O)([O-])[O-])P(=O)([O-])[O-])C(P(=O)([O-])[O-])P(=O)([O-])[O-].[Gd+3].[Gd+3].[Gd+3].[Gd+3],,,,,,
9245,129246,"[[5,9-Bis(diphosphonomethyl)-1,5,9-triazacyclododec-1-yl]-phosphonomethyl]phosphonic acid",C1CN(CCCN(CCCN(C1)C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O,,,,,,
9246,129247,"5-(N-(3-Ethylsulfonyl-2-(1-naphthylmethyl)propionyl)norleucyl)amino-5-cyclohexyl-1-morpholino-2,3-pentanediol",CCCC[C@@H](C(=O)NC(CC(C(CN1CCOCC1)O)O)C2CCCCC2)NC(=O)C(CC3=CC=CC4=CC=CC=C43)CS(=O)(=O)CC,,,,,,
9247,129248,"8-(3-Azidophenylmethoxy)-1,2,3-trimethylimidazol(1,2-a)pyridinium",CC1=C([N+](=C2N1C=CC=C2OCC3=CC(=CC=C3)N=[N+]=[N-])C)C,,,,,,
9248,129249,"[(2S)-1-[[1-[[(3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl] morpholine-4-carboxylate",CC(C)C[C@@H]([C@@H](C(CC1CCCCC1)NC(=O)C(CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)OC(=O)N3CCOCC3)O)O,,,,,,
9249,129250,5-Ethoxy-2-ethylmercaptobenzimidazole,CCOC1=CC2=C(C=C1)N=C(N2)SCC,,,,,,
9250,129251,CID 129251,[Li+].CCCCCC=CCC(C1=CC=C(C=C1)C=CC(CCCC(=O)[O-])O)O,,,,,,
9251,129252,5-Hydroxy-7-[4-(1-hydroxynon-3-enyl)phenyl]hept-6-enoic acid,CCCCCC=CCC(C1=CC=C(C=C1)C=CC(CCCC(=O)O)O)O,,,,,,
9252,129253,tert-Butoxycarbonyl-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartic acid phenethylamide,CCCC[C@@H](C(=O)NCC(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N(CCC3=CC=CC=C3)[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)OC(C)(C)C,,,,,,
9253,129254,CID 129254,CCC=CC=CC=CC=CC=COC[C@@H](COC(=O)C)OC(=O)C,,,,,,
9254,129255,N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl-L-phenylalaninamide,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)C(CC(C)C)CC(=O)NO,,,,,,
9255,129256,Nikkomycin pseudo-J,C[C@H]([C@@H](C1=NC=C(C=C1)O)O)[C@@H](C(=O)N[C@@H](C2C(C(C(O2)C3=CNC(=O)NC3=O)O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N,,,,,,
9256,129257,CID 129257,C[C@]12CCCC(=CC=C3C[C@H](C[C@@H](C3=C)O)O)[C@@H]1CCC2OCCCC(C)(C)O,,,,,,
9257,129258,Pre-kinamycin,CC1=CC2=C(C(=C1)O)C3=C(N2C#N)C(=O)C4=C(C3=O)C=CC=C4O,,,,,,
9258,129259,"[(1S,2R,3R,4R)-5-cyano-1,2,3,7-tetrahydroxy-3-methyl-6,11-dioxo-2,4-dihydro-1H-benzo[h]carbazol-4-yl] acetate",CC(=O)O[C@@H]1C2=C([C@@H]([C@H]([C@@]1(C)O)O)O)C3=C(N2C#N)C(=O)C4=C(C3=O)C=CC=C4O,,,,,,
9259,129260,"1-(3-(4-Hydroxyphenyl)-1-oxopropoxy)-2,5-dioxo-3-pyrrolidinesulfonic acid",C1C(C(=O)N(C1=O)OC(=O)CCC2=CC=C(C=C2)O)S(=O)(=O)O,,,,,,
9260,129261,"N-hydroxy-N-[3-(5,6,7,8-tetrahydronaphthalen-2-yl)prop-2-enyl]acetamide",CC(=O)N(CC=CC1=CC2=C(CCCC2)C=C1)O,,,,,,
9261,129262,((5-(2-(((4-Chlorophenyl)sulfonyl)amino)ethyl)-2-thienyl)oxy)acetic acid,C1=CC(=CC=C1S(=O)(=O)NCCC2=CC=C(S2)OCC(=O)O)Cl,,,,,,
9262,129263,N-(tert-Butylcarbonylglycylaminoethyl)-N-(ethyl)ammonium tetraphenylborate,[B-](C1=CC=CC=C1)(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.CC[NH2+]CCN(C(=O)CN)C(=O)C(C)(C)C,,,,,,
9263,129264,"N-(2-aminoacetyl)-N-[2-(ethylamino)ethyl]-2,2-dimethylpropanamide",CCNCCN(C(=O)CN)C(=O)C(C)(C)C,,,,,,
9264,129265,N-(4-Benzyloxybenzyl)acetohydroxamic acid,CC(=O)N(CC1=CC=C(C=C1)OCC2=CC=CC=C2)O,,,,,,
9265,129266,CID 129266,CCC(=O)N(C(=O)CNC(=O)[C@H](C)N)C(=O)OC(C)(C)C,,,,,,
9266,129267,CID 129267,C1[C@H]([C@@H]([C@H](C1=O)CCC=CCCC(=O)OC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3)OCC(COC4=CC=CC=C4)O)O,,,,,,
9267,129268,"1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine",CN1CCC(=CC1)C2CCCCC2,,,,,,
9268,129269,"1,2-Heptadecanoylphosphatidylcholine",CCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCC,,,,,,
9269,129270,"2-[2,3-Di(heptadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCC,,,,,,
9270,129271,CID 129271,CCCCC[C@@H](C=C[C@H]1[C@@H]2C[C@H]([C@@H]1CC=CCCCC(=O)O)N=N2)O,,,,,,
9271,129272,Deacetyl Ketoconazole,C1CN(CCN1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,,,,,,
9272,129273,"5,7-Dihydroxy-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline",COC1=CC(=CC(=C1OC)OC)CC2C3=C(CCN2)C(=CC(=C3)O)O,,,,,,
9273,129274,2-Hydroxycarbamazepine,C1=CC=C2C(=C1)C=CC3=C(N2C(=O)N)C=CC(=C3)O,,,,,['2-Hydroxycarbamazepine is a known human metabolite of carbamazepine.'],
9274,129275,N(1)-Benzyloxycarbonyl-N(8)-butoxycarbonylspermidine,CC(C)(C)OC(=O)NCCCCNCCCNC(=O)OCC1=CC=CC=C1,,,,,,
9275,129276,Nitrosomethylundecylamine,CCCCCCCCCCCN(C)N=O,,,,,,
9276,129277,CID 129277,CCCCCC(=O)C(CCCC)C1=C(C(=O)C(=C(O1)O)CCCC)CCCC,,,,,,
9277,129278,"3,5-Dichlorothioanisole",CSC1=CC(=CC(=C1)Cl)Cl,,,,,,
9278,129279,"N,N-Dimethyl-N',N'-dibenzylethylenediamine",CN(C)CCN(CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
9279,129280,"(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[3-hydroxy-2-[(1S,6S)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenoxy]oxane-2-carboxylic acid",CCCCCC1=CC(=C(C(=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O)[C@H]3C=C(CC[C@@H]3C(=C)C)C)O,,,,,,
9280,129281,tert-Butyloxycarbonyl-aminooxyacetyl-tryptophyl-methionyl-aspartyl-phenylalaninamide,CC(C)(C)OC(=O)NOCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N,,,,,,
9281,129282,4-Methacryloxyethyltrimellitic acid,CC(=C)C(=O)OCCOC(=O)C1=CC(=C(C=C1)C(=O)O)C(=O)O,,,,,,
9282,129283,3-Nitro-2-pyridinesulfenyl chloride,C1=CC(=C(N=C1)SCl)[N+](=O)[O-],,,,,,
9283,129284,"1,5-Pentanediamine, N-(6-methoxy-4-methyl-8-quinolinyl)-",CC1=C2C=C(C=C(C2=NC=C1)NCCCCCN)OC,,,,,,
9284,129285,Isovalerylalanine,C[C@@H](C(=O)O)NC(=O)CC(C)C,,,,,,
9285,129286,Butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide,CC(C)C[C@@H](C(=O)NCC(=O)NC(=O)[C@H](CCCN=C(N)N)NC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)OC(C)(C)C,,,,,,
9286,129287,2-(Indol-3-ylmethyl)indol-3-ylacetic acid,C1=CC=C2C(=C1)C(=CN2)CC3=C(C4=CC=CC=C4N3)CC(=O)O,,,,,,
9287,129288,CID 129288,C[C@]12CC[C@H]3[C@H]([C@H]1C(=C)C[C@@H]2O)CCC4=C3C=CC(=C4)OC,,,,,,
9288,129289,"6-Chloro-5-(cyclopentylmethyl)-2,3-dihydro-1H-indene-1-carboxylic acid",C1CCC(C1)CC2=C(C=C3C(CCC3=C2)C(=O)O)Cl,,,,,,
9289,129290,Planinin,COC1=C(C=C(C=C1)[C@@H]2[C@@H]3CO[C@H]([C@@H]3CO2)C4=CC5=C(C=C4)OCO5)OC,,,,,,
9290,129291,CID 129291,CCC=CC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC(=O)CCCCC(=O)O)O)O)O,,,,,,
9291,129292,CID 129292,COC1=CC2=C(C=C1)OC3=CC(=CC(=O)C3=C2O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
9292,129293,"2,5-Dipropyldecahydroquinoline",CCC[C@@H]1CCC[C@@H]2[C@H]1CC[C@@H](N2)CCC,,,,,,
9293,129294,3-Carboxymethylthiolactic acid,C(C(C(=O)O)O)SCC(=O)O,,,,,,
9294,129295,Entamizole,CC1=NC=C(N1CCO)[N+](=O)[O-].CN(C1=CC=C(C=C1)O)C(=O)C(Cl)Cl,,,,,,
9295,129296,Mollicellin G,CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=C(C(=C3)O)CC=C(C)C)C)C=O)O,,,,,,
9296,129297,Glutamate-1-semialdehyde,C(CC(=O)O)[C@@H](C=O)N,,,,,,
9297,129298,5-((4-Azidophenacyl)thio)uridine 5'-triphosphate,C1=CC(=CC=C1C(=O)CSC2=CN(C(=O)NC2=O)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=[N+]=[N-],,,,,,
9298,129299,CID 129299,C1=CC(=CC=C1C(=O)CSC2=CN(C(=O)NC2=O)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N[N+]#N,,,,,,
9299,129300,7-Ethenyloxycoumarin,C=COC1=CC2=C(C=C1)C=CC(=O)O2,,,,,,
9300,129301,"7-Chloro-6-fluoro-1-ethyl-1,4-dihydro-4-oxopyrido(2,3-c)pyridazine-3-carboxylic acid",CCN1C2=NC(=C(C=C2C(=O)C(=N1)C(=O)O)F)Cl,,,,,,
9301,129302,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(sulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CS)C(=O)O,,,,,,
9302,129303,"[(1S,3S,4S)-1,2,4-triacetyloxy-5-cyano-7-hydroxy-3-methyl-6,11-dioxo-2,3-dihydro-1H-benzo[h]carbazol-4-yl] 2-methylpropanoate",C[C@H]1C([C@H](C2=C([C@@]1(OC(=O)C)OC(=O)C(C)C)N(C3=C2C(=O)C4=C(C3=O)C(=CC=C4)O)C#N)OC(=O)C)OC(=O)C,,,,,,
9303,129304,4-Deacetyl-4-O-isobutyrylkinamycin C,CC(C)C(=O)O[C@@H]1C2=C([C@@H](C([C@@]1(C)O)OC(=O)C)OC(=O)C)C3=C(N2C#N)C(=O)C4=C(C3=O)C=CC=C4O,,,,,,
9304,129305,"(5S,12S)-5,12-Dihydroxyicosa-6,8,14-trienoic acid",CCCCCC=CC[C@H](CCC=CC=C[C@H](CCCC(=O)O)O)O,,,,,,
9305,129306,"Quinolinium, 1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-, bromide",CCCCCCCCCCCCCCCCCC1(OCC(O1)COC(=O)CCCCC[N+]2=CC=CC3=CC=CC=C32)C.[Br-],,,,,,
9306,129307,"1-[6-[(2-Heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium",CCCCCCCCCCCCCCCCCC1(OCC(O1)COC(=O)CCCCC[N+]2=CC=CC3=CC=CC=C32)C,,,,,,
9307,129308,1-Methyl-4-(4'-acetamidophenyl)pyridinium,CC(=O)NC1=CC=C(C=C1)C2=CC=[N+](C=C2)C,,,,,,
9308,129309,(Aminocarbonyl)phenylcarbamic acid 1-methylethyl ester,CC(C)OC(=O)N(C1=CC=CC=C1)C(=O)N,,,,,,
9309,129310,"(15S,16R,18S)-16-[(Dimethylamino)methyl]-16-hydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one",C[C@@]12[C@@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CN(C)C)O,,,,,,
9310,129311,CID 129311,CCCC(CCC)(CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O,,,,,,
9311,129312,"(15S,16S,18S)-16-Hydroxy-15-methyl-16-(methylaminomethyl)-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one",C[C@@]12[C@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CNC)O,,,,,,
9312,129313,"7-(Aminomethyl)-8-methyl-5,6,7,8-tetrahydro-13H-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacene-7,15-diol",C[C@@]12[C@@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CN)O,,,,,,
9313,129314,Cassigarol A,C1C(C2=CC(=C(C=C2C(C3=C1C=C(C=C3O)O)CC4=CC(=CC(=C4)O)O)O)O)C5=CC(=C(C=C5)O)O,,,['Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)'],,,
9314,129315,4-Cfmsa,C1=COC(=C1)CN.C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,,,,,,
9315,129316,"1-Piperidinepropanol, alpha-cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-",CC1CN(CCC1(C)C2=CC(=CC=C2)O)CCC(C3CCCCC3)O,,,,,,
9316,129317,(Hydroxy-2-naphthalenylmethyl)phosphonic acid,C1=CC=C2C=C(C=CC2=C1)C(O)P(=O)(O)O,,,,,,
9317,129318,"2-Cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enamide",CC(C)C1=CC(=CC(=C1O)C(C)C)C=C(C#N)C(=O)N,,,,,,
9318,129319,Dalcotidine,CCNC(=O)NCCCOC1=CC=CC(=C1)CN2CCCCC2,,,,,,
9319,129320,"7-[(2S,4S,5R)-4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid",C1[C@H]([C@H](O[C@H](O1)C(F)(F)F)C2=CC=CC=C2O)CC=CCCCC(=O)O,,,,,,
9320,129321,CID 129321,C1CCC(CC1)C(C=C[C@H]2[C@@H](C[C@@H]([C@@H]2CC=CCOCC(=O)O)Cl)O)O,,,,,,
9321,129322,Estatin B,C1=CC(=CC=C1CC(C(=O)NCCCCN=C(N)N)NC(=O)C2C(O2)C(=O)O)O,,,,,,
9322,129323,17-(Cyclopropylamino)androst-5-en-3-ol,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2NC4CC4)CC=C5[C@@]3(CCC(C5)O)C,,,,,,
9323,129324,"[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methanesulfonic acid",C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)COP(=O)(CS(=O)(=O)O)O)O)O)N,,,,,,
9324,129325,CID 129325,CCCCC(C)C[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCCCC(=O)OC)O)O,,,,,,
9325,129326,Eutypine,CC(=C)C#CC1=C(C=CC(=C1)C=O)O,,,,,,
9326,129327,Comeib,CN1CC2=C(N=CN2C3=CC=CC=C3C1=O)C4=NOC(=N4)C5CC5,,,,,,
9327,129328,"Ethyl 5-cyano-2-ethyl-1,6-dihydro-6-oxo-3-pyridinecarboxylate",CCC1=C(C=C(C(=O)N1)C#N)C(=O)OCC,,,,,,
9328,129329,CID 129329,CC(C)C[C@@H](C(=O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)N(C(CC2=CC=C(C=C2)O)C=O)C(=O)CC(C)C,,,,,,
9329,129330,3-[[1-[4-(Diaminomethylideneamino)butylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]oxirane-2-carboxylic acid,C1=CC=C(C=C1)CC(C(=O)NCCCCN=C(N)N)NC(=O)C2C(O2)C(=O)O,,,,,,
9330,129331,"2-(Diaminomethylideneamino)-3,4,5,14-tetrahydroxyicos-6-enoic acid",CCCCCCC(CCCCCCC=CC(C(C(C(C(=O)O)N=C(N)N)O)O)O)O,,,,,,
9331,129332,"(2S,3R,4R,5S,14R)-2-amino-3,4,5,14-tetrahydroxyicos-6-enoic acid",CCCCCC[C@H](CCCCCCC=C[C@@H]([C@H]([C@@H]([C@@H](C(=O)O)N)O)O)O)O,,,,,,
9332,129333,"1-Allyl-3,3-diethyl-5-methyl-2,4-piperidinedione",CCC1(C(=O)C(CN(C1=O)CC=C)C)CC,,,,,,
9333,129334,"2-Azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin",C1=C(C(=CC2=C1OC3=CC(=C(C=C3O2)Br)Br)I)N=[N+]=[N-],,,,,,
9334,129335,"5-Acetyloxy-2-amino-3,4,14-trihydroxyicos-6-enoic acid",CCCCCCC(CCCCCCC=CC(C(C(C(C(=O)O)N)O)O)OC(=O)C)O,,,,,,
9335,129336,"1H-Carbazole-1-acetic acid, 1,8-diethyl-2,3,4,9-tetrahydro-4-(2-propenyl)-, cis-",CCC1=C2C(=CC=C1)C3=C(N2)[C@@H](CC[C@@H]3CC=C)CC(=O)OCC,,,,,,
9336,129337,"2-Acetamido-3,4,5,14-tetrahydroxyicos-6-enoic acid",CCCCCCC(CCCCCCC=CC(C(C(C(C(=O)O)NC(=O)C)O)O)O)O,,,,,,
9337,129338,2'-Valeryl-6-methoxypurine arabinoside,CCCCC(=O)O[C@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=CN=C3OC)CO)O,,,,,,
9338,129339,"methyl 2-[2-[2-[[(2S)-6-amino-1-[[(2S)-2-[(2-aminoacetyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-1-oxohexan-2-yl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carboxylate",COC(=O)C1=CSC(=N1)C2=CSC(=N2)CCN[C@@H](CCCCN)C(=O)NC(=O)[C@H](CC3C=NC=N3)NC(=O)CN,,,,,,
9339,129340,4-(9-Acridinylamino)-N-(glycyl-histidyl-lysyl-glycyl)aniline,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)NCC(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC5C=NC=N5)NC(=O)CN,,,,,,
9340,129341,"1,3-Distearyl-2-octanoylglycerol",CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)O[13C](=O)CCCCCCC,,,,,,
9341,129342,"N,N-(Methyl-2-carboxyisopropyl)-4-fluoroaniline",CC(C)(C(=O)O)N(C)C1=CC=C(C=C1)F,,,,,,
9342,129343,"5,5-Diethyl-1-beta-D-glucopyranosylbarbituric acid",CCC1(C(=O)NC(=O)N(C1=O)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC,,,,,,
9343,129344,"(+-)-1-(3,4-Dimethoxybenzyloxymethyl)-N,N-dimethyl-1-(2-thienyl)propylamine 2-(4-hydroxybenzoyl)benzoic acid",CCC(COCC1=CC(=C(C=C1)OC)OC)(C2=CC=CS2)N(C)C.C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)O)C(=O)O,,,,,,
9344,129345,"2-(Dimethylamino)-2-(2-thienyl)butyl 3,4-dimethoxybenzyl ether",CCC(COCC1=CC(=C(C=C1)OC)OC)(C2=CC=CS2)N(C)C,,,,,,
9345,129346,N-Methylaniline N-glucuronide,CN(C1=CC=CC=C1)OC2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O,,,,,,
9346,129347,[2-[[1-(3-Acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene)-2-[(1-hydroxy-3-oxobut-1-en-2-yl)amino]-2-oxoethyl]amino]-1-(2-methyloxiran-2-yl)-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate,CC1=C2C=C(C=C(C2=CC=C1)C(=O)OC(C(=O)NC(=C3C(C(C4N3C4)O)OC(=O)C)C(=O)NC(=CO)C(=O)C)C5(CO5)C)OC,,,,,,
9347,129348,"(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile",CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)OC3=CC(=O)CC3)O)C,,,,,,
9348,129349,CID 129349,CC1=C2C=C(C=C(C2=CC=C1)C(=O)O[C@H](C(=O)NC(=C3[C@H]([C@@H]([C@H]4N3C4)O)OC(=O)C)C(=O)NCC(=O)C)[C@@]5(CO5)C)OC,,,,,,
9349,129350,"N(2),3-Ethenodeoxyguanosine",C1[C@@H]([C@H](OC1N2C=NC3=C2N4C=CN=C4NC3=O)CO)O,,,,,,
9350,129351,"10-Amino-1,4,7,8,9,10-hexahydro-6-methylbenzo(f)quinolin-3(2H)-one",CC1=CC2=C(CCC(=O)N2)C3=C1CCCC3N,,,,,,
9351,129352,5-(3-(2-Nitro-1H-imidazol-1-yl)propyl)-phenanthridinium bromide,C1=CC=C2C(=C1)C=[N+](C3=CC=CC=C23)CCCN4C=CN=C4[N+](=O)[O-].[Br-],,,,,,
9352,129353,5-[3-(2-Nitroimidazol-1-yl)propyl]phenanthridin-5-ium,C1=CC=C2C(=C1)C=[N+](C3=CC=CC=C23)CCCN4C=CN=C4[N+](=O)[O-],,,,,,
9353,129354,"1,3-Dipalmitoyl-2-(4-aminobutyryl)glycerol",CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCN.Cl,,,,,,
9354,129355,[2-(4-Aminobutanoyloxy)-3-hexadecanoyloxypropyl] hexadecanoate,CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCN,,,,,,
9355,129356,"(3R)-alpha,alpha,6beta-Trimethyl-6-(p-tolyl)-1,2-dioxane-3beta-methanol",CC1=CC=C(C=C1)[C@]2(CC[C@@H](OO2)C(C)(C)O)C,,,,,,
9356,129357,"2-Methyl-6-(4-methylcyclohex-3-en-1-yl)hept-4-ene-2,3,6-triol",CC1=CCC(CC1)C(C)(C=CC(C(C)(C)O)O)O,,,,,,
9357,129358,"Methyl 2-(1-hydroxy-3,4-dihydronaphthalen-2-yl)-2-oxoacetate",COC(=O)C(=O)C1=C(C2=CC=CC=C2CC1)O,,,,,,
9358,129359,"2(1H)-Pyrazinone, 6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-, 4-oxide",CC(C)CC1=[N+](C(=C(NC1=O)CC2=CNC3=CC=CC=C32)OC)[O-],,,,,,
9359,129360,"2-[6,8-Difluoro-9-[(4-methylsulfonylphenyl)methyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid",CS(=O)(=O)C1=CC=C(C=C1)CN2C3=C(CCCC3CC(=O)O)C4=C2C(=CC(=C4)F)F,,,,,,
9360,129361,Fercoperol,CC1(CCC(O1)C2(CCC(OO2)C(C)(C)O)C)C=C,,,,,,
9361,129362,Sigmoidin D,CC1([C@H](CC2=C(O1)C(=CC(=C2)[C@@H]3CC(=O)C4=C(C=C(C=C4O3)O)O)O)O)C,,,,,,
9362,129363,Seryl-prolyl-lysyl-lysine,C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O,,,,,,
9363,129364,3-(4-(2-((Methoxycarbonyl)oxy)-3-((octadecylcarbamoyl)oxy)propoxy)butyl)thiazolium,CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@H](COCCCC[N+]1=CSC=C1)OC(=O)OC.[I-],,,,,,
9364,129365,3-[4-[(R)-2-[(Methoxycarbonyl)oxy]-3-[[(octadecylamino)carbonyl]oxy]propoxy]butyl]thiazol-3-ium,CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@H](COCCCC[N+]1=CSC=C1)OC(=O)OC,,,,,,
9365,129366,CID 129366,CCCCCC(CCCCCC=C(C=CC=CC(=O)O)O)O,,,,,,
9366,129367,7-Amino-4-methylcoumarin-3-acetic acid,CC1=C(C(=O)OC2=C1C=CC(=C2)N)CC(=O)O,,,,,,
9367,129368,CID 129368,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CC3=C(C=C2)NC=NC3=O,,,,,,
9368,129369,9-Oxo-10-acridineacetohydroxamic acid,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3N2CC(=O)NO,,,,,,
9369,129370,N-(2-(1-Methoxymethyl)-2-(2-propoxyphenylcarbamoyloxy)ethyl)pyrrolidinium oxalate,CCCOC1=CC=CC=C1NC(=O)OC(CN2CCCC2)COC,,,,,,
9370,129371,"(3S,8R,9S,10R,13R,14S)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,7,8,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@H](CCC=C(C)C)C1CC[C@@]2([C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
9371,129372,CID 129372,CC1(C=CC2=C3C(=C(C4=C(N3C)C=CC(=C4)[N+](=O)[O-])O)C(=O)C=C2O1)C,,,,,,
9372,129373,CID 129373,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CN=CN2)N,,,,,,
9373,129374,Pentyldnm,CCCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O,,,,,,
9374,129375,Phthalyl-allysine-4-nitrobenzyl ester,C1=CC=C2C(=C1)C(=O)N(C2=O)[C@@H](CCCC=O)C(=O)OCC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
9375,129376,"1-Piperazineethanol, 4-(diphenylmethyl)-alpha-(2-((2-methyl-1H-indol-4-yl)oxy)ethyl)-",CC1=CC2=C(N1)C=CC=C2OCCC(CN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)O,,,,,,
9376,129377,Halonal,CCC1(C(=O)NC(=O)N(C1=O)C(=O)C2=CC=CC=C2F)C3=CC=CC=C3,,,,,,
9377,129378,Dodecyl 2-(dimethylamino)acetate,CCCCCCCCCCCCOC(=O)CN(C)C,,,,,,
9378,129379,CID 129379,CCC1=CC(=CC(=C1NC2=NCC[N-]2)CC)N[N+]#N,,,,,,
9379,129380,CID 129380,CCC1=CC(=CC(=C1NC2=NCCN2)CC)N[N+]#N,,,,,,
9380,129381,1-Nitroso-1-(2-chloroethyl)-3-(2-hydroxypropyl)urea,CC(CNC(=O)N(CCCl)N=O)O,,,,,,
9381,129382,CID 129382,C1CN(CCN(CCN1C(P(=O)([O-])[O-])P(=O)([O-])[O-])C(P(=O)([O-])[O-])P(=O)([O-])[O-])C(P(=O)([O-])[O-])P(=O)([O-])[O-].[Gd+3].[Gd+3].[Gd+3].[Gd+3],,,,,,
9382,129383,"[[4,7-Bis(diphosphonomethyl)-1,4,7-triazonan-1-yl]-phosphonomethyl]phosphonic acid",C1CN(CCN(CCN1C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O,,,,,,
9383,129384,N-(2-(Dimethylamino)ethyl)-5-methyl-4-acridinecarboxamide,CC1=C2C(=CC=C1)C=C3C=CC=C(C3=N2)C(=O)NCCN(C)C,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
9384,129385,4-Amino-4-methyl-2-pentyne-1-al,CC(C)(C#CC=O)N,,,,,,
9385,129386,Aminobutyryl-threonyl-asparaginyl-tyrosyl-threonine,CCC(C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N,,,,,,
9386,129387,Ebselen diselenide,C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2[Se][Se]C3=CC=CC=C3C(=O)NC4=CC=CC=C4,,,,,,
9387,129388,pyroGlu-Glu-Asp-Ser-GlyOH,C1CC(=O)N[C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)O,,,,,,
9388,129389,"3-(2-Hydroxyethylamino)methyl-1,8-dihydroxy-9,10-anthraquinone",C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CNCCO,,,,,,
9389,129390,"1-p-Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide",CCN(CC)CC(C)(C)C(=O)C=CC1=CC=C(C=C1)Cl.Br,,,,,,
9390,129391,"1-(4-Chlorophenyl)-5-(diethylamino)-4,4-dimethylpent-1-en-3-one",CCN(CC)CC(C)(C)C(=O)C=CC1=CC=C(C=C1)Cl,,,,,,
9391,129392,Dchaps,C[C@H](CCC(=O)NCCC[N+](C)(C)CCCS(=O)(=O)[O-])[C@@H]1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CCCC4)C)O)O)C,,,,,,
9392,129393,"3-[[(4R)-4-[(5S,7R,10S,12S,13R,17S)-7,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl-dimethyl-(3-sulfopropyl)azanium",C[C@H](CCC(=O)NCCC[N+](C)(C)CCCS(=O)(=O)O)[C@@H]1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CCCC4)C)O)O)C,,,,,,
9393,129394,"4,7-Dihydroxy-5-methoxy-6-methyl-8-formylflavan",CC1=C(C(=C2C(=C1OC)C(CC(O2)C3=CC=CC=C3)O)C=O)O,,,,,,
9394,129395,Tetracenomycin X,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)[C@@]4(C(=O)C=C([C@H]([C@@]4(C3=O)O)O)OC)OC)OC)C(=O)OC,,,,,,
9395,129396,CID 129396,CN(C)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Br)C3=CC=C(C=C3)O,,,,,,
9396,129397,N-(3-Acetamidopropyl)pyrrolidin-2-one,CC(=O)NCCCN1CCCC1=O,,,,,,
9397,129398,CID 129398,CCCCCCCCC=CCCCCCCCC(=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](C)NC(=O)[C@H](C)N,,,,,,
9398,129399,CID 129399,CCCCCCCCC=CCCCCCCCC(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N1CCC[C@H]1C(=O)NC(=O)[C@H](C(C)C)NCCC,,,,,,
9399,129400,K II Analgesic,CN([C@H]1CCCC[C@H]1N2CC=CC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl,,,,,,
9400,129401,8-Azido-2'-O-dansyladenosine triphosphate,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)O[C@@H]3[C@@H]([C@H](OC3N4C5=NC=NC(=C5N=C4N=[N+]=[N-])N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
9401,129402,"4-Thiazolecarboxamide, 2-methyl-N-(2-(nitrooxy)ethyl)-, monohydrochloride",CC1=NC(=CS1)C(=O)NCCO[N+](=O)[O-].Cl,,,,,,
9402,129403,"4-Thiazolecarboxamide, 2-methyl-N-[2-(nitrooxy)ethyl]-",CC1=NC(=CS1)C(=O)NCCO[N+](=O)[O-],,,,,,
9403,129404,Picropodophyllin-1-ethyl ether,CCO[C@@H]1[C@H]2COC(=O)[C@H]2[C@@H](C3=CC4=C(C=C13)OCO4)C5=CC(=C(C(=C5)OC)OC)OC,,,,,,
9404,129405,"2-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)amino-5-acetyl-4,6-dimethylpyrimidine",CC1=C(C(=NC(=N1)NCCN2CCN(CC2)C3=CC=CC=C3OC)C)C(=O)C.Cl.Cl.Cl,,,,,,
9405,129406,"1-(2-((2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)amino)-4,6-dimethyl-5-pyrimidinyl)ethanone",CC1=C(C(=NC(=N1)NCCN2CCN(CC2)C3=CC=CC=C3OC)C)C(=O)C,,,,,,
9406,129407,"ICI 204,448 hydrochloride",CN(C(CN1CCCC1)C2=CC(=CC=C2)OCC(=O)O)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl,,,,,,
9407,129408,CID 129408,C[C@@H](C(=O)CC(C(C(=O)N(C=C1CC(C(O1)N2C=CC(=O)NC2=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)O)N)N(C)C(=O)[C@H](CC5=CC(=CC=C5)O)NC(=O)[C@H](C)N)N,,,,,,
9408,129409,3-(N-Prolylamine)-2-oxo-1-pyrrolidineacetamide,C1C[C@H](NC1)C(=O)N[C@H]2CCN(C2=O)CC(=O)N,,,,,,
9409,129410,CID 129410,C[C@@H](C(=O)CC(C(C(=O)N(C=C1CC(C(O1)N2C=CC(=O)NC2=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)N)N(C)C(=O)[C@H](CC4=CC(=CC=C4)O)NC(=O)[C@H](C)N)N,,,,,,
9410,129411,CID 129411,C[C@@H](C(=O)CC(C(C(=O)N(C=C1CC(C(O1)N2C=CC(=O)NC2=O)O)C(=O)NC(CC3=CC(=CC=C3)O)C(=O)O)N)N(C)C(=O)[C@H](CC4=CC(=CC=C4)O)NC(=O)[C@H](C)N)N,,,,,,
9411,129412,2-n-Butyl-1-(4-carboxybenzyl)-4-chloroimidazole-5-acetic acid,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C(=O)[O-])CC(=O)[O-])Cl.[Na+].[Na+],,,,,,
9412,129413,2-Butyl-4-chloro-1-[4-carboxybenzyl]-1H-imidazole-5-acetic acid,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C(=O)O)CC(=O)O)Cl,,,,,,
9413,129414,Punctaporonin F,C[C@]12CC[C@@]3([C@@H]([C@]1([C@H](C=C2)O)CO)CC3(C)C)O,,,,,,
9414,129415,3-Acetamido-5-iodoproflavine,CC(=O)NC1=CC2=NC3=C(C=CC(=C3I)N)C=C2C=C1,,,,,,
9415,129416,Tetrabutyl squarate,CCCCN(CCCC)C1=CC(=C(C=C1)C2C(=O)C(C2=O)C3=C(C=C(C=C3)N(CCCC)CCCC)O)O,,,,,,
9416,129417,2-Carboxy-D-arabinitol 1-phosphate,C([C@H]([C@H]([C@](COP(=O)(O)O)(C(=O)O)O)O)O)O,,,,,,
9417,129418,"1,4-Bis(4-amidinophenoxy)butane",C1=CC(=CC=C1C(=N)N)OCCCCOC2=CC=C(C=C2)C(=N)N.Cl,,,,,,
9418,129419,Butamidine,C1=CC(=CC=C1C(=N)N)OCCCCOC2=CC=C(C=C2)C(=N)N,,,,,,
9419,129420,"1-[2-(1,3-Dioxolan-2-yl)ethyl]-4-(3-{1-[2-(1,3-dioxolan-2-yl)ethyl]quinolin-4(1H)-ylidene}prop-1-en-1-yl)quinolin-1-ium bromide",C1COC(O1)CCN2C=CC(=CC=CC3=CC=[N+](C4=CC=CC=C34)CCC5OCCO5)C6=CC=CC=C62.[Br-],,,,,,
9420,129421,"1-[2-(1,3-Dioxolan-2-yl)ethyl]-4-[3-[1-[2-(1,3-dioxolan-2-yl)ethyl]quinolin-4(1H)-ylidene]-1-propenyl]quinolinium",C1COC(O1)CCN2C=CC(=CC=CC3=CC=[N+](C4=CC=CC=C34)CCC5OCCO5)C6=CC=CC=C62,,,,,,
9421,129422,1-Amidino-3-(3-sulfamoylphenyl)urea,C1=CC(=CC(=C1)S(=O)(=O)N)NC(=O)N=C(N)N.Cl,,,,,,
9422,129423,1-(Diaminomethylidene)-3-(3-sulfamoylphenyl)urea,C1=CC(=CC(=C1)S(=O)(=O)N)NC(=O)N=C(N)N,,,,,,
9423,129424,N-(2-(Diethylamino)ethyl)-4-iodobenzamide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)I,,,,,,
9424,129425,"Allyl 2-O-(4-O-(3,6-di-O-methyl-beta-glucopyranosyl)-2,3-di-O-methyl-alpha-rhamnopyranosyl)-3-O-methyl-alpha-rhamnopyranoside",C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OCC=C)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC)O)OC)O)OC)OC)OC)O,,,,,,
9425,129426,"N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine",CC(C)C1=C(C2=CC=CC=C2N1C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC,,,,,,
9426,129427,2-Methoxy-3-phenylmethoxypropan-1-ol,COC(CO)COCC1=CC=CC=C1,,,,,,
9427,129428,CID 129428,CC=C(C)[C@@H]1[C@H]([C@H](C(C(=O)O1)(C)C)O)C,,,,,,
9428,129429,Panaxacol,CCCCCCC[C@H]([C@@H](CC#CC#CC(=O)CC)O)O,,,,,,
9429,129430,CID 129430,CC(C)(COP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSSC[C@@H](C(=O)O)NC(=O)CCC4=CC(=C(C=C4)N=[N+]=[N-])I)O,,,,,,
9430,129431,3-Benzyl-N-(methanesulfonyloxy)succinimide,CS(=O)(=O)ON1C(=O)CC(C1=O)CC2=CC=CC=C2,,,,,,
9431,129432,Histidyl-leucyl-aspartyl-isoleucyl-isoleucyl-tryptophan,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)N,,,,,,
9432,129433,Glutamyl-glycyl-valyl-tyrosyl-valyl-histidyl-prolyl-valine,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2C=NC=N2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N,,,,,,
9433,129434,Lactosyl isothiocyanate,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC([C@@H]([C@H]2O)O)N=C=S)CO)O)O)O)O,,,,,,
9434,129435,"2-[[(10S,11S,13S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-4-yl]sulfanyl]acetic acid",C[C@H]1CC2C3CCC4=C(C(=O)C=C[C@@]4(C3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)SCC(=O)O,,,,,,
9435,129436,1-Trimethylsilyl-1-propanol,CCC(O)[Si](C)(C)C,,,,,,
9436,129437,[1-Acetyloxy-4-[cyclohexyl(methyl)amino]naphthalen-2-yl] acetate,CC(=O)OC1=C(C2=CC=CC=C2C(=C1)N(C)C3CCCCC3)OC(=O)C,,,,,,
9437,129438,"1-(2,4-Dichlorophenyl)-2-phenylpropen-1-one",C=C(C1=CC=CC=C1)C(=O)C2=C(C=C(C=C2)Cl)Cl,,,,,,
9438,129439,Glycyl-alanyl-valine,C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)CN,,,,,,
9439,129440,N-(Cyclohexylcarbonyl)leucine,CC(C)CC(C(=O)O)NC(=O)C1CCCCC1,,,,,,
9440,129441,4-Methyl-5-(4-pyridinyl)thiazole-2-carboxamide,CC1=C(SC(=N1)C(=O)N)C2=CC=NC=C2,,,,,,
9441,129442,CID 129442,C(CN)CN=C(N)NN=CC=NNC(=NCCCN)N,,,,,,
9442,129443,2-Bromo-2'-deoxyadenosine triphosphate,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Br)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
9443,129444,"5-Amino-2,4-dihydroxy-alpha-methylphenylethylamine",CC(CC1=CC(=C(C=C1O)O)N)N,,,,,,
9444,129445,((3-(Bis(2-chloroethyl)amino)-4-methylphenyl)hydroxymethane)bisphosphonic acid,CC1=C(C=C(C=C1)C(O)(P(=O)(O)O)P(=O)(O)O)N(CCCl)CCCl,,,,,,
9445,129446,Tetraethyl squarate,CCN(CC)C1=CC(=C(C=C1)C2C(=O)C(C2=O)C3=CC(=C(C=C3)N(CC)CC)O)O,,,,,,
9446,129447,"3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenyl]prop-2-enoic acid",CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)C=CC(=O)O,,,,,,
9447,129448,"(6R)-4-hydroxy-2-methyl-6-[(8R,9S,10S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid",C[C@H](CC(CC(C)C(=O)O)O)[C@H]1CC[C@@H]2[C@@]1(C(C[C@H]3[C@H]2C(CC4[C@@]3(CCC(C4)O)C)O)O)C,,,,,,
9448,129449,"[(2R,3S,4R,5R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2S,3R,4R)-1,3,4,5-tetrahydroxypentan-2-yl]oxyoxan-3-yl] dihydrogen phosphate",C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O[C@@H](CO)[C@@H]([C@@H](CO)O)O)O)O)OP(=O)(O)O)O,,,,,,
9449,129450,"2-Methylbut-3-en-2-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate",CC(C)(C=C)OC(=O)C=CC1=CC(=C(C=C1)O)O,,,,,,
9450,129451,"2,6-ditert-butyl-4-[2-(5-methyl-1H-pyrazol-3-yl)ethenyl]phenol",CC1=CC(=NN1)C=CC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,,,,,,
9451,129452,Biarez-gamma,C1=CC=C2C(=C1)NC(=N2)N=NC3=C(C(=C(C=C3)O)C(=O)O)O,,,,,,
9452,129453,"(2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)piperidine",C1CCN([C@H](C1)CCO)C(=O)C=CC2=C3C=CC=CN3N=C2C4=CC=CC=C4,,,,,,
9453,129454,[4-(1-Pyridin-2-yl-3-pyrrolidin-1-ylprop-1-enyl)phenyl]methanol,C1CCN(C1)CC=C(C2=CC=C(C=C2)CO)C3=CC=CC=N3,,,,,,
9454,129455,"1-((6-Methylergolin-8-beta-yl)methyl)-2,4-imidazolidinedione-N6-oxide",C[N+]1(C[C@@H](CC2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC5=O)[O-],,,,,,
9455,129456,"5-(1-Azabicyclo[2.2.1]heptan-3-yl)-3-methyl-1,2,4-oxadiazole",CC1=NOC(=N1)C2CN3CCC2C3,,,,,,
9456,129457,4-Hydroxyamesergide,CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)NC4CCC(CC4)O)C5=C2C1=CC=C5,,,,,,
9457,129458,"3,7,12,22-Tetrahydroxycholestanoic acid",C[C@@H]([C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C)[C@@H](CCC(C)C(=O)O)O,,,,,,
9458,129459,CID 129459,COC(=O)CCC=C=CC[C@@H]1[C@H](CCC1=O)C=C[C@H](COC2=CC=CC=C2)O,,,,,,
9459,129460,N-[5-[[2-[4-(acridin-9-ylamino)anilino]-2-oxoethyl]carbamoyl]-1-methylpyrrol-3-yl]-4-amino-1-methylpyrrole-2-carboxamide,CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCC(=O)NC3=CC=C(C=C3)NC4=C5C=CC=CC5=NC6=CC=CC=C64)C)N,,,,,,
9460,129461,"4,5,6,7-Tetrahydro-1-butyl-4-oxo-2,6,6-trimethyl-indole-3-acetic acid",CCCCN1C(=C(C2=C1CC(CC2=O)(C)C)CC(=O)O)C,,,,,,
9461,129462,"1-Isobutyl-2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-3-indoleacetic acid",CC1=C(C2=C(N1CC(C)C)CC(CC2=O)(C)C)CC(=O)O,,,,,,
9462,129463,Methyl 2-cyano-3-ethylsulfanyl-3-methylsulfanylprop-2-enoate,CCSC(=C(C#N)C(=O)OC)SC,,,,,,
9463,129464,CID 129464,CC(C)(C)OC(=O)NCCCCC(C(=O)O)N[C@H](CC1=CC=CC=C1)C(=O)O,,,,,,
9464,129465,Deacylgymnemic acid,C[C@]12CCC(C(C1CC[C@@]3(C2CC=C4[C@]3(C[C@H]([C@@]5([C@@H]4CC([C@@H]([C@H]5O)O)(C)C)CO)O)C)C)(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,,,,,,
9465,129466,"6-Fluoro-1-cyclopropyl-1,4-dihydro-4-oxo-7-(pyrrol-1-yl)quinoline-3-carboxylic acid",C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4C=CC=C4)F)C(=O)O,,,,,,
9466,129467,Monacolin M,CC1CC(C2C(C(C=CC2=C1)C)CCC3CC(CC(=O)O3)O)OC(=O)CC(C)O,,,,,,
9467,129468,5-(1-(2-Pyrrolidinylcarbonyl)amino-3-methylbutyl)-2-tetrazolylacetamide,CC(C)CC(C1=NN=NN1CC(=O)N)NC(=O)C2CCCN2,,,,,,
9468,129469,"6-(4-Bromoacetamidobenzyl)-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid",C1CN(CCN(CC(CN(CCN(C1)CC(=O)O)CC(=O)O)CC2=CC=C(C=C2)NC(=O)CBr)CC(=O)O)CC(=O)O,,,,,,
9469,129470,CID 129470,CCCOCC1=C(C=CC(=C1)C(=O)CC)OCC(CNC(C)C)O.CCCOCC1=C(C=CC(=C1)C(=O)CC)OCC(CNC(C)C)O.C(=CC(=O)O)C(=O)O,,,,,,
9470,129471,3'-(Propoxymethyl)-4'-[2-hydroxy-3-(isopropylamino)propoxy]propiophenone,CCCOCC1=C(C=CC(=C1)C(=O)CC)OCC(CNC(C)C)O,,,,,,
9471,129472,"2-[(8S,9S,10S,11S,13S,14S,17R)-13-formyl-11-hydroxy-10-methyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethyl hydrogen sulfate",C[C@]12CCC(=O)CC1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4CCOS(=O)(=O)O)C=O)O,,,,,,
9472,129473,CID 129473,CC1=CC=C(C=C1)S(=O)(=O)NC[C@@H]2[C@@H]3CC[C@@H](C3)[C@@H]2C=CCCCC(=O)O,,,,,,
9473,129474,N-(alpha-Methylbenzyl)azelaamic acid,CC(C1=CC=CC=C1)NC(=O)CCCCCCCC(=O)O,,,,,,
9474,129475,2-(3-Chlorobenzyloxy)phenacyl alcohol,C1=CC=C(C(=C1)C(=O)CO)OCC2=CC(=CC=C2)Cl,,,,,,
9475,129476,CID 129476,C[C@H](C=CCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2C(=O)C=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
9476,129477,3-Iodo-4-aminobenzylguanidine,C1=CC(=C(C=C1CN=C(N)N)I)N,,,,,,
9477,129478,CID 129478,C[C@H](C=CC(C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2C(=O)C=C4[C@@]3(CCC(C4)O)C)C,,,,,,
9478,129479,CID 129479,C1=NC2=C(N1CCSC[C@@H](C(=O)O)N)C(=O)N=C(N2)N,,,,,,
9479,129480,CID 129480,CCC(C=C[C@@H](C)C1CC[C@@H]2[C@@]1(CCC3=C2C(=O)C=C4[C@@]3(CCC(C4)O)C)C)C(C)C,,,,,,
9480,129481,4-Amino-3-(5-methoxybenzo(b)furan-2-yl)butanoic acid,COC1=CC2=C(C=C1)OC(=C2)C(CC(=O)O)CN,,,,,,
9481,129482,N-(4-((2-Bromoethyl)methylamino)-2-butynyl)-2-pyrrolidone,CN(CCBr)CC#CCN1CCCC1=O,,,,,,
9482,129483,"(S)-1-(9H-Fluoren-9-ylmethyl) 5-oxo-1,2-pyrrolidinedicarboxylate",C1CC(=O)N([C@@H]1C(=O)O)C(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
9483,129484,N-Oxalylcysteine,C([C@@H](C(=O)O)NC(=O)C(=O)O)S,,,,,,
9484,129485,9-Aminoacridine-4-carboxamide,C1=CC=C2C(=C1)C(=C3C=CC=C(C3=N2)C(=O)N)N,,,,,,
9485,129486,Azaprophen,CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CC4CC(C3)N(C4)C,,,,,,
9486,129487,N-[3-(2-amino-1H-imidazol-5-yl)prop-2-enyl]-4-bromo-1H-pyrrole-2-carboxamide,C1=C(NC=C1Br)C(=O)NCC=CC2=CN=C(N2)N,,,,,,
9487,129488,"3,N(4)-Propanodeoxycytidine 5'-monophosphate",C1CC2(C=CN(C(=O)N2C1)[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)O)O)N,,,,,,
9488,129489,"1-Methyl-5-phenyl-2,3,4,4a,5,9b-hexahydro-1H-indeno(1,2-b)pyridine",CN1CCCC2C1C3=CC=CC=C3C2C4=CC=CC=C4,,,,,,
9489,129490,"5-(4-Aminophenyl)-2,3,4,4a,5,9b-hexahydro-1H-indeno(1,2-b)pyridine",C1CC2C(C3=CC=CC=C3C2NC1)C4=CC=C(C=C4)N,,,,,,
9490,129491,"4-(2,2-Diphenylethenyl)-1-(1-oxo-9-(3-pyridinyl)nonyl)piperidine",C1CN(CCC1C=C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CCCCCCCCC4=CN=CC=C4,,,,,,
9491,129492,4-(3-(2-Nitro-9-(10H)acridinon-10-yl)propyl)-1-piperazineethanol,C1CN(CCN1CCCN2C3=C(C=C(C=C3)[N+](=O)[O-])C(=O)C4=CC=CC=C42)CCO,,,,,,
9492,129493,2-(12-N-Dansylaminododecanoyl)-1-myristoylglycerol,CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCNS(=O)(=O)C1=CC=CC2=C1C=CC=C2N(C)C,,,,,,
9493,129494,CID 129494,CCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCN=C1C=CC(=N[N+]#N)C=C1N(O)[O-],,,,,,
9494,129495,"2-Furancarboxylic acid, 2-(4-(acetylamino)-3-oxo-2-isoxazolidinyl)tetrahydro-5-oxo-",CC(=O)NC1CON(C1=O)OC(=O)C2CCC(=O)O2,,,,,,
9495,129496,4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)-3(2H)-pyridazinone,CCOC1=C(C=CC(=C1)CNC2=C(C(=O)NN=C2)Br)OC,,,,,,
9496,129497,"5-Bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3-dimethoxybenzamide",CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2)Br)OC)OC,,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
9497,129498,"1-(1,3-Benzodioxol-5-yl)ethanamine",CC(C1=CC2=C(C=C1)OCO2)N,,,,,,
9498,129499,"5-Bromo-2,3-dimethoxy-N-((1-(4-fluorobenzyl)-2-pyrrolidinyl)methyl)benzamide",COC1=CC(=CC(=C1OC)C(=O)NCC2CCCN2CC3=CC=C(C=C3)F)Br,,,,,,
9499,129500,19-Hydroxy-4-androsten-17-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CCCC[C@]34CO,,,,,,
9500,129501,2-Aminoethylarsonic acid,C(C[As](=O)(O)O)N,,,,,,
9501,129502,CID 129502,CCOC(=O)CCCCCCCC=CCCCCCCC1=CC=CC=C1,,,,,,
9502,129503,"N,N-dimethyl-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine",CN(C)C1CCC2=C(C1)C3=C(C=C2)NC=C3,,,,,,
9503,129504,"11-(N-Methylnipecotyl)-6,11-dihydro-5H-pyrido(2,3-b)-1,5-benzodiazepin-5-one",CN1CCCC(C1)C(=O)N2C3=CC=CC=C3NC(=O)C4=C2N=CC=C4.Cl,,,,,,
9504,129505,Rispenzepine,CN1CCCC(C1)C(=O)N2C3=CC=CC=C3NC(=O)C4=C2N=CC=C4,,,,,,
9505,129506,"3-[4-(2,6-dimethylheptyl)phenyl]-N-(2-hydroxyethyl)butanamide",CC(C)CCCC(C)CC1=CC=C(C=C1)C(C)CC(=O)NCCO,,,,,,
9506,129507,"3-Benzyl-1,2,4-trioxolane",C1OC(OO1)CC2=CC=CC=C2,,,,,,
9507,129508,"2-(4-(3,4,5-Trichlorophenylureido)phenoxy)-2-methylpropionic acid",CC(C)(C(=O)O)OC1=CC=C(C=C1)NC(=O)NC2=CC(=C(C(=C2)Cl)Cl)Cl,,,,,,
9508,129509,"8-(3-Heptyloxiran-2-yl)oct-1-en-4,6-diyn-3-yl acetate",CCCCCCCC1C(O1)CC#CC#CC(C=C)OC(=O)C,,,,,,
9509,129510,27-Hydroxyoctacosanoic acid,CC(CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O)O,,,,,,
9510,129511,CID 129511,C1C[C@H](N(C1)C(=O)CCC(=O)C(CC2=CC=CC=C2)NC(=O)C=CC3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)O,,,,,,
9511,129512,4-Amino-3-(1-benzofuran-2-yl)butanoic acid,C1=CC=C2C(=C1)C=C(O2)C(CC(=O)O)CN,,,,,,
9512,129513,1-Methylphysostigmine,C[C@@]12CC[N+]([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)(C)C,,,,,,
9513,129514,Ppaps,CC1=C(C(=C(C(=N1)N=NC2=CC=CC=C2S(=O)(=O)O)COP(=O)(O)O)C=O)O,,,,,,
9514,129515,"2-Propanol, 1-((1-methylethyl)amino)-3-(2,4,6-tripropylphenoxy)-",CCCC1=CC(=C(C(=C1)CCC)OCC(CNC(C)C)O)CCC,,,,,,
9515,129516,3-bromo-N-[(1-ethylpyrrolidin-2-yl)methyl]-6-hydroxy-2-methoxybenzamide,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)O,,,,,,
9516,129517,"4-Acetyl-1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinone",CC1=C2CC(CCC2=C(C(=O)N1)C(=O)C)C3=CC=NC=C3,,,,,,
9517,129518,5-Chloro-3-(5-carboxypentyl)-1-methyl-2-(3-pyridyl)indole hydrochloride,CN1C2=C(C=C(C=C2)Cl)C(=C1C3=CN=CC=C3)CCCCCC(=O)O.Cl,,,,,,
9518,129519,5-Chloro-1-methyl-2-(3-pyridyl)-3-indolehexanoic acid,CN1C2=C(C=C(C=C2)Cl)C(=C1C3=CN=CC=C3)CCCCCC(=O)O,,,,,,
9519,129520,Regelin D,C[C@]12CCC(=O)C(C1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@@H]4C[C@@](C[C@@H]5O)(C)C(=O)OC)C)C)C)(C)C,,,,,,
9520,129521,Regelindiol A,C[C@H]1[C@@H](C[C@@H]([C@]2([C@H]1C3=CC[C@@H]4[C@]5(CC[C@@H](C(C5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C)O)C(=O)OC,,,,,,
9521,129522,"3-(1,3-benzodioxol-5-yl)-N-[2-(4-methoxyphenyl)ethyl]-N-methylprop-2-enamide",CN(CCC1=CC=C(C=C1)OC)C(=O)C=CC2=CC3=C(C=C2)OCO3,,,,,,
9522,129523,2-(4-Amino-5-fluoropentyl)guanidine,C(CC(CF)N)CN=C(N)N,,,,,,
9523,129524,Nauclecosidine,CC1=C(OC(=O)C2=C(N3CCC4=C([C@@H]3C=C12)NC5=CC=CC=C45)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
9524,129525,2-(2-Azido-4-nitrobenzoyl)-1-myristoylglycero-3-phosphoethanolamine,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[14CH2]N)OC(=O)C1=C(C=C(C=C1)[N+](=O)[O-])N=[N+]=[N-],,,,,,
9525,129526,CID 129526,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[14CH2]N)OC(=O)C1=C(C=C(C=C1)[N+](=O)[O-])N[N+]#N,,,,,,
9526,129527,2-Cdippo,C1=CC=C(C=C1)C(CN2C=CN=C2)(C(=O)C3=C(C=C(C=C3)Cl)Cl)Cl.Cl,,,,,,
9527,129528,"2-Chloro-1-(2,4-dichlorophenyl)-3-(1H-imidazol-1-yl)-2-phenylpropan-1-one",C1=CC=C(C=C1)C(CN2C=CN=C2)(C(=O)C3=C(C=C(C=C3)Cl)Cl)Cl,,,,,,
9528,129529,"1-Methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine",CCC1=CC=CC=C1C2=CCN(CC2)C,,,,,,
9529,129530,6-Difluoromethoxy-7-piperazinyl-3-quinolonecarboxylic acid,C1CN(CCN1)C2=C(C=C3C(=C2)NC=C(C3=O)C(=O)O)OC(F)F,,,,,,
9530,129531,Omphalone,CC1=COC(=C1)C2=CC(=O)C=CC2=O,,,,,,
9531,129532,CID 129532,CC1(C2CC1C(C(C2)NCC(CC3=CC(=C(C=C3)N=[N+]=[N-])I)O)CC=CCCCC(=O)O)C,,,,,,
9532,129533,5-Ribofuranosylnicotinamide,C1=C(C=NC=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
9533,129534,5-beta-D-Ribofuranosyl-3-(aminocarbonyl)-1-methylpyridinium iodide,C[N+]1=CC(=CC(=C1)C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O.[I-],,,,,,
9534,129535,"5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpyridin-1-ium-3-carboxamide",C[N+]1=CC(=CC(=C1)C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
9535,129536,"7-(3-(1-Amino-1-methylethyl)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid",CC(C)(C1CCN(C1)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F)N,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
9536,129537,4-amino-8-butyl-N-(cyclopropylmethyl)cinnoline-3-carboxamide,CCCCC1=C2C(=CC=C1)C(=C(N=N2)C(=O)NCC3CC3)N,,,,,,
9537,129538,"2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate",CC(CC(=O)ON1C(=O)CCC1=O)SSC2=CC=CC=N2,,,,,,
9538,129539,"5-(3-(2,6-Dichloro-4-(4,5-Dihydro-2-Oxazolyl)phenoxy)propyl)-3-Methyl Isoxazole",CC1=NOC(=C1)CCCOC2=C(C=C(C=C2Cl)C3=NCCO3)Cl,,,,,,
9539,129540,"(4R)-4-[(1S,3S,5S,7R,8S,9S,10S,13R,14S,17S)-1,3,7-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid",C[C@H](CCC(=O)O)[C@@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3([C@H](C[C@H](C4)O)O)C)O)C,,,,,,
9540,129541,"5,20-Dihydroxyicosa-6,8,11,14-tetraenoic acid",C(CCC=CCC=CCC=CC=CC(CCCC(=O)O)O)CCO,,,,,,
9541,129542,CID 129542,C[C@@]1(CC(=O)[C@]2([C@@]3([C@@H](CCC([C@H]3[C@H]([C@H]([C@@]2(O1)C)OC(=O)CCC(=O)NCCNC(=O)C4=C(C(=C(C=C4)N[N+]#N)I)[O-])O)(C)C)O)C)O)C=C,,,,,,
9542,129543,CID 129543,C[C@@]1(CC(=O)[C@]2([C@@]3([C@@H](CCC([C@H]3[C@H]([C@H]([C@@]2(O1)C)OC(=O)CCC(=O)NCCNC(=O)C4=C(C(=C(C=C4)N[N+]#N)I)O)O)(C)C)O)C)O)C=C,,,,,,
9543,129544,Sorbitol 3-phosphate,C([C@H]([C@H]([C@@H]([C@H](CO)O)OP(=O)(O)O)O)O)O,,,,,,
9544,129545,CID 129545,CCCCCC=C[C@H]([C@@H](C=CC=CCC=CCCCC(=O)O)O)O,,,,,,
9545,129546,CID 129546,CCC=CCC=C[C@H]([C@@H](C=CC=CCC=CCCCC(=O)O)O)O,,,,,,
9546,129547,CID 129547,CCCCCC=C[C@H]([C@@H](C=CC=CCCCCC(=O)O)O)O,,,,,,
9547,129548,"2,3-Diacetyl-4-hydroxy-4-methylcyclopent-2-en-1-one",CC(=O)OC1=C(C(CC1=O)(C)O)OC(=O)C,,,,,,
9548,129549,"4,6,10,12-Tetramethyltrideca-2,4-dien-7-one",CC=CC(=CC(C)C(=O)CCC(C)CC(C)C)C,,,,,,
9549,129550,"4-[2-Hydroxy-5-methyl-7-(3-methyloxiran-2-yl)-4-oxooct-6-enyl]piperidine-2,6-dione",CC1C(O1)C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,,,,,,
9550,129551,CID 129551,CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)[C@H](CC2=CN=CN2)N[C@H](CC3CCCCC3)[C@H](C4=NC=CN4)O,,,,,,
9551,129552,Arginomycin,CC(CCN(C)C(=N)N)C(C(=O)NC1C=CC(OC1C(=O)O)N2C=CC(=NC2=O)N)N,,,,,,
9552,129553,CID 129553,CCN[C@@H](CC(C)C)C(=O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C,,,,,,
9553,129554,CID 129554,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC(=C(C=C3)O)O)NC(=O)N(C)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5)C(=O)[O-])C.[Na+],,,,,,
9554,129555,"(2S,5R,6R)-6-[[(2R)-2-(3,4-dihydroxyphenyl)-2-[[methyl-(4-phenylbenzoyl)carbamoyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC(=C(C=C3)O)O)NC(=O)N(C)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5)C(=O)O)C,,,,,,
9555,129556,4-(Rhamnosyloxy)phenylacetonitrile,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=CC=C(C=C2)CC#N)O)O)O,,,,,,
9556,129557,"(+)-1-(Dichloromethyl)-5-(dichloromethylene)-2,2,4,4-tetrachloro-1,3-cyclopentanediol",C1(C(C(=C(Cl)Cl)C(C1(Cl)Cl)(C(Cl)Cl)O)(Cl)Cl)O,,,,,,
9557,129558,2-Mercaptomethylglutaric acid,C(CC(=O)O)C(CS)C(=O)O,,,,,,
9558,129559,"(+)-4-Hydroxy-3,3,5,5-tetrachloro-2-(trichloromethyl)-1-cyclopentene-1-carboxaldehyde",C(=O)C1=C(C(C(C1(Cl)Cl)O)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9559,129560,2-(4-Allyl-1-piperazinyl)-4-pentyloxyquinazoline,CCCCCOC1=NC(=NC2=CC=CC=C21)N3CCN(CC3)CC=C,,,,,,
9560,129561,5'-Methylthio-5'-deoxy-9-deazaadenosine,CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C2C=CN=C3N)O)O,,,,,,
9561,129562,"Ethanone, 1-(2-hydroxy-3-propyl-4-(4-(2-(4-(1H-tetrazol-5-yl)butyl)-2H-tetrazol-5-yl)butoxy)phenyl)-",CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCC2=NN(N=N2)CCCCC3=NNN=N3,,,,,,
9562,129563,CID 129563,C1=CC=C(C=C1)P(=S)(C2=CC=CC=C2)[S-].C1=CC=C(C=C1)[SbH]C2=CC=CC=C2,,,,,,
9563,129564,Diphenylphosphinodithioic acid,C1=CC=C(C=C1)P(=S)(C2=CC=CC=C2)S,,,,,,
9564,129565,5-(3-Aminopropyl)isoxazole,C1=C(ON=C1)CCCN,,,,,,
9565,129566,"3,6-dihydro-2H-oxazin-6-amine",C1C=CC(ON1)N,,,,,,
9566,129567,"Pyridazino(4,5-e)-1,4-diazepine",C1CN=CC2=CN=NC=C2N1,,,,,,
9567,129568,Maltose-maleimide,C1=CC(=O)N(C1=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
9568,129569,1-N-Palmitoylkanamycin A,CCCCCCCCCCCCCCCC(=O)NC1CC(C(C(C1OC2C(C(C(C(O2)O)O)O)CN)O)OC3C(C(C(C(O3)CO)O)N)O)N,,,,,,
9569,129570,5-Aminoformycin A,C1=CC=C(C=C1)COC[C@@H]2[C@H]([C@H]([C@@H](O2)C3=C4C(=NN3)C(=NC(=N4)N)N)OCC5=CC=CC=C5)OCC6=CC=CC=C6,,,,,,
9570,129571,"N-[5-amino-2-[3-(aminomethyl)-4,5,6-trihydroxyoxan-2-yl]oxy-4-[3,5-dihydroxy-6-(hydroxymethyl)-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-3-hydroxycyclohexyl]hexadecanamide",CCCCCCCCCCCCCCCC(=O)NC1CC(C(C(C1OC2C(C(C(C(O2)O)O)O)CN)O)OC3C(C(C(C(O3)CO)O)NC(=O)C(F)(F)F)O)N,,,,,,
9571,129572,Prepro-thyrotropin releasing hormone (160-169),C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)N)O,,,,,,
9572,129573,4-Trifluoromethylcoumarin phosphate,C1=CC2=C(C=C1OP(=O)(O)O)OC(=O)C=C2C(F)(F)F,,,,,,
9573,129574,CID 129574,CN1CCC23[C@@H]4[C@@H]1CC5=CC(=C(C(=C52)O[C@H]3[C@H](C=C4)O)O)[125I],,,,,,
9574,129575,"Dodecyl (1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) hydrogen phosphate",CCCCCCCCCCCCOP(=O)(O)OC1CC(N(C(C1)(C)C)O)(C)C,,,,,,
9575,129576,"N-Nitroso-N-methyl-p-aminobenzoic acid, 2-ethylhexyl ester",CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)N=O,,,,,,
9576,129577,"1-Oxaspiro(2.4)heptan-5-ol, 2,4,4,6,6-pentachloro-7-(dichloromethylene)-",C1(C(C(=C(Cl)Cl)C2(C1(Cl)Cl)C(O2)Cl)(Cl)Cl)O,,,,,,
9577,129578,6-Fluoro-5'-deoxypyridoxal,CC1=C(C(=C(N=C1F)C)O)C=O,,,,,,
9578,129579,"3-Acetoxy-5-(2-(dimethylamino)ethyl)-2,3-dihydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one",CC1=CC=C(C=C1)C2C(C(=O)N(C3=C(S2)C=C(C=C3)C)CCN(C)C)OC(=O)C,,,,,,
9579,129580,"[3-(5-Fluoro-2,4-dioxopyrimidin-1-yl)-2-methylphenyl] hydrogen carbonate",CC1=C(C=CC=C1OC(=O)O)N2C=C(C(=O)NC2=O)F,,,,,,
9580,129581,"(S)-10-(2,6-Dimethyl-4-pyridinyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid",C[C@H]1CSC2=C3N1C=C(C(=O)C3=CC(=C2C4=CC(=NC(=C4)C)C)F)C(=O)O,,,,,,
9581,129582,CID 129582,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)SO)OC(=O)CCCCCCCCCCCCCCC,,,,,,
9582,129583,"7,8-Dihydroxy-5,6-epoxy-1,4-dimethyl-5,6,7,8-tetrahydrophenanthrene",CC1=C2C=CC3=C(C2=C(C=C1)C)C4C(O4)C(C3O)O,,,,,,
9583,129584,"2,3,6,2',3',4',6'-Hepta-O-acetylcellobiose",CC(=O)OC[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](COC(=O)C)O)[C@@H]([C@H](C=O)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
9584,129585,CID 129585,C1=C(C(=O)N=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O[C@@H](CO)[C@H]([C@@H]([C@H](C=O)O)O)O)OP(=O)(O)O)O)O)[O-])N[N+]#N,,,,,,
9585,129586,CID 129586,C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O[C@@H](CO)[C@H]([C@@H]([C@H](C=O)O)O)O)OP(=O)(O)O)O)O)N[N+]#N,,,,,,
9586,129587,3-N-Methylparomomycin I,CNC1CC(C(C(C1OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,,,,,,
9587,129588,Phenylalanyl-leucyl-arginyl-phenylalanine,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N,,,,,,
9588,129589,Vita blue,C1=CC=C2C(=C1)C3(C4=C(C5=C(C=C4)C=C(C=C5)O)OC6=C3C=CC7=C6C=CC(=C7)O)OS2(=O)=O,,,,,,
9589,129590,"11,12-Dihydroxyicosa-2,4,6,8-tetraenoic acid",CCCCCCCCC(C(CC=CC=CC=CC=CC(=O)O)O)O,,,,,,
9590,129591,3-Azido-N-ethylcarbazole,CCN1C2=C(C=C(C=C2)N=[N+]=[N-])C3=CC=CC=C31,,,,,,
9591,129592,"7-Acetylaminobicyclo(3.2.0)hepta-3,6-dien-2-one",CC(=O)NC1=CC2C1C(=O)C=C2,,,,,,
9592,129593,(2S)-N-[(2S)-2-amino-3-cyclohexylpropanoyl]-N-[(2S)-2-[[(2S)-2-benzyl-3-tert-butylsulfonylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]-2-(butylamino)-3-methylbutanamide;methanesulfonic acid,CCCCN[C@@H](C(C)C)C(=O)N(C(=O)[C@H](CC1CCCCC1)N)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC=C3)CS(=O)(=O)C(C)(C)C.CS(=O)(=O)O,,,,,,
9593,129594,(2S)-N-[(2S)-2-amino-3-cyclohexylpropanoyl]-N-[(2S)-2-[[(2S)-2-benzyl-3-tert-butylsulfonylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]-2-(butylamino)-3-methylbutanamide,CCCCN[C@@H](C(C)C)C(=O)N(C(=O)[C@H](CC1CCCCC1)N)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC=C3)CS(=O)(=O)C(C)(C)C,,,,,,
9594,129595,Drummondin F,CC(=CCC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(C(=O)C(=C2O)C(=O)C)(C)CC=C(C)C)O)O)C,,,,,,
9595,129596,S-Nitrosocaptopril,C[C@H](CSN=O)C(=O)N1CCC[C@H]1C(=O)O,,,,,,
9596,129597,Avarol monoacetate,C[C@H]1CC[C@]2([C@H]([C@]1(C)CC3=C(C=CC(=C3)OC(=O)C)O)CCC=C2C)C,,,,,,
9597,129598,"2-(3-Chloropropyl)-2,5,7,8-tetramethyl-6-chromanol",CC1=C(C2=C(CCC(O2)(C)CCCCl)C(=C1O)C)C,,,,,,
9598,129599,1-Methyl-5-(4-dimethylaminophenylazo)indazole,CN1C2=C(C=C(C=C2)N=NC3=CC=C(C=C3)N(C)C)C=N1,,,,,,
9599,129600,1-Methyl-5-(4-methylaminophenylazo)indazole,CNC1=CC=C(C=C1)N=NC2=CC3=C(C=C2)N(N=C3)C,,,,,,
9600,129601,CID 129601,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCOCC(=O)O)O)O,,,,,,
9601,129602,5-(4-Methylaminophenylazo)indazole,CNC1=CC=C(C=C1)N=NC2=CC3=C(C=C2)NN=C3,,,,,,
9602,129603,1H-indazol-5-yl-(4-piperidin-1-ylphenyl)diazene,C1CCN(CC1)C2=CC=C(C=C2)N=NC3=CC4=C(C=C3)NN=C4,,,,,,
9603,129604,Madgmm,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2[C@H]([C@@H]([C@H](O[C@@H]2OC[C@@H]3[C@H]([C@@H]([C@@H]([C@@H](O3)OCCCCCCCCC(=O)OC)O)O)O)CO)O)O)CO)O)O,,,,,,
9604,129605,CID 129605,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)NCC=CC4=CN(C(=O)NC4=O)C5C[C@@H]([C@H](O5)COP(=O)(O)O)O)C(=O)O,,,,,,
9605,129606,"7-Ethylidene-1'-methoxyspiro[11-oxa-5-azatricyclo[6.3.1.04,9]dodecane-2,3'-indole]-2'-one",CC=C1CNC2CC3(C4CC1C2CO4)C5=CC=CC=C5N(C3=O)OC,,,,,,
9606,129607,Lavanducyanin,CC1=C(CCC(C1)(C)C)CN2C3=CC=CC=C3N=C4C2=CC=CC4=O,,,,,,
9607,129608,7-[(2-Benzyl-3-sulfanylpropanoyl)amino]heptanoic acid,C1=CC=C(C=C1)CC(CS)C(=O)NCCCCCCC(=O)O,,,,,,
9608,129609,"3-(2-Oxo-2,5-dihydro-3-furanyl)propanoic acid",C1C=C(C(=O)O1)CCC(=O)O,,,,,,
9609,129610,"(2,5-Dichloroanilino)ethenetricarbonitrile",C1=CC(=C(C=C1Cl)NC(=C(C#N)C#N)C#N)Cl,,,,,,
9610,129611,"Pyridinium, 1-(4-(2-(2-(octadecyloxy)ethoxy)ethoxy)butyl)-, methanesulfonate",CCCCCCCCCCCCCCCCCCOCCOCCOCCCC[N+]1=CC=CC=C1.CS(=O)(=O)[O-],,,,,,
9611,129612,1-[4-[2-[2-(Octadecyloxy)ethoxy]ethoxy]butyl]pyridinium,CCCCCCCCCCCCCCCCCCOCCOCCOCCCC[N+]1=CC=CC=C1,,,,,,
9612,129613,"(3,5-Dichloroanilino)ethenetricarbonitrile",C1=C(C=C(C=C1Cl)Cl)NC(=C(C#N)C#N)C#N,,,,,,
9613,129614,O-Palmityllongispinogenin,CCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC=C4[C@H]5CC(CC[C@@]5([C@H](C[C@]4([C@@]3(CCC2C1(C)C)C)C)O)CO)(C)C)C,,,,,,
9614,129615,3'-Hydroxy-4'-methoxydiclofenac,COC1=CC(=C(C(=C1O)Cl)NC2=CC=CC=C2CC(=O)O)Cl,,,,,,
9615,129616,Metadap,CCN(CC)C1=CC(=C(C=C1)N=NC2=NC=C(S2)C)O,,,,,,
9616,129617,"(2,8-Bis-trifluoromethyl-quinolin-4-yl)-pyridin-2-yl-methanol",C1=CC=NC(=C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,,,,,,
9617,129618,"1,3,4,6-Tetra-O-acetyl-2-chloroacetamido-2-deoxy-beta-glucopyranose",CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC(=O)C)NC(=O)CCl)OC(=O)C)OC(=O)C,,,,,,
9618,129619,"methyl 7-[(1S,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxy-3-methyloct-1-enyl]-5-oxocyclopentyl]-7-oxoheptanoate",CCCCC[C@@](C)(C=C[C@H]1[C@@H](CC(=O)[C@@H]1C(=O)CCCCCC(=O)OC)O)O,,,,,,
9619,129620,N-Acetyl-S-(pentachlorophenyl)-L-cysteine,CC(=O)N[C@@H](CSC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)C(=O)O,,,,,,
9620,129621,"Phenanthridinium, 8-amino-6-(4-aminophenyl)-5-ethyl-",CC[N+]1=C(C2=C(C=CC(=C2)N)C3=CC=CC=C31)C4=CC=C(C=C4)N,,,,,,
9621,129622,CID 129622,CCCCONNC=NC(=O)NC1=C(C=CC=C1C)C.Cl,,,,,,
9622,129623,CID 129623,CCCCONNC=NC(=O)NC1=C(C=CC=C1C)C,,,,,,
9623,129624,CID 129624,CCCCC(CC=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O)(C=C)O,,,,,,
9624,129625,6-O-Corynomycoloyltrehalose,CCCCCCCCCCCCCCCC(C(CCCCCCCCCCCCCC)C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O,,,,,,
9625,129626,"2,13-Divaleryldibenzo-18-crown-6",CCCCCC1=CC2=C(C=C1)OCCOCCOC3=C(C=CC(=C3)CCCCC)OCCOCCO2,,,,,,
9626,129627,8-Oxo-Adenosine-5'-Triphosphate,C1=NC(=C2C(=N1)N(C(=O)N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
9627,129628,"3-[5-(Acetyloxy)-4,5-dihydrofuran-3-yl]-N-(2-hydroxy-5-oxocyclopent-1-en-1-yl)prop-2-enimidic acid",CC(=O)OC1CC(=CO1)C=CC(=O)NC2=C(CCC2=O)O,,,,,,
9628,129629,"1,2-Dimyristoylglycero-3-phosphatidyl-N,N-dimethylethanolamine",CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN(C)C)OC(=O)CCCCCCCCCCCCC,,,,,,
9629,129630,"[(2R,3R,4R)-3,4-diacetyloxy-5-(4,6-dimethyl-9-oxoimidazo[1,2-a]purin-3-yl)oxolan-2-yl]methyl acetate",CC1=CN2C(=O)C3=C(N(C2=N1)C)N(C=N3)C4[C@@H]([C@@H]([C@H](O4)COC(=O)C)OC(=O)C)OC(=O)C,,,,,,
9630,129631,3-(2-(4-Cyclohexyl-1-piperazinyl)-2-phenylethyl)phenol,C1CCC(CC1)N2CCN(CC2)C(CC3=CC(=CC=C3)O)C4=CC=CC=C4,,,,,,
9631,129632,"Benzonitrile, 2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-hydroxy-",CC(C)(C)NCC(COC1=C(C=C(C=C1)O)C#N)O,,,,,"['Benzonitrile, 2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-hydroxy- is a known human metabolite of (R)-Bunitrolol.']",
9632,129633,CID 129633,CC(=NC1=CC(=CC(=C1)NC(=O)C(CO)O)NC(=O)C(CO)O)C2=C(OC(=C(C2=O)C(=O)C)O)O,,,,,,
9633,129634,"4-Piperidinecarboxamide, N-(4-amino-5-chloro-2-methoxyphenyl)-1-(phenylmethyl)-",COC1=C(C=C(C(=C1)N)Cl)NC(=O)C2CCN(CC2)CC3=CC=CC=C3,,,,,,
9634,129635,4-Tert-butyl-2-[(tert-butylamino)methyl]-6-(4-chlorophenyl)phenol,CC(C)(C)C1=CC(=C(C(=C1)C2=CC=C(C=C2)Cl)O)CNC(C)(C)C,,,,,,
9635,129636,"(3S,5R,10S,13R,14R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,5,6,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-7-one",C[C@H](CCCC(C)C)C1CC[C@@H]2[C@@]1(CCC3=C2C(=O)C[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
9636,129637,Succinic acid mono-3-guaiazulenamide,CC1=C2C(=CC(=C2C=C(C=C1)C(C)C)C)NC(=O)CCC(=O)O,,,,,,
9637,129638,8-Ketodeoxycoformycin,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C2NC=NCC3=O)CO)O,,,,,,
9638,129639,Diplodiol,CC[C@@H]1CCC2=C([C@H]1O)C(=O)C(=CO2)CO,,,,,,
9639,129640,"n-(2,6-Dimethylphenyl)-1-azabicyclo[2.2.2]octane-3-carboxamide",CC1=C(C(=CC=C1)C)NC(=O)C2CN3CCC2CC3,,,,,,
9640,129641,9-(9-Anthroyloxy)stearic acid,CCCCCCCCCC(CCCCCCCC(=O)O)OC(=O)C1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
9641,129642,"2-Iodo-6-isopropyl-3-methyl-2',4,4'-trinitrodiphenyl ether",CC1=C(C=C(C(=C1I)OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])C(C)C)[N+](=O)[O-],,,,,,
9642,129643,4-(N-Hydroxy-N-methylamino)quinoline 1-oxide,CN(C1=CC=[N+](C2=CC=CC=C21)[O-])O,,,,,,
9643,129644,5-Nitro-1-arabinofuranosyluracil,C1=C(C(=O)NC(=O)N1C2[C@H]([C@@H]([C@H](O2)CO)O)O)[N+](=O)[O-],,,,,,
9644,129645,1-Acetyl-2-phenethylhydrazine,CC(=O)NNCCC1=CC=CC=C1,,,,,,
9645,129646,4-[2-(Ethylamino)propyl]phenol,CCNC(C)CC1=CC=C(C=C1)O,,,,,,
9646,129647,4-(2-(Ethylamino)propyl)-2-methoxyphenol,CCNC(C)CC1=CC(=C(C=C1)O)OC,,,,,,
9647,129648,(-)-Glycinol,C1[C@@]2([C@H](C3=C(O1)C=C(C=C3)O)OC4=C2C=CC(=C4)O)O,,,,,,
9648,129649,CID 129649,C1=NC(=C2C(=N1)N(C=N2)C3[C@H]([C@@H]([C@H](O3)CO)O)N)N,,,,,,
9649,129650,CID 129650,C1=NC2=C(N1C3[C@H]([C@@H]([C@H](O3)CO)O)N)NC(=NC2=O)N,,,,,,
9650,129651,"1-Bromoacetyl-2,3,4,5-tetrahydro-1H-pyrido(3,2-b)azepine",C1CCN(C2=C(C1)N=CC=C2)C(=O)CBr,,,,,,
9651,129652,Cavilax,CCCC(=O)C.CCC(=O)C,,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,,
9652,129653,"3-[2-(3,4-Dihydroxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]prop-2-enal",C1=CC2=C(C=C1C=CC=O)OC(C(O2)C3=CC(=C(C=C3)O)O)CO,,,,,,
9653,129654,"(4S)-4-[(3S,5R,8R,9S,10S,13R,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-3-methylideneoxolan-2-one",C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4(C3(CC[C@@H]4[C@@H]5COC(=O)C5=C)O)C)O,,,,,,
9654,129655,3-Chloro-2-hydroxypropanal,C(C(C=O)O)Cl,,,,,,
9655,129656,1-(3-Carboxypropylcarbamoyl)-5-fluorouracil,C1=C(C(=O)NC(=O)N1C(=O)NCCCC(=O)O)F,,,,,,
9656,129657,1-Myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine,CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C,,,,,,
9657,129658,O-(1-O-Myristoyl-2-O-palmitoyl-L-glycero-3-phospho)choline,CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OCC[N+](C)(C)C,,,,,,
9658,129659,"2H-1-Benzopyran-2-one, 7-(sulfooxy)-",C1=CC(=CC2=C1C=CC(=O)O2)OS(=O)(=O)O,,,,,,
9659,129660,CID 129660,CCCCCC(=O)C(C([C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O)O,,,,,,
9660,129661,1-(3'-Amino-3'-carboxypropyl)uracil,C1=CN(C(=O)NC1=O)CC[C@@H](C(=O)O)N,,,,,,
9661,129662,"2-Pentenoic acid, 5-amino-, (Z)-",C(CN)C=CC(=O)O,,,,,,
9662,129663,"(2S)-7-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one",COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
9663,129664,"3,4-Dihydro-2,2-dimethyl-3-(2-propenyl)-2H-naphtho(1,2-b)pyran-5,6-dione",CC1(C(CC2=C(O1)C3=CC=CC=C3C(=O)C2=O)CC=C)C,,,,,,
9664,129665,2-(Fluoromethyl)glutamic acid,C(CC(CF)(C(=O)O)N)C(=O)O,,,,,,
9665,129666,"3-[(1,2,4a,5-Tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione",CC1CCC2(C(C1(C)CC3=C(C(=O)C=C(C3=O)OC)O)CCC=C2C)C,,,,,,
9666,129667,"Phenol, 4-(2-hydrazinoethyl)-",C1=CC(=CC=C1CCNN)O,,,,,,
9667,129668,"4-(3,4-Dimethoxyphenyl)but-3-en-1-ol",COC1=C(C=C(C=C1)C=CCCO)OC,,,,,,
9668,129669,"1-(4-chlorophenyl)-N,N,2-trimethylpropan-2-amine",CC(C)(CC1=CC=C(C=C1)Cl)N(C)C,,,,,,
9669,129670,"5,8-Dihydroxy-2-(2-phenylethyl)chromone",C1=CC=C(C=C1)CCC2=CC(=O)C3=C(C=CC(=C3O2)O)O,,,,,,
9670,129671,2-Naphthoylglycine,C1=CC=C2C=C(C=CC2=C1)C(=O)NCC(=O)O,,,,,,
9671,129672,CID 129672,CCCC[C@H]([C@@H](C=C[C@H]1CCC(=O)[C@@H]1CC=CCCCC(=O)O)O)F,,,,,,
9672,129673,CID 129673,C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)[C@H](CCSC)NC)NC(=O)[C@H](CC2=CC=C(C=C2)OC(=O)C)N,,,,,,
9673,129674,"9-(3,4-Dihydroxybutyl)adenine",C1=NC(=C2C(=N1)N(C=N2)CC[C@@H](CO)O)N,,,,,,
9674,129675,CID 129675,C1[C@H](O[C@@H]([C@H]([C@H]1O)O)[C@@H](C2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O)OP(=O)(O)OP(=O)(O)O)CO,,,,,,
9675,129676,3beta-Hydroxycholenoic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC=C(C4)O)C)C,,,,,,
9676,129677,alpha-Difluoromethyl-dopa,C1=CC(=C(C=C1C[C@@](C(F)F)(C(=O)O)N)O)O,,,,,,
9677,129678,2-[4-(2-Oxocyclohexylidenemethyl)phenyl]propionic acid,CC(C1=CC=C(C=C1)C=C2CCCCC2=O)C(=O)O,,,,,,
9678,129679,Methyl beta-xylobioside,CO[C@H]1[C@@H]([C@H]([C@@H](CO1)O[C@H]2[C@@H]([C@H]([C@@H](CO2)O)O)O)O)O,,,,,,
9679,129680,Nalpha-Acetylarginine-ethylamide,CCNC(=O)[C@H](CCCN=C(N)N)NC(=O)C,,,,,,
9680,129681,CID 129681,C[C@@H](C(=O)NCC(=O)NC(=O)[C@@H](CC1=CC=CC=C1)N(C)[C@@H](CCS(=O)C)CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC,,,,,,
9681,129682,5-Hydroxy-2-hydroxymethyl-1-methylpyrid-4-one,CN1C=C(C(=O)C=C1CO)O,,,,,,
9682,129683,1|A-Hydroxydeoxycholic Acid,C[C@H](CCC(=O)O)C1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(C(C[C@H](C4)O)O)C)O)C,,,,,,
9683,129684,"2,6-Dimethoxy-N-(5-(4-(pentafluoroethoxy)phenyl)-1,3,4-thiadiazol-2-yl)benzamide",COC1=C(C(=CC=C1)OC)C(=O)NC2=NN=C(S2)C3=CC=C(C=C3)OC(C(F)(F)F)(F)F,,,,,,
9684,129685,2-(2-Cyclohexylethylhydrazinylidene)propanoic acid,CC(=NNCCC1CCCCC1)C(=O)O,,,,,,
9685,129686,E-2001 Free,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CC(=O)C3=CC4=CC=CC=C4C=C3.Cl,,,,,,
9686,129687,2-(4-(4-Fluorobenzoyl)piperidin-1-yl)-2'-acetonaphthone,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CC(=O)C3=CC4=CC=CC=C4C=C3,,,,,,
9687,129688,"(2,6-Dimethylphenylsulfonyl)nitromethane",CC1=C(C(=CC=C1)C)S(=O)(=O)C[N+](=O)[O-],,,,,,
9688,129689,7-(N-(3-Aminopropyl)amino)heptan-2-one,CC(=O)CCCCCNCCCN,,,,,,
9689,129690,Glydip,CCCCCCCCCCCCCCCCCC(=O)OC(COP(=O)(O)O)COP(=O)(O)O,,,,,,
9690,129691,"(2S)-N-[(2S)-2-(6-aminohexanoylamino)-3-phenylpropanoyl]-2-[[(1R,2S)-3-cyclohexyl-1-hydroxy-1-(1,3-thiazol-2-yl)propan-2-yl]amino]-4-methylpentanamide",CC(C)C[C@@H](C(=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCN)N[C@@H](CC2CCCCC2)[C@H](C3=NC=CS3)O,,,,,,
9691,129692,CID 129692,CC1(C2=CC(=C3CSC(=O)NN3)C=CC2=NC1=O)SC,,,,,,
9692,129693,Eglin c (41-49),C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2)O,,,,,,
9693,129694,Eglin c (60-63),C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N)O,,,,,,
9694,129695,1-Naphthylacetylspermine,C1=CC=C2C(=C1)C=CC=C2CC(=O)NCCCNCCCCNCCCN,,,,,,
9695,129696,"3-(cyclopropanecarbonyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one",CN1CC2=C(N=CN2C3=CC=CC=C3C1=O)C(=O)C4CC4,,,,,,
9696,129697,"3-(cyclopropanecarbonyl)-8-fluoro-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one",CN1CC2=C(N=CN2C3=C(C1=O)C=C(C=C3)F)C(=O)C4CC4,,,,,,
9697,129698,"5-ethenyl-N-phenyl-4,5-dihydro-1,3-thiazol-2-amine",C=CC1CN=C(S1)NC2=CC=CC=C2,,,,,,
9698,129699,"(2S,5S)-2-(3-azido-5-methoxy-4-prop-2-enoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane",COC1=CC(=CC(=C1OCC=C)N=[N+]=[N-])[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
9699,129700,2-Diazonio-5-[2-[ethyl(nitroso)amino]-1-hydroxyethyl]phenolate,CCN(CC(C1=CC(=C(C=C1)[N+]#N)[O-])O)N=O,,,,,,
9700,129701,4-[2-[Ethyl(nitroso)amino]-1-hydroxyethyl]-2-hydroxybenzenediazonium,CCN(CC(C1=CC(=C(C=C1)[N+]#N)O)O)N=O,,,,,,
9701,129702,2'-Methoxy-5'-nitrobenzamil,COC1=C(C=C(C=C1)[N+](=O)[O-])CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N,,,,,,
9702,129703,"7-Amino-2,4,6-trimethylquinoline",CC1=CC(=NC2=C1C=C(C(=C2)N)C)C,,,,,,
9703,129704,2-(6-Hydroxyquinolyl)-2-thiazole-4-carboxylic acid,C1[C@@H](N=C(S1)C2=NC3=C(C=C2)C=C(C=C3)O)C(=O)O,,,,,,
9704,129705,2-(N-(2-Propynyl)aminomethyl)-1-methylindole,CN1C2=CC=CC=C2C=C1CNCC#C,,,,,,
9705,129706,CID 129706,CC(C)(C)C1=NC2=CC(=C(C=C2S1)N=C(N3CCN(CC3)C)S)OC,,,,,,
9706,129707,"1-Piperazinecarbothioic acid, 1-(2-(1,1-dimethylethyl)-5-methyl-6-benzothiazolyl)-2-methylhydrazide",CC1=CC2=C(C=C1N(C(=S)N3CCNCC3)NC)SC(=N2)C(C)(C)C,,,,,,
9707,129708,CID 129708,CN1CCN(CC1)CC(=NO)C2=CC=C(C=C2)CCC3=CC=CC=C3.Cl,,,,,,
9708,129709,CID 129709,CN1CCN(CC1)CC(=NO)C2=CC=C(C=C2)CCC3=CC=CC=C3,,,,,,
9709,129710,"7-chloro-5-methyl-3-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one",CC(C)C1=NC(=NO1)C2=C3CN(C(=O)C4=C(N3C=N2)C=CC=C4Cl)C,,,,,,
9710,129711,CID 129711,C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C2NC=NC3=O,,,,,,
9711,129712,Butoxycarbonylglutamyl-lysyl-lysine-4-methylcoumarinyl-7-amide,CC1=CC(=O)OC2=C1C=CC(=C2)N[C@@H](CCCCN)C(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)OC(C)(C)C,,,,,,
9712,129713,Uphit,CN(C1CCCC[C@@H]1N2CCCC2)C(=O)CC3=CC(=C(C=C3N=C=S)Cl)Cl,,,,,,
9713,129714,Phenyl 2-aminoethyl selenoxide,C1=CC=C(C=C1)[Se](=O)CCN,,,,,,
9714,129715,"2-(Fluoromethyl)-3-(3,7,11,15-tetramethylhexadecyl)naphthalene-1,4-dione",CC(C)CCCC(C)CCCC(C)CCCC(C)CCC1=C(C(=O)C2=CC=CC=C2C1=O)CF,,,,,,
9715,129716,"1a-(Fluoromethyl)-7a-(3,7,11,15-tetramethylhexadec-2-enyl)naphtho[2,3-b]oxirene-2,7-dione",CC(C)CCCC(C)CCCC(C)CCCC(=CCC12C(=O)C3=CC=CC=C3C(=O)C1(O2)CF)C,,,,,,
9716,129717,"Hexanoic acid, 2-hydroxy-3-((3-(1H-imidazol-4-yl)-2-((4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl)amino)-1-oxopropyl)amino)-5-methyl-, 1-methylethyl ester",CC(C)CC(C(C(=O)OC(C)C)O)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC2=CC=CC3=CC=CC=C32)CC(=O)N4CCOCC4,,,,,,
9717,129718,CID 129718,C1CCN(C(C1)CC=CC2=CC3=C(C=C2)OCO3)O,,,,,,
9718,129719,N-[1-(2-chlorophenyl)ethylideneamino]-2-hydroxyacetamide,CC(=NNC(=O)CO)C1=CC=CC=C1Cl,,,,,,
9719,129720,"2,4-Dimethoxybenzhydrylamine",COC1=CC(=C(C=C1)C(C2=CC=CC=C2)N)OC,,,,,,
9720,129721,N-Stearoyltyrosine methyl ester,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)OC,,,,,,
9721,129722,"N-Succinimidyl-2,4-dimethoxy-3-(tributylstannyl)benzoate",CCCC[Sn](CCCC)(CCCC)C1=C(C=CC(=C1OC)C(=O)ON2C(=O)CCC2=O)OC,,,,,,
9722,129723,"5H-Pyrrolo(1,2-a)imidazole, 6,7-dihydro-2-(4-(methylthio)phenyl)-3-(4-pyridinyl)-",CSC1=CC=C(C=C1)C2=C(N3CCCC3=N2)C4=CC=NC=C4,,,,,,
9723,129724,(2R)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[2-hydroxy-5-(4-hydroxyphenyl)phenyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid,C1=CC(=CC=C1C2=CC(=C(C=C2)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](C(=O)O)N)O,,,,,,
9724,129725,"5H-Pyrrolo(1,2-a)imidazole, 6,7-dihydro-2-(4-(methylsulfinyl)phenyl)-3-(4-pyridinyl)-",CS(=O)C1=CC=C(C=C1)C2=C(N3CCCC3=N2)C4=CC=NC=C4,,,,,,
9725,129726,"6,7-dimethoxy-2H-pyrazolo[3,4-b]quinolin-3-amine",COC1=CC2=CC3=C(NN=C3N=C2C=C1OC)N,,,,,,
9726,129727,"6,11-Eicosadienoic acid",CCCCCCCCC=CCCCC=CCCCCC(=O)O,,,,,,
9727,129728,CID 129728,C1=CC(=CN=C1)C(C(P(=O)([O-])[O-])P(=O)([O-])[O-])O,,,,,,
9728,129729,(2-Hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid,C1=CC(=CN=C1)C(C(P(=O)(O)O)P(=O)(O)O)O,,,,,,
9729,129730,Isonoraptazepine,C1CN2CC3=CC=CC=C3N4C=CC=C4C2CN1,,,,,,
9730,129731,"3-Isopropyl-5-(4-methylphenethyl)-1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)-3,5-pyridinecarboxylate",CC1=CC=C(C=C1)CCOC(=O)C2=C(NC(=C(C2C3=CC=CC=N3)C(=O)OC(C)C)C)C,,,,,,
9731,129732,6-(2-(di-n-Propylamino)ethyl)indole,CCCN(CCC)CCC1=CC2=C(C=C1)C=CN2,,,,,,
9732,129733,"1H-Benz(f)indol-7-amine, 5,6,7,8-tetrahydro-N,N-dipropyl-",CCCN(CCC)C1CCC2=C(C1)C=C3C(=C2)C=CN3,,,,,,
9733,129734,"3-[4-(2,2-Dicyanoethenyl)phenyl]prop-2-enoic acid",C1=CC(=CC=C1C=CC(=O)O)C=C(C#N)C#N,,,,,,
9734,129735,"(16-hydroxy-11,12-dimethoxy-1,1-dimethyl-2,8,14,15,17-pentaoxo-1,2,8,14,15,17-hexahydrochromeno[2',3':6,7]naphtho[2,1-g]oxazolo[3,2-b]isoquinolin-3a(4H)-yl)methyl 3-methylbutanoate",CC(C)CC(=O)OCC12CC3=C(C(=C4C(=C3)C=CC5=C4C(=O)C6=C(C5=O)OC7=CC(=C(C=C7C6=O)OC)OC)O)C(=O)N1C(C(=O)O2)(C)C,,,,,,
9735,129736,CID 129736,CCCCC=C[N+](=N[C@H](C)[C@H](C)O)[O-],,,,,,
9736,129737,"6a,9-Dimethyl-3-methylidene-7-(propan-2-yl)hexahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-4,6,7,8,8a,8b,9a(6aH,9H)-heptol",CC(C)[C@]1([C@H]([C@@]2([C@@]3([C@]1(C4(CC2([C@@]5(C3(O4)[C@@H](C(=C)CC5)O)O)C)O)C)O)O)O)O,,,,,,
9737,129738,"(1R,2S,5S,10S,11R,14S,15S,16S,17S,18R)-1,17-dihydroxy-10,11,18-trimethoxy-2,14,16-trimethyl-5-phenyl-4,19-dioxabicyclo[13.3.1]nonadec-12-en-3-one",C[C@H]1C=C[C@H]([C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC)OC,,,,,,
9738,129739,CID 129739,C1=CC(=C(C=C1C[C@@H](C(=O)N(C(=O)CNC=CC2=CNC3=C2C=CC(=C3)Br)C(=O)[C@H](CC4=CN=CN4)N)N)O)O,,,,,,
9739,129740,Ent-13-epi-12-acetoxymanoyl oxide,CC(=O)O[C@@H]1C[C@H]2[C@@]3(CCCC([C@H]3CC[C@@]2(O[C@]1(C)C=C)C)(C)C)C,,,,,,
9740,129741,Methyl 15-hydroxykauran-18-oate,CC1C2CC[C@H]3[C@@]4(CCC[C@@]([C@H]4CCC3(C2)C1O)(C)C(=O)OC)C,,,,,,
9741,129742,"N,N'-Bis(3-(ethylamino)propyl)-1,8-octanediamine",CCNCCCNCCCCCCCCNCCCNCC,,,,,,
9742,129743,"N,N-Dimethylanatoxin",CC(=O)C1=CCCC2CC[C@H]1[N+]2(C)C.[I-],,,,,,
9743,129744,"1-[(1R)-9,9-dimethyl-9-azoniabicyclo[4.2.1]non-2-en-2-yl]ethanone",CC(=O)C1=CCCC2CC[C@H]1[N+]2(C)C,,,,,,
9744,129745,CID 129745,C1CC1CN2CCC34[C@H]5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)NC(=O)C=CC7=CC=C(C=C7)Cl,,,,,,
9745,129746,CID 129746,CCCCC=C[N+](=N[C@H](C)C(=O)C)[O-],,,,,,
9746,129747,"Ethyl 5-cyano-1,4-dihydro-6-methyl-2-((4-pyridinylsulfonyl)methyl)-4-(2-(trifluoromethyl)phenyl)-3-pyridinecarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C(F)(F)F)C#N)C)CS(=O)(=O)C3=CC=NC=C3,,,,,,
9747,129748,4-Acetoxy-2-(4-methylphenyl)benzothiazole,CC1=CC=C(C=C1)C2=NC3=C(C=CC=C3S2)OC(=O)C,,,,,,
9748,129749,4-Hydroxy-2-(4-methylphenyl)benzothiazole,CC1=CC=C(C=C1)C2=NC3=C(C=CC=C3S2)O,,,,,,
9749,129750,"Methyl 4-azido-2,3,5,6-tetrafluorobenzoate",COC(=O)C1=C(C(=C(C(=C1F)F)N=[N+]=[N-])F)F,,,,,,
9750,129751,CID 129751,COC(=O)C1=C(C(=C(C(=C1F)F)N[N+]#N)F)F,,,,,,
9751,129752,"N-(4-(2-(2,4-Diamino-6-pteridinyl)propyl)benzoyl)-L-glutamic acid",CC(CC1=CC=C(C=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C2=CN=C3C(=N2)C(=NC(=N3)N)N,,,,,,
9752,129753,Threonyl-lysyl-glutamic acid,C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O,,,,,,
9753,129754,Naheedin,CCC(C)[C@@H]1C[C@@H]([C@H](O1)O)[C@@H]2CC=C3[C@]2(C[C@H]([C@H]4[C@]3([C@@H](C[C@@H]5[C@@]4(C=CC(=O)C5(C)C)C)OC(=O)C)C)O)C,,,,,,
9754,129755,N-Succinimidyl-2-methoxy 2-phenylacetic acid ester,CO[C@@H](C1=CC=CC=C1)C(=O)ON2C(=O)CCC2=O,,,,,,
9755,129756,Octahydro-2-methyl-trans-5(1H)-isoquinolone methiodide,CN1CC[C@@H]2[C@@H](C1)CCCC2=O.CI,,,,,,
9756,129757,"(4aR,8aS)-2-methyl-1,3,4,4a,6,7,8,8a-octahydroisoquinolin-5-one",CN1CC[C@@H]2[C@@H](C1)CCCC2=O,,,,,,
9757,129758,6-(4-Hydroxynonyl)oxan-2-one,CCCCCC(CCCC1CCCC(=O)O1)O,,,,,,
9758,129759,4-Methylseleno-2-oxobutanoic acid,C[Se]CCC(=O)C(=O)O,,,,,,
9759,129760,CID 129760,C(CC(=O)N[C@@H](CSS(C[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=C(C(F)(F)F)Cl)Cl)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,,,,,,
9760,129761,"[4-(2-Amino-1-methylimidazo[4,5-b]pyridin-6-yl)phenyl] hydrogen sulfate",CN1C2=C(N=CC(=C2)C3=CC=C(C=C3)OS(=O)(=O)O)N=C1N,,,,,,
9761,129762,4-((2-Chloroethyl) (2-mesyloxyethyl)amino)benzoic acid,CS(=O)(=O)OCCN(CCCl)C1=CC=C(C=C1)C(=O)O,,,,,,
9762,129763,4-((2-Chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid,CS(=O)(=O)OCCN(CCCl)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
9763,129764,N-((2-Fluoro-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-(methoxycarbonyl)glycine,COC1=C(C2=C(C=C1)C(=C(C=C2)F)C(=O)N(CC(=O)O)C(=O)OC)C(F)(F)F,,,,,,
9764,129765,"N-(4-(3-Oxo-6-amino-2,3-dihydro-1,2,4-benzotriazin-2-yl)benzoyl)glutamic acid",C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N2C(=O)N=C3C=C(C=CC3=N2)N,,,,,,
9765,129766,6-(Octadecylthio)purine,CCCCCCCCCCCCCCCCCCSSC1=NC=NC2=C1NC=N2,,,,,,
9766,129767,"5-Hydroxy-2-amino-3-methylimidazo(4,5-f)quinoline",CN1C2=CC(=C3C(=C2N=C1N)C=CC=N3)O,,,,,,
9767,129768,CID 129768,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1NOC4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,,,,,,
9768,129769,"2-Amino-3-methylimidazo(4,5-f)-quinoline 5-sulfate ester",CN1C2=CC(=C3C(=C2N=C1N)C=CC=N3)OS(=O)(=O)O,,,,,,
9769,129770,Sdz ICT 322,CN1[C@@H]2CC(C[C@H]1[C@@H]3[C@H]2O3)OC(=O)C4=CNC5=CC=CC=C54,,,,,,
9770,129771,CID 129771,CCCCC(CC=C[C@H]1[C@@H](C[C@@H]2[C@@H]1CC(O2)C(CCCC(=O)OC)I)O)(C=C)O,,,,,,
9771,129772,"2-[9-[(4-Chlorophenyl)methyl]-6-fluoro-1,2,3,4,4a,9a-hexahydrocarbazol-1-yl]acetic acid",C1CC(C2C(C1)C3=C(N2CC4=CC=C(C=C4)Cl)C=CC(=C3)F)CC(=O)O,,,,,,
9772,129773,"4,6-Diethyl-1,3,4,5-tetrahydropyrano(4,3-b)indole-4-acetic acid",CCC1=C2C(=CC=C1)C3=C(N2)C(COC3)CC(=O)OCC,,,,,,
9773,129774,"S-[(9a-Hydroxy-4,4-dimethyl-2-oxo-2,4,4a,5,6,8a,9,9a-octahydronaphtho[2,3-b]furan-7-yl)methyl] ethanethioate",CC(=O)SCC1=C[C@H]2C[C@@]3(C(=CC(=O)O3)C([C@H]2CC1)(C)C)O,,,,,,
9774,129775,3-(2-Methoxyphenyl)-1H-2-benzopyran-1-one,COC1=CC=CC=C1C2=CC3=CC=CC=C3C(=O)O2,,,,,,
9775,129776,5-Methoxyluzindole,CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CC3=CC=CC=C3,,,,,,
9776,129777,Endothelin (16-21) amide,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)N,,,,,,
9777,129778,CID 129778,C[C@@H](C(=O)CC(C(C(=O)N(C=C1CC(C(O1)N2C=CC(=O)NC2=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)N)N(C)C(=O)[C@H](CC4=CC(=CC=C4)O)N)N,,,,,,
9778,129779,"1-(2,4-difluoro-2H-1,3,5-triazin-1-yl)-2-methylisoindole",CN1C=C2C=CC=CC2=C1N3C=NC(=NC3F)F,,,,,,
9779,129780,N-Succinimidyl 3-(trimethylstannyl)benzoate,C[Sn](C)(C)C1=CC=CC(=C1)C(=O)ON2C(=O)CCC2=O,,,,,,
9780,129781,"[3-(2-Aminoethyl)-10-cyclohexyl-1-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-3,6-dihydroxydeca-1,7,9-trien-4-yl] dihydrogen phosphate",CCC1C=CC(=O)OC1C=CC(CCN)(C(CC(C=CC=CC2CCCCC2)O)OP(=O)(O)O)O,,,,,,
9781,129782,"[3-[8-(2-Aminoethyl)-10-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-5,8-dihydroxy-7-phosphonooxydeca-1,3,9-trienyl]cyclohexyl] 3-methylbutanoate",CCC1C=CC(=O)OC1C=CC(CCN)(C(CC(C=CC=CC2CCCC(C2)OC(=O)CC(C)C)O)OP(=O)(O)O)O,,,,,,
9782,129783,"[3-[8-(2-Aminoethyl)-10-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-5,8-dihydroxy-7-phosphonooxydeca-1,3,9-trienyl]cyclohexyl] 4-methylpentanoate",CCC1C=CC(=O)OC1C=CC(CCN)(C(CC(C=CC=CC2CCCC(C2)OC(=O)CCC(C)C)O)OP(=O)(O)O)O,,,,,,
9783,129784,"[3-[8-(2-Aminoethyl)-10-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-5,8-dihydroxy-7-phosphonooxydeca-1,3,9-trienyl]cyclohexyl] 4-methylhexanoate",CCC1C=CC(=O)OC1C=CC(CCN)(C(CC(C=CC=CC2CCCC(C2)OC(=O)CCC(C)CC)O)OP(=O)(O)O)O,,,,,,
9784,129785,"11-((4-(Aminoiminomethyl)-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one dihydrochloride",C1CN(CCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4)C(=N)N.Cl.Cl,,,,,,
9785,129786,Guanylpirenzepine,C1CN(CCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4)C(=N)N,,,,,,
9786,129787,"4-amino-5-chloro-N-[(3S,4R)-1-[4-[4-(dimethylamino)piperidin-1-yl]-4-oxobutyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide",CN(C)C1CCN(CC1)C(=O)CCCN2CC[C@H]([C@H](C2)OC)NC(=O)C3=CC(=C(C=C3OC)N)Cl,,,,,,
9787,129788,1-Methyl-4-cyclohexylpyridinium,C[N+]1=CC=C(C=C1)C2CCCCC2,,,,,,
9788,129789,"3-O-methyl 4-O-(3,4,5-trimethoxybenzoyl) (2S,3S,4R)-2-(1,3-benzodioxol-5-yl)-2-methyl-5-oxooxolane-3,4-dicarboxylate",C[C@]1([C@H]([C@H](C(=O)O1)C(=O)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC)C(=O)OC)C3=CC4=C(C=C3)OCO4,,,,,,
9789,129790,Isooncodine,CC1=C2C(=NC=C1)C3=CC(=C(C=C3C2=O)O)OC,,,,,,
9790,129791,Itopride hydrochloride,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC.Cl,,,,,,
9791,129792,"5-[5-(2,2-Dimethyl-6-methylidenecyclohexyl)-3-methylpent-2-enyl]phenazin-1-one",CC(=CCN1C2=CC=CC=C2N=C3C1=CC=CC3=O)CCC4C(=C)CCCC4(C)C,,,,,,
9792,129793,Ursodeoxycholic acid N-acetylglucosaminide,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)C)O)C,,,,,,
9793,129794,Mmoup,CC#CC(C)(C1=C2C3CC(C(C2(C(O3)CC1)OCOC)C)OCOC)O,,,,,,
9794,129795,N-(gamma-Aminobutyryl)glutamic acid,C(CC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN,,,,,,
9795,129796,Modipafant racemate,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)NC3=CC=CC=N3)C)C4=CC=C(C=C4)N5C(=NC6=C5C=CN=C6)C,,,,,,
9796,129797,"Msh, beta, (5-8)",CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
9797,129798,Cholecystokinin 33 (10-20),CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CO)N,,,,,,
9798,129799,Trifluoroacetamidopropyl-2-acetamido-2-deoxygalactopyranoside,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OCCCNC(=O)C(F)(F)F)CO)O)O,,,,,,
9799,129800,CID 129800,C(C(OC(C(F)F)(F)F)(OOO)OOO)(C(OO)(OO)OO)OOO,,,,,,
9800,129801,9-(2-Chloro-6-fluorobenzyl)-6-methylaminopurine,CNC1=C2C(=NC=N1)N(C=N2)CC3=C(C=CC=C3Cl)F,,,,,,
9801,129802,9-(2-Chloro-6-fluorobenzyl)-6-dimethylaminopurine,CN(C)C1=NC=NC2=C1N=CN2CC3=C(C=CC=C3Cl)F,,,,,,
9802,129803,CID 129803,CC(C(C1CN=C2C(N1)(C(=O)N=C(N2)N)O)O)O,,,,,,
9803,129804,"1H-Imidazole-1-ethanol, 2-nitro-alpha-(1-pyrrolidineylmethyl)-",C1CCN(C1)CC(CN2C=CN=C2[N+](=O)[O-])O,,,,,,
9804,129805,3-((4-(5-(Hydroxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)benzonitrile,C1C(OC(=O)N1C2=CC=C(C=C2)OCC3=CC(=CC=C3)C#N)CO,,,,,,
9805,129806,"(3R,5R)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid",CC(C)C1=NC(=NC(=C1C=C[C@@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,,,,,,
9806,129807,"(4-{[2-Hydroxy-3-(2-nitro-1h-imidazol-1-yl)propyl]amino}-2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl",CC1(CC(CC(N1[O])(C)C)NCC(CN2C=CN=C2[N+](=O)[O-])O)C,,,,,,
9807,129808,Cpcbs-bcpe mixt.,CC(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O.C1=CC(=CC=C1OS(=O)(=O)C2=CC=C(C=C2)Cl)Cl,,,,,,
9808,129809,"4-Morpholineethanol, alpha-((2-nitro-1H-imidazol-1-yl)methyl)-, monohydrochloride",C1COCCN1CC(CN2C=CN=C2[N+](=O)[O-])O.Cl,,,,,,
9809,129810,1-Morpholin-4-yl-3-(2-nitroimidazol-1-yl)propan-2-ol,C1COCCN1CC(CN2C=CN=C2[N+](=O)[O-])O,,,,,,
9810,129811,"12H-Dibenzo(d,g)(1,3,6)dioxazocine-12-propanamine, 2-chloro-N,N,beta-trimethyl-, monohydrochloride",CC(CN1C2=CC=CC=C2OCOC3=C1C=C(C=C3)Cl)CN(C)C.Cl,,,,,,
9811,129812,Traboxopine,CC(CN1C2=CC=CC=C2OCOC3=C1C=C(C=C3)Cl)CN(C)C,,,,,,
9812,129813,Pyroxyfur,C1=COC(=C1)COC2=NC(=CC(=C2)C(Cl)(Cl)Cl)Cl,,,,,,
9813,129814,CID 129814,C1=CC(=NCC(=O)NN)C(=CC1=N[N+]#N)N(O)[O-],,,,,,
9814,129815,"5-Amino-6-hydroxy-2-isopropylamino-1,2,3,4-tetrahydronaphthalene-1-ol",CC(C)N[C@@H]1CCC2=C([C@H]1O)C=CC(=C2N)O,,,,,,
9815,129816,"6-Amino-5,6,7,8-tetrahydronaphthalene-2,3-diyl dibenzoate",C1CC2=CC(=C(C=C2CC1N)OC(=O)C3=CC=CC=C3)OC(=O)C4=CC=CC=C4,,,,,,
9816,129817,N-Methyl-N'-(2-(((5-methyl-1H-imidazole-4-yl)methyl)thio)ethyl)guanidine,CC1=C(N=CN1)CSCCNC(=NC)N,,,,,,
9817,129818,"2,4-Diamino-5-cyano-6-iodopyridine",C1=C(C(=C(N=C1N)I)C#N)N,,,,,,
9818,129819,"2-[(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-indenyl)oxy]ethyl methacrylate",CC(=C)C(=O)OCCOC1C=CC2C1C3CCC2C3,,,,,,
9819,129820,Pentachlorophenyl methyl sulfoxide,CS(=O)C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
9820,129821,1-[1-(3-Nitrophenyl)cyclohexyl]piperidine,C1CCC(CC1)(C2=CC(=CC=C2)[N+](=O)[O-])N3CCCCC3,,,,,,
9821,129822,"N-Acetyl-S-(2,3-dichlorophenyl)cysteine",CC(=O)N[C@@H](CSC1=C(C(=CC=C1)Cl)Cl)C(=O)O,,,,,,
9822,129823,4-Hydroxyalprenolol glucuronide,CC(C)NCC(COC1=C(C=C(C=C1)O)CC=C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O,,,,,,
9823,129824,Methoxycarbonylcholine,C[N+](C)(C)CCOC(=O)OC.[I-],,,,,,
9824,129825,O-(Methoxycarbonyl)choline,C[N+](C)(C)CCOC(=O)OC,,,,,,
9825,129826,"2(1H)-Quinolinone, 3,4-dihydro-1-methyl-6-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-",CC1CC(=O)NN=C1C2=CC3=C(C=C2)N(C(=O)CC3)C,,,,,,
9826,129827,CID 129827,COC1=CC2=C(C(=CN(C2=CC1=O)OC)C(=O)O)O,,,,,,
9827,129828,"2H-1,3,2-Oxazaphosphorine, tetrahydro-2-(bis(2-chloroethyl)amino)-4-((6-hydroxyhexyl)thio)-, 2-oxide",C1COP(=O)(NC1SCCCCCCO)N(CCCl)CCCl,,,,,,
9828,129829,"2H-1,3,2-Oxazaphosphorine, tetrahydro-2-(bis(2-chloroethyl)amino)-4-((2-carboxyethyl)thio)-, 2-oxide",C1COP(=O)(NC1SCCC(=O)O)N(CCCl)CCCl,,,,,,
9829,129830,"2,7-Naphthalenedisulfonic acid, 3-azido-",C1=CC(=CC2=CC(=C(C=C21)N=[N+]=[N-])S(=O)(=O)O)S(=O)(=O)O,,,,,,
9830,129831,1-Methyl-4-amino-2-methylquinolinium,CC1=[N+](C2=CC=CC=C2C(=C1)N)C.[I-],,,,,,
9831,129832,"1,2-Dimethylquinolin-1-ium-4-amine",CC1=[N+](C2=CC=CC=C2C(=C1)N)C,,,,,,
9832,129833,"1H-Pyrido(4,3-b)indole, 2,3,4,4a,5,9b-hexahydro-8-methyl-, trans-",CC1=CC2=C(C=C1)N[C@H]3[C@H]2CNCC3,,,,,,
9833,129834,"Benzoic acid, 2-(acetyloxy)-, 2-((1-oxodecyl)oxy)-1-(((1-oxodecyl)oxy)methyl)ethyl ester",CCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCC)OC(=O)C1=CC=CC=C1OC(=O)C,,,,,,
9834,129835,CID 129835,CC1=C(C[C@@H](CC1)O)C=CC2=CCC[C@]3([C@H]2CC[C@@H]3C(C)CCC=C(C)C)C,,,,,,
9835,129836,"3,12b-dimethyl-2,3,4,6,7,12-hexahydro-1H-indolo[2,3-a]quinolizine",CC1CCC2(C3=C(CCN2C1)C4=CC=CC=C4N3)C,,,,,,
9836,129837,S-(2-((1-Methylethyl)phenylamino)-2-oxoethyl)-L-cysteine,CC(C)N(C1=CC=CC=C1)C(=O)CSC[C@@H](C(=O)O)N,,,,,,
9837,129838,Pyroglutamyl-tyrosyl-prolinamide,C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=C(C=C2)O)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N,,,,,,
9838,129839,"Dimethyl 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2)C(=O)OC,,,,,,
9839,129840,"Sulfonium, ethylmethyl(2,8,9-trioxa-5-aza-1-silabicyclo(3.3.3)undec-1-ylmethyl)-, iodide",CC[S+](C)C[Si]12OCCN(CCO1)CCO2.[I-],,,,,,
9840,129841,"Ethyl-methyl-(2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecan-1-ylmethyl)sulfanium",CC[S+](C)C[Si]12OCCN(CCO1)CCO2,,,,,,
9841,129842,CID 129842,CCCCCCCCCCCCOC(=O)C=CC1=CN=CN1.Cl,,,,,,
9842,129843,CID 129843,CCCCCCCCCCCCOC(=O)C=CC1=CN=CN1,,,,,,
9843,129844,"Benzaldehyde,4-chloro-, O-[3-[4-(2-chlorophenyl)-1-piperazinyl]-2-hydroxypropyl]oxime,hydrochloride (1:1)",C1CN(CCN1CC(CON=CC2=CC=C(C=C2)Cl)O)C3=CC=CC=C3Cl.Cl,,,,,,
9844,129845,1-({[(4-Chlorophenyl)methylidene]amino}oxy)-3-[4-(2-chlorophenyl)piperazin-1-yl]propan-2-ol,C1CN(CCN1CC(CON=CC2=CC=C(C=C2)Cl)O)C3=CC=CC=C3Cl,,,,,,
9845,129846,8-Dehydrocholesterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
9846,129847,"Bis(2,4,6-tribromophenyl) phosphorochloridate",C1=C(C=C(C(=C1Br)OP(=O)(OC2=C(C=C(C=C2Br)Br)Br)Cl)Br)Br,,,,,,
9847,129848,3-[4-[2-[4-(Didecylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate,CCCCCCCCCCN(CCCCCCCCCC)C1=CC=C(C=C1)C=CC2=CC=[N+](C=C2)CCCS(=O)(=O)[O-],,,,,,
9848,129849,3-[4-[2-[4-(Didecylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonic acid,CCCCCCCCCCN(CCCCCCCCCC)C1=CC=C(C=C1)C=CC2=CC=[N+](C=C2)CCCS(=O)(=O)O,,,,,,
9849,129850,4-(Carboxymethylmercapto)testosterone,C[C@]12CCC3C(C1CC[C@@H]2O)CCC4=C(C(=O)CC[C@]34C)SCC(=O)O,,,,,,
9850,129851,"3-(4-Fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione",CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)F)C(F)(F)F)C,,,,,,
9851,129852,"Acetamide, N-(3-((3-aminopropyl)amino)propyl)-",CC(=O)NCCCNCCCN,,,,,,
9852,129853,1-[Ethyl-(6-hydrazinylpyridazin-3-yl)amino]propan-2-ol,CCN(CC(C)O)C1=NN=C(C=C1)NN,,,,,,
9853,129854,Bromoacetamide-2-chloro-5-benzophenone,C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)Br)NC(=O)CCl,,,,,,
9854,129855,"Isophthalamide, N,N'-bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)acetamido)-2,4,6-triiodo-",CC(=O)N(CCO)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,,,,,,
9855,129856,benzyl N-[1-[(2-amino-2-methylpropanoyl)-[(2S)-2-aminopropanoyl]amino]-2-methyl-1-oxopropan-2-yl]-N-methylcarbamate,C[C@@H](C(=O)N(C(=O)C(C)(C)N)C(=O)C(C)(C)N(C)C(=O)OCC1=CC=CC=C1)N,,,,,,
9856,129857,"1-(2,2-Bis(propylthio)-2-(2-naphthalenyl)ethyl)-1H-imidazole monohydrochloride",CCCSC(CN1C=CN=C1)(C2=CC3=CC=CC=C3C=C2)SCCC.Cl,,,,,,
9857,129858,"1-[2-Naphthalen-2-yl-2,2-bis(propylsulfanyl)ethyl]imidazole",CCCSC(CN1C=CN=C1)(C2=CC3=CC=CC=C3C=C2)SCCC,,,,,,
9858,129859,Sialin,C(CCN)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)CNC(=O)CN,,,,,,
9859,129860,CID 129860,CC[C@@](C)(CC=C[C@@H](C)C1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C)O,,,,,,
9860,129861,CID 129861,C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N,,,,,,
9861,129862,Sulfenosine,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C(N=C2SN)N,,,,,,
9862,129863,S(alpha)-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O,,,['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)'],,,
9863,129864,Sulfonosine,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C(N=C2S(=O)(=O)N)N,,,,,,
9864,129865,Danca,CN(C)C1=CC2=C(C=C1)C=C(C=C2)C(=O)C3CCC(CC3)C(=O)O,,,,,,
9865,129866,(1-Nitrosopiperidin-2-yl) dihydrogen phosphate,C1CCN(C(C1)OP(=O)(O)O)N=O,,,,,,
9866,129867,"2,3-(Di-glutathion-S-yl)-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C(=C(C2=O)[C@@](CS)(C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)[C@@](CS)(C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
9867,129868,Oxymorphone-6-spirohydantoin,CN1CCC23[C@@H]4C5(CCC2(C1CC6=C3C(=C(C=C6)O)O4)O)C(=O)NC(=O)N5,,,,,,
9868,129869,Atiprimod,CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC,"['Investigated for use/treatment in cancer/tumors (unspecified), multiple myeloma, and rheumatoid arthritis.']",,,,,
9869,129870,"1-(3,4-Methylenedioxyphenyl)-2-butanamine",CCC(CC1=CC2=C(C=C1)OCO2)N,,,,,"['1-(3,4-Methylenedioxyphenyl)-2-butanamine is a known human metabolite of (2S)-1-(1,3-Benzodioxol-5-yl)-N-methyl-2-butanamine.']",
9870,129871,Preprovasoactive intestinal peptide (111-122),CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N,,,,,,
9871,129872,"2-(3-(1-Piperidinyl)propyl)-8,8-dipropyl-2-azaspiro(4.5)decane",CCCC1(CCC2(CC1)CCN(C2)CCCN3CCCCC3)CCC,,,,,,
9872,129873,Mitometh,CC(C(C1=CC=C(C=C1)Cl)C2=CC=CC=C2Cl)(Cl)Cl,,,,,,
9873,129874,"2-Ribofuranosyl-1,2,3-triazole-4,5-dicarboxamide",C([C@@H]1[C@H]([C@H]([C@@H](O1)N2N=C(C(=N2)C(=O)N)C(=O)N)O)O)O,,,,,,
9874,129875,Hael-chlorambucil,C[C@]12CCC(CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC(=O)N4)C)OC(=O)CCCC5=CC=C(C=C5)N(CCCl)CCCl,,,,,,
9875,129876,"1-Ribofuranosylpyrazole-3,4-dicarboxamide",C1=C(C(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N)C(=O)N,,,,,,
9876,129877,tert-Butyloxycarbonylprolyl-prolyl-prolyl-proline methyl ester,CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)OC,,,,,,
9877,129878,CID 129878,CC(=CN=NC(=NC1CCCC1)N)NNC(=NC2CCCC2)N,,,,,,
9878,129879,2-(4-hydroxy-3-methoxyphenyl)-N-octadec-9-enylacetamide,CCCCCCCCC=CCCCCCCCCNC(=O)CC1=CC(=C(C=C1)O)OC,,,,,,
9879,129880,"2,2,6,6-Tetramethyl-1-oxyl-delta(3)-piperidine-4-mercuribromide",CC1(CC(=CC(N1O)(C)C)[Hg]Br)C,,,,,,
9880,129881,Phenyl tetralone tosylhydrazone,CC1=CC=C(C=C1)S(=O)(=O)NN=C2C(CCC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
9881,129882,Vasoactive intestinal peptide (7-11),C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O,,,,,,
9882,129883,Decidium diiodide,C[N+](C)(C)CCCCCCCCCCC1=C2C(=C(C=C1C3=CC=CC=C3)N)C=CC4=C2C=C(C=C4)N.I.[I-],,,,,,
9883,129884,"10-(1,6-Diamino-3-phenylphenanthren-4-yl)decyl-trimethylazanium",C[N+](C)(C)CCCCCCCCCCC1=C2C(=C(C=C1C3=CC=CC=C3)N)C=CC4=C2C=C(C=C4)N,,,,,,
9884,129885,2-O-Talopyranosylmannopyranoside,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O[C@@H]2[C@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O)O,,,,,,
9885,129886,ethyl (2R)-2-[[(2S)-4-methyl-1-oxo-1-pyrrolidin-1-ylpentan-2-yl]amino]propanoate,CCOC(=O)[C@@H](C)N[C@@H](CC(C)C)C(=O)N1CCCC1,,,,,,
9886,129887,3-O-Talopyranosylmannopyranoside,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O[C@@H]2[C@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
9887,129888,CID 129888,CC1[C@](O1)(C=C[C@@H](C)C2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)C(C)C,,,,,,
9888,129889,CID 129889,C([C@]1([C@@H]([C@@H]([C@H](C(O1)O)O)O)O)N)O,,,,,,
9889,129890,CID 129890,C1CCOC(C1)NC2=NC(=O)C3=C(N2)N=CN3O,,,,,,
9890,129891,6-Hydroxy-6-methyl-heptan-3-one,CCC(=O)CCC(C)(C)O,,,,,,
9891,129892,"Substance P (6-11), glu(6)-",CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)O)N,,,,,,
9892,129893,"(4r,5r,8r)-9-Ethylidene-4,5,7,8,9,10-hexahydro-5,8-dihydroxy-4-propyl-1h-cyclonona[c]furan-1,3,6-trione",CCC[C@H]1[C@H](C(=O)C[C@H](C(=CC)CC2=C1C(=O)OC2=O)O)O,,,,,,
9893,129894,"3H-3-Benzazepine-3-propanamine, N-(2-(3,4-dimethoxyphenyl)ethyl)-1,2-dihydro-7,8-dimethoxy-N-methyl-1-phenyl-, monohydrochloride",CN(CCCN1CC(C2=CC(=C(C=C2C=C1)OC)OC)C3=CC=CC=C3)CCC4=CC(=C(C=C4)OC)OC.Cl,,,,,,
9894,129895,"3-(7,8-dimethoxy-1-phenyl-1,2-dihydro-3-benzazepin-3-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine",CN(CCCN1CC(C2=CC(=C(C=C2C=C1)OC)OC)C3=CC=CC=C3)CCC4=CC(=C(C=C4)OC)OC,,,,,,
9895,129896,6-Acetamidohexanal,CC(=O)NCCCCCC=O,,,,,,
9896,129897,"7-[(1R,2R,5S)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-5-enoic acid",C1COCCN1[C@@H]2[C@H]([C@H](CC2=O)OCC3=CC=C(C=C3)C4=CC=CC=C4)CC=CCCCC(=O)O,,,,,,
9897,129898,CID 129898,CC(=NNC(=NCOCCOC(=O)C)S)C1=CC=CC=N1,,,,,,
9898,129899,Capsimine,C[C@@H]1CC[C@@H](NC1)[C@@H](C)C2[C@@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)O,,,,,,
9899,129900,(3-Hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate,CCCCCCCCCCCCCCCCOCC(C)(COP(=O)([O-])OCC[N+](C)(C)C)O,,,,,,
9900,129901,2-[(3-Hexadecoxy-2-hydroxy-2-methylpropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCOCC(C)(COP(=O)(O)OCC[N+](C)(C)C)O,,,,,,
9901,129902,CID 129902,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COS(=O)(=O)N)O)O)C(=N)S,,,,,,
9902,129903,"1-(5'-O-Sulfamoyl-beta-D-ribofuranosyl)(1,2,4)triazole-3-carbonitrile",C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COS(=O)(=O)N)O)O)C#N,,,,,,
9903,129904,N-Glucopyranosyl-5-aminosalicylic acid,C1=CC(=C(C=C1N[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)O)O,,,,,,
9904,129905,"1,3-Propanediol, 2-((4-amino-5-bromo-7H-pyrrolo(2,3-d)pyrimidin-7-yl)methoxy)-",C1=C(C2=C(N=CN=C2N1COC(CO)CO)N)Br,,,,,,
9905,129906,"2,7-Diamino-3,8-dimethylphenazine",CC1=CC2=C(C=C1N)N=C3C=C(C(=CC3=N2)N)C,,,,,,
9906,129907,Isocapsicastrine,CC1CCC(NC1)[C@@H](C)[C@H]2C(C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CCC(C5)OC6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O,,,,,,
9907,129908,"2-Propanol, 1-((2-ethyl-7-benzofuranyl)oxy)-3-((1-methylethyl)amino)-",CCC1=CC2=C(O1)C(=CC=C2)OCC(CNC(C)C)O,,,,,,
9908,129909,"[(9R)-5,8,9-trihydroxy-5-methyl-9-[(9R,10R,13R,17S)-2,3,14-trihydroxy-10,13-dimethyl-6-oxo-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]decyl] 2-bromoacetate",C[C@]12CC[C@H]3C(=CC(=O)C4[C@@]3(CC(C(C4)O)O)C)C1(CC[C@@H]2[C@](C)(C(CCC(C)(CCCCOC(=O)CBr)O)O)O)O,,,,,,
9909,129910,"1-Naphthalenepropanamine, beta-phenyl-, hydrochloride",C1=CC=C(C=C1)C(CC2=CC=CC3=CC=CC=C32)CN.Cl,,,,,,
9910,129911,3-Naphthalen-1-yl-2-phenylpropan-1-amine,C1=CC=C(C=C1)C(CC2=CC=CC3=CC=CC=C32)CN,,,,,,
9911,129912,"8-Hydroxy-2-nitromethyl-7-nitro-1,4-benzodioxane",C1C(OC2=C(O1)C=CC(=C2O)[N+](=O)[O-])CO[N+](=O)[O-],,,,,,
9912,129913,"3-(3,4,5-Trimethoxyphenyl)propane-1,2-diol",COC1=CC(=CC(=C1OC)OC)CC(CO)O,,,,,,
9913,129914,N-Acetylglutaminylglutamine amide,CC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N,,,,,,
9914,129915,"(4R)-4-[(3R,5R,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-6,10,13-trimethyl-1,2,3,4,5,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid",C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC([C@H]4[C@@]3(CC[C@H](C4)O)C)(C)O)C,,,,,,
9915,129916,2-Fluoro-3-hydroxytyrosine,C1=CC(=C(C(=C1C[C@@H](C(=O)O)N)F)O)O,,,,,,
9916,129917,"8-Azabicyclo[3.2.1]octane-2,7-diol",C1CC(C2C(CC1N2)O)O,,,,,,
9917,129918,"N-(4-fluorophenyl)-3,4-bis(4-methoxyphenyl)aniline",COC1=CC=C(C=C1)C2=C(C=C(C=C2)NC3=CC=C(C=C3)F)C4=CC=C(C=C4)OC,,,,,,
9918,129919,CID 129919,CCOC(=O)C1CC(=O)C2=C1C3=C(C(=O)C(=CC3=C(O2)O)O)O,,,,,,
9919,129920,"2-Propyl-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran",CCCC1CCC(O1)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
9920,129921,"1,2,3-Trimethoxy-5-[4-(3,4,5-trimethoxyphenyl)buta-1,3-dienyl]benzene",COC1=CC(=CC(=C1OC)OC)C=CC=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
9921,129922,"7,25-Dihydroxycholesterol",C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(C=C4[C@@]3(CC[C@@H](C4)O)C)O)C,,,,,,
9922,129923,1-(4-Nitrophenyl)prop-2-en-1-ol,C=CC(C1=CC=C(C=C1)[N+](=O)[O-])O,,,,,,
9923,129924,"1,4-Dihydro-2,6-dimethyl-5-nitro-4-thieno-(3,2-c)pyridin-3-yl-3-pyridinecarboxylic acid",CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CSC3=C2C=NC=C3)C(=O)OC(C)C4=CC=CC=C4,,,,,,
9924,129925,1-(4-Hydroxybenzyl)-2-methylimidazole,CC1=NC=CN1CC2=CC=C(C=C2)O,,,,,,
9925,129926,"(N'-Methyl-N'-4-diazonium phenyl)(N-8-octanoic acid, 2-(trimethylammonium)ethyl ester)urea",CN(C1=CC=C(C=C1)[N+]#N)C(=O)NCCCCCCCC(=O)OCC[N+](C)(C)C,,,,,,
9926,129927,"endo-6-Methoxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylate hcl",CN1C2CCC1CC(C2)OC(=O)N3C4=C(C=CC(=C4)OC)NC3=O.Cl,,,,,,
9927,129928,(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate,CN1C2CCC1CC(C2)OC(=O)N3C4=C(C=CC(=C4)OC)NC3=O,,,,,,
9928,129929,"N-(3,5-Dichlorophenyl)-4-(4-hydroxy-2-methoxyphenyl)-1-piperazinecarboxamidine",COC1=C(C=CC(=C1)O)N2CCN(CC2)C(=NC3=CC(=CC(=C3)Cl)Cl)N,,,,,,
9929,129930,1-((1-(2-(Trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)methyl)pyrrolidin-2-one,C1CC(=O)N(C1)CC2CCN(CC2)C3=NC(=NC=C3)C(F)(F)F,,,,,,
9930,129931,CID 129931,CCN1C[C@@H](C#C1)CNC(=O)C2=CC(=CC3=C2OCC3)I,,,,,,
9931,129932,CID 129932,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3O)O)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O,,,,,,
9932,129933,CID 129933,CC(C)C(C=C[C@H]1[C@@H](CC(=C)[C@@H]1CC=CCCCC(=O)O)O)O,,,,,,
9933,129934,"Trans-6-[4,4-bis(4-fluorophenyl)-3-(1-methyl-1H-tetrazol-5-yl)-1,3-butadienyl]-tetrahydro-4-hydroxy-2H-pyran-2-one",CN1C(=NN=N1)C(=C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C=C[C@H]4C[C@@H](CC(=O)O4)O,,,,,,
9934,129935,"(5R,6S)-3-(aminomethyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)CN)C(=O)O)O,,,,,,
9935,129936,CID 129936,C[C@H](C(=O)N[C@@H](C)C(=O)NC(=O)[C@@H]1CCCN1[C@@H](C(C)C)C(=O)C(F)(F)F)NC(=O)CCC(=O)OC,,,,,,
9936,129937,"4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((trifluoromethyl)sulfonyl)oxy)-",CC1(C(N2C(S1)C(C2=O)OS(=O)(=O)C(F)(F)F)C(=O)O)C,,,['Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)'],,,
9937,129938,"(2S)-N-[(2S)-2-[[(2S)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]propanoyl]amino]propanoyl]-1-[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]pyrrolidine-2-carboxamide",C[C@@H](C(=O)NC(=O)[C@@H]1CCCN1[C@@H](C(C)C)C(=O)C(F)(F)F)NC(=O)[C@H](C)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C,,,,,,
9938,129939,CID 129939,CCCCCCCCCCOC(=O)CCCC=C[C@H]1[C@H]2CC[C@H](C2)[C@H]1CNS(=O)(=O)C3=CC=C(C=C3)Br,,,,,,
9939,129940,7-Diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin,CCN(CC)C1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=C(C=C3)N=C=S)C,,,,,,
9940,129941,"6-Methyl-5-pyridin-4-yl-3,6-dihydro-1,3,4-thiadiazin-2-one",CC1C(=NNC(=O)S1)C2=CC=NC=C2,,,,,,
9941,129942,5-[[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-hydroxy-7-methyl-N-[3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-yloctanamide,CCC(C)C(C(=O)NCC1=CC=CC=N1)NC(=O)C(CC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)NS(=O)(=O)C3=CC=CC4=C3C=CC=C4N(C)C)O)C(C)C,,,,,,
9942,129943,"1-[2-[4-(2-methoxy-6-phenyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)phenoxy]ethyl]pyrrolidine",COC1=CC2=C(C=C1)C(C(CCC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5,,,,,,
9943,129944,3-Quinuclidinyl atrolactate,CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
9944,129945,CID 129945,C1=C(C(=C(C(=C1I)[O-])I)N[N+]#N)C#N,,,,,,
9945,129946,CID 129946,C1=C(C(=C(C(=C1I)O)I)N[N+]#N)C#N,,,,,,
9946,129947,"2-((7-Hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino)-1-phenylethanol hcl",C1CC2=C(CC1NCC(C3=CC=CC=C3)O)C=C(C=C2)O.Cl,,,,,,
9947,129948,"2-[(7-Hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol",C1CC2=C(CC1NCC(C3=CC=CC=C3)O)C=C(C=C2)O,,,,,,
9948,129949,Nitrobenzyl-dota,C1CN(CCN(C(CN(CCN1CC(=O)O)CC(=O)O)CC2=CC=C(C=C2)[N+](=O)[O-])CC(=O)O)CC(=O)O,,,,,,
9949,129950,CID 129950,C1=CC2=C(C=C1C(=C[N+]#N)[O-])C3=C2C(=C(C=C3)N(CC(=O)O)CC(=O)O)OCCOC4=C(C=CC5=C4C6=C5C=C(C=C6)C(=O)C=[N+]=[N-])N(CC(=O)O)CC(=O)O,,,,,,
9950,129951,CID 129951,C1=CC2=C(C=C1C(=C[N+]#N)O)C3=C2C(=C(C=C3)N(CC(=O)O)CC(=O)O)OCCOC4=C(C=CC5=C4C6=C5C=C(C=C6)C(=C[N+]#N)[O-])N(CC(=O)O)CC(=O)O,,,,,,
9951,129952,"2-((7-Hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino)-1-(3-chlorophenyl)ethanol hcl",C1CC2=C(CC1NCC(C3=CC(=CC=C3)Cl)O)C=C(C=C2)O.Cl,,,,,,
9952,129953,"2-[(7-Hydroxy-1,2,3,4-tetrahydronaphth-2-yl)-amino]-1-(3-chlorophenyl)ethanol",C1CC2=C(CC1NCC(C3=CC(=CC=C3)Cl)O)C=C(C=C2)O,,,,,,
9953,129954,2-[(Pyridin-2-ylhydrazinylidene)methyl]benzenethiol,C1=CC=C(C(=C1)C=NNC2=CC=CC=N2)S,,,,,,
9954,129955,4-(Carbethoxynitrosamino)-4-(3-pyridyl)butanal,CCOC(=O)N(C(CCC=O)C1=CN=CC=C1)N=O,,,,,,
9955,129956,Aspartyl-aspartyl-glutamyl-aspartic acid,C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
9956,129957,N-Succinimidyl 4-(tri-n-butylstannyl)benzoate,CCCC[Sn](CCCC)(CCCC)C1=CC=C(C=C1)C(=O)ON2C(=O)CCC2=O,,,,,,
9957,129958,9-Methyl-7-bromoeudistomin D,CN1C2=CC(=C(C(=C2C3=C1C=NC=C3)Br)O)Br,,,,,,
9958,129959,"1H-Purine-2,6-dione, 3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-7-propyl-",CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(C)(C)O,,,,,,
9959,129960,"Piperazinium, 1-butyl-1-methyl-4-((2,3,4,5-tetrahydro-4-oxo-2-phenyl-1,5-benzothiazepin-3-yl)methyl)-, bromide, cis-",CCCC[N+]1(CCN(CC1)C[C@H]2[C@H](SC3=CC=CC=C3NC2=O)C4=CC=CC=C4)C.[Br-],,,,,,
9960,129961,CID 129961,CCCC[N+]1(CCN(CC1)CC2[C@H](SC3=CC=CC=C3NC2=O)C4=CC=CC=C4)C,,,,,,
9961,129962,Mamdmf,CC(=O)OCC1C(OC(=C1C(=O)OC)C2=CC3=C(C=C2)OCO3)C4=CC5=C(C=C4)OCO5,,,,,,
9962,129963,CID 129963,C1=CC(=C(C=C1N[N+]#N)[N+](=O)[O-])C(=NCCCCCCCN)[O-],,,,,,
9963,129964,CID 129964,C1=CC(=C(C=C1N[N+]#N)[N+](=O)[O-])C(=O)NCCCCCCCN,,,,,,
9964,129965,"1-[2-(4-Diazocyclohexa-1,5-dien-1-yl)ethyl]pyrrole-2,5-dione",C1C=C(C=CC1=[N+]=[N-])CCN2C(=O)C=CC2=O,,,,,,
9965,129966,Boc-glu(ofm)-oh,CC(C)(C)OC(=O)N[C@@H](CCC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13)C(=O)O,,,,,,
9966,129967,"8-Chloro-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine",CN1CCC2=C(C=CC(=C2)Cl)C(C1)C3=CC=CC4=C3OCC4,,,,,,
9967,129968,2-((3-(3-(1H-Tetrazol-5-yl)propoxy)phenoxy)methyl)quinoline,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)OCCCC4=NNN=N4,,,,,,
9968,129969,CID 129969,CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=O)C3=C2O)OC)C4=CC=C(C=C4)O)O)O)O,,,,,,
9969,129970,"2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N-(2-hydroxypropyl)-N-propylacetamide",CCCN(CC(C)O)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
9970,129971,CID 129971,COC1=C(C(=CC(=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
9971,129972,"2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N-(2-hydroxypropyl)acetamide",CC(CNC(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl)O,,,,,,
9972,129973,Hortensin,COC1=C(C=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)O)O)OC,,,,,,
9973,129974,Tricrozarin A,COC1=C(C(=O)C2=C(C1=O)C(=C3C(=C2O)OCO3)O)OC,,,,,,
9974,129975,4-(Maleinimido)phenyl isocyanate,C1=CC(=CC=C1N=C=O)N2C(=O)C=CC2=O,,,,,,
9975,129976,Butyloxycarbonyl-asparaginyl-glycyl-glycinamide,CCCCOC(=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)N,,,,,,
9976,129977,Bipinnatin-C,CC1=C2[C@@H](C(C[C@@H](C34[C@H](O3)[C@@H](C[C@]5([C@@H](O5)C(=C1)O2)C)OC4=O)OC(=O)C)C6(CO6)C)OC(=O)C,,,,,,
9977,129978,"3-(1H-imidazo[4,5-b]pyridin-2-yl)propanoic acid",C1=CC2=C(N=C1)N=C(N2)CCC(=O)O,,,,,,
9978,129979,Arginine-glycine-aspartate-O-methyltyrosine amide,COC1=CC=C(C=C1)C[C@@H](C(=O)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N)N,,,,,,
9979,129980,"Hexanoic acid, 6-(4-((5-(1H-imidazol-1-yl)pentyl)oxy)phenoxy)-2,2-dimethyl-",CC(C)(CCCCOC1=CC=C(C=C1)OCCCCCN2C=CN=C2)C(=O)O,,,,,,
9980,129981,"2,3-Dihydro-5H-oxazolo(3,2-a)thieno(3,2-d)pyrimidin-5-one",C1COC2=NC3=C(C(=O)N21)SC=C3,,,,,,
9981,129982,Cpd-TH,CN1C2=C(C(=O)N(C1=O)C)N=CN2[C@@H]3C(=O)C=C[C@H](O3)COCCCCCC(=O)O,,,,,,
9982,129983,CID 129983,C[C@H](C(=O)NC(=O)[C@H](CCCCN)NC(CCCN=C(N)N)C(=O)CCl)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
9983,129984,Tyrosyl-phenylalanyl-arginyl-lysyl-aspartic acid,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N,,,,,,
9984,129985,Dhp-TH,CN1C2=C(C(=O)N(C1=O)C)N=CN2[C@@H]3C(=O)C=C[C@H](O3)COCCCCCCO,,,,,,
9985,129986,CID 129986,CN1CN(C2=C1C(=O)N=C(N2)N)[C@H]3C[C@@H]([C@H](O3)CO)OP(=O)(O)O,,,,,,
9986,129987,"2-[5-[[1-(Carboxymethyl)-2,4,6-trioxo-1,3-diazinan-5-ylidene]amino]-2,4,6-trioxo-1,3-diazinan-1-yl]acetic acid",C(C(=O)O)N1C(=O)C(C(=O)NC1=O)N=C2C(=O)NC(=O)N(C2=O)CC(=O)O,,,,,,
9987,129988,CID 129988,CC1=CCCC2([C@H](O2)[C@@H](C[C@](C=C[C@@H](CC1)C(C)C)(C)O)O)C,,,,,,
9988,129989,"11-[[4-[4-(Diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-B][1,4]benzodiazepin-6-one",CCN(CC)CCCCC1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4,,,,,,
9989,129990,CID 129990,C1C2=C(N=C1N)N(CN(C2=O)CNC3C(C(C4C3O4)O)O)[C@@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O,,,,,,
9990,129991,Acreozast,CC(=O)OCC(=O)NC1=CC(=CC(=C1Cl)NC(=O)COC(=O)C)C#N,,,,,,
9991,129992,"14-[Bis(2-chloroethyl)amino]-7-methoxy-3-(prop-2-en-1-yl)-1,2,3,4,7,7a-hexahydro-4a,7-ethano-4,12-methano[1]benzofuro[3,2-e]isoquinolin-9-ol",COC12C=CC3(C[C@H]1N(CCCl)CCCl)[C@@H]4CC5=C6[C@]3([C@@H]2OC6=C(C=C5)O)CCN4CC=C,,,,,,
9992,129993,"(2R)-2-methylspiro[1,3-dioxolane-4,3'-1-azabicyclo[2.2.2]octane]",C[C@@H]1OCC2(O1)CN3CCC2CC3,,,,,,
9993,129994,3-Pgsgd,CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2CC[C@@]3(C4CC[C@@]5([C@H](CCC5C4CC=C3C2)[C@H](C)CC[C@H](CC)C(=C)C)C)C)O)O)O,,,,,,
9994,129995,3-Sgsgd,CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2CC[C@@]3(C4CC[C@@]5([C@H](CCC5C4CC=C3C2)[C@H](C)CC[C@H](CC)C(=C)C)C)C)O)O)O,,,,,,
9995,129996,CID 129996,CC(C)[C@H]1CCC(=C)[C@H](CC[C@@](C=C1)(C)O)OO,,,,,,
9996,129997,"6-N-Aziridinyl-3-hydrox-7-methyl-2,3-dihydro-1H-pyrrolo(1,2-a)benzimidazole-5,8-dione 3-acetate",CC1=C(C(=O)C2=C(C1=O)N3CCC(C3=N2)OC(=O)C)N4CC4,,,,,,
9997,129998,4-((2-Chloroethyl)methylamino)-2-butynyl N-(3-chlorophenyl)carbamate,CN(CCCl)CC#CCOC(=O)NC1=CC(=CC=C1)Cl,,,,,,
9998,129999,4-((2-Bromoethyl)methylamino)-2-butynyl N-(3-chlorophenyl)carbamate,CN(CCBr)CC#CCOC(=O)NC1=CC(=CC=C1)Cl,,,,,,
9999,130000,4-Hydroxymethyltetrahydrobenzopsoralen,C1CCC2=C(C1)C3=C(O2)C=C4C(=C3)C(=CC(=O)O4)CO,,,,,,
